{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Innoplexus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "## import the libraries\n",
    "import pandas as pd\n",
    "import nltk\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = pd.read_csv(\"train_F3WbcTw.csv\", na_values = (\"NA\", \" \", \"\"))\n",
    "data_test = pd.read_csv(\"test_tOlRoBf.csv\", na_values = (\"NA\", \" \", \"\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(5279, 4)\n",
      "(2924, 3)\n"
     ]
    }
   ],
   "source": [
    "print(data.shape)\n",
    "print(data_test.shape)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>unique_hash</th>\n",
       "      <th>text</th>\n",
       "      <th>drug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>9e9a8166b84114aca147bf409f6f956635034c08</td>\n",
       "      <td>256 (previously stable on natalizumab), with 5...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>e747e6822c867571afe7b907b51f0f2ca67b0e1a</td>\n",
       "      <td>On fingolimod and have been since December 201...</td>\n",
       "      <td>fingolimod</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>50b6d851bcff4f35afe354937949e9948975adf7</td>\n",
       "      <td>Apparently it's shingles! :-/ I do have a few ...</td>\n",
       "      <td>humira</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>7f82ec2176ae6ab0b5d20b5ffc767ac829f384ae</td>\n",
       "      <td>If the Docetaxel doing once a week x3 weeks th...</td>\n",
       "      <td>tagrisso</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>8b37d169dee5bdae27060949242fb54feb6a7f7f</td>\n",
       "      <td>CC, Stelara worked in a matter of days for me....</td>\n",
       "      <td>stelara</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                unique_hash  \\\n",
       "0  9e9a8166b84114aca147bf409f6f956635034c08   \n",
       "1  e747e6822c867571afe7b907b51f0f2ca67b0e1a   \n",
       "2  50b6d851bcff4f35afe354937949e9948975adf7   \n",
       "3  7f82ec2176ae6ab0b5d20b5ffc767ac829f384ae   \n",
       "4  8b37d169dee5bdae27060949242fb54feb6a7f7f   \n",
       "\n",
       "                                                text        drug  \n",
       "0  256 (previously stable on natalizumab), with 5...  fingolimod  \n",
       "1  On fingolimod and have been since December 201...  fingolimod  \n",
       "2  Apparently it's shingles! :-/ I do have a few ...      humira  \n",
       "3  If the Docetaxel doing once a week x3 weeks th...    tagrisso  \n",
       "4  CC, Stelara worked in a matter of days for me....     stelara  "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_test.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "unique_hash = data_test[\"unique_hash\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to C:\\Users\\VIVAN\n",
      "[nltk_data]     DSOUZA\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "## Cleaning the training data set\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.stem.porter import PorterStemmer\n",
    "nltk.download(\"stopwords\")\n",
    "corpus = []\n",
    "for i in range(0, 5279):\n",
    "    data[\"text\"][0]   ## check the first text\n",
    "    text = re.sub('[^a-zA-z]', \" \", data[\"text\"][i])\n",
    "    text = text.lower()\n",
    "    text = text.split()\n",
    "    ps = PorterStemmer()\n",
    "    text = [ps.stem(word) for word in text if not word in set(stopwords.words(\"english\"))]\n",
    "    text = \" \".join(text)\n",
    "    corpus.append(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['autoimmun diseas tend come cluster gilenya feel good think chang anyth wast time energi take tysabri feel amaz symptom dodgi color vision sinc alway know know last month year decad ive decid enjoy ride point worri',\n",
       " 'complet understand want tri result report lectur alway stand scrutini peer review public much still convinc hope work realli awar happi risk great think import present balanc way understand move straight first show promis anim studi use drug human still lot anim data gather human data gather anyon tell safe effect tell mani time anim studi follow human one major attrit point drug develop unpredict issu cladribin gilenya interact predict peopl tri doctor see pattern work go clemastin metformin excit given said current condit person risk toler make sens tri definit everyon',\n",
       " 'interest target p receptor rather like fingolimod hope soon see ae sae ye sure mean exactli quot nine patient report seriou advers event mg [ ] mg [ ] mg [ ] mg [ ] seriou advers event report patient new safeti signal occur compar bold studi patient report sae state seriou advers event report patient mayb read right mayb misprint pleas someth develop spm encourag siponimod linger long bodi',\n",
       " 'interest grand merci wonder lemtrada ocrevu sale would go prove anti cd induct',\n",
       " 'hi everybodi latest mri result brain cervic cord next neurologist appoint next coupl week new lesion brain cord relaps gilenya good sign one line cervic cord review concern goe lesion c show hypointens post gadolinium imag could repres artifact earli axon loss bothersom read kind symptom c c lesion awar would result chang dmt thank',\n",
       " 'give advic lemtrada chose cladribin thought drug doctor bart keen give peopl spm read http multipl sclerosi research blogspot com suppos therapi html',\n",
       " 'repli post jesszidek hi jess sorri read challeng health mention lot post want share info point first know said scare humira humira biolog success reduc symptom induc maintain diseas remiss reduc level fear help learn treatment option learn treatment option learn view understand ibd medic brochur http www crohnscolitisfound org asset pdf understand ibd med nov pdf would like talk contact help center info crohnscolitisfound org',\n",
       " 'well expect neurologist want start tysabri kept say happi kept say ye still lemtrada avail think would definit go like everi thing way behind took year longer australia get gilenya tysabri take gilenya everi second day vital still low white blood count last week day take box bird normal realli want tysabri consid attend voic concerns_but seem even toler ok averag time stop though becom jvc posit two year',\n",
       " 'think fingolimod miser failur progress ms trial human anim abort biogen fact stimul neuron gene express axon growth regener want progress patient human trial fail',\n",
       " 'thank much learn lot grace mention husband cancer bone liver adren addit lung brain met mention truli appreci comment hospic start hospic week ago insur allow palli care along continu anti cancer treatment thought hospic end life care thu hesit truli bless help equip medicin twice weekli visit give us bit measur husband extrem help meant ask opdivo tagrisso penetr blood brain barrier heard ye husband start opdivo treatment switch irinotecan chemo brain met first chemo end hospit pneumonia thank gina',\n",
       " 'vision one eye unrel eye inject howev problem began good eye get inject one eye alway horrifi experi mental still scari till today get use mani eye inject first year old year ago develop eye infect one could pinpoint exactli one one everi antibiot inject eye period week total inject big relief last antibiot avail job option left two year later cataract surgeri within week develop retin vein occlus also macular oedema came play well began avasrin inject lucenti would get frequent year later becam monthli inject stop count sometim inject becom pitch black first time terrifi told due eye pressur injur came back normal main thing make sure may may happen procedur eye condit least prepar true australia neither lucenti eylea cover govern unless one macular degener even though condit also vision threaten eylea extend time period inject biggest mileston achiev date grate ophthalmologist gone beyond profess make inject process comfort possibl research well done keep go eye priceless',\n",
       " 'signific bleed right eye need laser possibl surgeri longer term thank less left treat inject assess click expand ah ok mention macular oedema caus vitreou haemorrhag mention prolif diabet retinopathi pdr caus vitreou haemorrhag know mention laser differ type sometim macular oedema treat macular laser type use pdr call prp pan retin photocoagul appli peripheri retina good inform inject macular oedema http www diabeticretinopathi org uk lucentispatientsdr htm good inform laser treatment',\n",
       " 'object review evid support european union market author drug multipl sclerosi ms assess far postmarket research address inform gap time approv method databas identifi drug approv european medicin agenc gather data pivot trial european public assess report correspond public search medlin embas cochran librari trial registri postmarket random control trial test drug identifi form diseas result sinc approv interferon glatiram agenc examin drug treatment ms includ studi alemtuzumab daclizumab dimethyl fumar fampridin fingolimod peginterferon natalizumab teriflunomid analyz pivot trial enrol almost particip eleven compar new drug placebo interferon annual relaps rate primari outcom two third coprimari disabl progress studi alemtuzumab postmarket trial report final result ongo termin complet result avail none directli compar approv drug thu leav respect therapeut valu unknown data prevent diseas progress scarc none diseas modifi drug show effect disabl progress conclus lack compar evid data clinic effect hamper assess therapeut valu place therapi drug approv ms',\n",
       " 'multipl sclerosi ms thought inflammatori process involv differ area central nervou system cn variou point time caus diseas caus multipl sclerosi known environment genet factor thought predispos person develop diseas multipl sclerosi result destruct myelin surround nerv cn myelin fatti substanc insul nerv allow transmit inform brain myelin damag transmit inform delay also may misinterpret brain myelin destruct also known demyelin thought caus bodi immun cell enter cn disrupt normal barrier entri cell term blood brain barrier lead local swell known edema also damag nerv cell bodi term neuron loss prolong term axon loss plaqu area inflamm demyelin axon loss edema scar repres typic multipl sclerosi lesion area injuri initi trigger immun system attack known microglia cell cn take fragment myelin present fragment immun cell healthi individu present myelin fragment thought trigger immun cell attack cn peopl multipl sclerosi present myelin fragment may trigger exagger respons immun cell lead format plaqu around blood vessel cn sign symptom share stori perhap common symptom ms sensori disturb manifest tingl numb sensat throughout bodi visual disturb also among common symptom blur hazi vision color percept alter vision loss may occur develop optic neuriti inflamm optic nerv typic case optic neuriti person multipl sclerosi experi ocular pain eye movement common symptom includ loss balanc fine motor skill facial pain weak vertigo spin sensat limb weak paralysi impair control bladder bowel function fatigu depress memori loss individu advanc diseas lose abil walk may becom bedridden requir assist activ cure ms current vaccin treatment cure multipl sclerosi drug treat symptom share stori sever medic avail decreas number attack period relaps multipl sclerosi delay progress physic disabl doctor health care profession prescrib medic therapi treat gener symptom associ diseas depress muscl spasm fatigu bladder problem tremor shaki poor coordin sexual dysfunct interferon glatiram acet capaxon interferon beta avonex rebif interferon beta b betaseron glatiram acet copaxon exampl immun modifi drug use ms gener medic tend decreas frequenc attack patient mild moder relaps remit ms rrm rate new lesion appear magnet reson imag mri also reduc approxim one third interferon drug effect directli relat dose higher dose ifn toler gener effect whether delay onset new attack drug ultim long term impact disabl associ multipl sclerosi controversi howev clinic trial suggest patient receiv earli treatment benefici impact relaps disabl may match patient treatment delay research regard continu abil respond long term interferon beta beta b may limit patient develop persist high titer neutral antibodi patient treat glatiram also eventu develop antibodi antibodi seem limit glatiram activ multipl sclerosi slideshow make ms friendli home take ms quiz corticosteroid methylprednisolon solu medrol corticosteroid frequent use intraven speed recoveri ms attack help administ shortli within day onset attack corticosteroid work corticosteroid affect immunolog action inflamm swell immun respons associ acut sudden attack multipl sclerosi corticosteroid use short period reduc durat sever symptom associ sudden attack use medic individu allerg corticosteroid individu activ peptic ulcer diseas individu system fungal infect use caution use medic peopl diabet seizur hypertens congest heart failur osteoporosi tuberculosi viral infect impair liver function peopl take medic peopl consult doctor level medic may elev use along corticosteroid use solu medrol administ intraven iv day treat sudden multipl sclerosi attack steroid impact degre clinic recoveri rather shorten time recoveri drug food interact mani drug interact possibl contact doctor pharmacist take new prescript counter medic aspirin nonsteroid anti inflammatori drug ibuprofen advil naproxen alev medic associ stomach ulcer may increas risk develop stomach ulcer corticosteroid may decreas potassium level therefor caution must use take medic decreas potassium level diuret exampl furosemid lasix side effect ideal corticosteroid use short period order control sudden flare multipl sclerosi symptom short term use may caus fluid retent potassium loss stomach distress weight gain chang emot long term use associ seriou side effect osteoporosi calcium vitamin supplement advis adren insuffici psychosi immunosuppress peptic ulcer hypertens insomnia menstrual irregular acn skin atrophi elev blood sugar abnorm appear face cushingoid face increas risk infect cataract induct problem blood sugar level worsen diabet control chang diet initi oral antidiabet medic insulin may requir individu alreadi diabet dosag chang may need insulin antidiabet medic weight gain common problem high dose corticosteroid due fluid retent endocrin alter salt restrict advis doctor approv potassium supplement may need doctor may prescrib diuret water pill increas urin elimin excess fluid immunosuppress mitoxantron novantron food drug administr fda approv immunosuppress use treatment multipl sclerosi immunosuppress cyclophosphamid cytoxan azathioprin imuran methotrex rheumatrex trexal prescrib primarili special center efficaci multipl sclerosi remain controversi fda approv use drug substitut immun modul drug first line agent newli diagnos relaps remit multipl sclerosi rrm physician find role cytoxan imuran methotrex last resort measur patient respond fda approv drug fulmin malign cours multipl sclerosi may life threaten immunosuppress work group includ wide varieti agent work mani differ way interfer immun system process caus inflamm use medic individu allerg medic women pregnant breastfeed individu preexist bone marrow suppress individu diseas caus low blood count dose depend drug prescrib immunosuppress may administ oral intraven drug food interact use immunosuppress increas risk infect increas toxic bone marrow blood cell may lead cancer mani drug interact possibl contact doctor pharmacist begin new prescript counter medic side effect immunosuppress safe pregnanc may caus bone marrow blood cell toxic may lead cancer patient impair kidney liver function may need lower dose close monitor methotrex may caus toxic liver lung fibrosi pneumon even damag nervou system leukoencephalopathi myelopathi mitoxantron may caus heart problem requir monitor echocardiogram ultrasonographi heart therapi cyclophosphamid may caus bleed within bladder even bladder cancer follow doctor recommend fluid intak take medic indic immunosuppress drug multipl sclerosi mitoxantron novantron indic reduc neurolog disabl frequenc clinic relaps patient secondari chronic progress progress relaps worsen relaps remit multipl sclerosi e patient whose neurolog statu significantli abnorm relaps novantron indic treatment patient primari progress multipl sclerosi bad bug bite sex drive killer cancer tumor multipl sclerosi adult skin problem habit wreck teeth manag diabet minut erectil dysfunct type diabet warn sign health benefit sex scalp hair nail adhd symptom children therapi avail ms symptom fingolimod gilenya fingolimod gilenya daili oral medic treat ms approv us fda septemb first oral medic treat ms although exact mechan action fingolimod unclear appear work reduc number lymphocyt type white blood cell import immun inflamm process blood fingolimod taken daili capsul form cure ms shown decreas number ms flare slow develop physic disabl caus ms like mani inject therapi ms long term safeti fingolimod unknown common side effect fingolimod headach flu diarrhea back pain elev liver enzym blood cough side effect also possibl includ eye problem take drug regular ophthalmolog evalu plasmapheresi plasma exchang therapi sometim attempt treatment sever attack diseas respond corticosteroid therapi expens fda approv multipl sclerosi efficaci controversi iv immun globulin ivig although fda approv multipl sclerosi studi suggest ivig reduc rate second attack ivig administ week follow first attack research found benefit given patient condit least year yet other studi ivig given regular monthli schedul found small signific benefit improv clinic disabl fewer relaps new investig drug research addit treatment option continu advanc multipl approach investig base increas knowledg immun system abnorm cn lesion format multipl sclerosi includ approach counteract reduc immun system activ blood brain barrier disrupt neuron loss myelin loss among investig effort',\n",
       " 'mom diagnosi similar mine detect januari chest x ray pneumonia discov well spot lung non oper stage began treatment march radiat chemo abl keep yoga class walk side affect end treatment sever radiat burn pain took week get fatigu recov burn say feel better januari last pneumonia brutal place drug tagrisso prevent cancer spread see oncologist today get result last scan stay activ help treatment prayer mom',\n",
       " 'humira adalimumab inject protein antibodi use treat rheumatoid arthriti juvenil idiopath arthriti psoriat arthriti ankylos spondyl plaqu psoriasi humira also use treat crohn diseas drug tri without success treatment symptom common side effect humira includ inject site reaction red itch pain bruis swell bleed headach suffi nose sinu pain stomach pain tell doctor seriou side effect humira includ fast irregular pound heartbeat stomach pain blood stool mental mood chang sever headach easi bruis bleed dark urin yellow eye skin leg pain swell numb tingl arm hand leg feet unsteadi unexplain muscl weak difficulti speak chew swallow facial movement vision chang extrem fatigu joint pain butterfli shape rash nose cheek recommend dose humira adult patient rheumatoid arthriti ra psoriat arthriti psa ankylos spondyl mg administ everi week pediatr dosag determin child weight drug may interact humira tell doctor prescript counter medic supplement use pregnanc humira use prescrib unknown drug pass breast milk similar drug pass breast milk consult doctor breastfeed humira adalimumab side effect drug center provid comprehens view avail drug inform potenti side effect take medic complet list side effect other may occur call doctor medic advic side effect may report side effect fda fda rheumatoid arthriti slideshow take ra quiz joint friendli exercis slideshow humira consum inform get emerg medic help sign allerg reaction hive difficulti breath swell face lip tongu throat stop use adalimumab call doctor right away symptom lymphoma fever swollen gland night sweat gener feel ill joint muscl pain skin rash easi bruis bleed pale skin feel light head short breath cold hand feet pain upper stomach may spread shoulder loss appetit feel full eat small amount weight loss also call doctor new worsen psoriasi rais silveri flake skin liver problem fever bodi ach tired stomach pain right side upper stomach pain vomit loss appetit dark urin clay color stool jaundic yellow skin eye lupu like syndrom joint pain swell chest pain short breath patchi skin color worsen sunlight nerv problem numb tingl dizzi vision problem weak arm leg sign tuberculosi fever ongo cough weight loss fat muscl older adult may like develop infect cancer use adalimumab common side effect may includ headach cold symptom stuffi nose sinu pain sneez sore throat rash red bruis itch swell inject given complet list side effect other may occur call doctor medic advic side effect may report side effect fda fda read entir detail patient monograph humira adalimumab inject solut subcutan administr learn rheumatoid arthriti slideshow take ra quiz joint friendli exercis slideshow humira profession inform side effect seriou advers reaction describ elsewher label includ follow seriou infect [see warn precaut ] malign [see warn precaut ] clinic trial experi clinic trial conduct wide vari condit advers reaction rate observ clinic trial drug cannot directli compar rate clinic trial anoth drug may reflect rate observ practic common advers reaction humira inject site reaction placebocontrol trial patient treat humira develop inject site reaction erythema itch hemorrhag pain swell compar patient receiv placebo inject site reaction describ mild gener necessit drug discontinu proport patient discontinu treatment due advers reaction doubl blind placebo control portion studi patient ra e studi ra raii ra iii ra iv patient take humira placebo treat patient common advers reaction lead discontinu humira ra studi clinic flare reaction rash pneumonia infect control portion global humira clinic trial adult patient ra psa cd uc ps hs uv rate seriou infect per patient year humira treat patient versu rate per patient year control treat patient seriou infect observ includ pneumonia septic arthriti prosthet postsurg infect erysipela cellul diverticul pyelonephr [see warn precaut ] tuberculosi opportunist infect global control uncontrol clinic trial ra psa cd uc ps hs uv includ humira treat patient rate report activ tuberculosi per patient year rate posit ppd convers per patient year subgroup u canadian humira treat patient rate report activ tb per patient year rate posit ppd convers per patient year trial includ report miliari lymphat periton pulmonari tb tb case occur within first eight month initi therapi may reflect recrudesc latent diseas global clinic trial case seriou opportunist infect report overal rate per patient year case seriou opportunist infect tb fatal [see warn precaut ] autoantibodi rheumatoid arthriti control trial patient treat humira placebo treat patient neg baselin ana titer develop posit titer week two patient treat humira develop clinic sign suggest newonset lupu like syndrom patient improv follow discontinu therapi patient develop lupu nephriti central nervou system symptom impact long term treatment humira develop autoimmun diseas unknown liver enzym elev report sever hepat reaction includ acut liver failur patient receiv tnf blocker control phase trial humira mg sc everi week patient ra psa control period durat rang week alt elev x uln occur humira treat patient controltr patient sinc mani patient trial also take medic caus liver enzym elev e g nsaid mtx relationship humira liver enzym elev clear control phase trial humira patient polyarticular jia year alt elev x uln occur humira treat patient control treat patient alt common ast liver enzym test elev frequent among treat combin humira mtx treat humira alon gener elev lead discontinu humira treatment alt elev x uln occur open label studi humira patient polyarticular jia year control phase trial humira initi dose mg mg mg mg day respect follow mg everi week adult patient cd control period durat rang week alt elev x uln occur humira treat patient control treat patient phase trial humira pediatr patient crohn diseas evalu efficaci safeti two bodi weight base mainten dose regimen follow bodi weight base induct therapi week treatment alt elev x uln occur patient receiv concomit immunosuppress baselin none patient discontinu due abnorm alt test control phase trial humira initi dose mg mg day respect follow mg everi week patient uc control period durat rang week alt elev x uln occur humira treat patient control treat patient control phase trial humira initi dose mg mg everi week patient ps control period durat rang week alt elev x uln occur humira treat patient control treat patient control trial humira initi dose mg week mg week follow mg everi week start week subject hs control period durat rang week alt elev x uln occur humira treat subject control treat subject control trial humira initi dose mg week follow mg everi week start week adult patient uveiti exposur py py humira treat control treat patient respect alt elev x uln occur humira treat patient control treat patient immunogen patient studi ra ra ii ra iii test multipl time point antibodi adalimumab month period approxim adult ra patient receiv humira develop low titer antibodi adalimumab least treatment neutral vitro patient treat concomit methotrex mtx lower rate antibodi develop patient humira monotherapi versu appar correl antibodi develop advers reaction observ monotherapi patient receiv everi week dose may develop antibodi frequent receiv weekli dose patient receiv recommend dosag mg everi week monotherapi acr respons lower among antibodi posit patient among antibodi neg patient long term immunogen humira unknown patient polyarticular jia year age adalimumab antibodi identifi humira treat patient patient receiv concomit mtx incid compar humira monotherapi patient polyarticular jia year age year age older weigh kg adalimumab antibodi identifi humira treat patient one patient receiv concomit mtx patient rate develop antibodi adalimumab humira treat patient compar patient ra patient psa rate antibodi develop patient receiv humira monotherapi compar patient ra howev patient receiv concomit mtx rate compar ra adult patient cd rate antibodi develop pediatr patient crohn diseas rate antibodi develop patient receiv humira howev due limit assay condit antibodi adalimumab could detect serum adalimumab level mcg ml among patient whose serum adalimumab level mcg ml approxim total patient studi immunogen rate patient moder sever activ uc rate antibodi develop patient receiv humira howev due limit assay condit antibodi adalimumab could detect serum adalimumab level mcg ml among patient whose serum adalimumab level mcg ml approxim total patient studi immunogen rate patient ps rate antibodi develop humira monotherapi howev due limit assay condit antibodi adalimumab could detect serum adalimumab level mcg ml among patient whose serum adalimumab level mcg ml approxim total patient studi immunogen rate ps patient humira monotherapi subsequ withdrawn treatment rate antibodi adalimumab retreat similar rate observ prior withdraw anti adalimumab antibodi measur clinic trial subject moder sever hs two assay origin assay capabl detect antibodi serum adalimumab concentr declin mcg ml new assay capabl detect antiadalimumab antibodi titer subject independ adalimumab concentr use origin assay rate anti adalimumab antibodi develop subject treat humira among subject stop humira treatment week adalimumab serum level subsequ declin mcg ml approxim total subject studi immunogen rate use new titer base assay antiadalimumab antibodi titer measur hs subject treat humira antibodi adalimumab associ reduc serum adalimumab concentr gener extent reduct serum adalimumab concentr greater increas titer antibodi adalimumab appar associ antibodi develop safeti observ adult patient non infecti uveiti anti adalimumab antibodi identifi patient treat adalimumab howev due limit assay condit antibodi adalimumab could detect serum adalimumab level mcg ml among patient whose serum adalimumab level mcg ml approxim total patient studi immunogen rate use assay could measur anti adalimumab antibodi titer patient titer measur non infecti uveiti adult patient treat adalimumab correl antibodi develop safeti efficaci outcom observ data reflect percentag patient whose test result consid posit antibodi adalimumab titer highli depend assay observ incid antibodi includ neutral antibodi posit assay highli depend sever factor includ assay sensit specif assay methodolog sampl handl time sampl collect concomit medic underli diseas reason comparison incid antibodi adalimumab incid antibodi product may mislead advers reaction rheumatoid arthriti clinic studi data describ reflect exposur humira patient includ expos month expos greater one year adequ well control studi studi ra ra ii ra iii ra iv humira studi primarili placebo control trial long term follow studi month durat popul mean age year femal caucasian moder sever activ rheumatoid arthriti patient receiv mg humira everi week tabl summar reaction report rate least patient treat humira mg everi week compar placebo incid higher placebo studi ra iii type frequenc advers reaction second year open label extens similar observ one year doubl blind portion tabl advers reaction report patient treat humira placebo control period pool ra studi studi ra ra ii ra iii ra iv humira mg subcutan everi week n placebo n advers reaction prefer term respiratori upper respiratori infect sinus flu syndrom gastrointestin nausea abdomin pain laboratori test laboratori test abnorm hypercholesterolemia hyperlipidemia hematuria alkalin phosphatas increas headach rash accident injuri inject site reaction back pain urinari tract infect hypertens laboratori test abnorm report advers reaction european trial includ inject site erythema itch hemorrhag pain swell less common advers reaction rheumatoid arthriti clinic studi infrequ seriou advers reaction appear warn precaut advers reaction section occur incid less humira treat patient ra studi bodi whole pain extrem pelvic pain surgeri thorax pain cardiovascular system arrhythmia atrial fibril chest pain coronari arteri disord heart arrest hypertens encephalopathi myocardi infarct palpit pericardi effus pericard syncop tachycardia digest system cholecyst cholelithiasi esophag gastroenter gastrointestin hemorrhag hepat necrosi vomit endocrin system parathyroid disord hemic lymphat system agranulocytosi polycythemia metabol nutrit disord dehydr heal abnorm ketosi paraproteinemia peripher edema musculo skelet system arthriti bone disord bone fractur spontan bone necrosi joint disord muscl cramp myasthenia pyogen arthriti synov tendon disord neoplasia adenoma nervou system confus paresthesia subdur hematoma tremor respiratori system asthma bronchospasm dyspnea lung function decreas pleural effus special sens cataract thrombosi thrombosi leg urogenit system cystiti kidney calculu menstrual disord juvenil idiopath arthriti clinic studi gener advers reaction humira treat patient polyarticular juvenil idiopath arthriti jia trial studi jia jia ii similar frequenc type seen adult patient [see warn precaut advers reaction ] import find differ adult discuss follow paragraph studi jia humira studi patient year age polyarticular jia sever advers reaction report studi includ neutropenia streptococc pharyng increas aminotransferas herp zoster myositi metrorrhagia append seriou infect observ patient within approxim year initi treatment humira includ case herp simplex pneumonia urinari tract infect pharyng herp zoster studi jia patient experienc infect receiv humira without concomit mtx first week treatment type infect report humira treat patient gener similar commonli seen polyarticular jia patient treat tnf blocker upon initi treatment common advers reaction occur patient popul treat humira inject site pain inject site reaction respect less commonli report advers event patient receiv humira granuloma annular lead discontinu humira treatment first week treatment studi jia non seriou hypersensit reaction seen approxim patient includ primarili local allerg hypersensit reaction allerg rash studi jia patient treat humira neg baselin anti dsdna antibodi develop posit titer week treatment patient develop clinic sign autoimmun clinic trial approxim patient treat humira develop mild moder elev creatin phosphokinas cpk studi jia elev exceed time upper limit normal observ sever patient cpk level decreas return normal patient patient abl continu humira without interrupt studi jia ii humira studi patient year age year age older weigh kg polyarticular jia safeti profil patient popul similar safeti profil seen patient year age polyarticular jia studi jia ii patient experienc infect receiv humira includ nasopharyng bronchiti upper respiratori tract infect otiti media mostli mild moder sever seriou infect observ patient receiv humira studi includ dental cari rotaviru gastroenter varicella studi jia ii non seriou allerg reaction observ patient includ intermitt urticaria rash mild sever psoriat arthriti ankylos spondyl clinic studi humira studi patient psoriat arthriti psa two placebocontrol trial open label studi patient ankylos spondyl two placebo control studi safeti profil patient psa treat humira mg everi week similar safeti profil seen patient ra humira studi ra iv adult crohn diseas clinic studi humira studi adult patient crohn diseas cd four placebocontrol two open label extens studi safeti profil adult patient cd treat humira similar safeti profil seen patient ra pediatr crohn diseas clinic studi humira studi pediatr patient crohn diseas one doubl blind studi studi pcd one open label extens studi safeti profil pediatr patient crohn diseas treat humira similar safeti profil seen adult patient crohn diseas week open label induct phase studi pcd common advers reaction occur pediatr popul treat humira inject site pain inject site reaction respect total children experienc infect receiv humira studi pcd includ upper respiratori tract infect nasopharyng total children experienc seriou infect receiv humira studi pcd includ viral infect devic relat sepsi cathet gastroenter h n influenza dissemin histoplasmosi studi pcd allerg reaction observ children non seriou primarili local reaction ulcer coliti clinic studi humira studi patient ulcer coliti uc two placebocontrol studi one open label extens studi safeti profil patient uc treat humira similar safeti profil seen patient ra plaqu psoriasi clinic studi humira studi subject plaqu psoriasi ps placebo control open label extens studi safeti profil subject ps treat humira similar safeti profil seen subject ra follow except placebo control portion clinic trial ps subject humira treat subject higher incid arthralgia compar control vs hidraden suppurativa clinic studi humira studi subject hidraden suppurativa hs three placebocontrol studi one open label extens studi safeti profil subject hs treat humira weekli consist known safeti profil humira flare hs defin increas baselin abscess inflammatori nodul count minimum addit lesion document subject withdrawn humira treatment follow primari efficaci timepoint two studi uveiti clinic studi humira studi adult patient uveiti uv placebo control open label extens studi pediatr patient uveiti studi puv safeti profil patient uv treat humira similar safeti profil seen patient ra postmarket experi follow advers reaction identifi post approv use humira reaction report voluntarili popul uncertain size alway possibl reliabl estim frequenc establish causal relationship humira exposur gastrointestin disord diverticul larg bowel perfor includ perfor associ diverticul appendic perfor associ append pancreat gener disord administr site condit pyrexia hepato biliari disord liver failur hepat immun system disord sarcoidosi neoplasm benign malign unspecifi includ cyst polyp merkel cell carcinoma neuroendocrin carcinoma skin nervou system disord demyelin disord e g optic neuriti guillain barr syndrom cerebrovascular accid respiratori disord interstiti lung diseas includ pulmonari fibrosi pulmonari embol skin reaction steven johnson syndrom cutan vascul erythema multiform new worsen psoriasi sub type includ pustular palmoplantar alopecia lichenoid skin reaction vascular disord system vascul deep vein thrombosi',\n",
       " 'well theori gi tell accur standard practic endoscop histolog remiss need done scope suck day take better short long term health pancol uc sinc sept averag bm day time respons remiss therapi salofalk asa enema oral g clinic trial drug fail therapi entyvio anti madcam antibodi mg inject week studi drug remicad ml nicotin patch mg imuran mg',\n",
       " 'good minni realli wish could use curs word forum describ fistula deserv color languag uc crohn test posit map antibodi mycobacterium pg remiss chronic fistula fail seton pure tortur start stelara may mg imuran current day mostli normal stelara ivig occas',\n",
       " 'sebastian agre entir know alemtuzumab due long term use oncolog plu brain atrophi data look good yet see brain atrophi data ocrelizumab let alon posit data adam ye rituximab ocrelizamub target primarili b cell seem safe base trial result short term suspect malign take time develop present least alemtuzumab bodi opportun rebuild compet immun system without disrupt everi month',\n",
       " 'good luck reg day ago went listen top neuro speak new treatment progress ms local hospit ocrevu one went quit curiou came quit confus recommend unfortun avail canada yet said way get one train administ sound like best bet far interest hear make hear observ might make afterward thank post',\n",
       " 'bmc ophthalmol jan intravitr dexamethason implant versu intravitr anti vegf treatment treat patient retin vein occlus meta analysi gao l et al background retin vein occlus rvo common retin venou disord caus vision loss specif therapi develop controversi exist regard two treatment intravitr dexamethason implant anti vascular endotheli growth factor vegf goal studi compar effect safeti dexamethason implant anti vegf treatment rvo method pubm embas cochran librari databas search studi compar dexamethason implant anti vegf patient rvo best correct visual acuiti bcva central subfield thick cst intraocular pressur chang conjunctiv haemorrhag reduc va macular oedema extract final includ studi revman use conduct quantit analysi bia assess result four randomis control trial assess eye includ anti vegf treatment show better bcva improv mean differ [md] p cst decreas md p dexamethason implant howev dexamethason implant requir fewer inject advers effect dexamethason implant show significantli higher intraocular pressur iop cataract anti vegf treatment signific differ found conjunctiv haemorrhag reduc va macular oedema conclus anti vegf treatment show better function anatom improv less risk iop elev cataract format compar dexamethason implant thu anti vegf treatment first choic treat rvo patient pmid pmcid pmc doi',\n",
       " 'father egfr exon insert mutat found today pd l appar rare exon insert mean immunotherapi option treatment plan right keytruda carboplatin pemetrex anyon combin',\n",
       " 'repli post flower girl hi year got pregnant daughter cimzia mg prednison throughout pregnanc well nurs healthi perfect year old crohn flare littl first trimest steroid ok take pregnant got control found last week pregnant time littl differ entyvio low dose azathiaprin scare well med moreno azathiaprin gi doc rheumatologist told safe everyth read say mention drug think sinc found taken doc gonna happi',\n",
       " 'hello snigdha father diagnos lung cancer juli took tarceva iressa tagrisso took tagrisso last ten month unfortun pass away week ago hospit sinc decemb rd end last year live well travel lot collater damag tagrisso realli good like tell hospit admiss heart issu doctor say may caus tagrisso father done heart exam start tagrisso know exam could made live mayb would good talk cardiologist send posit vibe hope mom continu without pain think mani year hapi father lot time tell much love pleas contact whenev want best wish lm',\n",
       " 'first recommend stanford oncologist last recommend regular kaiser oncologist kkh diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'mention recent develop issu interest regard progress ms thu creat immpress massiv ongo activ around yet care examin reveal talk drug way enhanc drug trial design even inform quest umbrella drug trial tend support argument interpet trial basic research wherev hard evid present eagerli set asid circumstanti took step back could see disproport drug orient road offer destin fail long run rememb worn away hype inf gilenya tysabri bg alemtuzumab still talk newer drug stretch expect point break first b memori b fruit road research patient mani drug market chang cours get back answer basic ms',\n",
       " 'cours shortli post everyth good updat began develop gilenya cough like deep bronchiti like cough cough anyth also realli short breath particularli even toward end week wonder increas run around discov ga tank much smaller use huge adjust see neuro wednesday normal follow obvious discuss',\n",
       " 'rituxan main ms drug rituxan technic approv fda food drug administr multipl sclerosi sister ocrelizumab come explain comparison two post http www multipleexperi org ocrelizumab versu rituximab rituxan basic thing frustrat fda recogn biotin vitamin mg per day base clinic studi done link studi month take biotin post need specialti pharmaci get counter high dosag need prescript http www multipleexperi org high dose biotin multipl sclerosi month alpha lipoic acid vitamin mg also studi done regard multipl sclerosi inform studi post http www multipleexperi org alpha lipoic acid multipl sclerosi gabapentin mg gener neurontin take time day take twitch get weird back like seizur get baclofen mg take time day take muscl relax anti spastic agent toviaz mg overact bladder godsend topiram mg migrain also godsend relpak mg migrain take need b vitamin mcg vitamin mg fiber pill',\n",
       " 'last updat januari share comment tell friend editor healthday consid import develop neurolog decemb roundup includ latest research news journal articl well fda approv regulatori chang like affect clinic practic effect bup tap cathet chronic pain breast recon friday dec healthday news patient undergo autolog breast reconstruct incid chronic postsurg pain cpsp differ patient receiv transversu abdomini plane tap cathet deliv bupivacain salin bolu accord studi publish onlin dec pain practic full text subscript payment may requir iron defici anemia up risk hear loss u adult thursday dec healthday news among u adult hear loss associ iron defici anemia ida accord studi publish onlin dec jama otolaryngolog head neck surgeri full text case report adopt cell tx show promis glioblastoma thursday dec healthday news treatment autolog chimer antigen receptor car engin cell target tumor associ antigen interleukin receptor alpha il r associ tumor regress recurr multifoc glioblastoma accord case report publish dec issu new england journal medicin full text subscript payment may requir selumetinib activ children neurofibromatosi type thursday dec healthday news oral select inhibitor mapk kinas selumetinib activ children neurofibromatosi type inoper plexiform neurofibroma accord studi publish dec issu new england journal medicin full text subscript payment may requir post lunch nap tie better cognit elderli wednesday dec healthday news moder post lunch nap tie better cognit older adult accord studi publish onlin dec journal american geriatr societi full text subscript payment may requir bell palsi tie quadrival meningococc vaccin wednesday dec healthday news bell palsi prespecifi advers event associ menacwi crm quadrival meningococc conjug vaccin accord studi publish onlin dec pediatr full text opicapon levodopa adjunct cut motor fluctuat pd tuesday dec healthday news patient parkinson diseas pd receiv levodopa therapi experienc end dose motor fluctuat treatment mg day opicapon associ reduct mean daili time accord studi publish onlin dec jama neurolog full text subscript payment may requir editori subscript payment may requir person health care spend continu soar u tuesday dec healthday news consider increas person health care spend unit state highest amount diabet ischem heart diseas low back neck pain accord studi publish dec issu journal american medic associ full text editori subscript payment may requir dementia older women tie year rate weight loss tuesday dec healthday news women surviv late life rate weight loss year associ develop mild cognit impair mci dementia accord studi publish onlin dec journal american geriatr societi full text subscript payment may requir research post craniotomi analgesia uneven qualiti friday dec healthday news studi report pharmacolog adjuv analges modal post craniotomi pain control signific diverg research method accord review publish onlin dec pain practic full text subscript payment may requir induc hypothermia futil convuls statu epilepticu friday dec healthday news critic ill patient convuls statu epilepticu hypothermia ad standard care associ signific improv good function outcom day accord studi publish dec issu new england journal medicin full text subscript payment may requir va echo program feasibl manag sleep disord thursday dec healthday news u depart veteran affair extens commun healthcar outcom va echo program feasibl increas comfort manag common sleep complaint accord research publish onlin dec annal american thorac societi full text subscript payment may requir ocrelizumab target role b cell multipl sclerosi thursday dec healthday news ocrelizumab new fulli human monoclon anti cd antibodi caus b cell deplet associ lower relaps rate lower rate progress among patient relaps primari progress multipl sclerosi respect accord research publish onlin dec new england journal medicin abstract hauser full text abstract montalban full text editori risk postconcuss symptom earli exercis tuesday dec healthday news particip physic activ within seven day injuri associ reduc rate persist postconcuss symptom ppc accord studi publish dec issu journal american medic associ full text editori subscript payment may requir health care provid burnout neg affect qualiti safeti tuesday dec healthday news health care provid burnout neg associ qualiti safeti health care accord meta analysi publish recent journal gener intern medicin full text subscript payment may requir therapeut hypothermia benefit adult tbi tuesday dec healthday news adult children traumat brain injuri therapeut hypothermia benefici accord meta analysi publish onlin dec critic care medicin full text subscript payment may requir dea announc critic chang registr renew process monday dec healthday news drug enforc administr dea announc critic chang registr renew process accord report publish american academi famili physician inform noncardiovascular caus death common chd patient monday dec healthday news patient coronari heart diseas chd mortal often due noncardiovascular caus accord studi publish jan issu american journal cardiolog full text subscript payment may requir dysglycemia affect brain structur cognit senior monday dec healthday news older adult dysglycemia associ brain structur cognit accord studi publish onlin dec journal american geriatr societi full text subscript payment may requir ischem stroke risk eight week pci friday dec healthday news risk ischem stroke highest first two day percutan coronari intervent pci decreas gradual stay elev eight week accord studi publish jan issu american journal cardiolog full text subscript payment may requir integr neurolog medic home cut health care use friday dec healthday news model neurologist integr co locat primari care leverag curbsid electron tradit consult reduc unnecessari health care use accord studi publish onlin dec journal evalu clinic practic full text subscript payment may requir mri up diagnost accuraci fetal brain abnorm friday dec healthday news follow magnet reson imag mri mid pregnanc ultrasound could help improv diagnosi possibl fetal brain abnorm accord studi publish onlin dec lancet full text subscript payment may requir editori subscript payment may requir zika relat birth defect extens thought thursday dec healthday news zika abil damag infant brain may even far reach insidi previous thought two new studi suggest full text editori abstract full text editori fda issu new safeti info use anesthesia thursday dec healthday news repeat lengthi use longer three hour gener anesthet sedat drug may harm develop brain fetus children younger year old u food drug administr warn wednesday drug safeti commun inform stroke fib recurr low one year af ablat wednesday dec healthday news stroke atrial fibril af recurr low one year af ablat accord studi publish onlin dec journal cardiovascular electrophysiolog full text subscript payment may requir outcom base price suggest new costli drug wednesday dec healthday news outcom base price novel expens biopharmaceut support idea opinion piec publish onlin dec annal intern medicin full text subscript payment may requir cathet ablat fib link stroke elderli tuesday dec healthday news cathet ablat ca atrial fibril af associ stroke patient least year old associ complic accord studi publish onlin dec journal cardiovascular electrophysiolog full text subscript payment may requir blocker may appropri dementia patient tuesday dec healthday news blocker may medicin choic nurs home resid dementia accord studi publish onlin dec jama intern medicin full text subscript payment may requir editori subscript payment may requir risk ischem hemorrhag stroke type diabet tuesday dec healthday news risk ischem hemorrhag stroke increas type diabet increment increas risk increas hemoglobin c hba c accord studi publish novemb issu journal intern medicin full text effect statin alzheim may depend gender race monday dec healthday news effect statin use alzheim prevent may depend specif statin gender race ethnic patient accord studi publish onlin dec jama neurolog full text cdc colombia see increas zika relat microcephali monday dec healthday news colombia experienc sharp increas case infant microcephali accord research publish dec earli releas issu u center diseas control prevent morbid mortal weekli report full text prefront brain activ may predict risk fall elderli thursday dec healthday news measur healthi older adult brain activ may help determin futur risk fall accord studi publish onlin dec neurolog abstract full text subscript payment may requir higher nt probnp tie lower brain volum older adult thursday dec healthday news older adult without dementia higher n termin pro b type natriuret peptid nt probnp associ lower total brain volum accord studi publish onlin dec radiolog abstract full text nusinersen show promis spinal muscular atrophi thursday dec healthday news experiment drug infant spinal muscular atrophi type appear effect accord research publish onlin dec lancet full text subscript payment may requir editori subscript payment may requir read taken clinic may underestim ambulatori bp wednesday dec healthday news ambulatori blood pressur may better indic health risk clinic blood pressur accord new report publish onlin dec circul full text subscript payment may requir editori subscript payment may requir preval disabl percent u medic school wednesday dec healthday news preval disabl percent among medic student u allopath medic school accord research letter publish dec issu journal american medic associ theme issu medic educ full text subscript payment may requir learn intervent improv med student well wednesday dec healthday news specif learn intervent may improv emot well among medic student accord review publish dec issu journal american medic associ theme issu medic educ full text subscript payment may requir editori subscript payment may requir patient mortal end rotat team transit tuesday dec healthday news hospit patient hand origin medic team new set caregiv may ultim face higher risk earli mortal accord research publish dec issu journal american medic associ theme issu medic educ full text subscript payment may requir full text subscript payment may requir editori subscript payment may requir depress suicid ideat preval medic student tuesday dec healthday news preval depress depress symptom suicid ideat percent respect among medic student accord review publish dec issu journal american medic associ theme issu medic educ full text subscript payment may requir editori subscript payment may requir potenti unsaf med script dual user dementia tuesday dec healthday news veteran dementia veteran affair va medicar part dual system user increas rate potenti unsaf medic pum prescrib accord studi publish onlin dec annal intern medicin full text subscript payment may requir editori subscript payment may requir colon diverticular diseas may increas dementia risk tuesday dec healthday news patient colon diverticular diseas may increas risk dementia accord studi publish nov journal gastroenterolog hepatolog full text subscript payment may requir mani postconcuss syndrom recov monday dec healthday news minor patient postconcuss syndrom pc recov two third recov within one year accord studi publish onlin nov journal neurotrauma full text augment realiti game may help reliev phantom limb pain friday dec healthday news ampute experi phantom limb pain may benefit play virtual realiti game simul movement miss limb accord studi publish onlin dec lancet full text subscript payment may requir editori subscript payment may requir vitamin pregnanc might help prevent ms offspr friday dec healthday news newborn low level vitamin may higher odd develop multipl sclerosi ms later life accord studi publish onlin nov neurolog abstract full text subscript payment may requir editori subscript payment may requir csf rt quic high diagnost specif sensit prion friday dec healthday news cerebrospin fluid csf real time quak induc convers rt quic high diagnost specif sensit prion diseas accord studi publish onlin nov annal neurolog full text subscript payment may requir dabigatran may better warfarin bleed episod friday dec healthday news dabigatran less like warfarin caus recurr bleed atrial fibril patient experienc major bleed event accord studi publish onlin dec stroke full text subscript payment may requir cdc fewer u famili struggl pay medic bill thursday dec healthday news number peopl famili problem pay medic bill fell nearli million first six month accord report publish u center diseas control prevent nation center health statist nch inform',\n",
       " 'hi rebif year rotat inject site rememb take pain relief afterward et flu symptom use alo vera gel inject site relaps rebif go fingolimod good luck',\n",
       " 'tarceva month cope rash except eye lid eye drive insan refrain scratch use moisturis sorbelenerecommend oncolog nurs find use everi min skin dri fast bit depress honest perhap someth better sorbelen sharon',\n",
       " 'hi thank repli offici offer anyth realli look treatment would treat psoriasi well ms neuro mention rituximab would wait see dermatologist letter said could move one fairli easili want take advic first dermatologist said retuximab wouldnt work heard say probabl give gilenya scare side effect eye alreadi risk diabet know risk will take ms nurs sent info three treatment read support worri lean toward tysabri know say know explain well enough guess wait see thank repli appreci xx',\n",
       " 'anyon return previou chemo drug given period',\n",
       " 'sorri lab forc doctor shop alreadi got doctor perfectli happi suck massiv forc find new gp move three year ago current one good gp still miss old one sometim plu lot lax prescrib stuff know reason want stay gp yeah gi seven year look forward day leav replac good make decis whether switch hospit hope find good gi quickli dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'problem know hard lone journey happi help doctor feel tecentriq keep stabl great random thought insur cover tecentriq could tri appeal drugmak sometim provid medic free charg return monitor progress consid gamma knife brain lesion surgic remov mom doctor basic decid would approach get littl spot pop tecentriq prove work probabl bridg journey nowaday mani advanc come mani cancer seem breakthrough everi year two new treatment sclc nonexist last year someth happen year ago seem like lot promis develop everi month idea new treatment come work bridg get patient next point bridg stop work usual point someth new provid next bridg hope anyway realli best luck husband feel',\n",
       " 'hahaha thank laugh f uc symptom start januari diagnosi juli colonoscopi balsalazid juli januari predison sept nov dec jan march present mg day one dose lialda march confirm cannot toler mesalamin doctor want humira worri side effect',\n",
       " 'hi rich told inject sever tablet form dmd tecfidera gilenya aubagio mayb think right could ask neuro carol x',\n",
       " '[publish onlin june ] j neurooncol doi margolin k ernstoff ms hamid et al ipilimumab patient melanoma brain metastas open label phase trial lancet oncol goldberg sb getting sn mahajan et al pembrolizumab patient melanoma non small cell lung cancer untreat brain metastas earli analysi non randomis open label phase trial lancet oncol nation comprehens cancer network melanoma nccn guidelin version http nccn org updat februari access juli',\n",
       " 'may start target treatment medic taflinar mekinist fatigu worst side effect exper read',\n",
       " 'http www medicalnewstoday com articl php new multipl sclerosi culprit identifi still unclear caus multipl sclerosi new research close faulti immun system mechan involv develop condit new research identifi anoth type immun cell may play role ms multipl sclerosi ms autoimmun diseas caus immun system mistakenli attack myelin myelin substanc coat axon project allow neuron connect transmit inform process known demyelin affect correct function central nervou system condit character problem balanc coordin well eyesight name effect unit state ms affect peopl research still know sure caus ms littl littl uncov mechan play reveal cellular culprit involv neurologist roland martin immunologist mireia sospedra univers zurich univers hospit zurich switzerland colleagu shown type immun cell call b cell key autoimmun reaction character ms studi whose result publish journal cell scientist explain b cell influenc activ anoth type immun cell cell caus inflamm abl show first time certain b cell cell immun system produc antibodi activ specif cell caus inflamm brain nerv cell lesion roland martin b cell influenc cell studi ms tend focu role play cell develop condit sinc cell task trigger appropri immun respons detect presenc pathogen cell malfunct mistak healthi cell bodi pathogen caus harm lesion inflamm associ autoimmun diseas ms martin colleagu howev found cell may actual mistakenli activ special immun cell b cell becam appar research observ effect certain drug use treat ms martin say class ms drug call rituximab ocrelizumab led us believ b cell also play import part pathogenesi diseas drug author note halt brain inflamm remov b cell suggest immun cell ultim respons cell activ chain reaction order better understand role play b cell inflamm research analyz blood sampl peopl ms experiment vitro method notic b cell interact special cell boost activ influenc divid thu feed attack cycl becam clear b cell caus cell activ elimin former latter stop prolifer mean explain previous unclear mechan ms drug explain martin investig also note activ cell studi blood sampl includ popul cell activ brain inflamm relat ms martin team suggest cell abl read protein releas b cell recogn nerv cell brain scientist say cell first activ peripher blood migrat brain end attack myelin find explain new ms drug take effect also pave way novel approach basic research therapi ms say martin',\n",
       " 'saw peggi thank kc ruth suggest worri go rhumetologist suggest someth might interfer opdivo alway concern new med treatment look descript side effect opdivo take coleridg',\n",
       " 'hello everyon new first post made diagnos ms may year sever sudden seriou attack januari may diagnosi delay also grave diseas post thyroidectomi amongst myriad symptom biggest complaint intens chest pain doctor focus chest pain basic ignor symptom month almost relief receiv diagnosi final refer physician examin properli order necessari mri start transit om lifestyl best could soon diagnos great medit use music lot though make huge effort diet exercis period struggl diet fulli adher difficulti social situat famili friend realli enjoy way eat one thing adher though flax oil take fish oil vitamin e simpli feel better take fish oil still use flax oil toast instead butter includ linse diet also start take vitamin get serum level around least got nmol l nmol l winter mri thing start move quickli dmd front base mri symptom neurologist want dmd asap ran option right examin take radiolog report rule interferon bat discuss tecfidera aubagio gilenya tysabri lemtrada told prefer would tysabri lemtrada two sound terrifi pretti overwhelm left clinic first appoint bare hold togeth cri walk home consid lemtrada multipl autoimmun diseas histori grave diseas consid tecfidera time handl prospect drug caus nausea like hideou nausea month stage end focus gilenya tysabri pre screen test lean toward gilenya knew jcv statu took month result back knew jcv neg enough time gather inform emot reconcil risk pml chose start tysabri first line treatment treatment moment realli glad chose drug toler well basic side effect week first infus anoth attack far milder earlier year pain loss mobil patch numb leg torso spread bit weak slight worsen balanc second infus felt like rubbish whole month extrem letharg listless worst brain fog ever experienc unpleas third treatment turn point though notic improv infus could feel head clear felt refresh full energi treatment ran skip hospit day amaz gotten quit kick last treatment still steadi improv feel linger symptom paresthesia feet final went away symptom current white flash peripher left eye occasion pain rib memento one spinal lesion hope continu drug without seriou event tend joke belittl risk pml one way deal om focu tri make decis go also huge help make futur feel lot less bleak',\n",
       " 'conclus real life result suggest intravitr dexamethason implant effect safe eye dme ophthalmologica sourc ophthalmologica',\n",
       " 'adalimumab rch consum medicin inform leaflet leaflet answer common question humira contain avail inform take place talk doctor pharmacist medicin risk benefit doctor weigh risk use medicin benefit expect concern use medicin ask doctor pharmacist read leaflet care use humira keep medicin may need read humira use humira use treatment rheumatoid arthriti humira use reduc sign symptom moder sever activ rheumatoid arthriti pain diseas joint well slow protect damag joint sign symptom rheumatoid arthriti includ joint pain tender swell stiff polyarticular juvenil idiopath arthriti humira use reduc sign symptom moder sever activ polyarticular juvenil idiopath arthriti inflammatori diseas involv multipl joint patient year age older enthes relat arthriti humira use treat enthes relat arthriti inflammatori diseas joint children psoriat arthriti humira use reduc sign symptom well inhibit progress joint damag moder sever activ psoriat arthriti diseas joint skin similar rheumatoid arthriti well psoriasi factor ankylos spondyl humira use reduc sign symptom patient activ ankylos spondyl inflammatori diseas spine sign symptom ankylos spondyl includ back pain morn stiff crohn diseas humira use treatment moder sever crohn diseas inflammatori diseas digest tract adult children age year reduc sign symptom diseas induc maintain period symptom longer present humira given patient respond well enough convent therapi lost respons intoler infliximab anoth medicin use treat crohn diseas ulcer coliti humira use treatment moder sever ulcer coliti inflammatori bowel diseas patient respond well enough convent therapi intoler medic contraind therapi patient show respons within week continu treatment psoriasi humira use treat chronic plaqu psoriasi inflammatori diseas skin plaqu psoriasi also affect nail caus crumbl thicken lift away nail bed pain humira use moder sever form diseas adult sever form children adolesc year age respond well enough topic therapi phototherapi cannot given treatment hidraden suppurativa humira use treatment adult adolesc year age activ moder sever hidraden suppurativa acn inversa chronic often pain inflammatori skin diseas symptom may includ tender nodul lump abscess boil may leak pu commonli affect specif area skin breast armpit inner thigh groin buttock scar may also occur affect area doctor schedul follow appoint check progress continu treatment uveiti humira use treat non infecti intermedi posterior pan uveiti inflammatori diseas uveal tract eye humira use adult respond well corticosteroid whose diseas flare taper corticosteroid sign symptom includ inflamm vision impair pain activ ingredi medicin adalimumab fulli human monoclon antibodi monoclon antibodi protein made type blood cell fight foreign protein bodi adalimumab recognis bind specif protein tumour necrosi factor tnf alpha present increas level inflammatori diseas rheumatoid arthriti polyarticular juvenil idiopath arthriti enthes relat arthriti psoriat arthriti ankylos spondyl crohn diseas ulcer coliti hidraden suppurativa psoriasi uveiti ask doctor question medicin prescrib doctor may prescrib anoth reason medicin addict medicin avail doctor prescript long term effect humira growth develop children known use humira must use use humira allergi medicin contain adalimumab ingredi list end leaflet symptom allerg reaction may includ chest tight short breath wheez difficulti breath swell face lip tongu part bodi hive itch skin rash sever infect includ infect bloodstream activ tuberculosi infect occur bodi natur defenc lower alreadi use anakinra kineret medicin rheumatoid arthriti moder sever heart failur use medicin expiri date print label blister carton packag torn show sign tamper return pharmacist dispos use tell doctor allergi medicin food preserv dye tell doctor follow medic condit infect includ long term localis infect exampl leg ulcer histori recurr infect condit increas risk infect histori tuberculosi close contact someon tuberculosi symptom tuberculosi persist cough weight loss listless mild fever infect appear therapi tell doctor immedi case tuberculosi report patient treat humira doctor check sign symptom tuberculosi start medicin includ thorough medic histori chest x ray tuberculin test hepat b viru hbv carrier activ hbv think might risk contract hbv humira caus reactiv hbv peopl carri viru rare case especi take medicin suppress immun system reactiv hbv life threaten fungal infect live travel countri fungal infect common infect may develop becom sever take humira suffer uveiti doctor may check sign symptom neurolog diseas start medicin multipl sclerosi diseas nervou system demyelin diseas allerg reaction chest tight wheez dizzi swell rash blood disord low resist diseas heart condit includ congest heart failur heart attack worsen exist heart condit cancer autoimmun diseas lung diseas call chronic obstruct pulmonari diseas kidney liver problem tell doctor schedul vaccin tell doctor schedul vaccin recommend children possibl brought date immunis agreement current immunis guidelin prior initi humira therapi patient receiv humira receiv live vaccin tell doctor psoriasi suffer undergon phototherapi tell doctor pregnant plan becom pregnant consid use adequ contracept prevent pregnanc continu use least month last humira treatment humira use pregnanc clearli need pregnanc studi found higher risk birth defect mother use humira pregnanc compar mother diseas use humira use humira pregnanc babi may higher risk get infect import tell babi doctor healthcar profession humira use pregnanc babi receiv vaccin tell doctor breastfeed plan breastfe known whether humira pass breast milk breastfeed doctor may advis stop breastfeed use medicin told doctor pharmacist tell start use humira take medicin tell doctor pharmacist take medicin includ get without prescript pharmaci supermarket naturopath health food shop medicin humira may interfer doctor pharmacist inform medicin care avoid use medicin tell doctor pharmacist take anakinra kineret abatacept orencia medicin use treat form arthriti take two medicin togeth may increas risk infect humira taken togeth medicin use treat arthriti methotrex steroid pain medic includ non steroid anti inflammatori drug nsaid ibuprofen tell doctor take medicin treat condit use humira follow direct given doctor pharmacist care may differ inform contain leaflet understand instruct label leaflet ask doctor pharmacist help alway use humira exactli doctor instruct check doctor pharmacist unsur much use adult rheumatoid arthriti psoriat arthriti ankylos spondyl usual dose adult rheumatoid arthriti psoriat arthriti ankylos spondyl one mg inject fortnightli crohn diseas ulcer coliti usual dose adult crohn diseas ulcer coliti initi dose mg given four inject one day two inject day two day follow mg two week later given one day mg start two week later continu everi two week psoriasi uveiti usual dose adult psoriasi uveiti initi dose mg given inject follow mg given fortnightli start one week initi dose adult psoriasi depend respons doctor may increas dose frequenc mg everi week hidraden suppurativa usual dose adult hidraden suppurativa initi dose mg given inject one day inject per day two consecut day follow mg dose inject day two week later two week continu dose mg everi week doctor may prescrib medicin condit arthriti take medicin children polyarticular juvenil idiopath arthriti usual dose children polyarticular juvenil idiopath arthriti enthes relat arthriti depend bodi weight bodi weight kg usual dose mg given fortnightli bodi weight kg less kg recommend dose mg fortnightli bodi weight kg less kg usual dose mg fortnightli crohn diseas usual dose children crohn diseas depend bodi weight sever diseas bodi weight kg start dose mg given four inject one day two inject two day follow mg two week later given one day two week continu mg mg everi two week depend sever diseas bodi weight less kg start dose mg given two inject one day follow mg two week later two week continu mg mg everi two week depend sever diseas treatment crohn diseas children support good nutrit allow appropri growth psoriasi usual dose children psoriasi depend bodi weight bodi weight kg usual dose mg given weekli first two week fortnightli bodi weight less kg usual dose mg given weekli first two week fortnightli hidraden suppurativa usual dose adolesc year weigh least kg hidraden suppurativa initi dose mg two mg inject one day follow mg fortnightli start one week later inadequ respons doctor may increas dose mg everi week recommend use antisept wash daili affect area humira effect child condit week doctor may tell stop use humira use humira inject skin inject self administ given anoth person exampl famili member friend proper train inject techniqu doctor assist instruct prepar give inject humira use humira pre fill syring provid product inform inject instruct leaflet product read instruct care follow step step instruct explain self inject medicin attempt self inject sure understand prepar give inject doctor assist also show best self inject mix inject syring vial medicin set wash hand thoroughli set follow item clean surfac one pre fill syring humira inject one alcohol pad look expiri date syring use product month year shown check colour chang particl solut cloudi discolour flake particl must use use solut frozen choos inject site choos site thigh stomach except area around navel chang place inject time becom sore one area new inject given least cm last inject site rotat thigh stomach prepar inject site inject area skin tender redden bruis hard may mean infect wipe inject site enclos alcohol pad use circular motion touch area inject inject humira shake syring presenc one bubbl syring normal remov cap needl syring care touch needl let touch surfac one hand gentli grasp clean area skin hold firmli hand hold syring degre angl skin groov side one quick short motion push needl way skin releas skin first hand push plunger inject solut take second empti syring syring empti remov needl skin care keep angl insert use thumb piec gauz appli pressur inject site second littl bleed may occur rub inject site use plaster want throw away suppli humira syring never reus never recap needl inject humira immedi throw away use syring special sharp contain instruct doctor nurs pharmacist keep contain reach sight children long use keep use humira long doctor tell humira cure condit help control symptom ask doctor sure long take medicin forget use forget give inject inject next dose humira soon rememb inject next dose would origin schedul day forgotten dose tri make miss dose take one dose time use much overdos accident inject humira frequent told doctor immedi telephon doctor poison inform centr australia telephon go accid emerg nearest hospit even sign discomfort poison may need urgent medic attent alway take outer carton medicin use humira thing must check doctor receiv vaccin recommend children possibl brought date immunis agreement current immunis guidelin prior initi humira therapi vaccin oral polio vaccin given receiv humira becom pregnant use humira tell doctor immedi start new medicin tell doctor use humira tell doctor dentist pharmacist treat use humira go surgeri tell surgeon anaesthetist use humira doctor may recommend temporari discontinu humira keep doctor appoint progress check thing must give humira anyon els even condit use humira treat complaint unless doctor tell stop take humira without check doctor take humira anakinra kineret togeth take humira abatacept orencia togeth anakinra abatacept medicin use treat certain form arthriti thing care import tell doctor get symptom fever wound feel tire dental problem might get infect easili receiv humira treatment infect may seriou includ tuberculosi infect caus virus fungi bacteria opportunist infect sepsi may rare case life threaten doctor may recommend temporari discontinu humira care drive oper machineri know humira affect effect abil drive use machin whilst take medicin known side effect tell doctor soon possibl problem use humira even think problem connect medicin list leaflet medicin unwant side effect sometim seriou time may need medic attent get side effect alarm list possibl side effect may experi ask doctor pharmacist question may tell doctor immedi go accid emerg nearest hospit experi follow sign allerg reaction chest tight short breath wheez difficulti breath swell face lip tongu part bodi hive itch skin rash sign symptom suggest heart failur short breath exert upon lie swell feet sign symptom suggest blood disord persist fever bruis bleed pale list includ seriou side effect may need urgent medic attent hospitalis side effect uncommon tell doctor soon possibl notic follow sign tuberculosi persist cough weight loss listless fever sign infect fever malais wound dental problem burn urin might get infect easili receiv humira treatment sign nervou system disord numb tingl throughout bodi arm leg weak doubl vision sign soft tissu infect bump open sore heal list includ seriou side effect may need urgent medic attent seriou side effect rare tell doctor notic follow worri inject site reaction includ pain swell red itch upper respiratori tract infect includ cold runni nose sinu infect sore throat lower respiratori tract infect bronchiti pneumonia ear infect eye inflamm inflamm eye lid chang vision headach dizzi vertigo sensat disord increas cough sore throat abdomin symptom nausea vomit abdomin pain rash itch fatigu mouth inflamm ulcer muscl bone pain elev lipid depress anxieti increas heart rate viral infect includ flu cold sore blister chicken pox shingl bacteri infect includ urinari tract infect fungal infect chang mood feel low anxiou list includ common side effect humira usual mild short live laboratori result side effect observ humira may symptom may discov blood test includ increas lipid blood elev liver enzym increas uric acid blood tell doctor pharmacist notic anyth els make feel unwel side effect list may occur peopl case certain kind cancer patient take humira tnf blocker peopl seriou rheumatoid arthriti diseas long time may higher chanc get kind cancer affect lymph system call lymphoma affect blood call leukaemia take humira risk may increas rare occas specif sever type lymphoma observ patient take humira patient also treat azathioprin mercaptopurin addit rare case skin cancer observ patient take humira new skin lesion appear therapi exist lesion chang appear tell doctor case cancer lymphoma patient specif type lung diseas call chronic obstruct pulmonari diseas copd treat anoth tnf blocker copd heavi smoker discuss doctor whether treatment tnf blocker appropri use humira storag keep pre fill syring pack time use keep humira refriger c c freez keep humira refriger way children cannot get keep medicin right temperatur travel import travel car bu train plane form transport store pre fill syring room temperatur c maximum period day protect light remov refriger store room temperatur syring must use within day discard even return refriger write date first remov syring refriger label check long dispos inject humira immedi throw away use pre fill syring special sharp contain instruct doctor nurs pharmacist doctor tell stop use humira expiri date pass ask pharmacist medicin left product descript look like humira mg ml clear colourless steril solut mg adalimumab ml solut syring aust r mg adalimumab ml solut syring aust r mg adalimumab ml solut syring aust r follow pre fill syring pack avail pre fill syring alcohol pad humira mg ml humira mg ml pre fill syring pre fill syring alcohol pad humira mg ml pre fill syring ingredi humira contain adalimumab activ ingredi humira mg ml mg ml mg ml pre fill syring also contain ingredi includ mannitol citric acid monohydr sodium citrat dihydr monobas sodium phosphat dihydr dibas sodium phosphat dihydr sodium chlorid polysorb water inject distributor humira distribut australia abbvi pti ltd abn riordan street mascot nsw leaflet prepar',\n",
       " 'bit surpris honest background retinopathi pop convers optometrist still effect background retinopathi proxim macula concern becom maculopathi significantli observ nh clinic trial eylea perform best three drug offer macula odoema swell describ first post',\n",
       " 'del egfr l r egfr wt fig order nice mirror trend experiment determin affin inhibitor quantifi differenti bind tki variou mutant egfr calcul bind free energi use mmpbsa approach cours afatinib coval bond egfr henc one cannot use classic method comput bind energet carri use quantum mechan method outsid scope current studi therefor calcul bind free energi erlotinib gefitinib wildtyp mutant l r del egfr explor whether model construct accord experi clear calcul mirror experiment trend bind affin experiment ic figur differ experiment affin wild type egfr first glanc much larger calcul one howev upon care examin experiment data avail literatur [ ] find spread valu wild type egfr quit larg shown error bar',\n",
       " 'epicaptur urin dna methyl test earli detect aggress prostat cancer e reilli et al jco precis oncolog januari use artifici intellig detect cervic cancer nih director blog januari cancer surgeri genom era winter c et al british journal surgeri e e commentari role breast cancer surgeon person cancer care clinic util gene assay iglehart j dirk et al american journal surgeri jun cost effect genet test breast cancer risk respons fols henri et al cancer prevent research philadelphia pa apr cyp genotyp use tamoxifen breast cancer berri donald et al journal nation cancer institut sep data mine digit health record resourc constrain set reveal time immunophenotyp associ improv breast cancer outcom l pez pineda arturo et al bmc cancer sep experi attitud toward risk recurr test women breast cancer systemat review leggett laura e et al breast cancer research treatment apr genet cancer suscept test increas technolog increas complex yu peter paul et al journal clinic oncolog offici journal american societi clinic oncolog nov impact web base case conferenc cancer genet train outcom commun base clinician blazer kathleen r et al journal cancer educ offici journal american associ cancer educ jun inform variou databas cdc inform nih resourc cdc author public state public health genom program tier tabl epidemiolog studi translat implement studi evid synthesi guidelin review commentari tool method ethic legal social issu amd weekli clip gwa catalog grant support public genet test gtr genet diseas omim pubm review pubm clinic queri pharmgkb cdc inform databas databas includ gener cdc public health inform specif diseas health relat topic avail databas display genom inform variou cdc web page user also encourag conduct search cdc websit addit inform prevent cervic cancer st centuri cdc public health grand round januari famili histori cancer cdc divis cancer control prevent screen colorect cancer bowen et al cdc blog post august skin cancer prevent progress report cdc use genet risk score cancer screen yet robert et al cdc blog post juli cancer men sun safe selfi nearli million peopl treat skin cancer year unit state skin cancer seriou expens sometim even deadli marleah stori marleah breast cancer young age run famili prevent colorect cancer ca gelb cdc blog post mar thing prevent cancer look gene famili health cancer histori affect futur protect daughter cervic cancer colorect cancer famili histori cdc youtub video breast cancer awar fast fact breast cancer cme activ clinic antholog educ medic provid breast cancer young women know screen take action lower breast ovarian cancer risk summer sun safeti protect uv radiat get screen prostat cancer improv health qualiti life cancer cancer precis medicin popul scienc ahead mj khouri et al cdc blog post viral hepat liver cancer risk factor colorect cancer colorect cancer awar breast cancer cancer tobacco use tobacco use caus mani cancer cdc vital sign novemb lung cancer awar breast cancer young women cancer moonshot hereditari cancer popul genet screen mj khouri et al cdc blog post octob breast ovarian cancer breast cancer awar prostat cancer awar famili member colorect colon cancer risk factor skin cancer u healthcar facil capac meet colorect cancer screen goal news releas june cancer famili histori use genom prevent watch video cdc public health grandround april health dispar cancer liver cancer inform much know colorect cancer take cdc quiz risk factor colorect cancer colorect cancer screen save live talk doctor get screen cdc blog post famili histori eileen cancer survivor stori famili histori cervic uterin cancer get check symptom recommend realiti person stori hereditari cancer tell us r green fisk cdc blog post cervic cancer awar protect daughter cervic cancer person prescript surviv cancer g hilliard cdc cancer blog post novemb bring brave campaign breast ovarian cancer run famili fast fact vagin vulvar cancer [pdf kb] fast fact ovarian cancer [pdf kb] fast fact uterin endometri cancer [pdf kb] gynecolog cancer awar risk factor prostat cancer hereditari breast ovarian cancer public health implement toolkit cdc ovarian cancer inform colorect cancer awar genet test hereditari colorect cancer famili health histori lung cancer risk factor lung cancer lower lung cancer risk hpv cancer futur epidemiolog age precis medicin cancer cardiovascular diseas beyond know screen cervic cancer prevent fact sheet cervic cancer [pdf kb] cancer survivorship use genet stratif popul screen cancer human diseas bad luck act genet environment factor reduc cancer risk cancer prevent control cdc medscap expert commentari genet brca primari care katherin kolor medscap octob use genom precis prevent breast cancer muin j khouri genom health impact blog april case melanoma deadliest kind skin cancer caus exposur ultraviolet uv light cdc inform cancer prevent start childhood cdc paper target cancer screen averag risk individu p marcu et al j prev medicin juli cdc paper meet healthi peopl object reduc cancer mortal h weir et al prevent chronic diseas juli cdc inform improv health qualiti life cancer cancer men check gene report risk outcom brain cancer huge navig cdc inform cancer screen test cdc inform skin cancer awar check gene report relat risk male breast cancer huge navig cdc inform men get breast cancer cdc inform cancer women prevent control skin cancer cdc public health grand round cdc inform health dispar cancer cdc inform new analysi breast cancer subtyp could lead better risk stratif annual report nation show mortal incid cancer continu declin cdc tier genom applic implement toolkit public health depart detail inform hereditari breast ovarian cancer hboc cdc inform breast ovarian cancer run famili know brca chang life debbi wasserman schultz cdc blog post cdc know brca tool women carri certain genet chang brca gene increas risk get breast ovarian kind cancer young age cdc inform kidney cancer [pdf kb] cdc inform skin cancer prevent travel spring break forget pack protect sun go screen life nation colorect cancer action campaign cdc inform colorect cancer awar cdc inform world cancer day cdc join peopl organ govern agenc around world take proactiv approach fight cancer highlight solut within reach fight cancer beyond us go cdc inform databas cdc author genom public databas databas contain cdc author public public health genom includ infecti diseas newborn screen reproduct health genet test cancer chronic diseas birth defect development disabl environment occup health well laboratori bioinformat statist method popul base assess hpv genotyp specif cervic cancer surviv cdc cancer registri sentinel surveil system hallowel benjamin et al jnci cancer spectrum commun hereditari cancer social media content analysi tweet hereditari breast ovarian cancer lynch syndrom allen caitlin g et al journal cancer educ offici journal american associ cancer educ dec collabor method perform studi measur nicotin metabolit total nicotin equival human urin wang lanq et al cancer epidemiolog biomark prevent public american associ cancer research cosponsor american societi prevent oncolog may time cours analysi microrna induc mesenchym epitheli transit underscor complex underli molecular process lili loukia n et al cancer letter may mammographi use among women age year unit state qin jin et al breast cancer research treatment dec evalu modular decis support applic colorect cancer screen militello laura g et al appli clinic informat feb precis medicin requir precis laboratori rajeevan mangalathu et al journal molecular diagnost jmd mar util genet test analysi gene specif bill medicar claim data lynch juli et al genet medicin offici journal american colleg medic genet aug gut microbiota convent serrat precursor colorect cancer peter brandilyn et al microbiom dec emerg depart util californian sickl cell diseas paulukoni susan et al pediatr blood cancer jun cdc grand round famili histori genom tool cancer prevent control rodriguez juan l et al mmwr morbid mortal weekli report nov comparison dna test strategi monitor human papillomaviru infect preval simul lin carol et al bmc infecti diseas nov pattern trend age specif black white differ breast cancer incid mortal unit state richardson lisa c et al mmwr morbid mortal weekli report oct hepatocellular carcinoma risk alaska nativ children young adult hepat b viru retrospect cohort analysi gounder prabhu p et al journal pediatr aug consensu report weinman intern confer mesothelioma carbon michel et al journal thorac oncolog offici public intern associ studi lung cancer aug cancer epidemiolog descript cohort databas tool support popul base interdisciplinari research kennedi ami e et al cancer epidemiolog biomark prevent public american associ cancer research cosponsor american societi prevent oncolog jul activ impact state program address hereditari breast ovarian cancer triver katrina f et al healthcar basel switzerland valid standard extract method formalin fix paraffin embed tissu sampl lagheden camilla et al journal clinic virolog offici public pan american societi clinic virolog apr incid hepatocellular carcinoma accord hepat b viru genotyp alaska nativ peopl ching lanc k et al liver intern offici journal intern associ studi liver mar adher primari care physician evid base recommend reduc ovarian cancer mortal stewart sherri l et al journal women health mar implement gene recurr score test unit state lynch juli et al genet medicin offici journal american colleg medic genet feb gene integr set profil analysi context base approach infer biolog endpoint kowalski jeann et al nucleic acid research jan predict advanc stage diagnosi breast cancer sort influenc method detect access care biolog factor lipscomb joseph et al cancer epidemiolog biomark prevent public american associ cancer research cosponsor american societi prevent oncolog jan human papillomaviru genotyp oropharynx cancer surviv unit state america goodman marc et al european journal cancer oxford england dec malign transform hymenolepi nana human host muehlenbach ati et al new england journal medicin nov genom test cost effect test lynch syndrom patient newli diagnos colorect cancer rel gross scott et al healthcar basel switzerland contribut sickl cell diseas pediatr stroke burden among hospit discharg african american unit state baker charlott et al pediatr blood cancer dec cost effect routin test lynch syndrom newli diagnos patient colorect cancer unit state correct estim gross scott et al genet med jun quantit analysi rel mutagen five chemic constitu tobacco smoke mous lymphoma assay guo xiaoq et al mutagenesi may reduc risk breast cancer associ recreat physic activ vari statu huiyan et al cancer med jul confirm germlin glioma risk variant rs tp implic tumor tissu via integr analysi tcga data wang zhaom et al hum mutat jul annual report nation statu cancer featur incid breast cancer subtyp race ethnic poverti state kohler betsi et al j natl cancer inst jun djv evolut driver translat cancer epidemiolog analysi fund grant literatur lam tram kim et al j epidemiol apr lam et al respond drive evolut lam tram kim et al american journal epidemiolog apr opportun translat epidemiolog import role observ studi advanc precis oncolog marron michael et al cancer epidemiol biomark prev mar character larg structur genet mosaic human autosom machiela mitchel j et al j hum genet mar author repli spitz margaret r et al american journal epidemiolog mar leverag biospecimen resourc discoveri valid marker earli cancer detect schulli sheri et al journal nation cancer institut apr clinic util gene express profil women earli breast cancer overview systemat review marron michael et al genet med jul seer cancer registri biospecimen research yesterday tomorrow altekrus sean f et al cancer epidemiol biomark prev dec cancer genom epidemiolog navig nci onlin tool enhanc cancer epidemiolog research schulli sheri et al cancer epidemiol biomark prev nov overview recommend translat mileston genom test cancer chang christin q et al genet med jun endogen antibodi respons epiderm growth factor receptor associ immunoglobulin allotyp overal surviv patient glioblastoma pandey janardan p et al neuro oncolog may action plan translat cancer survivorship research care alfano catherin et al j natl cancer inst nov next gener larg scale epidemiolog research implic train cancer epidemiologist spitz margaret r et al j epidemiol nov thymidyl synthas genotyp direct chemotherapi patient gastric gastroesophag junction cancer goff laura w et al plo one e imput subset base associ analysi across differ cancer type identifi multipl independ risk loci tert clptm l region chromosom p wang zhaom et al hum mol genet dec util busi teutsch steven et al genet medicin offici journal american colleg medic genet dec outbreak pseudomona aeruginosa klebsiella pneumonia bloodstream infect outpati chemotherapi center dobb thoma e et al j infect control jul characterist associ genet counsel referr brca test among women larg integr health system bellcross cecelia et al genet med jan collabor biomedicin age big data case cancer shaikh abdul r et al j med internet re e cancer screen genet tale two paradigm hamilton jada g et al cancer epidemiol biomark prev jun associ demograph behavior characterist sunburn among u adult nation health interview survey holman dawn et al prev med jun q muin khouri cancer epidemiolog khouri muin j et al cancer discov feb total bodi skin examin skin cancer screen among u adult lakhani nahe et al prev med apr epigenet research cancer epidemiolog trend opportun challeng verma mukesh et al cancer epidemiol biomark prev feb potenti increas risk cancer commonli use medic umbrella review meta analys ioannidi j p et al ann oncol jan urin base human papillomaviru dna test screen tool cervic cancer high risk women mendez keimari et al int j gynaecol obstet feb person histori diabet genet suscept diabet risk brain glioma pool analysi observ studi kitahara cari et al cancer epidemiol biomark prev jan genet test strategi newli diagnos endometri cancer patient aim reduc morbid mortal lynch syndrom index case rel stewart alison et al plo curr systemat review cancer gwa candid gene meta analys reveal limit overlap similar effect size chang christin q et al eur j hum genet mar cancer genet toolkit improv access genet servic document use famili histori primari care clinician scheuner maren et al genet med jan biolog network predict chemic hepatocarcinogen use gene express data treat mice relev across human rat speci thoma reuben et al plo one e hepatocellular carcinoma hepat b viru famili matter mcmahon brian j et al clin gastroenterol hepatol dec microrna famili target multipl non small cell lung cancer prognost marker h cell bea b cell pacurari maricica et al int j oncol aug compar effect research cancer genom precis medicin current landscap futur prospect simond naoko et al j natl cancer inst jul mortal risk black women white women invas breast cancer hormon receptor p statu huiyan et al bmc cancer compar effect research cancer fund knowledg gap remain glasgow russel e et al j natl cancer inst jun opportun public health commun intervent futur research breast cancer younger women buchanan natasha et al j women health larchmt apr transform epidemiolog st centuri medicin public health khouri muin j et al cancer epidemiol biomark prev apr util epiderm growth factor receptor egfr test unit state case studi translat research lynch juli et al genet med aug use state cancer registri recruit young breast cancer survivor high risk rel protocol random trial test efficaci target versu tailor intervent increas breast cancer screen katapodi maria c et al bmc cancer provoc question cancer epidemiolog time scientif innov budgetari constraint lam tram kim et al cancer epidemiol biomark prev apr polygen inherit use popul screen common diseas khouri muin j et al genet medicin offici journal american colleg medic genet jun preval healthcar action women larg health system famili histori meet uspstf recommend brca genet counsel referr bellcross cecelia et al cancer epidemiol biomark prev apr driver translat cancer epidemiolog st centuri need opportun lam tram kim et al cancer epidemiol biomark prev feb opportun challeng select emerg technolog cancer epidemiolog mitochondri epigenom metabolom telomeras profil verma mukesh et al cancer epidemiolog biomark prevent public american associ cancer research cosponsor american societi prevent oncolog feb effect commun molecular genet test result primari care provid scheuner maren et al genet med jun known glioma risk loci associ glioma famili histori brain tumour case control gene associ studi melin beatric et al int j cancer may knowledg integr cancer current landscap futur prospect ioannidi john p et al cancer epidemiol biomark prev jan human papillomaviru genotyp high grade cervic lesion unit state hariri susan et al j infect di dec health behavior cancer screen among californian famili histori cancer townsend juli et al genet med mar associ adult height genet suscept risk glioma kitahara cari et al int j epidemiol aug multiwal carbon nanotub induc gene signatur mous lung potenti predict valu human lung cancer risk prognosi guo nanci l et al j toxicol environ health part genom wide associ studi glioma meta analysi rajaraman preetha et al hum genet dec smoke associ gene signatur lung cancer diagnosi prognosi wan ying wooi et al int j oncol oct frontier cancer epidemiolog challeng research commun epidemiolog genom research program nation cancer institut khouri muin j et al cancer epidemiol biomark prev jul multilevel research challeng implement genom medicin khouri muin j et al j natl cancer inst monograph may urinari naphthol metabolit chromosom aberr year old children orjuela manuela et al cancer epidemiol biomark prev jul genet variant igf igf ii igfbp adiponectin gene colon cancer risk african american white keku temitop et al cancer caus control jul detect clonal mosaic relationship age cancer jacob kevin b et al nat genet jun chronic occup exposur arsen induc carcinogen gene signal network neoplast transform human lung epitheli cell stueckl todd et al toxicol appl pharmacol jun build evid base decis make cancer genom medicin use compar effect research goddard katrina b et al genet medicin offici journal american colleg medic genet jul stakehold assess evid cancer genom test insight three case studi deverka patricia et al genet medicin offici journal american colleg medic genet jul estrogen relat gene contribut racial differ breast cancer risk rede kerryn w et al cancer caus control may relev pathogenesi test algorithm mismatch repair defect colorect carcinoma report associ molecular patholog funkhous william k et al j mol diagn cancer children nonchromosom birth defect fisher paul graham et al j pediatr jun stimul translat research cancer genom beyond bench bedsid schulli sheri et al genet med jan implement screen lynch syndrom among patient newli diagnos colorect cancer summari public health clinic collabor meet bellcross cecelia et al genet medicin offici journal american colleg medic genet jan use famili histori clinic guidelin diabet colorect cancer peterson brent et al j prev med jan go cdc author genom public databas state public health genom program databas databas focus state nation activ integr genom public health program clinic practic get record tier tabl databas cdc offic public health genom ophg conduct horizon scan systemat research method find follow novel technolog appear literatur identifi track progress genom test move research clinic public health practic aid organ horizon scan result ophg rank genom test famili health histori applic level evid see detail get record huge literatur finder databas databas contain publish literatur genet associ human genom epidemiolog get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record advanc molecular detect clip databas databas includ publish scientif literatur popular press articl tool databas emerg role pathogen genom host pathogen interact infecti diseas control prevent includ inform method evolut pathogen detect diagnosi outbreak epidemiolog transmiss antimicrobi vaccin host pathogen interact get record nation institut health web site surpris match cancer immunotherapi mismatch repair franci collin director blog june adren cancer ncat genet rare diseas inform center adren medulla cancer ncat genet rare diseas inform center tcga build clinic genom resourc pi wang nci blog may anal cancer ncat genet rare diseas inform center anaplast thyroid cancer ncat genet rare diseas inform center anemia nhlbi health topic site annual report nation overal cancer mortal continu declin prostat cancer mortal stabil nci press releas may approach blue ribbon panel recommend case lynch syndrom approach identifi care individu inherit cancer syndrom u clinic trial requir nci moonshot fund announc august approach identifi care individu inherit cancer syndrom u nci fund announc septemb approv osimertinib necitumumab increas lung cancer treatment option tumor born bad nih director blog may asbesto relat lung diseas nhlbi health topic site aspirin reduc cancer risk bile duct cancer ncat genet rare diseas inform center biliari tract cancer ncat genet rare diseas inform center biomark signatur prostat cancer nih research matter juli biomark test could reduc unnecessari biopsi detect prostat cancer nci june bladder cancer childhood ncat genet rare diseas inform center brain stem cancer ncat genet rare diseas inform center brca exchang aggreg data thousand brca variant inform understand cancer risk nci januari brca popul screen predict breast cancer g lippi et al ann tran med juli brca hereditari breast ovarian cancer syndrom ncat genet rare diseas inform center brca hereditari breast ovarian cancer syndrom ncat genet rare diseas inform center breast cancer prevent pdq patient version breast cancer childhood ncat genet rare diseas inform center breast cancer male ncat genet rare diseas inform center bring precis screen cancer cancer control p l n e portal cancer control p l n e portal provid access data resourc help planner program staff research design implement evalu evid base cancer control program cancer dispar cancer genom transform studi diagnos treat cancer nhgri apr cancer moonshot blue ribbon panel report cancer moonshot cartilagin cancer ncat genet rare diseas inform center cathet ablat nhlbi health topic site ccg fund opportun biospecimen process storag cerebr ventricl cancer ncat genet rare diseas inform center check genet condit test associ pancreat cancer nih genet test registri check cancer checkpoint inhibitor childhood cancer genom pdq health profession version childhood ovarian cancer ncat genet rare diseas inform center colorect cancer childhood ncat genet rare diseas inform center coronari calcium scan nhlbi health topic site crizotinib show promis childhood cancer cryo em imag captur key enzym tie cancer age nih director blog may decod telomer biolog cancer risk nih intramur research detect earli sign cancer blood nih research matter august dicer relat pleuropulmonari blastoma cancer predisposit syndrom ncat genet rare diseas inform center diffus gastric cancer ncat genet rare diseas inform center dissemin intravascular coagul nhlbi health topic site divid conquer molecular diagnosi cancer dna misfold reveal novel oncogen mechan dual biomark blood test show promis pancreat cancer earli detect nci news august enhanc risk base lung cancer screen may prevent death current approach epigenet may hold key arsen role cancer e hood environment factor nieh januari esophag cancer ncat genet rare diseas inform center esophag cancer childhood ncat genet rare diseas inform center establish universallynch syndrom screen commun fallopian tube cancer ncat genet rare diseas inform center famili colorect cancer ncat genet rare diseas inform center famili pancreat cancer ncat genet rare diseas inform center famili prostat cancer ncat genet rare diseas inform center famili stomach cancer ncat genet rare diseas inform center fanconi anemia nhlbi health topic site fda approv alectinib alk posit non small cell lung cancer fda approv pembrolizumab tumor specif genet featur nci june fda grant orphan drug statu selumetinib neurofibromatosi type nf treatment nci cancer research may fecal microbiota transplant help restor benefici bacteria cancer patient nih septemb find genet condit test associ thyroid cancer nih genet test registri find genet condit test associ kidney cancer nih genet test registri find pediatr cancer genom data pgdi nci septemb children cancer genom inform may help guid treatment decis gallbladd cancer ncat genet rare diseas inform center gene fusion may drive rare childhood brain tumor genet disord test associ gastric cancer nih genet test registri genet breast gynecolog cancer pdq nci octob genet colorect cancer pdq health profession version pdq cancer genet editori board nci februari genet prostat cancer pdq health profession version pdq cancer genet editori board nci may genet skin cancer pdq health profession version genom studi seek clue help explain breast cancer dispar nci june head neck cancer build evid base precis oncolog post februari dr franci collin heart transplant nhlbi health topic site hemochromatosi nhlbi health topic site hereditari breast ovarian cancer move toward precis prevent nih director blog post april hereditari diffus gastric cancer ncat genet rare diseas inform center hereditari leiomyomatosi renal cell cancer ncat genet rare diseas inform center genom shape precis medicin oncolog http www cancer gov news event cancer current blog genom profil test cancer nci dec http www cancer gov news event cancer current blog earli stage lung cancer biomark nci januari hurthl cell thyroid cancer ncat genet rare diseas inform center hypopharyng cancer ncat genet rare diseas inform center idiopath pulmonari fibrosi nhlbi health topic site inflammatori breast cancer ncat genet rare diseas inform center insight precis public health summit kidney renal cell cancer patient version kidney cancer childhood ncat genet rare diseas inform center larg studi verifi cancer risk women carri brca brca mutat nci juli laryng cancer ncat genet rare diseas inform center laryng cancer childhood ncat genet rare diseas inform center grantom grantom search engin analysi tool grant inform associ publish literatur evid base translat genom discoveri improv health care diseas prevent human genom epidemiolog literatur inform genom health impact scan databas huge literatur finder databas grant inform extract grant data pubm record nih report grant inform search diseas condit environment risk factor gene studi free text simpl analysi perform get record gwa catalog catalog qualiti control manual curat literatur deriv collect publish genom wide associ studi get record nih genet test registri genet test registri gtr provid central locat voluntari submiss genet test inform provid scope includ test purpos methodolog valid evid test use laboratori contact credenti overarch goal gtr advanc public health research genet basi health diseas search genet test registri cancer nih omim omim comprehens authorit compendium human gene genet phenotyp freeli avail updat daili search omim cancer pubm clinic queri pubm clinic queri util offer pubm search scientif literatur specif clinic research area search pubm clinic queri cancer pharmgkb pharmgkb pharmacogenom knowledg resourc encompass clinic inform includ dose guidelin drug label potenti clinic action gene drug associ genotyp phenotyp relationship search pharmgkb cancer pubm pubm compris million citat biomed literatur medlin life scienc journal onlin book citat may includ link full text content pubm central publish web site pubm link genet review articl cancer disclaim articl list public health knowledg base select cdc offic public health genom provid current awar literatur news inclus updat necessarili repres view center diseas control prevent impli endors articl method find cdc dhh assum respons factual accuraci item present select omiss content item impli endors posit taken cdc dhh opinion find conclus express origin author item includ updat person quot therein strictli way meant repres opinion view cdc dhh refer public news sourc non cdc websit provid sole inform purpos impli endors cdc dhh',\n",
       " 'real eye open diet fecal fat test requir mg fat intak day tend snack thing like pretzel rice cake recent ad fat dairi normal feel like give grace thing week drive nut alway petit almost doubl chin stick leg arm hard time love right yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wk minor flare august flare sinc oct acut pancreat balsalazid hosp day start humira reaction entyvio mg pred still wait chang',\n",
       " 'hi nev may abl get tysabri mostli class nd line drug mean gener need first line drug fail e relaps whilst unabl take eg side effect also get assum avail area ms activ e relaps within year mri show new lesion also depend drug therapi offer area tecfidera like avail everywher old inject drug betaferon avonex rebif copaxon although often slightli differ form copaxon three time week drug avonex plegridi per week subcutan rather weekli intramuscular gilenya anoth nd line drug interestingli lemtrada often first drug peopl ms highli activ odd situat peopl told go away think drug want find option limit avail area plu neurologist prefer also sometim neurologist describ person ms highli activ qualifi drug lesion brain alway manifest number relaps symptom good know prefer possibl get becom firmli attach choic complet devast find plenti issu relat dmd could offer ms nurs abl tell drug avail area also drug neurologist like offer sue',\n",
       " 'first quarter busi period medic oncolog group australia new group traine commenc special train medic oncolog traine recent complet train award fellowship move ahead career plan moga membership continu grow current traine consult member dr zarni lwin deputi chair progress new workforc studi complet pilot project late extens onlin survey distribut moga member come month gather import new data workforc assist long term servic facil workforc plan oncolog drug treatment oncolog drug group chair dr deme karikio continu make good progress advoc access oncolog drug record number notabl achiev late respons advic moga breast cancer expert pharmaceut benefit advisori committe pbac amend pharmaceut benefit schedul list medicin posit metastat breast cancer recommend chang list lapatinib posit metastat breast cancer restrict trastuzumab emtansin amend allow patient access follow treatment lapatinib pbac also recommend restrict word nab paclitaxel updat consist restrict trastuzumab group also made submiss prioriti approv number oncolog drug consid pbac march meet includ nivolumab non small cell lung cancer bevacizumab cervic cancer lenvatinib thyroid cancer olaparib ovarian cancer tamoxifen breast cancer prevent time group indic support submiss cetuximab metastat head neck cancer nintedanib non small cell lung cancer vismodegib basal cell carcinoma list address import area unmet need cancer patient increas risk cancer clinician list support strong randomis clinic trial data keep intern clinic best practic success submiss support chang list tamoxifen primari prevent breast cancer patient moder high risk result uniqu collabor moga tabl posit paper prepar lead australian breast cancer specialist prof kelli ann phillip use tamoxifen prevent breast cancer implic recent research paper present strong research data support approv list tamoxifen therapeut good administr pbac placement pharmaceut benefit scheme reduct risk invas breast cancer women moder high risk sinc prof phillip prof fran boyl chair moga breast cancer group anz breast cancer trial group work moga tga pbac depart health age astrazeneca enact chang educ profession educ plan well advanc australia asia pacif clinic oncolog research develop workshop acord septemb applic review particip offer place career enhanc program acord org au commun skill earli career oncologist new program develop young oncologist group australia yoga held april program includ seri workplac relat role play train actor relat plenari session burnout mind commun challeng could assist medic oncologist day day clinic practic dr georg au yeung yoga presid report good commun core profess medic oncologist innov educ initi provid young oncologist challeng valuabl learn opportun help build profession commun skill moga annual scientif meet implement innov immunotherapi held gold coast august immunotherapi becom increasingli import therapeut strategi cancer patient medic oncologist clinic trial demonstr signific clinic advantag array cancer stream convenor prof ken byrn plan scientif program focu innov approach implement immunotherapi practic includ major immuno oncolog forum conven prof grant macarthur dr alexand menzi prof justin steb imperi colleg london present keynot address meet share insight futur medic oncolog',\n",
       " 'st juli scientif commun mark birthday alfr gilman dr gilman receiv nobel prize physiolog medicin work g protein transmembran protein everi neurosci student know day import compon cellular signal involv practic manner intercellular commun brain cell best prion like protein long term memori mainten despit recent progress understand brain function still limit knowledg format storag long term memori semin paper publish month view seriou breakthrough field research demonstr long term memori maintain prion like protein protein call cpeb shown involv process like typic prion involv varieti neurodegen disord cpeb exist solubl aggreg form learn someth new synapt connect made solubl form cpeb synaps get convert insolubl aggreg aggreg turn synthesi protein need maintain memori new better compound depress anti depress prozac select serotonin uptak inhibitor ssri work slowli produc appreci effect mani week month administr also known associ number side effect result mani medic profession voic concern increas use ssri howev new compound call gaba nam work complet differ mechan may revolution treatment depress anim experi shown treat depress less hour minim side effect seriou improv compar ssri hope high drug soon test human anti malari treat parkinson diseas drug repurpos becom increasingli common strategi come look new approach treat variou condit reason lie fact mani patholog process share common biochem mechan result drug develop one condit may turn help treat someth els resent rather remark exampl repurpos involv parkinson diseas turn drug use prevent treatment malaria chloroquin amodiaquin reduc symptom improv behavior rat diseas hope drug might quickli develop treatment human fingolimod drug multipl sclerosi treatment huntington diseas anoth success drug repurpos stori came search treatment huntington diseas turn month cours fingolimod drug multipl sclerosi improv memori restor synapt plastic hippocampu mice huntington diseas drug good safeti profil research current plan studi human patient cross talk immun system age relat cognit declin last year research stanford demonstr blood young rat revers cognit declin old anim continu studi subject scientist found opposit true blood older anim circul bodi young rat turn blood older anim contain increas amount beta microglobulin b b compon immun system also particip shape commun brain cell experi increas amount b blood clearli link worsen perform memori test interestingli effect b revers cognit abil get restor b level decreas discoveri might pave way develop target drug prevent age relat cognit declin worst human probabl good distinguish odor paper smell percept publish scienc claim human distinguish least trillion odor new paper publish week ago elif journal significantli smaller impact factor cast seriou doubt valid claim new paper show number smell heavili depend number particip strict statist test use estim also appear origin claim base unproven assumpt human smell percept rather poorli understood present nonetheless trillion odor claim alreadi make way neurosci textbook case bad scienc perhap vitamin b provid benefit older peopl moder defici fact lack vitamin b lead seriou problem nervou system well establish vitamin b supplement provid obviou improv patient sever defici day vitamin b also routin prescrib older patient moder mild defici hope supplement help improv cognit motor function howev result new clinic trial show b supplement patient provid benefit whatsoev british research gave either b pill placebo group elderli year old patient one year end studi scientist compar patient perform batteri clinic test surprisingli singl differ pre trial result spot clearli time rethink current strategi b supplement tini brain lesion seriou risk stroke brain imag provid lot inform state health inform howev taken account clinician mean signific certain chang brain simpli alway clear one tradit disregard thing small lesion alway view insignific normal even healthi peopl new find publish month indic lesion associ increas risk stroke even death risk much three time higher compar patient without lesion clearli someth take consider medic profession antidepress may affect cognit develop interf rem sleep use antidepress grow fast recent year mani pediatrician even prescrib children variou disord latter might seriou concern howev compound tend disturb call rapid eye movement rem sleep rem sleep import convert daytim experi memori new find suggest rem sleep particularli crucial period rapid brain remodel e children adolesc lot higher cognit function skill get acquir develop antidepress serious disturb rem sleep thu potenti affect children abil learn adapt sleep depriv good night sleep might benefici traumat experi convent wisdom medic advic say good night sleep help reduc effect traumat event intrus memori flashback might wrong approach howev recent experi research subject peopl watch emot disturb movi either interrupt sleep sleep laboratori allow sleep comfort home turn peopl sleep depriv group good rememb emot disturb detail movi sleep known consolid memori appear sleep depriv might help prevent consolid traumat memori refer dangour allen e clark r elbourn fletcher letley l richard whyte k uauy r mill k effect vitamin b supplement neurolog cognit function older peopl random control trial american journal clinic nutrit doi ajcn dumoulin bridi aton seibt j renouard l coleman frank rapid eye movement sleep promot cortic plastic develop brain scienc advanc doi sciadv fioriti l myer c huang li x stephan j trifilieff p colnaghi l kosmidi drisaldi b pavlopoulo e kandel e persist hippocamp base memori requir protein synthesi mediat prion like protein cpeb neuron doi j neuron fischel j van dyke kvarta legat thompson rapid antidepress action restor excitatori synapt strength chronic stress neg modul alpha contain gabaa receptor neuropsychopharmacolog doi npp gerkin r castro j number olfactori stimuli human discrimin still unknown elif doi elif kim c han b moon j kim shin j rajan nguyen q sohn kim w han jeong kim k lee e tu naffin olivo j park c ring yoon h petsko g kim k nuclear receptor nurr agonist enhanc dual function improv behavior deficit anim model parkinson diseas proceed nation academi scienc doi pna porcheret k holm e goodwin g foster r wulff k psycholog effect analogu traumat event reduc sleep depriv sleep doi sleep smith l park j bieri g snethlag c lin k gontier g wabl r plambeck k udeochu j wheatley e bouchard j eggel narasimha r grant j luo j wyss coray villeda microglobulin system pro age factor impair cognit function neurogenesi natur medicin doi nm windham b deer b griswold wang w bezerra shibata butler k knopman gottesman r heiss g mosley small brain lesion incid stroke mortal annal intern medicin doi wood h neurodegen diseas could fingolimod provid cognit benefit patient huntington diseas natur review neurolog doi nrneurol imag via fotohunt shutterstock',\n",
       " 'ipoop reason point way gi explain sinc tri humira first potenti remicad still may produc signific result tri remicad first said would essenti reason tri humira great chanc would work either gave quick overview entyvio never heard somewhat disappoint never even came possibl old gi digress greatli intrigu possibl like said focus specif gi tract oppos block wbc entir bodi think interest tri entyvio point work well imuran sinc today mark one month point first day actual mg u b think right give increas humira tri move get test done friday check humira level bodi see built antibodi may show even worth up dosag may show stay system time may tri benedryl give anyth shot buy even one night bliss sleep boy miss day notsosickgirl bentyl prescript ion drug otc may give enema anoth shot rememb tri one hold evacu quickli also tri proctofoam past saw real result either third round pred mg week saw mild improv mg thing dip got stay steadi never got dose pred nocturn bm occur essenti sinc flare start last june day realli know energi keep go imagin good go feel much energi start get full night sleep abl accomplish anyth day final come research night entyvio seem like better option cours pend result upcom humira blood work mayb get lucki use iv yet mayb up humira help diagnos summer left side coliti current prednison mg humira everi week imuran mg current tri gluten free mostli dairi free sinc jan flare sinc june signific inflamm doc word post edit ihatepoop pm gmt',\n",
       " 'combin clemastin fumar biotin ocrevu azt',\n",
       " 'dont know anyth st mark sound place dont sound experienc uc surgeon someth odd first surgeri leav much colon also surgeri offer option like remicad biolog steroid may use want reduc inflamm quickli would go remicad get switch better hospit remicad work allow reduc steroid faster know within day respond remicad tell make sure st mark know dire circumst year old femal diagnos sever uc remicad mg kg imuran mg librax zofran need calcium vitamin slow fe',\n",
       " 'omnitrop somatropin form human growth hormon import growth bone muscl omnitrop use treat growth failur children adult lack natur growth hormon includ peopl turner syndrom prader willi syndrom short statur birth catch growth caus omnitrop may also use purpos list medic guid import inform use omnitrop cancer eye problem caus diabet treat prader willi syndrom overweight sever breath problem use omnitrop seriou ill due lung failur complic recent surgeri injuri medic trauma receiv omnitrop tell doctor past present medic condit especi allergi trauma surgeri diabet cancer breath problem liver kidney diseas scoliosi high blood pressur pancrea disord underact thyroid brain tumor also tell doctor medic use especi steroid diabet medic dosag medicin may need chang start use omnitrop stop use steroid suddenli chang medic dose without doctor advic call doctor sudden sever pain upper stomach nausea vomit fast heartbeat increas thirst urin weight loss vision chang sudden sever pain behind eye take medicin use omnitrop allerg somatropin benzyl alcohol seriou ill due lung failur complic recent surgeri injuri medic trauma cancer eye problem caus diabet diabet retinopathi treat prader willi syndrom overweight sever breath problem includ sleep apnea make sure omnitrop safe tell doctor diabet pituitari gland disord abnorm curvatur spine scoliosi underact thyroid histori head injuri brain tumor histori childhood brain cancer radiat treatment brand somatropin expect harm unborn babi includ genotropin omnitrop saizen serostim known whether certain brand somatropin harm unborn babi includ humatrop norditropin nutropin zomacton zorbtiv tell doctor pregnant plan becom pregnant treatment may safe breast feed babi use medicin ask doctor risk use omnitrop use omnitrop exactli prescrib doctor dose depend treat follow direct prescript label use medicin larger smaller amount longer recommend omnitrop inject muscl skin may shown use inject home self inject medicin understand give inject properli dispos use needl syring care provid show best place bodi inject omnitrop use differ place time give inject inject omnitrop place two time row prepar inject readi give shake medicin use medicin chang color particl call pharmacist new medicin use dispos needl syring follow state local law throw away use needl syring use punctur proof sharp dispos contain ask pharmacist get one throw away keep contain reach children pet use omnitrop may need frequent blood test growth progress need test often eye may also need check prader willi syndrom treatment program may also includ weight control follow doctor instruct close throw away omnitrop left expir date label pass see also dosag inform detail happen miss dose use miss dose soon rememb skip miss dose almost time next schedul dose use extra medicin make miss dose call doctor miss dose row happen overdos seek emerg medic attent call poison help line overdos caus tremor shake cold sweat increas hunger headach drowsi weak dizzi fast heartbeat nausea long term overdos may caus excess growth avoid use omnitrop get emerg medic help sign allerg reaction omnitrop hive difficult breath swell face lip tongu throat seriou breath problem may occur patient prader willi syndrom use omnitrop prader willi syndrom call doctor promptli develop sign lung breath problem short breath cough new increas snore also call doctor pain knee hip walk limp ear pain swell warmth drainag numb tingl wrist hand finger sever swell puffi hand feet pain swell joint pancreat sever pain upper stomach spread back nausea vomit high blood sugar increas thirst increas urin dri mouth fruiti breath odor increas pressur insid skull sever headach ring ear dizzi nausea vision problem pain behind eye sign adren gland problem extrem weak sever dizzi weight loss chang skin color feel weak tire common omnitrop side effect may includ swell rapid weight gain muscl joint pain headach pain itch skin chang medicin inject complet list side effect other may occur call doctor medic advic side effect may report side effect fda fda drug affect omnitrop tell doctor current medicin start stop use treatment omnitrop especi birth control pill hormon replac therapi insulin oral diabet medicin steroid medicin prednison dexamethason methylprednisolon other list complet drug may interact somatropin includ prescript counter medicin vitamin herbal product possibl interact list medic guid see also drug interact detail inform rememb keep medicin reach children never share medicin other use omnitrop indic prescrib',\n",
       " 'recent join egfr resist group learn healthunlock today week first episod may first side effect tagrisso seem combin onset menopaus bit intens subsid soon gobbl oz water bottl honest terrifi like littl kid first seem get use find better way manag great scour site egfr site learn tip help remedi dri skin rash basha',\n",
       " 'sure thing reason invent wheel disclaim inform find site consid medic advic decis made consent doctor otherwis risk top carolew famili elder post join fri nov pm locat ottawa ont canada quot post carolew thu nov pm everyon know adament benefit lipitor ms sinc start fingolimod trial dec th stop mg lipitor ooooooohhhhhhh chang foot drop bad miss lipitor bad restart wk ago get back mg od bare feel posit aspect must admit spastic better much better oct stop wait get new drug wonder go lipitor high hope think bad patient take lipitor even studi drug contraind new drug give lipitor past wonder ever get effect top cureorbust famili elder post join wed jul pm locat sydney australia quot post cureorbust fri dec carolew wrote must admit spastic better much better oct stop say spastic reduc sinc stop lipitor sinc oct top carolew famili elder post join fri nov pm locat ottawa ont canada quot post carolew sun dec lipitor realli help spastic back mg od better keep first dose fti thursday new drug lipitor top robbi famili elder post join thu jan pm locat northern ontario canada quot post robbi sun dec lipitor realli help spastic help carolew leg lock right get hard rock pain u think might help top cureorbust famili elder post join wed jul pm locat sydney australia quot post cureorbust sun dec pm carolew wrote new drug lipitor look first prioriti take lipitor hope go onto trial well plan keep take lipitor stuff work would expect even better research told contraind understand work total differ biolog mechan stop lipitor go downhil way tell doesnt work may work well lipitor think real test help take ie still exist regimin serious look health first prioriti top carolew famili elder post join fri nov pm locat ottawa ont canada quot post carolew mon dec pm robbi lock exactli instead get like stiff stick lipitor spasm much less gradual lipitor realiz easier get toilet bowl chair sure work everyon magic thank cureorbust agre may stay sinc contraind fti lipitor affect liver would realli watch liver function test way today saw neurologist gave month suppli studi drug oh feel first time accept studi wow final could placebo sure hope feel like lipitor fall back onto need would prefer realli someth activ first dose day drum roll take care keep post carolew top pauldog newbi post join wed aug pm anyon tri natur statin drug quot post pauldog wed aug pm friend mine ms think never got sever form take statin drug cholesterol mani year main question red rice yeast contain natur form activ substanc statin drug anyon tri form result advic dosag etc top dim famili elder post join thu feb pm locat greec contact contact dim websit quot post dim mon jan pm policosanol drug brand vanachol contain natur substanc high cholesterol daili dose contain policosanol mg omega gr phytosterol mg b mg b mg pholic acid mg interest ah top cureorbust famili elder post join wed jul pm locat sydney australia quot post cureorbust mon jan pm propos specif lower cholesterol statin anti inflamatori properti assist ms top peekaboo famili elder post join sun feb pm locat arizona contact contact peekaboo icq quot post peekaboo fri apr niacin taken w statin combin reduc heart attack risk accord univers washington studi suggest dose mg taken prevent mag may pg take statin ms therapi benefit may ouy weigh risk top jimmyleg volunt moder post join sat mar pm thank time quot post jimmyleg fri apr niacin establish altern statin take easi liver niacin flush fun bit masochist take straight niacin flush whole worm',\n",
       " 'hello angc offer copaxon tecfidera rule tecfidera stomach issu nurs said caus stomach issu first rule copaxon first time round left aubagio realli confus mif moment drug thing gilenya effect tecfidera offer never offer tysabri lemtrada would rather hit aggress rather wait bad turn round say sorri sp drug apolog rant fulli understand budget postcod suppos sam',\n",
       " 'enamour might tecfidera habit tri monitor www news resourc ensur peopl suddenli keel news regard tecfidera biogen pharmaceut make invari come financi page big citi fat cat eager check share price trend appar biogen share price taken knock late usual good sign thank due failur tragedi due competitor get close make anoth drug avail appar pipelin compani call celgen hot latest big hope supposedli effect safer tecfidera gilenya side effect thu far headach increas risk uti runni nose anyon els heard ozanimod',\n",
       " 'ocrevu fulli licens lemtrada tysabri tecfidera instant heart problem ocrevu put right back shit tri next list order prefer futur need follow lemtrada cladrabin book inject type mavenclad hsct done mexico food better moscow warmer russian like us much right risk septicaemia compar nearli uk nh anyth come along interim ocrevu',\n",
       " 'glanc cladribin look significantli better anyth els',\n",
       " 'sure oz what ocrevu us im bit touch',\n",
       " 'well know remicad work well consid anoth similar biolog within class remicad cimzia humira tnf alpha block biolog develop antibodi one tnf alpha blocker mean develop antibodi cimzia humira molecular structur differ enough immun system must start ground antibodi develop process might never develop antibodi cimzia humira could increas odd stelara complet differ class biolog complet differ mechan action gambl much like entyvio anoth entir differ class biolog aforement biolog class moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa two certainti life pay tax prednison side effect',\n",
       " 'hi janin thank respons due word limit unabl make clear mum tragic pass away end februari whilst tagrisso azd month question realli gain sort closur notic anoth forum research respons rate tagrisso posit realli thought would work met oncologist pass away said mother might work cancer becom aggress erlotinib wonder mani case patient posit tagrisso work find posit find wonder cancer allow progress got drug earlier would made differ perhap chemotherapi etc link post seem neg advic appreci thank',\n",
       " 'last saw neurologist back april last year told saw sign ms shift secondari progress sinc saw develop foot drop walk speed probabl halv distanc walk plummet know criteria spm rather rrm hope meet happi take gilenya dmt spm interferon mitoxantron take interferon caus depress took year ago mitoxantron effect peopl relaps like sound side effect way gilenya seem keep relaps bay apart one year ago know badli would suffer taken ye rrm spm label howev gentli bluntli appli label make differ feel day day make differ avail treatment condit content say rrm till neurologist say otherwis gentli hope',\n",
       " 'daughter test ro posit nsclc take crizotinib week recent scan ct bone show slight progress liver possibl new spot bone spine rib cancer lung node appear stabl even smaller blood work show high ldh low albumin reason believ crizotinib effect possibl ro detect fals posit test perform paraffin embed biopsi tissu fluoresc situ hybrid cell posit ro gene rearrang topic modifi year month ago fano topic modifi year month ago fano topic modifi year month ago fano topic modifi year month ago fano',\n",
       " 'okay anoth question remicad humira anti tnf one would assum bodi produc antibodi toward one sinc famili drug knowledg',\n",
       " 'thank info jerri took first treatment friday opdivo believ someth runnung low grade fever also lost appetit weak hope good sign',\n",
       " 'remicad year month ago start get sever joint pain swell wrist knee elbow etc pain swell move around call gi doctor get bloodwork check remicad antibodi call prometheu test anyway call coupl week later said everyth look fine continu infus see rheumatologist check caus joint pain got referr get see rheumatologist month meantim pcp bloodwork show posit ana possibl lupu sent anti dsdna test came back posit suggest lupu hope pain might caus remicad prometheu test antibodi neg realli confus prometheu test show antibodi remicad mean might full blown lupu drug induc lupu anyon similar problem',\n",
       " 'research learn mechan behind diseas target therapi patient egfr posit lung cancer becom wide use given myriad way malign evolv treatment landscap constantli shift accord edward garon th annual winter lung cancer confer miami beach cure sister public oncliv sat garon director thorac oncolog david geffen school medicin ucla discuss find recent clinic studi impact futur use immunotherapi non small cell lung cancer spoke bring immunotherapi egfr mutat start discuss optim regimen patient right garon think point optim approach immunotherapi popul patient one thing address talk dearth data regard popul patient strongest data date would argu impow studi three separ arm control arm regimen carboplatin paclitaxel avastin [bevacizumab] two studi arm one swap avastin tecentriq [atezolizumab] anoth quadruplet use drug carboplatin paclitaxel avastin tecentriq studi patient complet therapi egfr inhibitor shown group patient receiv quadruplet benefit respect progress free surviv although hazard ratio cross one least numer suggest overal surviv advantag well group patient interestingli clear benefit least clear benefit tecentriq substitut avastin realli beg question whether someth particular four drug togeth think date compel data set part approv quadruplet regimen someth often abl get patient base recommend nation comprehens cancer network next step data think data data patient larg clinic trial know whether effort replic larger number patient know pd pd l inhibitor look studi design although gener incorpor avastin one thing advantag impow studi compani own avastin tecentriq make easier run studi look quadruplet nonetheless biolog reason imagin inclus avastin import know particularli data japan certainli progress free surviv addit avastin clearli add egfr inhibitor tarceva [erlotinib] two studi assess also await data studi tarceva without cyramza [ramucirumab] concern toxic four drug regimen like certainli concern toxic one look impow studi one might expect toxic littl bit wors quadruplet would triplet way expect one issu asid toxic backbon regimen carboplatin paclitaxel avastin although reason approv regimen mani year lost favor among mani practition [who instead opt] carboplatin pemetrex littl hard find object data reason compar respect efficaci outcom particularli dispar talk practition tell toler part pointbreak studi toler assess one interest thing neuropathi one toxic clearli differ two frankli big issu practic hair loss mani patient continu work want lose hair lose hair someth associ peopl mind sick like anoth issu see potenti role later line therapi earlier think right thought would complet egfr tki data support pd pd l inhibitor prior egfr tki quit scant would forese one thing would also argu hope best get immunotherapi egfr mutant non small cell lung cancer think toxic signific regimen efficaci although studi certainli look better chemotherapi alon still hope better hope see come year',\n",
       " 'yesterday went see team qmc follow recent moar mother relaps thing certainli chang realm diseas modifi therapi notic seem failur toler attitud treatment first relaps year first almost year sinc start take tecfidera neurologist ms nurs keen discuss chang medic step first line treatment aggress effect second line option back realm weigh drug like stick wet finger air see way wind blow key contend finngolimod aka gilenya one pill day promis reduct relaps rate mean huge amount choos tecfidera still class first line like said variou team would like see move someth bit effect tysabri aka natalizumab intraven infus everi four week ms nurs describ act like velcro immun cell blood stream prevent pass blood vessel wall central nervou system nerv damag occur say ms trust public diseas modifi drug link open pdf tysabri highli effect categori dmd reduc number relaps two third sound great yeah hang treatment tysabri may increas risk progress multifoc leukoencephalopathi pml uncommon brain infect lead sever disabl even death pml caus mutat jc viru common infect complet unrel ms final alemtuzumab aka lemtrada aka campath taken two five day intraven infus month apart highli effect categori dmd reduc number relaps around alemtuzumab suppress immun system peopl vulner infect usual headach nausea sure right three seriou side effect report clinic trial overact underact thyroid gland lead thyroid disord affect peopl idiopath thrombocytopen purpura itp seriou disord prevent blood clot affect peopl kidney problem affect peopl side effect potenti seriou treatabl caught earli enough peopl take lemtrada inform earli sign symptom side effect talk ms nurs impli alemtuzumab risk associ certainli ms trust public impli mostli intens effect wipe lymphocyt read done next week go back qmc blood test see jc viru therefor less like develop pml first glanc lean toward tysabri sure post stevedomino email blogthi share twitter share facebook share pinterest label drug medic ms nurs relaps treatment comment swisslet said jesu set choic realli feel brother tri rememb probabl wrong choic equal right choic sigh wed jul pm stevedomino said know say sound pretti crappi least choic talk kate love ms nurs peopl first diagnos day get put straight onto dmt often one time chang consider less toler see goe attitud thu jul swisslet said kate taught inject fact fan love maxin wrote letter take australia show doctor dive medic made differ decis sent postcard great barrier reef never forgotten bless',\n",
       " 'thank merri world knowledg support actual join chemo support group fb everyon share knowledg experi get wig coupl week ago order coupl chemo cap look horribl guess wear around hous need poof read better buzz head rather shave ye hard one curl style hair everi day wash week guess sinc given mani option treatment almost seem futil want die time soon would talk wakeke make decis think mayb go scripp would difficult hate far home see say morn jump post saw dictir morn neutrophol us skip chemo week recheck blood work tuesday chemo next week day day granix inject go tri schedul get port put shudder pet scan go ask thought guess answer scan ask pain get know pain cgest left arm pit morn hard believ done fir mani year answer found coupl post peopl lcnelc also get keytruda opvido say immunotherapi wakele wari tri undiagnos sure immun probkem go sinc cancer diagnosi guess wait see wish talk',\n",
       " 'sure evil doctor bed pharmaceut compani make sensat conspiraci theori headlin think realiti like lot bore base verif guidelin said biolog first line treatment believ patient need diseas sever patient unrespons lesser treatment much stronger precursor prescrib biolog insur compani protocol procedur ensur medic tri first endoscop treatment use qualifi etc sure occasion bad egg outlier vast major doctor patient need heart sever nonrespons case warrant fast medic escal milder case nih uk differ nation run system give individu practic much overhead regul newer medic approv slowli uk usa take entyvio exampl goe newer equip procedur say usa quicker access new treatment idea process disadvantag usa cost without thorough vet new methodolog may better wast nih certainli cautiou system pro con howev neither system full peopl littl regard patient outcom moder ulcer coliti john uc histolog remiss rx remicad mg kg wk word contain uc liter figur suck ouch deuc mucu f ed lucif luck post edit ipoop gmt',\n",
       " 'hi everyon wonder anyon experienc pretti bad pseudo relaps know bad relaps space month second one happen week start gilenya start regain mobil christma final felt like recov woke christma morn nasti cold everyon get weaken amount abl walk expect noth mad thing sinc shake full night sleep sinc rd decemb sure insomnia caus cold increas dose baclofen start mid dec either way result complet lost use right leg yesterday aw nerv pain come exactli last relaps sept recov could pseudo relaps caus cold fact sleep could anoth full blown relaps',\n",
       " 'gilenya make slightli prone infect winter flu inject recommend must later year',\n",
       " 'health canada approv mavenclad therapi reduc frequenc ms exacerb delay diseas progress treatment gener recommend patient fail respond adequ unabl toler one ms therapi highli activ ms',\n",
       " 'imuran metabol mp within bodi take mp save step cyclosporin like prednison temporari rescu medic remicad humira simponi tnf alpha blocker similar med prescrib base patient doctor prefer xeljanz jak inhibitor complet differ entyvio madcam blocker complet differ stelera target regulatori cytokin il il complet differ gener want tri least differ class biolog differ mechan action consid surgeri far tri one class point diminish return fail two class third sometim work ye happen rescu third chanc success drop consider fail second moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa cannot spell suck without uc post edit ipoop pm gmt',\n",
       " 'lag plu opdivo clinic trial trial year side effect tumor continu shrink fantast ct scan pdl neg also cea number went stay trial year know combin drug save life stage iv lung cancer met liver pelvi subclavian mutat p',\n",
       " 'patient untreat non small cell lung cancer nsclc mutat epiderm growth factor receptor egfr central nervou system cn metastas baselin report better cn progress free surviv pf compar first gener egfr tyrosin kinas inhibitor tki gefitinib erlotinib cn pf reach certain subset patient administ osimertinib month standard egfr tki therapi p result preplan exploratori analysi phase flaura studi registr studi got osimertinib approv use first line therapi patient egfr mutat advanc nsclc report journal clinic oncolog flaura studi random doubl blind studi patient untreat egfr nsclc compar osimertinib standard egfr tki therapi gefitinib erlotinib subset analysi patient flaura cn metastas subset patient flaura includ current analys document cn metastas baselin seen brain scan assess neurologist blind manner relat articl pd pd l inhibitor may increas risk hyperprogress diseas nsclc plu carboplatin may effect nsclc patient interstiti lung diseas gefitinib continu therapi may effect nsclc post progress patient includ studi data provid patient measur nonmeasur cn metastas avail baselin brain scan cn full analysi set [cfas] sixti one patient treat osimertinib standard egfr tki end point assess includ cn pf cn object respons rate orr cn durat respons dor cn diseas control rate dcr cn progress median follow cn pf month patient osimertinib month patient standard egfr tki patient characterist balanc baselin median sum baselin cn tumor lesion size larger patient standard egfr tki vs mm osimertinib arm end point cn pf differ arm consid nomin statist signific cn progress seen approxim twice mani patient standard egfr tki vs osimertinib result new cn lesion patient osimertinib patient standard egfr tki cnn orr patient osimertinib patient standard egfr tki odd ratio [or] p patient least measur lesion baselin cn evalu respons set [cefr] osimertinib patient standard egfr tki patient cn orr patient osimertinib patient standard egfr tki p cn evalu respons set cefr popul median time respons week group howev median cn dor longer patient receiv egfr tki compar osimertinib vs month respect also popul cn dcr similar across group osimertinib egfr tki p studi author note taken togeth data report flaura data indic subgroup patient without known treat cn metastas baselin osimertinib provid protect effect develop brain metastas',\n",
       " 'good thought thank california risk analysi continu internet certainli plenti say rituximab ocrelizumab issu quit',\n",
       " 'hi marcel write j pouch psc sever pancol respond medicin surgeon describ colon look like bomb went insid post much live life uc j pouch inconveni j pouch noth compar went uc psc spend time worri diagnos j pouch surgeri know whether psc first uc matter chang diagnosi initi diagnosi scare babi ye j pouch surgeri afraid watch grow know lot psc ye monitor ye might someday need liver transplant good worri today worst problem today itch manag agre ipoop good understand medic issu make crazi focu good control take care year old femal buckey state init misdiagnos crohn oct nd opinion cleveland clinic rediagnos sever pancol ulcer coliti jun recurr c diff spring fecal transplant may psc diagnosi fail med asacol hd prednison humira flagyl vanco dificid step j pouch surgeri finish februari',\n",
       " 'hi felt fairli tire first week gilenya last hope cheer',\n",
       " 'hi guy think come gilenya anyon come gilenya experi side effect',\n",
       " 'wet macular eye inject lucenti one year eyelea right eye six weekli left hold monthli inject use give thought inject hope eye hold util finish book seventh year',\n",
       " 'site anyway imac end mean monoclon antibodi rituximab ocrevu end ocrevu rituxan areus non hodgkin lymphoma myesthenia gravi sp linda kind woman feet hit floor morn devil say oh crap repli quot follow user say thank howi jeani z stillstannd sunshin suze q',\n",
       " 'prolong corticosteroid therapi inflammatori bowel diseas ibd associ significantli increas mortal risk compar anti tumor necrosi factor therapi landmark studi spotlight edward v loftu jr md gastroenterolog updat ibd liver diseas meet one sever key studi safeti issu involv ibd medic publish past year other highlight dr loftu copanelist william j sandborn md includ studi provid persuas evid tnf inhibitor modestli increas lymphoma risk ibd patient degre similar thiopurin sever report address question whether preoper use vedolizumab patient undergo major abdomin oper ibd boost postop infect risk mortal impact prolong steroid vs anti tnf therapi bruce jancin mdedg news dr edward v loftu jr left dr william j sandborn retrospect cohort studi medicar medicaid patient ibd demonstr prolong corticosteroid therapi defin mg prednison equival month period significantli higher mortal rate compar ibd patient anti tnf agent come unpleas surpris mani physician widespread reluct turn continu chronic immunosuppress via anti tnf therapi patient challeng ibd particularli elderli individu multipl comorbid condit mani physician heard read much biolog risk seriou advers event opt instead multipl cours corticosteroid diseas control seriou mistak emphas dr loftu professor medicin director ibd interest group mayo clinic rochest minn say oh give patient anoth prednison taper want start take tnf inhibitor actual patient harm actual affect patient life expect declar messag ye steroid cheap steroid easi nobodi afraid steroid afraid steroid crohn diseas patient enter cohort new user anti tnf therapi subsequ mortal incid rate per person year compar rate per person year enter studi period prolong steroid user multivari analysi account potenti confound factor translat highli signific rel risk reduct mortal patient went anti tnf therapi j gastroenterol jan doi ajg similar trend seen ulcer coliti cohort ulcer coliti patient enter cohort new anti tnf therapi user mortal incid rate per person year compar rate receiv mg prednison next month repres rel risk reduct although favor trend achiev statist signific perhap smaller size ulcer coliti cohort',\n",
       " 'hello diagnos highli activ rrm juli relaps regularli first year diagnosi start tecfidera take tecfidera sinc april seem okay part march year relaps scan follow relaps show lesion brain spine also activ coupl lesion alreadi told continu tecfidera moment told need move onto differ stronger treatment tecfidera work anymor option suggest fingolimod lemtrada go much assum peopl know differ medic avail chosen lemtrada success rate whilst fimgolimod success know everyon experi complet differ wonder anyon lemtrada treatment felt rough side effect would recommend treatment mani thank advanc',\n",
       " 'year old husband diagnos ppm januari start ocrevu march novemb second infus notic thing may improv still cautious optimist realiz cure may take sever infus see slow progress',\n",
       " 'decemb immunotherapi tnbc begin begin immunotherapi emerg import approach treat rang cancer research increasingli interest tnbc potenti target agent tnbc immunogen cancer mean tumor like gener immun respons cancer tumor immunogen usual multipl mutat cell call tumor infiltr lymphocyt tnbc meet criteria first studi note possibl role immunotherapi tnbc keynot trial publish june studi found singl agent pembrolizumab keytruda produc intrigu respons tnbc patient heavili treat chemotherapi number small sever advanc patient respons continu month even year studi open door mani trial look differ aspect immunotherapi tnbc octob impass studi show signific respons combin immunotherapi agent chemotherapi first line therapi patient metastat non surgic treatabl tnbc studi look combin immunotherapi parp inhibitor chemotherapi studi investig patient like benefit cours treatment immunotherapi effect also number new immunotherapi agent trial two studi highlight sabc first scientif complex studi aim determin patient highest respons rate immunotherapi agent known atezolizumab agent impass studi trial show patient marker call pd l benefit treatment atezolizumab help research design futur trial person treatment tnbc patient second studi phase trial car therapi patient specif target mutat includ tnbc patient car technic complex form treatment cell remov patient genet engin inject back patient goal stimul ongo immun respons tumor use clinic trial patient rang leukemia lymphoma non small cell lung cancer tumor first trial includ tnbc patient phase studi small number patient earli result four tnbc patient includ data present sabc three respons treatment still far soon draw conclus futur car therapi tnbc',\n",
       " 'wynterstorm may due rais liver enzym side effect gilenya blood test yet sinc start medic arrang medic team ps medic thought googl around',\n",
       " 'although interferon beta ifn b ifn b fingolimod approv multipl sclerosi ms treatment yet includ nation list essenti medicin nlem formulari thailand studi aim evalu cost util ms treatment compar best support care bsc base societ perspect thailand method markov model cost health outcom lifetim horizon month cycl length conduct relaps remit ms rrm patient cost outcom data obtain publish studi collect major ms clinic thailand discount rate percent appli increment cost effect ratio icer calcul univari probabilist sensit analys perform result compar bsc icer patient rrm age year receiv fingolimod ifn b ifn us dollar usd per qualiti adjust life year qali gain respect thai societ willing pay wtp threshold usd per qali gain bsc highest probabl cost effect percent wherea ifn b fingolimod treatment show lower chanc cost effect percent percent respect conclus compar fingolimod interferon treatment bsc remain cost effect treatment rrm thailand base wtp threshold usd per qali gain result support inclus fingolimod interferon nlem treatment rrm unless price decreas special schema arrang',\n",
       " 'bg approv ms tecifdera heard present perform notic might cannib natalizumab tysabri bg highli effect agent low pml risk last yr seen bg tec moder effect treatment fingo gilenya crab drug think daclizumab place what opinion mousedoctor profg',\n",
       " 'claudepa great hear wife remiss congratul wonder vaccin fo mention mother ovarian cancer tri keytruda immunotherapi two infus monotherapi despit heard could work alon thank help',\n",
       " 'dr put rituxan well ask ocrelizumab dr said almost medicin person would choos rituxan use long hope best',\n",
       " 'hi emmad cladribin eagerli await inform respect neuro bart http multipl sclerosi research blogspot com suppos therapi html',\n",
       " 'hi beachgirl welcom gilenya seem well toler seem effect read member firsthand account use forum search function magnifi glass top left search gilenya',\n",
       " 'name charl diagnos stage b nsclc brochoscopi w biopsi confirm pet scan also confirm tumor cm x cm right lung suspect partial lung collaps went radiat treatment chemo infus taxol carboplatin rel side effect treatment lung continu make excess mucou inflamm month day treatment stop initi ct scan treatment scan show tumor least smaller cm know exactli much smaller lot seen scan suspect inflamm die tissu shrinkag could except continu cough expel less less matter pinkish red mucu today cough continu improv slowli lung appear feel like heal schedul start immunotherapi durvalumab tomorrow jan anxiou nervou differ whirlwind cancer other immunotherapi blog mainli durvalumab blog seem tri proactiv plan other seem could wrong though disqualifi first radiat doctor consult fit criteria treatment expect seem complac non chalant case without even see scan seem want put radiat part treatment chemo research shown chemo radiat concurr kill tumor better consecut treatment type cancer boy glad research one part success far tumor shrinkag goe also sinc part treatment anyth help treatment feel like tri eat healthi food like fresh veget close raw stand maintain bodili ph level due research belief help ph test strip chemo radiat continu keep ph immuno bless onc dr primari care provid radiat dr far indic research gone well read anywher x cm tumor shrunk much believ contribut medic treatment work hand hand one biggest factor god pray god help presenc know time work direct caus miracl hand consid decis help treatment part miracl nervous await time initi pet scan treatment hope immuno goe well know durvalumab given cur intent eye cannot hurt goal cur comment long wind hope whirlwind subsid hope correct place air comment never comment way tri monitor post immuno pet scan progress answer one repli thanxm charli',\n",
       " 'hi hardwal like similar situat partner diagnos year ago last year cognit abil decreas significantli point convers last min ultim end loop repetit struggl word last month issu eye point longer read struggl make peopl face photograph like wife partner let bother within famili unit home accord neuro suffer actual realis problem accept small problem memori god bless find go quit hard afraid peopl find stupid heartbreak use fierc independ muddl still tri fulfil life also children although oldest wonder interest partner ever gilenya',\n",
       " 'likewis welcom back kind troubl ms manag ignor start think mayb given stick ugli littl head tell woohoo still chanc symptom late got activ show mri neurologist probabl troubl mri result entir possibl new ms activ without actual relaps symptom valu worri person unless relaps symptom good news got appoint fairli quickli guess ms nurs initi say shift neuro appoint lot dmd get avail bit think research appoint least idea prefer get avail ie postcod lotteri allow tecfidera obvious easi one avail might abl get tysabri well given alreadi fail first line drug cours gilenya beta interferon although isr problem past may good option heavi duti drug lemtrada like may feel would activ relaps risk side effect see reason abl take dmd whilst shift work best luck appoint sue',\n",
       " 'free educ event ocrevu treatment relaps multipl sclerosi venu offer wheelchair access modest meal provid',\n",
       " 'apr alana wrote hello everyon nscl stage diagnos august treatment work put tarceva mg take two year well minor rash mild diarrhea bad cold cough cough lot blood present anyon experi cough blood would appreci respons pleas love prayer mike complet week radio therapi lung cancer cough blood last week put treatment sure wait anoth week see doctor good luck',\n",
       " 'repli post hippopostr sorri hear potenti diagnosi son diagnos year old well distress overwhelm pleas stay focu learn everyth diseas good commun healthcar team son mp allopurinol mani year work dr stop combin start anoth medic good liver kept lialda hope go anoth flare month ago went back dr time dr said need start remicad never allow biolog younger also refus determin get better without biolog rememb specif carbohydr diet scd diet cook make scd yougurt twice week bake almond bread familiar diet found tri hard becuas love bad food candi pizza hamburg fri etc well diet see improv bleed stop form stool know bad chron flare hospit week year old pleas googl specif carbohydr diet cours alway follow dr direct special daughter strong symptom hard strong posit heal possibl best luck pray quick recoveri daughter',\n",
       " 'live light presenc light shine brightli live other sarah young jesu call ok march mad sport fan care person march mad definit begun get march ground month kick march ct scan morn chemo afternoon midst recov sunday march tim flew denver tim confer swanapalooza want know tag along day perfect opportun meet dr camidg season travel stupidli carri heavi stuff plane across airport mad rush come home learn someth experi sure monday dr kim call us give us result ct scan exact word stabl stabl stabl yay mean keep keep alimta chemo everi four week next scan june phone call lunch one best friend grow trista realiz spent much time talk catch almost hour even take pictur heck year moment captur photo guess excit see talk catch pictur even cross mind odd jeeper note friday also forgot take chemo pictur first time think much go live part take document part good thing mayb hire paparazzi follow around month captur month pictur got back hotel lunch pretti much went bed wake next morn wipe chemo friday travel sunday long lunch time chang whatev feel much better tuesday tuesday appoint dr ross camidg may rememb follow ro der one top ro expert world work univers colorado anschutz cancer pavilion tim talk phone twice big decis make want get opinion know us somewhat want actual face face meet least great opportun realli mani question much sinc scan know stabl chat littl bit got question answer head airport anoth full day travel time tim stay confer second birthday celebr second celebr first one punta cana past weekend relax casual time bluffton sc friend mitch jill move year ago sheryl greg join us hung togeth realli nice stress free saturday realli day girl went old town bluffton walk around brunch took pontoon boat around lake neighborhood built around fun got back hous took nice short two hour nap went dinner awesom see mitch jill alway nice relax weekend midst crazi month lung forward updat moment peopl team donat person page bit ly lung kk may sound like much yet still two month team kk reach team member donat begun thank everyon alreadi donat excit year best year ever teamkk help hint want donat person page want team member donat link first join team much less confus way shirt new shirt year may dedic next blog post inform probabl team updat hate hijack blog want sure info get whoever would want team shirt alreadi lot peopl ask anyway meet vendor week get back shirt color style price everyth asap get order time',\n",
       " 'dorothi mom keytruda year began carbo alimta keytruda session went keytruda learn quit bit along way far thyroid need monitor regularli mom tsh test everi week receiv infus free test everi month thyroid issu common side effect monitor alreadi mom doc bring regular visit unless someth wrong need chang med mayb doc test thyroid give info far muscl pain mom uncommon heard sever enough caus someon limp also heard tendon pain immunotherapi caus inflamm even joint could relat immunotherapi think explain red skin agre tom contact doc report symptom may sort unrel infect need address asap far continu walk hard say exactli know root problem hope help bit take care steff',\n",
       " 'emma think bristol trial use chemo although hsct seem chemo cure stem cell rebuild immun system think ocrelizumab avail soon approv u price cours john',\n",
       " 'got agre ipoop long term pred simpli viabl option feel bad surgeri either mg pred felt quit good actual thing heal colon patholog report show sever chronic acut inflamm throughout colon test could get pred summer still okay tend alway flare wors winter acut flare up year happen autumn winter dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'friend recent diagnos nsclc stage lung met brain c start drug call tagrisso would benefit consult msk',\n",
       " 'februari final progress hunt treatment difficult form multipl sclerosi form stubbornli resist everi attempt find therapi catch expert say peopl form diseas keep expect low even new drug last stage develop appear big clinic impact reason new drug gener much interest though first time therapi primari progress ms impact first ms drug ever receiv breakthrough design food drug administr put experiment medicin fast track get review process quickli possibl agenc grant design earlier week read father daughter fight differ form ms primari progress ms rel rare form neurolog diseas person sever attack way peopl common relaps remit kind instead suffer slow steadi physic deterior hope recoveri fda approv drug treat relaps remit ms none shown work peopl primari progress diseas new breakthrough drug call ocrelizumab one six variou stage develop recalcitr form one affect percent estim american live ms friday compani behind ocrelizumab roch subsidiari genentech releas new phase trial data confer america committe treatment research multipl sclerosi held new orlean genentech alreadi publish first round result show impact wide rang measur peopl primari progress ms new data includ detail ocrelizumab affect subgroup patient well new inform work peopl relaps remit ms show whether also work common varieti diseas continu articl found ms view news help provid educ inform person affect ms keep current multipl sclerosi news inform opt websit click thank',\n",
       " 'silicon lubric bubbl eye randi much research think learn issu appar variou type syring avastin typic us anyway come steak steak syring wherea eylea typic come luer lock syring largest manufactur variou type syring us use silicon lubric syring make chanc get silicon patient eye differ luer lock syring lubric far less likelihood get onto needl steak type switch avastin eylea next inj hope work wet macular degener hope inform syring correct date cannot swear expert',\n",
       " 'j pain re dec abstract read full text paper hugo cl chen z chen et al multicent random control trial two group educ program fatigu multipl sclerosi short medium term benefit mult scler dec [epub ahead print] abstract ferraro planton morselli f et al systemat assess character chronic pain multipl sclerosi patient neurol sci dec [epub ahead print] abstract heesen c haas r melzig et al percept valu bodili function multipl sclerosi acta neurol scand dec [epub ahead print] abstract vitamin hongel k silva dg ritter et al efficaci safeti outcom vitamin supplement user fingolimod phase trial j neurol dec [epub ahead print]',\n",
       " 'hello name patrick year old data scientist base dubai ms gay diagnos ms andi gilenya sinc diagnosi far found consider relief drug howev come conserv irish famili father alway hard grow flamboy normal child want appar freak also never like use releas temper onto mother bigot mindset exert henc alway made busi relationship go first year univers mainli due incred shelter upbring still closet bulli mercilessli housem culmin nearli assault subsequ take next year anxieti condit thank occur reason gain courag came gay diagnos ms gp regular appoint notic one eye blink slower sent neurologist diagnos return univers got degre upon graduat join consult firm stay month even though spent year america homophob environ even got slap colleagu outsid work event never went hr fear tell famili work dubai lgbt inclus firm ye understand ironi lgbt dubai howev mainli work american june hear depend father send medic say threw hous last christma eve one anger fit never got proper apolog howev wors part came last june leav ireland back dubai last visit home corn hallway hous menacingli said low breather lucki longer control would let g ye word appear benign sentiment want control life scare know hate fact activ gay want know everyth would spout emot psycholog rhetor grew put way eldest sister hi favorit took year tell first boyfriend cathol relat marriag get optic conservat arriv back dubai subsequ appear experi frequent anxieti attack upon return dubai wors first time sinc diagnosi ms begun experienc seriou ms symptom doubt anxieti ms mutual exclus case email neurologist said normal ok last mri said stabl told result say see neurologist everi month annual mrii alway thought never receiv mri report post sent patient bad news ye know fool upon investig discov father open medic post subsequ destroy notifi result make matter wors day discoveri juli decid begin charg gilenya po ask littl extra know one would pay back postag expens help parent domin man violent temper duplicit stuff n think thank got enough suppli friend ireland last month enough next appoint advic would give someon situat difficult overbear homophob parent vocal zero faith career homophobia etc caus much sorrow behaviour mention neurologist next appoint never spoke medic profession one situat fear father manipul appear saint public demon behind door would threaten deni told sibl often hear mother tell other think listen mike father treat patrick badli gay yet would never tell someon power fear would appreci advic may give apologis went rant admir work websit greatli make differ kind regard patrick',\n",
       " 'chipofbag opdivo keytruda equival go target cell would unnecessari opdivo yervoy combo make lot sens opdivo mostli act cell tumor wherea yervoy mostli act cell circul cytotox lymphocyt associ protein ctla blockad impact human immun system expand pool circul cell may mechanist relat induct autoimmun inflammatori toxic http clincancerr aacrjourn org content full say reason pd inhibitor well toler wherea ctla inhibitor sever side effect also blockad differ target cell shut immun escap rout cancer usual use',\n",
       " 'keytruda creat autoimmun diseas lung pneumon put hospit day pneumonia put oxi read',\n",
       " 'case studi increas use infliximab biosimilar could lower cost million annual san francisco ca prnewswir new studi releas today pacif research institut found remov barrier hold back increas use biosimilar save could signific case studi infliximab use treat rheumatoid arthriti crohn diseas ill reform could realiz annual save million million click download copi studi american save lot prescript drug cost increas use lower cost gener medic said dr wayn winegarden author new studi next gener treatment develop govern market barrier must stand way use cheaper biosimilar biolog complex treatment studi found could save significantli barrier lift biosimilar use often biosimilar medicin lower cost altern patient provid unlik gener medic chemic ident origin product size complex biolog molecul make imposs make ident biolog molecul winegarden note greater use biosimilar potenti reduc cost treatment way increas use gener medic reform enact feder law reduc excess regulatori burden gener drug manufactur extend term clarifi right patent holder gener save u health system trillion alon biolog medic commonli use signific potenti estim global market grow billion billion one industri estim project increas biosimilar use cut price around percent impedi stronger biosimilar market winegarden use case studi biosimilar infliximab commonli known remicad use fight rheumatoid arthriti crohn diseas ulcer coliti chronic sever plaqu psoriasi activ psoriat arthriti show increas use biosimilar benefit patient employ taxpay among find annual per patient save remicad biosimilar would rang biosimilar grew becom one half infliximab market annual cost reduct employ sponsor health plan would high percent million million less save taxpay lower medicar cost util biosimilar could high percent million save annual collect could save million million year increas use biosimilar one drug alon dr wayn winegarden senior fellow busi econom pacif research institut also princip capitol econom advisor manag editor econostat pacif research institut www pacificresearch org champion freedom opportun person respons advanc free market polici idea follow pri facebook twitter linkedin',\n",
       " 'home ms inform public ms research updat siponimod baf siponimod baf updat main articl introduct fda approv medic experiment medic new direct ms research close note approv diseas modifi therapi ms pdf refer experiment medic new p receptor modul compani novarti oral medic studi sever dose studi spm previou ublituximab next ozanimod siponimod drug mechan action similar gilenya like gilenya work p receptor famili block movement lymph cell lymph node howev siponimod appear interact fewer receptor gilenya primari action p p receptor siponimod rel short half life compar gilenya mean drug stay bodi long research hope small differ minim cardiac issu expand phase iii multi nation studi siponimod involv peopl secondari progress ms publish lancet march particip random ratio receiv siponimod placebo trial schedul run three year pre specifi number confirm disabl progress event cdp occur primari endpoint time three month cdp studi found rel placebo siponimod reduc risk three month cdp percent cut risk six month cdp percent slow rate brain volum loss percent reduc annual relaps rate percent signific differ found siponimod placebo term two walk test studi trial eighteen percent patient siponimod group percent receiv placebo experienc seriou advers event decreas white blood cell heart rate rhythm abnorm well hypertens swell macula eye varicella zoster reactiv convuls occur often patient receiv siponimod placebo group rate infect cancer death differ group adjust initi dose siponimod mitig cardiac effect seen earli treatment medic novarti develop siponimod announc file new drug applic nda fda seek approv use p receptor modul spm rrm meanwhil result phase ii dose find studi siponimod first report trial complex design primari goal determin appropri dose carri forward futur trial approxim peopl particip studi six month proport relaps free patient percent mg group percent mg group percent mg group compar percent placebo group six month arr annual relaps rate lower individu take one three higher dose addit regard mri paramet mg dose reach statist signific versu placebo reduct activ lesion approxim percent previou ublituximab also known tg next ozanimod formerli rpc',\n",
       " 'present ectrim ocrevu relat death',\n",
       " 'dear member staff sister age diagnos nsclc stage iv adenocarcinom egfr mutat exon l r year ago tarceva littl less year follow chemotherapi carboplatin alimta develop mutat well tagrisso year howev summer gener well declin x ray show tumour progress new biopsi main tumour reveal tumour transform squamou lung cancer accord mutat analysi tumour follow marker p ck posit pd l neg oncologist suggest second round chemotherapi carboplatin gemzar would much appreci suggest regard treatment sister could pleas note live europ sweden would good idea add cetuximab chemotherapi consid diagnos squamou lung cancer awar clinic trial could suitabl case saw articl ly phase trial uk advic would highli appreci thank attent best regard eva topic modifi month week ago evani topic modifi month week ago evani',\n",
       " 'get initi infus stelara today feel jf',\n",
       " 'hello cancer mix origin egfr exon mutat still sensit tarceva tp r c notch e k fgfr l l mutat sensit tagrisso apart mutat thank kempten',\n",
       " 'melmel differ patient anoth get relaps everi tear sever year even treatment year ms keep play around brain silent reber avonex use get relaps everi month differ person anoth group peopl havent got well gilenya bad rebef',\n",
       " 'hi question brother histori diagnos nsclc adeno alk start cisplatin alimta alimta mainten good respons diseas progress start xalkori year stop work went back alimta month progress start zykadia work well last month lymph node disappear tumour one lung turn scar left lung tumour reduc size soon got report bad rash last coupl week face bodi stop take zykadia dermatologist gave medicin rash suddenli swear headach take dexa get normal ct scan report today say mm hyperdens lesion area punctat calcif target like fashion within right pariet tempor lobe lesion demonstr intens post contrast enhanc extens vasogen oedema caus effac ipsilater later ventricl subfalcin herniat along mid line shift patholog brainparenchym lesion identifi foreman magnum basal cistern capaci without evid transtentori herniat conclus imag featur keep metast deposit within right pariet tempor lobe whole brain radiat suggest question scare radiat cyberknif option gammaknif option best stop take zykadia need stop zykadia day till radiat stop zykadia jump nivolumab zykadia result better except brain lesion need carri zykadia avoid brain lesion zykadia cross brain barrier get alimta everi three month alimta cross brain barrier sorri question sound',\n",
       " 'major random receiv drug therapi given rel mild ms medic includ copaxon beta interferon tecfidera gilenya minor receiv tysabri alway wonder new drug compar rebif avonex anyon actual use anyway make hard understand drug effect compar one drug think know answer anyway accept new trial chicago ad ivig part experiment portion everyon receiv chemo time question want ask brain fog get way ugh',\n",
       " 'even stick ostomi crohn point may need medic actual good amount crohn patient go j pouch crohn diagnosi wonder stat need medic futur surgeon mention patient without issu keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'mani imod trial moment work p work like fingolimod need give free advertis surpris would work trial announc may report approv report remain seen happen fingolimod patent extend price plung make interest see imod top',\n",
       " '[continued] dr west also express doubt efficaci first second gener tki tagrisso failur action mutat shown primari option would like standard chemotherapi regimen egfr mutat posit patient tend respond well immunotherapi option respons rate group patient tend low good luck whichev treatment path chosen jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'think anyon onlin address happen cancer center perhap ask directli serum test blood sampl definit possibl seen posit result lead tagrisso standard care time bank insur cover test blood mani vendor test rang guardant health biocept foundat medicin other real issu realli primarili whether mutat might make sens look lab hundr think biocept individu test cost effect option instanc other rather long list test thousand dollar good luck dr west',\n",
       " 'tagrisso sinc juli great initi respons visibl cancer shrink point longer detect cancer journey treatment cancer type lung cancer diseas learn pet scan kidney valu requir husband follow valu kidney function creatinin normal rang urea normal rang would valu cancer journey treatment cancer type lung cancer diseas learn mix result treatment anyon mix result chemo immunotherapi uncl diagnos stage iv nsclc exon mutat spread bone cancer journey treatment cancer type lung cancer diseas learn video post onctalk local therapi metastat lung cancer saturday novemb grace partner swedish cancer institut present live webcast discuss local therapi cancer journey treatment cancer type lung cancer diseas learn lung cancer gener lung cancer chemotherapi rd line beyond scan pet ct etc surgic immunotherapi radiat therapi non small cell lung cancer non small cell lung cancer patient caregiv opportun particip studi rare patient voic hi approach whatnext group partner rare patient voic opportun particip studi specif non cancer journey survivorship cancer type lung cancer diseas learn lung cancer gener lung cancer',\n",
       " 'tomorrow ocrevu infus toler well think work info possibl secondari posit effect ocrevu deplet cell etc seem excit news though small studi hope data born overal hope mani other ocrevu work wonder encourag peopl research mayb think contact neuro nurs copay assist program happi new year way hope dawn well lot peopl',\n",
       " 'ocrevu first proven medic slow progress disabl even nice eventu agre guarante us would get current edss full time wheeli need crutch stand guess mean miss boat think ppm proven dmd whilst may need multipl med cope symptom need dmd drug unlik cost effect option nice sad ppm suffer sonia x',\n",
       " 'see focu label promot thread seem unusu vagu case bodi progress egfr exon detect genestrat dna detect get regular biopsi tagrisso holi water side effect would reluct use without solid justif motto first harm suggest send pleural fluid tumor tissu egfr requir much tissu test janin point sbxrt reason option singl site progress chemotherapi immunotherapi still proven option patient older age hope help',\n",
       " 'meet coverag registri data lemtrada effect compet ms tx better fingolimod interferon compar natalizumab john gever manag editor medpag today london data larg multipl sclerosi patient registri suggest alemtuzumab lemtrada effect key efficaci measur two common drug ms similar efficaci third research said analysi cover patient recent start alemtuzumab fingolimod gilenya interferon beta rebif avonex natalizumab tysabri alemtuzumab better fingolimod interferon least one follow outcom measur relaps risk disabl progress function improv less effect efficaci measur report toma kalincik md phd univers melbourn australia alemtuzumab natalizumab virtual dead heat relaps prevent reduc disabl progress kalincik told attende oral late breaker session european committe treatment research multipl sclerosi annual meet one outcom analyz entir studi alemtuzumab inferior anoth drug natalizumab like produc improv function abil first year treatment though subsequ year howev studi specif support one drugmak import limit address safeti efficaci outcom analyz includ effect mri detect brain lesion nevertheless robert fox md cleveland clinic involv analysi said data import inform clinician real world experi agent type analysi told medpag today allow us compar drug head head compar head head trial probabl major surpris evid result fox said still data provid confid emerg pictur alemtuzumab gain approv less year ago also point signific strength analysi use propens match make observ studi appl appl comparison put studi kalincik colleagu drew msbase databas current includ ms patient countri treat cumul patient year research focus patient treat alemtuzumab receiv interferon beta treat fingolimod treat natalizumab includ patient meet follow criteria definit ms standard diagnost criteria new treatment one four agent baselin score expand disabl statu scale age ms durat year least one relaps past year least month data prior start drug least month post initi follow minimum two post baselin visit least month apart patient also select could match other differ treatment type accord clinic demograph data propens match highlight comparison cite kalincik alemtuzumab vs interferon superior mitig relaps activ patient highli activ diseas disabl progress improv function abil alemtuzumab vs fingolimod superior prevent relaps otherwis compar alemtuzumab vs natalizumab compar relaps activ disabl progress natalizumab superior earli regress disabl kalincik said group also perform numer sensit analys variou paramet definit pre baselin diseas activ specifi differ minimum follow interv alter import chang overal result said _______________________ kalincik disclos relev relationship roch genzym novarti merck kgaa biogen webmd global sanofi genzym teva biocsl co author disclos multipl relev relationship industri',\n",
       " 'alimta year ago along cisplatin one worst alimta told doctor good chemo mainten chemo caus symptom think carbo like cisplatin caus problem dad describ symptom might also cancer also given iv fluid steroid everi day day chemo thing kept throw sick gain weight care help let dad get sick lose weight like talk dad oncologist iv ifus fluid steroid pick appetit also heart goe',\n",
       " 'janin thank much link good articl video know refer back think full genom test would make sens progress time soon mayb mutat discov test right think would uncov anyth worthwhil cathi dx stage iv adeno dec kra g pdl tumor sampl st line carboplatin alimta alimta mainten work well nd line keytruda work rd line imrt lung radiat gy current watch wait',\n",
       " 'thank much info see neurologist morn hope posit news also copaxon first diagnos last month start seriou side effect right inject feel gilenya',\n",
       " 'think efficaci wise roughli ocrevu may better safeti profil depend use continu use ocrevu risk infect increas',\n",
       " 'hi jimc thank quick respons father oncologist suggest chemo unfortun toler first low dose infus chemo clearli question receiv radiat treatment bone pretti clear new bone met radiat treatment also brought idea possibl combin two differ egfr tki oncologist respons outsid clinic trial seem think even probabl help much ad toxic patient bodi go back tarceva go help either sure agre total understand combin might work agre give someth especi someon life without even give tri think oncologist act good faith want suffer side effect drug think realli get second opinion thank much advic thought',\n",
       " 'quick updat mom onc appoint infus appoint onc recommend mom stay alimta respond alimta well sinc diagnosi onc feel keep ro mutat news back pocket futur mom stop respond alimta kind agre onc fix someth broken mom th round alimta session back perki self reason overlook consid crizotinib alimta also read crizotinib tendenc prevent brain met mom met whatsov knock wood alimta anoth reason comfort onc recommend thank bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test neg stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr start alimta alimta sinc usual ned chemo period less month month recent occurr jan alimta jan thru april ned april occurr cancer jan start alimta test posit ro june appt onc discuss futur tx plan',\n",
       " 'sam think seen paper even discuss rememb unfortun way find discuss thread see pd l express almost ec normal e littl bigger differ pd l high ec posit pd express opdivo keytruda work especi type ii ec also spliceosom mutat fine',\n",
       " 'hi everyon hope well cced letter st georg neurolog consult sent dr royal london hospit ask consid treat cladribin mavenclad wonder anyon treatment read cours appear taken consecut day two month nd cours month later treatment taken home hospit treatment wonder hope royal london dr treat give insight would great thank best wish jo',\n",
       " 'phx get accept biotin trial test high dosag mg x daili mani doc recommend evid supplement accord one studi could make ms wors see goe month slower still terribl optimist insur cover ocrevu may switch tri differ drug altogeth __________________ dave bexfield activems',\n",
       " 'therapeut lag fingolimod month tecfidera month apart b therapi',\n",
       " 'hi emili good hear husband respons wbr puls tarceva hard know approach caus improv although scan period puls tarceva wbr might provid clue good discuss radiat puls tarceva intrathec chemo none faculti member thread endors intrathec chemo lmc lung cancer tend work nearli well breast cancer lmc case also note tend especi difficult toler dr west conclud remark especi fear neg side effect wbrt also wildli optimist likelihood help least feel less intens intrathec chemotherapi might consid fair option patient declin week week appear thing worsen readili believ priorit comfort inclin minim intervent given possibl puls tarceva drive husband improv togeth gener lack enthusiasm intrathec chemo seem continu puls tarceva may reason option best husband jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'leogirl seem depend great risk pml case risk greater tysabri henc frequent monitor howev would worth ask question next time see neuro',\n",
       " 'mother diagnos stage b lung cancer januari surgeri remov lower left lobe follow round cisplatin etoposid chemo complet follow ct scan first scan clear month later next scan indic pleural effus nodul pet scan thoracentsi confirm cancer return thank cancer still contain lung start spread elsewher mainten chemo carboplatin taxol avastin complet round drug receiv avastin longer work would appreci inform drug type cancer',\n",
       " 'hi lefteyego sorri hear pain similar lucenti recent eyelea use differ antisept think chlorhexidin ask other luckili lot rins seem trick take painkil hour inj paracetamol think site eye also make differ skill injector plu quickli take long eye dri clinic give sooth drop inj help use lot prescrib drop hylotear dri eye pain underestim eye tear dri need lubric end day weigh week pain worth week sight differ everyon depend see guess wish well go forward hope thing get better x send hug x',\n",
       " 'think find much possibl ms kind decid variou drug option open ocrevu one offer mayb diagnos progress side effect well actual financi cost option ocrevu pp still need understand drug potenti benefit risk start benefit outweigh risk cost take afford togeth health insur look benefit think worth tri get inform sort head ie husband start sue',\n",
       " 'continu tradit provid time market feedback asco obr mdoutlook pleas share result mdoutlook th annual post asco survey field among global network cancer physician first quick poll publish obr blog cover one hottest topic asco melanoma follow result analysi publish tumor type list introduct quick poll methodolog respond geograph distribut american societi clinic oncolog asco annual meet held chicago il june melanoma quick poll launch email morn friday june th seri asco quick poll quick poll includ non small cell lung cancer nsclc gu prostat renal cancer gi cancer melanoma sent global distribut medic oncologist clinician clinic interest melanoma data taken june th complet respons respons usa respons receiv differ countri total financi incent provid particip survey result melanoma treater plan treat major v e braf melanoma patient vemurafenib conclus us melanoma treater slightli higher anticip usag vemurafenib major place stage iii stage iv melanoma patient vemurafenib ex us melanoma treater like place stage iv melanoma patient vemurafenib stage iii unresect melanoma patient place stage iv melanoma patient oppos stage iii patient physician plan select usag ipilimumab advanc metastat melanoma patient ipilimumab conclus largest proport us melanoma treater use ipilimumab unresect stage iii stage iv melanoma patient largest proport ex us melanoma treater use ipilimumab unresect stage iii stage iv melanoma patient less ex us melanoma treater use ipilimumab vs us melanoma treater melanoma treater rate clinic import clinic trial gsk mek inhibitor gsk braf highli import conclus overal melanoma treater view clinic trial test gsk gsk combin high major clinician rate clinic import high high less rate clinic import low major melanoma patient screen v e braf mutat next year conclus major us ex us melanoma patient screen v e braf mutat upcom year us patient ex us patient less patient screen previou year increas us increas ex us overal conclus melanoma treater plan use vemurafenib v e braf melanoma patient clinician plan use ipilimumab advanc metastat melanoma patient littl differ usag unresect stage iii stage iv melanoma patient respond view clinic trial test gsk gsk combin high clinic import melanoma treater doubl number patient screen v e braf mutat next year final thought quick poll fast way measur expect accept clinic data post major medic meet perhap use make assumpt adopt amongst provid today inform hungri environ speed poll conduct analyz advantag market plan pressur test accept data amongst key stakehold submit stefan terwindt evp arca group',\n",
       " 'clinic efficaci cladribin tablet patient relaps remit multipl sclerosi rrm final result week phase iiib extens trial clariti studi [abstract]',\n",
       " 'profg suggest alemtuzumab may treatment last resort show data suggest ocrelizumab induct therapi',\n",
       " 'golimumab detect circul fetu whose mother treat drug ulcer coliti accord case studi franc reuter health inform http www medscap com viewarticl src rsshttp www medscap com viewar sourc medscap medic news headlin',\n",
       " 'neuro told want either tecfidera gilenya lemtrada given appoint ms nurs explain everyth detail chanc could get appoint risk drug brain diseas tecfidera pml skin cancer gilenya henc difficult decis look ms trust websit think detail drug rachel',\n",
       " 'read interest find le berr et al report first case combin biolog agent tofacitinib manag inflammatori bowel diseas ibd recent approv small molecul tofacitinib treatment ulcer coliti multipl small molecul therapeut pipelin make co mbinat increasingli attract approach tri close therapeut gap ibd furthermor lack immunogen offer advantag biolog agent potenti allow sequenti therapi sourc clinic gastroenterolog hepatolog',\n",
       " 'receiv sever ten inject eylea eye last year also sever issu pain procedur doctor decid tri procedur without use lid speculum made differ world get sore afterward howev mild comparison experienc previous still use iodin doubl tripl wash afterward',\n",
       " 'donna appreci time taken tell experi disabl system file paperwork letter came request hear unfortun nc attorney repres hear system back log way attorney insur profit thing repres talk behalf complet paperwork thank one thing regard husband tysabri monthli infus last yr one guy usual infus wheelchair yr ago start take cbd oil hemp daili within week could walk ask md drug test read fals posit told purchas chronic pain current cut pain med night liver would great know relev l ask seen chang drastic final hope offend suggest tri normal life sherri byrd',\n",
       " 'team led dr murphi use genet engin mice human lung cancer cell cultur investig role altern erbb signal mutat kra driven adenocarcinoma found neratinib suppress tumor growth importantli enhanc activ mek inhibitor show prophylact treatment multi erbb inhibitor neratinib could complet prevent kra mutant cancer aris dr emilio casanova team vienna demonstr therapeut efficaci similar drug afatinib pre exist lung tumor dr murphi said import note studi demonstr requir simultan inhibit multipl egfr erbb receptor drug target singl member famili ineffect slow tumor growth limit studi preclin design work need determin whether multi erbb inhibit strategi would work patient accord dr murphi multi erbb inhibitor alreadi approv use egfr mutant erbb amplifi cancer make path clinic trial kra mutant diseas much direct howev drug sever target side effect skin gut epithelium toxic present limit relat articl biomark base blood test may extend reach ct screen certain lung cancer role braf mutat non small cell lung cancer still emerg evolv bevacizumab plu erlotinib may new standard care non small cell lung cancer determin way focu drug deliveri target organ would make drug use clinic set ad clinic use singl agent afatinib neratinib would like use combin trametinib anoth erk mek inhibitor found multi erbb inhibit ineffect establish diseas use singl agent effect combin second small molecul inhibitor small molecul screen could reveal excit new combin therapi extend benefit drug although addit research definit need result two studi offer hope patient advanc kra driven lung adenocarcinoma beyond develop therapi directli target mutant kra present approv drug target mutant kra lung cancer inde kra mutat wide use exclud patient treatment first gener egfr target therapeut dr murphi conclud two paper demonstr second gener egfr inhibitor also block signal erbb famili receptor show unexpect efficaci set need evalu new clinic trial specif diseas cohort refer',\n",
       " 'pleas crowdacur cladribin get licens uk knock effect worldwid promot label indic global',\n",
       " 'forc receiv rituximab label suspect alreadi tri get nh england give us permiss use rituximab post natalizumab patient jcv seroposit wait hear back indic abl also incorrect assum rituximab biosimilar ocrelizumab vice versa differ product rituximab less humanis henc higher incid anti drug antibodi infus reaction drug also slightli differ effector mechan way work base differ unlik nh england treat interchang drug',\n",
       " 'repli post bm new site want suggest possibl appli assist help pay medic mom take mani drug expens insan exampl take remicad appli jansen care path program compani seem offer someth similar annoy paperwork follow phone call etc help pay worth hope help small way best luck famili',\n",
       " 'said scope bad talk go mg mg weekli humira switch entyvio discuss decis regard option moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa look sick trust look like feel everyon would run scare within inch life',\n",
       " 'arsen heck drink point shove nitroglycerin ass stop scream abscess hope work keep us updat femal canada ivig pentasa entyvio infus respons discontinu uc crohn test posit map antibodi mycobacterium pg remiss flare almost year bad way due abx treatment gone wrong sigh',\n",
       " 'biolog price competit innov act bpci act sign law march part afford care act bpci act creat abbrevi approv process biosimilar goal demonstr biosimilar propos product origin product independ establish safeti effect propos product total evid approach taken fda evalu biosimilar approv result clinic trial import data preclin work also consid biosimilar approv use fda approv addit indic condit base concept call extrapol data data collect biosimilar preclin work show clinic result origin product biolog addit clinic trial conduct instanc clinic trial biosimilar filgrastim sndz studi effect safeti clinic trial whose particip treat breast cancer approv grant fda filgrastim sndz bone marrow stimul five indic approv origin product filgrastim patient cancer receiv myelosuppress chemotherapi treatment stop slow growth blood form cell bone marrow patient acut myeloid leukemia receiv chemotherapi patient cancer undergo bone marrow transplant patient undergo autolog peripher blood progenitor cell collect therapi method replac blood form stem cell destroy cancer treatment patient sever chronic neutropenia abnorm low count type white blood cell biosimilar approv fda includ filgrastim sndz current twelv biosimilar approv fda treatment specif condit fda approv six immunosuppres drug treatment certain form arthriti psoriasi ulcer coliti crohn diseas drug list order approv infliximab dyyb inflectra origin product infliximab remicad etanercept szz erelzi origin product etanercept enbrel adalimumab atto amjevita origin product adalimumab humira infliximab abda renflexi origin product infliximab remicad adalimumab adbm cyltezo origin product adalimumab humira infliximab qbtx ixifi origin product infliximab remicad septemb fda approv bevacizumab awwb mvasi treatment five type cancer non squamou non small cell lung cancer nsclc metastat colorect cancer mcrc glioblastoma metastat renal cell carcinoma persist recurr metastat carcinoma cervix bevacizumab awwb approv indic origin drug bevacizumab avastin could reach u market soon patent bevacizumab expir decemb fda approv trastuzumab dkst ogivri treatment peopl posit breast cancer posit gastric cancer growth promot protein found surfac cancer cell origin drug trastuzumab herceptin patent expir',\n",
       " 'get keytruda treatment month treatment everi week lung cancer dr call today gave best news ever pet scan yesterday mass lung shrink thank jesu',\n",
       " 'best knowledg tagrisso activ regular egfr mutat understand tagrisso also activ less commonli discuss nonreceptor protein howev heard tagrisso activ fgfr notch given presenc seem reason tri',\n",
       " 'thing first chemo carboplatin abrazan kill brain met doc said less happen although keep take lamict scar weird visio stuff happen otherwis chronic condit prognosi gotten pretti much vibe oncologist opdivo tumor pretti much gone away hypermetabol med speak good go year stage nsclc feel great good luck',\n",
       " 'shurel sound like ideal candid lemtrada fast act ms diagnos two year ago peopl spm well quot paper subject lemtrada call campath quot patient spm campath show sustain accumul disabl due uncontrol progress mark unrel cerebr atrophi attribut ongo axon loss rate cerebr atrophi greatest patient establish cerebr atrophi highest inflammatori lesion burden treatment contrast patient rr diseas show impress reduct disabl month campath h mean edss point perhap owe suppress go inflamm patient unusu activ diseas j neurol jan epub jul window therapeut opportun multipl sclerosi evid monoclon antibodi therapi know peopl get bore bang cladribin drum go anyway link blogspot post suggest cladribin work peopl spm well rrm wait work second dose last week http multipl sclerosi research blogspot com suppos wa',\n",
       " 'momof yroldboy constantli think son hope remicad bring need relief son first remicad infus saw huge differ attain clinic remiss doctor nd infus two week month later rd infus administ tri week interv saw symptom appear like mucu trace blood stool week interv remicad take methotrax remicad stop constantli cold abl shake last infus complaint tight chest within minut infus disappear afterward know much diseas thought share first hand inform hope thing improv son soon let us hope kind cure crohn avail soon thank peopl updat post experi provid guidanc variou situat websit gotoplac anxieti strike often',\n",
       " 'sandra_macgowan patient advic leaflet accompani gilenya suggest overdosag may induc bradycardia slow heart rate usual manag situat monitor heart rate ecg overnight whilst regularli check blood pressur happen day ago seem toler error get contact neuro team suggest',\n",
       " 'barryb also spm relaps neuro recent offer lemtrada worri possibl side effect decid pursu cladribin support gp unfortun wait list see dr schmierer least month ms patient referr wait list becom longer cladribin consider ms activ keep told time brain could access lemtrada fairli soon difficult know especi know whether would accept cladribin',\n",
       " 'everywher littl growth brain met heart met met mandibula littl growth fit asp progress better pseudoprogress would aggress growth would fit better pseudoprogress summer effus pericardium disappear use opdivo radiat mayb respons immunotherapi respons weak later subcutan lesion start shrink avastin ad treatment tini hole theori didnt respond immunotherapi unfortun like explan still immunotherapi isnt work moth buy time differnt tki obvious havent yet accept unavoid death difficult avoid point',\n",
       " 'hello melissa g condasmum besid ms happen work compani sponsor mavenclad uk product packag differ languag adveva name patient support program current held uk market promot mavenclad way much train think contribut part knowledg product go ocrevu rrm ppm mavenclad opinion three main advantag medic short cours oral treatment rrm tablet year two year sustain neda rate almost patient year edss progress patient compar mab lemtrada ocrevu tysabri unlik tysabri natalizumab gilenya fingolimod mavenclad induc continu immunosuppress deplet b cell slowli recov time supposedli prevent long term damag immun system case pml report year clinic trial led mavenclad approv ema frequent advers event ae lymphopenia one would expect mechan action drug herp zoster infect one disadvantag would point switch mavenclad therapi quit tricki wait time switch therapi guess neurologist handl wise also sure check famili plan start advis procreat mavenclad specif period time cours medic matter boy girl hope help best luck',\n",
       " 'navig world multipl sclerosi ms daunt task time whether diagnos sever year newli diagnos ever chang natur ms make live challeng random relaps flare unpredict progress enough drive person mad fortun ms treatment make seemingli insurmount beast somewhat tameabl tradit multipl sclerosi treatment option mani multipl sclerosi treatment option exist ms pill inject infus sever altern treatment avail find one give best result key diagnos neurologist initi tri tecfidera twice day pill help keep troublesom symptom ms bay unfortun success treatment physician refer doctor special multipl sclerosi ms physician put ocrevu infus receiv everi six month new lesion infus therapi relief symptom acquir new one mani differ type multipl sclerosi relaps remit rrm primari progress ppm secondari progress spm progress relaps prm sinc diagnos rrm focu treatment help form ms follow tradit multipl sclerosi treatment option rrm oral therapi common choic comfort needl requir regular dose schedul taken either twice daili includ tecfidera dimethyl fumar aubagio teriflunomid gilenya fingolimod self inject offer option choos train health profession administ medic includ betaseron interferon beta b avonex interferon beta copaxon glatiram acet zinbryta daclizumab plegridi pegyl interferon beta rebif interferon beta extavia interferon beta b glatopa glatiram acet intraven infus inject directli vein requir often self inject includ ocrevu ocrelizumab lemtrada alemtuzumab tysabri natalizumab novantron mitoxantron option medic come side effect may includ headach flu like symptom red pain swell inject site low white blood cell count nausea vomit diarrhea itch joint pain infect complet list possibl side effect consult medic websit physician complet list mani medic also requir regular blood monitor natur therapi ms want steer clear chemic treatment know also natur way help treat symptom ms far less expens tradit treatment may effect though medicin properti mani fda approv yet research proven method manag ms symptom see also ms treatment medic sleep problem ms best ms treatment center relaps ms might also like ms age ashwagandha indian herb also known queen ayurveda shown help stress cancer neurolog diseas leav plant help memori cognit function root help mobil movement issu ginkgo biloba shown help fatigu troublesom symptom ms take supplement daili dandelion root leaf antioxid anti inflammatori agent also help reliev fatigu common symptom ms ginger also strong anti inflammatori properti among mani thing help ms symptom turmer natur herb commonli use season contain curcuminoid shown neuroprotect properti import neurolog diseas like ms chines hemp seed becom popular choic help manag ms symptom calm effect central nervou system help spastic part cannabi famili contain fatti acid make great option natur treatment multipl sclerosi vitamin defici shown play major part develop ms take supplement help elimin least eas mani ms symptom dha docosahexaeno acid omega fatti acid found fish like salmon tuna mackerel help inflamm neurolog function protect central nervou system magnesium found natur green leafi veget fish nut supplement pill form excel sourc help myelin damag alway check physician make chang multipl sclerosi treatment plan',\n",
       " 'medicin may caus harm unborn babi take pregnant take pregnant may get pregnant use birth control prevent pregnanc pregnanc test done show pregnant start arava leflunomid use birth control trust prevent pregnanc take drug keep use birth control go process get rid extra leflunomid bodi need blood test show bodi free leflunomid stop take birth control get pregnant take arava leflunomid call doctor right away bad sometim deadli liver problem happen arava leflunomid tell doctor liver diseas medicin must use peopl certain liver problem liver function check told doctor tell doctor take drug rais chanc liver problem mani drug ask doctor pharmacist sure use arava see also orencia use treat rheumatoid arthriti need tell doctor take arava allergi leflunomid part arava leflunomid allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign health problem bone marrow diseas low blood cell count infect weak immun system take teriflunomid breast feed breast feed take arava leflunomid list drug health problem interact arava leflunomid tell doctor pharmacist drug prescript otc natur product vitamin health problem must check make sure safe take arava leflunomid drug health problem start stop chang dose drug without check doctor thing need know take arava tell health care provid take arava leflunomid includ doctor nurs pharmacist dentist blood work check told doctor talk doctor high blood pressur happen arava leflunomid blood pressur check told doctor talk doctor get vaccin take arava leflunomid stop take vaccin use arava leflunomid may either rais chanc infect make vaccin work well talk doctor may chanc get infect wash hand often stay away peopl infect cold flu may bleed easili care avoid injuri use soft toothbrush electr razor medicin may lower abil bone marrow make blood cell bodi need lead bad sometim deadli bleed problem infect tell doctor right away sign infect like fever chill bad sore throat ear sinu pain cough sputum chang color sputum pain pass urin mouth sore wound heal bruis bleed feel tire weak need tb tuberculosi test start arava leflunomid medicin stay bodi time stop take sometim doctor may give drug get rid drug faster talk doctor medicin may add chanc get type cancer talk doctor nerv problem happen arava leflunomid time nerv problem went away arava leflunomid stop sometim peopl nerv problem go away even arava leflunomid stop talk doctor take warfarin talk doctor may need blood work check close take arava leflunomid older use arava leflunomid care could side effect man sex femal could get pregnant wish father child talk doctor woman miss period unprotect sex think birth control work call doctor right away medicin arava best taken use arava leflunomid order doctor read inform given follow instruct close take without food gain benefit miss dose keep take arava leflunomid told doctor health care provid even feel well miss dose take miss dose soon think close time next dose skip miss dose go back normal time take dose time extra dose see also dosag inform detail side effect need call doctor right away warn caution even though may rare peopl may bad sometim deadli side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign bleed like throw blood throw look like coffe ground cough blood blood urin black red tarri stool bleed gum vagin bleed normal bruis without reason get bigger bleed bad cannot stop sign liver problem like dark urin feel tire hungri upset stomach stomach pain light color stool throw yellow skin eye sign high blood pressur like bad headach dizzi pass chang eyesight burn numb tingl feel normal pale skin bad skin reaction steven johnson syndrom toxic epiderm necrolysi may happen caus bad health problem may go away sometim death get medic help right away sign like red swollen blister peel skin without fever red irrit eye sore mouth throat nose eye bad sometim deadli lung problem happen arava leflunomid call doctor right away lung breath problem like troubl breath short breath cough new wors side effect arava drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away upset stomach throw diarrhea hair loss feel tire weak belli pain back pain headach dizzi side effect may occur question side effect call doctor call doctor medic advic side effect may report side effect fda fda may also report side effect http www fda gov medwatch see also side effect detail overdos suspect think overdos call poison control center get medic care right away readi tell show taken much happen store throw arava store room temperatur protect light store dri place store bathroom keep drug safe place keep drug reach children pet throw away unus expir drug flush toilet pour drain unless told check pharmacist question best way throw drug may drug take back program area consum inform use symptom health problem get better becom wors call doctor share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin drug may anoth patient inform leaflet check pharmacist question arava leflunomid pleas talk doctor nurs pharmacist health care provid think overdos call poison control center get medic care right away readi tell show taken much happen',\n",
       " 'consid cladribin http multipl sclerosi research blogspot com suppos therapi ms html st dose last month easi toler probabl safer effect fingolimod label gener publish data show good efficaci send email dr k websit dose info',\n",
       " 'u entyvio avail dosag form powder solut pharmacolog class monoclon antibodi use vedolizumab vedolizumab inject use treat crohn diseas ulcer coliti patient help medicin vedolizumab monoclon antibodi work immun system vedolizumab given direct supervis doctor use vedolizumab decid use medicin risk take medicin must weigh good decis doctor make vedolizumab follow consid allergi tell doctor ever unusu allerg reaction vedolizumab medicin also tell health care profession type allergi food dye preserv anim non prescript product read label packag ingredi care pediatr appropri studi perform relationship age effect vedolizumab inject pediatr popul safeti efficaci establish geriatr appropri studi perform date demonstr geriatr specif problem would limit use vedolizumab inject elderli pregnanc pregnanc categori explan trimest b anim studi reveal evid harm fetu howev adequ studi pregnant women anim studi shown advers effect adequ studi pregnant women fail demonstr risk fetu breast feed adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur case doctor may want chang dose precaut may necessari receiv vedolizumab especi import healthcar profession know take medicin list follow interact select basi potenti signific necessarili inclus use vedolizumab follow medicin usual recommend may requir case medicin prescrib togeth doctor may chang dose often use one medicin infliximab tofacitinib interact food tobacco alcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco medic problem presenc medic problem may affect use vedolizumab make sure tell doctor medic problem especi infect may decreas bodi abil fight infect proper use vedolizumab doctor train health profession give vedolizumab given needl place one vein vedolizumab come medic guid read follow instruct care ask doctor question precaut use vedolizumab import doctor check progress regular visit make sure vedolizumab work properli blood test may need check unwant effect vedolizumab may caus infus reaction receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow troubl breath swell face tongu throat vedolizumab may caus seriou allerg reaction includ anaphylaxi anaphylaxi life threaten requir immedi medic attent call doctor right away rash itch troubl breath troubl swallow swell hand face mouth vedolizumab bodi abil fight infect may reduc vedolizumab avoid near peopl sick wash hand often tell doctor ever infect would go away infect kept come back check doctor right away fever chill cough flu like symptom unusu tired weak vedolizumab may increas risk get rare brain infect call progress multifoc leukoencephalopathi pml call doctor right away back pain blur vision confus dizzi drowsi fever headach seizur unusu tired weak check doctor right away pain tender upper stomach pale stool dark urin loss appetit nausea vomit yellow eye skin could symptom seriou liver problem treat vedolizumab immun vaccin without doctor approv vaccin need current receiv vedolizumab take medicin unless discuss doctor includ prescript nonprescript counter [otc] medicin herbal vitamin supplement vedolizumab side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur common bodi ach pain chill difficulti breath ear congest fever headach loss voic nasal congest runni nose sneez sore throat unusu tired weak less common back pain chest tight flush nausea vomit weak rare cough difficulti swallow dizzi fast heartbeat hive itch skin rash puffi swell eyelid around eye face lip tongu tight chest incid known abdomin stomach pain blur vision clay color stool confus convuls dark urin drowsi headach loss appetit lower back side pain pain difficult urin unpleas breath odor vomit blood yellow eye skin side effect may occur usual need medic attent side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question common difficulti move muscl pain stiff pain joint side effect list may also occur patient notic effect check healthcar profession call doctor medic advic side effect may report side effect fda fda',\n",
       " 'angiogenesi foundat conven lead retina specialist patient caregiv vision advoc discuss need improv long term outcom peopl live neovascular age relat macular degener amd event co chair dr rishi p singh cleveland clinic diana savil chief innov offic angiogenesi foundat particip gave recommend improv treatment pathway amd discuss solut better long term patient outcom age relat macular degener lead caus blind peopl age two form amd wet dri progress amd vari ultim lead partial complet blind amd widespread impact mani million peopl u world popul age amd even preval number peopl amd worldwid project reach million diseas greatli impact qualiti life make difficult imposs read drive watch televis recogn love one live independ treatment avail peopl diagnos amd today wet amd highli treatabl groundbreak medicin call anti vegf therapi includ ranibizumab aflibercept anti vegf treatment work block molecul caus abnorm blood vessel growth eye drive progress wet amd anti vegf treatment dramat chang wet amd patient outcom help prevent even revers vision loss case anti vegf therapi revolutionari treatment wet amd long term studi data show dispar patient outcom long term without regular inject close monitor long term patient larg follow studi lose vision gain made clinic trial set mission alway improv live peopl diseas impact angiogenesi said diana savil neovascular wet form age relat macular degener perfect exampl huge differ made yet much work outcom significantli better [now] day medicin get point patient doctor forget like day medicin pretti aw said retina specialist dr carl baker see patient gener improv vision studi show time mani improv go away lot interest lot research figur summit doctor patient advoc engag substant frank discuss current amd treatment landscap area futur improv discuss topic includ differ short term long term patient outcom caus differ outcom identifi barrier desir futur state recommend action happi treatment still vision still thing alway done first coupl year get shot stress [thing] said particip dan berkeri live amd receiv anti vegf treatment hope shot continu job greatest hope research find cure realli aw lot peopl macular degener full summit follow roundtabl discuss synthes white paper publish fall foundat conven patient center amd summit octob patient share perspect experi live age relat macular degener',\n",
       " 'follow post whole time think trust next step given terribl ongo ordeal long commend make decis manag unfold best shift mindset point possibl put suffer behind damag choos get rid jpouch see gave best shot time choos life point new chapter live forward mani opportun ahead much joy shown tremend fortitud everi step way forev make compassion other struggl hardship deepen gratitud life opinion ahead send optim much support well respect admir endur young age uc yr flare use cortenema prednison allerg mesalamin hive fever mp fever remicad stop mo due joint pain anti tnf induc lupu neuropathi entyvio sinc oct far ok',\n",
       " 'hello oncolog nurs saw post studi use opdivo yervoy studi checkmat studi trial well small cell carcinoma might want ask doctor candid regimen assum still etoposid carboplatin knew patient use opdivo yervoy combin pretti well quit hope help',\n",
       " 'bloat belli everi time eat bad burn whole tract look pregnant rememb doc said might sibo small intestin bacteria overgrowth took xifaxim bam hour like pressur releas stomach almost near flat entyvio worst make gut churn stelara best guess need use antibiot bit keep post much blood late still feel happi tri probiot burn digest enzym luck want mess help also still pred mg yo yo ing tri get uc sinc mayo clinic say chron coliti dx chronic lyme biolog work took rafaximin sibo work awesom take asacol hd',\n",
       " 'say answer depend guarante first lot inflamm within intestin bodywid collater consequ thereof aggress immun system may target thing beyond larg intestin extra intestin manifest uc caus arthriti eye inflamm sinu inflamm rash etc etc wbc immun system attack dog other circul whole bodi within blood often flare arthriti muscl pain worst talk doubl whammi often remiss muscl pain arthriti pain gone complet suggest collater damag immun system quiet quiescent state issu gone say good chanc surgeri would help reliev pain second joint muscl pain unconnect state uc flare remiss cycl share mention pattern realli bad pain uc remiss exampl case surgeri may reliev pain someth els go unrel uc activ bodi inflamm want pursu uc medic tri tnf alpha block class uc biolog humira inflectra remicad entyvio madcam blocker xeljanz jak inhibitor complet differ mechan action chanc help moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa long minut depend side bathroom door',\n",
       " 'thank carm pdl relev opdivo believ think may keytruda stat dianem understand say good advic cancer includ nsclc sclc nsclc mani new advanc stat longer reflect someon diagnos today luck sclc noth new long time though potenti sign progress recent know stat reflect individu case reflect overal realiti type cancer hope someth rather avoid given prognosi rather focu concret decis step take time someon write lot encourag thing typic turn thet basic talk involv nsclc sclc anoth ball wax unfortun fatal danger get excit gener progress cancer treatment appli case overal tri thank day take balanc view toward futur basic educ make plan make much room either hope worri despair',\n",
       " 'admittedli limit knowledg ie patient would surpris use avastin lucenti eyelea produc benefit encount use prior anti vegf first trial seri might work us appear need gravit mean eventu roll altern current test',\n",
       " 'clarifi say tecentriq work oncologist give data info receiv read mayb would help publish data individu help genet test age sex stage etc point seen anyth mean also impress sclc test genet profil mutat marker least current doctor initi doctor penn said nsclc apolog wrong talk doctor due dilig research seem deck stack male alreadi spread brain diagnosi feel posit mayb work peopl mayb even want set horribl fall worst news famili could receiv appreci everyon respons kind word',\n",
       " 'main question keep confus gi doctor explain antibodi remicad caus lupu like condit sent bloodwork prometheu test told fine stay remicad ana anti dsana test total differ test antibodi remicad antibodi evid one test antibodi due remicad infus caus dile gi doctor pcp awar told see rheumatologist find caus joint pain make question possibl lupu biolog hope rheumatologist lot knowledg help get right treatment stop remicad hope see improv humira option tri first fail surgeri colostomi thank repli friend appreci input',\n",
       " 'epiderm growth factor receptor egfr suppress matur specif tumour suppressor like mirna respons hypox stress phosphoryl argonaut ago tyr associ egfr ago enhanc hypoxia lead elev ago phosphoryl turn reduc bind dicer ago inhibit mirna process precursor mirna matur mirna find suggest modul mirna biogenesi import stress respons tumour cell potenti clinic implic tag ago argonaut egfr epiderm growth factor receptor lung cancer microrna phosphoryl rc impact egfr inhibitor non small cell lung cancer progress free overal surviv meta analysi lee ck brown c gralla rj hirsh v et al j natl cancer inst apr examin impact epiderm growth factor receptor tyrosin kinas inhibitor egfr tki progress free surviv pf overal surviv os advanc non small cell lung cancer nsclc patient without egfr mutat egfr tki therapi statist significantli delay diseas progress egfr mutat posit egfrmut patient demonstr impact os egfr mutat predict biomark pf benefit egfr tki treatment set find support egfr mutat assess initi treatment egfr tki consid front line therapi egfrmut advanc nsclc patient tag egfr epiderm growth factor receptor lung cancer rc tyrosin kinas inhibitor preexist interstiti lung diseas invers correl tumor epiderm growth factor receptor mutat patient lung adenocarcinoma fujimoto tomii k takahashi imai lung cancer feb interstiti lung diseas ild especi idiopath pulmonari fibrosi shown associ lung carcinogenesi howev associ epiderm growth factor receptor egfr mutat statu preexist ild patient lung adenocarcinoma unknown studi show patient pulmonari adenocarcinoma ild lower probabl carri tumor egfr mutat tag egfr epiderm growth factor receptor interstiti lung diseas lung cancer rc random phase studi paclitaxel carboplatin without conatumumab first line treatment advanc non small cell lung cancer paz are l b lint b hsu cp ramlau r j thorac oncol jan studi evalu efficaci safeti pharmacokinet conatumumab combin paclitaxel carboplatin pc first line treatment advanc non small cell lung cancer nsclc although well toler addit conatumumab pc improv outcom unselect patient previous untreat advanc nsclc tag mag depreotid bcl l betain bim blood test carboplatin cd cd chemotherapi chfr cholin conatumumab cox cyclooxygenas detect diet e cadherin egfr ephx epiderm growth factor receptor erlotinib germlin mutat hierarch model histon deacetylas immun system inflamm kra lung cancer matrix metalloproteinas metastasi model mutat neuregulin non small cell lung cancer nrg nuclear medicin oncimmun paclitaxel paml patient phase trial phase ii polymorph radiat therapi radiosurgeri radiotherapi rc reirradi resist respons satb small cell lung cancer suvmax synovium temozolomid timp twist vorinostat inhibit twist lead activ oncogen induc senesc oncogen driven non small cell lung cancer burn tf dobromilskaya tran pt rudin cm mol cancer re jan recent demonstr basic helix loop helix transcript factor twist cooper mutant kra induc lung adenocarcinoma transgen mous model inhibit twist model led kra induc senesc current studi show silenc twist kra mutant human nsclc cell line well egfr mutat driven c met amplifi nsclc cell line result dramat growth inhibit either activ latent oncogen induc senesc program case apoptosi find suggest silenc twist oncogen driver depend nsclc repres novel promis therapeut strategi tag mag depreotid bcl l betain bim blood test cd cd chemotherapi chfr cholin cox cyclooxygenas detect diet e cadherin egfr ephx epiderm growth factor receptor erlotinib germlin mutat hierarch model histon deacetylas immun system inflamm kra lung cancer matrix metalloproteinas metastasi model mutat neuregulin non small cell lung cancer nrg nuclear medicin oncimmun paml patient phase trial polymorph radiat therapi radiosurgeri radiotherapi rc reirradi resist respons satb small cell lung cancer suvmax synovium temozolomid timp twist vorinostat associ dietari intak cholin betain lung cancer risk ying j rahbar mh forman mr gorlova oy plo one feb evid human anim research indic cholin metabol pathway may activ varieti diseas includ cancer report result case control studi lung cancer case control assess associ cholin betain dietari intak lung cancer result suggest cholin betain intak especi higher betain intak may protect lung cancer mitig advers effect smoke tag mag depreotid bcl l betain bim blood test cd cd chemotherapi chfr cholin cox cyclooxygenas detect diet e cadherin egfr ephx epiderm growth factor receptor erlotinib germlin mutat hierarch model histon deacetylas immun system inflamm kra lung cancer matrix metalloproteinas metastasi model mutat neuregulin non small cell lung cancer nrg nuclear medicin oncimmun paml patient phase trial polymorph radiat therapi radiosurgeri radiotherapi rc reirradi resist respons satb small cell lung cancer suvmax synovium temozolomid timp vorinostat therapeut effect mag depreotid non small cell lung cancer vivo vitro yu f lv yuan x lv z int j clin exp pathol studi show mag depreotid inhibit prolifer invas cell spc cell treatment mbq mag depreotid via tail vein significantli suppress vivo cancer growth induc apoptosi cancer cell find demonstr mag depreotid induc apoptosi nsclc cell directli kill nsclc cell provid evid radiotherapi nsclc tag mag depreotid bcl l bim blood test cd cd chemotherapi chfr cox cyclooxygenas detect e cadherin egfr ephx epiderm growth factor receptor erlotinib germlin mutat hierarch model histon deacetylas immun system inflamm kra lung cancer matrix metalloproteinas metastasi model mutat neuregulin non small cell lung cancer nrg nuclear medicin oncimmun paml patient phase trial polymorph radiat therapi radiosurgeri radiotherapi rc reirradi resist respons satb small cell lung cancer suvmax synovium temozolomid timp vorinostat impact epiderm growth factor receptor kra mutat clinic outcom resect non small cell lung cancer patient ragusa vannucci j crin l puma f j clin oncol jan surgeri yield best result non small cell lung cancer nsclc patient epiderm growth factor receptor egfr downstream factor kirsten rat sarcoma viral oncogen homolog kra variabl mutat nsclc mutat predict clinic respons tyrosin kinas inhibitor studi evalu incid correl egfr kra mutat clinicopatholog paramet outcom resect stage iii nsclc egfr kra mutat frequent adenocarcinoma prognost factor surviv egfr mutat could use identifi patient suitabl adjuv treatment target therapi result potenti improv outcom',\n",
       " 'thank much janin help mom liver enzym rise fast past day possibl due cancer also gallbladd inflamm symptom dead ultrasound today indic possibl inflamm possibl opdivo caus inflamm reason ask inde inflamm increas liver enzym possibl liver stress cancer may time give opdivo work thank ilan',\n",
       " 'suggest fingolimod combin anoth dmt',\n",
       " 'euretina award lectur issu ophthalmologica includ text euretina lectur francin behar cohen md phd deliv th euretina congress barcelona spain present stress need better understand corticosteroid mechan action order optimis use treatment ocular inflammatori condit cite research indic glucocorticoid may induc retin cell death pathway undetect classic toxicolog test add combin low dose glucocorticoid togeth antagonist mineralocorticoid receptor hold promis therapeut strategi treat ocular inflamm f behar cohen toward optim use ocular corticosteroid euretina award lectur ophthalmologica volum issu earli treatment secondari brvo provid best result patient macular oedema relat branch retin vein occlus brvo receiv intravitr dexamethason implant within first month condit onset achiev greater rapid longer last visual improv morpholog improv receiv implant later stage diseas accord result multi centr cobalt studi among brvo patient less three month mean improv best correct visual acuiti bcva letter letter six month respect follow initi inject dexamethason implant month treatment period receiv one inject patient receiv three inject yh yoon et al dexamethason intravitr implant earli treatment retreat macular edema relat branch retin vein occlus multicent cobalt studi ophthalmologica volum issu bevacizumab ranibizumab show similar efficaci rop find retrospect studi suggest bevacizumab ranibizumab similar efficaci treatment type retinopathi prematur rop affect zone retrospect studi includ eye patient initi diseas regress although four patient receiv bevacizumab two receiv ranibizumab show reactiv p eye bevacizumab group ranibizumab incomplet vascularis p mean spheric equival refract one year myopic bevacizumab group ranibizumab group p kimyon et al comparison bevacizumab ranibizumab treatment type retinopathi prematur affect zone ophthalmologica volum issu',\n",
       " 'look st lidwina read articl comment year old diagnos year ago symptom year went cancun walk outsid pyramid heat altitud symptom increas mononucleosi lyme diseas twice diagnos drop feet associ ms may leg brace first person penn med chester counti pa fda approv ocrevu infus may truli believ help infus twice year also prayer prevent diseas progress stress never good god bless anyon diagnos famili member',\n",
       " 'altern biolog humira side effect associ medic',\n",
       " 'congratul guy good jpouch suggest except j pouch org women health section talk insur compani ask one insur compani nurs coordin assign mayb assist get new doc even better get surgeon approv network coverag keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'shock know time portion error involv told last month secondari insur aetna technic secondari certain thing otherwis secondari medicaid error infus place wait last minut verifi insur sinc inform wrong need note doctor get approv done time order medicin medicin infus good thing delay feel good past day infus best idea also realiz infus suit per last insur hope come home infus would much easier date yet complet call time see statu still wait everi time ocrevu infus problem understand think infus site yet time hope best rd infus think strike',\n",
       " 'hello wonder anyon know anyth problem develop gilenya sinc earli april start lot headach etc settl somewhat howev got phone call yesterday let know last blood test friday th show white blood cell count seem want anoth blood test two month time see continu drop usual blood test three month apart question anyon els problem mean chang med past three year gone copaxon tecfidera gilenya anyway merri christma happi new year',\n",
       " 'age f swedish diagnos stage iv nsclc lpa egfr exon last june main tumor left lung one met right lung addit mani ground glass opac nodul lung tumor surgic remov mri brain pet ct sept show chang afatinib mg start oct ct dec show chang afatinib lower mg jan ct april show chang onkologist termin afatinib keep survey ct scan everi month read dr west propos algorithm manag asymptomat multifoc bac understand treat afatinib diffus progress taken month standard protocol stop medic progress thank laken',\n",
       " 'cnw telbec merck nyse mrk known msd outsid canada unit state announc today keytruda pembrolizumab monotherapi indic treatment metastat non small cell lung cancer nsclc adult whose tumour high pd l express egfr alk genom tumour aberr prior system chemotherapi treatment',\n",
       " 'year day sinc start remicad done wonder control crohn symptom think ever abl still ongo issu fistula abscess underli problem secondari crohn like chronic fatigu kidney stone psoriasi still go faith everi week get juic guess call iv drug user speak altern someth want go back year prior remicad fill pain surgeri weight loss depress probe worri loss friend anxieti etc want go back know newli diagnos feel say advanc everi day treatment crohn coliti better chanc get thru hope discov caus closur email blogthi share twitter share facebook share pinterest comment post comment newer post older post home subscrib post comment atom search blog blog archiv novemb octob septemb august normal might crohni get crohni style remicad day miss famili trip might crohni juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb novemb octob septemb august juli june may april march februari januari decemb pageview follow follow wish receiv updat pleas enter email blog artistslain shop collect crohn leav seat facebook vote top past year healthlin vote one top crohn blog gutsi writer drug price comparison benandbreakfast com logo design disclaim inform blog experi blogger blog inform intend heal treat prevent cure crohn diseas diseas definit caus crohn diseas current cure us suffer differ experi crohn mean medic expert profession pretend one decid take advic blog risk pleas alway check medic profession anyth blog sell person contact inform comment follow compani put inform spam list respons privaci practic advertis blog comment hand take respons smile laughter result read blog vern pictur window theme theme imag mammuth power blogger',\n",
       " 'husband stage b adeno nsclc right lung remov tumor gone round cisplatin alimta adjuv month treatment adeno lymph node show near origin tumor sight like lurker last rad treatment monday scan month realli posit manag mani symptom herb oil',\n",
       " 'ocrevu nearli third per dose rituxan made compani genentech repli quot follow user say thank agat howi jeani z jendi parsi stillstannd sunshin',\n",
       " 'center biosimilar recap top news week octob rituximab effect treat cutan lupu erythematosu studi find current treatment cutan lupu erythematosu cle commonli focus photoprotect topic therapi corticosteroid antimalari drug immunosuppress drug recent b cell deplet therapi rituximab shown promis treat system lupu erythematosu though feasibl treat cle rituximab well describ biosimilar rheumatolog roundup octob launch highli anticip product thu far biosimilar experi releas key new data multipl biosimilar product octob memor month biosimilar stakehold studi new patient treat ct p discontinu treatment often recent popul base studi examin prescrib util ct p versu refer infliximab infliximab na patient found discontinu switch common among patient began therapi biosimilar biosimilar filgrastim prove noninferior refer pbcm recent studi present annual scientif meet british blood transfus societi held brighton unit kingdom octob sought determin impact introduc biosimilar filgrastim sold unit kingdom zarzio number patient abl achiev target cd yield peripher blood stem cell mobil pbcm humira biosimilar advanc abbvi upadacitinib outperform adalimumab treat ra arriv biosimilar adalimumab european market caus enthusiasm among seek greater patient access lower cost treatment rheumatoid arthriti ra howev abbvi maker refer adalimumab humira reveal oral janu kinas inhibitor upadacitinib outperform placebo adalimumab phase studi largest studi date patient ibd find switch ct p safe effect real world data deriv switch studi reassur feasibl switch patient inflammatori diseas refer infliximab remicad biosimilar ct p sold inflectra remsima ambigu data patient inflammatori bowel diseas ibd rais question among clinician switch indic crohn diseas ulcer coliti top biosimilar articl week octob center biosimilar recap top news week octob top biosimilar articl week octob center biosimilar recap top news week octob administ nivestym home effect well receiv patient recent studi provid insight feasibl home administr biosimilar filgrastim pfizer recent approv nivestym option potenti reduc patient burden associ hospit administr',\n",
       " 'sure navig site correctli know look hope diagnos adenocarcinoma stage novemb lung liver brain bone whole brain local radiat late decemb start tarceva physic emot roller coaster tri keep mind go far forward difficult natur problem solv one',\n",
       " 'diagnos multipl sclerosi ms overwhelm learn variou type may treatment prognosi take time find descript type ms along short descript treatment avail ms categor four type name type describ treat bodi type also mild moder sever symptom ms receiv diagnosi probabl note laundri list symptom make lot sens ms symptom may includ follow prolong doubl vision loss vision partial complet loss vision typic occur one eye time tingl pain throughout bodi numb limb typic one side bodi problem bladder bowel function dizzi exhaust slur speech tremor unsteadi gait symptom easili associ seriou health condit may test ms requir make sure accur diagnosi made differ type ms four main type ms clinic isol syndrom ci primari progress ms ppm relaps remit ms rrm secondari progress ms spm review differ type ms import rememb ms unpredict diseas vari significantli person person also rare type ms primari type provid fairli comprehens view diseas cours ms may take live advertis clinic isol syndrom ci though clinic isol syndrom ci consid first ms type differ ms involv first episod singl incid symptom diagnos ci symptom must caus process found ms inflamm demyelin central nervou system symptom also must last hour chanc ci lead type ms vari anywher depend upon whether brain lesion consist ms found via mri two area damag central nervou system found occur differ time occurr second attack diagnosi ms like follow nation ms societi nmss describ ci two three time common women men seventi percent peopl diagnos ci age year averag year primari progress ms ppm primari progress ms ppm affect approxim peopl ms character disabl begin accumul slowli right onset may minor remiss seldom occur often temporari nation ms societi nmss state ppm character differ point time either activ occasion relaps evid new mri activ activ well progress evid diseas worsen object measur chang time without relaps new mri activ without progress peopl primari progress ms difficulti walk need assist everyday activ ppm appear equal men women median age onset year relaps remit ms rrm relaps remit ms rrm common form multipl sclerosi peopl ms initi diagnos peopl rrm go unpredict cycl exacerb remiss diseas progress symptom depend area brain spinal cord ms damag symptom come go other appear never come back two peopl alik exacerb durat symptom experi intens length level partial remiss multipl sclerosi associ america msaa state averag relaps form ms women three time like men develop disord median age onset rrm year secondari progress ms spm relaps remit mser transit secondari progress ms spm year first diagnos steadili progress phase ms character nerv damag loss place inflammatori process seen relaps remit ms spm symptom board rrm spm symptom slowli progress without relaps relaps occur usual temporari entir remit primari progress ms nation ms societi nmss state spm character differ point time either activ relaps evid new mri activ activ well progress evid diseas worsen object measur chang time without relaps without progress benign ms fifth type ms kind ms exhibit symptom never benign ms occur one fifth ms case treatment ms cure ms regardless stage ms goal treatment prevent disabl manag symptom speed recoveri process attack also quit medic option avail may slow progress ms treatment exacerb corticosteroid plasmapheresi use ms flare corticosteroid decreas inflamm includ oral prednison iv methylprednisolon plasmapheresi remov plasma blood blood mix albumin transfus back bodi typic done symptom new respond steroid see also treat ms ms symptom treatment multipl sclerosi care sleep problem ms might also like ms affect bodi treatment slow ms progress medic therapi known slow progress ppm suffer rrm suffer quit option beta interferon inject reduc frequenc sever relaps glatiram acet copaxon inject prevent immun system attack myelin dimethyl fumar tecfidera oral medic reduc amount relaps fingolimod gilenya also oral medic reduc amount relaps treatment manag symptom larg part ms treatment manag symptom physic therapi may help strengthen stretch muscl addit physic therapist may abl show perform adl easier muscl relax help suffer muscl spasm muscl stiff oral medic may use depend type symptom note antidepress depress next page debra offer advic make sens differ type ms',\n",
       " 'brand name zykadia medicin prescrib ceritinib use treat non small cell lung cancer nsclc spread nearbi tissu part bodi patient alreadi treat least one chemotherapi medic improv whose condit worsen ceritinib class medic call kinas inhibitor work block action abnorm protein signal cancer cell multipli help slow stop spread cancer cell use medicin medic may prescrib use ask doctor pharmacist inform medicin use ceritinib come capsul take mouth usual taken empti stomach day either least hour hour eat meal snack take ceritinib around time everi day follow direct prescript label care ask doctor pharmacist explain part understand take ceritinib exactli direct take less take often prescrib doctor doctor may decreas dose ceritinib tell stop take ceritinib period time treatment depend well medic work side effect may experi sure tell doctor feel treatment ceritinib special precaut follow take ceritinib tell doctor pharmacist allerg ceritinib medic ingredi ceritinib capsul ask pharmacist list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take sure mention follow antacid anticoagul blood thinner warfarin coumadin jantoven beta blocker atenolol tenormin labetalol normodyn metoprolol lopressor toprol xl nadolol corgard propranolol inder carbamazepin carbatrol epitol equetro tegretol teril certain medic human immunodefici viru hiv acquir immunodefici syndrom aid atazanavir reyataz indinavir crixivan nelfinavir viracept ritonavir norvir kaletra saquinavir inviras corticosteroid cyclosporin gengraf neoral sandimmun dihydroergotamin h e migran diltiazem cardizem dilacor tiazac ergotamin ergomar fentanyl abstral actiq durages fentora subsi ketoconazol nizor medic control blood pressur medic indigest heartburn ulcer cimetidin tagamet duexi esomeprazol nexium famotidin pepcid lansoprazol prevacid nizatidin axid omeprazol prilosec pantoprazol protonix rabeprazol aciphex ranitidin zantac nefazodon methadon dolophin methados phenytoin dilantin phenytek pimozid orap quinidin rifampin rifadin rimactan rifat sirolimu rapamun tacrolimu astagraf prograf telithromycin ketek verapamil calan covera isoptin verelan mani medic may interact ceritinib sure tell doctor medic take even appear list doctor may need chang dose medic monitor care side effect tell doctor herbal product take especi st john wort tell doctor ever diabet high blood sugar heart failur irregular heartbeat qt prolong irregular heart rhythm lead faint loss conscious seizur sudden death liver heart diseas tell doctor pregnant plan becom pregnant breast feed use birth control prevent pregnanc treatment least week treatment talk doctor birth control method work ceritinib may harm unborn babi becom pregnant treatment ceritinib call doctor immedi tell doctor breast feed breast feed take ceritinib surgeri includ dental surgeri tell doctor dentist take ceritinib know may experi hyperglycemia increas blood sugar take medic tell doctor immedi follow symptom take ceritinib extrem thirst frequent urin extrem hunger blur vision troubl think concentr breath smell like fruit tired special dietari instruct follow eat grapefruit drink grapefruit juic take medic forget take dose take miss dose soon rememb howev within hour next dose skip miss dose continu regular dose schedul take doubl dose make miss one side effect medicin caus ceritinib may caus side effect tell doctor symptom sever go away nausea diarrhea vomit constip stomach pain heartburn difficulti swallow fatigu rash chang vision side effect seriou experi symptom list special precaut section call doctor immedi pain right upper part stomach unusu bruis bleed dark urin yellow skin eye decreas appetit flu like symptom itch short breath fever chill sore throat ongo cough congest sign infect chest pain discomfort chang heartbeat heart palpit dizzi lightheaded faint ceritinib may caus side effect call doctor unusu problem take medic experi seriou side effect doctor may send report food drug administr fda medwatch advers event report program onlin [web] phone know storag dispos medic keep medic contain came tightli close reach children store room temperatur away light excess heat moistur bathroom unneed medic dispos special way ensur pet children peopl cannot consum howev flush medic toilet instead best way dispos medic medicin take back program talk pharmacist contact local garbag recycl depart learn take back program commun see fda safe dispos medicin websit [web] inform access take back program import keep medic sight reach children mani contain weekli pill minder eye drop cream patch inhal child resist young children open easili protect young children poison alway lock safeti cap immedi place medic safe locat one away sight reach [web] inform know keep appoint doctor laboratori doctor may order certain lab test check bodi respons ceritinib let anyon els take medic ask pharmacist question refil prescript import keep written list prescript nonprescript counter medicin take well product vitamin miner dietari supplement bring list time visit doctor admit hospit also import inform carri case emerg report medic inform consid individu patient advic chang natur drug inform pleas consult physician pharmacist specif clinic use american societi health system pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field american societi health system pharmacist inc make represent warranti express impli includ limit impli warranti merchant fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos entir monograph drug review thorough understand drug action use side effect american societi health system pharmacist inc endors recommend use drug inform substitut medic care ahf patient medic inform copyright american societi health system pharmacist inc east west highway suit bethesda maryland right reserv duplic commerci use must author ashp',\n",
       " 'hello approach year survivor anniversari januari stage lung cancer liver spine lymph met alk chemo crizotinib stabl start alectinib april due acquir resist crizotinib initi dose mg day alectinib super toxic much dose reduct labwork went mg alectinib per day past year stay stabl well brain mri last week show new brain met mm left cerebellum primari lung tumor stabl x cm new enlarg cm prevascular heart area lymph node discov june ct scan stabl septemb scan still new question patient nd line tki therapi develop brain met lymph node enlarg consid acquir resist nd line drug view entir patient forum target therapi video present cleveland clinic radiat oncologist want stereotact radiat brain met rd time brain radiat twice previous sbrt brain met [ st time met nd time met one wonder mani time go brain radiat remedi live ongo emerg brain met ] go request onc rebiopsi see new resist mutat may present guid new rd line drug decid would best next step rememb doctor video mention go ahead stay alectinib brain met lymph node develop thank way also big thank host patient confer post entir video help inform grace forum import valuabl',\n",
       " 'nov chucksan wrote wife noriko diagnos august stage squamou lung cancer nsclc pet ct scan novemb st schedul infus opdivo nivolumab month month diagnosi previous gone thru two combo regimen fail chemo similar immunolog fda approv drug lung cancer keytruda merck opdivo keytruda origin develp melanoma test number type cancer fda approv last year lung cancer oncologist dr howard jack west md came said cancel infus pet ct scan show wasfre cancer remiss origin estim mayb month new immunolog drug also call check point inhibitor pd name seem better success mani previou chemo type drug mani new clincal trail test simialr drug mani show lot promis ecstat hope even stage lung cancer thank brystol meyer squibb area seattl swedish hospit cancer institut dr west entir staff need fli across countri region seek best cancer center two nearest larg metro citi near mani time larg hospit cancer section univeristi teach medic hospit check oncologist special specif type cancer sure access latest clinic trail drug recent fda approv mani time lead edg succes treatment cours less stage surgeri raditaion success pleas stay far away altern clinic doctor product good food suppliment great gener health none cure cancer regardless mani phoni testimoni see site goe mexico mani foreign bogu clinic push coffe enema nonsens cure big buck medic phyician md top us medic univers hope chuck http www cancer org treatment treatmentsandsideeffect tre atmenttyp immunotherapi cancer immunotherapi immun checkpoint inhibitor target _blank rel nofollow http www cancer org treatment treatmentsandsideeffect tre target _blank rel nofollow http www cancer org treatment treatmentsandsideeffect tre http www cancerresearch org cancer immunotherapi impact cancer lung cancer target _blank rel nofollow http www cancerresearch org cancer immunotherapi impact target _blank rel nofollow http www cancerresearch org cancer immunotherapi impact http www googl com search newwindow rlz cahpzt_enu us q immunotherapi cancer treatment sa x ved ahukewjdg xqahuq mmkhwkdafwq qiipgeoag biw bih prais creator bless truli happi wife remiss eould like add mani mani year cone also opdivo scan last week show mm nodul upper right lobe oncologist other discuss case tumor board meet week opdivo almost yr prior immunotherapi permatrex caboplatin yr month without treatment tumor increas fro cm doctor decid immuno know decis week move forward keep faith heal becaua god ultim healer take care let staynin mm prayer elli',\n",
       " 'mainten dmt one keep take treatment work pill everi day inject time week infus month ms treatment categori kind treatment someth may need anoth treatment year later keep three treatment fit categori lemtrada hsct cladribin seem much effect mainten treatment jc viru john cunningham viru half popul carri time adult gener harmless peopl immunosuppress treatment jc viru give pml horribl demylin diseas kill peopl leav sever disabl seem frequent peopl tysabri although still rare also small number peopl got take gilenya tecfidera think',\n",
       " 'crohn diseas also call ileiti enter affect part gut mouth way anu major case howev lower part small intestin ileum affect symptom unpleas includ intestin ulcer discomfort pain accord center diseas control prevent crohn diseas affect peopl per although crohn diseas typic start age start age symptom pain commonli felt lower right side abdomen affect mani area gut crohn diseas symptom vari depend part gut affect symptom often includ pain level pain vari individu depend inflamm gut commonli pain felt lower right side abdomen ulcer gut ulcer raw area gut may bleed bleed patient might notic blood stool mouth ulcer common symptom diarrhea rang mild sever sometim may mucu blood pu patient may get urg go find noth come fatigu individu often feel extrem tire fever also possibl fatigu alter appetit may time appetit low weight loss result loss appetit anemia loss blood lead anemia rectal bleed anal fissur skin anu becom crack lead pain bleed possibl symptom arthriti uveiti eye inflamm skin rash inflamm liver bile duct inflamm delay growth sexual develop children ulcer coliti vs crohn diseas ulcer coliti caus inflamm ulcer top layer line larg intestin layer intestin may inflam ulcer crohn diseas also inflamm occur crohn diseas anywher along gut ulcer coliti appear larg intestin colon rectum crohn diseas patient bowel normal healthi section diseas part wherea ulcer coliti damag appear continu pattern diet children crohn diseas might need high calori liquid formula especi growth affect patient crohn diseas say follow food increas diarrhea cramp bulki grain dairi product spici food alcohol peopl feel like eat sever case may need feed intraven short period treatment bulki grain like contain bread worsen crohn diseas treatment may involv medic surgeri nutrit supplement aim control inflamm correct nutrit problem reliev symptom cure crohn diseas treatment help reduc number time patient experi recurr crohn diseas treatment depend inflamm situat sever diseas complic patient respons previou treatment recur symptom peopl long period even year without symptom known remiss howev usual recurr period remiss vari much hard know effect treatment imposs predict long period remiss go best food crohn diseas flare eat right food help peopl manag symptom crohn diseas find read medic crohn diseas anti inflamm drug doctor like start mesalamin sulfasalazin help control inflamm cortison steroid corticosteroid drug contain cortison steroid antibiot fistula strictur prior surgeri may caus bacteri overgrowth doctor gener treat prescrib ampicillin sulfonamid cephalosporin tetracyclin metronidazol anti diarrheal fluid replac inflamm subsid diarrhea usual becom less problem howev sometim patient may need someth diarrhea abdomin pain biolog biolog new type drug scientist develop live organ reduc bodi immun respons target protein lead inflamm biolog appear help peopl crohn diseas exampl biolog crohn includ infliximab remicad adalimumab humira mercaptopurin purinethol methotrex imuran azathioprin certolizumab pegol cimzia biolog treatment side effect includ vomit nausea weaker resist infect studi suggest use biolog reduc chanc person need abdomin surgeri within year percent introduct biolog research put figur percent biolog also appear reduc risk advers effect aris person use corticosteroid differ type biolog drug individu react differ doctor recommend suitabl option may suggest tri altern combin drug first one work surgeri major crohn diseas patient may need surgeri point medic longer control symptom solut oper surgeri reliev symptom respond medic correct complic abscess perfor bleed blockag remov part intestin help cure crohn diseas inflamm often return area next affect part gut remov crohn diseas patient may requir one oper live case colectomi need whole colon remov surgeon make small open front abdomin wall tip ileum brought skin surfac form open call stoma fece exit bodi stoma pouch collect fece doctor say patient stoma carri lead normal activ life surgeon remov diseas section intestin connect intestin stoma need patient doctor need consid surgeri care appropri everyon patient bear mind oper diseas recur peopl crohn diseas live normal activ live hold job rais famili function success caus exact caus crohn diseas unclear thought stem abnorm reaction immun system theori immun system attack food good bacteria benefici substanc unwant substanc attack white blood cell build line gut buildup trigger inflamm inflamm lead ulcer bowel injuri howev unclear whether abnorm immun system caus crohn diseas result factor may increas risk inflamm includ genet factor individu immun system environment factor around peopl crohn close rel condit ident twin crohn diseas twin percent chanc bacterium viru may play role e coli bacteria link crohn diseas instanc smoke anoth risk factor diagnosi doctor ask person sign symptom physic examin may reveal lump abdomen caus loop inflam bowel becom stuck togeth follow test may help diagnosi stool blood test biopsi sigmoidoscopi short flexibl tube sigmoidoscop use investig lower bowel colonoscopi long flexibl tube colonoscop use investig colon endoscopi symptom occur upper part gut long thin flexibl telescop endoscop goe esophagu stomach ct scan barium enema x ray reveal chang insid bowel complic symptom sever frequent likelihood complic higher follow complic may requir surgeri intern bleed strictur part gut narrow caus build scar tissu partial complet blockag intestin perfor small hole develop wall gut content leak caus infect abscess fistula channel form two part gut may also persist iron defici food absorpt problem slightli higher risk develop bowel cancer relat coverag stage crohn diseas crohn diseas caus chronic inflamm digest tract although crohn diseas tend get wors time symptom vari consider may sometim disappear week even year reason doctor usual classifi crohn differ stage learn read expect crohn infus crohn infus medic call biolog help reduc crohn symptom learn type crohn infus side effect expect read crohn diseas surgeri know surgeri cannot cure crohn diseas help reduc person symptom prevent life threaten complic articl learn differ type crohn diseas surgeri prepar expect recoveri read crohn diseas pregnanc crohn diseas pregnanc affect howev women conceiv crohn diseas remiss normal pregnanc healthi babi learn read diet tip crohn diseas crohn diseas affect gastrointestin tract choic diet nutrit may make differ individu feel spici food alcohol fatti sugari item exampl trigger flare peopl find dietari tip recommend may help manag condit read email email print share share crohn ibd gastrointestin gastroenterolog immun system vaccin addit inform articl last updat yvett brazier wed decemb visit crohn ibd categori page latest news subject sign newslett receiv latest updat crohn ibd refer avail refer tab refer content requir javascript enabl baumgart dogan b rishniw weitzman g bosworth b yantiss r berg cultur independ analysi ileal mucosa reveal select increas invas escherichia coli novel phylogeni rel deplet clostridial crohn diseas involv ileum ism journal retriev http www natur com ismej journal v n ab ismej html crohn diseas n american societi colon rectal surgeon retriev http www fascr org patient diseas condit crohn diseas crohn diseas caus april retriev http www nh uk condit crohn diseas page caus aspx epidemiolog ibd march cdc retriev http www cdc gov ibd ibd epidemiolog htm leena halm paulina paavola sakki ulla turunen maarit lappalaccinen martti f rkkil kimmo kontula june world journal gastroenterolog retriev http www ncbi nlm nih gov pmc articl pmc lichtenstein g r loftu e v isaac k l regueiro gerson l b sand b e march manag crohn diseas adult american colleg gastroenterolog retriev http gi org guidelin manag crohn diseas adult crohn diseas n cleveland clinic retriev http clevelandclin org health articl crohn diseas citat pleas use one follow format cite articl essay paper report mla nordqvist christian crohn diseas medic news today medilexicon intl dec web jan http www medicalnewstoday com articl php apa nordqvist c decemb crohn diseas medic news today retriev http www medicalnewstoday com articl php pleas note author inform provid sourc cite instead recommend relat news latest news alzheim blood test detect brain damag year symptom test blood level protein brain cell leak faulti die detect peopl alzheim diseas year symptom emerg immun system use chao prevent diseas new research find chaotic swing concentr certain protein key regul immun respons prevent chronic diseas reprogram immun cell attack cancer tumor macrophag immun cell eat pathogen cell debri often ineffect cancer cell co opt attack tumor common food addit may impact gut bacteria increas anxieti emulsifi mani food product new studi ask whether chemic might impact physiolog psycholog stool transplant super donor could cure new research suggest fecal transplant super donor could cure host condit rang irrit bowel syndrom alzheim',\n",
       " 'ocrelizumab reduc progress upper extrem impair patient primari progress multipl sclerosi find phase iii random oratorio trial show author edward j fox clyde markowitz angela applebe first publish novemb research articl http doi org abstract background upper extrem ue impair common primari progress multipl sclerosi ppm object exploratori analysi examin effect ocrelizumab confirm progress cp confirm improv ci ue impair patient oratorio method patient ppm receiv ocrelizumab mg placebo everi week week nine hole peg test hpt administ baselin bl everi week thereaft prespecifi exploratori endpoint includ chang hpt time proport patient cp hpt analysi popul includ intent treat itt patient subgroup stratifi bl hpt time expand disabl statu scale post hoc analys includ proport patient achiev sever threshold cp proport achiev ci hpt result among itt patient ocrelizumab significantli reduc chang hpt time week risk cp hpt time hand risk sever hpt progress versu placebo numer trend also favour ocrelizumab versu placebo respect achiev ci consist direct trend observ subgroup analys conclus ocrelizumab reduc risk ue disabl progress may increas possibl improv versu placebo ppm __________________ dave bexfield activems',\n",
       " 'happi long may continu samantha stop smoke jan diagnos left side uc th feb gluten dairi sulfit salicyl histamin intoler home fmt treatment juli ward reoccurr c difficil fail pentasa azathioprin final methotextr due allergi intoler take humira g prednison reduc week',\n",
       " 'hi blueberri two reason option think one import consider hing question symptomat mother symptom signific may push decis favor establish chemo regimen carbo alimta tend well toler prove effect signific percentag patient immunotherapi hand extrem effect smaller percentag patient often effect treatment take longer manifest anoth consider question chemo vs trial whether choos chemo first disqualifi patient trial later although trial mention list previou treatment exclus factor list first line therapi trial one emphas import factor though sinc mani trial immunotherapi agent even particular combin might avail someth similar jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'random phase trial niraparib mainten therapi initi chines patient extens diseas small cell lung cancer ed sclc accord inform poster present iaslc th world confer lung cancer toronto canada niraparib parp inhibitor effect patient brca mutat ovarian cancer well patient non brca mutat ovarian cancer respond platinum base chemotherapi sclc cell demonstr high level parp express sensit platinum base chemotherapi suggest target dna repair pathway may effect approach aim studi evalu niraparib mainten therapi ed sclc random doubl blind phase zl trial enrol approxim patient ed sclc demonstr respons platinum base chemotherapi relat articl fda grant acceler approv nivolumab small cell lung cancer copd may affect surviv patient small cell lung cancer lurbinectedin receiv fda orphan drug statu recurr small cell lung cancer elig trial patient need achiev complet partial respons prior platinum base chemotherapi regimen requir complet cycl etoposid plu cisplatin carboplatin patient randomli assign receiv niraparib placebo mainten set niraparib dose mg daili patient baselin bodi weight least kg baselin platelet count least l patient lower baselin bodi weight platelet count administ mg daili patient continu mainten therapi diseas progress intoler toxic stratif paramet includ gender lactas dehydrogenas level prophylact cranial irradi coprimari end point trial progress free surviv pf assess independ central radiolog review overal surviv secondari end point includ investig assess pf safeti toler qualiti life read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       " 'could new symptom result stop gilenya known rebound effect',\n",
       " 'hi galen tough call make one reason rebound effect would concern mani peopl convert jcv year think convers rate around per year reason think ocrevu effect class tysabri detail remain seen time howev lot reason believ pml risk much much lower consid drug rituximaub avail area happi send link detail wife tecfidera alway wonder next move either becom aggess dmt move tecfidera situat would go ocrevu person base ton studi paper read base real medic train wife also jcv like think dr least passiv good question follow om well',\n",
       " 'unfortun insur decid med take order might need tri remicad humira st much much quicker respons time entyvio med patient copay assist card manufactur uc sever determin med work dose work wager flare whole lot sever past one iv steroid sometim need make sure test recent pathogen caus like c diff respond steroid often red flag verifi infect infect worsen steroid help hang get better post edit ipoop gmt',\n",
       " 'ruth bader ginsburg lung cancer http www msn com en us news us ruth bader ginsburg read answer answer share rob experi squamou cell carcinoma l year ago oh back round four time brand new med yey bodi heard opdivo read comment gregp_wn question invas squamou ce year ago seem like everi day new type immunotherapi use doctor suggest type immunotherapi type cancer suit better treatment other curiou read answer answer share gregp_wn question invas squamou ce almost year ago biggest issu face week seriou problem let let hear answer answer share gregp_wn question hodgkin diseas year ago found treatment taken littl pep step mayb strong abil use blog post today issu take look http bit ly',\n",
       " 'miapi neuro correct retic cladribin present time yet approv nice present use label neuro may ask sign disclaim obtain dmt present time',\n",
       " 'complet full cours inject form cladribin easi toler highli recommend continu work day take shot home night drug clear day dose effect last year',\n",
       " 'hard believ one year ago wife receiv diagnosi cancer go two week potenti pneumonia stage iv lung cancer indescrib bless wonder oncolog team support famili friend dark time first week fill fear might happen wonder wife also bless found site straightforward honest inform care peopl let know alon journey site comfort wife continu trail treatment year later one success chemo treatment two unsuccess one behind us midst clinic trial yet know outcom cancer bit diagnos seem trade initi bone metastes liver one adren still great health otherwis wonder strong attitud move onward toward colleg graduat son may wed daughter juli lucki time work manag side effect treatment effect cancer know driver mutat potenti target therapi still go tri trial drug work want thank everyon site place read latest method see stori other go issu ask question know other travel along road certainli help go emot high low love one deal cancer mark first year thank much everyon grace wife lifelong non smoker dx adeno nsclc stage iv poorli diff bone met lymph node exon mutat x carbo alimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo effect add l growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl stabl add l growth trial start gemzar larg tumor reduct',\n",
       " 'much oral cladribin cost compar intraven patent intraven cladribin wast public money',\n",
       " 'like fine stress worri go aggrav crohn symptom thing like stress worri worth risk upset crohn ask good mr ms mr colon answer know get pre medic time remicad infus antihistamin benadryl claritin tylenol refus preme would definit insist pre med get infus slight increas risk infus reaction moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa two certainti life pay tax prednison side effect',\n",
       " 'soooooo happi actual problem get rituxan cover end ocrevu hope switch easili pleas keep touch often email youtwoheart yahoo com jami facebook jami koral starr',\n",
       " 'notsosicklygirl pretti sure posit respons due remicad sinc put iv steroid remicad day littl improv right remicad great assum remicad one trick ye diagnos via colonoscopi confirm biopsi also stool test show inflamm well blood test show high inflammatori marker ipoop agre think need tri med help unfortun doctor mention combin therapi sure mention next time speak thing taken turn though third infus see good respons first two infus diarrhea right time day infus day ago hope delay respons occasion blood time',\n",
       " 'sinc seem like us consid ask ocrevu avail sure insur situat short term could effect amount risk wife use tecfidera right',\n",
       " 'friday session someth long await subgroup analysi actrim http www actrim org forum index php program full program friday februari pm pm talk efficaci ocrelizumab patient ppm without gadolinium enhanc lesion baselin phase iii placebo control trial jerri wolinski univers texa health scienc center houston',\n",
       " 'human prescript drug label item code sourc ndc rout administr intraven dea schedul activ ingredi activ moieti ingredi name basi strength strength ustekinumab ustekinumab ustekinumab mg ml inact ingredi ingredi name strength edet disodium mg ml histidin mg ml histidin monohydrochlorid monohydr mg ml methionin mg ml polysorb mg ml sucros mg ml product characterist color yellow colorless light yellow score shape size flavor imprint code contain packag item code packag descript ndc vial singl use box ml vial singl use ndc vial singl use box ml vial singl use market inform market categori applic number monograph citat market start date market end date bla bla',\n",
       " 'year old wife nsclc adenocarcinoma surgic resect lower middl lob right lung six year ago follow adjuv cisplatin cancer return one year later lung alimta avastin everi four week three year progress time blood pressur alway high even medic six month ago decid take hiatu due chemo brain hiatu tia complic saw hypertens specialist chang medic brought blood pressur normal kept four month hiatu start sign progress put back alimta alon everi three week dose reduc avastin due tia two infus symptom cough wet rail sound exhal difficulti catch breath fatigu grew wors current hospit treat possibl pneumonia fever infect wait cultur ct show growth someth pulmonologist want bronchoscopi rule caus cancer growth cancer oncologist opinion alimta longer work want switch taxoter bu veryt reluct return avastin question sinc blood pressur control go back avastin sinc doublet alimta avastin kept progress free three year reluct move onto someth els possibl avastin synerget effect alimta avastin alon keep progress free case oncologist want go taxoter order knock effect wife reluct due hair loss oner side effect post cancergrac sever time past six year extrem grate respons help enorm chart cours treatment thank',\n",
       " 'food drug administr fda approv combin use keytruda pembrolizumab plu carboplatin either paclitaxel nab paclitacel treat patient metastat squamou non small cell lung cancer nsclc diseas account percent lung cancer accord merck manufactur immunotherapi agent agenc base approv result phase keynot trial recent present intern associ studi lung cancer th world confer lung cancer trial random patient receiv either mg keytruda patient placebo patient first day cycl first four cycl patient also receiv carboplatin either paclitaxel nanoparticl albumin bound [nab] paclitaxel patient follow median month keytruda regimen prolong median overal surviv month month vs month median progress free surviv month month vs month keytruda surviv benefit consist regardless pd l express among patient treat agent addit keytruda regimen demonstr superior respons rate percent vs percent compar placebo reduc risk diseas progress death percent grade higher side effect occur percent patient treat keytruda includ neutropenia percent anemia percent thrombocytopenia percent diahrrea percent keytruda fifth approv lung cancer space drug also approv treat certain type melanoma head neck cancer classic hodgkin lymphoma urotheli carcinoma microsatellit instabl high msi h solid tumor gastric cancer cervic cancer today approv expand current lung cancer indic includ combin treatment patient squamou cell carcinoma type lung cancer particularli difficult treat said roger perlmutt ph presid merck research laboratori approv fda potenti mean keytruda use improv surviv patient debilit diseas',\n",
       " 'repeat femal canada ivig pentasa uc crohn test posit map antibodi mycobacterium pg remiss flare year current deal peri anal abscess fistula rvf wait stelara',\n",
       " 'realiz rather late respons convers origin like share father experi hope may use other contempl wbrt age diagnos stage egfr exon delet nsclc adenocarcinoma liver bone brain metastas brain lesion rang mm mm size asymptomat first oncologist recommend wbrt father reluct concern late cognit effect radiat especi older patient request second opinion lung cancer specialist major teach hospit decis made defer wbrt favor tarceva short interv brain mri week done dramat respons week tarceva lesion decreas size enhanc longer visibl mri father subsequ consult neuro oncologist author aforement paper http www ncbi nlm nih gov pubm well neurosurgeon seem agreement wbrt would last resort least father case probabl mani factor affect decis proceed wbrt want share father stori sinc posit respons tki without need brain radiat judi bmj son jc mother wish best hope good respons treatment long time hope',\n",
       " 'marci slightli differ pair convent chemotherapi taxol carboplatin appear doctor believ pemetrex altima better drug combin mainten therapi nearli two year mainten therapi last infus cycl ad target therapi drug tarceva taxol carboplatin doctor understood tarceva would ineffect squamou cell non small cell lung cancer taxol carboplatin kept knock back tumor steff reveal secret convent chemotherapi side effect present occur time period infus present good idea record time side effect onset hour infus also success take side effect mitig medic hour schedul side effect onset chemo nurs gave advic work case experienc one sleepless night even infus like steroid along intens hunger nausea symptom start hour infus happen took anti nausea medic hour project start troubl side effect joint pain start hour infus last sever day mani toler altima carboplatin well hope side effect minim stay cours tom',\n",
       " 'hi bh see problem continu antibiot alimta wife receiv combin alimta tarceva use bactrim treat skin toxic hand given lung mass clot may want discuss oncologist whether actual need antibiot possibl imag clinic factor point simultan case pneumonia unreason return alimta last success mom previous experienc although mani oncologist would prefer switch someth new right wrong answer problem keytruda immunotherapi tend take longer chemotherapi show anti tumor effect effect subset patient want discuss issu doctor well jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'diagnos stage ib adenocarcinoma first surgial remov one lobe right lung well chemo requir year later march found metatic brain made stage iv gobsmack thought gone cyberknif chemo rest first chemo also carboplantin alimta last test show evid diseas said immedi temporari anyway alimta mainten side effect bad carboplantin almost kill still happi alimta side effect minim compar suspect say dad minim tell doc everyth side effect learn hard way one must stay hydrat like water plu doc might prescrib thing like neulasta help deal side effect doc help deal one tell go possibl keep journal symptom go doc speak someon told stage iv learn live cancer knock live life knock pleas post progress report know pull dad',\n",
       " 'alt compos il receptor fusion protein mutant form il target share il il pathway activ immun cell nivolumab prevent tumor cell evad combin two differ effect might work synergist elimin cancer cell note dr rolfo dr smit signific invari toxic hamper use il cytokin immunotherapi therapeut dose author new studi report subcutan inject g alt per kg weekli week four week cycl month safe drive nivolumab associ advers event rate author report dose limit toxic alt plu nivolumab identifi maximum toler dose post hoc analysi studi particip experienc partial respons suggest reassert control relaps ici refractori lung cancer note lead studi author john wrangl md medic univers south carolina charleston coauthor uniqu trial two complet differ type drug never combin human trial demonstr drug safe administ said senior studi author mark p rubinstein phd medic univers south carolina press releas relat articl time report palli care need lead appropri end life care nsclc osimertinib improv qualiti life global health statu non small cell lung cancer post hoc analysi suggest alt might salvag ici refractori nsclc dr rubinstein suggest dual immunotherapi non pd pd l ici yet approv u food drug administr nsclc effect immunotherapi regimen bring clinic benefit patient lung cancer resurrect clinic benefit resist emerg repres huge unmet need note abil alt induc immunotherapeut respons pd relaps refractori nsclc stimul surg renew interest cytokin combin treatment cancer inject site reaction flu like symptom common affect patient respect two patient experienc grade toxic lymphocytopenia fatigu anoth patient experienc grade heart attack grade toxic patient death report studi fund altor bioscienc nation institut health nih univers south carolina holl cancer center phase trial enrol ongo studi author report reason caution dr rolfo dr smit point osimertinib durvalumab show similar earli promis later demonstr troubl rate advers event even express optim studi laid foundat clinic investig use il agonist combin pd pd l inhibitor immunotherapi base treatment improv outcom patient nsclc tumor wrote combin treatment futur immunotherapi refer',\n",
       " 'hello enjoy read ur ms stori ms almost yr may suggest anoth anoth exercis diagnos back balto md john hopkin neurologist benjamin brook told best exercis ms swim take advis first anoth attack arm hand numb month join gym indoor outdoor pool took time get adjust water water comfort soul brain muscl worri get overh swim like get hair wet though took deep water jog class love exercis ur arm leg stomach get chlorin ur hair want suggest mayb would like tri spm stage copaxon inj year neuro switch gilenya use rollat help balanc issu enjoy read ur stori best give pool tri u may like stay away warm therapeut pool also best vicki vmkircher comcast net',\n",
       " 'articl reduc cost enhanc qualiti care ms kister corboy urg neurologist part improv afford ms medic unafford ms medic driven outrag price way tie benefit medic provid experi share includ simpl strategi lower cost without diminish qualiti care one impact use rituximab forerunn ocrelizumab like fda approv avail ridicul high price biggest barrier implement rituximab use insur carrier deni coverag fda approv ms neurologist afraid legal action prescrib non fda approv product drug compani incred good market product glossi ad promot brand bond entic mani promin neurologist speaker fee dinner first authorship new england journal articl studi design conduct analyz biogen roch alreadi busi creat fals distinct ocrelizumab rituximab lucenti avastin frighten neurologist believ would harm patient risk litig use rituximab label prescrib neurologist time legal risk ocrelizumab proven superior safer rituximab data exist studi roch biogen would afraid conduct swedish kaiser permanent neurologist negoti medic center allow use rituximab highli activ patient natalizumab option use rituximab increas dramat sweden kaiser permanent highli favor efficaci safeti profil high patient satisfact becom clearer pharma tri pressur swedish govern halt use rituximab met outrag neurologist swedish health care author review extens use rituximab ms deem scientif sound legal urg neurologist stand patient swedish neurologist done help patient get access rituximab editor note addit inform see recent articl rituximab multipl sclerosi retrospect observ studi safeti efficaci salzer j svenningsson r alp p et al',\n",
       " 'octob increas proport treatment chang limit interpret result initi iqwig evalu shall continu crizotinib xalkori avail sinc second line treatment patient advanc non small cell lung cancer high activ enzym anaplast lymphoma kinas crizotinib alreadi undergon dossier evalu use g ba limit decis manufactur submit anoth dossier iqwig assess second dossier patient elig treatment chemotherapi contain new result data cannot interpret meaning patient manufactur present new data result first dossier evalu therefor remain unchang read iqwig press releas [german]',\n",
       " 'question open lung biopsi tumor less cm know wait see especi doctor realli push surgeon background jan diagnos nsclc stage right lower lobectomi mutat egfr exon detect declar cure treatment quarterli biannual ct scan follow review sept mm tumor detect medic oncologist prescrib tarceva mg base previou occur tumor reduc size stabliz aug small perifissur nodul mm mm well mm mammari lymph nodul progress jan nodul still less cm oncologist want biopsi remov tumor situat cannot easili radiat biopsi pulmonologist impress surgeon find tumor small difficult open biopsi use hand feel tumor small oncologist want want wait surgeon will much confid especi read dr west talk adenoma situ potenti treatment lung cancer know go oncologist worth open lung biopsi tumor small even surgeon hesit',\n",
       " 'hello gilenya almost month suppress neutrophil dramat anyon els experienc well notic red spot tini quarter size hand feet blister rais itchi hurt tend go away week come back spot still hand feet schedul see dermatologist awhil know natur symptom medic also take medic thought',\n",
       " 'sth cladribin week ago simpl procedur day intect secondari effect realli pill given think rrm think pharma money make inyect differ situat eg advanc inject patent cheaper internet full scari stuff peopl report thing sometim could ms drug way hair lost case least yet still keep frizzi hair work earli day guess hope let see fingolimod think good stop relaps noth start spm take bad place secondari effect lymphocit low lymphopenia get wors time re_bound effect stop twice immun system back normal attack come back opinion drug stop spm beast would go sth caus troubl realli go case spm start yesr older younger noon predict take care xxx',\n",
       " 'first infus ocrelizumab next week',\n",
       " 'antibodi foregon conclus biolog never get antibodi biolog even without concurr immunomodul therapi get antibodi quickli best concurr immunomodul therapi believ highest odd antibodi format earli biolog treatment alreadi year alreadi got antibodi like get easi test antibodi unless becom problem reason discontinu med remicad infliximab oldest uc approv biolog percent human protein percent mous protein gener littl higher odd antibodi format rest rest percent human like entyvio even recommend immunomodul concurr treatment current clinic guidelin even worst case scenario antibodi drug dose increas counter act mani case antibodi format one medic predispos one alway develop antibodi everi medic isol one med food thought least fixat antibodi moder ulcer coliti john minor flare uc proctosigmoid rx remicad mg kg wk mg mp g lialda mg pred uc becom poop ninja sli sight unseen insan urgenc demand post edit ipoop gmt',\n",
       " 'term healthcar medicin oral medic ms still consid infanc come onto market five year ago oral medic ms savior mani provid relief inject talk last week provid hope research futur first diagnos oral treatment seem like still thought figment medic imagin year later hit market cheer sigh relief mani patient first scene gilenya gilenya believ work prevent certain type white blood cell cross blood brain barrier believ reduc inflamm damag nerv cell gilenya seem answer mani mser prayer shot soon mani began take report side effect came unusu drug often side effect high profil drug side effect high profil well one main side effect report heart issu within first hour take first dose sadli individu experienc worst side effect possibl pass away within hour take first dose led regul chang includ eeg prior start medic monitor hour hospit receiv first dosag gilenya also known caus vision breath liver problem individu prompt group urg fda use restrict medic alway two side everi coin though peopl report wonder relief symptom abl thing done year next emerg aubagio aubagio believ work inhibit function specif immun cell believ present ms patient happi anoth oral option besid gilenya prove research still march forward take aubagio one requir liver enzym check regularli aubagio could damag liver also side effect well flush hair loss hair thin among other aubagio year copaxon experienc major hair loss least thought major relaps take well clearli bodi tell time switch last oral medic make way world tecfidera tecfidera formal known bg formul specif peopl ms use germani higher dose treat acut flare up psoriasi year thought inhibit immun cell may specif antioxid properti might protect damag brain spinal cord main side effect report mani individu take tecfidera flush individu sadli pass away pml prompt stringent warn label jc viru test patient take tecfidera mention one medic far aubagio experienc would consid extrem hair loss clean shower floor everi day major relaps take possibl side effect notic anyth els love idea abl take oral medic ms instead inject bodi differ plan need transit tysabri futur definit look one oral option anyth els like medic come plenti side effect import rememb alway weigh risk versu benefit toler side effect put plainli medic work will put order get benefit medic make feel hot make skin look like tomato hour flush relaps free year import test posit jc viru level risk ok definit tough question answer littl honesti get real done husband cent one oral medic tri aubagio work hair fell relaps take includ subtl lesion brain may awesom thing peopl unfortun person never notic differ hair know frustrat watch frustrat like read want stay connect join lissm commun',\n",
       " 'jimmi carter pembrolizumab human monoclon antibodi umab mysteri although detail get technic love one get cancer highli recommend undergradu immunolog erridg afford introduct subject get discourag inform unlik understand keep read use googl encount new vocabulari new concept',\n",
       " 'diagnos nsclc jan chemo continu opdivo chemo actual honestli chang thing lifestyl still drink eat want whatev mayb death proof point either go live sure anyth outsid treatment dictat outcom',\n",
       " 'tell nearli four year ago nearli year type diabet know two year background retinopathi macular edema dme hit right eye blue vision acuiti drop due locat leakag close fovea laser rule left anti vegf viabl option one thing say work thank god vision restor next four month still caveat anti vegf inject eylea perman solut case persist dme requir sinc averag inject per year inject free pleasant hey maintain good vision happi go everi morn',\n",
       " 'know dr woolmor differ neuro first diagnos saw think move somewher els diseas modifi drug prescrib number clinic signific relaps certain time think two year gener start inject drug like betaferon copaxon work side effect problem may move anoth treatment gilenya taken capsul day know much tysabri given hospit everi month treatment depend ms affect time may need physiotherapi help eye specialist avail qe name treatment need year sure other think avail qe',\n",
       " 'thank fg around yr femal dx uc dx chang crohn coliti current total colectomi oct previous use remicad humira stelara imuran mp apriso asacol lialda delzicol pentasa cortenema cortifoam rowasa canasa entocort uceri uceri foam prednison gluten free supp vsl cal mag vit krill oil ezf',\n",
       " 'ncot technic remiss surgeri start entyvio still perian diseas two fistula year entyvio fistula close fine ever sinc got scope everi way last week diseas activ inflamm seen anywher say entyvio work pretti darn well wait work difficult part especi feel sick fortun realli sick start year old male diagnos crohn age ileostomi april revis surgeri june current med entyvio nexium past med humira remicad cimzia imuran mp mtx everi asa',\n",
       " 'turn multipl sclerosi exempt us relentless life feel like stuck fugu state one bad thing anoth begin wish could throw flag appeal univers throw damn bone alreadi flag univers supposedli benevol rot real bitch come make pour rain make start think life test might fail make think life unfair make forget grate greater sin none lost anoth felin famili past week want downplay go high brow circl life play elton john song inspir help find beauti long life well live quit simpli feel way even littl bit lost cat roger may entir dynam hous chang sudden littl vocal social pot stirrer gone hous went quiet ivan littlest kitti kind step roger void talk snuggl spent everi bedtim perform nighttim ritual circl head head but hand forehead pet squawk whole time like want lone make sure ok ok cat probabl none sentient intent felt like matter right knew someth wrong led believ minor issu chronic clog anal gland gross need keep eye happi play eat take care like perfectli healthi littl kitti exactli like roger complet fine saw diarrhea live room floor somehow caught put carrier without fall face adrenalin amaz thing bare stand without fall post prednison haze manag catch littl guy shove carrier call nephew alex panic came immedi took ivan emerg vet sure ivan go ok even tri go along bad shape knew stress trip good ridicul dysfunct bodi steroid last week give usual backlash could bare walk lemtrada leg cramp back vengeanc steroid basic got one day offic piss prednison feel complet reason complet irrat time shape go pranc cold night emerg vet ok though alex would handl text vet told doc thought ivan would ok vital realli good seem perfectli healthi except clog anal gland plan clean send home antibiot good caught got go fine went clean behind rectal exam realiz clog anal gland giant tumor see extend outsid bodi call explain even chose oper would like never abl go bathroom without difficulti keep clean would like terribl pain last long like ivan year old believ hear alreadi walk away idea anyth serious wrong happen telephon convers vet decid done want drive ivan went sleep strong enough roger went sleep alreadi hospit time roger first pet death even remot prepar would hit know know think could bear let ivan go without see one time alex solv problem drive minut back hous get drive back emerg vet held ivan pur loud sound like warm tini littl lawn mower arm kiss talk held tight littl heart stop want let go gone look peac like asleep like tini littl black sleep kitten want hold forev go four cat three strang go three cat two like kind seismic shift two left fred owen kinda quiet keep bit last day sinc ivan gone though glu side know cat know somehow know ok probabl sound crazi think miss ivan sinc thursday night went midst anoth famili crisi complet unrel univers work mysteri way need someon els need focu someth realli import someon love love even physic ideal stress bodi friend know basic night three day catch sleep day realli seen much daylight sinc thursday night feel strang three day pajama three day wake sun go mayb univers know need focu someth fail bodi poor sweet kitti need use famili crisi sinc pass thing get back normal may actual sleep tonight dark wake sun tomorrow sure go feel tomorrow mostli post prednison post lemtrada bodi asshol would kind love go outsid breath air feel cold see snow know soon type word might highli unlik go shape thing tomorrow mayb mayb later week get better patienc thing even resist everi fiber miss ivan miss work bodi miss outsid kind miss new fuck life lesson learn everi time turn around miss spontan smile take work bodi grant miss love winter sure start go rabbit hole thing miss littl pound fur ball incred impact grown woman human life honestli idea miss core hope cozi wherev',\n",
       " 'tysabri everi six month head everi year head c spine',\n",
       " 'present annual ectrim confer london septemb quot efficaci safeti siponimod secondari progress multipl sclerosi result placebo control doubl blind phase iii expand studi l kappo bar b cree r fox g giovannoni r gold p vermersch arnould sidorenko c wolf e wallstroem f dahlk neurolog clinic policlin depart medicin clinic research biomedicin biomed engin univers hospit basel switzerland neuroimmunolog unit montreal neurolog institut hospit mcgill univers montreal qc canada multipl sclerosi centr univers california san francisco san francisco ca mellen centr treatment research multipl sclerosi neurolog institut cleveland clinic cleveland oh unit state blizard institut bart london school medicin dentistri queen mari univers london london unit kingdom depart neurolog st josef hospit ruhr univers bochum bochum germani univers lill depart neurolog lill citi franc novarti pharma ag basel switzerland lycali sprl brussel belgium background high unmet need treatment delay disabl progress secondari progress multipl sclerosi spm siponimod baf oral activ select modul sphingosin phosphat receptor subtyp expand largest randomis control studi spm date object expand phase multicentr randomis doubl blind placebo control studi design evalu efficaci safeti toler siponimod treatment spm design method patient spm defin progress increas disabl month durat absenc independ relaps age year expand disabl statu scale edss score enrol elig patient randomis receiv either mg daili siponimod follow initi dose titrat start mg match placebo event driven studi design allow blind core studi stop pre specifi number confirm disabl progress cdp event occur primari efficaci outcom time month cdp measur edss key secondari outcom time confirm worsen baselin time foot walk test lesion volum chang baselin safeti assess includ report advers event ae seriou ae sae clinic notabl laboratori abnorm patient complet core phase offer receiv open label siponimod extens phase result overal patient randomis countri baselin demograph diseas characterist previous report repres patient popul spm overal patient complet core studi median time studi core studi complet month major patient particip year cdp event patient could maxim contribut one event primari endpoint ae report sae patient conclus top line efficaci safeti result expand studi present result larg control studi recruit activ spm popul without superimpos relaps determin siponimod delay disabl progress spm contribut better understand natur histori spm well control trial set _________________ disclosur fund sourc studi support novarti pharma ag basel switzerland ludwig kappo institut univers hospit basel receiv last year use exclus research support steer committe advisori board consult fee actelion addex bayer healthcar biogen idec biotica genzym lilli merck mitsubishi novarti ono pharma pfizer recepto sanofi santhera siemen teva ucb xenoport speaker fee bayer healthcar biogen idec merck novarti sanofi teva support educ activ bayer healthcar biogen csl behr genzym merck novarti sanofi teva royalti neurostatu system gmbh grant bayer healthcar biogen idec european union merck novarti roch research foundat swiss ms societi swiss nation research foundat amit bar particip speaker meet sponsor receiv consult fee amplimmun biogen idec diogenix genentech sanofi genzym glaxosmithklin novarti ono pharma teva neurosci recepto inc roch merck emd serono receiv grant support amplimmun biogen idec diogenix genentech sanofi genzym glaxosmithklin novarti ono pharma teva neurosci recepto inc roch merck emd serono bruce cree receiv person compens consult abbvi biogen idec emd serono medimmun novarti genzym sanofi aventi teva neurosci contract research support includ clinic trial acorda biogen idec emd serono hoffman la roch medimmun teva neurosci robert fox receiv compens serv consult speaker allozyn avanir biogen idec novarti questcor teva pharmaceut industri institut work receiv research support novarti gavin giovannoni steer committe member daclizumab trial abbvi steer committe member bg daclizumab trial biogen idec receiv consult fee advisori board meet honoraria speak physician summit consult fee advisori board meet steer committe oral cladribin trial merck serono steer committe member fingolimod siponimod trial novarti steer committe member laquinimod trial teva consult fee advisori board meet genzym sanofi honoraria speak sever medic educ meet steer committe member ocrelizumab trial roch consult fee relat dsmb activ synthon bv co chief editor multipl sclerosi relat disord elsevi ralf gold receiv compens serv consult speaker bayer healthcar biogen idec merck serono novarti teva neurosci institut work receiv research support bayer healthcar biogen idec merck serono novarti teva neurosci patrick vermersch receiv honoraria consult fee biogen idec genzym sanofi bayer novarti merck serono gsk almiral research support biogen idec genzym sanofi bayer merck serono sophi arnould tatiana sidorenko erik wallstroem frank dahlk employe novarti christian wolf partner lycali sprl serv consult novarti also receiv compens serv consult bbb desitin investitionsbank berlin keyru synthon mylan teva',\n",
       " 'thank kati repli thank thought treatment reason choic start treatment yet also offer ocrevu said would abl offer month said clinic trial go ask next appoint said littl side effect one comment help confus worri feel better talk peopl understand give opinion help thank',\n",
       " 'anyon experi treat met amplif met level hard get approv insur mother get conflict respons two differ doctor whether met level warrant treatment current tagrisso progress steadi month look next step',\n",
       " 'sorri took finish similar dxd may rrm biggi cluster episod within space three day iv steroid hospit job made great recoveri last affect easi dismiss diagnosi ms big deal affect fine three month later anoth partial paralysi episod usual hospit admitt steroid left crutch unsteadi decemb use rollat occas march need wheelchair distanc met neuro june year confirm suspect rrm ppm diagnosi last year believ neuro dxd ppm allow chanc use dmd even sinc chang diagnosi allow continu tecfidera request well know might good good luck gilenya',\n",
       " 'paul question would person opinion b cell deplet therapi dr martin duddi neurologist b cell deplet therapi depend kind approach scientif point view realli interest thing lot reason might work ms kind pragmat person look data realli great data think kind take regardless drug work look look virtual stop new mri activ six month relaps suppos one thing wait see good brain shrinkag know campath alemtuzumab sort year three four five saw maximum effect ocrelizumab come good brain shrinkag top stop new lesion come power combin ad fact seem work relaps form potenti progress form absenc relaps yeah kind excit time two thing togeth think show move deal peopl ms speak peopl progress diseas felt left long know everi new stori seem relaps diseas two big new stori progress diseas paul want also ask kind timelin might see ocrelizumab avail patient dr martin duddi minut european regul think halfway process understand like reach decis middl next year goe usual thing come nice year drug kind avail nh probabl still gut two year http shift ms msreport http www facebook com shift ms http www instagram com shiftdotm http twitter com shiftm',\n",
       " 'hey jana hope new diagnosi welcom rather scari diagnosi chang life final answer hope feel sorri hear bladder issu capoxon daili inject busi migrat gilenya clone medz effect anymor rsa live cannot choos medic neuro choos go plan realli hope medic effect diagnos year ago third treatment wish would could lot older diagnosi difficult diagnos suck want activ social bodi play well idea pleas ask want know peopl awesom support great help past site ask answer happi easter ms er',\n",
       " 'marlo ever type treatment sinc diagnos round lemtrada evid diseas activ sinc quick simpl problem free talk neurologist would ever relaps cladribin would probabl next choic anoth round lem probabl much help want lemmi talk friend request happi share contact detail pm xx',\n",
       " 'cimzia common crohn diseas would assum similar humira regard side effect certain ask crohn forum healingwel get answer moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa two certainti life pay tax prednison side effect',\n",
       " 'use visual multipl sclerosi journey rather complic journey foreign countri direct destin ever chang speak languag late visual multipl sclerosi complex maze kind like one pictur variou place make way see light shine mani place find continu make way maze light hard see seem gone entir feel muddl tri like hell hold shit togeth posit look forward ms beth late gotten bit much realiz recent mobil taken real turn wors sinc last relaps juli mobil alway issu begin mean troubl walk one first symptom weird feel leg leg leg feel confus enjoy walk around reservoir highland park sit one quarter mile lap super confus suddenli easi thing like freak walk easili anymor walk alway issu ampyra help honest help much late live fear stop time ever done accid forget second dose exampl leg becom complet useless almost immedi terrifi test life would like without especi big thing go work come week requir physic present schedul place offic liar admit mess head big time relaps unsteadi feet result vertigo final gave got cane accept unsteadi impact life troubl even get offic valet park right across street feel home bound antsi rare left hous beyond go work becom instantli frustrat awkward learn walk cane sorri stanley know tri honest leg drag like dead tree stump cane whole lot make leg walk better rememb first appoint great scott ms specialist said reason believ even need cane said get aggress treatment want soon progress would slow start feel bit better tysabri turn miracl wait day light corner maze allow hope would feel better relaps happen never quit made back stage even felt like million round high dose steroid made fat miser still back pre relaps level abil buy stanley felt like give felt like failur buy use best abil almost hate much thought would least cane peopl clearli see probabl tri mow without look like complet asshol kind nice seen tg sinc start use cane almost embarrass tell stanley afraid mayb disappoint know strang girl word without right one describ feel closest get feel shame outsid make joke use stanley accessori emphas import point convers bang ground definit thing occasion cannot deni insid resent shit stanley feel like outsid sign fail stuck ten feet maze help get next light corner troubl walk feet fifti feet leg start liter drag like inanim object stumbl foot everi turn head walk without lose bear come reli stanley kind thing semi effect walk distanc chore realiz late simpl fact kept walk much stuck dark corner maze see way one simpl fact disabl semi abl abl uncomfort abl life full awkward discomfort feel like quit one thing quit would walker help sure seem like anoth awkward thing carri around get car anoth devic make leg work better give someth lean stanley pretti good job guess could get rollat also allow sit get exhaust carri backpack full water drug comput collaps set rollat realli seem practic get wheel chair transport chair motor scooter walk walk far know deal realiti tri build life around realiti go place limit walk possibl also mean progress life progress maze slow dramat got desir social tire littl walk given day never sure much walk involv get point point b back outsid world got bare enough energi get offic back home home got bare enough energi take care home thing like laundri cat care go bathroom shower involv mani stair step live alon two stori hous unavoid peopl suggest consid thing like move somewher step sell home make new one somewher els without challeng day day life even thought drastic thing like sell hous move mom thing would mean work hard tri hard everi day job meant someon fulli abl someon semi abl thought make feel sick stomach instantli know right thing give yet still keep stumbl way maze tri get next area maze littl light shine idea get middl place light shine final understand diseas way make bearabl drive lost much use think made unwil give even littl bit yet live gray area entir disabl kind make life pretti freak complic walk kind import part life guess never thought much cours peopl simpl activ without even think see great scott april week third ocrevu infus april go talk go tell think get wors happi go tell sure patient treatment given everi six month seem make better definit gotten wors see nowher near walk damn cane physic realiti even tg deni go tell hope burst tear front ever present intern know suppos look bright side believ peopl realli realli much time leg carri much one handicap space anoth becom littl bit harder keep technic walk walk far like half pregnant abl crippl somewher feel like write worri anyon know dip dive part ms life know much experienc taught reassur believ reassur get better believ work daili maze get better would hard time ralli silli thing like win busi work make money peopl readi give silli thing like yet met new peopl late begin journey bit farther along much deal life silli job thing like rais kid famili thing make better know women mostli women get help anyth complet sure mayb decid complet honest shithol maze game play mayb help someon els feel less crazi write usual name fear rambl someth dread let loos like whiniest annoyingli pessimist friend never want take away littl bit power talk suddenli seem smaller less scari almost silli write dispel gigant huge way enorm fear write less power like magic gonna epic meet april hit great scott make great blog post meet tg usual result favorit blog post sinc find complet delight clearli calmli recount much suck ask realli still believ miracl drug actual right one introduc stanley',\n",
       " 'hi bfarz congratul great scan report glad stick tagrisso continu keep cancer control mixtur indol bac adenocarcinoma alway possibl invas compon becom aggress although long histori slow growth make less like slow grow cancer difficult determin whether treatment work well indol natur cancer jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'hey barbz feel hard say stelara work dose far mouth throat ulcer clear definit posit like fistula small larg bowel caus excess diarrhea weight loss tpn alreadi gain pound know stelara abl fix probabl look surgeri unfortun live tpn fentanyl forev',\n",
       " 'janin quick question direct read indol cancer elderli especi malign pleural effus thank much bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test neg stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr start alimta alimta sinc usual ned chemo period less month month recent occurr jan alimta jan thru april ned april occurr cancer jan start alimta test posit ro june appt onc discuss futur tx plan',\n",
       " 'sure whether add post start new one may end heart break read post see pain grief horribl diseas caus roller coaster natur treatment scan setback take toll dh sail first round folfox avastin even work day rd round everyth hit like brick wall visit hospit final day overnight home nausea vomit diarrhea final bay grate final abl eat sandwich week hold noth still incred worri sleep day hope med new norm scare tire impati still tri pray even imagin round day yet new ct show shrink tumor',\n",
       " 'anyon experi stop rebif outright need wean due back neuro th june know go come rebif handl side effect person miser cri time feel anxiou constant physic discomfort top mental side never use feel bad start fact deal quit well situat current holiday australia month week feel go abl relax enjoy trip come aw drug anybodi experi stop take bat make thing wors neuro told gilenya next step actual never want go rebif first place refus tecfidera read bad stori side effect put rebif thank much advanc',\n",
       " 'top approach trend therapi recommend use mani gasteroenteroligist start stronger med much much earlier within treatment process extinguish control uc spread extent sever produc best qualiti life control fast let move remiss forget uc could tri small adjust next month much along get past flare bm day put high end moder flare low end sever flare humira perfectli reason recommend symptom feel pretti good bm day realli forget bm day like remiss would whole lot better qualiti life stronger treatment say well bm day least better trap best whole lot better good save trump card sleev joker best tri treatment option get remiss mani biolog avail mani new treatment develop end rope tri humira moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa cannot spell suck without uc post edit ipoop gmt',\n",
       " 'angi randal chicago mom live multipl sclerosi excit introduc angi optimist inform websit well strong ms mani year live ms ms year medic use tysabri monthli infus one year great result knock wood natur therapi treatment fight ms tri eat clean diet mostli carb gluten free exercis regularli get lot sleep think rest key ms ms affect mother certainli precaut take part life modifi abl figur new normal motherhood definit make health prioriti also daughter someth ms wish peopl knew end world first diagnos assum worst thought life would never true degre ms diseas even year ago medic treatment advanc much new treatment option come everi year abl live full activ life diseas tri demonstr other blog well strong ms start blog show peopl advic someon newli diagnos know overwhelm begin suggest coupl thing find neurologist trust interview find someon realli confid seek other thrive diseas see attribut success learn take control situat find medic treatment option work posit hard begin go best asset throughout ms journey think futur ms treatment feel like everi day new medic horizon alway give hope excit ocrelizumab effect drug suppos high infus everi month seem ideal',\n",
       " 'weekend post alemtuzumab work peopl fingolimod beg question transit peopl fingolimod onto someth els debat natalizumab alreadi look post aspect highlight fingolimod natalizumab racehors drug keep cell trap stop enter brain kill drug diseas form cell accumul time starter order race brain stop drug diseas rebound peopl mani limod trial ongo take fingolimod siponimod measur place drug suppli stop end trial rebound go prevent even progress everi want call ms trial drug kill drug trap drug fingolimod trap diseas caus cell lymphoid tissu natalizumab trap diseas caus cell blood stop diseas process diseas caus cell accumul trap whilst drug treatment place howev see cell racehors wait run brain starter order wait go gate open remov drug cell escap get brain diseas activ occur whilst peopl view progress ms differ diseas think dumb view importantli danger view clear mani peopl activ lesion come go progress cours carri look patholog peopl progress ms activ lesion clear peopl progress ms benefit immun inhibit howev think also case racehors drug allow accumul damag cell peopl progress ms extent drug convert subclin relaps patholog relaps activ ms time bomb tick drug stop hors line wait go stop drug relaps occur sometim call rebound call resum synchron relaps case like word rebound damag ever name call need avoid happen sure drk case report pleas drk say md davion jb et al two case relaps primari progress multipl sclerosi fingolimod withdraw j neurol',\n",
       " 'hi stage lc spread bone spine neck went chemo next opdivo noth thrill got yet noth week treatment dose appear work treat would certainli tri mean time readi last appear help buddi hope opdivo shrunk tumor like magic depend pd protein tcell',\n",
       " 'janin thank respons appreci knowledg expertis forum bring address aw ill unfortun diseas hit peopl age everyon experi differ find help hear peopl stori mayb experi share mother help similar situat forum other learn lot cours diseas diagnosi treatment often undertaken patient much younger mother differ see test treatment regimen pursu come goal involv given mother advanc age frailti famili decis make process driven primarili goal maintain improv qualiti life follow goal extend time younger patient abl toler think revers usual true goal mind come question label use last line set often time especi case cancer doctor abl prescrib label treatment insur pick tab depend argument present feel much uncertainti test could leav larg popul benefit tagrisso interest hear opinion circumst condit would consid label prescript last line treatment inconclus test result seek label use tagrisso keep goal treatment mother ill continu monitor condit monthli liquid biopsi chose treatment pay greatest dividend correspond goal hope one test come back posit issu famili chi',\n",
       " 'oral medic much easier inject needl inject type med work horribl inject medicin would frequent miss time bruis gilenya year bright idea switch someth strong tecfidera month go back gilenya okay though well gilenya flare up often',\n",
       " 'want honest answer nh leagu leagu ahead healthcar system incred cost effici still get high qualiti drug surgeri treatment guy sorri blunt make laugh see american terrifi social medicin go describ pick doctor want doctor insur network fight fight stay x drug insur compani want switch drug cheaper instead even get x drug first place specialist ibd doctor within mile small rural town forth feel sorri us lose nh feel sorri us whatev replac much much wors ps extrem limit choic remicad humira past vedolizumab chang hospit doctor want miss american get profit privatis healthcar system post edit nicecupoftea gmt',\n",
       " 'wow realli realli suck sorri even imagin frustrat cd gastroparesi fibro arthriti gerd med remicad thing besought lord thrice depart said grace suffici thee strength made perfect weak gladli therefor rather glori infirm take pleasur infirm reproach necess persecut distress weak strong cor',\n",
       " 'much rechalleng rather clear afatinib best option slow rate growth cancer use instanc stereotact radiat area control lot inform go one cannot confid afatinib option next best would osimertinib erlotinib fewer side effect penetr brain better chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatin vinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan',\n",
       " 'yet anoth chapter begin ms histori tri keep diseas bay yesterday infus rituxan seventh attempt therapi tri interferon rebif copaxon tysabri fail get clinic trial lemtrada five year rel bliss follow stem cell transplant creep return move aubagio steadi ship somewhat rituxan slightli modifi form expect approv late year fda ocrevu aka ocrelizumab ocrevu soon recogn therapi progress multipl sclerosi rituxan logic choic month prior stem cell transplant began precipit slide without relaps perhap precursor secondari progress ms transplant stop dramat long relaps familiar un eb slide restart aubagio help nip felt need get aggress ocrevu still month away took shot get rituxan label initi deni insur compani ms specialist doc talk around first transfus went pretti well although slight allerg reaction coupl hour red face itchi littl extra benadryl prednison clear thing went smoothli although pretti dopey insert joke took six hour amf adventur predict next infus two week six month ish keep folk abreast progress although mayb bad word use success lack progress sound like __________________ dave bexfield activems',\n",
       " 'termin ileum inflam long time due ibd inflamm colon push back ileum complet erod away ic valv food dump straight colon ileum without stop caus pain cramp diarrhea ga malabsorpt nutrient gi say lifelong ic valv syndrom along small intestin bacteri overgrowth said common uc told problem crohn patient biopsi say uc joanna diagnos proctiti spread pancol append ileocec valv syndrom mg simponi everi week mg imuran daili mg nicotin patch mg welchol algaec magnesium curcumin vsl fish oil dao oral iron venof may scope clinic remiss ic valv anymor due inflamm small intestin formerli known bananagirl',\n",
       " 'thank agre know better liter eat month avoid bathroom trip care littl one got excit felt amaz know better sinc take nd dose humira yesterday today better less bathroom trip still semi liquid stool alway stay away crohn avoid food crab weak unfortun tri seem alway go back week feel amaz abl go w kid worri need tri harder',\n",
       " 'absolut idea self respect neurologist would offer someon rrm beta interferon rather option first line dmd beta interferon estim reduct relaps say rebif success year see want chang first dmd would neurologist offer tecfidera gilenya either would give relaps reduct peopl given lemtrada first dmd bold side effect seriou yet expect outcom regard ms excel would definit go back neurologist ask choic certainli oral therapi rather inject realli stronger option fit lifestyl suit individu plu effect drug opinion given enough option sue',\n",
       " 'hi steve correct valu use tarceva adjuv post surgeri set clearli establish evid long term treatment tarceva may benefici thorough discuss use tarceva set gracecast video cours state discuss possibl lung cancer alreadi cure surgeri radiat chemo way know although tend strong support obtain second opinion see discuss reason oncologist differ assess avail data sure get differ answer assum initi opinion wrong far develop resist sooner certainli concern howev third gener egfr inhibitor avail treat egfr inhibitor resist diseas research continu develop new treatment agent jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'daybyday partner need go emot rollercoast went post diagnosi much stuck shock denial phase need move forward respect also suffer ms need see life must go take time time forc subtl understand matern crave ocrevu may best dmt pregnanc recommend discuss dmt pregnanc plan neuro may drug e g would fit better plan whilst may genet factor contract ms part stori factor involv whilst risk pass ms margin increas definit',\n",
       " 'ppm tri ocrvea one dose split thank god bad reaction got sick bed whole week read post day ago hug use receiv denial assist dmt tecfidera past year inform assist futur enough get toward end month appoint neurologist end march request med refil issu heard weekend suggest go talk look ocrevu patient infus cover medicar take read post day ago hug use answer sign view previou answer mymsteam member said call biogen make tecfidera help cost live post day ago hug use tecfidera tysabri mani mri r talk ocrevu anyon experi drug post day ago hug use answer sign view previou answer mymsteam member said start take ocrevu week ago take second half seem okay long enough realli know',\n",
       " 'impact hurrican sandi resid mid atlant northeastern midwestern unit state devast msaa staff deepli sadden tragic loss life well destruct person possess home busi caus storm power outag ga shortag loss basic servic continu disrupt live million peopl effect particularli urgent individu disabl mind hope follow inform may help member ms commun need individu either lost medic lost power abl keep medic cold requir follow pharmaceut inform may assist specif note list provid msaa individu pharmaceut compani msaa updat list inform becom avail aubagio program name ms one one phone websit www msonetoon com avonex program name ms activesourc phone websit www avonex com storm note avonex lost improperli store result hurrican sandi replac cost betaseron program name betaplu phone websit www betaseron com storm note betaseron lost improperli store result hurrican sandi handl case case basi copaxon program name share solut phone websit www copaxon com storm note copaxon lost improperli store result hurrican sandi handl case case basi repres note copaxon left without refriger one month room temperatur extavia patient servic program phone websit www extavia com storm note extavia lost improperli store result hurrican sandi handl case case basi gilenya patient servic program phone websit www gilenya com storm note gilenya lost improperli store result hurrican sandi handl case case basi rebif program name ms lifelin phone websit www mslifelin com tysabri program name ms activesourc phone websit www tysabri com storm note tysabri lost improperli store result hurrican sandi replac cost sent directli infus center see full list pharmaceut assist program contact inform pleas visit http www mymsaa org ms sourc american red cross salvat armi commun food bank state offic emerg disast center organ unit methodist committe relief set throughout countri assist peopl crisi contact inform servic avail telephon inform search internet follow specif contact servic american red cross www redcross org red cross salvat armi www salvationarmyusa org state offic emerg manag http www fema gov region oper state offic agenc emerg manag unit methodist committe relief deliv health sanit kit well home repair case manag servic www umcor org articl unit methodist committe relief help disast http www umcor org umcor resourc news stori octob help fbi tip page avoid disast relief donat scam http www ic gov media aspx new jersey new york among state sever affect hurrican sandi follow state servic may assist new jersey nj state offic emerg http www state nj us njoem nj disast center provid link feder state disast center resourc http disastercent com newjersi newjersi htm commun food bank new jersey food resourc coordin fema food new york new york state offic emerg http www dhse ny gov oem new york disast center http disastercent com newyork newyork htm american red cross new york http www nyredcross org nyc food bank also help relief effort http www foodbanknyc org inform assist individu ms famili member member ms commun may contact msaa helplin email msaa msquestion mymsaa org',\n",
       " 'last week discuss inject abl medic week let discuss oral medic option avail oral medic hit market recent peopl ms stuck inject option clearli ideal patient would hear oral medic option someday futur know would actual happen eventu gilenya approv fda current three oral medic market approv relaps remit ms let take closer look medic gilenya gilenya new class medic call sphingosin phosphat receptor modul mouth scientist think work keep certain white blood cell lymph node therebi make imposs cross blood brain barrier get central nervou system make cell cannot get central nervou system reduc inflamm damag nerv cell sever studi done gilenya shown effect gilenya cut relaps compar avonex one year studi also prevent relaps compar placebo two year period fda approv use gilenya relaps remit ms sever side effect associ gilenya headach slow heart beat weak fatigu infect elev liver enzym diarrhea note uncommon side effect macular edema swell area retina respons central vision gilenya also known slow heart rate significantli especi first month treatment individu also might feel realli tire heart palpit chest pain feel dizzi usual someon experi symptom disappear within first day two treatment fda updat regul around patient first dose gilenya requir individu ecg receiv first dose six hour first dose also recommend first dose taken medic observ due patient unfortun pass away late take first dose gilenya far know definit link gilenya tecfidera tecfidera also known dimethyl fumar oral medic taken twice day specif develop peopl relaps remit ms similar chemic compound call fumaderm use germani mani year treat flare psoriasi specif way tecfidera work still unknown scientist think activ certain pathway bodi help protect nerv cell damag inflamm one studi two year period peopl take tecfidera experi relaps compar peopl placebo group tecfidera approv fda use relaps remit ms common side effect tecfidera includ flush stomach pain nausea diarrhea side effect seem present begin treatment dissip treatment progress case pml report patient take tecfidera actual pml rare deadli brain diseas happen individu take immuno suppress medic order develop pml individu must posit jc viru first routin blood test monitor jc viru statu recommend take ms med aubagio aubagio also known teriflunomid pyrimidin synthesi inhibitor work reduc number white blood cell central nervou system decreas inflamm overal protect nerv peopl ms sever studi aubagio proven effect placebo reduc relaps reduc disabl progress show decreas brain lesion aubagio approv fda use relaps remit ms common side effect aubagio includ headach nausea hair loss diarrhea elev liver test like symptom numb tingl hand feet less common seriou side effect includ elev blood pressur increas risk infect liver damag take aubagio need regular blood test monitor liver function blood cell count aubagio also associ sever birth defect neither women man take aubagio pregnanc plan aubagio remain bodi two year discontinu medic special treatment may need remov drug system plan becom pregnant usual take medic requir individu effect birth control method took aubagio year unfortun went treatment alreadi activ diseas state two relaps take medic like could take pill instead daili inject previou copaxon soon experienc side effect lot hair loss irregular blood cell count due relaps eventu chang medic arriv oral medic welcom relief mani ms patient repres constant advanc research develop hope futur bring mani option tabl',\n",
       " 'thank repli label intraven cladabrin avail nh hospit even hospit tend favour mitox also mavenclad ocrelizumab dispos rrm progress ms would favour case delet repli repli mousedoctor wednesday novemb pm iv clad sub cut clad avail use sub cut easier maven v ocrelizumab good drug talk pwm find suit person think moa similar delet repli repli mousedoctor wednesday novemb pm believ stay away mitox cancer risk',\n",
       " 'ye u doctor avail make comment thank diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'poor experi gilenya well tysabri pml risk high doc switch gilenya relaps next month put back tysabri despit high pml risk never fulli recov two relaps subsequ learn sustain perman heart damag gilenya pml risk went roof earli doctor refus tysabri desper stabil ms travel us germani lemtrada look way get wors rough month heavi fatigu ms start stabil improv stun ms never realli improv get major relaps might recov loss back total new thing improv deal long time immens fatigu cognit problem pain issu jump muscl eye sight pupil stop constrict oh relief sunni day mani would strong urg consid lemtrada time chang would happi talk lemtrada read blog first year lem lemtrada blogspot com fellow member tracyd also lemtrada blog lemtrada strongest medicin fight back ms spare week life get medicin basic wait work day year later take pill everi day medicin bodi week keep work keep ms bay best wish search right treatment take care emma',\n",
       " 'diagnos stage adenocarcinoma enrol clinic trial tecentriq initi treatment week apart follow surgeri patholog report show posit lymph node neg treatment continu treatment prevent recurr major side effect sister law small cell chemo went remiss evid diseas month cancer back spread bone liver brain would take drug',\n",
       " 'doctor togeth decid begin copaxon mg copaxon mg year gilenya year surviv viral enceph drug almost immedi joint began stiffen becam pain much lift use hand difficult feel like arthriti joint nurs ms clinic inform report side effect tri detox bodi',\n",
       " 'apolog gilenya',\n",
       " 'hi thought cladribin relaps remit ms peopl sp still relaps far understand idea work lymphocyt target bad bit immun system attack myelin relaps peopl know meanwhil tri research drug might eas anxieti either decid drug cope one way carol said tri get stress stress ms realli go well togeth sue',\n",
       " 'would make appoint gi asap technic inflectra ident remicad similar henc term biosimilar howev bodi may like small differ perhap develop antibodi inflectra idea honesti better nd rd infus would fight go back origin remicad dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'hi new shift ms need advic regard treatment diagnos put tecfadera gave terribl side effect move aubagio fail miser relaps month year got letter say could move gilenya tysabri lemantra psoriasi neuro look one would treat ask dermatologist possibl heard say probabl go give gilenya question say keen choic worri side effect macular oedema virtual lost sight eye due optic neuriti lose licens live farm mile anywher ask differ one ms nurs sent inform treatment letter lean toward tysabri like say know choic help would great feel confus worri progess need relaps stop thank',\n",
       " 'hi jacki heard correl per se take afatinib progress tarceva shown effect stop cancer progress vice versa mutat acquir tarceva afatinib good chanc tagrisso efficaci correl time unknown mechan resist tagrisso new much understand yet ask hesit tri guess els may help think bonu video excel explan nsclc specialist today patient begun show progress tarceva http cancergrac org lung gcvl_lu_combinations_other_options_egfr_acquired_resist best janin',\n",
       " 'fda accept prioriti review supplement biolog licens applic sbla eylea treatment diabet retinopathi patient regeneron report second quarter financi oper aug compani recent submit supplement biolog licens applic sbla eylea treatment diabet retinopathi regeneron pharmaceut inc nov vein occlus diabet macular edema dme well design treatment diabet retinopathi patient dme regeneron report fourth quarter full year financi feb initi phase studi treatment diabet retinopathi patient without diabet macular edema dme regn pdgfr beta unit state secur exchang commiss visual acuiti defin total number letter read correctli earli treatment diabet retinopathi studi etdr chart standard chart use download doc visual acuiti defin total number letter read correctli earli treatment diabet retinopathi studi etdr chart standard chart use regeneron report first quarter financi oper may march u food drug administr fda approv eylea treatment diabet retinopathi patient diabet sec file regeneron pharmaceut inc report one year data phase panorama studi treatment non prolif diabet retinopathi patient without diabet macular edema sec file regeneron pharmaceut inc apr compani expect expand ocular program includ addit indic diabet retinopathi dr excess regeneron pharmaceut inc form k may diabet retinopathi patient diabet macular edema dme sponsor diabet retinopathi clinic research network',\n",
       " 'hi travel spain month student visa remicad everi week intern health insur call cover biolog remicad statesid health insur reimburs need know cost anyon know cost either follow medic per mg vial spain remicad remsima inflectra someon must taken medic spain without insur find inform anywher els internet thank',\n",
       " 'jul mike_and_carolyn wrote hi laura thank repli take doxycyclin day take husband take morn empti stomach water take tarceva pm take togeth also time take ondansatron take use lotion cleaner tha work thank agian christ carolyni yet start chemo also take doxycyclin twice day instruct leaflet say alway taken meal full glass water prevent irrit eosophagu also taken even food least two hour bed direct also say taken upright posit hope help x',\n",
       " 'diagnos crohn month ago remicad sinc april insur recent switch inflectra cuz yay first inflectra infus past friday felt sinc today nauseat lighthead hold wall support cuz feel like go fall intens rn husband offer take er know reaction inflectra crohn symptom felt gener weak fatigu sinc infus usual tire rest day mayb hour never long feel kind like adjust imuran start novemb idea',\n",
       " 'sorri delay repli difficulti figur repli post repli question biopsi neg taken progress tarceva watch video youtub dr west show promis tagrisso neg patient also mention two trial recruit neg patient addit comment',\n",
       " 'click receiv ms news via e mail stori show written ms patient name laura fulli understand titl blog post pleas read laura entir stori make sens cost effect ms treatment question explan given fairli predict negoti payment insur go pay much would significantli reduc amount eventu paid increas bill clinic provid paid per year real cost treatment base today price still stagger amount consid continu mental struggl whether amount money worth big pictur consid age factor fair treatment cost affect health care dollar cost like take sizeabl chunk avail moni much treatment affect escal cost health insur ms chronic diseas known cure could conceiv continu treatment remaind life amass treatment cost million dollar fortun entir cost treatment cover privat health care insur along patient assist program tysabri cost paid noth pocket year imagin type bill part drive cost health insur pay lot everyon els think angri frustrat ms treatment cost often anoth remind escal bill usual form notic insur tell much bill actual paid today remind came differ way write dr gavin giavanonni bart ms blog written ms doctor research depart neuroimmunolog blizard institut bart london school medicin dentistri unit kingdom particular articl talk nice nation institut health care excel uk one function nice set price healthcar treatment includ drug cost nice decid consid fair price pay drug look option treat patient decid would cost effect govern health care system blog author also concern afford access drug polici nice affect treatment post observ recent confer anoth ground shift poster oratorio studi result ocrelizumab ppm studi first studi show dmt slow rate disabl progress ppm one signific thing happen field ms last year despit concern nice may view ocrelizumab treatment ppm favour nice alway assess cost effect use increment cost model ppm cost effect ocrelizumab compar alreadi e best support care write think treatment cost also wonder could put price might cost provid support care compar money spent drug would need much way help money could spent someon els pictur could chang quickli ms progress treatment found depend health care servic activ daili live would amount money take care nurs facil averag daili cost nurs home care day think money would save somewher someon decid cost effect tysabri show health care money would better spent put nurs home read question bart ms blog make concern us cost effect model might need control drug cost us way insur compani alreadi form often deni treatment author certain drug reimburs topic cost effect one core point list north american registri care research multipl sclerosi narcrm project major initi us part canada look link patient clinic data togeth health care econom core identifi inform collect databas regard disabl util health care resourc employ help better understand whether use expens therapi worthwhil econom standpoint save fewer hospit less disabl longer employ span decreas util health care resourc unlik system uk help cost live hous transport medic care peopl need due financi demand live chronic ill broad rang assist us health insur would pay live cost pay drug financi respons leav littl choic continu treatment despit escal cost linger question best avoid futur care need would pay resourc meantim hope next bill open caus requir treatment choke price well laura http insidemystori com ms view news provid educ inform resourc servic affect ms',\n",
       " 'hi janin sorri late repli ask echo make sure chf insist pleas thoracentesi make sure cancer mom thoracentesi biopsi fluid show cancer also echocardiogram done last thursday normal age accord cardiologist fluid visibl echo pleura suspicion right heart fail due fluid overload everytim cancer back mom alimta week ago schedul anoth infus wednesday breath improv usual alimta remark better even one session time worrisom keep finger cross work glad see husband remain ned met friend yesterday whose mother remain ned year initi treat stage diagnosi gave hope thank write take care bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test neg stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr start alimta alimta sinc usual ned chemo period less month month recent occurr jan alimta jan thru april ned april occurr cancer jan start alimta test posit ro june appt onc discuss futur tx plan',\n",
       " 'recent start gilenya due major issu side effect stop day suggest take tecfidera wonder anyon experi two best wish sarah',\n",
       " 'februari roch today announc us food drug administr fda accept compani new drug applic nda grant prioriti review entrectinib treatment adult paediatr patient neurotroph tropomyosin receptor kinas ntrk fusion posit local advanc metastat solid tumour either progress follow prior therapi initi therapi accept standard therapi treatment peopl metastat ro posit non small cell lung cancer nsclc nda base result integr analysi pivot phase ii startrk phase startrk phase alka trial data phase ib startrk ng studi fda expect make decis approv august read roch press releas',\n",
       " 'long remicad almost year curiou work fellow crohni',\n",
       " 'hi gate lemtrada experi inspir go ask move gilenya lemtrada noth work far copaxon tysabri gilenya tri get lemtrada next appoint ive decid sure read good report thank updat hope happi lemtrada',\n",
       " 'hey everybodi wonder anybodi thought dealt fertil issu melanoma treatment husband went braf inhibitor unabl go sperm bank beforehand accord side effect drug make person infertil got sick hope kid someday turn mid right still middl cancer treatment high tumour burden still sure keytruda work although thing look cautious optimist symptom stabl even slightli improv even keytruda work know chanc complet respond pretti low consid serious diseas still think futur stay posit right find wonder whether ever kid situat stabil anybodi els dealt someth like wonder go like get egg frozen someth even realli know mean sex life non exist month low testosteron lot pain killer unabl go hormon replac therapi pretti sure tradit way work us anyway',\n",
       " 'read anyth blog know daili writer written journal year stack stack paper book full scribbl day use actual app journal anyth phone comput ipad along preciou aka therapist cheryl much hope remain quasi sane without daili journal write cathart someth need want imagin happi make guy tell like read someth written beyond anyth could ever wish start put person write blog need commun need find peopl like could learn real peopl real ms bound much better manag diseas present great doctor realli shock day great scott clearli one best among ms specialist still quit get know everi time ask last walk mile maribeth resist throttl mostli like need big brain unless ms possibl understand feel like empath listen love help grate around thing consist everi singl day also need commun found one prop http www trippingonair com origin inspir take write public check win award stuff one person favorit ms blogger said still write journal thing need deal write first foremost thing privat believ keep thing privat much small topic infus new goo ocrevu newbi found struggl write musion newest infus would next logic blog post went bed tire bone juic abl sleep usual happen wrote journal morn read wrote last night made realiz need share well best descript could give felt infus repeat verbatim edit probabl million writer mistak includ first apolog marathon long blog post folk get whole thing might super human peopl gener like short pithi post tip hack whatev oh well gotta infus day today big number blog yet want talk alreadi bed late get maximum rest attempt shower get offic tomorrow brain overdr probabl tini pinch steroid inject bloodstream today make sleep elus would notabl accomplish amaz feat mention hope get littl boost got ocrevu last time realli first time feel unrealist optimist stupid thing thing like email entir staff tell go focus get offic infus day number bag may may commit offic tomorrow first day big nearli hour day allegheni gener infus center smart smart beth feel like need kick ass hit restart gave day big infus day number two stop believ bodi simpli oper outsid world regular slightli abil challeng human today hour feel like tri harder make happen stop brain undermin everi singl littl thing life trick figur without tri hard kick back relaps fall end hospit realli difficult determin line nose still bit purpl liter plain nose face one might say push far without realiz dire consequ far far honestli know scare feel come feel good day one quit long forgotten feel like specif symptom feel feet hit floor morn walk littl easier sudden burst energi lighten bolt look back day realiz pop advil like skittl like slow realiz pain suddenli quit pain feel light feel safeti feel peac never last long least late good place day ms quiet thing alway fail realiz good day constant nois head somehow usual run loop brain daili alway alway alway alway alway hurt hurt hurt hurt hurt repeat voic allow ms put veil life make everyth slightli less vivid slightli less clear slightli less appeal slightli less possibl know stop voic probabl stupid give kind clear line person sand test forc action present actual date take shower leav hous day believ work work allow scare sound inspir like much bullshit could actual hard might get shower tomorrow feel like limb suddenli made cook pasta might fall feet hit floor get bed world around could suddenli spin like craze whirli bird might throw might someth entir brand fuck new like abl see right one side entir bodi suddenli go complet numb could happen crazi ass mess diseas actual bodi entir uniqu differ us relat us strang club call multipl sclerosi digit friend help know someon els similar thing happen one time goe far ms ms look face make kind friend everi day complet utter surpris liter idea minut minut second second moment moment central nervou system cook girl friday immun system accept almost two year mess shock still accept listen bottom line everi day complet utter surpris even peopl ms unpredict almost better normal mean mine name call life holi shit scariest diseas also chang moment moment use one normal know felt thought knew life would chang million differ reason plan reason smart work hard made import plan would tell good kind love human would happi littl place world thing would go way part easi myth believ know none us first fuck clue go happen day week think know mayb look name diseas face accept chao begin accept diseas alway ugli facet eccentr like think know go go destroy simpli exist mayb mayb diseas teacher mayb learn stop think teacher mindless dolt start listen mayb honestli know point person evolut idea go happen next neither anyon els might sound crazi part make feel better know fact gospel accord beth truth never know never known alway complet crap shoot still shower go work offic tomorrow triumph gauntlet threw truth know know tri know certain post script origin plan overli ambiti day start today phone call call call call pm still shower brush teeth make import thing happen call feel like failur suck accept overli ambiti good thing final shower around pm shower kick ms ass never would abl get done got done today attempt go offic earli shower foolishli plan day rough infus experi know take time new goo make magic head final physic clean go offic tomorrow babi step still step right direct give much need pass hold commit today end tri tri hard enough',\n",
       " 'leo wow touch choic know opdivo fda approv treat small lung cell recurr follow convent chemotherapi abl find inform advantag pair opdivo yervoy offer sure medic oncologist abl provid data full disclosur experienc immunotherapi treatment two repeat convent chemotherapi taxol carboplatin experi repeat convent therapi affect tumor elimin reduc size third elimin stubborn tumor repeat radiat actual precis radiat cyberknif fri stubborn tumor look like three small tumor know folk precis radiat fri multipl tumor good result might includ precis radiat potenti treatment get precis radiat answer radiat oncologist stay cours tom',\n",
       " 'diet supplement chang life got steroid first time four year still need remain medic though vedolizumab well mesalazin azathioprin proven best treatment radic chang approach nutrit remain ill wingman proctiti need fix get bad fast realli realli unpleas mistook terribl flair alway found mesalazin enema effect though administr pleasant nh want medic drug cost fortun immunomodul particular unfortun diseas individu unpredict well understood follow protocol see diseas give medic still see diseas give stronger medic told diet big part believ year think yet enough inform tell patient anyth els saw nutritionist told asid avoid trigger tri vsl diet noth say goe bodi singl greatest impact sever diseas unfortun ibd still mani question mark lucki drug sometim help us avoid danger procedur remov mani variabl manag constant balanc act anyway good luck',\n",
       " 'one patient bridg fingolimod',\n",
       " 'strang coupl day final abl start take high dose biotin read thread biotin mani mostli show biotin walk speed increas seven second accord neurolog test doctor howev state still stand biotin help besid notic weak leg hip area hand also give problem sinc problem hand time anyway paid much attent yesterday realiz much wors got think mayb start take biotin might improv biotin vitamin opinion could hurt tri howev doctor need check doctor put univers possibl companion life intent signific partner fall love mayb readi despit ms gave univers know full well alon made mani mistak somebodi wrote via letgo websit like ebay sell stuff pick somebodi site like googl plu somebodi sent email tri pick guy cute pictur said could email back forth could hurt thing call hang like googl chat chat back forth coupl day fine littl weird call honey babe realli nice even know like yesterday wrote realli love context friendli kind way said repli peopl talk like block note univers know said chanc meet go date site ridicul go mention guy told govern incub children rais armi like clone war star war yesterday get email mom say awar new drug call ocrevu recent came multipl sclerosi suppos good call mom like hi nice meet know anyth rememb rituxan sister drug switch ocrevu cover insur switch get cover mother final goe oh yeah sound familiar funni proof read blog defens get live version time day via phone happi friday',\n",
       " 'quick search long term outcom ra patient treat rituxan find mention uptick cancer wonder though compar rituxamab ocrelizumab might direct comparison certainli differ appl orang mayb tri compar macintosh appl golden delici appl mean although rituxamab ocrelizumab erad cd cell someon differ mechan action possibl differ account ocrelizumab higher efficaci may also contribut possibl peril safeti profil ocrelizumab ra trial halt due opportunist infect patient death wherea rituxan use success safe treat ra year would seem indic differ bodi react two drug may similar tysabri dramat higher risk pml compar cell drug tysabri mechan action certainli lead higher risk pml compar drug like gilenya keep cell cn higher risk pml tysabri differ note dr g would will interview wheelchair kamikaz blog post would love talk therapeut lag implic treat progress ms patient could short telephon interview call run transcript blog post therebi allow explain theori straight hors mouth could also talk topic inclin think would tremend valu reader would give theori wider exposur among patient popul certainli deserv thank everybodi involv blog ms commun',\n",
       " 'seem condit autoimmun inflammatori uc possibl remicad may treat know certainli valid point concern wait see hope best unfortun us even autoimmun diseas categori enough moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g lialda x rowasa speed poop realli realli badli',\n",
       " 'alain thank comment yup bionx system want look see rl kit dl tour slight differ price figur differ one use inform possibl adjust weaker leg see batteri fit boom shorten consider accomod five foot noth frame see also mount rear tube know would affect ride weight one side instead center boom good thing research info give thank take glad ocrevu posit result must joy finger cross continu __________________ thank dream big never give',\n",
       " 'ann sorri hear lung cancer diagnosi broken femur ordeal go thru met leg bone vertebra new sinc begin treatment assum recent pet scan follow recent one serv base line mom receiv session carbo alimta keytruda lung cancer recurr continu keytruda nearli year work well great candid keytruda pd l level evid diseas nearli year keep finger cross receiv latest ct result hour like tom said weird thing pop earli treatment immunotherapi pet scan show activ area organ light activ tom said activ leg could due activ heal process time tell mom wait see program wait see prior initi diagnosi see lung nodul grew wait see scan hope show cancer return horribl part diseas great hand immunotherapi great thing lot peopl give time get work meantim continu regular appoint assum get blood test report side effect troubl issu keep close eye thing new plan attack need take care steff',\n",
       " 'appar peopl spm use ocrevu interest possibl mention articl appear medic period ms diagnos avonex copaxon member ms board sinc repli quot follow user say thank howi jeani z sunshin',\n",
       " 'thank pennstat kimba sorri jump thru hoop get ocrevu know frustrat hope work sorri ms neuro die ye scari start new med especi read report marco post',\n",
       " 'think fact right biogen ms rather deep pipelin ms space poach back one ex staff run earli ms develop pipelin biogen ms compani give also need rememb take big slice ocrelizumab sale ip came biogen via idec',\n",
       " 'lancet jan oral fingolimod primari progress multipl sclerosi inform phase randomis doubl blind placebo control trial lublin f miller dh freedman ms cree ba wolinski js weiner h lubetzki c hartung hp montalban x uitdehaag bm merschhemk li b putzki n liu fc h ring da kappo l inform studi investig author inform corinn goldsmith dickinson center multipl sclerosi icahn school medicin mount sinai new york ny usa electron address fred lublin mssm edu queen squar ms centr ucl institut neurolog london uk ottawa hospit research institut univers ottawa ottawa canada multipl sclerosi center univers california san francisco ca usa univers texa health scienc center houston houston tx usa brigham women hospit harvard medic school boston usa univers pari salp tri hospit aphp center clinic investig pari franc depart neurolog medic faculti heinrich hein univers sseldorf germani hospit universitari vall hebron barcelona spain vu univers medic center amsterdam netherland novarti pharma ag basel switzerland novarti pharmaceut corpor east hanov nj usa depart medicin clinic research biomedicin biomed engin univers hospit univers basel switzerland background treatment approv primari progress multipl sclerosi fingolimod oral sphingosin phosphat receptor modul effect relaps onset multipl sclerosi assess primari progress multipl sclerosi assess safeti efficaci fingolimod patient primari progress multipl sclerosi method inform multicentr doubl blind placebo control parallel group studi patient primari progress multipl sclerosi recruit across centr countri randomli alloc comput gener block receiv oral fingolimod placebo least month maximum year patient initi assign fingolimod mg per day placebo cohort howev protocol amend nov patient switch mask manner fingolimod mg wherea placebo continu match placebo onward patient assign receiv fingolimod mg day placebo cohort key inclus criteria age year clinic diagnosi primari progress multipl sclerosi year diseas progress two follow criteria posit brain mri posit spinal cord mri posit cerebrospin fluid addit elig criteria includ diseas durat year object evid disabl progress previou year patient studi investig mask group assign use novel primari composit endpoint base chang baselin expand disabl statu scale edss time walk test nine hole peg test assess time month confirm disabl progress studi particip treat least year randomis patient took least one dose studi drug primari efficaci analysi includ patient cohort assign placebo cohort safeti analysi includ patient cohort studi regist clinicaltri gov number nct studi close find patient randomli assign sept aug fingolimod mg placebo cohort fingolimod mg placebo cohort efficaci analysi set n consist patient randomli alloc fingolimod mg placebo baselin characterist similar across group repres primari progress multipl sclerosi popul women mean age year [sd ] mean edss [sd ] free gadolinium enhanc lesion end studi month confirm disabl progress occur patient fingolimod placebo group respect result kaplan meier estim ci patient fingolimod group versu patient placebo group risk reduct hazard ratio ci p safeti result gener consist studi fingolimod patient relaps onset multipl sclerosi lymphopenia occur patient fingolimod group versu none placebo group bradycardia five versu one first degre atrioventricular block three versu six seriou advers event occur patient fingolimod group placebo group includ macular oedema six versu six basal cell carcinoma versu nine interpret anti inflammatori effect fingolimod slow diseas progress primari progress multipl sclerosi therapeut strategi primari progress multipl sclerosi might need differ approach use relaps onset multipl sclerosi fund novarti pharma ag',\n",
       " 'heeeey fellow chroni julian australia melbourn year old first time post desper need advic approach start remicad take azathiorpin allopurinol gastro doctor told sever case crohn diseas base inflamm via colonoscopi crp level around mark faecal calprotectin littl result chang treatment doctor consid remicad battl sever malnutrit nasti common symptom crohn diseas put remicad desper oh miracl drug month im almost complet remiss scope crp faecal calprotectin level back normal clear experienc littl side effect remicad consid lucki first coupl month doctor recommend take remicad mp prevent bodi build antibodi sooner combo effect liver level doctor want mri liver found mild case psc primari scleros cholang form liver diseas doctor took mp liver level went straight back normal stay remicad alon truli work wonder cant thank far cant help think scari side effect take medic long term bring back titl thread im almost complet remiss scope result clear normal symptom hope could talk doctor lower dose minim risk long term use remicad anoth altern someon give anyon repli would greatli appreci god bless everyon battl terribl diseas',\n",
       " 'hi sorri hear go shock diagnosi other said give time come term diagnos almost year ago denial attitud forget might go away best part year got relaps put lot stress definit tri avoid put betaferon year diagnos help control gileni sinc septemb ms stabl sinc good dmt easi take compar inject need anymor info gilenya let know take care x',\n",
       " 'cours inform total durat year month includ extens phase edss deterior fingolimod effect suppress diseas activ cours studi clearli contradict',\n",
       " 'would stop natalizumab would transit onto anoth therapi latter could oral cladribin ocrelizumab fingolimod etc jcv neg stay natalizumab',\n",
       " 'fallaci argument impli work someon els know mean work convers side effect list experienc someon know reason someon whose medic histori circumst unfamiliar go experi orlando less enlighten amongst us perhap could expand sourc claim refer paper jone et al http brain oxfordjourn org content six year rounder view emerg say lemtrada gilyena bad put context around broadli good journal therapeut advanc drug safeti [sage ] recent paper entitl benefit versu risk latest therapi multipl sclerosi perspect review pre licens articl http www ncbi nlm nih gov pmc articl pmc forth point context everyth alemtuzumab good drug right circumst patient meet right criteria plenti thing make patient unsuit likewis gilenya believ recent post admin advoc particular cours action good even best dom',\n",
       " 'kw sinc neuro prescrib inject littl comment regard say older drug approv noth els avail legitim question came market today would get fda approv certainli question ask good question long peopl recommend stay tysabri jcv neg biogen make treatment recommend decis doctor patient domain vari individu circumst one popular fals internet rumor biogen recommend stay tysabri beyond two year call biogen told biogen make treatment recommend rumor fals ask long peopl stay tysabri jcv neg standard length time jc viru caus pml jc viru cannot get pml fals neg test happen word jcv antibodi titer threshold neg rang indetermin posit neg btw even neg peopl found jc viremia present coupl peopl test jcv neg get pml believ obvious posit rememb jc viru alon caus pml test neg fals neg pleas ask neuro ok approx chanc test neg jcv get pml quit small keep mind get test everi month tysabri chanc fluke test test neg actual posit diminish test may unlik subsequ consecut test neg test sever time row would suffici proof neg fall stat peopl taken tysabri develop pml die result pml check doctor risk chang time jcv neg interest question time element age exposur peopl chang jcv jcv noth unusu get older exposur possibl infect jcv unknown origin everi type jcv cannot get pml jcv remain second ask tysabri med mser put fail therapi ye often case alway treatment philosophi come play neuro want aggress right away stop ms track soon possibl neuro prefer wait see ms get bad go higher risk higher reward dmt like tysabri obvious patient person risk profil factor sleep decis make got pass sleep test neuro perhap neuro see suspect ms highli activ want treat aggress sure ask talk lean toward tysabri third pocket cost biogen co pay assist program almost everyon qualifi toward medicin anoth infus use make less k per year even higher sure call biogen fill straight insur co pay biogen pay also assist toward infus cost sure call biogen ask assist program state allow heard coupl fourth come tysabri trigger relaps ye mean instanc techniqu mitig elimin develop use long washout standard go anoth medicin howev found shorter wash period less like relaps occur lastli would say tysabri tremend effect slow diseas progress wife tysabri sinc except period market due pml concern remark good health jcv posit sinc first test jcv develop year ago major techniqu de risk pml sinc jcv extend time dose theori tysabri diminish satur time allow immun surveil jc viru far last fall zero case pml mser go week infus case pml control group number standard dose week appear though extend time dose benefici trial ongo neuro chang clinic practic data publish peer review adopt possibl peopl highli activ ms may abl go beyond week also littl need go beyond week first two year tysabri whether jcv neg pml risk low first two year treatment sure seen chart estim pml risk might want googl bart ms research blog find pml risk chart go site also pleas check charcot project seek viral caus ms need consider support tysabri risk pml ms also huge risk treat effect treatment decis doctor patient make togeth opt fda approv med educ ldn low dose naltrexon imo last thought ocrelizumab new impress med phase trial like get fda approv late thereabout neuro may choos med like tysabri know present littl risk pml first two year plan switch ocrelizumab becom avail may want stick tysabri proven superb track record effect littl pml risk patient remain jcv patient seen spoken regularli year infus center side effect tysabri larg non exist person observ pleas discuss side effect doctor other tysabri hope offer experi thread also mani mser jcv choos remain tysabri accept risk pml tysabri halt diseas progress thought best',\n",
       " 'real life observ studi denmark compar clinic diseas activ individu treat natalizumab versu fingolimod individu began treatment either drug first second line treatment juli march prospect record danish ms treatment regist two group propens score match',\n",
       " 'hertfordshir england pittsburgh pa tokyo prnewswir mylan n v nasdaq myl fujifilm kyowa kirin biolog co ltd today announc european commiss ec grant market author hulio product code fkb biosimilar abbvi humira adalimumab indic author follow adopt posit opinion committe medicin product human use chmp conclud develop program includ analyt function clinic immunogen data demonstr biosimilar refer product humira ec approv hulio appli european union eu member countri european econom area eea member state norway iceland liechtenstein mylan plan launch hulio across variou market europ oct mylan fujifilm kyowa kirin biolog partner earlier year fujifilm kyowa kirin biolog nonexclus royalti bear licens abbvi mylan sublicens use sale hulio european countri mylan presid rajiv malik comment pleas decis european commiss grant market author hulio fourth product mylan bring market area complex gener biosimilar proud leader market format made great progress fujifilm kyowa kirin biolog look forward continu import collabor delight hulio receiv approv european commiss said dr yoshifumi torii fujifilm kyowa kirin biolog presid ceo ec approv hulio mark signific mileston cooper mylan continu commit effort bring high qualiti afford biosimilar patient throughout european countri mylan europ presid jacek glinka ad biosimilar repres huge opportun europ drive better patient access high qualiti valu medic support healthcar system across region deliv ongo excel care face age popul increasingli stretch resourc hulio indic indic humira includ adult rheumatoid arthriti ankylos spondyl axial spondyloarthr without radiograph evid ankylos spondyl psoriat arthriti psoriasi hidraden suppurativa crohn diseas ulcer coliti uveiti children polyarticular juvenil idiopath arthriti age older enthes relat arthriti age older plaqu psoriasi age older crohn diseas age older hidraden suppurativa age older uveiti age older humira world best sell biolog medic brand sale approxim billion europ month end june accord iqvia adalimumab adalimumab inject biolog medic inhibit tumour necrosi factor tnf caus inflamm autoimmun diseas rheumatoid arthriti plaqu psoriasi crohn diseas ulcer coliti specif bind tnf adalimumab block activ therebi reduc inflamm diseas symptom mylan mylan global pharmaceut compani commit set new standard healthcar work togeth around world provid billion peopl access high qualiti medicin innov satisfi unmet need make reliabl servic excel habit right easi impact futur passion global leadership offer grow portfolio market product around world includ antiretrovir therapi peopl treat hiv aid global depend market product countri territori one world largest produc activ pharmaceut ingredi everi member approxim strong workforc dedic creat better health better world one person time learn mylan com routin post inform may import investor websit investor mylan com fujifilm kyowa kirin biolog fujifilm kyowa kirin biolog establish fujifilm corpor presid kenji sukeno hereinaft fujifilm kyowa hakko kirin co ltd presid coo masashi miyamoto hereinaft kyowa hakko kirin march compani develop manufactur market biosimilar pipelin includ adalimumab biosimilar hulio biosimilar anti vegf human monoclon antibodi bevacizumab product code fkb drug use treat rang cancer includ colorect non small cell lung cancer fujifilm kyowa kirin biolog establish centu biotherapeut ltd joint ventur develop commerci fkb astrazeneca plc merg technolog advanc product qualiti control analysi fujifilm develop mani year photograph film busi proprietari technolog know kyowa hakko kirin accumul biopharmaceut r manufactur fujifilm kyowa kirin biolog creat revolutionari product process reduc cost product biosimilar partnership compani develop manufactur reliabl high qualiti cost competit biosimilar product commerci product time manner strategi fujifilm kyowa kirin biolog aim hold lead posit expand biosimilar market learn busi fujifilmkyowakirin biolog com forward look statement mylan press releas includ statement constitut forward look statement includ regard mylan plan launch hulio across variou market europ oct statement made pursuant safe harbor provis privat secur litig reform act statement inher involv risk uncertainti actual futur result may differ materi express impli forward look statement factor could caus contribut differ includ limit success clinic trial partner abil execut new product opportun regulatori legal impedi partner abil bring product market risk inher product develop scope time outcom ongo legal proceed includ govern investig impact proceed partner busi action decis healthcar pharmaceut regul chang healthcar pharmaceut law regul inth unit state abroad impact competit strategi competitor third parti delay prevent product introduct effect chang partner custom supplier relationship custom purchas pattern chang third parti relationship chang econom financi condit busi mylan partner uncertainti matter beyond control manag risk detail mylan file secur exchang commiss mylan undertak oblig updat statement revis chang date releas',\n",
       " 'anoth year end still new treatment approv progress ms surpris old stori happen great ocrelizumab big talk action monke song lyric much talk enough action someth go',\n",
       " 'ocrevu potenc bomb bomb blow patient face upper respiratori fatal infect probabl side effect drug way intens rtx accord patient descript reason intens patient suffer question doubt',\n",
       " 'look like ocrelizumab first approv treatment ppm although idea date yet http www mstrust org uk z ocrelizumab',\n",
       " 'new diabet diabet retinopathi research indic peopl type diabet intens control blood sugar level landmark ction c ontrol c ardiovascular r isk iabet accord trial eye studi cut risk diabet retinopathi half follow analysi call accord follow eye studi accordion conduct four year stop intens blood sugar control regimen requir accord trial studi send power messag peopl type diabet worri lose vision said dr emili chew studi co author deputi director nation eye institut divis epidemiolog clinic applic well control glycemia blood sugar level posit measur last effect eye health pleas note howev cautionari issu unresolv caus factor relat blood sugar glycem control group origin accord studi discuss reader evalu care discuss physician research diabet care new diabet retinopathi research entitl persist effect intens glycem control retinopathi type diabet action control cardiovascular risk diabet accord follow studi publish juli edit diabet care peer review journal publish monthli american diabet associ ada diabet care journal health care practition intend increas knowledg stimul research promot better manag peopl diabet author emili chew md nation eye institut action control cardiovascular risk diabet follow accordion eye studi group action control cardiovascular risk diabet follow accordion studi group explan terminolog accord trial accord trial involv studi site across north america enrol particip type diabet purpos accord trial test three treatment strategi reduc risk cardiovascular diseas among peopl longstand type diabet maintain near normal blood sugar level intens glycem control improv blood lipid level lower ldl bad cholesterol triglycerid rais hdl good cholesterol lower blood pressur [editor note treatment phase glycem blood sugar control portion accord plan last year stop year due increas death among particip intens glycem control group analys thu far determin specif caus increas death howev benefit intens glycem therapi must weigh potenti risk notabl increas risk death observ accord trial ] accord trial eye studi analyz subset trial particip receiv laser photocoagul vitrectomi prolif diabet retinopathi data begin year four studi accord sponsor nation heart lung blood institut collabor nation institut diabet digest kidney diseas nation institut age nation eye institut center diseas control prevent read accord trial nation institut health clinic trial gov accordion follow eye studi accordion follow assess diabet retinopathi progress peopl particip accord accordion assess diabet retinopathi approxim four year intens glycem control portion studi end eight year enrol accord time averag c see explan percent intens therapi group percent standard therapi group howev diabet retinopathi advanc percent particip intens therapi group sinc enrol accord compar percent standard therapi group accordion fund nation heart lung blood institut part nation institut health type diabet type diabet formerli call adult onset type ii non insulin depend follow characterist usual occur age affect individu diabet occur pancrea produc enough insulin insulin defici bodi cell abl use insulin correctli effici insulin resist condit present glucos continu rise bloodstream suffici level insulin avail open cell allow glucos enter initi manag weight loss physic activ effect meal plan individu suffic period time diseas progress howev oral medic insulin may also requir primari risk factor includ increas age ethnic background african american latino nativ american asian famili histori obes learn diabet c test c blood test also known glycat hemoglobin hemoglobin c hba c primari tool use diagnos diabet pre diabet monitor blood glucos control peopl type type diabet test enabl health care provid diagnos diabet treat complic occur diagnos pre diabet prevent delay develop type diabet read establish c level use diagnos diabet pre diabet diabet signific c test research excerpt intens diabet treatment prevent damag vision unit press intern intens treatment diabet help prevent damag blood vessel retina often lead blind accord long term studi nation institut health research use aggress treatment maintain glycem control blood lipid level blood pressur cut risk develop diabet retinopathi half report research stop portion focus glycem control year plan year test increas death among particip though patient treat blood pressur blood lipid level continu rest intend test period tight control condit improv health patient reduc risk cardiovascular diseas treatment howev reduc progress retinopathi one third new studi research examin patient took part origin accord studi measur progress particip retinopathi four year treatment conclud measur blood glucos particip receiv intens standard care remain similar end previou studi percent particip seen advanc retinopathi less half percent receiv standard treatment whose condit progress diabet eye diseas diabet retinopathi although peopl diabet like develop cataract younger age twice like develop glaucoma peopl diabet primari vision problem caus diabet diabet retinopathi lead caus new case blind low vision adult age person diabet retinopathi may see retinopathi gener term describ damag retina retina thin light sensit tissu line insid surfac eye nerv cell retina convert incom light electr impuls electr impuls carri optic nerv brain interpret visual imag diabet retinopathi occur damag small blood vessel nourish tissu nerv cell retina prolif gener term mean grow increas rapid rate produc new tissu cell term prolif use relat diabet retinopathi describ growth prolifer abnorm new blood vessel retina non prolif indic process yet occur prolif diabet retinopathi affect approxim individu diseas four stage diabet retinopathi accord nation eye institut diabet retinopathi four stage mild non prolif retinopathi earli stage small area balloon like swell occur retina tini blood vessel moder non prolif retinopathi diseas progress blood vessel nourish retina becom block sever non prolif retinopathi mani blood vessel becom block disrupt blood suppli nourish retina damag retina signal bodi produc new blood vessel prolif retinopathi advanc stage signal sent retina trigger develop new blood vessel grow prolifer retina vitreou transpar gel fill interior eye new blood vessel abnorm ruptur bleed caus hemorrhag retina vitreou scar tissu develop tug retina caus damag even retin detach studi diabet care condens excerpt articl summari conclus full articl avail onlin result show intens glycem control confer endur protect progress diabet retinopathi even though glycat hemoglobin level similar year random year cessat clinic trial first studi peopl type diabet year durat establish cardiovascular diseas unlik newli diagnos particip unit kingdom prospect diabet studi ukpd demonstr effect phenomenon call metabol memori legaci effect studi type diabet accordion find demonstr similar legaci effect intens glycemia control progress retin diseas peopl establish type diabet moreov effect occur respons median year intens glycem control observ peopl type diabet addit cardiovascular risk factor whose mean diabet durat year whose initi mean hba c observ suggest glucos lower reduc progress retin diseas rel late cours diabet retina respond rel short term chang glucos level whether even shorter period glucos lower could achiev similar long term effect eye either type type diabet remain unknown summari studi result provid evid intens glycem control benefici reduc progress diabet retinopathi legaci effect evid peopl type diabet addit accordion retin result prior find demonstr posttreat benefit intens glycemia control progress eye kidney nerv diseas',\n",
       " 'regard last comment cours insensit downplay human tragedi biogen built busi around ms franchis show major crack tecfidera sale way tysabri pressur ocrevu news take anoth pillar ms platform would nice start direct research find caus cure diseas moneymak busi model better keep patient shackl obscen expens drug profoundli impact immun system long term consequ complet unknown',\n",
       " 'updat saw ibd specialist yesterday first follow colonoscopi may nd week ago let rewind say stress appoint afraid ibd specialist would give option like bulli pick one wait test result honestli look surgeri tri drop mg mg prednison last monday aw horribl withdraw symptom start bleed defeat knew bad sign went back mg stabil actual bad bm everi day requir dulcolax though much blood tenesmu much better taken bentyl week still fatigu manag live life despit albeit hous messi someth gotta give great symptom improv sinc depend prednison humira cortifoam realli consid win thing consid discuss treatment plan tpmt normal metabol mp imuran drug becam option antibodi humira humira serum level low ibd specialist crinkl nose said anyth humira level low wait amount time start new biolog decid option discuss humira imuran b remicaid imuran antibodi c stelara imuran entyvio imuran e divert colostomi temp heal f perman colostomi discuss pro con treatment wait patient ibd specialist finish make flow chart explain everyth ask question gave input first question candid j pouch knew answer would correct immedi elimin option divert colostomi state go surgeri would choos perman surgeri sinc ultim want though disappoint j pouch option happi ibd specialist said surgeri good option sinc never shown inflamm outsid colon said chanc develop diseas elsewher mayb surgeri would need take med anymor woot ultim want med free diseas free life encourag could live life want live ostomi bar complic readi surgeri yet told research read peopl stori encourag even peopl complic tend happi surgeri afraid recoveri time see peopl feel better immedi activ within week surgeri howev troubl get excit want feel good still struggl imagin life ostomi scare complic turn way plan ibd specialist total understood told like humira think help much wors steroid alon like side effect want tri ad mp imuran see help wean prednison humira imuran first choic said ok problem elimin remicaid altogeth respons good still use rowasa enema humira imuran allow get prednison chose stelara imuran next drug therapi mostli stelara work quickli entyvio consid go straight ostomi humira imuran fail realli depend thing go someth click visit got car leav cri feel scare confus felt reliev surgeri sound bad start posit vision life ostomi famili go vacat june th ask keep thing stabl return want enjoy ibd specialist said cours told add imuran worri drop prednison get back appreci blood drawn monitor june nd see ibd specialist june th blood drawn need get flu shot pneumonia vaccin nervou get plane also go disneyland rememb measl outbreak mg prednison humira imuran hand immun system relentless physic pretti strong right chanc good fine suggest stay healthi travel appreci think guy yr femal dx uc dx chang crohn coliti current humira apriso uceri foam enema prednison buproprion synthroid start humira feb mg week previous fail remicaid previous use asacol lialda delzicol pentasa cortenema rowasa canasa entocort uceri gluten free supp vsl cal mag vit krill oil ezf iron',\n",
       " 'osimertinib demonstr better clinic meaning efficaci well character safeti profil compar platinum pemetrex among patient epiderm growth factor receptor egfr posit advanc non small cell lung cancer nsclc follow progress egfr tyrosin kinas inhibitor tki treatment accord result present intern associ studi lung cancer iaslc th annual world confer lung cancer austria osimertinib potent irrevers central nervou system cn activ egfr tki select sensit egfrm resist mutat osimertinib indic treatment patient local advanc metastat egfr posit nsclc author present result aura nct trial phase open label random studi assess efficaci safeti osimertinib versu platinum base chemotherapi plu pemetrex among patient egfr posit advanc nsclc four hundr nineteen patient random either receiv osimertinib patient platinum pemetrex patient sixti four percent patient femal asian never smoker cn metastas egfr exon delet patient treat osimertinib median progress free surviv pf month compar month patient treat platinum pemetrex object respons rate orr also improv among patient treat osimertinib compar platinum pemetrex median durat respons month osimertinib month platinum pemetrex relat tumor node metastasi classif th edit chang grade higher advers event ae report patient treat osimertinib treat platinum pemetrex common ae group treat osimertinib diarrhea rash author conclud result establish new standard care patient refer',\n",
       " 'diagnos nsclc adenocarcinoma stage brain met march cyber knife ck brain met march resolv start tarceva april lobectomi novemb ned neck march ck anoth mm brain met januari recurr two brain met mm previous treat march octob multipl small lung nodul lung two bit larger mm pet activ lung two activ lymph node plu two brain met mm mm march liquid biopsi detect egfr april bronchoscopi lymph node fail may march except two lung nodul mm larger one brain met stabl mm anoth one mm new small met close optic nerv june plan tri tagrisso label one two month hope would help progress brain neck otherwis carbo alimta ck litt howev brain met grow schedul fraction ck juli brain met close optic nerv laser interstici thermal therapi litt mm brain met today receiv tagrisso unfortun abl echo wednesday good health otherwis question start tagrisso tomorrow saturday want wait anymor btw stop tarceva mg abl echocardiogram wednesday doctor still feel slow progress take big risk tri give tagrisso chanc abl establish statu place could actual abl tissu biopsi one lymph node locat aorta pulmonari arteri option start chemo reluct thank faith topic modifi year month ago faithaboveal topic modifi year month ago faithaboveal',\n",
       " 'past week warn issu side effect two ms treatment first u food drug administr warn slight risk serious worsen ms symptom someon use diseas modifi therapi gilenya fingolimod stop use fda alert said worsen symptom could result perman disabl alert fail provid detail rare problem week later fda issu anoth warn one lemtrada alemtuzumab risk sever stroke may involv tear arteri neck head case howev fda specif mani stroke report peopl treat lemtrada occur nearli year sinc fda approv lemtrada alemtuzumab treat relaps ms identifi worldwid case ischem hemorrhag stroke cervicocephal arteri dissect case report fda advers event report system faer databas occur within day administr drug patient ms ten case occur u three occur europ fda went say enough inform fulli assess individu risk factor occurr advers event within one day lemtrada administr suggest associ knee jerk reaction unsurprisingli quick respons news social media site came peopl treat lemtrada report among suffer stroke follow treatment comment gener other mani along line wish known treatment sure want use treatment other caution restraint say side effect everi medic writer also remind us sever side effect much frequent report lemtrada wrote gilenya warn day issu similarli advis diseas modifi treatment possibl side effect seriou other use treatment alway eye wide open fulli inform risk ms treatment benefit outweigh risk shortli wrote post bring everyon date experi lemtrada eight month past round two pleas say posit know know dmt carri certain level risk us consult neurologist make seriou risk benefit analysi start treatment proceed believ benefit outweigh risk also must will accept risk problem occur one thing need sure read beyond headlin warn receiv sure read full alert get complet pictur magnitud concern think probabl run higher risk incur seriou disabl time get automobil use medic design prevent disabl becom wors version post first appear one column ms news today websit',\n",
       " 'thought mom hope scan show posit result growth shrinkag mom first round keytruda w chemo cocktail last friday hope abl share updat us throughout treatment sure benefit mani forum fellow caregiv hope find way care face stress take care',\n",
       " 'repli post hippopostr remicad one sever biolog two type approach medic bottom therapi take lighter drug mesalmin work way top approach doctor prescrib biolog first line treatment avoid complic futur remicad lifesav struggl year find right medic put remiss medic still unsur talk child doctor see think hope help',\n",
       " 'hope four cycl carboplatin etoposid year sinc treatment high risk resist chemo know alway possibl radiat consid primari therapi time reach radiat oncologist input treatment interest consult expert seem move away immun therapi carbo etoposid tecentriq immun therapi leg see land radiat info provid help',\n",
       " 'video dr alic shaw join grace discuss control brain metastas patient molecular driven advanc non small cell lung cancer read lung cancer video librari control brain metastas patient molecular driven advanc nsclc laura giannini program director februari laura join global resourc advanc cancer educ program coordin nativ italian laura year experi work non profit sector spent last year live work south east asia latin america europ usa oversaw manag develop educ program disast affect area fluent english spanish italian love work peopl differ background cultur laura hold b read laura giannini program director alic shaw md ph grace faculti alic shaw director center thorac cancer paula keeff endow chair thorac oncolog massachusett gener hospit also associ professor medicin harvard medic school receiv b biochemistri harvard ph degre harvard medic school resid intern medicin massachusett gener hospit complet fellowship hematolog oncolog dana farber massachusett gener hospit complet postdoctor work laboratori dr read alic shaw md ph grace faculti karen reckamp md ms grace faculti karen reckamp md ms associ professor depart medic oncolog therapeut research citi hope comprehens cancer center cohccc receiv medic degre univers chicago master degre clinic investig ucla complet resid train intern medicin barn jewish hospit hematolog oncolog fellowship david geffen school medicin ucla read karen reckamp md ms grace faculti matt hiznay live forum moder patient advoc matt hiznay five year survivor metastat alk posit non small cell lung cancer born youngstown ohio grew small town poland ohio matt graduat poland seminari high school john carrol univers bachelor scienc degre magna cum laud read matt hiznay live forum moder patient advoc janet freeman daili patient advoc live forum moder janet freeman daili writer scienc geek lung cancer patient activist receiv diagnosi advanc non small cell lung cancer may becam metastat despit chemotherapi radiat learn genom test precis medicin onlin patient commun join clinic trial ro posit lung cancer evid diseas four year read janet freeman daili patient advoc live forum moder john cherol live forum moder patient advoc john cherol diagnos januari stage iv egfr lung cancer age start gilotrif afatinib acquir resist month luckili blood test show develop mutat start tagrisso april year also treat nine brain met gamma knife cleveland clinic read john cherol live forum moder patient advoc heather wakele md grace faculti dr wakele assist professor medicin stanford univers divis oncolog co leader lung cancer diseas manag group focu clinic research lung cancer patient particular interest anti angiogenesi agent dr wakele princip investig ongo intern lung cancer intergroup trial e investig potenti role bevacizumab addit adjuv chemotherapi resect earli stage non small cell lung cancer read heather wakele md grace faculti rachel sanborn md grace faculti graduat oregon health scienc univers medic degre dr rachel sanborn complet resid intern medicin univers illinoi chicago return portland fellowship hematolog medic oncolog oregon health scienc univers board certifi medic oncolog intern medicin read rachel sanborn md grace faculti boon wilder goodgam md grace faculti boon wilder goodgam md grew uganda father taught nation medic school move texa age complet high school earn undergradu degre univers texa austin mechan engin complet medic school baylor colleg medicin houston read boon wilder goodgam md grace faculti page first previou next last search form search featur content grace live yoga therapi present power yoga build resili video grace excit bring new seri surviv cancer congratul fantast year meet ami bickleman execut director video grace celebr year recognit would like introduc staff board member deepli involv bring grace life video introduc ami happi holiday make impact grace onehop articl onehop wine partner grace holiday donat purchas wine coffe gift grace latest video articl lung cancer video librari immunotherapi stage lll nsclc pacif trial imfinzi video dr karen kelli associ director clinic research uc davi comprehens cancer center met grace bring updat lung cancer video librari video dr kelli discuss lung cancer video librari tumor mutat burden current statu video dr sandip patel associ professor medicin moor cancer center uc san diego health join grace offer updat lung cancer video librari video dr patel discuss lung cancer video librari evolv standard molecular test advanc nsclc video dr sandip patel associ professor medicin moor cancer center uc san diego health join grace offer updat lung cancer video librari video dr patel discuss',\n",
       " 'adenocarcinoma lung brain met gefitinib month progress bit brain dr wakele switch tagresso sinc past month done gamma knife surgeri twice brain side effect overal minim nausea feel tire etc major continu live full busi day work exercis medit walk focu import thing life live mumbai india glad mayo connect jump post shalia thank share inform us hearten read success withgamma knife surgeri wonder read full busi life',\n",
       " 'hello grace sinc post sad report lost wife maria june nearli year battl stage iv nsclc say enough good thing inspir care receiv dr hens team northshor univers health system near chicago dr sequist massachusett gener hospit boston mention support guidanc receiv grace everyon tremend give us univers maria case diagnos stage iv multipl site spread yet beat ill long time thank larg part year month respons tarceva son actual thank genentech memori servic new question regard wife brother mexico also diagnos egfr exon del stage iv nsclc three year ago brain met two year stint afatinib progress neg reli radiat combin carboplatin pemetrex fight diseas foundat one report came wonder grace team treatment thought base clinic experi mutat identifi follow cours review detail treatment suggest provid report alter identifi egfr exon del e _a del pik ca e k crebbp truncat exon rb truncat exon tp r w addit find microsatelit statu ms stabl tumor mutat burden tmb low mut mb report alter identifi kra alk braf met ret erbb ro thank thought may dan',\n",
       " 'great news congrat babi girl happi well uc pancol dx march partial colectomi diverticul sept apriso g x day canasa uceri foam need supplement zinc l glutamin probiot reuteri pearl vsl folic acid coq turmer boswellia milk thistl nac reservatol colostrum glycin start entyvio constant flare sinc march reliev prednison remiss',\n",
       " 'us dumb sometim rituxan approv insur cost roughli year technic approv ms approv ocrelizumab year approv basic drug question higher health care price fall patient fair system great work well suppos hope continu feel better',\n",
       " 'ocrelizumab anoth monoclon antibodi wish would look anoth direct ann last edit stillstannd come time silenc betray mlk repli quot follow user say thank suze q',\n",
       " 'expert analysi ecco mg dose tofacitinib twice daili significantli improv remiss',\n",
       " 'hi wonder experi nivolumab father stage iv rcc found progress sutent doctor consid possibl option appreci feedback',\n",
       " 'good hear hope med bring dread steroid best luck year old femal diagnos uc age remiss entyvio imuran combo c imuran flare month current moder sever flare fail entyvio remicad steroid refract tacrolimu lialda uceri current med cortifoam x per day xeljanz start daili probiot vsl',\n",
       " 'offer gilenya second line treatment probabl live long distanc hospit tysabri monthli infus would inconveni expens understand mani peopl stop ty coupl year risk viral complic issu gilenya daili pill bit perform start involv day hospit thereaft regular monitor realli breez',\n",
       " 'firefrau get neurologist talk data brain atrophi drug want treat need fulli understand potenti drug alter cours brain atrophi alreadi start lemtrada best avail drug prevent brain atrophi assum given brain atrophi start know much data ocrevu effect progress ms like alter cours brain atrophi alreadi begun neurologist abl clearli explain benefit risk drug make inform choic',\n",
       " 'thank post post great insight helpful also worri cd come back cell ul month hsct btw know mitig inhibitor think md refer dmt trap lymphocyt lymph node fingolimod natalizumab ps correct wrong obrigado lui',\n",
       " 'success stori xeljanz noth els work fail remicad entyvio etc see suzi q husband stori www healingwel com commun default aspx f scare surgeri number poster done live excel afterward without medic worri futur flare good thing consid serious fail mani treatment worri somebodi say want avoid surgeri cost poster die due put way long chiron joseph month back moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa cannot spell suck without uc',\n",
       " 'hello greet everyon newbi diagnos nsclc decemb lung mass discov pet scan done workup gyn malign symptom mass cm r lung hilar mediatin node supraclvicular node gastrohepat node adenocarcinoma mutat pd l gastrohepat node turn neuroendocrin tissu still stage iv onward got port mri brain neg three cycl carbo alimta keytruda ok third treatment develop dermatomyos rare paraneoplast syndrom come underli malign case felt autoimmun side effect keytruda everyth stop hospit coupl time got high dose iv steroid mycophenol iv gammaglobulin revers effect keytruda sever month rehab later got better still muscl issu myopathi much better anyway last cat scan ned except mass stabl believ pseudotumor second opinion oncologist nci cancer center also feel see need furthur treatment time either realli question wonder anyon els seen overwhelm respon immunotherapi gotten ned oncologist optimist may prolong respons gyn cancer surgeri also seem ned guess skeptic grate none less nil desperandum',\n",
       " 'hi helen thank question individu encourag discuss treatment option healthcar team ms societi canada provid list clinic u offer ocrelizumab infus number import consider one mind consid travel abroad medic treatment click read consider detail thank dr k',\n",
       " 'tri antihistamin itch know itch allerg reaction sometim hot itchi hand feet scratch rub help stop itch antihistamin counterintuit work take loratadin tesco brand tri differ one find suit burn sensat touch area upper lip may side effect gilenya either way mild enough ignor',\n",
       " 'hi name barri stage four metastat melanoma last pet scan show cancer behav good news opdivo month see profil thing go well despit fact stage four anyway deal pain swell knee joint cancer doctor sent rheumatologist prescrib methotrex said would take minimum three week least would even notic benefit reach three week mark yet friend tell wonder cbd oil one night knee realli bother decid would give tri right swell weak pain spread left wrist right shoulder elbow right ankl seem wors wonder experi methotrex cbd oil cancer doctor say like spread joint swell pain still respons opdivo said stay bodi month hope aggrav cbd oil experi',\n",
       " 'dear jim onthemark thank much kind word onthemark wife mainten energi activ mostli attribut amaz spirit focu resourc first found diagnosi look said plan live mani year yet learn get great idea head never stand way carboplatin hit pretti hard plummet rbc almost quit point need transfus wbc enough need neulasta outsid worst day treatment still pretti much everyth normal opdivo probabl difficult effect caus coliti nonetheless took whatev medic need still travel israel midst opdivo treatment year later went galapago still hike faster mention amaz lucki call diagnosi near earli stage one could get base initi ct scan pulmunologist thought stage main lung tumor coupl lymph node two bone metastas past call oligometastat second effect treatment clinic trial drug kept cancer bay year virtual effect rbc wbc energi level improv expens neuropathi still present greatli reduc finish drug gemzar work well allow neuropathi improv expens phlebiti port put problem basic whatev need get life incred lucki spous take mani deep breath today teach cell biolog today talk cell receptor like egfr mutat caus cancer wife lifelong non smoker dx adeno nsclc stage iv poorli diff bone met lymph node exon mutat x carbo alimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo effect add l growth clinic trial drug larg reduct tumor met tumor growth liver met stabl stabl add l growth trial gemzar tumor reduct stabl',\n",
       " 'hiya lumbar punctur done show band initi stage diagnosi begin treatment ms extrem activ particularli within first month start gilenya howev signific flare sinc',\n",
       " 'dr steinman said worth risk nhe thank chart illumin found tonight ehealthm independ site compil fda advers report drug accord site august peopl pml take tysabri http www ehealthm com ds tysabri pro phalopathi serious outrag cheer husband dx rrm dx dual jugular vein stenosi ccsvi http ccsviinm blogspot com top harryz famili elder post join tue may pm locat london canada contact contact harryz icq updat tysabri august quot post harryz tue aug serious outrag cheer mind boggl german websit show total tysabri pml relat case see real number like said past biogen market depart great job sweep neg data tysabri proverbi carpet amaz compani protect immens incom danger drug harri top erinc famili elder post join sat jun pm locat montreal updat tysabri august quot post erinc wed aug year diagnos got impress littl symphoni pwm',\n",
       " 'eylea inj yr left eye prob inj right eye st inj felt like blue cover rip eyelash skin also dot heavi hand consequ pain ndand rd inj pain afterward eye swollen red crusti visit ask what wrong time told go see gp sinc oct seen gp clinic doc clinic consult one given differ dri eye drop noth today saw differ gp think bleathar caus st inj right eye ignor gp rang oncal ophthalm clinic ask seen urgent app morn sound unbeliev true sinc oct new team doc concern anyth give inj gpsaid carri inj known one doc actual ask got blethar repli say dont know tell said go gp last gp one someth may add eyelid eye still swollen sinc oct droop one side still ive bad experi last myh nervou next inj jan also mix date inject consult obnoxi loud wouldnt letm speak didnt even want look eye hope get sort morn',\n",
       " 'age eye age us accord vision council america industri trade organ american age older type visual impair vision loss decreas eye function make life challeng limit person independ mobil impair vision put risk seriou health condit well accid fall senior vision eye problem percent like involv motor vehicl accid exampl import awar age may affect vision symptom signal seriou eye condit seek help ophthalmologist eye specialist rundown condit look cataract cloudi eye lens photo credit scienc photo librari getti imag accord nation eye institut half senior age suffer cataract common caus blind world cataract involv cloud len area eye made mostli water protein person age protein eye may start collect cloud vision peopl develop cataract result smoke side effect diabet unfortun everyon develop cataract age cataract prevent highli treatabl surgeri surgeri quick rel painless typic perform outpati basi involv replac cloud len artifici intraocular len age relat macular degener amd photo credit nucleu medic art getti imag chronic eye diseas affect million american age older accord american academi ophthalmolog macular degener lead caus vision loss among american condit character damag macula part eye necessari see object clearli two form diseas dri macular degener wet macular degener major senior dri macular degener caus gradual thin macula percent patient develop wet form diseas abnorm blood vessel may leak blood fluid retina caus damag central vision treatment dri macular degener limit though nutrit supplement often slow progress diseas wet macular degener patient treat inject drug bevacizumab ranibizumab aflibercept stop growth blood vessel laser eye surgeri also shown effect diabet eye diseas photo credit medic line alami also known diabet retinopathi chronic condit caus diabet around million american diabet retinopathi accord nation eye institut diabet retinopathi caus damag blood vessel light sensit area back eye first condit caus minor vision problem difficulti see distanc diabet progress vision loss may eventu lead blind laser treatment use treat diabet retinopathi patient may vitrectomi surgeri gel like matter remov middl eye procedur follow laser surgeri remov blood scar tissu form eye doctor may give patient medic inject ranibizumab reduc inflamm stop growth blood vessel treatment may slow vision loss cure diabet retinopathi fulli restor vision presbyopia farsighted photo credit nei nih gov start around age eye begin lose focu condit known presbyopia age eye natur part get old affect nearli everyon presbyopia make daili activ read work comput especi challeng fortun mani individu eyeglass contact lens usual trick correct improv vision doctor increas strength prescript need time glaucoma damag optic nerv photo credit bsip sa alami glaucoma refer collect eye condit eventu damag optic nerv often alway result increas pressur eye known intraocular pressur glaucoma lead loss peripher vision time caus total blind left untreat estim million american glaucoma million accord nation eye institut optic nerv damag glaucoma known silent thief sight prevent lower intraocular pressur topic eye drop surgeri dri eye syndrom photo credit getti imag vision remain clear eye must suffici lubric mani senior experi dri eye low tear product though condit larg benign greatli impact vision caus person experi eye discomfort includ sting burn cure dri eye salin lubric drop artifici tear help reliev discomfort keep vision clearer also prescript drug help manag condit',\n",
       " 'dear jaquetap pleas let husband tri opdivo could pleasantli surpris notic side effect got appetit back etc help stabilis mani metastasi similar radiat chore daili drive cancer centr park wait treatment help opdivo certainli close year give religi ask lord support good luck margo',\n",
       " 'tri get canada wont budg pancol uc sinc sept averag bm day time respons remiss therapi salofalk asa enema oral g clinic trial drug fail therapi entyvio anti madcam antibodi mg inject week studi drug remicad ml nicotin patch mg imuran mg',\n",
       " 'old say medicin hear hoof beat think hors zebra logic behind adag common answer usual correct one well good hors us zebra sometim get lost shuffl ro lung cancer mean cancer driven mutat ro gene explos research current underway examin genet caus cancer ro rare account percent lung cancer fact march drug fda approv specif ro posit lung cancer xalkori crizotinib drug save life two year went confer two year ago focus acquir resist target medicin afternoon session broke mutat type egfr alk ro us zebra tickl pink see eight peopl ro sinc none us ever met anoth one better take pictur think ever mani ro er room sinc quest track other rare mutat along way met sever other equal driven form connect gather us zebra dazzl realli term group zebra start inform seri text messag kept tack peopl point one us said might less unwieldi form facebook group group becom place us share treatment journey discuss clinic trial exchang advic symptom manag pool knowledg month went told doctor group realiz wealth inform amass wheel start turn ton excit research happen cancer day small group us concern would get overlook rare breed zebra stick togeth someon group suggest approach bonni j addario lung cancer foundat ask would creat studi us long shot group peopl advanc cancer lose ask situat like face absolut terrifi dire diagnosi prognosi nice someon will listen concern even hearten offer help love surpris take step support exceedingli rare wonder actual put muscl money behind plan help reach goal exactli bonni j addario foundat past month subset ro group number peopl around globe particip confer call foundat creat connect research health care provid stakehold investig mutat ultim creat ro repositori serv research treatment mutat read incred patient driven initi lung cancer foundat websit http www lungcancerfound org patient ro someon know ro cancer pleas follow link answer onlin survey diseas easi step understand ro cancer http www lungcancerfound org patient ro survey beyond excit part initi empow part group patient speak heard metastat lung cancer realli suck met amaz peopl realli overlook dazzl zebra tori tomalia mani thing mom wife theatr artist mediocr cook buffi fan stinki chees aficionado also unfortun repeat visitor cancerland stay tune continu adventur facebook facebook com lungcancerblogg twitter twitter com lil_lytnin blog lil lytnin strike lung cancer lil lytnin blogspot com',\n",
       " 'help lay person ms went fingolimod start ocrelizumab articl tri understand better drug know everyon differ etc',\n",
       " 'hello rebif year quit signific relaps given option move cladribin option lemtrada think anxieti could handl potenti side effect wonder anyon els tablet form realis new wonder side effect effect thank',\n",
       " 'recent ask question like start either tecfidera gilenya soon nurs spoke said come drug gradual wait around month tri conceiv hope help',\n",
       " 'understand fear regard switch pill fwiw pill market show better slow progress interferon none caus depress flu like symptom tri gilenya tecfidera team gilenya forget pill option also tysabri monthli infus hsct lemtrada rememb peopl ms stop med end relaps far like end one especi consid look rebif tysabri ty known rebound effect basic guarante quit gonna relaps mayb call neurologist offic let know want seen sooner sometim folk cancel last minut snap earlier appoint good luck let us know goe',\n",
       " 'excit news ocrelizumab offer expand access program locat particip primari progress multipl sclerosi ocrelizumab grant prioriti review design announc expand access program ocrelizumab particip primari progress multipl sclerosi primari object expand access program eap provid ocrelizumab treatment elig particip primari progress multipl sclerosi ppm commerci avail unit state u indic ppm eap enabl particip receiv investig medic yet approv unit state food drug administr fda program nontradit studi placebo group enrol given activ medic follow strict protocol develop consult fda ocrelizumab eap enrol particip receiv studi medic given everi six month via two infus separ two week studi sponsor cover cost program specif medic procedur perform program outsid cost standard care medic procedur',\n",
       " 'said gene mutat egfr l correct second line tki tarceva mutat afatinib suggest also find immunotherapi work well egfr mutat read done sure someon may info also clinic trial specif mutat could check know locat check locat trial good luck matter treatment come next take care judi http clinicaltri gov ct show nct term nsclc l mutat rank p medic profession two time lung cancer survivor advoc stage iiia adeno dx sr chemo carbo alimta x ned local recurr surgeri remov lrl cm involv pleura chemo carbo alimta x ned',\n",
       " 'usual beg differ ob dr gi made sweep statement unsubstanti unfair rich peopl still abl get misleadin suggest work miss trick oracl nice tri protect nh rape well us die drug kill seven peopl withdrawn treatment rheumatoid arthriti triall properli thoroughli sp patient could good research seanchai provid evid patient die ocrelizumab arm unexpect system inflammatori syndrom could chanc still hope larger studi assur sever rheumatoid arthriti trial ocrelizumab termin overal benefit risk profil ocrelizumab favor realli mean patient die unexpectedli high ocrelizumab dose arm trial cladribin phase iii trial test cladribin multipl sclerosi publish new england journal medicin day fingolimod result report despit similar effect compar fingolimod increas frequenc neoplasm sever infect death compar placebo led neg report fda emea approv profil cladribin chemotherapeut drug use rare leukemia purin analog interfer dna synthesi usual cell metabol easili blood cell act cytotox drug cell sorri upset nice agre ocrelizumab need fight actual cure like insur polici nowaday worth paper written',\n",
       " 'well turn c diff infect could reason remicad work get control n current take vancomycin antibiot treat hope remicad still work work move anoth med like entyvio mark thank insight make sure mention doctor possibl underli infect parasit test order find',\n",
       " 'long term efficaci safeti ustekinumab refractori crohn diseas patient multicentr experi conclusionin cohort refractori cd patient receiv long term ustekinumab therapi patient continu ustekinumab treatment loss respons intoler surgeri good safeti profil sourc alimentari pharmacolog therapeut',\n",
       " 'scan post first want commend keep togeth seem calm level head twice age scare rabbit go second glad hospit get fluid care lug iv around pain alway garbag near hope get better remi work strongli suspect femal canada ivig pentasa uc crohn test posit map antibodi mycobacterium pg remiss flare year current deal peri anal abscess fistula rvf wait stelara',\n",
       " 'u amjevita pharmacolog class adalimumab use amjevita adalimumab atto inject use treat symptom prevent progress moder sever activ rheumatoid arthriti ankylos spondyl use children year age older juvenil idiopath arthriti medicin also use treat psoriat arthriti type arthriti caus pain swell joint along patch scali skin area bodi psoriat arthriti usual occur skin condit call psoriasi adalimumab atto may use alon combin medicin eg methotrex adalimumab atto inject also use treat symptom activ crohn diseas patient help medicin eg infliximab also use treat moder sever ulcer coliti patient treat medicin eg azathioprin corticosteroid mercaptopurin work well medicin may also use treat moder sever chronic plaqu psoriasi skin diseas red patch white scale go away medicin avail doctor prescript use amjevita decid use medicin risk take medicin must weigh good decis doctor make medicin follow consid allergi tell doctor ever unusu allerg reaction medicin medicin also tell health care profession type allergi food dye preserv anim non prescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatr specif problem would limit use adalimumab atto inject treatment juvenil idiopath arthriti children year age howev safeti efficaci establish children younger year age juvenil idiopath arthriti safeti efficaci establish use children geriatr appropri studi perform date demonstr geriatr specif problem would limit use adalimumab atto inject elderli howev medicin may caus seriou infect cancer often elderli may requir caution patient receiv adalimumab atto inject breast feed adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur case doctor may want chang dose precaut may necessari take medicin especi import healthcar profession know take medicin list follow interact select basi potenti signific necessarili inclus use medicin follow medicin usual recommend may requir case medicin prescrib togeth doctor may chang dose often use one medicin abatacept adenoviru vaccin anakinra bacillu calmett guerin vaccin live cholera vaccin live infliximab influenza viru vaccin live measl viru vaccin live mump viru vaccin live polioviru vaccin live rilonacept rotaviru vaccin live rubella viru vaccin live smallpox vaccin tofacitinib typhoid vaccin varicella viru vaccin live yellow fever vaccin zoster vaccin live interact food tobacco alcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco medic problem presenc medic problem may affect use medicin make sure tell doctor medic problem especi blood problem eg aplast anemia pancytopenia thrombocytopenia histori congest heart failur guillain barr syndrom histori infect fungal bacteri histori leukopenia low number white blood cell multipl sclerosi optic neuriti eye problem psoriasi skin diseas use caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copd granulomatosi polyangi use caution may increas chanc get new cancer diabet hepat b histori opportunist infect histori tuberculosi histori may increas chanc side effect infect activ use patient condit tuberculosi activ treat first receiv medicin proper use amjevita medicin given shot skin adalimumab atto may sometim given home patient need hospit clinic use medicin home doctor nurs teach prepar inject medicin sure understand use medicin medicin come medic guid patient instruct read follow instruct care ask doctor question use medicin home shown bodi area shot given use differ bodi area time give child shot keep track give shot make sure rotat bodi area help prevent skin problem medicin avail form may use prefil sureclick autoinjector prefil syring use autoinjector syring first gather item need clean flat surfac use cloth towel well light area wash hand soap water use medicin remov carton syring pen refriger place cloth allow minut syring autoinjector warm room temperatur warm medicin way remov needl cover prefil syring autoinjector allow medicin reach room temperatur remov immedi use check liquid syring autoinjector use view window clear colorless cloudi discolor particl float use syring autoinjector check amount liquid autoinjector close fill line seen window fill line show full dose medicin autoinjector full amount liquid use call pharmacist liquid clear place clean flat surfac shake medicin check expir date prefil syring autoinjector make sure date pass use medicin date pass choos inject site bodi eg thigh abdomen stomach area clean inject site fresh alcohol wipe let dri remov cap needl cover readi inject inject full amount medicin within minut cap cover remov use differ bodi area time give shot keep track give shot make sure rotat bodi area inject skin area red bruis tender hard psoriasi inject rais thick red scali skin patch skin lesion might small amount blood liquid inject site press hold dri clean cotton ball inject site second rub throw away use syring autoinjector hard close contain needl cannot poke punctur resist keep contain away children pet dose dose medicin differ differ patient follow doctor order direct label follow inform includ averag dose medicin dose differ chang unless doctor tell amount medicin take depend strength medicin also number dose take day time allow dose length time take medicin depend medic problem use medicin inject dosag form autoinjector prefil syring crohn diseas adult first week milligram mg inject skin divid dose may given four shot day two shot per day day week later dose mg given mainten dose mg given week everi week thereaft children use dose must determin doctor juvenil idiopath arthriti children year age weigh kilogram kg milligram mg inject skin everi week children year age weigh less kg mg inject skin everi week children younger year age use dose must determin doctor plaqu psoriasi adult first milligram mg inject skin mg week initi dose everi week thereaft children use dose must determin doctor psoriat arthriti rheumatoid arthriti ankylos spondyl adult milligram mg inject skin everi week doctor may adjust dose need children use dose must determin doctor ulcer coliti adult first week milligram mg inject skin divid dose may given four shot day two shot per day day week later dose mg given mainten dose mg given week everi week thereaft children use dose must determin doctor miss dose miss dose medicin take soon possibl howev almost time next dose skip miss dose go back regular dose schedul doubl dose storag keep reach children keep outdat medicin medicin longer need ask healthcar profession dispos medicin use store refriger freez protect medicin direct light keep medicin suppli origin packag readi use also travel store medicin cool carrier ice pack store room temperatur day precaut use amjevita use medicin long time import doctor check progress child regular visit allow doctor see medicin work properli decid whether continu use blood test may need check unwant effect child need skin test tuberculosi start use medicin tell doctor anyon home ever posit reaction tuberculosi skin test adalimumab atto temporarili lower number white blood cell blood may increas chanc get infect also lower number platelet necessari proper blood clot occur certain precaut take especi blood count low reduc risk infect bleed avoid peopl infect check doctor immedi child think get infect get fever chill cough hoars lower back side pain pain difficult urin check doctor immedi child notic unusu bleed bruis black tarri stool blood urin stool pinpoint red spot skin care use regular toothbrush dental floss toothpick medic doctor dentist nurs may recommend way clean teeth gum check medic doctor dental work done touch eye insid nose unless wash hand touch anyth els meantim care cut use sharp object safeti razor fingernail toenail cutter avoid contact sport situat bruis injuri could occur take medicin unless discuss doctor use abatacept orencia anakinra kineret togeth medicin may increas risk seriou side effect medicin may caus unwant effect may occur month year medicin use small number peopl includ children teenag use type medicin develop certain type cancer eg leukemia patient also develop type cancer call lymphoma talk doctor child unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss also check doctor right away skin red scali patch rais bump fill pu adalimumab atto may caus seriou allerg reaction includ anaphylaxi anaphylaxi life threaten requir immedi medic attent check doctor right away child rash itch swell face throat leg feet troubl breath chest pain receiv medicin check doctor right away child one symptom short breath swell face finger feet lower leg sudden weight gain may sign heart condit call congest heart failur chf peopl use medicin develop lupu like symptom treatment got better medicin stop check doctor right away child start chest pain short breath joint pain rash cheek arm sensit sun live vaccin immun child treat adalimumab atto child vaccin need current begin use adalimumab atto sure ask child doctor question needl cover autoinjector prefil syring contain dri natur rubber deriv latex may caus allerg reaction peopl sensit latex tell doctor child latex allergi start use medicin amjevita side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor immedi follow side effect occur common bodi ach pain chill cough diarrhea difficulti breath ear congest fever gener feel discomfort ill headach joint pain loss appetit loss voic muscl ach pain nausea pain tender around eye cheekbon shiver sneez sore throat stuffi runni nose sweat tight chest troubl breath troubl sleep unusu tired weak vomit less common abdomin stomach pain bleed gum nose bloat swell face arm hand lower leg feet chest pain dizzi eye pain faint fast slow irregular heartbeat gener feel tired weak hoars lower back side pain pain difficult urin rapid weight gain ring ear sore ulcer white spot lip mouth tingl hand feet unusu bleed bruis unusu weight gain loss incid known blind blister peel loosen skin blue yellow color blind blur vision dark color urin decreas vision diarrhea eye pain gener feel tired weak itch joint muscl pain light color stool red skin lesion often purpl center red irrit eye red scale crust skin stomach pain continu yellow eye skin side effect may occur usual need medic attent side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question common bleed blister burn cold discolor skin feel pressur hive infect inflamm itch lump numb pain rash red scar sore sting swell tender tingl ulcer warmth inject site rash incid known hair loss thin hair side effect list may also occur patient notic effect check healthcar profession call doctor medic advic side effect may report side effect fda fda',\n",
       " 'hi everyon drug seem promis sure understood fulli would block relaps good brain got hope understood happi lol http www ucsf edu news new multipl sclerosi drug ocrelizumab could halt diseas',\n",
       " 'ye link work hi sonia tri look far ahead ye shot atv ocrevu might good thing tke care georg',\n",
       " 'tuesday march pm san francisco kgo good day watch sarah warto climb stair might guess suffer multipl sclerosi shortli birth daughter year ago symptom kick effect abil walk probabl biggest issu mother newborn child want get run around warto said wait potenti approv new drug could chang cours diseas possibl life stephen hauser ucsf help overse test drug develop bay area base genentech clinic name ocrelizumab hauser say abl disrupt symptom less sever form multipl sclerosi call relaps ocrelizumab abl nearli complet stop diseas activ peopl relaps remit form multipl sclerosi hauser said say even abl reduc symptom much damag form diseas call progress ultim rob patient abil move peopl relaps ms spectacular news peopl progress ms door final open hauser said',\n",
       " 'clinic relaps experienc individu switch rituximab individu switch fingolimod within year natalizumab cessat',\n",
       " 'tuvigin gilenya trademark own pharma compani novarti perhap tuvigin follow drug gilenya patemt expir',\n",
       " 'abstractpurpos reviewwith rapidli evolv complement advanc target therapi inflammatori bowel diseas addit safeti side effect concern emerg purpos review consid variou risk biolog therapi inflammatori bowel diseas discuss mitig strategi recent findingstwo recent approv monoclon antibodi vedolizumab ustekinumab janu kinas inhibitor small molecul tofacitnib introduc number novel safeti risk consider review clinic trial real world safeti data date agent well review sourc current gastroenterolog report',\n",
       " 'hi everyon ulcer coliti sinc year old hid symptom month embarrass scare got horribl stand anymor almost surgeri remicad done realli well far problem sinc made shirt quot made smile hospit one thing made smile time still tri pay medic bill year thought mayb peopl would like shirt quot spread word ulcer coliti mayb make smile let know think like one mayb consid buy one ^_^ would like one crohn let know pleas link item sell fundrais healingwel rule allow even good caus post edit moder ipoop gmt',\n",
       " 'jayle present drug ppm ocrevu present approv use nh decis review review conclud sometim next year potenti treatment pipelin live hope',\n",
       " 'hi maceyma dublin well know mean worri brain inflamm dmt tysabri gilenya side effect attend st vincent tysabri closley monitor would imagin beaumont far know risk gileni bad would let nurs neurologist know concern see drug decid closley monitor sent friend request let know question hard decid med pick ann mari x',\n",
       " 'speaker david greco md associ neurologist pre registr requir contact organ regist read categori connecticut tag event food free genentech ms multipl sclerosi patient educ program treatment waterburi ct ms educ event ocrevu courtyard marriott ticket oct pm speaker david greco md associ neurologist pre registr requir contact organ regist',\n",
       " 'thank marco post final ppm love post made also help http www msworld org forum showthr ppm love spoke genentech patient advocaci today ocrevu manufactur switzerland avail end next week april u sure insur coverag formulari right understand someth call honeymoon period newli approv drug perhap one know someth articl ny time approv includ price http www nytim com ocrevu html agre marco final ppm love result look good rrm hope safeti profil continu good time anoth choic patient doctor consid good alan',\n",
       " 'hi linea wife lorlatinib week criz work well brain met problem question lorlatinib usual associ stabl diseas clear chest figur also median os pf prev resist rob',\n",
       " 'hi daxi circumspect interpret clinic trial egfr inhibitor sinc mum uncommon variant variant known respond significantli better second gener tki therapi like afatinib first third gener least first line treatment differ exon mutat respond best osimertinib third gener first line would read much studi focu mum initi mutat would also wonder brain met aros mum taken afatinib without know mutat present hard make infer inclin would tri rechalleng afatinib see chang rate growth slow thing afatinib also penetr blood brain barrier noteworthi mum rate progress chang taken afatinib bar use afatinib either alon combin jim suggest post sinc alreadi access osimertinib might best cours point avail chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatin vinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan',\n",
       " 'connect friend famili internet sew doll make cloth great grand daughter play cat charli jelli joan yr old greatgrand mom dxed uc fail med liada asacol mp remicad humira entyvio year much improv less trip potti less accid abl gain back lb supplement tumer vitb vitcd reuteri pearl dao need',\n",
       " 'hi jenni sorri hear tough time cladribin start cladribin last august septemb due second dosag later year far good though new episod latest mri decemb show new diseas activ lucki suffer ill winter cold rel plain sail downsid monthli blood check ideal terribl fear needl hospit consult royal london one lead research treatment realli keen choos option emma x',\n",
       " 'hey guy flare back june due antibodi entyvio gotten mg bump back mg start taper august current mg taper slower time mg week howev feel like realli harder time time around also think thyroid may hair fall profus tongu swollen normal regular period day late thing like fatigu crossov symptom end need endocrinologist ask pcp gi referr also think would benefit yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wk minor flare august flare sinc oct acut pancreat mesalamin allerg humira start pred bridg still entyvio start flare wors right mg pred',\n",
       " 'whtc radio roch immunotherapi tecentriq given older drug avastin chemotherapi improv surviv advanc lung cancer patient percent combin without tecentriq accord interim result late stage trial releas wednesday surviv benefit tecentriq plu chemotherapi avastin chemotherapi combin brief summari data becam avail wednesday phase iii studi involv peopl non squamou non small cell lung cancer nsclc whose cancer spread yet receiv chemotherapi detail data trial present next month annual meet american societi clinic oncolog roch conduct sever tecentriq lung cancer trial expect announc summer result trial drug combin alimta carboplatin tecentriq avastin chemo combin also show surviv advantag patient egfr alk mutat first treat drug target genet marker yet receiv chemotherapi compani said also show patient whose cancer spread liver live median month receiv four drug combin compar month given avastin chemotherapi estim american diagnos lung cancer year nsclc account percent case accord american cancer societi',\n",
       " 'redhil biopharma ltd announc posit top line safeti efficaci result first phase iii studi rhb crohn diseas map us studi studi success met primari endpoint key secondari endpoint top line result intent treat itt popul demonstr superior rhb placebo achiev remiss week defin crohn diseas activ index cdai valu less primari endpoint studi proport patient meet primari endpoint significantli greater rhb group compar placebo vs p studi also success met key secondari endpoint demonstr consist benefit crohn diseas patient treat rhb patient treat rhb also achiev statist signific greater respons week defin decreas cdai baselin compar placebo vs p patient treat rhb also experienc statist signific benefit achiev earli remiss defin remiss week vs p patient receiv rhb also experienc statist signific benefit durabl remiss week defin continu remiss throughout period vs p demonstr improv placebo week treatment remiss rhb arm continu favor placebo vs p analysi mainten remiss week subject note remiss week also demonstr statist signific benefit rhb placebo vs p rhb found gener safe well toler top line result demonstr activ placebo treatment group experienc similarli low rate seriou advers event treatment emerg advers event lead studi drug discontinu indic posit safeti profil rhb compani continu assess addit exploratori endpoint data becom avail includ mucos heal map statu qualiti life assess sub popul analys pharmacokinet addit data expect come month comment need login leav comment epgonlin org monitor collect advers event report advers event report nation report agenc manufactur learn zone epgonlin org learn zone lz area site dedic provid detail self direct medic educ diseas condit procedur inflammatori bowel diseas knowledg centr inflammatori bowel diseas ibd knowledg centr contain key inform relat epidemiolog pathophysiolog crohn diseas ulcer coliti highlight preval impact unmet need underli inflammatori process drive ibd consid key inflammatori pathway chronic obstruct pulmonari diseas copd view highlight recent congress present new expert video lead physician migrain knowledg centr migrain knowledg centr featur latest research preval impact migrain propos neurolog basi condit translat new excit drug therapi well current patient care strategi collat headach organis worldwid allerg rhiniti allerg rhiniti caus great strain workforc help reduc sick day improv product appropri treatment option fluid manag date latest evid effect procedur fluid manag chronic spontan urticaria csu use patient case studi discov expert diagnos treat chronic spontan urticaria acut advanc heart failur effect treatment acut heart failur defin advanc heart failur discov load relat content news journal articl clinic trial guidelin news phase iii im uniti studi stelara show continu efficaci year crohn diseas j j janssen cilag janssen pharmaceut compani johnson johnson announc new three year data phase iii im uniti studi demonstr ad month ago addit data phase iii map us studi rhb confirm benefit crohn redhil biopharma redhil biopharma report addit posit data map us studi first phase iii studi rhb ad month ago success phase iii studi map us studi rhb treatment crohn diseas redhil biopharma ltd redhil biopharma ltd announc posit top line safeti efficaci result first phase iii studi rhb ad month ago chmp recommend approv extens indic xeljanz ulcer coliti pfizer committe medicin product human use chmp adopt posit opinion recommend chang term ad month ago fda advisori committe recommend xeljanz treat ulcer coliti pfizer pfizer announc posit outcom fda gastrointestin drug advisori committe gidac meet met discuss pfizer supplement ad month ago load view news item journal articl safeti adalimumab pediatr patient polyarticular juvenil idiopath arthriti enthes relat arthriti psoriasi crohn diseas object evalu safeti adalimumab pediatr patient particip clinic trial juvenil idiopath arthriti polyarticular juvenil idiopath arthriti pediatr enthes relat arthriti ad month ago novel therapi treatment strategi patient inflammatori bowel diseas articl review current treatment option strategi provid updat statu drug develop program new therapeut agent inflammatori bowel diseas ibd ad month ago review articl predictor respons vedolizumab ustekinumab inflammatori bowel diseas aim summaris current data predictor respons vedolizumab ustekinumab ibd patient ad month ago safeti efficaci pharmacokinet vedolizumab patient simultan exposur anti tumour necrosi factor aim explor outcom patient co expos anti tnf vedolizumab ad month ago phase ii evalu anti madcam antibodi pf treatment crohn diseas report opera studi phase ii randomis doubl blind placebo control clinic trial design evalu efficaci safeti pf fulli human monoclon antibodi bind human mucos addressin cell adhes molecul ad month ago load view journal articl item clinic trial impact medic treatment sexual function patient crohn diseas investig propos month studi compar sexual function treatment patient crohn diseas initi therapi anti tnf drug treatment perian fistula intestin crohn ad month ago studi test whether pf safe improv diseas symptom patient crohn diseas opera adult crohn diseas clinic activ despit convent treatment elig studi patient may receiv one three dose pf experiment drug placebo inact drug ad month ago impact anti tnf exposur vedolizumab effect vedolizumab new medic use treatment crohn diseas ulcer coliti work block specif white blood cell alpha beta lymphocyt migrat area inflamm ad month ago multicent random doubl blind placebo control studi abt induct symptomat endoscop remiss subject moder sever activ crohn diseas inadequ respond intoler immunomodul anti tnf therapi determin efficaci safeti multipl dose abt subject moder sever activ crohn diseas histori inadequ respons intoler immunomodul anti tumor necrosi factor ad month ago personalis anti tnf therapi crohn diseas pant primari object studi investig mechan underli primari non respons pnr loss respons lor advers drug reaction adr anti tnf drug patient activ lumin crohn diseas ad month ago load view clinic trial item guidelin third european evid base consensu diagnosi manag ulcer coliti part current manag guidelin condens two paper [ ] second describ current therapeut manag [treatment activ diseas mainten medic induc remission] ad month ago third european evid base consensu diagnosi manag ulcer coliti part definit diagnosi extra intestin manifest pregnanc cancer surveil surgeri ileo anal pouch disord guidelin condens paper st detail definit classif diagnosi imag patholog manag special situat [eim pregnanc cancer surveil surgeri ileo anal pouch disord uc] ad month ago consensu guidelin ecco espghan medic manag pediatr crohn diseas object guidelin provid state art guidanc medic treatment long term manag children adolesc cd individu therapi base risk benefit base thorough review ad year ago crohn diseas manag crohn diseas chronic inflammatori diseas mainli affect gastrointestin tract diseas may progress peopl proport may develop extra intestin manifest',\n",
       " 'never know someth take help stop take thing go south know help happen occas switch cytoxan ocrevu last year feel punki two day infus',\n",
       " 'summari studi base john hopkin univers compar two treatment strategi peopl newli diagnos onset diagnosi past receiv minim treatment relaps remit form ms studi recruit approxim center nationwid one option escal approach patient start take less power therapi option switch potent therapi diseas activ continu approach involv start stronger therapi potenti effect also carri potenti greater risk signific advers effect tradit versu earli aggress therapi multipl sclerosi treat ms trial fund patient center outcom research institut pcori detail rational unmet need identifi specif treatment strategi relaps remit phase ms prevent delay reduc longer term disabl particularli unclear whether peopl experi diseas activ tradit first line diseas modifi therapi includ inject oral medic treat ms trial switch differ first line therapi escal immedi higher efficaci therapi therapi greater effect possibl side effect deliv via infus treat ms trial one two studi fund pcori help inform treatment decis around whether peopl ms would benefit earli possibl riski aggress therapi studi determin effect earli intens versu escal approach treatment relaps remit multipl sclerosi deliv ms elig detail investig seek particip diagnos relaps remit ms age year particip elig month exposur one ms diseas modifi therapi prior treatment rituximab ocrelizumab alemtuzumab mitoxantron cladribin experiment aggress therapi enrol criteria avail contact elig particip divid two group base whether show characterist may make higher risk long term disabl within group particip randomli assign either tradit earli aggress therapi particip neurolog specialist choos therapi within categori appropri deem low risk disabl initi randomli assign tradit therapi experi ongo diseas activ interest switch therapi randomli assign differ tradit therapi earli aggress therapi studi particip rang month depend enrol date studi relat activ occur around particip standard visit local health care provid primari outcom measur time sustain disabl progress determin expand disabl statu scale edss plu combin outcom includ chang either edss time foot walk test mobil leg function nine hole peg test measur upper extrem function investig also monitor symptom fatigu mobil cognit track brain mri scan also patient report outcom particip report percept condit obtain gain better understand full impact treatment contact learn enrol criteria studi find elig particip pleas email team john hopkin treatm jhmi edu connect particip site area site enrol follow citi current activ site pleas see studi list clinicaltri gov birmingham al phoenix az lo angel ca sacramento ca san francisco ca washington dc newark de gainesvil fl miami fl tampa fl chicago il kansa citi ks louisvil ky boston worcest baltimor md second site ann arbor mi detroit mi rochest mn bill mt great fall mt hackensack nj teaneck nj new york ny rochest ny stoni brook ny cincinnati oh columbu oh dayton oh westervil oh portland danvil pa pittsburgh pa nashvil tn dalla tx round rock tx salt lake citi ut norfolk va burlington vt seattl wa download brochur discuss issu think consid enrol ms clinic trial pdf without particip research studi ms research would come standstil read',\n",
       " 'main tumor lung rest lymph node one left arm pit chest stabl grow supraclavicular lymph node act kick origin clinic studi done went st week week carboplatin nab paclitaxel abraxan chemo pemrolizumab immunolog week nab paclitaxel abraxan chemo fli color speak advers reaction drug littl hair loss fact grew back thicker littl neuropathi feet reach base ankl word one other would enviou would like punch light take bottl extra medic nausea vomit prescrib diarrhea loss appetit etc least get call phase ii ye much type weather nice warm water bed stay time front f bedroom tv laptop smartphon side diagnos oct fact know biopsi lung cancer pet scan etc dec th start treatment think indi everi week everi week oct dec start week trip till nid april miss session delay one land ditch jan th rain sleet weather probabl highway snowplow get head home immun count would treatment harm besid made death father june th make enough red blood cell transfus everi week mother die dec th acut myocardi infract near blockag sepsi c diff stage acut onset kidney diseas besid full right side stroke nurs home sinc dec sat watch die slowli dec hour comfort care dnr advanc life sustain support surgeri aliv blockag would possibl made done damag good hope best well first round one chemo similar nab paclitaxel abraxan come along olgamari jump post wow amaz book lesson everyon say keep fight think say keep live good luck',\n",
       " 'day get find latest pet scan somewhat nervou tarceva dosag lower peopl live truli sit talk everyth thank peopl god tri give worri hard brave front karley sometim scan irrit use worri year day worri someth beyond control anyway enough worri chri draft fabul past sunday took karley stephen jaguar game much fun cold raini lost blast thank god peopl went amaz want donat good lung cancer caus donat www teamdraft org thank continu prayer pleas pray good scan friday feel like realli need prayer right god bless corinthian love patient kind love envi boast arrog rude insist way irrit resent rejoic wrongdo rejoic truth love bear thing believ thing hope thing endur thing',\n",
       " 'follow thread sinc begin firm believ ginger root tea relief arthriti pain shoulder easili see get juic fiber heat use could much better use mani herbal remedi time work ginger cinnamon two work ginger work great give cinnamon due blood get thin bruis easili ginger wonder stuff never notic much chang uc due find interest follow bit amaz talk real herbalist anoth moron like everi weed everyon lawn medicin purpos know thank share ginger research shall continu watch diagnos med triamteren hctz remicad infus wk interv mesalamin mg x day donnat tab x day hyoscyamin sulfat odt hour need omeprazol mg capsul day latanoprost op drop eye potassium mg x day metfonidazol mg x day ciprofloxacin hcl mg x day lorazepam mg xday need prednison mg week',\n",
       " 'mother diagnos nsclc chemo year start work stage iv pleural effus addit small nodul right lung chemo result stabil tumor resolv nearbi earli stage lymph node metastasi otherwis healthi keep weight exercis well chemo high blood pressur chemo start work almost year opdivo first month sign concern nearli year pet scan go lung biopsi concern area pancrea arm pit terrifi sinc believ immunotherapi go solut next great breakthrough question cannot seem find anywher peopl situat go back onto chemo drug treatment immunotherapi type possibl set back typic occurr oncologist said earli immunotherapi sometim look worst get better thought share find difficult find anyth posit inform immunotherapi find drug work due individu histolog option help offer famili would grate hear pleas pray everyth us god bless thank',\n",
       " 'brand name mekinist medicin prescrib trametinib use alon combin dabrafenib tafinlar treat certain type melanoma type skin cancer cannot treat surgeri spread part bodi use combin dabrafenib treat prevent return certain type melanoma surgeri remov affect lymph node trametinib also use combin dabrafenib treat certain type non small cell lung cancer nsclc spread nearbi tissu part bodi use combin dabrafenib treat certain type thyroid cancer spread nearbi tissu part bodi cannot treat therapi trametinib class medic call kinas inhibitor work block action abnorm protein signal cancer cell multipli help stop spread cancer cell use medicin medic may prescrib use ask doctor pharmacist inform medicin use trametinib come tablet take mouth usual taken day empti stomach least hour hour meal take trametinib around time everi day follow direct prescript label care ask doctor pharmacist explain part understand take trametinib exactli direct take less take often prescrib doctor stop take trametinib without talk doctor doctor may adjust dose trametinib depend respons treatment side effect experi talk doctor feel treatment ask pharmacist doctor copi manufactur inform patient special precaut follow take trametinib tell doctor pharmacist allerg trametinib medic ingredi trametinib tablet ask pharmacist list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take tell doctor ever lung diseas breath problem diabet bleed problem blood clot coliti inflamm colon stomach problem high blood pressur heart eye liver kidney diseas medic condit tell doctor pregnant plan becom pregnant becom pregnant take trametinib use birth control prevent pregnanc treatment trametinib month final dose talk doctor birth control method work becom pregnant take trametinib call doctor trametinib may harm fetu tell doctor breastfeed plan breastfe breastfe take trametinib month final dose know medic may decreas fertil women talk doctor risk take trametinib special dietari instruct follow unless doctor tell otherwis continu normal diet forget take dose take miss dose soon rememb howev less hour next schedul dose skip miss dose continu regular dose schedul take doubl dose make miss one side effect medicin caus trametinib may caus side effect tell doctor symptom sever go away dri skin sore mouth tongu dri mouth vomit loss appetit chang abil tast food tired side effect seriou experi symptom stop take trametinib call doctor immedi unusu bleed bruis bloodi black tarri stool cough vomit blood materi look like coffe ground noseble sever diarrhea stomach pain nausea fever chill rapid irregular pound heartbeat difficulti breath chest pain swell face arm leg ankl feet dizzi lightheaded weak short breath leg pain swell tender red warmth sever headach cough blur vision chang vision includ see halo blur outlin around object color dot loss vision eye pain dri red swollen eye rash red skin pimpl wart reddish bump bleed heal chang size color mole itch blister ulcer sore skin nail tingl burn red swell peel flake blister sore palm hand sole feet frequent urin increas thirst trametinib may increas risk develop new skin cancer cancer talk doctor risk take medic trametinib may caus side effect call doctor unusu problem take medic experi seriou side effect doctor may send report food drug administr fda medwatch advers event report program onlin [web] phone know storag dispos medic keep medic contain came tightli close away moistur light reach children place tablet contain daili weekli pill box store refriger freez remov desicc small packet includ medic absorb moistur bottl import keep medic sight reach children mani contain weekli pill minder eye drop cream patch inhal child resist young children open easili protect young children poison alway lock safeti cap immedi place medic safe locat one away sight reach [web] unneed medic dispos special way ensur pet children peopl cannot consum howev flush medic toilet instead best way dispos medic medicin take back program talk pharmacist contact local garbag recycl depart learn take back program commun see fda safe dispos medicin websit [web] inform access take back program case overdos case overdos call poison control helplin inform also avail onlin [web] victim collaps seizur troubl breath awaken immedi call emerg servic symptom overdos may includ follow vision problem inform know keep appoint doctor laboratori doctor order certain lab test treatment see safe receiv trametinib check bodi respons trametinib doctor also check skin chang begin treatment everi month treatment month treatment doctor also check blood pressur time time need let anyon els take medic ask pharmacist question refil prescript import keep written list prescript nonprescript counter medicin take well product vitamin miner dietari supplement bring list time visit doctor admit hospit also import inform carri case emerg report medic inform consid individu patient advic chang natur drug inform pleas consult physician pharmacist specif clinic use american societi health system pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field american societi health system pharmacist inc make represent warranti express impli includ limit impli warranti merchant fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos entir monograph drug review thorough understand drug action use side effect american societi health system pharmacist inc endors recommend use drug inform substitut medic care ahf patient medic inform copyright american societi health system pharmacist inc east west highway suit bethesda maryland right reserv duplic commerci use must author ashp',\n",
       " 'nope never wear glove honestli think empti pouch sanitari wipe butt least see cours wash hand done differ pre ostomi day year old male diagnos crohn age happi humira year august fail remicad cimzia imuran mp mtx ileostomi april began entyvio juli med except nexium',\n",
       " 'regret take drug recent found peopl stop take gilenya risk sever exaccerb thing white blood cell count drop low enough stop take count low may fortun come back neurologist want monthli blood test kind terrifi cant afford lose function',\n",
       " 'merck spent time turn patent drug c v patent oral prepar went lower hang fruit first earli relaps diseas plenti mri activ relaps facilit posit outcom detect time clariti oracl ms undertaken entir understand know ema look littl harder suspect cancer risk misinterpret lymphopenia advers effect effect movectro may obtain licens patent life would longer trial progress ms obviou follow project differ stori would surpris compani spend hundr million develop mavenclad progress diseas may chang heart work trial design chariot ms post next week first collabor meet taken place howev yet fund trial less million let know know somebodi abl will chip big current offer peopl progress ms entir compassion plausibl rational howev limit data total transpar peopl sign consent understood luck well know ocrelizumab requir year mani hundr patient show effect fat chanc detect differ control arm atm say treatment except well toler biotin trial allow inclus peopl dmt ye prepar includ peopl cladribin know whether memori cell brain affect contrari drug penetr cn cladribin certainli potenti time howev even know degre memori b cell peripher deplet first anecdot evid suggest work well way data preliminari encourag peopl progress ms lp cours year order obtain neurofila level howev mandatori',\n",
       " 'thank comment type employ quit physic current wait seen medic doctor ie want get rid downplay pain high pain toler point tear time day incred hard focu anyth els appoint ms specialist come think need tell everyth even cost employ role dismiss believ cannot perform inher duti med may effect role gilenya month first dmd sinc diagnosi guess small victori nil side effect yay',\n",
       " 'confus pdl inhibitor websit tecentriq respond therapi show complet respons data long term bc free opdivo patient complet respons data long term bc free keytruda overal respons rate complet respons data long term bc free may miss someth seem lot smoke littl fire three primari phl inhibitor market',\n",
       " 'hi cannedi thank ask feel lot better week ago fever cough take tagrisso day take tumor went cm cm susan',\n",
       " 'bad sometim deadli infect happen patient take infliximab dyyb peopl infect take drug lower immun system like methotrex steroid drug infect take antibiot recent past mani infect talk doctor tb tuberculosi seen patient start infliximab dyyb patient expos tb past never got infect test see expos tb start infliximab dyyb lymphoma cancer happen peopl take infliximab dyyb drug like deadli case talk doctor rare type cancer call hepatosplen cell lymphoma hstcl happen infliximab dyyb drug like case deadli almost case peopl use drug like one along certain drug azathioprin mercaptopurin time happen treatment crohn diseas ulcer coliti also case male teenag young men talk doctor use infliximab dyyb see also entyvio use methotrex prevent problem patient moder bad rheumatoid arthriti use treat crohn diseas use treat psoriat arthriti use treat plaqu psoriasi use treat ankylos spondyl use treat ulcer coliti may given reason talk doctor need tell doctor take infliximab dyyb allergi infliximab part infliximab dyyb allerg mous protein talk doctor allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign heart failur weak heart take drug abatacept anakinra take take anoth drug like one breast feed breast feed take infliximab dyyb list drug health problem interact infliximab dyyb tell doctor pharmacist drug prescript otc natur product vitamin health problem must check make sure safe take infliximab dyyb drug health problem start stop chang dose drug without check doctor thing need know take infliximab dyyb tell health care provid take infliximab dyyb includ doctor nurs pharmacist dentist medicin may lower abil bone marrow make blood cell bodi need lead bad sometim deadli bleed problem infect tell doctor right away sign infect like fever chill bad sore throat ear sinu pain cough sputum chang color sputum pain pass urin mouth sore wound heal bruis bleed feel tire weak get weaken bacteria like bcg bladder cancer use infliximab dyyb talk doctor skin check tell doctor skin chang like new wart skin sore reddish bump bleed heal chang color size mole hepat b carri viru infliximab dyyb caus viru becom activ lead bad sometim deadli liver problem test hepat b start infliximab dyyb need watch sign hepat take infliximab dyyb sever month stop talk doctor rare peopl use drug like one nervou system problem sometim problem gone away call doctor right away burn numb tingl feel normal chang eyesight dizzi seizur weak arm leg bad sometim deadli liver problem happen infliximab dyyb call doctor right away sign liver problem like dark urin feel tire hungri upset stomach stomach pain light color stool throw yellow skin eye abnorm heartbeat heart attack high low blood pressur stroke happen within hour infus sometim heart attack deadli loss eyesight also happen within hour infus talk doctor older use infliximab dyyb care could side effect use care children talk doctor use child make sure child date vaccin tell doctor pregnant plan get pregnant need talk benefit risk use infliximab dyyb pregnant use infliximab dyyb pregnant tell babi doctor babi may higher chanc get infect least month birth babi doctor also need decid babi get vaccin certain vaccin may caus infect lead bad health problem death given within month birth medicin infliximab dyyb best taken use infliximab dyyb order doctor read inform given follow instruct close given infus vein period time may chanc get infect wash hand often stay away peopl infect cold flu blood work check told doctor talk doctor medicin may affect certain lab test tell health care provid lab worker take infliximab dyyb talk doctor get vaccin use vaccin infliximab dyyb may rais chanc infect miss dose call doctor find see also dosag inform detail side effect need call doctor right away warn caution even though may rare peopl may bad sometim deadli side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign lupu like rash cheek bodi part sunburn easi muscl joint pain chest pain short breath swell arm leg sign high low blood pressur like bad headach dizzi pass chang eyesight weak side bodi troubl speak think chang balanc droop one side face blur eyesight chest pain pressur bad back pain pale skin swollen gland night sweat big weight loss loss eyesight black tarri bloodi stool skin lump growth fast slow heartbeat red scali patch bump pu fill fever chill itch hive chest pain pressur short breath drug given drug may given avoid heart failur happen infliximab dyyb well heart failur gotten wors peopl alreadi tell doctor heart diseas call doctor right away short breath big weight gain heartbeat normal swell arm leg new wors bad skin reaction steven johnson syndrom toxic epiderm necrolysi may happen caus bad health problem may go away sometim death get medic help right away sign like red swollen blister peel skin without fever red irrit eye sore mouth throat nose eye side effect infliximab dyyb drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away headach upset stomach throw belli pain feel tire weak flush irrit shot given sign common cold side effect may occur question side effect call doctor call doctor medic advic side effect may report side effect fda fda may also report side effect http www fda gov medwatch see also side effect detail overdos suspect think overdos call poison control center get medic care right away readi tell show taken much happen store throw infliximab dyyb need store infliximab dyyb home talk doctor nurs pharmacist store consum inform use symptom health problem get better becom wors call doctor share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin keep drug safe place keep drug reach children pet throw away unus expir drug flush toilet pour drain unless told check pharmacist question best way throw drug may drug take back program area medicin come extra patient fact sheet call medic guid read care read time infliximab dyyb refil question infliximab dyyb pleas talk doctor pharmacist health care provid think overdos call poison control center get medic care right away readi tell show taken much happen',\n",
       " 'question point treat advanc cancer say keytruda type drug ipilimumab time seem like would need',\n",
       " 'juhi kund lungev scienc writer last weekend close oncolog profession includ superstar lung cancer research mani member lungev scientif advisori board gather chicago attend annual meet american societi clinic oncolog asco year confer domin studi focus immunotherapi diseas treatment leverag bodi natur immun respons field immunotherapi burst option breakthrough new approach diseas manag flow research treatment lung cancer summar highlight asco confer immunotherapi immunotherapi found effect tumor cell express high level protein pd l howev pd l alway reliabl biomark tend fluctuat time area tumor may express pd l area also tumor make pd l protein still respond immunotherapi mind research work optim biomark use predict patient benefit immunotherapi found measur tumor mutat burden tmb number mutat tumor dna may promis approach predict patient respons immunotherapi sometim tmb may use conjunct pd l level provid guidanc cancer treatment one import phase clinic trial look bevacizumab anti cancer drug known reduc tumor abil promot blood vessel growth requir feed cancer patient advanc non squamou non small cell lung cancer nsclc initi result show ad atezolizumab immunotherapi drug bevacizumab carboplatin paclitaxel two chemotherapi drug often use doublet treatment decreas cancer progress increas overal surviv compar regimen without immunotherapi research need studi also rais hope patient egfr posit alk posit nsclc trial result note patient shown progress egfr tyrosin kinas inhibitor tki alk tki respond well combin approach bevacizumab doublet chemotherapi atezolizumab anoth key phase clinic trial studi effect ad immunotherapi agent current recommend first line treatment advanc squamou nsclc research found immunotherapi drug pembrolizumab ad doublet chemotherapi patient saw signific increas overal surviv studi like result chang current guidelin first line treatment patient advanc squamou nsclc mani differ clinic studi underway determin optim combin lung cancer treatment includ immunotherapi chemotherapi target therapi radiat also research conduct identifi optim sequenc treatment enhanc patient surviv rate qualiti life non small cell lung cancer driver mutat lot progress also happen nsclc driver mutat phase clinic trial patient advanc nsclc posit ret fusion promis result drug loxo select target ret fusion protein addit studi plan develop treatment option small cell lung cancer excit around rova continu lungev scientif advisori board member david carbon md phd ohio state univers present phase clinic trial result show protein dll found high level small cell lung cancer sclc tissu healthi tissu could first target therapi advanc sclc result show rova bind dll improv overal surviv sclc patient whose cancer return chemotherapi addit scientist explor potenti immunotherapi sclc data phase clinic trial suggest pembrolizumab may effect sclc patient progress chemotherapi whose tumor posit pd l protein earli detect final progress liquid biopsi continu field earli detect someon develop cancer blood often contain piec mutat dna escap die tumor cell tumor dna found blood often call circul dna ctdna plasma cell free dna plasma cfdna recent liquid biopsi test becom avail analyz ctdna determin whether patient cancer type cancer result studi present asco suggest techniqu may also use detect earli stage lung cancer research develop circul cell free genom atla ccga aim understand liquid biopsi use earli detect complement ct screen research underway hope develop techniqu use lifesav tool earli detect lung cancer presidenti address asco presid dr bruce johnson mention close abl treat half patient nsclc target therapi immunotherapi initi treatment encourag progress saw asco year confid next year bring even juhi kund scienc writer lungev categori earli detect immunotherapi mutat non small cell lung cancer nsclc small cell lung cancer',\n",
       " 'consid stelara great far instantan infus mood chang happi energi kid think happen took lot pain bodi bent stomach area feel sick drop pred yet mg take omoperzol work everi day new life sinc infus poop mushi bloodi sometim urgenc one accid sinc start would recommend fail humira entyvio mp remicad uc sinc mayo clinic say chron coliti dx chronic lyme biolog work took rafaximin sibo work awesom take asacol hd',\n",
       " 'hi yui welcom read suggest apolog redund done alreadi suggest emerg bag car offic desk etc alway undi wipe pad ziplock bag chang pant imodium bottl ensur time well love remiss carri undi imodium purs alway anxieti diseas prepar help anxieti come along flare never ate morn go get hour work empti give imodium time work basic flexibl alway readi dash run toilet would seem easi enough take steroid doubl edg sword unend list side effect happen immedi caus signific damag troubl get flare control may want tri entocort non system steroid mean absorb gut caus less like chang side effect still happen great advic imagardn momma uc crohn test posit map antibodi mycobacterium pg remiss chronic fistula fail seton pure tortur start stelara may mg imuran current stelara ivig occas',\n",
       " 'hi everyon diagnos year ago ms first went gilenya made foggi drive work next tri copaxon got use give shot mri neurologist said thought help rd month tecfidera manag med well decemb get anoth mri experienc lot bladder problem learn manag well although annoy want know anyon experienc problem bowel yuck know pretti subject sometim feel like muscl power empti bowel way constip feel enough strength need anyon els issu thank much',\n",
       " 'opdivo case miracl drug thought post shout seen previo post',\n",
       " 'check livewithcanc opdivo long time',\n",
       " 'hi dane life welcom forum diagnos lung cancer april due delay lab took end june oncologist decid put keytruda third treatment week ago seriou side effect far littl tire weaker mild joint pain occasion cough lot fluid dr say tumor cancer caus keytruda appetit good even put weight problem drive hour treatment good luck journey us',\n",
       " 'great see other posit result opdivo nivolumab wife continu well opdivo everi week next infus go everi week ct show problem blood result continu slowli improv august th year surviv sinc diagnosi stage squamou cell lung cancer treatment thru swedish hospit cancer institut seattl access new clinic trial drug thank god current year issu side effect might might due opdivo swell knee discomfort knee ankl similar arthriti see rheumatologist soon see due arthriti mayb side effect opdivo best hope go best largest cancer treatment center closet metropolotan citi us access clinic trial stay far far away altern medicin phoni clinic cure mexico germani countri sourc stay away slick well advertis tv center locat across countri best chuck',\n",
       " 'natalizumab exposur sinc nh england gave us permiss switch high risk natalizumab patient fingolimod continu de risk natalizumab treat popul hope prevent anyon centr get pml despit mser prepar stop natalizumab simpli well drug follow import headlin data slide mser regard risk base three identifi pml risk factor jcv serostatu durat treatment previou exposur immunosuppress addit appear titr level anti jcv antibodi also play role risk see need incorpor futur risk model develop simpl infograph help integr inform download print infograph inform plavina et al use jc viru antibodi index stratifi risk progress multifoc leukoencephalopathi natalizumab treat patient multipl sclerosi en multipl sclerosi therapeut object mser treat natalizumab presenc anti jcv antibodi jcv ab prior use immunosuppress increas durat natalizumab treatment especi greater year known risk factor progress multifoc leukoencephalopathi pml polyomavirus higher level antibodi correl increas viral burden increas diseas risk known whether jcv ab level correl pml risk natalizumab treat mser object analysi examin associ jcv ab index jcv antibodi level measur use stratifi jcv dx select assay pml risk natalizumab treat mser method analys involv jcv ab index data jcv ab mser enrol clinic studi clinic practic cross section analysi jcv ab index data mser without pml first perform assess potenti relationship jcv ab index known risk factor natalizumab treatment durat vs monthli infus prior use p valu calcul use wilcoxon rank sum test associ jcv ab index pml assess use avail longitudin data odd ratio or estim generalis estim equat logit link predict probabl use updat current pml risk estim jcv ab mser high low ab index appli bay theorem result jcv ab index data avail natalizumab treat pml mser least month prior pml diagnosi non pml jcv ab mser jcv ab index found associ number natalizumab infus p prior use p significantli associ pml risk p estim or least high versu low jcv ab index jcv ab mser updat pml risk estim longitudin stabil jcv ab index present conclus risk pml jcv ab neg natalizumab treat mser low per jcv ab mser low jcv ab index risk pml sever fold lower risk current attribut jcv ab mser utilis jcv ab index allow clinic meaning stratif pml risk jcv ab natalizumab treat mser figur bottom tabl deriv tabl present data differ way rather per thousand absolut risk realis figur deriv rel small number e case pml data confirm anyon els assum case emerg data set updat implic data mani mser well natalizumab low titr low index may choos stay natalizumab rather switch mser high risk elect stay natalizumab start monthli mri monitor earli sign pml idea behind latter strategi detect pml earli wash natalizumab clear pml pick asymptomat phase manag quickli mser much better highlight slide coi multipl',\n",
       " 'interest articl compar opdivo keytruda http blog sciencemag org pipelin archiv keytruda vs opdivo contest',\n",
       " 'london merck commit advanc patient care offer therapeut option help address unmet medic need peopl ms focu efficaci dose durabl safeti said luciano rossetti global head research develop merck biopharma busi look forward share addit data rebif cladribin tablet scientif commun year ectrim congress oral present includ comparison clariti clariti extens studi sought examin durat clinic outcom respons cladribin tablet result solar studi examin effect ad high dose cholecalciferol vitamin rebif therapi patient rrm poster present report clinic magnet reson imag outcom patient treat cladribin tablet rebif patient report outcom patient treat rebif sever health econom outcom research present highlight key issu face peopl ms includ pregnanc outcom addit data present merck sponsor satellit symposium reimagin ms treatment journey take place wednesday septemb bst hall excel panel session featur distinguish expert ms debat whether unmet need ms care remain consid ideal ms therapi might look like review current potenti futur therapi thursday septemb merck hold fourth annual grant multipl sclerosi innov gmsi award symposium million award one research support work aim improv understand ms ultim benefit patient symposium take place south galleri excel bst inform data present pleas review ectrim websit also visit merck booth year congress learn compani program commit advanc ms care cladribin tablet cladribin tablet oral small molecul prodrug select period target lymphocyt thought integr patholog process ms cladribin tablet current clinic investig approv use unit state canada europ rebif rebif interferon beta diseas modifi drug use treat relaps form multipl sclerosi ms similar interferon beta protein produc human bodi efficaci rebif chronic progress ms establish interferon thought help reduc inflamm exact mechan unknown rebif approv europ us regist countri worldwid rebif proven delay progress disabl reduc frequenc relaps reduc mri lesion activ area rebif administr rebismart electron auto inject devic approv us rebidos singl use dispos pen manual multidos inject pen rebislid rebif also administ autoinjector rebiject ii manual inject use readi use pre fill syring inject devic approv countri',\n",
       " 'safe food uniqu person definit honestli life chang concept need quickli learn safe food diagnosi nine year ago shortli began experienc symptom ibd quickli learn certain food could toler often regardless nutrit valu food item becam thing reli heavili luck faith brat diet banana rice applesauc toast give certain categori like dairi gluten sugar mostli live realm carb safeti cracker rice pasta bread roll safe food essenti certain time safe food especi paramount need function human whether go work run groceri store think straightli seem gener better chanc retain energi food less chanc rush bathroom eat food nearli anyth els tri crohn diseas flare year alway return version carb life stomach ruin keep much els insid often felt like eat terribl horribl good bad thing forc mani time wish skip food altogeth safe food rare let year endless amount gratitud final abl add food varieti life switch remicad infus march august although still play dose frequenc infus good day bad one first time year ibd becam stabl anytim previous found new flexibl abl eat enter chapter life sometim even enjoy food someth differ mani year abl fill plate diet thing sound good thing interest tri thing actual nutrit valu began meal plan luxuri never realli enjoy knew might last focus benefit exist back safe food septemb husband went second round vitro fertil success result current pregnanc first child first trimest experienc morn sick form daili nausea period vomit bowel gone confus regular bowel movement transit back diarrhea time day due hormon pregnanc meant everyth gotten use year chang realli quickli realiz fairli quickli feel queasi like stomach upset reach thing alway known safe food carb first felt concern would safeti food default diet mean babi get enough nutrient gi ob doctor assur mom first trimest goal eat whatev whenev babi take babi need unabashedli lot come prenat vitamin take doctor said import thing need focu stay hydrat luckili life ibd made pro found fascin safeti diet one default often last nine year serv beyond ibd flare expect util strategi pregnanc time life grate option understand thing gener keep gut calm ibd chronic ill surgeri time life safe food offer secur relief',\n",
       " 'hello reach thought appreci expertis thank back anoth question could cancer journey treatment cancer type lung cancer diseas learn treatment scleroderma sister law diagnos year ago stage adenocarcinoma would consid oligiomestast diseas round cancer journey diagnos cancer type lung cancer diseas learn biolog ok alectinib psoriasi along stage iv nsclc alk posit take alectinib nsclc ok take biolog like cosentyx stelara cancer journey treatment cancer type lung cancer diseas learn neuropathi autoimmun hi year prior diagnosi small cell lung cancer suffer small fiber neuropathi sure autoimmun relat cancer journey diagnos cancer type lung cancer diseas learn progess tagrisso tagrisso sinc juli great initi respons visibl cancer shrink point longer detect cancer journey treatment',\n",
       " 'awesom give us hope femal canada ivig pentasa entyvio infus respons discontinu uc crohn test posit map antibodi mycobacterium pg remiss flare almost year bad way due abx treatment gone wrong sigh',\n",
       " 'david wilson also extrem pain head ach found anesthet reaction chang type anesthet eylea inject discomfort',\n",
       " 'ye everyon els say stop basic imposs start bodi antibodi recogn protein foreign humira good second option work fast well develop reaction job realli well',\n",
       " 'oh nice approv ocrevu',\n",
       " 'pffft said exact thing blog year ago advic partner oncologist lol say must kid word melbourn renown neuro ongo immunomodul suppress associ indefinit use tysabri gilenya etc mab unlik hsct associ cancer pre au rituximab ocrelizumab partner oncologist sorta gave blank look let dwell ah stop snarki boo thank entri instead',\n",
       " 'regular mri doctor follow seen doc sinc brain mri lesion went ms doc last week send blood jc viru test back yet ms seem flare monthli time month friend took gilenya start heart attack doc said drug contribut heart attack start tecifedera say seem work fine swallow big pill tec capsul huge said got stuck throat entir day afraid drug pml risk mean day regim tysabri know tec concern',\n",
       " 'hey nicol issu ocrevu infus mild allerg reaction handl easili bit iv benedryl think start feel tini bit better sinc second half dose late may slip relaps without tysabri day pre ocrevu seriou come back still feel great honestli rememb last time could say felt great year two diagnosi start lose patienc wait everyon talk ms longer tell first year worst know long time wait somehow give tini bit hope thank kind word write probabl lose left mind alway nice someon els like read hang let know ocrevu infus goe',\n",
       " 'deputi billi kelleh ask minist busi enterpris innov number local enterpris offic client counti case dublin dublin citi n laoghair rathdown fingal south dublin year tabular form make statement matter [ ] view answer billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov number local enterpris offic support job counti case dublin dublin citi n laoghair rathdown fingal south dublin year tabular form make statement matter [ ] view answer written answer question busi minist busi enterpris innov share propos take question no togeth local enterpris offic leo first stop shop provid advic guidanc financi assist support wish start grow busi detail number leo support client number job micro enterpris support leo shown follow tabl counti basi includ four leo dublin pleas note relev detail avail result annual employ survey leo client complet q leo leo client leo client carlow cavan clare cork citi cork south cork w n doneg dublin citi dlr fingal dublin south galway kerri kildar kilkenni laoi leitrim limerick longford louth mayo meath monaghan offali roscommon sligo tipperari waterford westmeath wexford wicklow grand total leo total job ft pt total job ft pt carlow cavan clare cork citi cork south cork w n doneg dublin citi dlr fingal dublin south galway kerri kildar kilkenni laoi leitrim limerick longford louth mayo meath monaghan offali roscommon sligo tipperari waterford westmeath wexford wicklow grand total department staff recruit question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov number addit staff appoint depart state agenc bodi aegi depart estim cost hire addit staff depart state agenc bodi tabular form make statement matter [ ] view answer written answer question busi minist busi enterpris innov share depart consid overal alloc resourc need ongo basi workforc plan process need addit post consid conjunct budget revis estim take account deliveri urgent busi prioriti cannot met current staff resourc exercis undertaken context expans respons across depart light brexit global challeng grow number prioriti face depart includ signific increas number employ permit applic regard total addit critic post identifi meet depart prioriti overal cost approv addit staf request associ prioriti area identifi depart inform set follow tabl grade number addit post princip offic assist princip offic administr offic execut offic cleric offic total estim cost note posit may need review later year next cycl workforc plan undertaken particularli respect demand employ permit relat offic depart addit pay budget alloc offic director corpor enforc odc workplac relat commiss wrc odc alloc addit pay budget assist transit offic statutori agenc identif specif post requir part ongo work underway progress transit odc agenc statu wrc alloc addit pay provid addit resourc support extens function includ sector employe gain access servic agenc come within remit depart carri workforc plan exercis earli stage identifi follow addit posit cost associ agenc number addit post estim cost competit consum protect commiss enterpris ireland health safeti author ida ireland nation standard author ireland econom competit question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov view latest report nation competit council ireland competit challeng timelin implement recommend public [ ] view answer written answer question busi minist busi enterpris innov share improv ireland competit ensur ireland attract locat busi key econom prioriti govern highlight competit challeng economi face identifi action address issu within control nation competit council make valuabl contribut regard welcom council recent report ireland competit challeng report ncc messag clear ireland overal competit perform remain posit risk ireland prosper increas room complac threat pose brexit evolv global trade tax landscap mean must enhanc competit posit make economi resili withstand extern shock share council view improv competit need sustain public financ continu invest infrastructur talent drive innov product across sector economi moreov sever initi train across govern enhanc competit perform includ review sme polici design assess sme busi ecosystem rang support offer sme undertaken depart conjunct oecd develop industri strategi respond challeng opportun aris impact digit technolog develop sector strategi enterpris ireland client base futur growth loan scheme allow busi borrow year support capit invest enhanc competit depart depart taoiseach also prepar futur job programm cross govern initi strong focu improv product publish februari initi propos concret ambiti action enhanc product competit ensur well posit adapt transform chang economi face year ahead alongsid competit challeng ncc made submiss futur job initi highlight key action govern reflect find competit challeng content ncc submiss futur job initi finalis work permit data question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov number employ permit grant non eea worker year occup sector tabular form [ ] view answer billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov number applic work permit receiv year number applic remain process decemb year tabular form [ ] view answer written answer question busi minist busi enterpris innov share propos take question no togeth inform request deputi regard number employ permit grant non eea worker year list occup sector set tabular form employ permit section depart use intern standard occup classif soc code system classifi worker occup categori purpos collect calcul dissemin data sinc follow tabl set inform request deputi regard number applic accept year number applic remain process decemb year tabular form applic accept applic remain process decemb figur applic remain process decemb approxim occup sector work permit elig question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov occup sector highli skill elig occup list inelig categori employ list respect tabular form [ ] view answer written answer question busi minist busi enterpris innov share employ permit system manag oper highli skill elig occup list hseol inelig categori employ list icel occup list hseol highli skill job profession posit medicin ict scienc financ busi occup list icel gener occup lower skill requir e g person servic trade oper evid enough irish eea worker fill vacanc everi job labour market employ cannot find worker may elig employ permit order ensur employ permit scheme respons chang econom circumst labour market condit occup list review twice yearli keep pace rapid labour market chang proactiv identifi address shortag aris ireland leader eu wide link labour market intellig econom migrat polici guid research undertaken sola expert group futur skill need govern strategi well public consult process review list underway present expect finalis end januari review commenc public call submiss stakehold interest group request chang list submiss receiv respect rang occup submiss relev research data examin comprehens inform employ permit system avail depart websit www dbei gov ie attach hseol attach icel person injuri claim question billi kelleh share billi kelleh question deputi billi kelleh ask minist busi enterpris innov provid data detail suppli period [ ] view answer written answer question busi minist busi enterpris innov share detail request deputi oper matter person injuri assess board piab piab independ statutori agenc minist permit execut function interfer way day day oper function piab howev order assist deputi set follow tabl relev inform publish piab annual report year annual report publish yet tabl applic piab year applic receiv total motor claim receiv total public liabil claim receiv total employ liabil claim receiv sourc data piab annual report tabl award made award accept year award made number accept award sourc data piab annual report medic aid applianc provis question billi kelleh share billi kelleh question deputi billi kelleh ask minist health person detail suppli receiv new wheelchair make statement matter [ ] view answer written answer question health minist health share servic matter refer hse direct repli deputi home help servic provis question billi kelleh share billi kelleh question deputi billi kelleh ask minist health satisfi level qualiti servic provid home care compani detail suppli behalf hse plan ensur action taken immedi resolv care issu experienc person make statement matter [ ] view answer written answer question health minist state depart health share servic matter ask health servic execut respond directli deputi soon possibl medicin product avail question billi kelleh share billi kelleh question deputi billi kelleh ask minist health decis refus person detail suppli allergi prevent form pain relief obtain lidocain patch review matter urgenc make statement matter [ ] view answer written answer question health minist health share medicin play vital role improv health irish patient secur access exist new innov medicin key health servic object howev challeng safe sustain manner treatment must appropri proportion clinic decis make prescrib base patient need sound medic evid lidocain medic plaster licens localis relief post shingl pain adult patch licens use ireland reimburs commun drug scheme sinc clinic concern aros usag increas significantli point plaster use ireland entir uk nation health servic situat import appropri clinician review usag hse medicin manag programm mmp review use plaster review estim prescrib licens indic septemb follow clinic review hse introduc new reimburs approv system patch support appropri use patient care arrang patient gp consult appli mmp reimburs approv behalf patient applic refus clinician may submit appeal mmp make clear clinic case patient inform patient practition hse mmp websit hse ie yourmedicin outcom applic appeal reimburs lidocain patch matter mmp treat clinician deputi appreci minist health cannot interven individu case decis introduc new reimburs approv process particular treatment matter hse howev fulli support object hse medicin manag programm hospit group question michael mcgrath share michael mcgrath question deputi michael mcgrath ask minist health posit relat spend revenu alloc matern director south southwest hospit group make statement matter [ ] view answer written answer question health minist health share servic matter ask health servic execut respond directli soon possibl hospit group question michael mcgrath share michael mcgrath question deputi michael mcgrath ask minist health view request capit budget million matern director south southwest hospit group enabl second oper theatr open cork univers matern hospit deal servic improv make statement matter [ ] view answer written answer question health minist health share health servic execut respons deliveri healthcar infrastructur project ask hse respond directli relat matter hospit procedur question gerri adam share gerri adam question deputi gerri adam ask minist health number person undergon cataract surgeri year cost surgeri year [ ] view answer gerri adam share gerri adam question deputi gerri adam ask minist health hse locat cataract surgeri perform [ ] view answer gerri adam share gerri adam question deputi gerri adam ask minist health number person counti await cataract surgeri length time wait [ ] view answer written answer question health minist health share propos take question no inclus togeth improv access hospit treatment key prioriti govern wait list figur decemb publish last week ntpf show consider improv made number patient wait inpati day case procedur fallen peak juli repres reduct overal number patient wait procedur period wait list cataract reduc repres reduct furthermor number patient wait month almost halv sinc juli impact particularli noteworthi one consid improv wait list particular specialti focu inpati daycas action plan includ number wait month cataract procedur fallen sinc juli depart work close ntpf hse finalis schedul care access plan inpati daycas outpati regard ntpf hse continu work close hospit group invit propos improv access patient wait hospit procedur number person treat cataract ntpf direct role commiss patient treatment time procur treatment carri hse role ntpf administr payment hospit expenditur ophthalmolog annual financi statement finalis hse locat cataract surgeri perform children univers hospit templ street galway univers hospit letterkenni gener hospit mater misericordia univers hospit royal victoria eye ear hospit sligo region hospit south infirmari victoria univers hospit st vincent univers hospit univers hospit limerick univers hospit waterford nenagh hospit louth counti hospit inform request deputi regard number person counti await cataract surgeri set document follow link cataract vaccin programm question john curran share john curran question deputi john curran ask minist health age children may previous vaccin meningococc b diseas entitl vaccin hse make statement matter [ ] view answer john brassil share john brassil question deputi john brassil ask minist health hse undertaken cost analysi provis mening b vaccin children born octob consid make statement matter [ ] view answer john brassil share john brassil question deputi john brassil ask minist health hse establish number person affect mening b strain relat recent mening outbreak number person recent die due mening affect mening b strain make statement matter [ ] view answer john brassil share john brassil question deputi john brassil ask minist health plan extend mening b vaccin children born octob make statement matter [ ] view answer john brassil share john brassil question deputi john brassil ask minist health plan establish public awar campaign encourag uptak mening b vaccin booster programm make statement matter [ ] view answer r n shortal share r n shortal question deputi r n shortal ask minist health catch mening b programm provid children estim cost provid programm make statement matter [ ] view answer written answer question health minist health share propos take question no inclus togeth nation immunis advisori committe niac independ committe royal colleg physician ireland compris expert number specialti includ infecti diseas paediatr public health make recommend vaccin polici ireland recommend base preval relev diseas ireland intern best practic relat immunis relev appropri inform taken account decid make chang state immunis programm niac submit recommend depart consider foot recommend niac primari childhood immunis schedul amend includ introduct mening b vaccin babi born octob chang immunis schedul took effect decemb first dose vaccin administ children reach two month age second dose administ four month third final dose twelv month mening b diseas common babi age year old time administr vaccin immunis programm take account vaccin administ primari childhood immunis schedul provid free charg ireland second countri europ make men b vaccin avail free charg part nation immunis programm vaccin protect meningococc c diseas men c vaccin given month also note adolesc routin offer men c vaccin first year secondari school parent strongli advis ensur children immunis accord vaccin programm vaccin protect form mening septicaemia includ routin child vaccin programm hib vaccin pneumococc vaccin pcv plan introduc catch programm men b vaccin older children medic card elig vaccin administ gp free charg howev purchas vaccin cover medic card scheme eleven case meningococc diseas notifi health protect surveil centr hpsc sinc last week decemb three death among case due increas incid meningococc diseas last two week eleven case notifi compar case time period last year total meningococc case notifi compar provision data strain type identifi indic differ strain organ circul age group affect rang infant elderli two case notifi relat mening b none three death attribut strain diseas member public advis includ alreadi vaccin concern show symptom contact gp first instanc ensur medic expertis sought medicin product avail question john curran share john curran question deputi john curran ask minist health plan ensur drug pembrolizumab made avail person detail suppli make statement matter [ ] view answer written answer question health minist health share hse statutori respons medicin price reimburs decis accord health price suppli medic good act minist health statutori power function relat reimburs medicin addit section health act preclud direct hse provid treatment person servic individu confer elig individu would inappropri comment particular circumst individu patient ireland major patient access medicin publicli fund commun drug scheme line act nation framework agre industri compani would like medicin reimburs hse must appli new medicin ad reimburs list reimburs licens indic grant market authoris european medicin agenc ema health product regulatori author hpra hse decis medicin reimburs taxpay made object scientif econom ground advic nation centr pharmacoeconom ncpe pembrolizumab market authoris ireland eu number indic hse approv reimburs pembrolizumab follow indic monotherapi treatment advanc unresect metastat melanoma adult monotherapi first line treatment metastat non small cell lung carcinoma nsclc adult whose tumour express pd l tumour proport score tp egfr alk posit tumour mutat monotherapi treatment adult patient relaps refractori classic hodgkin lymphoma chl fail autolog stem cell transplant asct brentuximab vedotin bv transplant inelig fail bv note first part last indic reimburs hse alreadi reimburs anoth immunotherapi similar efficaci nivolumab lower cost patient transplant inelig fail bv receiv reimburs support pembrolizumab nivolumab market authoris sub group patient hse drug group review indic monotherapi treatment local advanc metastat urotheli carcinoma adult elig cisplatin contain chemotherapi whose tumour express pd l combin posit score cp follow indic current health technolog assess ncpe combin pemetrex platinum chemotherapi first line treatment metastat non squamou nsclc adult whose tumour egfr alk posit mutat monotherapi treatment local advanc metastat urotheli carcinoma adult receiv prior platinum contain chemotherapi reimburs applic receiv date follow indic monotherapi treatment recurr metastat head neck squamou cell carcinoma hnscc adult whose tumour express pd l tp progress platinum contain chemotherapi howev hse approv reimburs nivolumab treatment recurr metastat squamou cell cancer head neck adult progress platinum base therapi octob committe medicin product human use chmp european medicin agenc committe respons human medicin adopt posit opinion recommend chang term market authoris pembrolizumab includ new indic follow monotherapi adjuv treatment adult stage iii melanoma lymph node involv undergon complet resect hse commiss rapid review assess indic indic pembrolizumab approv european union time clinic trial variou immunotherapi includ pembrolizumab ongo global rang possibl indic may receiv market authoris eu next number year indic consid reimburs market authoris grant applic receiv department staff data question barri cowen share barri cowen question deputi barri cowen ask minist health number employe depart number profession qualifi organis detail suppli number relev profession qualif number profession qualif tabular form [ ] view answer barri cowen share barri cowen question deputi barri cowen ask minist health number employe depart authoris engag procur number profession qualifi organis detail suppli number relev profession qualif number profession qualif tabular form [ ] view answer written answer question health minist health share propos take question no togeth number employe depart end decemb term headcount depart hold record profession qualif held employe employe may member profession organis person capac pay membership fee depart would record membership depart pay corpor membership institut public administr three individu annual membership charter account ireland one individu membership charter institut manag account reimburs depart variou member staff engag procur good servic depart alongsid main duti staff abid procur guidelin procedur laid offic govern procur act advic appropri staff involv would requir profession qualif procur order undertak work',\n",
       " 'clinic trial john hopkin hospit baltimor maryland combin use opdivo lag test pdl neg howev cea level continu decreas treatment next ct scan earli feb',\n",
       " 'hi sorri late repli away vacat implant last month case last month next implant month affect previou shot wore one month wait period also could manag read write drive work without difficulti littl discomfort overal hear numer doctor websit ozurdex elimin remain fluid effici perman case rvo keep finger cross',\n",
       " 'video dr vamsidhar velcheti cleveland clinic join grace discuss updat lung cancer video librari video dr velcheti discuss gilotrif afatanib squamou non small cell lung cancer',\n",
       " 'home ms inform public ms research updat gilenya fingolimod gilenya fingolimod section main articl fda approv medic experiment medic new direct ms research close note trial phase investig drug treatment approv long term treatment ms pdf refer fda approv medic new data compani novarti pharmaceut corp oral medic mg capsul taken daili approv relaps form ms previou tysabri next laquinimod gilenya first class immuno modulatori drug call p receptor modul similar structur natur occur compon cell surfac receptor white blood cell white blood cell produc immun system fight infect diseas gilenya block potenti damag cell leav lymph node lower number blood tissu may reduc damag cn enhanc repair damag nerv within brain spinal cord although gilenya approv relaps remit ms rrm clinic trial continu evalu role ms month inform trial evalu effect gilenya rel placebo delay time sustain disabl progress patient ppm present fda approv medicin ppm import studi field enrol ppm patient inform trial complet trial data analysi complet novarti announc decemb unfortun primari outcom studi met gilenya show signific differ placebo combin disabl measur novel primari composit disabl endpoint use trial base increas disabl measur expand disabl statu scale edss foot time walk test fw hole peg test hpt key endpoint format new lesion percentag brain volum chang pbvc brain atrophi shrink reduct brain volum detail result trial present spring gilenya prevent accumul disabl patient ppm greater placebo furthermor pbvc differ gilenya placebo group unsurprisingli given agent success reduc relaps new mri lesion rrm patient fewer new mri lesion seen gilenya treat patient safeti result gener consist medic prior ms trial certainli disappoint gilenya significantli slow diseas progress ppm find like tysabri spm import implic understand progress diseas doubt allow research refin studi move forward anoth ongo gilenya clinic trial studi evalu safeti efficaci two dose fingolimod versu copaxon month trial compar market dose gilenya one half dose use copaxon comparison annual ms relaps sever mri measur diseas goal studi requir fda assess lower dose medic may equal effect reduc number relaps patient relaps form ms studi expect report data previou tysabri next laquinimod',\n",
       " 'choic want treat ms post say effect treatment rrm spm relaps lemtrada cladribin hsct said ocrezilumab way treatment ppm larg doubl blind placebo control trial shown drug realli work scienc',\n",
       " 'eylea u net product sale total revenu non gaap net incom non gaap net incom per share dilut gaap net incom gaap net incom per share dilut busi highlight eylea aflibercept inject intravitr inject first quarter net sale eylea unit state increas million million first quarter net sale first quarter neg impact decreas distributor inventori net sale first quarter benefit increas distributor inventori exclud chang inventori underli demand eylea unit state increas year year bayer healthcar llc commerci eylea outsid unit state first quarter net sale eylea outsid unit state million compar million first quarter first quarter regeneron recogn million share net profit eylea sale outsid unit state repay million develop expens target date fda decis supplement bla u regulatori approv eylea treatment diabet macular edema dme august applic market approv european union japan eylea dme also submit februari compani report posit two year result phase vista dme trial treatment dme first quarter compani supplement bla u regulatori approv eylea treatment macular edema follow branch retin vein occlus brvo accept fda target date fda decis supplement bla octob februari compani initi phase trial eylea combin regn antibodi platelet deriv growth factor receptor beta pdgfr beta co formul intravitr inject treatment neovascular age relat macular degener wet amd januari compani enter licens collabor agreement bayer healthcar joint develop commerci outsid unit state regn includ combin eylea treatment ocular diseas disord may compani enter research collabor licens agreement avalanch biotechnolog inc discov develop commerci novel gene therapi product treatment ophthalmolog diseas monoclon antibodi regeneron fifteen fulli human monoclon antibodi gener use compani velocimmun technolog clinic develop includ eight collabor sanofi highlight late stage antibodi pipelin includ alirocumab compani antibodi target pcsk proprotein convertas subtilisin kexin type lower ldl cholesterol ldl c current evalu global phase odyssey program odyssey program expect enrol patient current includ clinic trial alirocumab combin lipid lower agent monotherapi trial odyssey program studi everi two week dose alirocumab except choic choic ii studi everi four week dose trial odyssey program includ choic choic ii fulli enrol except patient odyssey outcom studi data nine phase trial expect avail mid along data previous announc odyssey mono trial form basi compani initi global regulatori file five abstract alirocumab present american colleg cardiolog meet march includ first present data posit phase odyssey mono trial data one year open label treatment heterozyg famili hypercholesterolemia patient data test alirocumab milligram mg dose everi four week patient statin addit april compani sanofi report posit result first phase studi alirocumab japanes patient sarilumab compani antibodi target il r rheumatoid arthriti current continu enrol global phase saril ra program saril ra phase program consist studi expect enrol approxim adult moder sever rheumatoid arthriti achiev adequ result treatment agent data first posit phase trial saril ra program mobil present upcom medic confer dupilumab compani antibodi target il r alpha allerg diseas current phase b test first quarter posit phase data dupilumab treatment moder sever atop dermat present annual meet american academi allergi asthma immunolog aaaai compani expect phase b data dupilumab treatment atop dermat becom avail second quarter phase b trial dupilumab asthma ongo phase trial nasal polyposi addit indic dupilumab clinic develop evalu human genet initi januari compani announc launch new human genet initi via newli creat wholli own subsidiari regeneron genet center llc rgc rgc leverag de identifi clinic molecular data human volunt medic relev associ blind fashion design preserv patient privaci rgc perform sequenc genotyp gener de identifi genom data object rgc expand use human genet discov valid genet factor caus influenc rang diseas major unmet medic need prospect improv drug discoveri develop process januari compani also announc rgc geising health system one largest integr health system unit state serv approxim million resid enter research collabor focus studi genet determin human diseas aim collabor build high throughput platform discov valid genet factor caus influenc rang diseas major unmet medic need first quarter financi result product revenu net product sale million first quarter compar million first quarter eylea net product sale unit state million first quarter compar million first quarter arcalyst net product sale million first quarter compar million first quarter total revenu total revenu increas million first quarter compar million first quarter total revenu includ collabor revenu million first quarter compar million first quarter collabor revenu increas primarili due increas compani net profit commerci eylea outsid unit state higher reimburs antibodi develop cost sanofi collabor revenu first quarter also includ million sale mileston earn bayer healthcar refer tabl summari collabor revenu research develop r expens gaap r expens million first quarter compar million first quarter higher r expens first quarter princip due increas r activ primarili relat compani antibodi collabor sanofi higher r headcount higher non cash share base compens expens first quarter r relat non cash share base compens expens million compar million first quarter sell gener administr sg expens gaap sg expens million first quarter compar million first quarter increas primarili due higher expens connect contribut profit organ assist patient chronic diseas condit higher non cash compens expens first quarter sg relat non cash share base compens expens million compar million first quarter cost collabor manufactur gaap cost collabor manufactur million first quarter compar million first quarter cost collabor manufactur increas primarili due royalti payabl third parti commenc may pursuant licens settlement agreement connect sale eylea outsid unit state cost collabor manufactur also includ cost produc commerci suppli eylea bayer healthcar zaltrap sanofi incom tax expens compani current pay expect pay near futur signific cash incom tax gaap incom tax expens million first quarter compar million first quarter effect tax rate first quarter compar first quarter effect tax rate first quarter neg impact expir end feder tax credit increas research activ ii loss incur foreign jurisdict rate lower feder statutori rate iii recent enact new york state tax legisl tax legisl reduc compani new york state incom tax rate zero percent effect howev also result one time charg relat compani reduc relat defer tax asset first quarter effect tax rate first quarter includ impact american taxpay relief act enact januari retroact extend variou expir tax provis includ credit increas research activ result first quarter compani recogn benefit full year feder research tax credit non gaap net incom exclud incom tax expens non gaap gaap net incom compani report non gaap net incom million per basic share per dilut share first quarter compar non gaap net incom million per basic share per dilut share first quarter compani report gaap net incom million per basic share per dilut share first quarter compar gaap net incom million per basic share per dilut share first quarter decreas gaap net incom result primarili compani higher effect tax rate first quarter describ cash posit march cash market secur total billion compar billion decemb regeneron record net product sale eylea unit state outsid unit state eylea net product sale compris sale bayer healthcar countri japan sale santen pharmaceut japan co promot agreement japanes subsidiari bayer healthcar compani recogn share profit includ percentag sale japan eylea sale outsid unit state within bayer healthcar collabor revenu statement oper press releas use non gaap net incom non gaap net incom per share financi measur calcul accord u gener accept account principl gaap compani believ present non gaap measur use investor exclud applic non cash share base compens expens fluctuat period period base factor within compani control compani stock price date share base grant issu ii non cash interest expens relat compani convert senior note sinc deem use evalu compani oper perform iii incom tax expens sinc compani current pay expect pay near futur signific cash incom tax due primarili util net oper loss tax credit carri forward therefor gaap incom tax expens deem use evalu compani oper perform manag use non gaap measur plan budget forecast assess histor perform make financi oper decis also provid forecast investor basi howev limit use non gaap financi measur exclud certain expens recur natur furthermor compani non gaap financi measur may compar non gaap inform provid compani non gaap financi measur present regeneron consid supplement substitut measur financi perform prepar accord gaap reconcili compani gaap non gaap result includ tabl press releas confer call inform regeneron host confer call simultan webcast discuss first quarter financi oper result thursday may access call dial u intern link webcast may access event present page regeneron websit www regeneron com replay confer call webcast archiv compani websit avail day regeneron pharmaceut regeneron lead scienc base biopharmaceut compani base tarrytown new york discov invent develop manufactur commerci medicin treatment seriou medic condit regeneron commerci medicin eye diseas colorect cancer rare inflammatori condit product candid develop area high unmet medic need includ hypercholesterolemia oncolog rheumatoid arthriti asthma atop dermat addit inform compani pleas visit www regeneron com forward look statement press releas includ forward look statement involv risk uncertainti relat futur event futur perform regeneron actual event result may differ materi forward look statement word anticip expect intend plan believ seek estim variat word similar express intend identifi forward look statement although forward look statement contain identifi word statement concern risk uncertainti includ among other natur time possibl success therapeut applic regeneron product product candid research clinic program underway plan includ without limit regeneron human genet initi unforeseen safeti issu result administr product product candid patient includ seriou complic side effect connect use regeneron product candid clinic trial likelihood time possibl regulatori approv commerci launch regeneron late stage product candid new indic market product includ without limit eylea treatment diabet macular edema macular edema follow branch retin vein occlus alirocumab sarilumab dupilumab ongo regulatori oblig oversight impact regeneron research clinic program busi includ relat patient privaci determin regulatori administr government author may delay restrict regeneron abil continu develop commerci regeneron product product candid compet drug product candid may superior regeneron product product candid uncertainti market accept commerci success regeneron product product candid abil regeneron manufactur manag suppli chain multipl product product candid coverag reimburs determin third parti payer includ medicar medicaid unanticip expens cost develop produc sell product abil regeneron meet sale financi project guidanc chang assumpt underli project guidanc includ without limit relat eylea u net product sale incom tax oblig potenti licens collabor agreement includ regeneron agreement sanofi bayer healthcar cancel termin without product success risk associ third parti intellectu properti pend futur litig relat thereto complet descript materi risk found regeneron file u secur exchang commiss includ form k fiscal year end decemb form q quarterli period end march forward look statement made base manag current belief judgment reader caution reli forward look statement made regeneron regeneron undertak oblig updat publicli forward look statement includ without limit financi project guidanc whether result new inform futur event otherwis press releas financi result attach press releas includ amount consid non gaap financi measur sec rule requir regeneron provid reconcili measur contact inform manisha narasimhan ph peter dworkin investor relat corpor commun',\n",
       " 'u food drug administr fda approv ventana alk f cdx assay accur select patient elig receiv anakinas lymphoma kinas alk tyrosin kinas inhibitor treatment compar anoth commonli use immunohistochemistri ihc assay ihc assay studi publish journal thorac oncolog shown studi research sought compar wide use ihc assay lung adenocarcinoma sampl fluoresc situ hybrid fish ihc ventana alk f cdx assay optiview amplif kit standard ihc test clone perform lung adenocarcinoma next gener sequenc perform sampl inconsist result fish ihc result show fda approv ihc assay sensit specif posit predict valu neg predict valu ihc assay sensit specif posit predict valu neg predict valu find suggest high degre fals posit ihc assay next gener sequenc perform sampl fish ihc data differ next gener sequenc confirm fish data suggest low proport patient alk rearrang neg alk protein express level low percentag patient without detect alk rearrang alk protein express posit relat durvalumab plu tremelimumab activ lung cancer studi also demonstr respons rate alk inhibitor fish neg ihc analysi posit case respons rate fish posit ihc analysi neg case refer',\n",
       " 'know disappoint ever optimist hashimoto crohn realli realli feel like give go liver deal normal fine anyway start mp dx crohn summer yay tri fail asa azathioprin mp remicad methotrex humira variou diet surgeri feb subtot colectomi end ileostomi first thing put remiss year second surgeri th juli revers stoma connect ileum rectum offici flare fun never begin',\n",
       " 'hello friend mom plan go nivolumab opdivo ipilimumab yervoy near futur anyon suggest complementari care expect side effect etc anyon know good scientif studi combin probiot supplement checkpoint inhibitor best ovcadaught',\n",
       " 'thank much inform felt alon long time would like hear stori similar mine sound like alk org good start alectinib also well nice meet',\n",
       " 'even hope everyon well result recent mri new lesion show current rebif mcg last year pretti stress coupl year lose husband follow year dad diagnos bowel cancer year go pip renew stop bit rubbish go put new activ speak ms nurs think may time switch med first new lesion sinc rebif could stress caus med becom less effect nurs mention possibl chang either gilenya tysabri said mayb bit read ask around peopl experi go hospit see neurologist anyon experi either sure mani tell experi start side effect wear kind thing xx',\n",
       " 'hi five welcom grace sorri hear stepmom diagnosi post rais question may affect futur treatment decis treatment alimta effect stop alimta due progress cancer progress later shown progress keytruda grow slowli rapidli stage iv diseas usual expect evid diseas disappear although small number patient achiev statu instead tumor shrinkag stabil good result treatment even slow growth toler agent may accept want get maximum benefit treatment move anoth line therapi immunotherapi keytruda patient show benefit immedi patient deriv long last benefit treatment base said assum time therapi chang especi sinc oncologist chang treatment first sign even minor progress would help know cancer cell ever test egfr alk target genet alter approv drug tarceva xalkori well agent target mutat current test clinic trial combin immunotherapi agent also studi number convent chemotherapi agent avail need chang treatment let us know answer question rais tri provid addit inform jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'honestli way cancer patient sinc diseas like cancer uc knack come back seem go dormant seem disappear word cure touchi remiss prefer cure gone never come back demolish complet rid diseas remiss symptom diseas seemingli suspend feel accur depict uc patient get versu total end cure feel though word disservic uc commun mani us get remiss dream seem almost imposs worst day achiev remiss throw cure word around excel idea opinion know word uc life whether current symptom real realiti need mental prepar better hope best expect worst expect best trash worst educ awar realiti diseas patient statist key also cure nonsens typic spam buzzword understand aspect well year old femal diagnos decemb ulcer pancol spent decemb februari hospit treatment remicad sever liver damag stop treatment immedi prednison caus sever weight gain well swollen feet leg becom non respons valcyt kill cmv infect tacrolimu bridg biolog medic entyvio current dose',\n",
       " 'inform compil susan well courtney review jack burk md msaa chief medic offic articl summari shingl caus reactiv varicella zoster viru vzv viru caus varicella chickenpox reactiv viru caus pain rash cluster fluid fill blister postherpet neuralgia phn common complic shingl caus chronic sometim excruci pain shingl vaccin zostavax recommend use peopl year older reduc risk shingl shingl vaccin live attenu vaccin could issu member ms popul medic may modul suppress immun system could pose risk live vaccin individu ms consid shingl vaccin discuss risk benefit doctor pleas note portion articl also appear msaa articl vaccin safeti ms shingl herp zoster overview shingl caus reactiv varicella zoster viru vzv viru caus varicella chickenpox usual occur decad initi chickenpox infect reactiv viru caus pain rash cluster fluid fill blister shingl contagi blister dri viru fill fluid transmit chickenpox someon previous expos viru come close contact open rash symptom shingl includ fever headach chill upset stomach last week month even year postherpet neuralgia phn common complic shingl caus chronic sometim excruci pain area rash occur chronic debilit pain vari mild sever disrupt one sleep mood activ daili live phn reduc one qualiti life potenti lead social withdraw depress even suicid report scar anoth potenti long term complic shingl rare case shingl infect lead pneumonia hear problem blind brain inflamm enceph death peopl one episod shingl second third episod possibl older individu ms risk shingl complic great without ms individu ms take immunosuppress medic associ risk becom even greater everyon risk shingl greatli increas get older particularli age risk develop phn caus continu chronic pain complic shingl increas age likelihood experienc longer last sever pain phn addit individu compromis suppress immun system also like experi complic shingl shingl vaccin accord center diseas control prevent cdc vaccin shingl also known herp zoster zoster recommend use peopl year older reduc risk shingl includ everyon age group contraind well peopl previou episod shingl chronic medic condit specif chronic medic condit list cdc includ kidney failur diabet rheumatoid arthriti chronic pulmonari diseas shingl vaccin approv food drug administr fda market brand name zostavax shingl vaccin given one dose subcutan skin arm common side effect vaccin includ red sore swell itch shot site headach receiv vaccin individu may around infant young children pregnant women peopl weaken immun system report made someon get chickenpox anoth person receiv shingl vaccin peopl may develop chickenpox like rash near inject site occur simpli precaut rash cover disappear shingl vaccin contain thimeros preserv contain mercuri sometim use vaccin seriou advers event seen shingl vaccin test approxim peopl without ms age older vaccin appear effect least six year may last longer older individu may get vaccin age appear effect peopl year studi found shingl vaccin reduc risk shingl percent older adult reduc risk phn percent also reduc sever durat pain associ phn safeti shingl vaccin difficult judg individu ms current data support use reassur complet vaccin fulli investig ms shingl vaccin thoroughli investig ill includ patient whose immun system may compromis diseas drug use treat diseas shingl vaccin live attenu vaccin issu individu ms mani vaccin use virus inactiv e kill viru chanc infect anyon shingl vaccin contain live virus attenu mean strength reduc point infect someon healthi uncompromis immun system mani individu variou health condit larg number individu ms take medic may modul suppress immun system live viru vaccin may conceiv abl infect someon whose immun system fulli function result either ill medic given treat ill addit fda approv long term diseas modifi therapi ms larg dose extend use steroid frequent prescrib treat ms relaps also suppress immun system less common treatment consid evalu safeti shingl vaccin includ experiment treatment ms studi clinic trial ms patient label treatment methotrex imuran azathioprin hematopoiet stem cell transplant hsct antivir medic guidelin shingl vaccin safeti accord extens report advisori committe immun practic harpaz r et al differ treatment need consid shingl vaccin may consid safe individu report origin nation center immun respiratori diseas divis viral diseas part center diseas control prevent follow gener guidelin remind individu strongli advis consult physician safeti shingl vaccin doctor need look person situat case case basi individu get shingl vaccin wait includ anyon ever life threaten sever allerg reaction gelatin antibiot neomycin anoth compon shingl vaccin individu weaken immun system hiv aid diseas affect immun system someon take medic weaken immun system peopl immunosuppress therapi includ high dose corticosteroid mg per day prednison equival last two week wait least one month discontinu therapi anyon moder sever acut ill includ anyon temperatur degre fahrenheit higher usual wait recov get vaccin individu may receiv vaccin includ anyon minor acut ill cold may vaccin peopl receiv short term corticosteroid therapi less two week low moder dose less mg per day prednison equival topic given via nasal skin inhal administr long term altern day treatment low moder dose short act system corticosteroid consid suppress immun system enough caus concern vaccin safeti therapi low dose methotrex equal less mg kg week azathioprin equal less mg kg day consid suppress immun system enough caus concern vaccin safeti special group circumst peopl previous shingl may vaccin although need wait rash clear peopl normal immun system anticip immunosuppress pleas see next bullet point without prior shingl vaccin receiv vaccin soon possibl immun intact vaccin administ least day initi immunosuppress therapi although expert advis wait one month accord msaa chief medic offic jack burk md ms drug consid immunosuppress consid immunomodul affect immun system differ nonetheless recommend patient consult doctor regard cdc recommend exampl recommend gilenya fingolimod immun day start gilenya regard individu receiv recombin human immun mediat immun modul especi antitumor necrosi factor agent adalimumab infliximab etanercept safeti efficaci shingl vaccin administ concurr unknown possibl administ vaccin initi therapi patient immun statu assess physician determin relev risk benefit otherwis vaccin defer least one month stop medic categori would includ ms medic tysabri [natalizumab] well mani experiment therapi present clinic trial lemtrada [alemtuzumab formerli campath] daclizumab [also known zenapax ] rituxan [rituximab] ocrelizumab ofatumumab [also known arzerra ] individu take one drug advis talk doctor assess risk benefit shingl vaccin conjunct type diseas modifi therapi peopl receiv blood product includ antibodi contain blood product may receiv shingl vaccin time list includ intraven immun globulin ivig plasma exchang would also fall categori specifi report patient receiv type treatment advis consult physician get shingl vaccin experi individu undergo hematopoiet stem cell transplant hsct limit consid case case basi patient immun statu assess physician determin relev risk benefit shingl vaccin approv administ least two year month transplant antivir medic may interfer replic live viru vaccin anyon take zovirax acyclovir famvir famciclovir valtrex valacyclovir regularli discontinu medic least hour administr shingl vaccin possibl medic use least day vaccin addit note shingl vaccin accord cdc shingl vaccin may given simultan vaccin includ flu vaccin vaccin must administ use separ syring differ inject site vaccin administ time shingl vaccin may still given time vaccin provid inactiv vaccin receiv anoth live attenu vaccin addit shingl vaccin time patient need wait least four week shingl vaccin receiv differ live attenu vaccin shingl vaccin recommend anyon receiv varicella chickenpox vaccin howev chickenpox vaccin becom avail unit state virtual peopl receiv vaccin chickenpox young receiv shingl vaccin reason cdc state healthcar provid need inquir one varicella vaccin histori sinc virtual person recommend age group least next decad receiv chickenpox vaccin addit cdc note anyon older without contraind get vaccin regardless whether rememb chickenpox studi show percent american age chickenpox patient need ask histori chickenpox blood test antibodi insur coverag resourc follow inform provid cdc websit shingl vaccin avail pharmaci doctor offic find local facil offer vaccin pleas visit www zostavax com medicar part plan cover shingl vaccin cost share vaccin vari medicar part b cover shingl vaccin medicaid may may cover vaccin privat health insur plan cover vaccin peopl age cover peopl age merck vaccin patient assist program provid free vaccin elig adult usual individu without insur inform pleas visit www merck com merckhelp vaccin home html call vaccin inform statement avail spanish languag pleas see www immun org vi interest individu may also go cdc websit inform shingl visit http www cdc gov vaccin vpd vac shingl default htm inform vaccin ms pleas refer msaa articl vaccin safeti ms inform addit msaa websit individu may call msaa inform ms treatment question msaa client servic depart may email msquestion mymsaa org refer much inform articl obtain center diseas control cdc prevent harpaz r et al recommend advisori committe immun practic acip nation center immun respiratori diseas center diseas control prevent',\n",
       " 'today met oncologist rd trip juic bar anoth mg bag opdivo nivo two week ago right nd infus full bodi check dermatologist fast appear lesion back right hand bit panic punch biopsi mole difficult wait four day patholog came back prais lord neg evil enemi mel kinda supris base high risk patholog sure think ned primari lmph node tumor disect well suspici growth remov onc said probabl anoth pet ct scan month stay bi weekli opdivo infus month check dermatologist lymph node check everi month also seemingli much issu opdivo slug feel bit tire day mild nausea blood work look great last three pre infus check seem like long road sinc novemb deal devil mel start nice see time thing go way sinc follow forum group see new member come anxieti fear road front like want say find comfort much life road mel realli help wick month peac',\n",
       " 'husband diagnos sclc februari almost year ago coupl pretti larg tumor right lung inoper lymph node involv well began chemo treatment week diagnosi use carboplatin etoposid cycl day start second cycl also began radiat tumor treatment day straight day low dose brain radiat treatment pci last februari juli correct tether statement practic live cancer center cancer metastas liver undergon two cycl chemo along one new immunotherapi drug tecentriq liver tumor gone remain smaller tecentriq time toler fairli well found spot rib bone stop chemo continu tesentriq ad drug call zometa bone strength get scan everi month instead everi like begin decis ultim famili cours would recommend treatment famili bless still us almost year appear grim situat begin sure right hard would take cours know go say ye tell honest truth hospit time low sodium need blood transfus got sepsi top alway strong man brick mason weaker person may abl endur endur realli believ strength import type treatment side effect usual someth help though hard road go would recommend extra time get bless everi day find new immunotherapi drug help sclc despit extrem rough journey alway hope everyon respond differ could easier time husband take care best luck near md anderson facil husband would strongli recommend hope share stori help keep us updat',\n",
       " 'cochran databas syst rev apr cd treatment diseas modifi drug peopl first clinic attack suggest multipl sclerosi filippini g del giovan c clerico beiki mattoscio piazza f fredrikson tramacer scalfari salanti g author inform scientif direct fondazion ircc istituto neurologico carlo besta via celoria milan itali cochran itali depart diagnost clinic public health medicin univers modena reggio emilia via del pozzo modena itali univers turin divis neurolog aou san luigi gonzaga region gonzol orbassano torino itali depart clinic neurosci karolinska institutet stockholm sweden depart epidemiolog biostatist kermanshah univers medic scienc kermanshah iran depart medicin divis brain scienc centr neurosci wolfson neurosci laboratori imperi colleg london du cane road london uk w nn institut social prevent medicin ispm univers bern finkenhubelweg bern switzerland background treatment multipl sclerosi chang last year advent diseas modifi drug mid herald period rapid progress understand manag multipl sclerosi support magnet reson imag earli diagnosi possibl enabl treatment initi time first clinic attack diseas modifi drug associ advers event patient clinician need weigh benefit safeti variou earli treatment option take inform decis object estim benefit safeti diseas modifi drug evalu studi randomis non randomis treatment first clinic attack suggest ms compar either placebo treatment assess rel efficaci safeti diseas modifi drug accord benefit safeti estim benefit safeti diseas modifi drug evalu studi randomis non randomis treatment start first attack earli treatment compar treatment start second attack anoth later time point delay treatment search method search cochran multipl sclerosi rare diseas cn group trial regist medlin embas cinahl lilac clinicaltri gov trial registri us food drug administr fda report search unpublish studi decemb select criteria includ randomis observ studi evalu one drug monotherapi adult particip first clinic attack suggest ms consid evid alemtuzumab azathioprin cladribin daclizumab dimethyl fumar fingolimod glatiram acet immunoglobulin interferon beta b interferon beta rebif avonex laquinimod mitoxantron natalizumab ocrelizumab pegyl interferon beta rituximab teriflunomid data collect analysi two team three author independ select studi extract data primari outcom disabl worsen relaps occurr least one seriou advers event ae withdraw studi discontinu drug ae time convers clinic definit ms cdm defin poser diagnost criteria probabl discontinu treatment dropout reason record secondari outcom synthes studi data use random effect meta analys perform indirect comparison drug calcul odd ratio hazard ratio hr along rel confid interv ci outcom estim absolut effect primari outcom evalu credibl evid use grade system main result includ randomis trial eight open label extens studi ole four cohort studi publish overal risk bia high report ae scarc qualiti evid associ result rang low low earli treatment versu placebo first month follow small non signific advantag earli treatment compar placebo disabl worsen fewer fewer particip disabl worsen interferon beta rebif teriflunomid relaps fewer fewer particip relaps teriflunomid earli treatment associ fewer particip least one seriou ae fewer particip earli treatment averag time fewer like withdraw studi due ae result mostli driven studi interferon beta b glatiram acet cladribin associ significantli withdraw ae earli treatment decreas hazard convers cdm hr ci compar activ intervent first month follow indirect comparison interferon beta rebif teriflunomid show differ reduc disabl worsen ci found differ includ drug respect hazard convers cdm interferon beta rebif teriflunomid associ fewer dropout ae compar interferon beta b cladribin glatiram acet or rang substanti uncertainti earli versu delay treatment find evid differ earli delay treatment disabl worsen maximum five year follow fewer particip earli treatment fewer import variabl across intervent earli treatment interferon beta b consider reduc odd particip disabl worsen three five year follow ci ci earli treatment group fewer particip relaps fewer fewer compar late treatment maximum five year follow earli treatment decreas hazard convers cdm follow year e five year follow hr ci draw conclus long term seriou ae discontinu due ae inadequaci avail data includ ole cohort studi author conclus low qualiti evid suggest small uncertain benefit earli treatment compar placebo reduc disabl worsen relaps advantag earli treatment compar delay disabl worsen heterogen depend actual drug use base low qualiti evid low qualiti evid suggest chanc relaps [lower] earli treatment compar delay earli treatment reduc hazard convers cdm compar either placebo treatment delay treatment short long term follow low qualiti evid suggest earli treatment associ fewer particip least one seriou ae compar placebo low qualiti evid suggest compar placebo earli treatment lead withdraw treatment discontinu due ae differ drug short term benefit safeti uncertain studi indirect comparison avail long term safeti earli treatment uncertain inadequ report unavail data',\n",
       " 'hi galatea base republ ireland lucki consult alreadi patient rituximab happi tri best luck gilenya hope transit goe well',\n",
       " 'hi gina encourag evid tagrisso cross blood brain barrier fairli well although mostli anecdot evid surpris husband doctor switch irinotecan establis track record cn diseas sorri troubl toler jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'explor forum one thing clear patient symptom find cross road start biolog without certainti fact crohn short sinc flare year sever rlq pain nausea vomit diarrhea loos wateri flare resolv week steriod diet modif take lialda mainten still experi rlq pain almost daili nausea vomit eat sinc lost approx lb last colon egd scope non specif inflamm noth impress biopsi last major flare june lialda month time wbc count k ct show enter ileu small bowel possibl coliti old gi somewhat lean ibd reluct start treatment felt best get second opinion current gi fairli certain base histori ct find like crohn small bowel access scope feel best start entyvio continu symptom rlq pain low grade temp nausea vomit eat say patient stori question forum anyon els diagnos base symptom non specif lab imag even though safer biolog come risk cours expens want best famili',\n",
       " 'sorri delay respons well overal uc bad peopl seen blood present bm sort sinc first true flare back septemb octob accord gi improv saw overal entyvio first drug actual truli help count devil tictac absolut notic massiv qualiti life improv sinc go entyvio januari one main motiv get surgeri due descript ion doctor gave basic said surgeri recoveri time good drug infus essenti uc well larg intestin anymor look around notic lot peopl j pouch still uc forum page know lot peopl help other still diseas wonder tri get truli accur pictur life post op mean would someon longer larg intestin still entyvio meslamin tri ask person never respond uc truli go away surgeri one asterisk kind situat [quote]how bad diseas reach point potenti complic wors right symptom liveabl mention earlier diseas detremen other lot problem still still go feel alway fatigu screw sleep cycl lot drug prednison primari offend cusp year old graduat colleg month ago tri start profession career even hire process posit right got would year solid train graduat academi flare would devast would ultim result either resign laid ada protect given sworn posit appar doctor parent feel best surgeri done truli mean uc drug flare up etc behind good realli want surgeri see qualiti life go backward',\n",
       " 'hi vvd welcom grace sorri hear mom diagnosi type cancer often refer mucin bac great deal inform avail site search term bac tend spread beyond lung mom case bulki adren gland suspici could non cancer caus instanc bac slow grow much treatment need start immedi although mucin form bac tend grow faster regard treatment produc tumor stabil mom case good result symptom blood cough etc improv also good sign respons chemo follow scan help assess result treatment statu cancer point cancer appear grow significantli option although patient get good respons immunotherapi respond well long time would certainli option especi sinc mom cancer egfr alk neg sinc lower percentag patient respond well immunotherapi dr west also note even patient egfr neg may receiv benefit tarceva point may option addit type lung cancer though rare seen individu oncologist often dr west estim oncologist treat patient mucin bac last coupl decad experi bac [have seen] patient mucin bac past decad two http cancergrac org forum index php topic msg msg mind mom might want seek second opinion oncologist experienc mucin bac [continu next post] jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'june u fda today approv coba egfr mutat test v blood base companion diagnost cancer drug tarceva erlotinib hydrochlorid first fda approv blood base genet test detect epiderm growth factor receptor egfr gene mutat non small cell lung cancer patient mutat present approxim percent non small cell lung cancer nsclc lung cancer lead caus cancer relat death among men women u though common men number death lung cancer women increas accord nation cancer institut estim american diagnos lung cancer die diseas year nsclc common type lung cancer nsclc tumor may shed tumor dna patient blood make possibl detect specif mutat blood sampl test tumor dna use blood sampl also call liquid biopsi approv liquid biopsi test make possibl deliv highli individu health care patient said alberto gutierrez ph director offic vitro diagnost radiolog health fda center devic radiolog health liquid biopsi also potenti allow physician identifi patient whose tumor specif mutat least invas way possibl detail go http www fda gov newsev newsroom pressannounc ucm htm',\n",
       " 'consecut use gilenya lemtrada caus diseas activ ms patient case report suggest http multiplesclerosisnewstoday com high ms activ seen patient consecut use immunotherapi case report utm_sourc multipl sclerosi utm_campaign f e b rss_non us_email_campaign utm_medium email utm_term _b fb dae f e b http www ncbi nlm nih gov pubm obrigado',\n",
       " 'colon part bodi digest system digest system remov process nutrient vitamin miner carbohydr fat protein water food help pass wast materi bodi digest system made esophagu stomach small larg intestin colon larg bowel first part larg intestin feet long togeth rectum anal canal make last part larg intestin inch long anal canal end anu open larg intestin outsid bodi enlarg anatomi lower digest system show colon organ gastrointestin stromal tumor occur colon see pdq summari gastrointestin stromal tumor treatment inform see pdq summari unusu cancer childhood treatment inform colorect cancer children health histori affect risk develop colon cancer anyth increas chanc get diseas call risk factor risk factor mean get cancer risk factor mean get cancer talk doctor think may risk colorect cancer risk factor colorect cancer includ follow famili histori colon rectal cancer first degre rel parent sibl child person histori cancer colon rectum ovari person histori high risk adenoma colorect polyp centimet larger size cell look abnorm microscop inherit chang certain gene increas risk famili adenomat polyposi fap lynch syndrom hereditari nonpolyposi colorect cancer person histori chronic ulcer coliti crohn diseas year three alcohol drink per day smoke cigarett black obes older age main risk factor cancer chanc get cancer increas get older enlarg polyp colon polyp stalk other inset show photo polyp stalk sign colon cancer includ blood stool chang bowel habit sign symptom may caus colon cancer condit check doctor follow chang bowel habit blood either bright red dark stool diarrhea constip feel bowel empti way stool narrow usual frequent ga pain bloat full cramp weight loss known reason feel tire vomit test examin colon rectum use detect find diagnos colon cancer follow test procedur may use physic exam histori exam bodi check gener sign health includ check sign diseas lump anyth els seem unusu histori patient health habit past ill treatment also taken digit rectal exam exam rectum doctor nurs insert lubric glove finger rectum feel lump anyth els seem unusu fecal occult blood test fobt test check stool solid wast blood seen microscop small sampl stool place special card special contain return doctor laboratori test blood stool may sign polyp cancer condit two type fobt guaiac fobt sampl stool special card test chemic blood stool special card chang color enlarg guaiac fecal occult blood test fobt check occult hidden blood stool small sampl stool place special card return doctor laboratori test immunochem fobt liquid ad stool sampl mixtur inject machin contain antibodi detect blood stool blood stool line appear window machin test also call fecal immunochem test fit enlarg fecal immunochem test fit check occult hidden blood stool small sampl stool place special collect tube special card return doctor laboratori test barium enema seri x ray lower gastrointestin tract liquid contain barium silver white metal compound put rectum barium coat lower gastrointestin tract x ray taken procedur also call lower gi seri enlarg barium enema procedur patient lie x ray tabl barium liquid put rectum flow colon x ray taken look abnorm area sigmoidoscopi procedur look insid rectum sigmoid lower colon polyp small area bulg tissu abnorm area cancer sigmoidoscop insert rectum sigmoid colon sigmoidoscop thin tube like instrument light len view may also tool remov polyp tissu sampl check microscop sign cancer enlarg sigmoidoscopi thin light tube insert anu rectum lower part colon look abnorm area colonoscopi procedur look insid rectum colon polyp abnorm area cancer colonoscop insert rectum colon colonoscop thin tube like instrument light len view may also tool remov polyp tissu sampl check microscop sign cancer enlarg colonoscopi thin light tube insert anu rectum colon look abnorm area virtual colonoscopi procedur use seri x ray call comput tomographi make seri pictur colon comput put pictur togeth creat detail imag may show polyp anyth els seem unusu insid surfac colon test also call colonographi ct colonographi biopsi remov cell tissu view microscop pathologist check sign cancer certain factor affect prognosi chanc recoveri treatment option prognosi chanc recoveri treatment option depend follow stage cancer whether cancer inner line colon spread colon wall spread lymph node place bodi whether cancer block made hole colon whether cancer cell left surgeri whether cancer recur patient gener health prognosi also depend blood level carcinoembryon antigen cea treatment begin cea substanc blood may increas cancer present stage colon cancer key point colon cancer diagnos test done find cancer cell spread within colon part bodi three way cancer spread bodi cancer may spread began part bodi follow stage use colon cancer stage carcinoma situ stage stage ii stage iii stage iv colon cancer diagnos test done find cancer cell spread within colon part bodi process use find cancer spread within colon part bodi call stage inform gather stage process determin stage diseas import know stage order plan treatment follow test procedur may use stage process ct scan cat scan procedur make seri detail pictur area insid bodi abdomen pelvi chest taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi mri magnet reson imag procedur use magnet radio wave comput make seri detail pictur area insid colon substanc call gadolinium inject patient vein gadolinium collect around cancer cell show brighter pictur procedur also call nuclear magnet reson imag nmri pet scan positron emiss tomographi scan procedur find malign tumor cell bodi small amount radioact glucos sugar inject vein pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell chest x ray x ray organ bone insid chest x ray type energi beam go bodi onto film make pictur area insid bodi surgeri procedur remov tumor see far spread colon lymph node biopsi remov part lymph node pathologist view tissu microscop look cancer cell may done surgeri endoscop ultrasound guid fine needl aspir biopsi complet blood count cbc procedur sampl blood drawn check follow number red blood cell white blood cell platelet amount hemoglobin protein carri oxygen red blood cell portion blood sampl made red blood cell carcinoembryon antigen cea assay test measur level cea blood cea releas bloodstream cancer cell normal cell found higher normal amount sign colon cancer condit three way cancer spread bodi cancer spread tissu lymph system blood tissu cancer spread began grow nearbi area lymph system cancer spread began get lymph system cancer travel lymph vessel part bodi blood cancer spread began get blood cancer travel blood vessel part bodi cancer may spread began part bodi cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi metastat tumor type cancer primari tumor exampl colon cancer spread lung cancer cell lung actual colon cancer cell diseas metastat colon cancer lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ call metastat cancer anim show cancer cell travel place bodi first form part bodi follow stage use colon cancer stage carcinoma situ enlarg stage colon carcinoma situ abnorm cell shown mucosa colon wall stage abnorm cell found mucosa innermost layer colon wall abnorm cell may becom cancer spread nearbi normal tissu stage also call carcinoma situ stage enlarg stage colon cancer cancer spread mucosa colon wall submucosa muscl layer stage colon cancer cancer form mucosa innermost layer colon wall spread submucosa layer tissu next mucosa muscl layer colon wall stage ii enlarg stage ii colon cancer stage iia cancer spread muscl layer colon wall serosa stage iib cancer spread serosa spread nearbi organ stage iic cancer spread serosa nearbi organ stage ii colon cancer divid stage iia iib iic stage iia cancer spread muscl layer colon wall serosa outermost layer colon wall stage iib cancer spread serosa outermost layer colon wall tissu line organ abdomen viscer peritoneum stage iic cancer spread serosa outermost layer colon wall nearbi organ stage iii stage iii colon cancer divid stage iiia iiib iiic enlarg stage iiia colon cancer cancer spread mucosa colon wall submucosa may spread muscl layer spread one three nearbi lymph node tissu near lymph node cancer spread mucosa submucosa four six nearbi lymph node stage iiia cancer spread mucosa innermost layer colon wall submucosa layer tissu next mucosa muscl layer colon wall cancer spread one three nearbi lymph node cancer cell form tissu near lymph node mucosa innermost layer colon wall submucosa layer tissu next mucosa cancer spread four six nearbi lymph node enlarg stage iiib colon cancer cancer spread muscl layer colon wall serosa spread serosa nearbi organ cancer spread one three nearbi lymph node tissu near lymph node cancer spread muscl layer serosa four six nearbi lymph node cancer spread mucosa submucosa may spread muscl layer cancer spread seven nearbi lymph node stage iiib cancer spread muscl layer colon wall serosa outermost layer colon wall spread serosa tissu line organ abdomen viscer peritoneum cancer spread one three nearbi lymph node cancer cell form tissu near lymph node muscl layer serosa outermost layer colon wall cancer spread four six nearbi lymph node mucosa innermost layer colon wall submucosa layer tissu next mucosa muscl layer colon wall cancer spread seven nearbi lymph node enlarg stage iiic colon cancer cancer spread serosa colon wall nearbi organ cancer spread four six nearbi lymph node cancer spread muscl layer serosa spread serosa nearbi organ cancer spread seven nearbi lymph node cancer spread serosa nearbi organ one nearbi lymph node tissu near lymph node stage iiic cancer spread serosa outermost layer colon wall tissu line organ abdomen viscer peritoneum cancer spread four six nearbi lymph node muscl layer colon wall serosa outermost layer colon wall spread serosa tissu line organ abdomen viscer peritoneum cancer spread seven nearbi lymph node serosa outermost layer colon wall nearbi organ cancer spread one nearbi lymph node cancer cell form tissu near lymph node stage iv enlarg stage iv colon cancer cancer spread blood lymph node part bodi lung liver abdomin wall ovari stage iv colon cancer divid stage iva ivb ivc stage iva cancer spread one area organ near colon liver lung ovari distant lymph node stage ivb cancer spread one area organ near colon liver lung ovari distant lymph node stage ivc cancer spread tissu line wall abdomen may spread area organ recurr colon cancer recurr colon cancer cancer recur come back treat cancer may come back colon part bodi liver lung treatment option overview key point differ type treatment patient colon cancer seven type standard treatment use surgeri radiofrequ ablat cryosurgeri chemotherapi radiat therapi target therapi immunotherapi new type treatment test clinic trial treatment colon cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment follow test may need differ type treatment patient colon cancer differ type treatment avail patient colon cancer treatment standard current use treatment test clinic trial treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial clinic trial open patient start treatment seven type standard treatment use surgeri surgeri remov cancer oper common treatment stage colon cancer doctor may remov cancer use one follow type surgeri local excis cancer found earli stage doctor may remov without cut abdomin wall instead doctor may put tube cut tool rectum colon cut cancer call local excis cancer found polyp small bulg area tissu oper call polypectomi resect colon anastomosi cancer larger doctor perform partial colectomi remov cancer small amount healthi tissu around doctor may perform anastomosi sew healthi part colon togeth doctor also usual remov lymph node near colon examin microscop see whether contain cancer enlarg resect colon anastomosi part colon contain cancer nearbi healthi tissu remov cut end colon join resect colon colostomi doctor abl sew end colon back togeth stoma open made outsid bodi wast pass procedur call colostomi bag place around stoma collect wast sometim colostomi need lower colon heal revers doctor need remov entir lower colon howev colostomi may perman enlarg colon cancer surgeri colostomi part colon contain cancer nearbi healthi tissu remov stoma creat colostomi bag attach stoma doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiofrequ ablat radiofrequ ablat use special probe tini electrod kill cancer cell sometim probe insert directli skin local anesthesia need case probe insert incis abdomen done hospit gener anesthesia cryosurgeri cryosurgeri treatment use instrument freez destroy abnorm tissu type treatment also call cryotherapi chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi chemotherapi place directli cerebrospin fluid organ bodi caviti abdomen drug mainli affect cancer cell area region chemotherapi chemoembol hepat arteri may use treat cancer spread liver involv block hepat arteri main arteri suppli blood liver inject anticanc drug blockag liver liver arteri deliv drug throughout liver small amount drug reach part bodi blockag may temporari perman depend use block arteri liver continu receiv blood hepat portal vein carri blood stomach intestin way chemotherapi given depend type stage cancer treat see drug approv colon rectal cancer inform radiat therapi radiat therapi cancer treatment use high energi x ray type radiat kill cancer cell keep grow two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place directli near cancer way radiat therapi given depend type stage cancer treat extern radiat therapi use palli therapi reliev symptom improv qualiti life target therapi target therapi type treatment use drug substanc identifi attack specif cancer cell without harm normal cell type target therapi use treatment colon cancer includ follow monoclon antibodi monoclon antibodi made laboratori singl type immun system cell antibodi identifi substanc cancer cell normal substanc may help cancer cell grow antibodi attach substanc kill cancer cell block growth keep spread monoclon antibodi given infus may use alon carri drug toxin radioact materi directli cancer cell differ type monoclon antibodi therapi vascular endotheli growth factor vegf inhibitor therapi cancer cell make substanc call vegf caus new blood vessel form angiogenesi help cancer grow vegf inhibitor block vegf stop new blood vessel form may kill cancer cell need new blood vessel grow bevacizumab ramucirumab vegf inhibitor angiogenesi inhibitor epiderm growth factor receptor egfr inhibitor therapi egfr protein found surfac certain cell includ cancer cell epiderm growth factor attach egfr surfac cell caus cell grow divid egfr inhibitor block receptor stop epiderm growth factor attach cancer cell stop cancer cell grow divid cetuximab panitumumab egfr inhibitor angiogenesi inhibitor angiogenesi inhibitor stop growth new blood vessel tumor need grow ziv aflibercept vascular endotheli growth factor trap block enzym need growth new blood vessel tumor regorafenib use treat colorect cancer spread part bodi gotten better treatment block action certain protein includ vascular endotheli growth factor may help keep cancer cell grow may kill may also prevent growth new blood vessel tumor need grow see drug approv colon rectal cancer inform immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi pd protein surfac cell help keep bodi immun respons check pd attach anoth protein call pdl cancer cell stop cell kill cancer cell pd inhibitor attach pdl allow cell kill cancer cell pembrolizumab type immun checkpoint inhibitor enlarg immun checkpoint inhibitor checkpoint protein pd l tumor cell pd cell help keep immun respons check bind pd l pd keep cell kill tumor cell bodi left panel block bind pd l pd immun checkpoint inhibitor anti pd l anti pd allow cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv colon rectal cancer inform new type treatment test clinic trial inform clinic trial avail nci websit treatment colon cancer may caus side effect inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment clinic trial includ patient yet receiv treatment trial test treatment patient whose cancer gotten better also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found nci clinic trial search webpag clinic trial support organ found clinicaltri gov websit follow test may need test done diagnos cancer find stage cancer may repeat test repeat order see well treatment work decis whether continu chang stop treatment may base result test test continu done time time treatment end result test show condit chang cancer recur come back test sometim call follow test check up treatment option colon cancer inform treatment list see treatment option overview section stage carcinoma situ treatment stage carcinoma situ may includ follow type surgeri local excis simpl polypectomi resect anastomosi done tumor larg remov local excis use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage colon cancer treatment stage colon cancer usual includ follow resect anastomosi use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage ii colon cancer treatment stage ii colon cancer may includ follow resect anastomosi use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage iii colon cancer treatment stage iii colon cancer may includ follow resect anastomosi may follow chemotherapi clinic trial new chemotherapi regimen surgeri use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage iv recurr colon cancer treatment stage iv recurr colon cancer may includ follow local excis tumor recur resect without anastomosi surgeri remov part organ liver lung ovari cancer may recur spread treatment cancer spread liver may also includ follow chemotherapi given surgeri shrink tumor surgeri radiofrequ ablat cryosurgeri patient cannot surgeri chemoembol hepat arteri radiat therapi chemotherapi may offer patient palli therapi reliev symptom improv qualiti life chemotherapi target therapi monoclon antibodi angiogenesi inhibitor immunotherapi clinic trial chemotherapi target therapi use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail learn colon cancer inform nation cancer institut colon cancer see follow colorect cancer home page colorect cancer prevent colorect cancer screen test detect colorect cancer polyp unusu cancer childhood treatment cryosurgeri cancer treatment drug approv colon rectal cancer target cancer therapi genet test hereditari cancer syndrom gener cancer inform resourc nation cancer institut see follow cancer stage chemotherapi support peopl cancer radiat therapi support peopl cancer cope cancer question ask doctor cancer survivor caregiv pdq summari pdq physician data queri pdq nation cancer institut nci comprehens cancer inform databas pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin summari come two version health profession version detail inform written technic languag patient version written easi understand nontechn languag version cancer inform accur date version also avail spanish pdq servic nci nci part nation institut health nih nih feder govern center biomed research pdq summari base independ review medic literatur polici statement nci nih purpos summari pdq cancer inform summari current inform treatment colon cancer meant inform help patient famili caregiv give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date board made expert cancer treatment specialti relat cancer summari review regularli chang made new inform date summari updat date recent chang inform patient summari taken health profession version review regularli updat need pdq adult treatment editori board clinic trial inform clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori trial answer certain scientif question order find new better way help cancer patient treatment clinic trial inform collect effect new treatment well work clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial clinic trial open patient start treatment clinic trial list pdq found onlin nci websit inform call cancer inform servic cancer permiss use summari pdq regist trademark content pdq document use freeli text cannot identifi nci pdq cancer inform summari unless whole summari shown updat regularli howev user would allow write sentenc nci pdq cancer inform summari breast cancer prevent state risk follow way [includ excerpt summary] best way cite pdq summari pdq adult treatment editori board pdq colon cancer treatment bethesda md nation cancer institut updat mm dd yyyi avail http www cancer gov type colorect patient colon treatment pdq access mm dd yyyi [pmid ] imag summari use permiss author artist publish use pdq summari want use imag pdq summari use whole summari must get permiss owner cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim inform summari use make decis insur reimburs inform insur coverag avail cancer gov manag cancer care page contact us inform contact us receiv help cancer gov websit found contact us help page question also submit cancer gov websit e mail us',\n",
       " 'hello fellow ms er hope everyon happi well quick question anyon take co codamol allevi pain top medic take gabapentin pregabalin omeprazol citalopram betahistin dihydrochlorid gilenya baclofen answer respons keep em clean much appreci fluffyolli xx',\n",
       " 'took stop usual peopl take stop matter long develop antibodi mean tri infus bodi reject like allerg reaction viru could get pretti sick think ye almost alway elev bodi make ton extra antibodi hang bloodstream patrol infliximab view foreign invad humira probabl fine probabl remicad thing besought lord thrice depart said grace suffici thee strength made perfect weak gladli therefor rather glori infirm take pleasur infirm reproach necess persecut distress weak strong cor',\n",
       " 'marlon_dagg ye pleas keep us updat ocrevu treatment mini diari speak benefit challeng etc',\n",
       " 'dear janin thank much link prompt respons town visitor see mom sorri acknowledg repli earlier go link hope discuss result mom onc next week mom chemo appoint keep updat thank much bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test neg stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr start alimta alimta sinc usual ned chemo period less month month recent occurr jan alimta jan thru april ned april occurr cancer jan start alimta test posit ro june appt onc discuss futur tx plan',\n",
       " 'result phase studi pembrolizumab chemotherapi pemetrex platinum base drug found combin result significantli longer overal surviv os progress free surviv pf compar chemotherapi alon reduc risk death patient metastat nonsquam non small cell lung cancer nsclc data present american associ cancer research confirm earlier phase studi find lead author leena gandhi md new york univers perlmutt cancer center nyu langon health new yok said data unequivoc alter clinician treat type nsclc studi first line therapi advanc nsclc lack target mutat egfr alk platinum base chemotherapi patient tumor proport score program death ligand pd l greater pembrolizumab replac cytotox chemotherapi dr gandhi also author phase studi said small number trial meant daili practic pattern chang number small make definit conclus patient phase studi howev estim rate os month pembrolizumab chemotherapi group compar placebo chemotherapi group median pf month pembrolizumab chemotherapi group month placebo chemotherapi group median os yet reach pembrolizumab chemotherapi group rate advers event almost ident two arm similar advers event grade higher relat articl immunotherapi lung cancer combin regimen path forward time report palli care need lead appropri end life care nsclc osimertinib improv qualiti life global health statu non small cell lung cancer result incred clear cut dr gandhi said earli look clear differ question result studi noth wait alter treatment regimen pd pd l inhibitor chemotherapi mount evid suggest pd pd l inhibitor effect treatment nsclc said instanc data present confer nivolumab ipilimumab advanc nsclc checkmat clinicaltri gov identifi nct found combin significantli prolong pf compar platinum doublet chemotherapi alon keynot studi clinicaltri gov identifi nct allow crossov pembrolizumab monotherapi patient demonstr diseas progress benefit combin shown patient level pd l express even pd l tumor proport score less dr gandhi said although greatest respons rate group differ found patient tumor proport score greater pembrolizumab combin group vs placebo combin group',\n",
       " 'would rituximab trial show profg other put trial cd target antibodi produc plasma cell best choic cd option cd may better extens data say ocrelizumab still work still worsen show time brain clearli relaps trial extens studi two year lost time placebo interferon caught cant think better exampl say dump crab',\n",
       " 'fyi read long articl includ research data method etc often skip lot middl part least first read conclus discuss clinic research discuss implic patient use often break taken induct therapi carbo taxol ava person watch close ct scan physic check onc everi week progress start caught earli enough treat chanc recoveri platinum base chemo toxic chemo good option peopl want need break recov go vacat sit couch without feel sick hand oncologist comfort break continu treatment may discuss fine recent research show anyon pdl express benefit checkpoint inhibitor immunotherapi pembrolizamub pembro shown longer last efficaci cytotox agent aka chemo health system requir use chemo progress allow use immunotherapi alimta alon much much common avaistin alon mani peopl use alimta avaitin data ecog trial matur know best keep us post best luck janin repli modifi month ago catdand forum moder repli modifi month ago catdand forum moder',\n",
       " 'go still give humira time decid go surgeri rout valli said abl j pouch boyfriend still want feel sexi around say thing matter creat pouch life like afterward mani uc patient candid j pouch know absolut sure colectomi colectomi want sure crohn diseas look larg intestin greater detail remov ensur truli uc case crohn patient elig j pouch long odd crohn want sure possibl moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa u c unimagin crapnado post edit ipoop gmt',\n",
       " 'sure avastin much differ lucenti eylea basic avastin come larger phial suitabl cancer treatment instead small one eye treatment manufactur drug far refus produc smaller amount suitabl eye treatment mean anoth compani transfer drug smaller phial may increas risk contamin thu infect fact actual happen avastin use lucenti eylea develop also heard patient treatment chang avastin one drug longer work mention tv mani million nh safe head',\n",
       " 'repli post lvkiefer coliti crohn remicad entyvio neither seem work tri imuran made deathli ill medicin react badli consid allerg caus vomit diarhea simultan kind like bad symptom crohn coliti amp folk done great one',\n",
       " 'hello femal live netherland diagnos june bilater internuclear ophthalmoplegia migran nausea sensori symptom mri show non enhanc brain lesion one brainstem lumbar punctur reveal presenc oligoclon band ino resolv still mild sensori symptom fatigu month followup mri end aug show chang lesion load volum start mg copaxon end septemb question nr dr recommend mri month copaxon start also mayb rebaselin month copaxon start right reach therapeut level lesion found month know whether creat cop start work question would good candid cladribin alemtuzumab question also vit defici would good supplement dose dr recommend iu day bit low vit benefici impact diseas thank beforehand repli best regard mp',\n",
       " 'lialda effect mild crohn studi show much effect placebo think appli mod sever cd pretti effect uc worth shot person never success cd gastroparesi fibro arthriti gerd med remicad thing besought lord thrice depart said grace suffici thee strength made perfect weak gladli therefor rather glori infirm take pleasur infirm reproach necess persecut distress weak strong cor',\n",
       " 'zyklon wrote wed feb point patient b jc viru level high doctor suggest stop limit choic time either continu drug high risk go drug free patient start ocrevu low pml risk forget risk immun reconstitut inflammatori syndrom iri case prove fatal lethal multipl sclerosi relaps natalizumab withdraw http n neurolog org content long natalizumab dramat reduc relaps patient activ multipl sclerosi ms may induc progress multifoc leukoencephalopathi pml rebound ms immun reconstitut inflammatori syndrom iri describ natalizumab withdraw even absenc pml data concern potenti sever neuropatholog event avail report case year old patient ms develop fulmin relaps month stop natalizumab lead death despit intens care immunosuppress therapi radiolog neuropatholog find provid interest data regard natur rebound man death provid interest data scienc comfort',\n",
       " 'ms specialist say ocrelizumab avail juli',\n",
       " 'stop take gilenya take year bad rebound effect month moment start relaps everi month ms becam agress rememb everi case differ take care good luck',\n",
       " 'hi dad diagnos stage iv nsclc bone metastasi sept start take irressa nov feb progress iressa enter azd trial current nd egfr inhibitor azd work well stabl close two year sinc start take azd amaz also wor eventu progress azd explor option understand immunotherpi drug effect egfr mutat patient also singl agent like keytruda combin agent wonder option current avail right mani thank fischer',\n",
       " 'hi christina suggest speak macular societi tel email contact websit thought csr wetmd separ condit although like brvo caus damag problem macular know treatment eg brvo give steroid implant wetmd suffer benefit suppos possibl incred unlucki develop two separ condit mayb one eventu trigger csr ten year treatment sound odd know anyth stress make wors lot dr seem know respond differ often clear path lucenti specif formul eye like eyelea unlik avastin although expens gener prefer whole bodi perspect also load dose proper inj check inj often got central blurri day would go blurri would come later oedema return worsen person lucenti known treatment csr sight worsen notic would give go peopl may person experi share use suspect best wish go forward x',\n",
       " 'hi tamara facebook either tri anoth stori tagrisso target therapi taken oral everyday egfr mutant effect drug also fast act peopl get pain relief within day outcom data date excel common side effect fatigu constip edema friend would benefit oz organ beet juic yuck work keep liver happi constip check petra sol c citru fiber lot crucifer veggi thank check michel yesterday pm repli swollen lymph node worri rower michel repli tomm topic nsclc group hi tom thank check sit airport watch plane get de ice kci head fla forget cancer first trip sinc diagnosi beach instead acupunctur get ct result next week take page bob book news good news glad hear treatment gone well far saw articl post anoth forum cbd contraind immunotherapi publish studi find link phone thought might want potenti explor airpark express bu driver morn name ned hope sign pray anoth great outcom let hippi protocol roll michel',\n",
       " 'hi diagnos rrm th bday ugh one year ago gilenya almost constant headach month read line peopl ms get headach neurologist seem care headach feel like brain actual hurt go pick someth fast horribl much anxieti ridicul worri day work headach get bad alway form headach know ms someth els truli exhaust pretend ok go home work sleep everi day guess part life tri stay posit lot life happi scare futur hold thank support pam',\n",
       " 'ms probabl start updat current health statu sort page regard current state ms whole oscillopsia nystagmu vertigo vision thing remain number one terribl symptom everi singl day cours day much wors other symptom becom part baselin impress alway go symptom life definit learn better live realli make less miser debilit although dizzi vision thing sort becom part new normal main symptom might actual hear complain often fatigu heavi sinc begin relaps realli impact life pretti neg way realli think never sit deep depress vision noth feel steadi alway almost alway feel complet defeat sever fatigu never want anyth sit stare wall alway exhaust everyth even brush teeth stuff would consid fun requir mental battl decid fact muster energi move even medic like nuvigil armodafinil ritalin methylphenid ms first got colorado coupl month ago want tri see gener physician possibl someth els ms contribut abund level fatigu hemochromatosi run famili mayb check anemia mani possibl symptom associ thing alreadi caus ms whole time develop health condit total mask ms like everyon ever saw assum new occurr symptom ms thing never get test someth actual hope result would come back posit mean yeah posit would mean someth ms life treat meant get tri someth ms warrant tri past could ticket relief new neurologist well saw physician assist ran lab check stuff neg hemochromatosi anemia idea vitamin b look fine damn point refer neurologist one want touch learn ms want mess risk su sent neurologist someth like right probabl reason sometim feel ever seem get opinion anyon neurologist cours alway go see noth ms yeah admit realli motiv call make appoint run low nuvigil neurologist offic back california return call messag call pharmaci regard refil went ahead made appoint appoint today prepar whole find new doctor game plagu mani peopl live chronic ill know game talk set appoint get appoint realiz doctor complet quack want hear anyth suggest actual spent even littl time educ diseas make inform decis regard treatment find anoth new doctor start whole process game well surpris noth like actual pretti awesom went histori refil prescript wrote new one set ampyra abl get ahold like year sent referr mri brain cervic spine talk littl ocrevu ocrelizumab even brought latest ms research topic learn latest ectrim european committe treatment research multipl sclerosi noth like expect worri would see neurologist graduat realli know anyth ms whatev whole paragraph introduct function anatomi brain textbook dedic ms thing rememb spent year medic school read book actual total qualifi ms specialist expert hmmm sound like issu newli graduat doctor think step god nope think anyway simpl fact even knew ectrim gave level comfort usual take coupl year build medic profession pretti happi',\n",
       " 'marion look tri get mother prescrib keytruda label seem pulmonari embol disqualifi everi trial look go next anyon interest look like ucsf keytruda trial specif cholangiocarcinoma patient enrol http clinicaltri gov ct show nct bostonguy know pleural effus increas result ag breath improv soon go trial pulmonari embol though right might side effect cancer thank info wish best mom',\n",
       " 'wife lumbar punctur posit leptomengen metatsi nsclc alk posit began new alectinib therapi seen mark improv day memori balanc gait along posit weight gain drug alectinib much easier toler crizotinib ceritinib hope smoother day awhil mani studi us point anyon know prognosi alectinib long efficaci pertain central nervou system pleas let know',\n",
       " 'hi sharon about au cq thought let know time frame jc test given max come back week month may depend live tysabri year june jc ocrevu would also first choic son expectantli wait becom avail happen insid year ty next best moment feel quit flu ish hr ty lot spoken experi noth one patient know call gogo juic week post diagnosi flare symptom lead diagnosi eas hope well keep us post carolin',\n",
       " 'eylea indic treatment neovascular wet age relat macular degener amd macular edema follow retin vein occlus rvo diabet macular edema dme diabet retinopathi dr patient dme eylea dosag administr import inject instruct ophthalm intravitr inject eylea must administ qualifi physician micron steril filter needl gaug inch ml luer lock syring gaug inch steril inject needl need eylea avail packag follow vial kit inject compon filter needl syring inject needl [ see suppli ] neovascular wet age relat macular degener amd recommend dose eylea mg ml microlit administ intravitr inject everi week approxim everi day monthli first week month follow mg ml via intravitr inject everi week month although eylea may dose frequent mg everi week approxim everi day monthli addit efficaci demonstr patient eylea dose everi week compar everi week [ see clinic studi ] patient may need everi week monthli dose first week month although effect recommend everi week dose regimen patient may also treat one dose everi week one year effect therapi patient assess regularli macular edema follow retin vein occlus rvo recommend dose eylea mg ml microlit administ intravitr inject everi week approxim everi day monthli [ see clinic studi ] diabet macular edema dme recommend dose eylea mg ml microlit administ intravitr inject everi week approxim everi day monthli first inject follow mg ml via intravitr inject everi week month although eylea may dose frequent mg everi week approxim everi day monthli addit efficaci demonstr patient eylea dose everi week compar everi week [ see clinic studi ] patient may need everi week monthli dose first week month diabet retinopathi dr patient dme recommend dose eylea mg ml microlit administ intravitr inject everi week approxim everi day monthli first inject follow mg ml via intravitr inject everi week month although eylea may dose frequent mg everi week approxim everi day monthli addit efficaci demonstr patient eylea dose everi week compar everi week [ see clinic studi ] patient may need everi week monthli dose first week month prepar administr eylea inspect visual prior administr particul cloudi discolor visibl vial must use glass vial singl use eylea avail packag follow vial kit inject compon filter needl syring inject needl [ see suppli ] use asept techniqu carri follow prepar step prepar intravitr inject follow medic devic singl use micron steril filter needl gaug inch ml steril luer lock syring mark measur ml steril inject needl gaug inch remov protect plastic cap vial see figur clean top vial alcohol wipe see figur remov gaug inch micron filter needl ml syring packag attach filter needl syring twist onto luer lock syring tip see figur push filter needl center vial stopper needl complet insert vial tip touch bottom bottom edg vial use asept techniqu withdraw eylea vial content syring keep vial upright posit slightli inclin eas complet withdraw deter introduct air ensur bevel filter needl submerg liquid continu tilt vial withdraw keep bevel filter needl submerg liquid see figur b ensur plunger rod drawn suffici back empti vial order complet empti filter needl remov filter needl syring properli dispos filter needl note filter needl use intravitr inject remov gaug inch inject needl packag attach inject needl syring firmli twist inject needl onto luer lock syring tip see figur readi administ eylea remov plastic needl shield needl hold syring needl point check syring bubbl bubbl gentli tap syring finger bubbl rise top see figur elimin bubbl expel excess drug slowli depress plunger plunger tip align line mark ml syring see figur b inject procedur intravitr inject procedur carri control asept condit includ surgic hand disinfect use steril glove steril drape steril eyelid speculum equival adequ anesthesia topic broad spectrum microbicid given prior inject immedi follow intravitr inject patient monitor elev intraocular pressur appropri monitor may consist check perfus optic nerv head tonometri requir steril paracentesi needl avail follow intravitr inject patient instruct report symptom suggest endophthalm retin detach e g eye pain red eye photophobia blur vision without delay [ see patient counsel inform ] vial use treatment singl eye contralater eye requir treatment new vial use steril field syring glove drape eyelid speculum filter inject needl chang eylea administ eye inject unus product must discard dosag form strength inject mg ml clear colorless pale yellow solut singl dose glass vial intravitr inject contraind ocular periocular infect eylea contraind patient ocular periocular infect activ intraocular inflamm eylea contraind patient activ intraocular inflamm hypersensit eylea contraind patient known hypersensit aflibercept excipi eylea hypersensit reaction may manifest rash pruritu urticaria sever anaphylact anaphylactoid reaction sever intraocular inflamm warn precaut endophthalm retin detach intravitr inject includ eylea associ endophthalm retin detach [ see advers reaction ] proper asept inject techniqu must alway use administ eylea patient instruct report symptom suggest endophthalm retin detach without delay manag appropri [ see dosag administr patient counsel inform ] increas intraocular pressur acut increas intraocular pressur seen within minut intravitr inject includ eylea [ see advers reaction ] sustain increas intraocular pressur also report repeat intravitr dose vascular endotheli growth factor vegf inhibitor intraocular pressur perfus optic nerv head monitor manag appropri [ see dosag administr ] thromboembol event potenti risk arteri thromboembol event ate follow intravitr use vegf inhibitor includ eylea ate defin nonfat stroke nonfat myocardi infarct vascular death includ death unknown caus incid report thromboembol event wet amd studi first year combin group patient treat eylea compar patient treat ranibizumab week incid eylea group compar ranibizumab group incid dme studi baselin week combin group patient treat eylea compar control group baselin week incid combin group patient treat eylea compar control group report thromboembol event patient treat eylea first six month rvo studi advers reaction follow potenti seriou advers reaction describ elsewher label',\n",
       " 'revscott stomach upset recognis side effect tuvigin gilenya howev tuvigin gilenya immuno suppress would leav expos run mill bug may harder shift',\n",
       " 'week prednison snack werewolf perfect descript crave like ever even get period want beef potato chocol specif peanut ms gain lb recent lost intent prior diagnos uc sort vigor exercis help combat go shake everyth make run toilet also moon face sure order new glass week ago fit fine pick look small face know go away ugh hope humira start today let ditch prednison soon left side coliti dx current mg prednison mg humira bi weekli saccharomyc boulardii x day wheat gluten free g lialda month caus migrain stop work budesonid mg week noth',\n",
       " 'laser time help lot pain faith levothyroxin mcg dicyclomin mg need clonazepam lamict duave two year humira two year simponi wait start entyvio need tb med least mont second load dose entyvio still entyvio isoniazid mg latent tb finish one year isoniazid latent tb yeah',\n",
       " 'upal basu roy mph phd director translat research program director patient forc lungev septemb end bang th world confer lung cancer host toronto summer unoffici end new york u food drug administr approv anoth drug dacomitinib lung cancer sure miss thing year world confer lung cancer world lung fondli refer biggest world lung ever conven deleg countri attend importantli meet showcas number practic chang scientif present mani list therefor go tri categor theme chang horizon practic chang scienc pertin entir patient journey screen treatment present may awar lung cancer screen use low dose comput tomographi ldct avail us individu high risk develop lung cancer howev case europ part world result nelson trial europ disclos meet soon chang trial set determin benefit ldct lung cancer screen enrol patient clearli demonstr benefit ct screen men high risk lung cancer benefit even pronounc women studi reinforc popul level benefit ldct also lay groundwork addit studi look gender differ lung cancer term lung cancer therapi excit news alk posit lung cancer clinic trial brigatinib alk inhibitor current approv patient progress crizotinib show drug work realli well first line set even patient brain metastas soon alk posit lung cancer patient may new first line treatment option lungev scientif advisori board member dr scott antonia present updat result pacif trial test immunotherapi chemotherapi radiat chemoradi stage iii non small lung cancer patient nsclc new result show ad checkpoint inhibitor durvalumab chemoradi provid clear surviv benefit stage iii nsclc patient big news given stage iii patient uniqu subset nsclc patient treatment option last least small cell lung cancer sclc may score big win result impow clinic trial show addit immunotherapi drug atezolizumab standard chemotherapi regimen sclc benefici standard care sclc chemotherapi past year inde big deal collabor key chang cours chang possibl without collabor lung cancer complex diseas requir multipl stakehold tabl come solut biggest impact collabor highlight oncogen driven patient group ro der alk posit egfresist ret renegad exon mutat group apart provid support patient caregiv increas awar diseas patient group acceler research rais fund research help patient enrol oncogen specif clinic trial provid tissu biospecimen creat new mous model studi uniqu subtyp lung cancer lungev scientif advisori board member dr david carbon point plenari talk scienc matter first step develop effect therapi robust basic scienc develop mous model studi uniqu subtyp lung cancer first phase test new drug creation new therapi treatment paradigm scientif commun also hard work creat new drug subset lung cancer hard treat one subset lung cancer mutat exon egfr gene mutat respond standard egfr tyrosin kinas inhibitor work scientif advisori board member dr john heymach show drug poziotinib may use rare subtyp lung cancer addit scientist creat new drug entrectinib ropotrectinib ro posit lung cancer drug show promis patient previous treat crizotinib never receiv ro inhibitor think lungev scientif advisori board member dr juli brahmer plenari present quot patient left behind commun strive left year world lung feel certain take step direct dr basu roy lungev director translat research program director patient forc categori clinic trial research person medicin research',\n",
       " 'hello everyon hope great day year old male diagnos ms year ago avoid take medic afraid side effect problem minor problem reli steroid right optic neuriti blind spot eye worst activ like work lower eye blind steroid help neru ophthalmologist told steroid help time forgot exactli took mri exam find caus know caus ms optic neuriti week ago start ms medic call gilenya vision still goe bad worri sinc happen chanc stop vision remain perfect',\n",
       " 'bad sometim deadli allerg reaction happen docetaxel inject non alcohol formula take docetaxel inject non alcohol formula ever allerg reaction docetaxel inject non alcohol formula drug polysorb risk death may rare happen docetaxel inject non alcohol formula rais peopl liver problem peopl get high dose drug risk also rais peopl certain type lung cancer treat platinum base chemo drug past medicin must given peopl high bilirubin level liver problem rais liver enzym health problem question talk doctor medicin may caus swell keep fluid bodi tell doctor swell weight gain troubl breath medicin may lower abil bone marrow make blood cell bodi need lead need blood transfus bad sometim deadli bleed problem infect tell doctor right away sign infect like fever chill sore throat bruis bleed feel tire weak medicin must given peopl low white blood cell count talk doctor blood work check told doctor talk doctor use docetaxel inject see also kisqali use treat cancer need tell doctor take docetaxel inject allergi docetaxel part docetaxel inject non alcohol formula allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign liver diseas rais liver enzym low white blood cell count take drug atazanavir clarithromycin indinavir itraconazol ketoconazol nefazodon nelfinavir ritonavir saquinavir telithromycin take voriconazol breast feed plan breast feed list drug health problem interact docetaxel inject non alcohol formula tell doctor pharmacist drug prescript otc natur product vitamin health problem must check make sure safe take docetaxel inject non alcohol formula drug health problem start stop chang dose drug without check doctor thing need know take docetaxel inject tell health care provid take docetaxel inject non alcohol formula includ doctor nurs pharmacist dentist avoid drive task action call alert clear eyesight see docetaxel inject non alcohol formula affect may chanc get infect wash hand often stay away peopl infect cold flu may bleed easili care avoid injuri use soft toothbrush electr razor upset stomach throw loos stool diarrhea hungri talk doctor may way lower side effect doctor may start drug help swell talk doctor get vaccin use docetaxel inject non alcohol formula may either rais chanc infect make vaccin work well rare bone marrow problem call myelodysplast syndrom md happen patient treat docetaxel inject non alcohol formula type leukemia also rare happen question talk doctor hair loss common docetaxel inject non alcohol formula time normal hair growth come back sometim hair growth gone back normal talk doctor peopl felt tire weak docetaxel inject non alcohol formula may last day sever week call doctor sign bad caus problem daili live go away rare lung problem happen docetaxel inject non alcohol formula call doctor right away sign lung breath problem like short breath troubl breath cough fever medicin caus sever bowel problem neutropen enterocol problem deadli sometim earli first day sign happen call doctor right away stomach pain without fever tender stomach diarrhea older use docetaxel inject non alcohol formula care could side effect medicin may caus harm unborn babi take pregnant use birth control trust prevent pregnanc take docetaxel inject non alcohol formula pregnant get pregnant take docetaxel inject non alcohol formula call doctor right away medicin docetaxel inject best taken use docetaxel inject non alcohol formula order doctor read inform given follow instruct close given infus vein period time steroid drug like dexamethason given docetaxel inject non alcohol formula lower side effect talk doctor tell doctor steroid drug use doctor told miss dose call doctor find see also dosag inform detail side effect need call doctor right away warn caution even though may rare peopl may bad sometim deadli side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign infect like fever chill bad sore throat ear sinu pain cough sputum chang color sputum pain pass urin mouth sore wound heal sign bleed like throw blood throw look like coffe ground cough blood blood urin black red tarri stool bleed gum vagin bleed normal bruis without reason get bigger bleed bad cannot stop sign liver problem like dark urin feel tire hungri upset stomach stomach pain light color stool throw yellow skin eye dizzi pass fast heartbeat heartbeat feel normal burn numb tingl feel normal bad headach chang hear muscl pain weak skin reaction medicin may caus tissu damag drug leak vein tell nurs red burn pain swell blister skin sore leak fluid drug go bodi medicin may caus certain eye problem call cystoid macular edema cme may need eye exam use docetaxel inject non alcohol formula call doctor right away chang eyesight like blur eyesight loss eyesight side effect docetaxel inject drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away upset stomach throw mouth irrit mouth sore feel tire weak hair loss chang nail dri skin chang tast chang sens smell constip hungri joint pain flush eye red tear weight loss heartburn side effect may occur question side effect call doctor call doctor medic advic side effect may report side effect fda fda may also report side effect http www fda gov medwatch see also side effect detail overdos suspect think overdos call poison control center get medic care right away readi tell show taken much happen store throw docetaxel inject need store docetaxel inject non alcohol formula home talk doctor nurs pharmacist store consum inform use symptom health problem get better becom wors call doctor share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin keep drug safe place keep drug reach children pet throw away unus expir drug flush toilet pour drain unless told check pharmacist question best way throw drug may drug take back program area drug may anoth patient inform leaflet check pharmacist question docetaxel inject non alcohol formula pleas talk doctor nurs pharmacist health care provid think overdos call poison control center get medic care right away readi tell show taken much happen',\n",
       " 'hello mom whole brain radiat multipl met brain lung cancer egfr exon neg end two month ago start tagrisso first line therapi due evid leptomening diseas unfortun develop symptom suggest interstiti lung diseas tagrisso respond well drug brain lung six week question sinc drug long progess diseas develop brain thank',\n",
       " 'david want tri sway one way regard continu keytruda want let know common first dose keytruda see swell look like growth cancer mom current experienc although symptom swell growth ct show thicken around area tumor backsid trachea pulmonologist scope trachea took biopsi report see swell scar tissu much els biopsi came back neg cancer point assum coupl thing may swell due immun system attack area could also mass cell bunch attack tumor may cancer cell area biopsi get mom finish th keytruda treatment keytruda chemo keytruda ct thicken th treatment cell pd l mutat whatev decid wish best look like quit journey take care steff',\n",
       " 'danield got carboplatin alimta avastin tumor shrank half stay stabl went mainten avastin stop chemic treatment tumor made ground gain matter week sick chemotherapi first week everi three week',\n",
       " 'jay hancock kaiser health news nov sherees hickson multipl sclerosi flare spasm leg symptom get wors could still walk take care son six year doctor diagnos diseas attack central nervou system earlier symptom slur speech vision problem resolv treatment other linger tire sometim still fell summer doctor switch ocrevu drug approv delay progress diseas clinic trial better older medicin genentech south san francisco base subsidiari swiss pharma giant roch make ocrevu one sever drug multipl sclerosi deliv intraven hospit clinic medicin becom increasingli expens group price mani case well year hospit deliv drug often take cut upcharg drug ad hefti fee infus clinic hickson receiv first two ocrevu infus outpati two week apart juli august bill came patient sherees hickson singl mother work health aid train medic coder live girard ohio ms left disabl work medicar also medicaid backup total bill two ocrevu infus taken outpati caresourc hickson medicar manag care plan paid discount hickson got bill balanc calcul share hospit insur reimburs continu read',\n",
       " 'opdivo side effect',\n",
       " 'hello ask commun anybodi expereinc tarceva overcom problem mother year old diagnos nsclc egfr mutat prescib tarceva mg june sever rash itch swallow joint pain went away month month treatment start develop nausea lack appetit say realli lack appetit sinc alway hungri want eat lost tast everi food bodi regist food tri consum includ water juic milk eat anyth due hunger becam weak doctor stop medic two week start gain back abil eat put mg take day develop symptom doctor suggest take tarceva month also antibiot day h pylori time regain abil eat start enjoy food eat month anyway doctor reduc drug mg day start take day ago see symptom cannot take food sight food make nauseat cannot eat tri sever nausea medicin none realli help anybodi kind problem tarceva way feel like die cancer die hunger confus sure pleas let know anybodi kind expereinc tarceva',\n",
       " 'start gilenya mid februari think experienc side effect know everyon differ think sever peopl post say felt bad start drug tri put gilenya search box',\n",
       " 'suspect md mean multipl use case ocrelizumab think ocrelizumab may becom standard treatment ms treatment two infus year effect good risk profil',\n",
       " 'mari take moment analyz worst case scenario ms tumor stroke good news less bad also consid nervou breakdown first exacerb trust judgement slow move diseas cours found earli enough respond correctli first breath pamper small way live one day time philosophi obsess make today good got time next appoint pass take opportun nice thing becom offici recogn ms pick fight yet pick someth start swing om perfect often time enough may want explor mani pharmaceut option peopl year ago found aubagio agreeabl middl hsct see thread would use ocrelizumab option keep head fight like mofo faith optim creat physiolog feedback loop heal good luck mar',\n",
       " 'multipl sclerosi trust announc nice approv ocrevu rrm certain restrict',\n",
       " 'ikhlaq ye alectinib proven effect brain mani peopl alectinib effect rest bodi sinc leptomening diseas lepto cancer line brain difficult treat alectinib would lead choic treatment sinc new treatment mani oncologist still want use radiat area caus symptom brother symptom brain met outsid line stereotact radiat may still option move alectinib new drug without much research direct lepto alk patient oncologist may info may need introduc idea excel exampl partner one treatment busi medic oncologist treat mani type cancer may know new practic promis written standard practic flow chart follow quot along articl nation institut health may help talk brother onc addit alectinib report activ alk nsclc patient leptomening diseas http www ncbi nlm nih gov pmc articl pmc case awar new confer video target therapi lung cancer patient forum held cleveland oh coupl week ago http cancergrac org lung target therapi lung cancer patient forum present handout keep us post best luck brother janin',\n",
       " 'hello mani time start post sure ask today full stori upon father diagnosi nsclc rib hip back brain liver kidney metastasi began chemo treatment radiat brain rib first respons within two month chemo almost back normal self put weight oxygen even back volunt air forc base full hope chemo stop work oncologist put immunotherapi tecentriq soon start treatment lost appetit weight becam weak slept lot seem like side effect treatment howev day ago new scan confirm treatment work tumor grow multipli oncologist said next cours treatment would radiat new tumor brain start new chemo immuno combo treatment unfortun day later home nurs worri contract pneumonia call paramed take hospit hospit doctor said kick pneumonia increas becam weaker sit get bed lot pain doctor said probabl coupl month recommend hospic contact oncologist confirm hospic patient best cours action trust knew best decid today make move hope would take best care get home let hospic feel made wrong choic know give right live amsterdam stay mom dayton oh care father thought best know provid enough need full time care know go',\n",
       " 'get feel rel great last six week week start plaquenil two week last remicad ach went away felt like thing manag noth seem bring back ach lack sleep stress food thought solut wake today day anoth dose remicad feel like total junk everyth oppress sore sick ach get noth differ top plan see rheumi thursday blood work result sinc talk phone wait week realli need discuss issu major snow storm come morn offic hour away first appoint call today reschedul basic told allow reschedul refus even tell next appoint offic like cancel two day notic thank listen guess low toler thing feel crappi',\n",
       " 'first time sinc diagnosi includ pharmaceut inform event initi rather apprehens found silli attend one close proxim glean good bit inform present also made import ms warrior contact even plan travel morgantown order hear posit effect lemtrada ms infus unfamiliar never consid infus part diseas treatment friend told anoth newer drug read major news paper ocrevu event pop somewher close consid attend lectur well recent doctor visit explain three medic treatment multipl sclerosi infus highest list time make sens evid expens time invas method requir entir day complet infus least happen twice year inject least effect new excit oral drug second infus supposedli bomb origin drug choic beta seron practic dinosaur world ms combat actual find rather excit mean ms research medic investig definit progress option explor daili basi give hope mysteri solv sooner later occur make work though drug compani need help weed best worst ye comrad mean human guinea pig agre go trial test result final result along way usual fairli game jump experi point realli anyth lose end goal around long possibl son senior high school next year colleg attend career explor driver licens interest acquir pretti much save life begin horribl medic journey owe best hang around long possibl big pharm event help learn better life decis even though realli relish idea infus treatment need learn job ms advoc learn easi get excit learn process equal disturb learn realiti said quest tri sad sack need share warn label drug hear tonight warn warrior super hero super hero boldli go man gone allow follow word frighten shake dive research seriou infus reaction lemtrada caus seriou infus reaction may caus death seriou infus reaction may happen receiv hour longer receiv lemtrada receiv infus healthcar facil equip staff train manag infus reaction includ seriou allerg reaction urgent heart breath problem watch receiv hour longer receiv lemtrada seriou infus reaction happen receiv lemtrada infus may stop tell healthcar provid right away follow symptom seriou infus reaction infus left healthcar facil swell mouth throat troubl breath weak fast slow irregular heartbeat chest pain rash lower chanc get seriou infus reaction healthcar provid give medicin call corticosteroid first infus treatment cours may also given medicin infus tri reduc chanc reaction treat happen certain cancer receiv lemtrada may increas chanc get kind cancer includ thyroid cancer skin cancer melanoma blood cancer call lymphoprolif disord lymphoma call healthcar provid follow symptom may sign thyroid cancer',\n",
       " 'roch ocrevu ocrelizumab addit report case progress multifoc leukoencephalopathi pml rais neurologist alarm despit analyst concern physician familiar treat pml said event neg affect medic uptak multipl sclerosi ms despit contrari market opinion fda advers event report system faer list three case pml ocrevu far follow one report case pml june expert discuss potenti addit effect ocrevu biogen tysabri natalizumab though ultim conclud case like due latter carryov effect',\n",
       " 'hello father suffer stg nsclc tripl neg pdl last month yr old sinc perform score doctor advis chemo carboplatin paclitaxel keytruda immunotherapi cycl help reduc pleural effus reduc tumor increas appetit pain significantli howev week ago doctor found new lesion c c cervic vertebra doctor say diseas progress keytruda need immedi stop need put paclitaxel ps given tarceva due lack option anyon els boat confus lot posit effect start keytruda cervic lesion new go make devoid treatment option whatsoev continu keytruda coupl cycl scan alreadi palli radiat cervic lesion fyi pleas advis help father surviv diseas long possibl thank sudipto',\n",
       " 'hey guy take tecfidera two year bad relaps offer cladribin lemtrada fingolimod chosen cladribin found actual avail area yet idea wonder anyon els wait cladribin avail area thank jemma',\n",
       " 'anoth reason take ocrelizumab progress ms ever becom avail',\n",
       " 'hi sameen welcom grace sorri hear progress mother cancer one line therapi tagrisso known effect lung cancer mutat efficaci clear non posit diseas safe tri certainli easili toler therapi chemotherapi realli question whether help follow scan show signific progress typic option would chemotherapi sinc alreadi tri immunotherapi target therapi want tri anoth chemotherapi option continu weaken point doctor feel someth toler unfortun want look palli therapi keep comfort possibl time patient improv result palli therapi gener good choic make patient comfort possibl best wish mother comfort jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'ad previou comment check full data present atrophi measur use mtr sensit mri techniqu purpos classic mri techniqu use alemtuzumab ocrelizumab trial hard compar appl orang',\n",
       " 'report current intern associ studi lung cancer th world confer lung cancer abstract pl new england journal medicin antonia et al phase iii pacif trial shown significantli improv overal surviv co primari endpoint durvalumab imfinzi vs placebo chemoradiotherapi unresect stage iii non small cell lung cancer nsclc earlier report trial support approv durvalumab set februari basi improv progress free surviv studi detail intern doubl blind trial patient random may april receiv durvalumab mg kg intraven iv n iv placebo everi week n month consolid patient unresect stage iii nsclc without progress cycl definit platinum base chemoradi random perform day receipt chemoradiotherapi stratifi accord age sex smoke histori primari endpoint progress free surviv assess blind independ central review overal surviv overal surviv data cutoff march median follow overal surviv month overal surviv month durvalumab group vs placebo group p median overal surviv reach confid interv [ci] month reach vs month confid interv [ci] month reach stratifi hazard ratio hr overal surviv durvalumab vs placebo p overal surviv benefit durvalumab observ across prespecifi subgroup updat analysi show median progress free surviv vs month stratifi hr ci discontinu studi treatment durvalumab group placebo group receiv addit anticanc therapi median time death distant metastasi month durvalumab group vs month placebo group stratifi hr ci new brain metastas found vs patient investig assess median time second progress death month vs month stratifi hr ci safeti profil safeti profil similar previous report grade advers event occur durvalumab group vs placebo group advers event led treatment discontinu vs patient common caus pneumon group vs advers event special interest occur vs grade vs seriou advers event occur vs patient advers event led death vs investig conclud [this] trial show surviv advantag durvalumab therapi concurr chemoradi therapi patient stage iii unresect nsclc new safeti signal identifi studi fund astrazeneca content post review american societi clinic oncolog inc asco necessarili reflect idea opinion asco',\n",
       " 'thank dr bhatia puri comment articl [ ] random clinic trial rct remain design refer evalu theoret effect treatment sampl size suffici rct ensur compar treat control group addit advantag margin causal estim e treatment effect entir treat popul vs entir control popul nevertheless well establish rct perform optim circumst represent treatment adher patient low frequenc morbid etc result non repres conclus real life practic [ ] observ studi close repres real life treatment effect treat control patient often non compar due lack random compar fingolimod vs natalizumab treat patient clinic radiolog outcom year [ ] studi compar outcom patient make work origin strengthen perceiv impress natalizumab clinic superior least patient aggress diseas agre safeti complianc data would strengthen research data unavail conclud articl [ ] rct need object compar natalizumab fingolimod barbin l rousseau c jousset n et al compar efficaci fingolimodvsnatalizumab french multicent observ studi neurolog zwarenstein treweek kind random trial need cmaj disclosur pleas contact editori offic journal neurolog org',\n",
       " 'like tri cladribin claim much progress like feel normal sang verdi requiem semi pro choir stand still minut home exhaust set sang twice extrem activ realli drain thigh muscl sure cladribin would help extrem urinari urgenc problem less minut reach toilet cloth mri come sometim activ shall plead cladribin',\n",
       " 'repli post ltrish hi trish year old son start stelara crohn treatment initi infus one mainten dose feel well side effect point take stelara methotrex previous humira month develop antibodi prevent happen deni insur first time approv appeal send best wish good health success new medic',\n",
       " 'start g yesterday year tec c anyway soon tell far littl tire anyway want bring seen anyon mention thread vision ekg first dose appoint home nurs came vision ekg nurs doctor came hous yesterday hour monitor arrang gilenya go program said option home test avail area said hell yeah live somewhat rural ks mile south kansa citi like live huge metropoli anyon els start g home option',\n",
       " 'avengr think address earlier post mayb much common except spent last year read everyth avail appli clinic trial foster relationship other clinic trial state fl miss last trial fight ms decad even though dx rrm key qualifi lem state depend insur carrier either must rrm relaps form ms payer becom bias us older patient want us deem progress declin coverag dmd think tysabri discuss lem taken drug lem requir infus first month particip year clinic trial reset immun system first day ms trait unlearn tysabri suppress immun system reset carri risk pml lem halt revers progress ms particip trial risk pml tysabri requir continu monthli infus forev slow progress ms se seriou drug howev common one lem thyroid relat easili detect manag use monthli blood test paid full genzym common rx drug lem research done right use approv drug take lem diminish chanc se ocrelizumab still year away approv best friend wc bound horribl disabl fight tht third year post lem walk mile day felt well round infus setback still benefit greatli short cheat sheet top head think hit major point talk neuro better yet find someon speed current best ms therapi tell tell think wish best matter decid',\n",
       " 'talk oncologist husband pet scan last week keytruda sinc mid novemb also got one low dose yervoy three week ago next one tomorrow mix result met shrunk fact one near spine put husband wheelchair hospit last novemb disappear one small new spot elsewher spine spot adren gland look brighter scan liver look littl wors blood work mix bag oncologist think new spot spine well brighter spot adren gland could due introduct yervoy sinc might led addit inflamm say hard tell scan liver issu might also yervoy go back blood work week half monitor liver close also get anoth pet scan three month bar worsen symptom meantim get clearer idea whether drug realli work said overal meet posit still pretti sad hope better news everyth shrunk guess keep play wait game',\n",
       " 'agre say fingolimod empti blood hope peopl well import altern peopl gene mean igg job properli',\n",
       " 'hello everyon hello coliti everyon thread research topic interest potenti get umbil cord stem cell therapi done coliti clinic got panama got touch stem cell institut panama quot k umbil cord stem cell treatment includ hotel accommod transport two peopl one thing though interest doctor contact said need stop remicad stem cell treatment read stop entyvio actual entyvio us went function doctor last week said perform umbil cord stem cell therapi patient umbil cord come frozen cold pack done via infus said multipl treatment need quot k first one k second one also said stem cell regul fda one need fda approv probabl qualiti control difficult problem find clinic conduct stem cell therapi umbil cord find mani peopl tri hope post someon done would share experi former cf fibromyalgia suffer symptom free year fibromyalgia complet gone immunizelab painrelief develop uc past treatment chines herb ayurveda acupunctur medit med prednison almost kill mesalamin hydrocortison enema noth hospit sever pancol remicad help stop work current entyvio',\n",
       " 'look honest answet happen stage lung cancer spread brain bone spine spinal fluid actual tarceva help',\n",
       " 'veg wrote perhap first thing test jvc marker someth like excus ignor know whether rule drug list ye think norm plan start gilenya tecfidera testif jc viru posit prior start saw week anoth rr ms drug approv eu zinbryta daklizumab seem potenti danger side effect guess time tell posit mention case jcv posit explor option hope get well',\n",
       " 'hi fano know would make connect low albumin crizotinib ineffecaci dr west said may well crizotinib actual associ directli caus decreas albumin level identifi yet low albumin level common enough cancer especi mildli decreas albumin realli set alarm bell patient rush emerg room low albumin level side effect caus visit er tend one get attent http cancergrac org lung topic low albumin level post jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'sorri continu understand ocrelizumab trial chang dogma regard ppm reinforc alreadi knew nearli decad old rituxan ppm trial encourag appear subgroup ppm patient anti cd drug moder effect name younger less disabl enhanc lesion popul repres greater ppm popul appear like see benefit drug ocrelizumab trial clearli frontload patient like respond base inform glean previou rituxan trial strang trial statist underpow prove disprov efficaci patient without enhanc lesion hate read nefari intent may none seem like gross oversight like consciou decis part drug manufactur muddi water come get drug approv seen reason believ ocrelizumab less effect rituxamab treat ppm rituxamab would appear much friendlier safeti profil clear reason ocrelizumab develop rituxamab due soon come patent decis nearli blew drug compani face ocrelizumab lupu crohn trial halt patient death ms trial prove save grace deem ms patient higher toler risk due morbid natur diseas neurologist other practic routin use rituxamab treat ppm patient rate success would expect given statist accru anti cd ppm drug trial doctor seem quit disgruntl fact ocrelizumab see much hype rituxan alreadi avail albeit label may safer agent grant progress battl ppm herald ocrelizumab appear least shroud sort reason concern reason develop potenti frighten side effect profil appear cleverli manipul trial data effect person like ppm yearn day real reason hope provid us drug compani research best ocrelizumab seem small increment step one mere replic efficaci alreadi exist drug honestli sorri come overli cynic critic work dr g put ocrelizumab seem much research group involv truli cut edg outsid box bang ocrelizumab drum detour discov long sought black swan forev alter ms treatment paradigm',\n",
       " 'month back ask neuro shingrix get answer nmss say cdc recommend shingrix non live vaccin prevent herp zoster shingl relat complic vaccin given two dose separ month recommend zostavax previous approv vaccin shingl shingrix approv adult year older whether prior episod herp zoster dose zostavax chronic medic condit unless specif reason individu get adult vaccin influenza pneumococc pneumonia vaccin studi shingrix done peopl ms howev two clinic studi shingrix increas immun mediat condit cdc indic person take low dose immunosuppress therapi go begin take immunosuppress medic take shingrix import discuss vaccin healthcar provid treat ms ensur appropri next ocrevu infus octob tri get shot earli juli',\n",
       " 'insomniacoffeelov offer tysabri option well gilenya went ocrevu bit aggress suspect may devic diseas help sinc ocrevu immunosuppress good luck gilenya hope goe well',\n",
       " 'hi finish round cisplatin alimta chemo boy cisplatin realli joke yeow still held whop lb weight throughout even got last infus go anyway first scan tumor drop cm suv max went lymphnod suv drop well go right direct least next meet surgeon told want anoth biopsi lymphnod want make sure longer cancer commit surgeri may dumb question activ cancer also tumor still activ remov activ tumor safe lymphnod know ask surgeon stuff lol cring idea cut live cancer know done alll time freak littl bad experi mom surgeri linger guess anyway tent schedul week taxol carbo radiat treatment pend surgeon determin say definit surgeri lol tom read blog receiv treatment know consid low dose chemo given radiat idea low half dose less ugghhh get thrush straight week gonna extrem grouchi oncologist keep tell bother much heh',\n",
       " 'fighterm claudepa would echo word think know horribl enemi fight win courag tenac help eventu overcom forum will abl make differ alway show messag capitul share search liter brown fluid drawn left plural caviti show rbc norm also work year votrient month go opdivo progress much longer surviv us question day come scourg beaten done fighterm made huge differ cours qualiti messag view nci vet',\n",
       " 'husband activ bleed sever symptom cannot wait around get person prefer one eylea inject horribl circumst prep povidon iodin allerg endur itch want scrach etc month heal leak found could wait month next inject problem see anti vegf inject prepar inject click expand dcukmod said pleas think suggest anyth option op husband refus get bed attent hospit mean noth would happen also state took assess medic condit account suggest safeti net suggest get someth done situat zero look like seriou potenti world would beat door seen asap talk recognis everyon react way experi other might find accept even unpalat endur sometim heavili compromis situat better problem ignor conscious unconsci click expand thank danger may get bed treatment day still depress refus get appoint laser tuesday next week inject follow week said attend lot depend see treatment need discuss prognosi may get okay ask pal clarifi happen appoint diagnost consult cancel rearrang later date buy us time plan get treatment start make enquiri referr elsewher want delay treatment would good know option thank support unbear desper tri hold togeth',\n",
       " 'diagnosi adenocarcinoma nsclc met adren gland possibl liver posit r neg alk kra ro pd pd l met treatment st carboplatin pemetrex shrinkag nd tarceva shrinkag week progress week rd pemetrex avastin toler th opdivo stabl week progress week th docetaxel toler th begin tagrisso question tagrisso good altern neg never smoker altern current treatment yale dr roggerio lilenbaum suggest suitabl clinic trial ct mass ny suggest doctor second opinion',\n",
       " 'fmt less blood stool start get form frequenc lot blood especi morn stool mushi piec frequenc hard realli call progress dx left side uc fulmin flare sinc start fmt clinic trial feb dx w mycobacterium avium paratuberculosi map sept stop amat week due intoler med other entyvio everi week low dose naltrexon mg bedtim natur ferment current statu linger rectal bleed otherwis healthi',\n",
       " 'hello sound like pretti unhelp way given diagnosi ms given pointer neurologist drug thought consid apart ignor inject contact detail ms nurs run option someon knowledg incred thoughtless doctor make want shout swear cours overwhelm may expect diagnosi even still hit like hammer forehead would anticip emot bit place next day week month mayb longer feel constrain see posit accept ms crap best imo fight big stick ie strong diseas modifi drug term diseas modifi drug dmd side effect balanc benefit point dmd reduc number sever relaps dmd vari wide efficaci balanc effect come potenti side effect first dmd market initi inject beta interferon copaxon join variant type interferon copaxon essenti though come milder side effect averag relaps reduct rate ad group aubagio day pill opinion give aubagio bodi swerv still got relaps reduct rate come long list possibl side effect drug categori mildli effect told ignor option next group categori effect gilenya cladribin tecfidera tablet relaps reduct rate possibl side effect seriou other side effect seem resolv drug stop gilenya tecfidera daili pill cladribin aka mavenclad taken year period time year would expect cladribin tecfidera best option group last categori effect lemtrada ocrevu tysabri infus averag relaps reduct rate significantli wors potenti side effect lemtrada taken year run risk attach includ develop autoimmun thyroid diseas tysabri month infus also risk particular rare brain viru call progress multifoc leukoencephalopthi pml develop antibodi viru call john cunningham viru jcv posit risk quit well manag regular blood test real consider newest categori ocrevu taken everi month iv infus significantli much less seriou potenti side effect would probabl safest best option group look http www mstrust org uk ms ms treatment ms decis aid decis aid goe lot detail variou drug benefit mean take possibl side effect given contact detail ms nurs talk well famili friend decis make like also affect close famili given access ms nurs tri phone neurologist secretari ask get touch nurs talk option someon understand fairli essenti use think pretti bad show bad old day given four video four inject avail film made drug compani told watch pick one time improv term number drug avail interperson term told avoid pick one other wish best luck choic drug chose lower risk categori drug would cours still potenti move one effect categori drug mani peopl face activ ms head straight effect drug get hold hope avoid potenti disabl futur part unlucki dmd side effect drug tri copaxon stop work ms year start relaps year relaps stop go give copaxon anoth whirl simpli option spent nearli year dmd free quit badli disabl reason would definit start decent dmd soon peopl bad experi mani drug sue',\n",
       " 'love articl alway person live ms year diagnos year know share diseas modifi therapi even particip clinic trial fail five therapi four cell deriv therapi copaxon therapi recent start ocrevu ocrelizumab first b cell deriv therapi hope one worth risk therapi frankli drug take take risk qualiti life matter right',\n",
       " 'headach mild start problem vision sometim difficult read focu eye one tarcet still use pazopanib mg per day stop complet headach turn way wors like biggest tumor start grow sooner later need plan possibl radiat pazopanib keytruda compin could kill tumor cm cant count see medic reason surgeri wouldnt possibl effect biggest tumor long reason oper tumor think continu tri find somepodi will oper biggest tumor start grow wait tumor caus emerg would give poor chang surviv cours new tumor appear chang everyth far hasnt happen need talk neurosurgeon like miss someth last time short interact surgeon ok possib die surgeri ye know statist good heatcar diseas rare doctor dont know anyth hard feel disappoint know advantac us dont get fight hard way univers hospit treat first still doenst recommend surgeri asp mean surgeri one patient year tki main tumor remov',\n",
       " 'look recommend manag side effect tagrisso diarrhea current take mg tri imodium caplet help much use lomotil',\n",
       " 'repli post coop thank inform everyon sinc last post son start wean prednison seen doctor nutritionist natur remedi son high dose liquid turmer heavi duti probiot digest enzym sbi protect immun health also iron still tri go gluten free start slow easi teenag boy start small chang recent test result pretti good inflamm test normal longer anem vitamin low surpris live mn much sun next step see gastro dr still recommend remicad pursu need pass get last blood test needl phobia get better stop us biolog need he pretti well honestli know prednison supplement dietari chang find soon prednison done goe back feel wors good luck everyon deal diseas hard know help hear other experi',\n",
       " 'first line treatment month standard chemo progress second line treatment month crizotinib symptom improv remark ct scan show slight progress mass liver determin work third line treatment month opdivo origin symptom return cough fatigu breath difficulti pend ct scan determin work question possibl return crizotinib opdivo data suggest would either effect could result seriou problem',\n",
       " 'well near breakdown boat load stress final given solid diagnosi rrm last mri show sign activ also told go start ocrevu treatment januari buzz even come close today good day',\n",
       " 'del egfr wt egfr l r water case two drug loos bound drug make noncoval interact henc trap water one constraint compact aris exon delet taken togeth structur interact may account increas activ afatinib exon delet result subsequ improv overal surviv observ pool analysi lux lux model consist emerg preclin clinic data regard preferenti activ afatinib egfr',\n",
       " 'nod ema convinc doubter cladribin benefici risk benefit profil would send messag gener use could give drug truli global potenti situat trial anoth induct treatment would potenti redund term safeti efficaci howev test gener cladribin versu ocrelizumab peopl relaps ms health econom outcom could interest',\n",
       " 'shot lucenti eye laser surgeri one eye await appoint eye far good notic improv sight',\n",
       " 'post past follow mix respons year ago mother law stage nsclc start iressa first line biopsi egfr posit back juli month mix respons attempt get aura trial back nov reject previous receiv kidney transplant certain anti reject immunosuppress med three round carboplatin pemetrex mainten pemetrex ever week three four month ago sinc hospit time pneumonia stop pemetrex stop work due complic cancer progress tube insert assist fluid seem help dr sent pleural fluid biopsi obtain compassion use applic approv osimertinib yet approv canada far know result came back neg mutat yesterday news dr also indic biopsi seem show even less pronounc prior egfr mutat sorri long wind start mil variou anti reject immunosuppress med kidney transplant novemb sound like without posit mutat option limit dr plan tri three round pemetrex see respons next option taxoter dr said much stronger could side effect wonder option immunosuppress current cours dr want get touch transplant kidney dr discuss option wonder idea send along three year anniversari diagnosi juli year appreci time',\n",
       " 'hi certainli place get sclc truli one worst noth wrong feel howev feel certainli noth offens voic howev want correct someth regard tecentriq clinic trial data gener oftentim read studi report headlin seem big deal get peopl excit studi tout major breakthrough report month improv pf os whatev baselin statist report across kind diseas medic howev practic mean prolong peopl live month rather mean peopl work sub popul sclc patient prolong life significantli mani case even longer time period studi immunotherapi seem work produc durabl respons distinct popul peopl usual eventu stop work help peopl husband tumor right genet profil chanc may well life saver much new treatment terribl diseas much uncertain peopl right sign genet test somehow work peopl right sign help crap shoot best luck everyth',\n",
       " 'cheer stumbler post repli concern daili pill self inject done year anyway gilenya moment look forward hear anymor opinion mske final decis',\n",
       " 'thank info neda theori gilenya fail stop progress diseas sequest b cell lymph node also thought fail rituxan intrathec trial progress patient reduc b cell activ brain effect understand decreas neurofila level therefor pull plug think need better medic monoclon antibodi medic destroy b cell plasma cell brain cladribin fit pictur progress ms brain access lower b cell',\n",
       " 'laura said lot question pleas post anyth realli person forum first thing first need regist gp resid near exet obvious know whether need medic insur access nh check soon knowledg whi wherefor pleas research make decis ppm idea gilenya dr [dr name remov moderator] royal devon exet hospit excel highli thought believ best tippi x',\n",
       " 'jacobo_santamarta_barr studi http clinicaltri gov ct show nct present recruit evalu whether ocrevu slow progress primari progress ppm secondari progress spm ms',\n",
       " 'hi sharonk thank son recov time mind express opinion treatment option first would choos gilyena nearli effect tysabri ocrevu also case pml report europ gilyena vastli greater number case report usa give paus also btw case pml tecfidera report europ much greater usa also biggest favor son educ use research site http multipl sclerosi research b tern html second would serious consid wait ocrevu begin tysabri difficult get reason ms often rebound vengeanc come drug tysabri keep certain destruct cell enter cn cell still circul blood stream tysabri remov cell rush caus major flare ms protocol switch tysabri ocrevu guess game right peopl go fine believ mani pleasant would give seriou thought wait ocrevu ms drug would even consid tysabri ocrevu poorli effect aw side effect combin jmho option might consid year old son would stem cell transplant legitim well respect institut ps spent year studi ms treatment behalf wife ms one first patient receiv tysabri earli trial continu extrem well today jc viru posit consid ocrevu best wish sharon son fortun pleas consid ocrevu virtual effect tysabri without pml risk true littl risk tysabri first two year treatment littl like ride tiger safe long stay get safe quit tricki drug would even come close consid effect treat ms jmho pleas understand peopl develop neutral antibodi particular drug may limit option case reason one approv drug may okay',\n",
       " 'mp felt great month later hospit day cyclosporin even met surgeon left hospit mp cyclosporin anoth month probabl would fine stop mp hate stuff could never sleep keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'hello new came across place look advic new treatment diagnos rrm ok rebif time recent mri activ lesion also suffer dizzi spell weak left hand worst terribl fatigu memori loss difficulti concentr got point peopl work dont know ms say look like someon taken batteri tri hard let peopl notic get harder also random symptom find hard say normal ms caus anyway went hospit today med look due mri result advic neurolagist go mavenclad gilenya read everyth could find also look sure choos like idea maveclad year treatment total day year know still need monitor seem ideal someth said bother sure said gilenya tablet daili mean stop effect wear mavenclad revers sure problem seem final also say treatment need year happen year noth mention anywher cours expect ms stay remiss think thing need email ms nurs say would yreat wirh mevenclad would work gilenya coupl altern side effect th gilenya seem wors drawn mavenclad realli hard make decis know none tell choos help know might other shoe least understand im deal thank read post would appriciat advic similar situat also anyon mavenclad treatment know start seen post anyon start thank',\n",
       " 'start entyvio tomorrow late afternoon nurs said plan hour dad want come bc would feel better told like get chemotherapi anyth embarrass goe rather sit read whatev make feel less big deal let come along bc know parent thing wonder make plan next day compar infus feel like might less side effect tri optimist kind feel like go breez anyon experi experi side effect',\n",
       " 'hi larri standard chemo pretti hard got carboplatin alimta avastin sick first week treatment okay shape week friend get chemo immunotherapi someth current think sick first week treatment seem work best luck wife',\n",
       " 'see believ regeneron pharmaceut want peopl see like retin diseas togeth intouch solut compani hascreat virtual augment realiti app call eye allow viewer experi blurri wavi line black patch caus differ type retin diseas app avail itun googl app store use without vr goggl work two mode stori mode viewer look around doctor offic full degre see three patient wait choos patient open person stori along video life like birthday parti picnic shown specif retin eye diseas view three diseas featur neovascular age relat macular degener wet amd diabet macular edema dme macular edema follow retin vein occlus mefrvo second view live mode engag phone camera allow viewer see whatev field vision three differ retin condit free daili newslett like stori subscrib fiercepharma biopharma fast grow world big idea come along daili subscrib reli fiercepharma must read sourc latest news analysi data drug compani make sign today get pharma news updat deliv inbox read go subscrib app includ brand regeneron treatment eylea origin meant tool sale rep use eye specialist physician howev work began idea grew broaden app use caregiv famili friend anyon retin diseas easi talk retin diseas clinic perspect term letter chart number gain challeng like day day experi retin diseas natali mancuso senior product manag market ophthalmolog regeneron said interview realli immers someon experi creat empathi want make sure get folk engag order drive action educ brent scholz vice presid execut creativ director intouch also note import empathi call app bridg understand patient first encount vision problem go doctor grip worri thought thing like abl drive lose independ scholz said pretti emot thing doctor great deal fact patient told us tend talk clinic dont alway seem fulli understand whatth patient feel what stake regeneron midst slowdown eylea superstar ed drive compani top line sinc u launch late compani recent offer expect singl digit percentag growth fall short invest commun predict forecast med expans rate',\n",
       " 'saw ms nurs yesterday ask cladribin question cannot prescrib teach hospit part formal trial cannot obvious will prescrib ticket would requir co oper oncolog well problem hospit could move also teach hospit person tell would prescrib neurolog nurs visit wife week away yet move london question geoff',\n",
       " 'hi adam happi new year diagnos uc month ago still struggl diseas say remiss yet sinc longer deal would like ask sun although live u year origin south america histori famili big side diseas inde first time heard diagnos still illiter topic howev one issu alway heard told run sun word sun peopl diseas auto immun diseas auto immun diseas trigger skin cancer even remiss take medic may caus skin cancer case right remicad imuran feedback provid south america rais sun cours never crazi one whole day sun without protect devast thank',\n",
       " 'wonder anyon ever combin two biolog humira stelara exampl find data notion guess requir cooper compet compani product unlik test',\n",
       " 'janin thank repli tri thing oncologist staff suggest either work knock wife tie citrucel imodium store brand combo see may help citrucel mention dr harman post link us could provid info chemo link layman version pro con chemo lung cancer would give us understand expect need go chemo rout oncologist mention alimta one drug want use also mention anoth drug start c want combin alimta moment cannot think name found written thank jkcath',\n",
       " 'today day start gilenya sure know feel anoth day anoth medic life multipl sclerosi ms like took part phase three clinic trial gilenya still went name fingolimod time trial coupl week liver react fair taken lot tylenol day blood test later found assign higher dose med trial still doctor standoffish place back onto med sinc hit market recent like mani ms funnel med tire side effect final decid worth risk trial error shop right med one thing realli never expect diagnos diseas alway figur doctor would set protocol drug treatment ms taught realiti bit differ truth everyon differ respond differ medic way easi decis figur medic proven effect must also consid toler amount type side effect bodi first medicin tri rebif fairli toler abl take medicin time everi time would take ibuprofen go sleep earli dosag even five year pass becam tire sleep three even week becam tire flu everi monday wednesday friday night mostli becam tire tire began realiz year son life fill tire version countless bedtim stori goodnight kiss went miss sad time chang almost two year ago began tecfidera drug suppos took medic religi reward prevent new lesion brain spine medicin differ longer inject fatigu flu three night week way tecfidera felt like cold glass water hand side effect experi med sever stomach pain turn red multipl time day see also relaps ms med multipl sclerosi best ms treatment center ms treatment center might also like ms walk deal side effect told side effect would lessen time told eat protein fat took pill would help problem life becam balanc act eat right food order get past side effect two year life yield pound weight gain without valid way lose pound becam depress felt overrun worn need free terribl side effect amaz daili stomach ach burn skin sensat mind day pile next page libbi experi tri new med deal side effect eat past med work well use began feel tunnel vision view life happi encroach first time mani year felt terrifi big decis quit came month ago shop mall husband son done everyth right eaten hearti breakfast low carb one day eat right enough husband look knew look well said honey need get someth eat turn red thought knew true burn began drip way scalp peopl alreadi begun stare rush healthiest thing could find pick cr pe accident chosen wrong kind want capres cr pe one actual chose cover can mushroom absolut worst meantim look like oompa loompa flush almost purpl face continu reaction shove terribl food throat sat tabl frozen verg tear husband get worri tri get talk head reel told everi doctor seen past two year side effect oftentim would turn red offic right eye search help none seem concern fluf like small tradeoff lose abil walk see could argu logic still empti shred yet word left husband want desper speak bodi burn tire eat time often stuff like tabl front second even thought mayb bodi meant live world mayb suppos live thought terrifi get dark never want give someth aw terribl horribl wrong look one set worri eye realiz husband son see see also relaps ms med multipl sclerosi best ms treatment center ms treatment center might also like book everi mser read time come final said need quit tecfidera drop tecfidera see easi step away tri someth new thick felt run short option idea tri gilenya clinic trial result riski honestli still might look though realiz thing gotten pretti dark dark person natur thing realli pile feel trap felt write today remind allow thing get dark turn around start walk toward light pride person never give person never quit sometim though quit one thing way continu anoth case med chose come run life rail life import med life worth risk tri someth scari new',\n",
       " 'aw lorrain crap shame stop tysabri exactli posit current dmd either tysabri gave rais liver enzym stop take tecfidera presum drug take jcv statu gave deplet lymphocyt stop alreadi bad side effect avonex fail copaxon ie start relaps given histori fact disabl ms year think anoth dmd possibl differ posit sure get anoth dmd even one got wors relaps reduct rate like beta interferon copaxon alreadi tri gilenya possibl one super drug bear risk lemtrada hsct cladribin got ms nurs get onto see avail otherwis appoint set see neurologist get secretari get one sort left adrift raft even someth good tysabri better noth hope abl get someth sort sue',\n",
       " 'grouseman wrote dose schedul sound similar wife current trial attempt irinotecan erbitux without avastin placebo drop fu previou folfiri ad erbitux think still get avastin base previou experi still ace inhibitor use avastin use though bp usual low begin infus monday noth day get hit problem know use higher dosag erbitux toler well rash came week right away think subsid prior yesterday infus cours interest ucsd trial contribut research class drug particularli ci dacomitinib still believ despit failur dacomitinib erlotinib big pfizer nsclc trial archer dacomitinib still superior egfr famili inhibitor ucsd trial look promis know egfr inhibitor becom resist one lay pathway divert make tumor resist revert egfr inhibitor becom effect wonder also dose schedul concentr use trial work similarli hit tumor hard relax enabl tumor slide altern signal pathway mani question hope trial answer wonder would consid use dacomitinib arm crowd fund trial also regard grouseman good point question grouseman thank first wish wife good result trial term point think mechanist goal delay resist via puls dose much mind rais interest question dacomitinib final trial protocol written yet discuss pi think intent focus use lmw egfr inhibitor better dose control pk cetuximab pk quit variabl peopl long half life big fan altern dose schedul gener strong scientif basi tri cheer dk',\n",
       " 'think descript protocol give cladribin websit omidm',\n",
       " 'ppm go mexico may hsct rituxan part process go check could replac rituxan ocrevu base info mayb worth',\n",
       " 'interest intraocular sustain drug deliveri system year particip clinic trial sever deliveri system articl describ recent develop technolog design deliv fluocinolon acetonid treat patient uveiti sustain period approach less invas current avail surgic implant system glanc surgic implant fluocinolon acetonid intravitr implant mg effect treat chronic uveiti howev requir surgic placement caus cataract format elev intraocular pressur less invas mg fluocinolon acetonid intravitr implant deliv inject pend fda approv treatment uveiti origin intravitr fluocinolon acetonid implant fluocinolon acetonid insolubl lipophil synthet corticosteroid first surgic implant fluocinolon acetonid intravitr implant evalu prototyp look like elong cylind implant eye patient sever panuv abl control inflamm predict deliveri system could releas drug year deem practic develop would way design studi assess well system work everyon involv includ mani patient investig would long gone time drug deplet also involv clinic evalu next gener devic surgic implant fluocinolon acetonid intravitr implant mg retisert bausch lomb valeant design releas drug roughli year us fda approv implant base result two phase studi implant indic treatment patient chronic uveiti affect posterior segment eye ie intermedi posterior panuv still find drug deliveri system use use patient either intoler system medic unilater diseas usual macular edema system find opportun improv surgic implant mg fluocinolon acetonid intravitr implant effect caus cataract format elev intraocular pressur iop import note cataract occur within year virtual everi phakic patient receiv implant fact whether sustain drug deliveri system steroid administ frequent enough long enough time period caus cataract rise iop implant although control often requir glaucoma procedur anoth drawback addit mg fluocinolon acetonid intravitr implant must surgic implant less invas option avail underli idea develop three year inject fluocinolon acetonid intravitr implant mg eyepoint pharmaceut use compani durasert technolog clinic evalu fluocinolon acetonid intravitr implant mg name iluvien alimera scienc approv fda treatment diabet macular edema dme patient previous treat cours corticosteroid clinic signific rise iop alimera scienc licens right dme indic eyepoint formerli psivida retain licens right develop implant use patient uveiti meanwhil alimera seek approv european union use iluvien treatment noninfecti posterior uveiti licens agreement eyepoint pilot studi new indic ad drug clinic test requir perform pilot investig initi studi ii inject mg fluocinolon acetonid intravitr implant patient posterior uveiti first provid inject fluocinolon acetonid intravitr implant two releas rate treat patient intermedi posterior panuv studi later modifi includ g day implant commerci avail version pilot trial implant place eye patient noninfecti intermedi posterior panuv primari endpoint chang statu uveiti studi eye look rate recurr time statu patient untreat fellow eye comparison eye inflamm eye none eye receiv implant recurr inflamm year time period wherea patient less sever affect fellow eye receiv implant significantli recurr ultim wors visual acuiti base result ii decid proceed phase trial undertaken center unit state europ india phase trial patient enrol control phase trial chronic uveiti recurr inflamm least year least one eye year enrol either two separ recurr requir treatment treat system immunosuppress steroid least month least two inject local therapi patient randomli assign receiv either inject mg fluocinolon acetonid intravitr implant sham procedur treatment administ clinic result primari endpoint recurr uveiti studi eye within month secondari endpoint recurr uveiti within year outcom measur includ recurr uveiti fellow eye year month uveiti recur treatment eye compar sham group differ statist signific year recurr rate sham treat eye treat eye year fewer treat eye untreat eye lost line visual acuiti word twice mani patient sham treatment group line greater loss discuss base result phase trial eyepoint submit new drug applic nda fda januari fluocinolon acetonid intravitr implant mg durasert three year posterior uveiti nda includ data two phase studi achiev primari efficaci endpoint month safeti profil patient treat implant consist safeti profil steroid treatment consid standard care diseas dexamethason intravitr implant mg [ozurdex allergan] fluocinolon acetonid intravitr implant mg fda given compani target date novemb respons nda follow observ base experi clinic trial record recurr inflamm ii observ recurr inflamm patient year implant seen recurr year also patient recurr believ latter case much cure diseas patient overal diseas activ decreas time iop respons iop respons steroid gener quit low phase studi month three eye implant group end need surgeri address iop elev compar two patient sham treat group minim differ two group experi patient develop iop respons tend earli develop one end year odd problem addit therapi whether patient requir addit system local therapi anoth import question get potenti reduct treatment burden group receiv implant patient need system therapi wherea patient receiv sham inject requir therapi twice mani patient need addit system therapi receiv implant need local therapi intra periocular steroid inject also much greater sham group compar treatment group figur size comparison year inject fluocinolon acetonid intravitr implant mg left surgic implant fluocinolon acetonid intravitr implant mg right draw comparison although surgic implant mg fluocinolon acetonid intravitr implant inject mg fluocinolon acetonid intravitr implant contain drug use similar sustain releas technolog place anatom locat par plana insert quit differ mg implant small cylindr polyimid tube inject gaug needl injector releas drug one end surgic implant mg implant lamin coat silicon polyvinyl alcohol figur mg implant releas drug semiperm membran port one advantag surgic implant drug deliveri devic come play vitrectom eye stay place move around also aphak eye inject implant tend move field vision lodg vitreou base could potenti migrat front eye caus problem cornea anoth inject treatment option patient uveiti dexamethason intravitr implant mg implant indic treatment noninfecti posterior uveiti last week month often use instanc sever inflamm look ahead hope inject mg fluocinolon acetonid intravitr implant achiev fda approv later year becom viabl option physician want provid long term therapi patient uveiti offic base procedur retisert [packag insert] waterford ireland bausch lomb revis decemb iluvien [packag insert] alpharetta ga alimera scienc revis novemb alimera scienc receiv accept file obtain approv iluvien non infecti posterior uveiti indic europ [press release] alimera scienc januari http investor alimerasci com index php news releas news releas detail alimera scienc receiv accept file obtain approv access june eyepoint pharmaceut product pipelin http eyepointpharma com pipelin access june pilot studi fluocinolon acetonid intravitr insert fa treat intermedi posterior panuv iluvien clinicaltri gov clinicaltri gov ct show nct access june jaff gj lin p keenan rt ashton p skalak c stinnett ss inject fluocinolon acetonid long act implant noninfecti intermedi uveiti posterior uveiti panuv two year result ophthalmolog safeti efficaci inject fluocinolon acetonid intravitr insert clinicaltri gov clinicaltri gov ct show nct access june safeti efficaci studi fluocinolon acetonid intravitr fai insert subject chronic non infecti posterior uveiti clinicaltri gov clinicaltri gov ct show nct access june jaff gj american uveiti societi winter meet park citi utah jan glenn j jaff md retina surgeon duke eye center durham north carolina member retina today editori advisori board glenn jaff duke edu financi disclosur consult eyepoint pharmaceut tag fluocinolon acetonid implant retisert implant uveiti relat news research test stem cell base retin implant dri amd encourag result physician research usc roski eye institut collabor california institut show first kind stem cell base retin gensight biolog announc toplin result phase clinic trial gs patient leber hereditari optic neuropathi lhon gensight biolog announc phase studi gs raav nd patient leber hereditari optic neuropathi lhon fail meet primari endpoint sh treat extend stop protocol wet amd long term outcom retrospect chart review perform eye patient neovascular age relat macular degener amd treat intravitr anti vascular endoth',\n",
       " 'rituxan sure doctor due sever round mg separ week first two next month cd absolut zero prior th ye like say switch ocrevu despit first line work fda approv ms like get vig rituxan provid old',\n",
       " 'ncot http jama jamanetwork com articl aspx articleid http www ada org en scienc research scienc news cannabi perio pancol uc sinc sept averag bm day time respons remiss therapi salofalk asa enema oral g clinic trial drug fail therapi entyvio anti madcam antibodi mg inject week studi drug remicad ml nicotin patch mg imuran mg',\n",
       " 'nsclc survivor like add side effect abnorm especi cisplatin alimta bare finish wbr long ago jim said still work carbo alimta fatigu extrem sometim would tri make someth eat go lay hit need rest push month chemo start get energi back howev still year get fatigu easili day unfortun call new normal person learn adjust differ still take folic acid daili stop alimta suppos done month complet alimta steroid realli tri eat varieti food probabl stay away spici acid eat smaller meal time day could make differ energi level wish best take care judi stage iiia adeno dx sr chemo carbo alimta x ned local recurr surgeri remov lrl cm involv pleura chemo carbo alimta x ned',\n",
       " 'love gilenya relaps sinc went variou cognit issu though',\n",
       " 'fda accept supplement biolog licens applic sbla tecentriq combin chemotherapi first line treatment peopl metastat non squamou nsclc egfr alk genom tumor aberr http www gene com media press releas fda accept genentech supplement biol',\n",
       " 'last night ocrevu approv ms primari progress relaps form ms given infus everi month first treatment approv primari progress ms huge breakthrough',\n",
       " 'sep oa novel therapi met ret braf oral abstract oa activ crizotinib met ro posit nsclc result ac trial deni moro sibilot nathali cozic mauric p rol josian otto julien mazier pierr jean souquet rastislav bahleda mari wislez sophi de guibert bertrand menneci christo chouaid renaud sabati suzanna bota radj gervai v roniqu verriel v roniqu haddad gilbert ferretti fr riqu nowak c line mahier ait oukhatar gill vassal',\n",
       " 'repli post mentinga sorri experi feel embarress go restroom anyon near terribl inconveni wish answer could make better husband said thing insensit think person understand hurt word especi joke topic self consciou welcom nd son birth spiral insan infect skin infect need medic attent one requir hospit recent start switch remicad entivyo hope help occur skin infect howev two week ago got shower notic small red circl spot arm think either eczema psoriasi come back husband time decid say skin issu anyon know absolut hurt crush self consciou look especi skin issu sinc dianos uc told comment hurt explain apolozi similar spous eras insecur caus comment thank littl coconut oil clear spot alway rememb remark time tinest flaw skin current see therapist help work emot uc much stress induc two littl one stress common theme person life also work full time life constant insan perhap see therapist alreadi help channel emot person understand sometim want feel taken consider dont know watch nail http www youtub com watch v edhdahrog great video show sometim men tend want fix problem instead listen ever like penpal email jveal gmail com commun everyth',\n",
       " 'ladybug wrote terribl hair loss start aubagio diet cut hair short stop aubagio start take gilenya biotin hair grow fast fill thin patch know aw feel hair long dread wash golf ball size ball hair hand time good luck realli good know ladybug ye cut hair short mean shower get block quickli much biotin take',\n",
       " 'hateuc may right realli posit ask thing work anyway bleed miracl got approv first place humira think option avail realli approv biolog huge deal expect grate samantha stop smoke jan diagnos left side uc th feb gluten dairi sulfit salicyl histamin intoler home fmt treatment juli ward reoccurr c difficil fail pentasa azathioprin final methotextr due allergi intoler current reduc pred g wait start humira next week',\n",
       " 'well opdivo stop work would like use yervoy booster onc say insur pay strong hear differ count could feedback coleridg',\n",
       " 'hi deb keytruda stage melanoma god sent yr ago treatment melanoma immunotherapi keytruda yr least anoth yr go treatment easi toler take hr start finish side effect toler far one fatigu bone ach brain fog far side effect stop immunotherapi immuno rash prednison hope back treatment wk work full time yr take time concentr fight heard lot great result immunotherapi lung cancer keep expand trail immunotherapi cancer respond convent chemo good luck mom hug jeanni',\n",
       " 'yesterday morn sit get call insur expedit review ancillari servic k infus deem necessari therefor review conduct usual standard time per polici wtf thought problem order drug turn never got author get drug administ author go doctor first step start call insur compani told never expedit receiv phone call deni get expedit need call doctor offic request call doctor offic wonder thank god howev never start author process go back infus center find took seven phone call back forth final got answer send form get review expedit soon possibl great thought complet differ thing decid refil everi day medicin get messag say pleas contact pharmaci insur card file expir know meant decid make phone call inform system say longer elig insur emblem health sinc state health insur first renew new york state medicaid approv system updat updat file emblem health well reason receiv notic discontinu medicaid error month got straighten immedi fix guess screen updat insur compani elig sit phone anoth hour contact state find truli still elig need verifi recertif year actual done system need updat howev insur quit easi either expedit updat insur screen compani end day yesterday still done iron middl get call author depart tell ancillari servic author pharmaci call said pharmaci servic inelig order medicin someth come right legal respons price ocrevu would like wait insur fix order told pleas order medicin get done know elig everyth fine liter phone differ part insur entir day yesterday good thing full time job full time job imagin make stuff',\n",
       " 'oh yeah ive talk peopl done much im entyvio thought zeljanz doctor read studi say low rate especi compar placebo good good remicad humira entyvio guess',\n",
       " 'health news octob ben hirschler london reuter frustrat delay new medicin reach countri small grow number patient turn onlin broker bill legal version dalla buyer club regul warn risk buy drug onlin amsterdam base social medwork see network trust supplier fill gap market latest drug diseas cancer migrain multipl sclerosi look rais profil expand sign former eu commission neeli kroe supervisori board secur million euro million new fund social impact ventur capit fund like ron woodroof aid patient movi dalla buyer club patient cannot get drug want local healthcar system use organ self import medicin abroad woodroof smuggl drug across mexican border social medwork custom place order onlin legal long prescript doctor letter state drug strictli person use past month group regist dutch ministri health medicin intermediari suppli patient includ british migrain suffer senti bera recent use system buy aimovig new monthli migrain inject amgen novarti first improv class drug target chemic involv trigger attack qualiti life poor thought worth tri work brilliantli bera said yet aimovig approv use within britain state health servic though bera hope soon reput mean one social medwork top seller despit price tag euro two autoinjector spokeswoman britain medicin healthcar product regulatori agenc confirm formal restrict import medicin person use past inform drug buy network help suppli cheap gener version treatment hiv hepat c dutch group charg fee around percent claim organ focus newli approv brand drug file photo pharmaceut tablet capsul arrang tabl photo illustr shot septemb reuter srdjan zivulov file photo custom countri line includ new cancer drug u approv yet avail elsewher well medicin chronic disord roch new multipl sclerosi treatment ocrevu founder sjaak vink say internet mean patient increasingli awar may wait month even year novel drug follow first approv elsewher realli need bridg gap situat ridicul said interview vink said inspir found organ delay european avail merck co innov cancer immunotherapi keytruda today group custom australia middl east asia well major european market franc itali germani britain drug delay could worsen brexit disrupt suppli line given rel speedi u approv current fewer custom america although spike u demand last year mitsubishi tanab pharma amyotroph later sclerosi drug radicut radicava approv first japan',\n",
       " 'meet someon tell multipl sclerosi ms hmm best thing first say hello feel sorri tell sister next door neighbour cousin cure ms certainli assum know diseas know ms sinc probabl five year beforehand accord neurologist suffer ill inform respons quit time career person ms ms terribl thing trial irrit sometim littl bit much depend diseas go person situat regard cope weather like larg varieti thing ms would never assum know anoth person experi know well current medic gilenya know peopl badli also know peopl medic extrem wherea ok rather extrem well think best thing meet person ms let lead convers peopl happi talk ms situat other bore talk still other want discuss thing peopl differ ms peopl experi differ diseas differ symptom depend bodi damag happen still happen symptom quit differ peopl ms suffer optic neuriti problem eye ms apart short sight peopl suffer pain wherea would say suffer pain fall one thing peopl ms agre fall peopl without ms also like talk peopl happili launch meet person ms say hi mayb talk weather start see convers goe',\n",
       " 'wow surpris noth post gilenya sinc march mean everyon take great without major side affect everyon move someth els reason recent start gilenya still bit nervou would like hear other experi thank advanc',\n",
       " 'fairli common peopl dose mg kg everi week fight insur get week dose insur deni doc abl appeal howev dose would pretti difficult get approv said flare week like switch everi week get solid remiss ad immunomodul mp take month work up week work move simponi entyvio also option given sever pancol worri could lose colon entyvio take full effect depend liber insur xeljanz jak inhibitor rather biolog might also option advantag xeljanz would take week tell work',\n",
       " 'montalban x et al ocrelizumab versu placebo primari progress multipl sclerosi n engl j med',\n",
       " 'zolgensma per patient gene therapi first car cell therapi novarti kymriah gilead kite yescarta launch europ spark gene therapi luxturna also approv europ late year novarti deal spark market luxturna europ therefor forefront groundbreak r behind cell gene therapi also look lead revolut price reimburs requir make commerci success next step process launch zolgensma avexi gene therapi spinal muscular atrophi sma file fda ema set gain approv region first half novarti hit headlin suggest price zolgensma could around bn mark would make easili expens biopharma product ever compani say price would justifi base fact patient requir one infus gene therapi rather long term treatment requir sma treatment avail biogen spinraza compani argu current ten year cost care sma type patient spinraza addit care cost somewher novarti ceo va narasimhan say compani explor novel reinsur model third parti would underwrit catastroph case child one rare condit ar first peanut allergi treatment potenti deadli allergi food everyday substanc rise around world current therapi help prevent life threaten anaphylaxi result us biotech compani aimmun look set bring first treatment market end year million peanut allergi suffer us similar number europ analyst say market could eventu worth bn annual fda grant ar fast track design peanut allergi septemb breakthrough therapi design peanut allergi age june aimmun therapeut submit drug fda decemb howev compani like mani other merci us govern shutdown mean mani fda staff unpaid leav threaten drug approv timelin drag longer europ compani expect file european medicin agenc ema first half epidiolex lead flower therapeut cannabinoid market last month seen huge growth interest therapeut potenti cannabi author allow regul access new gener product hand legitim compani pioneer product led gw pharma uk headquart firm work area sinc late gw pharma gain histor approv drug epidiolex fda june last year becom first ever prescript medicin deriv cannabi epidiolex first medicin base highli purifi plant deriv cannabidiol cbd lack high associ marijuana first new categori anti epilept drug a oral solut treat seizur associ lennox gastaut syndrom lg dravet syndrom patient two year age older two difficult treat epilepsi relat condit analyst believ gw pharma success commercialis drug us major global market add indic could blockbust treatment hand worth bn year compani wait novemb could launch product howev activ ingredi cbd need reschedul us law similar chang requir europ compani look set launch later year final regulatori approv q compani rapidli establish european corpor infrastructur led chief oper offic chri tovey hire staff medic affair market access market select candid strong epilepsi specialist diseas experi mayzent latest addit competit ms market novarti mayzent siponimod expect launch us q multipl sclerosi eu launch follow later year compani say latest trial result first studi secondari progress ms show meaning result success vital novarti bn franchis gilenya face increas competit analyst predict peak sale bn ultomiri alexion follow soliri alexion brace patent expiri blockbust soliri eculizumab use treat paroxysm nocturn haemoglobinuria pnh myasthenia gravi hit revenu around bn follow ultomiri alxn second gener pnh therapi npv bn drug match soliri efficaci trend toward superior improv dose gain earlier expect fda approv decemb takhzyro post merger takeda debut launch takeda chief execut christoph weber stake reput compani bn bn takeov shire need demonstr combin compani market muscl first test shire new blockbust wait takhzyro gain ema approv novemb rare diseas hereditari angioedema hae eu regul clear takhzyro lanadelumab prevent treatment hae patient age base clinic data show drug reduc hae attack typic swell area bodi abdomen face feet genit hand throat versu placebo analyst predict drug could make bn peak sale make one brightest prospect shire pipelin eu approv follow green light us august takhzyro first antibodi approv hae market hand exist treatment includ shire three exist product cinryz firazyr kalbitor collect made bn sale first nine month year almost sale come us market mainli suppli constraint cinryz recent year someth combin compani aim address compani maintain takhzyro potenti expand hae prevent market particularli intern market easier administ drug given subcutan inject take less minut deliv everi two week around fewer inject product hae prevent earli us take encourag accord shire q sale come moment shire big competitor hae csl haegarda product subcutan medicin launch last year tri steal market share cinryz administ intraven twice week analyst bernstein recent predict takhzyro eventu domin hae prophylaxi market share lentiglobin tdt gene therapi first europ gene therapi compani bluebird bio cours gain approv first product year europ expect approv ahead us cambridg massachusett base firm file gene therapi lentiglobin tdt ema last year treatment adolesc adult patient transfus depend thalassemia tdt non genotyp pivot data two studi sever inherit blood condit suggest gene therapi could transform care diseas provid cure mani patient one recent present studi seven eight patient longer need long term blood transfus continu show normal level haemoglobin bluebird say decis file europ first part thank lentiglobin accept ema prime fast track design allow earli discuss data requir trial design groundbreak therapi analyst william blair forecast lentiglobin could eventu hit global peak revenu tdt would depend efficaci harder treat genotyp patient sever thalassemia analyst predict drug price around per treatment level compar favour cost convent stem cell therapi unlik fellow boston base gene therapi compani spark therapeut bluebird led ceo nick leschli opt market product europ well us regulatori market market access team alreadi place europ advanc discuss contin payer includ valu base payment system daurismo new wave aml treatment mani year new therapi treatment acut myeloid leukaemia aml set rapid chang thank wave rival product arriv market includ pfizer daurismo first smoothen smo receptor inhibitor approv blood cancer fda clear daurismo glasdegib late novemb use combin low dose cytarabin patient newli diagnos aml age frail treat intens chemotherapi fda also approv abbvi roch venclexta venetoclax cytarabin hypomethyl agent azacitidin decitabin exact indic ad option patient popul take total number new drug aml last coupl year seven decad stagnat phase data submit support daurismo market applic show combin daurismo cytarabin reduc risk death compar cytarabin alon patient small molecul drug block part sonic hedgehog pathway also target cancer drug includ roch erivedg vismodegib novarti odomzo sonidegib basal cell carcinoma smaller patient popul aml analyst credit suiss predict approv aml could make glasdegib product addit upsid pfizer also get approv indic myelodysplast syndrom md acut lymphoblast leukaemia chronic myeloid leukaemia cml solid tumour meanwhil venclexta latest approv add grow momentum behind abbvi roch bcl inhibitor also file approv previous untreat aml patient inelig intens chemotherapi go along exist indic chronic lymphocyt leukaemia cll evaluatepharma predict could becom nearli bn product provid also pick approv aml indic like multipl myeloma vitrakvi novel addit immun oncolog market earlier year merck co msd becam first compani secur approv tissu agnost drug pd inhibitor keytruda pembrolizumab back cancer harbour biomark known microsatellit instabl high msi h merck msd look gain domin posit checkpoint inhibitor immuno oncolog io keytruda remain room growth market via new io agent particularli case consider percentag patient respond exist io treatment vitrakvi larotrectinib gain fda approv late novemb treat solid tumour neurotroph tyrosin receptor kinas ntrk gene fusion caus product trk famili protein drive tumour growth first us product approv loxo oncolog market partner bayer becom second compani get fda back drug treat cancer base specif genet mutat rather locat bodi europ market applic larotrectinib submit ema last august set potenti approv mid analyst oppenheim predict annual sale vikrakvi grow bn thank impress result clinic trial ntrk fusion rare loxo estim around new case advanc ntrk fusion cancer us year big challeng loxo bayer encourag oncologist test identifi patient may elig vitrakvi launch premium price tag per year howev bayer offer refund patient see benefit drug within three month moment companion diagnost ntrk fusion patient need identifi genom profil techniqu immunohistochemistri genet sequenc approach tend avail specialist centr compani say critic screen patient age advanc solid tumour action genom insight improv care inclus clinic trial loxo brought drug market ahead main rival entrectinib roch late stage test could submit approv end year erleada next gener prostat cancer treatment johnson johnson gain fda approv erleada februari got go ahead europ first treatment non metastat castrat resist prostat cancer crpc erleada apalutamid first drug clear strength metastasi free surviv mf trial endpoint use fda cancer drug approv analyst believ drug could achiev peak sale around bn face fierc competit like pfizer astella establish xtandi around prostat cancer case castrat resist patient show evid cancer spread time castrat resist diagnosi patient non metastat crpc high unmet need delay develop metastas progress advanc prostat cancer erleada approv data spartan studi involv patient non metastat crpc receiv either erleada placebo top hormon therapi gonadotropin releas hormon gnrh analogu surgic castrat median mf patient take erleada month compar month placebo arm j j need drug hit ground run exist prostat cancer blockbust zytiga face gener competit us account around half drug bn revenu also give j j leg look set big market tussl pfizer astella xtandi product also file approv us eu non metastat crpc strength mf data prosper trial buvid advanc opioid depend treatment opioid addict surg us sinc prescript drug oxycontin vicodin becam common remedi number condit last year american die overdos opioid peopl diagnos opioid depend us almost one million receiv treatment problem acut europ nevertheless still signific grow issu across contin grow need treatment help wean depend patient prescript drug street drug mani transit new opioid depend treatment market year cam market camuru compani headquart lund sweden cam inject solut slowli releas buprenorphin common drug use treat opioid addict bodi elimin need daili dosag well risk substanc make way onto black market product gain ema approv novemb fda approv decemb camuru current prepar launch drug first european market earli januari expect substanti sale treatment although take three six month ramp long term us market share number patient treat bn annual sale expect us market treatment opioid addict current domin indivor suboxon film place tongu day advantag treatment cam patient get continu treatment without run risk miss dose without visit clinic inject treatment today taken daili dose use long act inject expect increas come year compar similar treatment market indivior drug advantag flexibl inject volum lower taken weekli well monthli administ differ part bodi upadacitinib risankizumab twin anti inflamm blockbust make world biggest sell drug humira lost market exclus europ biosimilar competit abbvi well awar impend us patent expiri good news compani one two potenti blockbust like gain approv upadacitinib abbvi ra risankizumab co market boehring ingelheim psoriat arthriti crohn diseas inflammatori condit humira reach revenu around bn mean abbvi soon larg hole revenu fill see upadacitinib key compon post humira portfolio predict drug could eventu hit sale bn year risankizumab ad anoth bn bn peak abbvi present new data risankizumab candid psoriasi upadacitinib atop dermat suggest potenti lucr dermatolog franchis way announc file upadacitinib us europ decemb file risankizumab expect earli year three studi interleukin inhibitor risankizumab psoriasi present firm case drug ahead possibl regulatori approv also unveil mid stage data jak inhibitor upadacitinib atop dermat ad anoth clinic win earlier success rheumatoid arthriti risankizumab new data could import help abbvi differenti il inhibitor clutch new psoriasi treatment novarti lilli j j other jostl space increasingli crowd market analysi concentr patient report outcom data two studi compar risankizumab j j bn year il il inhibitor stelara ustekinumab one tnf inhibitor humira adalimumab current biggest sell drug world revenu bn analysi show patient risankizumab symptom free year treatment compar stelara group also signific improv abbvi drug humira qualiti life measur stelara anxieti depress risankizumab better compar drug came keep patient work without loss product caus skin disord meanwhil phase b result upadacitinib show drug abl improv skin lesion itch patient moder sever atop dermat eczema across dose test sustain treatment effect week upadacitinib alreadi phase trial atop dermat pick breakthrough design btd fda indic earlier year abbvi five trial go rheumatoid arthriti file indic end year new data atop dermat put cours addit indic drug analyst predict could unlock billion dollar plu market although abbvi oral jak inhibitor develop eye particular prize lilli alreadi approv olumi baricitinib pfizer pf rival abbvi upadacitinib gilead galapago filgotinib abbvi cast look like biggest competit threat also phase trial atop dermat risankizumab almost inevit go tough time claw market share increasingli competit moder sever psoriasi market sever new inject potenti also new oral therapi tyk inhibitor bristol myer squibb other outcom data could help abbvi persuad prescrib plump drug assum get regulatori approv likewis upadacitinib face competit ra atop dermat particularli filgotinib final see rapid increas uptak humira biosimilar across europ anoth factor temper demand new agent ant term price competit therapi area',\n",
       " 'three inject cladribin adjac day one two three month later depend lymphocyt count year later go process cladribin licens treatment ms australia bart provid peopl ms hospit link reliabl inform cladribin ms contain link scientif paper publish subject http multipl sclerosi research blogspot com suppos therapi html',\n",
       " 'excerpt osimertinib improv progress free surviv compar standard first line therapi patient egfr mutat non small cell lung cancer nsclc accord late break result flaura trial present today esmo congress madrid egfr mutat present around nsclc western popul rise asian popul egfr inhibitor superior chemotherapi first line treatment patient howev despit high respons rate good progress free surviv patient invari develop resist drug erlotinib gefitinib major patient resist mediat mutat go full articl wonder whether stori appli cancer case love one invit use ask cancer common servic',\n",
       " 'jan pm maryd wrote hi stage iv lung cancer met brain adren diagnos juli start chemotherapi right away target radiat determin stabl three week later spread brain complet whole brain radiat seven tumor final place nivolumab steadi slow size reduct last two year bare side effect immunotherapi truth suffer radiat nausea vomit lung adren short term memori loss brain radiat difficult nurs write everyth retrac step often would use cyber knife four tumor said opinion make immunotherapi first line treatment possibl combin treatment nivolumab kick wish best momfor mari said make immunotherapi first line treatment pleas aee keytruda pembrolizumab merck immunolgi drug simialr nivolumab opdivo fda approv firstlin treatment',\n",
       " 'hi year old woman recent diagnos wet macular degener one eye dri first western eye said extrafovi choroid neovascular outer rim readi inject yesterday second privat opinion guy call kashif qureshi london eye hospit harley street told extrem urgent inject day rush western eye first eylea inject yesterday afternoon wow didnt know expect realli scarey bad reaction probabl first one im ok today last night inject frighten doctor saw gave lot posit feedback inject im live hope also someth call charl bonnet syndrom hallucin ask privat doctor said hope would get less less inject kick nice site hear fellow suffer gotta strong',\n",
       " 'mean give opdivo anymor tri sbrt cryo met start recognit done local easili cryo jaw bone met dr littup anoth idea go dr lugnani spain cryoablat jaw bone met inject',\n",
       " 'control tbh peopl delay remicad coupl week without issu chanc okay much easier said done tri spend next week panick remicad truli put deep remiss hold quit last infus month even year depend person diseas dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'respond well anyth right hope ask non chemo option like rfa radiotherapi etc chemo far start ec joy move abraxan avastin work port problem forc break gemcitabin carboplatin joy eribulin joy cape thought work pain gone joy keep everyth cross vinorelbin would interest know tnbc peopl anyth differ might abl ask hope rest luck treatment xxx',\n",
       " 'thank suggest told dri eye also told use otc eye drop culprit gilenya stop take symptom slowli disappear month later back normal actual fell pretti good last week spite major stress go sinc septemb last year neuro decid must dmd decid aubagio one take well good patient start last week like omg suppos live feel like headach gone oh still slight one time motrin stop light sensit back blue eye curs type',\n",
       " 'hi dad year old found suspect lung cancer follow ct scan confirm got asap moffitt cancer center tampa pet scan confirm stage nsclc hope opdivo yervoy clinic trial offer heartbroken find day ago pet scan qualifi clinic trial whole tumor could safe remov need qualifi inch mass lung press bit right ventricl heart gone result pet scan ct show look contain one lung metastasi adren possibl fluid surround one lung needl biopsi set next thursday brain mri yesterday result feel thing move slow moffitt call day said want get anoth clinic trial research sole combin keytruda vorinostat phase ii cannot find info combin someth gut feel right think cancer hit aggress stage possibl chemo option keytruda togeth research trial seem like let see long extend life rather let hit aggress hope shrink tumor make year mental process tri get baptist md anderson jacksonvil live orlando second opinion seem like move slow made appoint second opinion tri get move anyon heard keytruda vorinostat test togeth right feel like might best first line treatment dad point child best parent dad want make wrong decis look signific help determin help beat thank help lisa',\n",
       " 'sever drug target pd checkpoint make immunotherapi effect combin drug combin respond stronger respons also side effect follow combin clinic trial approv combin checkpoint inhibitor checkpoint inhibitor e g opdivo plu yervoy combin checkpoint inhibitor immun modul like ox ido etc antibodi combin checkpoint inhibitor cytotox chemotherapi drug combin checkpoint inhibitor radiat combin target drug hand checkpoint like tim lag target togeth pd immun cell kill cancer nk cell macrophag cd antibodi remov eat signal cancer cell result macrophag engulf agonist tlr receptor activ immun cell innat immun system dendrit cell macrophag combin checkpoint inhibitor cancer vaccin get success also use immunotherapi engin cell til develop differ cancer chemokin cytokin adjuv immunotherapi problem immunosupress address treg macrophag n neutrophil trial combin clinic studi requir sever year need hang littl longer combo get approv',\n",
       " 'sorri appreci good news good news alreadi gone path seem second alemtuzumab treatment cycl put one back track wonder guilti approach switch strategi get natalizumab fingolimod alemtuzumab neuro need discuss strategi move forward mayb profg comment disturb neuro prescrib approv drug howev surpris know plenti risk avers wait see neuro would interest see centr uk prescrib guess could done freedom inform see ms drug prescrib centr done compani pharma find prescrib',\n",
       " 'conner keep finger cross see success follow journey close surgeri recommend son turn day desper altern solut famili year old diagnos ulcer coliti fall tri uceri lialda remicad canasa entyvio everi week imuran sinc june still remiss',\n",
       " 'understand feel tire constant fight want give gone thru half thru know noth anyon say make feel better want offer support note differ feel sorri one want feel piti other know quit say bull post sleep still support forum that come deris other theyr feel isnt cool imo think forum perfect place say say someth nice say noth uc pancol dx march partial colectomi diverticul sept apriso g x day canasa uceri foam need supplement zinc l glutamin probiot reuteri pearl vsl folic acid coq turmer boswellia milk thistl nac reservatol colostrum glycin start entyvio constant flare sinc march reliev prednison',\n",
       " 'remiss primari goal peopl crohn diseas biolog therapi help achiev remiss reduc symptom well heal damag intestin caus inflamm biolog therapi usual prescrib peopl sever crohn symptom found relief method guidelin recommend howev doctor prescrib biolog patient signific diseas first line approach biolog therapi work block certain chemic caus inflamm intestin biolog crohn diseas block protein call tumor necrosi factor tnf biolog block immun cell call integrin other act protein call interleukin il interleukin il biolog therapi stop inflamm gut anti tnf biolog bind block protein promot inflamm intestin also organ tissu mani peopl benefit medic sometim see improv immedi anywher eight week three anti tnf biolog humira remicad cimzia humira humira self administ treatment follow initi demonstr healthcar profession doctor decid handl inject give set pen dosag control medic insid also given instruct mani inject take first day initi day period patient typic use one humira pen everi two week remicad remicad may help patient gain control flare up may also help maintain remiss prevent symptom return remicad given directli bloodstream allow work immedi reliev symptom administ medic facil experienc healthcar profession close monitor side effect treatment remicad taken everi day three starter dose patient often see benefit six dose per year downsid remicad must given intraven medic facil two hour period cimzia cimzia administ small inject inject either given doctor offic home choos receiv treatment doctor offic option receiv treatment powder form powder mix steril water inject option use prefil syring syring contain medic alreadi mix measur dose use home doctor offic choos treatment get packag two syring instruct give treatment first three dose given everi two week abl take cimzia everi four week two anti integrin biolog crohn tysabri entyvio tysabri type biolog prevent inflamm caus white blood cell enter tissu block protein surfac cell tysabri given intraven everi four week take hour receiv full dose patient usual observ hour afterward tysabri typic use peopl respond well intoler tnf blocker immunomodul corticosteroid crohn patient consid tysabri awar seriou side effect tysabri user increas risk develop rare brain diseas call progress multifoc leukoencephalopathi pml result viru test advanc physician prescrib tysabri crohn warn patient risk also explain enrol prescrib program call touch program way receiv tysabri entyvio like tysabri entyvio approv treat adult moder sever crohn diseas respond well intoler reason take tnf blocker immunomodul corticosteroid work similarli tysabri act certain white blood cell prevent caus bowel inflamm associ crohn entyvio howev gut specif appear risk pml entyvio given doctor care intraven infus given minut first day therapi repeat week two week six everi eight week thereaft improv crohn diseas symptom occur week entyvio therapi discontinu prior start entyvio patient date immun stelara third class biolog il il agonist stelara drug class approv treat adult moder sever crohn respond well enough convent therapi drug target specif protein play key role inflamm process stelara initi given intraven supervis healthcar profession follow dose given via inject skin everi eight week either healthcar provid self administ patient train side effect although benefit often far outweigh risk biolog therapi present seriou side effect process biolog therapi reduc bodi abil fight infect caus tuberculosi infect includ brain infect also increas chanc certain type cancer patient take biolog especi younger patient one call hepatosplen cell lymphoma type cancer often fatal biolog therapi work differ other side effect may caus also vari ask doctor thoroughli explain possibl side effect discuss biolog therapi right takeaway biolog offer advantag treat crohn diseas drug specif target substanc bodi caus bowel inflamm doctor discuss option benefit risk help find effect treatment case biosimilar gener version biolog drug may avail manag crohn also save money doctor tell option',\n",
       " 'electrolyt certain nutrient chemic present bodi mani import function regul heartbeat allow muscl contract move major electrolyt found within bodi includ calcium magnesium potassium sodium phosphat chlorid ibd result electrolyt imbal mani reason rang dehydr due high output ostomi diarrhoea sick heat lack absorpt due scar intestin resect import replac miss electrolyt becom rebalanc done depend sever imbal minor imbal dietari chang may possibl drink rehydr solut anoth option treatment sever case includ fluid replac intraven hospit stay post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit mri definit magnet reson imag mri type scan use strong magnet field radio wave produc detail imag insid bodi mri scanner larg tube contain power magnet lie insid tube scan mri help identifi activ diseas ibd help locat strictur narrow intestin complic abscess post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask mri ulcer coliti ulcer coliti definit immunosuppress definit immunosuppress drug class drug suppress reduc strength bodi immun system exampl immunosuppress azathioprin imuran mercaptopurin purinethol infliximab remicad adalimumab humira certolizumab pegol cimzia methotrex rheumatrex cyclosporin gengraf neoral sandimmun tacrolimu astagraf xl hecoria natalizumab tysabri vedolizumab entyvio ustekinumab stelara post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit adhes definit adhes commonli caus scar surgeri less commonli scar due activ inflammatori bowel diseas adhes fibrou band form tissu caus pain blockag intestin post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit resect definit bowel resect surgic procedur part larg small intestin remov post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit proctocolectomi definit proctocolectomi surgic remov rectum part colon post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit hemicolectomi definit hemicolectomi involv surgeri remov right left portion colon',\n",
       " 'dear strike avonex first prescript drug hate everi inject felt flu year later gilenya approv make feel sick slow diseas progress three relaps take took month final relaps involv depth percept manag walk stair ms nurs told copaxon mani side effect daili inject effect newer drug accord clinic trial tysabri advers effect relaps sinc receiv tysabri infus half year anyhow stumbler state earlier mani option avail pleas check neurologist ms nurs benefit versu risk good luck',\n",
       " 'march checkmat checkmat phase random open label studi evalu combin opdivo mg kg plu yervoy mg kg versu sunitinib patient previous untreat advanc renal cell carcinoma rcc intermedi poor risk studi popul patient receiv opdivo mg kg plu yervoy mg kg everi three week four dose follow opdivo mg kg everi two week patient receiv sunitinib mg daili four week follow two week everi cycl recommend dose opdivo plu low dose yervoy combin opdivo mg kg follow yervoy mg kg infus intraven minut day everi three week four dose complet four dose combin opdivo administ intraven mg everi two week minut mg everi four week minut diseas progress unaccept toxic co primari efficaci outcom measur trial overal surviv object respons rate complet respons partial respons progress free surviv determin independ radiograph review committe irrc intermedi poor risk patient patient includ regardless pd l statu renal cell carcinoma renal cell carcinoma rcc common type kidney cancer adult account death worldwid year clear cell rcc preval type rcc constitut patient rcc approxim twice common men women highest rate diseas north america europ global five year surviv rate diagnos metastat advanc kidney cancer bristol myer squibb advanc oncolog research lead scientif understand extens portfolio investig compound approv agent differenti clinic develop program studi broad patient popul across type cancer clinic stage molecul design target differ immun system pathway deep expertis innov clinic trial design posit us advanc chemotherapi target therapi radiat therapi across multipl tumor potenti deliv next wave therapi sens urgenc also continu pioneer research help facilit deeper understand role immun biomark patient tumor biolog use guid treatment decis throughout journey understand make promis realiti mani patient may benefit therapi requir innov part also close collabor lead expert field partnership academia govern advocaci biotech compani support collect goal provid new treatment option advanc standard clinic practic opdivo opdivo program death pd immun checkpoint inhibitor design uniqu har bodi immun system help restor anti tumor immun respons har bodi immun system fight cancer opdivo becom import treatment option across multipl cancer opdivo lead global develop program base bristol myer squibb scientif expertis field immuno oncolog includ broad rang clinic trial across phase includ phase varieti tumor type date opdivo clinic develop program enrol patient opdivo trial contribut gain deeper understand potenti role biomark patient care particularli regard patient may benefit opdivo across continuum pd l express',\n",
       " 'thought also neg know fda ema consid use ocrevu nice need approv use nh accord professor giovannoni say quot uk patient may disappoint may hard nh fund everyon get drug like expens would expect narrow group peopl elig mean either postcod lotteri treatment depend live narrow group peopl e peopl primari secondari ms poor relat ms famili mani year deserv treatment nh get fund get privat prescript drug peopl abl afford exampl drug sativex approv nh england cost month privat prescript think mani us could afford hate think much ocrevu would cost ok sum think restrict use disappoint mani peopl peopl year donat hundr even thousand pound find treatment hope cure find live right area medic insur wealthi enough get treatment one donat money peopl get one afford regard mike',\n",
       " 'thought prayer come way jake hope thing work well give us updat soon abl daughter diagnos feb yr old time diagnosi crohn termin illium use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mg imuran jakeb regular member join dec post post pm gmt surgeri end uncov sort disturb news form small bowel cancer small tumor uncov fortun part think remov tumor chemotherapi take care issu like due cancer still remov cm jejunum less half small bowel remain want continu tpn leav recoveri help offset loss nutrient also see oncologist least urgent mind pain excruti yesterday got control much better today walk coupl time without huge issu pain also made feel good mix bag thing tri err side posit cancer thing reason realli shake much think come expect anyth day thank constant support insight happen would great help sure year old crohn sinc medicin remicad restart methotrex supplement vitamin zinc b multivitamin clo veteran member join feb post post pm gmt jake insight want know sorri go thru thought prayer remicad awhil issu short moment calm june partial obstruct scope everyth look good except soft tissu inflamm strictur area sigmoid sure would go away sent home return day excruci pain happen time june juli august ill kept septemb end colostomi reliev pain gone surgeon said inflam area atrophi predysplasia believ got mine surgeri follow year find cancer scope check year everi year go forward challeng road travel believ sometim lucki listen close bodi get sign symptom alert ing us someth need seen send posit thought way pleas let us know goe hug clo symptom start diagnosi diagnos uc diverticul hosp fistula dx chang crohn develop new skin rash eye problem pain joint hosp x new specialist said wors case seen hosp mm strictur stricturplasti mm colostomi med remicad methtrex folic acid vit calcium probiot turmer omega post edit clo pm gmt eruditepaul regular member join jan post post pm gmt would agre clo said follow statist cumul incid small bowel cancer cd diagnosi year year year expect incid base iowa white seer rate year year year www gastrojourn org articl fulltext howev danish studi show calcul lifetim risk year develop small larg bowel cancer patient crohn diseas compar danish popul ns post edit eruditepaul pm gmt',\n",
       " 'jayle neurologist told type ms three progress like walk stair ppm progress one escal ppm never stop whatev angl escal rise slow progress slow quick remain quick said also said ocrevu might help yet drug approv canada prescrib set anoth mri six month put lifetim wait list one mri per year continu collect paycheck lol',\n",
       " 'thank jennif share stori rais spirit realist hope would abl share target therapi current long year success pharmaceut career manufactur qualiti regulatori sole breadwinn famili minor children one colleg lost job due organ nov soon solid offer one work dec accept one dec senior level major pharma compani anoth state start date first week januari alway struggl depress high anxieti due high job demand lot travel time would short breath doctor would attribut anxieti thought reason start feel short breath furious continu job hunt nov symptom escal day accept job offer end emerg room x ray ct scan fluid test thoracentesi confirm malign pleural effus involv left lung later dec diagnos stage non small cell lung cancer egfr ive mutat start target therapi tagrisso day ago alreadi feel better symptom except cough although less frequent remain enorm dread replac much hope thank target therapi great medic team md anderson cancer center summit medic nj howev struggl ad fear without job health insur first time life famili especi children without mean insur dread cancer answer confirm avenu famili surviv keep push live healthi happi long life new normal take great solac stori survivor site would love connect',\n",
       " 'exactli kind thing talk romantic seen anyth sort everyon say freakin hard someon ask question answer best abil base experi say happi surgeri romantic guess eye one say happi remicad remiss mariann age dx pancol famili histori uc symptom start shortli quit smoke tri everi drug even remicad cyclosporin tri diet noth work step j pouch surgeri laparoscop restor proctocolectomi w temporari divert loop ileostomi step take surgeri ileostomi revers uc drug happi j poucher post edit byebyeuc gmt',\n",
       " 'know ino result relaps involv brain stem posterior fossa highli alarm sister similar progress quit fast year edss edss neuro want switch look anoth help stabl gilenya would place tri everyth chang highli effect therapi caus young ladi chang cladribin alemtuzumab ive answer q without read switch switch switch q vitd recommend iu daili pleas write email vitamin council',\n",
       " 'think depend bodi type bit alway hard time gain weight even coliti mine gone within month lower dose report longer think facial hair bother final shave bit issu either get better moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wk minor flare august flare sinc oct acut pancreat mesalamin allerg humira start pred bridg still entyvio start antibodi gone everi week mg pred',\n",
       " 'ok mri monday year lemtrada st round relaps wahoo mobil realli improv reli drug much top run home singl handedli work full time find hour week swim walk top hour day monday friday pleas find cure jcv put back tysbari',\n",
       " 'cannot express much medic help first prescrib terrifi review super pain sever psoriasi cover bodi given citrat free inject pen say felt noth mean noth thought inject yet prick psoriasi week treatment gone white scar wreck bodi remain medic incred liter chang life skin flake ooz get super red irrit sting everi movement like start medicin best part go websit sign humira card copay dollar five fricken dollar medic origin cost compani amaz nearli loss word effect painless citrat free formula report star post month ago rate humira adalimumab crohn diseas mainten report took humira remicad lower immun system develop tb start humira one shot hurt begin take feel like stomach crucifi top needl feel like spin went back remicad feel better ask doctor remicad humira less pain work better humira',\n",
       " 'hi andrey current cure ms rather medic help manag variou aspect diseas underli diseas cours dmt symptom manag gener well strategi benefici type ms ocrevu approv treatment earli primari progress ms ppm adult age base find clinic trial oratorio earli ppm defin diseas durat length time year sinc diagnosi level disabl addit magnet reson imag mri featur characterist inflamm indic activ diseas peopl outsid age rang edss score studi safeti efficaci ocrelizumab unknown health canada unabl provid author new drug assess safeti efficaci without clinic trial data individu interest ocrelizumab age encourag speak neurologist diseas modifi therapi dmt target inflamm peopl progress ms inflammatori activ gener benefit therapi peopl progress ms health care team great deal manag diseas includ rehabilit symptom manag dr k',\n",
       " 'chezi understand bad moon due pediod probabl yeah good bad day im glad never got relaps sinc start gilenya least',\n",
       " 'paulmorrison om month realli get medit part line either sure benefit gilenya diet presum gilenya ms stabilis addit lesion month mri also claim gilenya box problem om take meat fat end eat lot rice bread make fat accord mother internet anyway good luck give fag good anyth gave gasper use nicorett quick mist actual work howev get addict spray good luck',\n",
       " 'hi ladychelli diagnos son actual current tri babi number first piec advic alreadi talk doctor best handl ms tri becom pregnant pregnant well take gilenya first plan action stop take could safe conceiv pregnanc son wonder experi hardli ms symptom biggest piec advic prepar labor keep commun doctor plan right ms remain strong activ possibl wish best pregnanc journey question pleas hesit reach cali multiplesclerosi net team member',\n",
       " 'hi coco studi shown around half peopl egfr posit respond well tagrisso even number peopl remain less real efficaci stabil drug probabl tagrisso best option inde option nh would push hope respond treatment best janin',\n",
       " 'neuro bart blog seem favour fingolimod stop relaps tysabri might stop gap treatment also http multipl sclerosi research blogspot com clinic speak swi',\n",
       " 'definit spm rrm straightforward lot accumul disabl still relaps peopl put one categori neuro say label help dmd still relaps spite ms year plenti accumul disabl relaps realli sound like give seriou thought go onto dmd lot tri happi gilenya though know peopl hate',\n",
       " 'repli post ahainlin mental fear wors bite fail remi went humira work well year anxiou inject burn trust thought go feel like way wors realiti alway inject right bed way hurt could go sleep move around tri quiet brain much possibl',\n",
       " 'thank forum took mom univers hospit gene test result given us today result read ro rearrang intron addit find say tumor mutat burden tmb low mut mb therapi identifi ceritinib crizotinib therapi differ one anoth therapi identifi tumor mutat also understand ro identifi bodi report say unclear oncogen rearrang present say activ ro rearrang present fusion read old articl written dr west said patient ro rearrang respond favor alimta well patient ro respond alimta wait tri crizotinib later resort mom test report also state patient ro rearrang exhibit longer progress free surviv alimta mom still respond alimta pleural effus week breathless appetit return result treat import inform chang treatment consid point onc order test hope discuss result onc mom next visit variant also identifi none hold signific much known scientif literatur time report said one variant ro l v could point articl inform ro pertin result could share input would grate thank much bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test neg stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr start alimta alimta sinc usual ned chemo period less month month recent occurr jan alimta jan thru april ned april occurr cancer jan start alimta test posit ro june appt onc discuss futur tx plan',\n",
       " 'rotherhamdav thank share feedback gilenya didnt start gilenya yet still wait call',\n",
       " 'suppos wait anxious intermedi result phase clinic trial pd inhibitor opdivo keytruda also clinic trial pd l inhibitor tecentriq wife keytuda metastat tnbc sinc month well',\n",
       " 'hi grumpyman tecfidera nurs said work could tri gilenya even lemtrada assum appli tecfidera sound scari side effect soon wear within month scari seizur must plain wrong polish version give inform need fix asap ask ms nurs get soon possibl know long stay activ system may mean need time dmd good luck carol x',\n",
       " 'hi hope im includ describ good condit well wasnt daignos lobg ago saudi year old highschool student girl lost sight graduat highschool finish uni move scotland alon stay year studi english volunt citizen advic studi return countri mayb cant rememb done transplant eye plan eye job ny countri even shift time describ treatment nd vitamin anxiou month ago start gilenya develop atrophi scotland hate mention abyon smoke short time im still disabl one know suffer ms famili manag work',\n",
       " 'hi sunday thank repli sorri hear tagrisso work oncologist think acquir anoth mutat alongsid mean tagrisso work rather mutat chang pleural effus drain build thank best luck treatment would clinic trial immunotherapi',\n",
       " 'read believ main side effect problem relat avastin problem dose split use syring intend inject bodi use inject eye appar number lawsuit take place regard issu schmidtlaw com avastin issu well one least found relat much drug get bloodstream long stay despit similar visual outcom mani head head compar trial bevacizumab ranibizumab aflibercept wet amd signific differ molecular structur agent result differ pk [pharmacokinetic] profil system exposur intravitr inject result report show differ among three main intravitr vegf inhibitor system pk pharmacodynam may provid biolog plausibl potenti differ system safeti risk paper also provid informt bevacizumab bival monoclon antibodi ranibizumab monoval monoclon antibodi fragment aflibercept fusion protein bjo bmj com content earli',\n",
       " 'copi unrel comment sake discuss spam unnecessari recent studi found gilenya halt grey matter atrophi http www sciencedirect com scienc articl pii x gilenya less effect tysabri delay progress http onlinelibrari ectrim congress eu ectrim actrim ectrim j william l brown effect diseas modifi treatment convers html f media speaker risk assess hazard ratio convert spm among patient treat inject follow year gilenya follow year tysabri follow year lemtrada follow year compar match untreat patient higher hazard ratio lesser risk thought',\n",
       " 'european commiss approv twice daili mg dose tofacitinib citrat combin methotrex adult patient',\n",
       " 'p read post sound like could come prednison entyvio pred changevc hormon hormon disrupt caus temporari hairloss ad',\n",
       " 'consumpt least mg dietari long chain polyunsatur fatti acid lc pufa link decreas risk diabet retinopathi older patient type diabet accord research publish jama ophthalmolog aleix sala vila dpharm phd lipid clinic endocrinolog nutrit servic institut investigacion biom diqu barcelona spain colleagu conduct prospect studi within predim prevenc n con dieta medit anea trial determin mediterranean diet one supplement extra virgin oliv oil nut vs control diet effect primari cardiovascular prevent research recruit individu year age previou diagnosi type diabet primari studi outcom incid diabet retinopathi requir laser photocoagul vitrectomi antiangiogen therapi total n particip met target lc pufa recommend nearli new event document year follow adjust age sex intervent group lifestyl clinic variabl particip meet lc pufa recommend baselin mg compar fulfil recommend mg show rel reduc risk incid sight threaten dr conclud dr sala vila associ slightli stronger yearli updat lc pufa intak research note target lc pufa intak mg easili achiev weekli serv oili fish',\n",
       " 'oh wow aw get earlier deterior disgrac make want fight keep eye ocrelizumab though like lemtrada scare',\n",
       " 'read interest find le berr et al report first case combin biolog agent tofacitinib manag inflammatori bowel diseas ibd recent approv small molecul tofacitinib treatment ulcer coliti multipl small molecul therapeut pipelin make co mbinat increasingli attract approach tri close therapeut gap ibd furthermor lack immunogen offer advantag biolog agent potenti allow sequenti therapi http www cghjournal org articl fulltext rss ye sourc clinic gastroenterolog hepatolog',\n",
       " 'vanessa hello copaxon daili inject never issu regard gilenya declin treatment right dont rock boat feel listen gut instinct studi copaxon safe option never negit report awar alway stand correct otherwis best luck whatev decid upon jane',\n",
       " 'thank post cladribin sew chick due start shortli would mind call talk concern thank',\n",
       " 'great news keytruda seem promis kind side effect son jump post olga sat nov pm forum person stori updat topic p thailand dx yr old repli view year old thiland dx march hi keytruda approv asp approv cancer peopl get label oncologist find benefici receiv news prescrib boy us jump post arojussi sat nov pm forum person stori updat topic jussi finland dx repli view jussi finland dx fifth dose mri keytruda moth jump post phura sat nov pm forum person stori updat topic p thailand dx yr old repli view year old thiland dx march countri use approv drung understad could pl suggets hi rojussi thank much suggest keytruda use kid approv kd link inform keytruda kid hi martinbub thank much suggets',\n",
       " 'hello hope well daughter optic neuriti hospit april neurologist recommend two drug either copaxon ocrevu unsur pleas tell cours medic good luck',\n",
       " 'still fairli new crohn offic diagnos june week hospit bowel blockag sepsi remicad year stop work develop antibodi put humira didnt seem anyth gi took anyth methotrex coupl month diseas still activ noth sever far gi want tri stelara anyon bad side effect trish',\n",
       " 'hi thank repli updat complet two month half alectinib far improv tumor size start shrink yet slow progress someth better noth excit thing side effect like fatigu diarrhea last blood test show effect far kidney liver tumor marker go bad symptom gone away cough short breath except heavi activ thank god next scan nd apr let know wish healthi life',\n",
       " 'u renflexi avail dosag form powder solut therapeut class immunolog agent pharmacolog class infliximab use renflexi infliximab abda inject use adult treat crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti chronic sever plaqu psoriasi use children treat crohn diseas ulcer coliti infliximab abda inject monoclon antibodi work enhanc improv immun system medicin avail doctor prescript use renflexi decid use medicin risk take medicin must weigh good decis doctor make medicin follow consid allergi tell doctor ever unusu allerg reaction medicin medicin also tell health care profession type allergi food dye preserv anim non prescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatr specif problem would limit use infliximab abda inject treatment crohn diseas ulcer coliti children year older howev safeti efficaci establish children younger year appropri studi perform relationship age effect infliximab abda inject children plaqu psoriasi safeti efficaci establish appropri studi perform date demonstr infliximab abda inject help children juvenil rheumatoid arthriti efficaci establish geriatr appropri studi perform date demonstr geriatr specif problem would limit use infliximab abda inject elderli howev elderli patient like infect may requir caution patient receiv infliximab abda inject breast feed adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur case doctor may want chang dose precaut may necessari receiv medicin especi import healthcar profession know take medicin list follow interact select basi potenti signific necessarili inclus use medicin follow medicin usual recommend may requir case medicin prescrib togeth doctor may chang dose often use one medicin abatacept adalimumab adenoviru vaccin type live adenoviru vaccin type live alefacept anakinra bacillu calmett guerin vaccin live brodalumab certolizumab pegol cyclosporin etanercept fosphenytoin golimumab guselkumab influenza viru vaccin live ixekizumab measl viru vaccin live mump viru vaccin live natalizumab paclitaxel phenytoin polioviru vaccin live quinidin rilonacept rituximab rotaviru vaccin live rubella viru vaccin live sarilumab sirolimu smallpox vaccin tacrolimu tocilizumab tofacitinib typhoid vaccin ustekinumab varicella viru vaccin live vedolizumab warfarin yellow fever vaccin zoster vaccin live interact food tobacco alcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco medic problem presenc medic problem may affect use medicin make sure tell doctor medic problem especi aspergillosi fungu infect histori blastomycosi fungu infect histori blood bone marrow problem eg pancytopenia histori candidiasi fungu infect histori coccidioidomycosi fungu infect histori diabet guillain barr syndrom nervou system disord histori hepat b activ histori histoplasmosi fungu infect histori legionellosi bacteri infect histori leukopenia neutropenia low white blood cell listeriosi bacteri infect histori liver diseas multipl sclerosi histori optic neuriti eye problem pneumocystosi fungu infect histori psoriasi skin diseas seizur convuls histori thrombocytopenia low platelet blood use caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copd use caution may increas chanc get new cancer tuberculosi histori use caution patient may need addit tuberculosi therapi proper use renflexi doctor train health profession give medicin given needl place one vein medicin come medic guid import read understand inform sure ask doctor anyth understand may also receiv medicin help prevent possibl unwant effect inject precaut use renflexi import doctor check progress regular visit make sure medicin work properli blood test may need check unwant effect infliximab abda may caus infus reaction receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow short breath troubl breath swell face tongu throat bodi abil fight infect may reduc use infliximab abda import call doctor first sign infect check doctor right away fever chill cough flu like symptom unusu tired weak seriou skin reaction occur use medicin check doctor right away blister peel loosen skin chill cough diarrhea fever itch joint muscl pain red skin lesion sore throat sore ulcer white spot mouth unusu tired weak medicin may increas chanc lupu like syndrom liver diseas call autoimmun hepat check doctor right away dark brown color urin fever chill gener feel discomfort ill weak joint pain light color stool nausea vomit rash cheek arm wors sun sever tired upper right side stomach pain yellow eye skin small number peopl includ children teenag use medicin develop certain type cancer common patient lung diseas eg emphysema copd heavi smoker psoriasi patient phototherapi treatment long time phototherapi treatment ultraviolet light sunlight combin oral medicin make skin sensit light teenag young adult crohn diseas ulcer coliti also develop rare type cancer call hepatosplen cell lymphoma talk doctor unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss red scali patch rais bump pu skin use medicin may increas risk get skin cancer eg melanoma merkel cell carcinoma chang growth skin tell doctor right away treat infliximab abda immun vaccin without doctor approv live viru vaccin given infliximab abda child vaccin must current use infliximab abda talk child doctor question women babi receiv infliximab abda make sure babi doctor know use medicin need wait month give certain vaccin babi talk babi doctor question need skin test tuberculosi start use medicin tell doctor anyon home ever posit reaction tuberculosi skin test import heart check close receiv infliximab abda call doctor right away short breath swell ankl feet sudden weight gain take medicin unless discuss doctor includ abatacept orencia anakinra kineret tocilizumab actemra medicin call biolog use treat condit infliximab abda use medicin togeth infliximab abda may increas chanc seriou unwant effect renflexi side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur common accumul pu black tarri stool blur vision chest pain chill cough diarrhea difficulti swallow breath dizzi faint lightheaded get suddenli lie sit posit fever gener feel discomfort ill headach hive itch rash muscl pain stiff pain joint lower back side pain difficult urin pound ear puffi swell eyelid around eye face lip tongu slow fast heartbeat sore throat sore ulcer white spot lip mouth stuffi runni nose swollen gland swollen red tender area infect tight chest unexplain bleed bruis unusu tired weak weight loss yellow skin eye less common crack skin corner mouth sore red around fingernail toenail vagin burn itch discharg white patch mouth throat tongu rare abdomin stomach pain clay color stool confus cough sometim produc pink frothi sputum dark bloodi urin difficult fast noisi breath dri mouth faint loss conscious fast irregular breath gener feel discomfort ill weak increas sweat loss appetit nausea pain tender swell foot leg pale skin blue lip fingernail pinpoint red spot skin sever constip sunken eye swollen pain tender lymph gland armpit vomit incid known blister peel loosen skin bloodi nose chang mental statu difficulti speak heavier menstrual period muscl ach weak new mole chang size shape color exist mole mole leak fluid bleed numb tingl finger face feet red irrit eye red scale crust skin red skin lesion often purpl center seizur side effect may occur usual need medic attent side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question common acid sour stomach belch discomfort upset pain stomach ear congest heartburn indigest loss voic nasal congest pain tender around eye cheekbon side effect list may also occur patient notic effect check healthcar profession call doctor medic advic side effect may report side effect fda fda',\n",
       " 'poor thing think hope tri biolog entyvio might work realli well even simponi humira besid point may normal symptom lower dose prednison may clear know hate say though go forev know get one uti cold throw whole situat back action time energi everi year get easier older either last time flare cold month flare surgeri still take vsl co moder ulcer coliti diagnos pancol laryngopharyng reflux migrain battl extrem exhaust current med step one j pouch surgeri complet step two complet step complet',\n",
       " 'yo first remicad infus day ago day sever serum sick fever shot blood pressur realli low spent hr picu scare needless say abl take hope last effect time tell symptom serum sick fever chill sever joint pain hive swollen hand red eye dri mouth',\n",
       " 'heard lot talk recent new oral therapi tecfidera approv fda last spring multipl sclerosi third oral drug aim treat diseas one mani articl announc news new york time wrote self inject medicin like avonex biogen copaxon teva enter market still use major treat patient newer oral drug make inroad addit tecfidera two oral drug gilenya novarti approv aubagio sanofi approv septemb still inject therapi copaxon consid new drug great progress ms world think back diagnos time one therapi avail one betaseron two year switch new avonex week inject sound much appeal everi day inject suffer horribl side effect therapi felt like flu make difficult work full time take care babi boy singl mother copaxon hit market eager tri done research knew side effect profil much differ therapi struggl five year daili inject know lot peopl hard time decid would rather give shot everi day mean bodi toler without miser flu like side effect take daili inject daili dose hope like call ever sinc symptom free stick pun intend inject therapi oral therapi new proof work well inject drug convinc enough yet anyway admit take pill twice day sound like nice chang year say goe broken fix ms patient advoc opportun speak mani other share diseas lot patient newli diagnos idea therapi best alway person decis patient make guidanc neurologist encourag everyon type therapi matter long ms even current symptom free someth slow diseas one therapi work tri differ one nice far come past year patient lot choic still need cure fda remind us press releas new drug tecfidera drug provid cure multipl sclerosi import varieti treatment option avail patient said russel katz director divis neurolog product fda center drug evalu research multipl sclerosi impair movement sensat think profound impact person qualiti life let stick therapi work us best stay healthi get cure',\n",
       " 'repli post supersmal thank share experi decid start take entyvio start first infus next week definit keep eye side effect finger cross see improv',\n",
       " 'past week discuss variou type treatment multipl sclerosi includ inject medic oral medic week discuss infus medic four medic categori two approv recent tysabri novantron lemtrada ocrevu let take closer look tysabri tysabri monoclon antibodi design prevent damag immun cell enter bloodstream cross blood brain barrier brain spinal cord approv fda use ms tysabri consid immuno suppress medic use combin medic affect immun system given via infus month hospit local infus center doctor offic usual infus take around hour individu must observ hour afterward make sure complic reaction medic tysabri usual consid medic tri success seriou rare risk take tysabri immno suppress medic pml pml progress multifoc leukoencephalopathi potenti fatal brain infect caus jc viru take medic suppress immun system take tysabri longer period time two year test posit jc viru risk get pml increas take tysabri monitor everi six month via blood test jc viru pml tricki spot symptom similar symptom ms clumsi vision chang weak one side bodi person chang problem cognit think memori orient lead confus ever experi symptom think may pml import call doctor immedi side effect tysabri includ headach fatigu chest abdomin discomfort diarrhea depress rash joint pain tysabri also caus liver damag monitor detect blood test anoth reason keep regular appoint blood work although mani warn potenti side effect mani patient review medic call liquid gold find help symptom immens novantron novantron antineoplast anti cancer medic dna reactiv agent mean caus damag dna approv fda use ms novantron work stop prolifer b cell cell macrophag play role immun respons thought involv ms indic peopl secondari progress ms progress relaps ms worsen relaps remit ms novantron given via infus take minut due potenti damag heart take mg lifetim limit treatment year start take novantron heart test look problem call left ventricular eject fraction lvef clinic signific reduct reduct lvef take novantron also neutrophil count cell mm take novantron clear slowli bodi liver function impair well therefor need test proper liver function prior start novantron common side effect novantron includ nausea temporari hair thin temporari blue green urin urinari tract airway infect uneven heart rate weight gain chest pain tight seriou side effect includ heart diseas liver damag therapi relat acut leukemia tral lemtrada lemtrada monoclon antibodi focus cd protein surfac immun cell caus deplet lymphocyt approv fda use ms origin use approv much higher dose treatment chronic lymphocyt leukemia abil target immun cell lead scientist test potenti treatment ms lemtrada given infus five consecut day first three consecut day year later seriou side effect associ lemtrada rare bleed condit rare kidney condit life threaten infus reaction increas risk cancer autoimmun thyroid disord yike common less sever side effect includ rash headach fever nasal congest nausea urinari tract infect fatigu insomnia upper respiratori tract infect herp viral infect hive itch thyroid gland disord fungal infect pain joint extrem back diarrhea sinus sore mouth throat tingl dizzi abdomin pain flush vomit prior start medic individu vaccin varicella thyroid function test monitor everi three month receiv full cbc urinalysi month month last infus skin exam yearli monitor melanoma ocrevu ocrevu newest medic scene approv fda earli use primari progress ms first medic approv primari progress ms ocrevu monoclon antibodi target cd posit b lymphocyt lymphocyt contribut nerv damag ms ocrevu given via infus infus center doctor offic initi dose split two week first infus mg infus two week later anoth mg infus take least hour first two dose get one infus everi six month take least hour prior first dose need screen hepat b medic mani potenti side effect fatigu cough fever short breath nausea headach possibl infus relat reaction may occur well may includ throat irrit headach flush mild fever rash clinic trial sever individu develop abnorm growth tissu link growth medic still known clear medic strong mani includ caveat tri other first decid one medic individu decis talk mani peopl want end medic affect come bodi biolog never truli know someth work work tri tysabri two year start medic read numer patient review seem like one person love next hate continu page page final realiz need tri first start would infus would exhaust like spend rest day couch noth exhaust infus went exhaust lessen eventu got point walk infus center get infus go day almost like noth happen',\n",
       " 'robino wrote amaz drop cea number sound like opdivo work splendidli thank robino',\n",
       " 'mine recommend ocrevu due age immun system good age virginia repli quot follow user say thank agat howi jeani z sunshin',\n",
       " 'sorri lab forc doctor shop alreadi got doctor perfectli happi suck massiv forc find new gp move three year ago current one good gp still miss old one sometim plu lot lax prescrib stuff know reason want stay gp yeah gi seven year look forward day leav replac good make decis whether switch hospit hope find good gi quickli dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'hi greg father ask consid nivolumab actual want start next week ye side effect pretti bad hard decis start treatment find hope good rita',\n",
       " 'hello crohn sever year start take remicad take tb skin test come posit gi went ahead sinc chest x ray clear pneumonia infect anoth bout shingl due suppress immun system medicin work crohn past month notic slight swell neck doc suggest ct scan rule lymphoma scan show swollen lymph node doc advis remov lymph node biopsi luckili came back neg lymphoma sent analysi week later receiv diagnosi mycobacterium tuberculosi appar dormant reactiv due suppress immun system anyon gone tb treatment remicad help advic appreci thank',\n",
       " 'barryb neuro anybodi favor feed hope condit remain stabl ms chronic progress march even dmt except possibl lemtrada cladribin rituximab stem right tell adio favor anoth like bart treat like matter good luck sew chick fampyra help tremend abl lift leg work like magic take day within half hour transit weak seriou foot drop mobil disabl abl walk fairli normal gait use activ ingredi even year patent time releas product approv dmt effect type ms work help damag nerv conduct impuls effici drug compani give patient free day trial work everyon highli effect one third user particip clinic trial effect medic ever taken',\n",
       " 'got agre ipoop long term pred simpli viabl option feel bad surgeri either mg pred felt quit good actual thing heal colon patholog report show sever chronic acut inflamm throughout colon test could get pred summer still okay tend alway flare wors winter acut flare up year happen autumn winter dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'almost finish first month gilenya increas sever leg pain weak along daili headach last hour worri also increas fatigu weak check neuro yet',\n",
       " 'ms long character diseas brain white matter immun cell destroy myelin demyelin believ respons neuron death lead irrevers disabl individu ms howev first time team research identifi subtyp diseas mcm featur neuron loss demyelin brain white matter studi publish lancet neurolog research observ mcm part neuron becom swollen look like typic ms lesion indic white matter myelin loss mri team find support concept neurodegener demyelin occur independ ms underscor need sensit mri imag techniqu evalu brain patholog real time monitor treatment respons patient diseas studi open new arena ms research first provid patholog evid neuron degener occur without white matter myelin loss brain patient diseas comment bruce trapp cleveland clinic lead investig studi inform highlight need combin therapi stop disabl progress ms within studi research remov brain spinal cord autopsi individu die ms accord studi visual examin cerebr hemispher slice carri identifi brain without area cerebr white matter discolor indic demyelin lesion refer mcm brain cerebr white matter discolor demyelin lesion refer typic ms observ reveal brain white matter demyelin research also compar microscop tissu characterist brain spinal cord individu mcm tradit ms also individu without neurolog diseas although mcm tradit ms patient typic ms lesion spinal cord cerebr cortex latter group ms lesion brain white matter despit mcm brain reduc neuron densiti cortic thick hallmark brain degener also observ tradit ms import research twofold identif new ms subtyp highlight need develop sensit strategi properli diagnos understand patholog mcm said daniel ontaneda cleveland clinic co author studi ontaneda conclud hope find lead new tailor treatment strategi patient live differ form ms multipl sclerosi identifi new subtyp multipl sclerosi neurodegen diseas manag multipl sclerosi us fda assess cladribin tablet potenti treatment ask expert emerg therapi multipl sclerosi part ii stem cell futur research world multipl sclerosi day note editor sourc trapp bd vigno dudman j et al cortic neuron densiti cerebr white matter demyelin multipl sclerosi retrospect studi lancet neurolog doi x epub ahead print http newsroom clevelandclin org cleveland clinic research discov novel subtyp multipl sclerosi',\n",
       " 'art rena seem earli say receiv ocrevu improv understand literatur ocrevu decreas progress pleas let us know ocrevu help mom hope',\n",
       " 'took one bf sit cuz high anxieti start someth new see feel okay hour okay dinner take two uc sinc mayo clinic say chron coliti dx chronic lyme biolog work stelara love took rafaximin sibo work awesom',\n",
       " 'risk small realli much small risk will take person rather take risk relaps relaps gilenya year problem one flare old symptom that cours mileag may',\n",
       " 'recent year excit develop treat lung cancer genet test tumor sampl doctor identifi specif type lung tumor prescrib treatment design target immunotherapi also emerg treatment option certain type lung cancer advanc made treatment effect often fewer side effect type lung cancer two major type lung cancer non small cell lung cancer nsclc small cell lung cancer sclc nsclc account percent lung cancer includ adenocarcinoma common form lung cancer unit state among men women squamou cell carcinoma larg cell carcinoma sclc tumor account remain percent lung cancer unit state tend grow quickli nsclc tumor tumor classifi stage stage base whether cancer local lung local advanc spread nearbi lymph node lung area metastat spread part bodi treatment option print email share tweet lungev lung cancer helplin cancer care partner lungev nation lead lung cancer focus nonprofit organ provid lungev lung cancer helplin call lung view cancer care resourc help better cope lung cancer editor heather wakele md associ professor depart medicin divis oncolog stanford univers stanford cancer institut listen surgeri surgeri sometim combin chemotherapi common treatment option tumor confin lung advanc surgic techniqu allow doctor make much smaller incis remov tumor section lung affect cancer use video assist thoracoscop surgeri vat surgeon insert tube call thoracoscop chest devic light tini camera connect video monitor radiat therapi case surgeri possibl mani local advanc cancer radiat therapi sometim use either alon combin chemotherapi treatment may also use surgeri shrink tumor surgeri help prevent cancer come back recur extern beam radiat commonli use treat lung cancer standard extern beam radiat use machin direct beam multipl beam radiat tumor use ct computer tomographi mri magnet reson imag pet positron emiss tomographi scan allow radiat oncologist accur target tumor shape radiat beam size dimens tumor help spare healthi tissu newer form radiat call sbrt stereotact radiat stereotact abl radiat therapi sabr sometim use treatment earli stage lung cancer instead surgeri sbrt deliv higher dose radiat shorter period time approach minim impact healthi tissu patient high risk surgeri sbrt shown cur rate close expect rate surgeri ongo research tri determin patient could type focus radiat instead surgeri chemotherapi chemotherapi long effect treatment lung cancer continu one import element treatment mani patient chemotherapi extrem effect treat sclc also use treat nsclc chemotherapi help patient earli stage cancer remov surgeri combin radiat local advanc cancer also import part treatment patient advanc stage lung cancer chemotherapi drug approv fda treatment lung cancer includ cisplatin platinol carboplatin paraplatin common medic use treat lung cancer treatment approach includ either cisplatin carboplatin combin anoth chemotherapi drug pemetrex alimta pemetrex use combin chemotherapi cisplatin initi treatment advanc non squamou nsclc pemetrex also approv use alon treat advanc non squamou nsclc anoth chemotherapi given pemetrex use adenocarcinoma lung activ squamou cell lung cancer small cell lung cancer gemcitabin gemzar other drug use treat nsclc either combin cisplatin carboplatin initi treatment singl drug chemotherapi given drug work type nsclc paclitaxel taxol nab paclitaxel abraxan docetaxel taxoter drug form taxan chemotherapi given combin cisplatin carboplatin nsclc docetaxel frequent given alon later line therapi advanc stage lung cancer etoposid etopopho vepesid etoposid use combin cancer medic treatment sclc target treatment destroy cancer cell target therapi focus specif cell mechan thought import growth surviv tumor medic caus differ often less sever side effect chemotherapi research discov mutat gene call epiderm growth factor receptor egfr caus develop growth spread lung cancer approxim ten percent peopl lung cancer egfr mutat present tumor egfr inhibitor target therapi given pill form often use treat type lung cancer today four medic approv treatment option unit state lung cancer patient gene mutat erlotinib tarceva other u food drug administr fda first approv use erlotinib lung cancer erlotinib approv initi treatment patient nsclc spread part bodi certain type egfr mutat piec miss call delet egfr gene afatinib gilotrif fda approv afatinib initi treatment metastat nsclc patient egfr gene mutat delet treat success erlotinib gefitinib iressa juli fda approv gefitinib initi treatment patient nsclc whose tumor harbor specif type egfr gene mutat detect fda approv test osimertinib tagrisso novemb fda approv osimertinib treatment patient nsclc whose tumor specif egfr gene mutat start regrow treatment erlotinib afatinib gefitinib resist develop one drug tumor start grow newer egfr inhibitor drug call osimertinib tagrisso often work shrink cancer stop grow anoth gene mutat found lung cancer refer alk four target treatment fda approv option peopl whose cancer mutat crizotinib xalkori treatment approv fda treat metastat nsclc tumor alk gene mutat crizotinib block mutat alk gene stop growth tumor clinic trial found effect chemotherapi addit crizotinib approv treat peopl metastat nsclc tumor mutat ro gene ceritinib zykadia medic approv peopl metastat alk posit lung cancer cannot toler crizotinib whose cancer continu grow treat crizotinib approv newli diagnos patient alk posit lung cancer alectinib alcensa alectinib approv decemb patient lung cancer alreadi treat crizotinib result larg clinic trial novemb alectinib approv given first line treatment choic prior treatment brigatinib alunbrig april brigatinib approv patient alreadi treat crizotinib june fda approv target therapi dabrafenib trametinib administ combin patient nsclc mutat braf v e gene detect fda approv test gene mutat seen nsclc target therapi option may avail gene mutat tend common adenocarcinoma type nsclc import patient adenocarcinoma discuss valu genet test oncologist gene cancer cell evolv tumor may becom resist target therapi treatment medic meet challeng studi clinic trial cut blood suppli tumor anoth approach destroy cancer cell chang blood suppli tumor need grow blood vessel grow sever way process depend presenc substanc call vascular endotheli growth factor vegf produc tumor normal cell substanc stimul blood vessel penetr tumor suppli oxygen miner nutrient feed growth bevacizumab avastin monoclon antibodi work stop vegf stimul growth new blood vessel combin chemotherapi bevacizumab shown like shrink tumor help patient certain type nsclc adenocarcinoma live longer ramucirumab cyramza also use treat nsclc monoclon antibodi target vegf receptor help stop format new blood vessel ramucirumab often given chemotherapi drug docetaxel later line therapi anoth treatment stop work immunotherapi immun system constantli work keep us healthi recogn fight danger infect virus grow cancer cell gener term immunotherapi use immun system treatment cancer march fda approv immunotherapi nivolumab opdivo treatment metastat squamou nsclc unsuccess treat chemotherapi nivolumab work interf molecular brake known pd prevent bodi immun system attack tumor two addit drug categori approv octob atezolizumab tecentriq pembrolizumab keytruda pembrolizumab drug categori approv first line initi treatment lung cancer februari fda approv immunotherapi durvalumab imfinzi treatment patient stage iii nsclc whose tumor unabl surgic remov whose cancer progress treatment chemotherapi radiat treatment approach studi effect combin immunotherapi treatment nsclc studi mani clinic trial one promis approach pair nivolumab ipilimumab yervoy immunotherapi current approv fda treatment metastat melanoma anoth area ongo research combin immunotherapi chemotherapi first line treatment option fda approv use pembrolizumab combin chemotherapi first line treatment metastat nsclc addit effect potenti side effect ad radiat therapi immunotherapi current studi introduct manag treatment side effect print email share tweet import clinic trial clinic trial standard measur worth new treatment qualiti life patient receiv treatment reason doctor research urg peopl cancer take part clinic trial doctor guid make decis whether clinic trial right thing know often peopl take part clinic trial gain access benefit new treatment particip clinic trial fulli inform risk benefit trial includ possibl side effect clinic trial design test new treatment standard treatment find whether new treatment ad benefit stop take part clinic trial time reason listen cancer treatment caus side effect import report side effect experi health care team help manag report right away wait next appoint improv qualiti life allow stick treatment plan import rememb patient experi side effect patient may experi side effect list side effect chemotherapi side effect chemotherapi depend type dose drug given length time use includ fatigu tire hair loss diarrhea constip increas risk infect white blood cell easi bruis bleed chang memori think peripher neuropathi numb tingl hand feet side effect radiat therapi treatment chang skin includ dryness swell peel red blister reaction occur contact health care team appropri treatment prescrib especi import contact health care team open skin pain area could indic infect infect treat oral antibiot topic antibiot cream side effect target therapi target therapi drug effect bodi chemotherapi drug still caus side effect potenti side effect target therapi includ rash diarrhea liver problem elev liver enzym problem blood clot wound heal high blood pressur side effect immunotherapi immunotherapi travel bloodstream help prompt immun respons trigger attack healthi cell well cancer cell certain side effect may experienc includ fatigu decreas appetit digest tract symptom manag potenti side effect discuss later next section booklet manag digest tract symptom nausea vomit avoid food strong odor well overli sweet greasi fri highli season food nibbl dri cracker toast bland food easi stomach someth stomach take medic may help eas nausea mani effect medic nausea vomit develop recent year talk doctor whether may right diarrhea drink plenti water ask doctor use drink gatorad provid electrolyt well liquid electrolyt bodi salt must stay balanc cell work properli counter medicin loperamid imodium other prescript drug avail diarrhea use necessari diarrhea bad enough need medicin discuss doctor nurs choos food contain solubl fiber exampl bean oat cereal orang flaxse high pectin food peach appl orang grapefruit banana apricot also help avoid diarrhea loss appetit help maintain weight eat small meal throughout day easi way take protein calori tri includ protein everi meal keep feel full earli avoid liquid meal take small sip unless need liquid help swallow drink liquid meal focu liquid nutrit valu physic activ sometim take short walk hour meal help feel hungri keep high calori high protein snack hand hard boil egg peanut butter chees ice cream granola bar liquid nutrit supplement pud nut can tuna trail mix struggl maintain appetit talk health care team whether appetit build medic could right manag fatigu fatigu extrem tired help sleep one common side effect mani cancer treatment take medic doctor may lower dose drug long make treatment less effect experienc fatigu talk doctor whether take smaller dose right number tip reduc fatigu take sever short nap break take short walk light exercis possibl tri easier shorter version activ enjoy ask famili friend help task find difficult tire save energi thing find import also prescript medic may help modafinil health care team provid guidanc whether medic right approach individu circumst manag pain number option pain relief includ prescript counter medic import talk member health care team take counter medic determin safe interfer treatment treatment option commun health care team print email share tweet listen manag lung cancer import rememb consum health care best way make decis health care educ diagnosi member health care team includ nurs social worker patient navig tip improv commun health care team start health care journal health care journal notebook allow keep health inform one place may want write name contact inform member health care team well question doctor keep diari daili experi cancer treatment separ journal notebook differ section help keep organ prepar list question next medic appoint write question concern doctor may limit time ask import question first specif brief possibl bring someon appoint even journal prepar list question concern alway help support go appoint person accompani serv second set ear may also think question ask doctor rememb detail symptom treatment may forgotten write doctor answer take note help rememb doctor respons advic instruct cannot write answer ask person accompani mobil devic use take note write note help review inform later record visit doctor allow record convers doctor give chanc hear specif inform share famili member friend incorpor health care profession team oncologist oncolog nurs essenti member health care team health care profession help manag diagnosi treatment make sure oncologist know medic condit pain experienc consult primari care physician specialist need rememb thing commun manag treatment side effect faq print email share tweet cancer care free support servic program oncolog social worker provid emot support peopl cancer love one profession help cope challeng cancer diagnosi guid resourc cancer care offer free counsel profession oncolog social worker understand challeng face peopl cancer caregiv work one one develop strategi cope treatment side effect oncolog social worker also help commun doctor member medic care team health care issu import support group provid care environ share concern other similar circumst support group member come togeth help one anoth provid insight suggest way cope cancercar peopl cancer famili particip support group person onlin telephon financi help offer cancer care number organ assist cancer relat expens transport treatment child care home care learn cancer care help pleas call us hope visit www cancercar org www lungcanc org listen frequent ask question q breath affect surgeri chemotherapi surgeri reduc size lung cannot take much air medic also chang lung function lead short breath time difficulti breath report doctor prescrib pulmonari lung rehabilit therapi therapi may includ exercis train energi conserv techniqu breath strategi nutrit counsel improv lung function q lung cancer ret gene mutat drug studi type tumor ret protein send signal cell tell divid matur special perform specif function mutat ret gene signal get stuck caus uncheck cell growth discov mutat ret gene mutat link lung cancer three medic approv fda peopl type cancer ret mutat cabozantinib cometriq vandetanib caprelsa peopl thyroid cancer sunitinib sutent kidney cancer pancreat cancer gastrointestin stromal tumor gist talk doctor lung cancer clinic trial peopl ret gene mutat ask whether recommend prescrib medic label use prescript drug legal treat cancer drug approv fda q happen treatment stop work happen discuss altern treatment option doctor recommend base uniqu situat includ factor relat overal health note sever drug late phase clinic trial intend use initi lung cancer treatment becom less effect stop work q stage lung cancer surgic remov doctor say need chemo type treatment get second opinion cancer truli stage treatment surgeri recommend howev import get ct scan everi six month first two year surgeri check recurr new cancer first two year doctor recommend frequent get ct scan commun health care team print email share tweet resourc cancer care hope american cancer societi cancer net cancer support commun lungcan lungcanc org hope lung cancer allianc nation cancer institut find clinic trial emergingm',\n",
       " 'mother diagnos stage nsclc septemb efgr histori first tarceva carboplatin alimta plu tarceva tagrisso progress tagrisso start decemb tri one round keytruda pd l express due extrem cough rule pneumon ct scan done right second round keytruda scan show larg growth exist tumor new growth oncologist thought would better switch chemo tri control growth soon possibl immunotherapi tend take week month effect cancer could grown much round docetaxol noth cancer continu progress round navelbin ct scan show mix result tumor slightli smaller other remain grew tini bit continu navelbin much clearer progress show option mom oncologist thought would worth shot retri tagrisso still posit oncologist think higher chanc tagrisso work retri type immunotherapi said egfr posit patient good result immunotherapi mother rare case egfr posit high pd l express',\n",
       " 'also spent year year half wallow seem get wors wors final got rear someth activ start feel differ almost immedi first coupl week exhaust built strength got better honestli bother ms month year sinc first dx take vitamin vitamin b energi gilenya mostli stop klonopin work fireplac technician requir walk stand kneel lift cognit abil year patient ms never stop move licens residenci builder come fact bodi use matter hard push mean complain kinda strang year went build hous troubl walk time wallow angri fear stop die bodi work never good day never realli hope g work prm suck ms suck mser get prm pain never end never honestli choic bodi say mean one guy told ms lotto make happi funni laugh',\n",
       " 'hi jeanni often patient begin standard dosag mostli clinic trial shown dose toler patient specifi dosag shown efficaci maximum toler dose establish earli phase clinic trial lower dosag tend test oncolog much art scienc certainli room individu oncologist feel lower dose would minim side effect particular patient dose recommend unless cancer appear progress fast rate reason start low rais dose drug well toler respons less anticip although tough determin sinc patient achiev differ level respons stage iv diseas even stabil without tumor shrinkag good result far side effect larger dose taken less frequent tend well studi either number patient given puls tarceva e g mg everi four day seem experi signific side effect receiv mg per day jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'hi kempten think initi question would slight progress lung mass compar overal size thought continu tagrisso bit confirm progress determin rate growth dr west often state often make sens stay well toler treatment even face slow progress bad brake better brake cours local doctor best abl judg question origin percentag exon mutat unchang seem indic exon posit portion cancer progress sinc would expect percentag rise either way specul sinc unfortun understand resist progress well yet discuss treat tarceva failur tagrisso use tagrisso first line set even context good evid yet efficaci dr ramalingam state two month ago tagrisso studi first line therapi set see shut escap resist mechan pro activ improv outcom patient approach shown promis earli result studi larg clinic trial trial compar tagrisso directli tarceva iressa still learn mechan resist observ patient treat tagrisso first line set possibl subset patient use iressa tarceva receiv tagrisso might benefici earli time make firm statement issu present avail data base laboratori experi confirm patient http cancergrac org topic tagrisso first line tarceva therapi post [continu jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa repli modifi year month ago jimc forum moder repli modifi year month ago jimc forum moder',\n",
       " 'hi bettina year diagnos rebif tysabri fingolimod came fingolimod nov prepar start ivf jan feb year worst relaps ever slap bang middl first ivf tri mri show least new activ lesion neuro realli want stop ivf go straight lemtrada leav ivf anoth year didnt want one point appoint got frustrat threw hand air walk say would get someon els make see sens agre would least meet ms nurs start lemtrada much understand want babi interest said isnt unheard women babi lemtrada treatment understand say feel selfish want babi well alway pretti bad relaps luckili recov well husband also ms huge decis come treatment ivf despit relaps happi stuck gun want older alreadi much older want start famili way wait anoth year pregnanc kind ms breast feed deliv also offer protect relaps lucki enough nd round ivf work due late jan neuro want start lemtrada within week deliveri havent decid yet cant imagin would want leav newborn day even though come home night soon ms throw us mani mani curv ball great hear peopl didnt honestli believ go gut alway find someon disagre decis cant tell mani time call selfish tri babi ms didnt stop us good luck decis realli interest get whichev way choos go dont mind share cours hayey xx',\n",
       " 'neuro say ocrelizumab old drug rituxumab revampt much chang realli rituxumab move patent new version ocrelizumab pharma get money yet doctor bart blog seem excit ocrelizumab moyna',\n",
       " 'mapesg get trial ulcer coliti sinc juli pred mg upadacitinib clinic trial sinc octob colazid g entyvio vedolizumab sinc januari stop oct lost respons azathiporin mg stop due clinic trial',\n",
       " 'long term treatment diseas modifi therapi dmt appear lessen risk diseas worsen relaps remit multipl sclerosi rrm patient year follow studi suggest therapi seen benefit progress secondari progress multipl sclerosi spm studi onset secondari progress multipl sclerosi influenc current relaps multipl sclerosi therapi publish multipl sclerosi journal experiment translat clinic diseas modifi therapi dmt treatment aim reduc ms progress relaps remit form diseas spm research conduct retrospect analysi patient regist group research treatment multipl sclerosi gitem registri valencia spain initi patient clinic diagnos ms receiv treatment first line dmt interferon beta biogen avonex among brand name glatiram acet sold teva copaxon treatment dmt began patient experienc least one relaps previou year two relaps within previou three year rrm patient follow median year patient fail respond treatment given second line therapi name immun suppress novantron mitoxantron cyclophosphamid select second line dmt tysabri natalizumab gilenya fingolimod studi particip evalu regularli everi three six month chang expand disabl statu scale edss score relaps rate side effect decis stop treatment progress spm confirm patient previou edss score greater experienc six month worsen edss greater without evid relaps research wrote continu read',\n",
       " 'hi see inject silicon tini amount silicon oil use lubric insid needl although use needl contain silicon henc class action usa uk appar occasion use needl got small silicon bubbl first inject eylea subsequ problem inject elea inject almost complet cure small amount wetamd one eye person ok live small floater occasion appear',\n",
       " 'repli post justmari remicad sinc ever sinc hospit claim remiss base studi blood work result despit fals claim still occasion bloodi stool frequent symptom side effect mouth sore psoriasi abdomin cramp etc final switch hospit new gi want switch stalera much newer far appear effect start first stalera treatment yet see natur remedi like healthi diet correct vitamin supplement exercis littl pot may abl make differ without biolog system far feel much better remicad experi less symptom probabl keep treatment broke fix',\n",
       " 'said gp refer doctor bart second opinion ms neurologist refer talk cladribin want find might help',\n",
       " 'glad hear contentprof well go next infus week pancol dx fall current imuran lialda entyvio',\n",
       " 'peopl know medic stori tysabri four year four month gone downhil pretti steadili time nervou move gilenya less power lot side effect common chang coupl year ago make mistak christma told pml risk gone right one dose tysabri scare rebound relaps long tysabri first dose gilenya start gilenya day still nervou side effect physic deterior get still hope go cladribin end know month gilenya tri still hope get better physic state rather wors one sort get lift put hous hope best plan worst',\n",
       " 'fail remicad infliximab humira adalimumab consid entyvio vedolizumab xeljanz tofacitinib beav said simponi godlimumab yet anoth tnf alpha blocker sister medic humira remicad moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa cannot spell suck without uc',\n",
       " 'hi follow site sinc april diagnos rrm thought stroke yo femal sinc time sever relaps tri differ med agre second one leav bed ridden week last relaps june develop sever vertigo still fulli recov complet numb right side go hospit iv steroid refus take oral plu side led start fingolimod found give issu number symptomat med work mobil come goe reduc hour work kept fall asleep home suddenli one could wake readi come realli good doctor ms nurs contact time one tell peopl go complain experi someth differ realli say someth ask biggest issu annoy moment addit deal random stuff current constip odd accid like bu stop get bu bladder issu go abl pass urin utterli wet recent new year eve front mother urologist want self catheris bring alway nice read peopl deal dealt regular basi tri get one get random symptom deal x',\n",
       " 'fernando find stelara help periann crohn also fistula julia',\n",
       " 'mollymop sorri small chang know much fund drug bc live usa hope get approv btw wrote previou messag saw kindl chang word fix messag know anyth kadcyla experi abraxan avastin combo month stop bc kick butt even though still work use vinorelbin year cap year gemcitabin month still work toxic reaction breath letrozol ibranc finish th cycl hair lost mine x bother much nd time happi best luck ff',\n",
       " 'leogirl gilenya neuro monthli mri chang diseas activ past mri move annual mri head spine seem littl long new lesion without clinic symptom past like know go noggin',\n",
       " 'mother prednison almost four year polumyalgia rheumatica found recent reason horribl back pain could hardli walk extend use prednison mri show actual crack spine still shock cannot revers even though peopl feel fine realli top world end result devast deal even pain even associ polymyalgia never recov everyon differ pleas look con medicin take bewar regret inflammatori condit copd chest pain also shoulder pain due lift heavi object last year start prednison mg x two day back shall take day felt much better second day today third day feel much better copd symptom improv much also reduc swell shoulder magic taken shoulder pain improv much rais hand degre imposs two day back breathless due smoke relat copd get cure improv upto three day go shall updat ajit review crohn diseas mainten take mg x day along humira everi two week combin work well healthier year signific side effect anxieti told side effect pentasa year year stretch complet anxieti went away entir went back pentasa made connect fionafir crohn diseas mainten diagnos year emerg surgeri mass colon due build scar tissu inflamm coupl month mg x day frequenc flare up greatli reduc notic symptom one weight gain elev liver function test dosag reduc x day liver function normal weight gain still issu diet stress level seem import factor control flare up',\n",
       " 'week three gilenya felt aw limb leaden utter exhaust day also bad hayfeav weather hot sunni contact wonder ms nurs see could relaps bodi becom use new med previous copaxon ms nurs thought mostli like combin new need hayfeav hot weather turn correct end week three week four feel much better mile recumb trike ride next day mile nordic walk follow day anoth mile cycl activ easi terrain follow quieter day even book club board game group',\n",
       " 'opdivo year apart itchi rash feel good scan result today lymph node cant seen new growth anywher work well easi treatment far compar chemo dream wish dad best luck hope opdivo good',\n",
       " 'know someon may relaps go hard time thing could buy friend multipl sclerosi like comfort super soft blanket luxuri spa robe sheerl slipper cotton pajama need sleep hot steam eye mask cute silk one essenti oil mani heal properti make life easier alexa echo product assist shop entertain remind relax box set favorit televis show alf anyon tri audibl get two free audiobook glamor help shower chair cool vest squatti potti friend rave obvious gift never need text hug visit favor appreci welcom favorit gift idea also may enjoy read one step closer ms cure ocrevu show promi e new step diagnos ms stay connect modern day ms facebook twitter instagram pinterest pleas watch share ms awar video',\n",
       " 'hi hammer sorri learn sister diagnosi hope intrathec chemo forestal progress glaze stare portray one mani symptom wife experienc look one last photo togeth see wish famili best hope miracl sister bob sept wife beth year old non smoker dx stage adinocarcinoma nsclc egfr met liver bone brain sept oper replac right hip damag bone met sept dvt found leg start lovinox oct start tarceva mg per day januari surgeri stabil right femur follow radiat treatment april radiat treatment left femur may dx lmd start puls dose tarceva mg wk sept lost beth',\n",
       " 'read post thought felt gilenya made ms wors start gilenya june first month two bad past month symptom gotten progress wors major exacerb begin novemb week solumedrol ten day oral prednison felt littl better everi day seem littl numb feet gone knee left arm hand day face go see dr begin next week want drug stop slow worsen symptom go tri ocrevu',\n",
       " 'current gilenya pretti much relaps free sinc start take seven year ago drug recommend spm interferon beta mitoxantron peopl still relaps taken betaferon caus depress interferon beta option like sound mitoxantron side effect hang relaps remit label keep drug happi let neurologist use label regardless feel condit appoint think see neurologist year take prescrib medic also see ms nurs year six month appoint neurologist sometim sound like pwm get left devic medic suppos get see neurologist someth seriou happen',\n",
       " 'headach sinc small child progress got wors year old teenag link ton ms symptom age eventu diagnosi eye check recent find ms eye constantli chang three differ prescript also rule allergi trigger headach mine mainli tension headach environment end take advil sinu pill work like charm gilenya caus frequent headach well notic first month lot headach get better though pill bit longer ms pain long stay kind far rest diet stress figur work definit speak gp possibl medic eas pain headach also make sure get rest sleep issu right manag full night sleep without wake see sleep apnea specialist enjoy everi day come stress futur present tackl issu soon aris take time figur work',\n",
       " 'rememb often combin therapi best often singl medic get us rather take multipl medic simultan order achiev remiss might need remicad imuran mp mesalamin achiev remiss often take less medic sustain remiss initi achiev remiss expect med reduc sustain remiss moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa cannot spell suck without uc',\n",
       " 'fingolimod failur typic would first inject mani peopl need third round inject get maximum benefit ensur deplet alemtizumab',\n",
       " 'hi vender way understand ms basic involv demyelin neurodegener nerv brain spinal cord variou symptom fatigu bladder issu eye issu etc seem span across differ type ms although everyon regardless ms type exact symptom weird diseas huh differ cours diseas take though nation ms societi recent modifi descript four type ms cours prm fall activ ppm relaps ppm take dmd relaps acut inflammatori event chart nmss show four cours http www nationalmssocieti org ms type ms seem littl confus hope get feedback use gilenya wish good luck take care',\n",
       " 'nerv pain relat damag begun initi attack caus lose use domin arm hand month sever dose solumedrol pt regain motor function lost fine motor skill last damag begin chronic pain eventu includ arm hand affect leg side final ms hug associ symptom distinct nerv pain cannot improv typic pain medic pregabalin anti seizur low dose antidepress med help prior suffer spastic bladder featur sear pain help gabapentin found secret pain reduc year suffer experienc whole bodi pain syndrom describ gilenya four year back pain list possibl se learn experi lot ms nerv damag dmd stir pot mayb pot stir',\n",
       " 'hey ocrevu first two half infus much better symptom disappear lessen tremend walk fast without use walker cog fog gone along spastic cog fog swallow issu ms hug lessen fatigu tingl use numb tingli head toe get occasion tingl feet leg use bad numb tingli burn felt heavi pretti much back normal slight infus reaction first half itchi scalp took care reaction second half recent came shingl pain know ocrevu lower immun system probabl trigger recommend get vaccin believ vaccin given week prior infus lemtrada also immunosuppress go lemtrada neuro actual given med shingl take week lead shortli got ms specialist decid ocrevu never took med also heard posit thing lemtrada well decid dmt alway difficult let know question best luck',\n",
       " 'hope know cidp hereditari pass children far recoveri goe cidp littl year seem unfortun diseas take sometim abat go type nerv damag cidp mani medic profession consid two three year mark time heal symptom still present three year may stay us mani year good news newer treatment alway come forum full discuss newer treatment hsct rituximab ocrelizumab mani list forum post along link neurolog report cover addit treatment option booklet may offer help info cidp teen http g el b b n kgpr nuu wpengin netdna ssl com wp content upload teenyoungadult pdf way earli say like would get wors futur kid give time see heal mayb anoth year two least',\n",
       " 'good morn updat check read post last round chemo rough go one lower left lobectomi septemb follow round cisplatin alimta went st scan follow lobectomi chemo get readi radiat unfortun found new total new nodul lower right mm upper left mm schedul anoth biopsi next thursday larger one point radiat start earli februari hold till know go',\n",
       " 'one say humira affect might get remiss give old self back someth anyon promis truth crohn complex diseas even peopl remiss intestin still ongo issu fatigu ib joint problem etc say got luxuri time give humira go may one lucki one make decis think care go humira dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'follow histori origin post read articl would even print share dr insur provid deni coverag shame stori rituximab multipl sclerosi http neuroimmunolog wordpress com shame stori rituximab multipl sclerosi rituximab vs ocrelizumab multipl sclerosi http neuroimmunolog wordpress com rituximab vs ocrelizumab multipl sclerosi',\n",
       " 'hi molli molop ye experi laser eye treatment retinopathi plenti treatment mani treatment lost count probabl sever variat laser diagnos retinopathi joslin clinic assur total blind within two year refer ophthalmologist boston confirm diagnosi prognosi told treatment theori work laser photocoagul volunt guinea pig first laser treatment modifi weapon grade rubi fix strength durat return everi month burn year video joslin site lay oper tabl [in shirt tie] one follow treatment summer latest laser treatment decemb green argon far pain discomfort never much found locat burn make big differ rubi laser least pain time felt brief short pain doctor need aim close nerv high power doubt requir case thousand burn real estat avail futur treatment found place trust opinion skill doctor would agre treatment decis year ago award mani year good vision life agre research never heard laser sot advic doctor scientist includ nasa turn one rel charg apollo space mission use rubi laser mark land site moon messag email want talk',\n",
       " 'dose schedul sound similar wife current trial attempt irinotecan erbitux without avastin placebo drop fu previou folfiri ad erbitux think still get avastin base previou experi still ace inhibitor use avastin use though bp usual low begin infus monday noth day get hit problem know use higher dosag erbitux toler well rash came week right away think subsid prior yesterday infus cours interest ucsd trial contribut research class drug particularli ci dacomitinib still believ despit failur dacomitinib erlotinib big pfizer nsclc trial archer dacomitinib still superior egfr famili inhibitor ucsd trial look promis know egfr inhibitor becom resist one lay pathway divert make tumor resist revert egfr inhibitor becom effect wonder also dose schedul concentr use trial work similarli hit tumor hard relax enabl tumor slide altern signal pathway mani question hope trial answer wonder would consid use dacomitinib arm crowd fund trial also regard grouseman',\n",
       " 'get readi start stelara sometim sept also wonder fistula etc strang let stay last drug studi offer indic success close would continu provid drug seem rather cruel take get sick femal canada ivig pentasa entyvio infus respons discontinu uc crohn test posit map antibodi mycobacterium pg remiss flare almost year bad way due abx treatment gone wrong sigh',\n",
       " 'today u food drug administr fda approv pembrolizumab keytruda combin pemetrex alimta platinum first line treatment patient metastat nonsquam non small cell lung cancer egfr alk genom tumor aberr pembrolizumab previous grant acceler approv indic may base improv overal respons rate progress free surviv patient random pembrolizumab administ pemetrex carboplatin compar pemetrex carboplatin alon keynot studi keynot recent approv repres fulfil postmarket commit demonstr clinic benefit product action base result keynot random multicent doubl blind activ control studi enrol patient receiv first line treatment metastat nonsquam nsclc keynot patient random receiv pembrolizumab placebo combin pemetrex investig choic either cisplatin carboplatin everi week cycl follow pembrolizumab placebo pemetrex treatment pembrolizumab continu diseas progress unaccept toxic maximum month primari efficaci outcom measur overal surviv progress free surviv assess blind independ committe review use respons evalu criteria solid tumor version key result trial demonstr statist signific improv overal surviv patient random pembrolizumab chemotherapi hazard ratio [hr] confid interv [ci] p prespecifi interim analysi median overal surviv reach time data cutoff pembrolizumab plu chemotherapi arm month chemotherapi arm trial also demonstr improv progress free surviv patient random pembrolizumab plu chemotherapi hr ci p median progress free surviv month patient receiv pembrolizumab plu chemotherapi month receiv chemotherapi alon overal respons rate significantli higher vs p pembrolizumab plu chemotherapi arm median respons durat month month respect common advers reaction report patient keynot fatigu asthenia nausea constip diarrhea decreas appetit rash vomit cough dyspnea pyrexia recommend pembrolizumab dose schedul nonsquam nsclc mg intraven infus minut everi week second fda approv use real time oncolog review pilot program enabl fda review team begin analyz data applic submiss content post review american societi clinic oncolog inc asco necessarili reflect idea opinion asco',\n",
       " 'repli post cianphillip hi jami know look confirm unfortun diagnos eat microwav process food follow year time steroid work first time next flare work even mg day symptom final improv ramp mg per day naturapath alergen free liquid diet work took bunch chines herb enter coat peppermint work azacol never work even highest dose mercapterpurin mp work coupl year liver enzym test start come back danger rang stop recent remicad work year stop current flare remicad treat steroid make super sugar sensit requir insulin inject etc take hand pro prebiot everi day eat sour krout pickl live cultur unsweeten goat kefir garlic fish oil much toler year stay away milk nut black red pepper etc think culprit follow year eat without incid except spici food still hurt pretti consist say convinc treatment diet contraint addit offer minim benefit sometim enough assist remiss none consist mention previou poster regard one mani treatment untreat placebo group improv respond treatment math right may feel free correct possibl posit outcom could spontan e g placebo leav higher placebo efficaci treatment surpris fact check number mirror experi treatment kind experi made correl connect mani diet chang medic long run turn caus',\n",
       " 'review literatur found date pembrolizumab pd pd li inhibitor show signific surviv benefit chemotherapi given monotherapi part combin therapi metastat squamou nonsquam nsclc [non small cell lung cancer] statement research write new england journal medicin also present new data iaslc th world confer lung cancer toronto canada septemb base data merck sharp dohm maker pembrolizumab add treatment pembrolizumab combin chemotherapi result significantli longer overal surviv os progress free surviv pf compar chemotherapi alon squamou nsclc accord articl kaplan meier estim rate surviv year pembrolizumab combin arm placebo combin arm though trial conclud estim conclus date decis report second interim result occur efficaci boundari primari hypothes overal surviv progress free surviv met investig wrote origin set goalpost interim analysi occur event diseas progress death occur relat articl head head battl brigatinib appear best crizotinib durvalumab show overal surviv benefit patient stage iii nsclc despit promis trial result skeptic rais red flag anlotinib efficaci heavili treat nsclc doubl blind phase trial research run keynot trial randomli assign untreat metastat squamou nsclc patient receiv either mg pembrolizumab salin placebo cycl patient patient respect patient also treat carboplatin either paclitaxel nanoparticl albumin bound [nab] paclitaxel first cycl patient receiv paclitaxel also receiv premed glucocorticoid antihistamin patient allow crossov certain circumst patient switch placebo pembrolizumab diseas progress patient receiv subsequ pd pd l inhibitor prescrib outsid trial pd l express statu assess use agil technolog pd l ihc c pharmdx assay tumor imag schedul week everi week week everi week thereaft result use tool patient exclud trial could provid tumor sampl determin pd l statu os pf respons rate durat respons calcul use blind independ central review radiolog imag pd l tumor proport score greater seen patient regardless patient pd l express level overal surviv benefit observ across pembrolizumab combin group group median os follow month compar month placebo combin group hazard ratio death confid interv [ci] p median pf month month respect hazard ratio diseas progress death ci p risk death lower risk diseas progress death lower pembrolizumab combin group placebo combin group author wrote ad patient pd l posit tumor current avail data permit determin whether pembrolizumab plu chemotherapi greater efficaci pembrolizumab alon respons rate howev higher among individu receiv pembrolizumab base regimen compar rate observ placebo regimen patient place subgroup defin pd l tumor proport score outcom improv across categori pd l tumor proport score pembrolizumab chemotherapi group make studi author question use pd l biomark guid drug select advers event ae similar across treatment group although treatment discontinu pembrolizumab combin group occur frequent placebo combin group vs respect death due ae pembrolizumab base arm ae relat death placebo base arm read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       " 'arriv heavi hitter go back first instal ibd academi back basic rememb inflammatori bowel diseas fundament autoimmun disord immun system mistakingli attack bodi tissu inhibit counteract reaction immunomodul biolog use dampen autoimmun respons seriou concern use medic lymphocyt white blood cell center autoiummun widespread bodi target induc systemat local immunosuppress mean gut part bodi affect regular blood test usual done check liver kidney bone marrow function suppress effect drug immun system patient immunomodul biolog also encourag receiv yearli flu vaccin avoid live vaccin medic mani cell molecul involv autoimmun key player familiar refer back dive mechan util variou immunosuppress medic key vocab intestin mucosa tissu line gi tract made endotheli cell attack white blood cell autoimmun reaction basi ibd lymphocyt cell type white blood cell central immun respons ibd autoimmun disord antibodi protein circul blood follow product immun system respons foreign particl detect bodi may produc bodi creat artifici use drug cytokin signal protein essenti commun cell involv inflammatori respons may pro inflammatori anti inflammatori interleukin class cytokin involv modul immun respons develop lymphocyt tnf tumor necrosi factor alpha pro inflammatori cytokin central regul immun function target multipl biolog therapi autoimmun disord integrin receptor cell allow interact cell bodi madcam protein express endotheli cell small blood vessel intestin mucosa immunomodul drug modul weaken immun system order dampen inflammatori respons may use conjunct biolog dual therapi combin therapi increas chanc induc maintain remiss thiopurin azathioprin imuran oral mercaptopurin mp purinethol oral mechan action prevent activ lymphocyt keep attack intestin mucosa caus inflamm may take three month work therefor patient often steroid new medic kick methotrex subcutan sc inject mechan action addit act cellular level like thiopurin methotrex may also inhibit pro inflammatori cytokin like il interleukin tnf bloodstream tradit use treat rheumatoid arthriti lupu use crohn patient fail becom toler thiopurin shown effect uc must use caution women child bear age due risk birth defect miscarriag cyclosporin oral mechan action prevent lymphocyt produc cytokin multipli tradit use prevent reject follow organ transplant use patient sever uc much rapid onset action thiopurin take two week begin work tacrolimu oral topic mechan action also prevent lymphocyt make cytokin multipli tradit use prevent reject follow organ transplant use patient sever uc fistul crohn use topic activ crohn diseas around mouth perian area skin pyoderma gangrenosum biolog drug name end mab stand monoclon antibodi biolog antibodi design bind inhibit inflammatori factor molecular target involv immun respons ibd antibodi foreign protein immun system produc anti drug antibodi biolog caus drug stop work mani ibd patient switch anoth biolog form antibodi one list order fda approv oldest newest anti tnf mechan action bind block excess tnf bloodstream order prevent attack healthi cell gut see figur remicad infliximab infus everi week fda approv treat crohn diseas ulcer coliti adult children two biosimilar essenti gener avail renflexi infliximab abda inflectra infliximab dyyb also treat rheumatoid arthriti plaqu psoriasi psoriat arthriti ankylos spondyl humira adalimumab sc inject everi week fda approv treat crohn diseas adult children ulcer coliti adult also treat juvenil adult rheumatoid arthriti plaqu psoriasi psoriat arthriti ankylos spondyl hidraden suppurativa panuv cimzia certolizumab pegol sc inject everi week fda approv treat crohn diseas adult also treat rheumatoid arthriti psoriat arthriti ankylos spondyl simponi golimumab sc inject everi week fda approv treat ulcer coliti adult also treat rheumatoid arthriti psoriat arthriti ankylos spondyl excess amount tnf alpha caus immun system mistakenli attack healthi cell gi tract lead inflamm underli caus crohn symptom janssen biotech inc remicad belong class biolog medic known tnf blocker remicad bind tnf alpha block action janssen biotech inc anti integrin indic patient respond lost respons anti tnf tysabri natalizumab infus everi week mechan action bind integrin receptor cell block interact madcam protein blood vessel intestin mucosa prevent cell migrat blood stream attack intestin mucosa also block cell interact vcam protein endotheli cell elsewher bodi associ increas risk rare brain infect call progress multifoc leukoencephalopathi pml especi use conjunct anoth immunosuppress drug fda approv treat adult crohn diseas also treat multipl sclerosi entyvio vedolizumab infus everi week mechan action also bind integrin receptor cell block interact madcam prevent cell migrat gut affect vcam shown caus pml first current biolog target gut focus inflammatori pathway fda approv treat adult crohn diseas ulcer coliti target gut specif inflammatori mechan use exclus ibd anti interleukin stelara ustekinumab sc inject everi week mechan action target proinflammatori factor il il interleukin prevent activ lymphocty fda approv treat adult crohn diseas also treat plaqu psoriasi psoriat arthriti note dose list baselin guidelin medic follow induct stage treatment base individu respons schedul may adjust frequent dose individu class biolog shown effect treat case ibd current unknown given patient respond one biolog anoth seri molecular interact lead activ ibd inflammatori cascad complic web trigger interact mani mani potenti molecular target new treatment addit target pathway common mani autoimmun disord research also attempt develop new biolog gut specif mechan immunosuppress entyvio medic work way safer overal suppress immun system local manner make patient less suscept certain infect comparison older gener immunosuppress immun respons lead intestin inflamm activ inflammatori bowel diseas consist varieti pro inflammatori factor includ cytokin tna interleukin well activ multipl type white blood cell mainli variou cell molecul associ cell receptor repres potenti target ibd therapi top section figur show target associ drug intestin mucosa anti tnf anti interleukin bottom section show target border blood vessel anti integrin imag taken danes vuitton l peyrin biroulet l biolog agent ibd practic insight natur review gastroenterolog hepatolog page doi nrgastro strongli advoc involv decis regard treatment make sure take medic prescrib doctor supervis come next ibd academi surgeri ostomi sourc sciencedirect cytokin http www sciencedirect com topic neurosci cytokin sciencedirect interleukin http www sciencedirect com topic neurosci interleukin sciencedirect tumor necrosi factor alpha http www sciencedirect com topic immunolog microbiolog tumor necrosi factor alpha bio rad antibodi immunoglobulin http www bio rad antibodi com immunoglobulin antibodi html crohn coliti foundat immunomodul http www crohnscolitisfound org resourc immunomodul html crohn coliti uk azathioprin mercaptopurin http eu west amazonaw com file crohnsandcol org uk public azathioprine_ed_ b_ _feb_ pdf neurath thiopurin ibd http www ncbi nlm nih gov pmc articl pmc swaminath taunk r lawlor g use methotrex inflammatori bowel diseas user guid http www ncbi nlm nih gov pmc articl pmc segal r yaron n tartakovski b methotrex mechan action rheumatoid arthriti http www ncbi nlm nih gov pubm harding k mage c pharmacolog cyclosporin tacrolimu http www uptod com content pharmacolog cyclosporin tacrolimu american cancer societi monoclon antibodi treat cancer http www cancer org treatment treatment side effect treatment type immunotherapi monoclon antibodi html bendtzen k tumor necrosi factor alpha inhibitor induct antibodi autoantibodi autoimmun diseas http www uptod com content tumor necrosi factor alpha inhibitor induct antibodi autoantibodi autoimmun diseas jannsen biotech remicad work http www remicad com crohn diseas remicad work merck co renflexi prescrib inform http www merck com product usa pi_circular r renflexi renflexis_pi pdf pfizer inflectra prescrib inform http label pfizer com showlabel aspx id section medguid abbvi learn humira work moder sever crohn diseas http www humira com crohn humira work crohn ucb live cd http www cimzia com live cd jannssen biotech explor inject experi simponi offer http www simponi com biogen tysabri mechan action http www tysabrihcp com en_u home mechan action html cid ppc bng ty hcp brand v exact moa gclid ckhcql kitocfvdygqod tsnza gclsrc ds fda highlight prescrib inform tysabri http www accessdata fda gov drugsatfda_doc label lbl pdf takeda pharmaceut entyvio mechan action http www entyviohcp com mechan action jannsen biotech stelara http www stelarahcp com crohn diseas mechan action danes vuitton l peyrin biroulet l biolog agent ibd practic insight kristen weiss sander proud ostom third gener girl gut diagnos ibd passion patient educ encourag chronic ill knowledg part healthcar team kristen credit constant exampl support strong women famili determin thrive crohn diseas use ibd journey empow other',\n",
       " 'sister law diagnos year ago stage adenocarcinoma would consid oligiomestast diseas round cancer journey diagnos cancer type lung cancer diseas learn biolog ok alectinib psoriasi along stage iv nsclc alk posit take alectinib nsclc ok take biolog like cosentyx stelara cancer journey treatment cancer type lung cancer diseas learn neuropathi autoimmun hi year prior diagnosi small cell lung cancer suffer small fiber neuropathi sure autoimmun relat cancer journey diagnos cancer type lung cancer diseas learn progess tagrisso tagrisso sinc juli great initi respons visibl cancer shrink point longer detect cancer journey treatment cancer type lung cancer diseas learn pancoast four month ago start pain neck shoulder upper arm left side cervic shoulder upper arm mri cancer journey cancer type lung cancer head neck cancer',\n",
       " 'hi folk surpris neurologist suggest think join year studi new drug ocrelizumab plegridi year although relaps last mri show new lesion spinal cord due screen studi come friday know peopl studi uk wonder anyon els consid alreadi accept studi thank',\n",
       " 'clariti pretti sure let gilenya alreadi low lymphocyt count gilenya would lower even',\n",
       " 'offer mavenclad definit worth consid along side option final choic definit ms nurs help choos though',\n",
       " 'repli post zepolv came right place see peopl differ degre crohn sympathi get young age got ulcer coliti around age noth help eventu proctocollectomi thought problem got crohn bad uc still aw remicad two year noth tri entyvio hope work good luck',\n",
       " 'hi new forum diagnos ms sinc mani med help slow progress diseas current process set get start gilenya test jc viru came back neg lower chanc get pml side affect still kind nervou though anyon els take med love hear experi',\n",
       " 'hi jihm us get eylea chang doc thank inform gave forum regard silicon wonder would explain doc diagnos bubbl silicon test like think would prove perman irrit bubbl center vision silicon avastin inject pleas let us know legal action come along would known could gotten fda approv eye inject eylea would refus avastin eyesight preciou medic profess avoid anyth risk eyesight hope turn well eylea inject help',\n",
       " 'entyvio sort financi assist program think seen talk forum year old femal diagnos decemb ulcer pancol cmv anemia liver damag remicad fail prednison fail respons valcyt tacrolimu bridg biolog entyvio current dose uceri x iron infus blood transfus current case studi member patient ut southwest dalla tx',\n",
       " 'read http multipl sclerosi research blogspot com researchspeak rituxumab vs fingolimod html mayb read',\n",
       " 'year survivor nsclc came upon site accid first diagnos went conventi rout remov right lung chemotherapi appear cancer free return egfr mutat oral target therapi sinc remain first line drug tarceva gilotrif cancer check today growth tumor small stage oper symptom except side effect med know anyon els around long nsclc interest hear other still',\n",
       " 'diagnos stage nsclc april went radiat chemo ned small nodul grew small amount biopsi show cancer cell opdivo sinc septemb nodul smaller less solid hope someday gone minor side effect joint pain tire coupl day follow treatment noth compar chemo',\n",
       " 'mean scare want give inform given genetech post facebook ocrevu page two member develop cancer lung brain pancreat year someon suggest call drug compani mani given inform list opt go infus schedul stay tecfidera least inform good luck',\n",
       " 'anoth updat three infus seem wick headach within twenti four hour settl still get weird headach morn get move around day go day feel heavi head walk gener ok still balanc problem gener weak thing way better gilenya know turn jcv posit lemtrada avail new zealand expens either still progress definit good use avonex',\n",
       " 'first deserv much respect admir choos serv countri sorri hear diagnos good news advanc treatment option reason regul properli would abl continu full capac militari servic would question right choic mesalamin mesalamin famili drug consid antiqu therapi quit time initi treat prednison chanc would residu effect make seem like mesalamin might help type diagnost confirm diagnosi upper lower scope biopsi would recommend follow even second opinion treatment plan anoth gi might necessari good luck go forward militari servic keep us post progress daughter diagnos feb yr old time diagnosi crohn termin illium use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mg imuran',\n",
       " 'adjuv treatment erlotinib associ improv diseas free surviv versu chemotherapi chines patient epiderm growth factor receptor mutat stage iiia non small cell lung cancer indic phase ii trial result',\n",
       " 'fingolimod slow progress diseas measur combin disabl measur compar placebo',\n",
       " 'olympu trial rituximab trial patient ppm neg result halt progress suggest potenti decreas progress younger patient ppm younger yr old especi inflammatori lesion rituximab ocrelizumab ppm older inflammatori lesion hold excit final ocrelizumab result ppm',\n",
       " 'question two week ago left side face went numb appar reason numb sens week ago start feel like consist high someth curious one experienc past mani diagnos read repli view appreci ms hug author andis creat apr lean site journal note visit neuro rather bug staff cant handl stress bring lol sharp pain rib cage one side time second take breath away complet ask told lingo read repli view appreci feel like im die author lizzybel creat jun went beach day awesom time day bare keep eye open serious choos fun complet exhaust work yesterday took nap hour got ate went back bed hour today work still fight read repli view appreci happen anyon els author scott j creat jun avid avid energi drinker coffe connoisseur recent thought amount caffin take caffin effect anyon els trigger symptom tri nail caus symptom elimin mani variabl possibl read repli view appreci inabl use finger author luigi creat jun amongal symptomsof multipl sclerosi toconstantlycompar toa symptom muchth applic usingth fingersof thehand write typeor action minut feel asharp painin finger middl ringand littl finger subsequentin tous finger read repli view appreci frustrat author dag creat jun straggl multitud symptom almost unheard male ms kind tri explain symptom doctor listen fustrat got doctor would hear hospit unabl speak wright ms discov read repli view appreci ocd author amylm creat jun connect ms ocd impuls control disord know depress link ms wonder mental health issu well past year follow neurologist possibl ms possibl lesion read repli view appreci wonder neuro take next appoint author andis creat jun take roughli pill day includ gilenya well decid around th last month fed take pill quit far almost week everyth gilenya feel fine still get migrain noth wors read repli view appreci bladder cramp author lizzybel creat jun bladder cramp urinalysi neg anyon bladder spasm precursor incontininc ugh read repli view appreci constitut relaps author jtsokolov creat jun hello diagnos ms week ago symptom start tingl right hand went right arm leg left leg well realli scare go dr work tingl get intens translat tight read repli view appreci first symptom newli diagnos author sgandotra creat jun diagnos past april mri spinal tap symptom sever fatigu lot stress late notic lie still tri sleep upper bodi sometim entir bodi randomli spasm without warn everi minut read repli view appreci summer come author scott j creat may partial concern heat issu arriv soon pretti new wonder kind thing other done stay cool least help reduc relaps read repli view appreci menstrual cycl author americaninhongkong creat jun hi wonder anyon els see tight connect ms symptom menstrual cycl month read',\n",
       " 'may novarti announc fda approv gilenya first diseas modifi therapi f treatment children adolesc less year age relaps form multipl sclerosi rm make first diseas modifi therapi indic patients[ ] approv expand age rang gilenya previous approv patient age year older rm gilenya grant breakthrough therapi design fda decemb pediatr indic read entir articl',\n",
       " 'simponi mesalamin asacol lialda pentasa immunomodul azathioprin mp anyth often biolog like simponi plu class med simultan combat flare simponi plu immunomodul sometim plu mesalamin moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa unpatriot wipe bumm georg washington bill tp stall otherwis dire straight think georg would understand',\n",
       " 'neurologist recommend add lyrica sea medic provid addit relief nerv pain concern weight gain side effect experienc post year ago hug use answer sign view previou answer mymsteam member said littl weight gain watch eat cut back sweet post year ago hug use take gabapentin tell experi wwa tri take someth would caus fatigu much pain anyway take mertazapin sleep think caus bad morn fatigu either gilenya ms fatigu heat mertazapin low dose want altern mertazapin gabapentin bed experi take gabapentin edit origin post month ago hug use answer sign view previou answer mymsteam member said mymsteam member drove road three year time thousand mile day tractor trailer never caus fall asleep read post month ago hug use pain arm hand finger anybodi suffer pain arm hand finger prepar food eat late terribl achi feel arm burn pin needl hand electr shock pin needl pain tollarobl bad suggest ms famili post year ago hug use answer sign view previou answer mymsteam member said get pain left shoulder arm l r doc think rotat cuff post year ago hug use troubl sleep help post year ago hug use answer sign view previou answer mymsteam member said awok friday morn wonder wonder feel pretti good gymnasium post month ago hug use baclofen anybodi take baclofen like side effect doc want take mg time day read web figur ask expert thank post year ago hug use answer sign view previou answer mymsteam member said make number go take need post year ago hug use myth ms wish other would stop believ post year ago hug use answer sign view previou answer mymsteam member said tri find mymsteam member post month ago hug use gabapentin gabapentin still confus yesterday saw ms nurs recommend mg three time day mg describ new symptom hot feet feel like cover sweat dri touch think suffer side effect post year ago hug use answer sign view previou answer mymsteam member said take mg gabapentin daili nerv pain back constantli among place come go anti seizur medic also read post year ago hug use feel low finish lemtrada infus yesterday came home hospit around slept night suffer ach pain overyour bodi woke today feel numb lower half remind relaps symptom treatment manag mean easi ride today feel low isol feel partner understand serious go fed like feel fight alon read',\n",
       " 'sorri guy got bit end first post crohn mirowpl good luck entyvio mean know experi encourag one ever seen lot peopl say got remiss scifig ha yeah want gut prettier _ think whole would still pick clinic remiss hand would annoy symptom explan case would start think possibl caus think pin thing onto crohn per usual cm right technic crohn ileocolilti vast bulk diseas colon howev termin ileum affect well remov along colon henc neo new termin ileum report goe tri imuran mp mp nearli year far tell mp done noth except make burn easier sun good luck med edit tom thank certain stelara avail ask gi inflamm widespread seem stubborn treatment resist plu side ill entir colon inflam feel entir healthi either think immun system attack bit digest system thyroid eye etc sorri get bit time go bed think post edit nicecupoftea pm gmt',\n",
       " 'thank much respond tri search pharmaceut assist medicar websit could find page referenc keep look make phone call head littl clearer appreci help hope well ocrevu',\n",
       " 'surgeri jan th choic could went humira remi choos bc fact lower immun colon respond pred alway done surgeon gastro[for year ] agre surgeon said badli inflam colon yo want life normal put uc monster year extrem happi got surgeri anxieti med life good happi made choic emerg patient recoveri ok took life slow let bodi heal hope best u',\n",
       " 'hello folk thank f lab scifig bull know mean well certainli disagre lone nobodi get admit psychiatr ward loneli particularli nh one liter suicid look plan internet think understand withdrawn depress make someth overcom willpow could e g made convers staff local cafe like regular would done end struggl even place order without want cri bit viciou circl way depress make lone depress also make imposs socialis gain pleasur mean brother girlfriend friend alon enough protect issu obviou lifelong tendenc toward depress rate guess still seen doctor folk yep grant leav afternoon staff member told yesterday inform patient e section basic could go whenev want thought sound bit good true complet non surpris desper need cloth thing also would rather like see market squar pretti christma tree cover light rather go guy sound dubiou occup therapist knock door ask need anyth ye toilet roll desper use paper towel ridicul actual ran last night ask nurs girl overheard said could give realli nice unfortun nearli enough fault anyway ot mention someth standard issu let know crohn diseas go x day standard issu nearli enough anyway get tire would like write patient time may long phone meantim took photo earlier upload later later everyon p dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'current data concept pseudoprogress concern mani oncologist side equat wait long immuno work mistak recent articl dr jack west cancer grace differ cancer differ pseudoprogress rate melanoma fairli signific lung cancer percent http cancergrac org lung death pseudoprogress know w hen cut loss immunotherapi along think quot lung cancer present dr eddi garon say one import issu address issu pseudoprogress someth peopl immunotherapi field talk long time effect immunotherapi may immun cell infiltr tumor result rather get smaller tumor would actual get larger could certainli happen short period time would say date someth seen lot lung cancer colleagu melanoma certainli report signific issu patient initi growth tumor imag afterward shrink certainli sever intrigu anecdot sort individu patient peopl describ sort increas tumor volum get better would say actual quit uncommon lung cancer dilemma continu roll dice progress continu move onto next line treatment case first scan two round keytruda show mix result progress shrinkag hint perhap new thing sinc pd express high perform statu continu zero oncologist decid keep go anoth three infus rescan said convent wisdom would tell us move someth els buck convent wisdom full understand risk next scan two week five infus total clem',\n",
       " 'two isati cool pill went back sleep hour work headach far feel fine thank listen husband sure even though say probabl sick hear never end talk supplement medic poop day feel diari listen hate burden got week florastor pill day gave stop follow someth hard sometim gave much diarreah night thought first coupl day wow better nope week rotat antibiot luck either uc sinc mayo clinic say chron coliti dx chronic lyme biolog work stelara love took rafaximin sibo work awesom',\n",
       " 'much rechalleng rather clear afatinib best option slow rate growth cancer use instanc stereotact radiat area control lot inform go one cannot confid afatinib option next best would osimertinib erlotinib fewer side effect penetr brain better',\n",
       " 'brand name tafinlar medicin prescrib dabrafenib use alon combin anoth medic trametinib [mekinist] treat certain type melanoma type skin cancer cannot treat surgeri spread part bodi also use along trametinib treat prevent return certain type melanoma surgeri remov affect lymph node dabrafenib also use combin trametinib treat certain type non small cell lung cancer nsclc spread nearbi tissu part bodi also use treat certain type thyroid cancer spread nearbi tissu part bodi respond previou treatment dabrafenib class medic call kinas inhibitor work block action abnorm protein signal cancer cell multipli help stop spread cancer cell use medicin medic may prescrib use ask doctor pharmacist inform medicin use dabrafenib come capsul take mouth usual taken twice day empti stomach hour hour meal take dabrafenib hour apart around time everi day follow direct prescript label care ask doctor pharmacist explain part understand take dabrafenib exactli direct take less take often prescrib doctor stop take dabrafenib without talk doctor swallow capsul whole open break crush doctor may adjust dose temporarili perman stop treatment depend respons treatment side effect experi talk doctor feel treatment doctor pharmacist give manufactur patient inform sheet medic guid begin treatment dabrafenib time refil prescript read inform care ask doctor pharmacist question also visit food drug administr fda websit [web] manufactur websit obtain medic guid special precaut follow take dabrafenib tell doctor pharmacist allerg dabrafenib medic ingredi dabrafenib capsul ask pharmacist check medic guid list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take sure mention follow clarithromycin biaxin prevpac dexamethason gemfibrozil lopid ketoconazol midazolam nefazodon rifampin rifadin rifam rifat rimactan warfarin coumadin jantoven doctor may need chang dose medic monitor care side effect mani medic may also interact dabrafenib sure tell doctor medic take even appear list tell doctor ever diabet glucos phosphat dehydrogenas g pd defici genet condit bleed problem eye problem heart failur heart problem liver kidney diseas medic condit know medic may decreas fertil men women dabrafenib may temporarili perman stop sperm product howev assum cannot get someon els pregnant tell doctor pregnant plan becom pregnant plan father child partner becom pregnant take dabrafenib partner becom pregnant take dabrafenib call doctor dabrafenib may harm fetu know dabrafenib may decreas effect hormon contracept birth control pill patch ring implant inject use anoth method birth control prevent pregnanc partner treatment dabrafenib week final dose talk doctor birth control method work tell doctor breastfeed plan breastfe breastfe take dabrafenib week final dose surgeri includ dental surgeri tell doctor dentist take dabrafenib special dietari instruct follow unless doctor tell otherwis continu normal diet forget take dose take miss dose soon rememb howev less hour next schedul dose skip miss dose continu regular dose schedul take doubl dose make miss one side effect medicin caus dabrafenib may caus side effect tell doctor symptom sever go away headach joint muscl back pain nausea diarrhea constip loss appetit cough runni nose sore throat hair loss tired side effect seriou experi symptom call doctor immedi chang skin new wart skin sore red bump bleed heal chang size color mole rash red skin pimpl fever faint dizzi lightheaded weak chill decreas urin swell hand feet ankl lower leg frequent urin increas thirst eye pain red swollen eyelid sensit light blur vision vision chang includ see halo blur outlin around object color dot swell pain red peel skin palm sole feet ongo pain begin stomach area may spread back unusu bleed bruis bloodi black tarri stool cough vomit blood materi look like coffe ground chest pain short breath swell hand feet ankl lower leg fast irregular pound heartbeat yellow skin eye dabrafenib may increas risk develop new skin cancer cancer talk doctor risk take medic dabrafenib may caus side effect call doctor unusu problem take medic experi seriou side effect doctor may send report food drug administr fda medwatch advers event report program onlin [web] phone know storag dispos medic keep medic contain came tightli close reach children store room temperatur away excess heat moistur bathroom import keep medic sight reach children mani contain weekli pill minder eye drop cream patch inhal child resist young children open easili protect young children poison alway lock safeti cap immedi place medic safe locat one away sight reach [web] unneed medic dispos special way ensur pet children peopl cannot consum howev flush medic toilet instead best way dispos medic medicin take back program talk pharmacist contact local garbag recycl depart learn take back program commun see fda safe dispos medicin websit [web] inform access take back program case overdos case overdos call poison control helplin inform also avail onlin [web] victim collaps seizur troubl breath awaken immedi call emerg servic inform know keep appoint doctor laboratori doctor order certain lab test treatment check bodi respons dabrafenib doctor check skin chang everi month treatment month treatment let anyon els take medic ask pharmacist question refil prescript import keep written list prescript nonprescript counter medicin take well product vitamin miner dietari supplement bring list time visit doctor admit hospit also import inform carri case emerg report medic inform consid individu patient advic chang natur drug inform pleas consult physician pharmacist specif clinic use american societi health system pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field american societi health system pharmacist inc make represent warranti express impli includ limit impli warranti merchant fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos entir monograph drug review thorough understand drug action use side effect american societi health system pharmacist inc endors recommend use drug inform substitut medic care ahf patient medic inform copyright american societi health system pharmacist inc east west highway suit bethesda maryland right reserv duplic commerci use must author ashp',\n",
       " 'fda grant prioriti review design supplement biolog licens applic sbla tecentriq atezolizumab use combin carboplatin etoposid frontlin treatment patient extens stage small cell lung cancer es sclc sbla base phase impow studi ad tecentriq standard upfront carboplatin etoposid significantli prolong surviv patient es sclc fda action date decis sbla march median follow month median overal surviv os impow month tecentriq arm compar month placebo arm percent reduct risk death os event occur percent tecentriq arm percent control arm median progress free surviv pf month tecentriq group compar month placebo tecentriq associ higher six month pf rate percent vs percent doubl month pf rate percent vs percent compar placebo year sinc new initi treatment option extens stage small cell lung cancer deliv clinic meaning surviv benefit sandra horn chief medic offic head global product develop genentech roch manufactur tecentriq said statement work close fda bring tecentriq base regimen peopl difficult treat type lung cancer soon possibl ad horn global doubl blind random placebo control phase impow trial evalu efficaci safeti first line tecentriq adjunct therapi standard care combin carboplatin etoposid treatment na patient es sclc result studi present th world confer lung cancer result simultan publish new england journal medicin patient receiv four day cycl carboplatin auc mg ml min iv day one mg etoposid iv day patient also random receiv either concurr tecentriq mg iv day patient placebo patient induct phase treatment follow mainten therapi tecentriq placebo accord previou random assign everi three week progress diseas loss clinic benefit investig assess pf os intent treat popul serv primari endpoint secondari endpoint includ object respons rate orr durat respons safeti age demograph smoke statu repres diseas median age year rang tecentriq placebo group major male percent vs percent respect white percent vs percent former smoker percent vs percent tecentriq arm includ patient percent brain metastas percent liver metastas placebo group consist percent percent respect median durat treatment tecentriq month median dose receiv investig saw major differ orr arm percent vs percent respect median durat respons vs month tecentriq demonstr superior month percent vs percent month percent vs percent event free rate eighteen patient treat concurr tecentriq ongo respons compar patient control arm safeti profil regimen appear consist previous report safeti profil individu agent new find observ common grade treatment relat ae among tecentriq placebo arm includ neutropenia percent vs percent respect anemia percent vs percent decreas neutrophil count percent vs percent thrombocytopenia percent vs percent leukopenia percent vs percent immun relat advers event ira common tecentriq compar placebo percent vs percent common grade ira among tecentriq placebo arm includ rash percent vs percent respect hepat percent vs percent infus relat reaction percent vs percent pneumon percent vs percent coliti percent vs percent tecentriq approv fda indic non small cell lung cancer urotheli carcinoma articl origin appear oncliv com fda grant atezolizumab regimen prioriti review frontlin sclc',\n",
       " 'mayb paranoid read incid time time news surgeri also care home gynecologist abus thing isol incid die want cremat cut open none uc sinc remicad success made step back azathioprin current mg azathioprin wellbutrin mg zoloft mg ccherbal need algaec scope show inflamm scar dexa scan show decreas bone densiti new dexa scan still wait result',\n",
       " 'dear coleridg sinc joint inflamm pain anticip side effect immun therapi emerg long actual end therapi probabl talk first oncologist report may want see either doctor need understand opdivo bring printout side effect manufactur might help well timelin treatment prior joint issu manag pain work etc post high dose interleukin treatment year ago sharp pain shoulder joint initi diagnos frozen shoulder physic therapist indic would need therapi long year believ think problem lay around hospit total four week howev frozen shoulder disappear within three month fifth month past last hd il dose free cancer lung howev six week post last dose still big mess get smaller earlier scan ideal success immun therapi meant immun system rev taught counter rcc sinc rcc cancer develop way evad immun system like year lie quietli wait immun system complet uninterest proof system learn rcc like vaccin antibiot action',\n",
       " 'cherish other interest took bit effort get go persist help argument crib bart ms websit sent neurologist cladribin least effect treatment mayb hsct alemtuzimab clariti oracl ms trial use oral cladribin posit sipe et al cladribin treatment chronic progress multipl sclerosi lancet beutler et al treatment chronic progress multipl sclerosi cladribin proc nat acad sci usa stelmasiak et al effect parenter cladribin relaps rate patient relaps form multipl sclerosi result year doubl blind placebo control crossov studi mult scler j giovannoni et al placebo control trial oral cladribin relaps multipl sclerosi nejm giovannnoni et al sustain diseas activ free statu patient relaps remit multipl sclerosi treat cladribin tablet clariti studi post hoc subgroup analysi lancet neurol leist et al effect oral cladribin time convers clinic definit multipl sclerosi patient first demyelin event oracl ms phase randomis trial lancet cladribin safe dmt safer high efficaci dmt unlik alemtuzumab daclizumab caus secondari autoimmun caus pml much safer mitoxantron penetr spinal fluid plasma concentr blood aug cancer re mar work kill b lymphocyt decreas inflamm cn six subcutan inject cladribin one year give equival plasma concentr use clariti oracl ms trial j clin oncolog everyon ms need anti inflammatori treatment even progress ms patient cladribin get brain kill lymphocyt neuroprotect slow progess induct treatment consist mg year sub q inject within month requir singl wbc count st three nd three inject cladribin safe effect ms patient rel low cost think could help slow progress diseas prescrib anyth get go dr k schmierer spearhead cladribin effort bart help even look neuro recent attend asn meet vancouv doctor agre worth tri dr k sent protocol us almost month st dose blood work done wife gave inject also take antivir day prevent infect inject ridicul easi toler even though ml sub q inject ill rash inj site problem get blood work monday next dose later next week dmd year us put cost credit card st vial insur agre cover yet hope find supplier drug much difficult imagin opaqu price avail ps also take mg simvastatin day mayb also slow thing',\n",
       " 'mani year cladribin neda includ alemtuzumab neda valu two year post treatment prof g pleas elabor cladribin figur pretti sure alemtuzumab fare better cladribin trial',\n",
       " 'sorri horribl infus lucki infus reaction ocrevu latest infus two week ago unev know case peopl start ocrevu last fall latest infus first full infus two half dose neg effect actual felt pretti good afterward howev full dose absolut level physic mental bad day exhaust weak unsteadi rave b everyon around coupl day start feel back usual self week actual feel better infus found start ocrevu posit effect fatigu feel way week everyon react differ medic know experi could differ mine hope feel better possibl good coupl rough day',\n",
       " 'greet stepmom stage iv lung cancer met liver also metastas bone surgic remov octob asymptomat perform statu st line treatment alimta year recent finish four round second line treatment keytruda idea rd line treatment might appar clinic trial avail thank',\n",
       " 'even treatment k one time year ms treatment k year everi year die think closer k treatment nw cost compar dmd typic would pay year stem cell therapi speed recoveri chemotherapi treatment cur portion look ms therapi find mani root chemotherapi agent person theori could go intens chemotherapi regimin effect reput clinic around world offer similar treatment consider less cost clinic push stem cell treatment cure articl uniform extrem bias almost pharmacut payrol ms treatment also associ sever advers event includ death mani one year efficaci flare stop underli caus ocrevu new treatment reformul rituxan big pharma pull trial sinc run patent prove therapi avail research done stall maxim profit expens patient exploit collus insur industri would countri best interest fund non pharmacut trial actual find effect open sourc therapi instead fda assur billion dollar barrier big pharma navig afford treatment reach market',\n",
       " 'acid reflux medic taken hour period tarceva told cannot take prilosec longer interact new inform thank repli topic modifi year month ago elizoc topic modifi year month ago elizoc',\n",
       " 'medicar u medicar supplement insur part b medicar pay infus supplement pick rest found medicar prescript part pay much pill inject biolog drug tier insur price extrem wait u hit donut hole mayb would qualifi program humira help offset cost anyway infus drug ra tocilizumab actemra abatacept oriencia infliximab remicad rituximab rituxan golimumab simponia aria think certolizumab cimzia remicad orencia ithink month doctor go make chang put actemra know hope help good luck wish well',\n",
       " 'hello everyon diagnos rrm last week hooray coupl month test etc got lab back today jcv neg relief sinc consid tysabri question would appreci tip pointer ms specialist recommend go tysabri right gate realli sure think ask visit spent lot time highlight efficaci also said prescrib inject effect pill warn pml risk order jcv ratio test time unsur jcv statu recommend gilenya second choic depend felt jcv risk came back come back jcv neg admittedli easier decis make pretti sure recommend go tysabri first statist long peopl recommend typic stay tysabri jc neg seen pml risk factor laid year tysabri chang geometr time jcv seen thing jcv thing quantifi risk factor jcv realiz cours jcv statu could chang still requir monitor second seen suggest tysabri pretti high power drug peopl seem put fail therapi think ask visit much inform come would purpos recommend drug first time aggress lesion load thought welcom suspect lesion load case even though prior incid real reason believ anyth wrong third insur curiou pocket cost realiz vari across board tri prepar could impact wallet peopl typic pocket cost privat employ base insur extent gener fourth hard data suggest come tysabri trigger seriou relaps seen scare stori sure think last anyon jcv gotten pml tysabri sure question thank read',\n",
       " 'experienc floater inject go yr week apart disappear field vision bottom eye sever day sometim week even two inject larg floater shape like oliv slice dark rim bright white neon center remain still day beyond annoy get doubl size bend brighter sunshin even sunglass doctor switch lucenti right away report fda ask much inform took long time nobodi seem eager forthcom dealt drug manufactur compound lab lot number vial info silicon oil use coat needl manufactur syring wait fda run databas see whether report remain silicon droplet wait month give somebodi compound lab mess convinc',\n",
       " 'centenarian wrote eye wrote lot doctor prescrib fingolimod label call spm would find work well mani case mani misdiagnos anyway call rrm one studi laugh harm think peopl start see one statist shall make free least inexpens think good thing studi done doctor stop prescrib ineffect potenti harm drug time tell good thing everybodi think one studi last word think good doctor feel oblig everyth someon els book reckon doctor think word last continu beat poor anim alreadi dead doctor often let inform person make decis sometim even agre regardless studi done other conclud think play import role besid drug gatekeep case fentanyl doctor seem much control anyway',\n",
       " 'hello realli disappoint ocrevu make person prone risk breast cancer cancer well mom die pancreat cancer first mcg infus second mcg infus realli side effect infus except mild flush left facial cheek subsid drive home pleas nervou chanc develop ca would need anyon ocrevu year thought worri thank blue satin',\n",
       " 'predictor function vision chang follow cataract surgeri provis studi joshua barbosa varun chaudhari marko popov michael mak kaela gusenbau mohammad mohaghegh p evalu iophthalmolog mobil applic tool increas patient knowledg satisfact cataract surgeri mirian dang harri dang porcin cataract creation use formalin microwav treatment ophthalmolog wet lab robert w machuk sourabh arora morley kutzner karim f damji applic lean think cataract surgeri patient safeti waitlist resourc adrienn duimer edith imber carla servic hamza khan analysi intraocular len power calcul formula flat cornea henri chen michel ceniza n kevin wade intraocular len fractur complic laser posterior capsulotomi harmanjit singh iqbal ike k ahm diamond tam sarah l kwan acut present unidentifi intraocular foreign bodi munir iqbal rookaya mather practic pattern among cataract surgeon ottawa hospit nima noordeh michael myle intracapsular cataract extract buphthalm eye case report andr vicent ana cabugueira vanessa lemo livio costa duart amado nuno marqu joao feijao glaucoma econom analysi medic vs surgic manag open angl glaucoma canadian perspect hamza n khan adrienn duimer chronic prostaglandin analogu treatment persist depress intraocular pressur follow washout eddi liu vlad diaconita jillian belros cindi hutnik surgic manag uveiti glaucoma hyphema ugh syndrom moness masri tessa weinberg xavier campo ller chri rudniski jay ching chieh wang iqbal ike k ahm ocular surfac diseas among patient topic glaucoma drug therapi systemat review literatur nima mohammad shahi helena zakrzewski ali hafez cindi hutnik postur induc chang intraocular pressur treat glaucoma patient jeremi murphi paul art marcelo nicolela lesya shuba vection respons earli stage glaucoma martin j steinbach longitudin rate neuroretin rim retin nerv fibr layer chang glaucoma patient control studi convent anatom accur indic jaym r vianna vishva danthurebandara glen sharp ann belliveau donna hutchison marcelo nicolela balwantray chauhan correl retin nerv fiber layer thick axial length use optic coher tomographi oct bassam n al khalaf old old glaucoma compar analysi elderli middl age patient antoni clark christoph kranemann catherin birt hot topic effect oral inhal corticosteroid intraocular pressur patient ocular hypertens control glaucoma edward b moss yvonn buy darana yuen stephani low graham e trope rd prize co award excel research poster interact primari human trabecular meshwork cell metal alloy candid micro invas glaucoma surgeri wendi wan wang kelsey watson jeffrey dixon hong liu amin rizkalla cindi hutnik trabeculectomi sub conjunctiv ranibizumab prospect random control clinic trial mohammad hamid paul harasymowycz mark lesk daniel desjardin veronica flore fawzia djafari gisel li paradigm shift slt topic medic glaucoma vlad diaconita david schulz jillian belros yufeng nanci n chen dariusz gozdzik dania jamal eddi liu monali malvankar cindi hutnik util discern instrument assess qualiti internet websit peripher iridotomi paul huang ammar mahmood kevin j warrian patrick gooi relationship ophthalm characterist util valu glaucoma diabet retinopathi dr patient sera melisa thoma william hodg cindi hutnik monali malvankar complic year surviv canaloplasti glaucoma faisal almobarak excis fibrot capsul glaucoma drainag devic mitomycin c one year result without ologen f lix bernier turmel paul harasymowycz util discern instrument assess qualiti internet websit trabeculectomi ammar mahmood paul huang kevin j warrian patrick gooi hot topic screen glaucomat damag ganglion cell complex spectral domain oct pilot studi ghada seyam harmanjit singh paul harasymowycz neuro ophthalmolog assess qualiti neuro ophthalmolog referr tertiari practic cindi lam edward margolin uveiti multifoc electroretinogram may predict function retin deterior patient birdshot chorioretinopathi adrian c tsang paul bastianelli john hamilton stuart g coupland chloe gottlieb dissemin chronic mucocutan candidiasi present endogen candida albican endophthalm qianqian wang simon fr ric dufresn mari jo e aubin multipl evanesc white dot syndrom masquerad myopic choroid neovascular membran keyvan koushan',\n",
       " 'u inflectra ixifi remicad renflexi avail dosag form powder solut therapeut class immunolog agent pharmacolog class tumor necrosi factor inhibitor use infliximab infliximab inject use adult treat crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti chronic sever plaqu psoriasi also use children treat crohn diseas ulcer coliti infliximab inject monoclon antibodi work enhanc improv immun system infliximab avail doctor prescript use infliximab decid use medicin risk take medicin must weigh good decis doctor make infliximab follow consid allergi tell doctor ever unusu allerg reaction infliximab medicin also tell health care profession type allergi food dye preserv anim non prescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatr specif problem would limit use infliximab inject treatment crohn diseas ulcer coliti children year age older howev safeti efficaci establish children younger year age appropri studi perform relationship age effect infliximab inject children plaqu psoriasi safeti efficaci establish appropri studi perform date demonstr infliximab inject help children juvenil rheumatoid arthriti efficaci establish geriatr appropri studi perform date demonstr geriatr specif problem would limit use infliximab inject elderli howev elderli patient like infect may requir caution patient receiv infliximab inject pregnanc pregnanc categori explan trimest b anim studi reveal evid harm fetu howev adequ studi pregnant women anim studi shown advers effect adequ studi pregnant women fail demonstr risk fetu breast feed adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur case doctor may want chang dose precaut may necessari receiv infliximab especi import healthcar profession know take medicin list follow interact select basi potenti signific necessarili inclus use infliximab follow medicin usual recommend may requir case medicin prescrib togeth doctor may chang dose often use one medicin abatacept adalimumab adenoviru vaccin type live adenoviru vaccin type live alefacept anakinra bacillu calmett guerin vaccin live brodalumab certolizumab pegol cyclosporin etanercept fosphenytoin golimumab guselkumab influenza viru vaccin live ixekizumab measl viru vaccin live mump viru vaccin live natalizumab paclitaxel phenytoin polioviru vaccin live quinidin rilonacept rituximab rotaviru vaccin live rubella viru vaccin live sarilumab sirolimu smallpox vaccin tacrolimu tocilizumab tofacitinib typhoid vaccin ustekinumab varicella viru vaccin live vedolizumab warfarin yellow fever vaccin zoster vaccin live interact food tobacco alcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco medic problem presenc medic problem may affect use infliximab make sure tell doctor medic problem especi aspergillosi fungu infect histori blastomycosi fungu infect histori blood bone marrow problem eg pancytopenia histori candidiasi fungu infect histori coccidioidomycosi fungu infect histori diabet guillain barr syndrom nervou system disord histori hepat b activ histori histoplasmosi fungu infect histori legionellosi bacteri infect histori leukopenia neutropenia low white blood cell listeriosi bacteri infect histori liver diseas multipl sclerosi histori optic neuriti eye problem pneumocystosi fungu infect histori psoriasi skin diseas seizur convuls histori thrombocytopenia low platelet blood use caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copd use caution may increas chanc new cancer congest heart failur moder sever given patient condit tuberculosi histori use caution patient may need addit tuberculosi therapi proper use infliximab doctor train health profession give infliximab given needl place one vein must given slowli needl remain place least hour infliximab come medic guid read follow instruct care ask doctor question may also receiv medicin eg allergi medicin fever medicin steroid help prevent possibl unwant effect inject precaut use infliximab import doctor check progress regular visit make sure infliximab work properli blood test may need check unwant effect infliximab may caus infus reaction includ heart attack stroke chang blood pressur heart rhythm problem eg arrhythmia receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow short breath troubl breath swell face tongu throat bodi abil fight infect may reduc use infliximab import call doctor first sign infect check doctor right away fever chill cough flu like symptom unusu tired weak seriou skin reaction occur use infliximab check doctor right away blister peel loosen skin chill cough diarrhea fever itch joint muscl pain red skin lesion sore throat sore ulcer white spot mouth unusu tired weak infliximab may increas chanc lupu like syndrom liver diseas call autoimmun hepat check doctor right away dark brown color urin fever chill gener feel discomfort ill weak joint pain light color stool nausea vomit rash cheek arm wors sun sever tired upper right side stomach pain yellow eye skin small number peopl includ children teenag use infliximab develop certain type cancer common patient lung diseas eg emphysema copd heavi smoker psoriasi patient phototherapi treatment long time phototherapi treatment ultraviolet light sunlight combin oral medicin make skin sensit light teenag young adult crohn diseas ulcer coliti also develop rare type cancer call hepatosplen cell lymphoma talk doctor unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss red scali patch rais bump pu skin use infliximab may increas risk get skin cancer eg melanoma merkel cell carcinoma cervic cancer chang growth skin abnorm vagin bleed pelvic pain tell doctor right away treat infliximab immun vaccin without doctor approv live viru vaccin given infliximab child vaccin must current use infliximab talk child doctor question women babi receiv infliximab make sure babi doctor know use infliximab need wait month give certain vaccin babi talk babi doctor question need skin test tuberculosi start use infliximab tell doctor anyon home ever posit reaction tuberculosi skin test import heart check close receiv infliximab call doctor right away short breath swell ankl feet sudden weight gain take medicin unless discuss doctor includ abatacept orencia anakinra kineret tocilizumab actemra medicin call biolog use treat condit infliximab use medicin togeth infliximab may increas chanc seriou unwant effect infliximab side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur common chest pain chill cough dizzi faint fever flush red face headach hive itch rash muscl pain nasal congest nausea runni nose sneez sore throat stomach pain tight chest troubl breath unusu tired weak vomit less common back pain bloodi cloudi urin crack skin corner mouth diarrhea difficult pain urin frequent urg urin pain tender around eye cheekbon sore irrit mouth tongu sore red around fingernail toenail vagin burn itch discharg white patch mouth tongu rare abscess area infect contain pu black tarri stool blood urin stool bone joint pain constip feel full hernia lump abdomen stomach irregular pound heartbeat pain rectum pain spread abdomen stomach left shoulder pinpoint red spot skin stomach pain sever swollen pain gland tendon injuri unusu bleed bruis unusu weight loss yellow skin eye incid known bloodi nose burn tingl numb pain hand arm feet leg chang mental statu clay color stool continu vomit dark bloodi urin difficulti speak difficulti swallow fast heartbeat gener feel tired weak heavier menstrual period hoars inabl move arm leg itch puffi swell eyelid around eye face lip tongu light color stool loss appetit loss bladder control lower back side pain muscl spasm jerk extrem noisi breath painless swell neck armpit groin pale skin red scale crust skin red sore itch skin seizur sensat pin needl sever muscl weak sudden progress slow irregular breath sore welt blister stab pain sudden loss conscious sudden numb weak arm leg unpleas breath odor upper right stomach pain vomit blood side effect list may also occur patient notic effect check healthcar profession call doctor medic advic side effect may report side effect fda fda',\n",
       " 'avengr live socal progress ms consid dose methotrex among option offer tisch ms center nyc went cladribin use bart protocol thought less intrus like get past blood brain barrier knock leucocyt activ good slow progress dose ms much lower leukemia equival lower dose use success clariti optim ms clinic trial super easi dose even work next day ill effect rash headach ml sub q dose day done year felt much better interferon shot bit trickier dose copaxon packag insert cladribin internet make scari read paracelsu say sola dosi facit venenum hard part get neuro prescrib find special pharmaci would sell place cool ship iv cancer drug use label ms patient home help dr k bart talk neurologist send protocol neurologist current prescrib lemtrada agre cladribin worth tri took convinc read send journal articl prepar get label treatment prog ms think possibl slow progress easi toler rel inexpens paid mg vial retail insur agre cover monitor leucocyt level import safeti went x ^ l st dose took second check level novemb sorri long comment think safe easi may help spm think treatment like would good type ms patient good human data safeti efficaci treat ms even relaps mistak nerv damag smolder inflamm come back better save',\n",
       " 'gener mg tablet gener budesonid prescrib case need away home week trip come toward end year wonder use rescu medic instead pred instruct say take twice day find post ipoop state respond budesonid within week need much stronger cousin prednison addit age pill also say uceri help coupl year ago uceri tablet lie around realli take week budesonid help ideal recent scope unabl see doctor januari call even biopsi result almost month doctor mention humira prednison could long time mayb take per budesonid day start earli symptom want plan place case wait till januari confess recent borrow mg tab pred illeg shoot abl go groceri store walk dog celebr big birthday famili friend worth one day necessari wean day anyway end mg coupl day pred pill new uceri foam realli bad symptom never return could temporari continu beg small suppli pred use hand hope friend extra pred even know dog take mg diagnos left side inflamm three doctor opinion uc like crohn indetermin current gm lialda per day toler night choic gener rowasa cortison retent enema canasa option us medicar',\n",
       " 'repli post croninstc honestli diet differ everyon chron diseas tight intestin low fiber diet also develop lactos intoler diseas howev thing affect diseas also nsaid non steroid anti inflammatori drug remicad infus everi month taken two differ steroid get inflamm control stress anxieti also play major role whether stomach good bad day chron diseas chronic diseas diet cure import find diet best affect individu order help get diseas remiss diet alon',\n",
       " 'complet probabl relev went gilenya cladribin four week washout period follow post washout tysabri natalizamub lemtrada alemtuzumab read comment end see answer washout gilenya fingolimod lemtrada recommend long washout http multipl sclerosi research blogspot com rebound withd',\n",
       " 'hello one peopl buri head sand come find thing ill post go crap time anyway dx year ago done badli year copaxon year stop start bad reaction caus stress go lot emot thing divorc associ issu point toller copaxon well put onto anoth inject gave month gave aw headach last year gilenya start well year bit nightmar get everi littl bug go around pretti much feel ill time far year spent month sign work debilit fatigu bug sat flat unabl anyth last month urinari tract infect go away pill noth shift shingl month medic shift top horrid year yesterday left hand side face swell templ halfway neck new bulbou head go mildli annoy pain oh bottom spine also pain start yesterday well want find whether other gilenya find get disproportion amount ill virus infect whether anyon think gilenya might factor apart ms normal keep well avoid bug go around time type sat tenderli shingl rash bum sat slightli forward help back pain head tilt right help swollen face bit oh think vent apolog anyon inform view gilenya appreci feedback tempt stop take gradual cours would talk gp get appoint lotteri neurologist plu valu inform real life experi thank',\n",
       " 'hahahahaha thing worri sinc ms thing pronounc drug correctli even list let alon top pronounc tysabri teesabri much amus annoy partner neuro never fail correct lol pronounc ocrelizumab drug crazi enough even attempt understand would concern correct pronounci though',\n",
       " 'increas cancer risk mention literatur address somewhat offhand dr chin genentech articl optim howev temper concern increas cancer risk three trial cancer rate twice high among receiv ocrevu among respect control group patient rate malign ocrelizumab treatment remain within epidemiolog report clear relationship b cell suppress malign establish said chin also reassur patient genentech work understand rate numer higher http multiplesclerosisnewstoday com histori ocrevu defiant idea game chang multipl sclerosi therapi anyon explain within epidemiolog report mean seem get past doubl cancer rate three trial doubl enough cancer famili right thank gallow humor attempt help',\n",
       " 'hi thank much repli jimc tri get brain met resolv cyberknif one radiologist suggest cyberknif done scan check said got differ met left side well got line mening said cyberknif option go wbr plu said go cyberknif later wbr control line brain question switch alecensa avoid radiat alecensa penetr brain barrear must wbr possibl cyberknif wbr cope side effect wbr anyth help like medicin expect wbr term complet resolut brain met without cyberknif know sound bit silli everi case differ still chanc brother age good spirit happi cyberknif want go wbr wait repli thank much time kind regard',\n",
       " 'coliti research pleas keep updat go process well nice although crappi someon go exact thing timelin cours long mind give updat diagnos summer left side coliti current mg azathioprin mg taper prednison three dose entyvio anucort suppositori glutamin probiot',\n",
       " 'hope awesom first thing onc said start alectinib target therapi alk treatment resist might becom problem sent articl integr medic oncologist im start wonder pharma compani would arrang group discount number us wile abl travel clincal trial find guy ok take de wormer updat',\n",
       " 'quick updat cladribin second dose today day felt fine major se far inject quick hurt lil bit inject would far good',\n",
       " 'ms regimen includ water vitamin omega diet exercis medit stress free live prescript medic feed head bodi good stuff could alway better pizza day lot combat diseas take copaxon tecfidera year avail realli interest slow progress unless cours find way go back way disabl set go yet anoth mri mayb take gilenya doctor supervis cours appreci everybodi comment thank trip blog stuff actual part stuff combat diseas thank well je',\n",
       " 'gilenya last year first dose monitor unev lower borderlin lymphocyt count ongo initi month higher liver enzym count normal absolut issu gilenya conveni use relaps sinc start gilenya brain mri contrast month later start new lesion tspine mri contrast recent week new lesion good luck',\n",
       " 'husband stage iv nsclc micro brain met liver met spine met treat photon radiat egfr exon l r tagrisso start decemb lost june carboplatin alimta ad septemb chemo combo start due pain tagrisso reach area e pleural effus caus rib pain sneez problem spasm abdomin area sinc went away start system chemo finish cycl start mainten alimta way stabl point neck brain toler combo well littl issu also side note treat sbrt radiat septemb one liver met primari lung mass treat sbrt radiat juli everyth shrunk disappear pain chemo combo delay everi week due low platelet oncologist mention carboplatin may improv platelet question data regard stop carboplatin cycl go whole distanc cycl far effect know cycl time visit learn later visit comment oncologist concern carboplatin stop would progress sooner said protocol stop cycl go mainten risk allerg reaction stay carboplatin thank',\n",
       " 'articl multipl sclerosi cladribin tablet ad ifn activ relaps ms onward studi xavier montalban thoma p leist bruce cohen et al',\n",
       " 'mom diagnos month ago stage iv lung cancer met bone start carboplatin alimta keytruda still progress gemzar cycl still spread spine radiat lung spine weaken dose taxol put hospit week uti bronchiti get pain medicin right home ny option',\n",
       " 'fda approv dmt warn safeti manag strategi mose brand samkoff alemtuzumab lemtrada prescrib inform warn seriou sometim fatal autoimmun condit immun thrombocytopenia anti glomerular basement membran diseas seriou life threaten infus reaction possibl increas risk malign includ thyroid cancer melanoma lymphoprolif disord recommend safeti manag strategi recommend monitor lemtrada avail lemtrada rem program requir patient healthcar facil enrol prescrib pharmaci certif premed corticosteroid prior first three infus cours administ antivir agent herpet prophylaxi start first day continu minimum month complet dose cd lymphocyt count cell per microlit whichev occur later obtain thyroid function test prior init treamtn everi month month last infus monitor complet blood count monthli month last infus consid delay treatment patient activ infect infect fulli resolv administ live viral vaccin follow treatment cours daclizumab zinbryta prescrib inform warn hepat injuri includ liver failur autoimmun hepat immun mediat disord includ skin reaction lymphadenopathi non infecti coliti immun mediat disord acut hypersensit infect includ upper respiratori tract infect urinari tract infect viral infect depress suicid recommend safeti manag strategi recommend monitor zinbryta avail zinbryta rem program prior start treatment obtain baselin serum transaminas alt ast total bilirubin level test transaminas level total bilirubin monthli dose follow transaminas level total bilirubin monthli least six month last dose patient develop clinic sign symptom suggest hepat dysfunct measur serum transaminas total bilirubin interrupt discontinu treatment appropri use caution use medic hepatotox drug includ non prescript product dimethyl fumar tecfidera prescrib inform warn lymphopenia recommend safeti manag strategi recommend monitor recent cbc month start treatment annual clinic indic fingolimod gilenya prescrib inform warn bradycardia atrioventricular conduct first dose infect macular edema decreas pulmonari function liver injuri elev serum hepat transaminas hypertens recommend safeti manag strategi recommend monitor recommend screen white blood cell count serum transaminas determin serum bilirubin determin serum varicella zoster antibodi test patient histori chicken pox baselin ecg ophthalmolog evalu observ bradycardia least hour first dose hourli puls bp obtain ecg prior dose nad end observ period problem occur continu monitor overnight repeat first dose monitor higher risk patient monitor overnight ophthalmolog evalu month treatment event new visual symptom obtain pft clinic indic monitor bp treatment women childbear potenti use contracept treatment two month stop treatment glatiram acet copaxon glatopa gener equival mg dose prescrib inform copaxon prescrib inform glatopa warn lipoatrophi skin necrosi recommend safeti manag strategi recommend monitor site rotat essenti monitor interferon b avonex prescrib inform warn hepat hematolog abnorm depress iinject site reaction sc administr recommend safeti manag strategi recommend monitor cbc lft q mo first year q mo thereaft thyroid function test q mo first year yearli thereaft monitor mood chang educ site rotat sc ifn interferon b rebif prescrib inform warn hepat hematolog abnorm depress inject site reaction sc administr recommend safeti manag strategi recommend monitor cbc lft q mo first year q mo thereaft thyroid function test q mo first year yearli thereaft monitor mood chang educ site rotat sc ifn interferon b b betaseron prescrib inform warn hepat hematolog abnorm depress inject site reaction sc administr recommend safeti manag strategi recommend monitor cbc lft q mo first year q mo thereaft thyroid function test q mo first year yearli thereaftermonitor mood chang educ site rotat sc ifn interferon b b extavia prescrib inform warn hepat hematolog abnorm depress inject site reaction sc administr recommend safeti manag strategi recommend monitor cbc lft q mo first year q mo thereaft thyroid function test q mo first year yearli thereaft monitor mood chang educ site rotat sc ifn pegyl interferon b plegridi prescrib inform warn hepat injuri depress suicid seizur anaphylaxi allert reaction inject site reaction congest heart failur decreas peripher blood count autoimmun disord recommend safeti manag strategi recommend monitor monitor liver function encourag report depress sx suicid ideat use caution patient seizur disord teach inject techniqu site rotat monitor patient signific cardiac hx monitor complet blood count consid discontinu new autoimmun disord occur mitoxantron novantron prescrib inform warn cardiac toxic acut myelogen leukemia like occur cumul dose mg recommend safeti manag strategi recommend monitor baselin lvef repeat lvef prior dose treatment termin lvef continu monitor cardiac function complet treatment ocrelizumab ocrevu prescrib inform warn infus reaction potenti life threaten includ pruriti rash urticaria erythema bronchospasm throat irrit oropharyng pain dyspnea pharyng laryng edema flush hypotens pyrexia fatigu headach dizzi nausea tachycardia infect includ respiratori tract infect herp potenti pml hepat b reactiv possibl increas immunosuppress effect immunosuppress use prior ocrelizumab risk malign includ breast cancer may increas recommend safeti manag strategi recommend monitor premed corticosteroid antihistamin observ one hour follow infus administ vaccin least week prior administr ocrelizumab live attenu live vaccin treatment b cell replet femal patient follow recommend breast cancer screen protocol natalizumab tysabri prescrib inform warn progress multifoc leukoencephalopathi hypersensit reaction hepatotox includingacut liver failur enceph mening caus herp simplex varicella zoster virus recommend safeti manag strategi recommend monitor touch safeti monitor program risk factor pml antibodi posit jc viru prior treatment immunosuppress yr tysabri antibodi test repeat everi six month monitor continu six month end treatment collabor pml consortium pml registri nind teriflunomid aubagio prescrib inform warn infect elev serum hepat transaminas black box warn fetal death malform black box warn skin reaction blood pressur increas respiratori effect recommend safeti manag strategi recommend monitor pre treatment evalu infect pregnanc renal failur peripher neuropathi interstiti pulmonari diseas hypertens white blood cell count serum transaminas determin serum bilirubin determin treatment blood pressur monitor serum transaminas determin',\n",
       " 'thank jim prompt respons thought agre still think continu tagrisso may make sens although would also prefer hold later would greatli appreci dr creelan thought dilemma best',\n",
       " 'husband xeljanz month still full remiss appar side effect start feel better almost right away bleed stop month month felt confid work colonoscopi month start xeljanz show total remiss hope work take mg mg morn mg even spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper still taper prednison mg everi week develop osteoporosi due steroid',\n",
       " 'hi temporari ileostomi think metr small bowel left suppos metr straight think crohn come back go kill last flare year ago want die write keep get everi hour half throughout night wit end repeat want die tri azathioprin remicad mercaptopurin bodi reject drug remicad last chanc thought would grate appreci',\n",
       " 'carboplatin alimta avastin gave neulasta arm pro combat flu like symptom steroid take day treatment neausa help lot nausea bodi ach fatigu first week treatment month later remiss year later back start opdivo work clinic trial work side effect speak stage nsclc year still roll along keep faith motto alway someth new come pike',\n",
       " 'hi neuro appoint found new lesion suspect relaps septemb tecfidera year clearli work anymor neuro suggest go either cladribin fingolimod lemtrada prefer cladribin new mani experi peopl take cladribin onlin wonder whether anyon experi could share thank much',\n",
       " 'entyvio medic uc mayb addinv second med get true remiss moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa shower thought peopl surpris see blood toilet paper uc patient surpris paul regular member join oct post post yesterday pm gmt thank respons overal qualiti life improv hope better result biopsi show inflamm doc think may ib lialda year entyvio recent stop see would make differ alway wonder medicin actual anyth greenuc regular member join sep post post yesterday pm gmt ever tri probiot research ib probiot one come mind boulardii l rhamnosu gg gg varieti lot trial error requir everyon differ http www ncbi nlm nih gov pmc articl pmc http www optibacprobiot co uk learn lab blog boulardii probiot get ib health claim canada diagnos moder sever uc septemb medic lialda pill daili rowasa need diet limit carb sugar alcohol high protein high fat diet dbwithuc veteran member join feb post post yesterday pm gmt would tri probiot diet mod ib light use immodium ib med neither lialda entyevo affect symptom one bit inflamm gone anti inflammatori folk ib like gi symptom inflamm manag treat suck got anti inflammatori touch matter much time give good luck ischem coliti scope perf colon cm colon ileocec resect iv antib sepsi dx mod uc pancol rx lialda x major flare w antib sinu rx mg pred taper mp histol remiss rt tran wors sigmoid rx rowasa hydrocort curr soft form stool urgenc lialda x pred probiot vit c',\n",
       " 'read wiki ocrelizumab list drug work similar way triall sonia x',\n",
       " 'hi sew chick sorri cladribin work follow messag sinc may treatment royal london hospit octob blood test novemb came back lymphocyt meant treatment seen improv far sure chang still take anti viral tablet may tri contact hospit see inform tie posit moment would like know hve good experi cladribin wish well better luck futur',\n",
       " 'lung pair cone shape breath organ found chest lung bring oxygen bodi breath take carbon dioxid breath lung section call lobe left lung two lobe right lung slightli larger three thin membran call pleura surround lung two tube call bronchi lead trachea windpip right left lung bronchi sometim also affect lung cancer small tube call bronchiol tini air sac call alveoli make insid lung enlarg anatomi respiratori system show trachea lung lobe airway lymph node diaphragm also shown oxygen inhal lung pass thin membran alveoli bloodstream see inset two type lung cancer small cell lung cancer non small cell lung cancer summari small cell lung cancer treatment see follow pdq summari inform lung cancer non small cell lung cancer treatment unusu cancer childhood treatment lung cancer prevent lung cancer screen two main type small cell lung cancer two type includ mani differ type cell cancer cell type grow spread differ way type small cell lung cancer name kind cell found cancer cell look view microscop small cell carcinoma oat cell cancer combin small cell carcinoma smoke major risk factor small cell lung cancer anyth increas chanc get diseas call risk factor risk factor mean get cancer risk factor mean get cancer talk doctor think may risk lung cancer risk factor lung cancer includ follow smoke cigarett pipe cigar past import risk factor lung cancer earlier life person start smoke often person smoke year person smoke greater risk lung cancer expos secondhand smoke expos asbesto arsen chromium beryllium nickel soot tar workplac expos radiat follow radiat therapi breast chest radon home workplac imag test ct scan atom bomb radiat live air pollut famili histori lung cancer infect human immunodefici viru hiv take beta caroten supplement heavi smoker older age main risk factor cancer chanc get cancer increas get older smoke combin risk factor risk lung cancer increas sign symptom small cell lung cancer includ cough short breath chest pain sign symptom may caus small cell lung cancer condit check doctor follow chest discomfort pain cough go away get wors time troubl breath wheez blood sputum mucu cough lung hoars troubl swallow loss appetit weight loss known reason feel tire swell face vein neck test procedur examin lung use detect find diagnos stage small cell lung cancer follow test procedur may use physic exam histori exam bodi check gener sign health includ check sign diseas lump anyth els seem unusu histori patient health habit includ smoke past job ill treatment also taken laboratori test medic procedur test sampl tissu blood urin substanc bodi test help diagnos diseas plan check treatment monitor diseas time chest x ray x ray organ bone insid chest x ray type energi beam go bodi onto film make pictur area insid bodi enlarg x ray chest x ray use take pictur organ bone chest x ray pass patient onto film ct scan cat scan brain chest abdomen procedur make seri detail pictur area insid bodi taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi sputum cytolog microscop use check cancer cell sputum mucu cough lung biopsi remov cell tissu view microscop pathologist check sign cancer differ way biopsi done includ follow fine needl aspir fna biopsi lung remov tissu fluid lung use thin needl ct scan ultrasound imag procedur use find abnorm tissu fluid lung small incis may made skin biopsi needl insert abnorm tissu fluid sampl remov needl sent laboratori pathologist view sampl microscop look cancer cell chest x ray done procedur make sure air leak lung chest enlarg fine needl aspir biopsi lung patient lie tabl slide comput tomographi ct machin take x ray pictur insid bodi x ray pictur help doctor see abnorm tissu lung biopsi needl insert chest wall area abnorm lung tissu small piec tissu remov needl check microscop sign cancer bronchoscopi procedur look insid trachea larg airway lung abnorm area bronchoscop insert nose mouth trachea lung bronchoscop thin tube like instrument light len view may also tool remov tissu sampl check microscop sign cancer enlarg bronchoscopi bronchoscop insert mouth trachea major bronchi lung look abnorm area bronchoscop thin tube like instrument light len view may also cut tool tissu sampl may taken check microscop sign diseas thoracoscopi surgic procedur look organ insid chest check abnorm area incis cut made two rib thoracoscop insert chest thoracoscop thin tube like instrument light len view may also tool remov tissu lymph node sampl check microscop sign cancer case procedur use remov part esophagu lung certain tissu organ lymph node reach thoracotomi may done procedur larger incis made rib chest open thoracentesi remov fluid space line chest lung use needl pathologist view fluid microscop look cancer cell mediastinoscopi surgic procedur look organ tissu lymph node lung abnorm area incis cut made top breastbon mediastinoscop insert chest mediastinoscop thin tube like instrument light len view may also tool remov tissu lymph node sampl check microscop sign cancer light electron microscopi laboratori test cell sampl tissu view regular high power microscop look certain chang cell immunohistochemistri test use antibodi check certain antigen sampl tissu antibodi usual link radioact substanc dye caus tissu light microscop type test may use tell differ differ type cancer certain factor affect prognosi chanc recoveri treatment option prognosi chanc recoveri treatment option depend follow stage cancer whether chest caviti spread place bodi patient age gender gener health certain patient prognosi also depend whether patient treat chemotherapi radiat patient small cell lung cancer current treatment cure cancer lung cancer found patient think take part one mani clinic trial done improv treatment clinic trial take place part countri patient stage small cell lung cancer inform ongo clinic trial avail nci websit stage small cell lung cancer key point small cell lung cancer diagnos test done find cancer cell spread within chest part bodi three way cancer spread bodi cancer may spread began part bodi follow stage use small cell lung cancer limit stage small cell lung cancer extens stage small cell lung cancer small cell lung cancer diagnos test done find cancer cell spread within chest part bodi process use find cancer spread within chest part bodi call stage inform gather stage process determin stage diseas import know stage order plan treatment test use diagnos small cell lung cancer also use stage diseas see gener inform section test procedur may use stage process includ follow mri magnet reson imag brain procedur use magnet radio wave comput make seri detail pictur area insid bodi procedur also call nuclear magnet reson imag nmri ct scan cat scan procedur make seri detail pictur area insid bodi brain chest upper abdomen taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi pet scan positron emiss tomographi scan procedur find malign tumor cell bodi small amount radioact glucos sugar inject vein pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell pet scan ct scan may done time call pet ct bone scan procedur check rapidli divid cell cancer cell bone small amount radioact materi inject vein travel bloodstream radioact materi collect bone cancer detect scanner three way cancer spread bodi cancer spread tissu lymph system blood tissu cancer spread began grow nearbi area lymph system cancer spread began get lymph system cancer travel lymph vessel part bodi blood cancer spread began get blood cancer travel blood vessel part bodi cancer may spread began part bodi cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi metastat tumor type cancer primari tumor exampl small cell lung cancer spread brain cancer cell brain actual lung cancer cell diseas metastat small cell lung cancer brain cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ call metastat cancer anim show cancer cell travel place bodi first form part bodi follow stage use small cell lung cancer limit stage small cell lung cancer limit stage cancer lung start may spread area lung lymph node collarbon extens stage small cell lung cancer extens stage cancer spread beyond lung area lung lymph node collarbon place bodi recurr small cell lung cancer recurr small cell lung cancer cancer recur come back treat cancer may come back chest central nervou system part bodi treatment option overview key point differ type treatment patient small cell lung cancer six type standard treatment use surgeri chemotherapi radiat therapi immunotherapi laser therapi endoscop stent placement new type treatment test clinic trial treatment small cell lung cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment follow test may need differ type treatment patient small cell lung cancer differ type treatment avail patient small cell lung cancer treatment standard current use treatment test clinic trial treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial clinic trial open patient start treatment six type standard treatment use surgeri surgeri may use cancer found one lung nearbi lymph node type lung cancer usual found lung surgeri alon often use surgeri doctor also remov lymph node find cancer sometim surgeri may use remov sampl lung tissu find exact type lung cancer doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi chemotherapi place directli cerebrospin fluid organ bodi caviti abdomen drug mainli affect cancer cell area region chemotherapi way chemotherapi given depend type stage cancer treat see drug approv small cell lung cancer inform radiat therapi radiat therapi cancer treatment use high energi x ray type radiat kill cancer cell keep grow two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place directli near cancer way radiat therapi given depend type stage cancer treat extern radiat therapi use treat small cell lung cancer may also use palli therapi reliev symptom improv qualiti life radiat therapi brain lessen risk cancer spread brain may also given immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi type immun cell cell cancer cell certain protein call checkpoint protein surfac keep immun respons check cancer cell larg amount protein attack kill cell immun checkpoint inhibitor block protein abil cell kill cancer cell increas use treat patient advanc small cell lung cancer two type immun checkpoint inhibitor therapi ctla inhibitor ctl protein surfac cell help keep bodi immun respons check ctla attach anoth protein call b cancer cell stop cell kill cancer cell ctla inhibitor attach ctla allow cell kill cancer cell ipilimumab type ctla inhibitor pd inhibitor pd protein surfac cell help keep bodi immun respons check pd attach anoth protein call pdl cancer cell stop cell kill cancer cell pd inhibitor attach pdl allow cell kill cancer cell pembrolizumab nivolumab type pd inhibitor enlarg immun checkpoint inhibitor checkpoint protein pd l tumor cell pd cell help keep immun respons check bind pd l pd keep cell kill tumor cell bodi left panel block bind pd l pd immun checkpoint inhibitor anti pd l anti pd allow cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv small cell lung cancer inform laser therapi laser therapi cancer treatment use laser beam narrow beam intens light kill cancer cell endoscop stent placement endoscop thin tube like instrument use look tissu insid bodi endoscop light len view may use place stent bodi structur keep structur open endoscop stent use open airway block abnorm tissu new type treatment test clinic trial inform clinic trial avail nci websit treatment small cell lung cancer may caus side effect inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment clinic trial includ patient yet receiv treatment trial test treatment patient whose cancer gotten better also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found nci clinic trial search webpag clinic trial support organ found clinicaltri gov websit follow test may need test done diagnos cancer find stage cancer may repeat test repeat order see well treatment work decis whether continu chang stop treatment may base result test test continu done time time treatment end result test show condit chang cancer recur come back test sometim call follow test check up treatment option stage inform treatment list see treatment option overview section limit stage small cell lung cancer treatment limit stage small cell lung cancer may includ follow combin chemotherapi radiat therapi chest radiat therapi brain may later given patient complet respons combin chemotherapi alon patient cannot given radiat therapi surgeri follow chemotherapi surgeri follow chemotherapi radiat therapi radiat therapi brain may given patient complet respons prevent spread cancer brain clinic trial new chemotherapi surgeri radiat treatment use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail extens stage small cell lung cancer treatment extens stage small cell lung cancer may includ follow combin chemotherapi radiat therapi brain spine bone part bodi cancer spread palli therapi reliev symptom improv qualiti life radiat therapi chest may given patient respond chemotherapi radiat therapi brain may given patient complet respons prevent spread cancer brain clinic trial new treatment chemotherapi immunotherapi immun checkpoint inhibitor use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail treatment option recurr small cell lung cancer inform treatment list see treatment option overview section treatment recurr small cell lung cancer may includ follow chemotherapi immunotherapi immun checkpoint inhibitor radiat therapi palli therapi reliev symptom improv qualiti life laser therapi stent placement keep airway open intern radiat therapi palli therapi reliev symptom improv qualiti life clinic trial new chemotherapi treatment use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail learn small cell lung cancer inform nation cancer institut small cell lung cancer see follow lung cancer home page lung cancer prevent lung cancer screen drug approv small cell lung cancer tobacco includ help quit cigarett smoke health risk quit secondhand smoke cancer gener cancer inform resourc nation cancer institut see follow cancer stage chemotherapi support peopl cancer radiat therapi support peopl cancer cope cancer question ask doctor cancer survivor caregiv pdq summari pdq physician data queri pdq nation cancer institut nci comprehens cancer inform databas pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin summari come two version health profession version detail inform written technic languag patient version written easi understand nontechn languag version cancer inform accur date version also avail spanish pdq servic nci nci part nation institut health nih nih feder govern center biomed research pdq summari base independ review medic literatur polici statement nci nih purpos summari pdq cancer inform summari current inform treatment small cell lung cancer meant inform help patient famili caregiv give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date board made expert cancer treatment specialti relat cancer summari review regularli chang made new inform date summari updat date recent chang inform patient summari taken health profession version review regularli updat need pdq adult treatment editori board clinic trial inform clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori trial answer certain scientif question order find new better way help cancer patient treatment clinic trial inform collect effect new treatment well work clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial clinic trial open patient start treatment clinic trial list pdq found onlin nci websit inform call cancer inform servic cancer permiss use summari pdq regist trademark content pdq document use freeli text cannot identifi nci pdq cancer inform summari unless whole summari shown updat regularli howev user would allow write sentenc nci pdq cancer inform summari breast cancer prevent state risk follow way [includ excerpt summary] best way cite pdq summari pdq adult treatment editori board pdq small cell lung cancer treatment bethesda md nation cancer institut updat mm dd yyyi avail http www cancer gov type lung patient small cell lung treatment pdq access mm dd yyyi [pmid ] imag summari use permiss author artist publish use pdq summari want use imag pdq summari use whole summari must get permiss owner cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim inform summari use make decis insur reimburs inform insur coverag avail cancer gov manag cancer care page contact us inform contact us receiv help cancer gov websit found contact us help page question also submit cancer gov websit e mail us',\n",
       " 'hifrancishannon work like beauti two year stop one year three relaps went back time half dose everi day lymphocyt take half dose four year ms progress start go one year half dose spm fingolimod stop ms case hope better luck care rebounf effect take care xxx',\n",
       " 'medic use multipl sclerosi ms modifi diseas cours treat relaps also call attack exacerb manag symptom along essenti compon comprehens ms care medic help peopl manag ms enhanc comfort qualiti life modifi diseas cours follow u food drug administr fda approv diseas modifi agent pdf brochur reduc diseas activ diseas progress mani peopl relaps form ms includ relaps remit ms well progress form ms peopl experi relaps inject medic avonex interferon beta betaseron interferon beta b copaxon glatiram acet extavia interferon beta b glatiram acet inject glatiram acet gener equival copaxon mg mg dose glatopa glatiram acet gener equival copaxon mg dose plegridi peginterferon beta rebif interferon beta zinbryta daclizumab oral medic aubagio teriflunomid gilenya fingolimod tecfidera dimethyl fumar infus medic lemtrada alemtuzumab novantron mitoxantron ocrevu ocrelizumab tysabri natalizumab follow treatment plan doctor establish best possibl strategi manag ms earli ongo treatment diseas modifi therapi support ms coalit includ nation ms societi evid base consensu diseas modifi therapi pdf summari pdf may use discuss treatment option healthcar provid advoc insur access coverag paper last updat adher diseas modifi medic key element treatment effect help manag cost medic read patient assist program offer pharmaceut compani certain circumst healthcar provid may use medic treat ms fda approv diseas also call label use past decad sever medic use label ms manag relaps ms relaps caus inflamm central nervou system damag myelin coat around nerv fiber damag slow disrupt transmiss nerv impuls caus symptom ms relaps gradual resolv without treatment sever relaps involv loss vision sever weak poor balanc exampl interfer person mobil safeti overal abil function neurologist recommend treatment corticosteroid common treatment regimen three five day cours high dose intraven corticosteroid reduc inflamm end relaps quickli regimen may may follow slow taper oral prednison corticosteroid believ long term benefit diseas medic option includ high dose intraven solu medrol methylprednisolon high dose oral deltason prednison h p acthar gel acth manag symptom wide varieti medic use help manag symptom ms common symptom ms medic use treat symptom',\n",
       " 'still midst decis make process set lemtrada end last year new neuro point essenti last line treatment present gone onto move onto anyth els caus perman chang immun system ok number new drug potenti come onlin next year would mean one elig keen tackl thing strong dmt rrm activ also awar fact one need play long game present decis kind like pop guess probabl go tysabri month see work jvc statu increas mo becom high risk stay work move onto either gilenya lemtrada tough call incred stress feel much rememb bodi decis know sound obviou peopl tri influenc one way anoth scare certain risk experienc ill necessarili understand mean go',\n",
       " 'hi brief updat mom progress seek opinion round paclitaxel carbo dosag drop sinc nd round due low white blood cell count cea drop rd infus abl cope side effect pet scan done th round also shown satisfactori improv near tumor shrunk size activ howev cea valu also stabil increas th round th round next week primari doctor suggest paus afraid bodi cannot cope accumul toxic also consult nd opinion privat sector suggest test action mutat braf ret met exon skip anoth got neg result summari treatment far cea begin alimta carbo round cea drop alimta mainten round cea increas keytruda round cea increas paclitaxel carbo round cea drop go physic statu still good moment less cough better pet scan result compar time end keytruda treatment howev seem situat could go wors soon given rise cea valu run option queri still worth seek tri anoth immunotherapi though doctor govern privat sector suggest option seem pdl inhibitor avail area ctla still chemotherapi tri even use doctor refus suggest think realli need could find much inform onlin regard rd th line chemo treatment best regard mike',\n",
       " 'short term assess intravitr dexamethason implant use enhanc depth imag optic coher tomographi optic coher tomographi angiographi patient retin vascular diseas abstractintroductionto evalu short term efficaci safeti intravitr dexamethason implant idi patient macular oedema associ diabet retinopathi dr retin vein occlus rvo use enhanc depth imag optic coher tomographi edi oct estim effect dexamethason choroid retin vascular network use oct angiographi octa methodsfifteen eye patient macular oedema secondari diabet dr n retin vein occlus rvo n treat intravitr inject sustain releas idi primari efficaci end point chang best correct visual acuiti central macular thick cmt secondari end point chang choroid thick choroid retin vascular network determin octa resultscmt significantli reduc baselin h inject p http link springer com sourc advanc therapi',\n",
       " 'mom diagnos septemb nsclc realli sick time breath lose weight mental slept time workup spend week hospit pleural effus pulmonari embol came home hous plurex cathet drain cc first effus blood clot gone start feel better qualifi immunotherapi due pl percentag went keytruda three month felt well enough go home tumor shrink start grow doctor took keytruda put carboplatin pematrex six month last appoint doctor said would take carboplatin stabl mainten pemetrex would find said next set scan taken last monday well latest scan result anyon give word wisdom would suggest feel like tri get studi readi give fight know either last scan juli btw lung airway unremark exampl right lower lobe subpleur mass adjac atelectasi slightli increas measur x cm previous x cm right posterior upper lobe opac measur x cm unchang masslik subpleur consolid medial basal right lower lobe measur cm unchang slightli decreas focu interstiti thicken consolid medial basal segment left lower lobe new suspici nodul pleura pericardium unchang right pleural nodular thicken predominantli along lower lobe unchang small locul right pleural effus increas size nodul right obliqu fissur measur x cm previous x cm left pleural effus mediastinum thorac node increas adenopathi exampl paratrach measur x cm previous x cm paraesophag measur x cm previous x cm right supradiaphragmat measur x cm previous x cm thank obvious discuss doctor hope get thought go tell scan report go let doctor tell work hardli slept sibl much help mother medic issu sister get involv',\n",
       " 'much better interact mom doctor today regard clinic trial recent advanc sclc care advis even though still first line treatment bad idea get understand second line fast diseas recur spread lot new develop avail clinic trial even exist drug label use pick rout go depend lot specif characterist tumor exampl attract rout vs standard chemo effect first line opdivo yervoy label clinic trial particularli effect cancer high tumor mutat burden tmb keytruda label clinic trial particularli effect high pdl express rova clinic trial particularli effect high dll express question test specif characterist usual done sclc inde patholog report got test rather randomli pick second line treatment like opt one like work liter test order biopsi send away lab advis proactiv would biopsi pain damag worth sure go',\n",
       " 'rtp good point wife eat meal home thank mostli effort start tri scd diet strict adher anymor chang way eat complet sugar process food almost dairi grain complex carb starch save money cook home overal health proven cholesterol test weight loss marker much improv dx sept sulfasalazin work year current flare year g sulfasalazin g canasa mg iron supplement paleo scd base diet sever month humira far good',\n",
       " 'accord nation cancer institut patient diagnos non small cell lung cancer nsclc year percent chanc aliv year later patient stage iv diseas describ cancer spread distant site beyond origin tumor statist drop percent univers colorado cancer center studi publish journal thorac oncolog tell much optimist stori stage iv nsclc patient whose tumor test posit rearrang gene alk alk nsclc treat uchealth univers colorado hospit median overal surviv year mean popul instead percent patient aliv year diagnosi percent patient aliv year diagnosi show develop good target therapi alk posit lung cancer even patient stage iv diseas well mani mani year say jose pacheco md investig cu cancer center studi first author studi detail patient current studi percent never smoker median age year almost patient initi treat drug crizotinib earn fda approv august treat alk nsclc previous avail colorado academ medic center set clinic trial importantli treatment crizotinib patient current studi show evid worsen diseas percent transit anoth alk inhibitor commonli brigatinib alectinib ceritinib mani studi report shorter overal surviv patient stage iv alk nsclc treat crizotinib studi lower surviv outcom larg part lower percentag patient receiv next gen alk inhibitor progress crizotinib patient get next gen alk inhibitor phase clinic trial mani center access pacheco say combin therapi also factor anoth factor influenc surviv use pemetrex base chemotherapi alk lung cancer often addit target therapi alk inhibitor patient undergo chemotherapi sometim radiat howev mani chemotherapi choos often unclear specif chemotherapi success specif cancer stage patient characterist studi cu cancer center investig ross camidg md phd also senior author current studi suggest pemetrex work especi well alk form diseas tri use mainli pemetrex base chemotherapi alk lung cancer pacheco say possibl shorter surviv studi may associ use non pemetrex base chemotherapi interestingli exist brain metastas time diagnosi predict shorter surviv lot new alk inhibitor develop crizotinib get brain well work similarli brain compar outsid brain care surveil patient see develop brain met instead wait symptom treat monitor develop metastas imag brain see someth new sometim treat caus symptom pacheco say predict factor shorter surviv number organ found carri cancer time diagnosi benefit target therapi point year one longest median surviv ever report nsclc subpopul stage iv diseas pacheco say show benefit target therapi chang surviv lot patient think suggest type nsclc may becom much chronic condit rather termin diseas learn',\n",
       " 'time take prednison mayb best take dose long humira dose awhil mayb time consid move anoth biolog get remiss best way fix sleep issu never slept well mp one reason stop medic find pepto bismol tablet realli help ga diarrhea keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri total hip replac thank prednison current condit chronic pouchiti bad thought would current med stelara',\n",
       " 'sound like trawl find paper counter valu cladribin cladribin tabletten bei schubf rmiger multipl skleros noch ein purinanalogon oder echt therapeutisch innov schmidt nervenarzt oct doi howev articl german go comment take read german vocabulari good enough howev mayb drk may flick deal alot differ european languag within group azaothiaprin anti prolif cell recent shown inhibit rate relaps level found beta interferon way less expect clad http multipl sclerosi research blogspot com cheap chip azathioprin better html also induct therapi',\n",
       " 'oh man bought hous great hous crash put contract got one post uc diagnosi shudder think bathroom get us accid get bed bathroom congrat yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wk minor flare august flare sinc oct acut pancreat mesalamin allerg humira start pred bridg still entyvio start flare wors right mg pred',\n",
       " 'doc keep mind would want research breast feed take steroid enorm dose short term realli number insomnia blurri vision due high blood sugar mood chang longer term affect bone strength doc recommend take antacid counter digest effect learn go close zero sugar possibl steroid white rice flour count categori pump freez get babi week steroid ongo treatment ocrevu would recommend get go time brain mean dilli dalli around less effect drug cost ocrevu fall categori efficaci scari side effect wise treatment pleas oh pleas give permiss supermom sleep nutrit exercis medit key child rememb made feel tri focu allow process diagnosi tear anger frustrat etc take requir readjust new symptom pop educ depend sole neurologist much time read new develop',\n",
       " 'fda issu complet respons letter crl tie manufactur pre fill syring ask info suppli process addit want regeneron complet usabl studi evalu singl inject eylea pre fill syring approxim patient part pre approv process regeneron said expect complet studi andget inform fda earli expect process delay launch eylea pre fill syring may target date potenti approv eylea npdr free daili newslett like stori subscrib fiercepharma biopharma fast grow world big idea come along daili subscrib reli fiercepharma must read sourc latest news analysi data drug compani make sign today get pharma news updat deliv inbox read go subscrib news came tarrytown new york base regeneron report eylea hit primari endpointin phase trial patient take eylea everi everi week interv moder sever sever diabet retinopathi without treatment one third patient develop vision threaten complic diabet macular edema within one year regeneron said relat undervalu indic regeneron eylea could help weather novarti threat analyst said first trial npdr show reduct vision threaten complic develop diabet macular edema moder sever sever diabet retinopathi lead caus vision impair blind among work age adult eylea abl reduc complic even everi four month dose moreov abl revers anatom sever diseas georg yancopoulo regeneron chief scientif offic said statement import regeneron foundat drug assault treatment eylea gener billion sale regeneron last year withabout u sale come patient wet age relat macular degener amd new drug candid threaten eylea lock indic compani test blockbust drug area',\n",
       " 'parasit worm fungu bacteria etc easili overwhelm someon compromis immun system data show signific number peopl get overhwelm parasit worm fungu bacteria etc data show modestli elev risk certain specif infect post read like noth scare tactic skin cancer issu anybodi med get regular skin check show link remicad actual tripl risk recent studi show increas risk think tripl real concern skin cancer basal cell carcinoma squamou cell carcinoma melanoma sure good data whether remicad increas risk melanoma black box warn also well understood reason longer put boy young men combo therapi think appli sinc born exactli boy huff post link tell us number risk without quantifi look like scare tactic tell us risk treat uc crohn diseas better yet tell us risk aspirin otc taken hundr million peopl tell us risk prednison',\n",
       " 'quot link bart blog short pwppm unfortun miss relaps phase diseas simpli unlucki new lesion occur clinic eloqu site caus relaps bring attent neurologist earlier cours diseas present lost reserv capac good news posit trial ocrelizumab let hope regul payer allow pwppm access ocrelizumab remind bart blog year back say possibl pwppm fact rrm symptom mild never investig possibl ms feel true year weird symptom either bad enough see doctor last short time bother see doctor see doctor put anxieti anxieti medic note everyth put anxieti fact extent believ suffer anxieti believ hypochondriac mani year stop go see doctor altogeth even though suffer pin needl numb patch swallow problem dizzi pain especi fatigu bad case shingl face scalp final got doctor long stori short final got dx ms wonder mani dx ppm also similar histori odd unexplain symptom could mild episod rrm sorri longer meant pat xx',\n",
       " 'lancet neurolog decemb free access paper tipsheet revis mcdonald criteria diagnosi ms pdf aan practic guidelin current american academi neurolog clinic practic guidelin relat tool includ patient physician summari select guidelin addit tool new guidelin ad regularli clinic tool inject anxieti six session program call self inject anxieti train siac develop david c mohr phd darci cox psyd univers california san francisco ucsf behavior medicin research center bmrc shown effect help peopl overcom fear learn self inject siac patient workbook counselor manual download inform program develop valid manual counselor pdf patient workbook pdf siac background valid refer pdf health insur appeal letter abstract templat health insur appeal letter develop societi report coverag denial limit receiv directli peopl ms healthcar profession societi medic advisor determin treatment need address review approv templat letter new therapi evid emerg letter may develop dissemin sampl health insur appeal letter diseas modifi therapi aubagio avonex avonex follow st demyelin event betaseron betaseron appeal follow st demyelin event copaxon mg copaxon mg gilenya glatopa lemtrada novantron ocrevu plegridi rebif rebif follow st demyelin event rituxan tecfidera tysabri symptom manag rehab ampyra clean intermitt cather cool vest erectil dysfunct drug ivig lyrica neurontin neuro psycholog evalu plasmapheresi power oper vehicl provigil rehabilit inform patient appeal right avail ssdi claim privat disabl resourc guidebook webinar assist healthcar profession collabor ms patient process file claim ssdi ssi pdf privat long term disabl benefit pdf new ms list social secur disabl webinar physic activ resourc physic activ peopl multipl sclerosi pdf yoga program peopl ms focu peopl mild symptom ms pdf wheel mobil seat mobil evalu person multipl sclerosi pdf talk patient wheel mobil pdf choos mobil devic right pdf custom wheel mobil patient wtih ms guid mobil option prescript document pdf mental health webinar invit monthli network learn call mental health profession work peopl live ms famili view call schedul call interact look provid present case request offer topic interest us topic interest case discuss pleas reach andrea arzt andrea arzt nmss org previou webinar multipl sclerosi need know diseas adapt life ms emot challeng cope strategi cognit dysfunct ms recognit assess treatment profession challeng teach us school webinar also avail ce credit wake ahec ms need know diseas adapt life ms ms cognit dysfunct profession challeng clinic studi measur inform frequent use clinic measur includ descript administr score method psychometr properti literatur citat test form provid possibl ccsvi read latest inform ccsvi',\n",
       " 'question long remiss lot like old one piec string long piec string well depend depend use whether fray worn similarli long might go relaps stage remiss stage multipl sclerosi ms moment seem happili remiss stage ms like less year say less brief interlud relaps brief time call pseudoexacerb mean bodi feel fragil ms symptom jump hit may caus much stress get hot infect overli fatigu peopl ms intens cold thing caus goe away go back feel version good work hard reduc chanc stress life tri adopt easi go attitud life go flow much make sure keep cool hot weather attack seem part south australia moment air condit shade friend tri overdo thing know rest bodi forgiv thing may take mere minut work anyon ms may take day anyth pseudoexacerb go away becom full relaps good thing full relaps could lead brain forgotten work properli memori cognit almost switch overal muscl weak terribl feel bleuhh current remiss joy much hope particular piec string longer length journey moon back current medic posit life attitud increas level exercis sometim bodi love healthier diet work harder fix damag part bodi love write life brain frizzl abl write book thing like one photo mri year one would indic much damag done central nervou system gp indic would good went saw neurologist see well medic prescrib back wonder drug becam avail australia afford cost drug gilenya tablet take everi day rather inject drug avonex use inject thigh muscl week avonex work ok help symptom gilenya work much much better go back origin question long remiss last answer know gilenya may go work well forev may never anoth relaps moment love work tri keep happen bodi abl walk drive car brain abl less thing want happi ms stori hope other happi ms stori glad hear stori happi share sometim write bad thing take bad away',\n",
       " 'alimta usual administ anoth chemo drug potenti immunotherapi like keytruda carboplatin alimta keytruda lexiecat say oncologist make recommend signific advanc lung cancer treatment last two year treatment tailor individu produc best outcom best news longer one size fit approach lung cancer social worker cancer center understand reimburs work best wish prayer friend michel',\n",
       " 'thought potenti use ginger tumer extract tinctur year old ulcer pancol diagnos decemb admit month half hospit care due extrem symptom treatment given prednison remicad tacrolimu valcyt blood transfus celebrex neurontin pantoprazol bentyl entyvio',\n",
       " 'ok thank folk know sure hear result knowledg learn much valuabl learn thing want know ncot mean say luxuri time versu make decis get well say think care go humira tell know pleas make ok stand go br time least accid happen antibiot first time month get sicker tummi hurt time energi zero work full time know much longer joint leg hurt bad see avascular necrosi go along crohn stuff think joint better measur intestin health anyth els tell know humira pleas',\n",
       " 'hi emili happi new year famili happi learn husband well know devast lmd know husband remain stabl hope improv provid much hope other diagnosi hope husband continu improv saralb good fortun best wish bob beth sept wife beth year old non smoker dx stage adinocarcinoma nsclc egfr met liver bone brain sept oper replac right hip damag bone met sept dvt found leg start lovinox oct start tarceva mg per day januari surgeri stabil right femur follow radiat treatment april radiat treatment left femur may dx lmd start puls dose tarceva mg wk sept lost beth',\n",
       " 'diagnos nsclc januari put carboplatin abraxan surviv ok earli put gemzar noth thing look realli bad insur final approv opdivo septemb last year case amaz met brain vanish latest scan show noth inert nodul lung lung scare appar non activ nodul lymph node feel great weight remain steadi month blood count pretti good littl low rbc heck downsid realli bad rash itch like hell told gp doctor death rash decid went rash go everi two week opdivo chemo oncologist recent told rest life mainten recent request return work month work difficult high tech posit feel well enough resum say lucki work dramat improv outlook qualiti life good luck god bless',\n",
       " 'melibu diagnos seem trend unexplain symptom sinc diagnos read medic record thing like tridgemeni neuralgia bladder urgenc panic attack hand tingl realli wonder someth neurolog nt question realli make angri due intens headach request mri told need one hypochondriac lo behold found lesion old top addit new one hit hard lemtrada would next drug choic gilenya help stop progress',\n",
       " 'viibryd year half soon start medic mg start ach pain joint think anyth recent ankl surgeri attribut discomfort pain joint spread becam concern crohn diseas arthriti relat crohn diseas pain inflamm increas went see gi dr felt crohn arthriti start humira well help joint pain inflamm continu progress get wors refer primari rheumotologist start heavi dose prednison still diagnosi crohn arthriti bring',\n",
       " 'anyon experienc fever take mekinist tafinlar sister fever spike come call doc said side effect chemo possibl sign abl toler chemo give decadron steroid fever far bring temp doc told us give even chemo dose see oncologist friday wonder anyon els experienc afraid fever someth',\n",
       " 'would like ask long keytruda infus take leaflet minut ppl know take keytruda minut father take minut possibl wrong mani thank veronika',\n",
       " 'hi kaitlyn thank much check blog glad abl connect congrat pregnanc humira decad stay throughout entir first pregnanc son current month time around current wk pregnant would highli recommend stay medic want chanc put greater risk postpartum flare son pictur health thrive beauti rare even get sniffl vaccin babi get rotaviru concern humira stay babi system first six month son even cold mayb month kept low profil go target instanc week feel free contact directli blog question happi help guid',\n",
       " 'year old male recent diagnos ms last year rough suffer chronic pain due bad vasectomi octob left tri variou medic includ high dose gabapentin sometim spring start notic numb sensat left hand finger sinc car crash summer doctor ascrib possibl neck injuri prolaps august vasectomi revers sever hour oper full narcosi week oper left shoulder neck start hurt lot mri confirm prolaps neck sent hospit full ms survey unfortun took sever month dec ms less fact oligoclon band csf still miss though dec strong attack start went emerg unit mani hour wait gave solumedrol result attack sensat chang hand feet left quit weak push like crazi start dmt final last week approv ocrevu first infus two day wait start fight back ms slowli eat away myelin probabl year hindsight probabl mild attack march april set numb left hand nd attach august follow surgeri final rd attack decemb anyon attack per year experi dmt cours research like crazi complic diseas start look ocrevu suffici stop power halt diseas attack that tough question know anoth way would ask whether anyth add increas chanc current vitamin b c fish oil calcium linol acid chronic pain order ginkgo biloba magnesium flax seed oil let know think thank',\n",
       " 'schedul see ent dr today fiberopt laryngoscopi nasolaryngoscopi show complic tumor insid throat neck area swell growth part lung cancer treat lymph node shrunk start show symptom step backward taken clinic studi got put anoth chemo immunolog togeth chemo drug docetaxel taxoter pemrolizumab get st combo chemo drug sinc april alon area stabil supraclavicular lymph node act neck ct show noth new seen report yet blood test done get stud way go back biopsi lymph node ask realli suggest tri stay posit hope well chemo real side effect except lose littl hair neuropathi feet brace cold night went high low lower rain day time tell god us guid us noth easi far surviv right mind go around circl wait thing come though hope go astray wish warmer weather get thing done trip indi sya best laid plan mice men',\n",
       " 'durham n c busi wire jan aeri pharmaceut inc nasdaq aeri ophthalm pharmaceut compani focus discoveri develop commerci first class therapi treatment patient open angl glaucoma retina diseas diseas eye today announc u food drug administr fda review investig new drug applic ind ar dexamethason intravitr implant effect allow aeri initi human studi treatment macular edema due retin vein occlus rvo ind submit decemb aeri expect initi phase clinic studi later first quarter ar bio erod implant design releas steroid dexamethason six month sustain period method administr commonli use intravitr inject potenti benefit ar compar steroid product includ six month durat efficaci improv administr due smaller needl size possibl better safeti profil due lower peak drug level ar first ind stage treatment aeri retina pipelin import mileston compani said vicent anido jr ph chairman chief execut offic aeri quarter also plan file ind second retina product bio erod implant contain rho kinas protein kinas c inhibitor ar develop wet age relat macular degener diabet macular edema product demonstr potenti two enabl platform deliv drug back eye bio erod polym technolog licens dsm print manufactur technolog licens envisia advanc new treatment second signific therapeut area eye care continu pursu goal build next major ophthalm pharmaceut compani aeri pharmaceut inc aeri ophthalm pharmaceut compani focus discoveri develop commerci first class therapi treatment patient open angl glaucoma retina diseas diseas eye aeri first product rhopressa netarsudil ophthalm solut daili eyedrop approv u food drug administr fda reduct elev intraocular pressur iop patient open angl glaucoma ocular hypertens launch unit state april clinic trial rhopressa common advers reaction conjunctiv hyperemia cornea verticillata instil site pain conjunctiv hemorrhag inform rhopressa includ product label avail www rhopressa com aeri advanc stage product candid rocklatan netarsudil latanoprost ophthalm solut fix dose combin rhopressa wide prescrib pga prostaglandin analog latanoprost achiev month primari efficaci endpoint two phase registr trial mercuri mercuri also show safeti efficaci throughout month mercuri aeri submit rocklatan new drug applic nda may juli fda set pdufa prescript drug user fee act goal date complet fda review rocklatan nda march aeri continu focu global expans develop addit product candid technolog ophthalmolog includ wet age relat macular degener diabet macular edema inform avail www aeriepharma com forward look statement press releas contain forward look statement purpos safe harbor provis privat secur litig reform act may case use term predict believ potenti propos continu estim anticip expect plan intend may could might explor pursu word convey uncertainti futur event outcom identifi forward look statement forward look statement includ statement regard intent belief project outlook analys current expect concern among thing expect regard commerci manufactur rhopressa rocklatan futur product candid includ time cost aspect commerci launch rhopressa rocklatan futur product candid commerci market manufactur suppli manag capabl strategi success time cost ongo anticip preclin studi clinic trial rhopressa respect regulatori approv outsid unit state addit indic rocklatan futur product candid includ statement regard time initi complet studi trial statement press releas regard expect clinic trial ar ar result clinic trial time abil request obtain maintain fda regulatori author approv action respect applic rhopressa rocklatan futur product candid includ expect time time regulatori review file applic rhopressa rocklatan futur product candid potenti advantag rhopressa rocklatan futur product candid plan pursu develop addit product candid technolog within beyond ophthalmolog plan explor possibl use exist proprietari compound beyond glaucoma includ develop retina program abil protect proprietari technolog enforc intellectu properti right expect regard strateg oper includ abil licens acquir addit ophthalm product product candid technolog natur forward look statement involv risk uncertainti relat event competit dynam industri chang factor beyond control depend regulatori approv econom environment circumst may may occur futur may occur longer shorter timelin anticip discuss mani risk greater detail head risk factor quarterli annual report file secur exchang commiss sec particular fda approv rhopressa constitut fda approv rocklatan assur receiv fda approv rocklatan ar ar futur product candid fda approv rhopressa also constitut regulatori approv rhopressa jurisdict outsid unit state assur receiv regulatori approv rhopressa jurisdict outsid unit state receipt prescript drug user fee act pdufa goal date notif rocklatan constitut fda approv rocklatan new drug applic nda assur fda complet review pdufa goal date march fda requir chang addit data must made receiv approv nda ever fda approv nda addit accept ind discuss press releas constitut fda approv ar outcom later clinic trial ar may suffici submit nda fda receiv fda approv forward look statement guarante futur perform actual result oper financi condit liquid develop industri oper may differ materi forward look statement contain press releas forward look statement make press releas speak date press releas assum oblig updat forward look statement whether result new inform futur event otherwis date press releas view sourc version businesswir com http www businesswir com news home en contact media tad heitmann theitmann aeriepharma com investor ami bavishi abavishi aeriepharma com keyword unit state north america north carolina industri keyword health clinic trial health gener health sourc aeri pharmaceut inc copyright busi wire pub disc http www businesswir com news home en',\n",
       " 'thank poppi nssg keith took step email cleveland clinic yesterday see appoint email back offer consult dr daniel fish colorect surgeon googl much came current colorect dr kann oschner new orlean googl read bio oschner websit oschner current rank nation gastroenterolog dr kann special ibd particularli crohn like plu trust ibd specialist dr shah googl quit resum oschner best region houston hour drive away water right still quit far mayo jackson almost hour drive would fli may well go cleveland case assum dr kann offer colostomi thought would ok case appreci treat individu conced diseas could come back odd would favor reason never guarante like given option abl weigh base person experi goal dr shah dr kann offer diplomat although dr shah moment pushi control tri anyway pretti comfort wonder cleveland might say might appeal option outcom might better base hospit except level care cleanli oschner rank pretti high specialti experi visit dr shah locat hospit colonoscopi staff compet facil clean made trip mani time everyth familiar make much less stress proxim live make follow care much simpler keith consid j pouch remov goal surgeri get ibd medic except think rather continu oral mesalamin chronic pouchiti neccesit antibiot also stelara would satisfi ostomi realli bad choos keep pouch post edit plucki pm gmt',\n",
       " 'european union clear tofacitinib ulcer coliti european union clear tofacitinib ulcer coliti jak inhibitor indic adult moder sever activ ulcer coliti fail respond adequ intoler therapi intern approv sourc medscap medic news headlin',\n",
       " 'welcom spanish lesson feel like written long time mostli mani downward spiral want complain place soul decid dimens one experi depth detail like got derail made wrong turn back want turn around hell happen f thing realiz fragil happi took grant spit face luck god get moment light get mad melodramat symptom infus bad lot ms patient lot wors besid still lucki got privat room infus access great doctor amaz insur suppos inspir get togeth write dive spiral take medic marijuana candi later today woke sing opera style kermit voic song yesterday made coffe belt feel like mayb steroid high final kick got energi think iron coincident yesterday feel like futur friend blah blah blah last day laugh sing yesterday realli funni open email anoth long rider burst tear sing realiz roller coaster may complet yet wait want scienc solumedrol corticosteroid infus day gram day stop relaps track super power anti inflammatori shut activ lesion hard adren taken lightli dramat cut effect relaps tast soon iv goe tast like suck penni felt burn vein first time time mix salin feel anyth peopl say get energi love buzz get laundri done organ cracki behavior slept hour could also ativan gave anoth strong anti anxieti medic turn freak medic procedur trust medic industri complex healthi fear die pain human error rapid heart rate shallow breath good heal shut soon walk kind pleasant put black cloth red lipstick go get blanket pillow pull watercolor lay color pass littl scienc rituxin rituximab produc compani call genentech fairli certain genentech name evil corpor scifi show may guest star get medic world exactli like marvel comic rock star doctor crazi billionair mad scientist world hologram project weird shit sorri carri rituxin monoclon antibodi drug use blood cancer chemo immunosuppress act kill half immun system immun system made cell b cell ms drug act cell gener though react bodi fact b cell modul effect ms chang way scientist think ms rituxin use treat ms pretti success sinc stop lesion stop relaps help peopl rrm regain lost function use ask exact drug also act b cell come year name ocrelizumab mayb patent rituximab year would cheaper gener option made compani peopl could actual get afford help instead pay year rumor ocrelizumab drama continu ocrelizumab new brother rituxin basic exact drug coupl littl twerk patent price hearsay rituxin though use cancer year rheumatoid arthriti lupu ms autoimmun diseas safe success ocrelizumab howev seem lot instanc cancer mostli breast cancer rituxin bunch problem cancer would realli allow drug prescrib patient face disabl make big enough profit spend year million develop slightli wors version caus cancer start push super expens evil twin frighten mass know know shit head super scari make decis educ enough make tend turn everyth super dramat plot line start amus start believ realli know noth except read ugh breakdown point get infus rituxin doctor rock star got insur cover think word favorit ms blogger wheelchair kamikazi rogu prescrib rituxin hard get prescrib hard get approv still cancer med ms med still chemo still scari infus might make feel sick still kill half immun system sensit thing bodi kill unpleas feel like poison point poison new band name heheh rituxin last month get kill half immun system live indefinit half immun system think want tri fond immun system even though abus relationship hurt alway take back chop hand kill half start eye eye world goe blind lose feel nippl infus get rid numb make abl finish ride immun system get marriag counselor tri learn gentl kill stop eat brain want go natur rout want part system want believ strict diet medit strangl ms want faith slow deliber process control super honest think much faith realli like much control tri natur remedi tri use cranberri juic cure bladder infect bunch sex week piss razor blade sleep bathtub took ass dr pill want wholist peac anxieti ridden want get back hors liter figur battl insid time like trigger ms want focu ride rather focu want simpl goal next mile look like find water hors keep safe control anim stop focus someth bigger help peopl simpl task day day accomplish ident accomplish small goal everi day mile cover mile keep everyon healthi safe fed simpl ever peopl opinion peopl want scare hors peopl want talk mission diseas creep slowli make numb bare use hand univers conspir anymor yesterday lucki yesterday pretti success troubl seem far away bloat head achey want crawl hole readi count yesterday yet dramat steroid roller coaster mood swing would rather count pleasur laugh add glad laugh hallway hospit get woken depress spiral interview guy got addict porn get anymor one guy kept refer limp noodl laugh hard final got bed rambl know melodramat repress thing bare feel hand get exhaust type fix typo existenti feel exhaust even fathom futur chicken destroy hillsid aunt flo got town gotta go get feminin product slowli peak hole like groundhog day unless infus next week scare back insid hors safe wait realli miss littl camper super thank nanci davi racetoerasem peopl want support ride end help tremend call doctor behalf got treatment stuff roll research rituxin prescrib hope peopl start donat get back realli go find cure like beauti heiress ring leader medic genius find cure cost think anyth better contribut way remind tell medic marijuana candi next time p right wrote enough faith natur curesand got phone call woman ms run anim sanctuari futur beat ms without drug diet disciplin prayer got number friend read blog contact convo seem like fate seem crazi serious doubt call exactli right time go feel reinvigor natur heal depart feel like lot medit think weird figur stuff loud hope someon els think life death drug naturopath faith void kind stuff help thank dian zac',\n",
       " 'stool sampl taken test pathogen last two year yeah two year look like uc less like infecti coliti would ask anoth colonoscopi biopsi dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'back long break mom diagnos adenocarcinoma lung septemb age treat pneumonia month thoracentesi procedur one suspect cancer tumor nodul fluid er doc order biopsi fluid drain determin stage lung cancer mom alimta sinc short trial tarveva usual goe almost year symptom cancer reoccur alway manifest fluid lung suspect pneumonia novemb admit hospit short breath treat lasix sent home two hospit stay determin cancer back put alimta within week breath better finish week x session alimta last april mom start breathless three week ago pcp thought could pneumonia put amoxicillin chest x ray onc said x ray show sign cancer last ct octob clear past week mom breathless worsen visit pcp taken er yesterday treat lasix start erythromycin rocephin get ct morn enough fluid settl base tap x ray show lung plump fluid one doc said anoth said show condens onc review ct think progress start chemo mom hospit might let go home tomorrow depend breathless improv write ask test way determin cancer back way put back alimta thank much bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test neg stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr start alimta alimta sinc usual ned chemo period less month month recent occurr jan alimta jan thru april ned april occurr cancer jan start alimta test posit ro june appt onc discuss futur tx plan topic modifi year month ago catdand forum moder topic modifi year month ago catdand forum moder',\n",
       " 'hi carolin thank done bit research lemtrada definit readi yet recent read lot peopl go still bad relaps yep say much think thing settl bit worri happen futur great hear peopl like still wonder life heap convers someon line said thank ru cat thank brilliant littl concern cancer risk allevi lot angst wish could see neurologist realli like hit hard attitud hi temagami thank much detail repli ocrevu actual get sort program new neurologist appar ocrevu approv tga pb yet abl patient ocrevu hope june think one even though day gilenya major issu think probabl go ocrevu keen infus like take tablet keen ocrevu ad amount relaps protect actual point dr jelnick bit reluct right get bit older wrap head around bit think open definit let express point think still bit denial concentr abl go first solo us adventur plan diagnosi guess might feel emot impact bit gp ms nurs mate hope enough support outsid us need thank support',\n",
       " 'lorri would like clarifi observ made said lmc progress rapidli mean week like month wife diagnos may pass away septemb cours case exactli alik would set horizon month possibl gradual deterior pray take longer suggest contact hospic mean put hospic right away numer factor consid chose fight puls dose tarceva long see posit result contrari oncologist recommend month found difficult make hospic decis felt like give time realiz tarceva longer work great difficulti even swallow pill hospit hospic becam logic altern right way go realli meant number choic come hospic home nurs home dedic facil get duck line reason ok condit want go shop thing turn wors oncologist good assist make decis appropri cours action said hope pray said never come bear mom next valeri harper bob beth sept wife beth year old non smoker dx stage adinocarcinoma nsclc egfr met liver bone brain sept oper replac right hip damag bone met sept dvt found leg start lovinox oct start tarceva mg per day januari surgeri stabil right femur follow radiat treatment april radiat treatment left femur may dx lmd start puls dose tarceva mg wk sept lost beth',\n",
       " 'hi guy due start ocrelizumab earli feb think last week hardli data new year worth america exactlti consult told googl anyon els reluct tale someth got kuch histor data',\n",
       " 'read sometim wait best treatment defin longer wait mom histori juli abnorm spot chest xray pnuemonia petscan confirm small nodul right lung definit cancer lot littl sparkl throughout lung biopsi nodul confirm adenocarcinoma mom switch care roswel park anoth biopsi left lung ground glass sparkl came back inconclus neg octob wedg resect upper lower right lobe remov nodul tini margin check lymph node chest one calcifi none cancer surgeon said kind adenocarcinoma old subset longer use bac multifoc adenocarcinoma limpid featur stage iib egfr posit went thru round chemo cisplatin alitma end feb quiet everi month told ned back octob oncologist said area watch right lung tini realli give us much grow biopsi februari said littl chang extend next appt month went back month inform nodul one mm one mm one mm slowli chang grown sinc octob anywher mm gather see scan plan month goe pet scan confirm figur nodul good biopsi retest genet mutat talk tarceva treatment noth definit small slow grow treat wait',\n",
       " 'good luck hope work tri pentasa asacol neither much btw origin prescrib gener gastro consult clear go mine mostli small bowel endoscopi clear visual show stuff biopsi till mri show load strictur small bowel got proper diagnosi sent crohn specialist immedi took mesalazin asacol useless stuff comment start path tri thing get onto biolog case humira',\n",
       " 'pinki glad hear sorri hear none dr see fit give anyth pain relief would serious see get anoth pain mgt dr board sure awar two type pain mgt dr one inject procedur pain medic also rx pain med warrant sound much like saw one rx medic surgeon rx pain med probabl two week believ need pain med longer week think farther get shoulder surgeri better cervic done that lot surgeri recov worker compens insur bear deal mean stress rememb correctli ra assum humira except crohn diseas help issu end taken keep us post susi moder chronic pain psoriasi forum',\n",
       " 'ocrevu ocrelizumab pass phase trial fast track fda us author suppos approv th decemb year approv ema european author appar usual follow fda lead pass nice criteria myth dream realiti discuss ms nurs last month perhap believ bart blog http multipl sclerosi research blogspot com researchspeak ec even forum http www mssocieti org uk ms research treatment pipelin ocr cure slow halt progress good enough give hope quit honestli hope thing keep go day pretti short suppli nice approv seem bother dmt siponimod far along approv path http www mssocieti org uk ms research treatment pipelin sipo know drug without side effect potenti seriou one awar five half year ago holiday lisbon like normal person edss spend lot life watch mobil independ digniti disappear toilet ask much longer even go limit mobil price pay retain quit high price relish prospect life wheelchair contempl might been realli sympathis come late peopl forum realli wish could wish discov triall year ago none us would unfortun turn fals hope think paraphras dr jelinek better fals hope hope jo x',\n",
       " 'also simular problem type year bleed eye mani laser treatment vitrectomi eye stick rule work exercis even though disabl healthi diet plenti red veg fruit lutein eye vitamin keep control blood sugar especi sinc use freestyl libra eye improv',\n",
       " 'found fatigu get wors wors well spoke neurologist ldn said let wait see infus first ocrevu infus today far good',\n",
       " 'neuro told tri get pregnant take gilenya stop take gilenya month start get pregnant lymphocyt back normaal medic system keep start famili guess take bit plan ask neuro know detail',\n",
       " 'believ ms reason quit right imo mani peopl start rr later age say older mani peopl remain rr live never becom progress peopl diagnos initi rr younger diagnosi alter ppm within year gener pp diagnos year chang mri remiss phase seem differ within categori ppm rr sp varieti pp tend relaps mayb odd spot get temporarili wors real relaps fact dmd either work work well henc ocrevu scandal work ppm well rrm despit dmd avail think scandal peopl like definit rr least year decid progress year ago earlier summer seem like mildish mostli sensori relaps last month proper motor function relaps treat day high dose steroid complet remiss symptom year made slight improv much rehab neurologist went back note year ago astound improv right leg foot drop said seen hundr case foot drop never seen improv year medic miracl think dmd question whether qualifi classifi sp said start talk activ diseas inact equal mani neurologist pwm prefer use word advanc oppos divid us categori ye essenc think initi question ms correct load argument back forth within sue',\n",
       " 'wait long time someth come around approv fda treat ppm go wait ocrevu neurologist call suggest get lemtrada infus infus januari look find real world result may abl find someth web u k believ ocrevu use month good luck',\n",
       " 'second gener alk inhibitor ceritinib overcom resist crizotinib potent alk inhibitor develop second gener alk inhibitor ceritinib grant acceler approv fda second third gener inhibitor current evalu ceritinib fold potent crizotinib alk inhibit includ sever resist confer mutat includ leu met gli ala ile thr ser tyr result phase ascend trial clinicaltri gov identifi nct suggest ceritinib inde overcom crizotinib resist definit establish ceritinib standard option crizotinib resist set perform random trial compar ceritinib standard care singl agent chemotherapi alk posit patient fail prior crizotinib platinum base chemotherapi alic shaw md phd massachusett gener hospit boston one ascend investig told cancer therapi advisor multicent intern open label trial randomli assign patient alk rearrang stage iiib iv nsclc receiv ceritinib chemotherapi pemetrex docetaxel patient progress treatment chemotherapi crizotinib patient allow crossov ceritinib progress chemotherapi overal respons rate substanti higher ceritinib ci compar ci chemotherapi diseas control rate ceritinib chemotherapi median follow month ceritinib treatment significantli prolong pf month ci compar month ci chemotherapi hr p though os data matur half requir event yet occur time interim analysi death occur among patient receiv ceritinib patient receiv chemotherapi hr ci p subgroup analys includ age sex race perform statu diseas burden smoke histori previou respons crizotinib favor ceritinib patient brain metastas baselin respect also improv pf ceritinib compar chemotherapi suggest ceritinib cn activ gastrointestin gi toxic includ diarrhea nausea vomit occur frequent ceritinib chemotherapi encourag data present suggest ceritinib dose mg per day food similar exposur ceritinib mg fast significantli reduc gi toxic author note despit high rate gi toxic discontinu rate ceritinib due advers event patient report outcom also higher chemotherapi greater antitumor activ compar chemotherapi led improv score diseas relat symptom significantli longer time symptom deterior greater benefit overal health statu dr shaw said median time symptom deterior month ceritinib compar month chemotherapi accord questionnair data score composit pain dyspnea cough similar arm yet individu score dyspnea cough sore mouth dysphagia peripher neuropathi alopecia chest pain other favor ceritinib investig note questionnair analysi often noninterpret low number patient remain chemotherapi group',\n",
       " 'articl remind daunt decis u slow progress probabl spm tysabri trustworthi doc suggest ocrevu sure agre though famili histori breast cancer hard make decis',\n",
       " 'dear tamara sorri friend father took tagrisso month diagnos lung cancer stage iv juli took tarceva iressa tagrisso live realli well without collater damag year last decemb went hospit unfortun pass away week ago heart issu besid kidney lung failur doctor say mayb caus tagrisso friend take tagrisso mayb would good talk cardiologist hope friend continu fight cancer dear dad wish good luck best wish',\n",
       " 'new pml risk number becom common patient global treat natalizumab longer period time estim per patient test posit antibodi jcv clinic histori immun suppress treatment natalizumab receiv dose number pml case per http www ncbi nlm nih gov pubm husband dx rrm dx dual jugular vein stenosi ccsvi http ccsviinm blogspot com top harryz famili elder post join tue may pm locat london canada contact contact harryz icq updat tysabri august quot post harryz sun aug pm patient global treat natalizumab longer period time estim per patient test posit antibodi jcv clinic histori immun suppress treatment natalizumab receiv dose number pml case per http www ncbi nlm nih gov pubm [ quote] recal ago reader realli nasti thing say state tysabri go danger drug long term remind risk pml alarmist tri scare peopl hmmm scari risk problem continu escal harri',\n",
       " 'linger question topic [ ] find strang ocrevu cd blocker akin rituxan even map treatment nmosd although rituxan extens use diseas anyon idea doubl neg ab nmosd exist figment one imagin one hope better guidelin monitor cd cell count frequent end point pitfal variat end stage diseas earli onset diseas pregnanc vs dmd nmosd character pauciti data need better data also data collect hope openli share research mani mind work topic instead select refer ganesh practic current treat neuromyel optica neurolog clinic practic',\n",
       " 'paul would say current symptom dave bexfield mser expert founder activ mser well interest first right treatment biggest chang occur would say first two month went walk bare hundr metr could put even metr year one could hike mayb two mile rest longest hike mayb two half mayb three mile one day unfortun happen even though ideal candid treatment start backslid year four would notic quit well last studi updat could metr unaid quit unfortun back use walker littl bit frustrat better pretti much everi area cognit fine vision fine fatigu someon ms actual pretti well leg great start new treatment start aubagio realli cut year went rituxan right rituxan might switch ocrevu insur compani say sure see would oh hell yeah mean save life cure least case join shift ms commun http shift ms watch video http shift ms msreport http www facebook com shift ms http www instagram com shiftdotm http twitter com shiftm',\n",
       " 'mother pass away due stage iv non small cell adenocarcinoma ultim leptomengi carcinomatosi includ date clear timelin march realiz mom act odd best way could describ space letharg think much thought mayb take mani sleep pill night someth march call told fallen due poor balanc need get x ray wrist thought broken went walk clinic thought possibl copd get enough oxygen caus fog case follow primari order chest x ray everyth clear knew someth wrong insist brain mri day everyth chang found multipl stop count lesion brain need admit hospit immedi find caus point know primari cancer unsur type cancer sinc chest x ray clear test nodul lung found broncoscophi confirm stage iv non small cell adenocarcinoma poorli differenti chest x ray clear lung cancer bit linger cough noth alert multipl chest x ray came back clear incontin problem sinc least octob wonder relat coincid impati day develop plan care began whole brain radiat end total session end april come fog bit seem littl bit like began chemo wth mixtur carboplatin alimta avastin everi',\n",
       " 'worri eye line thing happen abl see one eye sever month vitrectomi could see bit cross eye sever week eventu eye line affect one got strength back',\n",
       " 'son age dx stage atyp poorli differenti nec neuroendocrin carcinoma treatment last resort oncologist abl get compassion care opdivo miracl hundr tumor gone other manag cant get rid constant brain metastatsi anyon success w avastin',\n",
       " 'ocrevu great news dave wish best',\n",
       " 'gilenya sinc neuro put part clinic trial visual problem take caus drug fact side effect sinc earli stage trial much happier gilenya betaferon',\n",
       " 'anyon know stelara help pay medicar peopl remicad stop help soon went medicar woman dx crohn back never heard year ago current remicad gallbladd surgeri liver biopsi reveal cirrhosi along hepat encelapathi esophag varic insur prevent see liver specialist concern greatli arthriti fibro need hope',\n",
       " 'thank support everyon help peopl gone plucki great hear well yay get prednison hope work way system quickli know took month feel anywher close normal stop diagnos ulcer coliti remiss lialda prednison respons entyvio remicad azathioprin opt three step j pouch surgeri complet step one subtot colectomi ileostomi may complet step two protocolectomi ileal pouch anal anastomosi loop ileostomi januari',\n",
       " 'folk crohn board lengthi remiss without anyth special talk year strong med follow particular diet sure mind could found someth took kept remiss long pat back accordingli short post co bed adventur vedolizumab land tomorrow',\n",
       " 'consid go roch instead could lower price drug rrm ppm roch make drug expect http www biopharmad com news impress drug launch roch ocrevu nh point cost effect limit health budget pay drug mean anoth drug oper get done somewher els henc need health funder use robust health econom model everi drug health funder increas budget everi time drug compani ask drug compani go continu rais price drug current futur quickli becom becom unsustain roch need demonstr ocreluzimab gener right health outcom everi dollar spent compar next best drug nh list fund roch justifi price base health outcom need drop price keep drop',\n",
       " 'hi paul ocrevu avail yet lot debat whether nice allow ppm patient receiv nh modest benefit peopl group facebook peopl america experi like ocrevu work',\n",
       " 'hi work bad reaction longer take either feel gilenya wors tecfidera howev everyon react differ trial error process hope whatev prescrib worka happi tell consult talk option',\n",
       " 'suspect letter neurologist confirm meet amend criteria relaps remit multipl sclerosi honest said shock neither radiologist local hospit neuro radiologist larger local hospit identifi spinal lesion latest mri despit fact appreci previou scan ask consid diseas modifi treatment would like opt appoint ms nurs th januari look like tecfidera lemtrada ocrevu opinion nervou look side effect print dvla form told car insur said need know travel insur alreadi screen ms disclos ci previous life insur told need write lifestyl chang medic condit note polici anyon els need tell actual need tell life insur compani could refus continu cover sorri question btw',\n",
       " 'sorri hear dad husband sclc brain met cycl chemo also wbrt tecentriq immunotherapi doctor said could possibl add month side effect side effect advanc stage cancer spread brain unless one tumor remov surgic sure whole lot done besid add littl time know peopl disagre go husband doctor said research done hope work dad get much time possibl',\n",
       " 'prednison good temporari water retent insati appetit lead weight gain best reduc salt intak limit bloat eat healthi fill snack unavoid though make sure take extra calcium potassium pred wast bodi light exercis joint also help reduc bone loss chanc get xeljanz stelara label sound horribl stay pred month await offici approv new med plan b xeljanz work moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa offic stand man held hostag hour pain within bathroom kept bowel sound like misunderstand',\n",
       " 'squamou cell left lower lobe remov lymph node involv ride marker tri chemo gave april tumor growth site lobectomi surgeri anoth surgeri could get tri opdivo duravalumab tumor grow slowli unrel cough squamou hard one treat best regard',\n",
       " 'probabl one list statist surgeri hospit readmit due blockag kink realli doubt mine due biolog gi biolog month prior surgeri keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'husband diagnos stage nsclc given radiat chemo went remiss short time month pet scan show lung lymph node went opdivo well pop colon cancer total unrel happen cancer famili got oper remov tumor cancer colon stage treatment need sinc treatment lung cancer progress lymph node chest neck abdomen oncologist decid continu opdivo put oral chemo drug afatinib anyon familiar sister law california took cancer free year feedback get would realli appreci',\n",
       " 'produc lucenti eylea claim surplu money gain use research better eye treatment drug produc avastin interest cancer treatment rather eye care low cost would anyth left research',\n",
       " 'use gilenya introduct state last year lemtrada approv gilenya stop gap measur like dmt lemtrada realli cannot offer anyth except conveni kept get wors feel get wors end start take lemtrada wrote quick synopsi tysabri lemtrada entri check research',\n",
       " 'didnt regret daignos start take gilenya ive normal still start gilenya insist speciali develop atrophi still fine fun life hate fact im take alway',\n",
       " 'wife otherwis healthi year old non smoker stage iv nsclc egfr treat brain met diagnos oct round carbo taxol switch tarceva last month progress seen date month ago scan began show hazi describ ground glass addit experienc warfarin failur last month small pe dalteparin breath becom big problem one seem know address anyon experienc acut short breath find resolut',\n",
       " 'way look colon huge part overal immun system health affect much bowel system far read howev go path medicin mesalamin enema immunosuppres probiot ad remicad entyvio well tri diet thing like gluten free low process sugar etc work wait surgeri smart move get hung opinion alway prefer keep organ reason favorit quot colleg roommat sometim get bear sometim bear get',\n",
       " 'home ms inform public ms research updat ms research updat updat main section fda approv medic experiment medic new direct ms research close note trial phase investig drug treatment approv long term treatment ms pdf refer view download pdf order copi written compil stephen krieger md michel fabian md includ addit materi margaret mccormick rn bsn mscn review jack burk md edit susan courtney year ms research updat publish jointli multipl sclerosi associ america msaa consortium multipl sclerosi center cmsc intern organ ms nurs iomsn msaa greatli appreci support cmsc iomsn assist product public ms research updat provid import new data approv experiment treatment ms valuabl resourc entir ms commun pleas note updat give overview research behind approv experiment medic therapi long term treatment multipl sclerosi includ inform symptom manag medic therapi addit inform ms symptom symptom manag well msaa program servic pleas visit mymsaa org call question msaa client servic depart may also email msquestion mymsaa org addit pleas note due time nation intern ms confer studi data confer could includ write inform public includ data present confer well import updat occur earli pleas visit msaa websit mymsaa org futur summari confer highlight learn consortium multipl sclerosi center cmsc pleas visit mscare org may also contact via phone via email info mscare org inform intern organ ms nurs iomsn pleas visit iomsn org introduct co author michel fabian md stephen krieger md year streamlin ms research updat refin emphas numer experiment drug current investig long term treatment multipl sclerosi ms entir new clinic trial data approv diseas modifi therapi dmt also includ pleas note order keep annual research updat current date histor background complet trial approv dmt longer includ view chart give overview approv dmt edit msaa ms research updat print stand alon issu reflect incred divers scope research progress ms nonetheless far much ongo research ms therapeut cover therefor complet list studi result could includ inform base wide rang sourc includ extens journal literatur ms manag review ongo clinic trial paper present major nation intern confer includ confer host american academi neurolog aan consortium multipl sclerosi center cmsc america european committe treatment research multipl sclerosi actrim ectrim year pass sinc unit state food drug administr fda approv betaseron interferon beta b first diseas modifi therapi ms begin ms treatment era watch wait approach ms therapi becom thing past favor proactiv strategi prevent ms diseas activ disabl prefer treatment often start person diagnos clinic isol syndrom ci defin singl attack appear one symptom characterist ms high risk develop ms diseas caus symptom appar use mri scan identifi lesion characterist ms expedit diagnosi numer studi multipl type dmt confirm earli treatment time ci benefici long term past two year seen approv new formul copaxon glatiram acet dose three time per week versu daili well new type interferon call plegridi peginterferon beta dose everi two week new agent given seri infus yearli lemtrada alemtuzumab approv fda end success research initi expand number approv medic choic diseas modifi therapi grown complex expert member organ multipl sclerosi coalit msc includ multipl sclerosi associ america msaa collabor develop write paper summar current evid support fda approv dmt long term treatment multipl sclerosi object provid evid effect medic provid support broad access approv therapi peopl ms unit state ultim goal enabl individu ms medic profession select appropri medic avail profession paper titl use diseas modifi therapi multipl sclerosi principl current evid avail msaa websit anyon review written expressli medic profession highli detail scientif style paper profession may access go mymsaa org msc dmt full follow releas profession paper member organ msc collabor develop summari written reader friendli style better serv broader ms commun paper avail msaa websit well titl use diseas modifi therapi multipl sclerosi principl current evid summari summari directli correl differ section found within profession version simplifi inform highlight main point incorpor commonli use terminolog addit summari follow extens glossari assist term specif describ ms process paper approv dmt valuabl counterpart research updat focus summar new emerg data cover avail therapi well emerg treatment still develop paper ms commun may access go mymsaa org msc dmt summari pleas note author report recent studi result avail time public everi effort made provid meaning time balanc inform medic keep length inform equal medic possibl pleas know differ length text way consid favorit toward one product addit refer cite newer studi result symptom manag drug fall scope report inform specif symptom ms treatment manag symptom pleas visit mymsaa org select symptom ms inform inform trial phase pleas refer page reader may also note studi involv progress form ms highlight mention progress ms appear bold type present approv dmt relaps form ms author public want also bring studi progress ms reader attent editor note initi studi result therapeut agent investig consid preliminari sinc addit studi evalu may need prove safeti efficaci agent msaa endors recommend specif product therapi reader advis consult physician make chang medic diet exercis treatment regimen fda approv medic ms research updat cover inform year earli must begin sober note regard failur two highli anticip clinic trial progress ms test approv medic relaps ms progress diseas possibl extend use well known medic progress ms may rigor explor unfortun discuss success relaps ms alway predict similar efficaci progress diseas begin unsuccess studi move numer posit avenu ongo ms research relaps progress form ms new data tysabri natalizumab gilenya fingolimod experiment medic administ oral laquinimod also known nerventra monoclon antibodi medic monoclon antibodi monoclon antibodi deriv cell ident clone singl cell replic produc anim tissu commonli laboratori mice human monoclon antibodi antibodi non human speci commonli mous whose protein sequenc modifi increas similar antibodi produc natur human monoclon antibodi extrem power effect specif direct toward certain part system leav part system untouch desir tri impact structur complex immun system name monoclon antibodi end mab includ natalizumab tysabri alemtuzumab lemtrada alreadi approv ms sever monoclon antibodi shown promis ms review section daclizumab zinbryta rituxan rituximab ocrelizumab ofatumumab also known arzerra vatelizumab new p receptor modul data present sever investig oral agent ongo clinic trial mechan similar gilenya isol lymphocyt damag myelin lymph node agent well toler reduc lesion relat rrm hope agent ozanimod rpc siponimod baf ponesimod maintain potenti improv efficaci safeti gilenya howev research continu remain vigil regard cardiovascular side effect bradycardia slow heart rate ozanimod formerli rpc siponimod baf ponesimod therapeut strategi masitinib also known kinavet masivet ibudilast tcelna formerli tovaxin tetracyclin antibiot statin new therapi investig earlier list approv experiment drug fraction mani treatment current studi follow among excit potenti therapi investig brief snapshot highli technic concept warrant depth explan futur pilot clinic trial encourag anti lingo lingo protein central nervou system whose role halt myelin prevent surviv neuron cell make organ bodi receiv instruct regard grow ceas grow without sort cellular check balanc tissu could grow without restraint seen malign anti lingo biib agent potenti remyelin properti anim studi show block protein respons stop growth myelin shown promot spinal cord remyelin axon integr anim model ms eae first trial experiment anti lingo stimul myelin repair human phase trial involv healthi adult volunt peopl relaps secondari progress ms complet trial intraven iv dose anti lingo well toler seriou advers event headach frequent advers event report first phase ii trial anti lingo call renew launch studi recruit patient newli diagnos ms involv visual pathway optic neuriti evalu drug effect remyelin result present spring primari outcom renew assess recoveri optic nerv function measur speed nerv conduct visual signal studi evalu test call full field visual evok potenti ff vep particip treat anti lingo compar placebo patient treat least five six dose anti lingo show percent improv optic nerv conduct latenc delay speed visual signal week compar placebo recoveri optic nerv conduct observ last studi visit week statist signific percent improv togeth data demonstr evid treatment effect continu improv observ week follow last studi dose studi show effect secondari endpoint includ chang thick retin layer optic nerv neuron axon measur optic coher tomographi oct visual function measur test vision call low contrast letter acuiti anti lingo gener well toler studi note two patient hypersensit allerg reaction time infus one patient liver function test abnorm resolv drug discontinu taken togeth result provid encourag indic anti lingo appear safe may facilit remyelin though meaning clinic outcom need assess larger trial end second larger phase ii trial synergi look drug combin avonex studi recruit approxim patient rrm spm examin degre patient improv disabl anti lingo sinc agent reduc relaps prevent new mri lesion studi anti lingo potenti remyelin therapi need util new endpoint prove efficaci includ measur recoveri improv physic visual cognit function assess effect ms result provid clinic inform drug efficaci neuroprotect repair within central nervou system cn result also address two fundament question effect seen optic neuriti studi replic area nervou system translat improv function patient ms either short long term experiment treatment investig potenti foster remyelin myelin repair includ agent earli stage develop still experiment name gsk rhigm proof principl data expect agent amilorid phenytoin sodium channel blockad accumul salt potassium within cell ms lesion may possibl contribut cellular injuri neurodegener breakdown nerv hypothesi would suggest block certain channel cell buildup molecul prevent neurodegener also prevent strategi test data present look use amilorid potassium spare diuret approv treatment high blood pressur congest heart failur medic may potenti provid neuroprotect activ effect amilorid studi peopl ppm use mri marker neurodegener outcom measur neuroprotect patient ppm underw mri scan amilorid treatment standard dose use high blood pressur period three year research found signific reduct develop brain atrophi well slow develop disabl treatment phase suggest amilorid may exert neuroprotect effect patient ppm amilorid readili cross blood brain barrier gain access cn precis mechan result clear pilot studi first effort peopl ms focu neuroprotect use amilorid support investig drug potenti neuroprotect agent ms phase ii trial studi agent optic neuriti initi data expect studi similar principl renew studi anti lingo discuss attempt foster protect repair optic nerv acut phase optic neuriti worth note strategi success studi anti seizur medic phenytoin brand name dilantin also work modul sodium channel phase ii clinic trial assess whether phenytoin could neuroprotect acut optic neuriti aon studi compris peopl aon random within two week symptom onset receiv either phenytoin mg per kg daili placebo three month primari outcom aon studi evalu structur retin nerv fiber layer rnfl macular volum mv six month visual function optic nerv imag visual evok potenti also measur origin particip follow studi end patient averag adjust affect eye rnfl thick six month higher activ group versu placebo result percent protect treatment effect adjust mv macular volum show percent protect treatment effect vision gener recov well signific differ visual outcom treatment group intrigu studi may broad implic found administr well known rel safe drug seem neuro protect period directli follow optic neuriti amilorid phenytoin may also repres potenti combin strategi conjunct immun modul diseas modifi therapi idebenon catena sovrima experiment drug similar coenzym q initi develop treat alzheim diseas cognit defect coenzym q produc within bodi necessari cell grow remain healthi substanc also work antioxid help prevent injuri oxid process explor ms oxid stress postul play role death myelin produc cell link ms progress oxid bodi natur metabol oxygen disturb occur process oxid stress result caus damag bodi cell tissu oxid stress believ contribut factor mani diseas includ affect nerv immun system doubl blind placebo control phase ii clinic trial idebenon sponsor nation institut neurolog disord stroke recruit particip ppm littl moder disabl trial began juli schedul complet septemb extens trial continu mi therapeut vaccin potent activ innat immun system provid immedi defens infect result long last protect immun side note help explain type immun system defens innat natur immun respons nonspecif type memori react way time encount foreign entiti viru bacteria mi primarili test cancer acquir infect goal enhanc inher capabl person immun system fight diseas phase ii studi evalu safeti toler iv administ mi peopl either ppm spm present interim result open label dose escal confirm trial show mi well toler identifi clinic dose evalu moreov dose confirm portion studi eight patient spm treat mi week show improv phase ii studi spm plan complet late transderm administr peptid small polish studi individu rrm evalu efficaci safeti transderm skin patch administr two dose level three myelin peptid mbp plp mog versu placebo lower dose group receiv mg three peptid annual relaps rate one year reduc percent compar placebo progress measur expand disabl statu scale edss slightli lower indic disabl worsen may slightli improv addit percent relaps free versu percent placebo group treat group also show decreas gadolinium enhanc lesion volum lesion volum treatment safe well toler approach use combin peptid may pursu futur studi il modul secukinumab cjm il one sever cytokin produc immun system cytokin small protein may stimul inhibit function cell il appear major inflammatori compon ms secukinumab human monoclon antibodi il preliminari studi administ intraven infus small number patient psoriasi rheumatoid arthriti uveiti variabl result proof concept trial rrm enrol patient show reduct gadolinium enhanc mri lesion compar placebo larger phase ii trial plan enrol approxim patient relaps ms design studi present ectrim fall cancel favor clinic develop cjm also target il administ subcutan inject design phase ii trial present ectrim fall date individu ms receiv experiment treatment sb firategrast oral agent thought reduc number activ white blood cell enter brain work via similar mechan tysabri posit result phase ii trial use gadolinium enhanc lesion primari outcom atl oral agent affect vla system molecular mechan util tysabri via novel mechan action fall class antisens oligonucleotid previous use ms result phase ii trial publish note atl decreas emerg new activ brain lesion compar placebo two month treatment approxim rrm patient develop path agent still consid pixantron pix investig altern effect cardio toxic drug novantron mitoxantron mix treatment aggress rrm spm phase ii studi patient aggress diseas result present show pixantron effect novantron less cardiotox although via differ mechan action rituximab ocrelizumab pixantron shown studi reduc b cell percent accord studi abstract pixantron structur similar novantron drug similar immuno suppress properti anim studi howev author state pixantron less toxic heart sr crh stabil neuropeptid also known aimspro phase ii doubl blind placebo control studi peopl spm present sr crh well toler given subcutan inject twice weekli four week result signific improv sever secondari endpoint endpoint includ ms function composit msfc time foot walk fw mean hole peg test hpt larger longer term studi warrant given promis result howev new trial present conduct new direct ms research new therapeut approach vitamin electrolyt vitamin biotin salt stem cell biomark genet studi microbiom ms close note summari futur diseas modifi therapi dmt ms continu promis term new inform current approv dmt excit result emerg therapi advanc genet biomark studi hold promis futur possibl person decis ms therapi precis biolog driven manner ever field ms research reli upon will particip patient clinic trial recogn ethnic racial genet cultur divers ms commun divers clinic trial popul lack data six random placebo control trial use examin baselin characterist clinic outcom white black asian hispan popul result challeng interpret due incred low number non white particip clinic trial turn make clinic trial result hard interpret real world field ms research need divers popul recruit clinic trial truli know medic global effect ms despit setback unsuccess trial progress ms ongo clinic trial ppm spm well investig neuroprotect remyelin repair offer great promis treatment progress ms goal revers damag caus diseas recent year arsen ms therapi grown consider way along new therapi come host new challeng risk requir vigil thought approach medic select manag clinician numer complex treatment option offer patient need patient educ awar becom crucial ever age empow highli inform patient true particip ms care collabor treatment team hope updat valuabl part process inform clinic trial pleas visit www clinicaltri gov inform ms treatment pleas contact msaa visit mymsaa org',\n",
       " 'read help given option copaxon inject caus problem find inform cladribin much appreci',\n",
       " 'fecal microbiota profil predict ustekinumab respons crohn fecal microbiota profil predict ustekinumab respons crohn data patient fecal microbiota use predict respons ustekinumab therapi crohn diseas research report reuter health inform sourc medscap patholog headlin',\n",
       " 'decemb clomipramin approv antidepress show potenti treat peopl progress multipl sclerosi ms diseas form treatment protect nerv variou process thought underli progress ms earli research show lab anim studi focus alreadi approv treatment titl systemat screen gener drug progress multipl sclerosi identifi clomipramin promis therapeut publish journal natur commun varieti therapi exist peopl relaps remit ms rrm mark exacerb flare fewer exist peopl progress ms one ocrevu ocrelizumab approv primari progress diseas among reason markedli differ underli process underli two type ms mechan caus damag progress ms alway relaps remit ms latter requir differ therapeut approach simon faissner research hotchkiss brain institut univers calgari canada studi first author said press releas progress ms involv sever aspect neurodegener accompani iron mediat neurotox immun cell activ oxid stress effect treatment essenti need address mechan read ms view news provid benefici multipl sclerosi educ inform resourc servic',\n",
       " 'hi welcom tecentriq brand name atezolizumab use certain type non small cell lung cancer origin fda approv excerpt e mail sent lungev recent big win small cell lung cancer sclc result impow clinic trial show addit immunotherapi drug atezolizumab standard chemotherapi regimen sclc benefici standard care sclc chemotherapi past year inde big deal want inform googl tecentriq small cell lung cancer ignor entri non small cell gener recommend dr googl sinc new treatment may way get info let us know question may support bridget',\n",
       " 'sorri pred truli aw remind temporari hope humira longterm ticket club remiss pred tri limit salt intak reduc bloat water retent prevent limit salt limit calcium potassium intak pred wast two thing system light weight bear exercis slow calcium wast pred number time year worst flare lost pound weight due flare regain pound weight due insati pred appetit week ceas pred notic coupl pound disappear water retent howev major weight gain sustain due increas calor intak eat big meal minut later starv like eaten day long tri eat fill low calor thing exampl air fill thing like bowl butter free popcorn water fill thing like bowl soup broth fill stomach free bit longer chronic ill easier get uc real rough bodi caus dramat weight loss pred caus dramat weight gain loos hair thing entir control fret thing let go one remicad infus spoke nice ladi crohn year say keep two set cloth one larger size one smaller size flare well got tire throw rebuy cloth differ size feel well prioriti els worri cannot control noth make uc wors moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa might uc leav hous wear sock return none emerg tp post edit ipoop gmt',\n",
       " 'thorac surgeon describ incis rib inch spread rib insert hand feel tumor pretti clear thoracotomi ask vat robot surgeri respons would use whatev mean necessari would remov littl tissu possibl would remov nodul hospit origin lobectomi lowest lobe right lung use da vinci robot system surgeon first use system find surgeri first time system use facil surgeon perform move differ facil surgeri would perform differ doctor typic heart lung surgeri daili experienc accord nurs spoke offic oncologist insisit tissu remov part wonder cya sinc never test new area use either pet biopsi start tarceva option discuss diagnos card clear describ tumor locat describ report look close spinal column surgeon suggest close heart report say slight increas right upper lobe nodul current measur x cm stabl subpleur nodul anterior right upper lobe measur mm stabl mm right intern mammari chain lymph node one call request second opinion consult ucla citi hope usc within drive distanc choos one call ask second opinion consult way ask dr west second opinion repli modifi year month ago snickerdoodl repli modifi year month ago snickerdoodl repli modifi year month ago snickerdoodl repli modifi year month ago snickerdoodl',\n",
       " 'site use inform prolif retinopathi http www diabeticretinopathi org uk prolif html laser treatment http www diabeticretinopathi org uk laserdiabetic_retinopathi html laser treatment profession http www diabeticretinopathi org uk laserdiabeticretinopathyprof html anti vegf http www diabeticretinopathi org uk lucentispatientsdr htm vitrectomi http www diabeticretinopathi org uk vitreous_hemorrhag html nh requir inform consent treatment feel understand treatment offer ask explan feel team give correct treatment could tri ask second opinion although balanc delay treatment',\n",
       " 'marlo oral chemotherapi option peopl ms professor david baker research oh lemtrada anoth name call alemtuzumab yeah alemtuzumab take apart mab mean monoclon antibodi alem name made tu mean origin made treat cancer alemtuzumab chemotherapi agent use treat multipl sclerosi believ ms driven effect cell get b cell cancer alemtuzumab use one cladribin essenti anoth one mitoxantron anoth one lot chemotherapi drug actual use ms work kill activ cell activ cell white blood cell yeah marlo right join shift ms commun http shift ms watch video http shift ms msreport http www facebook com shift ms http www instagram com shiftdotm http twitter com shiftm',\n",
       " 'hey everyon know quiet late frankli lot news report current trial progress mani new one open late continu watch close expect news flow increas hit big news engin aacr asco cancer confer especi asco later spring post blog today talk crowdfund effort new crc trial ucsd base upon good scientif idea elig kra wt kra mut dose egfr inhibitor erlotinib high dose day week rest week treatment hypothesi support data far cmax drive dose may increas activ well decreas skin toxic crc trial tell sure plan enter need crowdfund use help pay trial start sinc drug almost patent detail blog second half http adventuresinlivingterminallyopti cal trial cheer dk',\n",
       " 'total agre pharma come tabl approv occur e g ocrelizumab cladribin tri wait drk perform label treatment proper studi plan time knockout back get pilot data funder look whilst donald trump build wall tri build bridg move forward',\n",
       " 'apolog open question subject kind cover attempt answer goe depend pwm treat earli enough choos switch alemtuzumab peopl drop zero recoveri regardless baselin count guess appli ocrelizumab last manag print guid label cladribin see dose adjust avoid grade lymphopaenia fulli explain thank grade lymphopaenia teriflunomid bad thing mayb worth moder benefit teriflunomid offer better option avail suppos remain option stick crab drug know much love hahaha http multipl sclerosi research blogspot com clinicspeak neurospeak html',\n",
       " 'straydog walk lot burn stab pain littl better today taken mani percocet longer gi hospit put entocort said ct scan last week look good wait follow start new med retri humira cimzia guess nerv pain heel',\n",
       " 'humira actual gave psoriasi start lose hair round patch spot head size euro coin dri scabbi skin even bigger size knee clear week consult put humira',\n",
       " 'ocrevu intend ppm hope approv fda meet march also believ ppm spm patient may receiv lemtrada infus',\n",
       " 'nutshel ocrevu stem cell treatment look encourag time tell',\n",
       " 'home ms inform public ms research updat siponimod baf siponimod baf section main articl fda approv medic experiment medic new direct ms research close note approv long term treatment ms pdf refer experiment medic new p receptor modul compani novarti oral medic studi sever dose studi spm previou ofatumumab next ozanimod siponimod drug mechan action similar gilenya like gilenya work p receptor famili block movement lymph cell lymph node howev siponimod appear interact less receptor gilenya primari action p p receptor siponimod rel short half life compar gilenya mean drug stay bodi long research hope small differ minim cardiac issu rrm result phase ii dose find studi siponimod report trial complex design primari goal determin appropri dose carri forward futur trial approxim peopl particip studi six month proport relaps free patient percent mg group percent mg group percent mg group compar percent placebo group six month arr annual relaps rate lower individu take one three higher dose addit regard mri paramet mg dose reach statist signific versu placebo reduct activ lesion approxim percent excit news ms research last year surround announc result expand phase iii trial siponimod spm trial random patient spm siponimod versu placebo ratio two time mani patient given siponimod versu placebo primari endpoint expand trial time three month confirm disabl progress cdp cdp met particip develop increas disabl confirm repeat exam three month later trial abl show small yet statist signific decreas three month cdp percent studi drug compar placebo particip siponimod arm also show percent slower decreas brain volum compar placebo howev differ observ two group chang time foot walk relaps decreas group take siponimod overal patient toler drug well though seriou advers event infect occur siponimod group previou ofatumumab next ozanimod',\n",
       " 'infliximab [rmc] consum medicin inform leaflet leaflet answer common question inflectra contain avail inform take place talk doctor pharmacist medicin risk benefit doctor weigh risk use inflectra benefit expect concern given medicin ask doctor pharmacist keep leaflet may need read inflectra use inflectra contain activ ingredi infliximab inflectra approv biosimilar medicin compar safeti efficaci qualiti inflectra refer product establish infliximab monoclon antibodi produc human mous protein recombin technolog monoclon antibodi protein recognis bind certain special protein bodi infliximab act bind special protein bodi call tumour necrosi factor alpha tnf peopl diseas crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti psoriasi bodi produc much tnf caus bodi immun system attack normal healthi part bodi inflectra block damag caus much tnf rheumatoid arthriti rheumatoid arthriti inflammatori diseas joint inflectra use reduc sign symptom rheumatoid arthriti prevent damag joint also given diseas modifi medicin call methotrex ankylos spondyl ankylos spondyl inflammatori diseas spine inflectra reduc sign symptom ankylos spondyl therebi improv physic function psoriat arthriti psoriat arthriti inflammatori diseas joint psoriasi usual occur associ arthriti often finger toe affect although may occur part bodi inflectra use reduc sign symptom psoriat arthriti improv physic function adult respond well enough previou treatment diseas modifi anti rheumat drug dmard inflectra may given alon combin methotrex psoriasi psoriasi inflammatori diseas skin inflectra use treat patient moder sever psoriasi respond well enough treatment phototherapi convent system treatment treatment appropri crohn diseas crohn diseas chronic inflammatori diseas bowel may also affect part gut inflectra use treat moder sever crohn diseas adult patient children adolesc patient year old respond well enough treatment inflectra also reduc number abnorm open bowel skin call drain enterocutan fistula common complic crohn diseas ulcer coliti ulcer coliti inflammatori diseas bowel inflectra use treat sign symptom ulcer coliti adult patient children adolesc patient year old respond well enough treatment give inflectra children crohn diseas ulcer coliti younger year give inflectra children adolesc diseas doctor howev may prescrib inflectra anoth purpos ask doctor question inflectra prescrib given inflectra must given use inflectra allergi mous protein ingredi list end leaflet symptom allerg reaction inflectra may includ skin rash hive fatigu wheez difficulti breath low blood pressur use inflectra sever infect tuberculosi infect abscess repeat infect repeat infect use inflectra alreadi take anoth medicin arthriti contain substanc call anakinra never given inflectra congest heart failur use given tell doctor current infect prone infect histori infect inflectra may affect normal immun respons might get infect easili case seriou infect includ tuberculosi tb sepsi report patient treat inflectra ever close contact tb even treat ever close contact hepat b reactiv hepat b report peopl treat tnf blocker howev report rare live travel area fungal infect call histoplasmosi coccidioidomycosi blastomycosi common ask doctor know infect common area live travel infect caus fungu affect lung part bodi cancer type blood cancer call lymphoma report patient receiv tnf blocker report rare frequent expect peopl gener cancer lymphoma also report long histori crohn diseas rheumatoid arthriti ankylos spondil psoriat arthriti especi highli activ diseas take medicin reduc activ bodi natur defenc may like develop infect lymphoma peopl gener even without receiv tnf blocker inflectra pregnant plan becom pregnant like medicin inflectra recommend pregnanc must use adequ contracept avoid fall pregnant breast feed like medicin inflectra recommend breast feed known whether inflectra pass breastmilk diseas affect nervou system multipl sclerosi seizur experi numb weak tingl sight disturb suffer congest heart failur step must taken monitor chang condit treatment inflectra ongo blood disord histori blood disord schedul receiv vaccin patient receiv inflectra receiv type vaccin doctor discuss benefit use inflectra potenti risk take given medicin tell doctor take medicin includ buy without prescript pharmaci supermarket health food shop medicin may affect way medicin work use inflectra alreadi take anoth medicin arthriti contain substanc anakinra tell doctor alreadi take anoth medicin arthriti contain substanc abatacept tell doctor receiv treatment rheumatoid arthriti ankylos spondil psoriat arthriti psoriasi phototherapi treatment crohn diseas ulcer colliti prevent reject organ transplant tell doctor take inflectra receiv vaccin vaccin given treat inflectra doctor pharmacist abl tell given inflectra medicin inflectra given inflectra avail prescript inflectra given drip vein call infus least hour abl toler first two hour infus doctor may decid give next inflectra infus period less hour children adolesc year infus given least hour period observ follow treatment rheumatoid arthriti recommend start dose infus mg kg get addit dose mg kg week first infus everi week week treatment arthriti respond well enough mg kg dose doctor may decid gradual increas dose maximum mg kg everi week also take methotrex part treatment ankylos spondyl recommend start dose infus mg kg get addit dose mg kg week first infus everi week psoriat arthriti recommend start dose infus mg kg receiv addit dose mg kg week first infus everi week inflectra may given alon combin methotrex psoriasi recommend start dose infus mg kg get addit dose mg kg week first infus everi week crohn diseas recommend start dose crohn diseas adult children adolesc year closur fistula adult patient initi infus mg kg follow addit dose mg kg week first infus everi week case doctor may decid increas dose mg kg ulcer coliti recommend start dose ulcer coliti adult children adolesc year infus mg kg get addit dose mg kg week first infus everi week given inflectra thing must tell doctor nurs pharmacist medicin start upset symptom becom wors tell doctor dentist treat inflectra undergo surgic procedur tell doctor symptom tb persist cough weight loss listless fever infect appear immedi symptom hepat b upset stomach loss appetit vomit tired dark yellow brown urin yellow eye skin appear must immedi take inflectra receiv vaccin vaccin given treat inflectra continu take adequ contracept measur avoid pregnanc doctor also advis breastfe thing care tell doctor think infect inflectra may affect normal immun respons possibl may prone infect watch close sign infect tell doctor immedi develop skin rash hive doctor may discontinu inflectra symptom go away begin give medicin symptom resolv appropri treatment suffer congest heart failur tell doctor immedi condit worsen inflectra unlik make drowsi tire drive car work machineri side effect tell doctor nurs pharmacist soon possibl feel well given inflectra medicin side effect sometim seriou time may need medic treatment get side effect gener patient rheumatoid arthriti crohn diseas ankylos spondyl psoriat arthriti psoriasi alreadi take sever medicin treat diseas medicin may caus side effect get addit side effect new symptom pleas tell doctor ask doctor pharmacist answer question may alarm follow list possibl side effect may experi infus inflectra follow reaction may occur fever chill itchi hive chest pain low blood pressur high blood pressur short breath reaction like occur first second infus may also appear six month last infus tell doctor immedi notic follow pain tender chest muscl joint jaw swell hand feet ankl face lip mouth throat may caus difficulti swallow breath fever muscl pain joint pain tired abnorm chest sound rash itch symptom may indic heart failur e g short breath especi exercis lie swell feet tell doctor nurs soon possibl notic follow headach nausea vomit dizzi light headed fatigu fever rash hive itch sore throat cough hoars short breath chest pain back pain muscl pain abdomin pain indigest diarrhoea weight loss muscl wast problem urin chang way heart beat exampl notic beat faster flush dri skin increas sweat fluid retent new onset psoriasi mainli sole feet palm worsen rheumatoid arthriti rare case peopl take inflectra develop liver problem sign could problem includ jaundic skin eye turn yellow dark brown colour urin right side abdomin pain fever sever fatigu tired contact doctor immedi develop symptom tell doctor notic effect side effect mild moder sever side effect list may also occur patient side effect may appear six month last infus cancer clinic studi cancer seen patient receiv tnf blocker includ inflectra patient receiv treatment children adult treat tnf blocker chanc get lymphoma cancer may increas note howev patient longstand activ rheumatoid arthriti crohn diseas may alreadi higher risk develop cancer even without tnf blocker make difficult estim risk develop cancer patient nevertheless role tnfblocker develop cancer cannot exclud rare type cancer call hepatosplen cell lymphoma hstcl report rare adolesc young adult crohn diseas ulcer coliti receiv inflectra patient also receiv drug known azathioprin mercaptopurin case hstcl report patient receiv inflectra hstcl often result death role tnf blocker develop cancer children adolesc remain unclear talk doctor concern skin cancer melanoma merkel cell carcinoma basal cell carcinoma squamou cell carcinoma report rare patient treat tnfblocker includ inflectra tell doctor notic new skin lesion therapi exist lesion chang appear patient lung diseas call chronic obstruct pulmonari diseas histori heavi smoke may increas risk get cancer treat inflectra inflectra stop tell doctor immedi notic follow side effect even occur sever week stop treatment inflectra skin rash hive frequent infect symptom tb persist cough weight loss listless fever infect appear symptom hepat b upset stomach loss appetit vomit tired dark yellow brown urin yellow eye skin appear symptom may appear sever month last inflectra treatment continu take adequ contracept measur avoid pregnanc least month last infus inflectra doctor advis breastfe least month last infus inflectra tell doctor notic effect storag inflectra store c c refriger use beyond expiri date inflectra vial singl use unus portion discard product descript look like inflectra come white powder glass vial ingredi activ ingredi infliximab [rmc] mg per vial inact ingredi monobas sodium phosphat monohydr dibas sodium phosphat dihydr sucros polysorb sponsor pfizer australia pti ltd abn wharf road west ryde nsw australia toll free number australian registr number aust r',\n",
       " 'hi dr west heard much expertis bac lung cancer would like ask question pleas help save time make stori short juli wife stage ib lung cancer year old eastern asian non smoker right upper lobe remov singl tumor cm patholog report state cancer adenocarcinoma mix subtyp papillari bronchioloalveolar acinar well differenti viscer pleural invas present lymph node neg nowher els cancer finish round cisplatin alimta chemotherapi novemb follow ct pet scan everi year sinc februari ct discov new mm nodul right lower lobe nodul measur mm april pet scan juli ct mm januari pet scan mm februari ct mm june ct two new smaller nodul mm right lower lobe discov june ct biopsi juli patholog confirm big nodul cancer year doctor recommend tarceva next therapi given histori follow question wife adenocarcinoma bac featur lung cancer consid slow grow tarceva best therapi think help need schedul appoint see mani thank',\n",
       " 'decemb new england journal medicin publish spectacular result pair major intern clinic trial led hauser confirm ocrelizumab block inflamm drive diseas trial known opera opera ii compar effect safeti ocrelizumab interferon beta current standard treatment relaps remit ms ocrelizumab cut annual relaps rate percent reduc disabl percent shrank inflammatori lesion brain percent compar interferon separ clinic trial known oratorio found ocrelizumab could modestli slow advanc primari progress ms resist treatment phase iii trial shown ocrelizumab antibodi target cd molecul surfac b cell extrem effect relaps remit ms caus b cell circul blood bound nervou system orchestr inflamm b cell percent b cell bodi destroy reliabl sever month dose ocrelizumab treatment given infus everi six month trial sponsor f hoffman la roch roch compani hold patent ocrelizumab avail highli effect well toler treatment mean peopl dawn ms treat therapi essenti complet block inflamm myelin caus relaps remiss said hauser chair ucsf weill institut neurosci optimist outlook mani year even favor today research believ primari progress ms caus percent b cell live protect area within brain tissu ocrelizumab modestli effect target hidden b cell nonetheless first therapi effect primari progress ms hope patient approv ocrelizumab could mean new outlook patient sarah warto one hauser patient diagnos relaps remit ms colleg student decad ago warto experienc sever bout diseas symptom rang impair depth percept difficulti walk recent flare occur given birth daughter two year ago fairli sever attack realli limit abil use leg could walk minut minut like total differ person taken bodi said ocrelizumab horizon dream futur free relaps especi think second child find better model approv ocrelizumab mark shift treatment ms sever decad make one overcom mani hurdl year ago hauser colleagu told nation institut health propos test b cell target ms drug lack biolog plausibl time still wide accept anoth type immun cell known cell culprit behind ms idea base inaccur mous model diseas mice research could transmit ms like condit one anim anoth simpli transfer cell underli tissu chang mice close resembl human ms nevertheless research shrug discrep continu reli model hauser start laboratori harvard univers set find model ms fidel human diseas work continu move ucsf becom professor chair depart neurolog mani year setback hauser mid togeth postdoctor fellow luca massacesi claud genain develop new anim model replic behavior tissu chang seen human ms new model led hauser call first eureka moment saw antibodi tightli bound degener myelin protein antibodi could detect spinal fluid patient ms long use diagnost marker ms yet consid insignific diseas mechan produc b cell rather cell clearli complicit diseas new anim model research found could transmit ms like condit one anim anoth transfer antibodi b cell along cell paradigm chang field said hauser team believ antibodi work alongsid cell key myelin destruct would anoth coupl year realiz still hit nail head second eureka moment clinician scientist hauser eager appli laboratori discoveri toward new therapi colleagu wrote grant nih propos test exist cancer drug rituximab target b cell approv b cell lymphoma hope ms patient b cell kill drug would stop product antibodi caus inflamm nih dismiss propos suggest would fund switch cell therapi devast said hauser readi quit approach genentech maker rituximab month discuss everyon acknowledg low chanc success began preliminari trial would allow test one dose drug antibodi produc directli b cell long live intermedi cell known plasma cell would directli target drug hauser team believ would take sever dose drug elimin antibodi hope one dose would see tini littl effect would give us courag embark longer studi said hauser instead saw effect far dramat imagin almost immedi nearli complet blockad new inflamm peopl receiv drug said hauser stun result one dose told two thing first someth like help mani hundr thousand peopl second scienc driven experi wrong said hauser almost certainli antibodi instig nerv damag process would taken longer revers b cell import clinician scientist crosstalk bench bedsid key solv mysteri ms clinician scientist like hauser essenti conduit clinician scientist alway work two area said want understand deepli possibl caus diseas studi also feel respons drive understand forward better therapi today year later genentech acquir roch develop ocrelizumab newer b cell target drug design safer easier administ set drug path clinic studi ultim approv patient hope ocrelizumab make life chang differ mani hundr thousand peopl ms today mani may develop ms futur said hauser',\n",
       " 'anyon experi immunitherapi keytruda forigo',\n",
       " 'holtyc hi want add get cladribin end get cross tend hook possibl stop ms believ noth seen anyth hundr percent stop type ms best advic spend nine year life read ms forget live life noth go stop ms get life adapt new chang ms bring may sound bit depress believ',\n",
       " 'ocrevu use canada hope get soon',\n",
       " 'ken disinterest interest third parti reader would encourag keep get medicin first seemingli keep aliv damn good thing sure famili agre second altruist perspect contribut trial follow allow continu experi advers issu would forc counsel would continu say base read entir blog understand path also somewhat detach realli detach also fight bca view outsid nb ethicist simpli reader altern great therapi kill may fact make stronger aunt chemo lung cancer opdivo par cours cancer found way around pass long would worri discontinu would give cancer thing seek way back best anon reader',\n",
       " 'cumul pred year reckon thought gotten away unfortun effect bone loss take year come least teeth despit thorough brush bone loss subsequ gum recess periodont diseas scare lose teeth get older want dentur keith best luck new hip hope give new leas life dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'safe take vitamin c tarceva find literatur discuss',\n",
       " 'treatment combin provision reject peopl certain type lung cancer nh england decis review nation institut health care excel nice end march combin includ four drug immunotherapi atezolizumab tecentriq target drug call bevacizumab avastin plu two chemotherapi carboplatin paraplatin paclitaxel taxol nice review combin patient type lung cancer call non squamou non small cell lung cancer assess advanc diseas whose cancer cell carri one two genet fault cancer research uk polici manag rose gray said shame nice provision reject treatment lung cancer surviv lower mani type cancer crucial find new effect treatment option peopl diseas patient cancer current given combin chemotherapi drug combo cost effect combin atezolizumab significantli prolong amount time patient diseas stabl long live clinic trial compar group receiv combin minu atezolizumab nice said studi compar treatment combin current standard care overal benefit unknown nice also disagre long term surviv patient genet fault calcul combin consid cost effect nh trial studi question includ patient non small cell lung cancer receiv one three differ combin drug bevacizumab carboplatin paclitaxel atezolizumab carboplatin paclitaxel atezolizumab bevacizumab carboplatin paclitaxel patient lung cancer remain stabl around one half month longer averag receiv four drug compar receiv bevacizumab carboplatin paclitaxel four drug combin also boost surviv patient live around four half month longer averag take bevacizumab carboplatin paclitaxel side effect slightli wors group take four drug report case symptom rash loss appetit fever drug drug combin attack cancer differ way atezolizumab immunotherapi block molecul often found excess surfac cancer cell molecul call pd l tell immun cell attack cancer cell block pd l atezolizumab may unveil cancer cell immun system attack destroy bevacizumab target differ molecul call vascular endotheli growth factor vegf help cancer grow blood vessel attack growth blood vessel drug stop cancer gather food oxygen blood',\n",
       " 'hi guy quick backstori diagnos one month period remiss time sever pan coliti uceri prednison resist zero impact condit system side effect allerg mesalamin saw result imuran mp mercaptopurin decemb hospit lost sever amount weight colon inflamm caus blockag etc start humira time began saw littl relief short live began flare fairli quickli start remicad go th infus get everi week doubl dose feel better almost immedi go bm day bm howev still alway urgent diarrhea unfortun infus effect last week begin flare wait next dose doctor say max dosag remicad receiv opt start mercaptopurin see would work better togeth question would ditch remicad start new biolog normal work week diarrhea still even tho feel mostli better normal anyon els experienc someth similar post edit uc_girl gmt',\n",
       " 'hi jim thank repli affirm thought option move forward reason wonder would possibl doctor forum make comment option would consid patient present similarli mom given cancer histori suspicion convers last week onc like consid rechalleng tagrisso issu drug induc pneumon ask afatinib immunotherapi mention gener tki immunotherapi could also induc similar side effect given option consid would help control diseas brain bone lung risk justifi fact viabl treatment option avail side note mom never line convent iv chemotherapi would viabl option read literatur chemo tend extend life coupl month tend work well brain leptomening diseas accur least worth tri respond clinic respons short run retri tki therapi e g afatinib wise pursu rechalleng tki immunotherapi therapi thought realli confus look forward help guidanc possibl look forward hear back best hain',\n",
       " 'nearli half patient ocrelizumab achiev evid diseas activ neda kristina fior associ editor medpag today vancouv investig b cell monoclon antibodi ocrelizumab beat interferon stifl diseas activ multipl sclerosi year research report opera ii trial significantli larger proport patient experiment treatment achiev evid diseas activ neda versu respect anthoni traboulse md univers british columbia vancouv report american academi neurolog meet ocrelizumab anti cd monoclon antibodi target b cell avail immunosuppres therapi ms target cell research theoriz b cell may also play import role ms fact ocrelizumab would first b cell target therapi use ms physician current use rituximab label treat condit rituximab ocrelizumab made roch genentech test rituximab progress relaps remit ms promis result decid fund trial research said rituximab chimer ocrelizumab fulli human monoclon antibodi bind tightli target older drug infus reaction anti drug antibodi respons may lessen neda rrm opera ii neda composit relaps confirm disabl progress new enlarg gadolinium enhanc lesion new enlarg lesion patient random ocrelizumab mg infus everi week interferon beta three time week week investig previous report reduct annual relaps rate ocrelizumab trial compar interferon rel reduct opera rel reduct opera ii latest analysi found significantli ocrelizumab patient achiev neda compar treat interferon versu opera versu opera ii translat rel increas prevent diseas activ p traboulse said break neda individu compon larger proport ocrelizumab without relaps versu without week confirm disabl progress versu without gadolinium enhanc lesion versu without new enlarg lesion versu ocrelizumab relaps ms extrem import step forward david hafler md yale univers involv studi told medpag today risk progress multifoc leukencephalopathi seem rel low appear mri criteria effect treatment yet hafler said ms clinician probabl use first line drug long safeti profil remain seen raghav govindarajan md univers missouri also involv studi call drug promis relaps ms chang way think ms diseas told medpag today medic like natalizumab work cell predominantli thought ms new ppm data research also report result patient oratorio trial poster session much differ previous report ectrim barcelona traboulse said drug reduc rel risk week clinic disabl progress hr p trial enrol younger patient shorter durat progress diseas past progress ms trial first treatment crack open door show progress ms treatabl traboulse told medpag today know treatment work partial work better explor work improv get bigger impact patient traboulse note everyth effect relaps ms understand mechan better still struggl figur peopl progress hafler said effect seen oratorio trial modest best badli need understand ppm vari form ye probabl get approv ye use need better govindarajan said improv abl offer progress ms patient someth shown treat condit co occur symptom right provid support said much offer get wheelchair give botox spastic help swallow medic shown work make differ patient familiar situat remain seen whether ocrelizumab beat rituximab slow diseas activ ms although trial like done given roch genentech manufactur product compani stranger two compet drug singl condit one offer significantli cheaper price roch genentech manufactur bevacizumab avastin ranibizumab lucenti host ophthalm condit physician long prefer less costli bevacizumab especi studi larg show equal efficaci safeti profil two whether situat aris rituximab ocrelizumab remain specul biosimilar rituximab expect introduc eventu point market pressur may forc roch genentech drop price rituximab _________________ traboulse disclos financi relationship biogen hoffman laroch genzym serono teva',\n",
       " 'dear plucki brave woman admir get yet even though still abscess blah blah blah stelara realli help perfect bm form day still urgenc gi want least month see heal fistula rd dose day ago came viru immedi follow tri sort life well yesterday took ferri island spent day beach even public transit home take immodium urgenc near access clean bathroom fine today run tear knew would happen plu butt pressur pain build fear next abscess surgeri pain would consid divers upcom cr appoint octob differ cr one seen last year hope lift fix fistula mayb mayb respit gi also made referr mayo that long shot financi perspect fail gi tri map drug get psycholog strong enough mayb divers tini support system burnt realli think could handl perhap provid exampl need year old mom one frankli heartbreak struggl much think hard say follow suit femal canada ivig hold uc crohn test posit map antibodi mycobacterium pg remiss chronic perian abscess fistula fail seton pure tortur start stelara may mg imuran hope start anti map drug soon week repriev flare year flare tiresom',\n",
       " 'go mexico hsct next year current ocrevu know could replac rituxan ocrevu post hsct ask sinc would easier stay therapi replac rituxan',\n",
       " 'last infus friday week ago scan next thuesday immunotherapi caus swell hasnt settl scan immunotherapi littl moth similar case moth wasnt clear treatment respons scan six week drug holiday saw respons would like keep take avastin cediranib symptom scan cardiac mri confirm diseas progress like week discuss continu immunotherapi base scan result',\n",
       " 'eyesright correct ozurdex treat macular oedema alalex apolog pleas disregard comment use wet amd',\n",
       " 'kirkland quebec merck canada inc known msd outsid canada unit state announc provinc british columbia reimburs renflexi infliximab inject public drug plan effect august renflexi infliximab inject approv treatment crohn diseas ulcer coliti adult pediatr patient well fistulis crohn diseas rheumatoid arthriti ankylos spondyl psoriat arthriti plaqu psoriasi adult pleas see govern british columbia add renflexi formulari offer effect afford treatment option patient impact diseas said manon lafontain vice presid patient access merck canada commit continu work provinc territori throughout canada ensur broader access patient care need inform renflexi public list pleas consult http www gov bc ca asset gov health health drug coverag pharmacar newslett news pdf inflammatori bowel diseas inflammatori arthriti around canadian live crohn diseas ulcer coliti two main form inflammatori bowel diseas ibd canada also amongst highest rate childhood onset ibd world approxim children live diseas sinc crohn diseas canada almost doubl children age burden condit patient signific qualiti life substanti affect inflammatori arthriti affect canadian everi stage life irrespect gender ethnic common form includ rheumatoid arthriti ra psoriat arthriti pa ankylos spondyl canadian adult one everi ra affect person age women affect two three time frequent men support elig patient merck offer comprehens patient assist program renflexi elig patient merck harmoni patient assist program indic renflexi tm inform renflexi includ full product indic clinic data highlight pleas consult product monograph http www merck ca static pdf renflexi pm_e pdf merck biosimilar inform merck biosimilar visit www merckbiosimilar ca merck canada inc member canadian biosimilar forum allianc compani repres breadth biosimilar industri collect work increas awar access adopt biosimilar across canada inform visit www canadianbiosimilarsforum ca merck centuri merck lead global biopharmaceut compani known msd outsid unit state canada invent life bring forward medicin vaccin mani world challeng diseas prescript medicin vaccin biolog therapi anim health product work custom oper countri deliv innov health solut also demonstr commit increas access health care far reach polici program partnership today merck continu forefront research advanc prevent treatment diseas threaten peopl commun around world includ cancer cardio metabol diseas emerg anim diseas alzheim diseas infecti diseas includ hiv ebola inform oper canada visit www merck ca connect us youtub twitter merckcanada refer renflexi product monograph access juli avail http www merck ca static pdf renflexi pm_e pdf crohn coliti foundat canada impact inflammatori bowel diseas canada final report recommend access juli avail http www crohnsandcol ca crohns_and_col document report ccfc ibd impact report pdf ei benchimol cn bernstein bitton et al trend epidemiolog pediatr inflammatori bowel diseas canada distribut network analysi multipl popul base provinci health administr databas american journal gastroenterolog volum page access juli avail http www natur com articl ajg pdf crohn coliti canada risk access juli avail http crohnsandcol ca crohn coliti risk arthriti societi inflammatori arthriti access juli avail http www arthriti ca arthriti arthriti type z type inflammatori arthriti arthriti societi rheumatoid arthriti rheumatoid arthriti access juli avail http www arthriti ca arthriti arthriti type z type rheumatoid arthriti contact dominiqu quirion merck canada inc lesli haber lesli haber mccann com',\n",
       " 'glad mom hope uceri trick hold inflamm mesalamin med go med ladder would entyvio ye make case insur compani keep advoc research make inform decis applaud give big hug tough mom tougher yet make decis pleas continu keep us post best b',\n",
       " 'acid reflux medic taken hour period tarceva told cannot take prilosec longer interact new inform thank repli topic modifi year month ago elizoc topic modifi year month ago elizoc',\n",
       " 'liquid biopsi focu intens research group expert impanel american societi clinic oncolog colleg american pathologist asco cap report march studi multipl cancer type indic ctdna analysi identifi emerg resist mutat month earlier standard radiolog studi creat opportun test whether chang therapi clinic progress could improv outcom advanc genom analysi aid progress blood test sever factor pose challeng avail evid indic patient earli stage cancer harbor less one mutant templat molecul per millilit plasma cancerseek paper author state often beyond limit detect previous report technolog assess multipl mutat simultan yet anoth issu liquid biopsi identif underli tissu origin gene mutat drive multipl tumor type liquid biopsi base genom analysi alon gener cannot identifi anatom locat primari tumor therefor asco cap panel recogn promis result research thu far caution blood test base ctdna requir much extens broad base clinic trial use routin practic relat articl liquid biopsi may accur detect genom mutat urotheli carcinoma nsclc tissu rather liquid biopsi recommend identifi resist mechan evid clinic util littl evid clinic valid ctdna assay earli stage cancer treatment monitor residu diseas detect author said evid clinic valid clinic util suggest ctdna assay use cancer screen outsid clinic trial howev nation cancer institut said articl websit last novemb recent surg research relat liquid biopsi test analyz tumor dna blood call circul tumor dna ctdna sever ctdna base liquid biopsi test clinic develop fact u food drug administr fda gave approv blood base cancer test first time year ago coba egfr mutat test v detect epiderm growth factor receptor egfr gene mutat patient non small cell lung cancer help identifi may benefit treatment [erlotinib] howev fda advis mutat detect blood tumor biopsi perform determin nsclc mutat present approv liquid biopsi test make possibl deliv highli individu health care patient alberto gutierrez phd director offic vitro diagnost radiolog health fda center devic radiolog health silver spring maryland explain time liquid biopsi also potenti allow physician identifi patient whose tumor specif mutat least invas way possibl acceler pace research bring new evid support use liquid biopsi varieti way quickli address concern one member asco cap panel alexand lazar md phd fcap depart patholog genom medicin univers texa md anderson cancer center houston said via email field liquid biopsi move rapidli comment manuscript base literatur time discuss wrote review almost year ago excit work mani field publish literatur support use approach use liquid biopsi result determin therapi posit result clinic feasibl mutat present act upon reason less certainti regard clinic action neg result see particular mutat howev continu studi publish learn better appli test effect refer',\n",
       " 'thought consid entyvio sinc gut specif mayb would easier toler hate throw anoth option though sinc seem bit map say though real success humira hope definit deserv realli good break pleas continu keep us post hug b uc diagnos prob lialda day rowasa nightli period anucort supp cortifoam need need would like vsl slipperi elm metamucil capsul tri gluten free',\n",
       " 'follow time read everi post comment ocrevu sinc decemb like say help fact problem summar experienc ocrevu second half first infus caus anaphylact reaction abl continu medic rate lower bag salin administ concurr medic immedi headach infus walk somewhat improv declin month swell lower leg feet horribl start problem regul temperatur day alway cold night night sweat hormon test normal knew someth ocrevu thing realli start declin went next infus august came home infus discov start menstrual cycl stop januari year test done confirm fibroid uteru cyst ovari reason stop week ago total hysterectomi await news patholog see cancer found find advers event fda websit http fi fda gov hub stream aaec ab f dfafd list fibroid cyst uterin cancer addit known breast cancer risk thing report sinc trial start ran septemb report last updat seriou advers reaction tell lower true number plan report mine sure facebook jami coupl ocrevu page lot women discuss thing go like also rituxan prior say right would consid go back tri everi dmd gilenya lemtrada anoth name campath quit frankli two scare go realli point say medic caus problem diseas total understand frustrat',\n",
       " 'word reson especi today year fistula anniversari crohn termin diseas start look assist suicid possibl get femal canada ivig hold uc crohn test posit map antibodi mycobacterium pg remiss chronic perian abscess fistula fail seton pure tortur start stelara may mg imuran hope start anti map drug soon week repriev flare year flare tiresom',\n",
       " 'bob exactli prescrib imfinzi without pd l test unfortun work emphas enough import bio marker test hind sight believ bio marker test done treatment start nsclc bio marker test done imfinzi show work end pleural effus',\n",
       " 'sure what meant inflamatori activ sure everyon thatswhi symptom ive ask year regular mri scan one year could compar past one see progress ive alway refus decis might scupper chanc get ocrelizumab still mainli walk aid stick furnitur home use wheelchair outsid anyway im due see neurologist month il ask',\n",
       " 'thank repli pleural effus increas sinc first ct first ct done second ct done nodul along major minor fissur along right side nodul right side would pleural effus caus lot pain x cm addit front right rib area dad pain first biopsi site strang could caus sinc pain front pain sinc begin possibl nerv damag biopsi pdl result complet find appoint one hour higher start keytruda less start keytruda carbo alimta sinc super anxiou symptom pain sound reason thank input',\n",
       " 'experienc diabet macular edema inject arrest experienc appear complet revers scan shown eye free edema two year treatment inject intimid frighten seem includ link post made three year ago tudiabet first inject lucenti cross heart hope',\n",
       " 'interest report ocrevu patient receiv half dose ocrevu august serious one infect anoth sinc felt like crap get blood work next round next month look like actual get pull ocrevu take anymor immunoglobulin level critic low ivig treatment asap wonder drug wait take year wonder neuro say pull lot patient think strong dose suggest go back rituxan use swedish standard mg everi month instead us mg awhil even',\n",
       " 'father diagnosi nsclc plural effus pass year gone carboplatin cycl cisplatin gemcitabin cycl alimta cycl pembrolizumab cycl diseas show progress increas fluid metastat neck lymph node pleas advis chemo treatment immun treatment give tri also check new drug come trial let particip thank help',\n",
       " 'well seton word cannot describ pain best solut problem realli say within year truli think disabl issu hard keep area clean hour without home bathroom want discuss anyth els right depress wonder hot tub chemic harsh hot water sure eas pain lidocain even cover anymor insur great seton almost year depress crohn med entyvio mp',\n",
       " 'copaxon year major relaps sever damag solumedrol statrt gilenya help still somewhat progess wonder lemtrada thought lemtrada vs gilenya',\n",
       " 'thank jim thank janin kidney failur actual occur sixth infus alimta understand quit rare side effect alimta doubt prescrib know option tell would mostli requir dialysi read peopl last lot longer month tagrisso though hope one better believ worri thank jacki',\n",
       " 'thank respons sore morn feel lot better expect work quick also sure symptom bad enough given histori uc alway tend underestim amount pain wrong made signific differ side effect know feel yet finger cross continu work mind ask stop take humira enbril thank',\n",
       " 'hi matt georg om book chapter medic realli worth read newer med eg ocrelizumab give good run other avail best wish pipi',\n",
       " 'trial rituximab would benefici howev patent financ trial may problemat ocrelizumab probabl go approv rrm spm would lead one think rituximab would similar long histori use oncolog transplant autoimmun diseas',\n",
       " 'actual abl access full paper studi size small patient mix ppm spm least one ppm patient gadolinium enhanc lesion prior undergo hsct paper includ breakdown subset progress free surviv rate would love know patient fare best see data avail given burgeon hsct medic tourism industri exclud patient progress diseas larger robust studi efficaci hsct patient variou form progress ms urgent need treatment induc year stabil patient otherwis would see disabl progress ms commun urgent need know info hsct work patient progress ms display activ inflammatori marker also need shown given moder effect ocrevu even progress patient activ inflammatori marker treatment modal put halt progress year time warrant robust investig',\n",
       " 'husband bac mucu mutat year old read dr west well known bac husband suffer bronchorrhea type cancer th round chemo altima carboplatin get anoth ct scan next week right lung said stage percent use right lung small spot left lung sometim show ct scan show pet scan cancer anywher els except right lung plan treatment two altima infus go keytruda anyon type lung cancer mucu anyon success get rid mucu read much confus inform type lung cancer pleas help understand',\n",
       " 'mild case psoriasi one patch dandruff scale psoriat arthriti two year morn stiff swollen small joint knee pain endur almost two year doctor advic start stelara start dosag also prescrib remicaid week howev took almost week pharmaci fill remicaid within day take medicin felt better slightli stop daili celebrex pharmaci call pick remicaid said need within two week could feel better enough stop celebrex took second shot week ago point joint pain gone almost back normal abl wear wed ring remov finger stare swell back go gym build muscl back life good bobbi',\n",
       " 'osimertinib prolong progress free surviv pf compar earlier gener tyrosin kinas inhibitor tki regardless level pd l tumor express among patient advanc non small cell lung cancer nsclc accord analysi phase flaura trial present iaslc th world confer lung cancer toronto canada result trial demonstr osimertinib prolong pf compar gefitinib erlotinib patient egfr mutat nsclc effect pd l express frequent express tumor egfr mutat egfr tki unknown patient randomli assign treatment studi harbor egfr mutat suffici tissu pd l assess sp ventana immunohistochemistri test use evalu pd l tumor express tumor cell tc stain least consid posit relat articl pembrolizumab plu chemotherapi extend surviv longer chemotherapi alon studi head head battl brigatinib appear best crizotinib durvalumab show overal surviv benefit patient stage iii nsclc signific differ median pf among patient posit versu neg pd l tumor express receiv osimertinib treatment osimertinib result median pf compar month gefitinib erlotinib among patient whose tumor pd l posit hazard ratio [hr] ci similarli median pf among patient whose tumor neg pd l express month osimertinib compar month gefitinib erlotinib hr ci author conclud data support efficaci egfr tki includ osimertinib first line treatment egfr mutat advanc nsclc irrespect pd l express read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       " 'call doc let know get wors year old femal diagnos sever uc remicad mg kg imuran mg librax zofran need calcium vitamin slow fe',\n",
       " 'post past follow mix respons year ago mother law stage nsclc start iressa first line biopsi egfr posit back juli month mix respons attempt get aura trial back nov reject previous receiv kidney transplant certain anti reject immunosuppress med three round carboplatin pemetrex mainten pemetrex ever week three four month ago sinc hospit time pneumonia stop pemetrex stop work due complic cancer progress tube insert assist fluid seem help dr sent pleural fluid biopsi obtain compassion use applic approv osimertinib yet approv canada far know result came back neg mutat yesterday news dr also indic biopsi seem show even less pronounc prior egfr mutat sorri long wind start mil variou anti reject immunosuppress med kidney transplant novemb sound like without posit mutat option limit dr plan tri three round pemetrex see respons next option taxoter dr said much stronger could side effect wonder option immunosuppress current cours dr want get touch transplant kidney dr discuss option wonder idea send along three year anniversari diagnosi juli year appreci time',\n",
       " 'takeda announc phase iii visibl trial investig subcutan formul entyvio vedolizumab patient ulcer coliti met primari endpoint trial test entyvio mainten therapi adult patient moder sever activ ulcer coliti uc respond well entyvio result show significantli patient receiv sc formul vedolizumab achiev clinic remiss week versu placebo addit safeti data consist known safeti profil entyvio alreadi market intraven form new safeti signal identifi takeda announc yesterday submit entyvio approv crohn diseas japan comment need login leav comment epgonlin org monitor collect advers event report advers event report nation report agenc manufactur learn zone epgonlin org learn zone lz area site dedic provid detail self direct medic educ diseas condit procedur inflammatori bowel diseas knowledg centr inflammatori bowel diseas ibd knowledg centr contain key inform relat epidemiolog pathophysiolog crohn diseas ulcer coliti highlight preval impact unmet need underli inflammatori process drive ibd consid key inflammatori pathway chronic obstruct pulmonari diseas copd view highlight recent congress present new expert video lead physician allerg rhiniti allerg rhiniti caus great strain workforc help reduc sick day improv product appropri treatment option fluid manag date latest evid effect procedur fluid manag chronic spontan urticaria csu use patient case studi discov expert diagnos treat chronic spontan urticaria migrain knowledg centr migrain knowledg centr featur latest research preval impact migrain propos neurolog basi condit translat new excit drug therapi well current patient care strategi collat headach organis worldwid acut advanc heart failur effect treatment acut heart failur defin advanc heart failur discov transplant see inform best practic solid organ transplant expert discuss relat hot topic load relat content news journal articl clinic trial guidelin news phase iii im uniti studi stelara show continu efficaci year crohn diseas j j janssen cilag janssen pharmaceut compani johnson johnson announc new three year data phase iii im uniti studi demonstr ad day ago phase iii visibl trial subcutan entyvio show remiss rate ulcer coliti takeda result phase iii visibl clinic trial evalu efficaci safeti investig subcutan sc formul ad day ago addit data phase iii map us studi rhb confirm benefit crohn redhil biopharma redhil biopharma report addit posit data map us studi first phase iii studi rhb ad day ago phase iii unifi studi stelara posit ulcer coliti janssen biotech janssen biotech announc new data show treatment singl intraven iv dose stelara ustekinumab induc clinic remiss ad month ago success phase iii studi map us studi rhb treatment crohn diseas redhil biopharma ltd redhil biopharma ltd announc posit top line safeti efficaci result first phase iii studi rhb ad month ago load view news item journal articl safeti adalimumab pediatr patient polyarticular juvenil idiopath arthriti enthes relat arthriti psoriasi crohn diseas object evalu safeti adalimumab pediatr patient particip clinic trial juvenil idiopath arthriti polyarticular juvenil idiopath arthriti pediatr enthes relat arthriti ad month ago novel therapi treatment strategi patient inflammatori bowel diseas articl review current treatment option strategi provid updat statu drug develop program new therapeut agent inflammatori bowel diseas ibd ad month ago review articl predictor respons vedolizumab ustekinumab inflammatori bowel diseas aim summaris current data predictor respons vedolizumab ustekinumab ibd patient ad month ago safeti efficaci pharmacokinet vedolizumab patient simultan exposur anti tumour necrosi factor aim explor outcom patient co expos anti tnf vedolizumab ad month ago phase ii evalu anti madcam antibodi pf treatment crohn diseas report opera studi phase ii randomis doubl blind placebo control clinic trial design evalu efficaci safeti pf fulli human monoclon antibodi bind human mucos addressin cell adhes molecul ad month ago load view journal articl item clinic trial impact medic treatment sexual function patient crohn diseas investig propos month studi compar sexual function treatment patient crohn diseas initi therapi anti tnf drug treatment perian fistula intestin crohn ad month ago studi test whether pf safe improv diseas symptom patient crohn diseas opera adult crohn diseas clinic activ despit convent treatment elig studi patient may receiv one three dose pf experiment drug placebo inact drug ad month ago impact anti tnf exposur vedolizumab effect vedolizumab new medic use treatment crohn diseas ulcer coliti work block specif white blood cell alpha beta lymphocyt migrat area inflamm ad month ago multicent random doubl blind placebo control studi abt induct symptomat endoscop remiss subject moder sever activ crohn diseas inadequ respond intoler immunomodul anti tnf therapi determin efficaci safeti multipl dose abt subject moder sever activ crohn diseas histori inadequ respons intoler immunomodul anti tumor necrosi factor ad month ago personalis anti tnf therapi crohn diseas pant primari object studi investig mechan underli primari non respons pnr loss respons lor advers drug reaction adr anti tnf drug patient activ lumin crohn diseas ad month ago load view clinic trial item guidelin third european evid base consensu diagnosi manag ulcer coliti part current manag guidelin condens two paper [ ] second describ current therapeut manag [treatment activ diseas mainten medic induc remission] ad month ago third european evid base consensu diagnosi manag ulcer coliti part definit diagnosi extra intestin manifest pregnanc cancer surveil surgeri ileo anal pouch disord guidelin condens paper st detail definit classif diagnosi imag patholog manag special situat [eim pregnanc cancer surveil surgeri ileo anal pouch disord uc] ad month ago consensu guidelin ecco espghan medic manag pediatr crohn diseas object guidelin provid state art guidanc medic treatment long term manag children adolesc cd individu therapi base risk benefit base thorough review ad year ago crohn diseas manag crohn diseas chronic inflammatori diseas mainli affect gastrointestin tract diseas may progress peopl proport may develop extra intestin manifest',\n",
       " 'fluconazol counter medic uk mani women use thrush therefor vital inform known take fingolimod',\n",
       " 'result two earli phase clinic trial present american societi clinic oncolog annual meet provid evid prime immun system attack tumor potenti treatment certain cancer find also publish june new england journal medicin nejm although preliminari result notabl trial treatment produc substanti tumor shrinkag patient non small cell lung cancer extrem resist immun base therapi thu far trial leader explain mani patient tumor respons maintain year think one excit thing seen recent year said ross camidg ph lung cancer research univers colorado denver involv either studi lot progress made recent identifi molecular subtyp lung cancer specif target treatment promis immunotherapi someth actual cut across boundari may chang everi singl treatment paradigm current develop studi test investig drug target molecul known checkpoint molecul help restrain immun respons harm bodi tumor co opt checkpoint molecul weaken immun system abil erad tumor tumor shrinkag also seen patient melanoma kidney cancer previou studi shown cancer respond immunotherapi food drug administr fda approv immunotherapi patient tumor addit one patient ovarian cancer receiv one investig drug also tumor respons unleash immun respons two drug test trial monoclon antibodi one target receptor protein known pd surfac activ cell drug target bind partner ligand pd call pd l express higher normal level mani tumor cell tumor microenviron respons inflammatori stimuli agent develop bristol myer squibb primari funder trial fda approv first checkpoint molecul inhibitor ipilimumab yervoy treat advanc melanoma ipilimumab howev target differ checkpoint molecul ctla surfac activ cell patient trial also stomach breast colorect castrat resist prostat pancreat tumor grew despit multipl prior treatment nearli patient enrol trial test pd target agent slightli enrol trial test pd l target agent trial test escal dose drug start low dose signific side effect seen research increment increas dose patient enrol later result intrigu number respons also durabl note suzann topalian john hopkin univers school medicin led trial test pd target agent among patient respond pd target agent follow least one year respons persist least year',\n",
       " 'also switch gener start want see everyon els still coupl week worth lialda without issu sinc day suppli co pay pick script cv realiz switch got home thought doc renew day due see soon start mild flare fun diseas keep us guess post result problem gener lgreco new member join sep post post yesterday pm gmt lialda save card afraid gener may option move forward past week take half gener half lialda test notic differ besid frequent bm also up fiber diet ucingv regular member join mar post post yesterday pm gmt employ tri push everyon hsa hdhp plan phase ppo start end big problem cours buy lialda pocket current ppo charg pay also found switch gener without notic three month ago pay insur paid anticip push hsa plan start look price someon show app call goodrx find place cheapest price app say pill gener lialda mesalamin dr costco close pay insur compani mail order walmart right big differ price drug walmart differ go buy sure gener lialda buy deliveri mechan brand name lialda mesalamin dr offici gener name lialda deliveri mechan lialda ipoop forum moder join aug post post yesterday pm gmt zydu pharmaceut produc gener lialda gener asacohd www zydususa com product detail id www zydususa com product detail id moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa told dentist rather see gasteroenteroligist said take compliment johnnyuc new member join nov post post today gmt switch gener month ago blood mucu came back gi ask anyth chang told take gener lialda said switch back gone back name brand symptom disappear suppos allow differ formula will pay extra name brand glasw new member join apr post post today pm gmt anyon lialda remiss success take gener brand afford flare last flare horrif caus perman damag spine due side effect prednison want go humira seriou drug think take drug without risk lialda year keep stabl took asacol flare everi year releas system lialda differenti work compar asacol mesalamin work complet differ medicastioj releas system anyway wari go gener rout stay lialda caus eventu go broke insur cover much cost lialda stop co pay program realli dishearten say least',\n",
       " 'hello sorri present dmt work treatment decis ms difficult spous receiv third infus ocrevu believ ocrevu nearli good medicin tysabri great deal fatigu ms symptom numb right hand arm stab pain eye differ profound today compar disabl progress ocrevu tysabri put link gold standard compar med imo tysabri much superior slow disabl progress ocrevu chart confirm disabl progress http www medicin org uk emc ima b png natalizumab tysabri treatment show low cumul probabl confirm disabl worsen edss mileston long term set http www sciencedirect com scienc best wish prayer find best med',\n",
       " 'learn insur declin entyvio remi humira doc mention applic appeal declin within three week window anyon experi long appeal usual take bum consid option realli want take remi humira seem affect whole bodi instead gut male proctiti sinc pancol rx asacol x maint mg budesonid gerd mg pantoprazol flare everi month may move immun suppress tbd',\n",
       " 'hi fighterm l spain treat spanish nation health fail alimta iv week thing put opdivo matter l ask test even said l would pay onco said point test get problem stage v tri keep aliv cure thing tri littl bit harder mire peopl may live longer',\n",
       " 'ocrevu ocrelizumab new approv drug treatment patient relaps primari progress form multipl sclerosi rituxan sister drug ocrevu year comparison drug mostli illustr blog post ocrelizumab versu rituximab rituxan made error think compani basic drug easi transit last friday found infus place receiv rituxan ocrevu infus go train doctor request get infus done nyc start rituxan normal problem drive far step dad take work take long day like infus rituxan infus done two week later done make sidebar note point forward ocrevu everi six month wherea rituxan alway follow week apart protocol idea go citi infus begin mess also get appoint made call first time gave inform appoint requir told comput froze call right back ten minut later call shock call time tell make appoint doctor put order comput receiv ocrevu call doctor assist got voicemail sent email repli email told doctor put order soon receiv blood work back blood work ask blood work mind happen hour friday close clock hour get doctor send prescript blood test tuesday saw doctor chang ocrevu june alway plan find blood work frustrat top everyth els insur approv start order system appoint made say wtf next infus suppos juli will bet rituxan think readi transit even full week gave',\n",
       " 'well well well say updat blog neutrophil neutrophil sure alreadi well awar read shout emphat anyon everyon within physic digit hear rang neutrophil month sinc beauti sweet littl neut return count remain entir time highest normal neutrophil count fierc celebr bit extrem also extrem bone pain time warn bone marrow swell new cell activ would pain sheeeesh said thousand time anyon listen still shock neutrophil came back rapidli long noth bizarr first day hospit admiss neut count crept plummet back next week haematolog want discharg anc calcul daclizumab clear system treatment kick would take least month reach healthi neutrophil count damag revers drug would work mask fashun whilst day leav preced happen doctor idea theori daclizumab ms treatment interact cvid common variabl immun defici shut neutrophil product like scenario none doctor could confirm certainti actual happen daclizumab tga approv use rrm less year literatur lack understand incid peopl ms cvid extrem low ms approx cvid approx haematolog came numer occas flat told honestli idea immunolog told tri everyth could research like mad idea would ever recov height infect caught whilst neutropen look reassur ask doctor infecti diseas depart go die could offer realli hope week hospit blur one long horrif day august stand day liter got life back start like day basic tri make look present healthi possibl doctor would approv day leav essenti put cloth brush hair sick first month big improv sit bed tri make look nonchal full energi resid came told incred neutrophil count day come back amaz could cri consult came told count actual cri haematologist want check film eye celebr went lab came back shortli confirm blood abund fluffi littl white cell even consult haem team rotat ward duti came tell want crack bottl champagn spend week think like go die rush elat relief indescrib went day leav miss call hospit shortli left voicemail tell neutrophil count blood taken morn lay bed listen voicemail time space hour gone patient tick everi singl box highest risk categori complet normal rip sign door tell hospit staff visitor wear mask around stop gcsf inject stimul bone marrow start eat fruit veget need peel bacteria risk threw dettol kid reckless even haematologist seem surpris neutrophil dramat reappear reason flog bodi everi drug imagin final kick first time sinc admit plan discharg date went board room one week away time make sure neutrophil stay stabl gcsf start tinker dosag med picc consist caus noth grief frequent block would flush aspir mean blood often taken peripher point pic send drug call alteplas line break blood clot cours noth ever simpl whilst white blood cell behav beauti lead discharg extrem tachycard haemoglobin drop haematologist explan haemoglobin level except mayb bone marrow still bit slump knew like thing caus tachycardia anaemia haematologist worri might infect immunosuppress meant show symptom pull picc line earli case infect sourc tip picc sent test grow anyth day wait get frenemi picc line remov time came plan day discharg howev new think either blood clot lung slow intern bleed haemoglobin drop given anoth blood transfus haematolog overli concern possibl intern bleed worri possibl blood clot sent nuclear medicin enough radiat exposur felt blood transfus hour picc pull need cannul x ray look infect bodi spect scan first scan breath radioact ga second scan inject radioact dye scan lung compar radioact ga abl travel dye went discrep meant clot probabl worn crop top realis go scan arm head hour time got back ward nearli pm complet given discharg day one doctor came see scan confirm blood clot good go home hospit long strang feel discharg almost anticlimact reliev overwhelm sad scare someth would happen would die without constant observ good sleep entir time hospit drug induc insomnia ward nois haematolog ward loudest ward ever seem lot met call attest woken middl night iv med blood slept full hour bed night greatest woke heart race much normal wake heart rate start realli freak potenti intern bleed nice find one symptom bodi fault went see gastroenterologist day took one look extens drug chart said go word haematolog went back monash day methotrex ivig rather sheepish look haem team come let know gastro point still dapson prophylact drug overlook chart ran test blood turn dapson caus haemolysi destruct red blood cell also caus methomoglobinemia meant littl amount haemoglobin abl properli deliv oxygen around bodi noooooo wonder felt like shit unceremoni kick dapson curb could hang zinbryta gilenya tecfidera drug allow nowher near morgan blood club neutrophil haemoglobin stabl sloooooowli wean prednisolon like stay methotrex coupl year mtx seem kind wonder drug also good ms mysteri look like coeliac coeliac gut issu happi stay especi whilst bodi heal recondit recollect told first meal month infect non stop vomit start massiv dose methylprednisolon start feel bit human white bag hang top right corner call tpn feed picc line term nutrit abl eat like normal person put weight lowest hospit weigh kg feed tube put nose second time idea would eat normal throughout day night tube would deliv extra calori bodi desper need bare memori first tube admiss unwel bare lucid point definit could toler second tube lot pain threw everyth fed tube last entir hour pull tell much enjoy tube clinic nutrit doctor pretti unimpress threaten put peg tube tube surgic place stomach abdomen haematolog let anyon oper without neutrophil henc also wait surgeri ear long longer neutropen gastro float option peg tube last week laugh shout dilig consum fat shake protein supplement chocol life tough much happier health full time job moment hospit appoint treatment methotrex ivig day week decreas next coupl month abl go back work walter eliza hall institut current sequenc exom hope find defect gene immun system could potenti start treatment correct drug take daili amongst lot prophylact antibiot antivir antifung prop shitti immun system use think health solar system ms big bad sun comorbid planet orbit around ms start think ms actual planet cvid real sun ms definit take planetari cake big ol jupit cvid bastard given immun system defici antibodi immun system confront like attack shut variou function bodi see fit fair cvid like star distant galaxi first decad life much see idea exist began immunotherapi ms cvid becam enrag diagnos ms specialist neurologist year immunotherapi combin cvid later talli specialist team hit end ologist probabl one feel outrag much wrong bodi amount medic intervent requir stay aliv felt pretti bloodi shit hospit reason adjust fact hand dealt live best life panic futur fact much mani year left life hope thing go wrong els happen turn think gp put best week joke excel get sick said also incred good get better post pretti long even touch happen ms melanoma leav anoth blog post thank read end come along ride morgan xxx',\n",
       " 'addit pd antibodi pembrolizumab standard first line chemotherapi treatment na advanc non small cell lung cancer significantli improv respons rate progress free surviv research report esmo congress copenhagen today pembrolizumab class immunotherapeut anti cancer drug call checkpoint inhibitor target mechan tumour use shut bodi immun respons pembrolizumab enabl cell reactiv accomplish design facilit tumour cell kill said princip investig dr corey langer director thorac oncolog program abramson cancer center univers pennsylvania us phase ii keynot studi research random patient stage iiib iv chemotherapi naiv nonsquam non small cell lung cancer receiv four cycl carboplatin pemetrex mg everi three week without month treatment pembrolizumab mg everi three week median follow month research observ significantli greater object respons rate vs p patient receiv pembrolizumab well chemotherapi compar treat chemotherapi alon patient select amount pd l express tumour research note higher respons rate around pembrolizumab chemotherapi combin tumour pd l express greater equal particip pembrolizumab arm also experienc improv progress free surviv median month vs month although overal surviv rate similar two arm month surviv rate earli landmark assess higher incid advers event grade sever pembrolizumab arm compar chemotherapi alon arm vs impact treatment discontinu rate pembrolizumab arm compar chemotherapi arm treatment relat death common treatment relat advers event fatigu nausea common patient receiv pembrolizumab anemia common chemotherapi alon arm studi first random phase ii trial advanc treatment na non squamou non small cell lung cancer assess benefit ad monoclon antibodi target pd standard chemotherapi said langer benefit confirm ongo phase iii trial result may radic alter treatment paradigm advanc non small cell lung cancer comment studi dr raffael califano consult medic oncolog christi hospit univers hospit south manchest manchest uk said data combin chemotherapi plu pembrolizumab popul certainli encourag reassur see addit pembrolizumab first line chemotherapi manag toxic profil increas incid treatment relat advers event death notabl progress free surviv report standard arm much longer expect nearli doubl compar histor data could due patient select clinic molecular characterist patient enrol studi califano said order establish strategi adopt clinic practic result investig phase iii random studi similar design adequ power progress free surviv robust assess patient report outcom sourc esmo',\n",
       " 'condol loss sister hope allow time griev push hard work right uc pancol dx march partial colectomi diverticul sept apriso g x day canasa uceri foam need supplement zinc l glutamin probiot reuteri pearl vsl folic acid coq turmer boswellia milk thistl nac reservatol colostrum glycin start entyvio constant flare sinc march reliev prednison',\n",
       " 'thank much posit updat liquid biopsi dad local miami oncologist email result guardant remark singl mutat detect ro gene r h uncertain signific specif treatment avail found use crizotinib target ro lung cancer found trial multipl cancer type refer fusion chromosom transloc activ mutat involv ro gene would dad ro mutat count look ro discuss board saw cholangiocarcinoma patient might experi anyon tell dad kind ro mutat target thank',\n",
       " 'nifedipin petroleum jelli mix lidocain doc order get compound pharmaci anal skin tag pull caus bleed tear sometim mixtur help lot also coat whole bottom ointment help well thank diagnos proctiti april p c diff infect age nov crohn coliti mid transvers mild moder remiss march sept flare fail prednison balsalzid wean start humira prednison sinc past med cortifoam canasa rowasa balsalazid prednison',\n",
       " 'happen someon stop take ocrelizumab probabl peopl know answer alreadi sinc rituximab around year rebound similar natalizumab',\n",
       " 'addit result present today show experiment monoclon antibodi ocrelizumab slow progress disabl compar placebo phase iii trial studi known oratorio involv peopl primari progress ms compar placebo ocrelizumab significantli reduc risk progress clinic disabl also reduc time requir walk feet decreas volum brain lesion reduc rate whole brain volum loss week first larg scale clinic trial show posit result peopl primari progress ms genentech member roch group support trial press releas compani state plan seek market approv fda',\n",
       " 'hi new forum decemb th mom diagnos stage iv nsclc tumor patholog non squamou adenocarcinoma pd l less neg target mutat spot lung tumor nearbi lymph node tumor left adren gland least potenti brain met brain met scatter throughout brain sever frontal lobe least one left pariet least one right top cerebellum father took er major neurolog symptom insist fine despit fact right hand function begin entir whirlwind mom handl news exceedingli well partli tough nonsens partli tumor frontal lobe help respect henc think fine even know right hand work spent week hospit intens steroid reduc swell week inpati rehab help regain right hand function improv balanc etc still rehab began whole brain radiat came home finish treatment toler radiat well better everi day weigh next step qualiti life mom prioriti amazingli fortun experienc pain far interest clinic trial scientist former research pro clinic trial gener philosophi support mom choic even go quot pain nauseou feel sick intend keep way doc recommend cycl carboplatin pemetrex alimta pembrolizumab keytruda debat anyon experi treatment regimen will share',\n",
       " 'pcori award studi compar current drug rehab therapi ms magdalena kegel nation multipl sclerosi societi report patient center outcom research institut pcori grant nearli million fund four research project assess variou multipl sclerosi ms therapi clinic effect two grant cover studi compar diseas modifi treatment look identifi differ effect drug well assess downsid third fund project evalu drug allevi fatigu fourth assess whether ms patient live rural low incom area benefit equal well rehabilit provid phone internet access clinic base rehabilit project noteworthi patient engag key focu pcori fund research ms patient famili caregiv ms healthcar provid nurs physician contribut design perform studi pcori award welcom much need infus new ms research fund import real world question treatment strategi effect bruce bebo phd execut vice presid research nation ms societi said news releas pcori delight make new award address crucial evid gap question vital interest peopl u live multipl sclerosi ad joe selbi md mph execut director pcori studi provid signific new evid help patient famili clinician decid confid therapi avail work best given need prefer design select four studi came prioriti identifi workshop peopl ms healthcar provid scientist govern agenc pharmaceut industri repres health insur gather refin question pcori later use fund announc session identifi number evid gap issu put forward top prioriti workshop particip address four research project first grant million went studi explor biolog drug rituxan rituximab effect commonli use diseas modifi drug peopl relaps remit ms also also compar side effect drug studi base karolinska institutet sweden perform partnership healthcar insur provid kaiser permanent southern california anoth million goe project run research team univers alabama birmingham assess whether patient alabama mississippi rural low incom area benefit much exercis base rehabilit program deliv via internet telephon therapi provid clinic clinic provid servic area scarc put emphasi altern option three drug often use reliev fatigu peopl ms evalu studi univers california san francisco receiv million drug symmetrel amantadin provigil modafinil methylphenid known sever brand name includ ritalin rare compar side side final million award trial compar benefit side effect two oral diseas modifi treatment gilenya fingolimod tecfidera dimethyl fumar drug never directli compar although gener view similarli effect side effect might differ trial led research team base foundat carlo besta neurolog institut itali includ studi site u europ israel ms grant among grant total million support research variou diseas area approv pcori board governor last week',\n",
       " 'sugarplum lesion year feel progress know lemtrada work stop hope ocrevu slow hell wish best',\n",
       " 'ask dr week ago e biolog prevent delay surgeri said evid number surgeri come number peopl respond medic although biolog still year experi guess need time draw firm conclus dx pancol last remiss moder sever left side coliti sinc tri nearli drug quack option avail current work entyvio sure work',\n",
       " 'hi ldn almost year find need know facebook group call ldn research trust file section inform ldn immun stimul may work gilenya immun suppress ldn help fatigu gave endorphin still attack group refer dose mg take liquid pill get mg pill make liquid thu stabl live long way compound pharmaci good luck research',\n",
       " 'hi mohit welcom grace sorri hear recent progress father lung cancer though oncologist like continu tarceva even progress combin drug alimta pemetrex often progress signific enough third gener egfr tki tagrisso chosen addit doctor choos combin afatinib cetuximab effect quit challeng term combin side effect egfr posit patient often overlook standard chemotherapi tend quit effect subgroup patient regimen carboplatin cisplatin combin alimta taxol often use jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'neoadjuv erlotinib tarceva benefit select patient epiderm growth factor receptor egfr mutat non small cell lung cancer nsclc undergo complet resect stage iiia n diseas accord random studi compar erlotinib gemcitabin plu cisplatin neoadjuv treatment find present zhong et al european societi medic oncolog esmo congress abstract lba _pr result suggest promis use biomark guid neoadjuv egfr tyrosin kinas inhibitor treatment strategi stage iiia n nsclc said yi long wu md tenur professor guangdong lung cancer institut guangzhou china princip investig ctong studi first studi demonstr progress free surviv superior erlotinib gemcitabin plu cisplatin chemotherapi neoadjuv adjuv set stage iiia n egfr mutat nsclc dr wu ad ctong result total patient center china screen randomli assign therapi includ intent treat popul object respons rate orr neoadjuv erlotinib vs gemcitabin plu cisplatin chemotherapi confid interv [ci] vs ci odd ratio ci p neoadjuv therapi patient erlotinib group gemcitabin plu cisplatin group underw surgeri median progress free surviv significantli longer erlotinib month ci vs gemcitabin plu cisplatin chemotherapi month ci hazard ratio ci p overal surviv immatur report said dr wu grade toxic fewer erlotinib arm compar gemcitabin cisplatin arm current treatment strategi resect stage iiia n egfr mutat nsclc controversi explain dr wu egfr tyrosin kinas inhibitor shown improv prognosi patient advanc egfr mutant nsclc cisplatin base doublet chemotherapi neoadjuv treatment stage iiia n nsclc give patient [a] year overal surviv benefit said dr wu explain unmet medic need patient popul recent ctong trial [publish zhong et al lancet oncolog ] show first time adjuv gefitinib [iressa] could improv diseas free surviv month compar adjuv chemotherapi vs month n n resect nsclc rais possibl egfr tyrosin kinas inhibitor may play benefici role neoadjuv set subgroup content post review american societi clinic oncolog inc asco necessarili reflect idea opinion asco',\n",
       " 'wow thank anon din know theori prof vollmer realiz neuro option treat decid take risk leav boy fingolimod realli improv exam result mri',\n",
       " 'cc stelara work matter day gi will jump hoop get probabl worth consid one anti tnf stop work anoth pm ulcer coliti next surgeri schedul problem skin loop ad setup pm ulcer coliti next surgeri schedul familiar hollist probabl go first cut hole stoma go place directli skin protect leak stay skin pm ulcer coliti humira remicad cimzia simponi anti tnf shot base upon weight xeljanz also weight base stelara weightbas remicad well studi drug pm ulcer coliti unexpect scope result j pouch buckey think appoint gi go know issu complex mine see post anyth ulcer coliti next surgeri schedul congratul recommend get convex wafer new ostomi realli help liquid output probabl know loop ileo time littl pm ulcer coliti remicad infus get test remicad antibodi symptom serum sick ignor mine got wors start drop thing memori loss bone joint pain pm ulcer coliti super donor phenomenon fecal microbiota transplant segment cbc radio quirk quark show http www cbc ca radio quirk poop creat equal super pooper could life saver test ulcer coliti saw gi recommend xeljanz scare start thread check box includ signatur see med thought ad entyvio either prednison entocort blood test pm ulcer coliti saw gi recommend xeljanz scare anti tnf med like remicad anyth list signatur use rectal med steroid pm ulcer coliti recent taken friend heard take month jpouch fulli adjust pm ulcer coliti still experienc issu cuffiti song ladi ga diarrhea also caus sibo easi test taken test previous also home test sibo happen jpoucher certain antibiot',\n",
       " 'travel multipl sclerosi ordeal bit complex especi bit disabl mobil wise especi diseas modifi therapi like injectab copaxon rebif avonex betaseron extavia shot therapi needl airplan hmm requir keep eye temperatur cold hot practic advic activems cull fellow mser travel agent airlin staff cruis line disabl specialist person experi travel countri six contin mani diagnos mani use walk aid wheelchair serious get around even machu picchu made access gener tip letter doctor state multipl sclerosi good idea read woman deni extra drink flight look drunk claim ms doctor letter might help particular situat still drunk ms digress keep ms specialist phone number e mail hour pager number travel countri forget add countri code dial rememb differ exacerb pseudoexacerb accord nmss websit true exacerb worsen old symptom appear new one last least hour import stress heat fatigu easili happen travel could caus temporari symptom flare clear next day pace know bodi better anyon know go go put hurt bodi save climb kilimanjaro end holiday recov plane ride rememb everyth guidebook holiday call success choos activ wise build recoveri time check ego lot tool dispos make travel easier use wheelchair cane trek pole scooter rollat dispos undergar name someon stare bloodi care probabl wise take medic origin label contain come cryptic pill diseas modifi inject ms med okay sinc label dude especi custom realli like guess pill take tysabri lemtrada rituxan sure plan around infus date katmandu like infus center use underestim import reliabl travel companion need littl extra assist extra pair abl bodi hand leg godsend mental note bathroom travel intern avoid pass good one cell phone app help find public potti watch data fee oversea rememb hustl back natur call alway tend ring inopportun time travel remot area particular ventur outsid us non industri countri may want ask neurologist prescript oral steroid prednison way exacerb long trek trip say nepal dose oral steroid could trim attack symptom big time save vacat note previous taken oral steroid awar drug affect wait save dream trip retir kid grown feel better ms unpredict go carp diem seiz day savor moment make vacat unforgett right reason focu instanc make travel enjoy diseas run bull spain overli access bathroom jungl gym seiz day windi rail plan trip consid use travel agent special make arrang disabl especi use requir wheelchair sure inform agent special need current mobil equip bring need destin seat prefer etc detail list travel agent around us around us experienc work handicap folk http www disabledtravel com travel_ag htm europ sage travel gob trip dozen citi wheelchair access http www sagetravel com view accommod onlin make reserv note stair pool access restroom exercis room etc question e mail call want stuck go stair b b thought singl level also trust handicap access declar folk think access downright laughabl best solut sever mobil issu ask pic even video even trust area access peru cannot count number bathroom wheelchair access despit appear overs grab bar galor requir get chair anywher near toilet stall door often would close brought wheelchair anoth occas bathroom door open block toilet room access bathroom folk use wheelchair one activems discov larger bathroom grab bar especi help exhaust day hotel shower chair avail shower alreadi equip one better ask sink may may allow roll wheel ask doorway bathroom heck even bedroom may wide enough chair especi travel oversea tape measur minimum requir need time year travel absolut make differ prefer travel season less stand line easier get restaur better seat special event temperatur cooler heat wear travel toasti could turn vacat littl quest c consid cruis even cruiser travel ship extens pre post ms inde one trip nearli four month took around world host advantag unpack great fatigu disabl access good especi need mobil aid doctor alway onboard help relaps travel time often night sleep exhaust car ride recommend like alaska summer caribbean winter europ fall spring note travel agenc special adapt cruis shore excurs want far flung adventur african safari great travel x mean access c seat lodg spectacular kenya actual slept bed x size bedroom staff cater special need say multipl sclerosi languag travel countri speak languag download onto phone free ccessibl travel phrase book pdf lone planet ask access bathroom elev countless essenti disabl got way easier purchas travel insur book trip like aig travel guard travel insur compani recogn pre exist condit like ms purchas insur within day put deposit trip miss window ms event void travel insur meant buy travel insur space dolt plan travel insur intern www travelinsur com purchas day initi deposit rememb initi deposit includ fund trip penni word warn buy insur compani travel go belli sol alway recommend buy insur third parti travel agent compani cruis ship wheel athen greec cruis easi access option mser ride camel sahara desert hell gear unless need help walk around airport pack trek pole luggag avoid juggl two pole cane allow aboard airplan trek pole well tell anyon ask mobil aid ski pole almost alway frown upon forearm crutch problem flight attend may store anoth area plane fit overhead bin happen seat surf bathroom better yet could lucki enough set joint forearm crutch like trick pair develop dick fate http www youtub com watch v _imejao gow fold jiff store seat front easiest cool vest pack one evapor sinc lightweight uncharg perform poorli humid condit sinc usabl freezer hard find prefer around travel vest recharg ice glacier tek vest www glaciertek com room temperatur first line technolog vest www firstlinetech com one thing watch tsa love search bag carri cool vest hat scarv hydrat bead avoid someon paw luggag take carri inform screener mari washington go carri cool vest plane doctor note extrem help could confisc due gel fill evapor vest okay charg recent trip tsa let gel vest without question although announc one send xray unit airlin secur rep want remind cool vest actual wear go secur know gel pack look like scan bodi like bomb strap chest take tell friend break camera film chao like tini lightweight digit camera cell phone record travel memori photograph audio video weight save conveni slip pocket invalu like cane seat combo oh sound conveni crummi cane crummi seat get pant littl dirti sit curb must get wheeli bag alreadi one sens burn energi lug around granddad old militari issu trunk look cool lot sticker absolut smartest pack advic taken veteran travel make whatev bring fit singl carri bag especi go travel multipl destin ye includ go oversea three week never lose bag far easier handl larger luggag substanti lighter pawn travel companion need bring multipl form walk aid lose cane still trek pole vice versa also primarili use rollat walker bring cane forearm crutch heard one mser much troubl cobbleston street itali rollat essenti useless cane although meant slower go save vacat pair forearm crutch offer three time support singl cane make get around uneven surfac cake walk need help get around airport massiv hotel museum ask shi vacat want spend two day recov amount stubborn pride facil wheelchair borrow although forewarn often get beater recent trip boston got overconfid fail bring wheelchair none avail rent switch hotel one provid chair guest use weekend save trip seri short cab ride person favorit travel companion summertim travel umbrella particular sun safe umbrella gustbust order www innovagolf com handl wind mph provid instant shade relief heat great spectat sport long line outdoor plu come kinda handi rain need wheelchair travel plane ship full time scooter user mser suggest take manual chair possibl worri recharg batteri deal hassl stow chair manual chair brought gate without problem easier tote car one lightweight remov wheel even better rent wheelchair easili countri instanc franc virtual corner pharmaci chair rent qualiti iffi though usual less euro day made train travel much easier lug wheelchair public transport would get chair destin town alway count itali wheelchair imposs find lug scooter around worri get broken rent one destin compani usual deliv ride directli hotel pick finish dramat lower hassl factor mani cab equip tote scooter thank great tip ruth carri bag stack lap doubl luggag cart trek bhutan trusti pole cold water cool vest alway recommend plane airport travel person wheelchair sure gate check wheel take way actual board plane leav chair plane entri detach easili remov item take aboard plane person carri item includ seat cushion footplat armrest like bring small stuff sack well stuff everyth wheelchair knicknack stay one place limit risk someth fall bin clunk innoc stranger head take gear minim risk lose import piec equip serious suck lose left footplat got enjoy entir vacat leg cross even tinkl tsa precheck worth year global entri fli twice year probabl get speed secur check wait usual less minut get keep shoe belt liquid stay bag use wheelchair usual pat disappoint week last year full monti test hand chair explos residu super quick easi request wheelchair assist book flight bring check tell ticket agent request assist call someon person take whoever travel thru secur without stand long line right gate switch plane fli direct someon wait take next gate anyon let gate agent know call someon arriv destin someon take baggag claim rememb take dollar bill tip wheelchair assist help conserv energi mari oklahoma travel scooter electr wheelchair best gel cell dri cell batteri wet cell batteri rariti day airlin remov chair special storag hassl forget remov seat cushion etc pervent get lost belli plane scooter either gate check go check luggag forget secur key power pin someth bit stronger rubberband suggest fish line set throttl slowest set tape help prevent speedi joyrid much scooter wheelchair weigh heavi may allow flight recommend call ahead check restrict power chair remov joystick recommend least point downward littl bugger stick attent uncanni abil attract errant luggag look care airport chang airplan know far go gate exampl perth brisban australia domest intern termin actual separ airport easi transfer mobil impair alway allow longer time suggest make transfer notabl except home town melbourn intern domest flight one build mari washington take advantag earli board ask flight attend help need consid use curb side check luggag porter arriv airport save energi buck usual worth request isl forward seat airplan closer front airplan less walk anoth reason h ey sometim us mser go lavatori well realli gotta go front plane avail head rear intern flight alway check www seatguru com find seat close toilet sinc number locat variou area larg plane also note last row seat may reclin fulli walk aid often store behind seat make retriev cake speak bathroom hurt chang cloth carri fact consid mandatori sometim bodi suppos wear clean cloth lot better wear wet cloth wash airplan lavatori suggest hit restroom board cours dehydr advic drink plenti h jetlag may mitig sleep aid make even hour plane trip rel breez import word caution never drink alcohol take sleep aid tri first time airplan take companion unit airlin secur rep warn altitud alcohol ambien danger mix lot med keep person friend baggag confisc twice come go drug pack check luggag cours help matter transfer singapor note hang folk much tylenol actual kilo heroin get pictur bag delay coupl day fortun stash pill prevent natur critic pick cool sword cane kenya fit check luggag pretti much guarante confisc doc note cool sword cane stori woe flight attend quick help disabl travel scooter boon tire leg tsa frown sword cane crossbow wookie destin use wheelchair especi intern museum sight often free go straight front line question ask eiffel tower hour wait bam next elev hord peopl surround mona lisa bam front row access even closer abl bodi person sistin chapel access bam back corridor hidden passag vatican get cafe hotel hang bit ask toilet locat need well hidden would never find ever one hotel dinner befuddl bathroom around screen closet behind close door also downstair requir new plan stair limit one case waiter took differ build altogeth get easi access toilet see access bathroom ask one cafe hidden behind broom box rush cram everyth select enjoy get home far better memori race clock hit smithsonian museum one c afternoon take advantag break seek shade drink ici beverag sit energi save come handi later trust sometim conveni cost littl extra often money well spent roll may need scout ahead alter rout find curb cut sinc block nonexist okay found incred easili breakabl souvenir last day trip fit luggag cloth listen implor take larg suitcas ship home odd high break ship home cloth toss new treasur bag folk accommod ask tabl wall perfect stash forearm crutch spot near bathroom uncertain time seat upfront avoid maze diner front line us avoid travesti let disabl stop travel ms medic travel advic small soft side cooler ice park two watch accident freez med work great tote medic store carri backpack count extra carri copaxon avonex betaseron extavia never store temperatur higher degre fahrenheit rebif never see light day degre fahrenheit take cooler alway good idea travel inject even betaseron extavia requir refriger never know medic sit hot car hike oral drug gilenya aubagio tecfidera avoid extrem temp word leav roast glovebox hot car expos camp overnight siberia januari camp siberia januari recommend see therapist alway keep medic part carryon luggag one piec luggag afford lose smart prescript drug well letter doctor state multipl sclerosi person never stop secur boatload potenti subcutan weapon pull asid eyeglass screwdriv immedi confisc appropri scold xray machin use airport harm medic need call ahead hotel ask portabl refriger put room mini bar hotel abl honor request remov item minibar make room med sure later check bill minibar abil automat charg bill item remov fridg even put back bring coupl digit thermomet record ambient air temperatur put one hotel fridg keep one cooler transport drug store medic fridg unless certain freez degre thermomet bottl touch water tablespoon nice put coldest part fridg add med wait least hour freez even warmest set find new fridg instead lug around big sharp contain needl might consid needl clipper storag devic littl gadget clip needl store needl allow store syring safe look one local pharmaci bd safe clip one brand word caution medic wast usual toss trash need find place store empti least get poke bring extra dose case someth stupid pooch one inject drop bill gutter weather caus delay cancel stuck without medic travel tip like share fellow activ mser write dave activems org happi travel',\n",
       " 'hi simplest explan think relaps month initi b cell deplet treatment autoantigen b cell includ ebv present b cell cell induc relaps b cell die ocrelizumab b cell phagocytos macrophag b cell protein enter serum b cell protein taken macrophag instead b cell present cell enhanc autoreact cell relaps within month initi treatment question data happen immunolog immun system first week b cell die',\n",
       " 'hi honeyb lemtrada first line dmt uk mani newli dxd patient shift particularli aggress diseas offer want halt progress ticket discov earliest use gabapentin solv bladder pelvic pain switch pregabalin address need pregabalin pain ad gaba back solv puzzl sinc read gaba directli target lower part spine manag bladder cannabi avail press see get seen sever mention help richard prior sad right correct word spastic root much pain lucki case sure present like expect thank tip took gilenya four year wait lemtrada caus mani pain se lemtrada goal believ strong advoc state petit fda approv know clinic trial patient advic research investig state made compar drug rebif look like placebo mri encourag wait best wish',\n",
       " 'anyon cancer concern know anyon cancer upon use biolog crohn diagnosi year ago xifaxan pentasa sulfasalazin mayb stelara ileocol resect primari diseas focu ileum perian diseas xifaxan remiss year remiss activ firm believ supplement acupunctur pain mgmt',\n",
       " 'drug stelara may eas crohn diseas medic potenti help find relief treatment research say sourc webmd health',\n",
       " 'think go onto one treatment stop ms track treatment given twice get wors one heard lemtrada cladribin mitoxantron anti cd possibl hsct bmt talk neurologist one treatment pm give name neurologist give treatment would soon',\n",
       " 'hi jc welcom grace sorri hear mom diagnosi glad well address effus issu impact daili life true tarceva cross blood brain barrier effect brain metastas system therapi cross barrier one extent anoth problem concentr drug reach brain met often suffici effect fact common egfr posit lung canceer first show progress brain becom sanctuari site cancer cell result standard treatment multipl brain met whole brain radiat true wbrt side effect like appear time problem immedi benefit vs delay deterior qualiti life debat mani discuss issu signific neurolog symptom consequ reduct qualiti life caus progress brain met given suffici consider decis made forego delay wbrt would good close monitor symptom fairli short interv follow scan hope tarceva effect mom long time jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'realli interest level would need recov alemtuzumab cladribin fingolimod reason sensibl option level never great dmf last month encourag think switch tricki',\n",
       " 'exhaust nearli non surgic option point got xeljanz author start week go high expect given histori non respons biolog hope nonetheless yo male dx ulcer coliti tri fail lialda meslamin imuran azathioprin uceri remicad humira entyvio stelara current prednison xeljanz',\n",
       " 'thought lot treatment cost past year even rais question ohiohealth treat tysabri made biogen first went new locat januari cost around per month new medic provid follow neurologist decid go differ medic practic construct new build infus clinic move initi shock anger see cost treatment costli enough k per month old build jump per infus new one mean treatment cost would bill year check medic record stori find medic provid charg per treatment increas januari april part increas drug cost remaind infus clinic overhead question explan given fairli predict negoti payment insur go pay much would significantli reduc amount eventu paid increas bill clinic provid paid per year real cost treatment base today price still stagger amount consid continu mental struggl whether amount money worth big pictur consid age factor fair treatment cost affect health care dollar cost like take sizeabl chunk avail moni much treatment affect escal cost health insur ms chronic diseas known cure could conceiv continu treatment remaind life amass treatment cost million dollar fortun entir cost treatment cover privat health care insur along patient assist program tysabri cost paid noth pocket year imagin type bill part drive cost health insur pay lot everyon els think angri frustrat ms treatment cost often anoth remind escal bill usual form notic insur tell much bill actual paid today remind came differ way write dr gavin giavanonni bart ms blog written ms doctor research depart neuroimmunolog blizard institut bart london school medicin dentistri unit kingdom particular articl talk nice nation institut health care excel uk one function nice set price healthcar treatment includ drug cost nice decid consid fair price pay drug look option treat patient decid would cost effect govern health care system blog author also concern afford access drug polici nice affect treatment post observ recent confer anoth ground shift poster oratorio studi result ocrelizumab ppm studi first studi show dmt slow rate disabl progress ppm one signific thing happen field ms last year despit concern nice may view ocrelizumab treatment ppm favour nice alway assess cost effect use increment cost model ppm cost effect ocrelizumab compar alreadi e best support care write think treatment cost also wonder could put price might cost provid support care compar money spent drug would need much way help money could spent someon els pictur could chang quickli ms progress treatment found depend health care servic activ daili live would amount money take care nurs facil averag daili cost nurs home care day think money would save somewher someon decid cost effect tysabri show health care money would better spent put nurs home read question bart ms blog make concern us cost effect model might need control drug cost us way insur compani alreadi form often deni treatment author certain drug reimburs topic cost effect one core point list north american registri care research multipl sclerosi narcrm project major initi us part canada look link patient clinic data togeth health care econom core identifi inform collect databas regard disabl util health care resourc employ help better understand whether use expens therapi worthwhil econom standpoint save fewer hospit less disabl longer employ span decreas util health care resourc unlik system uk help cost live hous transport medic care peopl need due financi demand live chronic ill broad rang assist us health insur would pay live cost pay drug financi respons leav littl choic continu treatment despit escal cost linger question best avoid futur care need would pay resourc meantim hope next bill open caus requir treatment choke price well laura',\n",
       " 'got two stabl ground glass small lesion one mm anoth faint one x mm right lung read peopl experi web differ forum often state lesion rare grow larg thought case grow larg call ai grow larger cm question definit rather relat natur life histori lesion sub centimet ground glass lesion stabl year grow larg usual stay small chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatin vinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan topic modifi month week ago onthemark topic modifi month week ago onthemark',\n",
       " 'stumbler thank respons full stori lesion origin earlier mri along new enhanc lesion brain got start gilenya gilenya either new enhanc one brain spinal cord get relaps cord lesion one mention show hypo intens imag quit concern also warrant chang dmt despit new enhanc lesion sure one',\n",
       " 'humira inject treat complex perian fistul crohn diseas great came remiss reaccur flare infect infliximab reccomend treatment go period week treatment time develop excruci lower leg pain bare walk burn throb even walk head ach feel wors stop humira first infliximab infus yesterday feel like run bu anyon relat',\n",
       " 'best bowel movement year start remicad load may first wrist pain juli went away came back big time octob poor sleep worst even consid give remicad laugh suppos take someth day next infus januari',\n",
       " 'drug realli cost effect provid modest efficaci also work peopl use caldribin much effect drug induct therapi think time clear cupboard make room effect therapi horizon ocrelizumab spinimod ozanimond posin mod ofatumumab etc',\n",
       " 'mention dmt rrm think right say us ppm steadi progress ms symptom yet seem fampyra vari success hope eventu ocrevu approv uk improv lot person wh ch lot time balanc rubbish fall rather often exercis stretch resist keep mobil strong flexibl fit whatev type ms poppi question mindset mind matter obvious bad day non mser dwell situat mainli get life good mobil vehicl help take dog run go visit friend meal go shop etc retir situat bit differ someon young mean say plan give time soon hope help bit doom gloom xx',\n",
       " 'hi antonett fick funni mention gilenya given choic mavenclad gilenya told mavenclad higher effici rate hi stumbler thank input websit realli hope effect truli amanda',\n",
       " 'diagnos inflammatori arthriti ra septemb year old first plaquenil never seem help top develop terribl hive rash went away stop take next tri humira work great month symptom came back remicad almost year work great get infus everi week symptom love remicad gave life back slightli concern though develop anoth rash seem go away month deal tri steroid etc etc cross finger remicad caus rash cri',\n",
       " 'articl author topic appear injama neurolog may avail entireti onlin abstract quot rebound syndrom patient multipl sclerosi cessat fingolimod treatment staci ellen hatcher bs emmanuel waubant md phd bardia nourbakhsh md elizabeth crabtre hartman md jennif grave md phd ma author affili depart neurolog univers california san francisco import appropri sequenc agent strong immun system effect becom increasingli import transit requir care balanc safeti protect relaps case present herein highlight rebound event ceas fingolimod treatment may happen even short washout period week may perpetu despit steroid treatment immedi use fast act immun therapi rituximab object describ rebound syndrom patient multipl sclerosi ms cessat fingolimod treatment design set particip clinic demograph data extract electron medic record univers california san francisco multipl sclerosi center januari decemb magnet reson imag review ms neurologist j g e w b n e c h rebound syndrom defin new sever neurolog symptom ceas fingolimod treatment develop multipl new enhanc lesion exceed baselin activ review pubm databas januari decemb similar case sever diseas reactiv ceas fingolimod treatment use search term fingolimod either rebound reactiv particip includ stop receiv fingolimod januari decemb five patient identifi experienc rebound ceas fingolimod treatment exposur patient receiv treatment oral fingolimod variou durat main outcom measur occurr rebound ceas fingolimod treatment result mean sd age femal patient present case seri year patient stop fingolimod treatment within year period experienc sever relaps week ceas fingolimod treatment despit vari prior sever relaps remit cours particip experienc unexpectedli sever clinic relaps accompani drastic increas new enhanc lesion seen magnet reson imag evidenc median rang increas new gadolinium enhanc lesion median rang new lesion new lesion develop persist month despit treatment corticosteroid n initi b cell deplet therapi n addit patient identifi literatur review report sever relaps consist rebound syndrom similar featur case conclus relev case provid evid fingolimod rebound syndrom clinic relev frequenc highlight need determin best method sequenc discontinu ms therapi larg prospect registri popul base studi would help confirm rebound phenomenon determin contribut factor includ immun biomark increas risk syndrom entir articl seen',\n",
       " 'hi sick recent think flu took care dad day felt sick afraid may pass flu viru cough lot symptom slight high bodi temperatur f sometim chest congest mucu call pcp prescrib tamiflu azithromycin would like know okay take tamiflu azithromycin prevent chemo go chemo tomorrow continu three day kkh diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'predict assess pharmacogenet glutathion transferas gene efficaci platinum base chemotherapi non small cell lung cancer patient ye huan et al scientif report predict egfr mutat statu lung adenocarcinoma ct imag use deep learn wang shuo et al european respiratori journal jan http www cancer gov news event cancer current blog earli stage lung cancer biomark nci januari detect egfr mutat alk ro rearrang non small cell lung cancer use malign pleural effus sampl yao yi et al thorac cancer dec next gener sequenc circul tumor dna detect gene mutat lung cancer implic precis treatment lai jinhuo et al oncotarget therapi perform analysi sire next gener sequenc panel diagnost set focu nsclc routin sampl pepe francesco et al journal clinic patholog jan race poverti initi implement precis medicin lung cancer kehl kenneth l et al journal nation cancer institut dec genom biomark checkpoint efficaci highway precis medicin lung cancer ghiringhelli francoi et al oncotarget nov clinic util plasma base digit next gener sequenc patient advanc stage lung adenocarcinoma insuffici tumor sampl tissu genotyp zugazagoitia j et al annal oncolog offici journal european societi medic oncolog dec detect egfr mutat circul tumor dna ctdna retriev plasma interlaboratori qualiti assess czech republ linda capkov et al klinicka onkologi casopi cesk slovensk onkologick spolecnosti inform variou databas cdc inform nih resourc cdc author public state public health genom program tier tabl epidemiolog studi translat implement studi evid synthesi guidelin review commentari tool method ethic legal social issu amd weekli clip gwa catalog grant support public genet test gtr genet diseas omim pubm review pubm clinic queri pharmgkb cdc inform databas databas includ gener cdc public health inform specif diseas health relat topic avail databas display genom inform variou cdc web page user also encourag conduct search cdc websit addit inform lung cancer awar famili health histori lung cancer risk factor lung cancer lower lung cancer risk go cdc inform databas cdc author genom public databas databas contain cdc author public public health genom includ infecti diseas newborn screen reproduct health genet test cancer chronic diseas birth defect development disabl environment occup health well laboratori bioinformat statist method util genet test analysi gene specif bill medicar claim data lynch juli et al genet medicin offici journal american colleg medic genet aug consensu report weinman intern confer mesothelioma carbon michel et al journal thorac oncolog offici public intern associ studi lung cancer aug confirm germlin glioma risk variant rs tp implic tumor tissu via integr analysi tcga data wang zhaom et al hum mutat jul microrna famili target multipl non small cell lung cancer prognost marker h cell bea b cell pacurari maricica et al int j oncol aug compar effect research cancer genom precis medicin current landscap futur prospect simond naoko et al j natl cancer inst jul util epiderm growth factor receptor egfr test unit state case studi translat research lynch juli et al genet med aug multiwal carbon nanotub induc gene signatur mous lung potenti predict valu human lung cancer risk prognosi guo nanci l et al j toxicol environ health part smoke associ gene signatur lung cancer diagnosi prognosi wan ying wooi et al int j oncol oct chronic occup exposur arsen induc carcinogen gene signal network neoplast transform human lung epitheli cell stueckl todd et al toxicol appl pharmacol jun stakehold assess evid cancer genom test insight three case studi deverka patricia et al genet medicin offici journal american colleg medic genet jul multi wall carbon nanotub induc gene express mous lung associ lung patholog pacurari et al toxicol appl pharmacol aug go cdc author genom public databas state public health genom program databas databas focus state nation activ integr genom public health program clinic practic get record tier tabl databas cdc offic public health genom ophg conduct horizon scan systemat research method find follow novel technolog appear literatur identifi track progress genom test move research clinic public health practic aid organ horizon scan result ophg rank genom test famili health histori applic level evid see detail get record huge literatur finder databas databas contain publish literatur genet associ human genom epidemiolog get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record genom health impact scan databas databas includ publish scientif literatur evid base translat genom discoveri improv health care diseas prevent potenti impact popul health get record advanc molecular detect clip databas databas includ publish scientif literatur popular press articl tool databas emerg role pathogen genom host pathogen interact infecti diseas control prevent includ inform method evolut pathogen detect diagnosi outbreak epidemiolog transmiss antimicrobi vaccin host pathogen interact get record nation institut health web site approv osimertinib necitumumab increas lung cancer treatment option asbesto relat lung diseas nhlbi health topic site bring precis screen cancer enhanc risk base lung cancer screen may prevent death current approach fda approv alectinib alk posit non small cell lung cancer http www cancer gov news event cancer current blog earli stage lung cancer biomark nci januari idiopath pulmonari fibrosi nhlbi health topic site case lung cancer due smoke howev risk factor includ famili histori noninvas strategi lung cancer test nih research matter march non small cell lung cancer childhood ncat genet rare diseas inform center small cell lung cancer childhood ncat genet rare diseas inform center small cell lung cancer adult ncat genet rare diseas inform center target photoimmunotherapi approach cancer move forward two drug combin approv lung cancer braf mutat nci juli use gene express diagnos lung cancer accur fda approv gefitinib return u market patient lung cancer grantom grantom search engin analysi tool grant inform associ publish literatur evid base translat genom discoveri improv health care diseas prevent human genom epidemiolog literatur inform genom health impact scan databas huge literatur finder databas grant inform extract grant data pubm record nih report grant inform search diseas condit environment risk factor gene studi free text simpl analysi perform get record gwa catalog catalog qualiti control manual curat literatur deriv collect publish genom wide associ studi get record nih genet test registri genet test registri gtr provid central locat voluntari submiss genet test inform provid scope includ test purpos methodolog valid evid test use laboratori contact credenti overarch goal gtr advanc public health research genet basi health diseas search genet test registri lung cancer nih omim omim comprehens authorit compendium human gene genet phenotyp freeli avail updat daili search omim lung cancer pubm clinic queri pubm clinic queri util offer pubm search scientif literatur specif clinic research area search pubm clinic queri lung cancer pharmgkb pharmgkb pharmacogenom knowledg resourc encompass clinic inform includ dose guidelin drug label potenti clinic action gene drug associ genotyp phenotyp relationship search pharmgkb lung cancer pubm pubm compris million citat biomed literatur medlin life scienc journal onlin book citat may includ link full text content pubm central publish web site pubm link genet review articl lung cancer disclaim articl list public health knowledg base select cdc offic public health genom provid current awar literatur news inclus updat necessarili repres view center diseas control prevent impli endors articl method find cdc dhh assum respons factual accuraci item present select omiss content item impli endors posit taken cdc dhh opinion find conclus express origin author item includ updat person quot therein strictli way meant repres opinion view cdc dhh refer public news sourc non cdc websit provid sole inform purpos impli endors cdc dhh',\n",
       " 'reviv old thread diagnos moder sever pan coliti everyth remicad amaz new job insur made cost like per infus humira sinc seem hold remiss reason year ago gi chang stanc prescrib pain med ibd mayb realiz true thing help peopl live somewhat normal norco twice day like year although opioid year remiss opioid thing allow oper like normal human cramp urgenc diarrhea bleed fatigu gone take although agre risk addict even taken direct withdraw stop part realli suck withdraw symptom similar uc symptom feel better taper pain med still feel okay bleed return withdraw symptom go give anoth week see happen like mani mention risk addict opioid well worth altern mani case especi compar side effect biolog steroid',\n",
       " 'mesalamin intoler took doctor year half forc tri fail everi mesalamin drug move imuran thing final convinc scope show mild proctiti run bathroom time day throw night doctor kept insist might ib complic uc know anyon ib goe bathroom time day everi day matter eat scope improv symptom mesalamin may blame also consid someth like imuran mp next stop someth els note folk toler rectal mesalamin oral pan coliti current entyvio imuran mg need bentyl zofran hydrocortison suppositori klonopin tri asa flagyl cipro canasa prednison medrol uceri entocort fodmap scd elimin intermitt liquid diet mesalamin intoler',\n",
       " 'hi want know stelara effect read',\n",
       " 'great articl prof g howev seem big disconnect rest team instanc md dr karl seem thick ocrelizumab caldeibin better therapi brain atrophi low due therapi start latter alem littl odd ocr complet suppress observ inflam beat alem hand even start late eventu agre view complet point hope convinc other bring depart board nevertheless believ promnient ms author err think aaron boster also',\n",
       " 'paulin arr recent convers cladribin',\n",
       " 'brain tumor abl remov aa treat avastin current right gene drug might option find right mutat',\n",
       " 'hey everyon check good explain goal exactli right year pass said right leg sinc last time examin said good hope next year still wors wear told matur b cell destroy ocrevu stop progress ms brain said realli know occur occur get anoth brain mri right see april see improv differ receiv full dose said take long sinc turn administ faster pace sure glad hear unrel ocrev ask fall last time ask answer shortli strang fall bedroom knelt stood like someon push knew fallen backward time catch said common involv equilibrium inner ear whole balanc orient want care make sure alway someth grab hold second brain catch posit allow fall backward strang diseas ms think suddenli someth new occur told month later experienc weird sensat bathroom recogn grab hold sink pull bodi forward took coupl second brain bodi got sync avoid anoth fall told would keep happen without warn prepar unexpect finish increv tackl issu pcp agre provid script lyrica xanax even gave script diabet med sinc doctor hold hostag forc come appoint agre us time find anoth famili doctor see decemb well anyon question fire away hope answer dar r r never anxiou next day next day anxieti day enough troubl matthew repli quot follow user say thank agat howi jeani z stillstannd sunshin',\n",
       " 'hello ms month ago meet criteria ocrevu trial walk meter independ cane start research copaxon stop due allerg reaction tecfidera start walk independ within month use cane found coimbra protocol use high dose vitamin cure lifelong treatment program done protocol train doctor supervis start octob small relaps februari left leg start rag like right year scare doctor approv up vitamin dosag iu three day leg back normal never happen even steroid stabl sinc octob new symptom shown stay exist symptom worsen decid ale charg health tri rate go afraid would wheel chair decemb treatment program cure link fb group inform help pressur simpli point right direct could gather inform ask question help make inform decis http www facebook com group vitamindprotocolnorthamerica ref group_head link correctli call coimbra protocol ms autoimmun diseas north america good luck',\n",
       " 'ms preval women childbear age group young women receiv diagnosi ms frequent question effect diseas childbear vice versa studi undertaken past sever decad allow health profession provid answer question download pregnanc deliveri post partum fact sheet pdf next doctor visit effect ms fertil evid ms impair fertil lead increas number spontan abort stillbirth congenit malform sever studi larg number women repeatedli demonstr pregnanc labor deliveri incid fetal complic differ women ms control group without diseas effect pregnanc ms women ms counsel avoid pregnanc belief might make ms wors past year mani studi done hundr women ms almost reach opposit conclus pregnanc reduc number ms relaps especi second third trimest effect postpartum period relaps rate tend rise first three six month postpartum risk relaps postpartum period estim relaps appear contribut increas long term disabl studi long term follow women ms children increas disabl result pregnanc found pregnanc known associ increas number circul protein factor natur immunosuppress addit level natur corticosteroid higher pregnant nonpregn women may reason women ms tend well pregnanc use corticosteroid medic women use corticosteroid exampl methylprednisolon prednison acut ms relapsess may continu use pregnanc use prednison woman breastfeed care monitor special concern pregnant patient ms women gait difficulti may find get wors late pregnanc becom heavier center graviti shift increas use assist devic walk use wheelchair may advis time bladder bowel problem occur pregnant women may aggrav women ms pre exist urinari bowel dysfunct ms patient may also subject fatigu gener pregnanc appear affect long term clinic cours ms women ms wish famili usual success assist neurologist obstetrician addit resourc oh babi momentum articl umbil cord blood donat cord blood use benefit ms research worthwhil bank umbil cord blood benefit famili member might need umbil stem cell futur treatment get answer resourc get answer pregnanc registri pregnanc registri ms diseas modifi medic manufactur fda approv diseas modifi medic establish pregnanc registri monitor pregnanc outcom women take one drug within week becom pregnant pregnant learn learn pregnanc ms kara stori part pregnanc ms kara stori part medic manag pregnanc deliveri postpartum none diseas modifi medic aubagio avonex betaseron copaxon extavia gilenya glatopa lemtrada novantron ocrevu plegridi rebif tecfidera tysabri zinbryta approv use pregnanc women take medic discuss plan becom pregnant prescrib physician inform treatment consider women men reproduct year refer ms coalit consensu paper use diseas modifi therapi multipl sclerosi principl current evid women ms usual need special gynecolog care pregnanc labor deliveri usual women special manag need form anesthesia consid safe women labor deliveri seem well toler diseas modifi drug recommend breastfeed known excret breast milk woman also review medic take neurologist obstetrician order identifi safe pregnanc breastfeed studi indic increas risk relaps ms associ breastfeed',\n",
       " 'gypsyros post twice hope moder delet post ocrevu mean believ ms want someth suspect work good news pleas keep us updat',\n",
       " 'ed wonder statu sever time sinc last post great see one honestli inspir woman ppm recent rd ocrevu infus understand up down wonder follow treatment wait year diseas modifi medic come along overjoy immedi sign soon becam avail see improv stamina encourag thank share stori best wish continu progress good health keep faith karen riley',\n",
       " 'follow statement one present class action lawsuit mani compound pharmaci avastin use syring intend use diabet inject skin mani case barrel needl syring lubric silicon oil lubric may suitabl skin inject eye inject inject wet blood amd far first avastin without month long bubbl describ new ret doc u switch eylea next satisfi avastin result read possibl side effect drug use avastin lucenti eylea hope none side effect seriou type seem say doctor fault advers get new one skill techniqu injector everyth switch longer pain bloodshot eye go bed rest day pleas googl eye inject silicon lubric inform includ class action lawsuit',\n",
       " 'excus reactiv old thread cross road progress lung adren gland month afatinib cetuximab well multipl brain met stabl sometim presum credit afatinib plan move carboplatin alimta tagrisso avail yet howev concern control brain met think may less like hold chemo oncologist suggest continu afatinib low dose get chemo think combin well studi warn pancytopenia dr christin chung john hopkin sidney kimmel cancer centr http journal lww com oncolog time fulltext warning_about_chemotherapy_afatinib_combin aspx anoth articl seem report benefit accept risk profil combin afatinib paclitaxel lux lung trial would appreci input cancergrac feasibl combin afatinib chemo thank nj wife asian dx adenocarcinoma b egfr iressa great respons asymptomat brain met possibl lepto wbr continu iressa local progress primari tumor focal radiat pet scan tumor resolut continu iressa pet show flare primari ct stabl mri reappear brain met stabl brain met increas suv slight pleural effus afatinib cetuximab',\n",
       " 'wife first scan post initi opdivo round week exactli hope hard realli know good bad sinc oncologist said opdivo often show effect anoth month howev main lung tumor right middl lung grown small bit new nodul oncologist said could new metastas could initi site inflamm opdivo start work tell yet also two new lesion liver last two blood test shown increas ast alt liver enzym yet blood chemistri includ bilirubin alp quit normal blood physic sign liver malfunct increas liver enzym could increas size number liver lesion metastas could due initi inflamm kidney lesion caus opdivo tell yet unfortun opdivo liver enzym high still high week next round start wait week see enzym go switch someth els moment could possibl come back opdivo one dual immun combo futur luckili new lesion anywher els rest lung fine organ look fine noth new bone still seem surreal wife look feel great especi lower rbc first round carbo alimta got back week trip israel stamina endur normal lot walk hike etc cough come back occasion although much persist origin wait meantim start plan daughter wed juli wife lifelong non smoker dx adeno nsclc stage iv poorli diff bone met lymph node exon mutat x carbo alimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo effect add l growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl stabl add l growth trial start gemzar larg tumor reduct',\n",
       " 'woohoo plucki sound excel glad good week partial colectomi diverticul sept uc pancol dx march apriso g x day canasa uceri foam supplement zinc l glutamin probiot reuteri peral vsl folic acid coq turmer boswellia start entyvio wed constant flare sinc march reliev prednison',\n",
       " 'read lemtrada ocrelizumab thier suppress immun system make feel interest pursu hsct myleo version knock immun system build back instead repeatedli knock constantli immun compromis young children doctor offer pleas assist get test fill form submit applic will follow along assist way afterward keen see dr sadiq work offer way repar therapi',\n",
       " 'hilari bother read articl floor contradictori realli evid th cd cell critic ms ocrelizumab deplet th mayb work realli wait paragraph contradict',\n",
       " 'hah way round start colon year later move onto thyroid diagnos hashimoto thyroid levothyroxin appear keep well control sometim get paranoid hormon funki thing anyway canada mark said year mine realli struck symptom blood stool minor sporad along mucu month lose stool urgenc though thought colon cancer mayb realli bad stomach bug afraid go doctor fear would say cancer time peopl seem gone previou symptom diseas struck real got diagnosi mine start blue day diarrhoea bleed mucu urgenc abdomin pain either thing chronic constip child teenag sort constip late teen simpli eat green stuff first time life increas fibr intak year perfect poop crohn start never anoth normal poop exagger way would never claim mcdonald healthi meal suspect slightli healthier uk us hfc never big thing europ never big soda drinker usual orang juic meal tooth rot coke probabl healthier overal dx crohn summer yay tri fail asa azathioprin mp remicad methotrex humira variou diet surgeri feb subtot colectomi end ileostomi first thing put remiss year second surgeri th juli revers stoma connect ileum rectum offici flare fun never begin',\n",
       " 'listen issu address one profession kind lot uc patient research support group uc staff help kind pregnant remicad know monitor care avail need oper room ob doctor deliv child awesom even follow deliveri want meet littl girl must say great doctor move meet need find anoth one none came close yet anonym uc er post annonym uc ulcer coliti peopl anonym submit stori doctor review medic supplement review etc post stori site differ person stori hope account make sens adam founder ihaveuc com',\n",
       " 'thank janin thank bonu vid took month progress tarceva never got tri afatinib onc seen good result patient chemo tri nivo test posit put tagrisso last scan show complet metabol remiss though primari still visibl scan back mind awar averag time resist tagrisso month tenth month obvious patient differ choic go forward limit due chemo induc kidney failur last year wonder correl done guess thing look time data avail thank get back janin best jacki',\n",
       " 'time hampton road va doctor richmond nssg sound aw also mind thought would need reason consid surgeri seem somehow prematur like want life back intellectu ridicul realli tough shake reason think fatigu stuff improv bodi continu adjust expect remain doctor save troubl bring surgeri bring abl get remicad approv start today wait deliv said seem work remain option would entyvio take forev optimist clinic trial surgeri felt surgeri might best option qualiti life keep everyth cross remi work feel terrifi also littl like relief someon suggest current situat tenabl dx flare sinc rx lialda gx uceri sometim humira fail xeljanz toler deck remicad wtg approv',\n",
       " 'old thread tiredofcolon entyvio work undergo j pouch procedur male mid diagnos proctosigmoid uc februari current med lialda gm x daili gener rowasa need perian abscess june fistulotomi decemb doc still say uc crohn specif carbohydr diet start june still go strong happi depend depend sole think dale carnegi',\n",
       " 'hello diagnos stage iv metastat lung cancer august radiat treatment brain tumor result tumor bare detect reduc also treat chemo alimta cisplatin well keytruda treatment combo ongo mainten receiv alimta keytruda side affect except sensit weepi eye drippi nose week everi treatment md say heard find odd alway week week receiv next treatment recent read cbd oil possibl anti tumor effect start take week ago idea may reduc effect keytruda plan speak chemo pharmacist friday go next treatment much conflict inform web must care oncologist say studi recommend altern treatment advic far respond well treatment someth right hope win battl sure die exercis medit good us',\n",
       " 'recent studi relaps remit multipl sclerosi patient treat fingolimod natalizumab alemtuzumab found less like convert secondari progress ms spm compar treat interferon beta glatiram acet studi publish journal jama set determin associ use type time dmt risk convers spm one thousand five hundr fifti five rrm patient countri took part studi result reveal patient initi treat glatiram acet interferon beta lower hazard convers spm match untreat patient initi treatment fingolimod gilenya alemtuzumab lemtrada natalizumab tysabri associ lower risk convers initi treatment glatiram acet interferon beta probabl convers lower glatiram acet interferon beta start within five year diseas onset versu later glatiram acet interferon beta escal fingolimod alemtuzumab natalizumab within five year versu later hazard ratio current interferon beta glatiram acet first tier treatment rrm fingolimod second tier drug alemtuzumab natalizumab part top tier drug neurologist prescrib patient depend activ patient ms neurologist suggest drug suit lower tier drug success rate reduc relaps wherea higher tier drug alemtuzumab show reduc relaps versu placebo research conclud find consid along therapi risk may help inform decis diseas modifi therapi select',\n",
       " 'amaz drop cea number sound like opdivo work splendidli',\n",
       " 'rd infus opdivo predict tire bodi ach expect swell leg hand tight top hand small pocket fluid form hand actual sting burn night time extrem sleep guess neuropathi see doctor next thursday suggest get relief',\n",
       " 'hi everyon first post manag crohn diet low fodmap work great symptom control colonoscopi still show multipl ulcer doc worri one particular want start humira cimzia remicad conjunct azathioprin first month wonder anyon compar experi med scare tempt go remicad histori excit offic infus instead shot thank info j',\n",
       " 'hello coco sorri answer question detail sinc lay person without physician background far understood studi tri predict next mutat instead wait result patient trial abl scientif method complic comprehend guess quit reliabl found new mutat occur tagrisso therapi state posit allel ci tran impact effect tagrisso like singl agent combin older tki newest gener genet test might abl tell far know yet done routin pleas take grain salt profession realli know talk sorri limit inform find paper send link thank kempten',\n",
       " 'diagnosi adenocarcinoma lung major subtyp non small lung cancer nsclc nowaday trigger mandatori test tumor tissu alter four gene egfr alk ro recent braf present alter predict sensit specif target drug approv u food drug administr fda work better often longer standard chemotherapi better toler howev mani target action genom alter also known driver nsclc blog post briefli discuss goal promot molecular test four usual suspect mention patient alter may benefit fda approv drug enrol clinic trial test addit drug drug combin molecular alter nsclc fda approv treatment option egfr egfr mutat caucasian patient nsclc asian patient egfr mutat frequent non smoker mutat egfr either delet portion gene call exon mutat known l r exon two account egfr mutat rare mutat found exon four fda approv drug target egfr mutat erlotinib tarceva geftinib iressa afatinib gilotrif osimertinib tagrisso drug investig clinic trial mutat exon respond better afatinib erlotinib gefitinib alter exon may respond better osimertinib like drug current trial nazartinib egf poziotinib patient receiv egfr target drug almost inevit medic eventu stop work happen import conduct new mutat test determin mechan resist drug test perform biopsi resist lesion liquid biopsi via blood test sever known molecular alter lead resist go detail mani address use relev target drug alk gene alk involv chromosom transloc becom fuse anoth gene eml frequenc eml alk transloc nsclc much higher non smoker account mutat found non smoker crizotinib xalkori fda approv first line treatment tumor alk rearrang ceritinib alectinib brigatinib use treatment alk posit cancer develop resist prior treatment alk inhibitor lorlatinib may approv soon ro gene involv transloc nsclc case ro close relat alk crizotinib fda approv drug subtyp alk target drug alreadi approv alk subtyp ceritinib lorlatinib shown excel activ ro subtyp well entrectinib rdx pf also trial ro transloc nsclc braf mutat found nsclc case strongli associ smoke histori unlik three mutat v e predomin type braf mutat presenc tumor associ high rate respons combin dabrafenib tafinlar trametinib mekinist approv fda june molecular alter nsclc drug avail clinic trial met amplif high number copi met gene found newli diagnos nsclc case frequent alter drive resist egfr inhibitor egfr mutant cancer drug trial patient amplifi met crizotinib cabozantinib tivantinib glesatinib mgcd inc met exon skip particular form met alter metex result product potenti overact met protein encount nsclc case often older patient particularli characterist non smoker interest differ type lung cancer pulmonari sarcomatoid carcinoma harbor met exon skip case metex cancer also contain high number copi metex number drug might work metex posit tumor avail trial enrol includ crizotinib capmatinib tepotinib merestinib mutat egfr relat gene found case adenocarcinoma lung often asian patient mostli non smoker common mutat insert exon drug dacomimitinb neratinib pyrotinib test trial posit nsclc egfr target drug afatinib could also use subtyp ret gene alter nsclc case tend form pair rearrang one least five gene partner number drug cabozantinib vandetanib alectinib loxo blu rxdx test tumor clinic trial ntrk frequenc gene fusion transloc involv ntrk gene estim anywher nsclc case identifi mutat drug relev treatment subtyp entrectinib rxdx larotrectinib loxo avail trial alreadi shown good activ includ diseas metastas brain also relev trial investig drug like ds b tsr get test nsclc patient may target mutat egfr alk ro alter account provid strong rational test multipl mutat patient yet mandat nation comprehens cancer network nccn guidelin howev nccn strongli advis broader molecular profil goal identifi rare driver mutat effect drug may alreadi avail appropri counsel patient regard avail clinic trial numer provid offer mutat test test cover health insur plan discuss treat oncologist recent possibl get free mutat test cancer patient announc fifti hospit abl order test strata oncolog test specif nsclc cover mani rare mutat strata test process includ match patient potenti relev clinic trial rememb broad molecular profil key compon improv care patient nsclc nccn guidelin',\n",
       " 'offer opinion person experi use tecfidera well gilenya lemtrada rather comment attack advocaci lemtrada defi evid assum ms patient limit cognit skill instead believ blindli accept choic other may recommend treatment base differ prioriti chief among cost experi best judgement inform advoc research reput sourc ms societi ms trust ms associ america bart london jama neurolog publish clinic trial result among other lemtrada clinic trial result referenc show definit trial particip orlando friend diseas progress halt revers five year clinic trial result peer review document submit drug manufactur nation regulatori agenc approv ultim given around globe think pivot time ms research signific progress made breakthrough solut chang ms landscap treatment paradigm today best practic involv earli intervent efficaci dmt instead older practic treat patient increment stronger dmt begin less effect safer dmt theori believ respons stay inform seek care ms specialist stay current new innov',\n",
       " 'combin radiotherapi local system immunotherapi may clinic benefici treat type tumor urgent need howev develop clinic trial explor novel treatment regimen accord articl publish trend cancer novel immunotherapi enter clinic practic acceler rate clinician sure best combin radiotherapi local tumor radiotherapi shown abil enhanc respons immun checkpoint inhibitor similar ipilimumab nivolumab pembrolizumab toll like receptor agonist imiquimod includ agent yet approv investig human use sever pre clinic model cancer includ breast colorect brain melanoma lung prostat said lead studi author sandra demaria md professor radiat oncolog patholog weill cornel medicin new york new york said earli data show benefit combin radiotherapi immunotherapi patient melanoma non small cell lung cancer nsclc lymphoid malign dr clinic trial ongo cancer type well produc rather encourag result preliminari report respons seen combin radiat anti pd tumor type respons anti pd alon signific patient ovarian cancer small intestin adenocarcinoma data suggest use radiat patient immunotherapi appear gener safe benefit patient beyond local control tumor treat physician evalu patient abscop respons data need combin treatment recommend standard care dr demaria told cancer therapi advisor use radiat purpos gener anti tumor immun respons need better understand mechan involv dr demaria said mani unansw question whether greater immun respons trigger high low dose radiat given sever time differ tumor respond differ vari fraction regimen unfortun clinic studi radiat given base physician prefer standard care use palliat may produc desir effect said dr demaria need work think critic design clinic studi multidisciplinari topic base novel partnership among immunologist immunotherapist radiat oncologist accord dr demaria process uniqu radiat cancer treatment chemotherapi target therapi use patient receiv immunotherapi clinician still know treatment interact relat new drug combin may benefici newli diagnos myeloma patient raquibul hannan md phd assist professor radiat oncolog univers texa ut southwestern dalla said synergist approach radiat immunotherapi promis excit appli particularli stereotact abl radiotherapi sabr stereotact bodi radiat therapi sbrt call approach strateg combin sabr immunotherapi sabr ongo clinic trial nct nct design answer question cancer site immunotherapi respons strategi dr hannan told cancer therapi advisor multipl new immunotherapi chang standard care melanoma lung head neck bladder renal cancer benefit howev may limit malign dr hannan said mani site evalu determin even minim respons immunotherapi radiotherapi combin wherev respons possibl radiat therapi boost respons respons opportun radiat initi respons due fact radiat initi tumor specif respons tumor specif lack checkpoint inhibitor immunotherapi said dr hannan clinic trial identifi site respons sabr strategi opinion melanoma rcc first certainli site strategi prove synergist refer demaria coleman cn formenti sc radiotherapi chang game immunotherapi cancer cell',\n",
       " 'two step forward one huge step back sorri length time updat lot happen husband first treatment privat avastin inject notic improv week afterward enough get feet start walk last week see famili depress start lift bg level right insulin half stone healthi bmi could afford one round treatment privat transfer nh first appoint yesterday consult clinic seen dr consult absolut nightmar start finish despit warn husband anxieti issu fragil mental state dr complet insensit quit aggress approach realis cannot sugar coat thing tact way discuss prognosi even though husband seen improv first inject dr seem quit dismiss would see much improv understand guarante even consult cannot predict repond effect treatment came crush blow husband retreat bed want talk diagnosi non prolif retinopathi left eye sever prolif retinopathi right sever maculopathi eye right impair eye worst treatment plan eylea inject laser right begin intend speak pal monday see anyway see sympathet clinician next time honestli think husband could go struggl get wish could afford go whole thing privat anyon els similar experi',\n",
       " 'two scan get complet diagnosi though effus automat make stage iv know cancer load start tx prefer onc know health issu ad treatment decis age factor definit get anoth opinion good news alimta continu work need take care judi stage iiia adeno dx sr chemo carbo alimta x ned local recurr surgeri remov lrl cm involv pleura chemo carbo alimta x ned',\n",
       " 'repli post han one flare sent er mesalamin mainten still need prevent medicin gener either mp imuran first line move biolog like humira remicad sound like imuran work two med seen overkil see mayb tri mp next step understand imuran deriv like much differ good luck one way',\n",
       " 'littl two full year sinc offici diagnos multipl sclerosi decemb content entir blog summat struggl accept even understand inform actual meant serv kind proof crazi shit actual realli happen let face two rather shitti year got diagnosi began go downhil made wonder mere function know somehow made bodi kick disabl mode like ignor friend enlighten bodi throw diseas parti entir central nervou system invit limb useless fatigu made live zombi learn first time life real anxieti feel like chang complet differ person almost night stop recogn look mirror stop go night almost entir hard life decemb becam fuck hard guy alreadi know import understand mental affect diseas unleash understand last week felt downright amaz formerli outgo see seen beth girl could handl anyth turn home bound never want seen beth live mortal fear somehow abl think let alon walk sometim physic thing time physic thing ignor entir mental side happen tri fail look bright side swung back forth dire despair insan denial cheryl therapist keep reassur believ would get better pain start get back feet great relaps summer call mind like titl movi tri get back kind routin life get offic least day week tri function tri tri harder middl start feel intens fire bodi never felt anyth like think fairli high toler pain someth differ would feel creep spine around pm sit desk would begin feel desper know head knew could reli sandi bff also happen work help get car get hous daili cat chore get bed mere physic effort took get hous anoth locat render basic useless bodi riddl fire got fanci new ergonom chair amazingli comfort help newfound pain drag home drag bunch stair lay bed tear entir bodi fire base skull bottom feet fingertip eat mg ibruprofen everi four hour way much help even littl bit start think next day like go becom pretti consist sometim woke morn pain alreadi full forc start feel desper live kind normal life led kind pain begin panic could pretti well act normal real world great pretend toy idea ask great scott someth could take pain minut thought cross mind shudder drug word echo head cannot take singl addit prescript medic mean point diminish return right take mani med list probabl hard time believ also pain medic scare definit type person would inclin abus medic like one pill help bet two pill help much know good idea start feel pretti dark think could probabl tell post throughout tri keep humor alway remind peopl much wors grate everi minut everi day think true thing realli help much know peopl suffer make pain go away pain physic menac presenc like fire burn insid skin nobodi see feel like might consum help friend made onlin suggest consid tri cannabi pain mean read research ton possibl truli believ merit alreadi use homemad cannabi edibl help sleep night never reveal get suffic say person make liter angel earth one small detail get around cannabi legal pennsylvania know process legal medic cannabi process take lot time heard bit hard get card need becom patient get suppli limit number dispensari oh also might suspect great scott ms specialist medic mmj across board shocker struggl factual legal hurdl fact proven year life freak hate weed hate make feel hate smell hate smoke anyth except short spurt menthol ultra light thirti drink face five night week fun found weed basic repel terribl effect use thing husband aliv smoke pot everi day life knew hate ethic moral reason simpli fact soon took one hit joint instantli becam repel rememb tell know call shit dope reason gross would laugh laugh digress suffic say marijuana friend realli see becom fundament part life watch much help ms er friend meg particular inspir watch joy face chronicl daili walk instagram note new found joy walk someth fear lost forev anymor meg credit cannabi give life back read meg blog know much medic mmj ms could ever share check smile meg face make realli happi haunt time want smile want smile without smile feel like intern grimac rememb tell ms friend wish could get benefit relief without high instant um guess total stop admit entir comfort write told mani non ms friend make feel funni even though someth complet legal non psychoact still bother broken news mom member famili told closest friend one trust sure feel like dirti littl secret use cbd reliev pain hard admit write start realli chang best way start whole explor look relief pain inde found relief got lot let start begin start cbd oil cw hemp colorado seen stori guy cb sunday morn year ago link excerpt cnn documentari tell stori charlott kid seizur week stori heartbreak interest happi end cbd oil made stanley brother colorado chang charlott life henc name compani honor worth squirt pricey nasti tast oil tongu time day see could help pain took come half hour take oil felt pain get quiet disappear immedi got better start everyday product strong enough progress quickli everyday advanc much better better enough dive research discov kind pain degre sever ingest cbd oil effect way get cannabidiol blood stream time oil ingest process digest system liver etc someth like cbd fudg number bit reduct concentr distinct find anoth way get cannabidiol system without use oil mechan cannabidiol concentr would higher led anoth legal product call cbd shatter shatter crumbl clear solid break littl piec get cbd blood stream directli get vape pen use anoth hurdl know short stint smoker thirti suck liter hate smoke anyth know vape technic smoke feel essenti inhal vapor come heat cbd shatter vape pen look much like dab weed concentr devoid thc psychotrop effect realli skeptic turn get high super reliev found anoth form even highli concentr cbd form wax thing share info anyon want messag email want obvious doctor expert anyth relat cbd vape tell felt happi first time month past week thought take pain medic kind month buy advil liqui gel bulk anymor even better effect new practic constant churn head fear noth ever constant if fli around head quit liter hour day even find way dream ever present sometim crippl anxieti futur could hold quiet quiet anxieti voic still know probabl never go away complet mean diseas chronic degen kind deal especi one unpredict ms liter thing chang day day even minut minut yoke hang around unstylish neck difficult busi thing make voic quiet elud complet therapi expert ask cheryl cbd vape help help lot hate still feel wrong even though know hate tast peopl actual love go figur three four time day help maintain calm quiet mind help keep fire bodi bay even help loosen ridicul spastic muscl prevent move around natur way help nearli everyth dirti littl secret realli dirti wish knew judgey mostli mayb cheryl cure day tri learn accept thing ye discuss entir develop great scott alreadi steel medic debat sure ensu thing mac daddi ms drug right ocrevu life chang experi told would meh someth els help want open eye everi day mayb leav hous bit embrac damn cane sorri stanley perhap shower littl often research find littl side vape cbd experienc exactli zero side effect none might work forev go enjoy last go deal fact realli carri around might legal look legal pain free sever hour interv hell take feel like littl tree pictur lot time tri keep thing light airi often feel light airi make joke brush bad feel dark alon much time even surround peopl love near far littl ray light seep welcom even suck lung eat rock right someon told make feel better bet',\n",
       " 'septemb roch face fresh row drug price britain follow decis bodi respons medicin use within state health servic approv drug ocrevu treat highli disabl form multipl sclerosi june nation institut health care excel endors ocrevu relaps remit ms common type diseas reject rarer sever primari progress form ms ocrevu avail treatment primari progress ms sever drug relaps remit ms roch uk gener manag richard erwin said monday decis devast news patient read reuter articl',\n",
       " 'love hear great respons begin opdivo septemb th hope lucki thank',\n",
       " 'let neuro respons privat prescript india peopl affect ms access ms drug howev prescrib label neurologist mayb frighten pharma look favour importanli like follow prescrib pattern set licenc drug licenc give comfort adher best practis interest iran manufactur drug licenc make beta interferon appar heard concret proof treat hearsay make dmf fingolimod patent peopl go embargo mayb embargo impos creat cultur howev believ made movectro say stop manufactur programm licenc licenc gener cladribin one countri would help other quest white knight intent obtain licenc peopl comfort folow accept proceedur may give protect su anyth goe wrong howev throughout attempt amaz peopl power help us along path never want mention correspond never saw academ exercis anyway let see happen movectro get lisenc seen tomorrow post compar oral vers non oral rout',\n",
       " 'recent diagnos ms first ms attack probabl time mri reveal one lesion follow mri month later show chang told noth wrong year similar attack mainli loss sensat leg past year happen closer togeth seem much wors durat intens mri februari reveal extens amount lesion first appoint neurologist appoint said highli like ms would want aggress treatment appear quit advanc feel though necessari complet lumbar punctur everyth indic ms point took lot blood gave intens cours steroid mg prednisolon day ask return actual left appoint quit upset confirm ms jcv result come back could discuss realli cover anyth mention type ms assum rrm mention activ lesion seem talk differ matter know current symptom pain nerv pain constantli feel like thing crawl horribl fatigu leg weak tingli numb walk realli difficult headach horribl pretti much said sinc steroid work noth realli case brief sever medic done pretti much said none good strong enough choic gilenya tysabri lemtrada decid want gilenya option start ask question option told anoth patient would come back three week seem lean tysabri realli tell mention one drug ocrelizumab approv yet expect releas come month seem want put tysabri possibl switch one could tell anyth new drug studi releas yet discuss confus concern need aggress treatment will continu push appoint back back lean lemtrada appear period week decid treatment begin even choos next appoint week actual start treatment anyon recommend idea two drug even decid someth like',\n",
       " 'hi spider know ocrevu know fantast happi chang sx good bad',\n",
       " 'thank brad wow gilenya long time glad hear problem hope pump help spastic',\n",
       " 'hi kim sorri know ariel progress good evid cancer form lepto cure wait see essenti wait return problem wait saw symptom show quickli alway tamp imagin radiat area would difficult imposs safe nd time say start tagrisso stop side effect toxic oncologist rightli worri may miss opportun benefit tagrisso ultim ariel wish could give direct answer hope ariel well best janin',\n",
       " 'purpos studi http www mskcc org cancer care clini al assess safeti combin two drug varlilumab nivolumab patient advanc solid tumor continu grow despit treatment varlilumab investig drug bind protein immun cell call cd make immun system stronger nivolumab form immunotherapi work attach block molecul call pd shut immun respons hope bind protein drug combin activ immun system enhanc bodi abil detect destroy cancer cell',\n",
       " 'hi veg sure latest edit mine publish short section discuss fingolimod new promis drug much els convers nurs threw whole host possibl side effect realli hope hear peopl first hand experi rachel',\n",
       " 'tonometri test measur pressur eye call intraocular pressur doctor use check glaucoma slit lamp examin physician optometrist shine vertic slit light across eye look microscop help find mani eye problem fundoscop exam doctor give special eye drop widen pupil call dilat shine bright light back eye see retina refract vision problem doctor place seri lens front eye one time figur prescript correct lens visual acuiti test read seri ever smaller letter across room help doctor spot distanc vision problem read close help find problem near vision fluorescein angiographi doctor inject fluoresc dye vein take seri retin imag regular adult eye exam collect test may includ one mention plu other like eye movement eye treatment contact lens glass correct common eye problem like nearsighted farsighted astigmat lasik laser assist situ keratomileusi doctor creat thin flap cornea use laser reshap procedur improv nearsighted excess farsighted astigmat radial keratotomi rk doctor make seri small incis cornea reshap common treatment nearsighted rare use today photorefract keratectomi prk doctor rub surfac cell cornea use laser improv nearsighted farsighted astigmat cell grow back eye heal way would scratch lasek laser epitheli keratomileusi similar prk doctor peel back upper layer cornea cell use later reshap may replac remov flap afterward artifici tear eye drop lot like natur tear help treat dri irrit eye cyclosporin eye drop restasi anti inflammatori eye drop treat dri eye caus inflamm laser photocoagul doctor use laser part retina poor circul treat abnorm blood vessel directli often use diabet retinopathi also seal retin tear cataract surgeri doctor remov cloudi cataract replac natur len man made version',\n",
       " 'effect ocrelizumab reduc brain atrophi take co binat effect stop diseas right also bart say mechan term ppm combin therapi effect make ms benign diseas type',\n",
       " 'curiou know would consid tamoxifen women ocrevu famili histori breast cancer',\n",
       " 'ye initi keytruda month scan mix result follow scan show progress realli find much info keytruda docetaxel onlin mom thought trial next appoint also take blood send see mutat finger cross hope combo show improv best marci',\n",
       " 'start gilenya week ago dishow morn day must taken mistak flare sinc first week still ongo progress suffer alot pain time anyway know bad effect doubl dose kinda worri',\n",
       " 'helli realis answer half question think cladribin might cure peopl mayb sens cladribin seem stop deterior someth like half peopl see improv well think cladribin lemtrada lot cheaper drug take rest life effect drug compani want close huge market tecifidera tysabri gilenya etc etc probabl think cladribin better drug lemtrada effect less side effect cladribin may good drug compani want',\n",
       " 'caddo tumor test mutat possibl could qualifi target therapi drug instead tradit chemo nonsmal cell lung cancer get opdivo immunotherapi work everyon kept cancer stabl year tradit chemo carboplatin avastin alimta',\n",
       " 'drug fail effect strike larger target lung cancer hit bull eye smaller target present previous untreat form diseas research univers texa md anderson cancer center report natur medicin research provid scientif underpin clinic trial way drug poziotinib non small cell lung cancer specif alter call exon insert either epiderm growth factor receptor egfr human epiderm growth factor receptor effect treatment patient encourag earli clinic trial result show patient percent egfr exon mutat confirm tumor shrinkag poziotinib treatment say john heymach professor chair thorac head neck medic oncolog need see unpreced respons rate maintain remaind trial scientif find provid basi optim far patient enrol md anderson origin phase ii trial egfr enrol arm drug owner spectrum pharmaceut open multi center phase ii trial approv target therapi egfr mutat improv progress free surviv pf qualiti life patient seen respons rate rang percent among patient exon insert median pf patient two month far md anderson clinic trial median pf reach month percent patient either egfr diseas exon insert amount peopl diagnos annual unit state heymach also note patient exon insert never smoke deep dive exon heymach team start focu exon part drug repurpos pipelin open md anderson moon shot program collabor effort acceler develop scientif discoveri life save advanc week identifi problem focu upon lung moon shot three four exon patient noth offer point heymach said clinic tell us need decid deep dive exon postdoctor fellow jacqulyn robichaux ph colleagu test differ target therapi lung cancer cell line exon insert egfr found cell strongli resist drug work shux zhang pharmd ph associ professor experiment therapeut team conduct model known crystal structur egfr found exon insert dramat effect protein bind pocket drug connect block activ smaller misshapen pocket pose barrier target therapi also suggest structur characterist might make drug effect smaller better robichaux say team hypothes smaller egfr inhibitor high level halogen presenc group molecul help bind drug target receptor might greater activ exon diseas drew poziotinib egfr inhibitor fail common egfr mutat clinic trial structur poziotinib publish show small highli halogen test panel cell robichaux said resist test show poziotinib time potent cell drug compar specif poziotinib three target therapi exon mutat common target hit drug exon mutat time sensit poziotinib resist three drug structur analysi show poziotinib size flexibl allow fit deepli exon bind pocket larger drug either fit lack structur deep connect tumor shrink mous model team test drug mous model exon diseas compar afatinib second gener target therapi shown abil inhibit diseas cell line egfr mice treat poziotinib percent reduct diseas burden measur mri treat afatinib percent increas level almost equal untreat control exon mice percent reduct tumor burden compar percent reduct afatinib separ studi egfr poziotinib respons durabl week team test poziotinib mice egfr tumor develop patient poziotinib treat mice tumor burden reduc half treat afatinib reduct second studi mice anoth patient deriv egfr exon tumor poziotinib reduc tumor percent eight nine mice day possibl applic cancer heymach team contact spectrum pharmaceut find compani heymach group cooper provid poziotinib patient compassion use basi prepar launch md anderson clinic trial updat clinic trial result report detail later heymach robichaux colleagu studi resist mechan poziotinib develop way overcom resist egfr exon insert occur cancer lung cancer robichaux said investig whether type also might sensit poziotinib md anderson develop intellectu properti relat use poziotinib treatment exon insert cancer co author heymach robichaux zhang yasir elamin alissa poteet moniqu nilsson ph huiy sun emili roarti ph memet altan charl lu vassiliki papadimitrakopoul thorac head neck medic oncolog zhi tan experiment therapeut brett carter radiolog shengwu liu ph shuai li ting chen ph dana farber cancer institut boston adriana estrada berna ph anh le robert doebel ph univers colorado cancer center aurora co anna truini sarah goldberg katerina politi ph yale cancer center yale univers school medicin juli brahmer sidney kimmel comprehens cancer center john hopkin univers baltimor kwok kin wong ph laura isaac perlmutt cancer center new york univers addit initi moon shot fund research also support grant nation cancer institut p ca ro ca includ md anderson lung cancer spore grant p ca md anderson cancer center support grant p ca lung cancer research fund rexanna foundat fight lung cancer exon group david bruton jr chair tumor biolog stade fund egfr inhibitor resist mr mr william p hallman fund fox lung egfr inhibitor fund christin burg endow lung cancer research univers colorado cancer center burg famili miramount care foundat italian associ cancer research cancer prevent research institut texa nation scienc foundat nation institut gener medic scienc spectrum pharmaceut support clinic studi',\n",
       " 'diagnos stage lung cancer juli put afatinb juli drug resist appear apr x rt nodul may hope afatinib long posibl unfortun pleural effus start increas sinc end june stop afatinib put chemo carboplatin alimta sep tagrisso given free charg compassion scheme chemo quit even though work cea drop sep oct sep l pleural effus pe drain x ray show lung could expand origin posit onc ask tri practic breath exercis home anoth x ray today show help empti space occupi fluid problem pe caus cough month onc told live rest life said far awar treatment method expand lung consult lung specilist earli oct opini n trap lung due tumor entangl lung membran ask patient wait effect tagrisso pen trate lung expand oct l pleural effus pe drain sign expansi n found fact situat deterior need use oxygen concentr home grate advic problem overcom mani thank advanc',\n",
       " 'pastglori ask stop gilenya switch tysabri relaps washout',\n",
       " 'expert think fail tradit therapi get trial went citi hope ca lobectomi got tarceva trial without chemo first back',\n",
       " 'alway good trump card sleev ask card save joker end today qualiti life given treatment either work regardless use pretti much new uc medicin research biolog mani new novel one work therefor worri run option remi work well sinc suddenli fail still humira simponi entyvio xeljanz soon stelara option choos certainli consid point view decid whatev think best',\n",
       " 'stumbler thank alway mind whether choos tecfidera instead possibl side effect seem harsh main two concern fingolimod',\n",
       " 'well long one expect wait diet work month year show symptom improv work think month fair give mesalamin remicad show least improv discontinu vari respons realli make believ uc umbrella diseas simular symptom perhap us intoler specif food inturn aggrav symptom post edit ipoop pm gmt',\n",
       " 'hi adam read messag like tecfedira also problem left leg foot drop walk get wors offer ocrevu last day need get final approv accept desper tri anyth improv accept go berti',\n",
       " 'brand name tecentriq medicin prescrib atezolizumab inject use treat certain type urotheli cancer cancer line bladder part urinari tract spread cannot remov surgeri peopl unabl receiv platinum contain chemotherapi carboplatin cisplatin worsen treatment platinum contain chemotherapi medic also use treat certain type lung cancer non small cell lung cancer nsclc spread part bodi worsen treatment chemotherapi medic atezolizumab inject class medic call monoclon antibodi work block action certain protein cancer cell help person immun system fight cancer cell help slow tumor growth use medicin medic may prescrib use ask doctor pharmacist inform medicin use atezolizumab inject come liquid inject vein minut doctor nurs hospit medic facil usual inject everi week length treatment depend well bodi respond medic side effect experi atezolizumab inject may caus seriou reaction infus medic doctor nurs monitor care receiv medic experi follow symptom tell doctor immedi flush fever chill shake dizzi feel faint short breath difficulti breath itch rash back neck pain swell face doctor may need slow infus delay stop treatment treat medic experi certain side effect sure tell doctor feel treatment atezolizumab doctor pharmacist give manufactur patient inform sheet medic guid begin treatment atezolizumab inject time receiv medic read inform care ask doctor pharmacist question also visit food drug administr fda websit [web] manufactur websit obtain medic guid special precaut follow take atezolizumab inject tell doctor pharmacist allerg atezolizumab medic ingredi atezolizumab inject ask pharmacist check medic guid list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take doctor may need chang dose medic monitor care side effect tell doctor treat infect also tell doctor ever organ transplant lung breath problem diseas affect nervou system myasthenia gravi disord nervou system caus muscl weak guillain barr syndrom weak tingl possibl paralysi due sudden nerv damag autoimmun diseas condit immun system attack healthi part bodi crohn diseas condit immun system attack line digest tract caus pain diarrhea weight loss fever ulcer coliti condit caus swell sore line colon [larg intestine] rectum lupu condit immun system attack mani tissu organ includ skin joint blood kidney liver diseas tell doctor pregnant plan becom pregnant becom pregnant treatment month last dose talk doctor birth control method use treatment becom pregnant take atezolizumab inject call doctor immedi tell doctor breastfeed doctor may tell breastfe treatment month last dose special dietari instruct follow unless doctor tell otherwis continu normal diet side effect medicin caus atezolizumab inject may caus side effect tell doctor symptom sever go away back neck joint pain rash itch troubl fall asleep stay asleep extrem tired pale skin feel cold swell arm loss appetit nausea vomit diarrhea constip hair loss deepen voic hoars weight gain side effect seriou experi symptom call doctor immedi get emerg medic treatment diarrhea abdomin pain bloodi black tarri sticki stool ongo pain begin upper left middl stomach may spread back fever nausea vomit constip stomach bloat swell fever sore throat cough chill flu like symptom frequent urgent difficult pain urin sign infect pink red dark brown urin decreas urin swell leg ankl feet warm red swollen tender leg new worsen cough short breath chest pain cough may bloodi short breath chest pain yellow skin eye extrem tired bleed bruis easili nausea vomit abdomin pain dark color urin decreas appetit headach go away unusu headach increas thirst urin vision chang decreas sex drive fast heartbeat increas appetit sudden weight loss feel hot mood chang muscl weak numb tingl hand feet arm leg fever confus chang mood behavior sensit light neck stiff blurri doubl vision vision problem eye pain red dizzi feel faint feel hungri thirsti usual increas urin extrem tired weak breath smell fruiti chang mood behavior decreas sex drive irrit confus forget chest pain short breath irregular heartbeat swell ankl abl exercis like use atezolizumab inject may caus side effect call doctor unusu problem take medic experi seriou side effect doctor may send report food drug administr fda medwatch advers event report program onlin [web] phone case overdos case overdos call poison control helplin inform also avail onlin [web] victim collaps seizur troubl breath awaken immedi call emerg servic inform know keep appoint doctor laboratori doctor order certain lab test treatment atezolizumab inject check bodi respons medic import keep written list prescript nonprescript counter medicin take well product vitamin miner dietari supplement bring list time visit doctor admit hospit also import inform carri case emerg report medic inform consid individu patient advic chang natur drug inform pleas consult physician pharmacist specif clinic use american societi health system pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field american societi health system pharmacist inc make represent warranti express impli includ limit impli warranti merchant fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos entir monograph drug review thorough understand drug action use side effect american societi health system pharmacist inc endors recommend use drug inform substitut medic care ahf patient medic inform copyright american societi health system pharmacist east west highway suit bethesda maryland right reserv duplic commerci use must author ashp',\n",
       " 'hi told ocrelizumab avail australia cours ms sever ms year affect primarili hand cogn badder drive etc leg ok still quit mobil activ creep numb especi hand suggest spm rrm liver toler gilenya well stop year tysabri month swap stage ocrelizumab period jv ocrelizumab possibl affect spm ppm add biotin month definit notic posit affect biotin appear first drug asid biotin effect progress form ms http www medpagetoday com meetingc n g r',\n",
       " 'alemtuzumab deplet b cell would effect rituximab ocrelizumab ppm either mean alemtuzumab deplet b cell someth els go understand ignor discuss',\n",
       " 'good luck trip home seven hour ride felt like odyssey diagnos ulcer coliti remiss lialda prednison respons entyvio remicad azathioprin opt three step j pouch surgeri complet step one subtot colectomi ileostomi may complet step two protocolectomi ileal pouch anal anastomosi loop ileostomi januari',\n",
       " ...]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## print the training corpus\n",
    "corpus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1248.4868346277703\n"
     ]
    }
   ],
   "source": [
    "len1 = 0\n",
    "for i in corpus:\n",
    "    len1 = len1 + len(i)\n",
    "print(len1/5279)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "%matplotlib inline \n",
    "plt.style.use(\"ggplot\")\n",
    "plt.hist([len(s) for s in corpus], bins=50) \n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Clearning the testing data\n",
    "corpus_test = []\n",
    "for i in range(0, 2924):\n",
    "    data_test[\"text\"][0]\n",
    "    text = re.sub('[^a-zA-z]', \" \", data_test[\"text\"][i])\n",
    "    text = text.lower()\n",
    "    text = text.split()\n",
    "    ps = PorterStemmer()\n",
    "    text = [ps.stem(word) for word in text if not word in set(stopwords.words(\"english\"))]\n",
    "    text = \" \".join(text)\n",
    "    corpus_test.append(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['previous stabl natalizumab switch fingolimod',\n",
       " 'fingolimod sinc decemb way describ better like feel drunk without drink',\n",
       " 'appar shingl red spot left breast appear day ago sure connect show gp immedi said shingl appar co left day late prescrib anyth shingl gp prescrib useless amitryptilin probabl take even low dose make unbear groggi still entir happi co stomach pain bad lot bloat stuff fever far know anyon experi shingl seem like expect week _ dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'docetaxel week x week week claim less harsh efficaci everi week diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'cc stelara work matter day gi will jump hoop get probabl worth consid one anti tnf stop work anoth pm ulcer coliti next surgeri schedul problem skin loop ad setup pm ulcer coliti next surgeri schedul familiar hollist probabl go first cut hole stoma go place directli skin protect leak stay skin pm ulcer coliti humira remicad cimzia simponi anti tnf shot base upon weight xeljanz also weight base stelara weightbas remicad well studi drug ulcer coliti unexpect scope result j pouch buckey think appoint gi go know issu complex mine see post anyth ulcer coliti next surgeri schedul congratul recommend get convex wafer new ostomi realli help liquid output probabl know loop ileo time littl pm ulcer coliti remicad infus get test remicad antibodi symptom serum sick ignor mine got wors start drop thing memori loss bone joint pain pm ulcer coliti super donor phenomenon fecal microbiota transplant segment cbc radio quirk quark show http www cbc ca radio quirk poop creat equal super pooper could life saver test ulcer coliti saw gi recommend xeljanz scare start thread check box includ signatur see med thought ad entyvio either prednison entocort blood test ulcer coliti saw gi recommend xeljanz scare anti tnf med like remicad anyth list signatur use rectal med steroid pm ulcer coliti recent taken friend heard take month jpouch fulli adjust pm ulcer coliti still experienc issu cuffiti song ladi ga diarrhea also caus sibo easi test taken test previous also home test sibo happen jpoucher certain antibiot pm ulcer coliti still experienc issu cuffiti sl doctor say pouchiti chronic person tri med tri knock accept diagnosi get much ga unless treat',\n",
       " 'janssen biotech inc receiv fda approv new biolog stelara treatment crohn',\n",
       " 'thought thing would better one year ms talk husband last night live louisiana teacher love summer anymor depress everyon go lake suntan freak ghostli vampir also fail first month jcv blood work treatment neurologist move ocrevu transfus made sick way find info except cancer warn love write ladi keep nicol',\n",
       " 'dec basha fowler diagnos rd week dec egfr ive non small cell lung cancer stage iv tumor top lobe left lung metastas pleural line pleural caviti thank god spread organ brain oncologist devis target therapi tagrisso start treatment next day still roller coaster emot utter panic lost job nov accept offer full reloc dec state compani overshadow new health challeng sole breadwinn realli know famili get lung cancer survivor could share stori would love connect health life',\n",
       " 'hi start gilenya week ago woeful anxieti time period realli embarrass make feel like loser anxieti free long wonder gilenya could caus stop contracept pill know caus issu kind thank advanc repli',\n",
       " 'uncl still go treatment kind chemo keytruda realli kick butt today birthday hour treatment seem help angri stage realli blame anyth energi lost weight hair head thank vomit treatment round next treatment month mark plan anoth scan see treatment anyth anyon experi success combin stess depress see way normal activ social great sens humor hard aunt primari caregiv get brunt anger wonder next treatment done keep hope pray miracl qualiti life time hard watch feel way',\n",
       " 'daughter stage adenocarcinoma nsclc ro dx decemb standard chemo xalkori gave posit result dr want tri opdivo even though test neg pdl result mass tripl dr return chemo carboplatin alimta alimta mainten month dr recommend new combin unusu growth around previous radiat spot lung sure combin growth identifi evid next cours treatment given histori result unknown caus smear ct scan',\n",
       " 'hi nt toxic would probabl main object combin instanc chemo regimen tougher other though clear data show benefit combin treatment individu case may differ stori certainli possibl portion cancer respond one treatment one factor note increas size pleural effus usual consid strong evid progress warrant chang treatment realli come extent progress lymph node whether signific enough stop tarceva also although major respons chemo seen first two cycl one cycl two week may earli make accur assess efficaci chemo jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'thank jim thank janin kidney failur actual occur sixth infus alimta understand quit rare side effect alimta doubt prescrib know option tell would mostli requir dialysi read peopl last lot longer month tagrisso though hope one better believ worri thank jacki',\n",
       " 'hey ipoop tri click link work went websit click link work bit odd page link full document thepowerofpoop com brigg protocol dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'bad lifetim near sighted os led macular degener left eye went inject avastin year th eylea time warp distort improv greatli dark grey spot obscur central vision improv gotten wors half shot endur sear pain hour later mean terribl agon writh pain imagin direct shot ghost pepper spray would feel like wear pirat patch extrem light sensit ice help tini bit short time gobbl whatev gener pain med find leftov medicin cabinet hydrocon vicodin etc help much amount risk seem frequenc pain inject worsen sympathet ophthalmologist believ sensit antisept iodin insist necessari make point talk everi session rins rins three time normal rins cannot realli find secret sometim annoy ach hour sometim excruci ordeal hour look opinion fellow suffer anyon els doctor figur agoni go save eye endur suffer postpon lose eye year',\n",
       " 'janin ever heard kra mutat mutat someth anoth kra mutat friend alk facebook group think peopl group origin kra driver becom egfr alk posit could mistaken thank cathi dx stage iv adeno dec kra g pdl tumor sampl st line carboplatin alimta alimta mainten work well nd line keytruda work rd line imrt lung radiat gy current watch wait',\n",
       " 'import metric brain volum loss brain integr follow studi found fingolimod affect widespread diffus microgli activ nawm gm microglia nawm gm go stay activ forev previou damag lesion site constant neda may lead de activ use microgli activ nawm gm measur ms activ',\n",
       " 'hello guy hope well know post topic excus wrong place got bad relaps week ago hospit numb arm leg exact ran examin mri other told risk develop epilepsi came blue never heard thing realt ms never life epilept symptom anyth alik gilenya found new leisur well prescrib anoth drug prevent epilepsi make sleepi dizzi night similar problem confus right trust doctor cours mayb look comfort wish best',\n",
       " 'hi first scan take tagrisso week scan show mix result slight progress primari tumor nodul slight increas fluid build nodul also shrunk doctor suggest continu tagrisso anoth month sinc old scan use comparison done still tarceva three week start tagrisso told best option next treatment would chemo carbo pemetrex avastin consid option sinc read studi avastin proven treat brain metastasi specif mutat chemo would work effect far test posit read studi depend test result detect c cancer cell would resist third line tki sensit first third line tki http clincancerr aacrjourn org content long anyon inform detect c combin tki would appreci thought thank sunday',\n",
       " 'nice turn daclizumab mser nh newsspeak politicalspeak msblog nice publish apprais consult document daclizumab recommend nh within market authoris treat relaps form multipl sclerosi adult depress news interest mser england would expect daclizumab wide prescrib definit unmet need use well defin cohort patient said mani time daclizumab overtli immunosuppress therefor ideal switch drug patient high risk pml natalizumab also signific number patient highli activ diseas fail platform therapi fingolimod contraind would benefit daclizumab patient littl option treat alemtuzumab alemtuzumab failur nh england allow us give third fourth cours alemtuzumab rel larg popul patient even argu past patient highli activ diseas rapidli evolv sever ms jcv posit may choos daclizumab alemtuzumab first line daclizumab attribut make appeal patient alemtuzumab e self administ immunosuppress sincer hope biogen abbvi appeal decis wider ms commun let nice know disagre assess end day choic make implement personalis medicin ms realiti abl prescrib one licens ms therapi simpli disadvantag peopl ms live england cynic howev think nice simpli ask big discount price daclizumab nh rel list price game cat mous well tri test one reason nh get high cost drug cheaper develop countri countri put place version nice coi multipl',\n",
       " 'overthink ask see accept first say ye discuss like go would suit want talk crohn listen mention honest ditto unsympathet ex dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'thank clo dunno much longer go like excruci pain hour codein touch upper left pain hard describ stab gnaw say like someth chew away insid skin area ultra tender sensit got book anoth onlin appoint gp today one time neck anoth load paracetamol codein time ibuprofen drink cup tea think pain slowli get better ever sinc utter nonsens start alway much wors night pretti easi bear daytim past point depress hollow tired drug eyebal although feel particularli sedat debilit pain tri ici wrap yet gonna get pharmaci later buy whatev stuff pain sparkleplenti late antivir day ago almost certain late ask gp anyway also next entyvio infus th april month away judg last night gonna readi month',\n",
       " 'neurolog jul e e abstract read full text paper diseas modifi drug boyko boyko ov cladribin tablet potenti role key exampl select immun reconstitut therapi multipl sclerosi degen neurol neuromuscul di may abstract read full text paper sedal l winkel la j et al current concept multipl sclerosi therapi degen neurol neuromuscul di sep abstract read full text paper hendin b naismith rt wray se et al treatment satisfact significantli improv patient multipl sclerosi switch interferon beta therapi peginterferon beta everi week patient prefer adher jul abstract read full text paper sacc f lanzillo r signori et al determin therapi switch multipl sclerosi treatment na patient real life studi mult scler jul [epub ahead print] abstract metz c winkelmann loebermann et al immunogen predictor respons singl dose trival season influenza vaccin multipl sclerosi patient receiv diseas modifi therapi cn neurosci ther jul [epub ahead print] abstract houtchen mk bove r case gender base approach multipl sclerosi therapeut front neuroendocrinol jul pii [epub ahead print] abstract setayeshgar kingwel e zhu f et al use new oral diseas modifi therapi multipl sclerosi british columbia canada first five year mult scler relat disord jul [epub ahead print] abstract cascion tenenbaum n wendt j et al treatment retent fingolimod compar inject multipl sclerosi therapi african american patient subgroup analysi random phase studi mult scler relat disord jul [epub ahead print] abstract read full text paper zhang salter cutter g et al clinic trial multipl sclerosi mileston ther adv neurol disord jul abstract read full text paper romeo mal martinelli v dalla costa g et al assess role innov therapeut paradigm multipl sclerosi treatment respons acta neurol scand jul [epub ahead print] abstract mirabella prosperini l lucchini et al safeti efficaci dimethyl fumar multipl sclerosi italian multicent real world studi cn drug jul [epub ahead print] abstract naegelin rasenack andelova et al shorten washout week switch natalizumab fingolimod risk diseas reactiv multipl sclerosi mult scler relat disord jul [epub ahead print] abstract read full text paper lucchetta rc tonin fs borba hhl et al diseas modifi therapi relaps remit multipl sclerosi network meta analysi cn drug jul [epub ahead print] abstract alnajashi ha alshamrani fj freedman ms toler discontinu rate teriflunomid treat patient real world clinic experi neurosci riyadh jul abstract reen gk silber e langdon dw best method commun clinic trial data improv understand treatment patient multipl sclerosi valu health jul abstract rasmussen pv magyari moberg jy et al patient awar famili plan repres major knowledg gap multipl sclerosi mult scler relat disord jun [epub ahead print] abstract read full text paper schreiber k kant pfleger c et al high treatment adher satisfact motiv health relat qualiti life fingolimod patient relaps remit multipl sclerosi result month multicent open label danish studi patient prefer adher jun abstract read full text paper oshima tanimoto yuji k et al drug associ progress multifoc leukoencephalopathi multipl sclerosi patient mult scler jul [epub ahead print] abstract yamout bi sahraian ayoubi ne et al efficaci safeti natalizumab extend interv dose mult scler relat disord jul [epub ahead print] abstract robertson aungst collier r et al patient perceiv chang sexual dysfunct initi natalizumab multipl sclerosi mult scler j exp transl clin jun abstract read full text paper zecca c bellavia g brambilla l et al atyp post inject reaction delay onset follow glatiram acet mg need titrat cn drug jul abstract drug develop cohen ja comi g arnold dl et al efficaci safeti ozanimod multipl sclerosi dose blind extens random phase ii studi mult scler jul [epub ahead print] abstract read full text paper gold j marta meier uc et al phase ii baselin versu treatment studi determin efficaci raltegravir isentress prevent progress relaps remit multipl sclerosi determin gadolinium enhanc mri inspir studi mult scler relat disord jun [epub ahead print] abstract de ang f planton chataway j pharmacotherapi secondari progress multipl sclerosi overview cn drug jun abstract uitdehaag bmj disabl outcom measur phase iii clinic trial multipl sclerosi cn drug jun [epub ahead print] abstract read full text paper econom murley c yang f gyllensten h et al dispos incom trajectori work age individu diagnos multipl sclerosi acta neurol scand jul [epub ahead print] abstract famili landfeldt e castelo branco svedbom et al long term impact multipl sclerosi risk divorc mult scler relat disord jul [epub ahead print]',\n",
       " 'thought anoth reason peopl pick hsct cladribin lot descript person experi hsct gazillion facebook exampl equival fund stori cladribin mayb peopl favour hsct think humbug',\n",
       " 'repli plan offici ocrevu view post penkalet sorri dave forgot rituxan sorri dave forgot rituxan fyi saw doc yesterday ask patient feel better year say realli patient',\n",
       " 'research evalu macular pigment distribut pattern prognost marker diseas progress individu macular telangiectasia type part retrospect cohort studi analyz eye individu singl center studi measur pigment optic densiti dual wavelength fundu autofluoresc independ grader blind assign eye mpod distribut class increas loss macular pigment defin best correct visual acuiti read acuiti total scotoma size fundu control perimetri microperimetri break ellipsoid zone optic coher tomographi en face measur function morpholog outcom paramet evalu eye baselin month mean review period month sd month research found chang mpod class compar baselin morpholog function deficit limit area mpod loss follow record signific decreas mean va read acuiti well signific increas mean scotoma size ez break eye assign mpod class paramet remain stabl class eye research wrote result indic mpod distribut might serv prognost marker diseas progress function impair individu mactel sourc ller issa pc heeren tfc et al macular pigment distribut prognost marker diseas progress macular telangiectasia type j ophthalmol jul [epub ahead print] wide field oct map detect earli glaucomat structur progress investig evalu potenti use serial analysi combin wide field optic coher tomographi map detect structur progress individu earli glaucoma part retrospect observ studi analyz individu earli primari open angl glaucoma minimum three year follow involv serial spectral domain oct measur subject divid non progressor n progressor group n base serial stereo disc photographi red free photographi investig gener serial combin wide field oct map integr parapapillari retin nerv fiber layer macular ganglion cell inner plexiform layer map serial spectral domain oct softwar glaucoma specialist assess structur progress detect abil serial wide field oct map earli glaucomat eye compar sensit rnfl gcipl guid progress analys gpa main outcom measur includ diagnost abil serial wide field oct map earli glaucomat structur progress nineti four individu mean [sd] age [ ] year [ percent] women includ serial wide field oct map analysi show good agreement detect structur progress two glaucoma grader wide field oct thick map wide field oct deviat map map show earli glaucomat structur progress detect abil compar rnfl gcipl gpa sensit wide field oct thick map percent wide field oct deviat map percent rnfl gpa percent gcipl gpa percent p specif wide field oct thick map percent wide field oct deviat map percent rnfl gpa percent gcipl gpa percent p investig determin serial combin wide field oct map integr rnfl gcipl map perform well detect structur progress earli glaucomat eye ad confirm independ prospect studi might provid greater confid conclus sourc lee wj kim tj kim yk et al serial combin wide field optic coher tomographi map detect earli glaucomat structur progress jama ophthalmol jul [epub ahead print] visual outcom intraop complic post vitrectomi cataract surgeri scientist analyz visual outcom rate intraop complic phacoemulsif surgeri prior par plana vitrectomi part retrospect multicent databas studi includ eye underw phacoemulsif june march eight site unit kingdom studi eye classifi vitrectom prior ppv group non vitrectom depend vitreou state time cataract surgeri exclud eye multipl intraocular surgeri histori ocular diseas known caus cataract progress increas risk intraop complic phacoemulsif main outcom measur includ logmar visual acuiti rate intraop complic time interv cataract surgeri eye prior ppv group n compar non vitrectom group wors preoper logmar va vs p younger longer axial length nonvitrectom group n poorer mean vision vs four week p postop time point measur week smaller proport eye achiev postop va logmar snellen percent vs percent four week p rate posterior capsular ruptur differ prior ppv percent non vitrectom percent group incid zonular dialysi percent vs percent drop nuclear fragment percent vs percent higher prior ppv group p mean time interv ppv cataract surgeri day scientist found signific va improv post vitrectomi cataract surgeri eye exhibit wors mean postop vision logmar unit higher rate zonular dialysi drop nuclear fragment similar rate posterior capsul ruptur compar eye without prior ppv sourc soliman mk hardin js jaw f et al databas studi visual outcom intraop complic postvitrectomi cataract surgeri ophthalmolog juli [epub ahead print] anti vegf therapi dme real world outcom research assess real world visual acuiti outcom anti vascular endotheli growth factor therapi diabet macular edema perform retrospect analysi vestrum health retina databas aggreg longitudin electron medic record geograph demograph divers sampl case u retina specialist particip includ dme eye underw monthli anti vegf inject within four month first inject januari march follow data prior march eye divid three group base initi intravitr anti vegf agent aflibercept bevacizumab ranibizumab eye subdivid three cohort length follow six month cohort mutual exclus research assess va outcom number treatment cohort stratifi result baselin va total dme eye includ month cohort eye initi treat aflibercept mean month improv letter ci letter p inject averag similar outcom bevacizumab eye letter ci letter p averag inject ranibizumab eye letter ci letter p averag inject mean number corticosteroid macular panretin laser treatment session similar group month cohort stratifi baselin va aflibercept group final mean letter gain lost wors better bevacizumab group final mean letter gain lost wors better letter ranibizumab group final mean letter gain lost wors better research conclud real world va outcom follow anti vegf therapi dme meaning inferior note random control trial ad eye better baselin va gain fewer letter compar wors baselin va initi choic anti vegf agent correl visual outcom sourc ciulla ta bracha p pollack j et al real world outcom anti vascular endotheli growth factor therapi diabet macular edema unit state ophthalmolog retina juli [epub ahead print] will eye sponsor feasibl studi implant devic rp will eye hospit receiv u fda approv begin earli feasibl studi implant retina implant alpha am subretin devic individu blind due retin pigmentosa manufactur retina implant ag reutlingen germani devic design replac non function absent photoreceptor cell lost rp deterior surgic implant alpha am chip stimul remain compon visual system restor limit function vision blind rp individu compani say ri alpha am investig devic unit state receiv ce mark approv europ read glauko enter western therapeut institut agreement glauko corp enter research develop collabor agreement western therapeut institut japanes biotechnolog compani agreement glauko dwti conduct joint research develop novel intraocular product treat glaucoma use compound dwti proprietari rock inhibitor compound librari one dwti fundament technolog potenti design synthes new compound read essilor launch wavefront aberromet essilor instrument launch wam wavefront aberromet anterior chamber analysi visual need assess base shack hartmann wavefront technolog essilor say devic design fast effect space save fulli automat wavefront aberromet built eas navig larg touch screen wam provid seven detail measur second eye compani say devic help simplifi screen condit cataract glaucoma keratoconu learn review ophthalmolog onlin publish review group divis jobson medic inform llc jmi campu boulevard newtown squar pa subscrib jmi newslett manag subscript click chang email address repli email write chang address subject line make sure provid us old new address ensur deliveri pleas sure add reviewophth jobsonmail com address book safe sender list click want receiv futur email review ophthalmolog onlin advertis inform advertis e mail newslett creativ advertis opportun review ophthalmolog pleas contact sale manag jame henn michel barrett news submit news contact editor send e mail fax news',\n",
       " 'hi beachgirl gain weight gilenya remain constant loss gain',\n",
       " 'hi gilenya nearli three year annual scan mayb depend hospit kim',\n",
       " 'comprehens discuss side effect across current singl combo immuno drug start separ dolm se thread sinc opdivo littl someth everyon stat chart graph oh http co wanikuu gh',\n",
       " 'drug caus apoptosi slow kill rather burst ocrelizumab alemtuzumab explain low administr reaction ray',\n",
       " 'macular hole small break macula part eye respons detail central vision note macular hole differ macular degener although symptom similar eye work light pass cornea front eye focus len onto retina retina delic tissu line insid eye retina convert light electr signal travel along optic nerv brain brain interpret signal see world around light object look directli focus onto tini area retina call macula back eye macula mm across respons detail central vision colour vision provid vision need read recognis face drive car see colour clearli activ requir detail fine vision rest retina give side vision peripher vision macular hole one know exactli macular hole develop peopl other jelli vitreou fill space insid eyebal chang get older becom wateri move away back eye toward centr happen space left behind fill fluid produc eye chang vitreou usual caus problem vision although may increas floater flash vision floater usual appear small darkish fleck like strand cotton littl spider web move littl around field vision signific increas new floater flash examin eye care profession ophthalmologist optometrist peopl vitreou jelli firmli attach retina macula vitreou shrink pull macula caus small tear start macular hole fluid seep hole caus sight becom blur distort time hole get bigger caus vision problem optometrist find suspect macular hole ask referr ophthalmologist ideal retin surgeon soon possibl macular hole usual affect one eye though per cent chanc eye also get hole stage symptom macular hole peopl macular hole probabl chang central part vision chang rang straight line look wavi earli stage small blank patch centr vision late stage peopl may first notic troubl read small print distort look print page number differ stage macular hole stage usual class size hole layer eye affect import know earli stage possibl macular hole may heal without treatment mean sometim ophthalmologist simpli want regularli monitor small hole decid offer treatment howev case macular hole get bigger distort vision treatment need treatment attempt stop hole develop stage central vision lost prevent macular hole noth done prevent macular hole diet exercis thought contribut problem evid take kind medicin vitamin help fix macular hole case best treatment surgeri eye test least everi two year best way help ensur eye issu detect earli treatment macular hole macular hole requir surgeri eye surgeon normal want oper macular hole within six month found longer hole left larger normal becom harder success close hole case surgeri stop vision problem get wors peopl notic improv vision case gain suffici vision allow drive read rare howev perfect vision restor two main stage treatment surgeri remov vitreou insert ga eye recoveri period ga push retina back place hole close surgeri macular hole macular hole surgeri call vitrectomi gener perform local anaesthet eye surgeon remov vitreou jelli eye leav space ga insert surgeon also normal peel away fine membran across back eye ga insert eye help edg macular hole close togeth period usual week ga gradual absorb bodi replac natur fluid made eye recoveri surgeri hole close surgeri ga place normal vision poor ga absorb fluid taken place sight improv mani peopl may take sever month improv occur howev other oper main effect stop sight becom wors patient previou cataract surgeri may start notic gradual blur vision sever month due begin cataract format symptom macular hole uncommon macular hole eye even rare case hole close peopl good vision eye postur recent peopl macular hole surgeri requir spend signific period oper head face downward known postur howev becom increasingli common postur unnecessari may situat still need surgeon explain whether postur requir long surgeon decid need postur need plan thing oper probabl need help afterward stay face sever day difficult may made difficult problem arthriti import discuss surgeon medic problem may affect abil postur case may possibl get short term help social servic tip postur usual minut everi hour need spent face although surgeon may recommend otherwis time postur usual allow thing eat use bathroom appli post surgeri eye drop necessari lie complet flat mani peopl postur whilst sit chair tri differ postur posit help avoid stiff boredom exampl sit tabl lean forward onto tabl sit armchair lean onto small stool lie bed prop pillow either side stop roll onto back prepar postur prepar go hospit import expect start postur soon return home go hospit consid thing housework ensur home clear trip hazard shop food prepar eg prepar frozen meal arrang deliveri meal social servic talk surgeon rent postur tabl head rest cut face also contact foundat inform obtain may take week deliv sure leav enough time make sure postur furnitur aid right place live alon arrang someon stay consid need postur exampl keep thing may need frequent close eg tissu drink book phone help drink consid use straw entertain watch tv may possibl radio music close use laptop comput tablet ipad still abl use face complic macular hole surgeri two main complic associ oper cataract cataract cloud len insid eye previous cataract remov eye macular hole almost certain cataract form month year macular hole surgeri cataract usual remov normal way start affect vision mani peopl eventu develop cataract even macular hole macular hole surgeri may make cataract form somewhat earlier alreadi cataract form mani surgeon perform macular hole surgeri cataract surgeri time retin detach eye surgeon remov vitreou jelli peel membran retina small chanc retina may detach back eye happen usual step taken reattach retina soon possibl sometim surgeri talk surgeon possibl complic manag vision loss macular hole surgeri normal help maintain good vision rare second oper may need help close hole unsuccess central vision gener lost happen untreat macular hole peripher side vision remain normal sight eye still good peopl adjust quit quickli maintain normal activ vision eye poor extra help may need manag vision loss key prioriti maintain qualiti life independ contact low vision organis help work assess individu need determin aid technolog help mani excel solut help live well low vision review macular hole fact sheet order face sheet macular diseas foundat australia develop comprehens rang public macular degener diabet eye diseas macular diseas order resourc subscrib foundat newslett find free educ session come contact macular diseas foundat australia discuss low vision need receiv free inform low vision telephon helplin mactel curiou poorli understood disord blood vessel suppli central part retina see content macular telangiectasia sthash imfbq dpuf mactel curiou poorli understood disord blood vessel suppli central part retina see content macular telangiectasia sthash imfbq dpuf',\n",
       " 'oh feel like someth tri cladribin one therapi use other exhaust unfortun alway side effect could toler doc great respons peopl put cladribin betaseron avonex copaxon tysabri gilenya plegridi name year mostli side effect would alway stop better med research lot sometim think better practic self heal diet moder exercis medit thing like sometim prednison lol readin lot heal gut gluten feel like med treat symptom root caus ms tri figur year bout flare up sever alway heal though overload diet nutrit rid complet stress concern take cladribin first time abl feel better hope med still work becom concern know put someth bodi that toxic mess immun system bit hope reduc overact part immun system caus flare up physic better gerrrrr sorri long vent nice talk someon get new shift ms still tri get use thank lend ear',\n",
       " 'fingolimod ineffect ppm phase trial data may improv futur studi stephani sutherland even failur studi inform fingolimod diseas modifi treatment relaps remit multipl sclerosi',\n",
       " 'wow tire fatigu whatev want call want even move top vision realli suck make feel realli dizzi usual mean either way tri push actual get stuff done like minor chore final get work done blog might look like much first final merg old blog one post old blog part websit tri visit old url mattsm com redirect mayb sound like minor chang updat technic crap pain took forev get done noth work slowli time organ menu updat articl write new one ever want read older articl way back first diagnos ms found toward bottom right blog navig blog archiv like alway written blog far fatigu feel like anyth caus random wave sucki know cours fatigu suck enough also felt realli antsi restless horribl combin feel like die thirst go bathroom realli bad part bodi want move lie shut feel compel get back result liter sit desk stare floor hour wish could sleep even though tire even flip tv turn brain instead sit count hour till go sleep night night take tylenol pm melatonin admit sleep realli well get much go bathroom everi hour dream vivid unfortun wake morn right back extrem fatigu like got hour sleep coffe noth ritalin noth nuvigil make feel antsi ye tri provigil anyth day doctor prescrib adderal sort lost horribl stuck problem seem solut although much fatigu suck hardli compar vision dizzi caus make everyth feel imposs even type right keep hit wrong key hit backspac take time long write although partial think fine motor skill get wors fatigu kill everi ounc motiv might abl work motiv anyth cherri top back kill seem strain muscl lower back everi time arch bend back kill feel like alway keep straight pain take sometim like today pain radiat knee awesom ibuprofen effect kill pain scissor mow entir lawn technic grass shorter still need finish job right tool second hope final round lemtrada sometim septemb suppos schedul end septemb neurologist move new locat transfer new center make sure system insur good schedul hate schedul want know worst behind knock wood talk ocrelizumab approv end year hope knock ass like lemtrada realli look peopl react finger cross know better better get closer lemtrada infus anoth video hope make habit might easier sinc type get harder time tell know stare comput screen make horribl dizzi somewhat cross eye feel sort destroy option though actual career someday lemtrada work hospit might great idea immun compromis ugh hard time fall asleep last night stress day could career start feel better ugh hate know',\n",
       " 'nutshel sorri unsur tough choic first pill get easier howev feel still might want consid tecfidera instead gilenya realli shouldnt stop gilenya start realli need convinc tecfidera hand stop feel work well even though feel great still lot go cant see howev like never know realli dont know wife someth stronger tecfidera good mayb shouldnt anyth way know sure famili go date decid someth tri look back coupl week ectrim find year mayb give unless amaz new research pr problem go gilenya',\n",
       " 'bad mine get chronic degre flare year mayb worst go time day vomit time nurs pick bathroom floor pain bad cri scream famili want die save usual ivig within hour went time week later go time day last year develop fistula diseas chang uc cd humira ivig stelara help bowel monday go normal time day form regress possibl due new food excit tri ivig destroy stelara connor gta post edit u b tough gmt',\n",
       " 'aug mcnv diabet retinopathi patient dme dupix dupilumab inject atop dermat adult eylea aflibercept inject receiv fda approv macular oct baselin measur earli treatment diabet retinopathi studi etdr chart primari endpoint studi compar regeneron pharmaceut inc nov phase eylea panorama studi treatment diabet retinopathi fulli enrol u regulatori submiss expect regeneron submit biolog licens applic fda vegf visual acuiti measur score base total number letter read correctli earli treatment diabet retinopathi studi etdr eye chart pipelin power research develop engin famili hypercholesterolemia hofh aflibercept^ vegf trap aflibercept vegf trap non prolif diabet retinopathi npdr without dme sec file regeneron pharmaceut inc phase eylea panorama studi treatment diabet retinopathi fulli enrol u regulatori submiss expect aflibercept inject treatment diabet macular edema feb patient diabet macular edema said georg yancopoulo ph dme common complic diabet retinopathi dr sec file regeneron pharmaceut inc diabet grow diseas worldwid dme major caus vision loss peopl diabet retinopathi hope abl offer new anti pdgfr beta sep efficaci evalu use earli treatment diabet retinopathi scale etdr bcva patient random one three unit state secur exchang commiss form k jan nasal polyp eylea diabet retinopathi without diabet macular edema fasinumab ngf pain regn rsv respiratori syncyti',\n",
       " 'new forum want share experi crohn diseas biolog psoriasi put humira back crohn diseas doctor tri everi kind medic could possibl tri crohn diseas noth work multipl hospit stay sever surgeri final got approv humira would inject pen everi week month began develop rash leg slowli got bigger eventuali spread foot long spread leg feet doctor told psoriasi gave steroid cream help eventu spread bodi includ scalp hair began fall sevral bald patch depress angri decid take humira within coupl week everyth began clear within month complet gone didnt give doctor chanc upset either show pictur couldnt dismiss later place remicad infus everi week needless say issu humira psoriasi hate use cortison itch steroid cream inflamm red good lotion cerava best lotion found psoriasi thank everyon allow share experi',\n",
       " 'hi question brother histori diagnos nsclc adeno alk start cisplatin alimta alimta mainten good respons diseas progress start xalkori year stop work went back alimta month progress start zykadia work well last month lymph node disappear tumour one lung turn scar left lung tumour reduc size soon got report bad rash last coupl week face bodi stop take zykadia dermatologist gave medicin rash suddenli swear headach take dexa get normal ct scan report today say mm hyperdens lesion area punctat calcif target like fashion within right pariet tempor lobe lesion demonstr intens post contrast enhanc extens vasogen oedema caus effac ipsilater later ventricl subfalcin herniat along mid line shift patholog brainparenchym lesion identifi foreman magnum basal cistern capaci without evid transtentori herniat conclus imag featur keep metast deposit within right pariet tempor lobe whole brain radiat suggest question scare radiat cyberknif option gammaknif option best stop take zykadia need stop zykadia day till radiat stop zykadia jump nivolumab zykadia result better except brain lesion need carri zykadia avoid brain lesion zykadia cross brain barrier get alimta everi three month alimta cross brain barrier sorri question sound',\n",
       " 'apolog momordica notic post seen person may awar someth back mind thrown face like respiratori therapist wife well ye shocker slap face consid neither specialist crystal ball tell futur also right say fair enough mention concern speak absolut anoth thing opinion anyway glad hear otherwis wife receiv excel care oncologist care make true differ mention treatment tri see opdivo keytruda mention discuss could right base type mutat amaz love person care wife caregiv know fear grip exhaust take prayer dream import take good care right rememb wear abl properli look let alon wife leav link inform caregiv inform varieti topic probabl alreadi know hope may find inform help http www cancer ca en cancer inform cancer journey caregiv region ab pleas take care jodi',\n",
       " 'avastin uk time noth els licens myopic macular degener given option work well restor lost vision gave extra year use sight eye second bleed two year later lucenti licenc myopic macular degener lucenti never effect opinion option peopl help avastin prefer option novarti bayer make lucenti eyelea exploit nh patient long wonder though fight ensur potenti save plough back massiv overstretch eye clinic instead cover overspend elsewher nh',\n",
       " 'lung pair cone shape breath organ chest lung bring oxygen bodi breath releas carbon dioxid wast product bodi cell breath lung section call lobe left lung two lobe right lung slightli larger three lobe two tube call bronchi lead trachea windpip right left lung bronchi sometim also involv lung cancer tini air sac call alveoli small tube call bronchiol make insid lung enlarg anatomi respiratori system show trachea lung lobe airway lymph node diaphragm also shown oxygen inhal lung pass thin membran alveoli bloodstream see inset thin membran call pleura cover outsid lung line insid wall chest caviti creat sac call pleural caviti pleural caviti normal contain small amount fluid help lung move smoothli chest breath two main type lung cancer non small cell lung cancer small cell lung cancer see follow pdq summari inform lung cancer small cell lung cancer treatment unusu cancer childhood treatment lung cancer prevent lung cancer screen sever type non small cell lung cancer type non small cell lung cancer differ kind cancer cell cancer cell type grow spread differ way type non small cell lung cancer name kind cell found cancer cell look microscop squamou cell carcinoma cancer begin squamou cell thin flat cell look like fish scale also call epidermoid carcinoma larg cell carcinoma cancer may begin sever type larg cell adenocarcinoma cancer begin cell line alveoli make substanc mucu less common type non small cell lung cancer pleomorph carcinoid tumor salivari gland carcinoma unclassifi carcinoma smoke major risk factor non small cell lung cancer anyth increas chanc get diseas call risk factor risk factor mean get cancer risk factor mean get cancer talk doctor think may risk lung cancer risk factor lung cancer includ follow smoke cigarett pipe cigar past import risk factor lung cancer earlier life person start smoke often person smoke year person smoke greater risk lung cancer expos secondhand smoke expos asbesto arsen chromium beryllium nickel soot tar workplac expos radiat follow radiat therapi breast chest radon home workplac imag test ct scan atom bomb radiat live air pollut famili histori lung cancer infect human immunodefici viru hiv take beta caroten supplement heavi smoker older age main risk factor cancer chanc get cancer increas get older smoke combin risk factor risk lung cancer increas sign non small cell lung cancer includ cough go away short breath sometim lung cancer caus sign symptom may found chest x ray done anoth condit sign symptom may caus lung cancer condit check doctor follow chest discomfort pain cough go away get wors time troubl breath wheez blood sputum mucu cough lung hoars loss appetit weight loss known reason feel tire troubl swallow swell face vein neck test examin lung use detect find diagnos stage non small cell lung cancer test procedur detect diagnos stage non small cell lung cancer often done time follow test procedur may use physic exam histori exam bodi check gener sign health includ check sign diseas lump anyth els seem unusu histori patient health habit includ smoke past job ill treatment also taken laboratori test medic procedur test sampl tissu blood urin substanc bodi test help diagnos diseas plan check treatment monitor diseas time chest x ray x ray organ bone insid chest x ray type energi beam go bodi onto film make pictur area insid bodi enlarg x ray chest x ray use take pictur organ bone chest x ray pass patient onto film ct scan cat scan procedur make seri detail pictur area insid bodi chest taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi sputum cytolog procedur pathologist view sampl sputum mucu cough lung microscop check cancer cell thoracentesi remov fluid space line chest lung use needl pathologist view fluid microscop look cancer cell lung cancer suspect biopsi done one follow type biopsi usual use fine needl aspir fna biopsi lung remov tissu fluid lung use thin needl ct scan ultrasound imag procedur use locat abnorm tissu fluid lung small incis may made skin biopsi needl insert abnorm tissu fluid sampl remov needl sent laboratori pathologist view sampl microscop look cancer cell chest x ray done procedur make sure air leak lung chest enlarg fine needl aspir biopsi lung patient lie tabl slide comput tomographi ct machin take x ray pictur insid bodi x ray pictur help doctor see abnorm tissu lung biopsi needl insert chest wall area abnorm lung tissu small piec tissu remov needl check microscop sign cancer endoscop ultrasound eu type ultrasound may use guid fna biopsi lung lymph node area eu procedur endoscop insert bodi endoscop thin tube like instrument light len view probe end endoscop use bounc high energi sound wave ultrasound intern tissu organ make echo echo form pictur bodi tissu call sonogram enlarg endoscop ultrasound guid fine needl aspir biopsi endoscop ultrasound probe biopsi needl insert mouth esophagu probe bounc sound wave bodi tissu make echo form sonogram comput pictur lymph node near esophagu sonogram help doctor see place biopsi needl remov tissu lymph node tissu check microscop sign cancer bronchoscopi procedur look insid trachea larg airway lung abnorm area bronchoscop insert nose mouth trachea lung bronchoscop thin tube like instrument light len view may also tool remov tissu sampl check microscop sign cancer enlarg bronchoscopi bronchoscop insert mouth trachea major bronchi lung look abnorm area bronchoscop thin tube like instrument light len view may also cut tool tissu sampl may taken check microscop sign diseas thoracoscopi surgic procedur look organ insid chest check abnorm area incis cut made two rib thoracoscop insert chest thoracoscop thin tube like instrument light len view may also tool remov tissu lymph node sampl check microscop sign cancer case procedur use remov part esophagu lung certain tissu organ lymph node reach thoracotomi may done procedur larger incis made rib chest open mediastinoscopi surgic procedur look organ tissu lymph node lung abnorm area incis cut made top breastbon mediastinoscop insert chest mediastinoscop thin tube like instrument light len view may also tool remov tissu lymph node sampl check microscop sign cancer enlarg mediastinoscopi mediastinoscop insert chest incis breastbon look abnorm area lung mediastinoscop thin tube like instrument light len view may also cut tool tissu sampl may taken lymph node right side chest check microscop sign cancer anterior mediastinotomi chamberlain procedur incis made besid breastbon remov tissu sampl lymph node left side chest anterior mediastinotomi surgic procedur look organ tissu lung breastbon heart abnorm area incis cut made next breastbon mediastinoscop insert chest mediastinoscop thin tube like instrument light len view may also tool remov tissu lymph node sampl check microscop sign cancer also call chamberlain procedur lymph node biopsi remov part lymph node pathologist view tissu microscop look cancer cell one follow laboratori test may done studi tissu sampl molecular test laboratori test check certain gene protein molecul sampl tissu blood bodi fluid molecular test check certain gene chromosom chang occur non small cell lung cancer immunohistochemistri test use antibodi check certain antigen sampl tissu antibodi usual link radioact substanc dye caus tissu light microscop type test may use tell differ differ type cancer certain factor affect prognosi chanc recoveri treatment option prognosi chanc recoveri treatment option depend follow stage cancer size tumor whether lung spread place bodi type lung cancer whether cancer mutat chang certain gene epiderm growth factor receptor egfr gene anaplast lymphoma kinas alk gene whether sign symptom cough troubl breath patient gener health patient non small cell lung cancer current treatment cure cancer lung cancer found take part one mani clinic trial done improv treatment consid clinic trial take place part countri patient stage non small cell lung cancer inform ongo clinic trial avail nci websit stage non small cell lung cancer key point lung cancer diagnos test done find cancer cell spread within lung part bodi three way cancer spread bodi cancer may spread began part bodi follow stage use non small cell lung cancer occult hidden stage stage stage stage ii stage iii stage iv lung cancer diagnos test done find cancer cell spread within lung part bodi process use find cancer spread within lung part bodi call stage inform gather stage process determin stage diseas import know stage order plan treatment test use diagnos non small cell lung cancer also use stage diseas see gener inform section test procedur may use stage process includ follow mri magnet reson imag procedur use magnet radio wave comput make seri detail pictur area insid bodi brain procedur also call nuclear magnet reson imag nmri ct scan cat scan procedur make seri detail pictur area insid bodi brain abdomen lymph node taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi pet scan positron emiss tomographi scan procedur find malign tumor cell bodi small amount radioact glucos sugar inject vein pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell enlarg pet positron emiss tomographi scan patient lie tabl slide pet machin head rest white strap help patient lie still small amount radioact glucos sugar inject patient vein scanner make pictur glucos use bodi cancer cell show brighter pictur take glucos normal cell bone scan procedur check rapidli divid cell cancer cell bone small amount radioact materi inject vein travel bloodstream radioact materi collect bone cancer detect scanner pulmonari function test pft test see well lung work measur much air lung hold quickli air move lung also measur much oxygen use much carbon dioxid given breath also call lung function test bone marrow aspir biopsi remov bone marrow blood small piec bone insert hollow needl hipbon breastbon pathologist view bone marrow blood bone microscop look sign cancer three way cancer spread bodi cancer spread tissu lymph system blood tissu cancer spread began grow nearbi area lymph system cancer spread began get lymph system cancer travel lymph vessel part bodi blood cancer spread began get blood cancer travel blood vessel part bodi cancer may spread began part bodi cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi metastat tumor type cancer primari tumor exampl non small cell lung cancer spread brain cancer cell brain actual lung cancer cell diseas metastat lung cancer brain cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ call metastat cancer anim show cancer cell travel place bodi first form part bodi follow stage use non small cell lung cancer occult hidden stage occult hidden stage cancer cannot seen imag bronchoscopi cancer cell found sputum bronchial wash sampl cell taken insid airway lead lung cancer may spread part bodi stage stage abnorm cell found line airway abnorm cell may becom cancer spread nearbi normal tissu stage may adenocarcinoma situ ai squamou cell carcinoma situ sci stage stage cancer form stage divid stage ia ib stage ia tumor lung centimet smaller cancer spread lymph node stage ib tumor larger centimet larger centimet cancer spread lymph node tumor centimet smaller one follow found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node stage ii stage ii divid stage iia iib stage iia tumor larger centimet larger centimet cancer spread lymph node one follow may found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon stage iib tumor centimet smaller cancer spread lymph node side chest primari tumor lymph node cancer lung near bronchu also one follow may found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node one follow found tumor larger centimet larger centimet one separ tumor lobe lung primari tumor cancer spread follow membran line insid chest wall chest wall nerv control diaphragm outer layer tissu sac around heart stage iii stage iii divid stage iiia iiib iiic stage iiia tumor centimet smaller cancer spread lymph node side chest primari tumor lymph node cancer around trachea trachea divid bronchi also one follow may found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node side chest primari tumor lymph node cancer lung near bronchu also one follow found tumor larger centimet larger centimet one separ tumor lobe lung primari tumor cancer spread follow membran line insid chest wall chest wall nerv control diaphragm outer layer tissu sac around heart cancer may spread lymph node side chest primari tumor lymph node cancer lung near bronchu also one follow found tumor larger centimet one separ tumor differ lobe lung primari tumor tumor size cancer spread follow trachea carina esophagu breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iiib tumor centimet smaller cancer spread lymph node collarbon side chest primari tumor lymph node opposit side chest primari tumor also one follow may found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon tumor may size cancer spread lymph node side chest primari tumor lymph node cancer around trachea trachea divid bronchi also one follow found one separ tumor lobe differ lobe lung primari tumor cancer spread follow membran line insid chest wall chest wall nerv control diaphragm outer layer tissu sac around heart trachea carina esophagu breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iiic tumor may size cancer spread lymph node collarbon side chest primari tumor lymph node opposit side chest primari tumor also one follow found one separ tumor lobe differ lobe lung primari tumor cancer spread follow membran line insid chest wall chest wall nerv control diaphragm outer layer tissu sac around heart trachea carina esophagu breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iv stage iv divid stage iva ivb stage iva tumor may size cancer may spread lymph node one follow found one tumor lung primari tumor cancer found fluid around lung heart cancer spread one place organ near lung brain liver adren gland kidney bone sac around heart lymph node near lung stage ivb cancer spread multipl place one organ near lung recurr non small cell lung cancer recurr non small cell lung cancer cancer recur come back treat cancer may come back brain lung part bodi treatment option overview key point differ type treatment patient non small cell lung cancer ten type standard treatment use surgeri radiat therapi chemotherapi target therapi immunotherapi laser therapi photodynam therapi pdt cryosurgeri electrocauteri watch wait new type treatment test clinic trial chemoprevent radiosensit new combin treatment non small cell lung cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment follow test may need differ type treatment patient non small cell lung cancer differ type treatment avail patient non small cell lung cancer treatment standard current use treatment test clinic trial treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial clinic trial open patient start treatment ten type standard treatment use surgeri four type surgeri use treat lung cancer wedg resect surgeri remov tumor normal tissu around slightli larger amount tissu taken call segment resect enlarg wedg resect lung part lung lobe contain cancer small amount healthi tissu around remov lobectomi surgeri remov whole lobe section lung enlarg lobectomi lobe lung remov pneumonectomi surgeri remov one whole lung enlarg pneumonectomi whole lung remov sleev resect surgeri remov part bronchu doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use high energi x ray type radiat kill cancer cell keep grow two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place directli near cancer stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment day sever day radiat machin aim larger usual dose radiat directli tumor patient posit treatment less damag nearbi healthi tissu procedur also call stereotact extern beam radiat therapi stereotax radiat therapi stereotact radiosurgeri type extern radiat therapi use treat lung cancer spread brain rigid head frame attach skull keep head still radiat treatment machin aim singl larg dose radiat directli tumor brain procedur involv surgeri also call stereotax radiosurgeri radiosurgeri radiat surgeri tumor airway radiat given directli tumor endoscop way radiat therapi given depend type stage cancer treat also depend cancer found extern intern radiat therapi use treat non small cell lung cancer chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi chemotherapi place directli cerebrospin fluid organ bodi caviti abdomen drug mainli affect cancer cell area region chemotherapi way chemotherapi given depend type stage cancer treat see drug approv non small cell lung cancer inform target therapi target therapi type treatment use drug substanc attack specif cancer cell target therapi usual caus less harm normal cell chemotherapi radiat therapi monoclon antibodi tyrosin kinas inhibitor two main type target therapi use treat advanc metastat recurr non small cell lung cancer monoclon antibodi monoclon antibodi therapi cancer treatment use antibodi made laboratori singl type immun system cell antibodi identifi substanc cancer cell normal substanc blood tissu may help cancer cell grow antibodi attach substanc kill cancer cell block growth keep spread monoclon antibodi given infus may use alon carri drug toxin radioact materi directli cancer cell differ type monoclon antibodi therapi vascular endotheli growth factor vegf inhibitor therapi cancer cell make substanc call vegf caus new blood vessel form angiogenesi help cancer grow vegf inhibitor block vegf stop new blood vessel form may kill cancer cell need new blood vessel grow bevacizumab ramucirumab vegf inhibitor angiogenesi inhibitor epiderm growth factor receptor egfr inhibitor therapi egfr protein found surfac certain cell includ cancer cell epiderm growth factor attach egfr surfac cell caus cell grow divid egfr inhibitor block receptor stop epiderm growth factor attach cancer cell stop cancer cell grow divid cetuximab necitumumab egfr inhibitor tyrosin kinas inhibitor tyrosin kinas inhibitor small molecul drug go cell membran work insid cancer cell block signal cancer cell need grow divid tyrosin kinas inhibitor also angiogenesi inhibitor effect differ type tyrosin kinas inhibitor epiderm growth factor receptor egfr tyrosin kinas inhibitor egfr protein found surfac insid certain cell includ cancer cell epiderm growth factor attach egfr insid cell send signal tyrosin kinas area cell tell cell grow divid egfr tyrosin kinas inhibitor stop signal stop cancer cell grow divid erlotinib gefitinib afatinib osimertinib type egfr tyrosin kinas inhibitor drug work better also mutat chang egfr gene kinas inhibitor affect cell certain gene chang certain chang alk ro gene caus much protein made block protein may stop cancer grow spread crizotinib use stop protein made alk ro gene ceritinib alectinib brigatinib use stop protein made alk gene dabrafenib use stop protein made braf gene trametinib use stop protein made mek gene see drug approv non small cell lung cancer inform immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi pd protein surfac cell help keep bodi immun respons check pd attach anoth protein call pdl cancer cell stop cell kill cancer cell pd inhibitor attach pdl allow cell kill cancer cell nivolumab pembrolizumab atezolizumab durvalumab type immun checkpoint inhibitor enlarg immun checkpoint inhibitor checkpoint protein pd l tumor cell pd cell help keep immun respons check bind pd l pd keep cell kill tumor cell bodi left panel block bind pd l pd immun checkpoint inhibitor anti pd l anti pd allow cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv non small cell lung cancer inform laser therapi laser therapi cancer treatment use laser beam narrow beam intens light kill cancer cell photodynam therapi pdt photodynam therapi pdt cancer treatment use drug certain type laser light kill cancer cell drug activ expos light inject vein drug collect cancer cell normal cell fiberopt tube use carri laser light cancer cell drug becom activ kill cell photodynam therapi caus littl damag healthi tissu use mainli treat tumor skin line intern organ tumor airway pdt given directli tumor endoscop cryosurgeri cryosurgeri treatment use instrument freez destroy abnorm tissu carcinoma situ type treatment also call cryotherapi tumor airway cryosurgeri done endoscop electrocauteri electrocauteri treatment use probe needl heat electr current destroy abnorm tissu tumor airway electrocauteri done endoscop watch wait watch wait close monitor patient condit without give treatment sign symptom appear chang may done certain rare case non small cell lung cancer new type treatment test clinic trial summari section describ treatment studi clinic trial may mention everi new treatment studi inform clinic trial avail nci websit chemoprevent chemoprevent use drug vitamin substanc reduc risk cancer reduc risk cancer recur come back lung cancer chemoprevent use lessen chanc new tumor form lung radiosensit radiosensit substanc make tumor cell easier kill radiat therapi combin chemotherapi radiat therapi given radiosensit studi treatment non small cell lung cancer new combin new combin treatment studi clinic trial treatment non small cell lung cancer may caus side effect inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment clinic trial includ patient yet receiv treatment trial test treatment patient whose cancer gotten better also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found nci clinic trial search webpag clinic trial support organ found clinicaltri gov websit follow test may need test done diagnos cancer find stage cancer may repeat test repeat order see well treatment work decis whether continu chang stop treatment may base result test test continu done time time treatment end result test show condit chang cancer recur come back test sometim call follow test check up treatment option stage inform treatment list see treatment option overview section occult non small cell lung cancer treatment occult non small cell lung cancer depend stage diseas occult tumor often found earli stage tumor lung sometim cure surgeri use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage treatment stage may includ follow surgeri wedg resect segment resect photodynam therapi electrocauteri cryosurgeri laser surgeri tumor near bronchu use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage non small cell lung cancer treatment stage ia non small cell lung cancer stage ib non small cell lung cancer may includ follow surgeri wedg resect segment resect sleev resect lobectomi extern radiat therapi includ stereotact bodi radiat therapi patient cannot surgeri choos surgeri clinic trial chemotherapi radiat therapi follow surgeri clinic trial treatment given endoscop photodynam therapi pdt clinic trial surgeri follow chemoprevent use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage ii non small cell lung cancer treatment stage iia non small cell lung cancer stage iib non small cell lung cancer may includ follow surgeri wedg resect segment resect sleev resect lobectomi pneumonectomi chemotherapi follow surgeri surgeri follow chemotherapi extern radiat therapi patient cannot surgeri clinic trial radiat therapi follow surgeri use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage iiia non small cell lung cancer treatment stage iiia non small cell lung cancer remov surgeri may includ follow surgeri follow chemotherapi surgeri follow radiat therapi chemotherapi follow surgeri surgeri follow chemotherapi combin radiat therapi chemotherapi radiat therapi follow surgeri clinic trial new combin treatment treatment stage iiia non small cell lung cancer cannot remov surgeri may includ follow chemotherapi radiat therapi given period time one follow extern radiat therapi alon patient cannot treat combin therapi palli treatment reliev symptom improv qualiti life intern radiat therapi laser surgeri palli treatment reliev symptom improv qualiti life chemotherapi radiat therapi follow immunotherapi immun checkpoint inhibitor durvalumab clinic trial new combin treatment inform support care sign symptom includ cough short breath chest pain see pdq summari cardiopulmonari syndrom non small cell lung cancer superior sulcu often call pancoast tumor begin upper part lung spread nearbi tissu chest wall larg blood vessel spine treatment pancoast tumor may includ follow radiat therapi alon surgeri chemotherapi radiat therapi follow surgeri clinic trial new combin treatment stage iiia non small cell lung tumor grown chest wall may complet remov treatment chest wall tumor may includ follow surgeri surgeri radiat therapi radiat therapi alon chemotherapi combin radiat therapi surgeri clinic trial new combin treatment use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage iiib stage iiic non small cell lung cancer treatment stage iiib non small cell lung cancer stage iiic non small cell lung cancer may includ follow chemotherapi follow extern radiat therapi chemotherapi radiat therapi given separ treatment period time chemotherapi radiat therapi given separ treatment period time dose radiat therapi increas time chemotherapi radiat therapi given separ treatment period time chemotherapi alon given treatment chemotherapi radiat therapi follow immunotherapi immun checkpoint inhibitor durvalumab extern radiat therapi alon patient cannot treat chemotherapi extern radiat therapi palli therapi reliev symptom improv qualiti life laser therapi intern radiat therapi reliev symptom improv qualiti life clinic trial new extern radiat therapi schedul new type treatment clinic trial chemotherapi radiat therapi combin radiosensit clinic trial target therapi combin chemotherapi radiat therapi inform support care sign symptom cough short breath chest pain see follow pdq summari cardiopulmonari syndrom cancer pain use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail newli diagnos stage iv relaps recurr non small cell lung cancer treatment newli diagnos stage iv relaps recurr non small cell lung cancer may includ follow combin chemotherapi combin chemotherapi target therapi monoclon antibodi bevacizumab cetuximab necitumumab combin chemotherapi follow chemotherapi mainten therapi help keep cancer progress target therapi epiderm growth factor receptor egfr tyrosin kinas inhibitor osimertinib gefitinib erlotinib afatinib target therapi anaplast lymphoma kinas alk inhibitor alectinib crizotinib ceritinib target therapi braf mek inhibitor dabrafenib trametinib immunotherapi immun checkpoint inhibitor pembrolizumab without chemotherapi laser therapi intern radiat therapi tumor block airway extern radiat therapi palli therapi reliev symptom improv qualiti life surgeri remov second primari tumor surgeri remov cancer spread brain follow radiat therapi whole brain stereotact radiosurgeri tumor spread brain cannot treat surgeri clinic trial new drug combin treatment use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail progress stage iv relaps recurr non small cell lung cancer treatment progress stage iv relaps recurr non small cell lung cancer may includ follow chemotherapi target therapi epiderm growth factor receptor egfr tyrosin kinas inhibitor erlotinib gefitinib afatinib osimertinib target therapi anaplast lymphoma kinas alk inhibitor crizotinib ceritinib alectinib brigatinib target therapi braf mek inhibitor dabrafenib trametinib immunotherapi immun checkpoint inhibitor nivolumab pembrolizumab atezolizumab clinic trial new drug combin treatment use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail learn non small cell lung cancer inform nation cancer institut non small cell lung cancer see follow lung cancer home page lung cancer prevent lung cancer screen drug approv non small cell lung cancer target cancer therapi laser cancer treatment photodynam therapi cancer cryosurgeri cancer treatment tobacco includ help quit secondhand smoke cancer gener cancer inform resourc nation cancer institut see follow cancer stage chemotherapi support peopl cancer radiat therapi support peopl cancer cope cancer question ask doctor cancer survivor caregiv pdq summari pdq physician data queri pdq nation cancer institut nci comprehens cancer inform databas pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin summari come two version health profession version detail inform written technic languag patient version written easi understand nontechn languag version cancer inform accur date version also avail spanish pdq servic nci nci part nation institut health nih nih feder govern center biomed research pdq summari base independ review medic literatur polici statement nci nih purpos summari pdq cancer inform summari current inform treatment non small cell lung cancer meant inform help patient famili caregiv give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date board made expert cancer treatment specialti relat cancer summari review regularli chang made new inform date summari updat date recent chang inform patient summari taken health profession version review regularli updat need pdq adult treatment editori board clinic trial inform clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori trial answer certain scientif question order find new better way help cancer patient treatment clinic trial inform collect effect new treatment well work clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial clinic trial open patient start treatment clinic trial list pdq found onlin nci websit inform call cancer inform servic cancer permiss use summari pdq regist trademark content pdq document use freeli text cannot identifi nci pdq cancer inform summari unless whole summari shown updat regularli howev user would allow write sentenc nci pdq cancer inform summari breast cancer prevent state risk follow way [includ excerpt summary] best way cite pdq summari pdq adult treatment editori board pdq non small cell lung cancer treatment bethesda md nation cancer institut updat mm dd yyyi avail http www cancer gov type lung patient non small cell lung treatment pdq access mm dd yyyi [pmid ] imag summari use permiss author artist publish use pdq summari want use imag pdq summari use whole summari must get permiss owner cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim inform summari use make decis insur reimburs inform insur coverag avail cancer gov manag cancer care page contact us inform contact us receiv help cancer gov websit found contact us help page question also submit cancer gov websit e mail us',\n",
       " 'exactli took oral thrush week back gilenya went hike exert lot effort pass shall concer',\n",
       " 'alecensa month progress side effect experienc begin gone great drug',\n",
       " 'glad recoveri go well curiou whether diagnos osteoporosi osteonecrosi unfortun husband osteoporosi year prednison shock radiologist actual misread initi dexa said everyth normal endocrinologist caught gi know score doubl check radiologist conclus curiou whether case porosi preced necrosi spous diagnos uc develop antibodi remicad humira entyvio work infus thing seem work prednison earli march start xeljanz label remiss within month work endocrinologist get prednison neurologist deal neuropathi feet develop conjunct prednison taper',\n",
       " 'robbi ask alan look forward ectrim robbi look forward professor alan thompson neurologist well think ectrim extraordinari event get bigger everi year ms meet meet interest result announc like like go main lectur get real summari thing earli lectur day also like listen result trial know go interest trial present main interest progress ms look result progress know go trial discuss saturday think go suggest posit result trial secondari progress ms would amaz mean last year barcelona result posit trial primari progress ms ocrelizumab go process licens second drug progress would fantast robbi actual noth apart relaps remit drug professor alan thompson moment none mani drug relaps remit ms noth progress ms realli great breakthrough plug progress ms allianc involv rais profil progress encourag earli trial progress ms definit trial would basic two definit posit trial progress would fantast join shift ms commun http shift ms watch video http shift ms msreport http www facebook com shift ms http www instagram com shiftdotm http twitter com shiftm',\n",
       " 'inform lung cancer keytruda prove better chemotherapi wherea case opdivo keytruda select patient express pd l tumor',\n",
       " 'congratul great respons keytruda diagnos stage non small cell lung cancer march opdivo start later year fda approv happili stabl two half year treatment pretti well side effect muscl joint pain cours aw fatigu much better diagnosi start brain tumor lung tumor pulmonari embol come long way feel lucki thank think need think posit hope treatment work well also think opdivo miracl drug wish work well everybodi lisa',\n",
       " 'remicad month far crohn goe work great inflamm last colonoscopi humira previou develop fairli sever muscl pain colonoscopi discov humira work anyway switch remicad develop muscl pain much wors start six day prior last infus everi day got wors got could hardli walk within hour start infus pain start decreas even total gone three week six week cycl muscl pain start alreadi top doctor offic call today inform latest blood work anti bodi level high even though six week cycl remicad left system appoint see gi next week nurs told think option readi talk doctor one option go four week schedul remicad much like remicad see go four vs six week help much seem like sooner later muscl pain return option switch entyvio sterlara done research realli cannot see one better anyon experienc muscl pain remicad switch either drug good result gone someth els',\n",
       " 'thank much md anti jcv treatment market mani year ago gilenya tecfidera tysabri etc releas immunosuppress drug pml known sever side effect pharma could de risk tysabri gilenya almost complet',\n",
       " 'hi pinkperfect repli previou messag seen think lucenti talk tri eylea work avastin',\n",
       " 'natalizumab aidan said like fingolimod disrupt passag lymphocyt cn question drug cure ms sinc theori immun attack would caus diseas',\n",
       " 'checkpoint immunotherapi especi pd checkpoint pathway proven effect sever cancer type unfortun major patient still respond immun base approach therefor day asco mani talk poster discuss dealt strategi overcom resist immunotherapi combin well novel agent may hold synergist potenti exist approach renal cell carcinoma rcc common form kidney cancer laurenc albig ph gustav roussi univers pari saclay discuss two poster describ studi use immunotherapi combin first focus combin pd checkpoint immunotherapi pegilodecakin form immun modul interleukin cytokin also known among patient respond repres object respons rate median progress free surviv year month one year overal surviv rate combin treatment also associ clonal expans cell blood patient thu indic potenti use biomark respons second involv cxcr inhibit via x p combin axinitib tyrosin kinas inhibitor commonli use treat advanc kidney cancer cxcr receptor promot tumor blood vessel growth well recruit myeloid deriv suppressor cell mdsc regulatori cell treg suppress anti cancer immun respons elev express cxcr often found rcc tumor associ poor patient outcom block cxcr tyrosin kinas activ combin treatment led one complet respons ten partial respons patient addit stabl diseas translat diseas control rate albig end question right combin move forward larger clinic trial wonder perhap combin involv cxcr pd blockad might prove effect brian shuch yale school medicin follow albig discuss two poster present focus potenti use biomark advanc rcc patient treat pd immunotherapi one show killer cell among abund tumor infiltr immun cell treatment infiltr macrophag associ durabl clinic benefit immunotherapi studi also found wherea number tumor mutat rel low associ improv outcom presenc certain type mutat known indel involv insert delet dna segment posit signific impact overal surviv patient provid evid impact gut microbiom bacteria live within person digest system immunotherapi effect addit prospect analysi specif gut fingerprint abl predict patient would benefit pd checkpoint immunotherapi shown transplant either akkermansia muciniphila bacteroid salyersia abund human patient respond mice improv respons led shuch suggest potenti benefit profil even modul microbiom patient prior immunotherapi ask regul antibiot diet patient undergo treatment would benefici anoth focu day immunotherapi strategi patient advanc hpv associ cancer head neck cancer cervic cancer one approach led discuss christian hinrich nation cancer institut nci involv use patient exist cell metastat tumor identifi isol cell within patient recogn hpv specif antigen hinrich team expand infus back patient follow treatment chemotherapi aldesleukin recombin interleukin eighteen patient metastat cervic cancer treat five patient respond two complet respons remain ongo month year month year sinc infus non cervic cancer cohort consist eleven patient two experienc respons one patient anal squamou cell carcinoma scc anoth scc head neck hinrich conclud share team find post treatment engraft cell target hpv oncoprotein correl posit patient respons jame gulley ph nation cancer institut also led gave talk treat hpv associ cancer immunotherapi gulley approach involv bifunct fusion protein simultan target two immunosuppress pathway pd l immun checkpoint tgf b receptor seventeen patient hpv associ cancer six respond includ two whose tumor complet elimin five twelv patient known hpv posit tumor respond one complet diseas control rate respect hpv associ hpv posit patient cohort importantli gulley note immun activ seen across cervic anal head neck cancer type respons durabl ongo may breast cancer especi tripl neg breast cancer tnbc anoth tumor type hard treat proven vulner singl agent checkpoint immunotherapi effect combin strategi desper need patient popul end kari wisinski univers wisconsin carbon cancer center discuss poster present combin pembrolizumab radiat heavili pre treat metastat tnbc patient wisinski explain approach involv import immunolog respons known abscop effect wherebi irradi one tumor stimul immun activ metastat lesion elsewher bodi seventeen patient three partial respons respons rate may seem signific appear improv compar trial evalu pd immunotherapi heavili pre treat tnbc patient respons rate observ accord wisinski even impress howev metastat lesion entir elimin three patient partial respons import vast major cancer relat death due secondari metastat tumor two respons last half year week week last respons remain ongo almost one year week anoth immunotherapi strategi evalu tnbc addit cancer highlight timothi yap ph b b univers texa md anderson cancer center studi conduct yap led memori sloan ketter margaret callahan ph former cri postdoctor fellow combin nivolumab ico agonist jtx respons rate combin high other mention produc sever respons patient advanc gastric cancer non small cell lung cancer tnbc furthermor callahan yap team found tumor reduct coincid emerg ico cd cell popul thu may identifi potenti biomark respons trial investig valu target anoth import immun relat pathway cd present branimir sikic stanford univers school medicin cd act eat signal protect normal cell macrophag mediat cell eat phagocytosi cancer cell howev use trick protect well block cd receptor research hope would promot destruct tumor cell macrophag eight patient ovarian fallopian tube cancer receiv cd target hu f g two partial respons especi promis given patient treat six line prior therapi trial combin hu f g rituximab rituximab refractori non hodgkin lymphoma shown promis includ multipl complet respons discuss depth later asco addit trial combin hu f g pd immunotherapi plan adi diab univers texa md anderson cancer center showcas promis activ nktr design provid sustain signal interleukin pathway combin pd immunotherapi first line treatment patient metastat melanoma combin led object respons rate diseas control rate even patient pd l neg tumor benefit respond sever patient experienc complet respons includ one patient pd l neg tumor combin also benefici first line treatment patient kidney cancer rcc among patient twelv respond addit eight saw diseas stabil also sever complet respons patient popul among biomark associ posit respons increas cell natur killer cell prolifer blood increas killer cell tumor tumor initi pd l neg increas pd l express within three week treatment also associ posit respons sarcoma anoth hard treat tumor type benefit oncolyt viru combin well cell base immunotherapi present first studi led sandra angelo memori sloan ketter reveal benefit combin pd immunotherapi oncolyt viru vec patient metastat sarcoma produc respons patient secondli pilot studi involv creat tcr engin cell target cancer associ ny eso antigen patient liposarcoma six month sinc first patient treat eight far receiv infus custom cell four respond addit three stabl diseas final patient yet assess final updat axi cel cd target car cell immunotherapi non hodgkin lymphoma present moffitt cancer center frederick lock phase zuma clinic trial object respons rate patient complet respons median overal surviv yet reach interestingli lock team found respons deepen time show patient partial respons eventu becam complet respond surviv curv partial respond complet respond seem merg three month mark group similar progress free surviv rate point addit patient remain respons three month mark likelihood maintain respons one year mark day asco featur import updat cancer immunotherapi sure check blog tomorrow read recap',\n",
       " 'jimc normal still tumor pain palli radiat day alreadi finish radiat radiat suppos help shrink tumor reduc pain long take notic symptomat improv thank kkh diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'usual would mild flare year worst year ever sick origin put remicad lot side effect eventu built antibodi start humira pen shot hurt stomach take mg everi two week humira month say ucb symptom free never abl say thank humira save colon give life back',\n",
       " 'eagl glad got sort ask onc genet test sampl said done metatast wha spread lymphnod still metatast local metatast mayb dunno think right give durvamulab regardless pdl level anyway happi hear tagrisso work well',\n",
       " 'among paramet b cell patient ms produc elev level il mani info il target b cell treatment multipl sclerosi recent advanc remain challeng doi data identifi il import target modul autoimmun respons chronic inflamm il control th immun vivo inhibit convers convent cell foxp regulatori cell doi pna dind find info ocrelizumab act il interact b cell il',\n",
       " 'thank zoe would stop take gilenya danger see neurologist februari talk see plu even stop take month gilenya actual leav bodi system',\n",
       " 'chuck upset dismiss upset ridicul ye friend high place cancer field threat understand opdivo cure cancer work month wife outlier sincer hope remain point opdivo stop work cancer mutat that mutagen opdivo would kill happi cancer free meanwhil harm tri thing like ursol acid natur supplement oncologist said sure fwiw spirit crystal homeopath weird stuff scientif studi show promis unharm substanc given doctor appov hurt go die know go fight tri find way delay head direct possibl ration deter other look non toxic drug may help us point wife stop respond opdivo look trial data realli realli hope wrong folk need creativ look thing may help',\n",
       " 'rilonacept use treat symptom rare genet condit famili cold auto inflammatori syndrom fca muckl well syndrom mw fca mw inflammatori disord bodi develop certain symptom without known caus viru bacteria ill symptom includ fever chill fatigu joint pain seriou symptom may involv bone joint central nervou system deaf vision loss mental impair major organ kidney rilonacept may treat prevent symptom famili cold auto inflammatori syndrom fca muckl well syndrom mw howev medic cure inherit condit rilonacept may also use purpos list medic guid seriou sometim fatal infect may occur treatment rilonacept call doctor right away sign infect fever chill sore throat flu symptom easi bruis bleed noseble bleed gum loss appetit nausea vomit mouth sore unusu weak use medic allerg rilonacept type infect use rilonacept tell doctor activ chronic infect histori tuberculosi recurr infect high cholesterol triglycerid make sure current vaccin start treatment rilonacept tell doctor medic use especi drug treat arthriti psoriasi crohn diseas ankylos spondyl receiv live vaccin use rilonacept vaccin may work well time may fulli protect diseas avoid come contact anyon recent receiv live vaccin chanc viru could pass use medic allerg rilonacept type infect make sure rilonacept safe tell doctor condit activ chronic infect histori tuberculosi recurr infect high cholesterol triglycerid type fat blood make sure current vaccin start treatment rilonacept use rilonacept may increas risk develop certain type cancer talk doctor specif risk fda pregnanc categori c known whether rilonacept harm unborn babi tell doctor pregnant plan becom pregnant use medic known whether rilonacept pass breast milk could harm nurs babi use medic without tell doctor breast feed babi give medicin child younger year old without medic advic basicdescript back top rilonacept side effect get emerg medic help sign allerg reaction hive difficult breath swell face lip tongu throat seriou sometim fatal infect may occur treatment rilonacept call doctor right away new sign infect fever chill sore throat flu symptom easi bruis bleed noseble bleed gum nausea vomit loss appetit mouth sore unusu weak call doctor seriou side effect bloodi black tarri stool cough blood vomit look like coffe ground wheez chest tight troubl breath pain burn urin headach neck stiff increas sensit light purpl spot skin seizur convuls common side effect may includ cold symptom stuffi nose sneez cough sore throat nausea stomach pain diarrhea numb tingli feel pain swell red itch warmth blister bleed irrit medicin inject complet list side effect other may occur call doctor medic advic side effect may report side effect fda fda back top rilonacept interact receiv live vaccin use rilonacept vaccin may work well time may fulli protect diseas avoid come contact anyon recent receiv live vaccin chanc viru could pass live vaccin includ measl mump rubella mmr bacillu calmett gu rin bcg oral polio rotaviru smallpox yellow fever varicella chickenpox zoster shingl oral typhoid vaccin nasal flu influenza vaccin tell doctor medic use start stop use treatment rilonacept especi adalimumab humira certolizumab cimzia etanercept enbrel fingolimod gilenya golimumab simponi infliximab remicad leflunomid arava blood thinner warfarin coumadin jantoven list complet drug may interact rilonacept includ prescript counter vitamin herbal product possibl interact list medic guid back top rilonacept dosag follow direct prescript label use medicin larger smaller amount longer recommend rilonacept inject skin may shown use inject home use exactli prescrib doctor self inject medicin fulli understand give inject properli dispos use needl syring first dose may given two inject time differ place bodi rilonacept powder medicin must mix liquid diluent use use inject home sure understand properli mix store medicin use differ place stomach thigh upper arm time give inject care provid show best place bodi inject medic inject place two time row use rilonacept may need frequent blood test doctor offic singl use vial bottl medicin one use throw away one use even still medicin left inject dose use dispos needl throw away use needl punctur proof contain ask pharmacist get one dispos keep contain reach children pet store unmix powder medicin refriger protect light freez keep vial origin contain readi mix medicin mix rilonacept diluent store room temperatur use within hour protect light seek emerg medic attent call poison help line overdos symptom may includ sever form side effect list medic guid call doctor instruct miss appoint rilonacept inject',\n",
       " 'second go round avonex long stori first time almost five year ago rememb experi three month feel like pretti good howev last three week lot troubl walk lot stiff thigh much pain dw think fault avonex agre anyon els type problem take avonex go neuro tomorrow would like know talk think progress spm dx first symptom avonex copaxon tecfidera gilenya current dmt start aubagio back avonex hard beat person never give babe ruth',\n",
       " 'bffj new studi come everi day mechan ctla inhibit clear indic ipilimumab type igg antibodi caus treg deplet also costimulatori molecul ox gitr http www natur com icb journal v n full icb html manipul immun system care btw one inspir friend wrote pm wife pd l express take keytruda coupl time got strong overactiv cell develop cytokin releas syndrom could lethal lung cell inflam without infect cytokin attack lung tissu sever peopl die begin car cell trial need immun suppressor overcom syndrom',\n",
       " 'husband xeljanz month still full remiss appar side effect feel knew within two week help good luck take mg day mg morn afternoon spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper still taper prednison mg everi week develop osteoporosi due steroid',\n",
       " 'tumor keep get smaller look like mg pazo enough keep keytruda effect last summer certain would dead point',\n",
       " 'sorri go much add hope figur get relief soon diagnos hospit current sever proctiti current med flortistor entyvio sinc august pred mg',\n",
       " 'chicago pembrolizumab led superior overal surviv os among patient previous untreat advanc metastat non small cell lung cancer nsclc without egfr alk mutat pd l tumor proport score tp greater equal platinum base chemotherapi regimen accord data present plenari session american societi clinic oncolog annual meet sunday june data keynot studi previous demonstr first line pembrolizumab therapi led significantli prolong progress free surviv pf os among patient metastat nsclc studi particip target alter pd l tp greater equal keynot keynot clinicaltri gov identifi nct author evalu efficaci pembrolizumab among patient lower tp phase studi research randomli assign patient receiv pembrolizumab mg everi week investig choic chemotherapi includ paclitaxel plu carboplatin pemetrex plu carboplatin option pemetrex mainten therapi nonsquam histolog relat articl prophylact cranial irradi reduc incid brain metastas nsclc pembrolizumab chemotherapi combin significantli improv pf nsclc overal patient assign arm tp greater equal greater equal respect median follow month time analysi patient pembrolizumab arm continu therapi versu patient receiv pemetrex mainten therapi os significantli improv among patient tp treat pembrolizumab month compar month among patient receiv chemotherapi hazard ratio [hr] ci p among patient tp pembrolizumab led os month versu month chemotherapi arm hr ci p among patient tp patient pembrolizumab arm os month compar month among patient treat chemotherapi hr ci p moreov patient receiv pembrolizumab experienc lower rate treatment relat grade advers event compar chemotherapi vs pf outcom still investig author conclud data confirm potenti extend role pembrolizumab monotherapi standard first line treatment pd l express advanc metastat nsclc read cancer therapi advisor coverag american societi clinic oncolog asco meet visit confer page refer',\n",
       " 'inform provid nation multipl sclerosi societi import research progress occur offer new lead toward vision world free ms societi mobil peopl resourc everyon affect ms live best live stop ms track restor lost end ms forev continu pursu promis path uncov solut wherev opportun exist special focu progress ms nervou system repair lifestyl well gene environ result previou societi invest continu mount commit grow research fund even societi invest million new ongo research project initi brief summari signific research progress initi includ link detail stop ms posit result report three phase trial experiment therapi call ocrelizumab genentech member roch group show posit impact relaps ms first time larg scale trial modest impact primari progress ms societi collabor conven scientif workshop set research prioriti understand co morbid medic condit impact ms sever clinic trial outcom explor implic program develop find solut address co morbid may slow progress increas lifespan qualiti life peopl ms new studi uncov gene variat link respons ms therapi may open new treatment approach research toward import goal person medicin ms first gener version daili copaxon glatiram acet brand glatopa sandoz novarti compani develop collabor momenta pharmaceut approv fda distribut began sandoz june addit gener therapi expect soon scientist univers virginia uncov evid previous unrecogn network vessel facilit immun system activ brain team show evid network lymphat vessel mice peopl research need understand whether lymphat vessel play role ms whether present new opportun stop ms diseas activ result publish phase trial daclizumab high yield process zinbryta relaps ms show could significantli reduc relaps rate diseas activ observ mri scan cours year biogen abbvi appli regulatori agenc u europ obtain market approv treat peopl ms john dystel prize ms research went prof alastair compston univers cambridg drive breakthrough therapeut immunolog genet focu area progress ms clinic trial co fund societi repurpos oral epilepsi therapi call phenytoin show promis protect nervou system neuroprotect lead strategi slow stop progress disappoint result announc major trial tysabri natalizumab secondari progress ms gilenya fingolimod primari progress ms learn trial advanc understand process lead progress inform futur clinic trial design studi found ms progress faster continu smoke cigarett compar quit ms diagnosi may explain part societi fund studi show mice expos smoke show increas inflamm oxid stress ms outcom assess consortium rd annual meet fda ad new clinic trial data partner global effort develop tool provid sensit way detect benefit potenti treatment slow revers ms progress intern progress ms allianc held scientif meet ms pathophysiolog fund new collabor network plan grant grown member societi pharmaceut particip industri forum restor repair learn ms view news help provid educ inform person affect ms keep current multipl sclerosi news inform opt websit click thank',\n",
       " 'thank repli two differ opthomogi appoint today second opinion one advis vitrectomi suggest danger much blood eye atm complic happen gone suggest start inject first see goe reduc blood vessel said right eye sick left littl better finger cross tri stay posit polli alway experi make feel bit confid wish came goodluck futur cheer',\n",
       " 'waynexxl glad fine come gilenya one drug realli bad rebound come that usual within month otherwis relaps hit time wife follow om care also take tecfidera jcv risk low drug case basic peopl would got anyway part stop tysabri switch gilenya tecfidera becam jcv posit like problem impact switch tecfidera doesnt known pml issu lymphocyt level stay problem extend period time given risk profil benefit wouldnt choos aubagio first choic one option wife opt toward tecfidera aubagio actual realli good valu peopl fail drug doesnt seem like case jelinek book doesnt rule use dmt one reason say consid use side effect earlier drug flu like symptom etc might impact abil exercis etc tecfidera wife none first week realli miser doesnt even know taken track care pillbox',\n",
       " 'develop treatment multipl sclerosi past year success translat medicin timelin articl tintor et al chart major develop discuss implic current futur patient manag mar tintor angela vidal jordana jaum sastr garriga natur review neurolog review articl assess treatment outcom multipl sclerosi trial clinic set clinic trial outcom measur might determin whether drug worthi develop clinic might guid import treatment decis tur colleagu help clinician research navig maze option clinic neuroimag patient report composit outcom measur multipl sclerosi carmen tur marcello moccia frederik barkhof jeremi chataway jaum sastr garriga alan j thompson olga ciccarelli natur review neurolog scienc societi tension earli diagnosi misdiagnosi multipl sclerosi benefit earli treatment multipl sclerosi ms place pressur physician make diagnosi earli therebi increas risk misdiagnosi consider consequ patient health care system solomon corboy examin problem ms misdiagnosi includ probabl caus associ risk discuss tension earli diagnosi misdiagnosi might address andrew j solomon john r corboy natur review neurolog review articl autolog haematopoiet stem cell transplant treatment multipl sclerosi autolog haematopoiet stem cell transplant produc strike result patient aggress multipl sclerosi small trial review muraro et al provid overview procedur detail evid high efficaci multipl sclerosi provid recommend clinic use futur trial paolo muraro roland martin giovanni luigi mancardi richard nichola maria pia sormani riccardo saccardi natur review neurolog review articl treatment decis multipl sclerosi insight real world observ studi real world observ studi potenti answer question multipl sclerosi ms treatment random control trial cannot trojano colleagu discuss pitfal necessari safeguard observ studi insight studi provid treatment decis patient ms maria trojano mar tintor xavier montalban jan hillert toma kalincik pietro iaffaldano tim spelman maria pia sormani helmut butzkueven natur review neurolog review articl diseas modifi therapi infecti risk multipl sclerosi rang immunomodulatori therapi treat multipl sclerosi ms widen markedli recent year ms treatment becom effici improv efficaci accompani increas risk treatment associ infect review winkelman et al discuss mode action current avail ms therapi detail specif infect associ treatment consid inform influenc daili clinic use ms therapi minim associ infecti risk alexand winkelmann micha loebermann emil c reising han peter hartung uwe k zettl natur review neurolog review articl myeloid cell target medic multipl sclerosi review mishra yong consid myeloid cell monocyt macrophag microglia dendrit cell contribut patholog multipl sclerosi ms author also consid current multipl sclerosi treatment might directli indirectli affect cell manoj k mishra v wee yong natur review neurolog review articl aggress multipl sclerosi propos definit treatment algorithm subset patient multipl sclerosi ms demonstr rapid accumul disabl symptom refractori standard diseas modifi therapi rush colleagu present criteria identifi patient call aggress ms outlin efficaci variou therapi group patient author emphas need act quickli patient propos treatment algorithm aid clinic decis make carolina rush heather j maclean mark freedman natur review neurolog review articl defin score respons ifn multipl sclerosi rang therapeut option multipl sclerosi ms continu expand abil select appropri treatment patient becom increasingli import review sormani de stefano assess studi attempt classifi patient ms basi respons ifn treatment author also discuss develop use score system combin differ clinic mri marker aid definit earli respons drug maria pia sormani nicola de stefano natur review neurolog review articl b cell antibodi multipl sclerosi pathogenesi therapi increas evid support role b cell antibodi pathogenesi multipl sclerosi ms meinl colleagu discuss proinflammatori contribut b cell signal ms consid potenti target autoantibodi b cell respons variou ms therapi also summar marku krumbholz tobia derfuss reinhard hohlfeld edgar meinl natur review neurolog review articl fingolimod potenti novel therapi multipl sclerosi moder effect therapi current avail treatment multipl sclerosi ms new treatment ms neuroprotect properti well anti inflammatori effect need fingolimod could one potenti treatment articl akta et al examin underli biolog action prospect new therapi review data phase ii phase iii oral fingolimod clinic trial provid updat emerg field sphingosin phosphat receptor mediat therapi ms',\n",
       " 'updat saw ibd specialist yesterday first follow colonoscopi may nd week ago let rewind say stress appoint afraid ibd specialist would give option like bulli pick one wait test result honestli look surgeri tri drop mg mg prednison last monday aw horribl withdraw symptom start bleed defeat knew bad sign went back mg stabil actual bad bm everi day requir dulcolax though much blood tenesmu much better taken bentyl week still fatigu manag live life despit albeit hous messi someth gotta give great symptom improv sinc depend prednison humira cortifoam realli consid win thing consid discuss treatment plan tpmt normal metabol mp imuran drug becam option antibodi humira humira serum level low ibd specialist crinkl nose said anyth humira level low wait amount time start new biolog decid option discuss humira imuran b remicaid imuran antibodi c stelara imuran entyvio imuran e divert colostomi temp heal f perman colostomi discuss pro con treatment wait patient ibd specialist finish make flow chart explain everyth ask question gave input first question candid j pouch knew answer would correct immedi elimin option divert colostomi state go surgeri would choos perman surgeri sinc ultim want though disappoint j pouch option happi ibd specialist said surgeri good option sinc never shown inflamm outsid colon said chanc develop diseas elsewher mayb surgeri would need take med anymor woot ultim want med free diseas free life encourag could live life want live ostomi bar complic readi surgeri yet told research read peopl stori encourag even peopl complic tend happi surgeri afraid recoveri time see peopl feel better immedi activ within week surgeri howev troubl get excit want feel good still struggl imagin life ostomi scare complic turn way plan ibd specialist total understood told like humira think help much wors steroid alon like side effect want tri ad mp imuran see help wean prednison humira imuran first choic said ok problem elimin remicaid altogeth respons good still use rowasa enema humira imuran allow get prednison chose stelara imuran next drug therapi mostli stelara work quickli entyvio consid go straight ostomi humira imuran fail realli depend thing go someth click visit got car leav cri feel scare confus felt reliev surgeri sound bad start posit vision life ostomi famili go vacat june th ask keep thing stabl return want enjoy ibd specialist said cours told add imuran worri drop prednison get back appreci blood drawn monitor june nd see ibd specialist june th blood drawn need get flu shot pneumonia vaccin nervou get plane also go disneyland rememb measl outbreak mg prednison humira imuran hand immun system relentless physic pretti strong right chanc good fine suggest stay healthi travel appreci think guy yr femal dx uc dx chang crohn coliti current humira apriso uceri foam enema prednison buproprion synthroid start humira feb mg week previous fail remicaid previous use asacol lialda delzicol pentasa cortenema rowasa canasa entocort uceri gluten free supp vsl cal mag vit krill oil ezf iron',\n",
       " 'congratul great respons keytruda diagnos stage non small cell lung cancer march opdivo start later year fda approv happili stabl two half year treatment pretti well side effect muscl joint pain cours aw fatigu much better diagnosi start brain tumor lung tumor pulmonari embol come long way feel lucki thank think need think posit hope treatment work well also think opdivo miracl drug wish work well everybodi lisa',\n",
       " 'remind start entyvio pill cam think entyvio realli slow act perhap enough time rule complet start entyvio august januari dose final felt like someth diagnos w crohn med synthroid allergi med b liquid probiot fish oil turmer migrain med prn vicodin prn gall bladder remov start entyvio tri sulfasalazin asacol entocort imuran allerg humira remicad seriou joint pain fatigu stop dose mp cimzia pentasa mtx arava joint pain',\n",
       " 'result phase studi pembrolizumab chemotherapi pemetrex platinum base drug found combin result significantli longer overal surviv os progress free surviv pf compar chemotherapi alon reduc risk death patient metastat nonsquam non small cell lung cancer nsclc data present american associ cancer research confirm earlier phase studi find lead author leena gandhi md new york univers perlmutt cancer center nyu langon health new yok said data unequivoc alter clinician treat type nsclc studi first line therapi advanc nsclc lack target mutat egfr alk platinum base chemotherapi patient tumor proport score program death ligand pd l greater pembrolizumab replac cytotox chemotherapi dr gandhi also author phase studi said small number trial meant daili practic pattern chang number small make definit conclus patient phase studi howev estim rate os month pembrolizumab chemotherapi group compar placebo chemotherapi group median pf month pembrolizumab chemotherapi group month placebo chemotherapi group median os yet reach pembrolizumab chemotherapi group rate advers event almost ident two arm similar advers event grade higher relat articl immunotherapi lung cancer combin regimen path forward time report palli care need lead appropri end life care nsclc osimertinib improv qualiti life global health statu non small cell lung cancer result incred clear cut dr gandhi said earli look clear differ question result studi noth wait alter treatment regimen pd pd l inhibitor chemotherapi mount evid suggest pd pd l inhibitor effect treatment nsclc said instanc data present confer nivolumab ipilimumab advanc nsclc checkmat clinicaltri gov identifi nct found combin significantli prolong pf compar platinum doublet chemotherapi alon keynot studi clinicaltri gov identifi nct allow crossov pembrolizumab monotherapi patient demonstr diseas progress benefit combin shown patient level pd l express even pd l tumor proport score less dr gandhi said although greatest respons rate group differ found patient tumor proport score greater pembrolizumab combin group vs placebo combin group',\n",
       " 'hi sue discuss neuro rr spm definit told recent improv ask sure ms progress said sure anyon last damag disabl caus relaps otherwis return normal remiss definit progress ms also said mani peopl progress diseas relaps remiss dmd ms activ lot relaps never offer dmd yr confus realli lot think think elig treatment go find candid cladribin lisa',\n",
       " 'weekend post alemtuzumab work peopl fingolimod beg question transit peopl fingolimod onto someth els debat natalizumab alreadi look post aspect highlight fingolimod natalizumab racehors drug keep cell trap stop enter brain kill drug diseas form cell accumul time starter order race brain stop drug diseas rebound peopl mani limod trial ongo take fingolimod siponimod measur place drug suppli stop end trial rebound go prevent even progress everi want call ms trial drug kill drug trap drug fingolimod trap diseas caus cell lymphoid tissu natalizumab trap diseas caus cell blood stop diseas process diseas caus cell accumul trap whilst drug treatment place howev see cell racehors wait run brain starter order wait go gate open remov drug cell escap get brain diseas activ occur whilst peopl view progress ms differ diseas think dumb view importantli danger view clear mani peopl activ lesion come go progress cours carri look patholog peopl progress ms activ lesion clear peopl progress ms benefit immun inhibit howev think also case racehors drug allow accumul damag cell peopl progress ms extent drug convert subclin relaps patholog relaps activ ms time bomb tick drug stop hors line wait go stop drug relaps occur sometim call rebound call resum synchron relaps case like word rebound damag ever name call need avoid happen sure drk case report pleas drk say md davion jb et al two case relaps primari progress multipl sclerosi fingolimod withdraw j neurol',\n",
       " 'major research question multipl sclerosi ms determin person ms progress diseas cours respond treatment research attend american academi neurolog aan meet address crucial question look new emerg biomark ms biomark signatur found bodi object measur indic health reveal presenc progress diseas biomark interest ms right neurofila protein found nerv cell import mainten cell structur damag occur protein releas cerebrospin fluid blood measur cerebrospin fluid blood marker indic brain damag ms recent year research look level protein peopl diagnos ms found neurofila level associ ms moreov higher level serum neurofila present activ brain lesion diseas activ magnet reson imag outcom research built earlier find present result look neurofila biomark ms dr bar univers pensylvania dr calabresi john hopkin hospit dr kuhl univers basel dr sormani univers genoa evalu level neurofila blood cerebrospin fluid peopl ms treat differ diseas modifi therapi exampl dr bar measur level neurofila cerebrospin fluid withdrawn peopl treat ocrelizumab relaps remit ms understand go brain found treatment ocrelizumab reduc level white blood cell neurofila suggest neurofila might predict biomark effect treatment similarli dr kuhl dr calabresi show individu ms treat fingolimod natalizumab lower level neurofila blood compar peopl take mock drug dr thebault group dr freedman univers ottawa analyz blood serum cerebrospin fluid small group individu aggress ms receiv bone marrow transplant lower level neurofila found blood serum cerebrospin fluid receiv treatment encourag result although preliminari depict potenti neurofila monitor respons treatment togeth research identifi biomark easili obtain inexpens reliabl correl diseas progress use biomark measur lab still new clinic field might requir time implement standard practic said result present meet promis could hold great potenti fill critic gap clinic question biomark ms leav',\n",
       " 'much rechalleng rather clear afatinib best option slow rate growth cancer use instanc stereotact radiat area control lot inform go one cannot confid afatinib option next best would osimertinib erlotinib fewer side effect penetr brain better chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatin vinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan',\n",
       " 'hi amay mom standard chemo cocktail adenocarcinoma chemo keytruda recurr year later session keytruda chemo went keytruda year tom said pretti common growth earli scan growth attribut mani thing lot time inflamm mom case first glanc ct show look like cancer growth cancer cell found growth deem inflamm swell tumor attack immun system growth slowli start reced still present small year later although alway want hear evid diseas take time get keep finger cross good news tomorrow take care steff',\n",
       " 'daughter live bay area progress ms start ocrevu declin fast need doctor special progress diseas ucsf seem slip commun slat suggest advis',\n",
       " 'marc thank compliment regard healthnewsreview org recent stori ocrevu joy victori multimedia team launch podcast seri explor certain diseas tripl perspect patient healthcar provid journalist like ms wonder would will share thought patient perspect pleas email mlmjoyc umn edu thank michael',\n",
       " 'u inflectra ixifi remicad renflexi avail dosag form powder solut therapeut class immunolog agent pharmacolog class tumor necrosi factor inhibitor use infliximab infliximab inject use adult treat crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti chronic sever plaqu psoriasi also use children treat crohn diseas ulcer coliti infliximab inject monoclon antibodi work enhanc improv immun system infliximab avail doctor prescript use infliximab decid use medicin risk take medicin must weigh good decis doctor make infliximab follow consid allergi tell doctor ever unusu allerg reaction infliximab medicin also tell health care profession type allergi food dye preserv anim non prescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatr specif problem would limit use infliximab inject treatment crohn diseas ulcer coliti children year age older howev safeti efficaci establish children younger year age appropri studi perform relationship age effect infliximab inject children plaqu psoriasi safeti efficaci establish appropri studi perform date demonstr infliximab inject help children juvenil rheumatoid arthriti efficaci establish geriatr appropri studi perform date demonstr geriatr specif problem would limit use infliximab inject elderli howev elderli patient like infect may requir caution patient receiv infliximab inject pregnanc pregnanc categori explan trimest b anim studi reveal evid harm fetu howev adequ studi pregnant women anim studi shown advers effect adequ studi pregnant women fail demonstr risk fetu breast feed adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur case doctor may want chang dose precaut may necessari receiv infliximab especi import healthcar profession know take medicin list follow interact select basi potenti signific necessarili inclus use infliximab follow medicin usual recommend may requir case medicin prescrib togeth doctor may chang dose often use one medicin abatacept adalimumab adenoviru vaccin type live adenoviru vaccin type live alefacept anakinra bacillu calmett guerin vaccin live brodalumab certolizumab pegol cyclosporin etanercept fosphenytoin golimumab guselkumab influenza viru vaccin live ixekizumab measl viru vaccin live mump viru vaccin live natalizumab paclitaxel phenytoin polioviru vaccin live quinidin rilonacept rituximab rotaviru vaccin live rubella viru vaccin live sarilumab sirolimu smallpox vaccin tacrolimu tocilizumab tofacitinib typhoid vaccin ustekinumab varicella viru vaccin live vedolizumab warfarin yellow fever vaccin zoster vaccin live interact food tobacco alcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco medic problem presenc medic problem may affect use infliximab make sure tell doctor medic problem especi aspergillosi fungu infect histori blastomycosi fungu infect histori blood bone marrow problem eg pancytopenia histori candidiasi fungu infect histori coccidioidomycosi fungu infect histori diabet guillain barr syndrom nervou system disord histori hepat b activ histori histoplasmosi fungu infect histori legionellosi bacteri infect histori leukopenia neutropenia low white blood cell listeriosi bacteri infect histori liver diseas multipl sclerosi histori optic neuriti eye problem pneumocystosi fungu infect histori psoriasi skin diseas seizur convuls histori thrombocytopenia low platelet blood use caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copd use caution may increas chanc new cancer congest heart failur moder sever given patient condit tuberculosi histori use caution patient may need addit tuberculosi therapi proper use infliximab doctor train health profession give infliximab given needl place one vein must given slowli needl remain place least hour infliximab come medic guid read follow instruct care ask doctor question may also receiv medicin eg allergi medicin fever medicin steroid help prevent possibl unwant effect inject precaut use infliximab import doctor check progress regular visit make sure infliximab work properli blood test may need check unwant effect infliximab may caus infus reaction includ heart attack stroke chang blood pressur heart rhythm problem eg arrhythmia receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow short breath troubl breath swell face tongu throat bodi abil fight infect may reduc use infliximab import call doctor first sign infect check doctor right away fever chill cough flu like symptom unusu tired weak seriou skin reaction occur use infliximab check doctor right away blister peel loosen skin chill cough diarrhea fever itch joint muscl pain red skin lesion sore throat sore ulcer white spot mouth unusu tired weak infliximab may increas chanc lupu like syndrom liver diseas call autoimmun hepat check doctor right away dark brown color urin fever chill gener feel discomfort ill weak joint pain light color stool nausea vomit rash cheek arm wors sun sever tired upper right side stomach pain yellow eye skin small number peopl includ children teenag use infliximab develop certain type cancer common patient lung diseas eg emphysema copd heavi smoker psoriasi patient phototherapi treatment long time phototherapi treatment ultraviolet light sunlight combin oral medicin make skin sensit light teenag young adult crohn diseas ulcer coliti also develop rare type cancer call hepatosplen cell lymphoma talk doctor unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss red scali patch rais bump pu skin use infliximab may increas risk get skin cancer eg melanoma merkel cell carcinoma cervic cancer chang growth skin abnorm vagin bleed pelvic pain tell doctor right away treat infliximab immun vaccin without doctor approv live viru vaccin given infliximab child vaccin must current use infliximab talk child doctor question women babi receiv infliximab make sure babi doctor know use infliximab need wait month give certain vaccin babi talk babi doctor question need skin test tuberculosi start use infliximab tell doctor anyon home ever posit reaction tuberculosi skin test import heart check close receiv infliximab call doctor right away short breath swell ankl feet sudden weight gain take medicin unless discuss doctor includ abatacept orencia anakinra kineret tocilizumab actemra medicin call biolog use treat condit infliximab use medicin togeth infliximab may increas chanc seriou unwant effect infliximab side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur common chest pain chill cough dizzi faint fever flush red face headach hive itch rash muscl pain nasal congest nausea runni nose sneez sore throat stomach pain tight chest troubl breath unusu tired weak vomit less common back pain bloodi cloudi urin crack skin corner mouth diarrhea difficult pain urin frequent urg urin pain tender around eye cheekbon sore irrit mouth tongu sore red around fingernail toenail vagin burn itch discharg white patch mouth tongu rare abscess area infect contain pu black tarri stool blood urin stool bone joint pain constip feel full hernia lump abdomen stomach irregular pound heartbeat pain rectum pain spread abdomen stomach left shoulder pinpoint red spot skin stomach pain sever swollen pain gland tendon injuri unusu bleed bruis unusu weight loss yellow skin eye incid known bloodi nose burn tingl numb pain hand arm feet leg chang mental statu clay color stool continu vomit dark bloodi urin difficulti speak difficulti swallow fast heartbeat gener feel tired weak heavier menstrual period hoars inabl move arm leg itch puffi swell eyelid around eye face lip tongu light color stool loss appetit loss bladder control lower back side pain muscl spasm jerk extrem noisi breath painless swell neck armpit groin pale skin red scale crust skin red sore itch skin seizur sensat pin needl sever muscl weak sudden progress slow irregular breath sore welt blister stab pain sudden loss conscious sudden numb weak arm leg unpleas breath odor upper right stomach pain vomit blood side effect list may also occur patient notic effect check healthcar profession call doctor medic advic side effect may report side effect fda fda',\n",
       " 'hello would like know doctor use combin immunotherapi tki drug egfr patient combin two immunotherapi drug combin immunotherapi chemo combin therapi increas respons rate egfr patient dad recent ct scan show progress tagrisso diagnos leptomening metastasi nov brain mri dec still show stabl feel comfort immunotherapi alon heard respons rate egfr patient end sever health condit requir hospit kkh diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'schedul neuro appoint yesterday us current stabl gilenya view cladribin said put cladribin heartbeat strong advoc lemtrada quit patient lemtrada optimist cladribin get approv near futur fda see goe',\n",
       " 'trial failur gave result rememb compound licens australia russia may well europ merck submit document ema approv howev fda ema approv movectro sure would sun part programm sure get fingolimod goe gener cladribin patent deriv dead arriv depend stack better mayb peopl pay look forward day fingolimod goe gener although sure landscap may inde chang us novarti lost extens case australia sling mud like help know sling help right sling otherwis come across troll behaviour would like chang howev would like understand posit tri defend upset mayb get name like mudsling rather hide behind anaonym dish dirt',\n",
       " 'lung cancer lead caus cancer death men women unit state respons million death worldwid year advanc target molecular therapi improv outcom patient egfr driven tumor approxim peopl north america whose tumor driven mutat kra gener consid inelig therapi presenc mutat usual found codon eg kra g associ poor prognosi surviv poor respons egfr inhibit patient non small cell lung cancer nsclc howev new research two group work independ scotland vienna show signal erbb famili member necessari surviv prolifer kra driven tumor tyrosin kinas inhibitor tki block multipl erbb specif afatinib neratinib produc antitumor respons egfr one four erbb famili receptor tyrosin kinas found upstream kra g protein gtpase activ part erk mek pathway cell kra normal activ respons signal upstream receptor tyrosin kinas egfr erbb activ mutat kra thought confer independ upstream regul howev studi show g mutant kra continu requir input egfr erbb famili receptor order drive lung cancer explain daniel j murphi phd lead investig oncogen induc vulner group univers glasgow institut cancer scienc cruk beatson institut cancer research scotland relat articl biomark base blood test may extend reach ct screen certain lung cancer role braf mutat non small cell lung cancer still emerg evolv bevacizumab plu erlotinib may new standard care non small cell lung cancer patient kra driven tumor gener respons egfr specif inhibitor use treat lung cancer erlotinib gefitinib studi found kra mutat tumor progress increasingli express non egfr erbb ligand depend altern erbb famili signal surviv vienna studi inhibit erlotinib genet inactiv egfr led mutat kra adenocarcinoma overexpress erbb famili receptor thu work around loss egfr signal restor downstream growth factor activ use publicli avail data set biopsi human tumor vitro model mous model moll colleagu demonstr non egfr erbb signal activ appear necessari surviv human mous kra driven lung adenocarcinoma afatinib inhibit tumor growth',\n",
       " 'new diabet diabet retinopathi research indic peopl type diabet intens control blood sugar level landmark ction c ontrol c ardiovascular r isk iabet accord trial eye studi cut risk diabet retinopathi half follow analysi call accord follow eye studi accordion conduct four year stop intens blood sugar control regimen requir accord trial studi send power messag peopl type diabet worri lose vision said dr emili chew studi co author deputi director nation eye institut divis epidemiolog clinic applic well control glycemia blood sugar level posit measur last effect eye health pleas note howev cautionari issu unresolv caus factor relat blood sugar glycem control group origin accord studi discuss reader evalu care discuss physician research diabet care new diabet retinopathi research entitl persist effect intens glycem control retinopathi type diabet action control cardiovascular risk diabet accord follow studi publish juli edit diabet care peer review journal publish monthli american diabet associ ada diabet care journal health care practition intend increas knowledg stimul research promot better manag peopl diabet author emili chew md nation eye institut action control cardiovascular risk diabet follow accordion eye studi group action control cardiovascular risk diabet follow accordion studi group explan terminolog accord trial accord trial involv studi site across north america enrol particip type diabet purpos accord trial test three treatment strategi reduc risk cardiovascular diseas among peopl longstand type diabet maintain near normal blood sugar level intens glycem control improv blood lipid level lower ldl bad cholesterol triglycerid rais hdl good cholesterol lower blood pressur [editor note treatment phase glycem blood sugar control portion accord plan last year stop year due increas death among particip intens glycem control group analys thu far determin specif caus increas death howev benefit intens glycem therapi must weigh potenti risk notabl increas risk death observ accord trial ] accord trial eye studi analyz subset trial particip receiv laser photocoagul vitrectomi prolif diabet retinopathi data begin year four studi accord sponsor nation heart lung blood institut collabor nation institut diabet digest kidney diseas nation institut age nation eye institut center diseas control prevent read accord trial nation institut health clinic trial gov accordion follow eye studi accordion follow assess diabet retinopathi progress peopl particip accord accordion assess diabet retinopathi approxim four year intens glycem control portion studi end eight year enrol accord time averag c see explan percent intens therapi group percent standard therapi group howev diabet retinopathi advanc percent particip intens therapi group sinc enrol accord compar percent standard therapi group accordion fund nation heart lung blood institut part nation institut health type diabet type diabet formerli call adult onset type ii non insulin depend follow characterist usual occur age affect individu diabet occur pancrea produc enough insulin insulin defici bodi cell abl use insulin correctli effici insulin resist condit present glucos continu rise bloodstream suffici level insulin avail open cell allow glucos enter initi manag weight loss physic activ effect meal plan individu suffic period time diseas progress howev oral medic insulin may also requir primari risk factor includ increas age ethnic background african american latino nativ american asian famili histori obes learn diabet c test c blood test also known glycat hemoglobin hemoglobin c hba c primari tool use diagnos diabet pre diabet monitor blood glucos control peopl type type diabet test enabl health care provid diagnos diabet treat complic occur diagnos pre diabet prevent delay develop type diabet read establish c level use diagnos diabet pre diabet diabet signific c test research excerpt intens diabet treatment prevent damag vision unit press intern intens treatment diabet help prevent damag blood vessel retina often lead blind accord long term studi nation institut health research use aggress treatment maintain glycem control blood lipid level blood pressur cut risk develop diabet retinopathi half report research stop portion focus glycem control year plan year test increas death among particip though patient treat blood pressur blood lipid level continu rest intend test period tight control condit improv health patient reduc risk cardiovascular diseas treatment howev reduc progress retinopathi one third new studi research examin patient took part origin accord studi measur progress particip retinopathi four year treatment conclud measur blood glucos particip receiv intens standard care remain similar end previou studi percent particip seen advanc retinopathi less half percent receiv standard treatment whose condit progress diabet eye diseas diabet retinopathi although peopl diabet like develop cataract younger age twice like develop glaucoma peopl diabet primari vision problem caus diabet diabet retinopathi lead caus new case blind low vision adult age person diabet retinopathi may see retinopathi gener term describ damag retina retina thin light sensit tissu line insid surfac eye nerv cell retina convert incom light electr impuls electr impuls carri optic nerv brain interpret visual imag diabet retinopathi occur damag small blood vessel nourish tissu nerv cell retina prolif gener term mean grow increas rapid rate produc new tissu cell term prolif use relat diabet retinopathi describ growth prolifer abnorm new blood vessel retina non prolif indic process yet occur prolif diabet retinopathi affect approxim individu diseas four stage diabet retinopathi accord nation eye institut diabet retinopathi four stage mild non prolif retinopathi earli stage small area balloon like swell occur retina tini blood vessel moder non prolif retinopathi diseas progress blood vessel nourish retina becom block sever non prolif retinopathi mani blood vessel becom block disrupt blood suppli nourish retina damag retina signal bodi produc new blood vessel prolif retinopathi advanc stage signal sent retina trigger develop new blood vessel grow prolifer retina vitreou transpar gel fill interior eye new blood vessel abnorm ruptur bleed caus hemorrhag retina vitreou scar tissu develop tug retina caus damag even retin detach studi diabet care condens excerpt articl summari conclus full articl avail onlin result show intens glycem control confer endur protect progress diabet retinopathi even though glycat hemoglobin level similar year random year cessat clinic trial first studi peopl type diabet year durat establish cardiovascular diseas unlik newli diagnos particip unit kingdom prospect diabet studi ukpd demonstr effect phenomenon call metabol memori legaci effect studi type diabet accordion find demonstr similar legaci effect intens glycemia control progress retin diseas peopl establish type diabet moreov effect occur respons median year intens glycem control observ peopl type diabet addit cardiovascular risk factor whose mean diabet durat year whose initi mean hba c observ suggest glucos lower reduc progress retin diseas rel late cours diabet retina respond rel short term chang glucos level whether even shorter period glucos lower could achiev similar long term effect eye either type type diabet remain unknown summari studi result provid evid intens glycem control benefici reduc progress diabet retinopathi legaci effect evid peopl type diabet addit accordion retin result prior find demonstr posttreat benefit intens glycemia control progress eye kidney nerv diseas',\n",
       " 'gumbi thank worri surpris either day surpris someth work think cimzia approv treatment crohn uk anoth thing check rather tri stelara least someth differ anti tnf map treatment yeah would consid posit map mani antibiot cours coupl taken make differ fact metronidazol flagyl posit horribl stoma necessarili stop diseas crohn guarante said far stoma liter thing year given break crohn get stoma come back see better posit torn',\n",
       " 'biolog price competit innov act bpci act sign law march part afford care act bpci act creat abbrevi approv process biosimilar goal demonstr biosimilar propos product origin product independ establish safeti effect propos product total evid approach taken fda evalu biosimilar approv result clinic trial import data preclin work also consid biosimilar approv use fda approv addit indic condit base concept call extrapol data data collect biosimilar preclin work show clinic result origin product biolog addit clinic trial conduct instanc clinic trial biosimilar filgrastim sndz studi effect safeti clinic trial whose particip treat breast cancer approv grant fda filgrastim sndz bone marrow stimul five indic approv origin product filgrastim patient cancer receiv myelosuppress chemotherapi treatment stop slow growth blood form cell bone marrow patient acut myeloid leukemia receiv chemotherapi patient cancer undergo bone marrow transplant patient undergo autolog peripher blood progenitor cell collect therapi method replac blood form stem cell destroy cancer treatment patient sever chronic neutropenia abnorm low count type white blood cell biosimilar approv fda includ filgrastim sndz current twelv biosimilar approv fda treatment specif condit fda approv six immunosuppres drug treatment certain form arthriti psoriasi ulcer coliti crohn diseas drug list order approv infliximab dyyb inflectra origin product infliximab remicad etanercept szz erelzi origin product etanercept enbrel adalimumab atto amjevita origin product adalimumab humira infliximab abda renflexi origin product infliximab remicad adalimumab adbm cyltezo origin product adalimumab humira infliximab qbtx ixifi origin product infliximab remicad septemb fda approv bevacizumab awwb mvasi treatment five type cancer non squamou non small cell lung cancer nsclc metastat colorect cancer mcrc glioblastoma metastat renal cell carcinoma persist recurr metastat carcinoma cervix bevacizumab awwb approv indic origin drug bevacizumab avastin could reach u market soon patent bevacizumab expir decemb fda approv trastuzumab dkst ogivri treatment peopl posit breast cancer posit gastric cancer growth promot protein found surfac cancer cell origin drug trastuzumab herceptin patent expir',\n",
       " 'hi mri everi month sinc februari octob met neurologist blue said jc viru level risk zone pml need come gilenya took last one today wait month mri due st cours lemtrada point next year one seem know could everyth lengthi time look first time year could interest felt like nag everi time question next mri risk level feel justifi keep top also special blood test courier denmark everi month pml check stop year say need mri scan keep express concern led believ pml slow progress notic earli better chanc deal much hope spot month later good luck keep strong x',\n",
       " 'new fda approv zykadia ceritinib alk posit nsclc think poor choic initi treatment fda approv new therapi approxim patient nsclc molecular marker known alk rearrang cancer journey diagnos treatment cancer type lung cancer diseas learn target therapi target therapi alk target therapi patient forum septemb speaker highlight jame stevenson md grace excit continu build faculti agenda upcom target therapi patient forum septemb see inform present speaker highlight today introduc jame stevenson md cancer journey treatment cancer type lung cancer diseas learn target therapi imprecis medicin keytruda pembrolizumab chemo pd l nsclc readi prime time let start say fan immun checkpoint inhibitor keytruda pembrolizumab consid new standard care cancer journey diagnos treatment cancer type lung cancer diseas learn first line treatment target therapi chemotherapi immunotherapi immunotherapi wrong choic lung cancer patient amidst glow report immunotherapi lung mani cancer would understand patient physician tempt rush toward priorit immunotherapi first treatment strategi pursu fact cancer journey treatment cancer type lung cancer diseas learn target therapi first line treatment symptom second line treatment death pseudo progress know cut loss immunotherapi among mani novel concept manag immunotherapi potenti pseudo progress unusu phenomenon patient scan cancer journey diagnos treatment cancer type lung cancer diseas learn first line treatment target therapi second line treatment immunotherapi view commun forum local therapi metastat lung cancer hi grace member grace happi present partnership swedish cancer institut local therapi metastat lung cancer cancer journey diagnos treatment cancer type lung cancer diseas learn lung cancer drug target therapi alk target therapi egfr target therapi ro procedur treatment chemotherapi tumor marker test target therapi investig agent immunotherapi radiat therapi non small cell lung cancer progress tarceva neg progress year tarceva tissu biopsi show neg suggest experi next step onc suggest move afatinib opdivo pdl test cancer journey treatment cancer type lung cancer diseas learn lung cancer gener lung cancer target therapi egfr target therapi molecular test immunotherapi non small cell lung cancer vaxira stage nsclc anyon inform obtain use vaxira cuban drug stage advanc nsclc sure us citizen still travel cancer journey treatment cancer type lung cancer diseas learn angiogenesi rd line beyond target therapi investig agent non small cell lung cancer tagrisso acquir resist tarceva wife come long way stage iv lung cancer sinc develop acquir resist tarceva gene sequenc biopsi cancer journey diagnos treatment survivorship cancer type lung cancer diseas learn lung cancer target therapi egfr target therapi non small cell lung cancer',\n",
       " 'thank diagnos nsclc stage iv met bone one brain lesion hip lesion egfr exon g g februari know exon rare tarceva sinc mid march look like progress blood least neg physician consid new biopsi find place data suggest exon commonli mutat perhap compar exon seem choic progress rare mutat current standard next step med neg thank',\n",
       " 'fail remicad cimzia humira entivyo sigh insur cover stelara experiment unsubstanti sure experiment fda approv stelara last year crohn appeal decis probabl good chanc win appeal get gi offic involv appeal also state insur regul keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri total hip replac thank prednison current condit chronic pouchiti bad thought would current med stelara',\n",
       " 'howev vote count start higher leav predict go close look thing less affluent area vote much higher number predict swing leav entyvio infus tomorrow realli stay night watch proctiti pan coliti mani well year flare yr med help raw sauerkraut mezav xl x day march pseudomembran coliti treat flagyl thing harder sinc cours pred intoler aza mp oct start entyvio far good respons',\n",
       " 'holtyc understand concern father may option progress variant ms slight improv none nation institut clinic excel nice determin drug suppli nh base effect valu money lot research go http www mssocieti org uk research explor research emerg research treatment explor treatment trial resulttyp list sort relev page result howev futur look answer follow interest http multipl sclerosi research blogspot com cladribin peopl progress html father london base well could ask refer bart team see treat label',\n",
       " 'thank jo nock use post link buy also help symptom take care ulcer coliti sinc juli pred mg upadacitinib clinic trial sinc octob colazid g entyvio vedolizumab sinc januari stop oct lost respons azathiporin mg stop due clinic trial',\n",
       " 'novarti today announc posit result phase iii expand studi show oral daili baf siponimod significantli reduc risk confirm disabl progress compar placebo peopl secondari progress multipl sclerosi spm spm form ms character continu worsen neurolog function time independ relaps toplin result expand present nd congress european committe treatment research multipl sclerosi ectrim london uk baf investig select sphingosin phosphat p receptor modul initi first interpret data expand studi show treatment baf reduc risk three month confirm disabl progress compar placebo p risk reduct six month confirm disabl progress greater support robust data consist reduct risk three month confirm disabl progress across predefin subgroup signific differ favor baf compar placebo month annual relaps rate percent chang brain volum chang baselin volum lesion brain lesion identifi weight magnet reson imag scan differ chang baselin time foot walk test fw signific baf gener safe well toler profil compar drug class avail treatment option delay diseas progress spm high unmet need effect therapi accept safeti profil peopl condit said vasant narasimhan global head drug develop chief medic offic novarti novarti global leader understand role p receptor modul treatment ms posit result expand studi continu ongo effort innov meet need patient data posit stride forward unserv diseas area look forward evalu next step health author expand largest random control studi spm date patient enrol expand repres gener spm popul must diagnos spm also demonstr progress disabl two year prior studi major patient non relaps spm mean age studi entri year patient median expand disabl statu scale edss score correspond use walk aid novarti complet full analys expand data evalu next step consult health author full studi result includ data primari secondari endpoint submit public expand studi expand studi random doubl blind placebo control phase iii studi compar efficaci safeti baf versu placebo peopl secondari progress ms spm largest random control studi spm date includ peopl spm countri time studi individu enrol expand mean age year live ms approxim year patient receiv diagnosi spm also demonstr progress disabl two year prior studi also expand disabl statu scale edss score inclus median score correspond use walk aid patient random receiv either mg baf placebo ratio respect primari endpoint studi time three month confirm disabl progress measur edss versu placebo secondari endpoint includ delay time six month confirm disabl progress base edss versu placebo time confirm worsen least baselin time foot walk test fw lesion volum annual relaps rate arr safeti toler baf peopl spm baf siponimod baf siponimod investig select modul specif type sphingosin phosphat p receptor p receptor commonli found surfac specif cell resid central nervou system cn respons caus cn damag drive loss function secondari progress ms spm vitro studi show baf enter brain bind specif receptor may prevent activ harm cell help reduc loss physic cognit function associ spm multipl sclerosi multipl sclerosi ms chronic disord central nervou system cn disrupt normal function brain optic nerv spinal cord inflamm tissu loss evolut ms result increas loss physic e g walk cognit e g memori function three type ms relaps remit ms rrm secondari progress ms spm primari progress ms ppm spm character gradual worsen neurolog function time lead progress accumul disabl independ relaps sever affect patient abil carri everyday activ usual follow initi phase rrm account approxim ms diagnos quarter peopl rrm eventu go develop spm within year initi rrm diagnosi rise three quarter year remain high unmet need effect safe treatment help delay disabl progress spm ms affect around peopl us novarti multipl sclerosi novarti multipl sclerosi ms portfolio includ gilenya fingolimod p modul indic relaps form ms also develop pediatr ms extavia interferon beta b subcutan inject approv us treatment relaps form ms europ extavia approv treat peopl relaps remit ms secondari progress ms spm activ diseas peopl singl clinic event suggest ms addit baf siponimod develop spm investig compound includ ofatumumab omb fulli human monoclon antibodi develop relaps ms ofatumumab target cd current investig two phase iii pivot studi us sandoz divis novarti market glatopa glatiram acet inject mg ml first gener version teva copaxon mg disclaim forego releas contain forward look statement identifi word continu investig continu ongo effort stride forward look forward next step develop investig similar term express impli discuss regard potenti market approv baf omb potenti new indic label gilenya extavia regard potenti futur revenu baf gilenya extavia omb glatopa place undu relianc statement forward look statement base current belief expect manag regard futur event subject signific known unknown risk uncertainti one risk uncertainti materi underli assumpt prove incorrect actual result may vari materi set forth forward look statement guarante baf omb approv sale market particular time neither guarante gilenya extavia submit approv addit indic label market particular time guarante baf gilenya extavia omb glatopa commerci success futur particular manag expect regard product investig compound could affect among thing uncertainti inher research develop includ unexpect clinic trial result addit analysi exist clinic data unexpect regulatori action delay govern regul gener compani abil obtain maintain proprietari intellectu properti protect gener econom industri condit global trend toward health care cost contain includ ongo price pressur unexpect safeti qualiti manufactur issu risk factor refer novarti ag current form f file us secur exchang commiss novarti provid inform press releas date undertak oblig updat forward look statement contain press releas result new inform futur event otherwis novarti novarti pharmaceut corpor offer broad rang medicin cancer cardiovascular diseas endocrin diseas inflammatori diseas infecti diseas neurolog diseas organ transplant psychiatr diseas respiratori diseas skin condit locat east hanov nj novarti pharmaceut corpor affili novarti ag provid innov healthcar solut address evolv need patient societi headquart basel switzerland novarti offer diversifi portfolio best meet need innov medicin eye care cost save gener pharmaceut novarti global compani lead posit area group achiev net sale usd billion r throughout group amount approxim usd billion usd billion exclud impair amort charg novarti group compani employ approxim full time equival associ novarti product avail countri around world inform pleas visit http www novarti com novarti twitter sign follow novarti http twitter com novarti novarti multimedia content pleas visit www novarti com news media librari question site requir registr pleas contact media relat novarti com copaxon regist trademark teva pharmaceut industri ltd novarti media relat central media line e mail',\n",
       " 'amap therapi magic bullet everyon much higher success rate biolog citat pleas uc crohn possibl dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'well year wife diagnosi previou updat need start thank everyon dedic compass pass site cancer journey emot rocki path deal cancer inde bless place get clear focus inform peopl care much affect remain deepli grate year ago first start read stage nsclc afraid wife might even make long despit persist call mani way everi cancer everi patient uniqu statist still fear odd place everyth seem stabl good moment cancer still lurk around corner gemzar seem hold thing bay moment next ct scan next week alway apprehens w new ct keep keyboard finger cross wife feel realli good bit headach ach coupl day treatment noth like carbo wife amaz strength energi complet co chair huge fundrais gala synagogu continu x week esl tutor adult continu commun choru keep score basic treatment line effect line treatment ineffect one appar new metastas number month year son graduat colleg daughter got engag marri gone israel galapago quebec taken number small trip la toronto denver time also includ father death year ago unfortun fall section famili almost exactli year ago one graph speak site remain bright spot world fog fear wife lifelong non smoker dx adeno nsclc stage iv poorli diff bone met lymph node exon mutat x carbo alimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo effect add l growth clinic trial drug larg reduct tumor met tumor growth liver met stabl stabl add l growth trial gemzar tumor reduct stabl',\n",
       " 'guysssss updat work realli hard get healthi back shape sinc colectomi oct cannot believ month alreadi previous wrote hardest part heal process wean darn prednison coupl month ago sign fatloss program week time lost lb competit proud famili took vacat hawaii found pregnant crazi right one point thread thought life never well would never abl workout never anoth child glad wrong surgeri gave back life life good ostomi yr femal dx uc dx chang crohn coliti current total colectomi oct previous use remicad humira stelara imuran mp apriso asacol lialda delzicol pentasa cortenema cortifoam rowasa canasa entocort uceri uceri foam prednison gluten free supp vsl cal mag vit krill oil ezf post edit plucki pm gmt',\n",
       " 'hey everyon crohn small illieum believ call lol alreadi humira remicad crohn sinc remicad stop work doctor switch stelara get infus first time yesterday remaind time take shot first shot week sinc infus yesterday wonder long take stelara kick anyon experi side effect reach remiss anyth tell help thank',\n",
       " 'hi fano addit great inform alreadi provid janin write review anoth post dr west deal valu pd l test differ respons eventu approv keytruda opdivo point although opdivo seem efficaci pd l neg patient approv use patient keytruda due differ clinic trial led drug approv differ mechan action agent also note addendum post dr west soften stanc whether second line taxoter docetaxel clearli superior opdivo set also state feel patient get opportun treatment immunotherapi agent point jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'hello friend seek advic behalf mother gilotrif month first line treatment stage iv nsclc adenocarcinoma egfr exon never smoker respons initi posit recent medic seem less effect diseas shown progress given advanc age januari opt liquid biopsi test genet marker use genestrat test test unfortun came back neg realiz tissu biopsi conclus determin mutat depend site sampl fals neg still possibl use method greater chanc develop drug resist due mutat possibl posit enough circul tumor detect current sampl method find mutat easter egg hunt leav candid could potenti benefit question even though result mutat may neg new medic tagrisso still work germlin egfr genet marker would go far label treat tagrisso despit inclus result possibl drawback prescrib egfr chanc step would need prescrib tagrisso second line treatment label use treat egfr patient given condit tradit chemotherapi would overwhelm sincer chi topic modifi year month ago chidog topic modifi year month ago chidog',\n",
       " 'sth cladribin week ago simpl procedur day intect secondari effect realli pill given think rrm think pharma money make inyect differ situat eg advanc inject patent cheaper internet full scari stuff peopl report thing sometim could ms drug way hair lost case least yet still keep frizzi hair work earli day guess hope let see fingolimod think good stop relaps noth start spm take bad place secondari effect lymphocit low lymphopenia get wors time re_bound effect stop twice immun system back normal attack come back opinion drug stop spm beast would go sth caus troubl realli go case spm start yesr older younger noon predict take care xxx',\n",
       " 'diagnos stage adenocarcinoma dec one met hipbon anoth met hipbon discov may treat vat ull remov lung tumor radiat met current ned take tarceva sinc may hope stay ned due side effect first worst horribl acid reflux dosag reduc mg mg otherwis healthi year old femal non smoker struggl side effect tarceva reflux continu frequent diarrhea horribl fatigu depress rash eye sore nose alway terribl sore constantli runni hair fall stop grow food tast mouth alway sensit doctor casual ask want stop medic realli entertain much discuss pro con scare know high recurr stage lung cancer idea success other medic stay ned also wonder other taken break medic doctor impli one start medic cannot stop develop resist one time chanc opportun grow weari cumul effect side effect also know could much wors cours grate ned will need improv chanc stay way',\n",
       " 'repli post david remicad stelara sever other possibl side effect deal infect sinc knock immun system side effect warn odd took remicad imuran dx decad ago develop abnorm lymph respons develop tumor lymph node realli heart believ imuran blame scare lymphoma tumor remov everyth benign thank move humira work sever year got great remiss year recent fail humira becam hypotens blood pressur drop believ plummet bp exampl time odd reaction humira quit humira month bo return normal start stekara effect thu far got load infus keep finger cross work magic make well',\n",
       " 'hi patterson welcom whatnext glad found us also glad alreadi ask question cancer adenocarcinoma non squamou cell non small cell specif relat opdivo control cancer past year hope similar result keytruda',\n",
       " 'oncologist talk dental health beyond ask mouth sore oncologist busi peopl patient mani question cancer treatment miss ask import area affect overal well wallet treat system cancer treatment like affect oral health tip good oral hygien tip take care mouth fight cancer tip help newli diagnos lung cancer patient treatment make dental appoint soon possibl learn lung cancer get good clean fix lurk dental problem soon cancer treatment may make difficult deal dental issu futur keep dentist inform treatment treatment limit dentist dental problem exampl avastin bevacizumab dental hygienist dentist go need gentl gum cannot dental surgeri extract unless stop take drug xgeva denosumab anoth drug increas risk necrosi jaw good dental hygien import ever chemo notic teeth becam coat icki feel much easili better clean teeth like prevent tooth decay need invas dental procedur may need chang dental care product use mani cancer treatment make mouth sensit harsh spici flavor minti toothpast use year burn mouth first start take tarceva erlotinib find mani product made sensit mouth pharmaci got good result switch gentl fruit flavor dental product made children dentist also prescrib mild toothpast higher fluorid simpl salin rins help meal lighten brush techniqu consid use electr toothbrush water flosser dilig tooth clean effort scrub mouth clean hard teeth gum case brush vigor found easier correct problem use electr toothbrush make sure softest manual toothbrush find hand time electr toothbrush need recharg travel alon leav home dental hygienist recommend water flosser caution use gentl set watch reced gum unfortun gum tissu worn away gone forev gum start reced talk dentist soon possibl gentler touch may enough stave futur damag keep mouth moist saliva protect mouth well make easier swallow food dentist say dri mouth lead caus sudden widespread tooth decay rule one cancer treatment stay hydrat help also sever product market dri mouth use seem issu enjoy solut special kind candi contain sugar dentist strongli recommend suck xylitol hard candi stimul saliva suppress bacteria caus tooth decay worth invest friend lung cancer talk quandari decid whether worth spend money expens dental care know long abl benefit invest anyon ever toothach know get need dental care unpleas result rememb think diagnosi wast money acquir anyth new includ cloth yarn knit hobbi eyeglass new oncologist told get new glass peopl need get thing even use week qualiti life import dental health right eyeglass part live best life',\n",
       " 'damn anoth two week gone sinc februari post appoint doctor visit even new consult ad crohn diseas journey felt differ start stelara follow gi dr past week got explain everyth week stelara infus urgenc bowel pain flare spent time spare bathroom read second offic symptom run wild late mention diagnos fibromyalgia would like take time write blog focus specif still research ask perian diseas luckili abscess fistula fissur ouch told stelara could take week effect around time first self inject medic stelara needl differ humira pen use past automat button small needl see stelara shot normal needl style patient watch needl go skin inject time year home luckili around time inject time expect feel better around month anoth follow dr gi see maintain later week met plastic surgeri anoth follow appoint take blood pressur temperatur event plastic surgeri depart per usual temperatur littl high seem alway low grade fever blame immunocompromis alway keep constantli feel cold run fever went check blood pressur thought suffer heart attack blood pressur sky rocket high even sit wait area good minut hook right arm nut told high heart attack rang someth would take er immedi nurs shock went tell doctor tri left arm right arm time ask ever valv blood pressur issu told issu left arm right do decid possibl fluke explain log medic chart doctor dr r look ganglion cyst surgeri scar reason follow cyst area still tender rang movement nonexist babi left hand still use much avoid certain movement send shoot pain nerv grip still weak doctor look scar move wrist thumb around uncomfort almost seen surpris said look like come back almost insinu yet end doctor told would probabl still pain tender could wear brace help told want see three month make sure come back see still nerv pain mention take gabapentin unrel nerv pain help hand hand rememb get mri septum pierc call va reschedul outsid sourc would perform nose ring talk ladi appoint happen day told would call back call va week hear noth told anoth repres talk lunch call later afternoon transfer around time told would talk primari care team call primari care talk nurs told primari care hard time schedul outsid visit sinc musculoskelet issu perhap could set referr nurs phone mention rib issu never resolv januari x ray rib see primari care sinc area inflamm one singl rib mention primari care doctor dr c felt around left side rib note swollen area see ganglionectomi x ray got letter state lung clear real answer ask nurs littl confus kept bring right side breast never pain relat pleas note pain unrel breast nerv pain like electr shock happen sporad send shock outsid right breast still know answer nerv pain left side rib pain swell like lump near bottom rib left side sometim feel larger normal feel sore touch alway spot compar right side noth lump swell rib express nurs told would ask dr c return call call back dr c told x ray clear know nodul sort one rib told would need new consult gener surgeri find need remov luck need surgeri get ahead knock wood finger cross gener surgeri consult upcom week sure requir appoint scan sort whether anoth x ray mri sometim feel like live va visit va constantli call alreadi appoint year futur appoint alreadi plan call va anoth matter week prescript went onlin print current medic list medic crohn diseas pill take daili imuran mental health medic lexapro mark discontinu call request mark activ mention gi last visit need refil imuran soon like forgotten seen mental health sinc invas privaci worri make anoth visit let refil prescript luckili easi fix activ statu back normal otherwis past week gotten insomnia thought perhap problem help melatonin mirtazapin late night late alway anoth appoint could wors blog alway anoth appoint could wors blog sometim fall asleep wake middl night restless sometim fall asleep bodi crash sometim even face hair late either share social media stori daili activ home day pajama va hope help explain lack imag post usual bunch throughout think less hand one singl selfi bodi hurt back stomach head hand time pretti unev make medic bottl wreath hoard mess medicin bottl last coupl year may seen alreadi social media keep bottl like wristband procedur decid make wreath offic read real offic still ton thought creat one va mayb gi would like one also sign lexington take step walk year crohn coliti particip drop ball last year forgot regist made sure regist earli year held whitak ball park lexington septemb join team without donat donat cure ibd donat page like instead prefer donat go toward cure ibd goe research unlik fundrais page know mention last post start new job go first day learn rope expect everyth job complet differ told two interview compani thank opportun continu look elsewher harder look think health job search think hour job feel appoint avail doctor visit happen littl time advanc detail job requir well worri wellb bodi feel everi singl day hand difficult phlebotomi could choos would love focu write journal know matter find right fit think crohn fibromyalgia everyth els wrong suppos focu get well could wors thank read keep crohn journey pleas like could wors blog facebook alway inform like offer infus current struggl issu open ear happili take tip offer cure ibd continu donat cure crohn coliti encourag donat toward team page cure ibd fund rais alloc ibd research cure right donat www cureforibd donordr com campaign icbwblog ibd news today column welcom could wors column mari horsley previou post could wors februari stelara infus ganglionectomi pain ganglionectomi entyvio last goodby hello colonoscopi crohn diseas essenti emerg kit wego health nomin',\n",
       " 'childhood soft tissu sarcoma diseas malign cancer cell form soft tissu bodi soft tissu sarcoma occur children adult certain diseas inherit disord increas risk childhood soft tissu sarcoma common sign childhood soft tissu sarcoma painless lump swell soft tissu bodi diagnost test use detect find diagnos childhood soft tissu sarcoma test show may soft tissu sarcoma biopsi done mani differ type soft tissu sarcoma fat tissu tumor bone cartilag tumor fibrou connect tissu tumor skelet muscl tumor smooth muscl tumor call fibrohistiocyt tumor peripher nervou system tumor pericyt perivascular tumor tumor unknown origin blood vessel tumor certain factor affect prognosi chanc recoveri treatment option childhood soft tissu sarcoma diseas malign cancer cell form soft tissu bodi soft tissu bodi connect support surround bodi part organ soft tissu includ follow fat mix bone cartilag fibrou tissu muscl nerv tendon band tissu connect muscl bone synovi tissu tissu around joint blood vessel lymph vessel soft tissu sarcoma may found anywher bodi children tumor form often arm leg trunk chest abdomen enlarg soft tissu sarcoma form soft tissu bodi includ muscl tendon fat blood vessel lymph vessel nerv tissu around joint soft tissu sarcoma occur children adult soft tissu sarcoma children may respond differ treatment may better prognosi soft tissu sarcoma adult see pdq summari adult soft tissu sarcoma treatment inform treatment adult certain diseas inherit disord increas risk childhood soft tissu sarcoma anyth increas risk get diseas call risk factor risk factor mean get cancer risk factor mean get cancer talk child doctor think child may risk risk factor childhood soft tissu sarcoma includ follow inherit disord li fraumeni syndrom famili adenomat polyposi fap rb gene chang smarcb ini gene chang neurofibromatosi type nf werner syndrom risk factor includ follow past treatment radiat therapi aid acquir immun defici syndrom epstein barr viru infect time common sign childhood soft tissu sarcoma painless lump swell soft tissu bodi sarcoma may appear painless lump skin often arm leg trunk may sign symptom first sarcoma get bigger press nearbi organ nerv muscl blood vessel may caus sign symptom pain weak condit may caus sign symptom check child doctor child problem diagnost test use detect find diagnos childhood soft tissu sarcoma follow test procedur may use physic exam histori exam bodi check gener sign health includ check sign diseas lump anyth els seem unusu histori patient health habit past ill treatment also taken x ray x ray type energi beam go bodi onto film make pictur area insid bodi mri magnet reson imag procedur use magnet radio wave comput make seri detail pictur area bodi chest abdomen arm leg procedur also call nuclear magnet reson imag nmri enlarg magnet reson imag mri abdomen child lie tabl slide mri scanner take pictur insid bodi pad child abdomen help make pictur clearer ct scan cat scan procedur make seri detail pictur area insid bodi chest abdomen taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi enlarg comput tomographi ct scan abdomen child lie tabl slide ct scanner take x ray pictur insid abdomen ultrasound exam procedur high energi sound wave ultrasound bounc intern tissu organ make echo echo form pictur bodi tissu call sonogram pictur print look later test show may soft tissu sarcoma biopsi done one follow type biopsi usual use core needl biopsi remov tissu use wide needl procedur may guid use ultrasound ct scan mri incision biopsi remov part lump sampl tissu excision biopsi remov entir lump area tissu look normal pathologist view tissu microscop look cancer cell excision biopsi may use complet remov smaller tumor near surfac skin type biopsi rare use cancer cell may remain biopsi cancer cell remain cancer may come back may spread part bodi mri tumor done excision biopsi done show origin tumor may use guid futur surgeri radiat therapi placement needl incis biopsi affect success later surgeri remov tumor possibl surgeon remov tumor found involv plan biopsi order plan best treatment sampl tissu remov biopsi must larg enough find type soft tissu sarcoma laboratori test tissu sampl taken primari tumor lymph node area may cancer cell pathologist view tissu microscop look cancer cell find type grade tumor grade tumor depend abnorm cancer cell look microscop quickli cell divid high grade mid grade tumor usual grow spread quickli low grade tumor soft tissu sarcoma hard diagnos tissu sampl check pathologist experi diagnos soft tissu sarcoma one follow laboratori test may done studi tissu sampl molecular test laboratori test check certain gene protein molecul sampl tissu blood bodi fluid molecular test may done procedur biopsi help diagnos type cancer molecular test check certain gene chromosom chang occur soft tissu sarcoma revers transcript polymeras chain reaction rt pcr test laboratori test cell sampl tissu studi use chemic look chang express certain gene gene express make specif protein need structur function monitor bodi tissu organ test done order identifi type tumor cytogenet analysi laboratori test cell sampl bone marrow blood amniot fluid tumor tissu view microscop look chang chromosom fluoresc situ hybrid fish type cytogenet analysi immunocytochemistri test use antibodi check certain antigen marker sampl cell antibodi usual link enzym fluoresc dye caus cell marker becom visibl microscop type test may use tell differ differ type soft tissu sarcoma mani differ type soft tissu sarcoma cell type sarcoma look differ microscop soft tissu tumor group base type soft tissu cell first form summari follow type soft tissu sarcoma fat tissu tumor liposarcoma rare cancer fat cell liposarcoma usual form fat layer skin children adolesc liposarcoma often low grade like grow spread slowli sever differ type liposarcoma myxoid liposarcoma usual low grade respond well treatment cell myxoid liposarcoma certain genet chang call transloc part one chromosom switch place part anoth chromosom order diagnos myxoid liposarcoma tumor cell check genet chang pleomorph liposarcoma usual high grade like grow spread quickli less like respond well treatment bone cartilag tumor bone cartilag tumor mix bone cell cartilag cell bone cartilag tumor includ follow type extraskelet mesenchym chondrosarcoma type bone cartilag tumor often affect young adult occur head neck extraskelet osteosarcoma type bone cartilag tumor rare children adolesc like come back treatment may spread lung fibrou connect tissu tumor fibrou connect tissu tumor includ follow type desmoid type fibromatosi also call desmoid tumor aggress fibromatosi fibrou tissu tumor low grade like grow slowli may come back nearbi tissu usual spread distant part bodi rare tumor may disappear without treatment desmoid tumor sometim occur children chang adenomat polyposi coli apc gene chang gene caus famili adenomat polyposi fap fap inherit condit mani polyp growth mucou membran form insid wall colon rectum genet counsel discuss train profession inherit diseas possibl need gene test may need dermatofibrosarcoma protuberan rare tumor deep layer skin found children adult cell tumor certain genet chang call transloc part one chromosom switch place part anoth chromosom order diagnos dermatofibrosarcoma protuberan tumor cell check genet chang fibrosarcoma two type fibrosarcoma children adolesc infantil fibrosarcoma also call congenit fibrosarcoma type fibrosarcoma found children age year younger often occur infant may seen prenat ultrasound exam tumor often larg fast grow rare spread distant part bodi cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom order diagnos infantil fibrosarcoma tumor cell check genet chang similar tumor seen older children transloc often seen younger children adult fibrosarcoma type fibrosarcoma found adult cell tumor genet chang found infantil fibrosarcoma see pdq summari adult soft tissu sarcoma treatment inform inflammatori myofibroblast tumor fibrou tissu tumor occur children adolesc like come back treatment rare spread distant part bodi certain genet chang found half tumor low grade fibromyxoid sarcoma slow grow tumor affect young middl age adult cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom order diagnos low grade fibromyxoid sarcoma tumor cell check genet chang tumor may come back mani year treatment spread lung line wall chest caviti lifelong follow need myxofibrosarcoma rare fibrou tissu tumor found less often children adult scleros epithelioid fibrosarcoma rare fibrou tissu tumor come back spread place year treatment long term follow need skelet muscl tumor skelet muscl attach bone help bodi move rhabdomyosarcoma rhabdomyosarcoma common childhood soft tissu sarcoma children year younger see pdq summari childhood rhabdomyosarcoma treatment inform smooth muscl tumor smooth muscl line insid blood vessel hollow intern organ stomach intestin bladder uteru leiomyosarcoma smooth muscl tumor link epstein barr viru children also hiv diseas aid leiomyosarcoma may also form second cancer survivor inherit retinoblastoma sometim mani year initi treatment retinoblastoma call fibrohistiocyt tumor plexiform fibrohistiocyt tumor rare tumor usual affect children young adult tumor usual start painless growth skin arm hand wrist may rare spread nearbi lymph node lung peripher nervou system tumor peripher nervou system tumor includ follow type ectomesenchymoma rare fast grow tumor nerv sheath protect cover nerv part brain spinal cord occur mainli children ectomesenchymoma may form head neck abdomen perineum scrotum arm leg malign peripher nerv sheath tumor tumor form nerv sheath children malign peripher nerv sheath tumor rare genet condit call neurofibromatosi type nf tumor may low grade high grade malign triton tumor rare fast grow tumor occur often children nf pericyt perivascular tumor pericyt tumor form cell wrap around blood vessel pericyt tumor includ follow type myopericytoma infantil hemangiopericytoma type myopericytoma children younger year time diagnosi may better prognosi patient older year infantil hemangiopericytoma like spread part bodi includ lymph node lung infantil myofibromatosi infantil myofibromatosi anoth type myopericytoma fibrou tumor often form first year life may one nodul skin usual head neck area myofibroma nodul sever skin area muscl bone myofibromatosi tumor may go away without treatment tumor unknown origin tumor unknown origin place tumor first form known includ follow type alveolar soft part sarcoma rare tumor soft support tissu connect surround organ tissu commonli found limb occur tissu mouth jaw face may grow slowli may spread part bodi time diagnosi alveolar soft part sarcoma may better prognosi tumor centimet smaller tumor complet remov surgeri cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom order diagnos alveolar soft part sarcoma tumor cell check genet chang clear cell sarcoma soft tissu slow grow soft tissu tumor begin tendon tough fibrou cord like tissu connect muscl bone anoth part bodi clear cell sarcoma commonli occur deep tissu foot heel ankl may spread nearbi lymph node cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom order diagnos clear cell sarcoma soft tissu tumor cell check genet chang desmoplast small round cell tumor tumor often form abdomen pelvi tissu around test may form kidney desmoplast small round cell tumor may also spread lung part bodi cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom order diagnos desmoplast small round cell tumor tumor cell check genet chang epithelioid sarcoma rare sarcoma usual start deep soft tissu slow grow firm lump may spread lymph node extraren extracrani rhabdoid tumor rare fast grow tumor soft tissu liver peritoneum usual occur young children includ newborn occur older children adult rhabdoid tumor may link chang tumor suppressor gene call smarcb type gene make protein help control cell growth chang smarcb gene may inherit pass parent offspr genet counsel discuss train profession inherit diseas possibl need gene test may need extraskelet myxoid chondrosarcoma rare soft tissu sarcoma may found children adolesc time tend spread part bodi includ lymph node lung cell tumor usual genet chang often transloc part one chromosom switch place part anoth chromosom order diagnos extraskelet myxoid chondrosarcoma tumor cell check genet chang tumor may come back mani year treatment perivascular epithelioid cell tumor pecoma benign cancer pecoma may found children inherit condit call tuber sclerosi occur stomach intestin lung femal reproduct organ genitourinari organ primit neuroectoderm tumor pnet extraskelet ewe tumor see pdq summari ewe sarcoma treatment inform synovi sarcoma synovi sarcoma common type soft tissu sarcoma children adolesc synovi sarcoma usual form tissu around joint arm leg may also form trunk head neck cell tumor usual certain genet chang call transloc part one chromosom switch place part anoth chromosom larger tumor greater risk spread part bodi includ lung children younger year whose tumor centimet smaller better prognosi undifferenti unclassifi sarcoma tumor usual occur muscl attach bone help bodi move undifferenti pleomorph sarcoma malign fibrou histiocytoma high grade type soft tissu tumor may form part bodi patient receiv radiat therapi past second cancer children retinoblastoma tumor usual found arm leg may spread part bodi see pdq summari osteosarcoma malign fibrou histiocytoma bone treatment inform malign fibrou histiocytoma bone blood vessel tumor blood vessel tumor includ follow type epithelioid hemangioendothelioma epithelioid hemangioendothelioma occur children common adult year age usual occur liver lung bone may either fast grow slow grow third case tumor spread part bodi quickli see pdq summari childhood vascular tumor treatment inform angiosarcoma soft tissu angiosarcoma soft tissu fast grow tumor form blood vessel lymph vessel part bodi angiosarcoma skin deeper soft tissu form liver spleen lung rare children sometim one tumor skin liver rare infantil hemangioma may becom angiosarcoma soft tissu see pdq summari childhood vascular tumor treatment inform see follow pdq summari inform type soft tissu sarcoma includ summari childhood rhabdomyosarcoma treatment ewe sarcoma treatment unusu cancer childhood treatment gastrointestin stromal tumor certain factor affect prognosi chanc recoveri treatment option prognosi chanc recoveri treatment option depend follow part bodi tumor first form size grade tumor type soft tissu sarcoma deep tumor skin whether tumor spread place bodi amount tumor remain surgeri remov whether radiat therapi use treat tumor age sex patient whether cancer diagnos recur come back stage childhood soft tissu sarcoma key point childhood soft tissu sarcoma diagnos test done find cancer cell spread part bodi three way cancer spread bodi cancer may spread began part bodi childhood soft tissu sarcoma diagnos test done find cancer cell spread part bodi process use find cancer spread within soft tissu part bodi call stage standard stage system childhood soft tissu sarcoma order plan treatment import know type soft tissu sarcoma whether tumor remov surgeri whether cancer spread part bodi follow procedur may use find cancer spread sentinel lymph node biopsi remov sentinel lymph node surgeri sentinel lymph node first lymph node group lymph node receiv lymphat drainag primari tumor first lymph node cancer like spread primari tumor radioact substanc blue dye inject near tumor substanc dye flow lymph duct lymph node first lymph node receiv substanc dye remov pathologist view tissu microscop look cancer cell cancer cell found may necessari remov lymph node sometim sentinel lymph node found one group node procedur use epithelioid clear cell sarcoma pet scan pet scan procedur find malign tumor cell bodi small amount radioact glucos sugar inject vein pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell procedur also call positron emiss tomographi pet scan pet ct scan procedur combin pictur pet scan comput tomographi ct scan pet ct scan done time machin pictur scan combin make detail pictur either test would make three way cancer spread bodi cancer spread tissu lymph system blood tissu cancer spread began grow nearbi area lymph system cancer spread began get lymph system cancer travel lymph vessel part bodi blood cancer spread began get blood cancer travel blood vessel part bodi cancer may spread began part bodi cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi metastat tumor type cancer primari tumor exampl soft tissu sarcoma spread lung cancer cell lung soft tissu sarcoma cell diseas metastat soft tissu sarcoma lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ call metastat cancer anim show cancer cell travel place bodi first form part bodi recurr progress childhood soft tissu sarcoma recurr childhood soft tissu sarcoma cancer recur come back treat cancer may come back place part bodi progress childhood soft tissu sarcoma cancer respond treatment treatment option overview key point differ type treatment patient childhood soft tissu sarcoma children childhood soft tissu sarcoma treatment plan team health care provid expert treat cancer children treatment childhood soft tissu sarcoma may caus side effect eight type standard treatment use surgeri radiat therapi chemotherapi observ hormon therapi nonsteroid anti inflammatori drug target therapi immunotherapi new type treatment test clinic trial gene therapi patient may want think take part clinic trial patient enter clinic trial start cancer treatment follow test may need differ type treatment patient childhood soft tissu sarcoma differ type treatment avail patient childhood soft tissu sarcoma treatment standard current use treatment test clinic trial treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer clinic trial show new treatment better standard treatment new treatment may becom standard treatment cancer children rare take part clinic trial consid clinic trial open patient start treatment children childhood soft tissu sarcoma treatment plan team health care provid expert treat cancer children treatment overseen pediatr oncologist doctor special treat children cancer pediatr oncologist work health care provid expert treat children soft tissu sarcoma special certain area medicin may includ pediatr surgeon special train remov soft tissu sarcoma follow specialist may also includ pediatrician radiat oncologist pediatr hematologist pediatr nurs specialist rehabilit specialist psychologist social worker child life specialist treatment childhood soft tissu sarcoma may caus side effect inform side effect begin treatment cancer see side effect page side effect cancer treatment begin treatment continu month year call late effect late effect cancer treatment may includ physic problem chang mood feel think learn memori second cancer new type cancer late effect may treat control import talk child doctor effect cancer treatment child see pdq summari late effect treatment childhood cancer inform eight type standard treatment use surgeri surgeri complet remov soft tissu sarcoma done possibl tumor larg radiat therapi chemotherapi may given first make tumor smaller decreas amount tissu need remov surgeri call neoadjuv therapi follow type surgeri may use wide local excis remov tumor along normal tissu around amput surgeri remov part limb appendag cancer arm hand lymphadenectomi remov lymph node cancer moh surgeri surgic procedur use treat cancer skin individu layer cancer tissu remov check microscop one time cancer tissu remov type surgeri use treat dermatofibrosarcoma protuberan also call moh micrograph surgeri hepatectomi surgeri remov part liver second surgeri may need remov remain cancer cell check area around tumor remov cancer cell remov tissu need cancer liver hepatectomi liver transplant may done liver remov replac healthi one donor doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use high energi x ray type radiat kill cancer cell keep grow two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer certain way give radiat therapi help keep radiat damag nearbi healthi tissu type radiat therapi may includ follow stereotact bodi radiat therapi stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment day sever day radiat machin aim larger usual dose radiat directli tumor patient posit treatment less damag nearbi healthi tissu procedur also call stereotact extern beam radiat therapi stereotax radiat therapi intern radiat therapi use radioact substanc seal needl seed wire cathet place directli near cancer way radiat therapi given depend type stage cancer treat whether tumor complet remov surgeri extern intern radiat therapi use treat childhood soft tissu sarcoma chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi chemotherapi place directli cerebrospin fluid organ bodi caviti abdomen drug mainli affect cancer cell area region chemotherapi combin chemotherapi use one anticanc drug way chemotherapi given depend type cancer treat type soft tissu sarcoma respond treatment chemotherapi see drug approv soft tissu sarcoma inform observ observ close monitor patient condit without give treatment sign symptom appear chang observ may done complet remov tumor possibl treatment avail tumor like damag vital organ hormon therapi hormon therapi cancer treatment remov hormon block action stop cancer cell grow hormon substanc made gland bodi circul bloodstream hormon caus certain cancer grow test show cancer cell place hormon attach receptor drug surgeri radiat therapi use reduc product hormon block work antiestrogen drug block estrogen tamoxifen may use treat desmoid type fibromatosi nonsteroid anti inflammatori drug nonsteroid anti inflammatori drug nsaid drug aspirin ibuprofen naproxen commonli use decreas fever swell pain red treatment desmoid type fibromatosi nsaid call sulindac may use help block growth cancer cell target therapi target therapi type treatment use drug substanc attack cancer cell target therapi usual caus less harm normal cell chemotherapi radiat kinas inhibitor type target therapi block enzym call kinas type protein differ type kinas bodi differ action alk inhibitor may stop cancer grow spread crizotinib may use treat inflammatori myofibroblast tumor tyrosin kinas inhibitor tki block signal need tumor grow imatinib use treat dermatofibrosarcoma protuberan pazopanib may use treat desmoid type fibromatosi type recurr progress soft tissu sarcoma studi mani type newli diagnos soft tissu sarcoma type recurr soft tissu sarcoma sorafenib may use treat desmoid type fibromatosi new type tyrosin kinas inhibitor studi loxo entrectinib infantil fibrosarcoma trametinib epithelioid hemangioendothelioma type target therapi studi clinic trial includ follow mtor inhibitor type target therapi stop protein help cell divid surviv mtor inhibitor use treat desmoplast small round cell tumor studi treat perivascular epithelioid cell tumor pecoma epithelioid hemangioendothelioma sirolimu temsirolimu type mtor inhibitor therapi angiogenesi inhibitor type target therapi prevent growth new blood vessel need tumor grow angiogenesi inhibitor cediranib sunitinib thalidomid studi treat alveolar soft part sarcoma epithelioid hemangioendothelioma bevacizumab studi blood vessel tumor histon methyltransferas hmt inhibitor target therapi drug work insid cancer cell block signal need tumor grow hmt inhibitor tazemetostat studi treatment epithelioid sarcoma malign peripher nerv sheath tumor extraren extracrani rhabdoid tumor extraskelet myxoid chondrosarcoma synovi sarcoma heat shock protein inhibitor block certain protein protect tumor cell help grow ganetespib heat shock protein inhibitor studi combin mtor inhibitor sirolimu malign peripher nerv sheath tumor cannot remov surgeri antibodi drug conjug made monoclon antibodi attach drug monoclon antibodi bind specif protein receptor found certain cell includ cancer cell drug enter cell kill without harm cell lorvotuzumab mertansin antibodi drug conjug studi treatment rhabdomyosarcoma malign peripher nerv sheath tumor synovi sarcoma see drug approv soft tissu sarcoma inform immunotherapi immunotherapi treatment use patient immun system fight diseas substanc made bodi made laboratori use boost direct restor bodi natur defens diseas interferon type immunotherapi use treat epithelioid hemangioendothelioma interfer divis tumor cell slow tumor growth new type treatment test clinic trial summari section describ treatment studi clinic trial may mention everi new treatment studi inform clinic trial avail nci websit gene therapi gene therapi studi childhood synovi sarcoma recur spread cannot remov surgeri patient cell type white blood cell remov gene cell chang laboratori genet engin attack specif cancer cell given back patient infus patient may want think take part clinic trial patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment clinic trial includ patient yet receiv treatment trial test treatment patient whose cancer gotten better also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found nci clinic trial search webpag clinic trial support organ found clinicaltri gov websit follow test may need test done diagnos cancer find stage cancer may repeat test repeat order see well treatment work decis whether continu chang stop treatment may base result test test continu done time time treatment end result test show child condit chang cancer recur come back test sometim call follow test check up treatment option childhood soft tissu sarcoma inform treatment list see treatment option overview section newli diagnos childhood soft tissu sarcoma fat tissu tumor liposarcoma treatment liposarcoma may includ follow surgeri complet remov tumor cancer complet remov second surgeri may done chemotherapi shrink tumor follow surgeri radiat therapi surgeri clinic trial target therapi radiat therapi surgeri without chemotherapi bone cartilag tumor extraskelet mesenchym chondrosarcoma treatment extraskelet mesenchym chondrosarcoma may includ follow surgeri complet remov tumor radiat therapi may given surgeri chemotherapi follow surgeri chemotherapi without radiat therapi given surgeri clinic trial target therapi radiat therapi surgeri without chemotherapi extraskelet osteosarcoma treatment extraskelet osteosarcoma may includ follow surgeri complet remov tumor follow chemotherapi clinic trial target therapi radiat therapi surgeri without chemotherapi see pdq summari osteosarcoma malign fibrou histiocytoma bone treatment inform fibrou connect tissu tumor desmoid type fibromatosi treatment desmoid type fibromatosi may includ follow surgeri complet remov tumor treatment surgeri may includ follow observ chemotherapi radiat therapi antiestrogen drug therapi nonsteroid anti inflammatori drug nsaid therapi tumor complet remov surgeri treatment may includ follow observ treatment option possibl radiat therapi radiat therapi chemotherapi tumor cannot remov surgeri clinic trial target therapi clinic trial target therapi radiat therapi surgeri without chemotherapi treatment desmoid type fibromatosi come back may includ follow observ possibl surgeri later time chemotherapi dermatofibrosarcoma protuberan treatment dermatofibrosarcoma protuberan may includ follow surgeri complet remov tumor possibl may includ moh surgeri radiat therapi surgeri radiat therapi target therapi imatinib tumor cannot remov come back clinic trial target therapi radiat therapi surgeri without chemotherapi fibrosarcoma infantil fibrosarcoma treatment infantil fibrosarcoma may includ follow surgeri remov tumor possibl follow observ surgeri follow chemotherapi chemotherapi shrink tumor follow surgeri clinic trial target therapi radiat therapi surgeri without chemotherapi clinic trial target therapi tyrosin kinas inhibitor adult type fibrosarcoma treatment adult type fibrosarcoma may includ follow surgeri complet remov tumor possibl inflammatori myofibroblast tumor treatment inflammatori myofibroblast tumor may includ follow surgeri complet remov tumor possibl chemotherapi steroid therapi nonsteroid anti inflammatori drug nsaid therapi target therapi alk inhibitor clinic trial target therapi radiat therapi surgeri without chemotherapi low grade fibromyxoid sarcoma treatment low grade fibromyxoid sarcoma may includ follow surgeri complet remov tumor clinic trial target therapi radiat therapi surgeri without chemotherapi myxofibrosarcoma treatment myxofibrosarcoma may includ follow surgeri complet remov tumor clinic trial target therapi radiat therapi surgeri without chemotherapi scleros epithelioid fibrosarcoma treatment scleros epithelioid fibrosarcoma may includ follow surgeri complet remov tumor clinic trial target therapi radiat therapi surgeri without chemotherapi skelet muscl tumor rhabdomyosarcoma see pdq summari childhood rhabdomyosarcoma treatment smooth muscl tumor leiomyosarcoma treatment leiomyosarcoma may includ follow chemotherapi clinic trial target therapi radiat therapi surgeri without chemotherapi call fibrohistiocyt tumor plexiform fibrohistiocyt tumor treatment plexiform fibrohistiocyt tumor may includ follow surgeri complet remov tumor clinic trial target therapi radiat therapi surgeri without chemotherapi peripher nervou system tumor ectomesenchymoma treatment ectomesenchymoma may includ follow surgeri chemotherapi radiat therapi malign peripher nerv sheath tumor treatment malign peripher nerv sheath tumor may includ follow surgeri complet remov tumor possibl radiat therapi surgeri chemotherapi tumor cannot remov surgeri clinic trial target therapi radiat therapi surgeri without chemotherapi clinic trial target therapi tumor cannot remov surgeri clinic trial target therapi histon methyltransferas inhibitor clinic trial antibodi drug conjug clear whether give radiat therapi chemotherapi surgeri improv tumor respons treatment malign triton tumor malign triton tumor may treat rhabdomyosarcoma includ surgeri chemotherapi radiat therapi regimen target therapi radiat therapi surgeri without chemotherapi studi pericyt perivascular tumor infantil hemangiopericytoma treatment infantil hemangiopericytoma may includ follow chemotherapi infantil myofibromatosi treatment infantil myofibromatosi may includ follow combin chemotherapi tumor unknown origin place tumor first form known alveolar soft part sarcoma treatment alveolar soft part sarcoma may includ follow surgeri complet remov tumor possibl radiat therapi surgeri tumor cannot complet remov surgeri target therapi angiogenesi inhibitor clinic trial target therapi angiogenesi inhibitor children clinic trial target therapi radiat therapi surgeri without chemotherapi clear cell sarcoma soft tissu treatment clear cell sarcoma soft tissu may includ follow surgeri remov tumor possibl radiat therapi surgeri clinic trial target therapi radiat therapi surgeri without chemotherapi desmoplast small round cell tumor standard treatment desmoplast small round cell tumor treatment may includ follow surgeri complet remov tumor possibl chemotherapi follow surgeri chemotherapi target therapi mtor inhibitor radiat therapi epithelioid sarcoma treatment epithelioid sarcoma may includ follow surgeri remov tumor possibl chemotherapi surgeri radiat therapi surgeri clinic trial target therapi histon methyltransferas inhibitor extraren extracrani rhabdoid tumor treatment extraren extracrani rhabdoid tumor may includ follow combin surgeri remov tumor possibl chemotherapi radiat therapi clinic trial target therapi histon methyltransferas inhibitor extraskelet myxoid chondrosarcoma treatment extraskelet myxoid chondrosarcoma may includ follow surgeri remov tumor possibl radiat therapi clinic trial target therapi radiat therapi surgeri without chemotherapi clinic trial target therapi histon methyltransferas inhibitor perivascular epithelioid cell tumor pecoma treatment perivascular epithelioid cell tumor may includ follow surgeri remov tumor observ follow surgeri target therapi mtor inhibitor tumor certain gene chang cannot remov surgeri clinic trial target therapi radiat therapi surgeri without chemotherapi primit neuroectoderm tumor pnet extraskelet ewe tumor see pdq summari ewe sarcoma treatment synovi sarcoma treatment synovi sarcoma may includ follow surgeri radiat therapi chemotherapi may given surgeri chemotherapi clinic trial gene therapi clinic trial target therapi radiat therapi surgeri without chemotherapi clinic trial target therapi histon methyltransferas inhibitor clinic trial antibodi drug conjug undifferenti unclassifi sarcoma tumor includ undifferenti pleomorph sarcoma malign fibrou histiocytoma high grade standard treatment tumor treatment may includ follow clinic trial target therapi radiat therapi surgeri without chemotherapi see pdq summari osteosarcoma malign fibrou histiocytoma bone treatment inform treatment malign fibrou histiocytoma bone blood vessel tumor angiosarcoma soft tissu treatment angiosarcoma may includ follow surgeri complet remov tumor combin surgeri chemotherapi radiat therapi angiosarcoma spread target therapi bevacizumab chemotherapi angiosarcoma began infantil hemangioma clinic trial target therapi radiat therapi surgeri without chemotherapi epithelioid hemangioendothelioma treatment epithelioid hemangioendothelioma may includ follow surgeri remov tumor possibl immunotherapi interferon target therapi thalidomid sorafenib pazopanib sirolimu tumor like spread chemotherapi total hepatectomi liver transplant tumor liver clinic trial target therapi trametinib metastat childhood soft tissu sarcoma treatment childhood soft tissu sarcoma spread part bodi diagnosi may includ follow chemotherapi radiat therapi surgeri may done remov tumor spread lung stereotact bodi radiat therapi tumor spread lung treatment specif tumor type see treatment option childhood soft tissu sarcoma section use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail recurr progress childhood soft tissu sarcoma treatment recurr progress childhood soft tissu sarcoma may includ follow surgeri remov cancer come back first form spread lung surgeri follow extern intern radiat therapi radiat therapi alreadi given surgeri remov arm leg cancer radiat therapi alreadi given chemotherapi target therapi pazopanib clinic trial new chemotherapi regimen without target therapi pazopanib clinic trial check sampl patient tumor certain gene chang type target therapi given patient depend type gene chang use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail learn childhood soft tissu sarcoma inform nation cancer institut childhood soft tissu sarcoma see follow soft tissu sarcoma home page comput tomographi ct scan cancer drug approv soft tissu sarcoma target cancer therapi childhood cancer inform gener cancer resourc see follow cancer childhood cancer curesearch children cancer late effect treatment childhood cancer adolesc young adult cancer children cancer guid parent cancer children adolesc stage cope cancer question ask doctor cancer survivor caregiv pdq summari pdq physician data queri pdq nation cancer institut nci comprehens cancer inform databas pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin summari come two version health profession version detail inform written technic languag patient version written easi understand nontechn languag version cancer inform accur date version also avail spanish pdq servic nci nci part nation institut health nih nih feder govern center biomed research pdq summari base independ review medic literatur polici statement nci nih purpos summari pdq cancer inform summari current inform treatment childhood soft tissu sarcoma meant inform help patient famili caregiv give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date board made expert cancer treatment specialti relat cancer summari review regularli chang made new inform date summari updat date recent chang inform patient summari taken health profession version review regularli updat need pdq pediatr treatment editori board clinic trial inform clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori trial answer certain scientif question order find new better way help cancer patient treatment clinic trial inform collect effect new treatment well work clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial clinic trial open patient start treatment clinic trial list pdq found onlin nci websit inform call cancer inform servic cancer permiss use summari pdq regist trademark content pdq document use freeli text cannot identifi nci pdq cancer inform summari unless whole summari shown updat regularli howev user would allow write sentenc nci pdq cancer inform summari breast cancer prevent state risk follow way [includ excerpt summary] best way cite pdq summari pdq pediatr treatment editori board pdq childhood soft tissu sarcoma treatment bethesda md nation cancer institut updat mm dd yyyi avail http www cancer gov type soft tissu sarcoma patient child soft tissu treatment pdq access mm dd yyyi [pmid ] imag summari use permiss author artist publish use pdq summari want use imag pdq summari use whole summari must get permiss owner cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim inform summari use make decis insur reimburs inform insur coverag avail cancer gov manag cancer care page contact us inform contact us receiv help cancer gov websit found contact us help page question also submit cancer gov websit e mail us',\n",
       " 'hi jaquar understand choic seem one form betaferon e plegridi avonex offer option copaxon anoth inject similar relaps rate plegridi avonex often give peopl less side effect tecfidera daili pill much better relaps reduct rate fingolimod anoth pill better still tysabri given monthli infus reduct relaps rate perhap could talk variou option ms nurs neurologist tri figur reason offer two option count two option realli drug deliv differ form sorri seem answer question precis experi avonex copaxon tecfidera tysabri unfortun one rare peopl seem variou side effect mean take avonex tecfidera tysabri copaxon stop work give much help experi drug think option open mind drug best relaps reduct rate possibl depend system toler regard side effect sue',\n",
       " 'hi kmallori neuro also recommend ocrevu blood draw today also concern medicar approv side effect spm fatigu balanc issu promin symptom moment cours could chang frequent cog fog rear ugli head worst time anyon experienc infus side effect ocrevu new apprehens earli adopt treatment feedback would much appreci use dmd sinc stop tecfidera year ago thank roger',\n",
       " 'mean scare anyon check respons thread titl quit ty ocrevu cancer concern develop gynecolog cancer year tysabri advis go back immunosuppress medic fear cancer relaps oncologist said way neurologist thought ocrevu might possibl ad oncologist would pleas actual oncologist pleas ms drug except copaxon interferon toler yeah wise consid cancer risk hand relaps year could forget ms ask choos cancer ms',\n",
       " 'first thank much help histolog hear high unaccept risk pneumon go specif tagrisso azd immunotherapi read articl said pdl lower risk pneumon pd due method action see opdivo pd tecentriq pdl advertis egfr patient progress chemo egfr target therapi wife inform whether aforement higher risk go tagrisso immunotherapi true risk lower go pdl tecentriq option us point appear chemo applic trial egf asp hm recruit immunotherapi appear toxic sequenti treatment egfr inhibitor tagrisso immunotherapi stage iv nsclc adeno egfr mutat tarceva help carbo avastin alimta month avastin mainten month afatanib month clovi co month tagrisso azd month progress',\n",
       " 'antibodi nivolumab pembrolizumab target program cell death protein pd well ipilimumab target cytotox lymphocyt antigen ctla may promis patient small cell lung cancer sclc accord studi publish oncologist major chang last year know month within next year hope see checkpoint inhibitor approv said lead studi author leora horn md msc associ professor medicin clinic director thorac oncolog program vanderbilt ingram cancer center nashvil tennesse preliminari data shown promis respons rate nivolumab alon nivolumab ipilimumab singl agent pembrolizumab durabl respons low toxic profil multipl clinic trial includ ongo phase studi compar nivolumab topotecan second line therapi mainten studi first line platinum base therapi nivolumab nivolumab ipilimumab phase trial pembrolizumab follow platinum base chemotherapi said dr horn colleagu note patient respond first line chemotherapi though sclc aggress lung cancer subtyp patient eventu relaps approv agent beyond second line research hope soon chang report identif molecular target sclc may point combin immun checkpoint inhibitor new target therapi toxic profil agent non small cell lung cancer nsclc significantli lower chemotherapi differ anticip sclc approv major chang especi patient recurr extens stage diseas limit treatment option said dr horn hossein borghaei chief thorac oncolog associ professor depart hematolog oncolog fox chase cancer center philadelphia pennsylvania said move new era treatment sclc gener though particularli immunotherapi accord dr borghaei mani potenti activ treatment investig sclc clinic landscap could chang soon hard estim surviv improv immunotherapi dr borghaei told cancer therapi advisor mani disappoint think base seen immunotherapi agent far diseas limit data sclc hope see improv surviv catherin pietanza md colleagu recent report th congress european societi medic oncolog esmo rovalpituzumab tesirin rova antibodi drug conjug adc may promis patient relaps first line therapi preliminari data suggest posit overal respons rate orr accept side effect relat ipilimumab combin appear ineffect treatment sclc phase b sclc trial found wa orr clinic benefit rate studi includ patient research found common advers event ae fatigu experienc grade research note respons durabl trend toward improv overal surviv os',\n",
       " 'hi roadtrip sorri hear pain thank inquir updat pain come uc stori differ though pleas bear updat learn lot past year sinc first post overtaken excruci disabl joint pain mostli hand wrist write hold cup even lie still tini us advers reaction remicad ultim diagnos anti tnf induc lupu took year recov help oral prednison well awar downsid work along neuro pt get joint esp wrist hand function regain strength muscl wast prior unfortun develop th month mark remicad go great remi recov worst flare ever seem inconceiv stop said known would unfold still remicad regret despit month miseri recov advers effect remi extinguish flare got new qualiti life fact think stay month stop infus bought time enough overcom next big bad uc flare flatten function research option readi start entyvio octob happi report great ever sinc uc total quiet two downsid seem vulner respiratori infect extra intestin joint pain problem accompani uc mani us evid mang emerg flare like make sens sinc entyvio gut specif benefit live distinguish ibd relat joint pain inc inflammatori arthriti distinct occur remicad excruci wrist hand pain tell realli wreak havoc system caus polyneurophathi need stop realiz get know bodi better time get pain wrist hand weird swell wrist hand inc swollen finger blue knee swell bad walk bit need cortison inject plu round oral pred calm think expect get joint pain ibd without system anti inflammatori effect remicad mainten med smart rheumatologist key guid unfamiliar terrain along experienc neurologist lot blood lab definit expert diagnos rather gi case want get evalu other expertis would happi provid detail lesson learn help wish well cope feel like unend set challeng sinc uc close year pleas forgiv updat profil line also reach thoreau usual respond post lengthi thread parallel track disabl pain desper effort sens make differ manifest recoveri timelin good know recoveri post remicad best wish regular ibd relat pain possibl iv push solumedrol remi infus could help may worth tri uc yr flare use cortenema prednison allerg mesalamin hive fever mp fever remicad stop mo due joint pain anti tnf induc lupu neuropathi entyvio sinc oct far ok',\n",
       " 'tofacitinib manag ulcer coliti refractori anti tnf anti integrin therapi report patient activ ulcer coliti primari non respons three biolog infliximab adalimumab vedolizumab differ mechan action refus surgic treatment favor respons tofacitinib clinic endoscop remiss advers event observ use agent case illustr difficulti may face regard identif express proper mechan action involv pathogenesi ulcer coliti patient import anoth treatment option differ mechan action lik sourc arquivo de gastroenterologia',\n",
       " 'well done alway think peopl surgeri deserv medal cannot easi samantha stop smoke jan diagnos left side uc th feb gluten dairi sulfit salicyl histamin intoler home fmt treatment juli ward reoccurr c difficil fail pentasa azathioprin final methotextr due allergi intoler take humira final come prednison yay',\n",
       " 'gist asian peopl non small cell lung cancer nsclc whose tumor common mutat egfr gene call del might better surviv treat drug afatinib instead chemotherapi conclus recent clinic trial test afatinib volunt patient boehring ingelheim report posit data pre specifi subgroup analysi pivot phase iii lux lung trial afatinib asian non small cell lung cancer nsclc patient trial show patient common type egfr mutat exon delet del live significantli longer receiv first line treatment afatinib compar chemotherapi compani note overal surviv result pre specifi asian subgroup analysi consist overal del popul lux lung previous report asian phase iii lux lung trial patient del mutat live median one year longer start treatment afatinib rather standard chemotherapi guangdong academi medic scienc guangdong gener hospit vice presid princip investig lux lung trial yi long wu said afatinib first treatment demonstr signific overal surviv benefit nsclc patient del mutat common egfr mutat half world lung cancer case occur asia therefor egfr test nsclc patient import order identifi patient elig target therapi',\n",
       " 'hi bfarz congratul great respons tarceva hope scan result show tagrisso effect tarceva mani lung cancer drug case patient respond number year point patient drop statist due lack continu follow sinc tagrisso rel new certainli case hope becom one outlier patient respons particularli durabl discuss dr west post lepid predomin adenocarcinoma still often refer bac type lung cancer aggress also slow grow among least threaten case ever label lung cancer diagnosi possibl determin aggress particular patient cancer passag time help answer question histori describ cancer appear slow grow respons tarceva may long respons tagrisso well present progress second line tagrisso treat standard chemo agent perhap immunotherapi realli good tki address progress also mention oncologist face singl site progress radiat site continu tki far biopsi check new mutat progress suffici size biopsi may need chang therapi sinc tagrisso resist mutat target therapi biopsi may provid usabl inform said point doctor feel biopsi need liquid biopsi use bodili fluid rather tissu may recommend hope tagrisso effect long time jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'http sumo ly mozo submit link biotin research clinic studi show may help peopl progress form multipl sclerosi write perspect take medicin excerpt past blog post mind explain doctor notic get mg pill take time day ace pharmaci http highdosebiotin net complet th month somewher middl th month neurologist check back decemb time walk second faster ever walk offic mean mean noth one time maintain mark improv simpler term part clinic trial biotin second would seen improv person progress ms second mean effect life one bit get tire matter fast walk difficulti walk daili struggl fall frustrat chang walk second faster made differ read post http www multipleexperi org high dose biotin multipl sclerosi month chang anyth long run still struggl day except sit howev written post biotin past realli start think chang leg due biotin pretti convinc drug make walk better origin sure mani new thing start around time start rituxan ms version ocrelizumab come march physic therapi alpha lipoic acid also studi help ms see studi link http www multipleexperi org alpha lipoic acid multipl sclerosi sinc vacat realli abl take advantag good day stretch realli make see differ leg strong fatigu matter part fatigu walk much better last sure noth day someon bid like said yesterday post realist though multipl sclerosi come take soon bodi fatigu stage get easier easier stop take biotin absolut definit differ go even differ five minut day day hour five hour hour definit worth get multipl sclerosi patient hope check studi top page past blog honest take biotin one thing would agre take month see differ pleas patient tri http www multipleexperi org high dose biotin progress ms patient review rememb biotin vitamin wors case great hair nail',\n",
       " 'adher treatment plan best possibl strategi manag multipl sclerosi ms continu diseas modifi medic doctor recommend import part plan take diseas modifi medic long period time challeng import understand role diseas modifi therapi overal ms treatment plan awar obstacl often interfer adher plan earli treatment import ms expert recommend anyon diagnos relaps form ms consid begin treatment soon possibl associ risk lemtrada zinbryta gener recommend peopl alreadi inadequ respons two diseas modifi therapi novantron also gener reserv peopl diagnos secondari progress ms inadequ respons treatment peopl diagnos clinic isol syndrom ci first episod neurolog damag may benefit medic well possibl benefit medic includ reduct number new lesion shown magnet reson imagn mri reduct number exacerb also call relaps attack flare up reduct progress disabl probabl reduct futur diseas activ improv qualiti life individu diagnos primari progress ms talk healthcar provid start treatment ocrevu medic approv u food drug administr fda treatment primari progress ms start treatment earli diseas particularli import research indic perman damag may occur central nervou system cn even person experienc symptom avail medic effect earli diseas activ inflammatori later diseas gener progress neurodegen addit detail outlin ms coalit consensu diseas modifi treatment ms peopl reluct start treatment absenc symptom person whose symptom disappear may see reason start treatment howev research show diseas caus signific irrevers damag cn even experienc symptom time fear needl avail medic given inject skin muscl infus vein mani peopl hate needl howev manufactur medic offer support program help becom comfort effect tool avail help self inject anxieti oral medic also approv use ms expens medic expens insur coverag vari consider one insur plan anoth howev manufactur offer financi assist program help ensur anyon whose physician prescrib medic access fear side effect medic side effect peopl particularli whose ms symptom mild remiss may hesit take medic may make feel wors rather better howev physician nurs support program offer manufactur medic give tip strategi reduc side effect make manag side effect diminish time peopl stop take medic diseas modifi medic design long term use recommend peopl continu medic unless side effect sever medic clearli work better treatment becom avail howev mani peopl stop medic period week month reason feel better import rememb diseas modifi medic design reduc underli diseas activ treat symptom cure diseas make peopl feel better fact may abl feel work diseas modifi medic import invest futur work behind scene help slow diseas side effect make feel wors diseas peopl problem side effect other whatev side effect experienc best manag collabor healthcar team drug manufactur support program peopl experi intoler side effect improv time talk doctor medic option taken medic exacerb anyway none medic abl cure ms complet stop progress peopl continu experi occasion exacerb even take medic faith doctor determin mani relaps develop expect number new lesion offer treatment option mayb someth els would work better sinc take month medic begin work system switch frequent one drug anoth leav unprotect long period time best strategi give medic take suffici time doctor abl evalu effect insur stop cover medic take pharmaceut manufactur nation ms societi avail help sort insur issu insur compani longer cover medic take call assist soon possibl order avoid interrupt treatment solut found problem physician may recommend differ medic cover insur longer afford co payment medic insur compani rais lower co payment without notic anoth situat manufactur societi may abl assist stop medic without check see either resourc help question concern issu sure contact societi manufactur medic take',\n",
       " 'melissa g countri patient mavenclad switch interferon rebif betaseron betaferon much experi process go fingolimod start treatment cladribin howev patient switch fingolimod cladribin week major problem believ main issu fingolimod cessat quit tricki decid chang therapi sure neurologist want monitor white blood cell count period longer week without treatment would suffic cessat effect gilenya',\n",
       " 'recent month spastic go bonker especi right leg found might spastic later someth done beyond daili stretch enter baclofen dmt current ocrevu take med supplement vitamin daili ambien need viagra need fiber chew stool soften enter pictur occas right leg cooper straighten get stiffer neuro said time tri baclofen muscl relax start mg x day help tri mg made loopi somewher around day slightli higher dose night help much folk baclofen experi advic know common ms med __________________ dave bexfield activems',\n",
       " 'never understood comprehens guy anti vegf treatment piss retina commun much realli make money cours compar intravitr inject vitrectomi nonsens primari ppv resid manag post op care think abl one graduat resid get cours enough practic skill real world comprehens doc allow treat without piss subspecialist dri eye refer anyth requir otc artifici tear cornea glaucoma refer slt micropuls mig glaucoma treat medic plastic offer epil blepharoplasti attend lectur aao oculoplast liter said comprehensivist pleas refer us simpl bleph draw line went comprehens ophthalmolog offer comprehens care think ridicul patient refer doctor manag routin problem manag glaucoma manag dri eye manag intravitr inject refract obvious patient extrem complex need care specialist simpli need monthli eylea run mill wet amd rare million diseas process handl generalist',\n",
       " 'ibutilid anti arrhythm heart medic correct certain condit irregular heart rhythm ibutilid use help keep heart beat normal peopl certain heart rhythm disord atrium upper chamber heart allow blood flow heart ibutilid use peopl atrial fibril atrial flutter ibutilid may also use purpos list medic guid ibutilid caus life threaten irregular heart rhythm heart rate constantli monitor use electrocardiograph ecg sometim call ekg problem treat quickli receiv medic allerg ibutilid possibl tell doctor taken heart rhythm medic within past hour receiv ibutilid make sure ibutilid safe tell doctor congest heart failur fda pregnanc categori c known whether ibutilid harm unborn babi tell doctor pregnant known whether ibutilid pass breast milk could harm nurs babi tell doctor breast feed babi emerg situat may possibl tell caregiv health condit pregnant breast feed make sure doctor care afterward know receiv medicin basicdescript back top ibutilid side effect get emerg medic help sign allerg reaction hive difficult breath swell face lip tongu throat tell caregiv headach chest pain sever dizzi short breath light head feel like might pass common side effect may includ mild headach nausea complet list side effect other may occur call doctor medic advic side effect may report side effect fda fda back top ibutilid interact follow doctor instruct restrict food beverag activ tell doctor taken heart rhythm medic within past hour includ amiodaron disopyramid dofetilid dronedaron procainamid quinidin sotalol tell doctor medicin use start stop use treatment ibutilid especi citalopram fingolimod lumefantrin mifepriston saquinavir antibiot azithromycin clarithromycin erythromycin cancer medicin arsen trioxid degarelix nilotinib toremifen vandetanib vemurafenib medicin treat mental ill iloperidon pimozid thioridazin ziprasidon list complet drug may interact ibutilid includ prescript counter medicin vitamin herbal product possibl interact list medic guid back top ibutilid dosag ibutilid inject vein iv healthcar provid give inject ibutilid caus life threaten irregular heart rhythm heart rate constantli monitor use electrocardiograph ecg sometim call ekg problem treat quickli cardiac emerg equip also kept nearbi case need treat heart monitor may continu sever hour stop receiv ibutilid sinc medic given healthcar profession medic set overdos unlik occur receiv ibutilid clinic set like miss dose',\n",
       " 'diagnos year ago ppm tomorrow see doc get mri result go ocrevu becom avail',\n",
       " 'congrat much imagin deck life good gear thank continu post uc yr flare use cortenema prednison allerg mesalamin hive fever mp fever remicad stop mo due joint pain anti tnf induc lupu neuropathi entyvio sinc oct far ok',\n",
       " 'hi jennyo sorri hear footdrop speak ms nurs alreadi may abl offer physio help interest read say feel never quit know new symptom drug relat simpli ms relat often seem stress relat though twin wonder side effect worth drug posit effect almost drug tackl symptom never caus spent last six year tri deciph spider web life stori see kind pattern might lead blood brain barrier damag henc eventu ms feel new round think much closer ever gut bio must start thing go pist keep keep support health howev import control process noth els support drug sort posit way bodi less els deal make sens tri sort altern therapi copaxon drug seem remind day ms give sore inject site inflamm spinal cord mri look differ year neurologist pat back copaxon work well actual made differ keep us date cladribin seem effect drug serious consid back lemtrada seem best bunch tackl awri immun system hold onto hear tough reg cell tell immun system start fight must good wish best',\n",
       " 'hello grace team may recal wife diagnos egfr exon del poorli differenti nsclc septemb tarceva experienc two brain met switch tagrisso unconfirm suspicion wast progress miliari micronodul lung may switch carboplatin alimta mid may cycl alimta mainten learn week progress miliari spread lung difus inumer micro nodul got tini fine needl biopsi one nodul outsid lung path report neg target mutat also indic cancer longer egfr posit confirm mutat sclc question would unusu cancer lose egfr statu consid path analysi fals read cancer remain egfr rechalleng tarceva avastin month use tki view long one wait increas chanc success tki rechalleng e long take cancer sensit tki thank much fedback',\n",
       " 'new mattress come along way past year last year bought one purpl mattress comfort mattress ever [url]www onpurpl com[\\\\url] mayb pcp give script muscl relax happen futur keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'got approv humira work put remiss came back remicad work stelara work simponi seem work bit bit bring home seem like peopl fail biolog get result feelinglesscrappi new member join oct post post yesterday gmt start xeljanz week ago work better medic longer urgenc previous difficulti longer second wait time poop regardless want poop less x day massiv improv x good day normal time day diarrhea push blood stool grand total x sinc start take less number time bleed day lot pain ga first start take lessen lot overal happi thank god work ramess new member join jun post post yesterday gmt tri med humira entyvio remicad stelara work either tri see likelihood work none other feelinglesscrappi new member join oct post post yesterday pm gmt taken year taken due sever weight gain possibl futur complic brought stool day around day lot urgenc prednison imuran allerg reaction pentasa noth gave headach humira noth entyvio work somewhat decreas stool anywher near enough still bleed often mesalamin suppositori caus seriou pain put point worri caus fissur work pretti well overal abl forc take feelinglesscrappi new member join oct post post yesterday pm gmt diagnosi sever ulcer pancol order start prednison continu take take first pentasa imuran move onto humira final use suppositori entyvio time move onto xeljanz wait colon heal bit doctor start remov polyp caus said precancer also told medic last option surgeri remov colon would also take care polyp hope inform help xeljanz work well ramess new member join jun post post yesterday pm gmt ah surpris doctor tri biolog one avail none work enough simponi help enough tri xeljanz',\n",
       " 'local consolid therapi surgeri radiat proven prolong surviv patient oligometastat e three fewer metastas non small cell lung cancer nsclc whether patient greater metastat burden would also benefit known answer may found two new clinic trial combin local consolid therapi novel system treatment combat metastat nsclc two trial patient first receiv immun checkpoint inhibitor nivolumab ipilimumab lonestar trial tyrosin kinas inhibitor osimertinib northstar trial patient randomli assign receiv mainten therapi studi drug local consolid therapi follow mainten therapi shown local consolid therapi benefit nsclc patient oligometastat diseas expand paradigm includ patient polymetastat diseas said daniel gomez associ professor depart radiat oncolog univers texa md anderson cancer center hope combin local consolid therapi immunotherapi osimertinib extend surviv patient metastat diseas anywher bodi build promis find dr gomez colleagu hope combin local consolid therapi immun checkpoint inhibitor third gener egfr epiderm growth factor receptor inhibitor osimertinib extend surviv patient metastat nsclc beyond seen studi modal separ surviv benefit local consolid therapi demonstr recent phase ii trial patient oligometastat nsclc receiv first line therapi randomli assign receiv local consolid therapi mainten therapi median progress free surviv durat patient receiv local consolid therapi month significantli longer patient receiv mainten therapi month p first random control trial establish local consolid therapi slow diseas progress nsclc patient limit metastat diseas said dr gomez trial princip investig immun checkpoint inhibitor also shown benefit patient metastat diseas pd program cell death protein inhibitor nivolumab approv u food drug administr fda treat sever type cancer includ previous treat metastat nsclc furthermor combin nivolumab ctla cytotox lymphocyt antigen inhibitor ipilimumab alreadi approv fda treat metastat melanoma investig treatment metastat nsclc clinic trial egfr inhibitor osimertinib also shown promis nsclc march fda approv osimertinib treatment patient metastat nsclc egfr mutat one main gatekeep resist egfr inhibitor point mutat dr gomez said shown patient develop resist way treat osimertinib diseas respond new clinic trial northstar lonestar trial differ previou trial local consolid therapi use novel agent also includ patient oligometastat diseas also patient polymetastat diseas dr gomez said trial recent began enrol patient metastat nsclc northstar dr gomez md anderson princip investig multi institut northstar trial enrol patient previous untreat recurr stage iiib iv nsclc amen potenti cur treatment treatment na patient must tumor harbor egfr exon delet l r mutat wherea patient recurr diseas must egfr mutat aros treatment egfr inhibitor erlotinib gefitinib afatinib patient previous treat osimertinib anoth third gener tyrosin kinas inhibitor elig trial patient trial receiv osimertinib week whose diseas progress induct therapi randomli assign receiv osimertinib mainten therapi local consolid therapi follow osimertinib mainten therapi patient continu mainten therapi diseas progress unaccept toxic effect occur dr gomez colleagu compar progress free surviv patient receiv local consolid therapi patient lonestar lonestar trial enrol patient stage iv nsclc treatment na undergon one line chemotherapi target therapi patient whose diseas classifi adenocarcinoma must wild type egfr alk patient nsclc subtyp need test egfr alk statu mutat rare subtyp patient undergon system immunotherapi diseas inelig trial patient receiv two week cycl nivolumab ipilimumab patient whose diseas progress randomli assign receiv mainten therapi nivolumab ipilimumab local consolid therapi follow mainten therapi nivolumab ipilimumab patient continu mainten therapi year princip investig md anderson trial john heymach ph professor chair depart thorac head neck medic oncolog trial co princip investig dr gomez stephen swisher professor depart thorac cardiovascular surgeri head divis surgeri research compar overal progress free surviv patient receiv local consolid therapi determin local consolid therapi northstar lonestar trial multidisciplinari treatment team determin approach local consolid therapi whether patient treat surgeri radiat depend tumor locat extent diseas patient modal use treat lesion patient better suit hybrid approach lesion resect other irradi certain lesion tend better suit surgeri versu radiat therapi dr gomez said prefer use surgeri lung lesion resect lobectomi singl brain metastasi domin brain metastasi adren gland lesion resect rel modest risk metastas gener treat radiat surgeon radiat oncologist use whichev surgic radiat techniqu like achiev treatment goal lung lesion may resect open thoracotomi video robot assist thoracoscopi laparoscopi goal resect grossli neg surgic margin radiat therapi stereotact bodi radiat therapi common modal use although modal intens modul radiat therapi proton therapi avail goal radiat therapi ablat diseas whether use surgeri radiat main point aggress dr gomez said think treat mani lesion possibl key prolong surviv patient metastat nsclc inform contact dr daniel gomez dgomez mdanderson org learn clinic trial patient lung cancer visit www clinicaltri org read gomez dr blumenschein gr lee jj et al local consolid therapi versu mainten therapi observ patient oligometastat non small cell lung cancer without progress first line system therapi multi centr randomis control phase studi lancet oncol skoulidi f papadimitrakopoul va target gatekeep osimertinib egfr mutat posit non small cell lung cancer clin cancer re oncolog march volum issu',\n",
       " 'novarti basel switzerland announc us fda ema file accept siponimod new drug develop treat secondari progress multipl sclerosi adult',\n",
       " 'breast cancer risk ocrellizumab still undefin confid interv term risk still cross e yet sure risk would recommend women ocrelizumab enrol standard breast cancer screen appropri women meant self examin breast month taught encourag lot onlin content regard follow exampl http www youtub com watch v unjbwx ncvi http www youtub com watch v dupuejor http www youtub com watch v l xjiqgwhw',\n",
       " 'right bring combo specif anti pd combin keytruda opdivo exampl skim abstract seem combo anti pd monoclon tabl post quick skim seem similar',\n",
       " 'immun relat advers event ira relat treatment nivolumab associ better surviv among patient advanc non small cell lung cancer nsclc accord retrospect studi present iaslc th world confer lung cancer toronto canada largest studi date aim evalu whether develop ira predict nivolumab efficaci pretreat nsclc patient investig wrote pd pd l inhibitor prolong surviv patient advanc nsclc caus develop ira aim studi determin nivolumab efficaci associ ira defin advers event immunolog mechan requir monitor intervent relat articl pembrolizumab plu chemotherapi extend surviv longer chemotherapi alon studi head head battl brigatinib appear best crizotinib durvalumab show overal surviv benefit patient stage iii nsclc multicent retrospect studi includ patient advanc nsclc median age year male ira grade develop patient patient experienc grade grade event ira significantli associ prolong median progress free surviv pf month compar month patient experi ira p correspond hazard ratio hr ci p multivari analysi number ira develop also associ prolong pf patient least ira ira demonstr median pf month respect compar month patient sign ira p overal surviv os also better among patient ira median os month ira compar month without ira p correspond hr ci p multivari analysi patient least ira ira median os month month respect compar median os month patient ira p accord investig result studi suggest develop ira strong predictor surviv outcom nsclc patient receiv nivolumab line set read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       " 'awesom thank test subject butt hope bless continu femal canada ivig pentasa uc crohn test posit map antibodi mycobacterium pg remiss flare year current deal peri anal abscess fistula rvf wait stelara',\n",
       " 'hi kelyb congratul good respons treatment although wish cost treatment side effect assum caus symptom describ forum would tough guess may caus tagrisso sinc common symptom wide rang possibl caus alreadi done would good review medic doctor pharmacist sinc drug interact side effect common doctor also may want order blood work follow find caus defin caus tagrisso dose reduct certainli option mani patient respond well egfr tki suffer debilit side effect quit well lower dose lessen side effect patient seem particularli sensit tki term respons toxic time way know symptom caus particular drug reduc dose hold drug period time see symptom lessen good luck find relief symptom jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'slide anoth talk jerri wolinski alreadi avail break data ocrelizumab talk lot data trial http actrim confex com actrim meetingapp cgi paper',\n",
       " 'first ever abnorm pap await biopsi wbc tysabri link abnorm pap wonder gilenya well anyon els g four year',\n",
       " 'read cladribin gong see neurologist whether short bart seem think better ms drug whisper dare drug compani prefer other make money seem post say anyway mayb read bias way want tri drug http multipl sclerosi research blogspot com suppos wa',\n",
       " 'cnw astrazeneca canada today announc health canada approv imfinzi durvalumab treatment patient local advanc unresect non small cell lung cancer nsclc whose diseas progress follow platinum base chemoradi therapi crt approv imfinzi becom first approv immuno oncolog therapi follow crt patient set review health canada acceler approv framework imfinzi grant notic complianc condit noc c base data phase iii pacif trial demonstr imfinzi extend progress free surviv patient nearli one year month versu placebo ii patient diagnos stage iii set lung cancer spread part bodi treat intent cure cancer combin surgeri radiat therapi chemotherapi despit major eventu cancer spread past twenti year research improv outcom patient result signific benefit iii imfinzi first therapi abl delay progress lung cancer patient approv imfinzi base posit progress free surviv pf data phase iii pacif trial imfinzi demonstr improv median pf nearli one year month compar placebo repres per cent reduct rel risk progress death vs placebo patient regardless program death ligand pd l statu iv pacif trial ongo evalu overal surviv os unresect stage iii nsclc detail interim result pacif trial publish onlin new england journal medicin nejm overal incid sever advers event compar patient receiv imfinzi compar patient receiv placebo patient receiv imfinzi common advers reaction greater equal patient cough pneumon radiat pneumon upper respiratori tract infect rash v discontinu concurr crt due advers reaction regardless causal occur per cent patient receiv imfinzi vs per cent patient receiv placebo vi quot health canada approv imfinzi herald new era treatment stage iii unresect lung cancer despit often deadli prognosi attempt treat patient intent cure diseas long await new therapeut option offer hope post chemoradi therapi imfinzi proven approv treatment may significantli improv outcom patient within diseas set dr rosalyn juergen medic oncologist juravinski cancer centr approv mark signific mileston great proport lung cancer patient effect treatment option follow cur intent chemoradi progress free surviv rate seen imfinzi unpreced impact diseas set benefici treatment offer patient last two decad dr rob el maraghi medic oncologist simco muskoka region cancer centr last three year immunotherapi major develop treatment metastat lung cancer arriv imfinzi revolut treatment stage iii unresect non small cell lung cancer imfinzi delay recurr lung cancer median nearli addit year first immunotherapi stimul immun system address residu microscop diseas left undetect chemotherapi radiat give hope patient watch wait recurr major case dr mari florescu clinic investig assist clinic professor depart medicin universit de montr al health canada approv imfinzi welcom news patient live stage iii unresect non small cell lung cancer give better chanc surviv health canada approv first step call stakehold work togeth publicli fund need shem singh execut director lung cancer canada lung cancer stage iii advanc nsclc lung cancer lead caus cancer death men women canada commonli diagnos cancer accord canadian cancer societi cc approxim canadian diagnos lung cancer repres around per cent new cancer case vii stage iii non small cell lung cancer nsclc repres approxim per cent new nsclc diagnos approxim per cent patient unsuit surgeri viii canada averag per cent peopl diagnos nsclc like live five year diagnosi follow crt ix stage iii nsclc divid three stage iiia iiib iiic defin size locat tumour much cancer spread local possibl surgeri x patient diagnos set treat intent cure cancer major patient benefit chemoradi therapi per cent experi progress metastat diseas xi inform lung cancer visit www lvng ca imfinzi durvalumab imfinzi fulli human monoclon antibodi bind pd l block interact pd l pd cd counter tumour immun evad tactic releas inhibit immun respons imfinzi alreadi grant notic complianc condit noc c canada treatment patient local advanc metastat urotheli carcinoma bladder cancer diseas progress follow platinum contain chemotherapi whose diseas progress within month receiv platinum contain chemotherapi neoadjuv adjuv surgeri xii clinic studi imfinzi ongo includ mystic neptun pearl phase iii trial imfinzi studi st line treatment monotherapi combin tremelimumab anti ctla monoclon antibodi potenti new medicin treatment metastat nsclc poseidon trial investig imfinzi without tremelimumab combin chemotherapi similar patient popul astrazeneca approach immuno oncolog immuno oncolog io therapeut approach design stimul bodi immun system attack tumour astrazeneca medimmun biolog research develop arm io portfolio anchor immunotherapi design overcom anti tumour immun suppress believ io base therapi offer potenti life chang cancer treatment major patient astrazeneca astrazeneca global innov driven biopharmaceut busi primari focu discoveri develop commerci primari specialti care medicin transform live primari focu three import area healthcar cardiovascular metabol diseas oncolog respiratori inflamm autoimmun astrazeneca oper countri innov medicin use million patient worldwid canada employ employe across countri astrazeneca canada headquart locat mississauga ontario inform pleas visit compani websit www astrazeneca ca refer astrazeneca canada inc imfinzi durvalumab product monograph may ii ibid iii denton eve matthew conron improv outcom lung cancer valu multidisciplinari health care team journal multidisciplinari healthcar pmc apr avail http www ncbi nlm nih gov pmc articl pmc iv astrazeneca canada inc imfinzi durvalumab product monograph may v ibid vi ibid vii canadian cancer statist access april avail http www cancer ca en cancer inform cancer type lung statist region viii zhao q wang z huang w wang q yu zhou li b phase iii studi cisplatin pemtrex vinorelbin plu concurr late cours acceler hyperfraction radiotherapi patient unresect stage iii non small cell lung cancer oncotarget http doi org oncotarget ix auperin le pechoux c rolland e curran w furus k fournel p meta analysi concomit versu sequenti radiochemotherapi local advanc non small cell lung cancer journal clinic oncolog may http ascopub org doi full jco x nation comprehens cancer network nccn nccn clinic practic guidelin oncolog non small cell lung cancer version avail http www nccn org profession physician_gl pdf nscl pdf access januari xi bradley j paulu r komaki r master g blumenschein g schild bogart j choy h standard dose versu high dose conform radiotherapi concurr consolid carboplatin plu paclitaxel without cetuximab patient stage iiia iiib non small cell lung cancer rtog randomis two two factori phase studi lancet oncolog http www thelancet com journal lanonc articl pii fulltext xii astrazeneca canada inc imfinzi durvalumab product monograph may sourc astrazeneca inform michel marchion senior manag corpor commun astrazeneca canada tel x email michel marchion astrazeneca ca',\n",
       " 'hi ami chose copaxon diagnos realli easi fit day work well year howev got bad lipotrophi sever condit inject site switch tecfidera tecfidera tablet day much pleasant daili inject see ms nurs everi month blood test care white blood cell count go appoint make sure ask question need much know alreadi offer infus lemtrada tysabri big gun may offer first line treatment inject rebif avonex copaxon tablet tecfidera gilenya aubagio feel nervou ask someon accompani rememb decis make decis day ask time think good luck carol x',\n",
       " 'hey amanda mavenclad clone medic gilenya',\n",
       " 'avengr know edgarleroy cladribin us post may doctor differ us state offer differ drug ski pist way one mind ask found scari cladribin seem one milder ms drug side effect',\n",
       " 'mom diagnos nsclc approv keytruda small tumor lung even smaller hardli visibl one liver everyth els came back clear keytruda first treatment expect side effect know cancer differ would love hear someon taken even possibl could shrink liver tumor oper lung lead remiss obvious stage iv know seriou worri much time left question never told size spot lung liver may dumb question size matter give indic advanc ask question appoint tri learn much possibl thank advanc help provid',\n",
       " 'hello eyesight thank posit like realli want abl keep read along abl drive would wors nightmar present left eye fine dread thing happen one second inject eyelea last week lucenti appear help fact made thing seem wors hope eyelea stabilis like other report black disc told bubbl scari went coupl hour hope goe well x',\n",
       " 'potenti treatment non respond dr ariyan studi cours first exampl treat melanoma immunotherapi combin approach combin ipilimumab nivolumab recent becam first line treatment advanc melanoma clinic studi report object respons rate ipilimumab nivolumab compar ipilimumab monotherapi although median pf combin superior ipilimumab nivolumab alon month month respect still month best immunotherapi today combin ipilimumab pd inhibit still room make improv dr ariyan said nevertheless ili like take place pd inhibitor combin ipilimumab first line treatment advanc melanoma dr ariyan co author wrote littl role limb infus ctla blockad first line treatment invas natur ili need hospit hope futur abl use treatment patient otherwis respond dr ariyan said next step look combin peopl fail tradit immunotherapi ad relat articl obes associ improv melanoma outcom immunotherapi metastat melanoma clinic vismodegib induc melanoma patient treat basal cell carcinoma grow interest chemoimmunotherapi current push test variou chemotherapi immunotherapi mous studi clinic trial treat rang cancer type said gordon freeman phd professor medic oncolog dana farber cancer institut boston massachusett advanc melanoma phase trial found improv overal surviv combin ipilimumab dacarbazin compar dacarbazin alon ipilimumab paclitaxel carboplatin current evalu treatment non small cell lung cancer nsclc small cell lung cancer us food drug administr fda approv combin ipilimumab pemetrex carboplatin nsclc research also evalu target therapi mek kinas inhibitor treatment colorect cancer anti androgen therapi treatment prostat cancer anti angiogenesi therapi treatment kidney cancer combin pd inhibit precis target agent may advantag non target drug pemetrex non specif kill divid cell thu could hinder product cell immunotherapi act dr freeman explain',\n",
       " 'first ever infus schedul day thank share appreci know expect never dmt recent dx start ocrevu soon look forward',\n",
       " 'mike hello david good day today ms life ectrim morn think good piec work happen today inform think peopl know professor david baker neurologist well think probabl interest thing happen today news first time shown drug affect progress ms drug call siponimod shown slow rate disabl accumul peopl secondari progress ms first time happen phase three trial mean probabl readi go regul may far becom real drug think probabl one highlight meet other one thing realli realli interest studi sweden know drug come along call ocrelizumab pretti effect diseas modifi drug drug call ocrelizumab probabl regul moment interest thing problem drug gener cost kind influenc whether peopl get access sweden use like cheap version ocrelizumab got thousand peopl given access drug obvious look like work interest thing look long peopl drug actual take coupl year wherea pharmaceut compani want take everi six month forev might kind realli good news could mean effect might take drug long long time reduc side effect also suggest know doctor will tri thing outsid box good thing think drug may benefit peopl ms use produc market ms pharmaceut compani nevertheless use say epilepsi drug might valu multipl sclerosi one highlight like stick man like great mike topic think might risk move away big pharmaceut compani move sort gener area might less acceler term fund come kind treatment professor david baker definit definit think worri guess go burst bubbl mani year pharmaceut industri invest heavili ms drug one neurolog diseas treatment avail pharmaceut compani make money eventu happen drug protect patent patent run gener come along happen histor drug biolog difficult manufactur straight chemic first chemic come patent could potenti mean price plummet therefor pharmaceut compani may show less interest kind potenti good thing term get access drug restrict ration cost could bad thing pharmaceut compani may disinvest ms could well happen join shift ms commun http shift ms watch video http shift ms msreport http www facebook com shift ms http www instagram com shiftdotm http twitter com shiftm',\n",
       " 'apr pm ilex wrote opdivo side effect develop seriou rash besid nada zilch rash realli realli bad tumor shrank recov earlier nastier chemo abl go back work',\n",
       " 'hi five welcom grace sorri hear stepmom diagnosi post rais question may affect futur treatment decis treatment alimta effect stop alimta due progress cancer progress later shown progress keytruda grow slowli rapidli stage iv diseas usual expect evid diseas disappear although small number patient achiev statu instead tumor shrinkag stabil good result treatment even slow growth toler agent may accept want get maximum benefit treatment move anoth line therapi immunotherapi keytruda patient show benefit immedi patient deriv long last benefit treatment base said assum time therapi chang especi sinc oncologist chang treatment first sign even minor progress would help know cancer cell ever test egfr alk target genet alter approv drug tarceva xalkori well agent target mutat current test clinic trial combin immunotherapi agent also studi number convent chemotherapi agent avail need chang treatment let us know answer question rais tri provid addit inform jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'nil koch henriksen depart clinic epidemiolog clinic institut aarhu univers aarhu denmark danish multipl sclerosi registri neurosci centr rigshospitalet univers copenhagen copenhagen denmark melinda magyari danish multipl sclerosi registri neurosci centr rigshospitalet univers copenhagen copenhagen denmark danish multipl sclerosi center copenhagen univers hospit rigshospitalet copenhagen denmark finn sellebjerg danish multipl sclerosi center copenhagen univers hospit rigshospitalet copenhagen denmark per soelberg rensen danish multipl sclerosi center copenhagen univers hospit rigshospitalet copenhagen denmark danish multipl sclerosi registri neurosci centr copenhagen univers hospit rigshospitalet blegdamsvej dk copenhagen denmark koch henriksen stofanet dk background natalizumab fingolimod approv treatment activ relaps remit multipl sclerosi rrm denmark respect random head head studi compar two drug object compar clinic efficaci natalizumab fingolimod method data danish rrm patient start first second line treatment natalizumab fingolimod juli march prospect record danish multipl sclerosi ms treatment regist two treatment arm propens score match baselin covari use nearest neighbour method result propens score match left rrm case treatment group treatment annual relaps rate confid interv ci natalizumab ci fingolimod adjust relaps rate ratio ci p mean time first relaps year respect p differ chang expand disabl statu scale edss conclus found differ clinic diseas activ natalizumab fingolimod treat rrm patient real life observ studi howev lack magnet reson imag mri data propens score match may conceal higher efficaci natalizumab',\n",
       " 'peg ivig infus suppos last day surpris done hour learn quicker infus meant side effect nurs decid make go faster even though doctor order way year ago wonder could ocrevu repli quot follow user say thank agat howi jeani z jendi stillstannd',\n",
       " 'best luck next week solomon wish best possibl outcom ileostomi definit prefer sometim use find empti bag bit pain miss empti bag abl get go without worri stool pass butt burn becom absolut excruci kept control anal itch leakag said revers think would constantli wonder suspect would tri beat given j pouch go dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'surgeri recoveri slow immunomodul heal fast time requir step instead two step surgeon call would med enough time prior nd surgeri step want two step condit step tough recov want combin pre surgeri condit entocort similar steroid non system mayb one cycl knock flare keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'fingolimod secondari progress eae may comment see full paper may unless confirm realli secondari progress model suspect relaps progress relaps drive worsen synchronis line graph look secondari progress ask last two nod paper publish japan australia raw data got nowher import despit said abstract harvard group report model respons quickli cell immunosuppress fingolimod may work progress system great like fingolimod great primari progress ms tri spm doubt siponimod develop vitro fingolimod activ agent use hundr time p bind efficaci know cell killer food thought sp eae use',\n",
       " 'longish post question end start lower back pain around l lumbar vertebra along tingl equal leg week ago tingl new addit residu peripher neuropathi feet cisplatin end year ago lul vat adenocarcinoma lung yesterday start gentl lumbar stretch yoga pose found web much mobil comfort today yesterday still pain lower back tingl leg stand get dull ach leg symptom complet new aros simultan realiz lower back pain extrem common probabl worri noth never nowaday whenev get ailment wonder could cancer return whole subject guess pretti common hard know realli ration concern inevit mean cancer recurr real possibl still resect lung adenocarcinoma even act one hand hand everi one age process go cancer without abdomin chest ct scan without contrast show evid metastasi week ago refer bone area said specif focal destruct lytic sclerot osseou lesion abdomen pelvi question standard ct scan chest abdomen pelvi also imag spine way rule metastat spread spine sourc pain secondli way pain result cancer lower back nervou system sure spine includ term abdomen pelvi second question gener come grip cancer risk confront gener health problem post diagnosi chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatin vinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan topic modifi year month ago catdand forum moder topic modifi year month ago catdand forum moder',\n",
       " 'yeah buddi stan got go help film video blog go drive jeep feed water hors ride excit alreadi went tulsa trade car jeep problem check drive back last night sky orang distanc explain stan farmer burn field late make room new growth decid go find fire fun took jeep crazi eeri dirt road follow orang glow sky final crest littl hill acr acr acr burn grass got right next turn light got film smoke realli strong probabl good us truck pull trailer water guy stand back drove us keep eye fire probabl thought dork take pictur beauti made video tie high line hitch hors tree soon post video everyon know tie cow hitch nice partner given ms updat awhil basic fine take dri cordycep mushroom powder mushroom medicin gilenya made figur activ ingredi one strongest ms medicin might help say anyon tri medicin right also take turmer powder black pepper curcumin activ ingredi turmer super potent anti inflammatori make smoothi morn dump powder still take liquid liquid methyl b think liquid get absorb better take lot pill supplement worri overload pee tri space day someday better other learn curv still hard time chang diet eat steak haha tri put much pressur get road confid road routin easier eat anti inflammatori simpl diet go take',\n",
       " 'husband xeljanz month still full remiss appar side effect start feel better almost right away bleed stop month month felt confid work colonoscopi month start xeljanz show total remiss hope work take mg mg morn mg even spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper still taper prednison mg everi week develop osteoporosi due steroid',\n",
       " 'like post updat possibla work name wife use clinic trial drug see former post coupl week next ct scan done meantim want say today mark good moment wife ayso soccer refere number year boy girl year old game one two game week howev ever sinc cancer diagnosi year half ago refere first due carbo alimta treatment lower red blood cell reduc stamina consider non respons opdivo treatment side effect persist cough return work clinic trial initi treatment possibla treatment howev side effect hair neuropathi pain numb time seem affect blood cell energi level great today year half back refere ayso game afternoon two us went kayak hour morn mileston return hope ct scan coupl week continu show reduct lung tumor liver metastas one day one step forward time wife lifelong non smoker dx adeno nsclc stage iv poorli diff bone met lymph node exon mutat x carbo alimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo effect add l growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl stabl add l growth trial start gemzar larg tumor reduct',\n",
       " 'good news pediatr fingolimod result idea effect children result much better transform studi',\n",
       " 'saw current gi doc today say rn kind concern got back room quickli could lay step scale inde lost lb day freak hungri afraid eat thing want discuss doc answer q consid use immunomodul along humira sinc spike fever know option right q need pain med run hydrocodon prescrib refer pain manag specialist prescrib hydrocodon pill order chest x ray slew blood urin fecal test go labcorp pick test suppli told next time spike go er fact ever feel panicki due pain mental anguish etc hesit go er ask point admit said admit right alreadi done told first hospit day time left poop normal feel fine diseas never act like wateri solid wast never taken long see relief symptom finish doctor famili went qdoba dinner got kid size burrito bowl crave rice bean glad ate though would made sick eat much far regret eatng look forward finish bowl morn appoint local gi doc monday sinc good experi current gi offic today sure want switch current doc better credenti local gi easi talk establish relationship rn etc think go see local gi say cancel stick current gi yr femal diagnos hospit current apriso pm rowasa enema pm mg prednison mg mg pm liquid diet current wait approv start humira previous fail remicaid previous use asacol lialda delzicol pentasa cortenema canasa entocort uceri gluten free supp vsl cal mag vit krill oil',\n",
       " 'read page read much jack seem like know jackwagon listen anyth anyon say anyway ask question go ahead tri answer anyway ye hinder growth see blood mean nowher close remiss unless hemmi someth alik ye seriou flare hit lose muscl mass fast weigh lb squat lb set rep flare land hospit day week sever anemia hemoglobin abl squat set weigh lb point ye diseas hit fast diagnos year jan went prednison lialda enema got back normal april may back full blown flare prednison control went imuran remicad entyvio age colon remov jpouch procedur noth help severli anem much constant pain etc navi would perform medic anyway inflamm marker anyth show investig flare etc matter previou record show probiot sound great probiot help low amount user least forum talk like know whole lot surgeri requir ever came even met surgeon let alon diagnos doubt realli know would like boat best luck p attitud especi militari get absolut rock',\n",
       " 'found cm liaison brain surgeri day radiat spot remov tumor month later mri found mm tini abnorm tumor go last day treatment radiat monday would complet day hope anymor cell brain sinc lung nsclc far neg ct scan pet scan follow call surveil scan make sure ned feel great lung specialist said elig keytruda said data say readi know good thing bad oncologist say need chemo keytruda guess wait till anoth tumor come back wonder alway come back ugggh common denzil give perk knowledg look forward hear u r say time lol',\n",
       " 'know mention elus articl state appl peel excel natur tnf inhibitor actual came right said appl peel think per day gave tnf inhibit dose remicad mani appl peel day would leav ruin suffer hour last night eat small portion kale dinner sadli fibrou veggi bowel longer get along use friend fell year ago dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'mousedoctorsaturday juli pm howev pharma get burn posit result ocrelizumab ppm siponimod spm reward may ask bother mayb pharma get burn ocrelizumab ppm littl late mani mayb tri harder better result ppm earlier would onto better gold mine',\n",
       " 'hello lesion brain spine neruo told last mri result two day ago lesion left side brain grew bigger said could possibl grow black hole dead spot anyon explain reason want chang medicin tecfidera copaxon gilenya work therefor chang medicin scare tri anoth one due side effect long fda approv read post day ago hug use answer sign view previou answer mymsteam member said flipsid nd round lemtrada septemb said year sinc nd round long start feel read post day ago hug use assert doctor passiv person realli believ need becom assert doctor realiz ms mani unknown etc perhap doctor may less say first neurologist met diagnosi prescrib tecfidera told look ms internet learn actual start appoint think go tell mistaken ms look mri tone chang oh definit read post day ago hug use answer sign view previou answer mymsteam member said old school medicin say ms pain everyon differ everyon lesion differ effect degre read post day ago hug use infus center want see anyon get infus done moor cancer center la jolla think experi im go start infus decemb could use kind feed back lead start date thank much love post day ago hug use answer sign view previou answer mymsteam member said thank much respons mymsteam member post day ago hug use mri august found new spot spine anoth mri head today head full lesion alreadi spine spot mean bladder bowel last month gait becom brace made drop foot next week post day ago hug use answer mymsteam member said brain cervic thorac lesion mean symptom differ area bodi exampl hand fingertip feel read edit origin post day ago hug use best medicaid plan option cook counti resid insur cover tysabri infus doctor rush univers medic center experi hope give idea six blue cross commun famili health plan countycar health plan incook counti harmoni health plan illinicar health meridian health plan molina healthcar nextlevel health cook counti resid want sure cover much ppo pay read post day ago hug use answer sign view previou answer mymsteam member said got get decis made soon possibl take advic give email joshuakerouac gmail truli read post day ago hug use tattoo ms want get tattoo repres diseas anyway wonder anyon got one diagnos good idea',\n",
       " 'hey ladi man miss guy want catch pretti distract thing go well overal relish feel better mani way drink pedialyt day still felt dehydr drink normal amount fluid even cup coffe feel fine rosacea peri oral dermat mouth ulcer extraintestin issu current skin gorgeou done noth even moistur peri rectal fistula non issu sitz bath around cook light housework stand feet talk someon long want alway sit lay take break lean thing alway pain especi toilet use dread vacum carri groceri put away simpl task wore anymor tri take easi love abl live life peopl impress posit outlook truli believ canand live full life ostom hand night get emot fan scar particularli bikini scar swell go still look differ tri figur bag like base sampl arriv past coupl day hard suppos chang bag often luckili leak yet find empti lot kind process cumbersom point feel awkward wonder realli live ostomi forev shed tear worri frustrat hot mess wonder ever get hang ostom feel dishevel hair fell due stelara grow back stick everywher move even know alot cloth need buy belt ostomi underwear fluck know buy onlin cannot tri whyyyyi somebodi say need save drain task onlin research nap would nice ostomi person shopper home health nurs came today help chang bag might one sensura mio piec fit stoma mm bag flang heavi fold nice tri bigger bulkier two piec ostomi nurs right heavi post op still tender use barrier spray seal past powder tri deodor lubric bravo today good tri nurs today said skin look good relief area tender sure someth wrong start wean prednison drop mg mg today readi want feel bad oh mention hemoglobin fell hospit end anoth iron infus discharg friday felt littl light head hope anemia clear quickli bleed toddler think bag cool reassur husband coach low point incred support know mani peopl louisiana husband collaps surgeri found ton support around us peopl bring meal groceri mow lawn care pet even give us money lose faith world tire struggl silenc faith god mankind renew never repay peopl help us time need never miss opportun pay forward see way help serious tear eye right grate love guy yr femal dx uc dx chang crohn coliti current stelara apriso prednison wean previous use remicad humira imuran mp asacol lialda delzicol pentasa cortenema cortifoam rowasa canasa entocort uceri uceri foam gluten free supp vsl cal mag vit krill oil ezf post edit plucki pm gmt',\n",
       " 'want give updat post novemb son rd infus ocrelizumab april everyth still stabil sinc start ocrelizumab side effect even infus shortli infus got flue infect brother father came visit us day infus high temperatur day tire week ocrelizumab made differ equal sick wish well ing',\n",
       " 'front neurol nov abstract read full text paper siddiqui mk khurana budhia et al systemat literatur review network meta analysi cladribin tablet versu altern diseas modifi treatment relaps remit multipl sclerosi curr med re opin nov [epub ahead print] abstract read full text paper lublin fd cofield ss cutter gr et al long term follow random studi combin interferon glatiram acet multipl sclerosi efficaci safeti result year mult scler relat disord nov abstract gerber b cowl chen g et al impact treatment adher clinic econom outcom multipl sclerosi real world evid alberta canada mult scler relat disord nov abstract eagl stuart f chua et al treatment satisfact across inject infus oral diseas modifi therapi multipl sclerosi mult scler relat disord nov abstract eriksson car piehl f et al persist dimethyl fumar relaps remit multipl sclerosi popul base cohort studi eur j clin pharmacol nov [epub ahead print] abstract read full text paper moccia palladino r carotenuto et al year retrospect cohort studi compar interferon formul relaps remit multipl sclerosi mult scler relat disord nov [epub ahead print] abstract thelen j bruce catley et al baselin predictor dmt reiniti among patient multipl sclerosi follow mi cbt intervent j behav med nov [epub ahead print] abstract zimmer coslovski abraham et al adher fingolimod multipl sclerosi investig initi prospect observ singl center cohort studi patient prefer adher oct',\n",
       " 'kleo eight far next due dec never seen scan never offer show time wait doctor comment let talk till run thing say nod head give thumb concern question bring get soon possibl long feel good happi way treatment go week infus thing took differ direct cough congest advic get medic help one thing come mind last infus never took water even got home thing water pm cough start way think stupid move part water play big factor cough clear congest loosen thank good wonder order pet instead regular ct way could answer question stage let doctor interpret let tell cours action also want miss xma basket durvalumab',\n",
       " 'brand name portrazza import warn necitumumab inject may caus seriou life threaten problem heart rhythm breath doctor order certain test infus infus least week final dose check bodi respons necitumumab tell doctor ever lower normal level magnesium potassium calcium blood chronic obstruct pulmonari diseas copd high blood pressur heart rhythm problem heart problem experi follow symptom call doctor immedi chest pain short breath dizzi loss conscious fast irregular pound heartbeat keep appoint doctor laboratori talk doctor risk receiv necitumumab inject medicin prescrib necitumumab inject use gemcitabin gemzar cisplatin treat certain type non small cell lung cancer nsclc spread part bodi necitumumab inject class medic call monoclon antibodi work help immun system slow stop growth cancer cell use medicin medic may prescrib use ask doctor pharmacist inform medicin use necitumumab inject come liquid given intraven vein hour doctor nurs medic facil usual given certain day everi week length treatment depend well bodi respond medic side effect experi doctor may need stop delay treatment experi certain side effect import tell doctor feel treatment necitumumab may experi symptom fever chill short breath difficulti breath receiv follow dose necitumumab especi first second dose tell doctor healthcar provid experi symptom treatment experi reaction necitumumab doctor may stop give medic time may give slowli doctor may prescrib medic help prevent reliev symptom doctor tell take medic receiv dose necitumumab special precaut follow receiv necitumumab inject tell doctor pharmacist allerg necitumumab medic ingredi necitumumab inject ask pharmacist list ingredi tell doctor pharmacist prescript nonprescript medic vitamin nutrit supplement herbal product take plan take doctor may need chang dose medic monitor care side effect tell doctor pregnant plan becom pregnant becom pregnant receiv necitumumab inject use effect birth control prevent pregnanc treatment necitumumab inject least month final dose medic talk doctor birth control method work becom pregnant receiv necitumumab inject call doctor immedi necitumumab inject may harm fetu tell doctor breastfeed plan breastfe breastfe receiv necitumumab month final dose plan avoid unnecessari prolong exposur sunlight wear protect cloth sunglass sunscreen necitumumab inject may make skin sensit sunlight special dietari instruct follow unless doctor tell otherwis continu normal diet side effect medicin caus necitumumab inject may caus side effect tell doctor symptom sever go away acn dri crack skin diarrhea vomit weight loss sore lip mouth throat vision chang red wateri itchi eye red swell around fingernail toenail itch side effect seriou experi symptom call doctor immedi get emerg medic treatment leg pain swell tender red warmth sudden chest pain tight weak numb arm leg slur speech rash difficulti swallow cough blood necitumumab inject may caus side effect call doctor unusu problem receiv medic experi seriou side effect doctor may send report food drug administr fda medwatch advers event report program onlin [web] phone case overdos case overdos call poison control helplin inform also avail onlin [web] victim collaps seizur troubl breath awaken immedi call emerg servic symptom overdos may includ follow headach vomit nausea inform know ask pharmacist question necitumumab inject import keep written list prescript nonprescript counter medicin take well product vitamin miner dietari supplement bring list time visit doctor admit hospit also import inform carri case emerg report medic inform consid individu patient advic chang natur drug inform pleas consult physician pharmacist specif clinic use american societi health system pharmacist inc repres inform provid hereund formul reason standard care conform profession standard field american societi health system pharmacist inc make represent warranti express impli includ limit impli warranti merchant fit particular purpos respect inform specif disclaim warranti user advis decis regard drug therapi complex medic decis requir independ inform decis appropri health care profession inform provid inform purpos entir monograph drug review thorough understand drug action use side effect american societi health system pharmacist inc endors recommend use drug inform substitut medic care ahf patient medic inform copyright american societi health system pharmacist inc east west highway suit bethesda maryland right reserv duplic commerci use must author ashp',\n",
       " 'repli plan offici ocrevu view post activems even much differ rtx even much differ rtx ocrevu hope placebo effect good enough give bump hour afterward felt pretti darn good rememb',\n",
       " 'cancer run famili diagnos stage iv lung cancer septemb came complet shock healthi activ year old wife mother two young girl sinc learn anyon lung get lung cancer also learn import find doctor medic team trust want peopl around commit find cure diseas research found md anderson lung cancer symptom symptom lung cancer diagnosi felt pressur chest assum relat stress due recent move thought return regular fit routin would help feel better went jog new neighborhood surpris felt unusu breath assum viru possibl walk pneumonia went local walk clinic doctor took x ray chest told collaps lung need go emerg room right away spent four day hospit underw test fluid drain around left lung told like ovarian cancer due enlarg cyst one ovari found later size within normal rang noth symptom husband left hospit question answer lung cancer diagnosi next day friend recommend go anoth local hospit seek answer still fluid around lung need drain test doctor recommend exploratori surgeri woke surgeri famili visibl upset surgeon told stage iv adenocarcinoma type lung cancer mass upper left lobe lung anoth lower left lobe nodul chest belli prognosi good first question much time left surgeon said two week nine month oncologist want genet test tumor say might chang treatment plan wait two long week result ultim test posit alk genet mutat link lung cancer husband knew want get best care possibl set appoint md anderson immedi made plan fli houston meet new doctor came md anderson lung cancer treatment md anderson met dr vincent lam first thing told us give hope said job keep aliv cure found need stay strong keep fight recommend drug call crizotinib one first target therapi develop alk posit lung cancer felt realli comfort dr lam trust expertis agre partner local oncologist knoxvil husband start call medic team commun work togeth ensur get best treatment start take crizotinib twice daili though kept cancer stabl felt nauseou exhaust time kept get sick white blood cell count low dr lam suggest switch new target therapi drug call alectinib said new research indic strong possibl new drug would prevent cancer spread longer period time trust dr lam got local oncologist onboard within day start alectinib began feel normal energi back abl exercis could play daughter best part new target therapi made cancer disappear refer radiat oncologist dr daniel gomez suspici spot chest medic team advis wait six week start radiat therapi alectinib took care life today take alectinib pill twice day two year side effect experienc sun sensit achi feet morn get move pain goe away return md anderson everi day scan appoint dr lam eventu lung cancer build resist drug team plan place happen right result wonder call complet metabol respons shown evid diseas sinc novemb request appoint md anderson onlin call',\n",
       " 'toxic megacolon typic high fever associ still fever discontinu simponi least think discontinu know high fever lower temp fever thereaft thought seem possibl fever',\n",
       " 'bump pleas read folk want inform regard iron zamboni research husband dx rrm dx dual jugular vein stenosi ccsvi http ccsviinm blogspot com top paulmur famili member post join thu mar pm quot post paulmur sat feb pm said variou forum dx ironoverload hemochromotosi month dx ms first exacerb found lesion brain spine typic ms suffer ms symptom contantli mainli lot fatigu depress fog brain tingl anyway mention context absolut believ iron caus factor effect perhap alway ccsvi fact signific iron level start rise age also think rr part rrm stress vasodilat right perhap one trigger among other could caus stenosi reach tip point would start reflux perhap time stenosi retriet enough recoveri thought top lucki famili elder post join wed dec pm locat usa contact contact lucki icq websit quot post lucki sat feb pm keep thing interest borderlin anem whole life diagnos ms age exacerb first year diseas pregnanc terribl anemia chomp ice nine month straight time born start avonex year rebif tysabri constantli anem exacerb slow progress year fought procrit band aid dmd await test ccsvi ultrasound posit reflux ijv back borderlin anem sinc stop drug year ago still progress someon like fit equat top mshusband famili elder post join sun jan pm locat pittsburgh pa usa contact contact mshusband icq quot post mshusband sat feb pm still iron blood lucki whether lot littl top marcstck famili elder post join tue jan pm contact contact marcstck icq websit quot post marcstck sat feb pm problem associ iron deposit ccsvi ms iron deposit seen mani neurolog condit none associ ccsvi link pertin studi http www ncbi nlm nih gov pubm http www sciencedirect com scienc _o c http www ajnr org cgi content abstract http emedicin medscap com articl overview also nerv cell releas iron damag die iron deposit ms may effect rather caus marc www wheelchairkamikaz com top cece famili elder post join mon jan pm contact contact cece icq quot post cece sat feb pm marcstck wrote also nerv cell releas iron damag die iron deposit ms may effect rather caus seem like could cascad iron releas nerv cell die caus damag area howev truth scienc ultim emerg although sometim take long time arthur silverstein autoimmun histori earli struggl recognit top paulmur famili member post join thu mar pm quot post paulmur sat feb pm marc know iron went haywir due genet propens happen believ aspect health relat ccsvi ms perhap hh appear ccsvi condit may caus lesion think fact iron deposit appear diseas may mean set factor could add result ccsvi imag know lesion caus hh alon top bethr famili elder post join sun dec pm quot post bethr sun feb paulmur wrote marc know iron went haywir due genet propens happen believ aspect health relat ccsvi ms perhap hh appear ccsvi condit may caus lesion think fact iron deposit appear diseas may mean set factor could add result ccsvi imag know lesion caus hh alon lesion form iron level peak like mention elsewher one gene hemochromatosi enough rais iron level drop level iron phlebotomi normal level easi particularli overload doctor standard tired fatigu disappear instantli hour know whether laugh cri could free two year ago doctor taken notic high iron level got slightli normal ferritin measur find porphyria rare genet diseas yeah right doctor test rare point rare preval scottish irish northern european bloodlin porphyria carrier react iron drug love give contracept alcohol make brain strang thing like ms must heap genet interact go porphyria carrier never show sign mix iron pill much dairi produc beef whamo ms take drug big pharma would crumbl sort son diagnosi autism adhd niec diagnosi depress brother diagnosi stuf liver sister diagnos ms fix phlebotomi cessat drug contracept care diet money big pharma hmmmmm bad packag food industri put mani addit food chemic cocktail day everi breakfast food pack extra iron everyth highli preserv nitrat sulphit pretti healthi hit iron built decad whammi sister inject iron teenag got ms much earlier year',\n",
       " 'repli post carli good luck hope help symptom much mine side effect reaction fyi talk gi next day level good blood test prior think allerg reaction actual entyvio mayb someth packag know kind reaction happen time sound like go probabl tri stelara next definit keep us post entyvio goe cross finger toe know good',\n",
       " 'third differ type medic ask opdivo start week ago first treatment trial drug also immuntherapthi drug pleas excus spell could stay caus made cancer go per cent first time percent second time wonder one els opdivo canser gone thank mari',\n",
       " 'yeah fine tri azathioprin remicad combin aza entyvio aza prednison still nd step novemb jpouch happi result grow pain adapt up down',\n",
       " 'young patient whose live blight aggress blood cancer offer new hope experiment immunotherapi drug take part new trial experienc consider shrink tumour typic remain symptom free nearli eight month drug nivolumab one new gener smart medicin interfer abil cancer shield immun system known checkpoint inhibitor alreadi prove effect melanoma danger form skin cancer one type lung cancer scientist found take part experiment drug trial use nivolumab experienc shrinkag tumour gerri broom ap new studi look nivolumab abil tackl classic hodgkin lymphoma patient fail respond treatment reboot immun system use transplant stem cell taken bone marrow total patient took part phase ii trial rang age hodgkin lymphoma develop lymph system affect immun system blood cell call b lymphocyt peopl uk diagnos diseas classic form ill affect young adult earli older peopl patient suffer hodgkin lymphoma took part phase ii trial ed uthman flickr result checkmat trial present annual meet european haematolog associ copenhagen denmark due publish journal lancet oncolog jonathan pearc chief execut lymphoma associ said vital innov treatment develop made avail lymphoma patient want everyon affect lymphoma receiv best possibl treatment care option improv outcom qualiti life patient better',\n",
       " 'bad sometim deadli infect like tuberculosi shingl fungal infect bacteri viral infect happen patient take xeljanz tofacitinib tablet risk greater also take drug suppress immun system like methotrex corticosteroid get bad infect doctor may stop xeljanz tofacitinib tablet infect control call doctor right away fever chill sweat cough muscl ach short breath sputum chang color sputum red warm swollen pain blister skin weight loss belli pain loos stool diarrhea pain pass urin pass urin often feel tire weak tb tuberculosi seen patient start xeljanz tofacitinib tablet patient expos tb past never got infect test see expos tb start xeljanz tofacitinib tablet lymphoma skin cancer type cancer happen peopl treat xeljanz tofacitinib tablet talk doctor kidney transplant take drug work immun system greater risk problem certain white blood cell grow control call post transplant lymphoprolif disord caus epstein barr viru talk doctor use xeljanz see also otezla use treat rheumatoid arthriti use treat psoriat arthriti use treat ulcer coliti need tell doctor take xeljanz allergi tofacitinib part xeljanz tofacitinib tablet allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign liver diseas anemia infect low white blood cell count take rifampin take drug abatacept adalimumab anakinra certolizumab etanercept golimumab infliximab rituximab secukinumab tocilizumab ustekinumab vedolizumab take drug use suppress immun system like azathioprin cyclosporin mani drug ask doctor pharmacist sure breast feed breast feed take xeljanz tofacitinib tablet least hour last dose list drug health problem interact xeljanz tofacitinib tablet tell doctor pharmacist drug prescript otc natur product vitamin health problem must check make sure safe take xeljanz tofacitinib tablet drug health problem start stop chang dose drug without check doctor thing need know take xeljanz tell health care provid take xeljanz tofacitinib tablet includ doctor nurs pharmacist dentist viral infect like herp zoster becom activ xeljanz tofacitinib tablet tell doctor ever viral infect like herp zoster talk doctor hepat b c test may done hepat b c infect may get wors care talk doctor blood work check told doctor talk doctor high cholesterol happen xeljanz tofacitinib tablet question talk doctor may need skin check take xeljanz tofacitinib tablet talk doctor drink grapefruit juic eat grapefruit often talk doctor medicin may affect certain lab test tell health care provid lab worker take xeljanz tofacitinib tablet make sure date vaccin treatment xeljanz tofacitinib tablet talk doctor get vaccin use xeljanz tofacitinib tablet may either rais chanc infect make vaccin work well may chanc get infect wash hand often stay away peopl infect cold flu high blood sugar diabet talk doctor may like get infect medicin may use drug treat health condit also take drug talk doctor risk side effect may happen older use xeljanz tofacitinib tablet care could side effect medicin may caus fertil problem may affect abl children known go back normal question talk doctor abl get pregnant talk doctor may need use birth control prevent pregnanc take xeljanz tofacitinib tablet time last dose pregnant get pregnant take xeljanz tofacitinib tablet call doctor right away medicin xeljanz best taken use xeljanz tofacitinib tablet order doctor read inform given follow instruct close take without food gain benefit miss dose keep take xeljanz tofacitinib tablet told doctor health care provid even feel well miss dose skip miss dose go back normal time take dose time extra dose see also dosag inform detail side effect need call doctor right away warn caution even though may rare peopl may bad sometim deadli side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign liver problem like dark urin feel tire hungri upset stomach stomach pain light color stool throw yellow skin eye sign infect like fever chill bad sore throat ear sinu pain cough sputum chang color sputum pain pass urin mouth sore wound heal warm red pain skin sore bodi shingl chang color size mole skin lump growth feel tire weak chang bowel habit night sweat short breath muscl pain weak slow heartbeat heartbeat feel normal tear stomach bowel wall happen certain peopl take xeljanz tofacitinib tablet call doctor right away swell pain stomach bad get wors go away call doctor right away throw blood throw look like coffe ground upset stomach throw go away black tarri bloodi stool bad sometim deadli lung problem happen xeljanz tofacitinib tablet call doctor right away lung breath problem like troubl breath short breath cough new wors side effect xeljanz drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away headach loos stool diarrhea sign common cold runni nose sore throat stuffi nose side effect may occur question side effect call doctor call doctor medic advic side effect may report side effect fda fda may also report side effect http www fda gov medwatch see also side effect detail overdos suspect think overdos call poison control center get medic care right away readi tell show taken much happen store throw xeljanz store origin contain room temperatur store dri place store bathroom keep drug safe place keep drug reach children pet throw away unus expir drug flush toilet pour drain unless told check pharmacist question best way throw drug may drug take back program area consum inform use symptom health problem get better becom wors call doctor share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin medicin come extra patient fact sheet call medic guid read care read time xeljanz tofacitinib tablet refil question xeljanz tofacitinib tablet pleas talk doctor pharmacist health care provid think overdos call poison control center get medic care right away readi tell show taken much happen',\n",
       " 'pml brain viral infect occur clinic trial ocrevu treatment deplet b immun cell associ rare pml gener immunosuppress medic exposur higher rate cancer seen ocrevu vs placebo rebif although still infrequ unclear ocrevu truli caus malign random find trial prescrib inform recommend routin breast cancer screen',\n",
       " 'hi lamn hope mom well tagrisso long time great say ye flaura trial tagrisso demonstr efficaci brain anti cancer treatment penetr blood brain barrier lung cancer specialist want give tagrisso first tri see shrink elimin brain met tri radiat howev brain met caus symptom radiat may better quicker surer choic difficult say next step one thing time mom need anoth treatment may option avail mutat form treatment cancer way work around treatment known acquir resist research work address mutat mom may good fit promis trial drug test posit pd l express immunotherapi would choic egfr usual benefit immunotherapi chemotherapi effect singl agent like alimta may side effect work long time best luck mom janin',\n",
       " 'surgeon actual one think best plan action surgeri issu primari crohn doc main surgeon vacat week come back monday mid level ibd fill doc one reluct surgeri sure miss half small bowel sorri distinctli separ aspect surgeri team ibd team charg care surgeri team lead care inpati plan attack surgeri depart charg care go get picc line weekend sometim start tpn feed still npo give bowel rest bit main ibd doc surgeon go meet monday discuss meet discuss surgeri sound like surgeri team think need done need get done think may end semi fast track depend want still inpati seem plan place least strang anti surgeri ibd doc total get take necessari three area seem inflamm caus issu year old crohn sinc medicin remicad restart methotrex supplement vitamin zinc b multivitamin',\n",
       " 'post past follow mix respons year ago mother law stage nsclc start iressa first line biopsi egfr posit back juli month mix respons attempt get aura trial back nov reject previous receiv kidney transplant certain anti reject immunosuppress med three round carboplatin pemetrex mainten pemetrex ever week three four month ago sinc hospit time pneumonia stop pemetrex stop work due complic cancer progress tube insert assist fluid seem help dr sent pleural fluid biopsi obtain compassion use applic approv osimertinib yet approv canada far know result came back neg mutat yesterday news dr also indic biopsi seem show even less pronounc prior egfr mutat sorri long wind start mil variou anti reject immunosuppress med kidney transplant novemb sound like without posit mutat option limit dr plan tri three round pemetrex see respons next option taxoter dr said much stronger could side effect wonder option immunosuppress current cours dr want get touch transplant kidney dr discuss option wonder idea send along three year anniversari diagnosi juli year appreci time',\n",
       " 'glad find forum dad exon insert switch kadcyla took four round carboplatin pemetrex pembrolizumab although show improv round cancer spread round would love know peopl pyrotinib poziotinib clinic drug',\n",
       " 'consid cladribin http multipl sclerosi research blogspot com suppos therapi ms html st dose last month easi toler probabl safer effect fingolimod label gener publish data show good efficaci send email dr k websit dose info',\n",
       " 'never test best knowledg certainli want suppress immun system believ part fear unknown say take tnf alpha blocker remicad humira madcam blocker simultan entyvio suppress abil bodi call immun attack block tnf alpha also suppress bodi respons follow immun attack block madcam prevent wbc exit circulatori system also simultan immunomodul azathioprin mp mtx less wbc start bodi weak abil call follow attack would leav necessari infect beat sepsi uti bronchiti uti etc might need oozi bubbl roll around lol sure cumul immun suppress abil med honestli know got sepsi due combin mp also potent allopurinol combo requir everi week blood monitor durat precaut moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa review yelp trip advis terribl night uncomfort bed aw food least drug good hospit',\n",
       " 'dad go cycl keytruda carbo alimta monday pain hard understand seem verbal easili either blame moment ok other much last night sleep pretti fatigu week take nap day without pain med yesterday might contribut lack sleep night wish someth mom could help feel helpless moment like comment experi would super appreci none ok felt need vent',\n",
       " 'bristol myer squibb compani nyse bmi today announc committe medicin product human use chmp european medicin agenc adopt posit opinion recommend approv opdivo nivolumab plu low dose yervoy ipilimumab combin includ first line treatment patient intermedi poor risk advanc renal cell carcinoma rcc recommend review european commiss ec author approv medicin european union eu remain high unmet medic need patient advanc renal cell carcinoma said arvin yang ph develop lead melanoma genitourinari cancer bristol myer squibb encourag today posit opinion chmp look forward potenti bring first immuno oncolog combin therapi appropri rcc patient across eu chmp recommend base posit data phase checkmat clinic trial stop earli follow plan interim analysi show combin opdivo mg kg plu yervoy mg kg demonstr signific increas overal surviv os decreas risk death intermedi poor risk patient regardless pd l express level compar current standard care sunitinib hazard ratio [hr] confid interv [ci] p median os patient treat opdivo plu low dose yervoy yet reach ci estim [ne] compar month patient treat sunitinib opdivo plu low dose yervoy also deliv durabl respons higher object respons rate ci p n versu sunitinib ci n median durat respons durabl opdivo plu low dose yervoy yet reach ci ne among respond patient compar month sunitinib ci ne overal safeti profil consist prior studi opdivo combin low dose yervoy',\n",
       " 'dear friend wonder minut share thought hope week make decis next cours action medicin littl background info year old marri children age diagnos stage iv adenocarcinoma lc march egfr posit posit exon extens metastes brain bone rib spine femur etc lymphat system inumer nodul lung scatter throughout lobe first line treatment tarceva work brilliantli month produc near total respons notic sign cancer gone within week month progress began lung bone brain second line treatment tagrisso work well month respons dramat tarceva still extrem effect brain met clear still gone bone show extens heal lung dramat improv new met anywher last week month mark tagrisso scan show progress lung brain bone still clear mostli asymptomat energi level decent breath perfect good enough notic symptom except littl short breath especi morn time tagrisso question oncologist recommend chemo rd round treatment recommend pemetrexid alimta carboplatin agre would like preserv abil work full time like keep abil remain activ husband father long possibl experi sever side effect pemetrexid alimta carboplatin believ look someth differ pleas share also hesit abandon tagrisso yet think foolish wait next scan',\n",
       " 'emd serono inc maker cladribin tablet oral formul cladribin announc today receiv complet respons letter crl unit state food drug administr fda fda issu crl complet review applic howev situat fda abl approv applic without addit inform announc disappoint member ms commun hope see anoth option ad list avail diseas modifi therapi long term treatment ms accord emd serono fda found substanti evid cladribin tablet effect indic clariti studi cla ri bine ablet treat ms oral effect question fda look improv understand safeti risk overal benefit risk profil requir either addit analysi present avail data addit studi conduct drug compani plan request end review meet fda meet emd serono would find proceed data complet ongo clinic studi cladribin tablet could suffici answer fda question safeti emd serono note remain commit complet ongo studi cladribin tablet continu seek fda approv drug three ongo studi near complet top line result initi primari outcom studi expect end first half safeti data studi provid valuabl addit safeti data fda consid background inform cladribin investig oral drug studi long term treatment relaps form multipl sclerosi ms submit unit state food drug administr fda approv receiv fast track statu juli fast track statu reduc fda review time month six decis expect novemb howev agenc extend review time three month decis anticip februari cladribin tablet approv earlier year australia russia trade name movectroi european regul issu neg opinion regard whether benefit outweigh risk merck serono divis merck kgaa plan appeal neg decis came committe medicin product human use chmp european medicin agenc reject issu septemb prior fda extend review period drug inform cladribin tablet relat studi pleas see msaa onlin news articl fda extend review period oral cladribin anyon question may call msaa helplin speak consult written susan well courtney msaa senior writer creativ director review dr jack burk msaa chief medic offic',\n",
       " 'hi merile hope feel alright dr weiss say blog post cisplatin vs carboplatin want start brawl meet thorac oncologist good way start cisplatin vs carboplatin debat cisplatin lover feel cisplatin slightli effect carboplatin carboplatin lover argu carboplatin equival even cisplatin slight edg efficaci small differ inadequ compens dramat higher toxic http cancergrac org lung introduct first line therapi advanc nsclc adeno nsclc mani oncologist prefer alimta side effect profil less toxic howev partner drug often use taxol cytotox drug shown effect nsclc fine except gemcitabin toxic use concurr radiat import wait follow scan radiat inflamm caus radiat look like cancer ct pet radiat continu work time treatment stop specialist like wait least month complet radiat scan sometim radiat scar make difficult know even longer wait know better get wrong impress cancer grow sorri go hope gone best janin',\n",
       " 'sorri loss reader year wonder surgeri went condol joseph famili friend mom year old daughter diagnos apriso pill x day pill x daili purinethol mp mg daili everi day chewabl vitamin remicad start stop second infus start cimzia back remicad stop august remiss acheiv flare simponi simponi stop rd dose chang reinduct remicad methotrexa',\n",
       " 'obvious issu balanc concern enorm cost strict glucos control term demand patient time energi vigil worri seldom taken account uncrit prais ever lower blood sugar level mani medic journal articl littl weight given tripl sever hypoglycemia incid strict control regimen death hypoglycemia occur even disrupt patient social work life abil hold driver licenc import consider throw onto scale whatev physiolog valu lower blood sugar level case discount influenc genet continu autoimmun caus contribut etiolog complic also even good blood sugar level gambl sinc peopl fail pay dividend friend mine exampl alway better blood sugar control blind dialysi age patient pay heavi price good blood sugar valu invest may bring benefit addit metabol memori oper patient high blood sugar level year may continu gener new complic even though patient achiev perfect blood sugar control case exampl sinc type diabet year first home glucomet becam avail long histori hyperglycemia caus mani decad later four laser photocoagul treatment retinopathi even though c four rang last decad use strict control case mani other situat perhap use realli fine line draw exercis would accept life constant sever hypoglycemia incid undermin job social life legal right drive car return delay onset end stage renal failur year year onset year answer depend prioriti life healthi peopl choos smoke would rather live pleasur cigarett risk cancer heart diseas earli death diabet variat approach life perhap peopl would rather avoid hypoglycemia regiment life entir take risk other would answer question want calibr complic risk lifestyl valu highli individu',\n",
       " 'rebif first diagnos year coupl minor elaps gave new lesion right frontal lobe horn tell feet hot cold knew someth happen tell hot cool anyway turn yet anoth lesion nero chang gilenya nurs doctor come hous watch first hour took first dose everyth great gilenya great problem sinc relaps kind feel much freer shot howev find antidepress taken gilenya stop take mine go well medic celexa cours stop give anyth substitut withdraw crazi took forev find good one could take come depress bad almost went back rebif thank god takecymbalta seem work realli well take get use love gilenya glad side effect absolut none person love good luck question hesit ask',\n",
       " 'hey total feel pain start humira month ago bowel obstruct bad joint pain hand shoulder hip gi doc sent referr rheumatologist seen januari def recommend get referr sooner rather later wait pretti long sometim best luck',\n",
       " 'repli post carli entyvio sinc april help crohn immens remicad got shingl twice stop mp long time flare food poison decemb recov entyvio around oct nov start experienc itch everywher thought mayb allergi dri skin final realiz side effect entyvio earlier month bloodwork normal gi told keep eye will deal itch normal stool went infus today allerg reaction flush heart race dizzi blood pressur heart rate skyrocket stop infus midway take benadryl took hour get back near normal gi staff said reccomend anoth entyvio infus doctor still proceed give heavi dose steroid attempt counteract inpati set see next option possibl humira perhap tri see bodi toler keep eye sure effect especi itch mayb earli indic reaction miss good luck',\n",
       " 'recent studi show golimumab simponi effect salvag therapi refractori crohn patient fail anti tnf like humira remicad could worth tri link golimumab studi academ oup com jcag articl suppl_ year old femal issu began juli capsul endoscopi late march show suspect crohn ileocol colonoscopi april offici diagnos ulcer pancol w backwash ileiti current med remicad apriso x daili canasa mg suppositori nightli b inject monthli iu vit weekli remiss',\n",
       " 'thank janin wonder thing mutat disappear tagrisso therapi origin egfr exon mutat still detect assum go back tarceva might trick also got ct result neck pelvi happi met seen anywher lung tumor irradi dec jan continu shrink nice deal noth els hide singl visibl mass cerebellum mm mm month ago see onc tomorrow discuss would make sens test theori tarceva might effect wait sr brain lesion find lesion gone know time thank repli treasur input alway kempten',\n",
       " 'thank bang drum natalizumab biogen must tough time roch take lead ocrelizumab two decad rituximab went market take pharma ineffici asid realli like see somebodi nail diseas anti ebv treatment rituximab ocrelizumab chanc',\n",
       " 'hi caringinsc termin rcc kidney stage iv diagnos multipl differ treatment variabl rate success present triall opdivo nivolumab yet seen possibl treatment kidney cancer mani metastasi spine back shoulder bone hip rib skul liver lung etc start opdivo octob last year infus everi week three month treatment ct scan show remark result boni metastasi stabilis tumor liver shrunk hardli visibl lung tumor stabilis except new tumor pop overal good result notic side effect still opdivo next scan toward end april would advis go nivolumab give remark result cheerio margo',\n",
       " 'entyvio nine month sinc medicin experi crohn system everi week half even around bed time time diarrhea empti feel fine longer concern go eat leav hous emerg diarrhea howev last two week plu fight cold symptom although mayb littl better begin wonder ever get cold read experi other wonder entyvio complic recoveri',\n",
       " 'lucenti ranibizumab made human antibodi fragment work keep new blood vessel form retina sensori membran line insid eye peopl certain type eye disord new blood vessel grow retina leak blood fluid lucenti use treat wet form age relat macular degener lucenti also use treat swell retina caus diabet blockag blood vessel import inform receiv lucenti allerg ranibizumab type infect around eye receiv lucenti tell doctor glaucoma histori blood clot stroke call doctor sudden vision problem eye pain irrit discharg bleed eye swell around eye see flash light floater vision sudden numb weak bodi sudden sever headach problem speech balanc time monthli inject import medic effect call doctor instruct miss appoint receiv lucenti inject take medicin receiv lucenti allerg type infect around eye make sure lucenti safe tell doctor glaucoma histori blood clot stroke known whether lucenti harm unborn babi tell doctor pregnant plan becom pregnant known whether ranibizumab pass breast milk could affect nurs babi tell doctor breast feed lucenti given lucenti given inject eye doctor use medicin numb eye give inject receiv inject doctor offic clinic set short time inject eye check period make sure inject caus side effect lucenti usual given everi month peopl macular degener receiv first inject doctor may chang inject schedul everi month follow doctor dose instruct care time monthli inject import medic effect sure lucenti help condit caus harm effect eye need check regular basi miss follow visit doctor lucenti dose inform usual adult dose macular degener mg via intravitr inject month approxim day use neovascular wet age relat macular degener amd usual adult dose diabet retinopathi dme diabet retinopathi dme mg via intravitr inject month approxim day macular edema follow rvo mg via intravitr inject month approxim day use diabet macular edema dme diabet retinopathi dme macular edema follow retin vein occlus rvo usual adult dose macular edema dme diabet retinopathi dme mg via intravitr inject month approxim day macular edema follow rvo mg via intravitr inject month approxim day use diabet macular edema dme diabet retinopathi dme macular edema follow retin vein occlus rvo drug affect lucenti drug may interact ranibizumab includ prescript counter medicin vitamin herbal product tell health care provid medicin use medicin start stop use see also dosag inform detail happen miss dose call doctor instruct miss appoint receiv lucenti inject happen overdos sinc medicin given healthcar profession medic set overdos unlik occur avoid receiv lucenti medic may caus blur vision care drive anyth requir abl see clearli lucenti side effect get emerg medic help sign allerg reaction lucenti hive difficult breath swell face lip tongu throat call doctor eye pain red swell around eye blur vision tunnel vision eye pain see halo around light increas sensit light discharg bleed eye see flash light floater vision sudden numb weak especi one side bodi sudden sever headach problem speech balanc common lucenti side effect may includ',\n",
       " 'hello juliemari gosh load health problem deal realli hope aubagio work',\n",
       " 'recruit apr elig cancer histiocyt sarcoma juvenil xanthogranuloma langerhan cell histiocytosi lymphoma recurr central nervou system neoplasm recurr malign solid neoplasm refractori central nervou system neoplasm refractori malign solid neoplasm intervent ro patient receiv x ensartinib countri usa children oncolog group philadelphia pa nct studi oral pf c met hepatocyt growth factor tyrosin kinas inhibitor patient advanc cancer statu recruit elig cancer alk posit non small cell lung cancer nsclc c met depend nsclc ro marker posit nsclc system anaplast larg cell lymphoma advanc malign except leukemia intervent pf crizotinib rifampin itraconazol countri usa state australia republ korea note origin trial crizotinib expand time includ new arm nct nation lung matrix trial multi drug phase ii trial non small cell lung cancer statu yet recruit elig cancer non small cell lung cancer nsclc squamou cell carcinoma adenocarcinoma intervent ro patient receiv crizotinib countri unit kingdom uk nct ceritinib trametinib patient advanc alk posit non small cell lung cancer nsclc statu recruit elig cancer stage iiib iv ro phase alk non small cell lung cancer nsclc intervent ceritinib trametinib countri univers california san francisco expand access experiment drug nct expand access entrectinib cancer ntrk ro alk gene fusion statu avail elig cancer advanc cancer ntrk ntrk ntrk ro alk gene fusion unabl particip ongo entrectinib rxdx clinic trial intervent entrectinib countri contact ignyta startrktrial ignyta com call startrk',\n",
       " 'ye rubyroo stumbler sth someth tyre write long word rubyroo ms start gilenya dose stop progresson may stop relaps fight get cladribin atm moment',\n",
       " 'hello everyon remicad year final develop antibodi tri entyvio coupl year ago advers reaction larg bowel resect end colostomi octob crohn diseas symptom improv sinc surgeri howev eye joint muscl pain inflamm poorli stop remicad antibodi gi wonder howev said well tri humira cimzia stelara one prefer like crap shoot lol toss name cup draw one suggest would greatli appreci develop crohn small intestin besid remicad mg prednison daili thank much juli',\n",
       " 'check mavenclad compar term perform mention much better safeti profil info http multiplesclerosisnewstoday com argentina approv mavenclad relaps ms two offer uniqu risk consid pregnanc pretti sure tysabri certain period wash system wherea problem lemtrada',\n",
       " 'realli enough year start suffer badli decemb went work marri home noth marriag broke lost home job car came symptom muddl last month live famili purpos life suffer daili symptom brain fog anxieti weak fatigu balanc tremor eyesight self catheteris back pain togeth thing prevent life realli battl thing purpos feel get wors let even one day finish five day cours methylprednisolon yesterday feel aw eyesight wors everyth feel amplifi probabl one week last year felt posit eas gone everi day battl see point happi end sight keep take gilenya citalopram mirtazipin vit magnesium b respit want leav place',\n",
       " 'hey brian singl payer theori know practic less perfect system brother live montr al mani reader great britain brother bad experi canadian healthcar system mostli term lack access certain kind doctor long wait period certain procedur folk great britain ms patient strict guidelin drug receiv ocrevu receiv approv great britain deem cost effect whether good thing guess still need determin also quit sure singl payer would chang medic research model certainli would upend thing without financi incent think would see slowdown research overal mean defend current system think total piec crap suppos sort public privat hybrid system might work well know switzerland healthcar system public privat work well much smaller countri state previou comment realli need manhattan project style massiv effort direct exclus find caus cure varieti diseas fund think would public would mean rais tax anethema tax cut zealot seem upper hand last year confound conundrum one thing certain system stand result cure anytim soon especi diseas like ms patient turn custom life thank comment',\n",
       " 'mom diagnos stage nsclc oct done mani round radiat went chemo maintain chemo maintain chemo tumor start grow lung brain readi diagnos say last option opdivo second opdivo treatment today concern lost pound two week bare want eat anyon els love one go similar circumst start opdivo treatment success certain amount time feel like see sign afraid ask doctor want upset',\n",
       " 'go transit anoth anti tnf would strongli consid stelara first seem get best review rival remicad effect experi',\n",
       " 'crohn diseas also call ileiti enter affect part gut mouth way anu major case howev lower part small intestin ileum affect symptom unpleas includ intestin ulcer discomfort pain accord center diseas control prevent crohn diseas affect peopl per although crohn diseas typic start age start age symptom pain commonli felt lower right side abdomen affect mani area gut crohn diseas symptom vari depend part gut affect symptom often includ pain level pain vari individu depend inflamm gut commonli pain felt lower right side abdomen ulcer gut ulcer raw area gut may bleed bleed patient might notic blood stool mouth ulcer common symptom diarrhea rang mild sever sometim may mucu blood pu patient may get urg go find noth come fatigu individu often feel extrem tire fever also possibl fatigu alter appetit may time appetit low weight loss result loss appetit anemia loss blood lead anemia rectal bleed anal fissur skin anu becom crack lead pain bleed possibl symptom arthriti uveiti eye inflamm skin rash inflamm liver bile duct inflamm delay growth sexual develop children ulcer coliti vs crohn diseas ulcer coliti caus inflamm ulcer top layer line larg intestin layer intestin may inflam ulcer crohn diseas also inflamm occur crohn diseas anywher along gut ulcer coliti appear larg intestin colon rectum crohn diseas patient bowel normal healthi section diseas part wherea ulcer coliti damag appear continu pattern diet children crohn diseas might need high calori liquid formula especi growth affect patient crohn diseas say follow food increas diarrhea cramp bulki grain dairi product spici food alcohol peopl feel like eat sever case may need feed intraven short period treatment bulki grain like contain bread worsen crohn diseas treatment may involv medic surgeri nutrit supplement aim control inflamm correct nutrit problem reliev symptom cure crohn diseas treatment help reduc number time patient experi recurr crohn diseas treatment depend inflamm situat sever diseas complic patient respons previou treatment recur symptom peopl long period even year without symptom known remiss howev usual recurr period remiss vari much hard know effect treatment imposs predict long period remiss go best food crohn diseas flare eat right food help peopl manag symptom crohn diseas find read medic crohn diseas anti inflamm drug doctor like start mesalamin sulfasalazin help control inflamm cortison steroid corticosteroid drug contain cortison steroid antibiot fistula strictur prior surgeri may caus bacteri overgrowth doctor gener treat prescrib ampicillin sulfonamid cephalosporin tetracyclin metronidazol anti diarrheal fluid replac inflamm subsid diarrhea usual becom less problem howev sometim patient may need someth diarrhea abdomin pain biolog biolog new type drug scientist develop live organ reduc bodi immun respons target protein lead inflamm biolog appear help peopl crohn diseas exampl biolog crohn includ infliximab remicad adalimumab humira mercaptopurin purinethol methotrex imuran azathioprin certolizumab pegol cimzia biolog treatment side effect includ vomit nausea weaker resist infect studi suggest use biolog reduc chanc person need abdomin surgeri within year percent introduct biolog research put figur percent biolog also appear reduc risk advers effect aris person use corticosteroid differ type biolog drug individu react differ doctor recommend suitabl option may suggest tri altern combin drug first one work surgeri major crohn diseas patient may need surgeri point medic longer control symptom solut oper surgeri reliev symptom respond medic correct complic abscess perfor bleed blockag remov part intestin help cure crohn diseas inflamm often return area next affect part gut remov crohn diseas patient may requir one oper live case colectomi need whole colon remov surgeon make small open front abdomin wall tip ileum brought skin surfac form open call stoma fece exit bodi stoma pouch collect fece doctor say patient stoma carri lead normal activ life surgeon remov diseas section intestin connect intestin stoma need patient doctor need consid surgeri care appropri everyon patient bear mind oper diseas recur peopl crohn diseas live normal activ live hold job rais famili function success caus exact caus crohn diseas unclear thought stem abnorm reaction immun system theori immun system attack food good bacteria benefici substanc unwant substanc attack white blood cell build line gut buildup trigger inflamm inflamm lead ulcer bowel injuri howev unclear whether abnorm immun system caus crohn diseas result factor may increas risk inflamm includ genet factor individu immun system environment factor around peopl crohn close rel condit ident twin crohn diseas twin percent chanc bacterium viru may play role e coli bacteria link crohn diseas instanc smoke anoth risk factor diagnosi doctor ask person sign symptom physic examin may reveal lump abdomen caus loop inflam bowel becom stuck togeth follow test may help diagnosi stool blood test biopsi sigmoidoscopi short flexibl tube sigmoidoscop use investig lower bowel colonoscopi long flexibl tube colonoscop use investig colon endoscopi symptom occur upper part gut long thin flexibl telescop endoscop goe esophagu stomach ct scan barium enema x ray reveal chang insid bowel complic symptom sever frequent likelihood complic higher follow complic may requir surgeri intern bleed strictur part gut narrow caus build scar tissu partial complet blockag intestin perfor small hole develop wall gut content leak caus infect abscess fistula channel form two part gut may also persist iron defici food absorpt problem slightli higher risk develop bowel cancer relat coverag stage crohn diseas crohn diseas caus chronic inflamm digest tract although crohn diseas tend get wors time symptom vari consider may sometim disappear week even year reason doctor usual classifi crohn differ stage learn read crohn diseas surgeri know surgeri cannot cure crohn diseas help reduc person symptom prevent life threaten complic articl learn differ type crohn diseas surgeri prepar expect recoveri read diet tip crohn diseas crohn diseas affect gastrointestin tract choic diet nutrit may make differ individu feel spici food alcohol fatti sugari item exampl trigger flare peopl find dietari tip recommend may help manag condit read crohn diseas pregnanc crohn diseas pregnanc affect howev women conceiv crohn diseas remiss normal pregnanc healthi babi learn read expect crohn infus crohn infus medic call biolog help reduc crohn symptom learn type crohn infus side effect expect read email email print share share crohn ibd gastrointestin gastroenterolog immun system vaccin addit inform articl last updat yvett brazier wed decemb visit crohn ibd categori page latest news subject sign newslett receiv latest updat crohn ibd refer avail refer tab refer content requir javascript enabl baumgart dogan b rishniw weitzman g bosworth b yantiss r berg cultur independ analysi ileal mucosa reveal select increas invas escherichia coli novel phylogeni rel deplet clostridial crohn diseas involv ileum ism journal retriev http www natur com ismej journal v n ab ismej html crohn diseas n american societi colon rectal surgeon retriev http www fascr org patient diseas condit crohn diseas crohn diseas caus april retriev http www nh uk condit crohn diseas page caus aspx epidemiolog ibd march cdc retriev http www cdc gov ibd ibd epidemiolog htm leena halm paulina paavola sakki ulla turunen maarit lappalaccinen martti f rkkil kimmo kontula june world journal gastroenterolog retriev http www ncbi nlm nih gov pmc articl pmc lichtenstein g r loftu e v isaac k l regueiro gerson l b sand b e march manag crohn diseas adult american colleg gastroenterolog retriev http gi org guidelin manag crohn diseas adult crohn diseas n cleveland clinic retriev http clevelandclin org health articl crohn diseas citat pleas use one follow format cite articl essay paper report mla nordqvist christian crohn diseas medic news today medilexicon intl dec web feb http www medicalnewstoday com articl php apa nordqvist c decemb crohn diseas medic news today retriev http www medicalnewstoday com articl php pleas note author inform provid sourc cite instead recommend relat news latest news acupunctur may reduc menopaus symptom recent studi investig whether acupunctur might use nonpharmaceut way minim symptom occur menopaus japanes plant could hold key extend youth new research find compound tradit japanes medicin plant could boost cellular health protect ill effect age bacteria live insect could provid new antibiot insect harbor bacteria protect infect tap sourc could yield new antibiot combat grow threat drug resist halt cellular age new drug combo show promis first clinic trial human research test promis drug combin could help fight effect cellular age aggress brain cancer immunotherapi fail new research help explain glioblastoma tumor respond immunotherapi wherea major aggress cancer',\n",
       " 'mysteri cladribin reject approv fda ema safeti efficaci concern particular increas cancer risk note major concern option like gilenya tecfidera becam avail better safeti record approv russia australia',\n",
       " 'hi hain think suggest reason say simpli establish treatment lmc risk may accept circumst sinc mom afatinib coupl week expect scan start tagrisso rais possibl improv due afatinib might two best option point good luck whichev chosen jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'christina bennett ms addit today excit plenari session american societi clinic oncolog asco annual meet sever high impact clinic trial result report keynot practic chang abstract interim analysi phase iii keynot trial show four month longer median overal surviv os metastat squamou non small cell lung cancer nsclc patient receiv pembrolizumab plu tradit chemotherapi compar receiv placebo plu chemotherapi squamou non small cell lung cancer orphan almost step child develop chemo[immunotherapy] metastat lung cancer said charu aggarw md mph assist professor medicin hospit univers pennsylvania first time actual see upfront use immunotherapi combin chemotherapi squamou lung cancer keynot total particip untreat metastat squamou nsclc enrol random receiv either pembrolizumab plu chemotherapi placebo plu chemotherapi time interim analysi particip random pembrolizumab plu chemotherapi arm placebo plu chemotherapi arm particip stratifi pdl statu median os month pembrolizumab plu chemotherapi arm month placebo plu chemotherapi arm median progress free surviv pf month pembrolizumab plu chemotherapi arm compar month placebo plu chemotherapi alon arm data suggest pembrolizumab plu chemotherapi becom new standard care first line treatment metastat squamou nsclc across differ level pdl express said studi investig lui paz are md phd professor medicin hospit universitario de octubr pf benefit signific overal surviv benefit hazard ratio doubt mind benefit patient need adopt start today avail said dr aggarw safeti profil dr aggarw said overal toxic profil seem manag adept manag immun relat toxic sinc use agent clinic keynot frontlin pembrolizumab monotherapi gain traction abstract interim result phase ii keynot trial show respons rate advanc clear cell renal cell carcinoma rcc patient receiv pembrolizumab monotherapi front line set three patient achiev complet respons partial respons median progress free surviv month median overal surviv reach keynot singl arm open label design enrol particip advanc clear cell nonclear cell rcc elig patient measur diseas per recist criteria prior system therapi karnofski perform statu greater equal particip receiv pembrolizumab dose mg iv everi three week data cohort particip present frequenc advers event special interest consist seen pembrolizumab monotherapi tumor type said lead investig david f mcdermott md director biolog therapi cutan oncolog program beth israel deaco medic center treatment relat advers event grade occur patient treatment relat grade advers event occur patient discontinu due treatment relat advers event report patient said one patient die treatment relat pneumon naomi haa md associ professor medicin hospit univers pennsylvania describ keynot realli import studi ipilimumab nivolumab combin fda approv recent first line treatment kidney cancer high respons rate combin also lot toxic singl agent pembrolizumab impress respons rate less toxic continu complet respons rate high singl agent pembrolizumab ipilimumab nivolumab combin clear rescu peopl later ad second agent perhap spare peopl toxic think realli import first step answer like see someth futur would includ singl agent immun checkpoint inhibitor compar arm combin immun checkpoint inhibitor trial erdafitinib new hope advanc urotheli cancer abstract phase ii studi blc particip metastat unresect urotheli carcinoma treat erdafitinib oral pan fibroblast growth factor receptor fgfr inhibitor respons rate three percent patient complet respons partial respons result come month fda grant breakthrough therapi design erdafitinib patient metastat urotheli cancer realli excit trial comment dr haa solid tumor think grow awar differ subset urotheli cancer might benefit immun checkpoint inhibitor other might benefit altern treatment pathway trial enrol advanc urotheli carcinoma patient fgfr alter treat median cycl erdafitinib particip prior treatment immun check point inhibitor elig clinic trial erdafitinib met primari object achiev object respons rate percent said studi present arlen siefker radtk md professor depart genitourinari medic oncolog divis cancer medicin univers texa md anderson cancer center median pf month median os averag follow month month ten percent particip discontinu treatment result side effect seriou treatment relat advers event [trial] impress respons rate peopl pretti heavili pre treat interest patient respond drug resist immun checkpoint inhibitor said dr haa anoth car drive forward abstract investig car product lisocabtagen maraleucel relaps refractori non hodgkin lymphoma nhl show durabl respons accord result phase transcend nhl trial lisocabtagen maraleucel anti cd car cell overal respons rate patient core data set patient met studi inclus criteria complet respons month trial lisocabtagen maraleucel evalu two dose schedul singl dose vs two dose across dose level patient achiev month timepoint remain remiss last follow anti cd car cell remark efficaci group highli refractori aggress b cell non hodgkin lymphoma patient said caron jacobson md discuss studi dr jacobson medic director immun effector cell therapi program dana farber cancer institut median overal surviv reach popul note jeremi abramson md clinic director center lymphoma massachusett gener hospit nearli patient achiev complet respons remain aliv year [outcomes] far superior would anticip convent therapi larg chemo refractori dlbcl popul toxic dr abramson said think strikingli lisocabtagen maraleucel shown low manag toxic profil low rate sever cr [cytokin releas syndrome] neurotox percent percent respect continu therefor evalu product outpati administr',\n",
       " 'mum year ivstag small meta lymph node egfr exon g x month st line afatinib first reduct last three month slow progress pemetrex monotherapi month quit signific progress sinc finish afatinib liquid biopsi done outcom even origin mutat show tissu biopsi would problemat also one month ago lesion brain detect first consid brain metastasi doctor say might rather meningeom still quit sure want observ month think realli good chanc mum posit given long time slow progress afatinib best next step see tri osimertinib even without confirm mutat alreadi order form tagrix afford oncologist suggest erlotinib rather unusu st line afatinib promis much long term success follow up lux lung trial show patient took st gener tki erlotinib afatinib therapi month read result studi osimertinib patient neg pf osimertinib month seem noth lose even turn mum neg anyon give advic comment thank',\n",
       " 'hi folk want report month mark year ocrevu infus still walk albeit far year ago brain mri show chang well neuro said best case scenario expect happi see decemb th notic small increas strength right leg especi foot toe unexpect improv otherwis updat',\n",
       " 'stelara next humira work sure work',\n",
       " 'seem like use inform stelara xeljanz seem like good potenti option know go least treat hope way get better uceri someth similar would help know much hate steroid perhap even want consid even dread prednison co moder ulcer coliti current med step one j pouch surgeri complet step two complet step complet give man fish eat day teach man fish eat lifetim give man religion die pray fish',\n",
       " 'soy lb limit rough still take easi week everyth moder suffer setback pt last week overdo inflam scar tissu mean ask kid laid hospit need recov keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'good point guy lemm give info simponi almost year feel noth take shot month increas also noth feel start cbd oil went remiss week last flex sig past flare week start cbd felt gonna much show prove true current ad simponi doc order week done absolut noth past remicad year entyvio humira simponi last month',\n",
       " 'hi leogirl last mri back februari blood test month later question given date next mri august got call neurologist begin octob told jc viru level risk zone want come gilenya final mri januari gilenya month plan book hospit lemtrada feel fair month good frustrat sometim gilenya year awesom slightli gut come hey onward upward x',\n",
       " 'hang agre suck start entyvio thursday hold much hope sinc noth els work either surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia condit fib high blood pressur gout crohn edema cellul heart issu ost openia medic entyvio eliqui verapamil quinipril labetalol furosemid atorvastatin alluporinol vitamin',\n",
       " 'entyvio due fail remicad well gi good discuss xeljanz recent ibd center mass gener boston sever patient well recommend last option surgeri good feedback regard efficaci patient safeti hope help f diagnos feb left side uc steroid refractori fail mesalamin intoler remicad partial respons short remiss fall winter flare sinc feb current tacrolimu supp x daili wait start entyvio zoloft mostli dairi free avoid carrageenan like plagu',\n",
       " 'hello sinc post mom age nsclc stage adeno egfr alk neg continu okay diagnos earli gone carbo alimta alimta mainten month chemo break day tarceva due progress perform statu last year great would like find may candid target therapi immunotherapi need repeat bio marker test challeng remain tissu test need repeat biopsi get tissu effect blood test process detect mutat thank alway guidanc semon',\n",
       " 'guy need quick help cours treatment seem normal remicad mayb month help fistul crohn fine week infus start get mild symptom mostli stomach nois modest pain sometim littl diarrhea noth bowl shatter anyway weekend start experi modest pain right cheek around area abscess reach quit swollen could feel like golf ball size dens area rest took coupl hot bath calm bit still better call doc go remicad infus tomorrow worri perhap area around seton interior somewher gotten infect symptom doc told reschedul remicad week put flagyl seem right hate put remicad work know one week go turn two perhap also scar crapless sorri bad word frankli enough develop anoth abscess live also tri get colo rectal surgeon unfortun surgeri week thought appreci',\n",
       " 'everyon say humira shot hurt ice spot first say help familiar comfort inject pen also simponi ask sure whole lot differ humira simponi brand moder ulcer coliti john minor flare uc proctosigmoid rx remicad mg kg wk mg mp g lialda mg pred taper time assum game throne someth got toilet first morn household mani sibl',\n",
       " 'new fda approv zykadia ceritinib alk posit nsclc think poor choic initi treatment fda approv new therapi approxim patient nsclc molecular marker known alk rearrang cancer journey diagnos treatment cancer type lung cancer diseas learn target therapi target therapi alk target therapi patient forum septemb speaker highlight jame stevenson md grace excit continu build faculti agenda upcom target therapi patient forum septemb see inform present speaker highlight today introduc jame stevenson md cancer journey treatment cancer type lung cancer diseas learn target therapi imprecis medicin keytruda pembrolizumab chemo pd l nsclc readi prime time let start say fan immun checkpoint inhibitor keytruda pembrolizumab consid new standard care cancer journey diagnos treatment cancer type lung cancer diseas learn first line treatment target therapi chemotherapi immunotherapi immunotherapi wrong choic lung cancer patient amidst glow report immunotherapi lung mani cancer would understand patient physician tempt rush toward priorit immunotherapi first treatment strategi pursu fact cancer journey treatment cancer type lung cancer diseas learn target therapi first line treatment symptom second line treatment death pseudo progress know cut loss immunotherapi among mani novel concept manag immunotherapi potenti pseudo progress unusu phenomenon patient scan cancer journey diagnos treatment cancer type lung cancer diseas learn first line treatment target therapi second line treatment immunotherapi view commun forum local therapi metastat lung cancer hi grace member grace happi present partnership swedish cancer institut local therapi metastat lung cancer cancer journey diagnos treatment cancer type lung cancer diseas learn lung cancer drug target therapi alk target therapi egfr target therapi ro procedur treatment chemotherapi tumor marker test target therapi investig agent immunotherapi radiat therapi non small cell lung cancer progress tarceva neg progress year tarceva tissu biopsi show neg suggest experi next step onc suggest move afatinib opdivo pdl test cancer journey treatment cancer type lung cancer diseas learn lung cancer gener lung cancer target therapi egfr target therapi molecular test immunotherapi non small cell lung cancer vaxira stage nsclc anyon inform obtain use vaxira cuban drug stage advanc nsclc sure us citizen still travel cancer journey treatment cancer type lung cancer diseas learn angiogenesi rd line beyond target therapi investig agent non small cell lung cancer tagrisso acquir resist tarceva wife come long way stage iv lung cancer sinc develop acquir resist tarceva gene sequenc biopsi cancer journey diagnos treatment survivorship cancer type lung cancer diseas learn lung cancer target therapi egfr target therapi non small cell lung cancer',\n",
       " 'degre arthrit pain definit biolog get humira inject although crohn mainten keep inflammatori arthriti bay brother also humira arthriti could live without sound like realli need new gi doctor total differ group steroid caus last health problem show later life issu blame steroid use much younger take toll bodi surpris rheumi suggest biolog year crohn resect abcess fistula arthriti chronic hive dri eye humira antihistamin muro vitamin b vitamin life good',\n",
       " 'access march fabian pregnanc set multipl sclerosi continuum minneap minn multipl sclerosi demyelin diseas kappo l gold r miller dh et al efficaci safeti oral fumar patient relaps remit multipl sclerosi multicentr randomis doubl blind placebo control phase iib studi lancet montalban x hemmer b rammohan k et al efficaci safeti ocrelizumab primari progress multipl sclerosi result placebo control doubl blind phase iii oratorio studi [abstract ] proceed european committe treatment research multipl sclerosi ectrim congress octob barcelona spain kappo l weinshenk b pozzilli c et al interferon beta b secondari progress ms combin analysi two trial neurolog hartung hp gonsett r k nig n et al mitoxantron progress multipl sclerosi placebo control doubl blind randomis multicentr trial lancet langer gould anderson armstrong mj et al american academi neurolog top five choos wise recommend neurolog willi fox rj progress multipl sclerosi continuum minneap minn multipl sclerosi demyelin diseas birnbaum g stop diseas modifi therapi progress multipl sclerosi prospect studi neurolog suppl p p kister spelman alroughani r et al stabl ms patient stop diseas modifi therapi dmt increas risk relaps disabl progress compar patient continu dmt propens score match analysi msbase registr [abstract ] mult scler j suppl polman ch reingold sc banwel b et al diagnost criteria multipl sclerosi revis mcdonald criteria ann neurol solomon aj klein ep bourdett undiagnos multipl sclerosi challeng misdiagnosi ms neurolog solomon aj klein e disclos misdiagnosi multipl sclerosi harm continuum minneap minn multipl sclerosi boissi ar ford pj touch ms therapeut mislabel neurolog rudick ra miller ae multipl sclerosi multipl possibl continu problem misdiagnosi neurolog',\n",
       " 'care preoper plan help reduc complic cataract patient diabet help deal problem occur said francesco bandello md febo xxxiv congress escr copenhagen denmark diabet risk factor cataract associ ocular comorbid predispos complic compromis cataract surgeri outcom particularli critic need accur stage treat exist diabet eye diseas statu condit strongli predict visual outcom cataract surgeri stress clear evid phacoemulsif caus diabet retinopathi dr diabet macular oedema dme exacerb condit well control said dr bandello professor ophthalmolog univers vita salut milan itali howev clinic signific dme prolif diabet retinopathi pdr stabilis cataract surgeri reduc risk acceler ad accur stage requir comprehens ophthalmolog examin includ optic coher tomographi possibl fluorescein angiographi standardis echographi treatment option pdr includ panretin photocoagul prp anti vascular endotheli growth factor anti vegf therapi drcr net protocol howev know anti vegf therapi better prp stabilis improv visual acuiti eye pdr panretin cryopexi phacoemulsif combin vitrectomi endolas photocoagul may consid select case said dr bandello therapeut option dme includ anti vegf agent corticosteroid variou laser approach use either monotherapi combin base safeti issu dr bandello recommend use anti vegf agent first line intervent patient glaucoma low cardiovascular risk profil recent histori cardiovascular event corticosteroid howev would prefer patient elev risk cardiovascular event histori vitrectomi poor respons previou anti vegf therapi expect poor complianc repeat inject special consider preoper patient also evalu treat diabet keratopathi presenc affect accuraci intraocular len iol power calcul addit special consider iol select best choos iol larg diamet squar edg blue light filter optic len facilit visualis treatment peripher retina reduc posterior capsular opacif caus chromat discrimin defect provid addit photoprotect addit hydrophil iol anterior chamber iol avoid said dr bandello poorli dilat pupil intraop miosi also like patient diabet surgeon prepar manag problem addit prepar zonular instabl capsul damag eye previou vitreoretin surgeri sinc eye moder sever dr dme risk persist macular oedema dr progress cataract surgeri consid diabet dme common caus poor vision cataract surgeri dr bandello suggest surgeon consid intravitr administr anti vegf agent corticosteroid intraop control prevent progress condit vegf concentr aqueou humour predict risk postop macular oedema tend increas phacoemulsif although result larg randomis control trial need provid evid base recommend posit clinic outcom report sever studi patient diabet receiv intravitr inject anti vegf agent end cataract surgeri base multimod mechan action corticosteroid also play import therapeut role manag dme also report improv best correct visual acuiti central macular thick eye dme receiv sustain releas dexamethason implant ozurdex allergan cataract surgeri howev larger prospect randomis control trial also need establish benefit approach dr bandello said also note patient diabet increas risk develop cystoid macular oedema cataract surgeri francesco bandello bandello francesco hsr',\n",
       " 'great new ks glad hear stelara work look forward post truli help us sinc issu actual resolv lol diagnos left side uc vit vit c multivitamin previous tri coloz lialda asipro sulfasalazin rowasa canasa hydrocortison enema imuran humira fail made symptom wors step surgeri step surgeri step surgeri ks veteran member join sep post post gmt buckeyecrohni said thank repli keith anyth yet appoint gastro late next week know psc throw wrench gastro dr jpouch nice abl understand issu sinc live take immodium everyday sinc surgeri consist time day way better time day surgeri start new thread necessari appoint next week learn much nice peopl appreci us ibd er stick togeth buckey think appoint gi go know issu complex mine see post anyth keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'diagnos ms year ago primari symptom nerv pain manifest trigemin neuralgia sensat burn feet ankl feel like wear boot made lava two size small nearli anti epilept drug treat nerv pain gabapentin zonisamid carbamazepin pregabalin zonisamid take levetiracetam topiram week ago start aubagio failur inject tecfidera fingolimod sinc nerv pain got steadili wors point go mind pain possibl reason got wors current pain med lose efficaci ms got wors aubagio make wors seen ms nurs last week howev noth suggest allevi end rope sleep cannot get comfort posit lay cannot see way anti epilept left tri sodium valproat keen take ever hear back neuro start hurt way distract pain feet sure carri advic help would grate reciev sarah',\n",
       " 'hello tim softi look http www mstrust org uk ms ms treatment ms decis aid decis aid divid diseas modifi drug dmd group moder highli effect make life bit easier research think drug could also look forum http shift ms lot person experi written equal search specif drug consid get person view search awar subject view tend given free choic among drug expect someon recent diagnos activ ms offer beta interferon copaxon aubagio tecfidera might also offer gilenya mavenclad softi tim hand probabl also offer gilenya mavenclad aka cladribin lemtrada ocrevu dmd suppos reduc sever number relaps person increas efficaci come higher risk side effect take dmd give side effect although think treatment bit like insur polici may relaps without dmd drug like less less sever less relaps equal less disabl progress cost benefit scenario neurologist like prefer one drug anoth equal may set prescrib centr dmd familiar group drug name plu way take less like utterli confus time come choos drug also talk ms nurs sure opt drug oppos drug b c happi choic bodi risk sue',\n",
       " 'idea fda probabl useless fbi billion market replac gener seem like wish think one idea investig canada mavenclad avail would treat yank',\n",
       " 'jimc thank prompt respons possibl ask input dr west thank kkh diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'happi report infus side effect fatigu less remicad though skin reaction get solumedrol iv entyvio otherwis taper prednison month ago sign uc flare began juli hope best us use entyvio uc yr flare use cortenema prednison allerg mesalamin hive fever mp fever remicad stop mo due joint pain anti tnf induc lupu neuropathi take entyvio',\n",
       " 'chime biolog went entyvio end march take month start improv almost immedi slow steadi improv th dose pretti free symptom except mild one still spot linger microscop inflamm visual dr saw inflammt last colonoscopi howev know drain diseas fulli understand desir rid good luck uc pancol dx march partial colectomi diverticul sept apriso g x day canasa uceri foam need supplement zinc l glutamin probiot reuteri pearl vsl folic acid coq turmer boswellia milk thistl nac reservatol colostrum glycin start entyvio constant flare sinc march reliev prednison',\n",
       " 'home ms inform public ms research updat laquinimod also known nerventra laquinimod also known nerventra section main articl fda approv medic experiment medic new direct ms research close note approv long term treatment ms pdf refer experiment medic administ oral compani teva neurosci inc activ biotech oral medic taken daili dose tbd studi rrm ppm previou gilenya next rituxan although exact mechan action unknown laquinimod immunomodul appar effect cytokin small protein may stimul inhibit function cell interleukin immun system signal chemic enhanc regulatori cell activ reduc th inflammatori cell activ also appear reduc white blood cell penetr cn addit immunomodulatori action laquinimod increas level brain deriv neurotroph factor bdnf possibl contribut neuroprotect protect nerv myelin damag ms patient bdnf protein found brain help support nerv develop phase iii allegro studi individu rrm show compar placebo laquinimod reduc annual relaps rate percent progress disabl percent also effect sever mri outcom includ reduct brain atrophi percent bravo phase iii trial anoth global month doubl blind studi particip design evalu laquinimod efficaci safeti toler versu placebo august sponsor announc studi fail achiev primari goal reduc annual relaps rate although trend seen direct data adjust differ mri characterist start studi effect laquinimod relaps modest seen diseas modifi therapi rrm drug consid approv unit state result two separ analys pool data phase iii allegro bravo trial studi laquinimod present first analysi compar expect risk disabl progress given particular relaps rate seen pool data analysi effect laquinimod reduc risk disabl progress larger predict second analysi examin relationship relaps disabl look disabl progress relaps relaps free patient two trial one third patient progress relaps free suggest two outcom measur mediat differ pathway sinc laquinimod may effect disabl relaps new trial look primarili laquinimod disabl prevent impact design month trial efficaci safeti toler laquinimod subject relaps remit multipl sclerosi concerto design compar two dose laquinimod includ mg dose higher test prior phase iii studi placebo look confirm diseas progress cdp primari outcom first modern rrm trial priorit prevent disabl prevent relaps trial began enrol patient expect run furthermor base effect disabl prior trial laquinimod also studi ppm trial arpeggio began trial primarili evalu effect laquinimod brain atrophi secondarili clinic outcom design enrol approxim peopl anticip run end although concerto arpeggio trial design studi mg dose laquinimod evalu prior trial along higher dose januari teva announc decis discontinu higher dose laquinimod ongo studi eight patient high dose arm concerto arpeggio trial cardiovascular event versu none lower dose placebo arm decis made continu studi lower mg dose event occur may announc state concerto primari endpoint time cdp met encourag result seen secondari endpoint previou gilenya next rituxan',\n",
       " 'month first symptom onset dx begin june year began experienc skin numb lose feel finger thought oh weird come trial work stress thought weird made appoint pcp though hrm odd let blood work send neurologist blood work came back fine except increas vit ok done month neuro appoint time develop l hermitt go neuro like oh know exactli l hermitt caus inflamm spinal cord could caus lot thing ye ms one let get pictur c spine went week later came back show lesion said yeah good let look brain done day want see back follow morn stat brain mri show lesion sent lp done week result trickl follow month saw new neuro ms center end august like yeah ms well ci high chanc develop full blown ms evid ever flare start gilenya earli octob symptom onset june dx aug dmt octob',\n",
       " 'th entyvio infus week ago prednison coupl month cheat restrict food list everi without consequ even starbuck yay drink coffe everi morn sweeten creamer say yet remiss close still canasa everi night partial colectomi diverticul sept uc pancol dx march apriso g x day canasa uceri foam supplement zinc l glutamin probiot reuteri peral vsl folic acid coq turmer boswellia start entyvio wed constant flare sinc march reliev prednison',\n",
       " 'need clarif previou blog mention need everyon includ progress diseas dmt hope maintain hand function includ progress patient non enhanc mri scan usa ocrevu offer wonder risk versu benefit',\n",
       " 'well stabl meant bloodi pain bm day sleep night lost lb tramadol regularli keep pain bay still went work work surgeri went europ day littl difficult hemoglobin also around regularli need someth dramat end realli tri remicad entyvio year half diagnosi surgeri went ever realli get pred got week initi pred dose got remiss lialda rowasa came back went azathioprin thing seem improv got wors remicad stori rollercoast never actual get remiss',\n",
       " 'prescript galor spate news regard exist propos ms drug much neg side sever drug reject european regulatori agenc anoth seen specter deadli side effect continu rise although much malign ms activist commun mani drug prescrib ms fact improv qualiti life mani patient take although exorbitantli expens target root caus diseas remain unknown help portion ms popul approv drug shown reduc rate relaps rrm patient though much question whether actual slow insidi progress diseas inject crab drug copaxon rebif avonex betaseron demonstr clinic trial significantli reduc relaps rate one third patient take copaxon rel mild side effect profil three compound form beta interferon often make take suffer flulik symptom day two dose patient work though signific drop relaps rate substanti lessen impact diseas live unfortun decad use still clear whether drug influenc progress disabl recent report great britain challeng notion crab drug posit impact progress studi seem support claim drug least someth slow progress newer gener ms drug includ tysabri rituxan approv fda gylenia offer mark uptick efficaci reduct relaps rate ms symptom well proport patient popul benefici unfortun along increas efficaci come increas sever potenti side effect includ deadli brain infect cancer drug noth address underli caus ms work profoundli alter work complex littl understood human immun system consequ long term yet seen still sometim dramat improv experienc patient take drug led mani extrem retic give case tysabri person know sever patient sever year drug test posit viru caus pml ghastli brain infect still refus come tysabri posit impact live unlik ms voic internet unwil label current crop ms drug snake oil simpli posit influenc live mani patient certainli noth cure diseas doubt abil significantli impact progress ms know enough patient whose live remain rel product larg part due medic help recogn valu actual financi cost drug mind boggl price newli approv gylenia first oral medic approv ms come almost per year abhor fact ms turn goos continu lay golden egg mani pharmaceut compani appar posit effect compound ignor introduct crab drug ms known among physician diagnos adio diseas one littl could done combat advent drug matter flaw least put arrow quiver tri fight ms unfortun drug current approv ms shown work patient suffer relaps remit form diseas us suffer progress form remain shut even nomin effect treatment drug even trial use progress ms patient recent least attent turn plight suffer spm ppm okay enough bloviat current state ms drug rundown latest news regard ms pharmaceut fact mani articl link come financi websit speak volum sad state affair regard ms big busi biogen maker tysabri releas monthli report rate pml devast brain infect patient take drug first start tysabri therapi patient unit state enrol call touch program design care track sign infect risk pml infect result tysabri therapi long tout statist releas earlier month show infect rate patient take tysabri less two year fall well within figur start rise dramat patient surpass month mark incid pml long term therapi state per trend suggest longer patient tysabri higher risk infect first introduc tysabri quickli withdrawn market threat pml becam known reintroduc second half therefor major patient take yet reach danger zone state previous mani patient loath stop tysabri experienc sometim dramat relief ms symptom drug pml count increas mani patient tysabri grappl difficult decis european medicin agenc ema committe medicin product human use chmp recommend approv oral drug fampyra north america call ampyra ampyra approv fda drug thu far approv strictli symptomat relief ms compound increas walk speed approxim patient take patient ampyra also report overal increas muscl strength recommend drug chmp said convinc fampyra small effect walk speed meaning benefit patient effect speed could link meaning improv better coordin balanc stamina increas rang action committe view medicin uncertain benefit outweigh side effect includ pain dizzi paraesthesia unusu sensat like pin needl problem balanc well symptom similar multipl sclerosi could impair patient abil walk committe also note lack adequ long term data medicin benefit safeti well data group patient elderli patient epilepsi heart problem chmp conclud benefit fampyra outweigh risk recommend refus market author chmp also recommend approv experiment oral ms medic cladribin market giant drug compani merck cladribin use iv form anticanc agent sinc mid known possibl sever side effect reformul oral form name movectro drug went full trial regimen use rrm patient shown reduc rate ms relaps possibl imped speed diseas progress decid drug chmp concern medicin safeti increas number patient cancer observ trial movectro may indic increas risk cancer time increas dose committe also note benefit appropri dosag treatment fulli establish patient expect use medicin therefor point time chmp opinion benefit movectro outweigh risk recommend refus market authoris drug fda approv later year interest see fda follow european cousin decis chmp recommend approv oral ms drug gylenia formal known fingolimod fti drug alreadi approv fda hit market sometim first half year gylenia power drug greatli alter work human immun system compound trap immun system cell lymphat system therebi keep central nervou system rest bodi well one neurologist told tysabri keep cop certain neighborhood gylenia keep lock polic station mani patient relish thought give inject monthli infus simplic pain free action take daili oral tablet mechan drug give paus believ neurologist care prescrib drug interestingli gylenia test possibl neuroprotect agent drug may doubl barrel effect would wonder scienc could isol gylenia neuroprotect properti develop compound shield nerv cell ms diseas process develop seem far futur ms patient find incred frustrat million upon million dollar spent research develop market pharmaceut compound absolut noth actual cure diseas effect turn patient indentur servant big pharma unfortun medic research model evolv highli dysfunct beast one often ignor real patient benefit favor possibl huge financi gain aberr immun reaction seen ms essenti symptom yet undiscov diseas caus even fraction research dollar spent big pharma drug design suppress modul immun system instead spent find unknown caus might actual road cure damn diseas one hope belief fervent ccsvi advoc hold forth vascular abnorm prove vital import part ms diseas process least may investig ccsvi final wrench focu ms research away concept autoimmun onto model ms diseas immun system gone awri signifi greater ill still hidden long last bring hidden ill light post post per mentor wheelchair kamikaz',\n",
       " 'mom year old detect lung cancer th march l r mutat goe tarceva day ago fisrt two day tarceva headach felt vomot vomit symptom gone mild diarrhea day th day tarceva felt pain insid like someon tri scrape someth organ said symptom last hour gone pain gone felt realli good fesh th day tarceva mom uncomfort feel look fesh good appetit read tarceva resist realli worri mom side effect mean start resist could pleas tell symptom could help know tart time tarceva resist mani thank',\n",
       " 'larri glad ride well walk great veronica e trike love yesterday feel like go ride trick self told go short trip lot power fun went mn easi ride felt pretti good end great hour ride otherwis routin yoga medit walk mn morn mn even concentr tell bad leg push hill knee kick hill done year see improv thank also ocrevu feel slow pretti good monster list inflamm part one good experi ocrevu rixitan best alain',\n",
       " 'thing realli matter fed go someth like last relaps tell minor set back hiccup last forev week go still feel start think mayb inde last forev lot wait involv one multipl sclerosi particularli one young ms like ms month old practic ms babi share wait month first wait get approv tysabri got approv wait th th infus told feel better went month flush start ocrevu two month feel like utter excrement could bare get bed got tell amaz new drug would one get back road feel like thing month feel suddenli energet felt awesom nowher relaps two half month first ocrevu infus land hospit four day wait entir focus could get get back home could feel better got home final feel better part realli happen mean get better better mean occasion throw oppos everi time ingest food feel like drunk time versu time could argu would correct better better better nah back wait next great hope would novemb find look forward novemb get second full dose ocrevu hope mayb magic dose help feel better littl voic back brain whisper might diseas requir long game never develop diseas ok entir life turn upsid promis better come go without relief told would come focu next milepost next thing might get overli activ diseas control first time sinc whole crazi ride start mayb get back normal normal probabl never mayb establish new normal diseas affect everi part everi breath everi second everi day experienc ms er friend much older ms year assur come believ sometim make feel stupid believ fairi tale make back work last week made offic two day row felt awesom final leav hous liar admit hard hell practic forc front door look like forgot wear real cloth put makeup usual enjoy felt like put disguis someon imperson old happi realli also scare death use good hour day get hous offic ran good hour make home use one handi portabl puke bag time privaci home public among peopl look leadership suppos inspir inspir leader offic afraid everi minut everi hour outsid home becom back home week rest take long ago schedul week vacat think obvious need rest ya know get tire much rest rest wear rest faulti bodi never feel rest matter mani hour abl stay unconsci though know best thing feel anyth rest nobodi pressur everyon peer team colleagu boss support would expect situat like one person cooper probabl higher expect allow believ life new life one wait period anoth thing need deal wait get beyond tell love quieter slower life much like anyth els impos might like realli want like quiet slow term decidedli term sure term work ms term accept struggl whole phase grief thing rememb well went husband die almost year ago use frustrat hell realiz go phase happen nice plan consecut order happen time sometim complet order think phase start happen willi nilli experienc grief know noth grief tidi cannot control let thing wait peopl tell abl see side griev realli move new life almost like surpris happen realli put finger happen wonder never notic took feel see grief rear view mirror shock like old childhood friend suddenli move away sad spent much time togeth start feel comfort guy never realli good friend know miss friend grief much thought would never realli gone alway feel linger edg life mostli happi back remind could go away poof like silver line pretti obviou one realli silver line done thought never get sort normal life back one went poof actual made life realli start love transit go live suddenli forc acknowledg plan focus anyth moment realli kind lie noth gold stay ponyboy curti taught pre teen might gold anymor learn get great joy silver bronz sometim even get platinum slow strang life might chang might might one day feel like real alway novemb also hot anymor even believ say almost turn furnac tonight thought better almost gorgeou sleep weather better get noth gold stay icon line one favorit childhood book outsid e hinton refer poem robert frost natur first green gold hardest hue hold earli leaf flower hour leaf subsid leaf eden sank grief dawn goe day noth gold stay robert frost',\n",
       " 'immunotherapi checkpoint inhibitor anti program cell death pd program death ligand pd l pembrolizumab nivolumab anti cytotox lymphocyt antigen ctla ipilimumab high dose interleukin il dual immunomodul dual checkpoint inhibit ctla inhibitor plu pd inhibitor signal transduct inhibitor braf v raf murin sarcoma viral oncogen homolog b inhibitor patient test posit braf v mutat vemurafenib dabrafenib mek inhibitor trametinib cobimetinib kit inhibitor multikinas inhibitor sorafenib combin therapi signal transduct inhibitor braf inhibitor plu mek inhibitor dabrafenib plu trametinib vemurafenib plu cobimetinib chemotherapi palli local therapi two approach checkpoint inhibit target mitogen activ protein kinas mapk pathway demonstr improv progress free surviv pf overal surviv os random trial anti pd monotherapi pembrolizumab nivolumab demonstr improv efficaci outcom better safeti profil compar treatment use singl agent anti ctla ipilimumab investig choic chemotherapi combin anti pd anti ctla immunotherapi nivolumab ipilimumab also prolong pf os compar ipilimumab combin associ signific toxic rapid develop new agent combin remain question patient physician encourag consid clinic trial initi treatment time progress clinic trial address follow issu optim dose combin immunotherapi decreas toxic preserv efficaci select patient benefit combin immunotherapi versu monotherapi role pd l express biomark efficaci role mainten therapi valu sequenc therapi immunotherapi target therapi intralesion therapi talimogen laherparepvec vec vec genet modifi herp simplex viru type hsv oncolyt therapi approv local intralesion inject unresect cutan subcutan nodal lesion patient melanoma recur initi surgeri vec design replic within tumor caus lysi produc granulocyt macrophag coloni stimul factor gm csf releas antigen togeth viral deriv gm csf may promot antitumor immun respons howev exact mechan action unknown approv vec u food drug administr fda base data demonstr shrinkag lesion howev improv os effect viscer metastas improv qualiti life shown evid vec multin random open label trial nct patient randomli assign intralesion vec subcutan gm csf least month inject lesion [ ][ level evid iidiv ] elig patient stage iiib iiic iv melanoma unresect bidimension measur lesion primari endpoint durabl respons rate drr complet respons [cr] partial respons [pr] last month assess independ review studi stratifi site first recurr presenc liver metastas diseas stage previou nonadjuv system treatment median patient age year rang year patient baselin eastern cooper oncolog group ecog perform statu ps score stage iii diseas stage iv diseas b c previou therapi melanoma receiv patient first dose administ plaqu form unit pfu ml maximum ml lesion combin subsequ dose administ pfu ml ml inject lesion combin inject volum base size lesion inject viscer lesion allow patient treat vec confid interv [ci] drr versu ci patient receiv gm csf subgroup analysi suggest differ drr vec versu gm csf may greater earlier stage diseas treatment na diseas patient stage iiib iiic drr vec versu gm csf versu respect patient stage iv diseas versu respect patient stage iv b diseas versu respect patient stage iv c diseas patient treat vec gm csf first line therapi drr versu howev patient receiv treatment second line therapi greater drr versu median durat exposur vec week month patient expos year common advers event ae vec group fatigu chill pyrexia nausea influenza like ill inject site pain rate discontinu result toxic vec versu gm csf group ten death patient treat vec eight death consid result pd salmonella infect one myocardi infarct none consid relat therapi base find investig precaut vec live attenu hsv may caus life threaten dissemin herpet infect contraind immunocompromis pregnant patient healthcar provid close contact avoid direct contact inject lesion biohazard precaut prepar administr handl provid label detail prescrib inform treatment cycl lesion size provid fda label immunotherapi checkpoint inhibitor anti pd pd l pd pathway key immunoinhibitori mediat cell exhaust blockad pathway lead cell activ expans enhanc effector function pd two ligand pd l pd l two anti pd antibodi pembrolizumab nivolumab approv fda basi improv os random trial pembrolizumab evid pembrolizumab previous treat patient total patient unresect metastat melanoma diseas progress within week last dose ipilimumab braf v mutat posit previou treatment braf inhibitor randomli assign one two dose pembrolizumab mg kg mg kg everi week trial exclud patient autoimmun diseas condit requir immunosuppress histori sever immun relat advers event ira treatment ipilimumab median age year male ecog ps ecog ps eighteen percent patient tumor braf v mutat posit elev lactat dehydrogenas ldh c diseas brain metastas undergon two therapi advanc diseas primari outcom measur overal respons rate orr accord respons evalu criteria solid tumor recist version criteria assess blind independ central review [ ][ level evid iidiv ] orr determin independ central review ci p mg kg arm consist one cr pr patient median follow month patient minimum month follow among patient object respons ongo respons rang month month respons rate mg kg arm similar consist respons patient respons seen patient without braf v mutat approv dose mg kg administ intraven iv infus minut everi week pembrolizumab discontinu ae patient treat mg kg consid drug relat ae investig common ae mg kg versu mg kg arm fatigu vs pruritu vs rash vs common ae includ cough nausea decreas appetit constip arthralgia diarrhea frequent seriou ae occur total patient treat pembrolizumab includ renal failur dyspnea pneumonia cellul addit clinic signific ira includ pneumon coliti hypophys hyperthyroid hypothyroid nephriti hepat fda label provid recommend suspect ira includ withhold drug administ corticosteroid previous untreat treat patient multicent intern trial keynot [nct ] randomli assign patient metastat melanoma ratio receiv pembrolizumab mg kg iv q week q week four cycl ipilimumab mg kg q week [ ] patient stratifi ecog ps vs line therapi first line vs second line pd l express posit vs neg primari endpoint pf os [ ][ level evid iia ] approxim patient receiv previou system therapi advanc melanoma braf v mutat present patient approxim receiv previou braf inhibitor treatment studi enrol patient braf v mutat high ldh level symptomat rapidli progress diseas receiv anti braf therapi could provid rapid clinic benefit approxim patient pd l posit tissu sampl time second interim analysi os result cross prespecifi efficaci boundari two pembrolizumab group superior os ipilimumab group prespecifi one side alpha level data monitor safeti board dmsb recommend studi result unblind pembrolizumab made avail patient diseas progress ipilimumab group median durat follow time second interim analysi month patient death median os reach treatment group year estim surviv patient receiv pembrolizumab everi week hazard ratio [hr] death compar ipilimumab group ci p patient receiv pembrolizumab everi week hr death compar ipilimumab ci p patient treat ipilimumab benefit seen across subgroup except patient pd l neg tumor howev sinc subset small patient ci wide definit conclus could drawn studi grade ae consid relat studi drug pembrolizumab everi week pembrolizumab everi week ipilimumab rate studi drug discontinu result toxic pembrolizumab everi week pembrolizumab everi week ipilimumab one death result cardiac arrest occur ipilimumab group patient type diabet mellitu caus metabol imbal associ ipilimumab induc diarrhea nivolumab evid nivolumab previous treat patient acceler approv base plan noncompar interim analysi first patient receiv nivolumab least month follow multicent open label trial checkmat [nct ] randomli assign patient nivolumab mg kg q week investig choic chemotherapi either dtic mg iv q week combin carboplatin [area curv ] plu paclitaxel mg q week [fda label ][ level evid iiidiv ] patient requir unresect metastat melanoma progress treatment ipilimumab braf v mutat posit braf inhibitor trial exclud patient autoimmun diseas condit requir immunosuppress histori sever ira treatment ipilimumab median age patient year patient male ecog ps patient braf v mutat present patient c diseas elev ldh histori brain metastas receiv two system therapi previous metastat diseas orr os coprimari endpoint orr ci four cr pr assess recist criteria independ central review among patient respons ongo respons durat month respons seen patient without braf v mutat safeti analysi base patient nivolumab discontinu ae patient seriou ae occur patient grade grade ae occur patient common ae rash cough upper respiratori tract infect peripher edema import ae includ ventricular arrhythmia iridocycl increas amylas lipas dizzi neuropathi fda label provid recommend suspect ira includ withhold drug administ corticosteroid previous untreat patient total patient unresect stage iii stage iv melanoma without braf mutat randomli assign doubl blind multicent trial receiv nivolumab mg kg q week dtic match placebo q week dtic mg q week nivolumab match placebo q week primari endpoint os [ ][ level evid ia ] trial conduct center europ israel australia canada south america countri dtic standard first line treatment patient without braf mutat dmsb note potenti differ os safeti review june abbrevi report unplan interim databas lock review show signific differ os favor nivolumab dmsb recommend studi unblind allow patient dtic receiv nivolumab intend sampl size approxim patient total patient enter result doubl blind portion studi crossov amend show median os reach nivolumab group month ci dtic group os rate year ci nivolumab group ci dacarbazin group hr death ci p common ae nivolumab group fatigu pruritu nausea diarrhea nivolumab group patient discontinu studi treatment ae compar patient discontinu studi treatment dtic group ae potenti immunolog etiolog occur includ gastrointestin hepat pulmonari renal endocrin skin howev major resolv delay studi treatment glucocorticoid administr per manag guidelin nivolumab death attribut drug relat ae either group chang dose regimen nivolumab metastat melanoma popul pharmacokinet respons analysi dose exposur respons analysi flat dose mg nivolumab everi week consid pharmacokinet equival dose regimen mg kg clinic safeti efficaci two dose appear similar across bodi weight tumor type melanoma non small cell lung cancer renal cell carcinoma [ ] dose regimen approv fda monotherapi chang mg kg mg iv everi week diseas progress intoler toxic dose regimen mg kg iv nivolumab combin ipilimumab remain unchang therapi ipilimumab complet regimen chang mg dose everi week diseas progress intoler toxic anti cytotox lymphocyt antigen ctla ipilimumab ipilimumab human monoclon antibodi bind ctla therebi block abil regul cell activ prolifer effector function ipilimumab demonstr clinic benefit prolong os random trial approv fda two prospect random intern trial one previous untreat treat patient support use ipilimumab [ ] evid ipilimumab previous treat patient total patient previous treat unresect stage iii stage iv diseas hla posit enter three arm multin random doubl blind doubl placebo trial total patient randomli assign receiv ipilimumab mg kg q week dose glycoprotein gp peptid vaccin one hundr thirti seven patient receiv ipilimumab mg kg q week dose patient receiv gp vaccin patient stratifi baselin metastas previou receipt nonreceipt il therapi eighti two patient metastas brain baselin [ ][ level evid ia ] median os month among patient receiv ipilimumab alon month among receiv ipilimumab gp vaccin compar month patient receiv vaccin alon hr ipilimumab alon vs gp alon p hr ipilimumab plu vaccin vs gp alon p analysi year show among patient treat ipilimumab treat ipilimumab treat ipilimumab vaccin aliv compar patient receiv vaccin grade grade ira occur patient treat ipilimumab ira often includ diarrhea coliti endocrin relat event e g inflamm pituitari event requir cessat therapi institut anti inflammatori agent corticosteroid four case infliximab antitumor necrosi factor alpha antibodi drug relat death seven death associ ira previous untreat patient multicent intern trial randomli assign patient untreat metastat diseas adjuv treatment allow ratio receiv ipilimumab mg kg plu dtic mg placebo plu dtic mg week follow dtic alon everi week week patient stabl diseas object respons dose limit toxic effect receiv ipilimumab placebo everi week thereaft mainten therapi primari endpoint surviv patient stratifi accord ecog ps metastat stage approxim patient ecog ps remaind patient ecog ps approxim patient stage c diseas [ ][ level evid ia ] median os month ci ipilimumab dtic group versu month ci placebo dtic group estim surviv rate ipilimumab dtic group year year year hr death p placebo dtic group rate year year year common studi drug relat ae classifi immun relat grade grade ira seen patient treat ipilimumab plu dtic versu patient treat placebo plu dtic common event hepat enterocol drug relat death occur clinician patient awar immun mediat advers reaction may sever fatal earli identif treatment includ potenti administr system glucocorticoid immunosuppress accord immun mediat advers reaction manag guid provid manufactur necessari [ ] high dose il il approv fda basi durabl cr eight phase ii studi phase iii trial compar high dose il retreat provid assess rel impact os conduct evid high dose il base pool analysi patient eight singl multi institut trial institut conduct high dose il demonstr cr rate [ ] median follow time surviv patient least year median durat cr reach least month [ ] strategi improv therapi activ area investig dual immunomodul cell coexpress sever receptor inhibit cell function preclin data earli clinic data suggest coblockad two inhibitori receptor ctla pd may effect blockad either alon [ ] led phase iii trial nct compar singl agent combin dual checkpoint inhibit ctla inhibitor plu pd inhibitor evid ipilimumab plu nivolumab previous untreat patient intern random doubl blind trial checkmat previous untreat patient unresect stage iii iv melanoma randomli assign ratio arm nivolumab alon mg kg q week plu placebo arm nivolumab mg kg q week plu ipilimumab mg kg q week dose follow mg nivolumab q week arm ipilimumab alon mg kg q week dose plu placebo pf os coprimari endpoint studi power compar combin nivolumab plu ipilimumab ipilimumab monotherapi nivolumab monotherapi ipilimumab monotherapi studi power compar combin ipilimumab plu nivolumab nivolumab patient stratifi accord tumor pd l statu assess central laboratori immunohistochem test posit vs neg indetermin braf mutat statu v mutat posit vs wild type american joint committe cancer stage [ ][ level evid iia ] characterist baselin includ patient ecog ps elev ldh braf mutat c diseas minor patient pd l posit tumor prospect defin coprimari analysi pf occur patient least month follow treatment nivolumab alon combin ipilimumab result significantli longer pf ipilimumab alon result consist across prespecifi stratif factor median pf month ci nivolumab month ci nivolumab plu ipilimumab month ci ipilimumab prospect specifi coprimari analysi os occur month death rate os time point nivolumab group combin group ipilimumab group hr death combin vs ipilimumab [ ci p ] hr death nivolumab vs ipilimumab [ ci p ] [ ] descript analysi minimum follow month follow data found os rate nivolumab group patient treat combin ipilimumab group median os reach combin arm ci month reach median os singl agent nivolumab ipilimumab group month ci reach month ci respect hr death combin versu ipilimumab ci p nivolumab versu ipilimumab hr ci p ae highest combin arm need monitor care grade treatment relat ae occur patient nivolumab group patient ipilimumab group patient combin group frequent reason treatment discontinu diseas progress two monotherapi arm nivolumab ipilimumab frequent reason discontinu combin group toxic four therapi relat death report attribut neutropenia nivolumab group colon perfor ipilimumab group liver necrosi autoimmun myocard combin ipilimumab nivolumab analys pd l express level associ os year indic level express alon poor predict biomark os signal transduct inhibitor studi date indic braf mek mitogen activ erk [extracellular signal regul kinase] activ kinas inhibitor singl agent combin significantli impact natur histori melanoma although appear provid cure braf inhibitor vemurafenib vemurafenib oral avail small molecul select braf kinas inhibitor approv fda patient unresect metastat melanoma test posit braf v e mutat treatment vemurafenib discourag wild type braf melanoma data preclin model demonstr braf inhibitor enhanc rather regul mapk pathway tumor cell wild type braf upstream ra mutat [ ] evid vemurafenib previous untreat patient approv vemurafenib support intern multicent trial brim [nct ] screen patient previous untreat stage iiic iv melanoma braf v mutat identifi patient via coba braf v mutat test [ ] patient randomli assign receiv either vemurafenib mg po bid dtic mg iv q week coprimari endpoint rate os pf plan interim analysi dmsb determin os pf endpoint met prespecifi criteria statist signific favor vemurafenib recommend patient dtic group allow cross receiv vemurafenib [ ][level evid iia iidiii ] total patient evalu os although median surviv yet reach vemurafenib data immatur reliabl kaplan meier estim surviv curv os vemurafenib arm clearli superior dtic arm hr death vemurafenib group ci p surviv benefit vemurafenib group observ prespecifi subgroup exampl age sex ecog ps tumor stage ldh geograph region hr tumor progress vemurafenib arm ci p estim median pf month vemurafenib arm versu month dtic arm twenti patient non braf v e mutat braf v k braf v four patient braf v k mutat respons vemurafenib ae requir dose modif interrupt patient receiv vemurafenib receiv dtic common ae vemurafenib cutan event e arthralgia fatigu cutan squamou cell carcinoma scc keratoacanthoma develop patient treat simpl excis common ae dtic fatigu nausea vomit neutropenia refer pdq summari support palli care inform cope cancer previous treat patient total patient braf v e braf v k mutat enrol multicent phase ii trial vemurafenib administ mg po bid enrol patient stage c diseas elev ldh level patient receiv one previou therapi advanc diseas median follow month [ ][ level evid iiidiv ] independ review committe irc report respons rate ci eight patient achiev cr median durat respons per irc assess month ci respons evid first radiolog assess week howev patient respond receiv therapi month dabrafenib dabrafenib oral avail small molecul select braf inhibitor approv fda patient unresect metastat melanoma test posit braf v e mutat detect fda approv test dabrafenib braf inhibitor recommend treatment braf wild type melanoma vitro experi suggest may paradox stimul mapk signal result tumor promot evid dabrafenib intern multicent trial break [nct ] compar dabrafenib dtic total patient unresect stage iii iv melanoma braf v e mutat randomli assign ratio dabrafenib mg po qd dtic mg iv q week il allow previou treatment advanc diseas primari endpoint pf patient could cross time progress diseas confirm blind irc [ ][ level evid iidiii ] event hr pf ci p estim median pf month dabrafenib versu month dtic os data limit median durat follow crossov pr rate cr rate patient receiv dabrafenib versu pr rate cr rate receiv dtic frequent ae patient treat dabrafenib cutan find e hyperkeratosi papilloma palmar plantar erythrodysesthesia pyrexia fatigu headach arthralgia cutan scc keratoacanthoma occur patient basal cell carcinoma occur four patient mycosi fungoid occur one patient new melanoma occur two patient mek inhibitor trametinib trametinib oral avail small molecul select inhibitor mek mek braf activ mek mek protein turn activ mapk preclin data suggest mek inhibitor restrain growth induc cell death braf mutat human melanoma tumor braf activ mek mek protein turn activ mapk trametinib approv fda patient unresect metastat melanoma braf v e v k mutat determin fda approv test evid trametinib total patient screen braf mutat result elig patient braf v e braf v k one mutat [ ] one previou treatment biolog chemotherapi allow howev previou treatment braf mek inhibitor permit patient randomli assign ratio receiv trametinib mg qd iv chemotherapi either dtic mg q week paclitaxel mg q week crossov patient randomli assign chemotherapi allow therefor primari endpoint pf investig assess pf month patient receiv trametinib versu month chemotherapi group hr pf death ci p radiolog review blind treatment arm result similar outcom median os reach ae lead dose interrupt occur patient trametinib group chemotherapi group ae lead dose reduct occur patient receiv trametinib receiv chemotherapi common ae includ rash diarrhea nausea vomit fatigu peripher edema alopecia hypertens constip cardiomyopathi interstiti lung diseas central serou retinopathi retin vein occlus uncommon seriou ae associ trametinib studi cutan scc observ refer pdq summari support palli care inform cope cancer cobimetinib cobimetinib small molecul select mek inhibitor approv fda use combin braf inhibitor vemurafenib refer combin therapi signal transduct inhibitor section summari inform kit inhibitor earli data suggest mucos acral melanoma activ mutat amplif c kit may sensit varieti c kit inhibitor [ ] phase ii phase iii trial avail patient unresect stage iii stage iv melanoma harbor c kit mutat multikinas inhibitor sorafenib multikinas inhibitor sorafenib activ vascular endotheli growth factor signal raf mek erk pathway agent minim activ singl agent melanoma treatment two larg multicent placebo control random trial carboplatin paclitaxel without sorafenib show improv chemotherapi alon either first line treatment second line treatment [ ] combin therapi signal transduct inhibitor secondari resist braf inhibitor monotherapi patient braf v mutat may associ reactiv mapk pathway therefor combin signal transduct inhibitor block differ site pathway site multipl pathway activ area research braf inhibitor plu mek inhibitor dabrafenib plu trametinib evid dabrafenib plu trametinib previous untreat intern doubl blind phase iii trial without crossov randomli assign previous untreat patient unresect stage iiic stage iv melanoma braf v e v k mutat receiv combin dabrafenib mg po bid plu trametinib mg po qd dabrafenib plu placebo primari endpoint investig assess pf protocol includ prespecifi interim analysi os time analysi primari endpoint patient stratifi baselin ldh braf genotyp [ ][ level evid idiii ] median pf month combin versu month dabrafenib plu placebo hr death progress ci p updat data time final analysi os reveal median pf month combin versu month dabrafenib plu placebo hr pf death ci p unadjust multipl test [ ] prespecifi final analysi os conduct event median os month dabrafenib plu trametinib group event versu month dabrafenib plu placebo group event hr ci p perman discontinu studi drug report patient combin patient treat dabrafenib incid grade grade ae similar group incid combin incid dabrafenib pyrexia occur frequent combin treat immedi temporari cessat studi drug either group prophylact glucocorticoid may prevent recur episod hyperprolif cutan event includ cutan scc consid relat paradox activ mapk pathway occur less frequent addit mek inhibitor rare seriou ae includ decreas eject fraction chorioretinopathi previous untreat intern open label phase iii trial randomli assign previous untreat patient metastat melanoma braf v mutat receiv standard dose either combin dabrafenib plu trametinib vemurafenib first line therapi primari endpoint os [ ][ level evid iia ] interim analysi os plan final event occur per protocol dmsb use adjust efficaci boundari actual event side p efficaci p futil dmsb recommend stop efficaci interim analysi consid final analysi os protocol amend issu allow crossov combin therapi arm total patient combin arm vemurafenib group die hr ci p median os patient treat vemurafenib month median reach combin therapi arm vemurafenib plu cobimetinib evid vemurafenib plu cobimetinib previous untreat intern phase iii trial randomli assign patient previous untreat unresect stage iiic stage iv melanoma braf v mutat posit melanoma receiv combin vemurafenib mg po qd cobimetinib mg po qd day follow day rest period vemurafenib plu placebo primari endpoint investig assess pf crossov time pf allow patient stratifi stage geograph region two interim analys os prespecifi first specifi time analysi primari endpoint [ ][ level evid idiii ] median pf month combin versu month patient treat vemurafenib plu placebo hr death progress ci p first interim analysi os immatur event arm therefor median surviv reach either studi group rate withdraw therapi caus ae similar group rate found patient treat combin rate found patient treat vemurafenib six death attribut ae combin group three death attribut ae vemurafenib group incid grade grade ae similar group incid rate found patient treat combin rate found patient treat vemurafenib alon rare seriou ae includ chorioretinopathi retin detach decreas eject fraction qt prolong hyperprolif cutan event includ cutan scc consid relat paradox activ mapk pathway occur less frequent addit mek inhibitor chemotherapi dtic approv basi orr phase iii trial indic orr rare cr observ impact os demonstr random trial [ ] use control arm recent registr trial ipilimumab vemurafenib previous untreat patient metastat melanoma dtic shown inferior os temozolomid oral alkyl agent hydrolyz activ moieti dtic appear similar dtic iv administr random phase iii trial primari endpoint os howev trial design superior sampl size inadequ prove equival [ ] object respons rate dtic nitrosourea carmustin lomustin approxim [ ] respons usual short live rang month although long term remiss occur limit number patient attain cr [ ] random trial compar iv dtic temozolomid oral agent os month dtic versu month temozolomid hr ci data suggest similar dtic temozolomid benefit surviv demonstr either dtic temozolomid therefor demonstr similar result approv temozolomid fda [ ][ level evid iia ] extend schedul escal dose temozolomid compar dtic multicent trial european organis research treatment cancer eortc eortc [nct ] randomli assign patient improv seen os pf temozolomid group dose schedul result toxic standard dose singl agent dtic [ ][ level evid iia ] two random phase iii trial previous untreat patient metastat melanoma result fda approv vemurafenib [ ] ipilimumab [ ] includ dtic standard therapi arm vemurafenib braf v mutant melanoma ipilimumab show superior os compar dtic two separ trial agent modest singl agent activ includ vinca alkaloid platinum compound taxan [ ] attempt develop combin regimen incorpor chemotherapi e g multiag chemotherapi [ ] combin chemotherapi tamoxifen [ ] combin chemotherapi immunotherapi [ ] demonstr improv os publish data meta analysi random trial surviv inform compar chemotherapi biochemotherapi e chemotherapi plu interferon alon il report impact os [ ][ level evid iia ] palli local therapi melanoma metastat distant lymph node bear area may palliat region lymphadenectomi isol metastas lung gastrointestin tract bone sometim brain may palliat resect occasion long term surviv [ ] although melanoma rel radiat resist tumor palli radiat therapi may allevi symptom retrospect studi shown symptom relief shrinkag tumor radiat therapi may occur patient follow [ ] multipl brain metastas bone metastas spinal cord compress effect dose fraction schedul palliat melanoma metastat bone spinal cord unclear high dose per fraction schedul sometim use overcom tumor resist refer pdq summari cancer pain inform treatment option clinic evalu unresect stage iii stage iv recurr melanoma immunotherapi singl agent combin immunomodul target therapi singl agent combin therapi signal transduct inhibitor includ p k phosphoinositid kinas akt protein kinas b inhibitor cdk cyclin depend kinas addit braf mek inhibitor antiangiogenesi agent preclin data suggest increas vascular endotheli growth factor product may implic resist braf inhibitor [ ] target therapi specif melanoma popul smaller subset melanoma activ mutat may occur nra neuroblastoma ra viral [v ras] oncogen homolog c kit melanoma aris chronic sun damag skin acral mucos melanoma cdk cyclin depend kinas wherea gnaq frequent mutat uveal melanoma drug develop target pathway activ mutat current clinic trial',\n",
       " 'resect surgeri noth normal anymor lol ye gain back lb sinc jan yr old male might differ bit weight gain weigh lb ft use athlet also use weight work regularli lost almost muscl mass wife say arm leg like tooth pick hope continu help surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia fail remicad cimzia methotrex humir mp entyvio medic stelara verapamil quinipril labetalol clorithidon atorvastatin alluporinol elliqu',\n",
       " 'thank everyon dread row mum last night like row crept blue upset unexpect like row also someth complet stupid petti surfac relev thread gonna talk tri make long show parent capsul endoscopi report mum squirm inflamm ulcer said urgh horribl told basic told guy far could tell exhaust medic option basic either live crohn go back stoma sympathet caus row went garden centr mum nice afternoon got back got wine think actual alcohol one two tier one notic go drink often even far last night issu know long experi mum deep denial drink day die time right drunk bit annoy sometim get aw argument state seem spoil argument last night ask come easter sunday keen idea feel famili gather noth remot new surpris mum alway feel like physic crap eat larg meal virtual alway someth think peopl realli understand famili perk eat massiv meal drink alcohol get ever louder shriekier wherea get tired lower want go lie mum argu say alway feel like crap cite one two exampl appear obvious collaps rememb brought brother first mum somebodi turn ridicul argument ill brother think know crohn well sinc mention time time diseas longer mine also far milder form close brother never given sympathi diseas never given sympathi fight anyth like like two polit acquaint one anoth anyway mum tri tell brother ill well despit fact never surgeri never hospitalis never biolog seem remiss vast major time alway work full time two kid play sport goe holiday eat anyth etc yeah ill one get wrong sure problem nobodi reach middl age acquir problem along way proper lost temper would never tell brother face lucki diseas told mum howev quit drunk hard enough get sober sometim never mind drunk end proper sob meltdown someth coupl year dad join fun start get verbal aggress parent desper tri get leav sever minut mum gave went upstair left sob hallway dad volt face said safe drive like becam gentler went made cup tea calm enough drive home yeah proper grim night felt proper upset got home well way longer intend sorri folk read repli fact read last night obvious much fit state repli thank everyon post erudit paul yeah possibl pill cam get stuck strictur crohn tend give patient dummi pill first dissolv case get stuck dummi pill never saw pass abdomin x ray see pill given go ahead go ahead swallow real pill clo sparkleplenti pill cam load dose entyvio sinc th infus due th infus next week sure enough time entyvio kick ask gi noodlesnoodl think sure tysabri approv crohn yet anoth thing ask gi _ nssg long cours entocort last year actual help mg steroid work highest dose stop work even fulli come med done steroid liter stick plaster beav certainli travel london treatment necessari get hour train second seem quit fast _ know look symptom achalasia occasion get feel food stuck find someth quit hard swallow time anyway better go guy got hospit appoint get let know goe sorri yet anoth hideous long post alway look shorter white box dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'hi diller_lil welcom previou convers ocrevu use forum search function magnifi glass top left use term ocrevu locat',\n",
       " 'gelinya everi year coupl year start gilenya three month ago look forward think',\n",
       " 'contractor new york know anxieti feel morn day make job without go pant total accid surgeri know fun never humira know take mani week kick pred mani mani time mani mg pred u yea nasti flare bm hope humira help sooner later tell dr everyth go thru keep check let us know post edit timechamp gmt',\n",
       " 'switch copaxon gilenya sever allerg reaction copaxon inject reaction would caus temp go one time breath gilenya amaz year th unchang mri realli easi rememb take notic side effect person like small lesion load moment minor symptom compar realli chang life better take one pill instead copaxon shot also refer betaseron first year ms copaxon year gilenya gilenya best far',\n",
       " 'nivolumab monotherapi combin ipilimumab show encourag respons surviv rate among patient recurr small cell lung cancer sclc checkmat studi accord announc bristol myer squibb checkmat ongo phase open label trial evalu safeti efficaci differ dose schedul singl agent nivolumab nivolumab plu ipilimumab advanc metastat solid tumor sclc cohort checkmat includ patient diseas progress prior line treatment includ first line platinum base chemotherapi regimen analysi treatment nivolumab mg kg plu ipilimumab mg kg associ confirm object respons rate ci includ complet respons partial respons eleven percent patient treat nivolumab monotherapi achiev object respons rate investig observ respons regardless platinum sensit prior line therapi relat rovalpituzumab tesirin activ recurr small cell lung cancer median durat respons month ci reach combin arm reach singl agent nivolumab arm estim year overal surviv rate combin nivolumab alon new safeti signal observ longer follow durat refer',\n",
       " 'age relat macular degener amd amrd term appli age chang without obviou precipit caus occur central area retina macula peopl age year older [ ] amd progress chronic diseas central retina lead caus vision loss worldwid visual loss occur late stage diseas [ ] pathophysiolog [ ] amd characteris appear drusen macula accompani choroid neovascularis wet amd geograph atrophi dri amd two form amd differ pathophysiolog progress dri amd geograph atrophi ga characterist lesion dri amd soft drusen chang pigment hypopigment hyperpigment retin pigment epithelium rpe atrophi rpe becom extens time dri form advanc caus vision loss without turn wet form end stage dri form involv whole macula becom affect ga evolv dri amd common form amd occur case progress visual loss usual gradual eventu area partial complet atrophi rpe may may involv fovea dri amd chanc per year develop choroid neovascularis wet amd patient extrem larg drusen higher chanc amd convert wet form within five year [ ] wet amd neovascular amd exud amd wet type amd new blood vessel grow choriocapillari retina spread rpe fragil easili leak blood vessel initi grow macula start side retina grow toward centr take day grow macula other take week reoccur sometim mani year later consequ abnorm vessel growth haemorrhag scar format disciform scar wet amd account case amd advanc case wet amd definit consid advanc present progress vari month three year untreat becom sever visual impair within approxim two year end point type amd scar format known disciform macular degener approxim patient wet amd one eye also develop condit second eye within five year classif sever [ ] sever classif scheme base presenc sever characterist featur amd name drusen pigmentari irregular ga neovascularis classif system moder good predict progress highli precis detail age relat eye diseas studi are trial develop simpler classif system prove clinic use [ ] amd none small drusen earli amd multipl small intermedi drusen abnorm rpe intermedi amd extens intermedi one larg drusen ga involv fovea advanc amd ga involv fovea featur wet amd idiopath polypoid choroidopathi [ ] variant amd consist neovascularis primarili locat within choroid share featur amd involv macula seen age group share common non genet risk factor smoke hypertens share common genet risk factor howev contrast amd polypoid choroidopathi seen younger age group amd often occur nasal macula polypoid neovascular complex may leak bleed less like invad retina epidemiolog [ ] amd common caus sever visual impair older adult develop world amd respons two third registr visual impair uk estim preval amd uk year age age year around new diagnos uk year case dri amd wet amd account advanc amd preval increas line age popul [ ] amd common peopl caucasian ethnic women like men develop amd worldwid million peopl amd risk factor [ ] amd multi factori diseas environment genet compon play role develop sever risk factor link amd increas age main risk factor smoke risk factor new onset amd progress advanc diseas risk increas number pack year smoke synergist effect genet factor also seem relationship gene respons treatment famili histori sever gene associ risk develop dri amd sibl affect peopl four time greater chanc develop diseas concord ident twin presenc amd one eye greatli increas risk develop develop visual impair second eye within four year [ ] cardiovascular risk factor also associ wet amd [ ] studi suggest associ amd cumul eye damag ultraviolet light peopl light color eye like develop dri amd peopl diet high fat cholesterol high glycem index food low antioxid green leafi veget may like develop amd obes bmi greater increas risk time ethnic affect risk amd uncommon nativ african nativ australian common caucasian grow evid high cumul lifetim exposur sunlight also increas risk develop amd [ ] present [ ] symptom amd caus painless deterior central vision typic person age patient may initi asymptomat retin sign may detect incident routin eye test gener symptom reduct visual acuiti notic particularli near vision loss decreas contrast sensit abil discern differ shade size colour object appear differ eye abnorm dark adapt difficulti adjust bright dim light may central dark patch visual field notic night clear within minut eye adapt photopsia percept flicker flash light light glare visual hallucin charl bonnet syndrom occur sever visual loss caus visual hallucin often report unless specif ask dri amd symptom visual deterior tend gradual common present difficulti read initi smallest size print later larger print peopl may notic visual deterior one eye affect visual loss becom appar second eye becom affect ga bilater involv fovea patient may complain deterior central vision scotoma person may describ black grey patch affect central field vision normal left eye medic galleri mikael h ggstr via wikimedia common dri armd nation eye institut nih via wikimedia common wet amd symptom common symptom typic onset exud amd central visual blur distort patient complain straight line appear crook wavi visual deterior may develop quickli person may suddenli becom unabl read drive see fine detail facial featur express vision may suddenli deterior profound central visual loss event bleed may preced accompani shower floater dri amd exud amd occur second eye patient may suddenli becom awar visual loss fundu photo wet amd show bleed retina eye site sacramento examin examin may reveal normal decreas visual acuiti associ distort amsler grid see separ examin eye articl fundu examin reveal drusen discret yellow deposit macular area may becom paler larger confluent patient progress exud amd late diseas macular scar may develop resembl thick yellow patch macular area area sharpli demarc hypopigment hyperpigment peripher retina sometim seen repres ga rpe macular sign wet amd includ well demarc red patch repres intraretin subretin sub rpe haemorrhag fluid may patchi pigment differenti diagnosi [ ] painless loss vision caus refract error cataract corneal diseas eg fuch endotheli dystrophi posterior vitreou detach retin detach retin arteri occlus retin vein occlus central serou retinopathi cerebrovascular diseas includ amaurosi fugax transient ischaem attack stroke drug chemic includ methanol chloroquin hydroxychloroquin isoniazid thioridazin isotretinoin tetracyclin ethambutol pituitari tumour central nervou system tumour papilloedema macular hole primari open angl glaucoma central visual loss occur late optic atrophi condit caus similar retin sign observ amd includ diabet maculopathi macular degener associ high myopia greater dioptr atroph neovascular chang usual occur younger age amd differ natur histori respons treatment rare inflammatori syndrom caus choroid neovascularis exampl ocular histoplasmosi usual sign activ previou uveiti central serou retinopathi macular telangiectasia macular dystrophi usual inherit often symmetr type membranoprolif glomerulonephr investig [ ] secondari care investig aim confirm diagnosi assess extent diseas possibl intervent keep record order measur treatment effect diseas progress slit lamp biomicroscopi identifi drusen pigmentari exud haemorrhag atroph chang affect macula look characterist area area pallor sharpli defin scallop edg also help detect retin thicken elev due neovascular amd colour fundu photographi use record appear retina fluorescein angiographi use neovascular amd suspect order confirm diagnosi assess lesion fluorescein dye inject intraven photograph retina taken serial detect abnorm vasculatur leakag capillari indocyanin green angiographi may use visualis choroid circul provid addit inform fluorescein angiographi ocular coher tomographi produc high resolut cross section three dimension imag retina guidelin royal colleg ophthalmologist state test mandatori diagnosi monitor respons therapi reveal area ga may clinic visibl biomicroscopi manag suspect age relat macular degener [ ] amd suspect refer person urgent assess ideal seen within one week referr urgent referr particularli import peopl present distort rapid onset visual loss suggest wet amd refer one follow choic depend local referr pathway fast track macular clinic medic retina clinic treatment centr local district gener hospit eye servic optometrist option seen within one week optometrist abl refer directli ophthalmologist advis person either delay one week seen ophthalmologist symptom worsen whilst wait seen attend eye casualti soon possibl seek immedi medic attent expedit urgent specialist assess manag dri age relat macular degener treatment prevent progress dri amd although lifestyl adjust may slow progress manag consist mainli counsel smoke cessat visual rehabilit nutrit supplement expect benefit co exist visual impair cataract refractori error appropri manag although cochran review found possibl conclud avail data whether cataract surgeri benefici harm peopl amd [ ] current consider interest implant len system end stage diseas see advic support [ ] peopl diagnos amd receiv inform condit secondari care howev consid offer inform person develop worsen symptom develop symptom second eye either present soon possibl eye casualti similar urgent walk hospit eye clinic present soon possibl gp urgent referr made specialis servic inform secondari care treatment done slow progress explain mani peopl sever sight loss experi visual hallucin consid regist sight impair registr voluntari provid access benefit help appropri inform access low vision servic see signpost relev organis exampl macular societi provid support comprehens inform amd live amd print audio format royal nation institut blind peopl provid inform support includ contact detail local support group visual impair citizen advic provid advic avail benefit drive mani peopl amd abl drive depend sever diseas vision fulfil requir dvla person legal respons check whether eyesight good enough drive [ ] registr sight impair sever sight impair normal rule hold drive licenc uncertainti fit drive advis person contact dvla lifestyl advic [ ] advis smoker stop smoke reduc risk amd progress peopl exist diseas encourag person eat healthi balanc diet rich leafi green veget fresh fruit like improv concentr macular pigment fundu firm evid help slow progress amd sensibl unlik harm patient may advis take dietari supplement consult ophthalmologist would typic peopl intermedi amd one eye advanc amd one eye are trial follow work are conclud specif dietari supplement may reduc risk progress patient supplement wide sold are formula consist mg vitamin c iu vitamin e mg lutein mg zeaxanthin mg zinc mg copper evid support use supplement peopl less intermedi amd evid use primari prevent risk free zinc supplement caus small increas risk hospitalis due genitourinari condit possibl small increas risk heart failur associ vitamin e supplement patient diabet mellitu number studi look use statin ginkgo biloba extract contain flavonoid terpenoid antioxid properti slow diseas progress howev studi inconclus treatment option use uk visual rehabilit mainstay manag patient dri amd revolv around maximis remain visual function assist person maintain independ life long possibl may involv refract check make sure remain vision best low visual aid clinic referr help person make remain sight servic may includ provis train use optic aid magnifi advic light tactil aid electron aid non optic aid low vision servic may provid social servic commun optometrist eye depart voluntari sector person need regist sight impair access low vision servic fact access low vision servic person develop seriou visual difficulti give chanc adapt sever affect servic may also provid advic benefit concess support group peopl sight impair see separ sever partial sight impair articl manag wet age relat macular degener intravitr inject anti vascular endotheli growth factor anti vegf agent current standard care treatment carri ophthalmologist special interest retin macular problem intervent treatment take place either theatr design treatment clean room local anaesthet anti vegf inhibitor [ ] vegf pro angiogen growth factor also stimul vascular permeabl major role patholog neovascular amd sinc anti vegf therapi becom avail substanti improv prognosi peopl affect neovascular amd anti vegf drug includ ranibizumab bevacizumab aflibercept anti vegf drug administ intravitr inject usual given monthli three month variabl time thereaft depend respons treatment follow may beyond two year patient maintain vision current level third gain improv vision howev respond therapi patient understand risk associ intravitr inject instruct report symptom suggest endophthalm without delay pegaptanib current recommend nation institut health care excel nice treatment neovascular amd ranibizumab aflibercept recommend manufactur provid discount agre patient access scheme follow circumst appli eye treat best correct visual acuiti perman structur damag central fovea lesion size less equal disc area greatest linear dimens evid recent presum diseas progress blood vessel growth indic fluorescein angiographi recent visual acuiti chang recommend treatment ranibizumab continu peopl maintain adequ respons therapi bevacizumab develop system treatment colorect cancer cheaper whilst current licens intraocular use wide use around world account price studi suggest ranibizumab bevacizumab similar efficaci [ ]',\n",
       " 'hi crohn coliti humira sinc final wean prednison end februari remiss mild inflamm inch transvers colon everyth els normal uceri day still see blood littl pain doc think humira realli work last long steroid mention remicad next think entyvio crohn patient use entyvio risk get small bowel inflamm entyvio work colon never small bowel inflamm want either remicad still gold standard crohn thank diagnos proctiti april p c diff infect age nov crohn coliti mid transvers mild moder remiss march sept flare fail prednison balsalzid wean start humira prednison sinc past med cortifoam canasa rowasa balsalazid prednison',\n",
       " 'remicad yr stop work tri humira reaction today get first dose cimzia eat disord afraid weight gain caus anyon els plu heard caus hair loss worri question pleas let know new member forum ps crohn',\n",
       " 'jussi tri bring bp substitut pazopanib help hypotens tri make sure deliveri opdivo deliv heart tumor treat low bp long monthli dose cediranib revert hypotens mention',\n",
       " 'ocrevu want share inform interest know treatment made feel notic chang odd sensat new symptom old symptom vanish got somewhat better ms diagnos avonex copaxon member ms board sinc repli quot follow user say thank howi jeani z jendi stillstannd sunshin',\n",
       " 'diagnosi adenocarcinoma nsclc met adren gland possibl liver posit r neg alk kra ro pd pd l met treatment st carboplatin pemetrex shrinkag nd tarceva shrinkag week progress week rd pemetrex avastin toler th opdivo stabl week progress week th docetaxel toler th begin tagrisso question tagrisso good altern neg never smoker altern current treatment yale dr roggerio lilenbaum suggest suitabl clinic trial ct mass ny suggest doctor second opinion',\n",
       " 'hi birki diagnos april adenocarcinoma quit surpris quit smoke year go thought safe radiat surgeri rule luckili candid immunotherapi go third treatment tuesday side effect noth seriou current receiv keytruda think one newer immunotherapi drug oncologist said take nine week get good idea cancer respond hang birki keep date event evolv',\n",
       " 'oct jskoziol wrote hello close halloween great weight health diagnos stage nsclc jan opdivo case miracl drug thought post shout seen previo post wife noriko diagnos august stage squamou nsclc pet ct scan novemb st schedul infus opdivo nivolumab month month diagnosi previous gone thru two combo regimen fail chemo oncologist dr jack west came said cancel infus pet ct scan show wasfre cancer remiss ecstat hopeeven stage lung cancer thank brystol meyer squibb area seattl swedish hospit cancer institut best youjskozio keep spirit great progress chuck',\n",
       " 'wednesday april et vancouv april prnewswir firstcal qlt inc nasdaq qlti news tsx qlt news announc today enter exclus worldwid co develop licens agreement retinagenix llc develop activ synthet retinoid product treatment degen retin diseas term agreement qlt respons develop commerci product use ocular human diseas retinagenix particip research support co develop collabor elig receiv upfront payment us million payment upon achiev certain develop approv sale mileston well singl digit royalti net sale excit make announc today said bob butchofski presid chief execut offic qlt collabor first step forward strategi access develop commerci promis new technolog eye qlt core area therapeut expertis plan progress first drug candid retinagenix collabor clinic within next month degen diseas retina affect mani peopl worldwid lead vari degre irrevers blind said marco northland chairman retinagenix believ administr synthet retinoid could revers defect retinoid cycl patient believ qlt expertis retin diseas drug develop provid strong foundat success collabor synthet retinoid drug synthet retinoid drug use biochem strategi restor visual function retin degener well age retina genet diseas eye leber congenit amaurosi lca retin pigmentosa aris gene inactiv subsequ disrupt metabol pathway pathway advers affect natur age process may play role age visual deficit includ age relat macular degener retinagenix pre clinic studi demonstr oral administ synthet retinoid drug caus long last restor retin function qlt inc qlt global biopharmaceut compani special develop treatment eye diseas well dermatolog urolog condit combin expertis discoveri develop commerci innov drug therapi two uniqu technolog platform photodynam therapi atrigel creat product visudyn eligard inform visit web site www qltinc com retinagenix llc retinagenix privat held earli stage seattl wa base compani develop commerci synthet retinoid treatment retin diseas retinagenix spin univers washington co found david saperstein md krzysztof palczewski phd two intern recogn leader treatment retin diseas biochemistri vision respect marco northland season entrepreneur [snip]',\n",
       " 'want give updat start scan less frequent everi month get see everyth work mom scan last month everyth stabl doctor said normal tumor small becom told thing keep go way could possibl go less treatment schedul year keytruda amaz drug noth short miracl famili origin told may live see year surviv month without treatment year half cancer progress mani prayer answer hope',\n",
       " 'franck paterka birkenstock j zipp f siffrin v witsch e phenotyp antigen unexperienc th cell inflam central nervou system experiment autoimmun encephalomyel j neuroimmun pharmacol nov [epub ahead print] multipl sclerosi chronic dissemin inflamm central nervou system thought driven autoimmun cell genet associ studi multipl sclerosi larg number studi anim model diseas support role effector memori helper cell howev mechan underli relaps remiss chronic progress multipl sclerosi anim model experiment autoimmun encephalomyel clear particular scarc inform role central nervou system invad naiv helper cell process appli two photon laser scan microscopi could show vivo antigen unexperienc helper cell migrat deep parenchyma inflam central nervou system experiment autoimmun encephalomyel independ antigen specif use flow cytometr analys central nervou system deriv lymphocyt found antigen specif formerli naiv helper cell becam activ inflamm central nervou system encount correspond antigen debat ongo valu eae number immun modul go increasingli difficult develop new one go go head head current dmt need cours howev term basic scienc much need eae understand basic biolog could probabl get idea use less sever model basi rs central part eu law come use anim research somebodi coupl day ago extol virtu german ethic piec work take view favour know mani peopl read one could pose question often need invent wheel new technolog tell us someth essenti believ know alreadi cell see target get activ clear cell arriv cn antigen specif shown thirti year ago know migrat marker make import natalizumab fingolimod know previous antigen sensitizi pool import eae induct spend vast amount time work immun cell go eg lung spleen brain cell goe tissu die make new one go elsewher move cn live anoth day',\n",
       " 'gilenya sinc begin issu except lymphocyt count drop worrisom zone get test everi month make sure stay low far count keep come back otherwis issu',\n",
       " 'hi mohit welcom grace sorri hear recent progress father lung cancer though oncologist like continu tarceva even progress combin drug alimta pemetrex often progress signific enough third gener egfr tki tagrisso chosen addit doctor choos combin afatinib cetuximab effect quit challeng term combin side effect egfr posit patient often overlook standard chemotherapi tend quit effect subgroup patient regimen carboplatin cisplatin combin alimta taxol often use jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'stelara still fairli new crohn treatment might get lot repli done research time work answer psoriasi board psoriasi seem week reach strong therapeaut level good news stelara seem get rave review crohn patient seem best med come along sinc remicad hope good success daughter diagnos feb yr old time diagnosi crohn termin illium use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mg imuran',\n",
       " 'real game changer cyndi zagieboylo presid ceo nation ms societi summari u food drug administr approv ocrevu ocrelizumab genentech member roch group treatment primari progress ms relaps ms base clinic trial show signific benefit ms relaps progress first therapi specif approv treat primari progress ms potenti safeti issu identifi fda includ infus reaction infect may increas risk malign peopl take ocrevu ocrevu taken iv infus everi six month inform ocrevu avail genentech ocrevu pm eastern addit detail frequent ask question detail u food drug administr approv ocrevu ocrelizumab genentech member roch group use treatment primari progress ms relaps ms make first therapi treatment primari progress multipl sclerosi ocrevu avail first line treatment mean recommend approv label peopl tri ms therapi take ocrevu test children comment first therapi specif approv treat primari progress ms repres signific mileston said kathi costello ms anp bc mscn associ vice presid healthcar access nation ms societi grate final diseas modifi treatment peopl primari progress ms also import new option peopl relaps ms said bruce bebo phd execut vice presid research nation ms societi hope first mani new treatment approv peopl progress ms ocrevu ocrevu monoclon antibodi bind molecul cd surfac immun cell call b cell reduc number certain b cell circul blood b cell sever function includ make antibodi believ play role immun system mediat damag brain spinal cord tissu ms ocrelizumab administ intraven infus everi month first dose given two infus two week apart subsequ dose given singl infus potenti benefit primari progress ms oratorio studi involv peopl primari progress ms compar ocrevu inact placebo met primari endpoint show treatment ocrevu significantli reduc risk progress clinic disabl compar placebo peopl compar placebo ocrevu also reduc time requir walk feet decreas volum brain lesion relaps ms opera opera ii studi involv peopl relaps ms compar ocrelizumab interferon beta rebif emd serono pfizer ocrevu significantli reduc annual relaps rate compar rebif two year total peopl relaps ms addit ocrevu significantli delay confirm progress disabl edss scale compar rebif ocrevu also significantli reduc activ inflamm observ mri scan total damag mri scan compar rebif potenti risk prescrib inform medic guid pdf ocrevu includ sever warn precaut ocrevu caus wide varieti infus relat reaction frequent itchi skin rash irrit throat flush face fever headach symptom rare case life threaten infus reaction occur frequent first infus occur hour infus precaut peopl administ steroid antihistamin infus monitor least one hour infus ocrevu increas risk infect includ respiratori tract infect herp infect ocrevu administr delay peopl activ infect vaccin live live attenu vaccin recommend treatment b cell repopul follow treatment may increas risk malign cancer includ breast cancer peopl take ocrevu individu use ocrevu follow standard breast cancer screen guidelin clinic trial result ongo monitor trial particip indic imbal number cancer occur individu treat ocrevu compar interferon relaps remit trial placebo primari progress trial number small know sure relat directli ocrevu imbal requir continu care observ evalu data larger number individu pml although case pml progress multifoc leukoencephalopathi seriou brain infect occur clinic trial pml observ peopl take relat medic condit typic symptom divers progress day week includ progress weak one side bodi clumsi vision disturb chang think memori orient person hepat b viru reactiv although case hepat b viru reactiv report peopl take ocrevu occur peopl take similar medic initi treatment ocrevu individu blood test detect hepat b viru inform peopl ms contact genentech ocrevu pm eastern peopl qualifi genentech plan offer patient assist program genentech access solut access http www genentech access com comment price approv ocrevu excit mileston peopl primari progress ms encourag new option peopl relaps form diseas nation ms societi applaud genentech leadership set wholesal acquisit cost list price ocrevu per year nearli percent current market averag ms treatment continu escal price ms diseas modifi therapi creat barrier peopl ms get life chang medic action ocrevu genentech chang industri dynam peopl access life chang treatment need live best live encourag compani follow suit creat drug price trend keep patient first resourc read press releas fda download prescrib inform read fda snapshot describ clinic trial ocrevu read detail clinic trial ocrevu two paper publish decemb issu new england journal medicin ocrelizumab versu placebo primari progress multipl sclerosi dr xavier montalban other ocrelizumab versu interferon beta relaps multipl sclerosi dr stephen hauser other ocrevu trademark genentech member roch group rebif regist trademark merck kgaa emd serono inc faq fda approv ocrelizumab brand name ocrevu primari progress relaps form ms q ocrevu ocrevu ocrelizumab genentech member roch group monoclon antibodi bind molecul cd surfac immun cell call b cell reduc number certain b cell circul blood b cell sever function includ make antibodi believ play role immun system mediat damag brain spinal cord tissu ms q type ms ocrevu approv treat fda approv ocrelizumab treatment adult primari progress ms relaps ms q everyon primari progress ms benefit ocrevu know sinc like clinic trial ocrevu trial primari progress ms limit characterist peopl could particip trial includ peopl age edss expand disabl statu scale scale assess neurolog function use clinic trial score mean abl walk help walker bilater crutch devic side evid immun protein test spinal fluid oligoclon band possibl predict specif individu respond treatment use ocrevu clinic practic help determin like benefit q ocrevu help peopl secondari progress ms longer experienc relaps know far clinic trial ocrevu involv peopl relaps form ms primari progress ms result announc posit trial popul data yet whether ocrevu may effect peopl secondari progress ms longer experienc relaps q ocrelizumab taken ocrevu administ intraven vein infus everi month begin treatment two dose separ day singl infus everi month q ocrelizumab avail prescript accord genentech peopl may talk ms doctor take ocrevu compani expect suppli therapi avail two week around week april access medic also depend issu relat individu health insur q effect ocrevu primari progress ms oratorio studi involv peopl primari progress ms compar ocrevu inact placebo met primari endpoint show treatment ocrevu significantli reduc risk progress clinic disabl compar placebo peopl compar placebo ocrevu also reduc time requir walk feet decreas volum brain lesion q effect ocrelizumab relaps ms opera opera ii studi involv peopl relaps ms compar ocrelizumab interferon beta rebif emd serono pfizer ocrevu significantli reduc relaps rate compar rebif two year total peopl relaps ms addit ocrevu significantli delay confirm progress disabl edss scale compar rebif ocrevu also significantli reduc activ inflamm observ mri scan total damag mri scan compar rebif q individu relaps ms switch current therapi ocrevu decis whether take ocrevu made collabor ms doctor take account varieti factor includ effect therapi current use potenti risk benefit well cost lifestyl factor import question consid discuss doctor term ocrevu includ current therapi toler risk known side effect toler risk advers consequ might emerg longer term use medic choic affect abil plan becom pregnant q take anoth diseas modifi therapi ms long wait start ocrevu wash wait time current establish recommend switch anoth therapi ocrevu therefor decis wait proceed need made collabor ms doctor q potenti side effect ocrevu prescrib inform pdf ocrevu includ sever warn precaut ocrevu caus wide varieti infus relat reaction frequent itchi skin rash irrit throat flush face fever headach symptom rare case life threaten infus reaction occur frequent first infus occur hour infus precaut peopl administ steroid antihistamin infus monitor least one hour infus ocrevu increas risk infect includ respiratori tract infect herp infect ocrevu administr delay peopl activ infect vaccin need administ least week prior start ocrevu vaccin live live attenu vaccin recommend treatment b cell repopul follow treatment pml although case pml progress multifoc leukoencephalopathi seriou brain infect occur clinic trial pml observ peopl take relat medic typic symptom divers progress day week includ progress weak one side bodi clumsi vision disturb chang think memori orient person hepat b viru reactiv although case hepat b viru reactiv report peopl take ocrevu occur peopl take similar medic initi treatment ocrevu individu given blood test detect hepat b viru although long term safeti data avail medic work similar fashion medic deplet b cell long term safeti ocrevu unknown time q risk malign ocrevu may increas risk malign cancer includ breast cancer peopl take ocrevu individu use ocrevu follow standard breast cancer screen guidelin clinic trial result ongo monitor trial particip indic imbal number cancer occur individu treat ocrevu compar interferon relaps remit trial placebo primari progress trial number small know sure relat directli ocrevu imbal requir continu care observ evalu data larger number individu q ocrevu proven effect diseas modifi therapi ocrevu compar rebif interferon beta emd serono pfizer two phase iii studi total peopl relaps ms peopl relaps remit ms secondari progress ms experienc relaps ocrevu significantli reduc relaps rate two year compar rebif ocrevu compar clinic trial diseas modifi therapi q long would person take ocrevu specifi time limit take ocrevu like diseas modifi medic ocrevu would like continu person ms stabl experienc advers event new safeti issu could ascrib medic q peopl take ocrevu get special medic test monitor doctor need run blood test prior start medic test hepat b infect individu relaps ms ms doctor might like new baselin mri prior start new medic discret doctor individu use ocrevu follow standard breast cancer screen guidelin q ocrevu help mobil prevent get wors revers progress disabl base result clinic trial ocrevu like significantli revers individu disabl may help stabil oratorio trial primari progress ms treatment ocrevu significantli reduc risk progress clinic disabl reduc risk progress mean peopl take ocrevu trial less like demonstr worsen disabl peopl take placebo ocrevu also reduc time requir walk feet decreas volum brain lesion mean group peopl take ocrevu trial lower risk progress improv ft walk speed reduc volum brain lesion howev possibl predict one individu respond therapi q ocrevu reduc diseas activ relaps ms group peopl take ocrelizumab trial fewer relaps fewer new enlarg lesion mri less risk disabl worsen peopl take rebif interferon beta howev possibl predict one individu respond therapi q continu take supplement ocrevu biotin vitamin vitamin b etc ye howev essenti ms doctor know prescript counter medic supplement vitamin take q vaccin ocrevu flu shot pneumonia shot vaccin shingl individu wait week vaccin begin therapi ocrevu vaccin live live attenu virus recommend treatment ocrevu b cell repopul follow treatment individu speak doctor whether shot consid avail inactiv form q often mri ocrevu ms doctor guid often mri need revis recommend consortium ms center task forc standard mri protocol clinic guidelin diagnosi follow multipl sclerosi suggest brain mri approxim month switch new treatment routin brain mri everi month year relaps ms current recommend regard frequenc mri primari progress ms q immun system suppress compromis take ocrevu like catch ordinari infect take medic ocrevu increas risk infect includ respiratori tract infect herp infect q continu medic ocrevu ampyra baclofen bladder medic continu take ms symptom manag medic howev essenti ms doctor know prescript counter medic supplement vitamin take q need spinal tap start ocrevu q longer live home still get ocrevu live assist live facil nurs home whether live home facil affect abil ocrevu howev insur coverag may impact access medic q differ relaps remit ms secondari progress ms primari progress ms relaps remit ms rrm character clearli defin attack new increas neurolog symptom attack also call relaps exacerb follow period partial complet recoveri remiss secondari progress ms spm follow initi relaps remit cours mani peopl diagnos rrm eventu transit spm cours progress worsen neurolog function accumul disabl time primari progress ms ppm character worsen neurolog function accumul disabl onset symptom without earli relaps remiss relaps form ms phrase includ rrm well progress ms individu continu experi relaps q ocrevu like help disabl primari progress ms mild versu sever known benefit use ocrevu studi involv peopl primari progress ms includ individu age score edss disabl scale minim disabl abl walk help walker bilater crutch devic side possibl predict specif individu respond treatment q better take earlier later treat progress ms oratorio trial primari progress ms averag time diagnosi particip year known medic work peopl primari progress ms longer period time q better take ocrevu earlier later treat relaps ms gener earli consist treatment diseas modifi therapi recommend read howev yet specif known whether better use ocrevu earlier later known whether better use ocrevu diseas modifi therapi q point ocrevu work known point time ms therapi may stop work effect individu respond differ given therapi respons treatment must assess regularli ms doctor q ocrevu cost list price announc per year howev price ocrevu individu ms depend provis insur coverag degre individu elig program design assist pocket cost q nation ms societi respons post price ocrevu approv ocrevu excit mileston peopl primari progress ms encourag new option peopl relaps form diseas nation ms societi applaud genentech leadership set wholesal acquisit cost list price ocrevu per year nearli percent current market averag ms treatment continu escal price ms diseas modifi therapi creat barrier peopl ms get life chang medic action ocrevu genentech chang industri dynam peopl access life chang treatment need live best live encourag compani follow suit creat drug price trend keep patient first q health insur cover ocrevu coverag depend individu insur plan peopl qualifi genentech plan offer patient assist program genentech access solut access http www genentech access com q get inform support genentech provid help peopl gain access ocrevu physician peopl ms contact genentech inform access genentech access solut access http www genentech access com q ocrevu rituximab therapi use treat cancer ocrevu deriv rituximab rituximab ocrevu work deplet b cell howev two medic base publish report ocrevu manufactur differ rituximab ocrevu mostli human rituximab equal part mous human monoclon antibodi bind specif overlap area molecul immun b cell call cd cell also differ way rituximab ocrevu induc death cd b cell whether differ meaning term potenti effect ms term safeti difficult say time q therapi develop progress ms ye societi close watch clinic trial could lead treatment peopl progress form ms exampl posit result recent announc trial baf siponimod secondari progress ms addit studi includ ms smart trial test three therapi may nerv protect properti secondari progress ms ms societi u k sprint ms trial ibudilast oral anti inflammatori agent ongo peopl secondari progress primari progress ms thank uniqu collabor nih neuronext network medicinova nation ms societi ms stat studi get underway univers colleg london multicent trial test whether repurpos cholesterol lower therapi slow cours secondari progress ms societi provid fund societi also interest well research identifi exercis dietari approach help peopl ms live best live societi support sever clinic trial investig dietari intervent symptom manag potenti modifi diseas process q base trial result still need invest addit research progress ms ye need continu invest research find solut progress ms trial first success mani disappoint welcom develop must remain focus find better solut treat form progress ms continu leadership intern progress ms allianc fund research progress ms research program encourag compani commit develop treatment progress form ms',\n",
       " 'identif molecular target treat non small cell lung cancer nsclc chang treatment landscap diseas among commonli seen mutat alter epiderm growth factor receptor egfr chromosom transloc anaplast lymphoma kinas alk gene howev mutat braf also found nsclc braf mutat nsclc repres emerg target entiti among scenario oncogen driven nsclc anoth import brick pickax molecular wall nsclc alessandro leonetti md univers hospit parma itali colleagu wrote recent review braf nsclc braf protein kinas known play role mapk erk pathway involv cell growth prolifer surviv differenti braf mutat discov cancer greater incid certain tumor includ melanoma papillari thyroid carcinoma nsclc braf mutat gener occur exclus egfr mutat alk rearrang frequent activ braf mutat braf v e occur lung adenocarcinoma patient braf v e mutat found differ clinic paramet compar non v e mutat overal braf mutat commonli occur current former smoker braf v e mutat commonli seen light never smoker addit braf mutat includ braf v e mutat occur commonli women furthermor patient found braf v e mutat like shorter diseas free overal surviv rate relat articl bevacizumab plu erlotinib may new standard care non small cell lung cancer gefitinib plu platinum doublet chemotherapi may improv overal surviv egfr posit nsclc keynot pembrolizumab improv overal surviv non small cell lung cancer prognost impact attribut aggress histolog architectur like micropapillari one frequent associ braf v e mutat remain assess dr leonetti colleagu wrote review target braf two potent braf inhibitor vemurafenib dabrafenib approv u food drug administr fda treatment advanc metastat melanoma v mutat howev major patient treat inhibitor eventu develop resist drug research explor addit mek inhibitor overcom acquir resist braf inhibit melanoma specif two phase trial combin braf mek inhibitor untreat diseas shown respons rate median overal surviv approach year accord dr leonetti colleagu given strong result observ braf inhibit treatment braf mutat metastat melanoma perspect translat success braf inhibit tumor type harbor braf mutat rais interest clinician howev result differ solid tumor type mix emerg posit data nsclc result basket studi look braf v e non melanoma show among patient nsclc object respons patient reduct tumor size similarli retrospect studi vemurafenib treatment patient braf mutant nsclc show patient v e mutat diseas respons rate',\n",
       " 'hello diagnos year current gilenya far pretti good rebif two half year simpli got tire give shot day week next day feel like flu gilenya come pill one time day fear make sure rememb take day take two one day monitor first dose drop heart rate blood pressur experi lot side flare up difficult experi lot stress life basic think trial error find work best gilenya work would jump next option pass infus take much time small children lot year use gilenya issu good luck whatev choos rememb nobodi find work best good luck god bless',\n",
       " 'final decad th centuri approach congress unit state made special eff ort acceler medic research recogn paramount import neurolog diseas design decad brain purpos funnel fund time talent treatment ill affect nervou system multipl sclerosi benefit enorm eff ort explos drug trial occur period mani decad advanc sprang incred power new technolog sophist techniqu ad mri allow detect ms plaqu earlier accur ever led rapid diagnosi diseas averag time person first symptom ms definit diagnosi year use mri technolog reduc time six month plaqu caus symptom could often seen immedi power rapid painless mri scan provid inform incalcul bless doctor patient alik studi seri mri scan time show ms plaqu actual develop permit research track burden diseas total plaqu area individu patient time mri scan gave research faster sophist way test drug treat ms benefit new drug seen mri scan seen patient research treatment ms thu greatli acceler diseas yield secret painstak laboratori work research scientist laboratori work ms show us mani essenti aspect diseas key culprit ms white blood cell call cell although mani detail sequenc event process still remain learn know cell becom activ leav bloodstream enter brain tissu damag myelin fatti tissu insul protect nerv fiber cell identifi character detail recent discoveri also emphas myelin target destruct ms often underli nerv cell neuron axon damag well thought account perman disabl ms caus american led project discov decod gene human bodi focus attent role gene mani diseas monument studi peopl ms includ ident twin rear mile apart differ famili clearli demonstr gene play role determin get ms although appear singl ms gene seem someth fundament us e someth gene make one person suscept develop ms anoth yet anoth clue caus diseas cours sophist technolog limit medicin quantum leap comput well decad brain comput scientist built inform superhighway wove internet faster better commun data analysi brought ms doctor research world togeth increasingli power coalit larg databas assembl track analys thousand patient histori clarifi diseas variat respons treatment characterist pattern ms began emerg ms clinic research laboratori link share evalu new find symptom ms never amen therapi tizanidin introduc manag spastic use intrathec baclofen pump sever spastic becam wide avail deliv medic directli spinal cord reliev intens muscl stiff ness spasm improv made medic bladder manag e g tolterodin fatigu modafinil treatment sexual problem long neglect aspect ms took major leap forward introduct sildenafil better known viagra similar medic gabapentin introduc treat mani pain symptom rang sever face pain trigemin neuralgia burn pain limb drug develop rapid pace research also reveal mani way ms alter mind slow think affect memori new drug donepezil use treat problem alzheim diseas test ms refin rehabilit exercis physic therapi also benefit peopl ms mani new treatment markedli enhanc way physician calm symptom improv qualiti life year research drug treat actual diseas symptom came fruition beta interferon b betaseron introduc beta interferon avonex introduc mid glatiram acet copaxon arriv late mitoxantron novantron approv treat ms especi use slow chronic progress form diseas none therapi abl retard two year new centuri variat beta interferon rebif also introduc cours ms could alter reduc diseas activ prevent mani attack nataluzimab tysabri first whole new class drug call monoclon antibodi significantli suppress relaps ms sever larg trial treatment began widespread use delay procedur develop minim seriou infect patient develop treatment drug progress thu remark throughout histori ms untreat diseas one decad research develop drug suppress attack alter cours ms mani drug test includ oral cladribin may well first oral diseas modifi therapi approv ms two new monoclon antibodi rituximab rituxan alemtuzumab campath destroy immun cell regul ms attack fingolimod drug block cell enter nervou system studi clarifi valu treatment whatev ultim role nearli drug test histori ms still written accomplish fight ms last decad preced centuri let us hope new centuri see victori sourc loren rolak md willek van eeckhoutt ireland multipl sclerosi unauthor use duplic materi without express written permiss blog author owner strictli prohibit excerpt link may use provid full clear credit given willek van eeckhoutt ireland multipl sclerosi appropri specif direct origin content',\n",
       " 'new fda approv zykadia ceritinib alk posit nsclc think poor choic initi treatment fda approv new therapi approxim patient nsclc molecular marker known alk rearrang cancer journey diagnos treatment cancer type lung cancer diseas learn target therapi target therapi alk target therapi patient forum septemb speaker highlight jame stevenson md grace excit continu build faculti agenda upcom target therapi patient forum septemb see inform present speaker highlight today introduc jame stevenson md cancer journey treatment cancer type lung cancer diseas learn target therapi imprecis medicin keytruda pembrolizumab chemo pd l nsclc readi prime time let start say fan immun checkpoint inhibitor keytruda pembrolizumab consid new standard care cancer journey diagnos treatment cancer type lung cancer diseas learn first line treatment target therapi chemotherapi immunotherapi immunotherapi wrong choic lung cancer patient amidst glow report immunotherapi lung mani cancer would understand patient physician tempt rush toward priorit immunotherapi first treatment strategi pursu fact cancer journey treatment cancer type lung cancer diseas learn target therapi first line treatment symptom second line treatment death pseudo progress know cut loss immunotherapi among mani novel concept manag immunotherapi potenti pseudo progress unusu phenomenon patient scan cancer journey diagnos treatment cancer type lung cancer diseas learn first line treatment target therapi second line treatment immunotherapi view commun forum local therapi metastat lung cancer hi grace member grace happi present partnership swedish cancer institut local therapi metastat lung cancer cancer journey diagnos treatment cancer type lung cancer diseas learn lung cancer drug target therapi alk target therapi egfr target therapi ro procedur treatment chemotherapi tumor marker test target therapi investig agent immunotherapi radiat therapi non small cell lung cancer progress tarceva neg progress year tarceva tissu biopsi show neg suggest experi next step onc suggest move afatinib opdivo pdl test cancer journey treatment cancer type lung cancer diseas learn lung cancer gener lung cancer target therapi egfr target therapi molecular test immunotherapi non small cell lung cancer vaxira stage nsclc anyon inform obtain use vaxira cuban drug stage advanc nsclc sure us citizen still travel cancer journey treatment cancer type lung cancer diseas learn angiogenesi rd line beyond target therapi investig agent non small cell lung cancer tagrisso acquir resist tarceva wife come long way stage iv lung cancer sinc develop acquir resist tarceva gene sequenc biopsi cancer journey diagnos treatment survivorship cancer type lung cancer diseas learn lung cancer target therapi egfr target therapi non small cell lung cancer',\n",
       " 'hi quick question usual long patient need wait resum tagrisso lung radiat day week week thank kkh diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'weather conduc ride late cold windi scatter snow everi three four day get one pretti good ride mile includ short hill mostli flat trail keep weight work twice week yoga twice week occasion walk ellipt session though lot go realli need better weather occasion attend men ms group meet went one week ago watch one guy diagnos year ago declin rapidli aggress case ms start rituxan sometim last year disabl alreadi diminish nearli wheel chair bound walk cane impress recoveri ever person wit readili emphas push hard physic person notic lot small improv also taken togeth improv strength balanc endur realli hope ocrevu rituxan therapi work guy later larri',\n",
       " 'bizarr exampl work crizotinib xalcori billion usd cancer drug start oxindol sutent like lead c met kinas sugen pk properti lead terribl inject site precipit unpredict metabol new aminopyridin lead came ht kalamazoo pharmacia bought sugen compani eventu co crystal lead activ site c met combin structur info oxindol seri help dramat improv aminopyridin seri time lead fairli potent good pk properti poor target select consid plu compet second seri exquisit c met select eventu shelv pfizer pharmacia merger origin research team mostli laid pfizer transfer san diego former agouron project manag stay project languish eventu shelv amid post merger chao later biologist pfizer tri find medchem support alk sinc bind site c met alk somewhat similar c met seri screen bingo crizotinib taken clinic without modif sinc anim pk data potenc alk good poor select activ c met consid plu perfectli ration old fashion structur base drug design done perfectli ration way wrong kinas repurpos smart biologist take advantag target activ oh c met project manag pfizer took credit republish research sugen colleagu without put name public enorm promot becam pfizer fellow went start biotech compani',\n",
       " 'flex sig last tuesday got result back infect cmv etc howev activ coliti despit therapeut level humira system result said diffus chronic activ coliti mild activ surfac eros doctor initi recommend remicad sinc short initi respons humira howev verifi insur remicad simponi entyvio cover said lt look like cimzia thing cover hope know week common drug use never heard side effect anyon experi feel like go round round get nowher',\n",
       " 'seen anyth post durvalumab wonder look right place site immunotherapi well side effect would love hear infus oncologist put hold rash clear seem next start date end nov hope rash return',\n",
       " 'alectinib tyrosin kinas inhibitor tki notic small print ingredi list protein powder amino acid tyrosin mg per serv yike deliber ingest strive inhibit differ thing needless say come screech halt drink protein shake question avoid food ad tyrosin tki therapi thank alk alectinib sinc april prior month crizotinib chemo prior drug hand list right reason chang med crizotinib alectinib size progress primari lesion later left upper lobe discoveri brain met stereotact lung radiat oct stereotact brain radiat jan resolv met lung lesion stabl date howev size reduct sinc alectinib quarterli ct unabl tell lung lesion scar tissu diagnos age feb stage iv nsclc met never smoker healthi [except hypothyroid year synthroid] activ nd hand smoke asbesto radon alway organ white femal etc etc etc',\n",
       " 'thank everyon kind repli help know other gone know like eyesight emot point view spoke gp monday sign coupl week get anxiou work plu hope current haemorrhag drain bit second lot laser today surgeon unabl complet session said view quit hazi place recent bleed least manag said could also see laser last week look good current bleed delay next laser week allow hope clear said know stage would need vitrectomi suppos depend current bleed clear assur second time go lose sight said vision good retina look healthi undamag asid neovascularis reassur think entir go convinc told stabl appar version condit call florid happen rapidli sinc last screen septemb switch vegetarian vegan diet bg control gener health run improv rapidli result feel super healthi energis seem sad consequ happen dsn told carri lifestyl level control better long term follow appoint eye clinic next friday see thank everyon',\n",
       " 'busi wire fda approv atezolizumab combin genentech member roch group today announc u food drug administr fda approvedatezolizumab tecentriq combin avastin bevacizumab paclitaxel carboplatin chemotherapi initi first line treatment peopl metastat non squamou non small cell lung cancer nsclc egfr alk genom tumor aberr tecentriq regimen demonstr signific surviv benefit initi treatment metastat non squamou non small cell lung cancer said sandra horn chief medic offic head global product develop today approv support combin approach tecentriq lung cancer vision develop medicin improv outcom patient complex diseas approv base result phase iii impow studi show tecentriq combin avastin chemotherapi help peopl live significantli longer compar avastin chemotherapi median overal surviv [os] versu month hazard ratio [hr] percent ci p intent treat wild type itt wt popul safeti profil tecentriq combin consist observ previou studi genentech work fda postmarket commit pmc better understand character potenti effect tecentriq relat anti drug antibodi ada neutral antibodi nab across studi analysi ada impow studi show impact efficaci tecentriq tecentriq also approv fda treat peopl metastat nsclc diseas progress follow platinum contain chemotherapi progress appropri fda approv target therapi tumor egfr alk genet alter qualifi genentech offer patient assist program peopl take tecentriq genentech access solut doctor contact genentech access solut read',\n",
       " 'new england journal medicin jean charl soria md phd gustav roussi cancer campu univers pari sud colleagu phase iii flaura trial shown signific progress free surviv benefit third gener epiderm growth factor receptor egfr tyrosin kinas inhibitor tki osimertinib tagrisso vs standard egfr tki previous untreat advanc egfr mutant non small cell lung cancer nsclc osimertinib select inhibit egfr tki sensit egfr resist mutat studi detail doubl blind trial patient site countri advanc egfr exon delet l r mutat random decemb march receiv osimertinib mg daili n standard tki treatment consist gefitinib iressa mg daili erlotinib tarceva mg daili n standard tki select trial site except unit state site use erlotinib random stratifi accord tumor egfr mutat statu exon delet l r race asian non asian read perspect studi suresh ramalingam md treatment continu diseas progress unaccept side effect withdraw consent treatment beyond diseas progress permit set continu clinic benefit protocol amend allow patient standard tki group cross osimertinib blind confirm diseas progress post diseas progress document posit mutat statu primari endpoint investig assess progress free surviv osimertinib show efficaci superior standard egfr tki first line treatment egfr mutat posit advanc nsclc similar safeti profil lower rate seriou advers event jean charl soria md phd tweet quot osimertinib vs standard tki group median age year vs femal asian white vs never smoker one patient world health organ perform statu vs adenocarcinoma histolog metastat diseas vs viscer metastas vs central nervou system cn metastas exon delet l r mutat standard tki group patient receiv gefitinib receiv erlotinib progress free surviv data cutoff median durat total treatment exposur month osimertinib group vs month standard tki group patient continu receiv studi treatment median progress free surviv month osimertinib group vs month standard tki group hazard ratio [hr] p consist benefit osimertinib observ across predefin subgroup includ asian hr confid interv [ci] non asian patient hr ci patient exon delet hr ci l r mutat hr ci accord smoke histori hr ci never smoke hr ci median progress free surviv vs month among patient cn metastas hr p vs month among without cn metastas hr p object respons observ vs patient odd ratio p median durat respons vs month data overal surviv immatur interim analysi matur surviv rate month vs hr p nonsignific interim analysi diseas progress osimertinib group standard tki group receiv first subsequ anticanc therapi standard tki group receiv osimertinib osimertinib em egfr em mutat lung cancer osimertinib significantli improv progress free surviv vs standard efgr tki treatment benefit observ across examin subgroup includ among asian non asian patient accord egfr mutat type advers event advers event grade occur osimertinib group vs standard tki group common osimertinib group decreas appetit chang qt interv observ vs patient fatal case torsad de point prolong qt interv either group interstiti lung diseas report vs seriou advers event occur vs seriou advers event includ qt prolong one osimertinib patient interstiti lung diseas six osimertinib four standard tki patient advers event led dose interrupt vs dose reduct vs discontinu treatment vs advers event led death patient osimertinib group pneumonia respiratori tract infect cerebr infarct myocardi infarct pulmonari embol intestin ischemia patient patient standard tki group sepsi patient pneumonia endocard cognit disord pneumonia peripher arteri occlus dyspnea hemoptysi diarrhea gastrointestin hemorrhag respiratori failur circulatori collaps death specifi none death osimertinib group one death standard tki group due diarrhea consid possibl relat studi treatment investig conclud osimertinib show efficaci superior standard egfr tki first line treatment egfr mutat posit advanc nsclc similar safeti profil lower rate seriou advers event disclosur studi fund astrazeneca full disclosur studi author visit www nejm org refer soria jc ohe vansteenkist j et al osimertinib untreat egfr mutat advanc non small cell lung cancer n engl j med relat articl osimertinib new standard care initi treatment egfr mutant nsclc suresh ramalingam md dr ramalingam professor hematolog medic oncolog emori univers school medicin winship cancer institut atlanta mutat epiderm growth factor receptor egfr gene discov mutat local commonli',\n",
       " 'hi peopl curiou told begin tysabri administ monthli other six weekli infus wether find start feel wors come week four five mayb reason monthli still feel wonder drug mani say least function unlik tri gilenya',\n",
       " 'hi nell worri chemo imag grandmoth underw treatment throat cancer diagnos stage iv see point treatment someth chang sheer determin set start chemo know expect urgenc get chemo start right away due lymph node involv port went next day blur medic team great job get us prepar side effect minim tumor start shrink pretti quickli first dose carbo alimta keytruda take oral target therapi feel much better whatev decid group help pull done michel',\n",
       " 'atlanti wonder april get ocrevu ms diagnos avonex copaxon member ms board sinc repli quot follow user say thank howi jeani z jendi sunshin',\n",
       " 'ok thank make feel littl better remicad ask gi thing mention humira go see come wednesday far crohn thing seem like go disabl thing lower stress level read work high stress job manag might consid retir anyon got thought remicad versu humira get high stress environ',\n",
       " 'nov melissa wrote husband stage four nslc cure chemo qualifi last night said feel death take bodi said think make april still look sick possibl pleas read thru post chucksan wife experi wife remiss sinc last nov year stage nsclc squamou cell aug doctor said mayb month uncessess chemo doubl treatment went clinic trial jan year later fda approvedimmunolgi drugcal opdivo nivolumab two other keytruda terentriq new type drug mani case offer improv possbl remiss new drug time test outlook stage lung cancer improv dramat previou year hope get second opinion happi oncologist wife new doctor knowledg access clinic trial drug doctor local smaller cancer clinic look best lung cancer treatment closest larg metro citi cancer clinic hopsit mani connect med school best',\n",
       " 'hi mom diagnos stage iv nsclc egfr earli decemb januari start iressa fine month mom start show terribl stomach symptom first thought side effect iressa symptom got bad mom unabl eat blood test show elev liver enzym iressa stop found mom esophag thrush h pylori infect due prolong steroid use mom quadrupl therapi omeprazol amoxicillin clarithromycin dyflucan get much better iressa almost month part treatment mom omeprazol twice day mom onc say iressa work mom take ppi twice day mom gi doctor said could attempt stop ppi antibiot done said gastriti usual take anoth week complet resolv gi doctor said could tri decreas ppi day take pepcid twice day mom onc say mom need stay omeprazol twice day recommend mom tri alimta interim gastriti resolv look inform take tki omeprazol peopl experi alimta pemetrex term side effect account experi would help',\n",
       " 'md prof g drk resend email brazilian associ multipl sclerosi abem health initi msbrain health possibl adopt countri use cladribin altern shortag dmt mani citi hope soon get touch face brazil found similar problem peru',\n",
       " 'hi wonder anyon take fingolimod kind side effect particip clinic studi right diagnos month ago rrm take pill month notic hair fall much frequent brought neurologist said side effect curiou anyon els experienc issu besid stomach bowel problem pretti common let know thought',\n",
       " 'read studi claim botox work treatment depress posit first doubt efficaci well come hang hollywood pretti sure shit werkin lot depress frozen actress realli smile ok basic forgotten ms last month get certifi dive hang friend explor basic best time ever bodi love sun love swim ocean make hand feel normal boat mean run get tingli leg yay back realiti got word doctor white blood cell start come aliv mean b cell wake start eat brain time go back vampir land get infus latest ms drug news rant drug call rituxan around year highli effect safe blood cancer wide prescrib autoimmun diseas long time insur want cover month due search infus center new drug call ocrevu ocrelizumab first heard dinner doctor nanci davi race eras ms peopl herald ocrevu closest thing cure ever super excit last year fda approv march th public use read bunch articl paper blog thought rituxan first drug work b cell ocrevu second ms drug work cell honestli realli know mean illustr similar drug manufactur compani rituxan never put clinic trial ms rituxan came patent compani allow start make gener version price went happen genentech start develop ocrevu compani make drug basic mechan action diseas fair rituxan chimer molecul mean dna part human part anim mous peopl could allerg reaction mous part drug reaction usual happen first coupl time get monitor give iv steroid case ocrevu human believ better toler one ocrevu longer year peopl develop cancer tumor rituxan increas cancer peopl take year stick safe drug alreadi work rather abandon start scratch cuz money last infus got bill insur want pay medicin use label doctor wrote letter say import receiv time went back forth final agre pay time next time suppos get week two insur cover get pharmaci doctor work hospit give medicin bought pharmaci want doctor give infus cours would pay pocket infus last hour hook iv machin go twice next coupl week bad reaction happen shit show team surround deal order insur cover bill go infus center mayb hour away stranger without doctor cuz money everyon want bill asshol american medic industri complex tell next time switch ocrevu new breakthrough drug breakthrough mechan year old drug expens higher cancer rate cuz money link http www healthnewsreview org fake breakthrough fake news one physician research takeaway news coverag ms drug ocrevu http www wheelchairkamikaz com lead ms clinic issu cautionari html appar europ get rituxan ms pretti freeli way less expens someon social health care countri need marri next month time next infus sweden leader think prescrib rituxan anyon cherri blossom marri thought noth would happen get medic hamster wheel live life anyon eat healthi stay drug never know go happen ms anyway mayb super mild form drug noth anyway mri give radiat drug throw everyth wack sure denial fda approv form treatment studi will particip live sea play music go dive swim eat healthi happi sound like much better treatment need rememb terri wahl protocol modifi paleo diet exercis etc ditch drug treat diseas lifestyl chang damn hard though well awhil fell mayb worth anoth go finish first clinic trial confirm plan improv mood cognit function depress say anyth diseas progress mobil though link http wwwmsviewsandrelatednew blogspot com multimod nonpharmacolog html utm_sourc feedburn utm_medium feed utm_campaign feed blogspot fygjv stu view news well thought thing drug futur leav move xx',\n",
       " 'hi larri husband start tagrisso today alreadi chemo radiat summer immunotherapi stage stop hope help side effect wife drug help confus start happen',\n",
       " 'hi adam follow past two year live palo alto son diagnos great remicad built antibodi start entyvio load phase sure want go wonder uc manag lialda alon want add drug frighten want stay drug want either agre stress huge need get colleg concern long term affect med say rather colon obvious issu strict diet tough colleg student ye drink alcohol feel dr young stanford best ucsf thank inspir',\n",
       " 'hey guy flare back june due antibodi entyvio gotten mg bump back mg start taper august current mg taper slower time mg week howev feel like realli harder time time around also think thyroid may hair fall profus tongu swollen normal regular period day late thing like fatigu crossov symptom end need endocrinologist ask pcp gi referr also think would benefit yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wk minor flare august flare sinc oct acut pancreat mesalamin allerg humira start pred bridg still entyvio start flare wors right mg pred',\n",
       " 'thank steff tom mom non small cell adenocarcinoma start alimta carbo keytruda next week still wait gene test come back target therapi may still option happi know standard practic still feel like research clinic trial special food eat someth help go hard sit back let oncologist follow plan wait see happen doctor answer goal treatment well respond toler treatment mention second opinion consult research hospit ego kick blew understand goal treatment slow growth reduc cancer spread gain month life etc understand thank',\n",
       " 'hi everyon realli big deal progress noth tea sympathi far worri deafen silenc ocrelizumab ocrevu talk neuro let know know come assum approv medic get use idea someth progress cheer dave',\n",
       " 'leav lung cancer awar month thought might like review lung cancer headlin seen obr far importantli perhap controversi juli receiv anoth draft recommend u prevent servic task forc uspstf screen time lung cancer aim primarili heavi smoker adopt standard care medic practic peopl risk annual low dose comput tomographi ct screen could save live find lung cancer sooner still treatabl without controversi read find pipelin hit talk drug pipelin lung cancer pd pd l next gener immunotherapi merck mk bristol myer squibb nivolumab roch mpdl class compound design disabl program death protein call pd pd l prevent immun system spot attack cancer cell european cancer congress ecc present septemb earli stage trial patient non small cell lung cancer nsclc whose tumor treat mpdl saw tumor shrink respons rate smoker even encourag compar patient never smoke roch pd l inhibitor call potenti game changer lung cancer first target drug show activ difficult treat group smoker non smoker world confer lung cancer wclc octob bristol myer squibb releas addit surviv data earli stage studi pre treat patient nsclc nivolumab show extend live lung cancer patient forti two percent treat patient aliv year two year merck mk show posit result earli data small trial also present wclc patient studi whose cancer stop respond earlier round treatment immun system respons mk patient experienc tumor shrinkag august eli lilli co said necitumumab imc f combin standard chemotherapi agent extend overal surviv late stage studi patient squamou form nsclc spread part bodi compani plan seek u approv necitumumab first line treatment lilli ramucirumab improv surviv late stage trial stomach cancer late stage trial lung cancer ariad ap good chanc approv alk driven lung cancer novarti two promis new compound auy ldk might also treat alk mutat lung cancer list lung cancer therapi pipelin end screen risk smoke account lung cancer evid year annual screen peopl histori smoke might save live juli uspstf recommend current former smoker histori smoke pack day year well quit within last year get annual screen low dose comput tomographi ct expert said annual death lung cancer could avoid guidelin adopt task forc weigh benefit earli cancer detect risk patient risk includ exposur radiat ct scan number fals posit scan might turn could lead overtr patient expert also concern screen recommend might send wrong messag peopl e okay smoke septemb two new studi publish new england journal medicin made good case task forc recommend research found annual lung cancer screen low dose ct scan could success detect malign tumor spread part bodi annual screen three year period use ct scan caught earli stage lung cancer chest x ray improv abil accur detect cancer year year current draft recommend sync american societi clinic oncolog asco nation comprehens cancer network nccn organ recommend lung cancer screen low dose ct scan risk sinc may afford care act play medicar insur would cover scan elig patient without co pay deduct public comment period end august final recommend task forc expect time e cigarett kid fda twice mani u middl high school student use electron e cigarett mimic tradit cigarett deliv nicotin vapor year center diseas control prevent cdc said septemb govern report warn increas use hookah cigar e cigarett yet subject fda regul flavor like fruit candi gateway young peopl lifelong addict use stronger tobacco product public health threat seen troublesom uspstf recommend august physician counsel teen adolesc danger tobacco smoke routin offic visit anti smoke advoc public health group said fda move fast enough issu regul addit tobacco product air could kill anoth carcinogen offici identifi lead caus lung cancer year air breath octob world health organ offici classifi air pollut human carcinogen risk said breath second hand smoke air pollut would classifi among group human carcinogen cancer caus substanc like tobacco smoke asbesto ultraviolet radiat news report came around world year old girl jiangsu provinc youngest person record china diagnos lung cancer countri air pollut blame culprit fda activ let forget sever fda approv year lung cancer boehring ingelheim gilotrif afatinib approv juli patient late stage metastat nsclc whose tumor express specif type epiderm growth factor receptor egfr gene mutat detect fda approv test may coba egfr mutat test roch becam first fda approv companion diagnost detect egfr gene mutat intend use tarceva erlotinib roch drug expand use first line treatment patient nsclc whose cancer metastas egfr gene mutat',\n",
       " 'hello ive ms year offici new consult believ show syptom year diagnosi ive inject bad side effect im tecfidera moment use flush wasnt much issu ms control could still anyth want ive stop kickbox im ive relaps nerv pain fatigu emot stuff etc ms doctor advis consid chang medic option firstli stay drug isnt good doctor mention aubagio gilenya lemtrada mavenclad two tablet two infus ive told consid chang ive tri research would best honest im total confus anybodi give advis medic side effect etc would grate thank read post',\n",
       " 'lorri similar journey husband also lepto finish wbr puls dose tarceva start intrathec chemo depocyt friday mind tell kind chemo mom best wish mom emili',\n",
       " 'g edan depart neurolog chu renn renn franc two contrast treatment regimen ms induct versu escal rational behind escal therapi treatment start safe drug move aggress one ongo treatment fail escal approach interferon beta glatiram acet teriflunomid bg regard first line drug immunosuppress mitoxantron natalizumab fingolimod alemtuzumab ocrelizumab second line one intens immunosuppress autolog bone marrow transplant high dose cyclophosphamid third line one key success escal therapi defin upfront patient exact suboptim respons threshold next level therapeut option introduc given immunosuppress current avail present potenti seriou side effect induct strategi gener reserv patient activ aggress diseas patient acknowledg risk earli disabl neurolog function lost cannot regain diseas inher risk assum outweigh associ use power immunosuppress treatment strategi involv use immunosuppress minimum amount time need gain adequ control diseas activ diseas control achiev treatment switch mainten therapi better toler drug randomis studi demonstr induct mitoxantron follow mainten treatment afford better diseas control monotherapi interferon beta natalizumab also effect propens result rebound inflammatori diseas activ withdraw recent mere day cours intraven perfus alemtuzumab found bring long term clinic benefit earli relaps ms patient approach may use conserv mean use highli effect therapi whilst minimis exposur attend safeti risk ___________________ disclosur dr edan report grant person fee bayer merck teva pharma novarti person fee biogenidec sanofi lfb',\n",
       " 'gilenya made feel amaz techfidera howev agre stop good luck sure make best choic x',\n",
       " 'anyon els gain weight gilenya thank respons realli appreci inform med help know everyon differ help thank',\n",
       " 'lol go give talk american healthcar peopl seem go er constantli get c diff infect c diff infect board american never case c diff life ye stool cultur done everi time hospitalis incident visit e first time year diagnosi carri terrifi social medicin carri get vedolizumab infus safe knowledg civilis system treat whenev fall ill matter littl money call progress edit sorri lost temper bit mean tar american brush know mani reason peopl terrifi bogeyman simpli struggl get best care system like struggl mine post edit nicecupoftea gmt',\n",
       " 'think start chariti reason idea pay cladribin money rais use support ms research project chariti could bypass ineffici say ms societi spend larg proport money administr',\n",
       " 'ocrelizumab revers ocrelizumab therefor would need confid diagnosi would test wait result',\n",
       " 'well inflectra biosimilar remicad shrug left side coliti dx current inflectra imuran mg saccharomyc boulardii x day wheat free g lialda month caus migrain stop work budesonid mg week noth mg humira weekli week develop antibodi',\n",
       " 'mous dr ocrelizumab show reduct possibl infect compar say dmt copaxon copaxon better protect without infect miss someth biotin polysaccharid psa gut bacteria',\n",
       " 'american societi breast surgeon asbr week releas recommend genet test hereditari breast cancer societi say genet test made avail patient person histori breast cancer contrast guidelin nation comprehens cancer network nccn recommend test hereditari mutat breast cancer patient depend varieti factor includ famili medic histori age diagnosi ancestri peopl receiv breast cancer diagnosi asbr recommend follow nccn guidelin test support new asbr guidelin contend follow narrow guidelin test breast cancer patient lead patient hereditari mutat miss howev other express concern new guidelin could lead overtreat whether increas screen would save live realli unknown oti brawley john hopkin univers baltimor told washington post known increas cost pretti assum increas number women get prophylact surgeri shrink dispar african american like die cancer white american gap narrow accord feb report american cancer societi ac black men percent higher risk death cancer white men excess risk fallen percent excess risk fell percent percent black women period j leonard lichtenfeld act chief medic offic ac explain npr declin lung cancer due fall smoke rate african american play major role mortal improv say smoke decreas dramat black commun fact good news told npr immunotherapi glioblastoma trial test immunotherapi patient recurr glioblastoma found start checkpoint inhibitor keytruda pembrolizumab prior surgeri diseas live longer receiv drug surgeri longer typic patient recurr glioblastoma result publish feb natur medicin patient random receiv keytruda surgeri median length surviv day compar day patient start keytruda surgeri continu drug surgeri complet previou attempt use checkpoint inhibitor patient glioblastoma larg unsuccess research hypothes give drug pre surgeri set tumor still present allow activ immun cell associ tumor frederick lang md anderson cancer center houston involv studi told stat studi realli infus hope back field checkpoint inhibitor may effect use correct way',\n",
       " 'thank jim hope get month tagrisso kempten',\n",
       " 'brother stage lung cancer lung liver spine rib shoulder metastis spread usallytoo latefor surgeri radiat exact chemo long import know might better target chemo immunolog drug opdivo keytruda tercentiq give us much detail info citi treat top cancer center hospit local oncologuist wife stage squamou cell one lung spine rib lymph node brain year ago month chemo radiat help got clinic trial drug opdivo nivolumab two year later fda approv anoth month remiss ned evid diseas month total month origin diagnosi back pain new drug lead edg cancer posit respons extend lfe even remiss wife patient good result hope brother must act make sure top cancer clinic usual larg metro citi also oncologist special lung cancer sometim ask find best lung cancer doctor ask second opinion great idea reason wife still aliv first doctor gener medic oncologist access clinic trial drug drug also test along second drug combo opdivo epacadostat also keytruda epacadostat drug also quit efect stage melanoma areoth combosb test encourag result see post info wife battl lung cancer sure brother bio marker aka dna mutat test test see pd pd l let oncologist know drug might work best import oncologist done test get second opinion oncologist never heard epacadostat need chang realli question radiat stage best chuck',\n",
       " 'breakfast scientif session vitreoretin lymphoma dean eliott diabet retinopathi current investig therapi allen ho mysteri anti vegf switch case mysteri case david chow anti vegf switch case keyvan koushan anti vegf switch case geoff william anti vegf switch case geoff william anti vegf switch case keyvan koushan mysteri case john galic mysteri case sohel somani co develop accredit symposium multidisciplinari care diabet macular edema bayer sponsor symposium co develop bayer plan achiev scientif integr object balanc multidisciplinari care diabet macular edema david maberley alic cheng peter j lin refresh break scientif session ocular manag trauma dean eliott medic manag pvr dean eliott individu approach post traumat exploratori vitrectomi children young adult theodor stappler molecular design novel ocular tamponad theodor stappler panel discuss manag complex retin detach',\n",
       " 'compars treatment low cost antivascular endotheli growth factor vegf drug bevacizumab avastin expens altern aflibercept eylea ranibizumab lucenti cost effect diabet macular edema new studi found aflibercept ranibizumab time expens bevacizumab approv treatment cancer frequent repackag label treatment retin vascular diseas diabet macular edema dme caus swell retina macula abnorm blood vessel growth common caus vision loss among peopl diabet retinopathi vegf stimul growth abnorm blood vessel anti vegf drug administ intravitr inject',\n",
       " 'minnietoti constant fatigu issu us chronic diseas gi pcp told caus blood work look good mean feel great bodi take time recov sinc flare take get back normal hope also keep mind mental fatigu issu well blood test confirm bad wors physic fatigu best thing done recent month ago start see therapist first question take long decid need help said chronic ill caus anxieti depress host issu make diseas wors bless help get current ordeal encourag file long term disabl make need drastic discuss help look thing differ import hope help surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia fail remicad cimzia methotrex humir mp entyvio g medic stelara verapamil quinipril labetalol clorithidon atorvastatin alluporinol elliqui xanax er',\n",
       " 'year old husband diagnos stage octob two round chemo lobectomi rib resect remov cm upper right lobe tumor recov well surgeri follow radiat complet april ct scan radiat discov tumor adren gland adrenalectomi june next ct april came back good recent octob show lesion spleen one lymph node lung pet scan confirm activ doctor say biopsi need suggest treatment carboplatinum almita keytruda tp stk mutat hope work seen top oncologist univers chicago suddenli feel lot answer consid second opinion advic',\n",
       " 'thank janin mom current hospit recov slowli pneumon discharg day soon lung resolv still curiou doctor forum opinion term next treatment option e g resum tagrisso lower dose previous mg daili week tri one treatment propos e g afatinib immunotherapi other sure evidenc base treatment choic moment want get good opinion prior discuss option mom primari oncologist side note recent brain mri show signific reduct tumor lepto diseas month start tagrisso numer spot spot also asymptomat term headach brain symptom sinc start treatment given worth rechalleng tagrisso lower dose look forward hear back thank advanc best hain',\n",
       " 'hi cathi betaseron inject tire side effect lump inject sight anyway next appt neurologist go ask ocrevu whether fit best luck decis',\n",
       " 'diagnos w sever ra gener practition discov blood test alway common well mtx pill wk yr arava daili also enbrel humira actemra orencia zeljanz one work final start remicad infus first day slept hr day later chang yesterday miracl day one singl pain flare up pain free omg happi cri today good yesterday hope good luck rest',\n",
       " 'diagnosi chang coliti crohn happen quit regularli done amazingli well consid wrong diagnosi medic pretti much useless think certainli made right decis progress humira remicad would first choic humira proven effect therapi hard say done well first dose humira experienc syptom might need time drug reach strong therapeaut level like need stay cours wait awhil longer thing improv come week need see gi like updat bloodwork diagnost done meantim tri switch low residu diet give thing chanc calm thing get realli bad gi might suggest short cours prednison patch better assess humra takn hope feel better soon',\n",
       " 'bethani may want look tessalon perl prescript cough suppress mom took stent trachea made cough like crazi help quit bit recal make sleepi far treatment goe mom first round treatment week lobectomi month diagnosi mention everyon differ wait long take ra med system start surgeri recurr began treatment week two test came back except pet side effect everyon differ first time mom platinum base chemo radiat weekli felt pretti good throughout entir treatment typic lack energi also realli bad acid reflux control cocktail med recurr carbo alimta keytruda immunotherapi everi week first session fine second session start typic side effect chemo even though second bout chemo much tougher made minim help continu main caregiv dad disabl keytruda okay despit short breath may may caus keytruda side effect itchi skin use counter excema cream help bit know help thought share take care steff',\n",
       " 'home ms inform public ms research updat zinbryta daclizumab zinbryta daclizumab updat main articl introduct fda approv medic experiment medic new direct ms research close note approv diseas modifi therapi ms pdf refer fda approv medic new data withdrawn market compani biogen abbvi mg given via subcutan inject monthli approv rm voluntarili withdrawn market march previou ocrevu next tecfidera earli march biogen abbvi announc voluntari worldwid withdraw zinbryta relaps ms move came european medicin agenc rais new safeti concern relat report inflamm brain surround tissu inflammatori enceph meningoenceph among peopl take immun modul therapi previous identifi risk medic gener reserv use peopl experienc inadequ respons two ms medic minim potenti confus disrupt care individu take zinbryta fda work close medic manufactur ensur medic withdraw market ms research updat publish manufactur zinbryta plan medic avail need april peopl take zinbryta told contact doctor instruct stop zinbryta switch medic immedi tell new unexplain symptom withdraw zinbryta underscor fact clinic trial matter larg rigor perform cannot identifi safeti issu may emerg medic move widespread use follow approv fda regulatori agenc countri time clinic trial reveal safeti consider prompt medic fda approv indic note gener use patient satisfactori respons least two medic similarli would appear post approv surveil system work well flag rare seriou condit may associ use zinbryta previou ocrevu ocrelizumab next tecfidera dimethyl fumar',\n",
       " 'nice assess ocrelizumab primari progress ms ppm decid whether prescrib nh england wale scotland northern ireland carri separ apprais mean peopl ms current licens treatment ppm ms trust fulli commit support peopl ms get best appropri treatment hope ocrelizumab made avail peopl ppm undertaken survey peopl ppm specialist ms health profession gather view nice apprais gather nearli respons submit formal respons nice explain think ocrelizumab made avail nh cladribin approv scotland scottish medicin consortium smc approv mavenclad cladribin treatment activ relaps remit ms read decis read cladribin nh england updat account care fix definit account care broadli speak area base model healthcar provis perhap better describ integr care organis work togeth meet need local popul account care aim improv popul health tackl caus ill wider determin health form account care involv local author third sector alongsid nh organis work toward object king fund brief state develop account care england hold promis differ way work nh emphasi place popul system rather organis public concern account care contract legal challeng launch challeng shift annual budget popul rather payment servic use model nhse announc consult contract arrang account care organis like know account care complex hous common librari produc brief paper recent govern announc blue badg scheme consult elig depart transport current consult elig blue badg dft look clarifi regul guidanc ensur equal issu address pariti physic non physic disabl consult propos consid automat rout blue badg anyon pip score chang word current regul focu difficulti physic non physic experienc journey rather physic act walk consult open',\n",
       " 'op final better type googl humira lupu first thread came ye recent diagnos humira induc lupu year old male diagnos crohn diseas earli went year larg resect done ileostomi year first surgeri probabl one first peopl radic resect also abl talk doctor tri perform reanastomosi coupl year initi diagnosi cut crohn anoth year iliostomi even close stabl live short bowel syndrom year deem flare look back event trigger seri smaller event made life overwhelm becam overwhelmingli sick crap brain inde rough part three month bout seem like flu yet immedi shepherd toward remicaid fail interferon gold test twice pass third tri six month infus countless respiratori tract infect later swap humira complain remicaid seem realli help anyth neuropathi start remicad quick start journey painstakingli slow process two job countless doctor endless lost hour accentu fear pain five year life unfold like final better describ although go cleveland clinic test ana also found b regularli treat b due pernici anemia much colon resect mad gastroenterologist feel better situat well hell ye guy treat humira collect everi time pass go yearli colonoscopi egd five year tell problem ach joint neuropathi swell finger ankl etc last colonoscopi even three month ago meet prior day get scope say guy check everyth take mani sampl test everyth mean mind numb pain lyrica swallow get even littl relief get less pride sensit bullcrap last five year worn slight disagr constitut test everyth give stori xyz part special darn last time check thought treat autoimmun diseas scope everi year make excus need answer sound touch lash sent book colonoscopi appoint still realli shaken ai tell nurs want see gastroenterologist dr g seem like want work book scope appoint anyway say call back see anoth doctor coupl day pass get call good old dr g tell test know send sampl well thought ith time drew blood actual sent lab confus chines menu man frickin order everi test sun bill paid good whatev test could possibl cost end convers high hand remark tri outsmart said matter fact anyon ever heard well go cleveland clinic mayb answer lay bed sleep wonder ever deserv ye later get answer gastroenterologist schmuck real class knew constant pain yet complain well doctor must sucker paint go clinic tomorrow go file complaint go gather medic record facil tell complianc offic seal record know ever would trail first thing good doctor chang offici record go somewher els see gastro doc understand belli ach caus even greater harm mad could spit past five year humria great poor old butthol cost neuropathi watch tooth tooth cap lost teeth past five year time life humria great crohn otherwis live hell pain neuropathi thousand dollar hour wast one measli blood test humira photo aural sensit teeth fall ankl finger look like stuf sausag take humira poison',\n",
       " 'hello everyon father diagnos stage nsclc met bone brain tarceva month felt better within coupl week take tarceva scan two month show mix respons pretti much stabl diseas lung brain growth bone anoth biopsi find mutat egfr l r mutat doctor switch tagrisso anyway hope would work better brain anoth scan approx week tagrisso result pretti much stabl diseas brain growth bone made switch tagrisso start feel littl worst everi week anyth dramat someth famili member notic seem tire appetit also got worst could side effect due tagrisso main concern reason tagrisso might effect tarceva weak fragil first start tarceva actual abl gain back weight month take lose weight sinc take tagrisso understand tagrisso suppos work egfr patient even without also saw earlier studi indic respons rate neg patient around make whole thing confus could wrong think mani studi trial shown first gen tki like tarceva iressa high respons rate egfr exon patient someth rang question make sens someon stop tagrisso go back tarceva condit continu deterior given fact origin respond ok tho perfect tarceva sorri long post advic greatli appreci',\n",
       " 'updat decemb signific research advanc made offer new lead toward vision world free ms societi research portfolio project activ manag societi invest million new ongo research project initi around world support collabor innov conven thought leader leverag new technolog data invest train ensur robust futur workforc learn diseas funder peopl live ms year first therapi specif primari progress ms approv fda progress occur mani approach identifi solut peopl live ms today ultim lead prevent cure brief summari signific research progress initi aim stop ms track restor function end ms forev stop ms toward new therapi new understand fda approv ocrevu ocrelizumab peopl primari progress ms relaps ms societi fund earli laboratori clinic work b cell therapi led first diseas modifi treatment progress ms largest clinic trial yet children adolesc ms oral fingolimod gilenya reduc annual number relaps two year compar treatment interferon beta avonex two year fingolimod experienc relaps compar avonex group trial also show benefit measur mri side effect similar seen adult popul therapi current approv treatment pediatr ms result phase trial oral ibudilast mn medicinova inc peopl progress form ms suggest significantli slow rate brain atrophi shrinkag link cognit physic disabl ms intern studi report long term outcom bone marrow deriv stem cell transplant hsct peopl differ form ms year still experienc progress worsen symptom eight death occur earli develop procedur improv patient select transplant techniqu reduc mortal best outcom tend younger relaps ms less disabl use fewer ms therapi prior procedur addit research need better understand might benefit procedur compar benefit power immun modul therapi avail mcdonald criteria diagnosi ms revis hope speed diagnosi reduc chanc misdiagnosi intern panel conven auspic intern advisori committe clinic trial ms sponsor nation ms societi european committe treatment research multipl sclerosi panel publish revis lancet neurolog onlin decemb avail free registr n small studi conduct oregon health scienc univers antioxid lipoic acid shown reduc rate brain tissu loss atrophi compar placebo secondari progress ms societi agre help fund larger phase clinic trial evalu whether lipoic acid safe effect treatment progress ms clinic trial unit kingdom began societi co fund test abil statin cholesterol reduc drug slow secondari progress ms restor lost myelin repair well rehabilit scientist cincinnati children hospit medic center fund societi nih report experiment therapi mir promot growth nerv insul myelin improv function mice ms like diseas team continu test similar molecul lab necessari step test peopl ms gladston institut research collabor show blood coagul factor call fibrinogen may enter brain ms inflamm hinder myelin repair lab model reduc fibrinogen enhanc myelin repair suggest may futur strategi develop therapi repair myelin damag caus ms research queen univers belfast report immun cell call treg play role promot myelin repair pinpoint protein appear respons offer potenti target stimul myelin repair robin franklin phd lead scientist univers cambridg focus stimul brain repair mechan select recipi barancik prize innov ms research two studi research univers illi noi urbana champaign shepherd center atlanta provid evid even peopl moder sever movement issu may benefit exercis intern studi show high intens aerob train improv cognit better standard exercis research show import physic activ enabl peopl form ms live best live healthier diet lifestyl associ lower level disabl analysi survey involv peopl ms enrol narcom registri studi need determin healthi lifestyl actual reduc ms symptom whether symptom interfer abil engag healthi diet lifestyl societi fund sever studi diet approach advanc well solut research amsterdam report peopl ms healthi control show improv work memori brain activ connect part brain interact one anoth treatment repetit transcrani magnet stimul rtm devic gener electromagnet puls stimul brain activ rtm may futur role cognit rehabilit peopl ms studi need john dystel prize ms research went alan j thompson md dean univers colleg london faculti brain scienc pioneer research way address symptom improv qualiti life peopl ms leader driver intern progress ms allianc end ms explor risk factor understand prevent ms larg scale studi sweden suggest teen experi head trauma lead concuss especi significantli like develop ms find mean teen experi concuss develop ms research denmark boston fund part nation ms societi report newborn low blood level vitamin increas risk develop ms later life ad grow evid low vitamin level potenti risk factor ms new studi u germani fund part nation ms societi add mount evid potenti role intestin bacteria play brain inflamm underli ms offer hope probiot approach may develop test help reduc ms activ societi support intern ms microbiom consortium project advanc research research collabor leadership intern progress ms allianc launch three collabor network award focus find breakthrough progress ms co fund leadership societi engag strateg plan addit activ acceler pace progress ms research research paper publish societi led initi focus well research patient cohort registri stem cell therapi clinic measur track ms progress benefit therapi societi conven tykeson fellow confer build collabor cement commit promis young investig find solut ms fund societi intern ms microbiom consortium began recruit particip effort identifi influenc good bad gut bacteria ms sever initi around world track peopl ms better understand diseas underli patholog identifi driver progress make progress toward person medicin respond therapi best pcori patient center outcom research institut made new commit million studi compar benefit risk ms therapi rehabilit includ two studi compar earli aggress treatment vs gradual escal key question treat ms read year end progress societi strateg plan avonex regist trademark biogen gilenya regist trademark novarti ag ocrevu trademark genentech member roch group',\n",
       " 'ask neuro come decid move next get low liver function result whilst gilenya claribin tecfidera suggest lean toward cladribin interest hear anyon take work',\n",
       " 'burdensom process insur first infus schedul drove hour pour rain husband tens got cleveland thursday night make matter even better husband pack bag hotel car notic flat tire even make stuff funni chang tire hotel park lot rain yuck sat bed got infus center friday morn littl bit wait earli got seat nice littl reclin sat row across anoth row reclin five other get infus got ocrevu except one man got rituxan one get initi first dose anoth ladi get second half first dose other get six month dose nurs calm help ton nervou put iv gave oral med consist tylenol benadryl also gave small dose solu medrol iv let spous driver visitor come wait hour ocrevu come pharmaci arriv effici get start quickli everyon two minut start got flush sat quickli ask nurs medicin would make hot assur even time get medicin yet tri relax realiz small moment panic sat back breath good check vital everi minut record bp temp great whole way lip tongu start tingl sure say someth wonder anxieti side effect went ahead told nurs one super concern bad enough stop med increas ocrevu final time notic face itch said someth husband point break ask let nurs know time nurs arriv hive face neck chest quick deal stop ocrevu administ iv benadryl pepcid someth els rememb took effect hive disappear wait bit start ocrevu loopi super sleepi benadryl fine fwiw notic anyon els issu medicin went well notic major differ yet hour tire got back hotel go go dinner feel like get readi go order pizza deliveri instead much better drive home today thank got get medicin even though feel like complain time sinc diagnos know fortun hive super easi deal seem like easi trade treatment feel right one want share first experi dmt happen ocrevu well rest odd trip certainli one book',\n",
       " 'year rebif ttecfidera miseri n usea wer horribl restart due vomit feel great primperan nausea take capsul thin slice toast peanut butter feel like think willbfb ine time neurologist told better gilenya next',\n",
       " 'older biolog humira remicad cheapest biolog insur tri get first reason fact biosimilar closest thing gener biolog remicad e inflectra also humira newer biolog like entyvio xeljanz stelara two three time cost remi humira justifi reason might prefer xeljanz safer simpl pill etc moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa never realli appreci got gone toilet paper good exampl nealzi regular member join apr post post pm gmt week dosag remicad cost insur ml yet gotten approv doubl dose move week gi decid switch xeljanz actual work wherea remicad zippo estim cost insur day suppli xeljanz mg pill bottl told compar appl appl timefram week k xeljanz vs remicad sure resist fact take month updat approv overal formulari someth get fda approv formulari whole pre author appeal appeal process fortun pfizer interim servic hold free believ month suppli go approv given clindamycin staph infect stye kick whole uc fun c diff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzi q regular member join sep post post pm gmt bc bs maryland also massachusett approv xeljanz appeal handl quickli although approv one pill day instead four doctor offic realli top thing take longer week recollect downsid follow directli doc offic also call insur make sure went spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week curiou crapper regular member join may post post pm gmt remicad cash price approxim per mg bottl could extrapol whatev dosag get factor cost infus get hospit set cost usual lot clinic home infus servic cash price list xeljanz monthli suppli mg day would ra patient get cash price uc would doubl around k month cash price though depend insur provid decid bill cover thing could make differ feelinglesscrappi new member join oct post post pm gmt bcb doctor get approv bcb approv first dr explain current qualiti life approv nealzi regular member join apr post post gmt help respons thank let know bcb approv process differ side fda approv week pre author process bit longer readi taper mg pred monday st time sinc last year hope continu sever pancol patient given clindamycin staph infect stye kick whole uc fun c diff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzi q regular member join sep post post gmt blue cross blue shield maryland massachusett approv xeljanz us appeal whole process fast less two week believ primarili think doctor offic knew feel free call doc offic also insur directli make sure realli submit correct specialti pharmaci spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week nealzi regular member join apr post post gmt suzi q long spous prednison see long took get wonder mg sinc april gi direct drop everi day far good energi touch slow return eat still hook current monday go day mg day assum xeljanz take uc get stuck whatev level get stuck see spous experi think either need extend taper mayb suzi q spous pred high level year given clindamycin staph infect stye kick whole uc fun c diff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzi q regular member join sep post post pm gmt realli glad hear xeljanz may work steroid almost constantli time diagnos even though full remiss octob xeljanz lesson process gi understand prednison taper especi long term start feel quit ill oppos usual prednison lousi feel mg short breath memori issu usual also neuropathi seem get wors point saw endocrinologist said taper correctli may take longer feel sick went back slowli taper mg everi four week point went onto hydrocortison depend toler feel lousi associ worri get mg may want go slower peopl get low everi day see feel alway go back level feel lousi adjust thing go spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week nealzi regular member join apr post post pm gmt great advic one cut mg pred pill mani way dot powder thank felt short breath occasion heart palpit like one week sluggish glad ask year wow imagin pray uc symptom stay bay taper cautious optimist thank share suzi q given clindamycin staph infect stye kick whole uc fun c diff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred andrina veteran member join aug post post pm gmt stewiecat said start notic improv coupl week xeljanz doubl dose x mg twice per day seem dose guidelin uc interest take x mg spoke pharmacist said dose uc guess outcom glad fewer pill swallow uc sinc suzi q regular member join sep post post pm gmt nealzi mg prednison tablet end need slowli taper spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week feelinglesscrappi new member join oct post post pm gmt think prednison taper depend person length time prednison year last mg done month felt fine nealzi regular member join apr post post gmt feelinglesscrappi good know drop mg start tomorrow path month day roughli taper mg complet xeljanz hold mg',\n",
       " 'avastin inject myopic md uk work would dismiss old technolog would dismiss anyth els proven time work well bicycl exampl problem repackag us reason done correctli done correctli work mani year drug develop find research cost argument interest ye pharma need make profit cost manufactur distribut plough back develop paid salari year case find argument disingenu avastin came first lucenti simpli cut version avastin molecul made antibodi theoret reason smaller peptid might better think seen heard benefit realis practic though peopl undoubtedli better one rather seem cut way quit lot develop cost lucenti alreadi spent avastin realli think justifi extra lucenti r manufactur packag avastin intraocular use submit registr everyon would happi could charg quit lot readi use dose everyon know registr cost money must recoup would also pay confid put syring manufactur like buy origin manufactur spare expens motor vehicl sure qualiti safeti novarti argument seem avastin prescrib macular diseas regist uk unsuit registr regist elsewher unpleas dog manger attitud seem shot foot take chanc make profit sell avastin intraocular shot lower profit lucenti still signific revenu stream',\n",
       " 'blood test done check level humira trough dose take often give humira switch someth els make sure give humira best chanc work often mean increas dose increas frequenc inject also may mean combin immunomodul like imuran mp methotrex consid humira failur necessit switch entyvio work colon work small bowel colon data far seem show work quit well uc fairli well crohn max option humira give switch someth els whether entyvio remicad other',\n",
       " 'hi jim touch reason higher dosag post clinic trial new drug set first find highest safe dose drug test efficaci way drug get best possibl chanc show whether work manner test drug test dose efficaci signific toxic profil bad statist drug may approv govern agenc control drug us fda fda approv drug goe market drug compani littl reason spend million dollar test lower dose may turn lead less incom point doctor patient manipul dosag individu circumst aris think doctor patient would agre find least dosag need would great thing know difficult point find mass keep hope aliv figur one circumst requir doctor fiddl dose patient abl tri treatment without excess possibl sever advers event one oncologist say oncologist get baselin mri one question ask would mri chang treatment plan system anticanc treatment would treat brain met mri begin system treatment common case one need brain radiat begin system treatment today alectinib would first option alk nsclc non symptomat brain met non symptomat brain met alectinib would excel first choic thu mri chang treatment plan later get want know also get need cut medic cost minimum without chang treatment option hope help best janin',\n",
       " 'hi brother diagnos mar nsclc iv alk ci alimta alimta maintain xalkori ceritinib wbr octob lmd straight blood clot lung start blood thinner still oxygen last two month alectinib effect diseas progress liver pancrea got tumour bike duct bilirubin shoot start take steroid bilirubin reduc lft shoot doctor ercp suggest litr oxygen oxygen must drop alreadi seem imposs normal expect way exampl patient success ercp oxygen one use nivolumab good effect liver met heard good alk exampl suggest come situat kind regard',\n",
       " 'hi omega femal fingolimod year although may stop relaps stop rapid declin although spm still activ diseas process get cladribin think cladribin good choic may stop bit beast lemtrada may wors secondari effect noth effect abit gambl',\n",
       " 'vitamin suggest liquid drop buy vitamin vitamin k k need absorpt take anti spasmod med like dicyclomin bad last year anti spa med help margin still worth intens aw perian diseas fistula fissur thrombos hemorrhoid incontin biolog work even stelara made hair fall fair warn colectomi octob way better mine crohn coliti wean prednison spark lot extraintestin issu due inflamm joint muscl pain skin condit mouth ulcer rectum bleed decid tri charlott web cbd oil advanc formula help alot also increas appetit chill expens use hsa supplement also take thorn stress b complex bought amazon com help adren recov long term high dose prednison believ help also take gnc calcium magnesium gel capsul krill fish oil cap ezf iron pill gentl tummi vitamin vsl rememb sinc fridg feel lazi might take vitamin k drop take least iu day see much improv take iu calcium magnesium never skip supp vital cal mag help balanc electrolyt protect bone loss also sick water hydrat basic live appl juic unflavor pedialyt carri oz yeti cup everywher drank day night could also tri electrolyt drop like drip drop need add electrolyt anyth drink notic feel better good parch pedialyt also make popsicl littl kid babi section walmart cv tast f cking awesom toddler ask treat got best wish new job hope stelara work xo',\n",
       " 'ipoop reason point way gi explain sinc tri humira first potenti remicad still may produc signific result tri remicad first said would essenti reason tri humira great chanc would work either gave quick overview entyvio never heard somewhat disappoint never even came possibl old gi digress greatli intrigu possibl like said focus specif gi tract oppos block wbc entir bodi think interest tri entyvio point work well imuran sinc today mark one month point first day actual mg u b think right give increas humira tri move get test done friday check humira level bodi see built antibodi may show even worth up dosag may show stay system time may tri benedryl give anyth shot buy even one night bliss sleep boy miss day notsosickgirl bentyl prescript ion drug otc may give enema anoth shot rememb tri one hold evacu quickli also tri proctofoam past saw real result either third round pred mg week saw mild improv mg thing dip got stay steadi never got dose pred nocturn bm occur essenti sinc flare start last june day realli know energi keep go imagin good go feel much energi start get full night sleep abl accomplish anyth day final come research night entyvio seem like better option cours pend result upcom humira blood work mayb get lucki use iv yet mayb up humira help diagnos summer left side coliti current prednison mg humira everi week imuran mg current tri gluten free mostli dairi free sinc jan flare sinc june signific inflamm doc word post edit ihatepoop pm gmt',\n",
       " 'ever chang world research mani new advanc technolog come advanc chang way eye doctor look macular degener amd also chang way see macular pucker mp well research start late given doctor understand two condit articl discuss differ two condit point articl keep inform latest advanc well answer seek love one suffer amd mp recommend read articl macular degener amd eye condit result damag macula center vision mani peopl suffer condit amd also caus sever vision loss mani elderli damag amd caus curabl condit treatabl case doctor today use varieti treatment method slow stop damag amd caus treatment often begin are vitamin supplement diet lifestyl chang like remov smoke life may progress inject medic like lucenti eylea macugen visudyn administ offic ophthalmologist macular pucker macular pucker scar tissu form eye macula macula center retina one compon eye make eye light sensit enough scar tissu build make macula less sensit light may inhibit light filtrat mp epiretin membran give appear wrinkl cellophan macula condit sometim also known cellophan maculopathi like ask amd mp relat way answer two condit differ night day differ fact take two differ treatment amd take supplement laser inject treat macular pucker requir treatment earli stage blurri effect scar tissu macula minim case condit becom like age vitreou fluid eye shrink pull away retina caus blurri vision elderli peopl vision loss mp signific extens procedur like vitrectomi done treat sever case conclus macular degener macular pucker two differ issu present time blurri vision recommend visit eye care specialist soon possibl see eye doctor reduc risk vision loss ensur great vision long possibl either condit let hear experi one love dr travi zigler',\n",
       " 'sat first infus imfinzi jan nd seem well th worst part stick hand darn vein side effect blame exclus immuno drug knock wood began whirlwind vow would face blindli vow would everyth power resourc combat conquer possibl maintain posit attitud help god ask self someth help imfinzi work better least keep cancer metasis anoth area research question like crazi internet weigh find open mind good bad make decis act act find durvalumab tell less year old nsclc stage pdl blocker research pacif trial success found fact utterli wonder news sinc drug condit found work everyon claim side effect scari time know find lot great success stori miracul cure claim scientist decid look thing anyway complet scientif studi done h lee moffitt cancer center research institut tampa florida usa depart cancer imag metabol h lee moffitt cancer center research institut tampa florida usa depart pharmacolog toxicolog faculti pharmaci mansoura univers egypt exist immunotherapi includ pd blocker pd blocker pd durvalumab pdl join caus cell ignor cancer tumor destroy ye websit www ncbi nlm nih gov pmc articl pmc research avail like imfinzi know except pacif trial gave result administr drug oppos placebo percentag success failur overal rest theori due research websit address gave earlier scientif research done immunotherapi vitro vivo petri dish mice claim ph level cancer tumor key immunotherapi level success mechan thereof sinc imfinzi durvalumab pdl inhibitor blocker avail test test pd blocker known keytruda pd pdl work hand hand togeth fool cell kill tumor research state cell activ acid environ tumor claim mean even pd pdl molecul block fool cell cell activ due acid condit tri adjust ph level work call buffer therapi home tri make immuno work safe maximum rate hope littl side effect littl suppli togeth includ ph test strip vehicl buffer tumor ph elixir formula made take sinc chemo radiat also shown benefit ph buffer far bad news put least make fascin read like johnni subject n p u thanx',\n",
       " 'diagnosi nsclc adenocarcinoma posit r egfr neg met alk pd pd l kra oncomin test prior treatment carboplatin pemetrex tumor shrinkag tarceva month addit shrinkag signific progress current th cycl opdivo stabil shown third cycl scan possibl futur option oncologist consid tagrisso even though neg egfr posit comment efficaci tagrisso neg egfr posit patient suggest option futur treatment thank advanc',\n",
       " 'submiss consid pbac relat list medicin medicin prepar pharmaceut benefit scheme remain four relat list vaccin nation immunis program major submiss initi submiss resubmiss submiss new medicin submiss includ cea cua type econom evalu submiss yet unknown submiss medicin atc group l anti neoplast immunomodul agent medicin atc group musculoskelet medicin atc group n nervou system two submiss appear withdrawn pbac consid minor submiss includ publish agenda outcom submiss yield outcom recommend reject deferr insofar submiss includ multipl request number outcom exce number submiss submiss new medicin consid pbac recommend submiss known includ cea cua yield outcom recommend reject reject medicin atc group l reject medicin use patient cancer resubmiss yield outcom recommend insight reason submiss pembrolizumab keytruda use combin platinum base chemotherapi pemetrex disodium heptahydr treatment patient egfr wild type alk transloc neg non squamou non small cell lung cancer reject unclear pbac outcom blank unclear outcom made public four medicin recommend risk share agreement two medicin recommend basi comparison least costli altern medicin recommend manag access program pbac consid one submiss new biosimilar medicin pbac consid one submiss co depend technolog',\n",
       " 'mousedoctorwednesday june ocrelizumab pirt induct therapi lol long neuro payer reckon current state affair fact may becom sometim futur year year year year realli help get infus everi month right indetermin amount time cours come year time overdos whole bunch ms patient data avail suggest otherwis neuro say ooop know',\n",
       " 'ed tobia jan question quickli start diseas modifi therapi dmt multipl sclerosi ms diagnosi one frequent see brows onlin goe hand hand question dmt best start mani thing consid make decis recent ran across studi may help weigh benefit risk treat dmt studi recent publish journal american medic associ review record patient diagnos relaps remit ms rrm dmt better none studi found peopl rrm initi treat glatiram acet copaxon glatopa interferon beta avonex betaferon extavia rebif lower risk percent progress secondari progress ms spm peopl receiv treatment percent receiv fingolimod gilenya also lower risk percent versu percent natalizumab tysabri percent versu percent alemtuzumab lemtrada percent versu percent risk move rrm spm lower glatiram acet interferon beta treatment start quickli within five year diseas onset addit accord studi treatment newer dmt appear effect slow advanc diseas older glatiram acet interferon beta treatment among patient relaps remit ms initi treatment fingolimod alemtuzumab natalizumab associ lower risk convers secondari progress ms vs initi treatment glatiram acet interferon beta studi note messag treat ms quickli effect click continu read',\n",
       " 'sorri said level chang due activ cancer progress take care judi stage iiia adeno dx sr chemo carbo alimta x ned local recurr surgeri remov lrl cm involv pleura chemo carbo alimta x ned',\n",
       " 'teva gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi nation multipl sclerosi societi stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none denni n bourdett md scientif advisori board none gift none fund travel speaker honoraria nation multipl sclerosi societi fund travel consortium ms center paralyz veteran america editori board current neurolog neurosci report section editor present receiv modest compens serv section editor neurolog member editori board present patent use patent treatment multipl sclerosi cyclic peptid deriv cyclosporin patent pend thyromimet drug stimul remyelin multipl sclerosi publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi nation ms societi pi april present nation ms societi pi april present stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent use patent treatment multipl sclerosi cyclic peptid deriv cyclosporin debiopharma stock stock option research sponsor none stock stock option medic equip materi none legal proceed none ann h cross md scientif advisori board roch member scientif advisori board gift none fund travel speaker honoraria rockpoint give cme talk regard ms medic receiv honoraria speak video webmd academ cme bloomingdal ave ste wayn pa cme talk editori board brain patholog editori board ongo editori board journal neuroimmunolog editori board ongo appoint associ editor annal clinic translat neurolog new onlin journal ongo patent one four inventor publish royalti none employ commerci entiti none consult biogen ad hoc consult sanofi aventi genzym ad hoc consult novarti ad hoc consult teva neurosci ad hoc consult gerson lehrman group austin tx consult guidepoint global llc new york new york consult abbvi ad hoc consult emd serono ad hoc consult genentech ad hoc consult speaker bureau none activ actrim talk fall ectrim actrim meet boston spoke american academi neurolog annual meet receiv honorarium free registr one night hotel project knowledg livingston nj fee write case question etc prime educ inc fee give cme talk clinic procedur imag studi none research support commerci entiti roch site pi studi ocrelizumab primari progress ms oratorio back investig studi site ocrelizumab rrm opera studi began open label extens teva neurosci site pi studi vitamin ad low versu high dose glatiram acet studi fund nation ms societi usa teva contribut free charg copaxon studi particip ongo research support govern entiti nation institut health nind po ns biomark pathogenesi ms mous human overal princip investig pi project core renew research support academ entiti none research support foundat societi barn jewish hospit foundat pi conrad n hilton foundat stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none angela applebe md scientif advisori board none gift none fund travel speaker honoraria travel expens reimburs genzym novarti pharmaceut editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau genzym novarti pharmaceut speaker bureau activ none clinic procedur imag studi none research support commerci entiti current involv clinic trial sponsor novarti acorda sanofi aventi opexa therapeut genentech roch biogen research support govern entiti none research support academ entiti none research support foundat societi none stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none philip skidd md scientif advisori board none gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi none stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none diantha b howard scientif advisori board none gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti nih nlm r lm chen melton co investig nih nia r ag subcontract newhous aisen sub contract co investig nih ncrr p gm irvin data analyst clinic core research support academ entiti none research support foundat societi none stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none rebecca spain md scientif advisori board none gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti depart veteran affair b w oregon clinic translat research institut ul tr research support academ entiti va portland health care system oregon health scienc univers research support foundat societi nation ms societi conrad hilton foundat medic research foundat oregon race eras ms stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none michel h cameron md scientif advisori board serv scientif advisori board genzym corpor gift none fund travel speaker honoraria receiv compens travel consortium multipl sclerosi center receiv speaker honoraria multipl sclerosi associ america editori board editori advisori board member compens journal hand therapi patent none publish royalti receiv publish royalti follow book physic agent rehabilit research practic th edit elsevi physic rehabilit elsevi physic rehabilit physic therapist assist elsevi employ commerci entiti none consult provid consult walk speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti receiv research support depart veteran affair rehabilit research develop servic research support academ entiti none research support foundat societi receiv research support nation multipl sclerosi societi stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none edward kim md scientif advisori board serv advisori board genzym teva pharmaceut within past year gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi nation ms societi multicent random clinic trial high dose vs low dose vitamin stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none michel k mass md scientif advisori board none gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi none stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none vijayshre yadav md scientif advisori board genentech gift none fund travel speaker honoraria novarti inc honoraria editori board none patent none publish royalti none employ commerci entiti none consult consult bayer advisori meet consult biogen nation advisori committe consult teva ms medic advisori board meet speaker bureau novarti inc biogen idec activ none clinic procedur imag studi none research support commerci entiti biogen idec genentech research support govern entiti depart veteran affair primari investig research support academ entiti none research support foundat societi mcdougal foundat research grant fund nation ms societi nanci davi center without wall foundat race eras ms foundat nation institut health stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none ruth h whitham md scientif advisori board member data safeti monitor board two clinic trial treatment neuromyel optica sponsor chugai pharmaceut co gift none fund travel speaker honoraria none editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi none stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none erin e longbrak md phd scientif advisori board genzym teva gift none fund travel speaker honoraria genzym honoraria serv speaker patient event biogen honoraria serv speaker consult editori board none patent none publish royalti none employ commerci entiti none consult none speaker bureau none activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti nation institut health ul tr train grant research support academ entiti none research support foundat societi nation ms societi sylvia lawri physician fellowship stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none robert naismith md scientif advisori board acorda therapeut alkerm gift none fund travel speaker honoraria acorda therapeut speaker honoraria travel commerci alkerm consult travel commerci bayer healthcar consult speaker honoraria travel commerci biogen idec speaker honoraria travel commerci genentech speaker honoraria travel commerci genzym corpor speaker honoraria travel commerci emd serono consult honoraria travel commerci mallinckrodt consult honoraria travel commerci novarti consult honoraria travel commerci pfizer consult honoraria travel commerci teva consult honoraria travel commerci editori board journal watch present associ editor patent none publish royalti none employ commerci entiti none consult none speaker bureau acorda therapeut commerci biogen idec commerci genzym corpor commerci activ none clinic procedur imag studi none research support commerci entiti none research support govern entiti none research support academ entiti none research support foundat societi nation ms societi nation institut health stock stock option board director compens none licens fee payment technolog invent none royalti payment technolog invent none stock stock option research sponsor none stock stock option medic equip materi none legal proceed none gregori f wu md phd scientif advisori board commerci biogen gift none',\n",
       " 'lucki lucki neurologist prescrib cladribin one earli peopl drug merck still market year ago australia first cours pull market never got finish full treatment even get half cours still stabl month ever make wonder ms would gone got follow cours treatment brilliant drug best ever ye got mildli lymphopen badli gilenya realli hope assess suitabl serious hope merck manag get back market bart blog quit right lobbi return realli wonder drug find neuro prescrib subcutan form licenc ms taken list also sympathis deterior symptom wait get electr wheelchair immobil right bugger respond treatment realli hope cladribin trick slow thing best brog x',\n",
       " 'bring excel question happi provid inform knowledg publicli avail data question whether ad tagrisso chemo progress tagrisso help compar chemotherapi alon closest data question st gener tki like erlotinib continu tki improv respons rate oncolog defin patient shrinkag least system call recist howev surviv improv combin toler rash diarrhea chemo alon practic never done knowledg whether insur would pay dr johnson dr sequist world class everi trial differ rule pretti new trial allow patient continu drug past progress doctor feel help trial allow patient stop drug later get back trial although immuno trial seen except think progress brain differ progress rest bodi cancer grow non brain part bodi assum cancer resist mechan contrast cancer grow brain well control rest bodi drug simpli get brain outsid trial sometim radiat cancer brain go back origin drug rest bodi case st line egfr treatment erlotinib even trial prospect evalu approach',\n",
       " 'thank info word honest probabl nervou chemo glad found place question come place ask thank hour ago repli durvalumab eagl repli robert macaulay topic immunotherapi ask biomark test minimum get pdl test see good candid durvalamb biomark test realli way go found treatment good candid durvalamb sinc pdl test prior start treatment biomark test done target therapi day take tagrisso sinc egfr mutat b went stage durvalamb target therapi stop progress cancer revers lymph node base measur ct scan spot power prayer',\n",
       " 'diagnos uc year ago total colectomi surgeri revers year last year offici diagnos crohn opt surgeri becuas initi diagnos uc crohn issu pretti much wors case scenerio steriod depend mani year quick fix like prednison long term option mp ineffect doctor say need go biolog actual opt surgeri year ago instead go biolog littl fear side effect lifelong treatment found much info patient j pouch post surgeri result affect biolog need choos one soon given suggest entyvio remicad humira stelara anyon j pouch need go biolog affect someon know',\n",
       " 'final publish studi offer proof metastat alk lung cancer patient live year thank target therapi phenomen consid year crizotinib approv us alk non small cell lung cancer alk nsclc us seer databas list averag surviv metastat non small cell lung cancer less one year studi patient univers colorado one site origin clinic trial crizotinib alk nsclc median overal surviv time diagnosi stage iv diseas month year six year surviv woohoo note median surviv group remain aliv even longer patient diagnos crizotinib approv besid find patient stage iv alk posit nsclc prolong overal surviv studi also found brain metastas diagnosi stage iv diseas influenc overal surviv wow brain met automat death sentenc organ involv tumor stage iv present associ wors outcom bummer work prolong benefit pemetrex chemo associ better outcom patient studi chemo target therapi yay cancer research help lung cancer patient live longer read complet articl',\n",
       " 'sound like caus pred brain fog anxieti et al backup plan fail humira moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa screenwrit crohn diseas came icon scene movi alien alien burst guy abdomen musingli wonder whether uc pain meant',\n",
       " 'hi johan thank get back touch sorri hear ms progress realli good news start ocrevu licens yet finger cross help half french love world cup also love sushi often wonder ms would better xyz ultim best right obviou answerr',\n",
       " 'ugh compani control recent articl anther pharma ceo said moral requir make much money rais price gener antibiot ayn rand would proud www cnn com health drug price hike moral requir bn index html yo femal diagnos w uc mid transvers uc crohn coliti remiss sinc confirm scope dec current med entyvio asacol hd tab x day capozid day hypertens dexil otc loratadin day multivitamin day minor flare sinc start wk entyvio infus taper predinson steroid enema',\n",
       " 'friend facebook good see still around treatment supposedli approv fda march ocrelizumab avail spring help rrm progress form diseas good see',\n",
       " 'sent email spous diagnos uc develop antibodi remicad humira entyvio work infus thing seem work prednison earli march start xeljanz label remiss within month work endocrinologist get prednison neurologist deal neuropathi feet develop conjunct prednison taper',\n",
       " 'thank marco day wait nice drop visit us got email mssa news read everyth get hand ocrelizumab still find inform peopl tysabri switch guess patient come meantim take care given everyon site much hope chanc comfort ever need',\n",
       " 'rn mother recent diagnos stage iv nsclc sinc reloc louisiana florida receiv conflict prognosi data louisiana oncologist current florida oncologist know expect current info anyon similar situat would love hear rt anterior cervic lymph node involv eggr neg alk neg along follow mass inoper radiat recommend multipl rt later trachea largest cm pretrach cm retrocav cm subcarin cm left hilar cm posterior left mid lung x cm rt lower lung mm posterior left lower lung mm medial left upper lung mm posterior left upper lung mm rt mid lung mm mild moder pericardi effus start chemo cycl carbo alimta mom wonder lesion chemo palli worth make differ one oncologist said chemo one recommend realli confus read',\n",
       " 'sorri moa mechan action ye hospit could label clad believ clad clad avail uk soon mavenclad v sub cut dose similar monitor influenc white cell deplet determin mani dose treat anti viral maven v ocrelizumab head head moment like maven avail us ocrelizumab avail europ time test mayb real life experi msbase ocelizumab keep b cell none exist level ever may effect may carri risk death due seriou infect occur sle arthriti',\n",
       " 'well scari list cancer clinic trial ocrevu look long term safeti trial go much longer older relaps free sinc ocrevu new sx start summer see neuro fall ask pml scare cancer look like mavenclad get fda stamp approv us sometim soon anoth round research clinic trial ocrevu access person b cell level hope someon could spread infus time even month consider varieti fast b cell popul rebound like influenc cancer risk slow repopul get anoth round ocrevu knock immun system think tailor frequenc one person rebound rate',\n",
       " 'hello welcom need clarifi thing ms year specialist medic qualif say hospit inpati patient gave steroid discharg decid ms mri scan brain spine say dr doctor suggest go ocrevu tecfidera etc get rid bodi symptom reduc chanc relaps ms neurologist ms nurs need profession help tecfidera year struggl walk make better reduc chanc relaps pleas see medic advisor asap need good advic help sorri concern pleas see someon soon need action stabilis bodi berti',\n",
       " 'hello opdivo sinc aug along yervoy stage iv lung cancer met spine get opdivo everi week rd week get drug ct scan round tumor grew liver upper airway kidney said dr obvious work said soon scan get anoth nov wbc slightli elev everi thing els normal low level pdl protein thought high level opdivo would work good thing sick seem drug',\n",
       " 'reg sinc got ocrevu notic anyth posit read post everyday tri get glimmer hope hope symptom eas moos main far said stiff let go bit good hope hear moos',\n",
       " 'worri bio drug take care entyvio year strong almost lose pouch good luck',\n",
       " 'remicad month far crohn goe work great inflamm last colonoscopi humira previou develop fairli sever muscl pain colonoscopi discov humira work anyway switch remicad develop muscl pain much wors start six day prior last infus everi day got wors got could hardli walk within hour start infus pain start decreas even total gone three week six week cycl muscl pain start alreadi top doctor offic call today inform latest blood work anti bodi level high even though six week cycl remicad left system appoint see gi next week nurs told think option readi talk doctor one option go four week schedul remicad much like remicad see go four vs six week help much seem like sooner later muscl pain return option switch entyvio sterlara done research realli cannot see one better anyon experienc muscl pain remicad switch either drug good result gone someth els',\n",
       " 'might record discharg glad hear thing go well bit challeng first like said feel better overal worth feel free ask question keep us post male diagnos sever uc mostli vegan diet last year tri differ mesalimin treatment prednison uceri mp humira remicad fail also tri gluten free diet mani natur altern product success tri myriad probiot includ vsl final opt three step j pouch surgeri current recuper third surgeri',\n",
       " 'hi afi welcom grace evid efficaci afatinib egfr posit patient progress tarceva realli impress combin afatinib cetuximab seem work better difficult regimen toler signific skin issu diarrhea dr pennel state singl complet trial combin publish cancer discoveri dual inhibit egfr afatinib cetuximab kinas inhibitor resist egfr mutant lung cancer without mutat includ patient egfr mutant lung cancer progress prior tarceva iressa respons rate whether patient tumor acquir resist mutat averag durat respons month mention paper activ combin brain metastas skin rash diarrhea combin gener sever tarceva iressa alon http cancergrac org topic afatinibcetuximab combat acquir resist tki post dr west origin post combin found perhap regimen someth discuss wife oncologist jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'per janin xalkori recommend first line treatment standard care lung cancer ro xalkori stop work clinic trial consid option chemotherapi search clinicaltri gov specif ro lung cancer studi databas look ceritinib lorlatinib cabozantinib respect tki alk inhibitor yet recruit studi ldk patient non small cell lung cancer harbor ro rearrang non small cell lung cancer harbor ro rearrang drug ldk ceritinib recruit studi lorlatinib advanc alk ro rearrang lung cancer cn metastasi absenc measur extracrani lesion non small cell lung cancer nsclc drug lorlatinib massachusett gener hospit boston massachusett unit state recruit cabozantinib patient ret fusion posit advanc non small cell lung cancer genotyp ro ntrk fusion increas met axl activ non small cell lung cancer drug cabozantinib studi list link page janin post look lung cancer solid tumor http www lungcancerfound org patient ro trial treatment chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatin vinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan repli modifi month ago onthemark repli modifi month ago onthemark',\n",
       " 'discuss differ thread recent failur opdivo lung cancer want clarifi issu first opdivo fda approv advanc lung cancer second line treatment fail platinum base chemo howev bm greedi want use first line therapi patient independ stage pd l statu use instead chemotherapi chemotherapi actual help make tumor immunogen help tumor attract cell etc anyway broaden patient elig mistak trial fail show advantag opdivo first line therapi earli stage anoth interest inform issu numer trial report efficaci pembrolizumab keytruda nivolumab opdivo correl express pd l degre exampl keynot trial patient whose lung tumor high level pd l protein respons rate patient neg pd l also respond neg posit pd l test depend lot compani trial nivolumab cutoff use posit cell biopsi pembrolizumab cutoff atezolizumab also test pd l express differ use differ antibodi differ detect method anoth factor take consider pd l statu easili chang tumor tumor mani trick ya know time pd l express good enough marker exclud patient get pd pd l checkpoint inhibitor',\n",
       " 'remicad best track record fistula heal humira may well work though worth tri sure shame jump hoop might find humira work best still option least daughter diagnos feb yr old time diagnosi crohn termin illium use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mg imuran',\n",
       " 'articl link suggest use specif type anti depress tricycl ndri increas surviv lung cancer clinic statist signific way benefit seen ssri howev ndri mean norepinephrin dopamin reuptak inhibitor one wellbutrin happen medic take half year seem like realli easi thing tri extend surviv thought mayb peopl would interest articl freeli avail http www ncbi nlm nih gov pmc articl pmc chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatin vinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan topic modifi week day ago catdand forum moder topic modifi week day ago catdand forum moder',\n",
       " 'although advent anti vegf therapi explain administ via eye inject lucenti eylea avastin revolution treatment wet age relat macular degener amd still number person respond treatment non respond reduc respond continu pose signific challeng doctor research despit rel success drug treat cure wet amd retin specialist acknowledg need addit intervent treat wet amd effect one promis approach enter sever phase clinic trial earlier year explor treatment wet amd inhibit vascular endotheli growth factor vegf platelet deriv growth factor call pdgf also explain via inject drug fovista new drug candid ophthotech unfortun although innov approach show promis fovista prove effect data two drug phase clinic trial administ combin lucenti analyz clinic trial result decemb ophthotech releas follow inform edit length clariti ophthotech corpor today announc pre specifi primari endpoint [i e indic success] mean [or average] chang visual acuiti month achiev two pivot phase clinic trial investig superior fovista anti pdgf therapi combin lucenti anti vegf therapi compar lucenti monotherapi [i e use lucenti alone] treatment wet age relat macular degener amd addit fovista monthli lucenti regimen result benefit measur mean chang visual acuiti month time point disappoint result trial particularli patient afflict wet amd comment david r guyer chief execut offic ophthotech thank patient clinic investig staff particip trial continu analyz data two studi better understand trial result two clinic trial oph oph intern multicent random doubl mask control phase studi evalu safeti efficaci mg fovista administ combin lucenti call fovista combin therapi compar lucenti monotherapi [i e lucenti alone] trial patient random one two approxim equal size treatment group two phase trial enrol patient wet amd better understand result help understand process underli wet amd along current treatment cure wet age relat macular degener amd look world amd wet macular degener choroid part eye contain blood vessel nourish retina begin sprout abnorm blood vessel develop cluster macula call choroid neovascular neo new vascular blood vessel macula part retina provid clearest central vision new blood vessel abnorm tend break bleed leak fluid macula caus lift pull away base damag fragil photoreceptor cell sens receiv light result rapid sever loss central vision angiogenesi angiogenesi term use describ growth new blood vessel play crucial role normal develop bodi organ tissu sometim howev excess abnorm blood vessel develop occur diseas cancer tumor growth amd retin macular bleed substanc stop growth excess blood vessel call anti angiogen anti angio vessel genic develop anti neovascular anti neo new vascular blood vessel angiogenesi anti vegf treatment focu current anti angiogen drug treatment wet amd reduc level particular protein call vascular endotheli growth factor vegf bind cell inner line blood vessel vascular endotheli cell promot abnorm growth retina macula thu drug classifi anti vegf treatment present drug lucenti eylea avastin administ inject small needl directli eye surfac numb new approach angiogenesi anti pdgf treatment contrast vascular endotheli growth factor vegf bind cell inner line blood vessel endotheli cell platelet deriv growth factor pdgf bind cell outer line blood vessel pericyt cell pericyt thu vegf pdgf play relat separ role format growth new blood vessel vegf stimul abnorm blood vessel growth retina macula pdgf stabil matur blood vessel shield inner endotheli cell keep aliv despit anti vegf treatment result lucenti eylea avastin treatment render ineffect seen person non respond reduc respond research theoriz therefor combin anti vegf anti pdgf treatment target immatur matur blood vessel may effect anti vegf treatment alon call monotherapi anti pdgf therapi strip pericyt protect cell outer blood vessel cover outer protect cell gone inner endotheli cell expos anti vegf therapi elimin well current research anti pdgf treatment fovista fovista anti pdgf drug candid ophthotech potenti treatment wet amd use combin anti vegf drug ophthotech unit state base biopharmaceut compani special develop novel therapeut treat diseas back eye focu develop therapeut age relat macular degener sinc fovista inject eye via separ needl anti vegf drug treatment requir two separ inject pleas note although unsuccess clinic trial report involv fovista combin anti vegf drug lucenti simultan clinic trial progress anti vegf drug avastin eylea result clinic trial yet releas durasert insert psivida anoth anti pdgf treatment develop durasert sustain releas insert biotechnolog compani psivida compani also develop fda approv inject implant iluvien partnership alimera scienc treatment diabet macular edema sustain releas insert design deliv repurpos cancer drug call tki known block action vegf pdgf thu far insert use two pre clinic anim studi accord psivida ultim goal durasert project effect treat amd sustain basi six month singl inject target vegf pdgf avoid toxic system side effect [cancer drugs] frequent inject current amd anti vegf [injections] clinic trial clinic trial design phase base question studi seek answer phase clinic trial research test new drug treatment small group peopl first time evalu safeti determin safe effect dosag rang identifi possibl side effect phase clinic trial studi drug treatment given larger group peopl determin effect evalu safeti phase studi studi drug treatment given even larger group peopl confirm effect monitor side effect compar commonli use treatment collect inform allow drug treatment use safe phase studi unit state food drug administr fda approv drug continu studi determin addit inform drug risk side effect benefit optim use visionawar provid updat macular degener research becom avail',\n",
       " 'agre wwith ipoop check level addit may want stool test scope recent result hard know thing activ often rectum best rout treat rectal med mesalamin worth throw simpl stuff see get point free symptom stelara label uc avail crohn think test uc avail soon howev med simponi humira similar remicad action entyvio differ mechan xeljanz good option current state like hope get thing manag someth addit sinc said badli mayb dose adjust imuran though mg low peopl everi day could get level check see respond also add rectal steroid mesalamin oral mesalamin moder uc current med step j pouch surgeri complet step complet step complet sickli uc free give man fish eat day teach man fish eat lifetim give man religion die pray fish',\n",
       " 'genom analys egfr even exist understood drug like iressa tarceva work laboratori develop eva pcd tar get platform identifi clinic respond target agent function level use iressa year inde sever year egfr gene mutat discov regularli treat patient found sensit iressa difficult obtain drug us would dispatch patient famili member tokyo could purchas iressa return success treat famili member predic upon eva pcd find report use first line iressa later tarceva patient identifi eva pcd provid respons rate nagourney ra et al clinic respons egfr tki identifi drug induc cell death human nsclc primari cultur proc asco function profil effect one import aspect function analys biolog rigor patient favor eva pcd result respond tend respond durabl reflect predict valid biolog measur gene profil one patient show synergi combin tarceva plu avastin round th year egfr tki therapi one would need look long hard clinic program use gene driven therapi select find year survivor wait question await result patient genom profil confid found egfr mutat neg alk ro ra b raf c met experi patient one encount increasingli frequent reflect abil interrog human biolog level cellular function faster better accur genom platform genom analysi provid possibl respons eva pcd analysi provid probabl respons find answer wait question alway appreci thought comment dr robert nagourney intern recogn pioneer cancer research person cancer treatment year tedx speaker author book outliv cancer practic oncologist tripl board certifi intern medicin medic oncolog hematolog help cancer patient around world nagourney cancer institut long beach california info go nagourneycancerinstitut com',\n",
       " 'daze worri work relaps without steroid treatment take long time calm feel better start therapi work start tysabri coupl month ago ive improv dramat life goe ms scari use major newli diagnos patient wonder may bearabl major us els go work meet friend current work catch netflix want advic give make note new symptom report ms nurs spend minut day think ms that time limit set',\n",
       " 'remiss primari goal peopl crohn diseas biolog therapi help achiev remiss reduc symptom well heal damag intestin caus inflamm biolog therapi usual prescrib peopl sever crohn symptom found relief method guidelin recommend howev doctor prescrib biolog patient signific diseas first line approach biolog therapi work block certain chemic caus inflamm intestin biolog crohn diseas block protein call tumor necrosi factor tnf biolog block immun cell call integrin other act protein call interleukin il interleukin il biolog therapi stop inflamm gut anti tnf biolog bind block protein promot inflamm intestin also organ tissu mani peopl benefit medic sometim see improv immedi anywher eight week three anti tnf biolog humira remicad cimzia humira humira self administ treatment follow initi demonstr healthcar profession doctor decid handl inject give set pen dosag control medic insid also given instruct mani inject take first day initi day period patient typic use one humira pen everi two week remicad remicad may help patient gain control flare up may also help maintain remiss prevent symptom return remicad given directli bloodstream allow work immedi reliev symptom administ medic facil experienc healthcar profession close monitor side effect treatment remicad taken everi day three starter dose patient often see benefit six dose per year downsid remicad must given intraven medic facil two hour period cimzia cimzia administ small inject inject either given doctor offic home choos receiv treatment doctor offic option receiv treatment powder form powder mix steril water inject option use prefil syring syring contain medic alreadi mix measur dose use home doctor offic choos treatment get packag two syring instruct give treatment first three dose given everi two week abl take cimzia everi four week two anti integrin biolog crohn tysabri entyvio tysabri type biolog prevent inflamm caus white blood cell enter tissu block protein surfac cell tysabri given intraven everi four week take hour receiv full dose patient usual observ hour afterward tysabri typic use peopl respond well intoler tnf blocker immunomodul corticosteroid crohn patient consid tysabri awar seriou side effect tysabri user increas risk develop rare brain diseas call progress multifoc leukoencephalopathi pml result viru test advanc physician prescrib tysabri crohn warn patient risk also explain enrol prescrib program call touch program way receiv tysabri entyvio like tysabri entyvio approv treat adult moder sever crohn diseas respond well intoler reason take tnf blocker immunomodul corticosteroid work similarli tysabri act certain white blood cell prevent caus bowel inflamm associ crohn entyvio howev gut specif appear risk pml entyvio given doctor care intraven infus given minut first day therapi repeat week two week six everi eight week thereaft improv crohn diseas symptom occur week entyvio therapi discontinu prior start entyvio patient date immun stelara third class biolog il il agonist stelara drug class approv treat adult moder sever crohn respond well enough convent therapi drug target specif protein play key role inflamm process stelara initi given intraven supervis healthcar profession follow dose given via inject skin everi eight week either healthcar provid self administ patient train side effect although benefit often far outweigh risk biolog therapi present seriou side effect process biolog therapi reduc bodi abil fight infect caus tuberculosi infect includ brain infect also increas chanc certain type cancer patient take biolog especi younger patient one call hepatosplen cell lymphoma type cancer often fatal biolog therapi work differ other side effect may caus also vari ask doctor thoroughli explain possibl side effect discuss biolog therapi right takeaway biolog offer advantag treat crohn diseas drug specif target substanc bodi caus bowel inflamm doctor discuss option benefit risk help find effect treatment case biosimilar gener version biolog drug may avail manag crohn also save money doctor tell option',\n",
       " 'hi taken keytruda opdivo similar first mom stage travel anoth organ time standard treatment surgeri let get far immunotherapi get rid cancer keep stabl long time everybodi experi differ side effect vari time sever two realli first start immunotherapi runni nose eye hour everi morn week went away knee pain later went away almost three year take immunotherapi experienc fatigu cold time wait subsid also sever heartburn hit year drug take counter zantac twice day other rash sometim itch diarrhea requir medic calm peopl gave fever flu symptom infus four episod went away thing report short breath abdomin pain diarrhea good luck mom uncl also zero energi alway cold also tast food everyth tast lb right',\n",
       " 'year among advoc patient cancer appli select particip american associ cancer research aacr scientist survivor program ssp part program attend aacr annual meet held april new orlean program consist orient day includ excel cancer brief dr carolyn compton ssp session advoc met top research discuss specif topic immunotherapi fda polici present origin poster aacr poster session group project scientif advisor experienc ssp mentor help us explor major aspect cancer research even network event cours attend annual meet cancer research poster creat advoc talk varieti subject includ cancer journey advocaci organ outreach even person research project poster discuss benefit lung cancer social media lcsm commun twitter thank fellow lcsm chat core member valuabl suggest feedback understand everi present actual aacr meet least one present understand anyth gene edit technic come away better understand scope cancer research issu imped progress list topic want explor love listen research explain cut edg work might lead better cancer treatment fascin session attend discuss understand cell microenviron might promot inhibit cancer tumor respons therapi insight cancer cell metabol evolut method detect drive mutat cancer cell use epigenet block cancer caus pathway cell engin immun system person treatment valu cancer care debat patient research regulatori perspect cours imposs see everyth fascin poster session miss touch use virus prime immun respons improv effect therapi combin immunotherapi radiat inhibit dna repair cancer cell use big data inform cancer trial aspect ssp experi stood meet network patient survivor advoc across wide rang cancer type greet name hallway research thank live tweet open plenari session sit front row vice presid joe biden talk cancer moonshot attend plenari session cancer evolut target therapi friend fellow lung cancer advoc linnea olson see scan lung appear big screen dr jean cui lead chemist pfizer team develop current oral cancer therapi xalkori crizotinib person explain poster newest drug develop treat ro rearrang cancer well alk ntrk rearrang cancer highli recommend cancer patient advoc interest research appli program thank bonni j addario lung cancer foundat support applic aacr scientist survivor program view poster onlin collabor support lung cancer social media lcsm commun',\n",
       " 'day learn strength sorrow oral head neck cancer patient caregiv also acquir better understand scienc cancer treatment cancer possibl caus cancer prevent cancer today societi also face address new popul oral head neck cancer patient past cancer patient older adult avid smoker howev younger adult age diagnos hpv relat oropharyng cancer learn topic becom increasingli encourag immunotherapi new target therapi develop address cancer start newslett next mani month websit headandneck org hnca provid educ seri immunotherapi better educ oral head neck cancer commun clinic trial potenti futur therapi access treatment due hard work mani volunt support corpor partner head neck cancer allianc hnca expand program goal becom one stop shop patient love one famili member seek inform oral head neck cancer worldwid take step achiev goal everi day hnca dedic advanc prevent earli detect treatment rehabilit oral head neck cancer public awar research advocaci survivorship immunotherapi head neck oral caviti immunotherapi class medic use treat cancer alter individu immun system act induc enhanc immun respons medicin use treat human cancer provid addit approach control diseas unlik standard chemotherapi radiat therapi affect tumor cell well bodi normal cell immunotherapi directli interact host immun system order enhanc person fight cancer goal approach util bodi natur defens system erad diseas tri minim side effect number differ type immunotherapi immun checkpoint inhibitor promin class immunotherapi repres breakthrough cancer care medic act program cell death receptor block immun checkpoint normal cell ligand bind cell death receptor allow immun respons know harm bodi cancer cell produc abund amount ligand also bind cell death receptor cell ligand protein suppress immun respons therefor allow mutat cell evad bodi immun system destroy grow rapidli tumor exampl includ antibodi program cell death protein pathway pd ligand pd l ex nivolumab pembrolizumab antibodi cytotox lymphocyt associ antigen ctla anoth type immunotherapi date agent shown remark impact upon malign melanoma ctla downregul activ cell block antibodi cell remain activ allow attack tumor cell ctla current approv treatment melanoma non small cell lung cancer antibodi type similar function regul cell activ contrast base locat variat express time etc recent trial show impact head neck cancer agent continu studi multipl cancer type singl therapi combin immunotherapi combin cancer therapi expect medic becom common treatment mani differ cancer new therapi associ side effect immunotherapi appear good overal benefit risk profil common immun relat side effect dermatolog appear similar product tend mild manag support local care sometim aggress care might need side effect troublesom compar seen commonli use chemotherapi mouth pain mucos dri mouth tast chang nausea hair loss damag kidney nerv bone marrow suppress risk factor immunotherapi toxic well character may includ increas risk age gender presenc prior autoimmun condit combin immun therapi increas risk dermatolog side effect may associ increas sever side effect nevertheless side effect profil immunotherapi typic favor chemotherapi radiat minim side effect immunotherapi dose modif delay schedul discontinu therapi often consid goal prevent manag side effect treat dermatolog oral side effect continu immunotherapi greatest effect upon cancer manag may includ skin moistur prevent dehydr reduc local irrit avoid tight fit cloth wear light wick fabric avoid sun exposur wash skin soap water also help minim oral side effect option includ good basic oral care mouth rins hydrat avoid rough abras food remov sharp potenti irrit dental surfac dermatolog oral treatment local anti inflammatori immunosuppress therapi may includ steroid therapi topic system well medic reduc itch hydroxyzin diphenhydramin pain sever reaction anti tnf medic eg infliximab may consid articl contributor includ hnca board member joel epstein michael moor erza cohen cheri ann nathan articl first seri immunotherapi treatment oral head neck awar week set screen record earli detect key best outcom cancer oral head neck cancer earli detect also provid treatment opportun less invas best opportun success hnca host th annual oral head neck cancer awar week ohancaw april set record number screen site well individu screen week long nation intern event april hnca partnership hospit commun health center dental offic held event worldwid conduct free oral head neck screen event also offer hnca educ materi recommend individu test examin warrant goal continu grow deliv qualiti ohancaw educ activ screen hnca hallmark program ohancaw save hundr live earli detect thank thousand volunt clinician enthusiast commit time support commun host ohancaw screen said dr terri day hnca presid celebr ohancaw th anniversari look forward anoth banner year hnca wish acknowledg lilli oncolog bristol myer squibb merck support ohancaw unfortun individu diagnos oral head neck cancer everi day therefor organ want host screen support event throughout year regist go www headandneck org',\n",
       " 'retin vein occlus rvo preval vision threaten diseas macular edema common complic standard treatment rvo associ macular edema involv intravitr treatment anti vascular endotheli growth factor anti vegf agent ranibizumab bevacizumab aflibercept despit success agent clinic trial anti vegf agent may administ less frequent clinic practic studi research sought evalu efficaci safeti inject frequenc anti vegf drug treat macular edema secondari rvo clinic practic use multicent retrospect open label chart review patient year older receiv least intravitr inject anti vegf august septemb total patient year follow anti vegf treatment continu receiv anti vegf inject data avail year seventeen continu therapi data avail year total anti vegf inject administ ranibizumab bevacizumab aflibercept patient receiv repeat inject agent n patient switch agent least time studi period control clinic trial conduct approv ranibizumab administ monthli month need year contrast studi patient receiv mean rang anti vegf inject year rang year rang year mean interv inject rang month across first inject primari end point combin visual anatom respons measur best correct visual acuiti better central retin thick mcm less time domain optic coher tomographi mcm less spectral domain optic coher tomographi visit achiev patient first inject real world studi mean [ ] [ ] anti vegf inject administ yearli respons anti vegf therapi suboptim mani patient write author frequent inject may improv outcom patient achiev dri macula even monthli inject refer jumper jm dugel pu chen blinder kj walt jg anti vegf treatment macular edema associ retin vein occlus pattern use effect clinic practic echo studi report clin ophtalmol doi opth',\n",
       " 'wife noriko diagnos august stage squamou lung cancer nsclc pet ct scan novemb st schedul infus opdivo nivolumab month month diagnosi previous gone thru two combo regimen fail chemo similar immunolog fda approv drug lung cancer keytruda merck opdivo keytruda origin develp melanoma test number type cancer fda approv last year lung cancer oncologist dr howard jack west md came said cancel infus pet ct scan show wasfre cancer remiss origin estim mayb month new immunolog drug also call check point inhibitor pd name seem better success mani previou chemo type drug mani new clincal trail test simialr drug mani show lot promis ecstat hope even stage lung cancer thank brystol meyer squibb area seattl swedish hospit cancer institut dr west entir staff need fli across countri region seek best cancer center two nearest larg metro citi near mani time larg hospit cancer section univeristi teach medic hospit check oncologist special specif type cancer sure access latest clinic trail drug recent fda approv mani time lead edg succes treatment cours less stage surgeri raditaion success pleas stay far away altern clinic doctor product good food suppliment great gener health none cure cancer regardless mani phoni testimoni see site goe mexico mani foreign bogu clinic push coffe enema nonsens cure big buck medic phyician md top us medic univers hope chuck http www cancer org treatment treatmentsandsideeffect tre http www cancerresearch org cancer immunotherapi impact http www googl com search newwindow rlz cahpzt_enu us q immunotherapi cancer treatment sa x ved ahukewjdg xqahuq mmkhwkdafwq qiipgeoag biw bih',\n",
       " 'fortun rare doctor critic control never experienc one mean day control great doctor rather awe dedic put toward control compar averag patient think kater unfortun percept diabet experi medic profess cast shadow life interest use hate loath diabet everi day everi test frustrat addit frustrat almost daili diabet also scari sad overwhelm look back post ten year ago see wrote diabet experi gain tight control low carb diet use pump cgm sugar surf techniqu daili review adjust basal rate ratio taken frustrat diabet still annoy time caus emot turmoil first year diabet life night ate higher carb meal gram surprisingli stress give big rel speak bolu go class studi shown insulin potenc vari wide felt like inject big dose unknown system sure enough bg went mmol l correct correct sent mmol l brief glimps life use like daili basi rare like enough keep track answer loosen control live consequ tri avail techniqu find work tighten control stick resist low carb year insist bg variabl work inde low carb answer bg still highli variabl compar mani see still need monitor close adjust frequent often larg amount even control nearli tight peopl post glad gave techniqu shot even realli want tri profound impact life attitud toward diabet seydlitz well c four rang past decad yet four laser photocoagul treatment period said mani post blood sugar swing wildli thought glycem variabl import mayb even import high blood sugar caus complic c may import c alon realli indic whether someon good control say averag blood sugar standard deviat time rang better measur hyperglycem memori may true also studi like follow dcct show even temporari period good control benefit reduc complic decad road',\n",
       " 'father diagnosi nsclc plural effus pass year gone carboplatin cycl cisplatin gemcitabin cycl alimta cycl pembrolizumab cycl diseas show progress increas fluid metastat neck lymph node pleas advis chemo treatment immun treatment give tri also check new drug come trial let particip thank help',\n",
       " 'californeadreamin londonlad jolea devast that could say absolut unknown result fail way say one path better im still young never kidney lung heart problem far futur treatment life path age treatment start tomorrow whatev subsgio tecfidera gilenya age even age protect brain partli sacrific part idk absolut inhuman want someth legit treatment vulner patient',\n",
       " 'sorri hear current regim work seem rhyme reason work differ peopl agre tri everi variat theme remicad downsid throw mp back mix sinc work know whether anoth anti tnf might next step entyvio peopl work interim may also want explor anyon area particip stelara clinic trial husband gi one patient great result quickli problem clinic trial may end placebo first cours big propon xeljanz get label think path choos wrong path sinc still big scienc experi stelara xeljanz may approv next year still drug option time pass spous diagnos uc develop antibodi remicad humira entyvio work infus thing seem work prednison earli march start xeljanz label remiss within month work endocrinologist get prednison neurologist deal neuropathi feet develop conjunct prednison taper',\n",
       " 'took x iu day month iu day total vitamin pretti low ng ml idea realli wanna pay anoth find winter go take mainten dose iu day test level next spring bit worri vitamin k part brief googl inform scienc clue yet one day might www healthlin com nutrit vitamin vitamin k section think pick vitamin k supplement anyway multi vitamin supplement includ vitamin k dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'hi fellow travel stage c adenocarcinoma lung cancer went remiss two year c far tumor week start radiat day week chemo time gram cannabi oil day gram vit c iv twice week natur supplement treatment put remiss start someth call durvalumab immunotherapi genet test tumor proport score tp high pd l express nsclc everi week iv hope everyon enjoy season',\n",
       " 'well turn c diff infect could reason remicad work get control n current take vancomycin antibiot treat hope remicad still work work move anoth med like entyvio mark thank insight make sure mention doctor possibl underli infect parasit test order find',\n",
       " 'home ms inform public motiv motiv winter spring research news american academi neurolog meet highlight research news american academi neurolog meet highlight section american academi neurolog meet highlight tecfidera approv long term treatment ms american academi neurolog meet highlight written jack burk md edit susan well courtney american academi neurolog aan th annual meet took place san diego california march larg medic confer present latest find research treatment neurolog condit includ multipl sclerosi ms cover studi relat ms would possibl issu motiv follow import highlight gener studi adher diseas modifi therapi dmt medic reduc risk ms relaps percent increas number individu relaps free two year women ms children may experi slower rate disabl progress women never pregnant studi need confirm find diseas factor may play role whether patient becom pregnant herp zoster vaccin hzv effect ms studi ms patient patient suffer increas mri damag clinic indic increas ms symptom three month vaccin studi suggest hzv safe use ms patient fda approv diseas modifi therapi ms pegyl interferon beta peginterferon beta chemic modif interferon beta avonex molecul allow given subcutan skin everi two four week contrast current week deeper intramuscular inject studi test experiment therapi safeti effect approv fda would give patient option use singl dose auto injector prefil syring less frequent previou studi benefit trial patient clinic isol syndrom ci treat betaseron interferon beta b placebo two year diagnos clinic definit ms cdm time everyon switch betaseron follow extens studi eight year show group stabl low disabl level although patient treat immedi betaseron follow ci fewer relaps delay treatment fda approv dose copaxon glatiram acet mg given daili via subcutan inject gala studi patient receiv either mg dose three time per week subcutan placebo experiment dose reduc relaps mri lesion compar placebo fda approv less frequent treatment option copaxon may becom avail rebif interferon beta studi use rebismart inject devic electron autoinjector monitor drug adher electron dose log german studi found percent adher rate three month initi auto injector use data small number women becam pregnant within day take tysabri natalizumab suggest advers effect pregnanc outcom c recommend potenti harm pregnanc stand women recommend get pregnant tysabri higher dose mg oral aubagio teriflunomid reduc relaps rate disabl mg dose reduc relaps disabl patient fewer relaps prior treatment less disabl take aubagio four year patient safeti studi oral gilenya fingolimod show unexpect safeti concern well suggest disabl may improv four year treatment switch gilenya prior week discontinu tysabri lower risk relaps began therapi gilenya week stop tysabri combin analysi two tecfidera dimethyl fumar bg clinic trial show given twice per day tecfidera reduc relaps disabl also accept safeti profil higher number patient free diseas activ versu placebo treat patient two year trial period experiment ms therapi three year extens studi oral drug laquinimod treat patient continu less risk disabl compar placebo also new safeti issu occur lemtrada alemtuzumab drug infus intraven three five consecut day entir first year effect rebif reduc overal diseas activ advers event includ thyroid platelet problem consist previou studi daclizumab also known zenapax monoclon antibodi given inject shown less diseas mri activ compar placebo one year select studi particip given week washout period without treatment reiniti drug show evid rebound diseas activ follow washout period ms patient ocrelizumab b cell target monoclon antibodi low diseas mri activ last least week last dose new safeti concern experienc vitamin continu link ms optic neuriti treatment vitamin demonstr posit immun system chang decreas inflamm demyelin african american ms tend lower vitamin level ms disabl studi progress type ms fourteen primari progress ms ppm patient involv clinic trial oral drug amilorid potassium spare diuret may neuroprotect activ preliminari result suggest posit effect mri disabl inform doubl blind multicent studi evalu gilenya fingolimod mg versu placebo ppm patient flexibl durat three five year measur time sustain disabl progress enrol ppm patient complet preliminari studi secondari progress ms spm patient evalu effect oral statin drug simvastatin preliminari result show posit influenc mri clinic disabl outcom studi necessari confirm result siponimod baf oral drug class drug gilenya ident larg studi design spm patient underway smaller studi relaps remit ms rrm encourag base relaps mri result interest paper high dietari salt implic increas autoimmun neuro inflamm markedli boost th helper cell driven autoimmun respons eae experiment diseas similar ms mice th immun system cell lymphocyt involv inflamm caus damag myelin nerv ms th boost properti dietari salt also seen human theori salt may increas ms inflamm far reach practic dietari implic ms patient glucos level sugar level blood found predictor level disabl ms patient studi need prove causal relationship ms patient smoke increas sever ms reason includ fact smoke caus damag chang immun system blood pressur regul system ms patient certain genet pattern hla drb increas level spinal cord damag compar ms patient without hla drb highlight valu examin brain spinal cord microscop link find genet factor chronic cerebrospin venou insuffici ccsvi propos caus ms damag due block venou drainag brain studi differ found proport ms patient ccsvi compar healthi peopl without ms studi suggest ccsvi common ms patient gener popul walk gait measur ms patient ampyra dalfampridin first take ampyra drug drug reinstat research found walk becam wors patient take drug improv ampyra reinstat tecfidera approv long term treatment ms written susan well courtney review jack burk md unit state food drug administr fda announc march approv tecfidera dimethyl fumar bg first line therapi long term treatment relaps form multipl sclerosi ms tecfidera manufactur biogen idec th drug third oral medic approv diseas modifi therapi dmt long term treatment ms approv dosag mg taken pill form twice daili tecfidera may distinct dual mechan action first immunomodul modul affect immun system function exhibit anti inflammatori properti second tecfidera may neuro protect effect potenti protect nerv [axons] myelin cover damag phase iii defin placebo control studi enrol patient result show percent reduct proport patient relaps studi period compar placebo percent reduct risk sustain disabl progress least week phase iii confirm placebo control studi enrol patient result show reduct relaps rate percent tecfidera compar placebo studi compar placebo individu given tecfidera significantli reduc diseas activ shown magnet reson imag mri scan commonli report side effect flush gastrointestin event diarrhea nausea vomit abdomin pain occur often begin treatment decreas frequenc first one two month medic reduc white blood cell lymphocyt count seen first year treatment lymphocyt diseas fight cell fda recommend prior start tecfidera annual thereaft still treatment patient given complet blood count monitor abil fight infect inform pleas see mymsaa org news tecfidera approv msaa full articl approv tecfidera addit inform tecfidera may found visit www tecfidera com biogen idec patient assist program www msactivesourc com addit msaa websit mymsaa org individu may call msaa inform ms treatment question msaa client servic depart may email msquestion mymsaa org back',\n",
       " 'hi sunday welcom grace sorri cancer progress tarceva hope chanc tri tagrisso ask oncologist comment question let us know blood test turn best janin',\n",
       " 'patient treat adalimumab increas risk infect may becom seriou lead hospit death infect includ tb invas fungal infect bacteri viral caus opportunist pathogen includ legionella listeria risk benefit therapi care consid prior treatment initi patient chronic recurr infect evalu latent tb treat necessari prior initi therapi monitor patient close sign symptom infect treatment includ possibl develop tb patient test neg prior treatment consid empir antifung therapi risk patient develop sever system ill lymphoma malign fatal report pediatr adolesc patient treat tumor necrosi factor tnf blocker adalimumab postmarket case hepatosplen cell lymphoma hstcl usual fatal report patient treat tnf blocker includ adalimumab primarili adolesc young adult male crohn diseas ulcer coliti case occur patient receiv concomit treatment azathioprin mercaptopurin subcutan rout solut patient treat adalimumab atto increas risk infect may becom seriou lead hospit death infect includ tb invas fungal infect bacteri viral caus opportunist pathogen includ legionella listeria risk benefit therapi care consid prior treatment initi patient chronic recurr infect evalu latent tb treat necessari prior initi therapi monitor patient close sign symptom infect treatment includ possibl develop tb patient test neg prior treatment consid empir antifung therapi risk patient develop sever system ill lymphoma malign fatal report pediatr adolesc patient treat tumor necrosi factor tnf blocker includ adalimumab product postmarket case hepatosplen cell lymphoma hstcl usual fatal report patient treat tnf blocker includ adalimumab product primarili adolesc young adult male crohn diseas ulcer coliti case occur patient receiv concomit treatment azathioprin mercaptopurin subcutan rout solut patient treat adalimumab adbm increas risk infect may becom seriou lead hospit death infect includ tb invas fungal infect bacteri viral caus opportunist pathogen includ legionella listeria risk benefit therapi care consid prior treatment initi patient chronic recurr infect evalu latent tb treat necessari prior initi therapi monitor patient close sign symptom infect treatment includ possibl develop tb patient test neg prior treatment consid empir antifung therapi risk patient develop sever system ill lymphoma malign fatal report pediatr adolesc patient treat tumor necrosi factor tnf blocker adalimumab adbm postmarket case hepatosplen cell lymphoma hstcl usual fatal report patient treat tnf blocker includ adalimumab adbm primarili adolesc young adult male crohn diseas ulcer coliti case occur patient receiv concomit treatment azathioprin mercaptopurin commonli use brand name see also stelara u amjevita cyltezo humira avail dosag form solut therapeut class antirheumat pharmacolog class monoclon antibodi use humira adalimumab inject use treat symptom prevent progress activ rheumatoid arthriti ankylos spondyl use children year age older juvenil idiopath arthriti medicin also use treat psoriat arthriti type arthriti caus pain swell joint along patch scali skin area bodi psoriat arthriti usual occur skin condit call psoriasi adalimumab may use alon combin medicin eg methotrex dmard adalimumab inject also use treat symptom activ crohn diseas patient help medicin infliximab also use treat moder sever ulcer coliti patient treat medicin eg azathioprin corticosteroid mercaptopurin work well adalimumab inject may also use treat chronic plaqu psoriasi skin diseas red patch white scale go away also use treat moder sever hidraden suppurativa chronic skin diseas small pain lump skin adult children year age older medicin also use treat non infecti intermedi posterior panuv adult children year age older medicin avail doctor prescript use humira decid use medicin risk take medicin must weigh good decis doctor make medicin follow consid allergi tell doctor ever unusu allerg reaction medicin medicin also tell health care profession type allergi food dye preserv anim non prescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatr specif problem would limit use adalimumab inject treatment juvenil idiopath arthriti non infecti uveiti children year age older treatment hidraden suppurativa children year age older howev safeti efficaci establish children younger year age juvenil idiopath arthriti non infecti uveiti children younger year age crohn diseas children younger year age hidraden suppurativa children condit geriatr appropri studi perform date demonstr geriatr specif problem would limit use adalimumab inject elderli howev medicin may caus seriou infect cancer often elderli may requir caution patient receiv adalimumab inject breast feed adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur case doctor may want chang dose precaut may necessari take medicin especi import healthcar profession know take medicin list follow interact select basi potenti signific necessarili inclus use medicin follow medicin usual recommend may requir case medicin prescrib togeth doctor may chang dose often use one medicin abatacept adenoviru vaccin anakinra bacillu calmett guerin vaccin live cholera vaccin live infliximab influenza viru vaccin live measl viru vaccin live mump viru vaccin live polioviru vaccin live rilonacept rotaviru vaccin live rubella viru vaccin live smallpox vaccin tofacitinib typhoid vaccin varicella viru vaccin live yellow fever vaccin zoster vaccin live interact food tobacco alcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco medic problem presenc medic problem may affect use medicin make sure tell doctor medic problem especi blood problem eg aplast anemia pancytopenia thrombocytopenia histori congest heart failur guillain barr syndrom histori infect fungal bacteri histori leukopenia low number white blood cell multipl sclerosi optic neuriti eye problem psoriasi skin diseas use caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copd granulomatosi polyangi use caution may increas chanc get new cancer diabet hepat b histori opportunist infect histori tuberculosi histori may increas chanc side effect infect activ use patient condit tuberculosi activ treat first receiv medicin proper use adalimumab section provid inform proper use number product contain adalimumab may specif humira pleas read care medicin given shot skin adalimumab may sometim given home patient need hospit clinic use medicin home doctor nurs teach prepar inject medicin sure understand use medicin medicin come medic guid patient instruct use leaflet read follow instruct care ask doctor question use medicin home shown bodi area shot given use differ bodi area time give child shot keep track give shot make sure rotat bodi area help prevent skin problem inject skin area red bruis tender hard psoriasi inject rais thick red scali skin patch skin lesion medicin avail form may use pen prefil syring use pen syring first gather item need clean flat surfac use cloth towel well light area wash hand soap water use medicin remov carton syring pen refriger place cloth allow minut syring pen warm room temperatur warm medicin way remov needl cover prefil syring pen allow medicin reach room temperatur remov right away use check liquid syring pen use view window clear colorless cloudi discolor particl float use syring pen check amount liquid pen close fill line seen window fill line show full dose medicin pen full amount liquid use call pharmacist liquid clear place clean flat surfac shake medicin check expir date prefil syring pen make sure date pass use medicin date pass choos inject site bodi eg thigh abdomen stomach area clean inject site fresh alcohol wipe let dri remov cap needl cover readi inject inject full amount medicin within minut cap cover remov might small amount blood liquid inject site press hold dri clean cotton ball inject site second rub dose dose medicin differ differ patient follow doctor order direct label follow inform includ averag dose medicin dose differ chang unless doctor tell amount medicin take depend strength medicin also number dose take day time allow dose length time take medicin depend medic problem use medicin inject dosag form pen prefil syring crohn diseas adult children year age older weigh kilogram kg first week milligram mg inject skin divid dose may given four shot day two shot per day day week later dose mg given mainten dose mg given week everi week thereaft children year age older weigh kg less kg first week mg inject skin divid dose may given two shot day week later dose mg given mainten dose mg given week everi week thereaft children younger year age use dose must determin doctor hidraden suppurativa adult first week milligram mg inject skin divid dose may given four shot day two shot per day day week later dose mg given weekli mainten dose mg given start week children year age older weigh kilogram kg dose base bodi weight must given doctor first week mg inject skin divid dose may given four shot day two shot per day day week later dose mg given weekli mainten dose mg given start week children year age older weigh kg kg dose base bodi weight must given doctor first day mg inject skin mg day mainten dose mg given everi week children younger year age weigh less kg use dose must determin doctor juvenil idiopath arthriti children year age weigh kilogram kg milligram mg inject skin everi week children year age weigh less kg mg inject skin everi week children year age weigh less kg mg inject skin everi week children younger year age weigh less kg use dose must determin doctor plaqu psoriasi adult first milligram mg inject skin mg week initi dose everi week thereaft children use dose must determin doctor psoriat arthriti rheumatoid arthriti ankylos spondyl adult milligram mg inject skin everi week doctor may adjust dose need children use dose must determin doctor ulcer coliti adult first week milligram mg inject skin divid dose may given four shot day two shot per day day week later dose mg given mainten dose mg given week everi week thereaft children use dose must determin doctor uveiti adult first milligram mg inject skin mg week initi dose everi week thereaft children year age weigh kilogram kg milligram mg inject skin everi week children year age weigh less kg mg inject skin everi week children year age weigh less kg mg inject skin everi week children younger year age weigh less kg use dose must determin doctor miss dose miss dose medicin take soon possibl howev almost time next dose skip miss dose go back regular dose schedul doubl dose storag keep reach children keep outdat medicin medicin longer need ask healthcar profession dispos medicin use store refriger freez keep medicin origin carton protect light use frozen thaw travel may store medicin room temperatur day throw away unus medicin day store medicin extrem heat cold temperatur throw away use syring pen hard close contain needl cannot poke keep contain away children pet precaut use humira use medicin long time import doctor check child progress regular visit allow doctor see medicin work properli decid whether continu use blood urin test may need check unwant effect child need skin test tuberculosi use medicin tell doctor anyon home ever posit reaction tuberculosi skin test adalimumab temporarili lower number white blood cell blood may increas chanc get infect also lower number platelet necessari proper blood clot occur certain precaut take especi blood count low reduc risk infect bleed avoid peopl infect check doctor right away child think get infect get fever chill cough hoars lower back side pain pain difficult urin check doctor right away child notic unusu bleed bruis black tarri stool blood urin stool pinpoint red spot skin care use regular toothbrush dental floss toothpick medic doctor dentist nurs may recommend way clean teeth gum check medic doctor dental work done touch eye insid nose unless wash hand touch anyth els meantim care cut use sharp object safeti razor fingernail toenail cutter avoid contact sport situat bruis injuri could occur take medicin unless discuss doctor use abatacept orencia anakinra kineret togeth medicin may increas risk seriou side effect medicin may caus unwant effect may occur month year medicin use small number peopl includ children teenag use type medicin develop certain type cancer eg leukemia patient also develop rare type cancer call lymphoma talk doctor child unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss also check doctor right away child skin red scali patch rais bump fill pu adalimumab may caus seriou allerg reaction includ anaphylaxi life threaten requir immedi medic attent check doctor right away child rash itch swell face throat leg feet troubl breath chest pain receiv medicin check doctor right away child one symptom swell face finger feet lower leg sudden weight gain may sign heart condit call congest heart failur chf peopl use medicin develop lupu like symptom treatment got better medicin stop check doctor right away child start chest pain joint pain rash cheek arm sensit sun live vaccin immun child treat adalimumab child vaccin need current use adalimumab sure ask child doctor question needl cover prefil syring pen contain dri natur rubber deriv latex may caus allerg reaction peopl sensit latex tell doctor child latex allergi use medicin seriou skin reaction occur treatment medicin check doctor right away child follow symptom use medicin blister peel loosen skin red skin lesion sever acn skin rash sore ulcer skin fever chill use medicin take medicin unless discuss doctor includ prescript nonprescript counter [otc] medicin herbal vitamin supplement humira side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor immedi follow side effect occur common bodi ach pain cough ear congest ga abdomin stomach pain hoars lightheaded loss voic lower back side pain muscl ach pain nasal congest pain tender around eye cheekbon rapid sometim shallow breath shiver stomach full sunken eye thirst troubl sleep warmth skin wrinkl skin less common abnorm vagin bleed discharg agit arm back jaw pain black tarri stool bleed gum nose blind bloat swell face arm hand lower leg feet blood stool chang bowel habit bloodi cloudi urin blur vision broken bone chang size shape color exist mole chang skin color chest pain tight heavi chill clear bloodi discharg nippl cold hand feet confus constip cough cough spit blood decreas urin decreas vision depress difficulti breath difficulti burn pain urin dimpl breast skin dizzi drowsi eye pain faint fast slow irregular heartbeat fever forget frequent urg urin gener feel ill hair loss headach hive itch skin rash increas thirst invert nippl irregular breath irregular puls irrit light color stool loss appetit lump breast arm lump swell abdomen stomach mole leak fluid bleed muscl cramp spasm nausea new mole night sweat blood pressur puls noisi breath numb tingl arm leg face pain red swell arm leg without injuri present pale skin persist non heal sore skin pink growth puffi swell eyelid around eye face lip tongu rais firm bright red patch red swell breast see hear thing seizur sharp back pain rib shini bump skin slur speech problem swallow sneez sore skin breast heal sore throat sore ulcer white spot lip mouth spit blood stiff neck stomach pain stop heart sudden high fever low grade fever month sweat swell face finger feet lower leg swollen gland swollen neck vein tired troubl breath activ troubl think unconsci unexplain bruis bleed unpleas breath odor unusu tired weak unusu weight gain loss visual disturb vomit vomit blood materi look like coffe ground yellow skin eye incid known blister peel loosen skin diarrhea joint muscl pain pinpoint red spot skin red skin lesion often purpl center red irrit eye red scale crust skin unusu bleed bruis side effect may occur usual need medic attent side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question common bladder pain bleed blister burn cold discolor skin feel pressur hive infect inflamm itch lump numb pain rash red scar sore sting swell tender tingl ulcer warmth inject site pound ear less common abnorm heal decreas height difficulti move difficulti walk dri mouth heartburn indigest loss hear loss strength energi menstrual chang muscl joint stiff tight rigid muscl pain weak pain back rib arm leg shaki leg arm hand feet swell red joint side effect list may also occur patient notic effect check healthcar profession call doctor medic advic side effect may report side effect fda fda',\n",
       " 'done research sb interestingli enough issu consist lab monitor ad nutrient foreign moment diseas bad go three time week fluid ad potassium need add tpn support picc receiv start accept certain thing accept full fulltim hour week workweek may never option futur though sure get back eventu health turn corner think good answer soon tomorrow roll around main ibd doc main surgeon get togeth along current team believ surgeri answer much quickli would believ sinc alreadi admit surgeri floor surgeri team make sens keep surgeri possibl week say iv steroid tpn make sure diseas calm right prior surgeri smart peopl charg case sure think keyword smart much remov believ option anyth remov especi keep get admit obstruct low fiber low residu diet year old crohn sinc medicin remicad restart methotrex supplement vitamin zinc b multivitamin',\n",
       " 'hi diagnos crohn diseas tri ton medic remicad humira methotrex mp entyvio even stelara allerg reaction other stop respond noth realli put remiss latest visit gi doctor develop fistula connect colon bladder colonoscopi week later show pretti sever inflamm blood fistula work gi recommend surgeri surgeri abscess first resect understand need part sigmoid colon resect nervou enough healthi colon rectum use reconnect colostomi real possibl make littl nervou anyon tip insight life colostomi sigmoid resect realli appreci thank knorb join jan search board messag relat topic fistula surgeri ladi join jun hi crohn recent start read consid crohn resec well join oct diagnos sinc crohn read pain surgeri crohn mattison join nov surgeri may resect small read crohn coliti commun forum thank help monitor crohn coliti commun abus report sent inform crohn coliti commun site replac physician advic alway check person physician take action regard health crohn coliti foundat websit support educ grant rule welcom crohn coliti commun websit associ ccfa org support educ grant abbvi pleas read top rule post messag share stori alway courteou sensit other intend audienc crohn coliti foundat onlin commun intend patient caregiv famili friend commun intend industri repres advertis individu permit particip site meet crohn coliti commun brows site see commun talk find issu import join share stori feel comfort site regist share thought regular basi stay secur rememb site view anyon internet except registr person page search engin avail within site guard privaci follow simpl rule share address phone number detail famili anyth els would feel uncomfort other read post person email awar may receiv spam e mail spammer gather address web read react post care agre offend someon post take step back think repli sinc talk person must recogn may misunderstand stori post pleas sensit other feel ask clarif act search start new topic keep messag board easi use pleas use search bar locat topic interest start new thread start new thread pleas use obviou subject head word catch attent other topic archiv day inact view past topic post click archiv topic within forum stick guidelin keep site safe everyon pleas post doctor name treatment facil name treatment specif contact inform other without consent link websit uncertain content advertis request fundrais item sale request studi survey questionnair particip provoc inform share photo pleas use good tast appropri imag ad photo profil person stori photo jpg format follow rule crohn coliti commun moder routin scan messag board delet tasteless post post inappropri messag pictur use offens languag post multipl occas notifi via email account inactiv report foul play help crohn coliti commun moder report anyon post inappropri messag pictur click report abus button messag email ccfacommun ccfa org question concern pleas feel free email us ccfacommun ccfa org question concern want feel comfort term condit post stori question concern inform commun grant crohn coliti foundat author agent permiss publish reproduc record use stori crohn coliti commun author agent see fit medium forum manner help crohn coliti commun mission agre releas hold harmless crohn coliti commun liabil third parti may aris releas inform third parti third parti agre text content made person parent guardian shall exclus properti crohn coliti commun crohn coliti commun cannot verifi everi claim made third parti contributor commun respons authent inform post',\n",
       " 'start take b start gilenya feel better tecfidera know tablet respons go cut tri find',\n",
       " 'first publish werewolf [ ] year avail new gener anti cancer drug new zealand driven polit decis much medic one patient advanc melanoma made lot initi public fuss pharmac polit master sought manag demand expens treatment limit state fund advanc skin cancer week lung cancer patient put posit need mount public highli polit campaign qualifi similar state fund life save treatment basic peopl skin cancer qualifi state fund drug lung cancer current good medic reason exist polit decis contain pharmaceut cost health budget especi babi boomer enter age bracket risk cancer rise spend public health tightli constrain big budget defenc item contrast fund demand anoth stori pharmac meat sandwich caught rise public demand sky high expens drug one hand beehiv driven demand frugal given potenti scale demand recent increas pharmac fund mere drop bucket also help pharmac abil make coher decis oversea test result new drug still come chang landscap almost monthli basi initi pharmac follow trend global market fund opdivo bristol myer squibb bm anti cancer drug first gate late test market race keytruda similar drug develop merck sharp dohm msd drug tend work second level treatment first line respons drug work induc bodi immun system counter cancer cell everi patient benefit drug relev current bio marker involv diagnost test protein call pd l june bm tri spectacularli fail score decis goal opdivo ongo market battl keytruda ala though test result show opdivo provid better result chemotherapi patient rate pd l express rang plu compani share price sank almost overnight news [ ] almost simultan msd releas test result keytruda show glow outcom patient rate pd l express rang plu keytruda market profil msd share price rose substanti wake clearli though two set test measur appl orang opdivo test ambiti attempt measur drug first line treatment potenti amid class patient includ earli onset e plu express tumour diseas keytruda test confirm drug efficaci later diseas cycl rate express top taken togeth test suggest futur use drug unlik monotherapi administ earli isol instead futur may well combin drug taken togeth drug e g opdivo plu anoth bm drug call yervoy hope expand ambit condit respons expens treatment bm ceo giavanni caforio sum new outlook opdivo light recent test goal link first line set decid answer two import question everi patient first question answer studi role monotherapi trial tell us role monotherapi like limit small subset patient express pd l high level believ know previou studi report long time ago second question becom therefor role combin therapi remain confid studi look combin therapi first line becom even import answer question believ studi clearli answer definit question use monotherapi pd first line set like limit patient express pd high level word combin may eventu enabl immun system biolog drug deploy far earlier diseas cycl even perhap first line treatment yet repeat caforio main point current opdivo keytruda use first line monotherapi treatment limit patient express pd l protein high level plainli miracl cure everyon test market pattern outlin also help explain pharmac zigzag opdivo keytruda past month right though fierc competit lower price either drug much hope pharmac shorten patent term less expens gener replac appear horizon eight year like patent term drug forese lung cancer common form cancer new zealand state fund keytruda late stage treatment option non small cell lung cancer nsclc would highli expens pharmac look hope oversea test evid might help target patient would stand benefit drug genuin problem us fda guidelin make pd l level pre condit treatment perhap process involv still somewhat mysteri [ ] still consensu regard valu pd l express nsclc predict marker respons across board posit pd l predict respons alway guarante lack pd l exclud respons obvious one must conclud pd l one sever [ ] mani factor determin likelihood respons compound pd l problem lack defin criteria pd l posit tumor realli mean like emerg combin may increas effect scope treatment peopl eliug mention combin price someth els pharmac nervous ponder cancer meanwhil stand still disturbingli sign segment cancer patient may stand benefit treatment also face potenti relaps given capac cancer develop resist [ ] recent [ ] studi came unsettl conclus patient',\n",
       " 'samuelmanu follow om diet month follow diet ms class stabl could diet could gilenya could fast could care relaps sinc diagnosi recent switch wahl protocol still relaps free go anoth mri month see new lesion also think benefit ms exagger benefit gener help sure revers diseas immun system skeptic still follow religi els got',\n",
       " 'new genet research diabet led team harvard medic school identifi potenti new therapi target runx explain significantli reduc abnorm blood vessel growth retina hallmark advanc diabet eye diseas although research conduct vitro explain laboratori studi human retin cell mous retina studi author hope inhibit runx may also help manag abnorm retin blood vessel growth number eye condit wet macular degener retinopathi prematur earlier diseas process abnorm blood vessel chanc develop hope may opportun chang treatment paradigm condit said co author leo kim ph instead treat patient abnorm blood vessel form eye may abl give patient eye drop system medic prevent develop first place research diabet new diabet research titl identif runx mediat aberr retin angiogenesi translat identif protein chang reduc abnorm blood vessel growth occur retin diseas includ diabet retinopathi publish onlin first april diabet publish american diabet associ diabet present origin research normal abnorm physic process occur diabet mellitu includ laboratori anim human research author jonathan lam daniel j oh lindsay l wong dhanesh amarnani cindi park windhol angi v sanchez jonathan cardona velez declan mcguon anat stemmer rachamimov dean eliott dian r bielenberg tave van zyl lishuang shen xiaowu gai patricia amor leo kim joseph f arboleda velasquez harvard medic school boston massachusett gener hospit boston children hospit lo angel lo angel ca universidad pontificia bolivariana medellin colombia first terminolog use research brief explan key term use diabet research angiogenesi describ growth new blood vessel play crucial role normal develop bodi organ tissu howev excess abnorm blood vessel develop also occur diseas cancer tumor growth macular degener diabet retinopathi retin macular bleed vitro refer process take place test tube cultur dish typic laboratori vivo refer process take place live human organ neovascular refer eye diabet retinopathi wet age relat macular degener describ abnorm blood vessel growth retina neo new vascular blood vessel neovascular also featur eye health condit includ retinopathi prematur cancer runx runt relat transcript factor protein human encod runx gene runx protein activ gene help control develop blood cell vegf protein call vascular endotheli growth factor stimul abnorm blood vessel growth retina macula research excerpt research identifi new target abnorm blood vessel growth eye via medic xpress [researchers] identifi novel therapeut target retin neovascular abnorm blood vessel growth retina hallmark advanc diabet eye diseas prolif diabet retinopathi transcript factor runx found abnorm retin blood vessel inhibit runx small molecul drug research achiev percent reduct retinopathi preclin [mean human clinic trial begun] model find pave way new therapi address diabet retinopathi condit involv abnorm vessel growth within retina current treatment control retin neovascular requir inject larg protein [i e lucenti eylea avastin ] eye patient often month studi open door novel mode treatment base small molecul could cross biolog barrier treatment could self administ patient elimin need intravitr inject said co author joseph f arboleda velasquez ph diabet report author studi tissu patient prolif diabet retinopathi identifi presenc runx diseas blood vessel normal blood vessel next use small molecul drug origin develop cancer therapi inhibit activ runx eye led signific reduct abnorm blood vessel studi author hope inhibit runx may present target opportun manag retinopathi certain eye condit perhap earlier diseas process abnorm blood vessel develop futur studi test whether drug deliv topic eye drop rather inject explor relationship runx vegf factor seemingli play role angiogenesi diabet eye diseas diabet retinopathi although peopl diabet like develop cataract younger age twice like develop glaucoma peopl diabet primari vision problem caus diabet diabet retinopathi lead caus new case blind low vision adult age person diabet retinopathi might see retinopathi gener term describ damag retina retina thin light sensit tissu line insid surfac eye nerv cell retina convert incom light electr impuls electr impuls carri optic nerv brain interpret visual imag diabet retinopathi occur damag small blood vessel nourish tissu nerv cell retina prolif gener term mean grow increas rapid rate produc new tissu cell term prolif use relat diabet retinopathi describ growth prolifer abnorm new blood vessel retina non prolif indic process yet occur prolif diabet retinopathi affect approxim individu diseas four stage diabet retinopathi accord nation eye institut diabet retinopathi four stage mild non prolif retinopathi earli stage small area balloon like swell occur retina tini blood vessel moder non prolif retinopathi diseas progress blood vessel nourish retina becom block sever non prolif retinopathi mani blood vessel becom block disrupt blood suppli nourish retina damag retina signal bodi produc new blood vessel prolif retinopathi advanc stage signal sent retina trigger develop new blood vessel grow prolifer retina vitreou transpar gel fill interior eye new blood vessel abnorm ruptur bleed caus hemorrhag retina vitreou scar tissu develop tug retina caus damag even retin detach learn current treatment diabet retinopathi treatment avail diabet eye diseas visionawar org studi journal diabet excerpt studi abstract prolif diabet retinopathi pdr common caus blind develop world work adult popul affect type type diabet mellitu identifi runt relat transcript factor runx gene upregul cd vascular endotheli cell obtain human pdr fibrovascular membran fvm via transcriptom analysi vitro studi use human retin microvascular endotheli cell hrmec [i e cell inner line blood vessels] show increas runx rna protein express respons high glucos wherea runx inhibit reduc hrmec migrat prolifer tube format immunohistochem stain runx show reactiv vessel patient deriv fvm angiogen tuft retina mice oxygen induc retinopathi oir suggest runx upregul hallmark aberr retin angiogenesi inhibit runx activ ro small molecul result signific reduct neovascular tuft oxygen induc retinopathi oir support feasibl target runx aberr retin angiogenesi',\n",
       " 'experi entyvio read well reciev seem stelara get best review newer anti tnf one consist critic entyvio take quit long time work might good choic recommend homework first daughter diagnos feb yr old time diagnosi crohn termin illium use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mg imuran',\n",
       " 'welcom entyvio log thread kinaydein_grrl welcom forum see uceri list medic strongli advis speak gi switch pred uceri bridg uceri might effect prednison certainli work much safer steroid http share salix com share pi uceri pi pdf nearli system work also mention either remicad simponi know keep open option event entyvio someday fail someth consid also mayb good probiot could certainli help caus alreadi one someth strongli think http www ncbi nlm nih gov pubm mkl recollect post infus issu hope issu resolv pancol dx fall current imuran lialda entyvio',\n",
       " 'hello realli difficult earli day differenti relaps progress ms one reason relaps remit ms kind name impli get complet remiss symptom also time frame actual spoken fact rrm alway give complet remiss might find never properli feel feet sort get use chang sensori symptom forget like abl feel thing properli finger sole feet whatev problem time take remiss sometim week often least alway month much time would pass forget problem one day thing would suddenli occur spasm leg even sure long keep diari way found keep track even year sinc first symptom forget x happen check diari app see x happen caus get check diari app nearli year old check time even though progress neurologist tend reluct day definit diagnos someon outset progress one reason diseas modifi drug dmd avail ppm even possibl ocrevu given thumb week neurologist uncertain diagnos rrm simpli dmd sort go back progress diagnosi cours marker indic exactli progress progress often peopl start rr diagnosi could potenti chang month year pp spm se ask seem straightforward question easi answer question add fact peopl rrm realli sever disabl relaps peopl ppm much gentl progress disabl see winner loser unfortun ms bloodi unlucki varieti sue',\n",
       " 'report patient activ ulcer coliti primari non respons three biolog infliximab adalimumab vedolizumab differ mechan action refus surgic treatment favor respons tofacitinib clinic endoscop remiss advers event observ use agent case illustr difficulti may face regard identif express proper mechan action involv pathogenesi ulcer coliti patient import anoth treatment option differ mechan action like tofacitinib resumo os inibidor da janu kinas jak sido incorporado ao tratamento de doen imunomediada como artrit reumatoid e al disso sido testado tratamento da psor ase e doen inflamat ria intestinai tanto na retocolit ulcerativa quanto na doen de crohn tofacitinib uma droga grupo da pequena mol cula de uso oral que inib janu kinas e e em menor grau janu kinas esta inibi promov bloqueio de uma rie de citocina pr inflamat ria que est envolvida na patog nese da doen inflamat ria intestinai e desempenham important papel no processo imun tai como ativa fun e prolifera linfocit aacu http www scielo br scielo php script sci_arttext pid l sourc arquivo de gastroenterologia',\n",
       " 'leav behind bs got second infus let final talk infus unfortun full dose mg specialti pharmaci order mg two week back take half way would start ocrevu second infus suppos full dose howev infus basic find good vein iv readi rock problem find vein due excess use steroid odd year vein habit roll collaps shrink difficult find vein iv luckili took twice first start steroid drip thank god mg mg howev let real mg steroid iv joke steroid pack sick highest start mg mention oral drug steroid drip take roughli half hour benadryl realli get via pill iv drip push iv line one reaction pill would say drip came second slow still like morph drip push iv line shock learn tell take slow help watch though flush line benadryl still remain goe shoot blood goe right heart lung almost seiz breath second cough second later fine expect scari also make littl dizzi eventu tire like noth ever experienc come directli blood push iv line drip expect like benadryl take home medicin easi usual step drip start slow increas everi half hour goe slow start build say one advers reaction somebodi offic person minor reaction ear would itch like allergi act first time rituxan happen stop give littl benadryl start ocrevu light paid mind total drip last hour morn woke headach say anyth raini snowi day ny could weather relat also prone migrain could truth biggest side effect last time rituxan steroid probabl feel mayb tomorrow question feel free ask',\n",
       " 'year old femal cancer good health march diagnos nsclc stage egfr exon four brain met treat cyber knife ck week later eventu resolv tarceva sinc april vat lobectomi novemb ned neck sinc vat two year one mm brain met treat ck januari continu work recent latest scan mri show progress two brain met previous treat seem come back one mm seem stabl sinc octob one grown mm mm one lymph node light pet scan suv one lung nodul light grown multipl tini lung nodul mention pet report small show suv follow cea month gone three guardant liquid biopsi would pick nf noth els doctor request anoth liquid biopsi urin test trovagen find continu egfr mutat got result phone earlier today told egfr came one test detect still want tissu biopsi check offer follow neg laser interstici thermal therapi litt one brain met chemo posit tagrisso respons rate compar tagrisso vs chemo carboplatin alimta could tri tagrisso one two month chemo litt chemo penetr brain cours tissu biopsi definit throw light matter take want start treatment multitud thank faith',\n",
       " 'type monoclon antibodi use cancer detect therapi monoclon antibodi laboratori produc substanc locat bind cancer cell substanc studi treatment cancer small piec protein call urokinas enzym dissolv blood clot prevent form type antiangiogenesi agent type antimetastat agent also call urokinas plasminogen activ upa deriv peptid aap enzym normal found healthi kidney may found high level urin kidney problem use biomark detect damag kidney caus drug agent may also use diagnos certain kidney liver disord also call alanin aminopeptidas abarelix listen uh bayr eh lix drug use reduc amount testosteron made patient advanc symptomat prostat cancer treatment option avail belong famili drug call gonadotropin releas hormon gnrh antagonist also call plenaxi abca pathway listen path way describ group protein cell work togeth help remov extra cholesterol certain fat tissu bodi chang abca pathway may lead diseas heart blood vessel drug substanc affect pathway studi prevent treatment diseas abcd rate listen ray ting stage system prostat cancer use abcd b refer cancer confin prostat c refer cancer grown prostat spread lymph node place bodi refer cancer spread lymph node place bodi also call jewett stage system whitmor jewett stage system abdomen listen ab doh men area bodi contain pancrea stomach intestin liver gallbladd organ abdomin listen ab dah mih nul abdomen part bodi chest hip contain pancrea stomach intestin liver gallbladd organ abdomin ultrasound listen ab dah mih nul ul truh sownd procedur use examin organ abdomen ultrasound transduc probe press firmli skin abdomen high energi sound wave transduc bounc tissu creat echo echo sent comput make pictur call sonogram also call transabdomin ultrasound abdomin x ray listen ab dah mih nul ex ray x ray organ insid abdomen x ray type radiat pass bodi onto film make pictur area insid bodi x ray may use help diagnos diseas abdominoperin resect listen ab dah mih noh payr ih nee ul ree sek shun surgeri remov anu rectum part sigmoid colon incis made abdomen end intestin attach open surfac abdomen bodi wast collect dispos bag outsid bodi open call colostomi lymph node contain cancer may also remov oper abegrin listen beh grin substanc studi treatment type cancer condit abegrin bind protein surfac blood vessel may prevent growth new blood vessel tumor need grow may also prevent spread cancer type antiangiogenesi agent type metastasi inhibitor type monoclon antibodi also call etaracizumab human monoclon antibodi medi medi abemaciclib listen uh beh muh sy klib drug use treat hormon receptor posit hr neg breast cancer advanc spread part bodi use aromatas inhibitor postmenopaus women treat hormon therapi use fulvestr women whose diseas got wors treatment hormon therapi abemaciclib also use alon men women whose diseas got wors treatment hormon therapi previou chemotherapi also studi treatment type cancer abemaciclib block certain protein may help keep cancer cell grow type cyclin depend kinas inhibitor also call verzenio aberr crypt foci listen uh bayr unt kript foh sy cluster abnorm tube like gland line colon rectum aberr crypt foci form colorect polyp one earliest chang seen colon may lead cancer also call acf abi drug use treat breast cancer come back spread part bodi also use carboplatin treat advanc non small cell lung cancer patient abl surgeri radiat therapi also use gemcitabin hydrochlorid treat pancreat cancer spread part bodi studi treatment type cancer abi form anticanc drug paclitaxel may caus fewer side effect paclitaxel stop cancer cell grow divid may kill type mitot inhibitor type antimicrotubul agent also call abraxan nanoparticl paclitaxel paclitaxel albumin stabil nanoparticl formul protein bound paclitaxel abirateron acet listen bih ra teh rone seh tayt drug use prednison treat prostat cancer spread part bodi use patient whose cancer castrat resist respond treatment lower testosteron level whose cancer high risk castrat sensit respond treatment lower testosteron level also studi treatment type cancer abirateron acet lower amount androgen male hormon testosteron made bodi may stop growth cancer cell need androgen grow abirateron acet type antiandrogen also call zytiga ablat listen blay shun medicin remov destruct bodi part tissu function ablat may perform surgeri hormon drug radiofrequ heat method abnorm listen ab mul normal describ state condit behavior unusu differ consid normal abnorm lesion growth bodi may benign cancer precancer premalign like becom cancer malign cancer abo blood group system listen blud groop si tem system use group human blood differ type base presenc absenc certain marker surfac red blood cell four main blood type b ab blood transfus abo blood group system use match blood type donor person receiv transfus peopl blood type donat blood anyon call univers donor peopl blood type ab accept blood donor call univers recipi peopl type b receiv match blood type blood abr test listen test test use detect type hear loss hear loss caus injuri tumor affect nerv involv hear electrod place head certain tone click sound made electrod measur nerv signal brain react sound also call auditori brain stem respons test baer test brain stem auditori evok respons test abraxan listen uh brak sayn drug use treat breast cancer come back spread part bodi also use carboplatin treat advanc non small cell lung cancer patient abl surgeri radiat therapi also use gemcitabin hydrochlorid treat pancreat cancer spread part bodi studi treatment type cancer abraxan form anticanc drug paclitaxel may caus fewer side effect paclitaxel stop cancer cell grow divid may kill type mitot inhibitor type antimicrotubul agent also call abi nanoparticl paclitaxel paclitaxel albumin stabil nanoparticl formul protein bound paclitaxel abrikossoff tumor listen ah bree kah sof mer rare type soft tissu tumor usual begin schwann cell cell hold nerv cell place occur anywher bodi usual occur skin head neck especi mouth tongu may also occur chest breast esophagu stomach intern organ abrikossoff tumor benign cancer may malign cancer spread quickli nearbi tissu usual occur middl age adult also call granular cell tumor abscess listen ab se enclos collect pu tissu organ confin space bodi abscess sign infect usual swollen inflam absolut neutrophil count listen ab soh loot noo troh fil kownt measur number neutrophil blood neutrophil type white blood cell help bodi fight infect absolut neutrophil count may use check infect inflamm leukemia condit lower person absolut neutrophil count higher risk get infect absolut neutrophil count less mean high risk get infect cancer treatment chemotherapi may reduc absolut neutrophil count also call anc absolut risk listen ab soh loot risk measur risk certain event happen cancer research likelihood person free specif type cancer given age develop cancer certain period time exampl woman year age known risk factor breast cancer absolut risk get breast cancer lifetim year mean one everi seven women develop breast cancer absorpt listen ub sorp shun process take nutrient digest system blood use bodi abt substanc studi treatment lymphoma type cancer block enzym keep cancer cell die type bcl famili inhibitor also call navitoclax abt substanc studi treatment cancer type angiogenesi inhibitor abt substanc studi treatment cancer belong famili drug call sulfonamid abt substanc studi treatment sever type cancer abt block action sever growth factor may also block growth new blood vessel tumor need grow may caus cancer cell die type receptor tyrosin kinas inhibitor type angiogensi inhibitor also call multitarget receptor tyrosin kinas inhibitor abt abt substanc studi treatment breast cancer caus mutat chang brca brca gene also studi treatment type cancer block enzym involv mani function cell includ repair dna damag dna damag may caus normal cell action uv light anticanc drug radiat use treat cancer abt may caus cancer cell die type poli adp ribos polymeras inhibitor also call parp inhibitor abt veliparib abvd abbrevi chemotherapi combin use treat hodgkin lymphoma includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vinblastin sulfat dacarbazin also call abvd regimen abvd regimen listen reh jih men abbrevi chemotherapi combin use treat hodgkin lymphoma includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vinblastin sulfat dacarbazin also call abvd abv abbrevi chemotherapi combin use radiat therapi treat childhood hodgkin lymphoma includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vincristin sulfat etoposid also call abv regimen dbve dbve regimen abv regimen listen reh jih men abbrevi chemotherapi combin use radiat therapi treat childhood hodgkin lymphoma includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vincristin sulfat etoposid also call abv dbve dbve regimen abv pc abbrevi chemotherapi combin use radiat therapi treat childhood hodgkin lymphoma includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vincristin sulfat etoposid prednison cyclophosphamid also call abv pc regimen dbve pc dbve pc regimen abv pc regimen listen reh jih men abbrevi chemotherapi combin use radiat therapi treat childhood hodgkin lymphoma includ drug doxorubicin hydrochlorid adriamycin bleomycin sulfat vincristin sulfat etoposid prednison cyclophosphamid also call abv pc dbve pc dbve pc regimen abx egf drug use alon anticanc drug treat certain type colorect cancer spread part bodi use patient whose cancer alreadi treat whose cancer got wors treatment anticanc drug also studi treatment type cancer abx egf bind protein call epiderm growth factor receptor egfr found normal cell type cancer cell block protein may help keep cancer cell grow abx egf type monoclon antibodi also call panitumumab vectibix ac abbrevi chemotherapi combin use type therapi treat breast cancer includ breast cancer spread come back includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid also call ac regimen ac regimen listen reh jih men abbrevi chemotherapi combin use type therapi treat breast cancer includ breast cancer spread come back includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid also call ac acalabrutinib listen uh ka luh broo tih nib drug use treat mantl cell lymphoma patient alreadi receiv least one treatment also studi treatment type cancer acalabrutinib block protein call bruton tyrosin kinas btk may help keep cancer cell grow type tyrosin kinas inhibitor also call calquenc acapha listen ka fuh mixtur six herb use china prevent treat diseas lung esophag cancer studi unit state canada prevent lung cancer peopl use smoke acceler partial breast irradi listen ak seh leh ray ted par shul brest ih ray dee ay shun type radiat therapi given part breast cancer acceler partial breast irradi give higher dose shorter time given standard whole breast radiat therapi acceler partial breast irradi may given use intern extern sourc radiat also call partial breast irradi acceler phase chronic myelogen leukemia listen ak seh leh ray ted fayz krah nik eh lah jeh nu loo kee mee uh phase chronic myelogen leukemia diseas progress phase cell blood bone marrow blast cell immatur blood cell acceler radiat therapi listen ak seh leh ray ted ray dee ay shun thayr uh pee radiat treatment total dose radiat given shorter period time fewer day compar standard radiat therapi acceler fraction radiat therapi listen ak seh leh ray ted frak shun ray dee ay shun thayr uh pee radiat treatment total dose radiat divid small dose treatment given day total dose radiat also given shorter period time fewer day compar standard radiat therapi accol listen koh layt drug use prevent treat symptom asthma block substanc caus inflamm lung type antiasthmat agent leukotrien receptor antagonist also call zafirlukast ace inhibitor listen hih bih ter drug use lower blood pressur ace inhibitor type antihypertens agent also call angiotensin convert enzym inhibitor acetaminophen listen uh see tuh mih nuh fen drug reduc pain fever inflamm belong famili drug call analges acet listen seh tayt form acet acid acid found vinegar acet acid listen uh see tik sid acid found vinegar acet acid also use dissolv substanc need make medicin product plastic aceton listen seh tone chemic substanc found natur small amount plant tree volcano forest fire aceton also made bodi fat broken also found tobacco smoke car exhaust trash landfil industri aceton use plastic fiber medicin household cleaner glue nail polish remov expos high level aceton may irrit skin eye nose throat lung caus headach nausea vomit dizzi confus loss conscious health problem acetyl group listen seh til groop small molecul made two carbon three hydrogen one oxygen atom acetyl group ad remov molecul may affect molecul act bodi acetyl listen seh tih lay shun chemic reaction small molecul call acetyl group ad molecul acetyl protein may affect act bodi acetylcholin listen seh til koh leen chemic made type nerv cell use send messag cell includ nerv cell muscl cell gland cell releas nerv end carri signal cell side synaps space nerv cell cell acetylcholin help control memori action certain muscl type neurotransmitt acetylcystein listen seh til si teh een drug usual use reduc thick mucu eas remov also use revers toxic high dose acetaminophen also call n acetyl l cystein n acetylcystein acetyl l carnitin listen seh til kar nih teen form natur substanc carnitin studi way prevent tissu damag caus chemotherapi carnitin made muscl liver tissu found certain food meat poultri fish dairi product use mani cell bodi make energi fat also call acetyl l carnitin hydrochlorid alcar acetyl l carnitin hydrochlorid listen seh til kar nih teen hy droh klor ide form natur substanc carnitin studi way prevent tissu damag caus chemotherapi carnitin made muscl liver tissu found certain food meat poultri fish dairi product use mani cell bodi make energi fat also call acetyl l carnitin alcar acf cluster abnorm tube like gland line colon rectum acf form colorect polyp one earliest chang seen colon may lead cancer also call aberr crypt foci achlorhydria listen ay klor hy dree uh lack hydrochlor acid digest juic stomach hydrochlor acid help digest food acid listen sid chemic give hydrogen ion water form salt combin certain metal acid sour tast turn certain dye red acid made bodi gastric acid help organ work way exampl acid hydrochlor acid acid measur scale call ph scale scale valu neutral ph valu less show increas acid acid base balanc listen sid bay ba lunt medicin state right amount acid base blood bodi fluid keep normal acid base balanc import bodi work way also call acid base equilibrium acid base equilibrium listen sid bay ee kwuh lih bree um medicin state right amount acid base blood bodi fluid keep normal acid base equilibrium import bodi work way also call acid base balanc acidif listen sih dih fih kay shun process make becom acid acid substanc give hydrogen ion water form salt combin certain metal acid listen sih dih tee describ amount acid substanc acid chemic give hydrogen ion water form salt combin certain metal acid measur scale call ph scale scale ph valu neutral ph valu less show increas acid acitretin listen sih treh tin substanc use prevent cancer treatment psoriasi belong famili drug call retinoid acn substanc studi treatment type cancer acn weaken adenoviru carri p gene tumor cell caus die type gene therapi also call rad p recombin adenoviru p sch acn listen ak nee disord skin oil gland hair gland becom inflam acolbifen hydrochlorid listen ay kole bih feen hy droh klor ide substanc studi prevent breast cancer women high risk breast cancer acolbifen hydrochlorid bind estrogen receptor bodi block effect estrogen breast type select estrogen receptor modul serm acoust listen uh koo tik sound hear acoust neurofibromatosi listen uh koo tik noor oh fy broh muh toh si genet condit tumor form nerv inner ear caus loss hear balanc tumor may also occur brain nerv skull spinal cord may caus loss speech eye movement abil swallow also call neurofibromatosi type nf acquir immunodefici syndrom listen uh kwi erd ih myoo noh deh fih shun see sin drome diseas caus human immunodefici viru hiv peopl acquir immunodefici syndrom increas risk develop certain cancer infect usual occur individu weak immun system also call aid acquir pure red cell aplasia listen uh kwi erd sel uh play zhuh rare disord bone marrow make almost red blood cell may caus infect certain drug patient disord may also thymoma tumor thymu autoimmun condit lupu erythematosu rheumatoid arthriti acridin carboxamid listen krih deen kar bok suh mide substanc studi treatment cancer type topoisomeras inhibitor also call daca acromegali listen kroh meh guh lee condit pituitari gland make much growth hormon normal growth skeleton finish caus bone hand feet head face grow larger normal acromegali caus pituitari gland tumor acrylonitril listen ak rih loh ny tril substanc use make plastic rubber textil expos acrylonitril may increas risk develop certain cancer lung brain prostat cancer ac abbrevi chemotherapi combin use treat breast cancer includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol also call ac regimen ac taxol regimen ac regimen listen reh jih men abbrevi chemotherapi combin use treat breast cancer includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol also call ac ac taxol regimen ac taxol regimen listen tak sol reh jih men abbrevi chemotherapi combin use treat breast cancer includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol also call ac ac regimen actemra listen ak tem ruh drug use treat sever life threaten cytokin releas syndrom caus type immunotherapi call chimer antigen receptor car cell therapi use patient age year older actemra also use treat certain type arthriti condit caus inflamm line arteri also studi treatment condit actemra bind receptor protein call interleukin il made white blood cell cell bodi may help lower bodi immun respons reduc inflamm actemra type monoclon antibodi also call tocilizumab acth hormon made pituitari gland acth act outer part adren gland control releas corticosteroid hormon acth made time stress also call adrenocorticotrop hormon corticotropin ac th regimen listen reh jih men abbrevi chemotherapi combin use treat breast cancer includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol trastuzumab herceptin also call ac ac regimen sequenti ac taxol trastuzumab regimen actinex listen ak tih nex drug put skin treat growth caus sun exposur form actinex taken mouth studi treatment prostat cancer actinex antioxid may block certain enzym need tumor growth also call masoprocol ndga nordihydroguaiaret acid actin keratosi listen ak tih nik kayr uh toh si thick scali patch skin may becom cancer usual form area expos sun face scalp back hand chest common peopl fair skin also call senil keratosi solar keratosi actinomycin listen ak tih noh sin drug use treat ewe sarcoma gestat trophoblast tumor wilm tumor certain type testicular cancer also use treat rhabdomyosarcoma children studi treatment type cancer actinomycin come bacterium streptomyc parvulu damag cell dna may kill cancer cell type anticanc antibiot also call cosmegen dactinomycin action studi listen ak shun stuh dee cancer prevent clinic trial studi focus find whether action peopl take prevent cancer activas listen ak tih vay form tissu plasminogen activ made laboratori help dissolv blood clot use treat heart attack stroke clot lung also studi treatment cancer type system thrombolyt agent also call alteplas r tpa recombin tissu plasminogen activ activ listen ak tih vayt biolog stimul cell rest state becom activ caus biochem function chang activ cell activ surveil listen ak tiv ser vay lent treatment plan involv close watch patient condit give treatment unless chang test result show condit get wors activ surveil may use avoid delay need treatment radiat therapi surgeri caus side effect problem activ surveil certain exam test done regular schedul may use treatment certain type cancer prostat cancer urethr cancer intraocular eye melanoma type expect manag activ daili live listen ak tih vih teez day lee lih ving task everyday life activ includ eat dress get bed chair take bath shower use toilet instrument activ daili live activ relat independ live includ prepar meal manag money shop housework use telephon also call adl acto listen ak tose drug use treat type diabet studi prevent head neck cancer may abl stop leukoplakia condit affect mouth develop cancer type thiazolidinedion also call pioglitazon ac abbrevi chemotherapi combin use treat breast cancer includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol trastuzumab herceptin also call ac regimen ac th regimen sequenti ac taxol trastuzumab regimen ac regimen listen reh jih men abbrevi chemotherapi combin use treat breast cancer includ drug doxorubicin hydrochlorid adriamycin cyclophosphamid follow treatment paclitaxel taxol trastuzumab herceptin also call ac ac th regimen sequenti ac taxol trastuzumab regimen acupoint listen ak yoo poynt specif spot bodi acupunctur needl may insert control pain symptom also call acupunctur point acupressur listen ak yoo preh sher applic pressur local massag specif site bodi control symptom pain nausea type complementari altern medicin acupunctur listen ak yoo punk cher techniqu insert thin needl skin specif point bodi control pain symptom type complementari altern medicin acupunctur needl listen ak yoo punk cher nee dul stainless steel needl slightli thicker human hair acupunctur needl insert skin specif point bodi control pain symptom acupunctur point listen ak yoo punk cher poynt specif spot bodi acupunctur needl may insert control pain symptom also call acupoint acupunctur point inject listen ak yoo punk cher poynt jek shun procedur drug vitamin herbal extract fluid inject bodi acupunctur point use syring needl acupunctur like transcutan electr nerv stimul listen ak yoo punk cher like tranz kyoo tay nee us ee lek trih kul nerv stim yoo lay shun procedur mild electr current appli certain acupunctur point spot bodi acupunctur needl may insert control pain symptom skin studi treatment dri mouth caus radiat therapi cancer also call alten acupuncturist listen ak yoo punk cheh rist person train acupunctur therapi use thin needl insert skin specif point bodi control pain symptom acupunctur type complementari altern medicin acustimul listen ak yoo stim yoo lay shun mild electr stimul acupunctur point control symptom nausea vomit acut listen uh kyoot symptom sign begin worsen quickli chronic acut bacteri prostat listen uh kyoot bak teer ee ul pro tuh ty ti inflamm prostat gland begin suddenli get wors quickli caus bacteri infect symptom includ fever chill bodi ach pain lower back genit area burn feel urin problem empti bladder way acut leukemia listen uh kyoot loo kee mee uh rapidli progress cancer start blood form tissu bone marrow caus larg number white blood cell produc enter blood stream acut lymphoblast leukemia listen uh kyoot lim foh bla tik loo kee mee uh type leukemia blood cancer come quickli fast grow acut lymphoblast leukemia mani lymphoblast immatur white blood cell blood bone marrow also call acut lymphocyt leukemia acut lymphocyt leukemia listen uh kyoot lim foh sih tik loo kee mee uh type leukemia blood cancer come quickli fast grow acut lymphocyt leukemia mani lymphoblast immatur white blood cell blood bone marrow also call acut lymphoblast leukemia acut myeloblast leukemia listen uh kyoot eh loh bla tik loo kee mee uh aggress fast grow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myelogen leukemia acut myeloid leukemia acut nonlymphocyt leukemia aml anll acut myelogen leukemia listen uh kyoot eh lah jeh nu loo kee mee uh aggress fast grow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myeloid leukemia acut nonlymphocyt leukemia aml anll acut myeloid leukemia listen uh kyoot eh loyd loo kee mee uh aggress fast grow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myelogen leukemia acut nonlymphocyt leukemia aml anll acut myeloid leukemia myelodysplasia relat chang listen uh kyoot eh loyd loo kee mee uh eh loh di play zhuh ree lay ted chayn jiz type acut myeloid leukemia least patient blood bone marrow myeloblast immatur white blood cell patient one follow condit myelodysplast syndrom md myelodysplast myeloprolif neoplasm md mpn cell chang certain chromosom similar found md least cell least two type blood cell abnorm acut myeloid leukemia myelodysplasia relat chang usual occur older adult poor prognosi also call aml mrc acut nonlymphocyt leukemia listen uh kyoot non lim foh sih tik loo kee mee uh aggress fast grow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myelogen leukemia acut myeloid leukemia aml anll acut pain listen uh kyoot payn pain come quickli sever last rel short time acut promyelocyt leukemia listen uh kyoot proh eh loh sih tik loo kee mee uh aggress fast grow type acut myeloid leukemia mani immatur blood form cell blood bone marrow usual mark exchang part chromosom also call apl promyelocyt leukemia acut radiat sick listen uh kyoot ray dee ay shun sik ne seriou ill caus expos high dose certain type radiat usual short period time symptom acut radiat sick usual occur right exposur may happen time may come go symptom includ nausea vomit diarrhea headach dizzi weak fatigu bleed hair loss swell itch red skin skin problem larg dose radiat may caus death also call acut radiat syndrom radiat poison radiat sick radiat sick syndrom acut radiat syndrom listen uh kyoot ray dee ay shun sin drome seriou ill caus expos high dose certain type radiat usual short period time symptom acut radiat syndrom usual occur right exposur may happen time may come go symptom includ nausea vomit diarrhea headach dizzi weak fatigu bleed hair loss swell itch red skin skin problem larg dose radiat may caus death also call acut radiat sick radiat poison radiat sick radiat sick syndrom acyclovir listen ay sy kloh veer substanc use prevent treat cytomegaloviru herp simplex infect may occur bodi immunosuppress belong famili drug call antivir ad drug use treat bladder carcinoma situ get better treatment bacillu calmett guerin bcg use patient cannot surgeri right away remov part bladder ad given solut cathet place bladder block certain enzym need cell divis dna repair may kill cancer cell ad type anthracyclin antibiot type topoisomeras inhibitor also call valrubicin valstar adc substanc made monoclon antibodi chemic link drug monoclon antibodi bind specif protein receptor found certain type cell includ cancer cell link drug enter cell kill without harm cell adc use treat cancer also call antibodi drug conjug adcc type immun reaction target cell microb coat antibodi kill certain type white blood cell white blood cell bind antibodi releas substanc kill target cell microb also call antibodi depend cell mediat cytotox antibodi depend cellular cytotox adcetri listen ad seh tri drug use anticanc drug treat system anaplast larg cell lymphoma peripher cell lymphoma includ angioimmunoblast cell lymphoma cd posit treat therapi also use anticanc drug treat stage iii stage iv classic hodgkin lymphoma treat therapi adcetri also use treat certain type hodgkin lymphoma anaplast larg cell lymphoma mycosi fungoid treat therapi also studi treatment type cancer adcetri contain monoclon antibodi bind protein call cd found lymphoma cell also contain anticanc drug may help kill cancer cell adcetri type antibodi drug conjug also call brentuximab vedotin sgn adderal listen deh rawl combin drug use treatment attent deficit hyperact disord adhd narcolepsi sleep disord type stimul also call dextroamphetamin amphetamin addict listen uh dik shun uncontrol crave seek use substanc drug alcohol addison diseas listen dih sun dih zeez rare disord adren gland make enough certain hormon symptom includ weight loss loss appetit nausea vomit diarrhea muscl weak fatigu low blood sugar low blood pressur patchi dark skin case disord caus immun system problem may also caus infect cancer diseas also call adren insuffici ade abbrevi chemotherapi combin use treat childhood acut myeloid leukemia aml includ drug cytarabin ara c daunorubicin hydrochlorid etoposid phosphat also call ade regimen ade regimen listen reh jih men abbrevi chemotherapi combin use treat childhood acut myeloid leukemia aml includ drug cytarabin ara c daunorubicin hydrochlorid etoposid phosphat also call ade adenin listen deh neen chemic compound use make one build block dna rna also part mani substanc bodi give energi cell adenin type purin adenocarcinoma listen deh noh kar sih noh muh cancer begin glandular secretori cell glandular cell found tissu line certain intern organ make releas substanc bodi mucu digest juic fluid cancer breast pancrea lung prostat colon adenocarcinoma adenocarcinoma situ listen deh noh kar sih noh muh sy condit abnorm cell found glandular tissu line certain intern organ uteru cervix lung pancrea colon adenocarcinoma situ occur often cervix may becom cancer spread nearbi normal tissu also call ai adenoid cystic carcinoma listen deh noyd si tik kar sih noh muh rare type cancer usual begin salivari gland adenoma listen deh noh muh tumor cancer start gland like cell epitheli tissu thin layer tissu cover organ gland structur within bodi adenopathi listen deh nah puh thee larg swollen lymph gland adenosarcoma listen den oh sar koh muh tumor mixtur adenoma tumor start gland like cell epitheli tissu sarcoma tumor start bone cartilag fat muscl blood vessel connect support tissu exampl adenosarcoma wilm tumor adenosin triphosph listen uh deh nuh seen tri fo fayt substanc present live cell provid energi mani metabol process involv make rna adenosin triphosph made laboratori studi patient advanc solid tumor see decreas weight loss improv muscl strength also call atp adenosi listen deh noh si diseas abnorm chang gland breast adenosi benign condit lobul larger usual adenosquam carcinoma listen deh noh skway mu kar sih noh muh type cancer contain two type cell squamou cell thin flat cell line certain organ gland like cell adenoviru listen den oh vy ru member famili virus caus infect respiratori tract eye gastrointestin tract form adenovirus caus diseas use gene therapi carri gene may fix defect cell kill cancer cell adh benign cancer condit cell normal line breast duct cell look abnorm microscop adh increas risk breast cancer also call atyp ductal breast hyperplasia atyp ductal hyperplasia adi peg substanc studi treatment melanoma liver cancer type cancer break amino acid arginin may block growth cancer cell need arginin grow type iminohydrolas also call pegyl arginin deiminas adjunct agent listen junkt ay jent cancer therapi drug substanc use addit primari therapi adjunct therapi listen junkt thayr uh pee anoth treatment use togeth primari treatment purpos assist primari treatment also call adjunct therapi adjunct therapi listen junk tiv thayr uh pee anoth treatment use togeth primari treatment purpos assist primari treatment also call adjunct therapi adjust disord listen uh ment di der condit person respond stress event ill job loss divorc extrem emot action caus problem work home adjuv therapi listen joo vunt thayr uh pee addit cancer treatment given primari treatment lower risk cancer come back adjuv therapi may includ chemotherapi radiat therapi hormon therapi target therapi biolog therapi adl activ daili live task everyday life basic adl includ eat dress get bed chair take bath shower use toilet instrument activ daili live iadl activ relat independ live includ prepar meal manag money shop housework use telephon also call activ daili live administr listen ad mih nih stray shun medicin act give treatment drug patient also refer way given dose often given adnex mass listen ad nek sul lump tissu near uteru usual ovari fallopian tube adnex mass includ ovarian cyst ectop tubal pregnanc benign cancer malign cancer tumor adolesc listen doh leh sent young person begun puberti yet becom adult adolesc child experi physic hormon chang mark transit adulthood adolesc gener age year adopt cell therapi listen uh dop tiv sel thayr uh pee type immunotherapi use patient cell type immun cell help bodi fight diseas cancer cancer therapi cell taken patient blood tumor tissu treat laboratori substanc make better abl target patient cancer cell kill larg number treat cell grown laboratori given back patient help immun system fight cancer type adopt cell therapi includ chimer antigen receptor cell car cell therapi tumor infiltr lymphocyt til therapi also call cellular adopt immunotherapi cell transfer therapi ado trastuzumab emtansin listen doh tra zoo mab em tan seen drug use treat posit breast cancer spread part bodi use patient alreadi treat anticanc drug call trastuzumab type drug call taxan may also use patient whose cancer recur come back adjuv therapi drug also studi treatment type cancer ado trastuzumab emtansin contain monoclon antibodi call trastuzumab bind protein call found breast cancer cell also contain anticanc drug call dm may help kill cancer cell ado trastuzumab emtansin type antibodi drug conjug also call kadcyla dm adren cancer listen uh dree nul kan ser cancer form tissu adren gland two gland locat kidney adren gland make hormon control heart rate blood pressur import bodi function adren cancer start outsid layer adren gland call adrenocort carcinoma adren cancer start center adren gland call malign pheochromocytoma adren cortex listen uh dree nul kor tex outer part adren gland small organ top kidney adren cortex make androgen corticosteroid hormon adren gland listen uh dree nul small gland make steroid hormon adrenalin noradrenalin hormon help control heart rate blood pressur import bodi function two adren gland one top kidney also call supraren gland adren insuffici listen uh dree nul suh fih shen see rare disord adren gland make enough certain hormon symptom includ weight loss loss appetit nausea vomit diarrhea muscl weak fatigu low blood sugar low blood pressur patchi dark skin case disord caus immun system problem may also caus infect cancer diseas also call addison diseas adren medulla listen uh dree nul meh doo luh inner part adren gland small organ top kidney adren medulla make chemic epinephrin adrenalin norepinephrin noradrenalin involv send nerv signal adrenalectomi listen uh dree nul ek toh mee surgeri remov one adren gland small organ top kidney adrenalin listen uh dreh nuh lin hormon neurotransmitt also call epinephrin adrenocort listen uh dree noh kor tih kul made outer layer adren gland produc steroid hormon adren gland top kidney adrenocort cancer listen uh dree noh kor tih kul kan ser rare cancer form outer layer tissu adren gland small organ top kidney make steroid hormon adrenalin noradrenalin control heart rate blood pressur bodi function also call adrenocort carcinoma cancer adren cortex adrenocort carcinoma listen uh dree noh kor tih kul kar sih noh muh rare cancer form outer layer tissu adren gland small organ top kidney make steroid hormon adrenalin noradrenalin control heart rate blood pressur bodi function also call adrenocort cancer cancer adren cortex adrenocorticotrop hormon listen uh dree noh kor tih koh troh pik hor mone hormon made pituitari gland adrenocorticotrop hormon act outer part adren gland control releas corticosteroid hormon adrenocorticotrop hormon made time stress also call acth corticotropin adreview listen dreh vyoo drug contain form radioact iodin call use find certain type tumor includ pheochromocytoma neuroblastoma radiat may help show cancer cell bodi adreview type radioconjug also call mibg iobenguan iodin metaiodobenzylguanidin adriamycin pf listen ay dree uh sin brand name doxorubicin hydrochlorid use treat mani type cancer adriamycin pf brand taken market longer avail adriamycin rdf listen ay dree uh sin brand name doxorubicin hydrochlorid use treat mani type cancer adriamycin rdf brand taken market longer avail adult progeria listen uh dult proh jeer ee uh inherit disord mark rapid age begin earli adolesc patient may shorter averag health problem loss gray hair harden arteri thin bone diabet thin harden skin also increas risk cancer especi osteosarcoma type bone cancer adult progeria caus mutat chang gene involv cell divis type autosom recess gene diseas also call werner syndrom ws adult ricket listen uh dult rih ket condit adult bone becom soft deform enough calcium phosphoru usual caus enough vitamin diet get enough sunlight problem way bodi use vitamin symptom includ bone pain muscl weak condit occur children call ricket also call osteomalacia adult cell leukemia lymphoma listen uh dult sel loo kee mee uh lim foh muh aggress fast grow type cell non hodgkin lymphoma caus human cell leukemia viru type htlv mark bone skin lesion high calcium level enlarg lymph node spleen liver also call atll adulter listen uh dul teh runt substanc ad product list ingredi substanc end product accid product made adulter may food drug product adulter may caus product harm cheaper make work adult type fibrosarcoma listen uh dult fy broh sar koh muh type cancer form fibrou connect tissu occur anywher bodi adult type fibrosarcoma may spread nearbi tissu part bodi lung bone may also recur come back treatment adult type fibrosarcoma usual occur young middl age adult also occur children type soft tissu sarcoma advanc direct listen ad van duh rek tiv legal document state person wish receiv medic care person longer abl make medic decis seriou ill injuri advanc direct may also give person spous rel friend author make medic decis anoth person person longer make decis differ type advanc direct includ live durabl power attorney dpa healthcar resuscit dnr order unit state law advanc direct may differ state state may allow certain type advanc direct advanc cancer listen ad vanst kan ser cancer unlik cure control treatment cancer may spread first start nearbi tissu lymph node distant part bodi treatment may given help shrink tumor slow growth cancer cell reliev symptom advanc practic nurs listen ad vanst prak ti regist nurs addit educ train diagnos treat diseas advanc practic nurs licens state level certifi nation nurs organ cancer care advanc practic nurs may manag primari care patient famili base practic agreement doctor also call apn np nurs practition advers effect listen ad ver eh fekt unexpect medic problem happen treatment drug therapi advers effect may mild moder sever may caus someth drug therapi given also call advers event advers event listen ad ver eh vent unexpect medic problem happen treatment drug therapi advers event may mild moder sever may caus someth drug therapi given also call advers effect advil listen ad vil drug use treat fever swell pain red prevent bodi make substanc caus inflamm type nonsteroid anti inflammatori drug nsaid also call ibuprofen motrin ae substanc made shark cartilag studi abil prevent growth new blood vessel tumor need grow type antiangiogenesi agent aee substanc studi treatment cancer belong famili drug call protein tyrosin kinas inhibitor angiogenesi inhibitor aeg substanc studi treatment cancer aeg may kill cancer cell block product protein call xiap help cell live longer also make cancer cell sensit anticanc drug type antisens oligonucleotid type chemosensit agent also call gem aerob listen ayr oh bik biochemistri reaction need oxygen happen happen oxygen present aerob exercis listen ayr oh bik ek ser size physic activ increas heart rate bodi use oxygen help improv person physic fit aerob metabol listen ayr oh bik meh ta buh lih zum chemic process oxygen use make energi carbohydr sugar also call aerob respir cell respir oxid metabol aerob respir listen ayr oh bik re pih ray shun chemic process oxygen use make energi carbohydr sugar also call aerob metabol cell respir oxid metabol aerodigest tract listen ayr oh dy je tiv trakt combin organ tissu respiratori tract upper part digest tract includ lip mouth tongu nose throat vocal cord part esophagu windpip aerosol listen ayr oh sah lize medicin turn liquid drug fine mist inhal afatinib dimal listen ay fa tih nib dy may lee ayt drug use treat non small cell lung cancer nsclc spread part bodi use patient whose cancer certain mutat chang gene call epiderm growth factor receptor egfr also use treat squamou cell nsclc spread part bodi got wors treatment anticanc drug includ platinum also studi treatment type cancer afatinib dimal block certain protein made mutat egfr gene may help keep cancer cell grow may also prevent growth new blood vessel tumor need grow afatinib dimal type tyrosin kinas inhibitor type antiangiogenesi agent also call gilotrif affin listen uh fih nih tee chemistri biolog strength attact two substanc two chemic antigen antibodi affin reagent listen uh fih nih tee ree ay jent chemistri biolog compound bind specif substanc protein nucleic acid mani affin reagent antibodi use analyz tissu sampl help diagnos diseas afinitor listen uh fih nih tor drug use exemestan treat postmenopaus women advanc breast cancer hormon receptor posit neg also use treat advanc renal cell carcinoma type kidney cancer certain type pancreat lung gastrointestin neuroendocrin tumor afinitor also use treat renal angiomyolipoma type benign kidney tumor subependym giant cell astrocytoma type benign brain tumor patient tuber sclerosi block protein involv cell divis may help keep abnorm cell includ cancer cell grow may also prevent growth new blood vessel tumor need grow afinitor contain activ ingredi everolimu type kinas inhibitor type angiogenesi inhibitor afinitor disperz listen uh fih nih tor di perz drug use treat subependym giant cell astrocytoma type benign brain tumor certain type seizur patient tuber sclerosi afinitor disperz block protein involv cell divis may help keep abnorm cell grow may also prevent growth new blood vessel tumor need grow may also help prevent treat seizur patient afinitor disperz contain activ ingredi everolimu type kinas inhibitor type angiogenesi inhibitor aflatoxin listen fluh tok sin harm substanc made certain type mold aspergillu flavu aspergillu parasiticu often found poorli store grain nut consumpt food contamin aflatoxin risk factor primari liver cancer afp protein normal produc fetu afp level usual undetect blood healthi adult men women pregnant elev level afp suggest presenc either primari liver cancer germ cell tumor also call alpha fetoprotein afp substanc studi treatment cancer afp kill cancer cell stop divid type aminoflavon ag substanc studi treatment cancer belong famili drug call angiogenesi inhibitor protein tyrosin kinas inhibitor ag drug use treat recurr ovarian epitheli fallopian tube primari periton cancer gotten better treatment anticanc drug includ platinum use help keep cancer come back ag also use patient whose cancer certain mutat chang brca brca gene alreadi treat least two type anticanc drug also studi treatment type cancer ag block enzym involv mani cell function includ repair dna damag block enzym may help keep cancer cell grow may kill ag type poli adp ribos polymeras inhibitor also call parp inhibitor ag rubraca rucaparib camsyl ag substanc studi treatment cancer belong famili drug call glycinamid ribonucleotid formyl transferas inhibitor ag substanc studi treatment cancer matrix metalloproteinas inhibitor belong famili drug call angiogenesi inhibitor also call prinomastat ag substanc studi treatment liver cancer belong famili drug call thymidyl synthas inhibitor also call nolatrex thymitaq aganglion megacolon listen ay gang glee ah nik meh guh koh lun condit certain nerv cell miss muscl layer part larg intestin caus sever constip blockag larg intestin constip stool becom hard dri difficult pass bowel movement occur less often normal symptom includ swollen abdomen vomit bloodi diarrhea ga lack energi troubl gain weight aganglion megacolon present birth symptom may appear later child life condit link increas risk thyroid cancer neuroblastoma also call hirschsprung diseas agc find abnorm cell pap test glandular cell come inner part cervix line uteru find may sign cancer seriou condit test may need also call atyp glandular cell agent studi listen ay jent stuh dee cancer prevent clinic trial studi whether take certain medicin vitamin miner food supplement prevent cancer also call chemoprevent studi age relat macular degener listen ayj ree lay ted kyoo ler dee jeh neh ray shun condit slow breakdown cell center retina light sensit layer nerv tissu back eye block vision center eye caus problem activ read drive age relat macular degener often seen peopl age also call amd armd macular degener agglutinin listen uh gloo tih nin substanc make particl bacteria cell stick togeth form clump mass aggrav factor listen gruh vay ting fak ter someth make condit wors exampl tobacco smoke aggrav factor asthma aggress listen uh greh siv medicin describ tumor diseas form grow spread quickli may also describ treatment sever intens usual aggress fibromatosi listen uh greh siv fy broh muh toh si type soft tissu tumor form fibrou connect tissu usual arm leg abdomen may also occur head neck aggress fibromatos usual benign cancer often recur come back treatment spread nearbi tissu rare spread part bodi may occur adult children also call desmoid tumor desmoid type fibromatosi aggress lymphoma listen uh greh siv lim foh muh type lymphoma grow spread quickli sever symptom also call high grade lymphoma intermedi grade lymphoma aggress system mastocytosi listen uh greh siv si teh mik ma toh sy toh si rare condit mani mast cell type white blood cell build certain tissu organ bodi includ bone marrow lymph node bone liver spleen small intestin aggress system mastocytosi may get wors quickli caus sever symptom organ damag sometim may becom mast cell leukemia rare type leukemia aggress system mastocytosi usual occur adult also call asm agit listen jih tay shun condit person unabl relax still person may tens irrit becom easili annoy small thing may eager argument unwil work caregiv make situat better agnogen myeloid metaplasia listen ag noh jeh nik eh loyd meh tuh play zhuh progress chronic diseas bone marrow replac fibrou tissu blood made organ liver spleen instead bone marrow diseas mark enlarg spleen progress anemia also call chronic idiopath myelofibrosi idiopath myelofibrosi myelosclerosi myeloid metaplasia primari myelofibrosi agonist listen guh nist drug substanc bind receptor insid cell surfac caus action substanc normal bind receptor agoraphobia listen gor uh foh bee uh intens fear open place situat may hard escap help may avail peopl agoraphobia usual anxiou panic attack public place may also fear alon troubl leav home usual avoid elev bridg public place agoraphobia type phobia type anxieti disord agranulocyt listen ay gran yoo loh site type white blood cell monocyt lymphocyt agranulocyt agu term use describ abnorm cell come gland wall cervix lower narrow end uteru abnorm cell found small number pap smear procedur use detect cervic cancer may sign seriou lesion cancer term use atyp glandular cell also call atyp glandular cell uncertain signific atyp glandular cell undetermin signific aha one group substanc found sever type fruit milk use skin care product reduc wrinkl soften skin exampl aha glycol acid lactic acid citric acid also call alpha hydroxyl acid fruit acid aicardi syndrom listen ay kar dee sin drome rare genet disord mark lack tissu connect left right halv brain seizur lesion back eye retina brain eye abnorm problem may includ unusu facial featur defect hand spine rib development gastrointestin problem aicardi syndrom occur almost alway newborn girl peopl aicardi syndrom increas risk certain tumor hepatoblastoma type liver cancer choroid plexu tumor rare tumor form brain aid listen diseas caus human immunodefici viru hiv peopl aid increas risk develop certain cancer infect usual occur individu weak immun system also call acquir immunodefici syndrom aid defin cancer listen deh fy ning kan ser type cancer person infect human immunodefici viru hiv high risk develop person hiv develop one cancer mean aid aid defin cancer includ kaposi sarcoma certain type non hodgkin lymphoma cervic cancer aid relat cancer listen ree lay ted kan ser type cancer like occur peopl infect human immunodefici viru hiv aid relat cancer includ kaposi sarcoma non hodgkin lymphoma cervic cancer hodgkin lymphoma cancer mouth throat liver lung anu ai condit abnorm cell found glandular tissu line certain intern organ uteru cervix lung pancrea colon ai occur often cervix may becom cancer spread nearbi normal tissu also call adenocarcinoma situ ajcc stage system listen stay jing si tem system describ amount spread cancer patient bodi use tnm describ size tumor spread cancer nearbi tissu n describ spread cancer nearbi lymph node describ metastasi spread cancer part bodi system creat updat american joint committe cancer ajcc intern union cancer uicc ajcc stage system use describ type cancer also call tnm stage system akt group enzym involv sever process relat cell growth surviv akt enzym help transfer signal insid cell akt enzym type serin threonin protein kinas also call protein kinas b akynzeo listen ay kin zee oh combin two drug use prevent nausea vomit caus chemotherapi combin netupit palonosetron hydrochlorid akynzeo block action chemic brain may trigger nausea vomit akynzeo type antiemet also call netupit palonosetron hydrochlorid alagil syndrom listen luh jeel sin drome rare disord defect small tube carri bile fluid help digest fat liver small tube may narrow abnorm shape may fewer normal caus bile build liver may lead cirrhosi scar liver liver damag alagil syndrom also affect part bodi includ heart kidney blood vessel eye face spine usual occur infant children may inherit alanin aminopeptidas listen luh neen uh mee noh pep tih day enzym normal found healthi kidney may found high level urin kidney problem use biomark detect damag kidney caus drug agent may also use diagnos certain kidney liver disord also call aap alanin transferas listen luh neen tranz feh ray enzym found liver tissu high level alanin transferas releas blood may sign liver damag cancer diseas also call serum glutam pyruv transaminas sgpt alanosin listen uh lan oh seen substanc studi treatment cancer belong famili drug call antimetabolit also call sdx albin listen al bih nih zum group genet condit mark littl none pigment melanin skin hair eye peopl albin may vision problem white yellow hair reddish violet blue brown eye pale skin albumin listen al byoo min type protein found blood egg white milk substanc alcar listen kar form natur substanc carnitin studi way prevent tissu damag caus chemotherapi carnitin made muscl liver tissu found certain food meat poultri fish dairi product use mani cell bodi make energi fat also call acetyl l carnitin acetyl l carnitin hydrochlorid alcl aggress fast grow type non hodgkin lymphoma usual cell type cancer cell express marker call cd ki surfac may appear lymph node skin bone soft tissu lung liver also call anaplast larg cell lymphoma alcohol listen al kuh hol chemic substanc found drink beer wine liquor also found medicin mouthwash household product essenti oil scent liquid taken certain plant made chemic process call ferment use sugar yeast differ type alcohol type use make alcohol drink call ethyl alcohol ethanol drink regular larg amount alcohol may increas risk certain type cancer cancer mouth throat esophagu breast liver colon rectum alcohol ablat listen al kuh hol blay shun inject ethanol alcohol skin directli tumor kill cancer cell ultrasound ct scan use guid needl tumor also call ethanol ablat pei percutan ethanol inject alcohol depend listen al kuh hol dee pen dent chronic diseas person crave drink contain alcohol unabl control drink person diseas also need drink greater amount get effect withdraw symptom stop alcohol use alcohol depend affect physic mental health caus problem famili friend work regular heavi alcohol intak increas risk sever type cancer also call alcohol alcohol listen al kuh haw lih zum chronic diseas person crave drink contain alcohol unabl control drink person diseas also need drink greater amount get effect withdraw symptom stop alcohol use alcohol affect physic mental health caus problem famili friend work regular heavi alcohol intak increas risk sever type cancer also call alcohol depend aldara listen al dar uh drug use treat earli basal cell skin cancer also use treat actin keratosi skin condit may becom cancer genit wart aldara also studi treatment condit type cancer may help immun system kill abnorm cell includ cancer cell aldara type immun respons modifi also call imiquimod aldehyd listen al deh hide type chemic substanc made alcohol aldehyd found essenti oil scent liquid taken plant aldesleukin listen al de loo kin drug use treat melanoma renal cell carcinoma type kidney cancer spread part bodi also studi treatment type cancer aldesleukin form interleukin made laboratori aldesleukin increas activ growth lymphocyt b lymphocyt type white blood cell may help immun system kill cancer cell aldesleukin type biolog respons modifi also call proleukin recombin human interleukin aldosteron listen al do teh rone steroid hormon made adren cortex outer layer adren gland help control balanc water salt kidney keep sodium releas potassium bodi much aldosteron caus high blood pressur build fluid bodi tissu aldosteron type mineralocorticoid hormon aldrich syndrom listen drich sin drome inherit immun disord occur young boy caus eczema type skin inflamm decreas number platelet blood cell help prevent bleed frequent bacteri infect peopl aldrich syndrom increas risk develop leukemia lymphoma also call wiskott aldrich syndrom alecensa listen leh sen suh drug use treat non small cell lung cancer spread part bodi anaplast lymphoma kinas alk posit also studi treatment type cancer alecensa block certain protein made alk gene block protein may stop growth spread cancer cell alecensa type tyrosin kinas inhibitor also call alectinib alectinib listen uh lek tih nib drug use treat non small cell lung cancer spread part bodi anaplast lymphoma kinas alk posit also studi treatment type cancer alectinib block certain protein made alk gene block protein may stop growth spread cancer cell alectinib type tyrosin kinas inhibitor also call alecensa alefacept listen uh leh fuh sept drug use treat certain skin condit studi treatment cutan skin relat cell cancer cell non hodgkin lymphoma alefacept made combin part antibodi protein block growth type cell type fusion protein type immunosuppress also call amev alemtuzumab listen lem zoo mab drug use treat b cell chronic lymphocyt leukemia also studi treatment type cancer alemtuzumab bind protein call cd found type immun cell cancer cell may help immun system kill cancer cell alemtuzumab type monoclon antibodi also call campath alendron sodium listen uh len droh nayt soh dee um drug use treat certain bone condit osteoporosi paget diseas bone also studi treatment hypercalcemia high level calcium blood bone pain caus cancer alendron sodium slow breakdown bone prevent loss calcium type bisphosphon also call fosamax alh benign cancer condit cell normal breast lobul cell look abnorm microscop alh increas risk breast cancer also call atyp lobular breast hyperplasia atyp lobular hyperplasia alimta listen uh lim tuh drug use alon cisplatin treat certain type non small cell lung cancer local advanc spread part bodi also use cisplatin treat malign pleural mesothelioma patient whose cancer cannot treat surgeri also studi treatment type cancer alimta stop cell use folic acid make dna may kill cancer cell type folat antagonist also call ly pemetrex disodium aliqopa listen lih koh puh drug use treat follicular lymphoma relaps come back treatment least two anticanc therapi also studi treatment type cancer aliqopa block certain protein may help keep cancer cell grow may kill type kinas inhibitor also call copanlisib hydrochlorid alk gene listen jeen gene make protein call anaplast lymphoma kinas alk involv cell growth mutat chang form alk gene protein found type cancer includ neuroblastoma non small cell lung cancer anaplast larg cell lymphoma chang may increas growth cancer cell check chang alk gene tumor tissu may help plan cancer treatment also call anaplast lymphoma kinas gene alk inhibitor hih bih ter substanc block activ protein call anaplast lymphoma kinas alk help control cell growth block protein may help keep cancer cell grow spread alk inhibitor use treat cancer type target therapi also call anaplast lymphoma kinas inhibitor alkali listen al kuh ly chemic dissolv water combin acid form salt make acid less acid alkali bitter tast turn certain dye blue alkali help bodi work way exampl alkali sodium hydroxid alkalin listen al kuh lih nih tee refer amount alkali alkali chemic dissolv water combin acid form salt make acid less acid alkalin listen al kuh lih nih zay shun process lower amount acid solut medicin alkali sodium bicarbon may given patient lower high level acid blood urin caus certain medicin condit alkaloid listen al kuh loyd member larg group substanc found plant fungi alkaloid contain nitrogen made laboratori nicotin caffein codein vincristin alkaloid alkaloid vincristin use treat cancer alkeran listen al keh ran drug use treat multipl myeloma also use treat ovarian epitheli cancer cannot remov surgeri also studi treatment type cancer alkeran may kill cancer cell damag dna stop divid type alkyl agent also call melphalan alkyl agent listen al kuh lay ting ay jent type drug use treatment cancer interfer cell dna inhibit cancer cell growth type leukemia blood cancer come quickli fast grow mani lymphoblast immatur white blood cell blood bone marrow also call acut lymphoblast leukemia acut lymphocyt leukemia allegra listen uh leh gruh drug use treat certain allergi symptom block chemic releas allerg respons caus itch sneez runni nose wheez wateri eye type antihistamin also call fexofenadin allergen listen ler jen substanc caus allerg respons exampl includ pollen mold certain food allerg respons listen uh ler jik reh spont hypersensit immun reaction substanc normal harmless would caus immun respons peopl allerg respons may caus harm symptom itch inflamm tissu injuri allogen listen loh jeh nay ik taken differ individu speci also call allogen allogen bone marrow transplant listen loh jeh nay ik bone mayr oh tranz plan tay shun procedur person receiv stem cell cell blood cell develop genet similar ident donor allogen stem cell transplant listen loh jeh nay ik stem sel tranz plan tay shun procedur person receiv blood form stem cell cell blood cell develop genet similar ident donor often sister brother could unrel donor allogen listen loh jeh nik taken differ individu speci also call allogen allograft listen loh graft transplant organ tissu cell one individu anoth individu speci ident twin allopath medicin listen loh pa thik meh dih sin system medic doctor healthcar profession nurs pharmacist therapist treat symptom diseas use drug radiat surgeri also call biomedicin convent medicin mainstream medicin orthodox medicin western medicin allopurinol listen loh pyoor rih nol drug lower high level uric acid byproduct metabol blood caus cancer treatment allovectin listen loh vek tin substanc studi gene therapi agent treatment cancer increas abil immun system recogn cancer cell kill tran retino acid listen tranz reh tih noh ik sid nutrient bodi need small amount function stay healthi tran retino acid made bodi vitamin help cell grow develop especi embryo form tran retino acid made laboratori put skin treat condit acn taken mouth treat acut promyelocyt leukemia fast grow cancer mani immatur blood form cell blood bone marrow tran retino acid studi prevent treatment type cancer also call atra retino acid tretinoin vitamin acid alo emodin listen loh eh muh din substanc found certain plant includ alo vera belong famili compound call anthraquinon shown anti inflammatori anticanc effect alopecia listen loh pee shuh lack loss hair area bodi hair usual found alopecia side effect cancer treatment aloxi listen uh lok see drug use prevent nausea vomit caus chemotherapi also use prevent nausea vomit surgeri aloxi block action chemic serotonin bind certain nerv may trigger nausea vomit block serotonin may help lessen nausea vomit aloxi type serotonin receptor antagonist type antiemet also call palonosetron hydrochlorid alpha emitt radiat therapi listen al fuh ee mih ter ray dee ay shun thayr uh pee therapi use radioact substanc give type high energi radiat call alpha particl kill cancer cell radioact substanc inject vein travel blood collect certain tissu bodi area bone cancer type radiat may caus less damag nearbi healthi tissu alpha emitt radiat therapi use treat prostat cancer spread bone studi treatment type cancer alpha hydroxyl acid listen al fuh hy drok sil sid one group substanc found sever type fruit milk use skin care product reduc wrinkl soften skin exampl alpha hydroxyl acid glycol acid lactic acid citric acid also call aha fruit acid alpha adrenerg antagonist listen al fuh dreh ner jik ta guh nist substanc relax muscl tissu blood vessel prostat gland improv flow urin blood alpha adrenerg antagonist use treat symptom mani condit benign prostat hyperplasia bph high blood pressur blood circul problem also call alpha blocker alpha blocker listen al fuh blah ker substanc relax muscl tissu blood vessel prostat gland improv flow urin blood alpha blocker use treat symptom mani condit benign prostat hyperplasia bph high blood pressur blood circul problem also call alpha adrenerg antagonist alpha fetoprotein listen al fuh fee toh proh teen protein normal produc fetu alpha fetoprotein level usual undetect blood healthi adult men women pregnant elev level alpha fetoprotein suggest presenc either primari liver cancer germ cell tumor also call afp alpha lipoic acid listen al fuh lih poh ik sid substanc studi abil protect normal cell side effect chemotherapi prevent peripher neuropathi numb tingl burn weak hand feet alpha lipoic acid made bodi found food organ meat spinach broccoli pea brussel sprout rice bran also made laboratori alpha lipoic acid type antioxid chemoprotect agent alpha tocopherol listen al fuh toh kah feh rol nutrient bodi need small amount stay healthi work way fat solubl dissolv fat oil found seed nut leafi green veget veget oil alpha tocopherol boost immun system help keep blood clot form also help prevent cell damag caus free radic highli reactiv chemic alpha tocopherol studi prevent treatment type cancer type antioxid also call vitamin e alprazolam listen al pray zoh lam drug use treat anxieti disord panic attack studi treatment nausea vomit caus cancer treatment type benzodiazepin also call xanax alprostadil listen al pro tuh dil drug use treat impot inabl erect studi treatment sexual problem men surgeri prostat cancer type vasodil also call pge prostaglandin e alten listen procedur mild electr current appli certain acupunctur point spot bodi acupunctur needl may insert control pain symptom skin studi treatment dri mouth caus radiat therapi cancer also call acupunctur like transcutan electr nerv stimul alteplas listen al teh play form tissu plasminogen activ made laboratori help dissolv blood clot use treat heart attack stroke clot lung also studi treatment cancer type system thrombolyt agent also call activas r tpa recombin tissu plasminogen activ alter listen teh ray shun chang result someth differ origin altern medicin listen ter nuh tiv meh dih sin treatment use instead standard treatment standard treatment base result scientif research current accept wide use less research done type altern medicin altern medicin may includ special diet megados vitamin herbal prepar special tea magnet therapi exampl special diet may use instead anticanc drug treatment cancer altretamin listen al treh tuh meen anticanc drug belong famili drug call alkyl agent alum listen lum chemic substanc contain aluminum sulfat second chemic usual potassium sulfat use shrink tissu stop bleed boost immun respons vaccin aluminum listen uh loo mih num metal element found combin element earth crust also found small amount soil water mani food use medicin dentistri mani product foil can pot pan airplan side roof high level aluminum bodi harm alunbrig listen uh lun brig drug use treat non small cell lung cancer spread part bodi anaplast lymphoma kinas alk posit use patient whose cancer gotten wors treatment cannot take crizotinib type anticanc drug alunbrig block certain protein made alk gene block protein may stop growth spread cancer cell alunbrig type tyrosin kinas inhibitor also call brigatinib alvac cea vaccin listen vak seen cancer vaccin made form canarypox viru caus diseas peopl studi treatment kind cancer viru chang laboratori make protein call carcinoembryon antigen cea tumor marker alvac cea vaccin may help immun system find kill cancer cell make cea alveolar rhabdomyosarcoma listen al vee oh ler rab doh oh sar koh muh soft tissu tumor common older children teenag begin embryon muscl cell cell develop muscl bodi occur mani place bodi usual occur trunk arm leg also call arm alveolar soft part sarcoma listen al vee oh ler sar koh muh soft tissu tumor common older children teenag begin soft support tissu connect surround organ tissu alveolar soft part sarcoma usual occur leg also occur arm hand head neck caus growth new blood vessel help tumor grow spread also call asp alveoli listen al vee oh ly tini air sac end bronchiol tini branch air tube lung alveoli lung bloodstream exchang carbon dioxid oxygen carbon dioxid blood pass lung alveoli oxygen lung pass alveoli blood alvocidib listen al voh sih dib substanc studi treatment sever type cancer stop cell divid may kill cancer cell type cyclin depend kinas cdk inhibitor also call flavopiridol hmr alzheim dementia listen alt hy mer deh men shuh brain disord usual start late middl age old age get wors time symptom includ loss memori confus difficulti think chang languag behavior person also call alzheim diseas alzheim diseas listen alt hy mer dih zeez brain disord usual start late middl age old age get wors time symptom includ loss memori confus difficulti think chang languag behavior person also call alzheim dementia amanita phalloid listen muh ny tuh fuh loy deez type poison mushroom harm effect kidney liver respons fatal case mushroom poison also call death cap amantadin hydrochlorid listen uh man tuh deen hy droh klor ide drug use treat infect caus influenza viru block abil viru infect cell make viru particl also use treat symptom parkinson diseas amantidin hydrochlorid type antivir agent amatuximab listen muh tuk sih mab substanc studi treatment mesothelioma amatuximab bind protein call mesothelin found cancer cell amatuximab may help immun system kill cancer cell type monoclon antibodi also call anti mesothelin monoclon antibodi morab morab ambien listen bee un drug use treat insomnia inabl sleep anxieti type imidazopyridin sed hypnot also call zolpidem amd condit slow breakdown cell center retina light sensit layer nerv tissu back eye block vision center eye caus problem activ read drive amd often seen peopl age also call age relat macular degener armd macular degener amd drug use autolog stem cell transplant patient non hodgkin lymphoma multipl myeloma amd given togeth granulocyt coloni stimul factor g csf help move stem cell bone marrow blood stem cell collect store given back patient amd type chemokin receptor antagonist also call mozobil plerixafor amelanot melanoma listen ay meh luh nah tik meh luh noh muh type skin cancer cell make pigment melanin skin lesion often irregular may pink red light brown tan gray edg ameluz listen meh looz drug use treat actin keratosi skin condit may becom cancer ameluz taken abnorm cell includ cancer cell expos certain type light becom activ kill cell ameluz contain activ ingredi aminolevulin acid hydrochlorid type photosensit agent amethopterin listen meh thop teh rin drug use treat mani type cancer also use treat rheumatoid arthriti sever psoriasi type skin condit amethopterin stop cell use folic acid make dna may kill cancer cell may also lower bodi immun respons amethopterin type antimetabolit type antifol also call methotrex mtx rheumatrex trexal amev listen meh veev drug use treat certain skin condit studi treatment cutan skin relat cell cancer cell non hodgkin lymphoma amev made combin part antibodi protein block growth type cell type fusion protein type immunosuppress also call alefacept amg substanc studi treatment cancer bind protein call hepatocyt growth factor hgf may caus cancer cell grow block may caus cancer cell die amg type monoclon antibodi also call anti hgf monoclon antibodi amg amg drug use prevent treat certain bone problem use brand name xgeva prevent bone problem caus multipl myeloma solid tumor spread bone also use certain patient treat giant cell tumor bone cannot remov surgeri treat hypercalcemia caus cancer get better treatment bisphosphon amg also use brand name prolia increas bone mass certain patient breast cancer prostat cancer high risk break bone also use treat osteoporosi men postmenopaus women high risk break bone amg also studi treatment condit type cancer bind protein call rankl keep rankl bind anoth protein call rank surfac certain bone cell includ bone cancer cell may help keep bone break cancer cell grow amg may also prevent loss calcium bone type monoclon antibodi also call denosumab amg drug use treat thrombocytopenia low platelet level patient immun thrombocytopen purpura itp get better treatment itp condit platelet destroy immun system amg bind thrombopoietin receptor caus bone marrow make platelet type thrombopoietin receptor agonist also call nplate romiplostim amg substanc studi treatment type cancer belong famili drug call angiogenesi inhibitor protein kinas inhibitor amh hormon made ovari femal testicl male amh help form male femal reproduct organ also help control hormon act ovari make follicl egg grow woman menstrual cycl measur amount amh blood may help diagnos infertil condit polycyst ovarian syndrom menopaus certain type ovarian tumor may also help determin sex infant sex clear also call anti mullerian hormon amifostin listen mih fo teen drug use help protect kidney patient receiv cisplatin type anticanc drug advanc ovarian cancer also use help reduc dri mouth patient receiv radiat therapi surgeri head neck cancer amifostin help protect healthi tissu side effect caus certain type cancer treatment type chemoprotect agent type radioprotect agent also call ethyol amikacin listen mih kay sin antibiot drug use treat infect belong famili drug call aminoglycosid antibiot amino acid listen uh mee noh sid one sever molecul join togeth form protein common amino acid found protein amino acid sequenc listen uh mee noh sid see kwent arrang amino acid protein protein made differ kind amino acid structur function protein determin kind amino acid use make arrang aminobenzo acid listen uh mee noh ben zoh ik sid nutrient vitamin b complex bodi need small amount function stay healthi bacteria live intestin need aminobenzo acid surviv aminobenzo acid found grain food anim studi radiosensit substanc make tumor cell sensit radiat therapi treatment certain skin disord also call paba para aminobenzo acid aminocamptothecin listen uh mee noh kamp toh theh kin anticanc drug belong famili drug call topoisomeras inhibitor aminoglutethimid listen uh mee noh gloo teth ih mide anticanc drug belong famili drug call nonsteroid aromatas inhibitor aminoglutethimid use decreas product sex hormon estrogen women testosteron men suppress growth tumor need sex hormon grow aminoglycosid antibiot listen uh mee noh gli koh side tee ah tik substanc work mani type bacteria includ streptomycin gentamicin neomycin aminoglycosid antibiot use treat bacteri infect aminolevulin acid listen uh mee noh leh vyoo lih nik sid activ ingredi drug use treat actin keratosi skin condit may becom cancer also studi treatment condit type cancer aminolevulin acid taken abnorm cell includ cancer cell expos certain type light becom activ kill cell may also help find type cancer cell expos certain type light aminolevulin acid type photosensit agent aminolevulin acid hydrochlorid listen uh mee noh leh vyoo lih nik sid hy droh klor ide drug use brand name ameluz levulan kerastick treat actin keratosi skin condit may becom cancer also use brand name gleolan imag agent surgeri certain type brain tumor aminolevulin acid hydrochlorid also studi treatment condit type cancer aminolevulin acid hydrochlorid taken abnorm cell includ cancer cell expos certain type light becom activ kill cell may also help find type cancer cell expos certain type light aminolevulin acid hydrochlorid type photosensit agent aminopterin listen mih nop teh rin anticanc drug belong famili drug call antimetabolit amiodaron hydrochlorid listen mee oh duh rone hy droh klor ide drug use treat certain type abnorm heart rhythm gotten better drug amiodaron hydrochlorid affect electr activ heart type antiarrhythm agent also call corderon amitriptylin listen mih trip tih leen drug use treat depress may given treat anxieti sleep disord pain also studi oral gel form treatment nerv pain caus chemotherapi amitriptylin type tricycl antidepress also call amitriptylin hydrochlorid amitriptylin hydrochlorid listen mih trip tih leen hy droh klor ide drug use treat depress may given treat anxieti sleep disord pain also studi oral gel form treatment nerv pain caus chemotherapi amitriptylin hydrochlorid type tricycl antidepress also call amitriptylin aml aggress fast grow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myelogen leukemia acut myeloid leukemia acut nonlymphocyt leukemia anll aml mrc type acut myeloid leukemia least patient blood bone marrow myeloblast immatur white blood cell patient one follow condit myelodysplast syndrom md myelodysplast myeloprolif neoplasm md mpn cell chang certain chromosom similar found md least cell least two type blood cell abnorm aml mrc usual occur older adult poor prognosi also call acut myeloid leukemia myelodysplasia relat chang ammonia listen uh moh nyuh ga made nitrogen hydrogen strong odor irrit skin eye nose throat lung ammonia made bacteria decay plant anim found water soil air ammonia also made bodi protein break laboratori ammonia chang liquid use medicin fertil household clean liquid product also ad cigarett increas effect nicotin bodi ammonium tetrathiomolybd listen uh moh nee um teh truh thi oh muh lib dayt substanc studi treatment mani type cancer ammonium tetrathiomolybd remov extra copper bodi remov copper may prevent growth new blood vessel tumor need grow may kill cancer cell ammonium tetrathiomolybd type chelat agent type antiangiogenesi agent amniot fluid listen nee ah tik floo id clear slightli yellow fluid surround protect unborn babi grow pregnanc amniot fluid cushion babi help keep temperatur womb constant also help grow babi lung digest system bone develop properli amniot fluid contain babi cell substanc sampl amniot fluid may taken check health babi test genet chang may sign genet diseas condit amniot fluid also may use learn sex babi amonafid listen ay moh nah fide substanc studi treatment cancer belong famili drug call topoisomeras inhibitor intercal agent amoxicillin listen uh mok sih sih lin drug use treat bacteri infect amoxicillin form penicillin made laboratori kill certain type bacteria type antibiot amoxicillin clavulan potassium listen uh mok sih sih lin kla vyoo la nayt puh ta see um drug use treat bacteri infect ad chemic clavulan potassium antibiot amoxicillin increas amount time antibiot stay activ bodi amoxicillin clavulan potassium type combin antibiot also call augmentin amphotericin b listen fuh tayr ih sin drug use treatment infect caus fungi type antifung amplimexon listen plih mek son substanc studi treatment type cancer includ pancreat lung breast prostat melanoma multipl myeloma belong famili drug call cyanoaziridin deriv also call imexon ampulla listen puh luh sac like enlarg canal duct ampulla vater listen puh luh vah ter enlarg duct liver pancrea point enter small intestin ampulla vater cancer listen puh luh vah ter kan ser cancer form ampulla vater enlarg duct liver pancrea join enter small intestin symptom includ jaundic abdomin pain nausea vomit weight loss also call ampullari cancer ampullari cancer listen puh layr ee kan ser cancer form ampulla vater enlarg duct liver pancrea join enter small intestin symptom includ jaundic abdomin pain nausea vomit weight loss also call ampulla vater cancer amput listen pyoo tay shun remov surgeri limb arm leg bodi part injuri diseas diabet cancer amrubicin listen roo bih sin substanc studi treatment lung cancer type anthracyclin analog amsacrin listen suh kreen anticanc drug belong famili drug call topoisomeras inhibitor amuvatinib listen yoo va tih nib substanc studi treatment type cancer may block certain protein involv cancer cell growth dna repair block protein may make cancer cell sensit anticanc drug radiat therapi amuvatinib type tyrosin kinas inhibitor also call mp amygdalin listen uh mig duh lin substanc found pit fruit apricot raw nut plant amygdalin use countri treatment cancer shown work human clinic trial approv use unit state amygdalin sometim call vitamin b amylas listen mih lay enzym help bodi digest starch amyloidosi listen muh loy doh si group diseas protein build certain organ local amyloidosi throughout bodi system amyloidosi amyloidosi may either primari known caus secondari caus anoth diseas includ type cancer multipl myeloma hereditari pass parent children mani organ affect amyloidosi organ affect may depend whether amyloidosi primari secondari hereditari form anabol steroid listen nuh bah lik stayr oyd type steroid use medicin repair bodi tissu increas appetit growth muscl anabol steroid made laboratori testosteron male hormon anagrelid listen ag lide drug use decreas number platelet blood order prevent blood clot anakinra listen nuh kin ruh substanc use treat rheumatoid arthriti studi treatment cancer anakinra block action interleukin il type interleukin receptor antagonist also call kinaret anal listen ay nul anu anu open rectum last part larg intestin outsid bodi anal cancer listen ay nul kan ser cancer form tissu anu anu open rectum last part larg intestin outsid bodi anal pap smear listen ay nul smeer procedur cell scrape line anu open rectum outsid bodi look microscop use find cancer chang cell may lead cancer anal pap smear also show condit cancer infect inflamm also call anal pap test anal pap test listen ay nul procedur cell scrape line anu open rectum outsid bodi look microscop use find cancer chang cell may lead cancer anal pap test also show condit cancer infect inflamm also call anal pap smear analgesia listen nul jee zhee uh pain relief analges listen nul jee zik drug reduc pain analges includ aspirin acetaminophen ibuprofen analog listen nuh log chemistri substanc similar ident anoth analysi listen uh na lih si process anyth complex separ simpl less complex part anaphylact shock listen nuh fih lak tik shok sever sometim life threaten immun system reaction antigen person previous expos reaction may includ itchi skin edema collaps blood vessel faint difficulti breath death anaplast listen nuh pla tik term use describ cancer cell divid rapidli littl resembl normal cell anaplast larg cell lymphoma listen nuh pla tik larj sel lim foh muh aggress fast grow type non hodgkin lymphoma usual cell type cancer cell express marker call cd ki surfac may appear lymph node skin bone soft tissu lung liver also call alcl anaplast lymphoma kinas listen nuh pla tik lim foh muh ky nay protein help control cell growth made anaplast lymphoma kinas alk gene may chang type cancer anaplast larg cell lymphoma neuroblastoma non small cell lung cancer chang alk gene caus cancer cell grow spread anaplast lymphoma kinas type receptor tyrosin kinas anaplast lymphoma kinas gene listen nuh pla tik lim foh muh ky nay jeen gene make protein call anaplast lymphoma kinas alk involv cell growth mutat chang form alk gene protein found type cancer includ neuroblastoma non small cell lung cancer anaplast larg cell lymphoma chang may increas growth cancer cell check chang anaplast lymphoma kinas gene tumor tissu may help plan cancer treatment also call alk gene anaplast lymphoma kinas inhibitor nuh pla tik lim foh muh ky nay hih bih ter substanc block activ protein call anaplast lymphoma kinas alk help control cell growth block protein may help keep cancer cell grow spread anaplast lymphoma kinas inhibitor use treat cancer type target therapi also call alk inhibitor anaplast thyroid cancer listen nuh pla tik thi royd kan ser rare aggress type thyroid cancer malign cancer cell look differ normal thyroid cell anastomosi listen uh na toh moh si procedur connect healthi section tubular structur bodi diseas portion surgic remov anastrozol listen troh zole drug use treat certain type breast cancer postmenopaus women also studi treatment type cancer anastrozol lower amount estrogen made bodi may stop growth cancer cell need estrogen grow anastrozol type nonsteroid aromatas inhibitor also call arimidex anatom listen nuh tah mik anatomi studi structur plant anim anatomist listen uh na tuh mist person special train anatomi studi structur anim plant anatomi listen uh na toh mee studi structur plant anim anc measur number neutrophil blood neutrophil type white blood cell help bodi fight infect anc may use check infect inflamm leukemia condit lower person anc higher risk get infect anc less mean high risk get infect cancer treatment chemotherapi may reduc anc also call absolut neutrophil count ancestim listen se tim substanc caus blood stem cell cell type cell develop chang differ type blood cell increas number action cell blood studi treatment myelodysplasia ancestim type recombin stem cell growth factor also call r methuscf recombin human methionyl stem cell factor stemgen ancillari test listen sih layr ree clinic trial medic test patient part origin studi design androblastoma listen droh bla toh muh rare type ovarian tumor tumor cell secret male sex hormon may caus viril appear male physic characterist femal also call arrhenoblastoma sertoli leydig cell tumor ovari androgen listen droh jen type hormon promot develop mainten male sex characterist androgen ablat listen droh jen blay shun treatment suppress block product action male hormon done testicl remov take femal sex hormon take drug call antiandrogen also call androgen depriv androgen suppress androgen depriv listen droh jen deh prih vay shun treatment suppress block product action male hormon done testicl remov take femal sex hormon take drug call antiandrogen also call androgen ablat androgen suppress androgen receptor listen droh jen reh sep ter protein bind male hormon call androgen androgen receptor found insid cell male reproduct tissu type tissu cancer cell prostat cancer androgen bind androgen receptor insid cancer cell caus cancer cell grow also call ar androgen receptor posit listen droh jen reh sep ter pah zih tiv describ cell protein bind androgen male hormon cancer cell androgen receptor posit may need androgen grow cell may stop grow die treat substanc block bind action androgen hormon also call ar androgen suppress listen droh jen suh preh shun treatment suppress block product action male hormon done testicl remov take femal sex hormon take drug call antiandrogen also call androgen ablat androgen depriv androgen independ listen droh jen describ abil tumor cell grow absenc androgen hormon promot develop mainten male sex characterist mani earli prostat cancer requir androgen growth advanc prostat cancer often androgen independ androstanolon listen droh stan uh lone hormon made testosteron prostat test certain tissu need develop maintain male sex characterist facial hair deep voic muscl growth high amount androstanolon may increas growth prostat cancer make harder treat also call dht dihydrotestosteron anecdot report listen nek doh tul reh port incomplet descript medic treatment histori one patient anecdot report may publish place peer review scientif journal anemia listen uh nee mee uh condit number red blood cell normal anesthesia listen ne thee zhuh loss feel awar caus drug substanc anesthesia keep patient feel pain surgeri procedur local anesthesia loss feel one small area bodi region anesthesia loss feel part bodi arm leg gener anesthesia loss feel complet loss awar feel like deep sleep anesthesiologist listen ne thee zee ah loh jist doctor special train give drug agent prevent reliev pain surgeri procedur anesthet listen ne theh tik drug substanc caus loss feel awar local anesthet caus loss feel one small area bodi region anesthet caus loss feel part bodi arm leg gener anesthet caus loss feel complet loss awar feel like deep sleep anetholtrithion listen neh thol tri thi one substanc studi treatment cancer angelica root listen jeh lih kuh root root group herb call angelica use cultur treat certain medic problem includ gastrointestin problem loss appetit feel full ga angiocept listen jee oh sept substanc studi treatment cancer angiocept may prevent growth new blood vessel tumor need grow may kill cancer cell type vascular endotheli growth factor receptor vegfr inhibitor type antiangiogenesi agent also call ct vegfr inhibitor ct angiofibroma listen jee oh fy broh muh benign cancer tumor made blood vessel fibrou connect tissu angiofibroma usual appear small red bump face especi nose cheek common patient tuber sclerosi genet disord caus skin lesion seizur mental problem angiofibroma type vascular tumor angiofollicular lymph node hyperplasia listen jee oh fuh lih kyoo ler limf node hy per play zhuh rare disord benign cancer growth form lymph node tissu two main way angiofollicular lymph node hyperplasia occur local unicentr multicentr unicentr angiofollicular lymph node hyperplasia affect one group lymph node one part bodi usual chest abdomen may caus symptom multicentr angiofollicular lymph node hyperplasia affect mani group lymph node lymphoid tissu bodi weaken immun system caus problem infect fever weight loss fatigu night sweat nerv damag anemia peopl angiofollicular lymph node hyperplasia increas risk lymphoma also call castleman diseas giant lymph node hyperplasia angiogenesi listen jee oh jeh neh si blood vessel format tumor angiogenesi growth new blood vessel tumor need grow process caus releas chemic tumor host cell near tumor angiogenesi inhibitor listen jee oh jeh neh si hih bih ter drug substanc keep new blood vessel form cancer treatment angiogenesi inhibitor may prevent growth new blood vessel tumor need grow also call antiangiogenesi agent angiogram listen jee oh gram x ray comput imag ct scan mri blood vessel blood flow bodi dye may inject cathet small tube arteri vein make blood vessel easier see angiogram may use check aneurysm bulg blood vessel wall blockag arteri blood clot problem tumor angiographi listen jee ah gruh fee procedur x ray blood vessel blood vessel seen inject dye show x ray angioimmunoblast cell lymphoma listen jee oh ih myoo noh bla tik sel lim foh muh aggress fast grow type cell non hodgkin lymphoma mark enlarg lymph node hypergammaglobulinemia increas antibodi blood symptom may includ skin rash fever weight loss night sweat angiolymphoid hyperplasia eosinophilia listen jee oh lim foyd hy per play zhuh ee oh sih noh fih lee uh rare benign cancer tumor small blood vessel surround lymphocyt eosinophil type white blood cell angiolymphoid hyperplasia eosinophilia usual form skin especi skin head occur area bodi bone skin may appear firm pink red bump may itchi pain tumor bone may caus swell pain angiolymphoid hyperplasia eosinophilia sometim caus injuri often come back treatment angiolymphoid hyperplasia eosinophilia common young middl age adult type vascular tumor also call epithelioid hemangioma histiocytoid hemangioma angiomyolipoma listen jee oh oh lih poh muh benign noncanc tumor fat muscl tissu usual found kidney angiomyolipoma rare caus symptom may bleed grow larg enough pain caus kidney failur common patient tuber sclerosi genet disord benign tumor grow kidney brain eye heart lung skin caus seizur mental problem skin lesion angioplasti listen jee oh pla tee procedur enlarg open blood vessel becom narrow block plaqu buildup fat cholesterol inner wall blood vessel exampl angioplasti balloon angioplasti laser angioplasti angiosarcoma listen jee oh sar koh muh type cancer begin cell line blood vessel lymph vessel cancer begin blood vessel call hemangiosarcoma cancer begin lymph vessel call lymphangiosarcoma angiostatin listen jee oh sta tin protein normal made bodi also made laboratori studi treatment cancer angiostatin may prevent growth new blood vessel tumor need grow type antiangiogenesi agent angiotensin convert enzym inhibitor listen jee oh ten sin kun ver ting en zime hih bih ter drug use lower blood pressur angiotensin convert enzym inhibitor type antihypertens agent also call ace inhibitor angiozym listen jee oh zime substanc studi treatment cancer angiozym special type rna made laboratori stop protein call vascular endotheli growth factor receptor vegfr made may prevent growth new blood vessel tumor need grow type angiogenesi inhibitor type ribozym also call rpi anhidrosi listen hih droh si rare condit sweat gland make littl sweat affect whole bodi small part bodi anhidrosi may caus sever burn radiat infect inflamm injuri skin may also caus certain medicin condit affect skin nerv connect tissu sweat gland may inherit part genet condit develop later life also call hypohidrosi anhydrovinblastin listen hy droh vin bla teen anticanc drug belong famili drug call mitot inhibitor anidulafungin listen uh nih dyoo luh fun jin drug use treat infect caus fungi belong famili drug call antifung anim model listen nih mul mah dul anim diseas either like diseas human anim model use studi develop progress diseas test new treatment given human anim transplant human cancer tissu call xenograft model anim studi listen nih mul stuh dee laboratori experi use anim studi develop progress diseas anim studi also test safe effect new treatment test peopl anim assist therapi listen nih mul uh si ted thayr uh pee type therapi use dog pet improv physic mental health patient certain acut chronic diseas studi way reliev distress cancer patient undergo treatment pain also call pet facilit therapi aniridia listen nih rih dee uh disord person born without part iri color tissu front eyebal aniridia usual affect eye caus eye problem includ sensit light loss vision anll aggress fast grow diseas mani myeloblast immatur white blood cell lymphoblast found bone marrow blood also call acut myeloblast leukemia acut myelogen leukemia acut myeloid leukemia acut nonlymphocyt leukemia aml annamycin listen nuh sin substanc studi treatment cancer belong famili drug call anthracyclin antibiot anorexia listen nuh rek see uh abnorm loss appetit food anorexia caus cancer aid mental disord e anorexia nervosa diseas anorexia nervosa listen nuh rek see uh ner voh suh eat disord mark intens fear gain weight refus maintain healthi weight distort bodi imag peopl anorexia nervosa abnorm loss appetit food tri avoid eat eat littl possibl an part nervou system control muscl intern organ heart blood vessel lung stomach intestin gland salivari gland sweat gland one part an help bodi rest relax digest food anoth part help person fight take flight emerg also call autonom nervou system involuntari nervou system ansamycin listen suh sin anticanc drug belong famili drug call antineoplast antibiot antagonist listen ta guh nist medicin substanc stop action effect anoth substanc exampl drug block stimul effect estrogen tumor cell call estrogen receptor antagonist antenat listen tee nay tul time femal pregnant birth occur also call prenat anterior listen teer ee er human anatomi front structur structur found toward front bodi anterior mediastinotomi listen teer ee er mee dee stih nah toh mee procedur tube insert chest view tissu organ area lung breastbon heart tube insert incis next breastbon procedur usual use get tissu sampl lymph node left side chest also call chamberlain procedur anterior mediastinum listen teer ee er mee dee uh sti num area front part chest lung also call prevascular space anterior pelvic exenter listen teer ee er pel vik eg zen teh ray shun surgeri remov urethra lower part uret uteru cervix vagina bladder anterior urethr cancer listen teer ee er yoo ree thrul kan ser diseas malign cancer cell found part urethra tube urin leav bodi closest outsid bodi anthracenedion listen thruh seen dy one anticanc drug belong famili drug call anticanc antibiot anthracyclin listen thruh sy klin type antibiot come certain type streptomyc bacteria anthracyclin use treat mani type cancer anthracyclin damag dna cancer cell caus die daunorubicin doxorubicin epirubicin anthracyclin anthraquinon listen thruh kwih none type anticanc drug antiandrogen listen tee droh jen substanc keep androgen male hormon bind protein call androgen receptor found prostat cell cell tissu treatment antiandrogen may stop prostat cancer cell grow exampl antiandrogen use treat prostat cancer flutamid bicalutamid enzalutamid nilutamid antiandrogen therapi listen tee droh jen thayr uh pee treatment drug block action androgen male hormon bodi androgen testosteron bind protein call androgen receptor found prostat cancer cell cell tissu antiandrogen therapi keep androgen bind receptor may keep cancer cell grow use treat prostat cancer antiangiogenesi listen tee jee oh jeh neh si prevent growth new blood vessel antiangiogenesi agent listen tee jee oh jeh neh si ay jent drug substanc keep new blood vessel form cancer treatment antiangiogenesi agent may prevent growth new blood vessel tumor need grow also call angiogenesi inhibitor antiangiogen listen tee jee oh jeh nik reduc growth new blood vessel antianxieti agent listen tee ang zy eh tee ay jent drug use treat symptom anxieti feel fear dread uneasi muscl tight may occur reaction stress antianxieti agent block action certain chemic nervou system also call anxiolyt anxiolyt agent antiapoptot listen tee pop tah tik someth prevent apoptosi apoptosi type cell death seri molecular step cell lead death antibacteri listen tee bak teer ee ul substanc kill bacteria stop grow caus diseas antibiot listen tee ah tik drug use treat infect caus bacteria microorgan antibodi listen tee bah dee protein made plasma cell type white blood cell respons antigen substanc caus bodi make specif immun respons antibodi bind one specif antigen purpos bind help destroy antigen antibodi destroy antigen directli other make easier white blood cell destroy antigen antibodi type immunoglobulin antibodi therapi listen tee bah dee thayr uh pee treatment use antibodi help bodi fight cancer infect diseas antibodi protein made immun system bind specif marker cell tissu monoclon antibodi type antibodi made laboratori use diagnosi treatment cancer treatment monoclon antibodi may kill cancer cell directli may block develop tumor blood vessel may help immun system kill cancer cell antibodi depend cell mediat cytotox listen tee bah dee deh pen dent sel mee dee ay ted sy toh tok sih sih tee type immun reaction target cell microb coat antibodi kill certain type white blood cell white blood cell bind antibodi releas substanc kill target cell microb also call adcc antibodi depend cellular cytotox antibodi depend cellular cytotox listen tee bah dee deh pen dent sel yoo ler sy toh tok sih sih tee type immun reaction target cell microb coat antibodi kill certain type white blood cell white blood cell bind antibodi releas substanc kill target cell microb also call adcc antibodi depend cell mediat cytotox antibodi drug conjug listen tee bah dee kon jih gut substanc made monoclon antibodi chemic link drug monoclon antibodi bind specif protein receptor found certain type cell includ cancer cell link drug enter cell kill without harm cell antibodi drug conjug use treat cancer also call adc anticachexia listen tee kuh kek see uh describ drug effect work cachexia loss bodi weight muscl mass anticanc antibiot listen tee kan ser tee ah tik type anticanc drug block cell growth interf dna genet materi cell also call antineoplast antibiot antitumor antibiot anticanc therapi listen tee kan ser thayr uh pee treatment stop prevent cancer anticarcinogen listen tee kar sih noh jeh nik prevent delay develop cancer anti ccr monoclon antibodi mln listen tee mah noh kloh nul tee bah dee substanc studi treatment atherosclerosi build fat arteri also studi treatment cancer spread bone anti ccr monoclon antibodi mln bind protein call ccr found surfac certain bone cell white blood cell cancer cell anti ccr monoclon antibodi mln block action substanc involv keep healthi bone mass may help keep cancer cell spread grow bone type monoclon antibodi also call mln anti cd immunotoxin listen tee ih myoo noh tok sin monoclon antibodi link toxic substanc studi treatment type b cell cancer anti cd immunotoxin made laboratori bind cd protein surfac normal b cell b cell tumor kill cell anti cd immunotoxin listen tee ih myoo noh tok sin monoclon antibodi link toxic substanc studi treatment type b cell cancer anti cd immunotoxin made laboratori bind cd protein surfac normal b cell b cell tumor kill cell anti cd immunotoxin cat listen tee ih myoo noh tok sin drug use treat hairi cell leukemia came back get better least two system therapi includ treatment purin nucleosid analog type anticanc drug anti cd immunotoxin cat contain monoclon antibodi call moxetumomab bind protein call cd found b cell type white blood cell type leukemia cell also contain bacteri toxin call pe may help kill cancer cell anti cd immunotoxin cat type immunotoxin also call cat lumox moxetumomab pasudotox anti cd monoclon antibodi listen tee mah noh kloh nul tee bah dee substanc studi treatment type leukemia lymphoma anti cd monoclon antibodi bind protein call cd found type blood cell type leukemia lymphoma cell anti cd monoclon antibodi may help immun system kill cancer cell type monoclon antibodi anti cea antibodi listen tee tee bah dee antibodi carcinoembryon antigen cea protein present certain type cancer cell anticoagul listen tee koh gyuh lunt substanc use prevent treat blood clot blood vessel heart also call blood thinner anticonvuls listen tee kun vul sunt drug substanc use prevent stop seizur convuls also call antiepilept antidepress listen tee dee preh sunt drug use treat depress antidiarrh listen tee dy uh ree ul substanc use treat diarrhea frequent wateri bowel movement antiemet listen tee eh meh tik drug prevent reduc nausea vomit anti epcam pseudomona exotoxin fusion protein listen tee soo doh moh nu ek soh tok sin fyoo zhun proh teen substanc studi treatment certain type head neck cancer anti epcam pseudomona exotoxin fusion protein made link monoclon antibodi fragment toxic protein may kill cancer cell bind epcam protein surfac epitheli cell type cancer cell also call proxinium vb antiepilept listen tee eh pih lep tik drug substanc use prevent stop seizur convuls also call anticonvuls antiestrogen listen tee es truh jin substanc keep cell make use estrogen hormon play role femal sex characterist menstrual cycl pregnanc antiestrogen may stop cancer cell grow use prevent treat breast cancer also studi treatment type cancer antiestrogen type hormon antagonist also call estrogen blocker antifibrinolyt agent listen tee fy brih noh lih tik ay jent type drug help blood clot prevent breakdown protein call fibrin main protein blood clot antifibrinolyt agent may use help prevent treat seriou bleed patient certain condit hemophilia heavi menstrual bleed type vascular tumor may also use help prevent control bleed surgeri traumat injuri antifol listen tee foh layt type drug stop cell use folic acid make dna may kill cancer cell certain antifol use treat type cancer inflammatori condit rheumatoid arthriti also call folat antagonist folic acid antagonist antifung listen tee fun gul drug treat infect caus fungi antigen listen tih jen substanc caus bodi make immun respons substanc antigen includ toxin chemic bacteria virus substanc come outsid bodi bodi tissu cell includ cancer cell also antigen caus immun respons antigen also use marker laboratori test identifi tissu cell antigen present cell listen tih jen preh zen ting sel type immun cell boost immun respons show antigen surfac cell immun system antigen present cell type phagocyt also call apc antigen present cell vaccin listen tih jen preh zen ting sel vak seen vaccin made antigen antigen present cell apc apc boost immun respons present antigen surfac cell immun system also call apc vaccin antiglobulin test listen tee glah byoo lin laboratori test identifi antibodi bind surfac red blood cell platelet destroy test use diagnos certain blood disord patient make antibodi red blood cell platelet also use determin blood type also call coomb test anti hgf monoclon antibodi amg listen tee mah noh kloh nul tee bah dee substanc studi treatment cancer bind protein call hepatocyt growth factor hgf may caus cancer cell grow block may caus cancer cell die anti hgf monoclon antibodi amg type monoclon antibodi also call amg antihistamin listen tee tuh meen type drug block action histamin caus fever itch sneez runni nose wateri eye antihistamin use prevent fever patient receiv blood transfus treat allergi cough cold antihormon therapi listen tee hor mone thayr uh pee treatment drug surgeri radiat order block product action hormon antihormon therapi may use cancer treatment certain hormon abl stimul growth type tumor antihypertens agent listen tee hy per ten siv ay jent type drug use treat high blood pressur mani differ type antihypertens agent work differ way lower blood pressur remov extra fluid salt bodi other relax widen blood vessel slow heartbeat person may respond better fewer side effect one drug anoth patient need one antihypertens agent lower blood pressur anti idiotyp vaccin listen tee ih dee oh tipe vak seen vaccin made antibodi see antibodi antigen bind anti idiotyp vaccin stimul bodi produc antibodi tumor cell anti igf r recombin monoclon antibodi mk listen tee ree kom bih nunt mah noh kloh nul tee bah dee substanc studi treatment mani type cancer anti igf r recombin monoclon antibodi mk bind protein call insulin like growth factor receptor igfr surfac cell may prevent cell grow igf present may also kill cancer cell anti igf r recombin monoclon antibodi mk type monoclon antibodi also call mk anti il chimer monoclon antibodi listen tee ky meer ik mah noh kloh nul tee bah dee drug use treat rare condit call castleman diseas patient hiv human herpesviru also studi treatment multipl myeloma anti il chimer monoclon antibodi bind protein call interleukin il made white blood cell cell bodi anti il chimer monoclon antibodi may help reduc inflamm stop growth cancer cell abnorm blood cell type monoclon antibodi also call cclb cnto siltuximab sylvant anti inflammatori listen tee fla muh tor ee reduc inflamm anti inflammatori agent listen tee fla muh tor ee ay jent drug substanc reduc inflamm red swell pain bodi anti inflammatori agent block certain substanc bodi caus inflamm use treat mani differ condit anti inflammatori agent studi prevent treatment cancer antilymphocyt globulin listen tee lim foh site glah byoo lin serum blood contain antibodi bind human cell antilymphocyt globulin given patient stem cell transplant kill cell lower risk graft versu host diseas gvhd also use treat gvhd kidney transplant help keep bodi reject kidney also call antithymocyt globulin anti mesothelin monoclon antibodi morab listen tee meh zoh thee lin mah noh kloh nul tee bah dee substanc studi treatment mesothelioma anti mesothelin monoclon antibodi morab bind protein call mesothelin found cancer cell anti mesothelin monoclon antibodi morab may help immun system kill cancer cell type monoclon antibodi also call amatuximab morab antimetabolit listen tee meh ta boh lite drug similar natur chemic normal biochem reaction cell differ enough interfer normal divis function cell antimicrobi listen tee kroh bee ul substanc kill microorgan bacteria mold stop grow caus diseas antimicrotubul agent listen tee kroh byool ay jent type drug block cell growth stop mitosi cell divis antimicrotubul agent interfer microtubul cellular structur help move chromosom mitosi use treat cancer antimitot agent listen tee tah tik ay jent type drug block cell growth stop mitosi cell divis use treat cancer also call mitot inhibitor anti mullerian hormon listen tee myoo layr ee un hor mone hormon made ovari femal testicl male anti mullerian hormon help form male femal reproduct organ also help control hormon act ovari make follicl egg grow woman menstrual cycl measur amount anti mullerian hormon blood may help diagnos infertil condit polycyst ovarian syndrom menopaus certain type ovarian tumor may also help determin sex infant sex clear also call amh antineoplast listen tee nee oh pla tik block format neoplasm growth may becom cancer antineoplast antibiot listen tee nee oh pla tik tee ah tik type anticanc drug block cell growth interf dna genet materi cell also call anticanc antibiot antitumor antibiot antineoplaston listen tee nee oh pla ton substanc isol normal human blood urin test type treatment tumor aid antioncogen listen tee koh jeen type gene make protein call tumor suppressor protein help control cell growth mutat chang dna antioncogen may lead cancer also call tumor suppressor gene antioxid listen tee ok sih dent substanc protect cell damag caus free radic unstabl molecul made process oxid normal metabol free radic may play part cancer heart diseas stroke diseas age antioxid includ beta caroten lycopen vitamin c e natur manufactur substanc antiparasit listen tee payr uh sih tik drug use treat infect caus bacteria parasit also use treatment cancer anti pdgfr alpha monoclon antibodi imc g listen tee al fuh mah noh kloh nul tee bah dee drug use doxorubicin treat soft tissu sarcoma cannot treat radiat therapi surgeri use patient whose cancer alreadi treat anthracyclin type anticanc drug also studi treatment type cancer anti pdgfr alpha monoclon antibodi imc g bind receptor protein call platelet deriv growth factor pdgf found type cancer cell block protein receptor may help keep cancer cell grow prevent growth new blood vessel tumor need grow anti pdgfr alpha monoclon antibodi imc g type monoclon antibodi also call anti platelet deriv growth factor receptor alpha monoclon antibodi imc g imc g lartruvo olaratumab anti platelet deriv growth factor receptor alpha monoclon antibodi imc g listen tee playt let deh rive groth fak ter reh sep ter al fuh mah noh kloh nul tee bah dee drug use doxorubicin treat soft tissu sarcoma cannot treat radiat therapi surgeri use patient whose cancer alreadi treat anthracyclin type anticanc drug also studi treatment type cancer anti platelet deriv growth factor receptor alpha monoclon antibodi imc g bind receptor protein call platelet deriv growth factor pdgf found type cancer cell block protein receptor may help keep cancer cell grow prevent growth new blood vessel tumor need grow anti platelet deriv growth factor receptor alpha monoclon antibodi imc g type monoclon antibodi also call anti pdgfr alpha monoclon antibodi imc g imc g lartruvo olaratumab antiprogestin listen tee proh je tin substanc prevent cell make use progesteron hormon play role menstrual cycl pregnanc antiprogestin may stop cancer cell grow studi treatment breast cancer antiprogestin type hormon antagonist antipsychot listen tee sy kah tik type drug use treat symptom psychosi includ hallucin sight sound smell tast touch person believ real real delus fals belief dementia loss abil think rememb learn make decis solv problem antipsychot block action certain chemic nervou system also call antipsychot agent neurolept agent antipsychot agent listen tee sy kah tik ay jent type drug use treat symptom psychosi includ hallucin sight sound smell tast touch person believ real real delus fals belief dementia loss abil think rememb learn make decis solv problem antipsychot agent block action certain chemic nervou system also call antipsychot neurolept agent antiretrovir therapi listen tee reh troh vy rul thayr uh pee treatment drug inhibit abil human immunodefici viru hiv type retrovirus multipli bodi antisens agent listen tee sent ay jent small piec dna rna bind specif molecul rna block abil rna make protein work way antisens agent may use block product protein need cell growth studi treatment sever type cancer also call antisens oligonucleotid antisens c fo listen tee sent substanc studi treatment cancer studi treatment rheumatoid arthriti certain skin condit block product protein call c fo help control cell growth may kill cancer cell need c fo grow type antisens oligonucleotid also call c fo antisens oligonucleotid antisens dna listen tee sent small piec dna bind specif molecul rna block cell abil use rna make protein work way antisens dna may use block product protein need cell growth studi treatment mani type cancer antisens oligonucleotid listen tee sent ah lih goh noo klee oh tide small piec dna rna bind specif molecul rna block abil rna make protein work way antisens oligonucleotid may use block product protein need cell growth studi treatment sever type cancer also call antisens agent antisens oligonucleotid therapi listen tee sent ah lih goh noo klee oh tide thayr uh pee treatment antisens oligonucleotid small piec dna rna bind specif molecul rna block cell abil use rna make protein work way antisens oligonucleotid studi treatment mani type cancer also call antisens therapi antisens rna listen tee sent small piec rna bind specif molecul rna block cell abil use rna make protein work way antisens rna may use block product protein need cell growth studi treatment mani type cancer antisens therapi listen tee sent thayr uh pee treatment antisens oligonucleotid small piec dna rna bind specif molecul rna block cell abil use rna make protein work way antisens oligonucleotid studi treatment mani type cancer also call antisens oligonucleotid therapi antisoci listen tee soh shul describ behavior ignor right other practic law societi anti tgf beta monoclon antibodi gc listen tee bay tuh mah noh kloh nul tee bah dee substanc studi treatment breast cancer spread part bodi also studi treatment cancer condit anti tgf beta monoclon antibodi gc bind protein call transform growth factor beta tgf beta found cancer cell anti tgf beta monoclon antibodi gc may help keep cancer cell grow prevent growth new blood vessel tumor need grow type monoclon antibodi type antiangiogenesi agent also call fresolimumab gc antithymocyt globulin listen tee thi moh site glah byoo lin serum blood contain antibodi bind human cell antithymocyt globulin given patient stem cell transplant kill cell lower risk graft versu host diseas gvhd also use treat gvhd kidney transplant help keep bodi reject kidney also call antilymphocyt globulin anti trail r mab listen tee substanc studi treatment type cancer bind protein call trail r surfac tumor cell may kill tumor cell anti trail r mab type monoclon antibodi also call hg etr mapatumumab anti trail r mab hg etr listen tee substanc studi treatment type cancer bind protein call trail r surfac tumor cell may kill tumor cell anti trail r mab hg etr type monoclon antibodi also call hg etr lexatumumab antituberculosi listen tee ber kyoo loh si describ drug effect work tuberculosi contagi bacteri infect usual affect lung antitumor listen tee mer stop abnorm cell growth antitumor antibiot listen tee mer tee ah tik type anticanc drug block cell growth interf dna genet materi cell also call anticanc antibiot antineoplast antibiot anti vegfr monoclon antibodi listen tee mah noh kloh nul tee bah dee substanc bind receptor protein call vascular endotheli growth factor vegf may found type cancer cell may prevent growth new blood vessel tumor need grow differ type anti vegfr monoclon antibodi studi treatment cancer substanc type antiangiogenesi agent type monoclon antibodi anti vegfr fulli human monoclon antibodi imc b listen tee ful ee hyoo mun mah noh kloh nul tee bah dee drug use drug treat colorect cancer non small cell lung cancer spread part bodi use alon anoth drug treat cancer stomach gastroesophag junction area esophagu connect stomach advanc spread part bodi also studi treatment type cancer anti vegfr fulli human monoclon antibodi imc b bind receptor protein call vascular endotheli growth factor vegf may found type cancer cell may prevent growth new blood vessel tumor need grow anti vegfr fulli human monoclon antibodi imc b type antiangiogenesi agent type monoclon antibodi also call cyramza imc b ramucirumab antivir listen tee vy rul drug use treat infect caus virus anu listen ay nu open rectum outsid bodi anxieti listen ang zy eh tee feel fear dread uneasi may occur reaction stress person anxieti may sweat feel restless tens rapid heart beat extrem anxieti happen often time may sign anxieti disord anxiolysi listen ang zee ah lih si level sedat person relax may awak person abl answer question follow instruct anxiolysi caus special drug use help reliev anxieti certain medic surgic procedur also call minim sedat anxiolyt listen ang zee oh lih tik drug use treat symptom anxieti feel fear dread uneasi muscl tight may occur reaction stress anxiolyt block action certain chemic nervou system also call antianxieti agent anxiolyt agent anxiolyt agent listen ang zee oh lih tik ay jent drug use treat symptom anxieti feel fear dread uneasi muscl tight may occur reaction stress anxiolyt agent block action certain chemic nervou system also call antianxieti agent anxiolyt aorta listen ay tuh largest arteri bodi carri oxygen rich blood away heart vessel reach rest bodi aortocoronari bypass listen ay toh kor uh nayr ee pass surgeri healthi blood vessel taken anoth part bodi use make new path blood around block arteri lead heart restor flow oxygen nutrient heart also call cab coronari arteri bypass ap substanc studi treatment soft tissu bone cancer also studi treatment solid tumor hematolog cancer ap stop cell divid may caus cancer cell die type mtor inhibitor also call ridaforolimu ap substanc studi treatment head neck cancer may kill cancer cell carri anticanc drug tumor type platinum compound apalutamid listen puh loo tuh mide drug use treat prostat cancer spread part bodi use patient whose cancer castrat resist respond treatment lower testosteron level apalutamid bind protein call androgen receptor found prostat cancer cell protein bind androgen male hormon may caus cancer cell grow apalutamid block protein may keep cancer cell grow type antiandrogen also call erleada apc type immun cell boost immun respons show antigen surfac cell immun system apc type phagocyt also call antigen present cell apc vaccin listen vak seen vaccin made antigen antigen present cell apc apc boost immun respons present antigen surfac cell immun system also call antigen present cell vaccin apc vaccin use treat prostat cancer spread part bodi use patient symptom whose cancer castrat resist respond treatment lower testosteron level apc made patient immun cell treat laboratori gm csf type growth factor protein found prostat cancer cell apc may help immun system kill prostat cancer cell type cellular adopt immunotherapi also call proveng sipuleucel apc f vaccin made immun system cell taken patient prostat cancer frozen futur use cell treat laboratori growth factor attach protein call prostat acid phosphatas pap found prostat cancer cell apc f inject patient may caus cell type white blood cell kill tumor cell pap apheresi listen feh ree si procedur blood collect part blood platelet white blood cell taken rest blood return donor also call pheresi apidra listen uh pee druh drug use control amount sugar blood patient diabet mellitu form hormon insulin made laboratori apidra get blood faster insulin inject skin shortli meal type therapeut insulin also call insulin glulisin apl aggress fast grow type acut myeloid leukemia mani immatur blood form cell blood bone marrow usual mark exchang part chromosom also call acut promyelocyt leukemia promyelocyt leukemia aplast anemia listen ay pla tik uh nee mee uh condit bone marrow unabl produc blood cell aplidin listen ap lih deen substanc studi treatment cancer obtain marin organ apn regist nurs addit educ train diagnos treat diseas apn licens state level certifi nation nurs organ cancer care apn may manag primari care patient famili base practic agreement doctor also call advanc practic nurs np nurs practition apo l listen ay poh cell protein attach certain molecul cancer cell may kill cell apo l studi treatment cancer also call tnf relat apoptosi induc ligand trail tumor necrosi factor relat apoptosi induc ligand apocrin gland listen poh krin type gland found skin breast eyelid ear apocrin gland breast secret fat droplet breast milk ear help form earwax apocrin gland skin eyelid sweat gland apocrin gland skin armpit groin area around nippl breast apocrin gland skin scent gland secret usual odor anoth type gland eccrin gland simpl sweat gland produc sweat apolizumab listen puh liz yoo mab substanc studi treatment hematolog blood cancer apolizumab bind protein call id found surfac type immun cell cancer cell may help immun system kill cancer cell type monoclon antibodi apoptosi listen pop toh si type cell death seri molecular step cell lead death one method bodi use get rid unneed abnorm cell process apoptosi may block cancer cell also call program cell death appendag listen uh pen dij medicin bodi part arm leg attach main part bodi appendectomi listen pen dek toh mee surgeri remov appendix small finger shape pouch end first part larg intestin appendix listen uh pen dix small fingerlik pouch stick cecum first part larg intestin near end small intestin appetit listen peh tite desir satisfi physic mental need food sex adventur aprepit listen uh preh pih tunt drug use drug prevent nausea vomit caus chemotherapi also use prevent nausea vomit surgeri aprepit block action certain chemic brain may trigger nausea vomit block chemic may lessen nausea vomit aprepit type antiemet type substanc p neurokinin receptor antagonist also call emend aptivu listen ap tih vu drug use anoth drug ritonavir treat patient infect hiv viru caus aid treat anti hiv drug aptivu block hiv viru make copi type anti hiv agent type proteas inhibitor also call tipranavir sodium aqueou listen kwee us water ar protein bind male hormon call androgen ar found insid cell male reproduct tissu type tissu cancer cell prostat cancer androgen bind ar insid cancer cell caus cancer cell grow also call androgen receptor ar listen describ cell protein bind androgen male hormon cancer cell ar may need androgen grow cell may stop grow die treat substanc block bind action androgen hormon also call androgen receptor posit ara c drug use drug treat acut lymphoblast leukemia acut myeloid leukemia aml chronic myeloid leukemia cml also use prevent treat type leukemia spread mening three thin layer tissu cover protect brain spinal cord also studi treatment type cancer ara c block cell make dna may kill cancer cell type antimetabolit also call cytarabin aranesp listen ayr uh nesp drug use treat anemia caus chronic kidney diseas type chemotherapi aranesp form erythropoietin substanc natur made kidney made laboratori help bone marrow make red blood cell aranesp type antianem type erythropoiesi stimul agent also call darbepoetin alfa arctigenin listen ark tih jeh nin substanc found certain plant includ burdock shown antivir anticanc effect arctigenin belong group substanc call lignan arctiin listen ark tine substanc found certain plant includ burdock shown anticanc effect arctiin belong group substanc call lignan aredia listen uh reh dee uh drug use treat hypercalcemia high blood level calcium caus certain type cancer also use anticanc drug treat multipl myeloma breast cancer spread bone also use treat paget diseas bone aredia may help keep bone break prevent loss calcium bone type bisphosphon also call pamidron disodium areola listen ayr ee oh luh area dark color skin breast surround nippl arginin listen ar jih neen one twenti common amino acid build block protein arginin studi nutrit supplement treatment prevent cancer condit also call l arginin arginin butyr listen ar jih neen byoo tuh rayt substanc studi treatment cancer argon beam coagul ablat listen ar gon beem coh gyuh lay ter blay shun procedur destroy tissu electr current pass stream argon ga tissu use treat endometriosi condit stop blood loss surgeri arimidex listen uh rih mih dex drug use treat certain type breast cancer postmenopaus women also studi treatment type cancer arimidex lower amount estrogen made bodi may stop growth cancer cell need estrogen grow arimidex type nonsteroid aromatas inhibitor also call anastrozol arixtra listen uh rik struh drug use prevent blood clot form insid blood vessel leg studi prevent blood clot cancer patient includ women surgeri cancer reproduct tract type anticoagul also call fondaparinux fondaparinux sodium armd condit slow breakdown cell center retina light sensit layer nerv tissu back eye block vision center eye caus problem activ read drive armd often seen peopl age also call age relat macular degener amd macular degener armodafinil listen ar moh da fih nil drug use treat certain sleep disord narcolepsi make patient feel alert awak also studi treatment insomnia fatigu patient treat cancer armodafinil act part brain control sleep wake type wake promot agent also call nuvigil arm soft tissu tumor common older children teenag begin embryon muscl cell cell develop muscl bodi occur mani place bodi usual occur trunk arm leg also call alveolar rhabdomyosarcoma aromasin listen uh roh muh sin drug use treat advanc breast cancer earli stage breast cancer estrogen receptor posit er use postmenopaus women whose cancer alreadi treat tamoxifen also studi treatment type cancer aromasin lower amount estrogen made bodi may stop growth cancer cell need estrogen grow aromasin type aromatas inhibitor also call exemestan aromatas inhibitor listen uh roh muh tay hih bih ter drug prevent format estradiol femal hormon interf aromatas enzym aromatas inhibitor use type hormon therapi postmenopaus women hormon depend breast cancer aromatherapist listen uh roh muh thayr uh pist person practic type complementari medicin call aromatherapi therapi use plant oil give strong pleasant smell promot relax sens well plant oil usual inhal put skin use wet cloth bath massag aromatherapi listen uh roh muh thayr uh pee type complementari altern medicin use plant oil give strong pleasant aroma smell promot relax sens well heal aromatherapi infus listen uh roh muh thayr uh pee fyoo zhun process heat without boil mixtur water essenti oil scent liquid taken plant releas pleasant aroma aromatherapi infus may also refer process heat herb liquid releas essenti oil inhal oxygen scent aromatherapi infus studi complementari therapi use addit standard treatment reliev pain shorten recoveri time patient undergo colonoscopi aromatherapi massag listen uh roh muh thayr uh pee muh sazh type complementari altern medicin use rub knead skin plant oil give strong pleasant aroma smell promot relax sens well heal aromat listen ayr oh tik odor often pleasant spici arous listen uh row zul state alert readi respond wake sleep arranon listen ayr rah non drug use treat cell acut lymphoblast leukemia cell lymphoblast lymphoma use patient whose cancer gotten better recur come back treatment anticanc drug arranon stop cell make dna may kill cancer cell type antimetabolit also call u nelarabin arrhenoblastoma listen uh ree noh bla toh muh rare type ovarian tumor tumor cell secret male sex hormon may caus viril appear male physic characterist femal also call androblastoma sertoli leydig cell tumor ovari arsen listen ar nik poison chemic use kill weed pest also use cancer therapi arsen trioxid listen ar seh nik tri ok side drug use treat acut promyelocyt leukemia apl certain chromosom abnorm fusion gene call pml rar alpha use tretinoin newli diagnos patient use alon patient whose cancer gotten better come back treatment anticanc drug arsen trioxid also studi treatment type cancer arsen trioxid damag fusion protein made pml rar alpha fusion gene may help keep cancer cell grow may kill also call trisenox art therapi listen thayr uh pee treatment use make art respons art improv one physic mental emot well art therapi sometim use togeth psychotherapi talk therapi arteri embol listen ar teer ee ul em boh lih zay shun procedur blood suppli tumor abnorm area tissu block arteri embol small incis cut made inner thigh cathet thin flexibl tube insert guid arteri near tumor abnorm tissu cathet place small particl made tini gelatin spong bead inject block arteri stop flow blood tumor abnorm area tissu arteri embol use treat type liver cancer kidney cancer neuroendocrin tumor may also use treat uterin fibroid aneurysm condit also call tae transarteri embol arteriogram listen ar teer ee oh gram x ray arteri person receiv inject dye outlin vessel x ray arteriographi listen ar teer ee ah gruh fee procedur x ray arteri arteri seen inject dye outlin vessel x ray arteri listen ar tuh ree blood vessel carri blood heart tissu organ bodi arthralgia listen ar thral juh joint pain arthriti listen ar thri ti diseas caus inflamm pain joint artifici pacemak listen ar tih fih shul pay may ker electron devic implant bodi monitor heart rate rhythm give heart electr stimul beat normal run batteri long thin wire connect heart also call cardiac pacemak pacemak arzerra listen ar zayr uh drug use alon anticanc drug treat certain type chronic lymphocyt leukemia cll also studi treatment type cancer arzerra bind protein call cd found b cell type white blood cell type leukemia lymphoma cell arzerra may block cd help immun system kill cancer cell type monoclon antibodi also call humax cd ofatumumab arzoxifen hydrochlorid listen ar zok sih feen hy droh klor ide substanc studi treatment osteoporosi breast cancer arzoxifen hydrochlorid made laboratori bind estrogen receptor bodi type select estrogen receptor modul serm also call ly hydrochlorid asbesto listen be tu group miner take form tini fiber asbesto use insul heat fire build loos asbesto fiber breath lung caus sever seriou diseas includ lung cancer malign mesothelioma cancer found line lung chest abdomen asbesto swallow may caus cancer gastrointestin tract asbestosi listen be toh si lung diseas caus breath particl asbesto group miner take form tini fiber symptom includ cough troubl breath chest pain caus scar perman damag lung tissu asbestosi increas risk lung cancer malign mesothelioma cancer found line lung chest abdomen asc h find abnorm cell pap test mean abnorm squamou cell tissu line outer part cervix asc h may sign high grade squamou intraepitheli lesion hsil may becom cervic cancer untreat test may need also call atyp squamou cell cannot exclud high grade lesion ascit listen uh sy teez abnorm buildup fluid abdomen may caus swell late stage cancer tumor cell may found fluid abdomen ascit also occur patient liver diseas ascorb acid listen uh skor bik sid nutrient bodi need small amount function stay healthi ascorb acid help fight infect heal wound keep tissu healthi antioxid help prevent cell damag caus free radic highli reactiv chemic ascorb acid found fruit veget especi citru fruit strawberri cantaloup green pepper tomato broccoli leafi green potato water solubl dissolv water must taken everi day ascorb acid studi prevent treatment type cancer also call vitamin c ascu listen find abnorm cell tissu line outer part cervix ascu common abnorm find pap test may sign infect certain type human papillomaviru hpv may also sign benign cancer growth cyst polyp menopaus women low hormon level test hpv test may need also call asc us atyp squamou cell undetermin signific asc us find abnorm cell tissu line outer part cervix asc us common abnorm find pap test may sign infect certain type human papillomaviru hpv may also sign benign cancer growth cyst polyp menopaus women low hormon level test hpv test may need also call ascu atyp squamou cell undetermin signific asept necrosi listen ay sep tik neh kroh si condit loss blood flow bone tissu caus bone die common hip knee shoulder ankl may caus long term use steroid medicin alcohol abus joint injuri certain diseas cancer arthriti may also occur point time cancer treatment includ methotrex bisphosphon corticosteroid also call avascular necrosi ischem necrosi osteonecrosi ashkenazi jew listen ash keh nah zee jooz one two major ancestr group jewish individu ancestor ashkenazi jew live central eastern europ e g germani poland russia group call sephard jew includ whose ancestor live north africa middl east spain jew live unit state ashkenazi descent asm rare condit mani mast cell type white blood cell build certain tissu organ bodi includ bone marrow lymph node bone liver spleen small intestin asm may get wors quickli caus sever symptom organ damag sometim may becom mast cell leukemia rare type leukemia asm usual occur adult also call aggress system mastocytosi asparaginas listen payr uh jih nay drug use treat acut lymphoblast leukemia studi treatment type cancer enzym taken bacterium escherichia coli e coli break amino acid asparagin may block growth tumor cell need asparagin grow also call elspar l asparaginas asparaginas erwinia chrysanthemi listen payr uh jih nay er wih nee uh krih san theh drug use anticanc drug treat acut lymphoblast leukemia enzym come erwinia chrysanthemi bacterium use patient cannot take similar drug come e coli bacterium also studi treatment type cancer break amino acid asparagin may block growth cancer cell need asparagin grow may also kill cancer cell also call erwinaz asparla par la drug use drug treat acut lymphoblast lymphoma children young adult age month year asparla form drug l asparaginas link substanc call sc peg make drug stay bodi longer l asparaginas enzym taken bacterium escherichia coli e coli break amino acid asparagin may stop growth cancer cell need asparagin grow asparla type protein synthesi inhibitor also call calaspargas pegol ezn sc peg e coli l asparaginas aspart transaminas listen par tayt tranz mih nay enzym found liver heart tissu high level aspart transaminas releas blood may sign liver heart damag cancer diseas also call serum glutam oxaloacet transaminas sgot aspergillosi listen per jih loh si infecti fungal diseas occur often skin ear nasal sinus lung peopl suppress immun system aspergillu listen per jih lu fungi commonli found soil certain type aspergillu may caus diseas especi peopl suppress immun system aspir aspir pronounc pih rit refer fluid tissu substanc withdrawn bodi caviti cyst tumor aspir pronounc pih rayt refer act withdraw fluid tissu substanc needl also refer accident breath food fluid lung caus seriou problem pneumonia lung problem aspir listen pih ray shun remov fluid tissu needl also accident breath food fluid lung aspirin listen pih rin drug reduc pain fever inflamm blood clot aspirin belong famili drug call nonsteroid anti inflammatori agent also studi cancer prevent asp soft tissu tumor common older children teenag begin soft support tissu connect surround organ tissu asp usual occur leg also occur arm hand head neck caus growth new blood vessel help tumor grow spread also call alveolar soft part sarcoma assay listen say laboratori test find measur amount specif substanc assent process listen uh sent prah se process requir law children adolesc given easi understand inform clinic trial help decid want take part trial patient given chanc ask question happen trial done ask formal consent enter trial come parent guardian assess listen uh se ment healthcar process use learn patient condit may includ complet medic histori medic test physic exam test learn skill test find patient abl carri task daili live mental health evalu review social support commun resourc avail patient asset listen set someth financi valu person own benefit use money jewelri artwork invest real estat car exampl asset assist devic listen uh si tiv dee vise tool help person disabl certain task exampl cane wheelchair scooter walker hear aid special bed assist technolog listen uh si tiv tek nah loh jee devic technolog help disabl person exampl special grip hold utensil comput screen monitor help person low vision read easili comput control talk telephon make sound louder lifter help person rise chair asthenia listen thee nee uh weak lack energi strength asthma listen az muh chronic diseas bronchial airway lung becom narrow swollen make difficult breath symptom includ wheez cough tight chest short breath rapid breath asthma attack may brought pet hair dust smoke pollen mold exercis cold air stress astrocyt listen troh site larg star shape cell hold nerv cell place help develop work way astrocyt type glial cell astrocytoma listen troh sy toh muh tumor begin brain spinal cord small star shape cell call astrocyt asymmetri listen ay sih meh tree lack absenc balanc proport part thing asymptomat listen ay sim toh tik sign symptom diseas asymptomat inflammatori prostat listen ay sim toh tik fla muh tor ee pro tuh ty ti inflamm prostat gland symptom presenc white blood cell prostat fluid rt aggress cancer central nervou system kidney liver occur young children also call att rht atyp teratoid rhabdoid tumor',\n",
       " 'result quick grace search first video list latest one date thought suggest crizotinib lead choic mom case sinc alreadi take alimta well onc probabl want keep long work side effect limit noth take daili pill may eas lot side effect brought weekli trip cancer center iv infus http cancergrac org lung tag ro long thread page patient group forum http cancergrac org topic alk ro nsclc patient group',\n",
       " 'ye correct hsct superior alemtuzumab natalizumab ocrelizumab cladribin',\n",
       " 'increas risk seriou infect involv variou organ system site may requir hospit result death tuberculosi frequent dissemin extrapulmonari invas fungal infect may dissemin bacteri e g legionellosi listeriosi viral infect opportunist infect report see infecti complic caution care consid risk benefit prior initi adalimumab therapi patient chronic recur infect evalu patient latent tuberculosi infect prior period adalimumab therapi indic initi appropri antimycobacteri regimen prior initi adalimumab therapi close monitor patient infect includ activ tuberculosi neg tuberculin skin test treatment discontinu adalimumab seriou infect sepsi occur consid empir antifung therapi seriou system ill occur patient risk invas fungal infect malign lymphoma malign fatal report children adolesc receiv tnf block agent see malign lymphoprolif disord caution aggress usual fatal hepatosplen cell lymphoma report mainli adolesc young adult crohn diseas ulcer coliti receiv tnf block agent includ adalimumab patient receiv combin immunosuppress agent includ tnf block agent thiopurin analog azathioprin mercaptopurin introduct see also stelara biolog respons modifi diseas modifi antirheumat drug dmard recombin dna deriv human immunoglobulin g igg monoclon antibodi specif human tumor necrosi factor tnf tnf use humira rheumatoid arthriti adult use manag sign symptom rheumatoid arthriti induc major clinic respons improv physic function inhibit progress structur damag associ diseas adult moder sever activ rheumatoid arthriti use alon combin methotrex nonbiolog dmard juvenil arthriti manag sign symptom moder sever activ polyarticular juvenil idiopath arthriti children use without methotrex psoriat arthriti use manag sign symptom psoriat arthriti improv physic function inhibit progress structur damag associ diseas adult activ psoriat arthriti use alon combin nonbiolog dmard ankylos spondyl manag sign symptom activ ankylos spondyl crohn diseas use reduc sign symptom crohn diseas induc maintain clinic remiss adult moder sever activ diseas inadequ respons convent therapi also use reduc sign symptom diseas induc clinic remiss adult moder sever activ crohn diseas lost respons intoler infliximab ulcer coliti use induc sustain clinic remiss adult moder sever activ ulcer coliti inadequ respons immunosuppress agent corticosteroid azathioprin mercaptopurin efficaci patient lost respons intoler tnf block agent establish plaqu psoriasi manag moder sever chronic plaqu psoriasi adult candid system therapi phototherapi system therapi medic less appropri use patient close monitor regular follow visit clinician humira dosag administr gener concomit therapi methotrex nonbiolog dmard corticosteroid nsaia analges may continu adult rheumatoid arthriti psoriat arthriti ankylos spondyl methotrex corticosteroid nsaia analges may continu pediatr patient juvenil idiopath arthriti aminosalicyl corticosteroid may continu adult crohn diseas ulcer coliti azathioprin mercaptopurin methotrex may continu necessari adult crohn diseas azathioprin mercaptopurin may continu necessari adult ulcer coliti see malign lymphoprolif disord caution administr sub q inject avail prefil syring prefil inject pen vial preserv free singl use vial institut use use promptli withdraw solut vial administ sub q inject everi week everi week administ sub q inject thigh abdomen make abdomin inject within cm inch umbilicu rotat inject site give new inject cm inch old site make inject area skin tender bruis red hard scar stretch mark inject psoriat lesion intend use guidanc supervis clinician may self administ clinician determin patient caregiv compet safe administ drug appropri train medic follow necessari initi self administ dose made supervis health care profession dosag pediatr patient juvenil arthriti sub q children year age weigh kg mg everi week children year age weigh kg mg everi week adult rheumatoid arthriti sub q mg everi week patient receiv methotrex may obtain addit benefit weekli dose mg psoriat arthriti sub q mg everi week ankylos spondyl sub q mg everi week crohn diseas sub q mg day four mg inject one day two mg inject per day consecut day follow mg week later day start mainten dosag mg everi week day week mg dose ulcer coliti sub q mg day four mg inject one day two mg inject per day consecut day follow mg week later day start mainten dosag mg everi week day week mg dose clinic remiss achiev week day discontinu adalimumab plaqu psoriasi sub q initi mg follow mg everi week mainten dosag start week initi dose prescrib limit adult crohn diseas manufactur state safeti efficaci continu adalimumab beyond year evalu clinic studi plaqu psoriasi manufactur state safeti efficaci continu adalimumab beyond year evalu clinic studi caution humira contraind known hypersensit adalimumab ingredi formul warn precaut warn infecti complic increas risk seriou infect involv variou organ system site may requir hospit result death opportunist infect caus bacteri mycobacteri invas fungal viral parasit opportunist pathogen e g aspergillosi blastomycosi candidiasi coccidioidomycosi histoplasmosi legionellosi listeriosi pneumocystosi tuberculosi report particularli patient receiv concomit therapi immunosuppress agent e g methotrex corticosteroid infect frequent dissemin see box warn increas incid seriou infect observ concomit use tnf block agent anakinra abatacept see specif drug interact patient year age comorbid condit receiv concomit therapi immunosuppress agent e g corticosteroid methotrex may increas risk infect initi adalimumab patient activ infect includ local infect consid potenti risk benefit drug prior initi therapi patient histori chronic recur opportunist infect patient underli condit may predispos infect patient expos tuberculosi resid travel region tuberculosi mycos histoplasmosi coccidioidomycosi blastomycosi endem close monitor patient adalimumab therapi sign symptom infect e g fever malais weight loss sweat cough dyspnea pulmonari infiltr seriou system ill includ shock new infect occur therapi perform thorough diagnost evalu appropri immunocompromis patient initi appropri anti infect therapi close monitor patient discontinu adalimumab seriou infect sepsi develop evalu patient activ latent tuberculosi risk factor tuberculosi prior period therapi indic initi appropri antimycobacteri regimen treatment latent tuberculosi infect prior adalimumab therapi also consid antimycobacteri therapi prior adalimumab therapi individu histori latent activ tuberculosi adequ cours antimycobacteri treatment cannot confirm individu neg tuberculin skin test risk factor tuberculosi consult tuberculosi specialist recommend decid whether initi antimycobacteri therapi monitor patient includ neg tuberculin skin test activ tuberculosi strongli consid tuberculosi patient develop new infect receiv adalimumab especi previous travel countri tuberculosi highli preval close contact individu activ tuberculosi failur recogn invas fungal infect led delay appropri treatment consid empir antifung therapi patient risk invas fungal infect develop sever system ill whenev feasibl consult specialist fungal infect make decis regard initi durat antifung therapi decid whether reiniti tnf block agent therapi follow resolut invas fungal infect reevalu risk benefit particularli patient resid region mycos endem whenev feasibl consult specialist fungal infect malign lymphoprolif disord lymphoma malign fatal report postmarket surveil children adolesc receiv tnf block agent particularli receiv immunosuppress agent e g azathioprin methotrex concomitantli malign includ lymphoma case e g hodgkin diseas non hodgkin lymphoma variou malign e g leukemia melanoma solid organ cancer includ rare malign usual associ immunosuppress malign usual observ children adolesc e g leiomyosarcoma hepat malign renal cell carcinoma median time occurr month rang month initi tnf block agent dose fda conclud increas risk malign tnf block agent children adolesc howev strength associ fulli character hepatosplen cell lymphoma rare aggress usual fatal cell lymphoma report mainli adolesc young adult crohn diseas ulcer coliti receiv tnf block agent thiopurin analog mercaptopurin azathioprin patient receiv combin immunosuppress agent includ tnf block agent thiopurin analog unclear whether occurr relat use tnf block agent use tnf block agent conjunct immunosuppress agent control studi lymphoma report frequent patient receiv adalimumab tnf block agent control patient patient crohn diseas rheumatoid arthriti ankylos spondyl psoriat arthriti plaqu psoriasi chronic inflammatori diseas especi highli activ diseas chronic exposur immunosuppress therapi may increas risk lymphoma even absenc tnf block agent therapi may difficult measur ad risk tnf block agent azathioprin mercaptopurin acut chronic leukemia fatal report postmarket surveil tnf block agent adult pediatr patient particularli receiv immunosuppress agent concomitantli leukemia commonli acut myeloid leukemia chronic lymphocyt leukemia chronic myeloid leukemia gener occur first year therapi fda conclud possibl associ tnf block agent develop leukemia interpret find complic patient rheumatoid arthriti may increas risk leukemia independ treatment tnf block agent malign e g breast colorect lung prostat melanoma nonmelanoma skin cancer occur patient receiv adalimumab control studi tnf block agent adult increas risk malign e g patient copd histori heavi smoke patient wegen granulomatosi receiv concomit cyclophosphamid greater proport malign occur patient receiv tnf block agent compar control patient immun relat diseas e g crohn diseas shown increas risk cancer independ treatment tnf block agent other e g juvenil idiopath arthriti unknown whether increas risk cancer consid possibl monitor occurr malign follow treatment tnf block agent consid risk benefit tnf block agent includ adalimumab prior initi therapi patient known malign success treat nonmelanoma skin cancer decid whether continu therapi patient develop malign care consid risk benefit agent especi adolesc young adult especi treatment crohn diseas ulcer coliti examin patient particularli histori prior prolong immunosuppress therapi histori psoralen uva light puva therapi nonmelanoma skin cancer adalimumab therapi warn precaut sensit reaction anaphylaxi angioedema allerg reaction e g allerg rash anaphylactoid reaction fix drug erupt nonspecifi drug reaction urticaria observ seriou allerg reaction anaphylaxi occur immedi discontinu adalimumab initi appropri therapi needl cover prefil syring adalimumab contain dri natur rubber latex handl individu sensit latex hbv reactiv increas risk reactiv hbv infect patient chronic carrier viru e hepat b surfac antigen posit [hbsag positive] use multipl immunosuppress agent may contribut hbv reactiv screen risk patient prior initi therapi evalu monitor hbv carrier sever month therapi safeti efficaci antivir therapi prevent hbv reactiv establish discontinu adalimumab initi appropri treatment e g antivir therapi hbv reactiv occur known whether adalimumab readminist control reactiv hbv infect achiev caution advis situat nervou system effect new onset exacerb central peripher nervou system demyelin disord e g multipl sclerosi optic neuriti guillain barr syndrom report rare patient receiv adalimumab tnf block agent exercis caution consid adalimumab therapi patient preexist recent onset central peripher nervou system demyelin disord hematolog effect possibl pancytopenia includ aplast anemia leukopenia thrombocytopenia consid discontinu patient confirm hematolog abnorm cardiovascular effect worsen chf new onset chf report patient receiv adalimumab tnf block agent use caution care monitor patient heart failur immunolog reaction antibodi format possibl format autoimmun antibodi lupu like syndrom report manifest suggest lupu like syndrom develop discontinu adalimumab antibodi adalimumab may develop long term immunogen remain determin immun patient may receiv inactiv vaccin avoid live vaccin e g measl viru vaccin live mump viru vaccin live rubella viru vaccin live smallpox vaccin typhoid vaccin live oral varicella viru vaccin live yellow fever vaccin see interact psoriasi new onset psoriasi includ pustular palmoplantar psoriasi exacerb exist psoriasi report tnf block agent includ adalimumab patient experienc improv follow discontinu tnf block agent consid possibl monitor manifest e g new rash new worsen psoriasi particularli pustular palmoplantar psoriasi hepat effect sever hepat reaction includ acut liver failur report patient receiv tnf block agent serum alt elev time uln observ patient receiv adalimumab causal relationship clear mani patient receiv concomit therapi drug known increas liver enzym concentr e g methotrex nsaia specif popul pregnanc categori b see pediatr use caution lactat distribut milk small amount appear unlik absorb breast fed infant although use nurs women without appar advers effect breast fed infant system bioavail milk effect exposur nurs infant unknown potenti absorpt neonat preterm infant also unknown use caution see pediatr use caution pediatr use safeti efficaci use juvenil idiopath arthriti establish pediatr patient safeti efficaci manag juvenil idiopath arthriti establish pediatr patient year age studi children year age data patient weigh kg limit review vaccin statu child administ age appropri vaccin possibl prior initi adalimumab malign fatal report children adolesc receiv tnf block agent includ adalimumab see malign lymphoprolif disord caution neonat infant expos adalimumab utero may impair immun respons data suggest adalimumab cross placenta clinic import elev concentr infant unknown consid risk benefit administ live vaccin infant expos adalimumab utero safeti live vaccin infant unknown geriatr use substanti differ efficaci rel younger adult incid seriou infect malign adalimumab treat patient year age higher incid younger adult overal incid infect malign higher geriatr popul gener younger adult use caution common advers effect adult infect e g upper respiratori tract infect sinus inject site reaction headach rash pediatr patient year age infect inject site pain inject site reaction hypersensit reaction e g local allerg sensit reaction rash increas cpk concentr interact humira administ concomitantli aminosalicyl methotrex dmard corticosteroid immunomodulatori agent e g azathioprin mercaptopurin nsaia clinic studi see concomit therapi dosag administr drug metabol hepat microsom enzym increas level tnf chronic inflamm may suppress format cyp isoenzym antagon tnf activ adalimumab may normal format cyp enzym drug metabol cyp isoenzym low therapeut index monitor therapeut effect serum concentr follow initi discontinu adalimumab adjust dosag need biolog antirheumat agent abatacept anakinra rituximab tocilizumab see specif drug interact biolog agent use manag rheumatoid arthriti psoriat arthriti ankylos spondyl crohn diseas ulcer coliti plaqu psoriasi manufactur state data regard concomit use adalimumab insuffici concomit use adalimumab biolog dmard recommend use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect vaccin patient may receiv inactiv vaccin avoid live vaccin see also pediatr use caution data avail secondari transmiss infect live vaccin adalimumab treat patient specif drug drug interact comment abatacept increas incid infect seriou infect without addit clinic benefit report abatacept tnf block agent rheumatoid arthriti concomit use recommend use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect anakinra increas incid seriou infect neutropenia without addit clinic benefit report anakinra etanercept anoth tnf block agent rheumatoid arthriti concomit use recommend use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect cyclosporin possibl effect cyclosporin metabol increas level tnf chronic inflamm may suppress format cyp isoenzym antagon tnf activ adalimumab may normal format cyp enzym monitor therapeut effect concentr cyclosporin follow initi discontinu adalimumab adjust dosag need influenza viru vaccin inactiv antibodi titer adalimumab treat rheumatoid arthriti patient protect albeit lower placebo treat patient methotrex decreas adalimumab clearanc dosag adjust necessari natalizumab increas risk progress multifoc leukoencephalopathi pml seriou infect avoid concomit use manag crohn diseas pneumococc polysaccharid vaccin differ antibodi respons adalimumab placebo treat rheumatoid arthriti patient rituximab increas risk seriou infect report patient receiv rituximab subsequ receiv tnf block agent use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect theophyllin possibl effect theophyllin metabol increas level tnf chronic inflamm may suppress format cyp isoenzym antagon tnf activ adalimumab may normal format cyp enzym monitor therapeut effect serum concentr theophyllin follow initi discontinu adalimumab adjust dosag need tnf block agent concomit use recommend tocilizumab concomit use studi possibl increas immunosuppress increas risk infect avoid concomit use use caution switch one biolog dmard anoth sinc overlap biolog activ may increas risk infect warfarin possibl effect warfarin metabol increas level tnf chronic inflamm may suppress format cyp isoenzym antagon tnf activ adalimumab may normal format cyp enzym monitor therapeut effect warfarin follow initi discontinu adalimumab adjust dosag need humira pharmacokinet absorpt bioavail bioavail approxim peak serum concentr achiev hour distribut extent distribut synovi fluid distribut milk small amount appear cross placenta elimin metabol metabol fate undetermin elimin rout unknown half life week rang day special popul patient adalimumab antibodi clearanc adalimumab higher clearanc adalimumab lower increas age patient year age stabil storag parenter inject c freez use solut frozen travel store cool carrier ice pack protect light store origin carton time administr action potent antagonist tnf biolog activ high specif affin tnf tnf bind inactiv lymphotoxin tnf prevent bind tnf cell surfac tnf receptor therebi block biolog activ tnf immunoglobulin g igg made phage display technolog amino acid sequenc human germlin contain nonhuman compon artifici fuse human peptid sequenc indistinguish structur function natur occur human igg produc recombin dna technolog mammalian cell express system purifi process includ specif viral inactiv remov step advic patient import patient read manufactur patient inform medic guid prior initi therapi time prescript refil import instruct patient caregiv regard proper dosag administr adalimumab includ use asept techniqu proper dispos needl syring determin patient caregiv compet safe administ drug increas suscept infect import seek immedi medic attent sign symptom suggest infect e g fever fatigu cough warm red pain skin sore bodi muscl ach diarrhea stomach pain short breath weight loss burn urin urinari frequenc develop risk lymphoma includ hepatosplen cell lymphoma leukemia malign use tnf block agent import inform patient caregiv increas risk cancer develop children adolesc young adult take account clinic util tnf block agent rel risk benefit immunosuppress drug risk associ untreat diseas import promptli inform clinician sign symptom malign e g unexplain weight loss fatigu abdomin pain persist fever night sweat easi bruis bleed swollen lymph node neck underarm groin hepatomegali splenomegali occur import inform clinician new worsen medic condit e g neurolog condit [e g demyelin disorders] heart failur autoimmun disord [e g lupu like syndrome] psoriasi cytopenia import alert clinician allergi latex exist import promptli contact clinician manifest allerg reaction e g urticaria facial swell difficulti breath occur import take drug prescrib alter discontinu therapi without first consult clinician import women inform clinician plan becom pregnant plan breast feed import inform clinician exist contempl concomit therapi includ prescript otc drug well concomit ill histori cancer tuberculosi hbv infect chronic recur infect import inform patient import precautionari inform see caution prepar excipi commerci avail drug prepar may clinic import effect individu consult specif product label detail pleas refer ashp drug shortag resourc center inform shortag one prepar adalimumab rout dosag form strength brand name manufactur parenter inject subcutan use mg ml humira avail dispos prefil syring alcohol swab abbott mg ml humira avail dispos prefil syring prefil inject pen alcohol swab singl use vial abbott ahf di essenti copyright select revis may american societi health system pharmacist inc east west highway suit bethesda maryland refer abbvi inc humira adalimumab inject prescrib inform north chicago il sep abbvi inc humira adalimumab medic guid north chicago il may weinblatt keyston ec furst de et al adalimumab fulli human anti tumor necrosi factor monoclon antibodi treatment rheumatoid arthriti patient take concomit methotrex armada trial arthriti rheum http www ncbi nlm nih gov pubm dopt abstractplu felson dt anderson jj boer et al american colleg rheumatolog preliminari definit improv rheumatoid arthriti arthriti rheum http www ncbi nlm nih gov pubm dopt abstractplu felson dt anderson jj boer et al american colleg rheumatolog preliminari core set diseas activ measur rheumatoid arthriti clinic trial arthriti rheum http www ncbi nlm nih gov pubm dopt abstractplu felson dt anderson jj lang mlm et al improv rheumatoid arthriti clinic trial defin fifti percent seventi percent improv core set measur rather twenti percent arthriti rheum http www ncbi nlm nih gov pubm dopt abstractplu sharp jt score radiograph abnorm rheumatoid arthriti radiol clin north http www ncbi nlm nih gov pubm dopt abstractplu rau r adalimumab fulli human anti tumor necrosi factor monoclon antibodi treatment activ rheumatoid arthriti initi result five trial ann rheum di suppl ii ii http www ncbi nlm nih gov pubm dopt abstractplu http www pubmedcentr nih gov picrend fcgi tool pmcentrez artid blobtyp pdf abbott laboratori abbott park il person commun amgen pfizer corpor enbrel etanercept subcutan inject prescrib inform thousand oak ca sep keyston ec kavanaugh af sharp jt et al radiograph clinic function outcom treatment adalimumab human anti tumor necrosi factor monoclon antibodi patient activ rheumatoid arthriti receiv concomit methotrex therapi random placebo control week trial arthriti rheum http www ncbi nlm nih gov pubm dopt abstractplu weinblatt keyston ec furst de et al long term efficaci safeti adalimumab plu methotrex patient rheumatoid arthriti armada year extend studi ann rheum di dec epub ahead print navarro sarabia f ariza ariza r hernandez cru b et al adalimumab treat rheumatoid arthriti cochran databas syst rev cd meas pj gladman dd ritchlin ct et al adalimumab treatment patient moder sever activ psoriat arthriti result doubl blind random placebo control trial arthriti rheum http www ncbi nlm nih gov pubm dopt abstractplu gladman dd meas pj cifaldi et al adalimumab improv joint skin relat function impair patient psoriat arthriti patient report outcom adalimumab effect psoriat arthriti trial adept ann rheum di nov epub van der heijd kivitz schiff mh et al efficaci safeti adalimumab patient ankylos spondyl result multicent random doubl blind placebo control trial arthriti rheum http www ncbi nlm nih gov pubm dopt abstractplu bristol myer squibb orencia abatacept prescrib inform princeton nj sep food drug administr center drug evalu research inform healthcar profession tumor necrosi factor tnf blocker market remicad enbrel humira cimzia simponi fda alert rockvil md aug avail fda websit access nov http www fda gov drug drugsafeti postmarketdrugsafetyinformationforpatientsandprovid drugsafetyinformationforheathcareprofession ucm htm food drug administr center drug evalu research fda alert inform healthcar profession cimzia certolizumab pegol enbrel etanercept humira adalimumab remicad infliximab rockvil md food drug administr sep avail fda websit access oct http www fda gov drug drugsafeti postmarketdrugsafetyinformationforpatientsandprovid ucm htm lovel dj ruperto n goodman et al adalimumab without methotrex juvenil rheumatoid arthriti n engl j med http www ncbi nlm nih gov pubm dopt abstractplu targan sr hanauer sb van devent sjh short term studi chimer monoclon antibodi ca tumor necrosi factor crohn diseas n engl j med http www ncbi nlm nih gov pubm dopt abstractplu humira adalimumab risk evalu mitig strategi rem fda websit http www fda gov download drug drugsafeti postmarketdrugsafetyinformationforpatientsandprovid ucm pdf access oct us food drug administr fda drug safeti commun drug label tumor necrosi factor alpha tnf blocker includ warn infect legionella listeria bacteria rockvil md sep fda websit access oct http www fda gov drug drugsafeti ucm htm us food drug administr fda drug safeti commun safeti review updat report hepatosplen cell lymphoma adolesc young adult receiv tumor necrosi factor tnf blocker azathioprin mercaptopurin rockvil md apr fda websit access jul http www fda gov drug drugsafeti ucm htm genentech actemra tocilizumab inject prescrib inform south san francisco ca apr papp k crowley j ortonn jp et al adalimumab moder sever chronic plaqu psoriasi efficaci safeti retreat diseas recurr follow withdraw therapi br j dermatol http www ncbi nlm nih gov pubm dopt abstractplu genentech rituxan rituximab inject prescrib inform south san francisco ca apr biogen idec inc tysabri natalizumab inject prescrib inform cambridg sep janssen biotech inc simponi golimumab inject prescrib inform horsham pa jan reinisch w sandborn wj homm dw et al adalimumab induct clinic remiss moder sever activ ulcer coliti result randomis control trial gut http www ncbi nlm nih gov pubm dopt abstractplu sandborn wj van assch g reinisch w et al adalimumab induc maintain clinic remiss patient moder sever ulcer coliti gastroenterolog e http www ncbi nlm nih gov pubm dopt abstractplu adalimumab brigg gg freeman rk yaff sj drug pregnanc lactat refer guid fetal neonat risk th ed philadelphia lippincott william wilkin reinisch w sandborn wj panaccion r et al week efficaci adalimumab patient moder sever activ ulcer coliti fail corticosteroid immunosuppress inflamm bowel di http www ncbi nlm nih gov pubm dopt abstractplu abbvi inc humira adalimumab instruct use singl use pen north chicago il jul abbvi inc humira adalimumab instruct use singl use pre fill syring north chicago il jan',\n",
       " 'dx stage b nsclc one year ago done well tradit chemo radiat left cm nodul doctor imfinzi kill last littl cancer make sick stop would like second opinion doctor contact local nyc want gone',\n",
       " 'complet agre see therapist one best decis ever made diseas affect us physic mental well import mental emot healthi physic healthi especi face major procedur surgeri actual began see therapist surgeri truli felt like shell person help decid continu see year later still session month great unbias ear listen offer valuabl advic friend famili unabl provid therapist play big part overal health well stelara juli inflammatoryboweldiseas net team member',\n",
       " 'scari time chronic ill signific pain associ time found gener pain med whenev admit hospit exacerb reason never will maintain pain relief home least alway option go er pain get realli bad everi time done ct scan see horribl insid admit pain relief iv nutrit sound like may easi option pain med restrict get stricter actual med student mention get tylenol er last time luckili actual doctor came order substanti pain relief left wonder teach current student pain relief day year old femal husband son diagnos cd januari resect start stelara june current bad flare work tpn fentanyl patch oxycodon hope back work octob past med mp humira remicad cimzia',\n",
       " 'thank step lead hous two room worri much think push littl much yesterday tri take pain medic output scenario make sens abdomen small go attempt shower today easi hospit ground level chair rail live big citi kinda hard get lot exercis walk hous multipl time still stand straight look littl awkward haha dx sever pancol appear crohn take humira bi weekli month lialda x day mg prednison mg calcium vit flare sinc',\n",
       " 'hi everyon found jcv gilenya ish year never tysabri hope would abl go futur sinc heard great thing might want someth stronger gilenya question gilenya caus jcv anyon randomli jcv anyth need worri',\n",
       " 'electrolyt certain nutrient chemic present bodi mani import function regul heartbeat allow muscl contract move major electrolyt found within bodi includ calcium magnesium potassium sodium phosphat chlorid ibd result electrolyt imbal mani reason rang dehydr due high output ostomi diarrhoea sick heat lack absorpt due scar intestin resect import replac miss electrolyt becom rebalanc done depend sever imbal minor imbal dietari chang may possibl drink rehydr solut anoth option treatment sever case includ fluid replac intraven hospit stay post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit mri definit magnet reson imag mri type scan use strong magnet field radio wave produc detail imag insid bodi mri scanner larg tube contain power magnet lie insid tube scan mri help identifi activ diseas ibd help locat strictur narrow intestin complic abscess post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask mri ulcer coliti ulcer coliti definit immunosuppress definit immunosuppress drug class drug suppress reduc strength bodi immun system exampl immunosuppress azathioprin imuran mercaptopurin purinethol infliximab remicad adalimumab humira certolizumab pegol cimzia methotrex rheumatrex cyclosporin gengraf neoral sandimmun tacrolimu astagraf xl hecoria natalizumab tysabri vedolizumab entyvio ustekinumab stelara post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit adhes definit adhes commonli caus scar surgeri less commonli scar due activ inflammatori bowel diseas adhes fibrou band form tissu caus pain blockag intestin post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit resect definit bowel resect surgic procedur part larg small intestin remov post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit proctocolectomi definit proctocolectomi surgic remov rectum part colon post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit hemicolectomi definit hemicolectomi involv surgeri remov right left portion colon',\n",
       " 'cc stelara work matter day gi will jump hoop get probabl worth consid one anti tnf stop work anoth pm ulcer coliti next surgeri schedul problem skin loop ad setup pm ulcer coliti next surgeri schedul familiar hollist probabl go first cut hole stoma go place directli skin protect leak stay skin pm ulcer coliti humira remicad cimzia simponi anti tnf shot base upon weight xeljanz also weight base stelara weightbas remicad well studi drug ulcer coliti unexpect scope result j pouch buckey think appoint gi go know issu complex mine see post anyth ulcer coliti next surgeri schedul congratul recommend get convex wafer new ostomi realli help liquid output probabl know loop ileo time littl pm ulcer coliti remicad infus get test remicad antibodi symptom serum sick ignor mine got wors start drop thing memori loss bone joint pain pm ulcer coliti super donor phenomenon fecal microbiota transplant segment cbc radio quirk quark show http www cbc ca radio quirk poop creat equal super pooper could life saver test ulcer coliti saw gi recommend xeljanz scare start thread check box includ signatur see med thought ad entyvio either prednison entocort blood test pm ulcer coliti saw gi recommend xeljanz scare anti tnf med like remicad anyth list signatur use rectal med steroid pm ulcer coliti recent taken friend heard take month jpouch fulli adjust pm ulcer coliti still experienc issu cuffiti song ladi ga diarrhea also caus sibo easi test taken test previous also home test sibo happen jpoucher certain antibiot',\n",
       " 'tofacitinib receivedexpand approv treat adult moder sever ulcer coliti drug approv treat rheumatoid arthriti patient psoriat arthriti sourc jama',\n",
       " 'rachschad sorri ms caus problem regular everi three week suggest trigger doctor view ocrevu lemtrada difficult comparison find mser one therapi experienc doctor view best base side effect profil patient feedback apprais medic research behind treatment good luck whichev choos realli hope break horrend cycl',\n",
       " 'husband decid particip stelara studi given much hope would work end get xeljanz label game changer put remiss day away step surgeri phase mainten studi rumor fda approv uc may horizon nice thing xeljanz pill know within week whether work spous diagnos uc develop antibodi remicad humira entyvio work infus thing seem work prednison earli march start xeljanz label work uc symptom abl eat almost everyth fresh fruit veget first time year struggl final taper prednison',\n",
       " 'ocrelizumab monoclon antibodi affect action bodi immun system monoclon antibodi made target destroy certain cell bodi may help protect healthi cell damag ocrelizumab use treat multipl sclerosi relaps progress form ocrelizumab may also use purpos list medic guid possibl side effect ocrelizumab ocrevu get emerg medic help sign allerg reaction hive difficult breath swell face lip tongu throat side effect may occur inject hour later tell caregiv right away feel dizzi sleepi nauseat light head feverish sweati itchi red skin rash headach fast heartbeat chest tight troubl breath swell irrit throat call doctor fever chill cough yellow green mucu stab chest pain wheez feel short breath skin warmth red swell skin sore blister pu ooz cold sore fever blister around lip nerv pain tingl burn pain pin needl feel mood behavior chang confus memori problem weak one side bodi problem vision speech walk ocrelizumab treatment may delay perman discontinu certain side effect common side effect may includ reaction inject respiratori infect affect nose sinus throat lung complet list side effect other may occur call doctor medic advic side effect may report side effect fda fda import inform know ocrelizumab ocrevu ocrelizumab may caus unpleas side effect medicin inject hour later tell caregiv right away unusu discomfort inject call doctor unpleas side effect dizzi nausea skin rash chest tight troubl breath within hour inject discuss healthcar provid receiv ocrelizumab ocrevu treat ocrelizumab allerg activ infect hepat b tell doctor receiv vaccin within past week make sure ocrelizumab safe tell doctor type activ infect histori use medicin weaken immun system carrier hepat b schedul receiv vaccin use ocrelizumab may increas risk develop certain type cancer breast cancer ask doctor specif risk known whether medicin harm unborn babi tell doctor pregnant plan becom pregnant use effect birth control prevent pregnanc use medicin least month last dose known whether ocrelizumab pass breast milk could affect nurs babi tell doctor breast feed ocrelizumab given ocrevu start treatment ocrelizumab doctor may perform test make sure hepat b infect ocrelizumab inject vein iv healthcar provid give inject may given medic prevent certain side effect ocrelizumab first dose ocrelizumab split separ infus receiv infus week apart follow dose given everi month ocrelizumab must given slowli infus take hour minut complet watch close least hour receiv ocrelizumab make sure allerg reaction medic ever hepat b ocrelizumab caus condit come back get wors need frequent blood test check liver function treatment sever month stop use medicin skin cancer slideshow take skin cancer quiz sun damag skin slideshow pictur happen miss dose ocrevu call doctor instruct miss dose ocrelizumab happen overdos ocrevu seek emerg medic attent call poison help line avoid receiv ocrelizumab ocrevu receiv live vaccin use ocrelizumab could develop seriou infect live vaccin includ measl mump rubella mmr polio rotaviru typhoid yellow fever varicella chickenpox zoster shingl nasal flu influenza vaccin drug affect ocrelizumab ocrevu tell doctor medicin recent use treat multipl sclerosi drug may interact ocrelizumab includ prescript counter medicin vitamin herbal product tell doctor current medicin medicin start stop use get inform ocrevu pharmacist provid inform ocrelizumab rememb keep medicin reach children never share medicin other use medic indic prescrib everi effort made ensur inform provid cerner multum inc multum accur date complet guarante made effect drug inform contain herein may time sensit multum inform compil use healthcar practition consum unit state therefor multum warrant use outsid unit state appropri unless specif indic otherwis multum drug inform endors drug diagnos patient recommend therapi multum drug inform inform resourc design assist licens healthcar practition care patient serv consum view servic supplement substitut expertis skill knowledg judgment healthcar practition absenc warn given drug drug combin way constru indic drug drug combin safe effect appropri given patient multum assum respons aspect healthcar administ aid inform multum provid inform contain herein intend cover possibl use direct precaut warn drug interact allerg reaction advers effect question drug take check doctor nurs pharmacist',\n",
       " 'hi everyon father age diagnos nsclc egfr alk neg brain mri bone scan clear yesterday ct scan show nodul grown cm cm along small nodul dad pretti sever pain right rib area take deep breath also pressur first biopsi site take tylenol around clock pain one oncologist order second biopsi check genet molecular marker want wait result start treatment biopsi done today result back least week second oncologist want start dad keytruda alimta carboplatin come monday dad extrem anxiou want get start asap still contempl wait genet test result come back wait start treatment monday help provid info need',\n",
       " 'immunolgi drug work cancer differ manner',\n",
       " 'uf difficult one born stuck drug work gilenya faf ye stop relaps stop go spm afraid drug denial get wors chang drug work noth stop spm went unoffici spm year later spm mani choic avail stronger drug ask dr ask stop spm person hstc cladribin choic atm xx',\n",
       " 'father go petscan tomorrow septemb two cycl abraxan carbo keytruda high dose vitamin c second line treatment genom test came back two week ago show egfr l r high amplif c met report recommend osimertinib tagrisso warn high c met may contribut resist part world',\n",
       " 'bravo larri see ride much wind ride forest ear wind tree top feel like spring last coupl week done good ride week regular mile feet gain tomorrow first full dose ocrevu excit see improv littl alain',\n",
       " 'hi new read post sourc strength inform extrem difficult time world shatter father diagnos nsclc squamou cell carcinoma stage iv march primari right lung tumour x cm met hilar mediastinum lymph node lot bone short breath energi appetit distress persist cough white yellowish phlegm fear could stand chemo first high dose iv vitamin c lose carboplatin gemzar april follow second infus april high hope high dose vitamin c alway full energi ate better felt better first two day vitamin c infus petscan april howev show new lesion around neck increas size number lesion bone tumour lung decreas littl onc said treatment fail move keytruda pd l biopsi came back posit first keytruda infus april far side effect fatigu reduc appetit still lot cough debilit take anoro inhal morn relvar inhal sleep strang cough less sleep night read fighterm post exchang sad hear without til tumour infiltr lymphocit even pd l high keytruda immunotherapi work onc said earlier mention til first histopatholog report biopsi mean father til would like ask worth tmb genom sequenc test squamou cell explor possibl line treatment option tmb us malaysia cost usd self paid insur cover onc supplier offer tmb know better scarix oncodna belgium foundat one onc said chanc squamou cell mutat target therapi work low advis us drop tmb think afraid keytruda work father option second keytruda infus may onc advis month instead everi week day slow watch cough distress think ct scan instead petscan second keytruda infus confirm pneumon true pneumon show pet thank much anyon could help us inform sorri long post peggi',\n",
       " 'childhood rhabdomyosarcoma diseas malign cancer cell form muscl tissu certain genet condit increas risk childhood rhabdomyosarcoma sign childhood rhabdomyosarcoma lump swell keep get bigger diagnost test biopsi use detect find diagnos childhood rhabdomyosarcoma certain factor affect prognosi chanc recoveri treatment option childhood rhabdomyosarcoma diseas malign cancer cell form muscl tissu rhabdomyosarcoma type sarcoma sarcoma cancer soft tissu muscl connect tissu tendon cartilag bone rhabdomyosarcoma usual begin muscl attach bone help bodi move rhabdomyosarcoma common type soft tissu sarcoma children begin mani place bodi three main type rhabdomyosarcoma embryon type occur often head neck area genit urinari organ occur anywher bodi common type rhabdomyosarcoma alveolar type occur often arm leg chest abdomen genit organ anal area anaplast least common type rhabdomyosarcoma children see follow pdq treatment summari inform type soft tissu sarcoma childhood soft tissu sarcoma adult soft tissu sarcoma certain genet condit increas risk childhood rhabdomyosarcoma anyth increas risk get diseas call risk factor risk factor mean get cancer risk factor mean get cancer talk child doctor think child may risk risk factor rhabdomyosarcoma includ follow inherit diseas li fraumeni syndrom pleuropulmonari blastoma neurofibromatosi type nf costello syndrom beckwith wiedemann syndrom noonan syndrom children high birth weight larger expect birth may increas risk embryon rhabdomyosarcoma case caus rhabdomyosarcoma known sign childhood rhabdomyosarcoma lump swell keep get bigger sign symptom may caus childhood rhabdomyosarcoma condit sign symptom occur depend cancer form check child doctor child follow lump swell keep get bigger go away may pain bulg eye headach troubl urin bowel movement blood urin bleed nose throat vagina rectum diagnost test biopsi use detect find diagnos childhood rhabdomyosarcoma diagnost test done depend part cancer form follow test procedur may use physic exam histori exam bodi check gener sign health includ check sign diseas lump anyth els seem unusu histori patient health habit past ill treatment also taken x ray x ray organ bone insid bodi chest x ray type energi beam go bodi onto film make pictur area insid bodi ct scan cat scan procedur make seri detail pictur area insid bodi abdomen pelvi lymph node taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi enlarg comput tomographi ct scan abdomen child lie tabl slide ct scanner take x ray pictur insid abdomen mri magnet reson imag procedur use magnet radio wave comput make seri detail pictur area bodi skull brain lymph node procedur also call nuclear magnet reson imag nmri enlarg magnet reson imag mri abdomen child lie tabl slide mri scanner take pictur insid bodi pad child abdomen help make pictur clearer pet scan positron emiss tomographi scan procedur find malign tumor cell bodi small amount radioact glucos sugar inject vein pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell enlarg positron emiss tomographi pet scan child lie tabl slide pet scanner head rest white strap help child lie still small amount radioact glucos sugar inject child vein scanner make pictur glucos use bodi cancer cell show brighter pictur take glucos normal cell bone scan procedur check rapidli divid cell cancer cell bone small amount radioact materi inject vein travel bloodstream radioact materi collect bone cancer detect scanner enlarg bone scan small amount radioact materi inject child vein travel blood radioact materi collect bone child lie tabl slide scanner radioact materi detect imag made comput screen bone marrow aspir biopsi remov bone marrow blood small piec bone insert hollow needl hipbon sampl remov hipbon pathologist view bone marrow blood bone microscop look sign cancer enlarg bone marrow aspir biopsi small area skin numb bone marrow needl insert child hip bone sampl blood bone bone marrow remov examin microscop lumbar punctur procedur use collect cerebrospin fluid csf spinal column done place needl two bone spine csf around spinal cord remov sampl fluid sampl csf check microscop sign cancer cell procedur also call lp spinal tap test show may rhabdomyosarcoma biopsi done biopsi remov cell tissu view microscop pathologist check sign cancer treatment depend type rhabdomyosarcoma biopsi sampl check pathologist experi diagnos rhabdomyosarcoma one follow type biopsi may use fine needl aspir fna biopsi remov tissu fluid use thin needl core needl biopsi remov tissu use wide needl procedur may guid use ultrasound ct scan mri open biopsi remov tissu incis cut made skin sentinel lymph node biopsi remov sentinel lymph node surgeri sentinel lymph node first lymph node group lymph node receiv lymphat drainag primari tumor first lymph node cancer like spread primari tumor radioact substanc blue dye inject near tumor substanc dye flow lymph duct lymph node first lymph node receiv substanc dye remov pathologist view tissu microscop look cancer cell cancer cell found may necessari remov lymph node sometim sentinel lymph node found one group node follow test may done sampl tissu remov light microscopi laboratori test cell sampl tissu view regular high power microscop look certain chang cell immunohistochemistri test use antibodi check certain antigen sampl tissu antibodi usual link radioact substanc dye caus tissu light microscop type test may use tell differ differ type cancer fish fluoresc situ hybrid laboratori test use look gene chromosom cell tissu piec dna contain fluoresc dye made laboratori ad cell tissu glass slide piec dna attach certain gene area chromosom slide light view microscop special light type test use find certain gene chang revers transcript polymeras chain reaction rt pcr test laboratori test cell sampl tissu studi use chemic look certain chang structur function gene cytogenet analysi laboratori test cell sampl tissu view microscop look certain chang chromosom certain factor affect prognosi chanc recoveri treatment option prognosi chanc recoveri treatment option depend follow patient age bodi tumor start size tumor time diagnosi whether tumor complet remov surgeri type rhabdomyosarcoma embryon alveolar anaplast whether certain chang gene whether tumor spread part bodi time diagnosi whether tumor lymph node time diagnosi whether tumor respond chemotherapi radiat therapi patient recurr cancer prognosi treatment also depend follow bodi tumor recur came back much time pass end cancer treatment cancer recur whether tumor treat radiat therapi stage childhood rhabdomyosarcoma key point childhood rhabdomyosarcoma diagnos treatment base part stage cancer sometim base whether cancer remov surgeri three way cancer spread bodi cancer may spread began part bodi stage childhood rhabdomyosarcoma done three part stage system base size tumor bodi whether spread part bodi stage stage stage stage group system base whether cancer spread whether cancer remov surgeri group group ii group iii group iv risk group base stage system group system low risk childhood rhabdomyosarcoma intermedi risk childhood rhabdomyosarcoma high risk childhood rhabdomyosarcoma childhood rhabdomyosarcoma diagnos treatment base part stage cancer sometim base whether cancer remov surgeri process use find cancer spread within tissu part bodi call stage import know stage order plan treatment doctor use result diagnost test help find stage diseas treatment childhood rhabdomyosarcoma base part stage sometim amount cancer remain surgeri remov tumor pathologist use microscop check tissu remov surgeri includ tissu sampl edg area cancer remov lymph node done see cancer cell taken surgeri three way cancer spread bodi cancer spread tissu lymph system blood tissu cancer spread began grow nearbi area lymph system cancer spread began get lymph system cancer travel lymph vessel part bodi blood cancer spread began get blood cancer travel blood vessel part bodi cancer may spread began part bodi cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi metastat tumor type cancer primari tumor exampl rhabdomyosarcoma spread lung cancer cell lung actual rhabdomyosarcoma cell diseas metastat rhabdomyosarcoma lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ call metastat cancer anim show cancer cell travel place bodi first form part bodi stage childhood rhabdomyosarcoma done three part childhood rhabdomyosarcoma stage use three differ way describ cancer stage system group system risk group stage system base size tumor bodi whether spread part bodi stage stage tumor size may spread lymph node found one follow favor site eye area around eye head neck tissu next brain spinal cord gallbladd bile duct uret urethra test ovari vagina uteru rhabdomyosarcoma form favor site better prognosi site cancer occur one favor site list said unfavor site enlarg tumor size size tumor may compar size pea cm peanut cm grape cm walnut cm lime cm egg cm peach cm grapefruit cm stage stage cancer found unfavor site one area describ favor stage tumor larger centimet spread lymph node stage stage cancer found unfavor site one area describ favor stage one follow true tumor larger centimet cancer spread nearbi lymph node tumor larger centimet cancer may spread nearbi lymph node stage stage tumor may size cancer may spread nearbi lymph node cancer spread distant part bodi lung bone marrow bone group system base whether cancer spread whether cancer remov surgeri group cancer found place start complet remov surgeri tissu taken edg tumor remov tissu check microscop pathologist cancer cell found group ii group ii divid group iia iib iic iia cancer remov surgeri cancer cell seen tissu taken edg tumor remov view microscop pathologist iib cancer spread nearbi lymph node cancer lymph node remov surgeri iic cancer spread nearbi lymph node cancer lymph node remov surgeri least one follow true tissu taken edg tumor remov check microscop pathologist cancer cell seen furthest lymph node tumor remov check microscop pathologist cancer cell seen group iii cancer partli remov biopsi surgeri tumor remain seen eye group iv cancer spread distant part bodi cancer diagnos cancer cell found imag test cancer cell fluid around brain spinal cord lung fluid abdomen tumor found area risk group base stage system group system risk group describ chanc rhabdomyosarcoma recur come back everi child treat rhabdomyosarcoma receiv chemotherapi decreas chanc cancer recur type anticanc drug dose number treatment given depend whether child low risk intermedi risk high risk rhabdomyosarcoma follow risk group use low risk childhood rhabdomyosarcoma low risk childhood rhabdomyosarcoma one follow embryon tumor size found favor site may tumor remain surgeri seen without microscop cancer may spread nearbi lymph node follow area favor site eye area around eye head neck tissu near ear nose sinus base skull gallbladd bile duct uret urethra test ovari vagina uteru embryon tumor size found favor site may tumor remain surgeri seen microscop cancer may spread nearbi lymph node intermedi risk childhood rhabdomyosarcoma intermedi risk childhood rhabdomyosarcoma one follow embryon tumor size found one favor site list tumor remain surgeri seen without microscop cancer may spread nearbi lymph node alveolar tumor size favor unfavor site may tumor remain surgeri seen without microscop cancer may spread nearbi lymph node high risk childhood rhabdomyosarcoma high risk childhood rhabdomyosarcoma may embryon type alveolar type may spread nearbi lymph node spread one follow part bodi near tumor first form fluid around brain spinal cord fluid lung abdomen recurr childhood rhabdomyosarcoma recurr childhood rhabdomyosarcoma cancer recur come back treat cancer may come back place part bodi lung bone bone marrow less often rhabdomyosarcoma may come back breast adolesc femal liver treatment option overview key point differ type treatment patient childhood rhabdomyosarcoma children rhabdomyosarcoma treatment plan team health care provid expert treat cancer children treatment childhood rhabdomyosarcoma may caus side effect three type standard treatment use surgeri radiat therapi chemotherapi new type treatment test clinic trial immunotherapi target therapi patient may want think take part clinic trial patient enter clinic trial start cancer treatment follow test may need differ type treatment patient childhood rhabdomyosarcoma treatment standard current use treatment test clinic trial treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer clinic trial show new treatment better standard treatment new treatment may becom standard treatment cancer children rare take part clinic trial consid clinic trial open patient start treatment children rhabdomyosarcoma treatment plan team health care provid expert treat cancer children rhabdomyosarcoma form mani differ part bodi mani differ kind treatment use treatment overseen pediatr oncologist doctor special treat children cancer pediatr oncologist work health care provid expert treat children rhabdomyosarcoma special certain area medicin may includ follow specialist pediatrician pediatr surgeon radiat oncologist pediatr hematologist pediatr radiologist pediatr nurs specialist geneticist cancer genet risk counselor social worker rehabilit specialist treatment childhood rhabdomyosarcoma may caus side effect inform side effect begin treatment cancer see side effect page side effect cancer treatment begin treatment continu month year call late effect late effect cancer treatment rhabdomyosarcoma may includ physic problem chang mood feel think learn memori second cancer new type cancer late effect may treat control import talk child doctor effect cancer treatment child see pdq summari late effect treatment childhood cancer inform three type standard treatment use surgeri surgeri remov cancer oper use treat childhood rhabdomyosarcoma type surgeri call wide local excis often done wide local excis remov tumor tissu around includ lymph node second surgeri may need remov cancer whether surgeri done type surgeri done depend follow bodi tumor start effect surgeri way child look effect surgeri child import bodi function tumor respond chemotherapi radiat therapi may given first children rhabdomyosarcoma possibl remov tumor surgeri rhabdomyosarcoma form mani differ place bodi surgeri differ site surgeri treat rhabdomyosarcoma eye genit area usual biopsi chemotherapi sometim radiat therapi may given surgeri shrink larg tumor doctor remov cancer seen time surgeri patient given chemotherapi surgeri kill cancer cell left radiat therapi may also given treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use high energi x ray type radiat kill cancer cell stop grow two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer certain way give radiat therapi help keep radiat damag nearbi healthi tissu type extern radiat therapi includ follow conform radiat therapi conform radiat therapi type extern radiat therapi use comput make dimension pictur tumor shape radiat beam fit tumor allow high dose radiat reach tumor caus less damag nearbi healthi tissu intens modul radiat therapi imrt imrt type dimension radiat therapi use comput make pictur size shape tumor thin beam radiat differ intens strength aim tumor mani angl volumetr modul arc therapi vmat vmat type radiat therapi use comput make pictur size shape tumor radiat machin move circl around patient treatment send thin beam radiat differ intens strength tumor treatment vmat deliv faster treatment imrt stereotact bodi radiat therapi stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment day sever day radiat machin aim larger usual dose radiat directli tumor patient posit treatment less damag nearbi healthi tissu procedur also call stereotact extern beam radiat therapi stereotax radiat therapi proton beam radiat therapi proton beam therapi type high energi extern radiat therapi radiat therapi machin aim stream proton tini invis posit charg particl cancer cell kill type treatment caus less damag nearbi healthi tissu intern radiat therapi use radioact substanc seal needl seed wire cathet place directli near cancer use treat cancer area vagina vulva uteru bladder prostat head neck intern radiat therapi also call brachytherapi intern radiat implant radiat interstiti radiat therapi type amount radiat therapi given depend age child type rhabdomyosarcoma bodi tumor start much tumor remain surgeri whether tumor nearbi lymph node extern radiat therapi usual use treat childhood rhabdomyosarcoma certain case intern radiat therapi use chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi chemotherapi place directli cerebrospin fluid organ bodi caviti abdomen drug mainli affect cancer cell area region chemotherapi chemotherapi may also given shrink tumor surgeri order save much healthi tissu possibl call neoadjuv chemotherapi everi child treat rhabdomyosarcoma receiv system chemotherapi decreas chanc cancer recur type anticanc drug dose number treatment given depend whether child low risk intermedi risk high risk rhabdomyosarcoma see drug approv rhabdomyosarcoma inform new type treatment test clinic trial summari section describ treatment studi clinic trial may mention everi new treatment studi inform clinic trial avail nci websit immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer type cancer treatment also call biolog therapi biotherapi differ type immunotherapi vaccin therapi cancer treatment use substanc group substanc stimul immun system find tumor kill vaccin therapi studi treat metastat rhabdomyosarcoma immun checkpoint inhibitor therapi use bodi immun system kill cancer cell two type immun checkpoint inhibitor studi treatment childhood rhabdomyosarcoma come back treatment ctla protein surfac cell help keep bodi immun respons check ctla attach anoth protein call b cancer cell stop cell kill cancer cell ctla inhibitor attach ctla allow cell kill cancer cell ipilimumab type ctla inhibitor pd protein surfac cell help keep bodi immun respons check pd attach anoth protein call pdl cancer cell stop cell kill cancer cell pd inhibitor attach pdl allow cell kill cancer cell nivolumab pembrolizumab pd inhibitor enlarg immun checkpoint inhibitor checkpoint protein pd l tumor cell pd cell help keep immun respons check bind pd l pd keep cell kill tumor cell bodi left panel block bind pd l pd immun checkpoint inhibitor anti pd l anti pd allow cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer target therapi target therapi type treatment use drug substanc attack cancer cell target therapi usual caus less harm normal cell chemotherapi radiat differ type target therapi mtor inhibitor stop protein help cell divid surviv sirolimu type mtor inhibitor therapi studi treatment recurr rhabdomyosarcoma tyrosin kinas inhibitor small molecul drug go cell membran work insid cancer cell block signal cancer cell need grow divid mk cabozantinib malat tyrosin kinas inhibitor studi treatment recurr rhabdomyosarcoma patient may want think take part clinic trial patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment clinic trial includ patient yet receiv treatment trial test treatment patient whose cancer gotten better also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found nci clinic trial search webpag clinic trial support organ found clinicaltri gov websit follow test may need test done diagnos cancer find stage cancer may repeat test repeat order see well treatment work decis whether continu chang stop treatment may base result test test continu done time time treatment end result test show child condit chang cancer recur come back test sometim call follow test check up treatment option childhood rhabdomyosarcoma inform treatment list see treatment option overview section previous untreat childhood rhabdomyosarcoma treatment childhood rhabdomyosarcoma often includ surgeri radiat therapi chemotherapi order treatment given depend bodi tumor start size tumor type tumor whether tumor spread lymph node part bodi see treatment option overview section summari inform surgeri radiat therapi chemotherapi use treat children rhabdomyosarcoma rhabdomyosarcoma brain head neck tumor brain treatment may includ surgeri remov tumor radiat therapi chemotherapi tumor head neck near eye treatment may includ chemotherapi radiat therapi tumor remain come back treatment chemotherapi radiat therapi surgeri remov eye tissu around eye may need tumor head neck near ear nose sinus base skull near eye treatment may includ radiat therapi chemotherapi tumor head neck near eye near ear nose sinus base skull treatment may includ chemotherapi radiat therapi surgeri remov tumor tumor head neck cannot remov surgeri treatment may includ chemotherapi radiat therapi includ stereotact bodi radiat therapi tumor larynx voic box treatment may includ chemotherapi radiat therapi surgeri remov larynx usual done voic harm rhabdomyosarcoma arm leg chemotherapi follow surgeri remov tumor tumor complet remov second surgeri remov tumor may done radiat therapi may also given tumor hand foot radiat therapi chemotherapi may given tumor may remov would affect function hand foot lymph node dissect one lymph node remov sampl tissu check microscop sign cancer tumor arm lymph node near tumor armpit area remov tumor leg lymph node near tumor groin area remov rhabdomyosarcoma chest abdomen pelvi tumor chest abdomen includ chest wall abdomin wall surgeri wide local excis may done tumor larg chemotherapi radiat therapi given shrink tumor surgeri tumor pelvi surgeri wide local excis may done tumor larg chemotherapi given shrink tumor surgeri radiat therapi may given surgeri tumor diaphragm biopsi tumor follow chemotherapi radiat therapi shrink tumor surgeri may done later remov remain cancer cell tumor gallbladd bile duct biopsi tumor follow chemotherapi radiat therapi tumor muscl tissu around anu vulva anu scrotum anu surgeri done remov much tumor possibl nearbi lymph node follow chemotherapi radiat therapi rhabdomyosarcoma kidney tumor kidney surgeri remov much tumor possibl chemotherapi radiat therapi may also given rhabdomyosarcoma bladder prostat tumor top bladder surgeri wide local excis done tumor prostat bladder top bladder chemotherapi radiat therapi given first shrink tumor cancer cell remain chemotherapi radiat therapi tumor remov surgeri surgeri may includ remov prostat part bladder pelvic exenter without remov rectum may includ remov lower colon bladder girl cervix vagina ovari nearbi lymph node may remov chemotherapi given first shrink tumor surgeri remov tumor bladder prostat done intern extern radiat therapi may given surgeri surgeri remov tumor bladder prostat intern radiat therapi given surgeri rhabdomyosarcoma area near testicl surgeri remov testicl spermat cord lymph node back abdomen may check cancer especi lymph node larg child year older radiat therapi may given tumor cannot complet remov surgeri rhabdomyosarcoma vulva vagina uteru cervix ovari tumor vulva vagina treatment may includ chemotherapi follow surgeri remov tumor intern extern radiat therapi may given surgeri tumor uteru treatment may includ chemotherapi without radiat therapi sometim surgeri may need remov remain cancer cell tumor cervix treatment may includ chemotherapi follow surgeri remov remain tumor tumor ovari treatment may includ chemotherapi follow surgeri remov remain tumor metastat rhabdomyosarcoma treatment chemotherapi radiat therapi surgeri remov tumor given site tumor first form cancer spread brain spinal cord lung radiat therapi may also given site cancer spread follow treatment studi metastat rhabdomyosarcoma clinic trial immunotherapi vaccin therapi use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail refractori recurr childhood rhabdomyosarcoma treatment option refractori recurr childhood rhabdomyosarcoma base mani factor includ bodi cancer come back type treatment child need child treatment refractori recurr rhabdomyosarcoma may includ one follow surgeri radiat therapi chemotherapi clinic trial target therapi immunotherapi sirolimu ipilimumab nivolumab pembrolizumab clinic trial target therapi tyrosin kinas inhibitor mk cabozantinib malat chemotherapi clinic trial check sampl patient tumor certain gene chang type target therapi given patient depend type gene chang use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail learn childhood rhabdomyosarcoma inform nation cancer institut childhood rhabdomyosarcoma see follow soft tissu sarcoma home page comput tomographi ct scan cancer drug approv rhabdomyosarcoma target cancer therapi childhood cancer inform gener cancer resourc see follow cancer childhood cancer curesearch children cancer late effect treatment childhood cancer adolesc young adult cancer children cancer guid parent cancer children adolesc stage cope cancer question ask doctor cancer survivor caregiv pdq summari pdq physician data queri pdq nation cancer institut nci comprehens cancer inform databas pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin summari come two version health profession version detail inform written technic languag patient version written easi understand nontechn languag version cancer inform accur date version also avail spanish pdq servic nci nci part nation institut health nih nih feder govern center biomed research pdq summari base independ review medic literatur polici statement nci nih purpos summari pdq cancer inform summari current inform treatment childhood rhabdomyosarcoma meant inform help patient famili caregiv give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date board made expert cancer treatment specialti relat cancer summari review regularli chang made new inform date summari updat date recent chang inform patient summari taken health profession version review regularli updat need pdq pediatr treatment editori board clinic trial inform clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori trial answer certain scientif question order find new better way help cancer patient treatment clinic trial inform collect effect new treatment well work clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial clinic trial open patient start treatment clinic trial list pdq found onlin nci websit inform call cancer inform servic cancer permiss use summari pdq regist trademark content pdq document use freeli text cannot identifi nci pdq cancer inform summari unless whole summari shown updat regularli howev user would allow write sentenc nci pdq cancer inform summari breast cancer prevent state risk follow way [includ excerpt summary] best way cite pdq summari pdq pediatr treatment editori board pdq childhood rhabdomyosarcoma treatment bethesda md nation cancer institut updat mm dd yyyi avail http www cancer gov type soft tissu sarcoma patient rhabdomyosarcoma treatment pdq access mm dd yyyi [pmid ] imag summari use permiss author artist publish use pdq summari want use imag pdq summari use whole summari must get permiss owner cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim inform summari use make decis insur reimburs inform insur coverag avail cancer gov manag cancer care page contact us inform contact us receiv help cancer gov websit found contact us help page question also submit cancer gov websit e mail us',\n",
       " 'mlgilber okay long term concern heard note realli higher gener risk origin prescrib neuro extra screen case still decid ocrevu best bet know sfrox seem convinc pml risk yet find studi patient get pml asid research believ actual got tysabri switch ocrevu sure risk concern know get ocrevu insur first drug challeng sinc alreadi past hurdl familiar aspect busi side good thing consid thought guess find th stumbler absolut plan want see peopl might experi mayb miss reason potenti logic behind ultim call think find new neurologist',\n",
       " 'rainout work one thursday least littl chore would leav breathless went emerg room told happen kept run test put breath treatment oxygen etc even done brain scan fast forward cancer sent oncologist test told stage lung cancer spread lung spot brain also big enough evalu fast forward prescrib keytruda two infus anoth scan skull sinc time period nov jan also late stage copd',\n",
       " 'vixen like ocrevu treatment last neuro apt show improv walk speed still rigid leg gate mri june third appt want see well lesion post excit see well',\n",
       " 'major drug compani block access medicin cheapli effect save thousand peopl go blind want launch expens product market ophthalmologist around world initi inject tini quantiti colon cancer drug call avastin eye patient wet macular degener common condit older age lead sever impair eyesight blind report remark success low cost one phial split use dozen patient genentech compani invent avastin want use way instead appli licens fragment avastin call lucenti packag tini quantiti suitabl eye higher cost specul us suggest could cost per dose instead less compani say lucenti specif design eye modif avastin year test prove safe unless avastin approv uk nation institut clinic excel nice univers avail within nh genentech declin appli licenc use avastin nice cannot consid spite grow drug bill nh apprais probabl approv lucenti next year although nice role look cost effect say cannot apprais drug pass use nh unless drug refer depart health depart say hand tie drug compani appli licens use refer nice made first move said depart health spokeswoman need step get licenc get licens new drug condit badli need slow progress blind avastin mani patient get sight back one two inject avastin first use human eye philip rosenfeld ophthalmologist us awar anim studi carri genentech show potenti eye condit unlicens use avastin spread across contin entir word mouth one doctor anoth inject eye consider success professor rosenfeld publish result websit launch us collat experi doctor around world although evid good regul requir randomis control trial grant licenc gener drug compani afford carri prof rosenfeld said real issu drug compani profit truli wonder drug said show good [the drug companies] flip side greedi would like see govern fund clinic trial drug avastin public interest rise drug bill big problem side atlant uk said david wong chairman scientif committe royal colleg ophthalmologist doctor fight battl persuad primari care trust pay drug stop patient go blind wait nice decid lucenti anoth expens drug call macugen decis expect end next year peopl diagnos age relat macular degener uk year patient point view eye condit deterior quickli question wait said professor wong talk day week rather month question noth say randomis control trial prove avastin valu call primari care trust agre pay plan phase new drug condit last night genentech said main concern use avastin treat eye condit patient safeti small singl centr uncontrol studi avastin perform safeti data patient treat avastin label collect standard organis fashion said spokeswoman compani pharmaceut firm say need launch drug high price hundr million pound spent develop critic point compani calcul also includ market budget',\n",
       " 'mtx imuran take month get optimum therapeaut level hope see continu improv mainten realli worri growth point either daughter diagnos yr age like diseas least year previou earli teen time kid go physic matur daughter way behind first round prednisnon mainten imuran grew year reason restrict growth seem relat activ inflamm get differ view remicad attest state art drug mani remicad year combin therapi use endors call top approach elimin risk undermed give diseas chanc progress damag other would prefer use necessari resist overkil go well mtx year get fresh start remicad optim time take med well mtx choos continu great one thing would stay top symptom regular diagnost blood screen good luck hope thing go well keep us post ipoop forum moder join aug post post gmt glad better right path treatment seem like good due dilig caution verifi blood work like thing sometim ad anoth month current treatment take reach remiss time ad anoth med necessari end wait labwork see far height qualiti life whole aim remiss remiss healthiest happiest grow tandem peer like weed doubt flare badli growth might impact therefor want limit flare sever durat strive make remiss long flare infrequ mild short possibl might regain percentag lost growth rebound blame bone breakag ill prednison iv solumedrol long term cumul long time end kid kid sometim someth sudden unexpect break bone otherwis innoc play accid would hesit put remicad mtx enough prematur say whether remi necessari believ worri put child remi certainli good convers pediatr gasteroenteroligist though moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa even superman hold back insurmount forc uc urgenc bet spiffi spandex short would least hold mess crohnsmum new member join nov post post gmt hi guy thank much reassur check albumin esr level well normal blood normal limit week mtx consult happi escal treatment remicad thank support advic hope maintain remiss futur',\n",
       " 'well go time settl could take pain pill could move posit pain remain sever realli know fever definit vomit would start thing progress lot pain pain also middl left right dead center upper pain realli sound like agre continu better get check wait bad jennif diagnos crohn diseas suffer sinc current take methotrex mg remicad questran fail humira imuran caus pancreat cimzia',\n",
       " 'best doctor treat ibd doctor highli train specialist ibd e gastroenterologist know import diagnost test understand ulcer coliti dietari intervent induct mainten remiss inflammatori bowel diseas author conclus effect dietari intervent cd uc uncertain thu firm conclus regard benefit harm dietari intervent cd uc ulcer coliti flare long term remiss fecal transplant hi europ hospit play fmt fact hospit start experi dr said think miracl cure pm ulcer coliti humira work like charm year would save hard earn money see gastroenterologist person bad experi holist doctor well wast ton time money ulcer coliti pred alway lose effect time mean meaning compar current state inflamm begin would come medic use treat coliti assum ulcer coliti pred alway lose effect time also think difficult compar inflamm medic pre diagnosi inflamm term symptom diseas extent first flare start pm ulcer coliti ok back question consciou last scope sinc went rectum lowest sigmoid colon watch everi time took biopsi bleed make sens think ulcer coliti saw gi recommend xeljanz scare thank ipoop learn microbiolog post sinc role xeljanz expens articl interest see peopl work pm ulcer coliti saw gi recommend xeljanz scare love perspect definit emot rollercoast last drug surgeri identifi posit mention post success surgeri pm ulcer coliti saw gi recommend xeljanz scare fwiw xeljanz biolog press releas pfizer http www ncbi nlm nih gov pmc articl pmc think advantag develop antibodi pm ulcer coliti saw gi recommend xeljanz scare probabl think live vaccin could take switch directli azathioprin entyvio ulcer coliti saw gi recommend xeljanz scare p articl safeti profil xeljanz ulcer coliti saw gi recommend xeljanz scare xeljanz shown specif give higher risk get shingl someon take drug compar infect rate azathioprin actual compar',\n",
       " 'may rememb terribl flare gi bleed upper gi track inflam colon took three week hospit stay get stabl enough come home im remicad hair fall im wonder remicad nurish anyon els loos hair sever joint pain back know side effect remicad year ago thing happen joint auntkay straydog forum moder join miss key valu en us post post gmt auntkay glad see post seem like forev sorri read still issu jeesh would will bet hair loss result malnutrit malnutrit infect two big culprit hair loss cp forum one member name seashel written excel post hair loss lot detail use search featur type chronic pain forum hair loss find post respond new member lose hair perfor bowel member undernourish doubl whammi hit long back remicad stop dr usual hesit retri someon stop ask health issu take care susi moder chronic pain psoriasi forum auntkay veteran member join apr post post gmt hi straydog thank take time respond sinc forum mani thing happen take disabl retir due back injuri back surgeri l fusion year later sijoint fusion partici hystorectomi that crohn diseas decid rear ugli head remicad sinc woke sleep dragon becam dehydr gastric bleed land hospit three week colon inflam upper gi track even abl toler ice chip gi decid put back remicad infus given hospit done incorrectli remicad hung nobodi ever check till bag empti later night thought heart attack blood pressur shot extremli high chest felt like someon squeez tight felt like someon tri put fist thru chest came gave someth bring bp ekg place heart monit one night woke pool blood realli thought may get hospit thought crohn lack care would death see fighter still kick come home start lose hair witch set back emotionali husband still fight liver diseas tri get list liver transplant auntkay',\n",
       " 'dear dr x prescrib medicin ranibizumab bevacizumab produc novarti would pleas look medic purpos manufactur request protest object novarti prescrib avastin wet macular degener none medic appli protest compani sincer etc cc novarti similar bayer applic',\n",
       " 'howev make decis fact mayb swiss guy work someon like genzym want think alemtuzumab safer merck want think cladribin safer drug risk drug perman deplet immun system go carri risk howev weight benefit risk control ms properli knowledg pro con mayb achil heel ocrelizumab swiss guy one european regul advisor get choic take get licenc',\n",
       " 'mirowpl thank sorri stelara work complet partial better similar entyvio think work partli tri find',\n",
       " 'convinc pharma lower drug cost within reach tri stress much instead look posit high cost ms drug make lucr market diagnos sinc aubagio tecfidera lemtrada plegridi approv ocrelizumab way trial done repair restor sure soar cost one reason pharmaceut compani invest much ms',\n",
       " 'mitoxantron good ppm ye ye activ ms e gd enhanc lesion mri increas lesion load due side effect profil bart ms essenti stop use mitoxantron replac label parenter cladribin would like includ rituximab mix even better would get treat licens product ppm moment one show town ocrelizumab',\n",
       " 'brain lesion treat gamma knife get bad access em stage nsclc went away chemo lucki told least problem yeah everi time turn around bad month wife famili prepar die went opdivo sept cancer went poof feel great opdivo kinda noth drug work friend fine',\n",
       " 'control tbh peopl delay remicad coupl week without issu chanc okay much easier said done tri spend next week panick remicad truli put deep remiss hold quit last infus month even year depend person diseas dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'hi hard data unfortun averag realli tell stori given kind work make big deal someth like two month averag move mean someth hope studi keytruda opdivo seem like winner last trial result thing earli stage develop individu success stori check site facebook sclc group onlin resourc usual publish individu case studi long fact peopl sclc involv earli studi aliv well year immunotherapi one know made year keytruda believ facebook group peopl made year extens also right biomark pd pd l winner nsclc lot debat even relev sclc believ rare sclc anyway howev found go journey mom lot latest think realli publish see snatch onlin often find unless save somewher fashion came across studi write longer locat indic tmb tumor mutat burden microsatellit instabl seem relev sclc term immunotherapi efficaci certain investig clinic relev mutat continu clinic studi ye given uncertainti genet test usual done sclc anyway got foundat one test interest result one lead expert sclc associ lungev believ memori sloan ketter offer us free charg genet panel even accur show mom high microsatellit instabl high tmb doctor said bode well term immunotherapi efficaci quit rare sclc none certain smartest peopl diseas believ mom diagnos almost exactli year ago small primari tumor singl brain metastasi caus seizur found issu begin brain met surgic remov lucki enough possibl treat gamma knife chemo took care primari tumor quit quickli cycl total tumor basic gone cancer free ever sinc suffer side effect treatment except hair loss bloat steroid day bone pain neulasta opt consolid radiat also standard care sclc either promis studi forward think doctor recommend side effect either continu well point like make right sclc deck stack stat good though better find onlin date howev hope good realist look someon like mom long term survivor live fear wait day scan come back ugli alreadi done much better odd fact given averag surviv time diagnosi like month alreadi beaten husband told month inde averag howev doctor tell beat averag might husband husband anyway side effect symptom statu scan post chemo wish best luck',\n",
       " 'thank comment onthemark today found data aura studi http www ahdbonlin com issu march vol seventh annual payer guid tagrisso osimertinib approv patient non small cell lung cancer egfr mutat addit patient adenocarcinoma lung receiv previou treatment egfr mutat metastat nsclc site extrathorac metastasi includ bone brain liver somat egfr mutat addit includ exon delet l r g x guess would mean g x transform mayb less frequent common mutat mum take first pill osimertinib today see oncologist monday cant lose time insist erlotinib take anoth coupl day get approv mayb even longer summer time vacat mum without treatment sinc th may realli long time someon experienc post tki progress oncologist week vacat substitut suppos decid erlotinib earlier want hope oncologist approv osimertinib dont think afford anoth weak treatment stop osimertinib coupl day take could lower chanc use drug effect treatment later',\n",
       " 'went gilenya due relaps rate tri join trial lymphocyt count must rebound least low normal anyon post came back time went week sinc gone high enough join trial folk rebound month',\n",
       " 'non small cell lung cancer nsclc spread far wide treat kind balanc act cure like slow aim reliev symptom improv qualiti life side effect possibl newer therapi help lot option today year ago number tumor overal health come play decid doctor start test learn nsclc help guid best treatment target therapi work best cancer come gene chang caus cell grow divid control mani gene often hard know one blame nsclc though doctor track culprit one known chang get target therapi mean take drug attack cancer cell specif way base gene differ doctor test look alk gene chang get drug help block alectinib alecensa brigatinib alunbrig crizotinib xalkori ceritinib zykadia lorlatinib lorbrena common side effect minor chang vision stomach upset throw diarrhea peopl problem fall milder side efgr gene chang get differ set drug one afatinib gilotrif dacomitinib vizimpro erlotinib tarceva gefitinib iressa osimertinib tagrisso slow fast tumor grow spread side effect includ skin rash diarrhea braf gene chang two main drug use one dabrafenib tafinlar trametinib mekinist work differ way effect may caus itch hair loss issu gene chang grow list gene defect caus nsclc target drug one reason look clinic trial research test new medicin immunotherapi make sens specif gene chang doctor check tumor cell level protein call pd l high immunotherapi often best place start use immun system bodi defens germ attack cancer cell take pembrolizumab keytruda drug help bodi see cancer cell someth fight like cold viru typic side effect includ tired cough stomach upset rash joint pain chemotherapi chemo standard treatment gene chang high pd l use drug kill cancer cell side effect includ hair loss mouth sore stomach upset sever chemo drug use nsclc best result doctor give two time bodi strong enough two even one help usual get four six cycl chemo take week finish treatment might keep take call mainten drug often anoth chemo medicin research show slow cancer help live longer doctor may also add drug along chemo med non squamou nsclc might also take pembrolizumab immunotherapi drug might get bevacizumab avastin anoth target drug may keep take one mainten drug squamou nsclc doctor might suggest target therapi drug necitumumab portrazza treatment brain bone area around lung common place cancer spread get specif care base end problem caus bone may get radiat curb pain caus fluid build around lung might need thin tube chest drain easili one place like brain adren gland might surgeri remov tumor chang treatment sometim first therapi tri work well hope still option start immunotherapi doctor may suggest chemo start one set chemo drug might tri anoth add target therapi depend health far cancer spread want treatment also want start approach call palli care earli aim keep comfort possibl help manag stress',\n",
       " 'dannibrett ocrevu may approv uk avail america sometim would involv clinic trial number year noth fresh product line',\n",
       " 'today realiti age global popul urbanis exponenti obes rate emphasi sedentari lifestyl case diabet inevit upsurg diabet come loss vision caus damag capillari retina back eye due excess glucos blood patient poorli control diabet recent diagnosi feel like candid develop diabet retinopathi consult eye specialist best manag prevent strategi clear healthi vision futur ophthalmologist provid appropri vision care guidelin follow utmost import unclear eye health diabet affect vision help guid live understand diabet retinopathi diabet retinopathi affect eyesight often within diseas diabet eye blood oxygen struggl reach blood vessel retina made vast collect tini nerv allow perceiv colour light surround environ normal healthi eye nerv suppli enough blood within equal tini blood vessel within often within diseas diabet eye blood oxygen struggl reach blood vessel develop inhibit eye abil job caus damag retina turn loss vision anyon diabet risk develop retinopathi import monitor progress keep diseas check posit chang lifestyl longer durat diabet poorer control blood glucos factor blood pressur greater risk develop complic diseas peopl poorli control diabet either type type develop diabet retinopathi first stage diabet retinopathi call non prolif diseas process enter prolif phase requir urgent treatment ophthalmologist prolif diabet retinopathi sever damag visual function fortun level diseas far less common particularli glucos control improv diabet place enorm pressur bodi also global public health system import monitor progress keep diseas check posit chang lifestyl feel major risk factor develop diabet retinopathi speak doctor thwart vision loss associ health problem gain control diabet healthi chang make bedrock diabet eye diseas prevent manag lifestyl influenc link tobacco use sedentari lifestyl poor diet particularli overconsumpt highli process food close associ rate progress diabet retinopathi retinopathi relat risk factor loss vision requir seriou adjust routin diabet retinopathi throw spanner work come manag diabet sooner retinopathi diagnos effect manag techniqu treatment avert vision loss way forward despit challeng ahead number self manag strategi implement see beyond visual problem healthi chang make bedrock diabet eye diseas prevent manag ask doctor assist throughout transit phase ensur right track keep blood sugar blood pressur blood lipid level within target rang one first step take prevent vision loss regular visit healthcar provid healthi diet exercis take medic prescrib doctor factor help achiev goal reach love one support time also help overcom hurdl even ask famili member close friend join journey healthier lifestyl way everyon best interest heart left untreat diseas progress wait advanc stage symptom like blur vision eyestrain headach appear pay visit eye specialist wait late diabet retinopathi progress diseas lead blind left untreat wait advanc stage symptom like blur vision eyestrain headach appear pay visit eye specialist regular eye health check import weapon diabet retinopathi often present earli warn sign surgic option avail prevent vision loss cours gain control health maintain blood sugar level import step take main treatment avail revers prevent loss vision patient diabet retinopathi includ laser photocoagul intravitr inject case vitrectomi studi show long term visual acuiti result treatment strategi remark patient retain drive vision least one eye cours gain control health maintain blood sugar level import step take prevent vision loss diabet retinopathi nonetheless cannot stress enough regular eye exam integr diseas manag prevent look futur vision outlook patient risk alreadi suffer diabet retinopathi murki advanc technolog laser surgic expertis educ subject well regular screen prompt treatment visual loss diabet dramat improv like gain control diabet help call us fill onlin enquiri form friendli team member readi discuss person need eye laser centr ophthalmologist specialis treatment mani eye diseas includ diabet retinopathi centr employ latest techniqu equip detect manag progress diseas inform provid educ servic intend serv medic advic anyon seek specif ophthalm advic assist consult optometrist ophthalmologist zheng congdon n worldwid epidem diabet retinopathi indian journal ophthalmolog p gregg j callaghan g hay c diabet lifestyl book face fear make chang long healthi life new harbing public yau j w roger l kawasaki r lamoureux e l kowalski j w bek chen j dekker j fletcher grauslund j haffner global preval major risk factor diabet retinopathi diabet care pp cundiff k nigg c r diet diabet retinopathi insight diabet control complic trial dcct medscap gener medicin p chew e ferri f l csaki k g murphi r p agr n e thompson j reed g f schachat p long term effect laser photocoagul treatment patient diabet retinopathi earli treatment diabet retinopathi follow studi ophthalmolog pp',\n",
       " 'similar experi start gilenya put washout effect copaxon three day finish copaxon first gilenya pill noth happen two week start peculiar sensori symptom mild swallow problem cognit issu well ach pain rang nurs team panic told ms effect untreat copaxon system gilenya yet taken effect settl three week later',\n",
       " 'remiss primari goal peopl crohn diseas biolog therapi help achiev remiss reduc symptom well heal damag intestin caus inflamm biolog therapi usual prescrib peopl sever crohn symptom found relief method guidelin recommend howev doctor prescrib biolog patient signific diseas first line approach biolog therapi work block certain chemic caus inflamm intestin biolog crohn diseas block protein call tumor necrosi factor tnf biolog block immun cell call integrin other act protein call interleukin il interleukin il biolog therapi stop inflamm gut anti tnf biolog bind block protein promot inflamm intestin also organ tissu mani peopl benefit medic sometim see improv immedi anywher eight week three anti tnf biolog humira remicad cimzia humira humira self administ treatment follow initi demonstr healthcar profession doctor decid handl inject give set pen dosag control medic insid also given instruct mani inject take first day initi day period patient typic use one humira pen everi two week remicad remicad may help patient gain control flare up may also help maintain remiss prevent symptom return remicad given directli bloodstream allow work immedi reliev symptom administ medic facil experienc healthcar profession close monitor side effect treatment remicad taken everi day three starter dose patient often see benefit six dose per year downsid remicad must given intraven medic facil two hour period cimzia cimzia administ small inject inject either given doctor offic home choos receiv treatment doctor offic option receiv treatment powder form powder mix steril water inject option use prefil syring syring contain medic alreadi mix measur dose use home doctor offic choos treatment get packag two syring instruct give treatment first three dose given everi two week abl take cimzia everi four week two anti integrin biolog crohn tysabri entyvio tysabri type biolog prevent inflamm caus white blood cell enter tissu block protein surfac cell tysabri given intraven everi four week take hour receiv full dose patient usual observ hour afterward tysabri typic use peopl respond well intoler tnf blocker immunomodul corticosteroid crohn patient consid tysabri awar seriou side effect tysabri user increas risk develop rare brain diseas call progress multifoc leukoencephalopathi pml result viru test advanc physician prescrib tysabri crohn warn patient risk also explain enrol prescrib program call touch program way receiv tysabri entyvio like tysabri entyvio approv treat adult moder sever crohn diseas respond well intoler reason take tnf blocker immunomodul corticosteroid work similarli tysabri act certain white blood cell prevent caus bowel inflamm associ crohn entyvio howev gut specif appear risk pml entyvio given doctor care intraven infus given minut first day therapi repeat week two week six everi eight week thereaft improv crohn diseas symptom occur week entyvio therapi discontinu prior start entyvio patient date immun stelara third class biolog il il agonist stelara drug class approv treat adult moder sever crohn respond well enough convent therapi drug target specif protein play key role inflamm process stelara initi given intraven supervis healthcar profession follow dose given via inject skin everi eight week either healthcar provid self administ patient train side effect although benefit often far outweigh risk biolog therapi present seriou side effect process biolog therapi reduc bodi abil fight infect caus tuberculosi infect includ brain infect also increas chanc certain type cancer patient take biolog especi younger patient one call hepatosplen cell lymphoma type cancer often fatal biolog therapi work differ other side effect may caus also vari ask doctor thoroughli explain possibl side effect discuss biolog therapi right takeaway biolog offer advantag treat crohn diseas drug specif target substanc bodi caus bowel inflamm doctor discuss option benefit risk help find effect treatment case biosimilar gener version biolog drug may avail manag crohn also save money doctor tell option',\n",
       " 'appar forget workshop present student srsli think look like realiz lionel barrymor insan prof leroy th hour realli good remind calendar use etc slip away puckish malfunct synaps well stay talk sister six hour went bed struggl real sort laugh sinc also forgot take tecfidera morn realiz need reassess plan cope skill slow hell think celebr world ms day slow sister talk great deal kind bulldoz whatev need done got ms dx cope thing say well ok get right clinic trial doubt trial ocrelizumab soon approv save much overinflam brain realli ms gave choic sooo slow way month relaps start march remind forcibl ye sick ye go away ye need find time rest slow hell quit fortun feel like probabl work point need rest perhap ignor enough slip relaps know feel world ms day grate awesom job awesom boss good enough brain enough synaps take slack burn one sens humor need person assist forc sleep rest would perfectest rx ever enjoy day slay demon smile plow obstacl nap srsli',\n",
       " 'thank share yout stori dad diagnos treatement second cycl alimta cisplatin week th cycl keytruda plan pet end march see tesult nice hear treatment work hope doctor stop cisplatin second one sinc neuropathi problem leg side effect also hope get cbd oil worri interact keytruda find anyth pleas let know doctor say long continu keytruda keep us post ina',\n",
       " 'pre test start gilenya answer got along thing made chang mind give folder differ doctor need see frequent need see felt like wasnt go problem go problem',\n",
       " 'look like publish today http www mstrust org uk news news ms nice reject ocrelizumab committe made recommend current diseas modifi treatment approv primari progress multipl sclerosi clinic trial result show ocrelizumab slow worsen disabl peopl condit includ loss upper limb function howev plausibl cost effect estim ocrelizumab compar best support care alon much higher nice normal consid accept use nh resourc scenario present compani therefor ocrelizumab cannot recommend treat earli primari progress multipl sclerosi adult http www nice org uk guidanc gid ta document apprais consult',\n",
       " 'repli plan offici ocrevu view post penkalet great news realli hope slow great news realli hope slow beast think help alain',\n",
       " 'aah hsct effect safer alemtuzumab ocrelizumab natalizumab think know answer question hsct novemb talk hematologish live ahsct year say alemtuzumab good cancer patient diseas',\n",
       " 'went remicad entyvio moder success still take oral lialda folic acid supplement say scale sorri hear friend crash one thing found trial learn school autoimmun diseas trigger stress stress bodi produc excess amount wbc lab call fals posit complet blood count destress import case prevent wbc go site inflamm us colon',\n",
       " 'hi name harri uk diagnos high school crohn diseas grow high school six form definit rough fill lot tough experi make post anyon go question queri experi want share listen offer help support anyon look friend similar condit share stori alway around listen talk med omeprazol azathioprin mesalazin stelara methotrex humira prednison hydrocortison feel free email harri g macgil gmail com make sure repli thank read',\n",
       " 'ditto clo high antibodi ideal remi becom less effect odd side effect like joint pain jump lot consid switch anoth tnf alpha block biolog humira simponi moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa might uc leav hous wear sock return none emerg tp',\n",
       " 'dkb stop take pouchiti work went biolog cimzia help lot wear day need switch someth get whole month still fight evil insur compani stelara found enteragam tast difficult handl took ate tast bad would also mix citru flavor drink keith dx sever pancol june previou med asa predison mp remicad humira simponi cyclosporin twice step j pouch surgeri current condit chronic pouchiti bad thought would current med cimzia sulfasalazin rotat antibiot futur med stelara current wait insur approv',\n",
       " 'childhood rhabdomyosarcoma diseas malign cancer cell form muscl tissu certain genet condit increas risk childhood rhabdomyosarcoma sign childhood rhabdomyosarcoma lump swell keep get bigger diagnost test biopsi use detect find diagnos childhood rhabdomyosarcoma certain factor affect prognosi chanc recoveri treatment option childhood rhabdomyosarcoma diseas malign cancer cell form muscl tissu rhabdomyosarcoma type sarcoma sarcoma cancer soft tissu muscl connect tissu tendon cartilag bone rhabdomyosarcoma usual begin muscl attach bone help bodi move rhabdomyosarcoma common type soft tissu sarcoma children begin mani place bodi three main type rhabdomyosarcoma embryon type occur often head neck area genit urinari organ occur anywher bodi common type rhabdomyosarcoma alveolar type occur often arm leg chest abdomen genit organ anal area anaplast least common type rhabdomyosarcoma children see follow pdq treatment summari inform type soft tissu sarcoma childhood soft tissu sarcoma adult soft tissu sarcoma certain genet condit increas risk childhood rhabdomyosarcoma anyth increas risk get diseas call risk factor risk factor mean get cancer risk factor mean get cancer talk child doctor think child may risk risk factor rhabdomyosarcoma includ follow inherit diseas li fraumeni syndrom pleuropulmonari blastoma neurofibromatosi type nf costello syndrom beckwith wiedemann syndrom noonan syndrom children high birth weight larger expect birth may increas risk embryon rhabdomyosarcoma case caus rhabdomyosarcoma known sign childhood rhabdomyosarcoma lump swell keep get bigger sign symptom may caus childhood rhabdomyosarcoma condit sign symptom occur depend cancer form check child doctor child follow lump swell keep get bigger go away may pain bulg eye headach troubl urin bowel movement blood urin bleed nose throat vagina rectum diagnost test biopsi use detect find diagnos childhood rhabdomyosarcoma diagnost test done depend part cancer form follow test procedur may use physic exam histori exam bodi check gener sign health includ check sign diseas lump anyth els seem unusu histori patient health habit past ill treatment also taken x ray x ray organ bone insid bodi chest x ray type energi beam go bodi onto film make pictur area insid bodi ct scan cat scan procedur make seri detail pictur area insid bodi abdomen pelvi lymph node taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi enlarg comput tomographi ct scan abdomen child lie tabl slide ct scanner take x ray pictur insid abdomen mri magnet reson imag procedur use magnet radio wave comput make seri detail pictur area bodi skull brain lymph node procedur also call nuclear magnet reson imag nmri enlarg magnet reson imag mri abdomen child lie tabl slide mri scanner take pictur insid bodi pad child abdomen help make pictur clearer pet scan positron emiss tomographi scan procedur find malign tumor cell bodi small amount radioact glucos sugar inject vein pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell enlarg positron emiss tomographi pet scan child lie tabl slide pet scanner head rest white strap help child lie still small amount radioact glucos sugar inject child vein scanner make pictur glucos use bodi cancer cell show brighter pictur take glucos normal cell bone scan procedur check rapidli divid cell cancer cell bone small amount radioact materi inject vein travel bloodstream radioact materi collect bone cancer detect scanner enlarg bone scan small amount radioact materi inject child vein travel blood radioact materi collect bone child lie tabl slide scanner radioact materi detect imag made comput screen bone marrow aspir biopsi remov bone marrow blood small piec bone insert hollow needl hipbon sampl remov hipbon pathologist view bone marrow blood bone microscop look sign cancer enlarg bone marrow aspir biopsi small area skin numb bone marrow needl insert child hip bone sampl blood bone bone marrow remov examin microscop lumbar punctur procedur use collect cerebrospin fluid csf spinal column done place needl two bone spine csf around spinal cord remov sampl fluid sampl csf check microscop sign cancer cell procedur also call lp spinal tap test show may rhabdomyosarcoma biopsi done biopsi remov cell tissu view microscop pathologist check sign cancer treatment depend type rhabdomyosarcoma biopsi sampl check pathologist experi diagnos rhabdomyosarcoma one follow type biopsi may use fine needl aspir fna biopsi remov tissu fluid use thin needl core needl biopsi remov tissu use wide needl procedur may guid use ultrasound ct scan mri open biopsi remov tissu incis cut made skin sentinel lymph node biopsi remov sentinel lymph node surgeri sentinel lymph node first lymph node group lymph node receiv lymphat drainag primari tumor first lymph node cancer like spread primari tumor radioact substanc blue dye inject near tumor substanc dye flow lymph duct lymph node first lymph node receiv substanc dye remov pathologist view tissu microscop look cancer cell cancer cell found may necessari remov lymph node sometim sentinel lymph node found one group node follow test may done sampl tissu remov light microscopi laboratori test cell sampl tissu view regular high power microscop look certain chang cell immunohistochemistri test use antibodi check certain antigen sampl tissu antibodi usual link radioact substanc dye caus tissu light microscop type test may use tell differ differ type cancer fish fluoresc situ hybrid laboratori test use look gene chromosom cell tissu piec dna contain fluoresc dye made laboratori ad cell tissu glass slide piec dna attach certain gene area chromosom slide light view microscop special light type test use find certain gene chang revers transcript polymeras chain reaction rt pcr test laboratori test cell sampl tissu studi use chemic look certain chang structur function gene cytogenet analysi laboratori test cell sampl tissu view microscop look certain chang chromosom certain factor affect prognosi chanc recoveri treatment option prognosi chanc recoveri treatment option depend follow patient age bodi tumor start size tumor time diagnosi whether tumor complet remov surgeri type rhabdomyosarcoma embryon alveolar anaplast whether certain chang gene whether tumor spread part bodi time diagnosi whether tumor lymph node time diagnosi whether tumor respond chemotherapi radiat therapi patient recurr cancer prognosi treatment also depend follow bodi tumor recur came back much time pass end cancer treatment cancer recur whether tumor treat radiat therapi stage childhood rhabdomyosarcoma key point childhood rhabdomyosarcoma diagnos treatment base part stage cancer sometim base whether cancer remov surgeri three way cancer spread bodi cancer may spread began part bodi stage childhood rhabdomyosarcoma done three part stage system base size tumor bodi whether spread part bodi stage stage stage stage group system base whether cancer spread whether cancer remov surgeri group group ii group iii group iv risk group base stage system group system low risk childhood rhabdomyosarcoma intermedi risk childhood rhabdomyosarcoma high risk childhood rhabdomyosarcoma childhood rhabdomyosarcoma diagnos treatment base part stage cancer sometim base whether cancer remov surgeri process use find cancer spread within tissu part bodi call stage import know stage order plan treatment doctor use result diagnost test help find stage diseas treatment childhood rhabdomyosarcoma base part stage sometim amount cancer remain surgeri remov tumor pathologist use microscop check tissu remov surgeri includ tissu sampl edg area cancer remov lymph node done see cancer cell taken surgeri three way cancer spread bodi cancer spread tissu lymph system blood tissu cancer spread began grow nearbi area lymph system cancer spread began get lymph system cancer travel lymph vessel part bodi blood cancer spread began get blood cancer travel blood vessel part bodi cancer may spread began part bodi cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi metastat tumor type cancer primari tumor exampl rhabdomyosarcoma spread lung cancer cell lung actual rhabdomyosarcoma cell diseas metastat rhabdomyosarcoma lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ call metastat cancer anim show cancer cell travel place bodi first form part bodi stage childhood rhabdomyosarcoma done three part childhood rhabdomyosarcoma stage use three differ way describ cancer stage system group system risk group stage system base size tumor bodi whether spread part bodi stage stage tumor size may spread lymph node found one follow favor site eye area around eye head neck tissu next brain spinal cord gallbladd bile duct uret urethra test ovari vagina uteru rhabdomyosarcoma form favor site better prognosi site cancer occur one favor site list said unfavor site enlarg tumor size size tumor may compar size pea cm peanut cm grape cm walnut cm lime cm egg cm peach cm grapefruit cm stage stage cancer found unfavor site one area describ favor stage tumor larger centimet spread lymph node stage stage cancer found unfavor site one area describ favor stage one follow true tumor larger centimet cancer spread nearbi lymph node tumor larger centimet cancer may spread nearbi lymph node stage stage tumor may size cancer may spread nearbi lymph node cancer spread distant part bodi lung bone marrow bone group system base whether cancer spread whether cancer remov surgeri group cancer found place start complet remov surgeri tissu taken edg tumor remov tissu check microscop pathologist cancer cell found group ii group ii divid group iia iib iic iia cancer remov surgeri cancer cell seen tissu taken edg tumor remov view microscop pathologist iib cancer spread nearbi lymph node cancer lymph node remov surgeri iic cancer spread nearbi lymph node cancer lymph node remov surgeri least one follow true tissu taken edg tumor remov check microscop pathologist cancer cell seen furthest lymph node tumor remov check microscop pathologist cancer cell seen group iii cancer partli remov biopsi surgeri tumor remain seen eye group iv cancer spread distant part bodi cancer diagnos cancer cell found imag test cancer cell fluid around brain spinal cord lung fluid abdomen tumor found area risk group base stage system group system risk group describ chanc rhabdomyosarcoma recur come back everi child treat rhabdomyosarcoma receiv chemotherapi decreas chanc cancer recur type anticanc drug dose number treatment given depend whether child low risk intermedi risk high risk rhabdomyosarcoma follow risk group use low risk childhood rhabdomyosarcoma low risk childhood rhabdomyosarcoma one follow embryon tumor size found favor site may tumor remain surgeri seen without microscop cancer may spread nearbi lymph node follow area favor site eye area around eye head neck tissu near ear nose sinus base skull gallbladd bile duct uret urethra test ovari vagina uteru embryon tumor size found favor site may tumor remain surgeri seen microscop cancer may spread nearbi lymph node intermedi risk childhood rhabdomyosarcoma intermedi risk childhood rhabdomyosarcoma one follow embryon tumor size found one favor site list tumor remain surgeri seen without microscop cancer may spread nearbi lymph node alveolar tumor size favor unfavor site may tumor remain surgeri seen without microscop cancer may spread nearbi lymph node high risk childhood rhabdomyosarcoma high risk childhood rhabdomyosarcoma may embryon type alveolar type may spread nearbi lymph node spread one follow part bodi near tumor first form fluid around brain spinal cord fluid lung abdomen recurr childhood rhabdomyosarcoma recurr childhood rhabdomyosarcoma cancer recur come back treat cancer may come back place part bodi lung bone bone marrow less often rhabdomyosarcoma may come back breast adolesc femal liver treatment option overview key point differ type treatment patient childhood rhabdomyosarcoma children rhabdomyosarcoma treatment plan team health care provid expert treat cancer children treatment childhood rhabdomyosarcoma may caus side effect three type standard treatment use surgeri radiat therapi chemotherapi new type treatment test clinic trial immunotherapi target therapi patient may want think take part clinic trial patient enter clinic trial start cancer treatment follow test may need differ type treatment patient childhood rhabdomyosarcoma treatment standard current use treatment test clinic trial treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer clinic trial show new treatment better standard treatment new treatment may becom standard treatment cancer children rare take part clinic trial consid clinic trial open patient start treatment children rhabdomyosarcoma treatment plan team health care provid expert treat cancer children rhabdomyosarcoma form mani differ part bodi mani differ kind treatment use treatment overseen pediatr oncologist doctor special treat children cancer pediatr oncologist work health care provid expert treat children rhabdomyosarcoma special certain area medicin may includ follow specialist pediatrician pediatr surgeon radiat oncologist pediatr hematologist pediatr radiologist pediatr nurs specialist geneticist cancer genet risk counselor social worker rehabilit specialist treatment childhood rhabdomyosarcoma may caus side effect inform side effect begin treatment cancer see side effect page side effect cancer treatment begin treatment continu month year call late effect late effect cancer treatment rhabdomyosarcoma may includ physic problem chang mood feel think learn memori second cancer new type cancer late effect may treat control import talk child doctor effect cancer treatment child see pdq summari late effect treatment childhood cancer inform three type standard treatment use surgeri surgeri remov cancer oper use treat childhood rhabdomyosarcoma type surgeri call wide local excis often done wide local excis remov tumor tissu around includ lymph node second surgeri may need remov cancer whether surgeri done type surgeri done depend follow bodi tumor start effect surgeri way child look effect surgeri child import bodi function tumor respond chemotherapi radiat therapi may given first children rhabdomyosarcoma possibl remov tumor surgeri rhabdomyosarcoma form mani differ place bodi surgeri differ site surgeri treat rhabdomyosarcoma eye genit area usual biopsi chemotherapi sometim radiat therapi may given surgeri shrink larg tumor doctor remov cancer seen time surgeri patient given chemotherapi surgeri kill cancer cell left radiat therapi may also given treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use high energi x ray type radiat kill cancer cell stop grow two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer certain way give radiat therapi help keep radiat damag nearbi healthi tissu type extern radiat therapi includ follow conform radiat therapi conform radiat therapi type extern radiat therapi use comput make dimension pictur tumor shape radiat beam fit tumor allow high dose radiat reach tumor caus less damag nearbi healthi tissu intens modul radiat therapi imrt imrt type dimension radiat therapi use comput make pictur size shape tumor thin beam radiat differ intens strength aim tumor mani angl volumetr modul arc therapi vmat vmat type radiat therapi use comput make pictur size shape tumor radiat machin move circl around patient treatment send thin beam radiat differ intens strength tumor treatment vmat deliv faster treatment imrt stereotact bodi radiat therapi stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment day sever day radiat machin aim larger usual dose radiat directli tumor patient posit treatment less damag nearbi healthi tissu procedur also call stereotact extern beam radiat therapi stereotax radiat therapi proton beam radiat therapi proton beam therapi type high energi extern radiat therapi radiat therapi machin aim stream proton tini invis posit charg particl cancer cell kill type treatment caus less damag nearbi healthi tissu intern radiat therapi use radioact substanc seal needl seed wire cathet place directli near cancer use treat cancer area vagina vulva uteru bladder prostat head neck intern radiat therapi also call brachytherapi intern radiat implant radiat interstiti radiat therapi type amount radiat therapi given depend age child type rhabdomyosarcoma bodi tumor start much tumor remain surgeri whether tumor nearbi lymph node extern radiat therapi usual use treat childhood rhabdomyosarcoma certain case intern radiat therapi use chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi chemotherapi place directli cerebrospin fluid organ bodi caviti abdomen drug mainli affect cancer cell area region chemotherapi chemotherapi may also given shrink tumor surgeri order save much healthi tissu possibl call neoadjuv chemotherapi everi child treat rhabdomyosarcoma receiv system chemotherapi decreas chanc cancer recur type anticanc drug dose number treatment given depend whether child low risk intermedi risk high risk rhabdomyosarcoma see drug approv rhabdomyosarcoma inform new type treatment test clinic trial summari section describ treatment studi clinic trial may mention everi new treatment studi inform clinic trial avail nci websit immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer type cancer treatment also call biolog therapi biotherapi differ type immunotherapi vaccin therapi cancer treatment use substanc group substanc stimul immun system find tumor kill vaccin therapi studi treat metastat rhabdomyosarcoma immun checkpoint inhibitor therapi use bodi immun system kill cancer cell two type immun checkpoint inhibitor studi treatment childhood rhabdomyosarcoma come back treatment ctla protein surfac cell help keep bodi immun respons check ctla attach anoth protein call b cancer cell stop cell kill cancer cell ctla inhibitor attach ctla allow cell kill cancer cell ipilimumab type ctla inhibitor pd protein surfac cell help keep bodi immun respons check pd attach anoth protein call pdl cancer cell stop cell kill cancer cell pd inhibitor attach pdl allow cell kill cancer cell nivolumab pembrolizumab pd inhibitor enlarg immun checkpoint inhibitor checkpoint protein pd l tumor cell pd cell help keep immun respons check bind pd l pd keep cell kill tumor cell bodi left panel block bind pd l pd immun checkpoint inhibitor anti pd l anti pd allow cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer target therapi target therapi type treatment use drug substanc attack cancer cell target therapi usual caus less harm normal cell chemotherapi radiat differ type target therapi mtor inhibitor stop protein help cell divid surviv sirolimu type mtor inhibitor therapi studi treatment recurr rhabdomyosarcoma tyrosin kinas inhibitor small molecul drug go cell membran work insid cancer cell block signal cancer cell need grow divid mk cabozantinib malat tyrosin kinas inhibitor studi treatment recurr rhabdomyosarcoma patient may want think take part clinic trial patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment clinic trial includ patient yet receiv treatment trial test treatment patient whose cancer gotten better also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found nci clinic trial search webpag clinic trial support organ found clinicaltri gov websit follow test may need test done diagnos cancer find stage cancer may repeat test repeat order see well treatment work decis whether continu chang stop treatment may base result test test continu done time time treatment end result test show child condit chang cancer recur come back test sometim call follow test check up treatment option childhood rhabdomyosarcoma inform treatment list see treatment option overview section previous untreat childhood rhabdomyosarcoma treatment childhood rhabdomyosarcoma often includ surgeri radiat therapi chemotherapi order treatment given depend bodi tumor start size tumor type tumor whether tumor spread lymph node part bodi see treatment option overview section summari inform surgeri radiat therapi chemotherapi use treat children rhabdomyosarcoma rhabdomyosarcoma brain head neck tumor brain treatment may includ surgeri remov tumor radiat therapi chemotherapi tumor head neck near eye treatment may includ chemotherapi radiat therapi tumor remain come back treatment chemotherapi radiat therapi surgeri remov eye tissu around eye may need tumor head neck near ear nose sinus base skull near eye treatment may includ radiat therapi chemotherapi tumor head neck near eye near ear nose sinus base skull treatment may includ chemotherapi radiat therapi surgeri remov tumor tumor head neck cannot remov surgeri treatment may includ chemotherapi radiat therapi includ stereotact bodi radiat therapi tumor larynx voic box treatment may includ chemotherapi radiat therapi surgeri remov larynx usual done voic harm rhabdomyosarcoma arm leg chemotherapi follow surgeri remov tumor tumor complet remov second surgeri remov tumor may done radiat therapi may also given tumor hand foot radiat therapi chemotherapi may given tumor may remov would affect function hand foot lymph node dissect one lymph node remov sampl tissu check microscop sign cancer tumor arm lymph node near tumor armpit area remov tumor leg lymph node near tumor groin area remov rhabdomyosarcoma chest abdomen pelvi tumor chest abdomen includ chest wall abdomin wall surgeri wide local excis may done tumor larg chemotherapi radiat therapi given shrink tumor surgeri tumor pelvi surgeri wide local excis may done tumor larg chemotherapi given shrink tumor surgeri radiat therapi may given surgeri tumor diaphragm biopsi tumor follow chemotherapi radiat therapi shrink tumor surgeri may done later remov remain cancer cell tumor gallbladd bile duct biopsi tumor follow chemotherapi radiat therapi tumor muscl tissu around anu vulva anu scrotum anu surgeri done remov much tumor possibl nearbi lymph node follow chemotherapi radiat therapi rhabdomyosarcoma kidney tumor kidney surgeri remov much tumor possibl chemotherapi radiat therapi may also given rhabdomyosarcoma bladder prostat tumor top bladder surgeri wide local excis done tumor prostat bladder top bladder chemotherapi radiat therapi given first shrink tumor cancer cell remain chemotherapi radiat therapi tumor remov surgeri surgeri may includ remov prostat part bladder pelvic exenter without remov rectum may includ remov lower colon bladder girl cervix vagina ovari nearbi lymph node may remov chemotherapi given first shrink tumor surgeri remov tumor bladder prostat done intern extern radiat therapi may given surgeri surgeri remov tumor bladder prostat intern radiat therapi given surgeri rhabdomyosarcoma area near testicl surgeri remov testicl spermat cord lymph node back abdomen may check cancer especi lymph node larg child year older radiat therapi may given tumor cannot complet remov surgeri rhabdomyosarcoma vulva vagina uteru cervix ovari tumor vulva vagina treatment may includ chemotherapi follow surgeri remov tumor intern extern radiat therapi may given surgeri tumor uteru treatment may includ chemotherapi without radiat therapi sometim surgeri may need remov remain cancer cell tumor cervix treatment may includ chemotherapi follow surgeri remov remain tumor tumor ovari treatment may includ chemotherapi follow surgeri remov remain tumor metastat rhabdomyosarcoma treatment chemotherapi radiat therapi surgeri remov tumor given site tumor first form cancer spread brain spinal cord lung radiat therapi may also given site cancer spread follow treatment studi metastat rhabdomyosarcoma clinic trial immunotherapi vaccin therapi use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail refractori recurr childhood rhabdomyosarcoma treatment option refractori recurr childhood rhabdomyosarcoma base mani factor includ bodi cancer come back type treatment child need child treatment refractori recurr rhabdomyosarcoma may includ one follow surgeri radiat therapi chemotherapi clinic trial target therapi immunotherapi sirolimu ipilimumab nivolumab pembrolizumab clinic trial target therapi tyrosin kinas inhibitor mk cabozantinib malat chemotherapi clinic trial check sampl patient tumor certain gene chang type target therapi given patient depend type gene chang use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail learn childhood rhabdomyosarcoma inform nation cancer institut childhood rhabdomyosarcoma see follow soft tissu sarcoma home page comput tomographi ct scan cancer drug approv rhabdomyosarcoma target cancer therapi childhood cancer inform gener cancer resourc see follow cancer childhood cancer curesearch children cancer late effect treatment childhood cancer adolesc young adult cancer children cancer guid parent cancer children adolesc stage cope cancer question ask doctor cancer survivor caregiv pdq summari pdq physician data queri pdq nation cancer institut nci comprehens cancer inform databas pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin summari come two version health profession version detail inform written technic languag patient version written easi understand nontechn languag version cancer inform accur date version also avail spanish pdq servic nci nci part nation institut health nih nih feder govern center biomed research pdq summari base independ review medic literatur polici statement nci nih purpos summari pdq cancer inform summari current inform treatment childhood rhabdomyosarcoma meant inform help patient famili caregiv give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date board made expert cancer treatment specialti relat cancer summari review regularli chang made new inform date summari updat date recent chang inform patient summari taken health profession version review regularli updat need pdq pediatr treatment editori board clinic trial inform clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori trial answer certain scientif question order find new better way help cancer patient treatment clinic trial inform collect effect new treatment well work clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial clinic trial open patient start treatment clinic trial list pdq found onlin nci websit inform call cancer inform servic cancer permiss use summari pdq regist trademark content pdq document use freeli text cannot identifi nci pdq cancer inform summari unless whole summari shown updat regularli howev user would allow write sentenc nci pdq cancer inform summari breast cancer prevent state risk follow way [includ excerpt summary] best way cite pdq summari pdq pediatr treatment editori board pdq childhood rhabdomyosarcoma treatment bethesda md nation cancer institut updat mm dd yyyi avail http www cancer gov type soft tissu sarcoma patient rhabdomyosarcoma treatment pdq access mm dd yyyi [pmid ] imag summari use permiss author artist publish use pdq summari want use imag pdq summari use whole summari must get permiss owner cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim inform summari use make decis insur reimburs inform insur coverag avail cancer gov manag cancer care page contact us inform contact us receiv help cancer gov websit found contact us help page question also submit cancer gov websit e mail us',\n",
       " 'podcast cancer net editori board member dr brian rini dr jorg garcia discuss new research kidney prostat cancer present european societi medic oncolog congress held octob nineteenth twenti third munich germani transcript [music] asco listen podcast cancer net cancer inform websit produc american societi clinic oncolog known asco world lead profession organ doctor care peopl cancer purpos podcast educ inform substitut profession medic care intend use diagnosi treatment individu condit guest podcast express opinion experi conclus mention product servic organ activ therapi constru asco endors cancer research discuss podcast ongo data describ may chang research progress podcast cancer net editori board member dr brian rini dr jorg garcia discuss new research kidney prostat cancer present european societi medic oncolog congress held octob nineteenth twenti third munich germani dr rini professor medicin cleveland clinic lerner colleg medicin case western reserv univers dr garcia assist professor medicin cleveland clinic lerner colleg medicin case western reserv univers also staff member depart solid tumor oncolog cleveland clinic taussig cancer institut asco would like thank dr rini dr garcia discuss research dr rini hello brian rini cleveland clinic taussig cancer center professor medicin lead gu program cleveland clinic join friend colleagu dr jorg garcia dr garcia thank brian jorg garcia gu medic oncologist cleveland clinic well dr rini go talk today highlight genitourinari gu cancer european societi medic oncolog meet took place coupl month ago munich germani one major cancer meet lot big data start present meet addit main asco meet meet go start talk coupl highlight renal cancer dr garcia describ coupl highlight prostat cancer kidney cancer gener speak pretti excit time year ago went wave vegf target therapi therapi target blood vessel sort becam standard care excit frankli time much els avail patient metastat kidney cancer realli foundat treat diseas last decad recent start use immun stimul agent commonli call immunotherapi io therapi use across mani mani malign especi kidney cancer way treat metastat kidney cancer still use therapi target blood vessel also call vegf target therapi increasingli use immun therapi recent effort actual combin differ modal probabl largest data present someth call javelin trial random phase iii trial compar patient metastat kidney cancer gotten prior treatment receiv either sunitinib vegf target agent standard care last year combin axitinib anoth vegf target therapi plu avelumab avelumab class drug mention immunotherapeut also call checkpoint inhibitor mechan work mani combin studi start report coupl report third come next month realli transform way kidney cancer patient treat walk door mention larg phase iii trial rational realli differ way attack cancer attack blood vessel tri stimul immun system patient treat trial patient treat either sunitinib combin therapi shown call progress free surviv usual describ patient long control tumor significantli greater combin therapi almost month believ one highest ever report diseas compar month sunitinib signific advantag term diseas control primari end point trial also look respons rate talk respons realli patient signific amount tumor shrink scan seen overal popul receiv combin therapi half patient object respons peopl degre tumor get smaller tumor get littl bit smaller necessarili call respons get least smaller threshold respons half patient reach threshold high number compar usual percent singl agent anti blood vessel drug importantli patient complet respons one great thing immunotherapi done kidney cancer chang mindset littl bit realli tri control diseas recogn subset patient cure diseas realli true larg scale ever realli certainli time new regimen control diseas longer lead potenti cure diseas cure part obvious need time pass need follow patient etc think certainli possibl report overal surviv result although data call rel immatur mean good thing patient still aliv receiv either regimen quit yet say regimen make patient live longer averag certainli benefit term tumor shrinkag diseas control time data come interestingli also similar studi involv combin axitinib pembrolizumab data present meet press releas happen come first day meet show also effect term tumor shrinkag diseas control interestingli also show surviv benefit one thing sort next year rel merit regimen certainli ident differ side effect profil differ way help patient differ patient might help etc good news number regimen like get approv next month come next wave work tri figur best appli patient certainli excit data first combin regimen includ drug like axitinib includ pill inhibit blood vessel main piec data want go privileg present differ trial present similar one trial call immot trial take patient kidney cancer yet treat random either sunitinib mention standard therapi anoth combin immun agent anti blood vessel agent name drug atezolizumab bevacizumab regimen shown effect lung cancer cancer clinic data studi present gu symposium earli present esmo correl studi secondari scientif analys often happen larg clinic trial detail analys done bit complic suffic say look patient tumor look express gene tumor differ tumor differ biolog express differ gene one stori emerg analysi sampl trial also small prior trial patient tumor rich blood vessel reliant angiogenesi patient tumor reliant cell immun system effect obvious patient type tumor cell individu tumor data realli start show trend differ biolog subtyp kidney cancer anybodi treat patient know give group patient drug peopl respond wonder unfortun other everywher mean underli tumor differ larg data set larg analys start sort say genet basi clinic differ observ patient think import first step hope toward individu therapi treat everybodi combin treat certain patient one drug certain patient anoth drug patient combin mention mani combin come would nice test would allow us choos best combin best patient yet would say unfortun littl way point data present esmo think start take step character tumor last thing mention someth call sarcomatoid tumor word sarcomatoid appli kidney cancer subset mayb tumor gener aggress cell microscop spindl shape word sarcomatoid mean alway difficult treat look like howev immun therapi patient popul particularli suscept actual better immun therapi genet signatur appli specif tumor surprisingli say immun rich environ character express gene relev immun system provid biolog basi clinic observ made year hope make us smarter think immun therapi certainli go benefit patient sarcomatoid kidney cancer think much clear clinic data point toward esmo data realli provid biolog basi summar kidney cancer esmo one phase iii trial present javelin axitinib plu avelumab show advantag sunitinib interest biolog data certainli come combo move forward ask dr garcia comment kidney cancer data mention describ prostat updat dr garcia thank brian think excel overview excit data perhap comment lack biomark inde put lot pressur select patient select therapi patient metastat renal cell carcinoma think javelin trial trial also come soon space think clinician go face challeng decid dual immun oncolog approach sequenti manner matter also perhap look combin vascular disrupt agent plu immunotherapi clearli need actual look clinic featur patient diseas make treatment decis abl pin biomark help us guid best approach patient front dr rini yeah agre good problem mani activ drug tri decid one give patient go big challeng move forward dr garcia great let move briefli review think probabl excit report esmo munich prostat cancer similar brian mention obvious lot movement manag patient advanc prostat cancer think last year chang practic manag patient walk offic metastat prostat cancer patient either primari tumor resect radiat therapi primari definit treatment time go progress develop system diseas patient never chanc prostat treat either surgeri radiat therapi latter group uncommon psa screen least north america see perhap percent patient walk offic metastat diseas way background standard care men advanc diseas last decad suppress testosteron call castrat remov testosteron either medic surgic orchiectomi us unit state medic suppress call hormon therapi basic inject receiv variou interv suppress function pituitari access testicl patient suppress testosteron therefor diseas get control tradit patient longer live suppress testosteron like develop resist approach tradit done happen talk chemotherapi talk novel oral agent abl inhibit signal within prostat cancer cell allow growth signal hormon bodi make specif renal gland agent abirateron acet agent capabl suppress testosteron product hormon also activ signal within prostat cancer growth divid patient main group walk offic metastat diseas call high volum low volum definit actual process american data call charter data patient high volum diseas specif speak viscer metastas uncommon prostat cancer mean lung diseas liver diseas men metastas bone one outsid spine pelvic region receiv hormon chemotherapi clearli ad docetaxel base chemotherapi men drastic improv outcom french last year present data trial call latitud trial look util oral therapi front combin testosteron suppress case use abirateron acet trial also specif aim patient metastat diseas high volum featur although definit high volum diseas bit differ american definit includ viscer diseas presenc bone metastas includ gleason score reflect biolog tumor patient trial also demonstr patient receiv combin abirateron acet suppress testosteron drastic improv outcom often time tell patient adt hormon suppress abirateron decreas risk die prostat cancer almost latitud charter data america standard care either use chemotherapi abirateron patient popul good sens patient low volum diseas throughout time british also help us littl bit support role chemotherapi patient british trial call stamped complex trial statist speak trial basic take signific number patient metastat diseas basic backbon treatment case suppress testosteron androgen depriv therapi add newer treatment time allow flexibl remov treatment perform ad new treatment becom part use patient trial actual demonstr coupl year ago addit docetaxel base chemotherapi patient metastat diseas made peopl live longer specif reduc risk mortal diseas therefor solidifi role docetaxel similar american data also includ arm includ abirateron data also present last year demonstr signific surviv improv patient metastat diseas biggest question offer patient low volum metastas data actual stratifi patient volum diseas actual present esmo year think nutshel quit simpl patient low volum diseas high volum diseas whether use french definit american definit regardless volum addit abirateron patient metastat diseas drastic improv outcom reduc rel risk mortal therapi standard care low volum patient suppress testosteron ad abirateron acet perhap interest data also arm within trial look addit radiat therapi primari tumor men metastat diseas primari tumor treat mean radiat upfront surgeri walk offic metastat diseas random patient standard care time adt suppress testosteron docetaxel combin plu radiat therapi prostat tumor saw data surviv improv take comer mean high low volum patient howev stratifi volum diseas low volum diseas high volum diseas clear signific surviv improv men metastat diseas low volum diseas went receiv adp mean suppress testosteron addit docetaxel base chemotherapi radiat therapi prostat gland almost differ year surviv hazard ratio risk reduct mortal call tell patient around almost risk reduct mortal get radiat therapi primari tumor practic see someon low volum metastat prostat cancer primari place standard care becom suppress testosteron addit abirateron acet primari radiat prostat tumor period high volum patient would argu standard care remain either suppress testosteron plu docetaxel base chemotherapi suppress testosteron plu abirateron think us practic simpli use combin oral therapi plu suppress testosteron lastli know interest provoc trial trial call era look combin particular agent abirateron acet radiopharmaceut agent also approv men advanc castrat resist prostat cancer mean men becom resist lack testosteron go develop progress diseas bone rational behind combin agent life prolong agent sinc abirateron use pre chemotherapi space set radium radionuclid also use particular patient popul thought mayb combin novel oral hormon approach radionuclid base approach could actual lead better improv outcom castrat resist prostat cancer patient trial look patient castrat resist diseas never seen chemotherapi random receiv either combin abirateron plu radium abirateron match placebo primari end point trial look surviv along reduct skelet symptomat event like patient develop symptom boni metastas common site metastas men prostat cancer specif relat need radiat therapi pain control develop fractur requir orthoped surgeri develop tumor spine push spinal canal possibl lead neurolog symptom primari end point trial learn trial realli drastic differ outcom mean abil delay progress diseas differ surviv group mean ad radium improv outcom learn combin abirateron radium unfortun increas risk patient popul develop fractur specif either patholog fractur site boni metastas complic area boni diseas lead bone fractur big issu clinician use combin abi radium sinc trial think refrain use combin think import physician understand trial test time use radium castrat resist diseas aim test combin agent think radium remain life prolong agent offer patient castrat resist diseas specif patient popul agent label combin oral agent abirateron actual use point trial result studi chang label radium unit state also european region think fair say us refrain use combin oral agent whether mean combin radium anoth oral agent ar inhibitor remain seen clearli signific increas patholog fractur almost differ patient combin arm think us would concern see patient develop complic combin think realli know biolog behind happen think fair say data confid enough us use clinic practic summar think standard care prostat cancer low volum high volum diseas use suppress testosteron oral agent abirateron acet patient low volum diseas primari tumor place radiat therapi primari tumor standard care time remain debat think us treat patient system therapi road given time probabl includ radiat oncologist offer radiat therapi secondli use combin radium abirateron acet someth one support data new trial look combin agent brian know comment thought dr rini sure yeah mean tell lot go prostat cancer well think mayb broaden area think control primari tumor patient whose diseas alreadi spread dr garcia mention data radiat primari tumor subset patient especi patient low volum sometim call oligometastat diseas studi ongo look treat patient aggress either radiat surgic remov primari surgic remov lymph node even radiat metastat site hope window cure prostat cancer patient expand includ low volum patient think lot work done think patient may benefit think ongo trial help defin total differ concept thought advanc prostat cancer realli certainli time like thank dr garcia excel summari thank tune podcast tell gu cancer realli given small slice went one meet lot import studi go lot import data come larg phase iii trial chang standard care chang better continu move forward clinic research thank attent dr garcia thank brian thank opportun asco thank dr rini dr garcia learn genitourinari cancer www cancer net podcast use pleas take minut subscrib rate review show appl podcast googl play cancer net support asco conquer cancer foundat fund breakthrough research everi type cancer help patient everywher help fund cancer net program like donat conquer org support [music]',\n",
       " 'excerpt third gener epiderm growth factor receptor egfr tyrosin kinas inhibitor tki osimertinib effect first line treatment egfr mutat non small cell lung cancer nsclc accord late break abstract present european lung cancer confer elcc geneva switzerland second late break abstract confirm drug effect patient mutat egfr inhibit standard care nsclc patient egfr activ mutat nearli develop resist develop mutat osimertinib potent inhibitor origin egfr mutat exon exon studi present today investig whether use osimertinib first line therapi egfr mutat posit nsclc would result favour efficaci due delay mediat resist studi includ patient two phase expans cohort aura trial local advanc metastat egfr mutat nsclc thirti patient receiv mg day receiv mg day first line set median follow month go full articl question stori let us know comment wonder whether stori appli cancer case love one invit use ask cancer common servic',\n",
       " 'thank english good better peopl whose first languag english realli appreci take time answer question mayb stelara better option think want chang medic get back vacat june th case go well want ruin famili vacat',\n",
       " 'recruit apr elig cancer histiocyt sarcoma juvenil xanthogranuloma langerhan cell histiocytosi lymphoma recurr central nervou system neoplasm recurr malign solid neoplasm refractori central nervou system neoplasm refractori malign solid neoplasm intervent ro patient receiv x ensartinib countri usa children oncolog group philadelphia pa nct studi oral pf c met hepatocyt growth factor tyrosin kinas inhibitor patient advanc cancer statu recruit elig cancer alk posit non small cell lung cancer nsclc c met depend nsclc ro marker posit nsclc system anaplast larg cell lymphoma advanc malign except leukemia intervent pf crizotinib rifampin itraconazol countri usa state australia republ korea note origin trial crizotinib expand time includ new arm nct nation lung matrix trial multi drug phase ii trial non small cell lung cancer statu yet recruit elig cancer non small cell lung cancer nsclc squamou cell carcinoma adenocarcinoma intervent ro patient receiv crizotinib countri unit kingdom uk nct ceritinib trametinib patient advanc alk posit non small cell lung cancer nsclc statu recruit elig cancer stage iiib iv ro phase alk non small cell lung cancer nsclc intervent ceritinib trametinib countri univers california san francisco expand access experiment drug nct expand access entrectinib cancer ntrk ro alk gene fusion statu avail elig cancer advanc cancer ntrk ntrk ntrk ro alk gene fusion unabl particip ongo entrectinib rxdx clinic trial intervent entrectinib countri contact ignyta startrktrial ignyta com call startrk',\n",
       " 'good luck tomorrow yr holi moli diagnos enjoy period remiss like two year follow initi diagnosi symptom free suffer flare got control enjoy anoth two year remiss howev start flare often longer period prednison lot stress daughter went bitter divorc thing went haywir uc hospit thought go take hospit pine box soooo sick tri remicad humira condit spiral downhil qualiti life suck big time decid someth got old',\n",
       " 'gilead galapago announc oral jak inhibitor filgotinib hit goal phase iii trial patient rheumatoid arthriti fail treatment result good news partner inflammatori condit contend also studi ulcer coliti crohn diseas ankylos spondyl finch trial filgotinib adult moder sever activ rheumatoid arthriti achiev primari endpoint proport patient achiev american colleg rheumatolog respons acr week filgotinib mg mg dose achiev significantli higher acr respons placebo read acr week higher dose compar placebo news particular fillip galapago saw share rise announc gilead share also john mchutchinson john mchutchison md chief scientif offic head research develop gilead said data show potenti drug candid combin diseas modifi drug help patient activ ra respond adequ current biolog data particularli encourag look ahead phase iii result ongo finch trial explor filgotinib popul patient rheumatoid arthriti first jak inhibitor market pfizer xeljanz tofacitinib alreadi earn excess bn year ra revenu anoth player lilli olumi though held back safeti concern analyst predict showdown filgotinib abbvi rival upadacitinib next decis event jak inhibitor market abbvi look lead race market phase iii data hand show upadacitinib effect abbvi bn year inject tnf blocker humira adalimumab ra come clinic respons gaug doctor patient new result filgotinib follow close behind posit result ankylos spondyl last week',\n",
       " 'hi advoc year old mom take tarceva sinc januari year want everyth make sure overlook anyth would provid best chanc long pf tarveca sinc respond well primari tumor shrink x mm januari x mm stabl right hillier node x mm last ct still show residu nodular pleural carcinomatosi treatment also complet resolv moder larg malign pleural effus sign metastasi sensit medic sever reaction mg mg realli well asid numb variou part bodi come go treatment improv rapid pace would consid tarveca best treatment someon profil would consid investig combin therapi recent studi publish uc davi say mani dismiss surgeri advanc stage nsclc howev may benefit overlook mom treat major research univers hear lo angel never evalu surgeri due mpe patient seek surgic evalu despit mpe residu nodular pleural carcinomatosi seen thank john',\n",
       " 'kind unreal think tumor abl hijack cell bid anoth immuno arena list told lead investig oncolyt viral therapi pair checkpoint inhibitor probabl pembro keytruda expans arm ovarian cancer phase alreadi start dose monotherapi short ph safeti alreadi establish prior trial diseas type year would say combo ing http www genelux com gl onc gl onc',\n",
       " 'hi coco sorri hear mom posit tagrisso work wait month wonder drug work oncologist team suggest get anoth lung biopsi see new mutat may mom like might acquir anoth mutat easi figur take time rebiopsi next treatment option would get chemo enrol clinic trial take care',\n",
       " 'immun checkpoint inhibitor becom approv commerci avail patient previous treat advanc nsclc dr eddi garon medic oncologist ucla summar key data explain current role treatment cancer journey diagnos treatment cancer type lung cancer diseas learn molecular test target therapi mainten therapi second line treatment distinct among current avail oral egfr inhibitor egfr mutat posit nsclc dr greg rieli medic oncologist mskcc consid evid whether clinic signific differ among current avail first second gener oral egfr inhibitor patient egfr mutat cancer journey diagnos treatment cancer type lung cancer diseas learn target therapi molecular test mainten therapi avastin ad egfr tki therapi egfr mutat posit nsclc dr jack west medic oncologist review evid favor ad avastin bevacizumab egfr inhibitor tarceva erlotinib patient lung cancer harbor activ egfr mutat cancer journey diagnos treatment cancer type lung cancer diseas learn target therapi first line treatment molecular test mainten therapi symptom mainten therapi advanc nsclc concept mainten therapi advanc lung cancer emerg past year dr jack west medic oncologist review concept behind treatment option patient cancer journey diagnos treatment cancer type lung cancer diseas learn mainten therapi target therapi possibl live cancer novemb lung cancer awar month mark year grace celebr empow lung cancer patient video linnea duff cancer journey treatment diagnos cancer type lung cancer diseas learn target therapi mainten therapi symptom',\n",
       " 'repli plan offici ocrevu view post penkalet great news realli hope slow great news realli hope slow beast think help alain show result forum jump time gmt time',\n",
       " 'home ms inform public motiv motiv summer fall research news new drug applic accept treatment pediatr ms confer highlight research news new drug applic accept treatment pediatr ms confer highlight fda accept applic cladribin tablet juli emd serono inc announc unit state food drug administr fda accept new drug applic nda cladribin tablet oral formul cladribin investig treatment relaps form ms accept european commiss august canada decemb cladribin current approv treatment relaps ms countri trade name mavenclad studi cladribin shown reduc diseas activ patient relaps ms includ disabl progress annual relaps rate mri activ potenti advers event includ lymphopenia condit caus abnorm low count white blood cell play role fight infect herp zoster accord msaa ms research updat cladribin select target immun system b cell cell lead deplet cell follow distinct pattern reconstitut new cell cell produc medic interest dose regimen two annual cours given maximum day two year develop note approach avoid continu suppress immun system follow first two year treatment need year fda accept gilenya pediatr ms may novarti announc gilenya fingolimod approv unit state food drug administr fda treatment children adolesc age relaps multipl sclerosi ms first diseas modifi therapi dmt approv form diseas age group known pediatr ms nearli percent diagnos relaps form diseas children experi approxim two three time mani relaps individu adult onset ms prior approv diseas modifi therapi dmt ms approv adult treatment approv specif children adolesc ms fda approv gilenya base result phase iii paradigm studi clinic trial evalu safeti effect gilenya versu avonex interferon beta children adolesc age relaps ms paradigm first studi compar two ms therapi approv adult children adolesc ms enrol young individu ms studi conduct site countri paradigm doubl blind random multi center phase iii studi durat two year follow five year open label extens phase studi particip either given avonex weekli intramuscular inject gilenya oral pill taken daili compar avonex group take gilenya experienc percent reduct annual relaps rate period two year side effect advers event similar seen clinic trial adult inform gilenya treat pediatr ms individu may visit www gilenya com call gilenya speak member novarti support team research highlight aan cmsc annual meet result numer signific studi report annual meet american academi neurolog aan held lo angel april annual meet consortium multipl sclerosi center cmsc took place nashvil may post juli msaa provid summari interest find confer topic articl includ updat experiment diseas modifi therapi dmt continu studi effect safeti approv dmt compar analysi approv dmt new diagnost test strategi well hot topic ms latter section includ inform stem cell transplant gut microbiom medic marijuana read full summari pleas see research highlight aan cmsc annual meet individu without internet access pleas call msaa request print copi read msaa latest articl onlin pleas visit websit mymsaa org go latest news gener inform speak train client servic specialist pleas call msaa helplin extens question msaa client servic depart may also email msquestion mymsaa org written susan well courtney msaa senior writer review dr jack burk msaa chief medic consult back',\n",
       " 'gilead scienc galapago announc finch global random placebo control phase iii studi glpg filgotinib investig select jak inhibitor adult moder sever activ rheumatoid arthriti prior inadequ respons intoler biolog agent achiev primari endpoint proport patient achiev american colleg rheumatolog percent respons acr week also week proport patient achiev acr acr low diseas activ lda da crp filgotinib gener well toler finch trial new safeti signal compar report previou trial filgotinib treatment emerg advers event seriou advers event mostli mild moder sever seriou advers event occur percent patient placebo mg mg group respect proport patient discontinu studi drug due treatment emerg advers event also similar across group two case uncompl herp zoster report filgotinib group two major advers cardiovascular event mace identifi one subarachnoid hemorrhag placebo group one myocardi ischemia filgotinib mg group one case non seriou retin vein occlus filgotinib mg group report deep venou thrombosi dvt pulmonari embol pe death malign gastrointestin perfor opportunist infect includ activ tuberculosi comment analyst focus safeti factor trial grow concern janu kinas jak inhibitor class drug includ filgotinib may affect blood clot howev gilead galapago found report deep venou thrombosi dvt pulmonari embol pe come finch far comment need login leav comment epgonlin org monitor collect advers event report advers event report nation report agenc manufactur learn zone epgonlin org learn zone lz area site dedic provid detail self direct medic educ diseas condit procedur alkalin phosphatas alp lab assess discov overview hypophosphatasia detail requir facilit time accur detect low alkalin phosphatas migrain knowledg centr migrain knowledg centr featur latest research preval impact migrain propos neurolog basi condit translat new excit drug therapi well current patient care strategi collat headach organis worldwid chronic obstruct pulmonari diseas copd view highlight recent congress present new expert video lead physician acut advanc heart failur effect treatment acut heart failur defin advanc heart failur discov psoriasi see inform psoriasi pathophysiolog sign symptom comorbid treatment option allerg rhiniti allerg rhiniti caus great strain workforc help reduc sick day improv product appropri treatment option atop dermat atop dermat knowledg centr educ resourc intend healthcar profession provid credibl medic inform epidemiolog pathophysiolog burden atop dermat well diagnost techniqu treatment regimen guidelin recommend chronic spontan urticaria csu use patient case studi discov expert diagnos treat chronic spontan urticaria load relat content news journal articl clinic trial guidelin news phase iii select monotherapi trial abt show benefit week rheumatoid arthriti abbvi abbvi announc new patient report outcom data ongo phase iii select monotherapi trial evalu abt upadacitinib mg ad day ago integr safeti analysi olumi six year eli lilli incyt eli lilli compani incyt corpor announc find updat integr safeti analysi olumi baricitinib base ad day ago phase iv interim data h p acthar gel show reduc diseas activ rheumatoid arthriti mallinckrodt mallinckrodt report interim data midway point enrol ongo phase iv multicent studi assess ad day ago detail result phase iii finch trial filgotinib rheumatoid arthriti gilead galapago gilead scienc inc galapago nv announc detail result phase iii finch clinic trial filgotinib ad day ago celltrion advanc remsima sc subcutan version remsima biosimilar file europ year celltrion inc announc compani complet phase iii clinic trial remsima sc subcutan sc version ad month ago load view news item journal articl updat subcutan methotrex inflammatori arthriti psoriasi aim articl review avail literatur data sc mtx treatment inflammatori arthriti special emphasi ra psoriasi examin differ oral mtx treatment ad month ago predict respons methotrex rheumatoid arthriti narr review seek cover variou genotyp phenotyp characterist investig predictor treatment respons mtx ra ad month ago efficaci safeti interleukin antagonist rheumatoid arthriti systemat review meta analysi rheumatoid arthriti patient high level pro inflammatori interleukin augment blockad interleukin receptor extern interleukin receptor antagonist modifi progress diseas ad month ago emerg role il inhibit patient affect rheumatoid arthriti diabet object review role il ra efficaci il block agent control diseas possibl decreas concomit enhanc atherosclerot process ad month ago safeti adalimumab pediatr patient polyarticular juvenil idiopath arthriti enthes relat arthriti psoriasi crohn diseas object evalu safeti adalimumab pediatr patient particip clinic trial juvenil idiopath arthriti polyarticular juvenil idiopath arthriti pediatr enthes relat arthriti ad month ago load view journal articl item clinic trial compar efficaci safeti studi gp enbrel patient rheumatoid arthriti equira demonstr equival efficaci gp eu author enbrel patient moder sever activ ra inadequ respons diseas modifi anti rheumat drug dmard includ methotrex mtx ad month ago multicent studi evalu certolizumab pegol compar placebo subject axspa without x ray evid c axspand patient activ axial spondyloarthr without x ray evid ankylos spondyl sign inflamm randomli assign receiv certolizumab pegol czp mg everi two week placebo ad month ago studi compar abt monotherapi methotrex monotherapi subject rheumatoid arthriti ra previous taken methotrex select earli random doubl blind studi compar abt monotherapi methotrex mtx monotherapi mtx na subject moder sever activ rheumatoid arthriti ad month ago studi moder sever rheumatoid arthriti particip ra build purpos studi determin whether baricitinib milligram mg daili qd superior placebo treatment particip moder sever activ rheumatoid arthriti ad year ago efficaci safeti sarilumab adalimumab monotherapi patient rheumatoid arthriti saril ra monarch primari object demonstr sarilumab monotherapi superior adalimumab monotherapi respect sign symptom assess diseas activ score ad year ago load view clinic trial item guidelin updat asa eular manag recommend axial spondyloarthr assess spondyloarthr intern societi eular recommend provid date guidanc manag patient axspa ad month ago spondyloarthr diagnosi manag guidelin cover diagnos manag spondyloarthr suspect confirm adult year older aim rais awar featur spondyloarthr provid clear advic ad month ago bsr bhpr guidelin treatment axial spondyloarthr includ ankylos spondyl biolog guidelin provid evid base guidanc uk clinician prescrib biolog adult patient axspa includ criteria start treatment choic drug assess respons treatment ad month ago bsr bhpr guidelin prescript monitor non biolog diseas modifi anti rheumat drug purpos guidelin provid date evid base recommend safe use non biolog dmard adult year old ad month ago bsr bhpr guidelin prescrib drug pregnanc breastfeed part ii analges drug use rheumatolog practic object guidelin provid evid base recommend impli legal oblig clinician follow prescrib drug commonli use manag multisystem rheumat condit',\n",
       " 'never heard anyth reduc life expect regard either rituxamab ocrelizumab obvious drug carri risk primarili opportunist infect think way quantifi impact life expect logic could even increas life expect success curtail ms diseas activ thu decreas chanc death ms complic cours conjectur ms medic patient must determin toler risk balanc potenti reward take drug',\n",
       " 'asian patient alk posit advanc non small cell lung cancer nsclc demonstr improv outcom alectinib compar crizotinib first line set accord result phase alesia trial present esmo congress munich germani global phase alex trial alectinib significantli prolong progress free surviv pf compar crizotinib among patient alk posit nsclc without prior treatment hazard ratio [hr] ci purpos trial determin asian patient would experi similar benefit seen popul alex trial investig open label phase alesia trial randomli assign asian patient alk posit stage iiib stage iv nsclc receiv alectinib crizotinib patient receiv prior system treatment patient asymptomat central nervou system cn metastas allow enrol primari end point pf assess via investig analysi secondari end point pf assess independ review committe time cn progress object respons rate orr durat respons dor overal surviv os cn orr qualiti life safeti relat articl atezolizumab combo improv pf os stage iv non small cell lung cancer resist mechan identifi nsclc progress first line osimertinib brigatinib found effect alk posit nsclc brain met compar crizotinib alectinib met primari end point signific improv pf median yet reach compar month crizotinib hr ci p pf found similar assess independ analysi hr ci p os data immatur median arm yet reach orr higher alectinib compar crizotinib p dor also longer alectinib median yet reach compar month crizotinib time cn progress also yet reach alectinib month crizotinib hr ci p grade grade advers event ae less common alectinib rate compar crizotinib rate seriou ae alectinib crizotinib respect discontinu occur patient alectinib crizotinib arm respect discontinu due ae author conclud alesia studi result consist global alex studi confirm clinic benefit alectinib asian patient advanc alk posit nsclc read cancer therapi advisor coverag esmo meet visit confer page refer',\n",
       " 'honestli use cannabi feel cancer fight properti rather enjoy combin lorlatinib need speak maker molecul psychoact qualiti creativ person enjoy xo linnea',\n",
       " 'frustrat inform rituxan met new neurologist last month brought research show minim almost nonexist rise cancer risk ocrevu knew immedi meant malign melanoma histori mine let argu keep rituxan knew melanoma would use linda kind woman feet hit floor morn devil say oh crap repli quot follow user say thank agat cheri howi jeani z jendi stillstannd sunshin',\n",
       " 'go meal feel good surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia condit fib high blood pressur gout crohn edema cellul heart issu ost openia medic entyvio eliqui verapamil quinipril labetalol clorithidon atorvastatin alluporinol vitamin',\n",
       " 'sent email spous diagnos uc develop antibodi remicad humira entyvio work infus thing seem work prednison earli march start xeljanz label remiss within month work endocrinologist get prednison neurologist deal neuropathi feet develop conjunct prednison taper',\n",
       " 'husband stage non small cell metastat lung cancer diagnos august egfr mutat put tarceva work month time discov cancer metastas hip bone given radiat hip work well complet took away hip pain put tagrisso',\n",
       " 'ellina allow take oral vitamin c tarceva bought today mg pill slow releas vit c doxycyclin might use see paper anyway take doxycyclin anyway one affect microbiota damag oral vit c act inhibitor glycolysi cancer cell get oxid form via glucos transport reduc form',\n",
       " 'mayb say repress immun system work suppress bodi natur immun cours noth els work take question show u cabl tv call monster insid parasit know mani episod discuss variou parasit worm fungu bacteria larva everyday environ part harmless us normal immun system easili overwhelm someon compromis immun system previou studi alreadi indic increas risk infect lymphoma evid publish journal american medic associ suggest remicad tripl risk skin cancer anoth black box issu describ cancer occur children young adult began take tnf blocker remicad humira cimzia along immunesuppress medicin mp fda fix problem updat warn section drug label www huffingtonpost com rebecca kaplan social secur administr_b_ html patient ibd depend medic antibiot anti inflammatori steroid immunosuppress control inflamm ulcer pain caus diseas benefici medic caus sever side effect includ nausea vomit heartburn night sweat insomnia hyperact high blood pressur stunt growth children patient immunosuppress risk develop lymphoma tuberculosi kidney liver damag anaphylaxi seizur potenti seriou fatal infect',\n",
       " 'uugghh sorri hear marci familiar combo suggest heard go back keytruda ad someth els along unawar result mom chemo alimta carbo keytruda first infus time triplet approv month earlier studi shown patient better respons overal recal correctli dad keytruda first sinc cancer respond carbo alimta throw anoth kind chemo along immunotherapi perhap combin work feel otherwis',\n",
       " 'curr neurol neurosci rep sep infect patient receiv multipl sclerosi diseas modifi therapi grebenciucova e pruitt author inform multipl sclerosi divis dave depart neurolog clinic neurosci northwestern univers feinberg school medicin chicago il usa elena grebenciucova northwestern edu multipl sclerosi divis depart neurolog perelman school medicin univers pennsylvania convent avenu philadelphia pa usa purpos review paper system review risk infect associ current diseas modifi treatment discuss pre treatment test recommend infect monitor strategi patient educ recent find asid glatiram acet interferon beta therapi multipl sclerosi treatment variou degre impair immun surveil may predispos patient develop commun acquir opportunist infect infect rare seen neurolog practic neurologist awar monitor infect educ patient medic specif risk particular interest discuss risk pml associ recent approv b cell deplet therapi ocrelizumab particularli switch natalizumab risk infect associ ms treatment becom one import factor choic therapi balanc overal risk versu benefit continu evalu treatment',\n",
       " 'thank repli think know ulcer coliti thank state howev state obviou look understand mani thread kefir past question look identifi kefir home run success hear detail implement like thing detail make differ one take kefir combin specif preibot perhap work one take kefir combin lot sugar fri food process food work obviou exampl detail much specif prebiot one use kefir work mani time day take kefir still requir daili mainten success certain period e week abl balanc gi track specif thread kefir realli realli work anoth thread discuss kefir gener diagnos pancol march tri drug steroid mesalamin etc current vedolizumab new experiment gut specfic monoclon antibodi current entir colon heal except rectum recto sigmoid are stubborn noth seem work except high dose steroid royalflush new member join jan post post gmt hi ibdgal kefir milk grain work tremend one simpl chang done uc medic diet chang attitud chang meet someon ib uc etc tell kefir milk success rate tri peopl like million still trek kefir milk start veget fruit smoothi vitamix juic slow mastic juicer use carrot celeri appl orang etc vari amount stuff told avoid find high qualiti veget base enzym kefir water kefir milk addit smoothi juic daili like use skip day kefir use kefir grain start pack recal brand whole milk warm milk bit boil hot warm touch mix grain two quart ball jar cover jar w towel leav counter hour refriger last second jar warm milk split last jar remain amount two jar continu kefir grain use grain month histori lead kefir vitamix smoothi juic enzym gave lot energi boost immun system slept better less flare result less trip bathroom kefir multipli success kefir beyond integr kefir milk say quadrupl success smoothi juic enzym stay away spici food donut fast food bad food told avoid kefir milk allow indulg whether conveni hang friend time save meal e g fast food restaur etc thing time time stupid kefir get back track quickli month long flare day pain scale reduc urgenc erad bathroom time reduc least go without fast food spici layer bean dip differ bean layer old flare trigger kefir keep everyth balanc speak solid poo quick evacu go back sit time minut get everyth huge drop quantiti tp use wipe go potti leav go well anywher memor clean bathroom way locat kefir well stupid begin bleed flare kefir stop pain bleed discomfort within day two versu week end pain blood urgenc mention poor attitud amaz amaz uc med year liver thank blood test keep show probiot take enzym mlm call tranont call life buy friend work lower price get whole food like kefir dosag averag take oz per day even first even kefir middl night littl ga go chang morn bodi adjust good went back even time simpli take coupl big chug throughout day versu one glass even recent research tri non thc cbd oil work well friend year old son chron made massiv differ within week new add daili routin made posit chang truli hope help notsosicklygirl forum moder join dec post post pm gmt friend use post surgeri huge kefir made long period guess work well surgeri done kombucha yogurt person kefir moder uc current med step j pouch surgeri complet step complet step complet sickli uc free give man fish eat day teach man fish eat lifetim give man religion die pray fish mariamaria regular member join aug post post pm gmt tast good use coffe smoothi etc chug medicin purpos dx left side ulcer coliti jan current salofalk tablet scd fmt treatment sinc nov remiss sinc june royalflush new member join jan post post gmt find kefir milk tast like yogurt fan plain yogurt ad drop stevia ad stevia drop two pure vanilla extract grew tire pour drop mix drink clean put away take straight day grew accustom flavor big issu everi get yogurt face reaction ton better clean regard mix found mix well fruit smoothi tri veget smoothi drink coffe know thick though doubt would mix well plu sure hot water would affect kefir uniform charli veteran member join jul post post gmt happen know kefir bacteria elimin lactos milk assum could use anoth base diagnos proctosigmoid uc hiatial hernia w gerd current med lialda gm x daili duloxetin rowasa need vsl occasion one day multi vitamin curcumin occasion scd year lost willpow royalflush new member join jan post post gmt hi sinc research kefir howev stick head kefir consum lactos ferment process therefor lower lactos end product tangi end product lower amount remain lactos ferment hour aid get remain lactos low possibl shake glass jar coupl time hour period longer sit room temperatur longer ferment lower remain lactos recal long ferment recommend hour sit lot tangier bitter hour also recal kefir aid lactos digest like yogurt kefir produc symptom lactos intoler kefir bacteria help digest lactos rememb read studi involv small group take kefir fast think lactos intoler intoler group report less ga compar drink straight milk also measur ga particip breath hydrogen mayb show less ga digest tract scienc right began kefir extra ga guy found posit side effect date milk like side effect kefir milk lactos intoler howev consum dairi especi milk would wreck gut mrsmith new member join jan post post pm gmt never much success kefir still drink occas never significantli effect symptom far could tell addit whilst consum massiv amount kefir may transient shift balanc gut microbiom realiti nativ gut bacteria specialis surviv colon wherea microorgan found kefir quickli outcompet unabl perman colonis gut true almost everi probiot sourc investig need bacteria specialis live gut realist get faecal transplant',\n",
       " 'gotta go hospit blood test guy meant entyvio infus yesterday guy rang say pharmaci medic bit annoy massiv deal arrang next monday instead ibd nurs rang say blood test done sinc novemb sever test done inpati christma want go phone infus cancel go monday problem get blood done thank guy phone let know _',\n",
       " 'boot thank repli love sun make feel great watch skin happili sit sun hour sun cream everi minut even though told everi hour would enough give anyway sun best medicin ask person question say gilenya great come neuro believ becom spm obvious naiv thought work progress new lesion activ progress worri said thought activ paus want better word thank answer person',\n",
       " 'pentasa year everi time colonoscopi crohn progress final end hospit sever inflamm told gi doc pentasa probabl work back except mp realli altern month ago switch humira mani side effect pentasa howev',\n",
       " 'hi newli diagnos rrm consid treatment option see thread mavenclad cladribin wonder anyon experi newli licens drug seem attract treatment week year year wonder anyon start treatment think think current lean toward tecfidera read mani help post slightli put side effect difficult decid mani thank paula',\n",
       " 'mark cahil lead industri across europ work diabet center america special diabet eye diseas base dublin though continu laser lead thing get wors iv told ye jelli pull retina good wait see would mine stop pull bleed act vitrectomi laser clear jelli laser work get vessel properli blood vitreou henc vitrectomi laser op risk cours terrifi told wors risk vitrectomi allow retina continu pull eventu disast line trust god soon stabl bleed stop laser work month done click expand dread one question monday laser haemorrhag go keep tug reopen sure need laser near base abnorm grown vessel pull jelli fall away wither heard mani vitrectomi stori improv vision fix problem make want suggest anti vegf instead hope us stop point futur year get point hope minim loss vision hope recoveri stabilis happen soon x',\n",
       " 'amaz never need dmt found ocrevu gener ok infus mayb littl tire ok one time nice never choic dmt ms pretti intens right gate think gave great blog post',\n",
       " 'hi remi imuran year deep remis take everi week due infect week without infus luckili infect gone schedul monday make week feel scare might flare feel dull ach belli atm dont know crohn stress much also sooo scare get infus next week remicad wont work antibodi etc tip experi',\n",
       " 'ask hero ms specialist mani neurolog diseas trust noold nuero decis use ocrevu cure ms differ drug attack differ thing brain drug work well one person may work anoth well ocrevu would stick mani dmd crapshoot go latest pipelin first two dose ocrevu last month one drug time stick good luck',\n",
       " 'peopl taller longer abdomen usual experi high output problem sinc tall might reason slower output keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'thank much beav inform use read post humira seem suffici studi use around concept come across find sinc start humira think regularli least year',\n",
       " 'cnw competit bureau announc today close investig alleg abus domin janssen inc canadian pharmaceut compani own johnson johnson bureau investig consid whether janssen engag conduct shield biolog drug remicad competit biosimilar drug like inflectra renflexi includ alleg predatori price well conduct could exclud disadvantag biosimilar competitor care review fact bureau conclud insuffici evid demonstr janssen conduct substanti lessen prevent competit relev market therefor time bureau unabl conclud competit act contraven biosimilar drug rel new canada like play import role keep health cost futur biosimilar drug provid patient safe effect treatment option price often far lower origin biolog accordingli although bureau conclud investig continu close monitor canadian biolog biosimilar industri respond develop potenti disrupt competit critic sector economi bureau hesit take appropri action maintain promot competit pharmaceut industri detail bureau investig find pleas consult comprehens posit statement quot biosimilar vital competit pharmaceut industri offer canadian benefit lower price drug treatment cost upward thousand dollar year bureau take alleg harm competit serious vigilantli monitor conduct compani pharmaceut industri matthew boswel interim commission competit quick fact biolog drug deriv live organ tend complex tradit small molecul drug biosimilar drug highli similar version origin biolog biolog one fastest grow pharmaceut product segment canada high cost continu growth usag contribut signific increas pharmaceut expenditur first introduc remicad approv treatment number condit adult condit children includ crohn diseas ulcer coliti current two approv biosimilar remicad canada inflectra pfizer canada inc approv remicad adult indic renflexi merck canada inc approv remicad indic adult children conduct investig bureau gather evid obtain inform interview key market particip includ pharmaceut manufactur public privat insur hospit physician infus clinic network trade associ relat product competit bureau statement regard inquiri alleg anti competit conduct janssen associ link competit pharmaceut industri competit bureau independ law enforc agenc ensur canadian busi consum prosper competit innov marketplac www competitionbureau gc ca enquiri complaint stay connect sourc competit bureau',\n",
       " 'decemb ed tobia dozen diseas modifi therapi avail treat ms shot infus pill effect other market intellig compani spherix global insight regularli survey treatment use neurologist influenc select latest spherix quarterli survey show prescrib new ms patient half neurologist survey say choos pill first diseas modifi treatment relaps ms matter level diseas activ newli diagnos patient half survey neurologist treatment choic influenc level diseas activ patient diseas activ low percent group prefer pill tecfidera gilenya aubagio thirti nine percent prefer inject copaxon diseas activ high howev treatment choic one med consid highli effici gilenya tysabri ocrevu someon suffer needl fatigu use avonex mani year follow sever year tysabri infus lemtrada tell prefer oral med think ms patient would also prefer kind treatment like produc best outcom prefer pill click continu read',\n",
       " 'recommend product get guy found success prefer amazon get someth keep take stop problem come back mani mg take best time day take food thank advanc diagnos pancol march tri drug steroid mesalamin etc current vedolizumab new experiment gut specfic monoclon antibodi current entir colon heal except rectum recto sigmoid are stubborn noth seem work except high dose steroid',\n",
       " 'also fail remicad entyvio xeljanz month normal person last summer use bathroom x per day lot blood mucu etc sleep hour time mg prednison doctor scope recommend xeljanz last resort surgeri sort xeljanz script insur admit hospit iv steroid day left hospit feel lot better wait xeljanz start start mg x per day labor day us last year start notic improv coupl week noth drastic slow steadi improv start taper prednison goal start met goal day spare symptomat remiss gotten scope confirm clinic remiss go x morn like uc mayb later day blood mucu bloat ga cramp anyth els side effect one increas cholesterol went low ish total around stabl sinc xeljanz probabl save life good luck hope xeljanz done',\n",
       " 'realli want thing normal anyway never realli need normalci normal new normal typic sens normal live metastat cancer live well must say need develop mani strategi work around lot help definit worth qualiti life realli matter mayb strategi work other learn rememb energi limit import kind tricki move target day great energi deep deep odd tired day though wake get go go strong noon anybodi guess learn week longer abl push like alway old life done done kind like babi okay priorit sometim bonu time someth love love alway believ make great sens well lot thing love anymor yet normal okay discov love lot thing focus time one still like photographi natur mayb adjust learn new thing thing like write blog sure time read love read pretti much anyth four book go right one fiction two health relat one nonfict natur base none educ first short breath huf puf realli found good strategi except go slow steadi like much run spring determin walk new orthofeet sneaker digest system issu first start crizotinib took differ med system could toler imodium went everywher never knew bout diarrhea advanc notic usual pad dispos underwear extra cloth dispos wipe carri backpack everywher seem normal becam routin addit cloth tri rememb carri food know eat case eat avail queen lorlatinib current target therapi drug digest system issu much less time finger cross lorlatinib brought new challeng refer earlier one neuropathi common peopl chemotherapi drug peopl diabet much love go barefoot cannot even hous anyon inkl neuropathi feet start wear shoe slipper time learn hard way hand neuropathi tri acupunctur help tremend tri ointment cannabinoid oil found someth yet say give relief neuropathi wear glove work even drive keep feet well pad work best stand still long period time lot peel veggi thing sure bother fortun tri work luckili good sleeper bother much night oh ye ignor feel tick crawl ankl mayb probabl neuropathi best check spend lot time look ankl weight interest problem past year four month fire fall decid buy absolut need cloth becam sick began lose weight time start crizotinib march lost lb ever terribl overweight cancer take toll radiat number esophagu month eat much eat mostli liquid form food etc far cloth went thank radiat stand anyth near neck wear bra daughter bought size small stretchi pant v neck loos top prefer wardrob ever sinc eventu gain weight back crizotinib weight gain common drug idea store lorlatinib began juli everyon know target therapi drug still clinic trial problem degre start gain pound week ye one pound per week eeek simpli feel better eat abl exercis enough thank stretchi cloth move medium keep mind fire resolut bought need begin feel uncomfort extra weight januari gain sinc begin lorlatinib juli januari much pregnanc weight gain march januari lb weight gain pregnanc combin without even tri lose gain back plu final januari trial nurs mention someon success paleo diet tri wrote earlier paleo work immedi lost pound gain long feel well learn weight loss cancer treatment weight gain side effect common work around eat well wear comfi cloth final tri understand normal think mayb greatest lesson greatest bless gain journey okay let even ask other thing anyth someon els littl ill began truli understand gratitud express grate grate peopl care want thing make life easier brighter struggl someth life still want everyth feel badli ask help let someon els energi strength feel love grate like look thing brighten day late week go dana farber scan blood work brain mri ekg oncolog appoint dan drive wait patient everi step day post updat hope weekend prayer posit energi thought follow cancer journey give strength basebal softbal start children fun time grandpar find joy everyday everi day dan famili littl dachshund dotti matilda nigerian dwarf goat',\n",
       " 'repli post jrwilson thank final made back read close help doc basic let pick med want tri first go back forth potenti side effect worri whether newer med safe etc humira cimzia remicad option mention also take azathioprin six month someon hate take medic big deal',\n",
       " 'idea ocrelizumab avail europ ppm fair fda approv drug still wait lose brain',\n",
       " 'hi mastectomi gilenya surgeon hold gilenya day happi neutrophil count reduct white cell kept antibiot drain bit longer usual anyon interest dose reduct option evid heard ms research blog japanes use gilenya found women low bmi unfortun problem often got leukopaenia could manag prolong dose interv often altern day suggest neuro contact drug compani basic said recommend paper other found effect strategi make sens first principl long half life drug also time frame ecg monitor hold recomm week use hold day strategi get quicker lift wcc mostli success go troubl know except relaps current altern happi chang soon time work transit without rebound judi',\n",
       " 'hi candycan mean make ms wors frequent relaps gilenya new lesion gilenya [i]feeling[ i] like [i]symptoms[ i] wors sinc start feel like symptom wors without chang frequenc sever relaps number brain lesion someth els [i]your[ i] neuro say gilenya make ms wors base give impress gilenya [i]caused[ i] someon els exacerb',\n",
       " 'thank updat ipoop wonder uc thank alway us knowledg calm rational simmer linger inflamm load dose entyvio week sinc next dose next week realli anxiou see push total remiss form bm day day bit mild cramp dull pain lower left mucu blood still low energi tired appetit good gain weight coffe moder overal good oh prednison use canada night uceri foam morn post edit flowersg pm gmt',\n",
       " 'year old woman diagnos stage squamou cell lung cancer month ago shock one famili histori get start smoke switch ecig year ago contain nicotin start lose hair year ago everi time brush hair end littl gob brush ask doctor time told could caus number thing cancer never mention cancer doctor said candid keytruda treatment far go everi week receiv keytruda via v go nd treatment wednesday anyon get treatment numb sinc diagnosi strong believ lord day sign birth certif also sign death certif numb also peac whatev plan dad live get discuss friend ex sister law ear bend also one insist help everi way everyth els truli bless',\n",
       " 'hi blueberri great input janin mother similar situat age stage iv met diagnos feb start chemo switch crizotinib test alk posit reason well last scan show stabl situat sure get mother test mutat overal read peopl done quit well vari durat span sever year janin point mani option avail mother oncologist help navig toward feasibl option wish best thank dj',\n",
       " 'usual would mild flare year worst year ever sick origin put remicad lot side effect eventu built antibodi start humira pen shot hurt stomach take mg everi two week humira month say ucb symptom free never abl say thank humira save colon give life back',\n",
       " 'hi sameen sorri mother better deep vein thrombosi pericardi effus common symptom lung cancer neither typic side effect tagrisso mother oncologist would need explain keep mother drug probabl think wors drug drug caus mani side effect normal targisso go work know first week side effect manag treatment option reason enough give drug coupl week show hope show improv anti cancer treatment comfort care best janin',\n",
       " 'year updat analysi demonstr differ overal surviv os among patient local advanc non small cell lung cancer nsclc receiv prophylact cranial irradi pci compar observ alon limit statist power prevent definit conclus overal surviv benefit accord result phase trial present iaslc th world confer lung cancer toronto canada previou result trial show pci prolong diseas free surviv df reduc number brain metastas compar observ purpos analysi determin decad follow conclus trial use pci prolong os trial randomli assign patient stage iii nsclc progress surgeri radiat therapi without concurr chemotherapi patient treat pci receiv gy fraction primari endpoint os secondari endpoint includ df neurocognit function qualiti life relat articl impress cn respons osimertinib compar standard egfr tki patient cn metastas baselin pd pd l inhibitor may increas risk hyperprogress diseas nsclc plu carboplatin may effect nsclc patient interstiti lung diseas differ os pci observ arm median follow year entir cohort year live patient hazard ratio [hr] ci p author note current data power detect hypothes differ hr side signific level suggest definit conclus overal surviv cannot drawn data patient undergo surgeri howev pci result significantli prolong surviv compar observ hr ci p df remain improv pci compar observ hr ci p includ analysi nonsurg patient p patient observ arm time like develop brain metastas compar individu pci arm p although inform neurocognit function across cohort previous publish suggest pci significantli alter overal function year compar observ trend larger declin pci arm howev demonstr significantli greater declin hopkin verbal learn test immedi recal p delay recal p compar observ insuffici data evalu neurocognit function year updat analysi author conclud data indic pci continu significantli improv df reduc brain metastas note studi inadequ power detect os read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       " 'sorri work would done place hope steroid kick soon f uc symptom start januari diagnosi juli colonoscopi nd colonoscopi august confirm left side uc intoler mesalamin azathioprin remicad start feb discontinu bc antibodi sever joint pain predison sept nov dec jan march may juli',\n",
       " 'stellara imuran painkil requir',\n",
       " 'diagnos crohn month ago remicad sinc april insur recent switch inflectra cuz yay first inflectra infus past friday felt sinc today nauseat lighthead hold wall support cuz feel like go fall intens rn husband offer take er know reaction inflectra crohn symptom felt gener weak fatigu sinc infus usual tire rest day mayb hour never long feel kind like adjust imuran start novemb idea',\n",
       " 'six year remicad infus replac prior intak prednison must say quit effect howev year got shingl eye subsequ post herpet neuralgia still itch almost five year later august got cellul right arm pain infect requir seven day stay hospit antibiot follow week long iv administr home better stop remicad long enjoy remiss never return gi doc suggest entyvio like even heck broke fix wish tamper immun system bring disast',\n",
       " 'never respond antitnf drug tri simponi without respons probabl wait month move remicad also dud respons rate remicad highest biolog use treat uc get sleep think mg prednison would need sleep aid sinc abl get sleep get urgenc say uc treat hope get test result figur way go uc well manag see get sleep unfortun pill stop urgenc reduct inflamm order reduc need find treatment work one take seem trick moment tri rectal med eat earlier mesalamin higher dose pred tri get slower taper necessari stool test perhap bug need treatment co moder ulcer coliti diagnos pancol laryngopharyng reflux migrain battl extrem exhaust current med step one j pouch surgeri complet step two complet step complet',\n",
       " 'mavenclad licens defi worth look discuss ms team risk secondari autoimmun unlik lemtrada lemtrada remain one riskiest option term seriou side effect best long term result prevent brain atrophi tysabri riski jcv posit potenti rebound effect come lemtrada mavenclad perman chang immun system hope better good luck make choic',\n",
       " 'hello friend seek advic behalf mother gilotrif month first line treatment stage iv nsclc adenocarcinoma egfr exon never smoker respons initi posit recent medic seem less effect diseas shown progress given advanc age januari opt liquid biopsi test genet marker use genestrat test test unfortun came back neg realiz tissu biopsi conclus determin mutat depend site sampl fals neg still possibl use method greater chanc develop drug resist due mutat possibl posit enough circul tumor detect current sampl method find mutat easter egg hunt leav candid could potenti benefit question even though result mutat may neg new medic tagrisso still work germlin egfr genet marker would go far label treat tagrisso despit inclus result possibl drawback prescrib egfr chanc step would need prescrib tagrisso second line treatment label use treat egfr patient given condit tradit chemotherapi would overwhelm sincer chi topic modifi year month ago chidog topic modifi year month ago chidog',\n",
       " 'purpos report clinic outcom intravitr dexamethason implant patient retin pigmentosa cystoid macular edema method multicent retrospect case seri eye retin pigmentosa cystoid macular edema underw intravitr dexamethason implant primari outcom measur best correct visual acuiti logmar central macular thick statist analys use two tail comparison wilcoxon sign rank test result total eye patient mean age year rang mean follow plu sourc retina',\n",
       " 'hey everyon crohn small illieum believ call lol alreadi humira remicad crohn sinc remicad stop work doctor switch stelara get infus first time yesterday remaind time take shot first shot week sinc infus yesterday wonder long take stelara kick anyon experi side effect reach remiss anyth tell help thank',\n",
       " 'got luckiest guy aliv still aliv start broke rib lucki break led x ray spot lung discov gotten test symptom might well late alreadi stage iii back dark age option chemo radiat surgeri fortun combin chemo upper left lobectomi chemo enough leav ned almost five year diagnos cancer alreadi stage iv thousand spot everywher lung target genet treatment avail test neg two mutat treatabl time surgeon told get affair order oncologist admit best person treat lung cancer specialist even get clinic return phone call went anoth oncologist anoth system second time five year plan funer think month live start chemo test genet mutat part research protocol time test posit egfr mutat odd fals neg need get test reason finish chemo continu avastin kidney protest spill protein skyrocket blood pressur sometim avastin continu affect cancer cell long bodi case meant avastin alon seven month treatment eleven month tarceva month sinc cancer spread back hip radiat hip pain relief grate effect sinc time even use wheelchair get around back gym everi day next unbeliev good luck oncologist told cancer progress noth offer besid spot radiat chemo better inform next day got sign clinic trial azd tagrisso first appoint three day trial close new patient go let fact trial thousand mile away san diego live portland get way tagrisso month without progress grate everi day plan keep hang around next treatment need avail cure plan treat lung cancer chronic diseas rather death sentenc cancer also seriou impact qualiti life better gone close guard fierc independ person one learn alon share friend famili given could imagin return make easier keep open becom love prioriti clear know import peopl thing life result start share stori first email famili friend blog www dannwons com taken one step write book share stori learn find hope joy mean life love come much sharper relief past twelv year link http amzn hgi rt known first diagnos would know share complet stranger even miracl fact still aliv right track new treatment friend let best continu outrun cancer dann wonser twelv year stage iv lung cancer survivor still activ treatment public speaker member nation local committe lung cancer lobbi state feder congress usa lung cancer issu read dann journey websit live portland oregon',\n",
       " 'janet freeman daili cofound ro der write post respons comment seen recent privat facebook group ro posit ro cancer mani member ro cancer take target therapi crizotinib xalkori tyrosin kinas inhibitor tki approv us fda alk non small cell lung cancer nsclc ro nsclc mani alk ro nsclc patient long term stabil evid diseas ned crizotinib toler well patient suggest might take vacat crizotinib peopl chemo think could help avoid develop resist crizotinib could allow stay drug longer start take drug later cancer return oncologist might even agre idea pleas crizotinib xalkori work toler consult ro expert stop treatment doctor tell stop take crizotinib medic reason like sever side effect toxic temporarili surgeri radiat follow advic stop take crizotinib want drug vacat ro cancer rare diseas oncologist seen ro patient usual follow fast move research diseas dr ross camidg dr robert doebel among hand doctor treat dozen ro alk patient crizotinib global consid expert ro nsclc told think bad idea patient stop take xalkori ned stabl drug reason gave target therapi chemo tki inhibit cancer kill metastat cancer patient cancer cell like remain blood lymphat system bodi mean detect say evid diseas instead cancer free stop treatment stop inhibit cancer cell cancer remain resum grow sometim fast cell continu mutat guarante crizotinib effect cancer restart drug vacat tki flare well document egfr alk patient tki like xalkori tki flare patient tki stop take drug see cancer grow quickli week two restart drug alway work much evid may happen ned patient stop take tki except one studi studi egfr nsclc patient evid diseas tarceva tki like xalkori stop take cancer drug saw cancer return within year chronic myeloid leukemia cml patient tki gleevec abl stop take tki blood cancer aggress deadli lung cancer patient right make mind treatment case evid diseas crizotinib year ask stop crizotinib dr camidg told want stop take cancer drug go expert opinion share click share twitter open new window click share facebook open new window click share reddit open new window click share linkedin open new window click email friend open new window click share googl open new window like like load publish gray connect diagnos non small cell lung cancer may cancer becam metastat octob never smoke anyth except salmon evid diseas sinc januari thank precis medicin clinic trial patient anyon get lung cancer use engin degre mit sbme caltech aeronaut ms engr enjoy year career aerospac system engin technic translat sort research scientif engin subject help other understand new gizmo could benefit time left want use skill help other lung cancer increas visibl knowledg lung cancer among also studi brain research enjoy travel write scienc fiction geek sort scienc stuff',\n",
       " 'cannot express much medic help first prescrib terrifi review super pain sever psoriasi cover bodi given citrat free inject pen say felt noth mean noth thought inject yet prick psoriasi week treatment gone white scar wreck bodi remain medic incred liter chang life skin flake ooz get super red irrit sting everi movement like start medicin best part go websit sign humira card copay dollar five fricken dollar medic origin cost compani amaz nearli loss word effect painless citrat free formula report star post month ago rate humira adalimumab crohn diseas mainten report took humira remicad lower immun system develop tb start humira one shot hurt begin take feel like stomach crucifi top needl feel like spin went back remicad feel better ask doctor remicad humira less pain work better humira',\n",
       " 'stage nsclc adenocarcinoma bone metastasi start carboplatin alimta avastin chemo treatment wonder triplet effect treat bone metastasi well also receiv zoledron acid everi three week treat bone met limit public relat effect standard chemo bone metastasi found target drug erlotinib gifatinib effect treat bone metastasi afraid bone met progress would like find treatment bone met parallel chemo treatment probabl add gefitinib triplet found one paper discuss combo observ improv peopl involv trial thank irina',\n",
       " 'kidney stone referr get blast broken humira develop antibodi humira come stellara work differ way humira alongsid imuran ensur develop antibodi honestli tri follow reason diet alway succeed tri hope long',\n",
       " 'hello research internet month feel mayb time post dad stori dad recal ever take advil nevermind go see doctor start act strang begin august past summer forget thing distant strang mood bad feel told mom take emerg room got wors second week long stori short found night tumor lung brain biopsi later stage iv metatast melanoma braf mutat world gone complet upsid father rock famili one best men world found august th tumor lung brain never found site melanoma began found fact uncl grandfath dad side earli stage melanoma caught treat first plan action craniotomi earli septemb remov larg tumor leav two smaller one recov surgeri well set back pneumonia put icu day discov blood clot leg blood thinner depict bleed ulcer put filter blood clot ceas blood thinner steroid anti seizur medic antibiot pill ever seen dad even look anoth mri hospit discov one month surgeri inumer tumor growth brain octob th start mekinist tafinlar combo start work well mri decemb show diseas stabl tumor stabl smaller two grown littl shrunk disappear gain weight strength back hope combo target therapi shrunk tumor lung consider realli look forward januari mri howev could tell go good base eye chang start go backward cognit mental statu behavior got news last week mri show mani new tumor grow everi area final result progress diseas medic work brain stop take start whole brain radiat today day might chanc take combo ipilimumab nivolumab oncologist say danger chanc take life cancer point mani tumor brain gro agress sure much time left doctor seem amaz still us heard term week radiat know one tell much time reason feel import tri find except treasur everi day anyon insight advic word think need type tri focu thank listen',\n",
       " 'day hell saturday realli poorli chest infect three week due fingolimod immun system weak seem shift even antibiot last monday develop numb lower back accompani sever nerv pain discov go number two five day friday feel realli poorli went doctor gp thought could cauda equina syndrom thing never even heard basic nerv lower lumber compress lead symptom bladder bowel retent pain eventu becom complet incontin obvious scari fuck gp rang hospit want direct transfer said take symptom exactli meet criteria gp rang ms nurs royal free said speak one neurologist call back tell whether need go e final got call back gp told go e pm friday night like fuck sinc knew exactli expect anyway took e saturday morn yesterday begun hellish day wait till seen one doctor wait seen orthopaed doctor wait orthopaed doctor get advic registrar ish told go blue light ambul addenbrook hospit appar cauda equina syndrom treat immedi oper neurosurgeon affect cannot revers got addenbrook expect go straight mri scanner wait assess neurosurgeon third neurolog examin day wait till pm go actual mri scanner allow anyth eat whole time case need oper spinal cord absolut fuck terrifi mri pm enough need get back cambridg last train pm decid go pm call say cauda equina syndrom thing time got fourteen hour feck hospit still closer know heck caus numb thank symptom get better went gone work yesterday sunday happen everyon utter surpris need someth normal anyth doctor nurs blood test mri want feel like could blend disappear crazi appar cauda equina thing happen peopl ms anytim significantli frighten possibl fact anoth ladi ms investig thing thing anymor work pretend ok ill seem tarnish everyth life constantli hit invis forc field fatigu hand continu tremor despit medic think straight task eleven year walk without stick even though rememb day neuropath pain feel like alon island one reach tire drug mri doctor read ms text book life feel like slowli eb away catch flow like water hand see end want free',\n",
       " 'could pfizer xeljanz becom challeng abbvi humira tv ad crown pfizer anti inflammatori drug boast three indic spent million tv ad decemb behind perenni top spender humira million thank xeljanz new indic ulcer coliti got nod may ad rheumatoid arthriti psoriat arthriti nod last month pfizer unleash torrent ad spend back new indic spent million introductori ulcer coliti treatment commerci accord data real time tv ad tracker ispot tv humira competitor anti tnf drug unlik xeljanz first drug class jak inhibitor clear treat ulcer coliti one reason humira often lead pharma tv ad spend spread seriou cash across drug three indic arthriti psoriasi crohn ulcer coliti industri research veeva unifi clinic oper survey share thought quick survey first qualifi respond receiv amazon gift card appreci time qualifi survey respond enter draw win amazon gift card complet survey meanwhil pfizer prevnar continu season ad blitz pneumococc pneumonia vaccin follow eli lilli diabet med trulic johnson johnson xarelto drop sight third month row pfizer lyrica drug face patent expir spent million tv ad decemb overal tv ad spend pharma top decemb million fuel part chart topper humira xeljanz million uptick among top novemb finish million octob million humira movement stay abbvi anti inflammatori drug total estim spend million million novemb number spot seven three arthriti three ulcer coliti crohn one psoriasi biggest ticket ad bodi proof est million humira tv commerci bodi proof xeljanz xr movement move pfizer oral rheumatoid arthriti ulcer coliti med total estim spend million million novemb number spot five biggest ticket ad differ direct est million xeljanz tv commerci differ direct prevnar movement move pfizer pneumococc pneumonia vaccin total estim spend million million novemb number spot three biggest ticket ad miss life est million prevnar tv commerci miss life trulic movement move eli lilli glp diabet drug total estim spend million million novemb number spot three biggest ticket ad est million trulic tv commerci xarelto movement list last month johnson johnson next gen anticoagul total estim spend million number spot two biggest ticket ad select est million xarelto tv commerci select otezla movement move celgen oral treatment plaqu psoriasi total estim spend million million novemb number spot two biggest ticket ad littl thing est million commerci avail request advertis eliqui movement pfizer bristol myer squibb next gener anticoagul total estim spend million million novemb number spot three biggest ticket ad next est million eliqui tv commerci next jardianc movement list last month eli lilli boehring ingelheim sglt diabet treatment total estim spend million number spot one biggest ticket ad jardianc ask heart jardianc tv commerci jardianc ask heart ozemp movement list last month novo nordisk glp diabet med total estim spend million number spot three biggest ticket ad oh est million ozemp tv commerci oh latuda movement list last month sunovion pharmaceut antipsychot total estim spend million number spot one biggest ticket ad lauren stori',\n",
       " 'joan sorri hear diagnosi subsequ ill happi hear success stem cell would love know exactli kind improv experienc think fda realli target clinic offer day stem cell infus use adipos deriv materi like noth scam clinic separ expand mesenchym stem cell harvest dose administ like effect realli anxiou give ocrelizumab tri would suggest talk doctor rituxamab current avail use mechan action newer drug also appear lot safer use decad pretti good safeti record wish best gratifi know blog help even small way',\n",
       " 'hi diggiti trawl site look info experi differ dmd copaxon almost year neuro feel longer work well would like switch tecfidera gilenya lemtrada although neuro favour gilenya concern pregnanc risk current singl would hate jepodis small chanc may ever children go lemtrada end find lean toward tecfidera moment find much info lemtrada mani thank rachel',\n",
       " 'quick question wonder anyon experi share immuno target therapi sclc trial shown efficaci keytruda opdivo sclc certain circumst previous sign work sclc typic even test genet sequenc protein express etc process get test done pdl tmb genet sequenc anyon taken keytruda opdivo anyth els sclc result share experi anyth share would help',\n",
       " 'well know remicad work well consid anoth similar biolog within class remicad cimzia humira tnf alpha block biolog develop antibodi one tnf alpha blocker mean develop antibodi cimzia humira molecular structur differ enough immun system must start ground antibodi develop process might never develop antibodi cimzia humira could increas odd stelara complet differ class biolog complet differ mechan action gambl much like entyvio anoth entir differ class biolog aforement biolog class moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa two certainti life pay tax prednison side effect',\n",
       " 'agre kevinaki noth seem right ophthalmologist plan year ahead whatev eye condit may time span far long know eye respond treatment past standard regim eylea inject instanc load dose inject first year treatment today regim longer strictli follow perhap due cost cut mainli found alway necessari therefor benefici everybodi know avastin lucenti differ rule principl treatment inde get anoth opinion give sorri suffer much end save eyesight must sure worth take care let us know share worri concern rememb mani us gone though traumat time sympathis alon',\n",
       " 'hi sorri hear experi lucenti crvo year back vision got wors within week four week first eyelia improv eyelia doctor switch ozurdex even better result nd ozurdex four week back give idea improv drive licens eye test yesterday guess read letter last line well wish best hope eyelia work',\n",
       " 'new first time post wife diagnos nsclc stage alk mutat never smoker activ exercis full treatment carbo alimta plu year alimta mainten crizotinib year forc ceritinib due brain met balnc issu also time whole brain radiat mistak brain met size reduc stabl radiat ceritinib bone met shoulder palli rad bone met hip spine doc read bone scan believ size increas onc believ last scan wife confus short term memori loss notic along fast lost balanc use walker quick long last fatigu onc doc say noth lose tri alectinib point may help bone spine met brain met may caus balanc leg control alectinib start brain mri schedul check size met check alectinib work want second guess mayb wbr use ceritinib fear factor believ last longer expect met alreadi spine rib adren lymph behind retina initi diagnos respond well everi treatment wear know could affect wbr fear met spine caus issu also thought thank note till qualiti life pretti good thing consid',\n",
       " 'new site nsclc adenocarcinoma well diagnos juli cm mass right lung lymph node pleura took crizotinib chemo shrunk tumor stage met exon pneumonectomi right lung look long term survivor met exon know lucki thank god great doctor ucsf wish love hope heal',\n",
       " 'ye studi show wellbutrin effect control induc remiss uc patient sad read young one get diseas perhap consid entyvio gut specif half hour infus conveni prepar wait week see work wish strength resili',\n",
       " 'sure awar humira elev blood sugar slightli put prednison look crohn back lost coupl feet intestin thank bag boy month quit happi lose bag soon certain go problem retir made even happier middl manag problem deal folk want sell us medicar insur tend use one use fake local number get us answer block phone number show unannounc home stress reduc stress pretti low keep tri sure awar food caus problem gassi plant like cabbag broccoli limit caus problem found ad miralax coffe morn slightli smooth realli help common problem sure calcium supplement take mg vit daili calcium citrat potassium citrat recommend dr side benefit kidney stone attack last year',\n",
       " 'mother diagnos stage nsclc two year back progress recent lmd treat tagrix mg lmd gener work tagrisso effect stage know lmd control test need done',\n",
       " 'two step forward one huge step back sorri length time updat lot happen husband first treatment privat avastin inject notic improv week afterward enough get feet start walk last week see famili depress start lift bg level right insulin half stone healthi bmi could afford one round treatment privat transfer nh first appoint yesterday consult clinic seen dr consult absolut nightmar start finish despit warn husband anxieti issu fragil mental state dr complet insensit quit aggress approach realis cannot sugar coat thing tact way discuss prognosi even though husband seen improv first inject dr seem quit dismiss would see much improv understand guarante even consult cannot predict repond effect treatment came crush blow husband retreat bed want talk diagnosi non prolif retinopathi left eye sever prolif retinopathi right sever maculopathi eye right impair eye worst treatment plan eylea inject laser right begin intend speak pal monday see anyway see sympathet clinician next time honestli think husband could go struggl get wish could afford go whole thing privat anyon els similar experi click expand bibabe shame setback nh bit lotteri thing could use armouri upsid gp ask treatment transfer nomin consult want lead husband care step gp make referr specif see perereson omon team know person experi seen someon diabet eye relat incred impress gp ask would like see someon els know would like see made specif enquiri go rout potenti impact wait time person want see first appoint avail secondli rerceiv appoint call check see person one team impact wait time either way journey challeng pleas give',\n",
       " 'thank scohn dad exon delet ask stanford oncologist diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'hi skrri nnag lol well notic im sun notic weird floater hope due gilenya see small tini sign black fli dreami way danc air stop one area focu real thing fli far reach place tini usual small thing like put small dusti spot wall thing like besid im headach im tri co op take gilenya ive see invis color flater sinc childhood definit shape',\n",
       " 'oxford uk research kennedi institut nuffield depart orthopaed rheumatolog musculoskelet scienc univers oxford work clinician nh lothian found inject anti tnf drug adalimumab dupuytren diseas nodul result reduct cell characterist respons progress dupuytren diseas base laboratori data tumour necrosi factor tnf drive develop myofibroblast cell type caus dupuytren diseas research team explor effect anti tnf drug inject directli dupuytren nodul tissu result far promis data shown concentr formul adalimumab inject directli diseas tissu may effect target cell respons dupuytren diseas said jagdeep nanchah md phd univers oxford professor hand plastic reconstruct surgeri led studi bring new hope peopl suffer disabl condit current wait situat deterior watch hand lose function bad enough surgeri lengthi recoveri ahead less ideal situat find randomis trial phase recruit patient dupuytren diseas schedul surgeri edinburgh remov diseas tissu hand two week prior surgeri receiv singl inject vari dose anti tnf drug placebo tissu remov surgeri usual discard analys laboratori team found adalimumab dose mg formul ml reduc express fibrot marker smooth muscl actin sma type procollagen week post inject suggest drug could use stop growth diseas caus myofibroblast cell also found drug safe well toler find publish line journal ebiomedicin publish lancet dupuytren diseas common condit hand affect uk popul caus finger curl irrevers palm current nice approv treatment earli diseas typic peopl told return gp finger becom bent hand function impair anti tnf drug adalimumab humira current licens eu treatment number condit includ rheumatoid arthriti crohn diseas ulcer coliti overal excel safeti profil delight receiv fund wellcom trust depart health test whether adalimumab work patient earli stage dupuytren diseas said professor sir marc feldmann co author former director kennedi institut conjunct professor sir ravind maini sir marc identifi tnf therapeut target patient rheumatoid arthriti kennedi institut long histori success translat laboratori find clinic said professor fiona powri director institut type work requir close collabor laboratori scientist clinic trialist clinician scientist mani year research continu investig use drug treat dupuytren diseas phase b trial call ridd trial current run oxford edinburgh contact jagdeep nanchah jagdeep nanchah kennedi ox ac uk',\n",
       " 'love everi singl word especi humor humor one thing appreci right first ocrevu yesterday noth like tire rain debacl get sat huge surg nurs vanderbilt ms clinic pro calm also got hive back side lower abdomen itchi yeah beauti calm husband help calmli let nurs know kept small lid crazi bc other infus well ask sweet nurs repetit go die probabl time pro amaz paus ocrevu benedryl magic hive gone back home sleep thru observ one els room issu read post help would love hear second dose went will share thank',\n",
       " 'mechan differ target differ keytruda opdivo target pd checkpoint cell sensibl use togeth yervoy target anoth cell checkpoint ctla drug target differ molecul combin lung cancer addit yervoy opdivo increas respons rate two fold ido differ target protein catabol tryptophan product reaction creat immunosuppress environ tumor rational inhibit reaction mention chemo drug interest thing e g cyclohosphamid high concentr work inhibitor cell divis low concentr work treg immunosuppress cell mechan complet differ depend cyclohosphamid concentr mayb case ido inhibitor tri highest toler concentr get desir result know detail concoct',\n",
       " 'drug current remicad use take mp remicad made feel horribl also tri imuran past wonder take past perman made sensit sun rememb got rash past one anyon think entyvio would differ sinc target gut bought glove drive wonder allerg sunscreen ipoop forum moder join aug post post yesterday gmt long ago discontinu mp moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa shower thought peopl surpris see blood toilet paper uc patient surpris',\n",
       " 'vanessa relaps last told need chang medic betaferon work well enough chang tysabri gilenya relaps free sinc gilenya sinc septemb great inject year howev lower immun system care get infect ongo symptom relaps like dmt help stop progress good luck decis ann mari x',\n",
       " 'haha guess one use ocrevu plan drive hope feel ok afterward x',\n",
       " 'non small cell lung cancer nsclc spread far wide treat kind balanc act cure like slow aim reliev symptom improv qualiti life side effect possibl newer therapi help lot option today year ago number tumor overal health come play decid doctor start test learn nsclc help guid best treatment target therapi work best cancer come gene chang caus cell grow divid control mani gene often hard know one blame nsclc though doctor track culprit one known chang get target therapi mean take drug attack cancer cell specif way base gene differ doctor test look alk gene chang get drug help block alectinib alecensa brigatinib alunbrig crizotinib xalkori ceritinib zykadia lorlatinib lorbrena common side effect minor chang vision stomach upset throw diarrhea peopl problem fall milder side efgr gene chang get differ set drug one afatinib gilotrif dacomitinib vizimpro erlotinib tarceva gefitinib iressa osimertinib tagrisso slow fast tumor grow spread side effect includ skin rash diarrhea braf gene chang two main drug use one dabrafenib tafinlar trametinib mekinist work differ way effect may caus itch hair loss issu gene chang grow list gene defect caus nsclc target drug one reason look clinic trial research test new medicin immunotherapi make sens specif gene chang doctor check tumor cell level protein call pd l high immunotherapi often best place start use immun system bodi defens germ attack cancer cell take pembrolizumab keytruda drug help bodi see cancer cell someth fight like cold viru typic side effect includ tired cough stomach upset rash joint pain chemotherapi chemo standard treatment gene chang high pd l use drug kill cancer cell side effect includ hair loss mouth sore stomach upset sever chemo drug use nsclc best result doctor give two time bodi strong enough two even one help usual get four six cycl chemo take week finish treatment might keep take call mainten drug often anoth chemo medicin research show slow cancer help live longer doctor may also add drug along chemo med non squamou nsclc might also take pembrolizumab immunotherapi drug might get bevacizumab avastin anoth target drug may keep take one mainten drug squamou nsclc doctor might suggest target therapi drug necitumumab portrazza treatment brain bone area around lung common place cancer spread get specif care base end problem caus bone may get radiat curb pain caus fluid build around lung might need thin tube chest drain easili one place like brain adren gland might surgeri remov tumor chang treatment sometim first therapi tri work well hope still option start immunotherapi doctor may suggest chemo start one set chemo drug might tri anoth add target therapi depend health far cancer spread want treatment also want start approach call palli care earli aim keep comfort possibl help manag stress',\n",
       " 'u might relaps u spm natalizumab could inhibit relaps one thing thought also reduct inflamm natalizumab lemtrada ocrelizumab good someon post know anymor ocrelizumab rituximab extrem effect prevent gad lesion matter make anyway',\n",
       " 'hi sch welcom new site sorri hear uncl unusu mix result treatment howev month sinc last scan diagnos would difficult say happen could alreadi new met horizon alreadi grow larg enough pick scan first diagnos typic follow someon treatment ct scan everi month give better idea happen treatment except special situat pet realli go tell onc anyth ct ct much cheaper uncl suffer worsen symptom would reason continu keytruda howev overwhelm major peopl egfr mutat respond immunotherapi alon would continu combo alimta immunotherapi long side effect manag mani promis treatment trial mutat exon world link group specif connect share inform exon egfr often respond treatment grace member scohn much tune happen area wife mutat exon avail knowledg respons send messag dashboard http www exon group org hope uncl well best janin',\n",
       " 'breakthrough ibd research present crohn coliti congress la vega nv estim million american live inflammatori bowel diseas ibd includ crohn diseas ulcer coliti current cure diseas studi present crohn coliti congress partnership crohn coliti foundat american gastroenterolog associ la vega nv februari highlight advanc treatment patient ibd jak inhibitor continu expand reach ulcer coliti studi titl gut select oral administ pan jak inhibitor td demonstr favor safeti toler pharmacokinet signal clinic activ subject moder sever activ ulcer coliti w j sandborn univers california san diego et al signific need effect safe oral therapeut option moder sever ulcer coliti oral jak inhibitor potenti system immunosuppress pan jak inhibitor td design broad inhibitor jak pathway potenti advantag ulcer coliti larg topic effect demonstr earli signal efficaci moder sever ulcer coliti biolog therapi target immun cell traffick intestin effect signific ibd patient alreadi benefit therapi vedolizumab sever studi present crohn coliti congress highlight biolog also show promis treatment ulcer coliti crohn diseas etrolizumab treatment modul soluabl madcam level serum patient crohn diseas j mcbride genentech inc south san francisco california et al long term safeti efficaci anti mucos addressin cell adhes molecul madcam antibodi shp ulcer coliti open label extens studi turandot ii w j sandborn univers california san diego et al long term safeti efficaci pharmacokinet anti mucos addressin cell adhes molecul madcam monoclon antibodi shp crohn diseas opera ii studi w j sandborn univers california san diego et al abstract accept crohn coliti congress publish inflammatori bowel diseas offici journal crohn coliti foundat gastroenterolog offici journal american gastroenterolog associ feb attribut crohn coliti congress request coverag crohn coliti congress crohn coliti congress take place feb la vega combin strength nation lead ibd patient organ crohn coliti foundat premier gi profession associ american gastroenterolog associ aga togeth commit conven greatest mind ibd transform patient care crohn coliti congress must attend meet ibd profession learn http crohnscolitiscongress org aga institut american gastroenterolog associ trust voic gi commun found aga grown member around globe involv aspect scienc practic advanc gastroenterolog aga institut administ practic research educ program organ www gastro org like aga facebook follow us twitter amergastroassn check video youtub join aga linkedin crohn coliti foundat crohn coliti foundat mission cure crohn diseas ulcer coliti improv qualiti life children adult affect diseas foundat rank third among lead health non profit percentag expens devot research toward cure cent everi dollar foundat spend go mission critic program foundat consist meet standard organ monitor chariti includ better busi bureau wise give allianc give org american institut philanthropi charitywatch org',\n",
       " 'diagnos uc everi medic asa mp remicad humira current entyvio still symptom although better sinc start entyvio year ago right go time day urgenc half time qualiti life better still happi colonoscopi last year found dysplasia colon mean much higher risk develop colon cancer doctor recommend surgeri realli worri surgeri life look like afterward kind food drink avoid love cup coffe enjoy beer wine well toler surgeri also profession musician trombonist concern length recoveri time anyon els experi deal someth like mani thank hope move toward healthier life togeth cheer',\n",
       " 'start stelara fail remicad humira entyvio cimzia short span year cross finger caus think last option',\n",
       " 'crohn diseas also call ileiti enter affect part gut mouth way anu major case howev lower part small intestin ileum affect symptom unpleas includ intestin ulcer discomfort pain accord center diseas control prevent crohn diseas affect peopl per although crohn diseas typic start age start age symptom pain commonli felt lower right side abdomen affect mani area gut crohn diseas symptom vari depend part gut affect symptom often includ pain level pain vari individu depend inflamm gut commonli pain felt lower right side abdomen ulcer gut ulcer raw area gut may bleed bleed patient might notic blood stool mouth ulcer common symptom diarrhea rang mild sever sometim may mucu blood pu patient may get urg go find noth come fatigu individu often feel extrem tire fever also possibl fatigu alter appetit may time appetit low weight loss result loss appetit anemia loss blood lead anemia rectal bleed anal fissur skin anu becom crack lead pain bleed possibl symptom arthriti uveiti eye inflamm skin rash inflamm liver bile duct inflamm delay growth sexual develop children ulcer coliti vs crohn diseas ulcer coliti caus inflamm ulcer top layer line larg intestin layer intestin may inflam ulcer crohn diseas also inflamm occur crohn diseas anywher along gut ulcer coliti appear larg intestin colon rectum crohn diseas patient bowel normal healthi section diseas part wherea ulcer coliti damag appear continu pattern diet children crohn diseas might need high calori liquid formula especi growth affect patient crohn diseas say follow food increas diarrhea cramp bulki grain dairi product spici food alcohol peopl feel like eat sever case may need feed intraven short period treatment bulki grain like contain bread worsen crohn diseas treatment may involv medic surgeri nutrit supplement aim control inflamm correct nutrit problem reliev symptom cure crohn diseas treatment help reduc number time patient experi recurr crohn diseas treatment depend inflamm situat sever diseas complic patient respons previou treatment recur symptom peopl long period even year without symptom known remiss howev usual recurr period remiss vari much hard know effect treatment imposs predict long period remiss go best food crohn diseas flare eat right food help peopl manag symptom crohn diseas find read medic crohn diseas anti inflamm drug doctor like start mesalamin sulfasalazin help control inflamm cortison steroid corticosteroid drug contain cortison steroid antibiot fistula strictur prior surgeri may caus bacteri overgrowth doctor gener treat prescrib ampicillin sulfonamid cephalosporin tetracyclin metronidazol anti diarrheal fluid replac inflamm subsid diarrhea usual becom less problem howev sometim patient may need someth diarrhea abdomin pain biolog biolog new type drug scientist develop live organ reduc bodi immun respons target protein lead inflamm biolog appear help peopl crohn diseas exampl biolog crohn includ infliximab remicad adalimumab humira mercaptopurin purinethol methotrex imuran azathioprin certolizumab pegol cimzia biolog treatment side effect includ vomit nausea weaker resist infect studi suggest use biolog reduc chanc person need abdomin surgeri within year percent introduct biolog research put figur percent biolog also appear reduc risk advers effect aris person use corticosteroid differ type biolog drug individu react differ doctor recommend suitabl option may suggest tri altern combin drug first one work surgeri major crohn diseas patient may need surgeri point medic longer control symptom solut oper surgeri reliev symptom respond medic correct complic abscess perfor bleed blockag remov part intestin help cure crohn diseas inflamm often return area next affect part gut remov crohn diseas patient may requir one oper live case colectomi need whole colon remov surgeon make small open front abdomin wall tip ileum brought skin surfac form open call stoma fece exit bodi stoma pouch collect fece doctor say patient stoma carri lead normal activ life surgeon remov diseas section intestin connect intestin stoma need patient doctor need consid surgeri care appropri everyon patient bear mind oper diseas recur peopl crohn diseas live normal activ live hold job rais famili function success caus exact caus crohn diseas unclear thought stem abnorm reaction immun system theori immun system attack food good bacteria benefici substanc unwant substanc attack white blood cell build line gut buildup trigger inflamm inflamm lead ulcer bowel injuri howev unclear whether abnorm immun system caus crohn diseas result factor may increas risk inflamm includ genet factor individu immun system environment factor around peopl crohn close rel condit ident twin crohn diseas twin percent chanc bacterium viru may play role e coli bacteria link crohn diseas instanc smoke anoth risk factor diagnosi doctor ask person sign symptom physic examin may reveal lump abdomen caus loop inflam bowel becom stuck togeth follow test may help diagnosi stool blood test biopsi sigmoidoscopi short flexibl tube sigmoidoscop use investig lower bowel colonoscopi long flexibl tube colonoscop use investig colon endoscopi symptom occur upper part gut long thin flexibl telescop endoscop goe esophagu stomach ct scan barium enema x ray reveal chang insid bowel complic symptom sever frequent likelihood complic higher follow complic may requir surgeri intern bleed strictur part gut narrow caus build scar tissu partial complet blockag intestin perfor small hole develop wall gut content leak caus infect abscess fistula channel form two part gut may also persist iron defici food absorpt problem slightli higher risk develop bowel cancer relat coverag crohn diseas pregnanc crohn diseas pregnanc affect howev women conceiv crohn diseas remiss normal pregnanc healthi babi learn read crohn diseas surgeri know surgeri cannot cure crohn diseas help reduc person symptom prevent life threaten complic articl learn differ type crohn diseas surgeri prepar expect recoveri read diet tip crohn diseas crohn diseas affect gastrointestin tract choic diet nutrit may make differ individu feel spici food alcohol fatti sugari item exampl trigger flare peopl find dietari tip recommend may help manag condit read expect crohn infus crohn infus medic call biolog help reduc crohn symptom learn type crohn infus side effect expect read stage crohn diseas crohn diseas caus chronic inflamm digest tract although crohn diseas tend get wors time symptom vari consider may sometim disappear week even year reason doctor usual classifi crohn differ stage learn read email email print share share crohn ibd gastrointestin gastroenterolog immun system vaccin addit inform articl last updat yvett brazier wed decemb visit crohn ibd categori page latest news subject sign newslett receiv latest updat crohn ibd refer avail refer tab refer content requir javascript enabl baumgart dogan b rishniw weitzman g bosworth b yantiss r berg cultur independ analysi ileal mucosa reveal select increas invas escherichia coli novel phylogeni rel deplet clostridial crohn diseas involv ileum ism journal retriev http www natur com ismej journal v n ab ismej html crohn diseas n american societi colon rectal surgeon retriev http www fascr org patient diseas condit crohn diseas crohn diseas caus april retriev http www nh uk condit crohn diseas page caus aspx epidemiolog ibd march cdc retriev http www cdc gov ibd ibd epidemiolog htm leena halm paulina paavola sakki ulla turunen maarit lappalaccinen martti f rkkil kimmo kontula june world journal gastroenterolog retriev http www ncbi nlm nih gov pmc articl pmc lichtenstein g r loftu e v isaac k l regueiro gerson l b sand b e march manag crohn diseas adult american colleg gastroenterolog retriev http gi org guidelin manag crohn diseas adult crohn diseas n cleveland clinic retriev http clevelandclin org health articl crohn diseas citat pleas use one follow format cite articl essay paper report mla nordqvist christian crohn diseas medic news today medilexicon intl dec web feb http www medicalnewstoday com articl php apa nordqvist c decemb crohn diseas medic news today retriev http www medicalnewstoday com articl php pleas note author inform provid sourc cite instead recommend relat news latest news acupunctur may reduc menopaus symptom recent studi investig whether acupunctur might use nonpharmaceut way minim symptom occur menopaus japanes plant could hold key extend youth new research find compound tradit japanes medicin plant could boost cellular health protect ill effect age bacteria live insect could provid new antibiot insect harbor bacteria protect infect tap sourc could yield new antibiot combat grow threat drug resist halt cellular age new drug combo show promis first clinic trial human research test promis drug combin could help fight effect cellular age aggress brain cancer immunotherapi fail new research help explain glioblastoma tumor respond immunotherapi wherea major aggress cancer',\n",
       " 'upal basu roy mph phd senior director research non small cell lung cancer nsclc common type lung cancer compris diagnos case lung cancer treatment nsclc depend stage diseas stage iii nsclc primari origin tumor larg cancer spread lymph node center chest lymph node side primari tumor stage nsclc often refer local advanc lung cancer divid stage iiia iiib iiic base lymph node affect size primari tumor read lung cancer stage us food drug administr approv immunotherapi drug durvalumab also known brand name imfinzi treatment local advanc stage iii nsclc follow definit chemoradi base result pacif trial unlik immunotherapi approv stage iv metastat nsclc durvalumab first immunotherapi approv subset nsclc patient sat patrick ford md mb bch associ professor oncolog john hopkin school medicin discuss result pacif trial mean survivor commun dr ford expert immunotherapi lung cancer led sever global phase immunotherapi clinic trial produc webinar convers watch stage iii nsclc tradit treat definit concurr chemoradi approxim one third nsclc patient stage iii local advanc diseas diagnosi stage iii highli heterogen treatment may involv surgeri chemotherapi chemoradi definit concurr chemoradi without surgeri choic treatment patient jointli made patient healthcar team includ medic oncologist [who provid cancer treatment drugs] surgic oncologist [who provid cancer treatment surgery] radiat oncologist [who provid cancer treatment radiation] definit concurr chemoradi defin chemotherapi radiat therapi combin treatment patient receiv radiat therapi day chemotherapi infus understand radiat therapi significantli advanc past decad radiat therapi often administ intens modul radiat therapi imrt intens radiat adapt match precis shape size tumor minim damag surround tissu heart lung pacif trial result pacif trial chang approach treat stage iii nsclc though stage iii patient respond chemoradi chanc cancer recur quit high pacif trial design test whether addit immunotherapi drug durvalumab patient complet chemoradi decreas chanc recurr result pacif trial indic patient receiv durvalumab chemoradi higher progress free surviv pf overal surviv os addit durvalumab almost tripl pf patient aliv month treatment base highli promis result treatment durvalumab becom standard care stage iii patient receiv definit concurr chemoradi test immunotherapi biomark pd l requir us ongo studi determin patient may deriv benefit other drug durvalumab work enhanc chemoradi tradit use alon treatment stage iii nsclc durvalumab human monoclon antibodi block program death ligand pd l protein tumor cell patient receiv chemoradi treatment lead gradual kill lung cancer tumor antigen releas blood circul attract immun cell cancer howev cancer cell escap immun system produc high level pd l protein durvalumab block pd l unmask cancer cell provid addit attack tumor chemoradi imag courtesi dr ford immunotherapi chemoradi differ immunotherapi har patient immun system fight cancer wherea chemoradi directli kill cancer cell stage iii nsclc chemoradi follow durvalumab deliv one two punch lung cancer side effect patient expect start durvalumab side effect durvalumab compar pd pd l block antibodi howev unlik immunotherapi durvalumab administ patient complet chemoradi treatment may residu side effect chemoradi patient healthcar team discuss best manag residu side effect gener seriou side effect durvalumab rare common side effect see clinic manag easili among may fatigu musculoskelet pain chang hormon level decreas appetit nausea accumul fluid caus swell lower leg hand stage iii nsclc patient may candid chemoradi may use discuss durvalumab may treatment option start treatment also invit check new free download patient educ booklet stage iii nsclc educ activ made possibl grant astra zeneca relat read immunotherapi stage iii lung cancer improv cure rate radiat drug dispel myth surround clinic trial cancer dr basu roy lungev senior director research categori clinic trial research immunotherapi non small cell lung cancer nsclc',\n",
       " 'colon part bodi digest system digest system remov process nutrient vitamin miner carbohydr fat protein water food help pass wast materi bodi digest system made esophagu stomach small larg intestin colon larg bowel first part larg intestin feet long togeth rectum anal canal make last part larg intestin inch long anal canal end anu open larg intestin outsid bodi enlarg anatomi lower digest system show colon organ gastrointestin stromal tumor occur colon see pdq summari gastrointestin stromal tumor treatment inform see pdq summari unusu cancer childhood treatment inform colorect cancer children health histori affect risk develop colon cancer anyth increas chanc get diseas call risk factor risk factor mean get cancer risk factor mean get cancer talk doctor think may risk colorect cancer risk factor colorect cancer includ follow famili histori colon rectal cancer first degre rel parent sibl child person histori cancer colon rectum ovari person histori high risk adenoma colorect polyp centimet larger size cell look abnorm microscop inherit chang certain gene increas risk famili adenomat polyposi fap lynch syndrom hereditari nonpolyposi colorect cancer person histori chronic ulcer coliti crohn diseas year three alcohol drink per day smoke cigarett black obes older age main risk factor cancer chanc get cancer increas get older enlarg polyp colon polyp stalk other inset show photo polyp stalk sign colon cancer includ blood stool chang bowel habit sign symptom may caus colon cancer condit check doctor follow chang bowel habit blood either bright red dark stool diarrhea constip feel bowel empti way stool narrow usual frequent ga pain bloat full cramp weight loss known reason feel tire vomit test examin colon rectum use detect find diagnos colon cancer follow test procedur may use physic exam histori exam bodi check gener sign health includ check sign diseas lump anyth els seem unusu histori patient health habit past ill treatment also taken digit rectal exam exam rectum doctor nurs insert lubric glove finger rectum feel lump anyth els seem unusu fecal occult blood test fobt test check stool solid wast blood seen microscop small sampl stool place special card special contain return doctor laboratori test blood stool may sign polyp cancer condit two type fobt guaiac fobt sampl stool special card test chemic blood stool special card chang color enlarg guaiac fecal occult blood test fobt check occult hidden blood stool small sampl stool place special card return doctor laboratori test immunochem fobt liquid ad stool sampl mixtur inject machin contain antibodi detect blood stool blood stool line appear window machin test also call fecal immunochem test fit enlarg fecal immunochem test fit check occult hidden blood stool small sampl stool place special collect tube special card return doctor laboratori test barium enema seri x ray lower gastrointestin tract liquid contain barium silver white metal compound put rectum barium coat lower gastrointestin tract x ray taken procedur also call lower gi seri enlarg barium enema procedur patient lie x ray tabl barium liquid put rectum flow colon x ray taken look abnorm area sigmoidoscopi procedur look insid rectum sigmoid lower colon polyp small area bulg tissu abnorm area cancer sigmoidoscop insert rectum sigmoid colon sigmoidoscop thin tube like instrument light len view may also tool remov polyp tissu sampl check microscop sign cancer enlarg sigmoidoscopi thin light tube insert anu rectum lower part colon look abnorm area colonoscopi procedur look insid rectum colon polyp abnorm area cancer colonoscop insert rectum colon colonoscop thin tube like instrument light len view may also tool remov polyp tissu sampl check microscop sign cancer enlarg colonoscopi thin light tube insert anu rectum colon look abnorm area virtual colonoscopi procedur use seri x ray call comput tomographi make seri pictur colon comput put pictur togeth creat detail imag may show polyp anyth els seem unusu insid surfac colon test also call colonographi ct colonographi biopsi remov cell tissu view microscop pathologist check sign cancer certain factor affect prognosi chanc recoveri treatment option prognosi chanc recoveri treatment option depend follow stage cancer whether cancer inner line colon spread colon wall spread lymph node place bodi whether cancer block made hole colon whether cancer cell left surgeri whether cancer recur patient gener health prognosi also depend blood level carcinoembryon antigen cea treatment begin cea substanc blood may increas cancer present stage colon cancer key point colon cancer diagnos test done find cancer cell spread within colon part bodi three way cancer spread bodi cancer may spread began part bodi follow stage use colon cancer stage carcinoma situ stage stage ii stage iii stage iv colon cancer diagnos test done find cancer cell spread within colon part bodi process use find cancer spread within colon part bodi call stage inform gather stage process determin stage diseas import know stage order plan treatment follow test procedur may use stage process ct scan cat scan procedur make seri detail pictur area insid bodi abdomen pelvi chest taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi mri magnet reson imag procedur use magnet radio wave comput make seri detail pictur area insid colon substanc call gadolinium inject patient vein gadolinium collect around cancer cell show brighter pictur procedur also call nuclear magnet reson imag nmri pet scan positron emiss tomographi scan procedur find malign tumor cell bodi small amount radioact glucos sugar inject vein pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell chest x ray x ray organ bone insid chest x ray type energi beam go bodi onto film make pictur area insid bodi surgeri procedur remov tumor see far spread colon lymph node biopsi remov part lymph node pathologist view lymph node tissu microscop check cancer cell may done surgeri endoscop ultrasound guid fine needl aspir biopsi complet blood count cbc procedur sampl blood drawn check follow number red blood cell white blood cell platelet amount hemoglobin protein carri oxygen red blood cell portion blood sampl made red blood cell carcinoembryon antigen cea assay test measur level cea blood cea releas bloodstream cancer cell normal cell found higher normal amount sign colon cancer condit three way cancer spread bodi cancer spread tissu lymph system blood tissu cancer spread began grow nearbi area lymph system cancer spread began get lymph system cancer travel lymph vessel part bodi blood cancer spread began get blood cancer travel blood vessel part bodi cancer may spread began part bodi cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi metastat tumor type cancer primari tumor exampl colon cancer spread lung cancer cell lung actual colon cancer cell diseas metastat colon cancer lung cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ call metastat cancer anim show cancer cell travel place bodi first form part bodi follow stage use colon cancer stage carcinoma situ enlarg stage colon carcinoma situ abnorm cell shown mucosa colon wall stage abnorm cell found mucosa innermost layer colon wall abnorm cell may becom cancer spread nearbi normal tissu stage also call carcinoma situ stage enlarg stage colon cancer cancer spread mucosa colon wall submucosa muscl layer stage colon cancer cancer form mucosa innermost layer colon wall spread submucosa layer tissu next mucosa muscl layer colon wall stage ii enlarg stage ii colon cancer stage iia cancer spread muscl layer colon wall serosa stage iib cancer spread serosa spread nearbi organ stage iic cancer spread serosa nearbi organ stage ii colon cancer divid stage iia iib iic stage iia cancer spread muscl layer colon wall serosa outermost layer colon wall stage iib cancer spread serosa outermost layer colon wall tissu line organ abdomen viscer peritoneum stage iic cancer spread serosa outermost layer colon wall nearbi organ stage iii stage iii colon cancer divid stage iiia iiib iiic enlarg stage iiia colon cancer cancer spread mucosa colon wall submucosa may spread muscl layer spread one three nearbi lymph node tissu near lymph node cancer spread mucosa submucosa four six nearbi lymph node stage iiia cancer spread mucosa innermost layer colon wall submucosa layer tissu next mucosa muscl layer colon wall cancer spread one three nearbi lymph node cancer cell form tissu near lymph node mucosa innermost layer colon wall submucosa layer tissu next mucosa cancer spread four six nearbi lymph node enlarg stage iiib colon cancer cancer spread muscl layer colon wall serosa spread serosa nearbi organ cancer spread one three nearbi lymph node tissu near lymph node cancer spread muscl layer serosa four six nearbi lymph node cancer spread mucosa submucosa may spread muscl layer cancer spread seven nearbi lymph node stage iiib cancer spread muscl layer colon wall serosa outermost layer colon wall spread serosa tissu line organ abdomen viscer peritoneum cancer spread one three nearbi lymph node cancer cell form tissu near lymph node muscl layer serosa outermost layer colon wall cancer spread four six nearbi lymph node mucosa innermost layer colon wall submucosa layer tissu next mucosa muscl layer colon wall cancer spread seven nearbi lymph node enlarg stage iiic colon cancer cancer spread serosa colon wall nearbi organ cancer spread four six nearbi lymph node cancer spread muscl layer serosa spread serosa nearbi organ cancer spread seven nearbi lymph node cancer spread serosa nearbi organ one nearbi lymph node tissu near lymph node stage iiic cancer spread serosa outermost layer colon wall tissu line organ abdomen viscer peritoneum cancer spread four six nearbi lymph node muscl layer colon wall serosa outermost layer colon wall spread serosa tissu line organ abdomen viscer peritoneum cancer spread seven nearbi lymph node serosa outermost layer colon wall nearbi organ cancer spread one nearbi lymph node cancer cell form tissu near lymph node stage iv enlarg stage iv colon cancer cancer spread blood lymph node part bodi lung liver abdomin wall ovari stage iv colon cancer divid stage iva ivb ivc stage iva cancer spread one area organ near colon liver lung ovari distant lymph node stage ivb cancer spread one area organ near colon liver lung ovari distant lymph node stage ivc cancer spread tissu line wall abdomen may spread area organ recurr colon cancer recurr colon cancer cancer recur come back treat cancer may come back colon part bodi liver lung treatment option overview key point differ type treatment patient colon cancer seven type standard treatment use surgeri radiofrequ ablat cryosurgeri chemotherapi radiat therapi target therapi immunotherapi new type treatment test clinic trial treatment colon cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment follow test may need differ type treatment patient colon cancer differ type treatment avail patient colon cancer treatment standard current use treatment test clinic trial treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial clinic trial open patient start treatment seven type standard treatment use surgeri surgeri remov cancer oper common treatment stage colon cancer doctor may remov cancer use one follow type surgeri local excis cancer found earli stage doctor may remov without cut abdomin wall instead doctor may put tube cut tool rectum colon cut cancer call local excis cancer found polyp small bulg area tissu oper call polypectomi resect colon anastomosi cancer larger doctor perform partial colectomi remov cancer small amount healthi tissu around doctor may perform anastomosi sew healthi part colon togeth doctor also usual remov lymph node near colon examin microscop see whether contain cancer enlarg resect colon anastomosi part colon contain cancer nearbi healthi tissu remov cut end colon join resect colon colostomi doctor abl sew end colon back togeth stoma open made outsid bodi wast pass procedur call colostomi bag place around stoma collect wast sometim colostomi need lower colon heal revers doctor need remov entir lower colon howev colostomi may perman enlarg colon cancer surgeri colostomi part colon contain cancer nearbi healthi tissu remov stoma creat colostomi bag attach stoma doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiofrequ ablat radiofrequ ablat use special probe tini electrod kill cancer cell sometim probe insert directli skin local anesthesia need case probe insert incis abdomen done hospit gener anesthesia cryosurgeri cryosurgeri treatment use instrument freez destroy abnorm tissu type treatment also call cryotherapi chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi chemotherapi place directli cerebrospin fluid organ bodi caviti abdomen drug mainli affect cancer cell area region chemotherapi chemoembol hepat arteri may use treat cancer spread liver involv block hepat arteri main arteri suppli blood liver inject anticanc drug blockag liver liver arteri deliv drug throughout liver small amount drug reach part bodi blockag may temporari perman depend use block arteri liver continu receiv blood hepat portal vein carri blood stomach intestin way chemotherapi given depend type stage cancer treat see drug approv colon rectal cancer inform radiat therapi radiat therapi cancer treatment use high energi x ray type radiat kill cancer cell keep grow two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place directli near cancer way radiat therapi given depend type stage cancer treat extern radiat therapi use palli therapi reliev symptom improv qualiti life target therapi target therapi type treatment use drug substanc identifi attack specif cancer cell without harm normal cell type target therapi use treatment colon cancer includ follow monoclon antibodi monoclon antibodi made laboratori singl type immun system cell antibodi identifi substanc cancer cell normal substanc may help cancer cell grow antibodi attach substanc kill cancer cell block growth keep spread monoclon antibodi given infus may use alon carri drug toxin radioact materi directli cancer cell differ type monoclon antibodi therapi vascular endotheli growth factor vegf inhibitor therapi cancer cell make substanc call vegf caus new blood vessel form angiogenesi help cancer grow vegf inhibitor block vegf stop new blood vessel form may kill cancer cell need new blood vessel grow bevacizumab ramucirumab vegf inhibitor angiogenesi inhibitor epiderm growth factor receptor egfr inhibitor therapi egfr protein found surfac certain cell includ cancer cell epiderm growth factor attach egfr surfac cell caus cell grow divid egfr inhibitor block receptor stop epiderm growth factor attach cancer cell stop cancer cell grow divid cetuximab panitumumab egfr inhibitor angiogenesi inhibitor angiogenesi inhibitor stop growth new blood vessel tumor need grow ziv aflibercept vascular endotheli growth factor trap block enzym need growth new blood vessel tumor regorafenib use treat colorect cancer spread part bodi gotten better treatment block action certain protein includ vascular endotheli growth factor may help keep cancer cell grow may kill may also prevent growth new blood vessel tumor need grow see drug approv colon rectal cancer inform immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi pd protein surfac cell help keep bodi immun respons check pd attach anoth protein call pdl cancer cell stop cell kill cancer cell pd inhibitor attach pdl allow cell kill cancer cell pembrolizumab type immun checkpoint inhibitor enlarg immun checkpoint inhibitor checkpoint protein pd l tumor cell pd cell help keep immun respons check bind pd l pd keep cell kill tumor cell bodi left panel block bind pd l pd immun checkpoint inhibitor anti pd l anti pd allow cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv colon rectal cancer inform new type treatment test clinic trial inform clinic trial avail nci websit treatment colon cancer may caus side effect inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment clinic trial includ patient yet receiv treatment trial test treatment patient whose cancer gotten better also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found nci clinic trial search webpag clinic trial support organ found clinicaltri gov websit follow test may need test done diagnos cancer find stage cancer may repeat test repeat order see well treatment work decis whether continu chang stop treatment may base result test test continu done time time treatment end result test show condit chang cancer recur come back test sometim call follow test check up treatment option colon cancer inform treatment list see treatment option overview section stage carcinoma situ treatment stage carcinoma situ may includ follow type surgeri local excis simpl polypectomi resect anastomosi done tumor larg remov local excis use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage colon cancer treatment stage colon cancer usual includ follow resect anastomosi use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage ii colon cancer treatment stage ii colon cancer may includ follow resect anastomosi use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage iii colon cancer treatment stage iii colon cancer may includ follow resect anastomosi may follow chemotherapi clinic trial new chemotherapi regimen surgeri use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage iv recurr colon cancer treatment stage iv recurr colon cancer may includ follow local excis tumor recur resect without anastomosi surgeri remov part organ liver lung ovari cancer may recur spread treatment cancer spread liver may also includ follow chemotherapi given surgeri shrink tumor surgeri radiofrequ ablat cryosurgeri patient cannot surgeri chemoembol hepat arteri radiat therapi chemotherapi may offer patient palli therapi reliev symptom improv qualiti life chemotherapi target therapi monoclon antibodi angiogenesi inhibitor immunotherapi clinic trial chemotherapi target therapi use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail learn colon cancer inform nation cancer institut colon cancer see follow colorect cancer home page colorect cancer prevent colorect cancer screen test detect colorect cancer polyp unusu cancer childhood treatment cryosurgeri cancer treatment drug approv colon rectal cancer target cancer therapi genet test hereditari cancer syndrom gener cancer inform resourc nation cancer institut see follow cancer stage chemotherapi support peopl cancer radiat therapi support peopl cancer cope cancer question ask doctor cancer survivor caregiv pdq summari pdq physician data queri pdq nation cancer institut nci comprehens cancer inform databas pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin summari come two version health profession version detail inform written technic languag patient version written easi understand nontechn languag version cancer inform accur date version also avail spanish pdq servic nci nci part nation institut health nih nih feder govern center biomed research pdq summari base independ review medic literatur polici statement nci nih purpos summari pdq cancer inform summari current inform treatment colon cancer meant inform help patient famili caregiv give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date board made expert cancer treatment specialti relat cancer summari review regularli chang made new inform date summari updat date recent chang inform patient summari taken health profession version review regularli updat need pdq adult treatment editori board clinic trial inform clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori trial answer certain scientif question order find new better way help cancer patient treatment clinic trial inform collect effect new treatment well work clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial clinic trial open patient start treatment clinic trial list pdq found onlin nci websit inform call cancer inform servic cancer permiss use summari pdq regist trademark content pdq document use freeli text cannot identifi nci pdq cancer inform summari unless whole summari shown updat regularli howev user would allow write sentenc nci pdq cancer inform summari breast cancer prevent state risk follow way [includ excerpt summary] best way cite pdq summari pdq adult treatment editori board pdq colon cancer treatment bethesda md nation cancer institut updat mm dd yyyi avail http www cancer gov type colorect patient colon treatment pdq access mm dd yyyi [pmid ] imag summari use permiss author artist publish use pdq summari want use imag pdq summari use whole summari must get permiss owner cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim inform summari use make decis insur reimburs inform insur coverag avail cancer gov manag cancer care page contact us inform contact us receiv help cancer gov websit found contact us help page question also submit cancer gov websit e mail us',\n",
       " 'sorri hear diseas still activ ncot sure challeng case unrel diseas activ ask get stelara xeljanz ask clinic trial go join lot new med clinic trial right would think london area opportun esophag transit time surprisingli slow achalasia symptom feel food stuck esophagu food like mash potato peanut butter stomach time within reason small bowel time also slow like esophagu interest know drug speed transit time know often use',\n",
       " 'recent stress fractur right th metatars bone traumat event caus appear metastat though bone met pelvic bone rib due stage alk nsclc wore boot week heal zometa xgeva past year sinc diagnosi brigatinib sinc juli year mainten alimta round taxol carboplatin start treatment know possibl jaw necrosi femur fractur bisphosphon anyon heard stress fractur reason bone would heal relat treatment',\n",
       " 'nh litig unfortun individu nh decis lose massiv public court case destroy individu life thing final chang neurologist financ decid best cours patient fingolimod natalizumab approv consensu safe discontinu plan studi pharma paid research god help children prescrib either one drug long term without lack immun surveil ie malign infect current safe exit plan come drug drug prove b cell cell downstream effect go field effect think confirm caus ms insid outsid make studi ai astrocyt hot microglia oligodendrocyt neuron function critic move forward research',\n",
       " 'hi question brother histori diagnos nsclc adeno alk start cisplatin alimta alimta mainten good respons diseas progress start xalkori year stop work went back alimta month progress start zykadia work well last month lymph node disappear tumour one lung turn scar left lung tumour reduc size soon got report bad rash last coupl week face bodi stop take zykadia dermatologist gave medicin rash suddenli swear headach take dexa get normal ct scan report today say mm hyperdens lesion area punctat calcif target like fashion within right pariet tempor lobe lesion demonstr intens post contrast enhanc extens vasogen oedema caus effac ipsilater later ventricl subfalcin herniat along mid line shift patholog brainparenchym lesion identifi foreman magnum basal cistern capaci without evid transtentori herniat conclus imag featur keep metast deposit within right pariet tempor lobe whole brain radiat suggest question scare radiat cyberknif option gammaknif option best stop take zykadia need stop zykadia day till radiat stop zykadia jump nivolumab zykadia result better except brain lesion need carri zykadia avoid brain lesion zykadia cross brain barrier get alimta everi three month alimta cross brain barrier sorri question sound',\n",
       " 'input surgeon howev entyvio biolog wish would tri think entyvio caus first surgeri colon resect doctor pro medicin pro biolog anti surgeri even agre possibl ask entyvio could caus damag section colon said way know sure possibl expect say way conced possibl even sure entyvio harm good part entyvio begin theybdid clinic trial entyvio clinic diagnos crohn diagnos psc med tri mesalamin imuran mp remicad humira entyvio simponi methotrex surgeri colon resect loop ileostomi surgeri ostomi closur diseas came back right away wors surgeri total proctocolectomi happi stoma back',\n",
       " 'agre wwith ipoop check level addit may want stool test scope recent result hard know thing activ often rectum best rout treat rectal med mesalamin worth throw simpl stuff see get point free symptom stelara label uc avail crohn think test uc avail soon howev med simponi humira similar remicad action entyvio differ mechan xeljanz good option current state like hope get thing manag someth addit sinc said badli mayb dose adjust imuran though mg low peopl everi day could get level check see respond also add rectal steroid mesalamin oral mesalamin moder uc current med step j pouch surgeri complet step complet step complet sickli uc free give man fish eat day teach man fish eat lifetim give man religion die pray fish',\n",
       " 'know tagrisso taken leader tom galli often said battl side effect plain white rice work well sure jump soon give specif hang judi',\n",
       " 'take gilenya know except relaps get new lesion soon tri paus relaps come decis drug abstract way understand disconnect lesion symptom goe way e damag invis mri may may pick amongst day day variabl time lead disabl choos everyth avail om dmd',\n",
       " 'right cimzia like label uc prescript ion might get initi insur denial prescrib appeal mean cannot work uc studi significantli enough prescrib know whole lot cimzia call talk insur see figur ask remicad simponi possibl could approv appeal worstcas scenario simponi humira closest pen inject remicad iv administ hospit outpati infus center sure matter much',\n",
       " 'also put cladribin search box site find experi describ detail pretti bad short disabl relaps month two first two round cladribin wonder gilenya month first dose',\n",
       " 'floo droe kor ti sone index term fluorohydrocortison acet fludrocortison acet fluohydrison acet fluohydrocortison acet dosag form excipi inform present avail limit particularli gener consult specif product label tablet oral acet gener mg pharmacolog categori corticosteroid system pharmacolog potent mineralocorticoid high glucocorticoid activ use primarili mineralocorticoid effect promot increas reabsorpt sodium loss potassium renal distal tubul metabol hepat half life elimin plasma hour biolog hour use label indic adren insuffici primari addison diseas partial replac therapi primari adrenocort insuffici salt lose adrenogenit syndrom treatment salt lose adrenogenit syndrom congenit adren hyperplasia label use idiopath orthostat hypotens clinic experi suggest fludrocortison conjunct increas sodium intak may benefici treatment idiopath orthostat hypotens [kearney ] [lanier ] addit data may necessari defin role fludrocortison condit base european feder neurolog societi efn guidelin diagnosi manag orthostat hypotens fludrocortison effect recommend first line monotherapi manag orthostat hypotens septic shock data two doubl blind placebo control random trial suggest combin hydrocortison plu fludrocortison may benefici patient septic shock refractori initi volum resuscit vasopressor trial hydrocortison plu fludrocortison improv mortal compar placebo also aid rapid revers shock [annan ] [annan ] note corticosteroid administ treatment sepsi absenc shock septic shock respons fluid resuscit vasopressor expert use hydrocortison monotherapi without fludrocortison corticosteroid indic [rhode ] [sccm esicm [annan ]] contraind hypersensit fludrocortison compon formul system fungal infect document allergen cross reactiv corticosteroid limit howev similar chemic structur pharmacolog action possibl cross sensit cannot rule certainti dose adult adren insuffici primari addison diseas oral initi mg daili morn combin hydrocortison cortison usual mainten dose mg daili hypertens develop dose reduct suggest antihypertens may necessari hypertens remain uncontrol endocrin societi [bornstein ] manufactur label dose prescrib inform may reflect current clinic practic mg daili transient hypertens develop reduc dose mg daili mainten dosag rang mg time weekli mg daili salt lose adrenogenit syndrom congenit adren hyperplasia oral mg daili endocrin societi recommend mainten dose rang mg daili combin hydrocortison patient congenit adren hyperplasia due hydroxylas defici speiser orthostat hypotens label use kearney lahrmann lanier oral initi mg daili conjunct high salt diet adequ fluid intak may increas increment mg per week maximum dose mg daili note dose exceed mg daili may benefici predispos patient unwant side effect eg hypertens hypokalemia septic shock label use note corticosteroid use septic shock respons volum resuscit vasopressor rhode sccm esicm [annan ] oral mg daili via nasogastr tube day combin iv hydrocortison annan annan dose geriatr refer adult dose dose pediatr adren insuffici autoimmun aldosteron defici compon addison diseas replac therapi label dose limit data avail oral mg daili betterl kliegman congenit adren hyperplasia salt loser eg hydroxylas defici label dose limit data avail note use combin glucocorticoid therapi eg hydrocortison concurr sodium replac therapi may requir particularli young infant oral infant children adolesc activ grow usual rang mg daili divid dose dose high mg day may necessari aap aap speiser adolesc fulli grown mg daili aap speiser dose renal impair dosag adjust provid manufactur label use caution dose hepat impair dosag adjust provid manufactur label use caution administr oral administ without regard food gi upset may take food septic shock label use administ via nasogastr tube annan annan dietari consider system use mineralocorticoid corticosteroid may requir diet increas potassium vitamin b c folat calcium zinc phosphoru decreas sodium fludrocortison decreas dietari sodium often requir increas retent sodium usual desir therapeut effect storag store c c f f avoid excess heat canadian label recommend store c c f f drug interact acetylcholinesteras inhibitor corticosteroid system may enhanc advers toxic effect acetylcholinesteras inhibitor increas muscular weak may occur monitor therapi aldesleukin corticosteroid may diminish antineoplast effect aldesleukin avoid combin amphotericin b corticosteroid system may enhanc hypokalem effect amphotericin b monitor therapi androgen corticosteroid system may enhanc fluid retain effect androgen monitor therapi antacid may decreas bioavail corticosteroid oral manag consid separ dose hour budesonid enter coat tablet could dissolv prematur given drug lower gastric acid unknown impact budesonid therapeut effect consid therapi modif antidiabet agent hyperglycemia associ agent may diminish therapeut effect antidiabet agent monitor therapi aprepit may increas serum concentr corticosteroid system manag dose adjust need singl mg aprepit dose regimen reduc oral dexamethason methylprednisolon dose iv methylprednisolon dose antiemet regimen contain dexamethason reflect adjust consid therapi modif axicabtagen ciloleucel corticosteroid system may diminish therapeut effect axicabtagen ciloleucel manag avoid use corticosteroid premed axicabtagen ciloleucel corticosteroid may howev requir treatment cytokin releas syndrom neurolog toxic consid therapi modif baricitinib immunosuppress may enhanc immunosuppress effect baricitinib manag use baricitinib combin potent immunosuppress azathioprin cyclosporin recommend concurr use antirheumat dose methotrex nonbiolog diseas modifi antirheumat drug dmard permit consid therapi modif bcg intraves immunosuppress may diminish therapeut effect bcg intraves avoid combin bile acid sequestr may decreas absorpt corticosteroid oral monitor therapi calcitriol system corticosteroid system may diminish therapeut effect calcitriol system monitor therapi ceritinib corticosteroid may enhanc hyperglycem effect ceritinib monitor therapi coccidioid immiti skin test immunosuppress may diminish diagnost effect coccidioid immiti skin test monitor therapi corticorelin corticosteroid may diminish therapeut effect corticorelin specif plasma acth respons corticorelin may blunt recent current corticosteroid therapi monitor therapi cyp induc strong may decreas serum concentr corticosteroid system monitor therapi cyp inhibitor strong may increas serum concentr corticosteroid system monitor therapi deferasirox corticosteroid system may enhanc advers toxic effect deferasirox specif risk gi ulcer irrit gi bleed may increas monitor therapi deferasirox corticosteroid may enhanc advers toxic effect deferasirox specif risk gi ulcer irrit gi bleed may increas monitor therapi denosumab may enhanc advers toxic effect immunosuppress specif risk seriou infect may increas monitor therapi desirudin corticosteroid system may enhanc anticoagul effect desirudin specif corticosteroid may increas hemorrhag risk desirudin treatment manag discontinu treatment system corticosteroid prior desirudin initi concomit use cannot avoid monitor patient receiv combin close clinic laboratori evid excess anticoagul consid therapi modif desmopressin corticosteroid system may enhanc hyponatrem effect desmopressin avoid combin diltiazem may increas serum concentr corticosteroid system monitor therapi echinacea may diminish therapeut effect immunosuppress consid therapi modif estrogen deriv may increas serum concentr corticosteroid system monitor therapi fingolimod immunosuppress may enhanc immunosuppress effect fingolimod manag avoid concomit use fingolimod immunosuppress possibl combin monitor patient close addit immunosuppress effect eg infect consid therapi modif fosaprepit may increas serum concentr corticosteroid system activ metabolit aprepit like respons effect consid therapi modif hyaluronidas corticosteroid may diminish therapeut effect hyaluronidas manag patient receiv corticosteroid particularli larger dose may experi desir clinic respons standard dose hyaluronidas larger dose hyaluronidas may requir consid therapi modif indacaterol may enhanc hypokalem effect corticosteroid system monitor therapi indium capromab pendetid corticosteroid system may diminish diagnost effect indium capromab pendetid avoid combin isoniazid corticosteroid system may decreas serum concentr isoniazid monitor therapi leflunomid immunosuppress may enhanc advers toxic effect leflunomid specif risk hematolog toxic pancytopenia agranulocytosi thrombocytopenia may increas manag consid use leflunomid load dose patient receiv immunosuppress patient receiv leflunomid anoth immunosuppress monitor bone marrow suppress least monthli consid therapi modif loop diuret corticosteroid system may enhanc hypokalem effect loop diuret monitor therapi macimorelin corticosteroid system may diminish diagnost effect macimorelin avoid combin mifamurtid corticosteroid system may diminish therapeut effect mifamurtid avoid combin mifepriston may diminish therapeut effect corticosteroid system mifepriston may increas serum concentr corticosteroid system manag avoid mifepriston patient requir long term corticosteroid treatment seriou ill condit e g immunosuppress follow transplant corticosteroid effect may reduc mifepriston treatment avoid combin mitotan may decreas serum concentr corticosteroid system consid therapi modif natalizumab immunosuppress may enhanc advers toxic effect natalizumab specif risk concurr infect may increas avoid combin neuromuscular block agent nondepolar may enhanc advers neuromuscular effect corticosteroid system increas muscl weak possibl progress polyneuropathi myopathi may occur consid therapi modif nicorandil corticosteroid system may enhanc advers toxic effect nicorandil gastrointestin perfor report associ combin monitor therapi nivolumab immunosuppress may diminish therapeut effect nivolumab consid therapi modif nonsteroid anti inflammatori agent cox select corticosteroid system may enhanc advers toxic effect nonsteroid anti inflammatori agent cox select monitor therapi nonsteroid anti inflammatori agent nonselect corticosteroid system may enhanc advers toxic effect nonsteroid anti inflammatori agent nonselect monitor therapi ocrelizumab may enhanc immunosuppress effect immunosuppress monitor therapi pidotimod immunosuppress may diminish therapeut effect pidotimod monitor therapi pimecrolimu may enhanc advers toxic effect immunosuppress avoid combin quinolon corticosteroid system may enhanc advers toxic effect quinolon specif risk tendon tendon ruptur may increas monitor therapi ritodrin corticosteroid may enhanc advers toxic effect ritodrin monitor therapi roflumilast may enhanc immunosuppress effect immunosuppress consid therapi modif salicyl may enhanc advers toxic effect corticosteroid system specif includ gastrointestin ulcer bleed corticosteroid system may decreas serum concentr salicyl withdraw corticosteroid may result salicyl toxic monitor therapi sargramostim corticosteroid system may enhanc therapeut effect sargramostim specif corticosteroid may enhanc myeloprolif effect sargramostim monitor therapi sipuleucel immunosuppress may diminish therapeut effect sipuleucel monitor therapi tacrolimu system corticosteroid system may decreas serum concentr tacrolimu system convers discontinu corticosteroid therapi tacrolimu concentr may increas monitor therapi tacrolimu topic may enhanc advers toxic effect immunosuppress avoid combin telaprevir corticosteroid system may decreas serum concentr telaprevir telaprevir may increas serum concentr corticosteroid system manag concurr use telaprevir system corticosteroid recommend possibl consid altern use togeth employ extra caution monitor close excess corticosteroid effect diminish telaprevir effect consid therapi modif tertomotid immunosuppress may diminish therapeut effect tertomotid monitor therapi thiazid thiazid like diuret corticosteroid system may enhanc hypokalem effect thiazid thiazid like diuret monitor therapi tisagenlecleucel corticosteroid system may diminish therapeut effect tisagenlecleucel manag avoid use corticosteroid premed time treatment tisagenlecleucel except case life threaten emerg resist cytokin releas syndrom consid therapi modif tofacitinib immunosuppress may enhanc immunosuppress effect tofacitinib manag concurr use antirheumat dose methotrex nonbiolog diseas modifi antirheumat drug dmard permit warn seem particularli focus potent immunosuppress consid therapi modif trastuzumab may enhanc neutropen effect immunosuppress monitor therapi urea cycl disord agent corticosteroid system may diminish therapeut effect urea cycl disord agent specif corticosteroid system may increas protein catabol plasma ammonia concentr therebi increas dose urea cycl disord agent need maintain concentr target rang monitor therapi vaccin inactiv immunosuppress may diminish therapeut effect vaccin inactiv manag vaccin efficaci may reduc complet age appropri vaccin least week prior start immunosuppress vaccin immunosuppress therapi revaccin least month immunosuppress discontinu consid therapi modif vaccin live corticosteroid system may enhanc advers toxic effect vaccin live corticosteroid system may diminish therapeut effect vaccin live manag dose equival less mg kg mg per day prednison administ less week consid suffici immunosuppress creat vaccin safeti concern higher dose longer durat avoid consid therapi modif warfarin corticosteroid system may enhanc anticoagul effect warfarin monitor therapi test interact corticosteroid may affect nitrobluetetrazollum test bacteri infect produc fals neg result advers reaction frequenc defin cardiovascular cardiac failur cardiomegali edema hypertens central nervou system delirium depress emot labil euphoria hallucin headach increas intracrani pressur insomnia malais nervous person chang pseudotumor cerebri psychiatr disturb psychosi seizur vertigo dermatolog acn vulgari atroph striae diaphoresi erythema hyperpigment maculopapular rash skin atrophi skin rash suppress skin test reaction urticaria endocrin metabol cush syndrom diabet mellitu glycosuria growth suppress hirsut hpa axi suppress hyperglycemia hypokalemia hypokalem alkalosi impair glucos toler menstrual diseas neg nitrogen balanc gastrointestin abdomin distent esophag ulcer pancreat peptic ulcer hematolog oncolog bruis petechia purpura hypersensit anaphylaxi gener local lipoatrophi inject site neuromuscular skelet amyotrophi bone fractur myasthenia myopathi osteonecrosi femor humer head osteoporosi vertebr compress fractur ophthalm cataract exophthalmo glaucoma increas intraocular pressur miscellan wound heal impair warn precaut concern relat advers effect adren suppress may caus hypercortisol suppress hypothalam pituitari adren hpa axi particularli younger children patient receiv high dose prolong period hpa axi suppress may lead adren crisi withdraw discontinu corticosteroid done slowli care anaphylactoid reaction rare case anaphylactoid reaction observ patient receiv corticosteroid immunosuppress prolong use may increas risk infect mask acut infect includ fungal infect prolong exacerb viral infect limit respons kill inactiv vaccin exposur chickenpox measl avoid corticosteroid use cerebr malaria viral hepat close observ requir patient latent tuberculosi tb tb reactiv restrict use activ tb fulmin dissemin tb conjunct antituberculosi treatment amebiasi rule patient recent travel tropic climat unexplain diarrhea prior initi corticosteroid use extrem caution patient strongyloid infect hyperinfect dissemin fatal occur kaposi sarcoma prolong treatment corticosteroid associ develop kaposi sarcoma case report note discontinu therapi consid goedert myopathi acut myopathi report high dose corticosteroid usual patient neuromuscular transmiss disord may involv ocular respiratori muscl monitor creatin kinas recoveri may delay psychiatr disturb corticosteroid use may caus psychiatr disturb includ euphoria insomnia mood swing person chang sever depress psychot manifest preexist psychiatr condit may exacerb corticosteroid use diseas relat concern cardiovascular diseas use caution patient hf hypertens use may associ fluid retent electrolyt disturb hypertens use caution follow acut mi corticosteroid associ myocardi ruptur diabet use corticosteroid caution patient diabet mellitu may alter glucos product regul lead hyperglycemia gastrointestin diseas use caution patient gi diseas diverticul fresh intestin anastomos activ latent peptic ulcer ulcer coliti abscess pyogen infect due perfor risk hepat impair use caution patient hepat impair includ cirrhosi long term use associ fluid retent myasthenia gravi use caution patient myasthenia gravi exacerb symptom occur especi initi treatment corticosteroid ocular diseas use caution patient cataract glaucoma increas intraocular pressur open angl glaucoma cataract occur prolong use use caution patient histori ocular herp simplex corneal perfor occur use activ ocular herp simplex consid routin eye exam chronic user osteoporosi use caution patient osteoporosi high dose long term use corticosteroid associ increas bone loss osteoporot fractur renal impair use caution patient renal impair fluid retent may occur seizur disord use corticosteroid caution patient histori seizur disord seizur report adren crisi thyroid diseas chang thyroid statu may necessit dosag adjust metabol clearanc corticosteroid increas hyperthyroid patient decreas hypothyroid one concurr drug therapi issu drug drug interact potenti signific interact may exist requir dose frequenc adjust addit monitor select altern therapi consult drug interact databas detail inform special popul elderli risk advers effect use caution elderli smallest possibl effect dose shortest durat pediatr may affect growth veloc growth develop routin monitor pediatr patient warn precaut discontinu therapi withdraw therapi gradual taper dose stress patient may requir higher dose subject stress ie trauma surgeri sever ill monitor paramet blood pressur blood glucos electrolyt weight growth develop children hpa axi suppress pregnanc risk factor c pregnanc consider anim reproduct studi conduct fludrocortison advers event observ corticosteroid anim reproduct studi studi shown associ first trimest system corticosteroid use oral cleft park wylli pradat system corticosteroid may also influenc fetal growth decreas birth weight howev inform conflict lunghi hypoadren may occur newborn follow matern use corticosteroid pregnanc monitor system corticosteroid need pregnanc gener recommend use lowest effect dose shortest durat time avoid high dose first trimest leachman lunghi fludrocortison may use treat women pregnanc requir therapi congenit adren hyperplasia primari adren insuffici bornstein speiser patient educ discuss specif use drug side effect patient relat treatment hcahp hospit stay given medicin taken give new medicin often hospit staff tell medicin often hospit staff describ possibl side effect way could understand patient may experi nausea vomit insomnia agit patient report immedi prescrib sign infect sign high blood sugar confus fatigu increas thirst increas hunger polyuria flush fast breath breath smell like fruit sign cush diseas weight gain upper back abdomen moon face sever headach slow heal sign adren gland problem sever nausea vomit sever dizzi pass muscl weak sever fatigu mood chang lack appetit weight loss sign low potassium muscl pain weak muscl cramp abnorm heartbeat sign pancreat sever abdomin pain sever back pain sever nausea vomit sign skin chang acn stretch mark slow heal hair growth sign dvt edema warmth numb chang color pain extrem sever loss strength energi irrit tremor tachycardia confus sweat lot dizzi short breath excess weight gain swell arm leg angina menstrual chang bone pain joint pain vision chang behavior chang depress seizur burn numb feel bruis bleed sever abdomin pain black tarri bloodi stool vomit blood hcahp educ patient sign signific reaction eg wheez chest tight fever itch bad cough blue skin color seizur swell face lip tongu throat note comprehens list side effect patient consult prescrib addit question intend use disclaim print given patient inform intend serv concis initi refer health care profession use discuss medic patient must ultim reli discret experi judgment diagnos treat advis patient',\n",
       " 'probabl one list statist surgeri hospit readmit due blockag kink realli doubt mine due biolog gi biolog month prior surgeri keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'anyon know possibl hsct without loss fertil bmt unit offer egg harvest bank addit everyon hsct left infertil haematologist quot figur gener woman hsct will sacrific fertil downsid treatment seldom discuss option treat earli alemtuzumab failur anti cd therapi rituximab ocrelizumab daclizumab pleas note gener comment necessarili appli specif individu patient',\n",
       " 'get readi start stelara sometim sept also wonder fistula etc strang let stay last drug studi offer indic success close would continu provid drug seem rather cruel take get sick femal canada ivig pentasa entyvio infus respons discontinu uc crohn test posit map antibodi mycobacterium pg remiss flare almost year bad way due abx treatment gone wrong sigh',\n",
       " 'ncot glad pull avoid convers climat chang wonder xma realli thrill entyvio someth quit drop fecal cal amaz actual keep put mine someth take box contain poop post offic kinda throw monday though honor last one measur start entyvio last juli insan dose humira see score femal canada ivig hold uc crohn test posit map antibodi mycobacterium pg remiss flare year current deal fistula includ rectal vag vulvodynia caus ibd take mg gabapentin start humira sept mg weekli start hyperbar oxygen dec',\n",
       " 'never plan ahead much soon would definit get ltd coverag post month ago hug use sensat clitor penil erect stimul last hour nortriptylin nerv pain realli help hurt symptom flare post month ago hug use answer sign view previou answer mymsteam member said paullinuk sorri understand say explain bit pleas thank post month ago hug use relationship issu love life partner much sometim drive absolut batti guy good come take care domest chore thing around hous never worri make bed wash cloth cook meal sweep take trash easili hinder task could name dilig come side left offic job year ago work small famili busi read post month ago hug use answer sign view previou answer mymsteam member said nzrick actual work construct busi raini season basic shut read post month ago hug use tysabri cladribin struggl choos hi new site still tri find way round hope right offer choic tysabri cladribin struggl choos previous copaxon work realli well limit side effect year relaps stop due lipoatrophi run place inject tecfidera hate side effect felt like crap develop new lesion bit read edit origin post month ago hug use answer sign view previou answer mymsteam member said ive infus tysabri happi dont work longer one coukd like work post infus side effect read post month ago hug use anyon start mavenclad cladribin finish week one gotten nauseat leg pain wonder leg pain due heat wave go never sort neuropath leg pain past post month ago hug use answer sign view previou answer mymsteam member said see famili doc put second week pill reliev went see head nurs work',\n",
       " 'hi tagrisso month wonder lot fewer side effect take gabapentin neuropathi chemo help sleep mind race continu year nsclsc year one happi person tagrisso becom avail end med avail toenail fingernail aw thing best wish prayer mom',\n",
       " 'hi blueberri sorri hear mother diagnosi wife yo never smoker also diagnos stage iv nsclc last year current clinic trial anoth type drug process think clinic trial end come lot question anoth coupl thought sure interim result talk may want ask result trial combin smoker vs non smoker oncologist told us thing read subsequ appear immunotherapi gener tend work better smoke relat nsclc non smoker opdivo work wife inde work non smoker may want see interim result combo show thing jimc said may also want talk oncologist extent mother nsclc also talk trial coordin term long would want mother trial drug combo gener go trial time want work want make sure would long enough know whether combo effect said could go trial standard cargo alimta need find one treatment negat possibl also found dr west discuss molecular marker immunotherapi http cancergrac org lung valu pdl test comment found search cancer grace decid time clinic trial versu convent chemotherapi use import part ask question oncologist feel comfort possibl make decis wish al best may mother find effect treatment whatev path take wife lifelong non smoker dx adeno nsclc stage iv poorli diff bone met lymph node exon mutat x carbo alimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo effect add l growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl stabl add l growth trial start gemzar larg tumor reduct',\n",
       " 'across group patient higher baselin nfl level larger lesion volum baselin r p month nfl level new enlarg lesion count r p also correl patient higher nfl level lower normal brain volum r p across group baselin correl percentag brain volum chang baselin month month baselin nfl level fingolimod r p r p r',\n",
       " 'dear janin thank much inform happi hope learn clinic trial go moment exon forgot say live finland one grandchildren live philadelphia famili therefor trial osimertinib philli may juli sound interest wonder non us citizen recruit trial access clinic trial would prioriti seem clinic trial take place us ask feel particip clinic trial mainten alimta get dose alimta everi three week trial end felt abandon scan remain stabl two year first break gradual start feel safe enjoy normal life trust doctor know time start get treatment howev help feel uneasi know cancer progress luckili slow grow stabl long period chemo session far dear scohn thank tell wife treatment amaz drug actual design exon prove effect pharma compani abl find new user group target drug great gemzar still work option need ask doctor exon mutat also gemzar might worth tri thank much encourag wish best luck wife mani month gemzar heartfelt thank paulina never smoker bac stage iv dx feb cm infiltr detect rul ct scan possibl spicul carcinoma treatment progress dvt treatment feb diagnos bac rl lll primari tumor diam cm feb apr x cisplatin alimta may april mainten alimta clinic trial round alimta week interv primari tumor cm nodul rl clean stabl sinc june dec slight progress march x carboplatin taxol stabl march ct guid needl biopsi april dg papillari adenocarcinoma exon may progress treatment juli progress new nodul enlarg ggo multipl metastas rl spread also lingula x alimta juli august good respons decreas ggo reliev symptom cough mucu x alimta oct nov slow progress sinc nov cough mucu sob',\n",
       " 'prayer come way surpris opt entyvio stelara first mention either decid cimzia hope thing start improv soon keep us post',\n",
       " 'theoret differ continu immunosuppress associ ongo undefin period time rituximab ocrelizumab treatment know concept induct v mainten treatment tell better safeti wise reconstitut system post induct treatment ongo immuno suppress associ non induct therapi rituximab ocrelizumab',\n",
       " 'readi n farago f de braud f atmaca hellmann schneider j g spigel r moreno v chau hann c l eder j p steel n l pieter fairchild j antonia j articl titl third line nivolumab monotherapi recurr sclc checkmat abstract introduct patient recurr sclc topotecan remain approv second line treatment outcom poor checkmat phase multicent open label studi nivolumab nivolumab plu ipilimumab sclc advanc metastat solid tumor previous treat one platinum base chemotherapi report result third later line nivolumab monotherapi treatment sclc method analysi patient limit stage extens stage sclc diseas progress two chemotherapi regimen receiv nivolumab monotherapi mg kg everi week diseas progress unaccept toxic primari end point object respons rate secondari end point includ durat respons progress free surviv overal surviv safeti result decemb novemb patient began receiv third later line nivolumab monotherapi median follow month first dose databas lock object respons rate confid interv median durat respons month rang month patient progress free month month overal surviv rate respect grade treatment relat advers event occur patient three patient discontinu treatment relat advers event conclus nivolumab monotherapi provid durabl respons well toler third later line treatment recurr sclc result suggest nivolumab monotherapi effect third later line treatment patient popul intern associ studi lung cancer keyword adult cancer chemotherapi control studi age surviv rate major clinic studi overal surviv fatigu cancer recurr cancer growth diarrhea drug safeti drug withdraw monotherapi treatment durat skin manifest cancer stage follow progress free surviv phase clinic trial nausea random control trial pruritu rash drug fatal surviv time immunotherapi multicent studi drug respons phase clinic trial small cell lung cancer decreas appetit sclc nivolumab human male femal prioriti journal articl pd inhibitor third line journal titl journal thorac oncolog volum issu issn publish elsevi inc',\n",
       " 'stelara imuran look like humira fail',\n",
       " 'smell mine without nada liquid place drop ostomi bag absorb smell know forget empti bag wake spous dead sleep friend use said smell like normal person differ everyon fart pass ga oh ye also make grumbl old man talk sound put hand muffl alreadi let ki notic nois happen much big deal freak diseas major peopl abl get control medic clo symptom start diagnosi diagnos uc diverticul hosp fistula dx chang crohn develop new skin rash eye problem pain joint hosp x new specialist said wors case seen hosp mm strictur stricturplasti mm colostomi med remicad methtrex prednison folic acid vit calcium pro biotic',\n",
       " 'gone gym regularli whenev symptom allow leav hous never big problem sure beat run bike street day abdomin exercis possibl everyth schedul person trainer class male dx w uc flare sinc asacol hd mg day start remicad nonrespons dc start humira nonrespons dc hydrocortison enema help regress stop start entyvio restart hydrocortison start umass ibd_aid diet improv w entyvio hydrocortison ibd aid colonoscopi show clinic remiss',\n",
       " 'believ read comment mayb note someon ask pronounc drug name post someon know other know either anonymousthursday februari pm would nice guy could post pronounc variou ms drug name eg would like know emphasi copaxon g sound like gilenya heard doctor nurs pronounc mani differ way dont get listen peopl pronounc drug dont meet peopl ms day day basi',\n",
       " 'hi uc friend doctor say medic resist version uc last three year tri imuran humira inflectra like remicad thing work prednison consid surgeri go talk surgeon friday wonder saw improv symptom uc exampl arthriti muscl pain surgeri wonder expect think surgeon would abl help question',\n",
       " 'would make appoint gi asap technic inflectra ident remicad similar henc term biosimilar howev bodi may like small differ perhap develop antibodi inflectra idea honesti better nd rd infus would fight go back origin remicad dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'opdivo similar keytruda year far good',\n",
       " 'hi welcom grace sorri hear progress tagrisso howev one first question ask much progress especi target therapi well toler reluct abandon particular agent face slow limit progress realli state much progress lung progress small locat grown may reason continu tagrisso get maximum benefit drug dr west fond say bad brake better brake tagrisso keep progress slow may better switch anoth regimen may may effect carboplatin alimta tend one best toler platinum combin therapi lung cancer alimta singl agent often well toler mani patient extend period time use mainten therapi round platinum doublet side effect nausea tend well manag medic wrong choic sinc pace develop lung cancer treatment increas recent year good reason get everyth drug benefit new agent becom avail good luck treatment either way jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'except uc around long modern food chemic one antibiot came along theori caus uc pleas generalis caus uc rant evil modern life connor said uc rare western world peopl mostli got drink contamin milk got uc usual die nonsens well sever uc sometim kill peopl day steroid modern surgeri yeah case uc sever life threaten countless number peopl must learn live mild moder uc life colonoscopi came along must almost imposs get diagnosi dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'well start gilenya monday sadli phone call last friday dash dream turn even though chicken pox child varicella test result came back neg wait minimum week gilenya two dose chicken pox vaccin ms activ probabl fuss right steriod april worn spasm roof even baclofen pain often unbear spasm breath hurt walk even uncoordin spasm choke everyth includ saliva air tongu back feel like someon stuck lidocain patch left side list go biggest annoy still got count lucki start ofcours feel like best place right mental physic tri feel dishearten like chang realiti make easier cope husband noon els know everyth gotten wors mum know treatment delay person keep date want annoy friend honestli think good make upset stuck right tri keep busi make card energi even tri walk feel though intermitt foot drop make even harder even know mani wors honestli feel like take much run point month ago manag start enjoy life hardli much anyth issu ms take life sinc last april glad know almost taken life past pain noon understood get head right',\n",
       " 'thank janin post excel inform certainli make sens investig immunotherapi e clinic trial janin mention directli test mainten therapi bevacizumab pemetrex combin bevacizumab pemetrex follow carboplatin paclitaxel bevacizumab advanc non squamou nsclc onthemark',\n",
       " 'catch week top rheumatolog gastroenterolog clinic practic regulatori polici busi news world biosimilar studi examin potenti role biolog treat primari scleros cholang primari scleros cholang psc chronic immun mediat progress biliari diseas close associ inflammatori bowel diseas ibd psc cure case eventu requir patient receiv liver transplant given efficaci biolog treat ibd potenti treat psc drug matter interest healthcar provid review address role anti tnf intestin beh et diseas intestin beh et diseas bd immun mediat chronic inflammatori intestin diseas difficult treat part pathogenesi intestin bd unclear howev data use anti tumor necrosi factor anti tnf drug accumul treatment inflammatori bowel diseas ibd similar clinic present potenti treat bd agent investig switch refer infliximab ct p unlik evok differ ada new studi publish alimentari pharmacolog therapeut sought test antigen compar refer infliximab biosimilar spanish studi switch biosimilar infliximab ibd safe effect month research spain biosimilar use encourag way save cost expand access biolog therapi recent report multicent prospect observ studi patient inflammatori bowel diseas ibd switch refer infliximab biosimilar ct p inflectra remsima gastroenterologist recount clinic experi switch patient biosimilar see reason healthcar provid intent go back forth needlessli see concern bad thing would happen said jason schairer md effect infliximab treatment cd associ improv mental health crohn diseas cd involv physic psycholog social impair neg impact patient qualiti life high level anxieti depress observ patient cd review find switch biosimilar infliximab patient ibd accept question whether switch patient refer biolog avail biosimilar subject extens debat especi patient inflammatori bowel diseas ibd indic evid relev clinic outcom switch limit celltrion report posit phase result subcutan inflectra cd celltrion present new research demonstr formul infliximab biosimilar intend subcutan administr compar intraven administ option phase studi compar subcutan formul self administ fda approv intraven formul patient activ crohn diseas cd fda approv jak inhibitor treat ulcer coliti provid altern anti tnf agent week fda approv expand indic janu kinas jak inhibitor tofacitinib xeljanz includ adult moder sever ulcer coliti tofacitinib first oral medicin approv long term use uc provid altern anti tumor necrosi factor anti tnf drug must inject infus',\n",
       " 'would certainli tri entyvio xeljanz stelara still tri differ drug find husband stori search xeljanz site surgeri schedul tri remicad humira entyvio abl get xeljanz miracl drug trick stelara clinic trial uc peopl good luck crohn xeljanz got approv fda uc us summer challeng drug work differ peopl work fun spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week',\n",
       " 'age relat macular degener amd damag occur macula locat back eye directli line sight macula part eye respons sharp central vision enabl person pinpoint object recogn face deterior occur older age mani individu name suggest two type amd first type dri amd character breakdown macular tissu caus buildup form underneath retin layer call drusen yellow deposit drusen increas size tissu back eye may cut blood suppli occur new blood vessel form tend leak lead second type macular degener wet exud amd type macular degener lead devast loss vision amd prevent eat approxim cup leafi green veget day boost antioxid help fight free radic take part age relat breakdown macula wear proper uv protect healthi exercis regimen smoke may also decreas risk amd fact smoke increas amd risk four time vitamin supplement avail antioxid lutein zeaxanthin shown help filter oxid chemic harm blue light caus damag macula howev import consult eye doctor begin new eye vitamin ocular health formula eye love use daili patient definit approv us patient dri amd commonli monitor amsler grid patient given grid monitor vision function see part grid miss wavi line may indic condit chang wet amd begin like becom candid anti vegf inject anti vegf vascular endotheli growth factor drug use stop new blood vessel format track eylea avastin lucenti name drug success use time drug aim preserv vision case improv sight your suffer macular degener dont wait begin supplement definit dont delay eye exam love hear amd especi hear success stori youv got one post comment one love dr jenna rufino silva age relat macular degener portug ger group print',\n",
       " 'posit thing pregnant ms symptom better controll babi born symptom come back talk doctor back therapi babi born good luck pregnanc would start tri babi third month medicin want rebound effect like hapen stop fingolimod',\n",
       " 'often lucenti stabilis condit time need fewer inject amd hope keep vision stabl glad hear problem access eyelea us england consult gave good advic follow appoint first lucenti inject overlook month fortun harm done vision stabl time told fluid detect scan inject week inject follow clinic longer week alway week pro activ ensur appoint time futur took word know clinic make fuss polit appoint late good luck take day come easier said done know need bit tea sympathi good old rant',\n",
       " 'us food drug administr fda approv drug lucenti',\n",
       " 'never particip trial kind howev crizotinib first line treatment diagnos alk posit adenocarcinoma work beauti side effect month time scan show progress switch alectinib work well even fewer side effect bless mani option us day',\n",
       " 'complet infus yesterday along ct head neck torso ultrasound thyroid result today still clean scan far overal side effect minim discuss exit strategi keytruda infus includ next two infus space week apart follow month scan still clear stop two year calendar time infus equat year actual treatment thank brilliant scientist accomplish consid start aggress modular melanoma happi valentin day everyon login regist post repli regist login keytruda infus clean scan result billb pm repli keytruda infus clean scan result scoobi pm repli keytruda infus clean scan result mmh pm repli keytruda infus clean scan result billb pm repli keytruda infus clean scan result bubbl pm repli keytruda infus clean scan result jbronicki pm repli keytruda infus clean scan result kst pm repli keytruda infus clean scan result sing pm repli keytruda infus clean scan result amcread pm repli keytruda infus clean scan result chrispl repli keytruda infus clean scan result texmelanomex pm repli keytruda infus clean scan result lkb pm repli expand collaps topic suspect number five possibl insitu almostalic pm repli go right next stage charact went keliod recoveri three month suspect insitu need look interest thing share anyon ever heard stage two insitu side side path report first one came back new one two mole merg grow close cdkn posit wonder mine get start like galaxi star collid much inform ssm melanoma birth',\n",
       " 'daughter stage adenocarcinoma nsclc ro dx decemb standard chemo xalkori gave posit result dr want tri opdivo even though test neg pdl result mass tripl dr return chemo carboplatin alimta alimta mainten month dr recommend new combin unusu growth around previous radiat spot lung sure combin growth identifi evid next cours treatment given histori result unknown caus smear ct scan',\n",
       " 'minnietoti constant fatigu issu us chronic diseas gi pcp told caus blood work look good mean feel great bodi take time recov sinc flare take get back normal hope also keep mind mental fatigu issu well blood test confirm bad wors physic fatigu best thing done recent month ago start see therapist first question take long decid need help said chronic ill caus anxieti depress host issu make diseas wors bless help get current ordeal encourag file long term disabl make need drastic discuss help look thing differ import hope help surgeri resect termin ilium open heart surgeri infect lymphocel surgic remov crainotomi remov benign tumor adomin hernia fail remicad cimzia methotrex humir mp entyvio g medic stelara verapamil quinipril labetalol clorithidon atorvastatin alluporinol elliqui xanax er',\n",
       " 'ye remicad uc medic current sure option mercaptopurin allerg mesalamin lost respons steroid one miss last time blood work remicad concentr left doctor said fast metabol go medicin quicker',\n",
       " 'lack biomark major obstacl investig myelin repair use metabol incorpor cholin analog propargyl cholin p cho label visual newli synthes myelin cn mice induc experiment autoimmun encephalomyel eae develop unbias coloc analysi quantifi p cho incorpor specif myelin find indic p cho inject mice recov eae either spontan follow glatiram acet treatment result signific elev incorpor myelin offer novel strategi assess remyelin anim model remyelin potenti candid drug glaterim acet drug clue work mechan action shake stick today mechan infer pro remyelin realli happen way recov attack actual studi look remyelin think take dye light myelin one alreadi call fingolimod bind myelin layer realli well',\n",
       " 'sinc ocrevu inject recommend done want talk neurologist',\n",
       " 'norway rituximab time use label rrm first infus anti cd monoclon antibodi chimer mous variabl human constant region read blog may make neutral antibodi probabl toward mous compon titer may becom reduc multipl treatment cycl nevertheless worri signific risk individu level drug may low efficaci guy agre luckili ocrelizumab approv norway report site blog say drug neutral antibodi found number still date studi suggest may unsaf switch ritruximab ocrelizumab anti cd brain atrophi',\n",
       " 'episod event smolder progress sinc mani brain lesion atrophi brain mainli thin spinal cord lot nerv damag accumul disabl view ms sinc relaps doubt mani current drug prevent relaps gilenya crab etc would help avail time besid new attack blood brain barrier lead relaps someth els go cn lead progress disabl slowli eat reserv neurolog abil realli notic loss function get drug stop inflammatori attack cn import believ treat earli possibl effect drug hsct prevent damag recommend',\n",
       " 'repli post saradarrow hi sara terrifi start humira hate needl nowher near bad expect would recommend son inject stomach found less pain thigh also let humira warm minut ice inject site right inject thing hard sometim nois pen make inject sudden surpris sometim make jump bit hold pen tightli enough skin make much much easier avoid misfir also listen music inject make littl less seriou hope son found good solut work',\n",
       " 'hi updat receiv copi letter neuro sent gp decid take steroid option two day iv next week oral tail two three week said make substanti differ symptom would worth chang dmd tecfidera gilenya sinc feel deterior sinc relaps pseudo relaps decid give go read steroid thread wonder worth email ms nurs ask omeprazol possibl sleep tablet avail wait get appoint louis',\n",
       " 'repli post kelliwithchron ulcer coliti two healthi pregnanc result two healthi boy remicad pregnanc classifi high risk meant got bunch extra free ultrasound piec mind import stress induc ibd know scari think pass diseas along child honest zero famili histroy ibd end uc chanc increas parent ibd realiti famili histori autoimmun disord children chanc get auto immun disord told pregnanc would chanc uc get better stay get wors would say first feel better howev stress less alreadi child need rest could rest second say stay mainli father pass away unexpectedli pregnant second thank abl work emot without stress children brought much joy life howev medic safe pregnanc would talk gi lucki gi absolut best gi opinion brother law ob best ob opinion commun easi pregnanc ob gi talk regularli felt comfort confid decis health babi health option though huge support foster children strength life lesson learn could much good children wish best decis',\n",
       " 'continu give entivio chanc deal year old symptom sinc octob diagnos januari ibd ulcer coliti pancol current apriso humira uceri valtrex vari tri almost everi healthfood thing world help could cure herb vitamin diet good day bad day lot sleep',\n",
       " 'dear moder doctor read number exit articl publish spanish group silibinin extract milk thistl paper prove silibinin prolong time tarceva resist recent public prove silibinin reduc brain met lung cancer use concurr systemat treatment current tarceva two month realli worri possibl brain met would like tri silibinin worri could interfer tarceva neg way may pleas ask advis mani thank',\n",
       " 'part train clinician understand import eye health especi age adult one import eye diseas need abl recogn age relat macular degener amd result vision loss common adult age amd character either dri amd wet amd dri amd common affect patient amd patient lose vision slowli time wet amd caus sever vision loss blind differenti import patient start dri amd later develop wet amd test amd includ dilat eye exam fluorescein angiographi optic coher tomographi oct retina examin abnorm blood vessel sign drusen seen patient amd patient also examin amsler grid look like piec graph paper patient wet amd see line wavi bent type amd treat combin vitamin miner call are age relat eye diseas studi are formula formula includ high dose vitamin vitamin c beta caroten zinc found help patient macular degener smoker encourag stop smoke smoke increas risk amd quit actual slow progress diseas treatment patient wet amd includ vascular endotheli growth factor vegf inhibitor photodynam therapi laser surgeri research also look use stem cell therapi still preliminari phase surgic option also explor importantli encourag older patient get regular eye exam earlier treatment initi amd better sharon brien mpa pa c practic physician assist health coach ashevil n c',\n",
       " 'hi sue thank kind wish ye neuro right low lymphocyt gener good thing rrm tec ms dmd aim im case unfortun look may scan high level activ lesion neuro said must high rogu lymphocyt within low count think one small number patient experi rebound effect stop tec also happen stop tysabri gilenya case get lemtrada sooner later sort grate tell mani mani ms friend manag ms without dmd success stop dmd choic actual feel better everyon physiolog differ differ reaction experi drug dmd end follow lot advic georg jelinek sensibl extrem http overcomingm org good luck',\n",
       " 'found sleep day day treatment paclitaxel carboplatin avastin also go go person get frustrat everyth food anoth issu treatment one go smell textur food make difficult prepar meal wonder husband help meal prep cleanup spend much time around food love cold food though chemo make feel differ thing even watch commerci entic anymor love eat give info pamphlet hospit sure cover littl thing chemo patient goe thru wish best journey live day full potenti hug',\n",
       " 'first ocrevu infus june first infus felt like describ last day reaction infus two week later felt pretti good hope start get full dose one visit decemb reaction rest allow bodi adjust hope feel better soon',\n",
       " 'lung cancer awar month opportun focu promis research field recent health expert around globe gather toronto world confer lung cancer case miss need refresh compil list key find present event know durvalumab found prolong surviv patient stage iii unresect non small cell lung cancer nsclc phase trial valid drug progress free surviv pf benefit found overal surviv os benefit studi overal surviv durvalumab versu placebo chemoradiotherapi stage iii nsclc patient experienc better pf brigatinib crizotinib ongo phase studi research compar efficaci brigatinib crizotinib alk posit local advanc metastat nsclc treat alk inhibitor far head head analysi investig found pf longer patient treat brigatinib vs crizotinib studi brigatinib vs crizotinib patient alk inhibitor naiv advanc alk nsclc first report phase trial phase trial niraparib initi patient extens diseas small cell lung cancer ed sclc approxim patient ed sclc enrol random doubl blind trial goal studi evalu efficaci niraparib mainten therapi ed sclc studi ph studi niraparib mainten therapi l platinum respons extens diseas small cell lung cancer patient nintedanib surviv benefit coupl pemetrex cisplatin patient unresect malign pleural mesothelioma mpm revers observ phase trial nintedanib phase studi demonstr statist signific clinic meaning improv surviv pf studi nintedanib pemetrex cisplatin patient unresect mpm phase iii result lume meso trial whole brain radiotherapi wbrt concurr erlotinib benefit patient nsclc multipl brain metastas wbrt alon phase studi research enrol particip nsclc least metastat brain lesion randomli assign receiv either wbrt wbrt plu concurr erlotinib studi phase trial whole brain radiotherapi concurr erlotinib versu wbrt alon nsclc brain metastas relat articl perspect combin immunotherapi nsclc ct screen reduc lung cancer death high risk asymptomat patient tislelizumab show antitumor activ lung cancer aprepit plu palonosetron dexamethason found effect prevent chemotherapi induc nausea vomit cinv patient local advanc metastat lung cancer phase random trial patient local advanc metastat lung cancer administ either aprepit placebo addit palonosetron dexamethason studi phase iii random trial palonosetron dexamethason without aprepit prevent full dose singl day cisplatin base cinv lung cancer patient advanc metastat previous treat nsclc may benefit receiv metformin atezolizumab research retrospect explor use metformin patient nsclc random phase oak trial investig atezolizumab treatment advanc metastat previous treat nsclc studi retrospect descript analysi metformin atezolizumab advanc non small cell lung cancer oak trial darbepoetin alfa noninferior placebo os pf anem patient nsclc receiv myelosuppress chemotherapi doubl blind random placebo control phase studi found darbepoetin alfa significantli reduc odd transfus hemoglobin g dl studi doubl blind random placebo control phase noninferior studi darbepoetin alfa anemia advanc nsclc refer iaslc th world confer lung cancer intern associ studi lung cancer septemb access novemb',\n",
       " 'offici cannabi legal canada avail prescript readili avail without prescript peopl may start use conjunct replac cancer treatment ctoam want cancer patient love one know fact make life alter potenti harm decis help cancer patient famili awar option crucial ctoam goal save live improv cancer care everyon check issu ctoam newslett learn myth truth cannabi cancer treatment want life save inform deliv straight inbox sign monthli newslett truth cannabi cancer help harm truth cannabi cure cancer sever pervas conspiraci theori claim cannabi someth els simpl natur cure cancer giant pharmaceut compani hide fact year howev theori key flaw first giant pharmaceut compani alreadi found cure would huge profit given half us get cancer point live therefor best capitalist interest suppress moreov number peopl would need complicit keep secret magnitud would stagger mani decad secret supposedli kept doubt least one peopl would come forward truth either hero make money stori realiti simpl conspiraci hide cure cancer cannabi otherwis scienc base perspect mani clinic studi subject year still evid cancer cure cannabi studi impli cannabi effect cancer petri dish mislead even saliva kill cancer petri dish know saliva kill cancer person explain alex rolland oncogenom expert ctoam director scientif research truth cannabi help symptom relat chemotherapi radiat year cannabi prescrib help allevi nasti side effect chemotherapi radiat shown help reduc nausea increas appetit decreas stress improv sleep truth smoke cannabi may increas chanc develop lung cancer burn plant matter natur releas carcinogen cannabi cigarett rare filter less tightli pack allow smoke get lung compar tobacco cigarett peopl typic hold cannabi smoke lung much longer tobacco cigarett amount tar deposit lung smoke cannabi cigarett roll cannabi approxim four time despit studi current show weak link smoke cannabi develop lung cancer consid whether smoke cannabi potenti risk lung cancer taken account truth cannabi benefit harm cancer treatment chemotherapi radiat remain standard cancer treatment within canadian public healthcar system howev precis oncolog target treatment continu grow popular use cannabi addit impact peopl tend think anyth natur like cannabi interact pharmaceut medicin true cannabi interact cancer treatment interact benefici harm depend variabl involv consid alreadi use cannabi part cancer care import speak cancer care team potenti interact treatment current truth smoke cannabi cure cancer help unpleas side effect cancer treatment smoke cannabi may increas risk lung cancer potenti benefit harm differ kind cancer treatment critic openli discuss cannabi use care team time goe depth research subject grow hope continu uncov full potenti cannabi hold cancer care like know precis oncolog target treatment want speak expert cannabi might impact current cancer treatment contact us today discov scientif proven work book free consult today give us minut feel confid cancer treatment option katherin lung cancer success stori year old katherin diagnos non small cell lung cancer nsclc offer standard chemotherapi ctoam cancer specialist recommend get test egfr mutat biopsi test reveal katherin egfr posit nsclc biopsi provid public oncologist base data public oncologist tri first gener egfr inhibitor tarceva unfortun katherin stop respond drug eight month katherin oncologist told standard chemotherapeut drug would provid temporari relief would stop progress diseas start platinum base regimen side effect strong ct scan show diseas progress katherin readi accept reach ctoam consult read katherin lung cancer treatment improv treatment success reduc stress doubt greater confid whatev action take cancer treatment ctoam second opinion ctoam alway year ahead standard care cancer expert spend everi day research latest advanc cancer care use target treatment like immunotherapi cancer patient mani year long standard care start use explor rang servic packag discov right fit ctoam servic packag right cancer time essenc discov live longer precis oncolog schedul free consult today noth lose year gain book free consult cancer expert today question pleas contact us anytim ctoam cancer care consult scienc support thing cancer sign ctoam newslett stay date latest advanc cancer treatment diagnost support',\n",
       " 'hi antonett fick funni mention gilenya given choic mavenclad gilenya told mavenclad higher effici rate hi stumbler thank input websit realli hope effect truli amanda',\n",
       " 'ghadiri fitz gerald l rezk li r nyirenda haegert giacomini ps bar antel j reconstitut peripher immun repertoir follow withdraw fingolimo mult scler doi background follow fingolimod cessat immun reconstitut lack thereof may consequ diseas rebound safeti commenc altern therapi object examin degre profil peripher blood lymphocyt reconstitut follow fingolimod withdraw method total lymphocyt count tlc cd cd cell count measur multipl sclerosi ms patient pre treatment fingolimod month post cessat cell subset analyz use flow cytometri result week post fingolimod cessat tlc reconstitut variabl correl age treatment durat pre treatment tlc despit normal tlc cd cd ratio month naiv subset remain lower effector memori subset higher frequenc compar pre treatment drug induc increas ratio regulatori pathogen th contain central memori popul appear rapidli return baselin conclus earli peripher lymphocyt reconstitut fingolimod withdraw remain partial heterogen rel frequenc circul naiv memori cell subset may recov mani month even clinic laboratori test normal analyz specif compon peripher immun repertoir help defin overal immun statu patient determin whether assess immun measur implic time safeti commenc altern therapi fingolimod immun migrat inhibit agent mean rebound occur cell come nich supposedli held loss sphingosin one phosphat receptor howev examin blood see subset white cell disappear blood also see individu loss white blood cell studi reiter issu say despit withdraw drug peopl reconstitut immun system would perhap suggest fingolimod may deplet immun stem cell progenitor peopl reconstitut properli say action simpl blockad migrat may suggest kill cell know happen evid literatur question common issu reconstitut immun system open infect effector memori cell common consist mechan express ccr sphingosin ne phosphat one receptor use allow naiv central memori cell exit lymphoid gland furthermor cell reconstitut alway memori cell repopul quicker naiv cell howev concern individu reconstitut mean may risk infect leav problem transit fingolimod wait long start next treatment rebound diseas activ could occur howev may heard suggest fingolimod switch alemtuzumab mean diseas activ return case fingolimod trap cell lymph gland think bone marrow alemtuzumab get delet antibodi quickli gone fingolimod keep cell away antibodi howev lack lymphocyt deplet long term problemat seen peopl cell number recov use anoth immun deplet coi none',\n",
       " 'thank let join diagnos crohn year ago initi alot pain circumst chang lot le stress pretti much symptom free apart diarrohea til rectovagin fistula seton anyon tell long like commenc humira shortli gi ad methotrex mean downhil post edit kiwig gmt',\n",
       " 'thank repli lisa spent hour today lab work result rutger keytruda infus begin mom done readi mind apt infus u imagin stress tire refus go back went thru schedul apt bask ridg glad thing went smooth prob end go',\n",
       " 'taken varieti biolog remicad first develop anti dsdna antibodi need stop almost three year went humira month develop sever reaction due extrem high anti dsdna antibodi mind antibodi differ antibodi remicad switch simponi year coupl flare up joint stop develop allergi medic manifest head bottom feet rash take stelera month love done joint back pain gone peripher joint pain free crohn still remiss mind intestin crohn went remiss remicad stay sinc moder crohn diseas osteoarthr irrit bowel forum cd ankylos spondyl small fiber peripher neuropathi avascular necrosi peripher arteri diseas pulmonari hypertens degen disc diseas asthma sever allergi host medic problem',\n",
       " 'one say humira affect might get remiss give old self back someth anyon promis truth crohn complex diseas even peopl remiss intestin still ongo issu fatigu ib joint problem etc say got luxuri time give humira go may one lucki one make decis think care go humira dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'meet amit program manag larg credit card compani male chicago ulcer coliti diagnos marri two kid otherwis healthi human th drug uc possibl per gi potenti near surgeri decis amit sold first web page mortgag broker use netscap favorit instrument tabla like read kid novel read school current symptom bm per day abdomin pain bm food intak trigger bm blood stool scope march complet clean full remiss biopsi neg colonoscopi travel abroad flex sig may moder coliti biopsi posit amit ulcer coliti stori diagnos uc start mba program work full time stress kid small requir lot attent stress high hospit time requir iv steroid seemingli hospit stay requir new medicin also visit mayo clinic day univers chicago gi dept doctor inform last visit may need surgeri simponi work humira class drug fail tofacitinib market week chose surgeri would tri anyth avail today fecal transplant drug approv like tofacitinib rate shingl patient seriou altern therapi doctor well vers head dept major hospit still ever address diet anyway previou gi told sinc med eat whatev pleas still shock would choos empow patient materi http www crohnscolitisfound org live crohn coliti bookstor html perhap specif doctor us ask doctor reduc inflamm turmer respons lucki evid prove would help anyth might ask doctor tri besid surgeri medic non allopath clinic healer would recommend someon junctur current take simponi imuran mg lialda canasa tramadol ask get shingrix shot prepar newest medicin approv uc tofacitinib med surgeri want prepar make decis medic histori initi lialda mesalamin work fine year st hospit inpati stay imuran ad anoth stay mp ad blood test period determin caus liver toxic determin immunosuppress work introduc biolog next line defens first remicad entyvio simponit hospit stay current w simponi still take lialda imuran part combo therapi current regim work flare month howev last visit doctor mention surgeri first time ever ask look depress altern humira would chanc work tofacitinib someth would like feedback anyon site option increas frequenc simponi start today humira low success rate tofa citinib littl data surgeri dr believ improv qualiti life read procedur still go time day potenti med convinc written amit submit coliti vent area',\n",
       " 'hi follow diseas modifi drug approv use nh uk avail drug may vari england scotland wale northern ireland aubagio teriflunomid avonex interferon beta betaferon interferon beta b brabio glatiram acet copaxon glatiram acet extavia interferon beta b gilenya fingolimod lemtrada alemtuzumab mavenclad cladribin plegridi peginterferon beta rebif interferon beta tecfidera dimethyl fumar tysabri natalizumab hope help start point tell one recommend neurologist rr pp expect contributor help anthoni',\n",
       " 'two main group within total white cell popul lymphocyt neutrophil broadli speak lymphocyt activ viral infect neutrophil bacteri everyth immun complex gilenya sequest lymphocyt lymph node instead circul prevent messeng activ cn said total number actual preserv readi act need less circul thu measur blood test reduct lymphocyt count may report less expect mani centr toler said lower count longer risk atyp infect herp zoster shingl commonli even fear pml gilenya user reduc total white cell count neutrophil problemat respond lower dose may need stop surgeri want adequ neutrophil number fuss lymphocyt basic answer complic problem suspect junior doctor experi lymphocyt count abnorm normal gilenya consult later overrid need clarifi exactli count ask full result opportun discuss manag low white cell count gilenya reduc dose prolong dose interv everi third day made activ decis risk infect relaps see post forum help enough happi add requir judi',\n",
       " 'hello guy write look advic start take gilenya day ago sinc got relaps hospit howev order professor jelinek book start read read medicin hit hard doctor share inform howsoev year old plane child year two definit feel like left disabl give birth wors child sort disabl also th day take got yeast infect still antibiot give advic stop drug long guess damag big afraid anoth relaps om program one week precis start right got hospit feel lot better sinc mayb gilenya advic would much appreci wish well',\n",
       " 'accord studi publish cancer octogenarian nonagenarian stage iii non small cell lung cancer nsclc receiv cancer direct care despit evid standard care concurr chemotherapi plu radiotherapi crt improv overal surviv os although nsclc one commonli diagnos form cancer manag among patient age year older remain larg unstudi studi investig access nation cancer data base ncdb evalu treatment outcom elderli patient newli diagnos advanc nsclc three treatment group identifi patient receiv treatment patient receiv definit radiat patient receiv crt variou patient demograph includ age sex race comorbid insur statu educ resid incom diseas characterist assess one quarter patient receiv crt compar patient receiv therapi wors os outcom observ among patient receiv treatment hazard ratio [hr] ci radiat hr ci compar patient receiv crt propens score match baselin variabl show receiv crt associ wors os outcom hr ci relat articl proton therapi may reduc radiat exposur non small cell lung cancer fda accept supplement new drug applic osimertinib first line treatment egfr mutant nsclc phase trial sbrt gene therapi prior nivolumab nsclc two year os estim ci crt arm ci radiat arm ci treatment arm p live lower educ area odd ratio [or] ci african american ci associ receiv cancer direct care refer',\n",
       " 'tecfidera slow rate deterior wherea lemtrada cladribin potenti stop ms deterior peopl see improv symptom understand neurologist prescrib tecfidera gilenya tysabri anymor seem everyon choos stop ms slow ms would anyway choos slow option',\n",
       " 'complet agre poppi expect diseas modifi drug chang day day symptom dmd purpos reduc number sever relaps take tecfidera still relaps work rather swap gilenya probabl qualifi tysabri better drug fewer side effect better averag relaps reduct rate qualif tysabri activ ms ie still frequent relaps tri fail anoth dmd relaps dmd suppos manag side effect would probabl better stick one rather switch differ drug howev say damag caus previou relaps give ongo symptom probabl talk ms nurs deal ongo symptom could drug therapi treatment aid help sue',\n",
       " 'gregorioallegri aml certainli well inform friend oncolog doc mayb well inform tri www amlglobalport com look clinicaltri gov search acut myeloid leukemia make sure get mutat profil aml like nsclc actual complex sever diseas vari genet caus lucki may target therapi trial join use label e g ponatinib vs certain mutant form flt target therapi might consid pd checkpoint inhibitor opdivo keytruda ncbi nlm nih gov pd inhibitor might better choic target therapi diseas quit advanc tend work almost mutat type amaz big pharma keep tri chemo drug opinion effect versu diseas appear superfici investig limit take grain salt comput chemist oncolog doc ga',\n",
       " 'sorri hear chemo work dmfan encourag news immunotherapi opdivo shown great promis shrink lung tumor even tumor spread brain even tumor disappear famili member lung cancer met brain small cell lung cancer differ beast hard even still say may happen everyon react differ much depend type lung cancer non small small sub type brain health issu treatment alreadi done mani thing multi factori know hear frustrat give answer look sorri one truli answer question dad doctor know situat best hope opdivo provid great result dad keep us updat jodi',\n",
       " 'ann sorri hear lung cancer diagnosi broken femur ordeal go thru met leg bone vertebra new sinc begin treatment assum recent pet scan follow recent one serv base line mom receiv session carbo alimta keytruda lung cancer recurr continu keytruda nearli year work well great candid keytruda pd l level evid diseas nearli year keep finger cross receiv latest ct result hour like tom said weird thing pop earli treatment immunotherapi pet scan show activ area organ light activ tom said activ leg could due activ heal process time tell mom wait see program wait see prior initi diagnosi see lung nodul grew wait see scan hope show cancer return horribl part diseas great hand immunotherapi great thing lot peopl give time get work meantim continu regular appoint assum get blood test report side effect troubl issu keep close eye thing new plan attack need take care steff',\n",
       " 'azpref might also tri contact fred hutchinson seattl work seattl cancer care allianc univers washington highli regard amaz research mani biotech compani husband current undergo immunolog treatment metastat melanoma far fine opdivo sinc june good luck',\n",
       " 'barryb cherish doctor bart prescrib cladribin part trial give peopl ms want sign disclaim say want cladribin rather ms drug market get refer anoth doctor think self refer got appoint dr schmierer bart actual royal london part bart hospit trust refer neurologist said first three set inject cladribin four week washout gilenya take time inject three adjac day royal london blood test check lymphocyt count four week later gp surgeri week three lot inject royal london blood test everi four week go forward monitor lymphocyt thing done gp surgeri symptom walk two stick lot difficulti lift feet make hard go upstair mean fall quit bit problem bladder control urgenc frequenc past though got lot better year ago wors coupl week ago gilenya system poor balanc weak arm hand leg twitch night improv seen recent hope cladribin find easier lift feet walk upstair lift leg hand stair night last first time abl month month bladder fine today hour session physio manag get back onto chair instead help reduc drug take stop leg twitch know sound like small thing import get wors got bit better even see improv cladribin would worth deterior stop hope see improv',\n",
       " 'chose go everyth possibl gilenya scare ms possibl rebound effect come risk pml skin cancer stay make constantli question decis take said relaps immedi side effect plan eventu come medic readi yet',\n",
       " 'sure avastin much differ lucenti eylea basic avastin come larger phial suitabl cancer treatment instead small one eye treatment manufactur drug far refus produc smaller amount suitabl eye treatment mean anoth compani transfer drug smaller phial may increas risk contamin thu infect fact actual happen avastin use lucenti eylea develop also heard patient treatment chang avastin one drug longer work mention tv mani million nh safe head',\n",
       " 'hello new came across place look advic new treatment diagnos rrm ok rebif time recent mri activ lesion also suffer dizzi spell weak left hand worst terribl fatigu memori loss difficulti concentr got point peopl work dont know ms say look like someon taken batteri tri hard let peopl notic get harder also random symptom find hard say normal ms caus anyway went hospit today med look due mri result advic neurolagist go mavenclad gilenya read everyth could find also look sure choos like idea maveclad year treatment total day year know still need monitor seem ideal someth said bother sure said gilenya tablet daili mean stop effect wear mavenclad revers sure problem seem final also say treatment need year happen year noth mention anywher cours expect ms stay remiss think thing need email ms nurs say would yreat wirh mevenclad would work gilenya coupl altern side effect th gilenya seem wors drawn mavenclad realli hard make decis know none tell choos help know might other shoe least understand im deal thank read post would appriciat advic similar situat also anyon mavenclad treatment know start seen post anyon start thank',\n",
       " 'electrolyt certain nutrient chemic present bodi mani import function regul heartbeat allow muscl contract move major electrolyt found within bodi includ calcium magnesium potassium sodium phosphat chlorid ibd result electrolyt imbal mani reason rang dehydr due high output ostomi diarrhoea sick heat lack absorpt due scar intestin resect import replac miss electrolyt becom rebalanc done depend sever imbal minor imbal dietari chang may possibl drink rehydr solut anoth option treatment sever case includ fluid replac intraven hospit stay post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit mri definit magnet reson imag mri type scan use strong magnet field radio wave produc detail imag insid bodi mri scanner larg tube contain power magnet lie insid tube scan mri help identifi activ diseas ibd help locat strictur narrow intestin complic abscess post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask mri ulcer coliti ulcer coliti definit immunosuppress definit immunosuppress drug class drug suppress reduc strength bodi immun system exampl immunosuppress azathioprin imuran mercaptopurin purinethol infliximab remicad adalimumab humira certolizumab pegol cimzia methotrex rheumatrex cyclosporin gengraf neoral sandimmun tacrolimu astagraf xl hecoria natalizumab tysabri vedolizumab entyvio ustekinumab stelara post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit adhes definit adhes commonli caus scar surgeri less commonli scar due activ inflammatori bowel diseas adhes fibrou band form tissu caus pain blockag intestin post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit resect definit bowel resect surgic procedur part larg small intestin remov post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit proctocolectomi definit proctocolectomi surgic remov rectum part colon post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit hemicolectomi definit hemicolectomi involv surgeri remov right left portion colon',\n",
       " 'dread one question monday laser haemorrhag go keep tug reopen sure need laser near base abnorm grown vessel pull jelli fall away wither heard mani vitrectomi stori improv vision fix problem make want suggest anti vegf instead hope us stop point futur year get point hope minim loss vision hope recoveri stabilis happen soon x click expand ask inject told stage would help would make everyth wors may need inject line fluid told inject bleed gone month stop inject bleed activ',\n",
       " 'alright sofia_gaston start ocrevu tuesday known ms sinc novemb whether input good know honesti suffer none infus relat side effect wait get second half infus week tuesday guess realli talk good gonna hey know noth diseas game pheasant take marlon',\n",
       " 'juhi kund lungev scienc writer last weekend close oncolog profession includ superstar lung cancer research mani member lungev scientif advisori board gather chicago attend annual meet american societi clinic oncolog asco year confer domin studi focus immunotherapi diseas treatment leverag bodi natur immun respons field immunotherapi burst option breakthrough new approach diseas manag flow research treatment lung cancer summar highlight asco confer immunotherapi immunotherapi found effect tumor cell express high level protein pd l howev pd l alway reliabl biomark tend fluctuat time area tumor may express pd l area also tumor make pd l protein still respond immunotherapi mind research work optim biomark use predict patient benefit immunotherapi found measur tumor mutat burden tmb number mutat tumor dna may promis approach predict patient respons immunotherapi sometim tmb may use conjunct pd l level provid guidanc cancer treatment one import phase clinic trial look bevacizumab anti cancer drug known reduc tumor abil promot blood vessel growth requir feed cancer patient advanc non squamou non small cell lung cancer nsclc initi result show ad atezolizumab immunotherapi drug bevacizumab carboplatin paclitaxel two chemotherapi drug often use doublet treatment decreas cancer progress increas overal surviv compar regimen without immunotherapi research need studi also rais hope patient egfr posit alk posit nsclc trial result note patient shown progress egfr tyrosin kinas inhibitor tki alk tki respond well combin approach bevacizumab doublet chemotherapi atezolizumab anoth key phase clinic trial studi effect ad immunotherapi agent current recommend first line treatment advanc squamou nsclc research found immunotherapi drug pembrolizumab ad doublet chemotherapi patient saw signific increas overal surviv studi like result chang current guidelin first line treatment patient advanc squamou nsclc mani differ clinic studi underway determin optim combin lung cancer treatment includ immunotherapi chemotherapi target therapi radiat also research conduct identifi optim sequenc treatment enhanc patient surviv rate qualiti life non small cell lung cancer driver mutat lot progress also happen nsclc driver mutat phase clinic trial patient advanc nsclc posit ret fusion promis result drug loxo select target ret fusion protein addit studi plan develop treatment option small cell lung cancer excit around rova continu lungev scientif advisori board member david carbon md phd ohio state univers present phase clinic trial result show protein dll found high level small cell lung cancer sclc tissu healthi tissu could first target therapi advanc sclc result show rova bind dll improv overal surviv sclc patient whose cancer return chemotherapi addit scientist explor potenti immunotherapi sclc data phase clinic trial suggest pembrolizumab may effect sclc patient progress chemotherapi whose tumor posit pd l protein earli detect final progress liquid biopsi continu field earli detect someon develop cancer blood often contain piec mutat dna escap die tumor cell tumor dna found blood often call circul dna ctdna plasma cell free dna plasma cfdna recent liquid biopsi test becom avail analyz ctdna determin whether patient cancer type cancer result studi present asco suggest techniqu may also use detect earli stage lung cancer research develop circul cell free genom atla ccga aim understand liquid biopsi use earli detect complement ct screen research underway hope develop techniqu use lifesav tool earli detect lung cancer presidenti address asco presid dr bruce johnson mention close abl treat half patient nsclc target therapi immunotherapi initi treatment encourag progress saw asco year confid next year bring even juhi kund scienc writer lungev categori earli detect immunotherapi mutat non small cell lung cancer nsclc small cell lung cancer',\n",
       " 'hi wonder anyon heard anyth avail treatment wise alectinib leptomenig diseas alectinib pretti good see slow chang wife gate eye focu hear well cough concern alectinib slowli becom ineffect note month sinc start treatment scan schedul week want prepar need thank much know god bless us thu far keep move forward year sinc diagnos nsclc stage thank',\n",
       " 'speak clinic trial particular particip clinic trial think benefit coupl less obviou way number one much close monitor would otherwis relaps treat immedi wherea would like drag week first trial relaps tend start slowli build come suddenli benefit psycholog need know everyth possibl help coupl caveat son relaps remit ms control arm approv therapi placebo progress ms approv therapi may approv live ocrevu progress ms like must placebo control side affect risk less well known trial unknown risk trial less scari certain brain damag choos particip other feel differ one size fit person regret particip even though diseas progress zero sinc best luck whatev choos heidi',\n",
       " 'first thank barnsburi share ask gi also particip trial longest seen someon success said year interest hear long made two week next infus want post updat transpar week start salad ate share someon get sick gave bad ga nausea coupl day figur pick littl bug got better get period start also unusu sever time period heavi usual hope correl sinc though say feel uc like feel like someth go stomach lower gi tract also eat kale salad food best diet choic also fatigu ach pain associ flare travel next two week gener make bit constip see goe updat next infus ask bloodwork check inflamm see notic chang post infus dx st entyvio infus respond well current entyvio colaz florastor vsl previous apriso hair loss flagyl prednison mesalamin enema tinidazol align lialda imuran allerg asacol ineffect remicad allerg humira ineffect anusol canasa cortifoam',\n",
       " 'sorri guy got bit end first post crohn mirowpl good luck entyvio mean know experi encourag one ever seen lot peopl say got remiss scifig ha yeah want gut prettier _ think whole would still pick clinic remiss hand would annoy symptom explan case would start think possibl caus think pin thing onto crohn per usual cm right technic crohn ileocolilti vast bulk diseas colon howev termin ileum affect well remov along colon henc neo new termin ileum report goe tri imuran mp mp nearli year far tell mp done noth except make burn easier sun good luck med edit tom thank certain stelara avail ask gi inflamm widespread seem stubborn treatment resist plu side ill entir colon inflam feel entir healthi either think immun system attack bit digest system thyroid eye etc sorri get bit time go bed think post edit nicecupoftea pm gmt',\n",
       " 'conner keep finger cross see success follow journey close surgeri recommend son turn day desper altern solut famili year old diagnos ulcer coliti fall tri uceri lialda remicad canasa entyvio everi week imuran sinc june still remiss',\n",
       " 'option go studi join studi compar afatinib vs afatinib cetuximab iv rash benefit combin consid get tarceva gilotrif studi thank',\n",
       " 'thank lot carm greg livewithcanc concern first mom crazili well done sever round chemo hair loss side effect whatsoev tire nauseou sick shovel snow renov master bedroom xxx everyth normal carboplatin etoposid howev yet know chemo work scan end week nevertheless even assum work chanc first line chemo sclc mean much sclc typic cours diseas even peopl get complet respons achiev ned first line chemo diseas typic come roar back within year point littl done actual tri figur round plan right option base respons partial respons complet respons term new treatment right checkmat also keynot show thing keytruda understand doctor prescrib opdivo yervoy keytruda label addit rova trial around us howev limit studi seem show efficaci treatment sclc depend certain condit keytruda seem work well pdl express high tmb opdivo high tmb rova high express dll mom biopsi tissu sent test genet sequenc plu tmb pdl hand seem commerci avail test dll hope result point one direct vs other round need mom around long enough new research perhap genet sequenc result prove use thank day mom well need face fact diseas year surviv rate unlik cancer stat remain relev almost noth happen new diseas decad unlik nsclc exampl want sure everyth keep mom aliv',\n",
       " 'hi jim hope well back report mom ct look good still research xalkori link janin point check also stumbl upon refer alimta somewhat effect prevent revers brain met mom met stick one possibl prevent confus stick alimta thank much support time give unselfishli best bee yr old mom never smoker er breathless diagnos malign pleural effus stage v bronchiogen adenocarcinoma lung tarceva th thoracentesi diarrhea nausea rash egfr alk test neg stop tarceva er th thoracentesi renal failur blood transfus alimta well toler stroke lost right side speech hospit sugar due decadron seventh round alimta ongo rehab stroke ct show recurr start alimta alimta sinc usual ned chemo period less month month recent occurr jan alimta jan thru april ned april occurr cancer jan start alimta test posit ro june appt onc discuss futur tx plan',\n",
       " 'tuesday april edt cambridg mass busi wire biogen nasdaq biib present new data demonstr breadth divers market pipelin multipl sclerosi ms therapi th annual meet american academi neurolog aan vancouv canada compani announc today data support biogen establish portfolio includ prescrib oral ms treatment world tecfidera dimethyl fumar demonstr abil differenti product meet distinct need peopl live ms ms complex life long diseas affect person differ peopl ms divers treatment need critic varieti therapeut option avail provid robust efficaci differ mechan action also offer flexibl transit anoth treatment need said ralph kern senior vice presid worldwid medic world lead ms portfolio grow pipelin biogen continu focu ms care impact greatest number peopl live ms global tecfidera data showcas strong sustain efficaci newli diagnos ms patient reinforc earlier treatment tecfidera critic improv long term clinic outcom addit real world compar effect data show tecfidera associ significantli lower annual relaps rate arr rel glatiram acet interferon teriflunomid arr similar tecfidera fingolimod data support establish combin benefit tecfidera offer includ strong sustain efficaci well character long term safeti profil oral conveni nearli year clinic experi tysabri natalizumab data highlight real world evid demonstr proven long term efficaci safeti particularli use earlier cours diseas addit biogen data present highlight impact zinbryta daclizumab hyp cognit outcom target mechan action moa data show caus broad immun cell deplet effect total lymphocyt count revers within approxim eight week upon treatment discontinu highlight biogen aan data present',\n",
       " 'extend releas inject day protein bind plasma bound albumin alpha glycoprotein special popul elderli half life increas time special popul gender clearanc approxim lower women special popul note cigarett smoke clearanc approxim higher smoker use label indic oral treatment manifest schizophrenia treatment acut mix mania episod associ bipolar disord monotherapi combin lithium valproat mainten treatment bipolar disord combin fluoxetin treatment resist bipolar depress im extend releas zyprexa relprevv treatment schizophrenia im short act zyprexa intramuscular treatment acut agit associ schizophrenia bipolar mania label use chemotherapi associ acut delay nausea vomit prevent adult data random phase iii studi support use oral olanzapin combin dexamethason palonosetron prevent acut delay chemotherapi induc nausea vomit chemotherapi na patient receiv highli emetogen chemotherapi [navari ] data random phase ii studi includ chemotherapi na patient receiv moder highli emetogen chemotherapi regimen also suggest oral olanzapin combin dexamethason palonosetron may benefici prevent acut delay nausea vomit [navari ] chemotherapi associ breakthrough nausea vomit adult data random control phase iii studi support use oral olanzapin manag breakthrough nausea vomit associ highli emetogen chemotherapi [navari ] base antiemet guidelin american societi clinic oncolog oral olanzapin may use manag breakthrough nausea vomit chemotherapi associ breakthrough refractori nausea vomit pediatr base pediatr oncolog group ontario pogo guidelin treatment breakthrough prevent refractori chemotherapi induc nausea vomit oral olanzapin may benefici manag breakthrough refractori nausea vomit breakthrough nausea vomit occur children receiv acut prophylaxi highli emetogen chemotherapi olanzapin may ad antiemet regimen refractori nausea vomit occur despit use antiemet prophylaxi highli emetogen chemotherapi intervent chang ht antagonist addit aprepit unsuccess olanzapin may ad antiemet regimen delirium base nation institut health clinic excel nice nation clinic guidelin centr ncgc guidelin diagnosi prevent manag delirium short term cours olanzapin usual week consid treatment delirium individu distress consid risk other verbal non verbal de escal techniqu ineffect inappropri recommend use antipsychot drug caution patient condit parkinson diseas dementia lewi bodi delusion infest also call delusion parasitosi data limit number patient studi case report suggest olanzapin may benefici treatment delusion infest also call delusion parasitosi [bosman ] [freudenmann ] [kenchaiah ] [lim ] [merja ] addit data may necessari defin role olanzapin condit psychosi agit associ dementia data random doubl blind control trial support use olanzapin treatment psychosi agit relat dementia [de deyn ] [meehan ] [schneider ] [street ] [sultzer ] [verhey ] addit trial may necessari defin role olanzapin condit base american psychiatr associ apa practic guidelin use antipsychot treat agit psychosi patient dementia antipsychot olanzapin may consid treatment agit psychosi certain patient dementia howev evid efficaci modest use limit patient whose symptom danger sever caus signific patient distress due safeti risk associ antipsychot use base world feder societi biolog psychiatri wfsbp guidelin biolog treatment alzheim diseas dementia drug treatment olanzapin behavior psycholog aspect includ hyperact psychosi recommend low dose short durat last option address caus factor use psychosoci intervent post traumat stress disord data two small random doubl blind placebo control trial studi support use mono adjunct therapi olanzapin treatment post traumat stress disord [carey ] [stein ] addit trial may necessari defin role olanzapin condit base american psychiatr associ apa practic guidelin treatment patient posttraumat stress disord world feder societi biolog psychiatri wfsbp guidelin pharmacolog treatment posttraumat stress disord adjunct olanzapin suggest treatment option patient concomit psychot symptom present first line approach ineffect control symptom tourett syndrom data limit number patient studi suggest olanzapin may benefici treatment tourett syndrom children adolesc adult [budman ] [mccracken ] [onofrj ] [stamenkovic] [stephen ] addit data may necessari defin role olanzapin condit base european societi studi tourett syndrom tourett canada guidelin drug therapi includ olanzapin effect recommend manag tourett syndrom improv qualiti life tic pain distress interfer daili function caus sustain social emot problem howev evid support use limit similarli base american academi child adolesc psychiatri aacap practic paramet treatment children adolesc tic disord drug therapi includ olanzapin effect recommend manag moder sever tic caus sever impair qualiti life chronic tic disord includ tourett syndrom limit evid risk weight gain metabol side effect aacap guidelin recommend olanzapin use first line medic canadian guidelin recommend avoid use patient overweight baselin children adolesc adult contraind contraind list manufactur label canadian label hypersensit olanzapin compon formul dose adult schizophrenia oral initi mg daili increas mg daili within day thereaft adjust mg daili week interv recommend maximum mg day mainten mg daili dose mg daili use treatment resist schizophrenia howev support evid limit apa [lehman ] special risk patient initi mg daili recommend patient debilit predisposit hypotens reaction exhibit combin factor may result slower metabol olanzapin eg nonsmok femal patient year may pharmacodynam sensit olanzapin increas dose caution clinic indic extend releas inject im note establish toler oral olanzapin prior chang extend releas inject maximum dose mg everi week mg everi week patient establish oral olanzapin mg daili initi dose mg everi week dose mg everi week dose mainten dose mg everi week mg everi week patient establish oral olanzapin mg daili initi dose mg everi week dose mainten dose mg everi week mg everi week patient establish oral olanzapin mg daili initi mainten dose mg everi week special risk patient initi mg everi week recommend patient debilit predisposit hypotens reaction exhibit combin factor may result slower metabol olanzapin eg nonsmok femal patient year may pharmacodynam sensit olanzapin increas dose caution clinic indic bipolar acut mix manic episod oral monotherapi initi mg daili increas mg daili interv less hour mainten mg daili recommend maximum dose mg day combin therapi lithium valproat initi mg daili dose rang mg daili agit acut associ bipolar disord schizophrenia short act inject im initi dose mg lower dose mg may consid clinic factor warrant addit dose mg may consid howev hour initi dose hour second dose allow dose evalu respons maximum total dose mg day special risk patient consid lower dose mg patient debilit predisposit hypotens reaction may pharmacodynam sensit olanzapin short act inject iv label rout note iv rout studi emerg depart patient close monitor respiratori depress chan cole martel taylor world feder societi biolog psychiatri wfsbp expert consensu panel recommend use intraven medic manag agit except case altern wfsbp [garriga ] monotherapi iv initi mg may provid two addit mg dose minut interv need maximum mg taylor note lower dose mg singl dose studi concomitantli midazolam chan howev concomit use parenter olanzapin benzodiazepin recommend due potenti excess sedat cardiorespiratori depress depress depress associ bipolar disord combin fluoxetin oral initi mg even adjust toler usual rang mg daili see note treatment resist depress combin fluoxetin oral initi mg even adjust toler rang mg daili see note note olanzapin fluoxetin combin [symbyax] use individu compon fluoxetin olanzapin rather fix dose combin product symbyax approxim dosag correspond follow olanzapin mg fluoxetin mg symbyax olanzapin mg fluoxetin mg symbyax olanzapin mg fluoxetin mg symbyax olanzapin mg fluoxetin mg symbyax olanzapin mg fluoxetin mg symbyax special risk patient initi mg daili recommend patient predisposit hypotens reaction hepat impair exhibit combin factor may result slower metabol olanzapin eg femal elderli nonsmok statu may pharmacodynam sensit olanzapin increas dose caution clinic indic chemotherapi associ acut delay nausea vomit prevent label use oral mg day chemotherapi day follow mg daili day combin dexamethason palonosetron day navari navari chemotherapi associ breakthrough nausea vomit label use oral mg daili day navari delirium label use oral mg daili day nice delusion infest also call delusion parasitosi label use oral initi mg daili increas gradual base respons toler mg day maximum mg day freudenmann heller addit data may necessari defin role olanzapin condit post traumat stress disord label use oral initi mg daili adjust dose base respons toler everi week mg daili carey stein tourett syndrom label use initi mg daili increas gradual base respons toler usual dosag rang mg daili pringsheim roessner initi dosag increment mg weekli biweekli commonli use dosag adjust clinic trial maximum dosag mg day budman onofrj stamenkov discontinu therapi american psychiatr associ apa canadian psychiatr associ cpa world feder societi biolog psychiatri wfsbp guidelin recommend gradual taper antipsychot avoid withdraw symptom minim risk relaps apa [lehman ] cerovecki cpa [addington ] wfsbp [hasan ] risk withdraw symptom may highest highli anti cholinerg dopaminerg antipsychot cerovecki stop antipsychot therapi patient schizophrenia cpa guidelin recommend gradual taper month apa guidelin recommend reduc dose month apa [lehman ] cpa [addington ] continu anti parkinson agent brief period discontinu may prevent withdraw symptom cerovecki switch antipsychot strategi suggest cross titrat gradual discontinu first antipsychot gradual increas new antipsychot overlap taper maintain dose first antipsychot gradual increas new antipsychot taper first antipsychot abrupt chang abruptli discontinu first antipsychot either increas new antipsychot gradual start treatment dose evid support ideal switch strategi taper rate limit result conflict cerovecki remington dose geriatr refer adult dose short act im oral consid lower start dose mg daili elderli patient may increas clinic indic toler close monitor orthostat blood pressur extend releas im consid lower start dose mg everi week elderli patient increas dose caution clinic indic delirium label use oral patient year oral mg daili day nice psychosi agit associ dementia label use short act im initi dose mg addit dose mg may consid howev least hour initi dose least hour second dose allow dose evalu respons maximum drug exposur mg per episod meehan oral initi mg daili necessari gradual increas base respons toler exceed mg daili patient without clinic signific respons week taper withdraw therapi patient adequ respons attempt taper withdraw therapi within month unless symptom recur previou taper attempt assess symptom least monthli taper least month withdraw therapi apa [reu ] de deyn schneider street sultzer verhey dose pediatr bipolar acut mix manic episod adolesc year oral initi mg daili adjust mg daili target dose mg daili dose rang mg daili depress associ bipolar disord combin fluoxetin children adolesc year oral initi mg daili even combin fluoxetin adjust dose need toler safeti dose mg olanzapin combin fluoxetin dose mg studi pediatr refer adult dose note olanzapin fluoxetin combin symbyax schizophrenia adolesc year oral initi mg daili adjust mg daili target dose mg daili dose rang mg daili chemotherapi associ breakthrough refractori nausea vomit label use infant children adolesc oral mg kg dose daili maximum mg dose necessari may increas mg kg dose daili maximum mg dose flank tourett syndrom label use children adolesc initi mg daili increas gradual base respons toler usual dosag mg daili aacap [murphi ] pringsheim initi dosag increment mg weekli biweekli use dosag adjust clinic trial maximum dosag mg day mccracken stephen dose renal impair dosag adjust necessari remov dialysi dose hepat impair dosag adjust provid manufactur label except use combin fluoxetin separ compon initi olanzapin dose limit mg daili use caution case hepat liver injuri report olanzapin use reconstitut inject extend releas dilut direct final concentr mg ml shake vigor mix form yellow opaqu suspens follow reconstitut suspens may store room temperatur use within hour shake vigor resuspend prior administr foam form let vial stand allow foam dissip use immedi suspens syring suspens may irrit skin wear glove reconstitut inject short act reconstitut mg vial ml swfi result solut mg ml use immedi within hour follow reconstitut discard unus portion mix diazepam lorazepam haloperidol syring administr short act inject may administ im iv label rout administ inject subcutan im administr inject slowli deep muscl label iv rout administ rapid iv push taylor dizzi drowsi note patient remain recumb examin indic postur hypotens bradycardia problem extend releas inject im gluteal inject administ iv subcutan needl insert muscl aspir verifi blood appear massag inject site use diluent syring needl provid conveni kit obtain new kit aspir blood occur tablet may administ without regard meal oral disintegr remov foil blister peel back push tablet foil place tablet mouth immedi upon remov tablet dissolv rapidli saliva may swallow without liquid may administ without food meal dietari consider tablet may taken without regard meal product may contain phenylalanin storag inject extend releas store control room temperatur exceed c f inject short act store c c f f excurs permit c c f f freez protect light tablet oral disintegr tablet store c c f f excurs permit c c f f protect light moistur drug interact abirateron acet may increas serum concentr cyp substrat high risk inhibitor monitor therapi abobotulinumtoxina anticholinerg agent may enhanc anticholinerg effect abobotulinumtoxina monitor therapi acetylcholinesteras inhibitor may diminish therapeut effect anticholinerg agent anticholinerg agent may diminish therapeut effect acetylcholinesteras inhibitor monitor therapi acetylcholinesteras inhibitor central may enhanc neurotox central effect antipsychot agent sever extrapyramid symptom occur patient monitor therapi aclidinium may enhanc anticholinerg effect anticholinerg agent avoid combin alcohol ethyl cn depress may enhanc cn depress effect alcohol ethyl monitor therapi alizaprid may enhanc cn depress effect cn depress monitor therapi amifampridin may diminish anticholinerg effect anticholinerg agent anticholinerg agent may diminish therapeut effect amifampridin monitor therapi amisulprid antipsychot agent may enhanc advers toxic effect amisulprid manag drug list except monograph discuss detail separ drug interact monograph avoid combin amisulprid may enhanc qtc prolong effect qt prolong antipsychot moder risk avoid combin amphetamin antipsychot agent may diminish stimulatori effect amphetamin monitor therapi anticholinerg agent may enhanc advers toxic effect anticholinerg agent monitor therapi antidiabet agent hyperglycemia associ agent may diminish therapeut effect antidiabet agent monitor therapi antihepacivir combin product may decreas serum concentr olanzapin monitor therapi anti parkinson agent dopamin agonist antipsychot agent second gener [atypical] may diminish therapeut effect anti parkinson agent dopamin agonist manag consid use altern antipsychot agent possibl patient parkinson diseas atyp antipsychot necessari consid use clozapin quetiapin may convey lowest interact risk consid therapi modif azelastin nasal cn depress may enhanc cn depress effect azelastin nasal avoid combin benzodiazepin olanzapin may enhanc advers toxic effect benzodiazepin manag avoid concomit use parenter benzodiazepin im olanzapin due risk addit advers event e g cardiorespiratori depress olanzapin prescrib inform provid specif recommend regard oral administr avoid combin blonanserin cn depress may enhanc cn depress effect blonanserin consid therapi modif blood pressur lower agent may enhanc hypotens effect antipsychot agent second gener [atypical] monitor therapi brimonidin topic may enhanc cn depress effect cn depress monitor therapi bromoprid may enhanc advers toxic effect antipsychot agent avoid combin bromperidol may enhanc cn depress effect cn depress avoid combin buprenorphin cn depress may enhanc cn depress effect buprenorphin manag consid reduc dose cn depress avoid drug patient high risk buprenorphin overus self inject initi buprenorphin patch butran brand mcg hr adult use cn depress consid therapi modif bupropion may enhanc neuroexcitatori seizur potenti effect agent seizur threshold lower potenti monitor therapi cannabidiol may enhanc cn depress effect cn depress monitor therapi cannabi may decreas serum concentr cyp substrat high risk induc monitor therapi cannabi may enhanc cn depress effect cn depress monitor therapi carbamazepin may decreas serum concentr olanzapin monitor therapi chloral betain may enhanc advers toxic effect anticholinerg agent monitor therapi chlormethiazol may enhanc cn depress effect cn depress manag monitor close evid excess cn depress chlormethiazol label state appropri reduc dose use combin must use consid therapi modif chlorphenesin carbam may enhanc advers toxic effect cn depress monitor therapi cimetropium anticholinerg agent may enhanc anticholinerg effect cimetropium avoid combin clarithromycin qt prolong antipsychot moder risk may enhanc qtc prolong effect clarithromycin manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi clozapin qt prolong antipsychot moder risk may enhanc qtc prolong effect clozapin manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi cn depress may enhanc advers toxic effect cn depress monitor therapi cyp induc moder may decreas serum concentr cyp substrat high risk induc monitor therapi cyp inhibitor moder may decreas metabol cyp substrat high risk inhibitor monitor therapi cyproteron may decreas serum concentr cyp substrat high risk induc monitor therapi deferasirox may increas serum concentr cyp substrat high risk inhibitor monitor therapi deutetrabenazin may enhanc advers toxic effect antipsychot agent specif risk akathisia parkinson neurolept malign syndrom may increas monitor therapi dimethinden topic may enhanc cn depress effect cn depress monitor therapi domperidon qt prolong agent moder risk may enhanc qtc prolong effect domperidon manag consid altern drug combin combin monitor qtc interv prolong ventricular arrhythmia patient addit risk factor qtc prolong may even higher risk consid therapi modif doxylamin may enhanc cn depress effect cn depress manag manufactur diclegi doxylamin pyridoxin intend use pregnanc specif state use cn depress recommend monitor therapi dronabinol may enhanc cn depress effect cn depress monitor therapi droperidol qt prolong antipsychot moder risk may enhanc qtc prolong effect droperidol manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi eluxadolin anticholinerg agent may enhanc constip effect eluxadolin avoid combin fluoxetin may enhanc qtc prolong effect qtc prolong agent moder risk monitor therapi flupentixol qt prolong antipsychot moder risk may enhanc qtc prolong effect flupentixol manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi fluvoxamin may increas serum concentr olanzapin monitor therapi gastrointestin agent prokinet anticholinerg agent may diminish therapeut effect gastrointestin agent prokinet monitor therapi glucagon anticholinerg agent may enhanc advers toxic effect glucagon specif risk gastrointestin advers effect may increas monitor therapi glycopyrrol oral inhal anticholinerg agent may enhanc anticholinerg effect glycopyrrol oral inhal avoid combin glycopyrronium topic may enhanc anticholinerg effect anticholinerg agent avoid combin guanethidin antipsychot agent may diminish therapeut effect guanethidin monitor therapi haloperidol qt prolong antipsychot moder risk may enhanc qtc prolong effect haloperidol manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi hydrocodon cn depress may enhanc cn depress effect hydrocodon manag avoid concomit use hydrocodon benzodiazepin cn depress possibl agent combin altern treatment option inadequ combin limit dosag durat drug consid therapi modif hydroxyzin may enhanc cn depress effect cn depress monitor therapi iohexol agent seizur threshold lower potenti may enhanc advers toxic effect iohexol specif risk seizur may increas manag discontinu agent may lower seizur threshold hour prior intrathec use iohexol wait least hour procedur resum agent nonelect procedur consid use prophylact anticonvuls consid therapi modif iomeprol agent seizur threshold lower potenti may enhanc advers toxic effect iomeprol specif risk seizur may increas manag discontinu agent may lower seizur threshold hour prior intrathec use iomeprol wait least hour procedur resum agent nonelect procedur consid use prophylact anticonvuls consid therapi modif iopamidol agent seizur threshold lower potenti may enhanc advers toxic effect iopamidol specif risk seizur may increas manag discontinu agent may lower seizur threshold hour prior intrathec use iopamidol wait least hour procedur resum agent nonelect procedur consid use prophylact anticonvuls consid therapi modif ipratropium oral inhal may enhanc anticholinerg effect anticholinerg agent avoid combin itoprid anticholinerg agent may diminish therapeut effect itoprid monitor therapi kava kava may enhanc advers toxic effect cn depress monitor therapi lamotrigin may enhanc sed effect olanzapin monitor therapi levosulpirid anticholinerg agent may diminish therapeut effect levosulpirid avoid combin lithium may enhanc neurotox effect antipsychot agent lithium may decreas serum concentr antipsychot agent specif note chlorpromazin monitor therapi magnesium sulfat may enhanc cn depress effect cn depress monitor therapi mequitazin antipsychot agent may enhanc arrhythmogen effect mequitazin manag consid altern one agent possibl combin specif contraind mequitazin label describ combin discourag consid therapi modif methotrimeprazin cn depress may enhanc cn depress effect methotrimeprazin methotrimeprazin may enhanc cn depress effect cn depress manag reduc adult dose cn depress agent initi concomit methotrimeprazin therapi cn depress dosag adjust initi clinic effect methotrimeprazin dose establish consid therapi modif methylphenid antipsychot agent may enhanc advers toxic effect methylphenid methylphenid may enhanc advers toxic effect antipsychot agent monitor therapi metoclopramid may enhanc advers toxic effect antipsychot agent avoid combin metyrosin cn depress may enhanc sed effect metyrosin monitor therapi metyrosin may enhanc advers toxic effect antipsychot agent monitor therapi mianserin may enhanc anticholinerg effect anticholinerg agent monitor therapi minocyclin may enhanc cn depress effect cn depress monitor therapi mirabegron anticholinerg agent may enhanc advers toxic effect mirabegron monitor therapi mirtazapin cn depress may enhanc cn depress effect mirtazapin monitor therapi nabilon may enhanc cn depress effect cn depress monitor therapi nitroglycerin anticholinerg agent may decreas absorpt nitroglycerin specif anticholinerg agent may decreas dissolut sublingu nitroglycerin tablet possibl impair slow nitroglycerin absorpt monitor therapi obetichol acid may increas serum concentr cyp substrat high risk inhibitor monitor therapi onabotulinumtoxina anticholinerg agent may enhanc anticholinerg effect onabotulinumtoxina monitor therapi ondansetron may enhanc qtc prolong effect qt prolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi opioid analges cn depress may enhanc cn depress effect opioid analges manag avoid concomit use opioid analges benzodiazepin cn depress possibl agent combin altern treatment option inadequ combin limit dosag durat drug consid therapi modif orphenadrin cn depress may enhanc cn depress effect orphenadrin avoid combin oxatomid may enhanc anticholinerg effect anticholinerg agent avoid combin oxomemazin may enhanc cn depress effect cn depress avoid combin oxycodon cn depress may enhanc cn depress effect oxycodon manag avoid concomit use oxycodon benzodiazepin cn depress possibl agent combin altern treatment option inadequ combin limit dosag durat drug consid therapi modif paraldehyd cn depress may enhanc cn depress effect paraldehyd avoid combin peginterferon alfa b may increas serum concentr cyp substrat high risk inhibitor monitor therapi pentamidin system may enhanc qtc prolong effect qt prolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi perampanel may enhanc cn depress effect cn depress manag patient take perampanel drug cn depress activ avoid complex high risk activ particularli drive requir alert coordin experi use combin consid therapi modif pimozid may enhanc qtc prolong effect qt prolong agent moder risk avoid combin piribedil antipsychot agent may diminish therapeut effect piribedil piribedil may diminish therapeut effect antipsychot agent manag use piribedil antiemet neurolept contraind use antipsychot neurolept except clozapin recommend avoid combin potassium chlorid anticholinerg agent may enhanc ulcerogen effect potassium chlorid manag patient drug substanti anticholinerg effect avoid use solid oral dosag form potassium chlorid avoid combin potassium citrat anticholinerg agent may enhanc ulcerogen effect potassium citrat avoid combin pramlintid may enhanc anticholinerg effect anticholinerg agent effect specif gi tract consid therapi modif qt prolong agent highest risk may enhanc qtc prolong effect olanzapin manag consid altern combin patient risk factor eg older age femal sex bradycardia hypokalemia hypomagnesemia heart diseas higher drug concentr like greater risk toxic consid therapi modif qt prolong antidepress moder risk qt prolong antipsychot moder risk may enhanc qtc prolong effect qt prolong antidepress moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi qt prolong antipsychot moder risk may enhanc qtc prolong effect olanzapin manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk except amisulprid clozapin droperidol flupentixol olanzapin pimozid monitor therapi qt prolong class ic antiarrhythm moder risk may enhanc qtc prolong effect qt prolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi qt prolong kinas inhibitor moder risk qt prolong antipsychot moder risk may enhanc qtc prolong effect qt prolong kinas inhibitor moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi qt prolong miscellan agent moder risk may enhanc qtc prolong effect qt prolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk except domperidon monitor therapi qt prolong moder cyp inhibitor moder risk may enhanc qtc prolong effect qt prolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi qt prolong quinolon antibiot moder risk may enhanc qtc prolong effect qt prolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi quinagolid antipsychot agent may diminish therapeut effect quinagolid monitor therapi ramosetron anticholinerg agent may enhanc constip effect ramosetron monitor therapi rimabotulinumtoxinb anticholinerg agent may enhanc anticholinerg effect rimabotulinumtoxinb monitor therapi ritonavir may decreas serum concentr olanzapin monitor therapi rufinamid may enhanc advers toxic effect cn depress specif sleepi dizzi may enhanc monitor therapi saquinavir qt prolong antipsychot moder risk may enhanc qtc prolong effect saquinavir manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi secretin anticholinerg agent may diminish therapeut effect secretin manag avoid concomit use anticholinerg agent secretin discontinu anticholinerg agent least half live prior administr secretin consid therapi modif select serotonin reuptak inhibitor cn depress may enhanc advers toxic effect select serotonin reuptak inhibitor specif risk psychomotor impair may enhanc monitor therapi serotonin modul may enhanc advers toxic effect antipsychot agent specif serotonin modul may enhanc dopamin blockad possibl increas risk neurolept malign syndrom antipsychot agent may enhanc serotonerg effect serotonin modul could result serotonin syndrom except nicergolin monitor therapi sodium oxyb may enhanc cn depress effect cn depress manag consid altern combin use combin use need consid minim dose one drug use sodium oxyb alcohol sed hypnot contraind consid therapi modif sulpirid antipsychot agent may enhanc advers toxic effect sulpirid avoid combin suvorex cn depress may enhanc cn depress effect suvorex manag dose reduct suvorex cn depress may necessari use suvorex alcohol recommend use suvorex drug treat insomnia recommend consid therapi modif tapentadol may enhanc cn depress effect cn depress manag avoid concomit use tapentadol benzodiazepin cn depress possibl agent combin altern treatment option inadequ combin limit dosag durat drug consid therapi modif teriflunomid may decreas serum concentr cyp substrat high risk induc monitor therapi tetrabenazin may enhanc advers toxic effect antipsychot agent monitor therapi tetrahydrocannabinol may enhanc cn depress effect cn depress monitor therapi tetrahydrocannabinol cannabidiol may enhanc cn depress effect cn depress monitor therapi thalidomid cn depress may enhanc cn depress effect thalidomid avoid combin thiazid thiazid like diuret anticholinerg agent may increas serum concentr thiazid thiazid like diuret monitor therapi tiotropium anticholinerg agent may enhanc anticholinerg effect tiotropium avoid combin tobacco smoke may diminish therapeut effect olanzapin tobacco smoke may decreas serum concentr olanzapin monitor therapi topiram anticholinerg agent may enhanc advers toxic effect topiram monitor therapi trimeprazin may enhanc cn depress effect cn depress monitor therapi umeclidinium may enhanc anticholinerg effect anticholinerg agent avoid combin valproat product may decreas serum concentr olanzapin monitor therapi voriconazol may enhanc qtc prolong effect qt prolong antipsychot moder risk manag monitor qtc interv prolong ventricular arrhythmia agent combin patient addit risk factor qtc prolong may even higher risk monitor therapi zolpidem cn depress may enhanc cn depress effect zolpidem manag reduc intermezzo brand sublingu zolpidem adult dose mg men also receiv cn depress dose chang recommend women avoid use cn depress bedtim avoid use alcohol consid therapi modif advers reaction oral cardiovascular orthostat hypotens central nervou system drowsi dose depend adolesc adult extrapyramid reaction dose depend adult adolesc akathisia adolesc adult parkinsonian like syndrom includ akinesia cogwheel rigid extrapyramid syndrom hypertonia hypokinesia make faci tremor dizzi adult adolesc headach adolesc fatigu dose depend adolesc adult insomnia endocrin metabol increas serum prolactin adolesc adult weight gain adult report high adolesc gastrointestin increas appetit adolesc adult xerostomia dose depend adult adolesc dyspepsia adult adolesc constip adolesc adult hepat increas serum ast adolesc decreas serum bilirubin adolesc increas serum alt x uln adolesc adult neuromuscular skelet weak dose depend miscellan accident injuri cardiovascular chest pain peripher edema tachycardia hypertens central nervou system person disord abnorm gait hypertonia restless adolesc fall older adult articul impair endocrin metabol increas gamma glutamyl transferas adolesc adult increas uric acid menstrual diseas includ amenorrhea hypomenorrhea delay menstruat oligomenorrhea breast chang male femal adolesc includ discharg enlarg galactorrhea gynecomastia lactat disord gastrointestin abdomin pain adolesc vomit diarrhea adolesc genitourinari urinari incontin adult older adult sexual disord adolesc anorgasmia delay ejacul erectil dysfunct chang libido abnorm orgasm sexual dysfunct urinari tract infect hematolog oncolog bruis hepat increas liver enzym adolesc increas serum alkalin phosphatas neuromuscular skelet tremor dose depend limb pain adolesc adult arthralgia adult adolesc back pain muscl rigid adolesc dyskinesia ophthalm amblyopia respiratori rhiniti cough nasopharyng adolesc pharyng epistaxi adolesc respiratori tract infect adolesc sinus adolesc miscellan fever inject frequenc alway defin unless otherwis note advers event report placebo control trial adult patient extend releas im inject zyprexa relprevv also refer advers reaction note oral therapi cardiovascular hypertens hypotens short act solut im inject prolong q interv ecg orthostat hypotens short act solut im inject central nervou system headach sedat drowsi im inject formul akathisia short act solut im inject dizzi im inject formul fatigu extrapyramid reaction solut im inject abnorm think auditori hallucin parkinsonian like syndrom short act solut im inject restless pain abnorm dream procedur pain sleep disord dysarthria dermatolog acn vulgari endocrin metabol weight gain gastrointestin diarrhea vomit xerostomia increas appetit nausea long act im formula short act solut inject tooth infect toothach abdomin pain flatul genitourinari vagin discharg hepat increas liver enzym infect viral infect local pain inject site im inject formul abscess inject site neuromuscular skelet arthralgia back pain muscl spasm stiff tremor long act im formula short act solut inject otic otalgia respiratori cough nasal congest nasopharyng upper respiratori tract infect pharyngolaryng pain sneez miscellan fever postmarket case report abdomin distens accommod disturb agranulocytosi alopecia anaphylactoid reaction angioedema ataxia cerebrovascular accid chill coma confus delirium diabet mellitu diabet ketoacidosi diabet coma difficulti micturit dress syndrom dri eye syndrom dysarthria facial edema hangov effect hepat injuri cholestat mix hepat hyperbilirubinemia hypercholesterolemia hyperglycemia hyperlipidemia hypermenorrhea hypertriglyceridemia hypoproteinemia impot increas creatin phosphokinas intestin obstruct jaundic ketosi leukocytosi eosinophilia leukopenia liver steatosi mastalgia mydriasi myopathi nausea neurolept malign syndrom neutropenia osteoporosi pancreat polyuria postinject delirium sedat syndrom priapism pruritu pulmonari edema pulmonari embol respiratori depress cole restless leg syndrom rhabdomyolysi seizur skin photosensit skin rash sleep apnea syndrom obstruct health canada shirani speech disturb stupor suicid tendenc syncop tardiv dyskinesia thrombocytopenia tongu edema transient ischem attack urinari frequenc urinari retent urinari urgenc urticaria vasodil venou thrombosi withdraw syndrom alert u box warn increas mortal elderli patient dementia relat psychosi elderli patient dementia relat psychosi treat antipsychot drug increas risk death analys placebo control trial modal durat week larg patient take atyp antipsychot drug reveal risk death drug treat patient time risk death placebo treat patient cours typic week control trial rate death drug treat patient approxim compar rate placebo group although caus death vari death appear either cardiovascular eg heart failur sudden death infecti eg pneumonia natur observ studi suggest similar atyp antipsychot drug treatment convent antipsychot drug may increas mortal extent find increas mortal observ studi may attribut antipsychot drug oppos characterist patient clear olanzapin approv treatment patient dementia relat psychosi postinject delirium sedat syndrom zyprexa relprevv advers reaction sign symptom consist olanzapin overdos particular sedat includ coma delirium report follow inject olanzapin extend releas er olanzapin er must administ regist health care facil readi access emerg respons servic inject patient must observ health care facil health care provid least hour risk olanzapin er avail restrict distribut program call zyprexa relprevv patient care program requir health care provid health care facil patient pharmaci enrol warn precaut concern relat advers effect alter cardiac conduct may alter cardiac conduct life threaten arrhythmia occur therapeut dose antipsychot anticholinerg effect may caus anticholinerg effect constip xerostomia blur vision urinari retent use caution patient decreas gastrointestin motil paralyt ileu urinari retent bph xerostomia visual problem includ narrow angl glaucoma rel neurolept olanzapin moder potenc cholinerg blockad richelson blood dyscrasia leukopenia neutropenia agranulocytosi sometim fatal report clinic trial postmarket report antipsychot use presenc risk factor eg preexist low wbc histori drug induc leuko neutropenia prompt period blood count assess discontinu therapi first sign blood dyscrasia absolut neutrophil count mm cerebrovascular effect increas incid cerebrovascular effect eg transient ischem attack stroke includ fatal report placebo control trial olanzapin unapprov use elderli patient dementia relat psychosi cn depress may caus cn depress impair physic mental abil patient must caution perform task requir mental alert eg oper machineri drive may moder highli sedat comparison antipsychot apa [lehman ] dose relat effect observ dyslipidemia dose relat increas cholesterol triglycerid note use caution patient preexist abnorm lipid profil compar antipsychot risk dyslipidemia high solmi esophag dysmotil aspir antipsychot use associ esophag dysmotil aspir risk increas age use caution patient risk aspir pneumonia ie alzheim diseas particularli patient year herzig maddalena extrapyramid symptom may caus extrapyramid symptom ep includ pseudoparkinson acut dyston reaction akathisia tardiv dyskinesia risk reaction gener much lower rel typic convent antipsychot frequenc report similar placebo risk dystonia probabl ep may greater increas dose use convent antipsychot male younger patient factor associ greater vulner tardiv dyskinesia includ older age femal gender combin postmenopaus statu parkinson diseas pseudoparkinson symptom affect disord particularli major depress disord concurr medic diseas diabet previou brain damag alcohol poor treatment respons use high dose antipsychot apa [lehman ] soar weiser consid therapi discontinu sign symptom tardiv dyskinesia fall may increas risk fall due somnol orthostat hypotens motor sensori instabl complet fall risk assess baselin period treatment patient diseas medic may also increas fall risk hyperglycemia atyp antipsychot associ develop hyperglycemia case may extrem associ ketoacidosi hyperosmolar coma death olanzapin may greater associ hyperglycemia atyp antipsychot use caution patient diabet disord glucos regul monitor worsen glucos control patient risk factor diabet eg obes famili histori baselin fast blood sugar fb period assess glucos regul compar antipsychot risk hyperglycemia high solmi hyperprolactinemia may caus dose relat increas prolactin level clinic signific hyperprolactinemia patient breast cancer prolactin depend tumor unknown clinic manifest increas prolactin level includ menstrual sexual breast relat event multiorgan hypersensit reaction drug reaction eosinophilia system symptom [dress] potenti seriou sometim fatal multiorgan hypersensit reaction dress report symptom may includ cutan reaction rash exfoli dermat eosinophilia fever lymphadenopathi system complic eg hepat nephriti pneumon myocard pericard discontinu olanzapin dress suspect neurolept malign syndrom nm use may associ nm monitor mental statu chang fever muscl rigid autonom instabl orthostat hypotens may caus orthostat hypotens use caution patient risk effect would toler transient hypotens episod cerebrovascular diseas cardiovascular diseas hypovolemia concurr medic use may predispos hypotens bradycardia suicid ideat possibl suicid attempt inher psychot ill bipolar disord use caution high risk patient initi therapi prescript written smallest quantiti consist good patient care temperatur regul impair core bodi temperatur regul may occur caution strenuou exercis heat exposur dehydr concomit medic possess anticholinerg effect weight gain signific weight gain baselin weight observ antipsychot therapi incid vari product dose relat chang observ olanzapin monitor waist circumfer bmi compar antipsychot risk weight gain high solmi diseas relat concern cardiovascular diseas use caution patient sever cardiac diseas hemodynam instabl prior myocardi infarct ischem heart diseas hypercholesterolemia dementia [u box warning] elderli patient dementia relat psychosi treat antipsychot increas risk death compar placebo death appear either cardiovascular eg heart failur sudden death infecti eg pneumonia natur use caution patient lewi bodi dementia parkinson diseas dementia due greater risk advers effect increas sensit extrapyramid effect associ irrevers cognit decompens death apa [reu ] olanzapin approv treatment dementia relat psychosi hepat impair use caution patient hepat diseas impair may increas transaminas primarili alt parkinson diseas use caution patient parkinson diseas antipsychot may aggrav motor disturb apa [lehman ] apa [reu ] renal impair use caution patient renal diseas seizur use caution patient risk seizur includ histori seizur head trauma brain damag alcohol concurr therapi medic may lower seizur threshold elderli patient may increas risk seizur increas preval predispos factor concurr drug therapi issu drug drug interact potenti signific interact may exist requir dose frequenc adjust addit monitor select altern therapi consult drug interact databas detail inform special popul adolesc use patient year age may result increas weight gain sedat well greater increas ldl cholesterol total cholesterol triglycerid prolactin liver transaminas level compar adult adolesc patient maintain lowest dose necessari smoker olanzapin level may lower patient smoke smoker may requir daili dose higher nonsmok order obtain equival olanzapin concentr tsuda howev manufactur routin recommend dosag adjust dosag form specif concern intramuscular formul two zyprexa formul intramuscular inject zyprexa relprevv extend releas formul zyprexa intramuscular short act extend releas im inject zyprexa relprevv postinject delirium sedat syndrom [u box warning] sedat includ coma delirium includ agit anxieti confus disorient observ follow use zyprexa relprevv event associ inadvert rapid rise serum concentr administ regist health care facil patient continu monitor hour symptom olanzapin overdos symptom develop highest first hour may occur within hour risk syndrom cumul inject recoveri expect hour upon determin alert statu patient escort destin drive oper heavi machineri remaind day unexplain death two unexplain death patient receiv zyprexa relprevv report patient die day receiv appropri dose drug patient found high blood concentr olanzapin postmortem unclear death result postinject delirium sedat syndrom pdss fda safeti commun restrict distribut program zyprexa relprevv avail restrict distribut program prescrib health care facil pharmaci regist program abl prescrib distribut dispens zyprexa relprevv patient enrol meet condit program short act im inject zyprexa intramuscular patient remain recumb drowsi dizzi hypotens bradycardia hypoventil rule close monitor orthostasi prior repeat dose concurr use im iv benzodiazepin recommend fatal report though causal determin phenylalanin product may contain phenylalanin polysorb dosag form may contain polysorb also known tween hypersensit reaction usual delay reaction report follow exposur pharmaceut product contain polysorb certain individu isaksson lucent shelley thrombocytopenia ascit pulmonari deterior renal hepat failur report prematur neonat receiv parenter product contain polysorb alad cdc see manufactur label warn precaut discontinu therapi discontinu antipsychot therapi american psychiatr associ apa canadian psychiatr associ cpa world feder societi biolog psychiatri wfsbp guidelin recommend gradual taper antipsychot avoid physic withdraw symptom includ anorexia anxieti diaphoresi diarrhea dizzi dyskinesia headach myalgia nausea paresthesia restless tremul vomit apa [lehman ] cpa [addington ] lambert wfsbp [hasan ] risk withdraw symptom highest follow abrupt discontinu highli anti cholinerg dopaminerg antipsychot cerovecki addit factor durat antipsychot exposur indic use medic half life risk relaps consid schizophrenia reliabl indic differenti minor major relaps drug discontinu howev studi medic well stabil patient discontinu indic patient relaps within month indefinit mainten antipsychot medic gener recommend especi patient multipl prior episod episod within year apa [lehman ] iv administr iv administr studi emerg depart set patient close monitor respiratori depress ie puls oximetri chan cole martel taylor monitor paramet mental statu vital sign clinic indic blood pressur baselin repeat month antipsychot initi yearli weight height bmi waist circumfer baselin repeat week initi chang therapi quarterli consid switch differ antipsychot weight gain initi weight cbc clinic indic monitor frequent first month therapi patient pre exist low wbc histori drug induc leukopenia neutropenia electrolyt liver function annual clinic indic person famili histori obes diabet dyslipidemia hypertens cardiovascular diseas baselin repeat annual fast plasma glucos level hba c baselin repeat month start antipsychot yearli fast lipid panel baselin repeat month initi antipsychot ldl level normal repeat year interv frequent clinic indic chang menstruat libido develop galactorrhea erectil ejaculatori function visit first week antipsychot initi dose stabl yearli abnorm involuntari movement parkinsonian sign baselin repeat weekli dose stabil least week introduct week signific dose increas tardiv dyskinesia everi month high risk patient everi month ocular examin yearli patient year everi year younger patient ada lehman marder extend releas im inject sedat delirium hour dose pregnanc risk factor c pregnanc consider advers event observ anim reproduct studi olanzapin cross placenta detect cord blood birth newport antipsychot use third trimest pregnanc risk abnorm muscl movement extrapyramid symptom [eps] withdraw symptom newborn follow deliveri symptom newborn may includ agit feed disord hypertonia hypotonia respiratori distress somnol tremor effect may self limit requir hospit acog recommend therapi pregnanc individu treatment psychiatr medic pregnanc incorpor clinic expertis mental health clinician obstetrician primari health care provid pediatrician safeti data relat atyp antipsychot pregnanc limit routin use recommend howev woman inadvert expos atyp antipsychot pregnant continu therapi may prefer switch agent fetu yet expos consid risk benefit acog treatment need woman plan pregnanc treatment initi pregnanc olanzapin may use larsen olanzapin may caus hyperprolactinemia may decreas reproduct function male femal health care provid encourag enrol women year age expos olanzapin pregnanc atyp antipsychot pregnanc registri http www womensmentalhealth org pregnancyregistri patient educ discuss specif use drug side effect patient relat treatment hcahp hospit stay given medicin taken give new medicin often hospit staff tell medicin often hospit staff describ possibl side effect way could understand patient may experi agit loss strength energi constip dri mouth nausea weight gain increas appetit back pain inject site irrit patient report immedi prescrib sign infect sign high blood sugar confus fatigu thirst hunger polyuria flush fast breath breath smell like fruit anxieti confus sever fatigu weak sever headach abnorm movement twitch chang balanc difficulti swallow difficulti speak mood chang suicid ideat behavior chang sever dizzi pass bradycardia tachycardia lack sweat seizur drool vision chang memori impair chest pain swell arm leg burn numb feel swollen gland enlarg breast nippl discharg sexual dysfunct amenorrhea sign neurolept malign syndrom fever muscl cramp stiff dizzi sever headach confus chang think tachycardia abnorm heartbeat sweat lot sign tardiv dyskinesia unabl control bodi movement tongu face mouth jaw stick mouth pucker puf cheek hcahp educ patient sign signific reaction eg wheez chest tight fever itch bad cough blue skin color seizur swell face lip tongu throat note comprehens list side effect patient consult prescrib addit question intend use disclaim print given patient inform intend serv concis initi refer health care profession use discuss medic patient must ultim reli discret experi judgment diagnos treat advis patient',\n",
       " 'keep diari know suppos long see up down relaps part feel need except cours come head neuro believ inject stop none slow relaps rate tri differ one stop tecfidera fingolimod extrem side effect advic ms nurs neuro mif say least forc take terifluonomid consid anyth els also concern turn round say want take anymor honest quit close burn bridg neuro thank repli agre take dmd sarah',\n",
       " 'drug chemo therapi target therapi tarceva result rash sever nail chang fatigu kept cancer bay year switch tagrisso side effect work month far',\n",
       " 'final sever year drug rrm tri plegridi tecfidera final back get ocrevu clinic trial work spectacularli excit amus infus center netbook usb silent film lucki lionel barrymor rasputin shirt let see goe ye appli reciev copay assist ocrevuscopay com interest',\n",
       " 'kimberlamb yervoy pd l inhibitor ctla inhibitor show superior respons opdivo opdivo alon combin block differ checkpoint cancer escap combo checkpoint like opdivo keytruda opdivo tecentriq would total redund',\n",
       " 'start stelara past spring humira treatment began fail first infus load dose went fine given benadryl first inject littl inject site redd day later next inject itch side stomach around inject site week next inject extrem itch guess thought reaction get better wors time stelara help crohn symptom final inject worst reaction immedi start itch week next went neck face lip swell rash blister bit look like chicken pox seen derm gi immunologist agre stelara taken treat prednison topic cream antibodi remicad go back took almost year ago stelara rash continu finish prednison cours wonder stelara reaction trigger anoth type autoimmun skin condit biopsi next week anyon els reaction like biolog never skin issu thank amat join nov search board messag relat topic solut uc prob jamesmadison join mar diagnos uc usua read cbd ulcer coliti mskelli join jun post board regard read humira possibl drug ljkclark join jul anyon develop drug induc lupu humir read crohn coliti commun forum thank help monitor crohn coliti commun abus report sent inform crohn coliti commun site replac physician advic alway check person physician take action regard health crohn coliti foundat websit support educ grant rule welcom crohn coliti commun websit associ ccfa org support educ grant abbvi pleas read top rule post messag share stori alway courteou sensit other intend audienc crohn coliti foundat onlin commun intend patient caregiv famili friend commun intend industri repres advertis individu permit particip site meet crohn coliti commun brows site see commun talk find issu import join share stori feel comfort site regist share thought regular basi stay secur rememb site view anyon internet except registr person page search engin avail within site guard privaci follow simpl rule share address phone number detail famili anyth els would feel uncomfort other read post person email awar may receiv spam e mail spammer gather address web read react post care agre offend someon post take step back think repli sinc talk person must recogn may misunderstand stori post pleas sensit other feel ask clarif act search start new topic keep messag board easi use pleas use search bar locat topic interest start new thread start new thread pleas use obviou subject head word catch attent other topic archiv day inact view past topic post click archiv topic within forum stick guidelin keep site safe everyon pleas post doctor name treatment facil name treatment specif contact inform other without consent link websit uncertain content advertis request fundrais item sale request studi survey questionnair particip provoc inform share photo pleas use good tast appropri imag ad photo profil person stori photo jpg format follow rule crohn coliti commun moder routin scan messag board delet tasteless post post inappropri messag pictur use offens languag post multipl occas notifi via email account inactiv report foul play help crohn coliti commun moder report anyon post inappropri messag pictur click report abus button messag email ccfacommun ccfa org question concern pleas feel free email us ccfacommun ccfa org question concern want feel comfort term condit post stori question concern inform commun grant crohn coliti foundat author agent permiss publish reproduc record use stori crohn coliti commun author agent see fit medium forum manner help crohn coliti commun mission agre releas hold harmless crohn coliti commun liabil third parti may aris releas inform third parti third parti agre text content made person parent guardian shall exclus properti crohn coliti commun crohn coliti commun cannot verifi everi claim made third parti contributor commun respons authent inform post',\n",
       " 'hi stumbler nice id btw got good team specialist doctor nurs feel like famili sort nice kind talk nurs discuss carri report pml henc need lumbar punctur whichev decid chang gone long time mani question answer may say choic gilenya mavenclad lemtrada new one call ocrevu avail next month report pml around macclesfield south manchest stockport remain posit way dark ginger hair kid wore glass age say ging maketh man',\n",
       " 'still fairli new crohn offic diagnos june week hospit bowel blockag sepsi remicad year stop work develop antibodi put humira didnt seem anyth gi took anyth methotrex coupl month diseas still activ noth sever far gi want tri stelara anyon bad side effect trish',\n",
       " 'frankielideo good high level understand would suggest given prefer solv issu forget gilenya costli us maintain daili treatment forev could select instead lemtrada part nh get safer effect treatment complet month way dmt cost requir state cost relat ms could insur polici provid employ medicar depend age healthcar cost unpredict recent effort unilater social tradit free market base healthcar system repres fulli one sixth nation economi see cost skyrocket avail declin result btw novel infus requir lemtrada one reason select older dmt',\n",
       " 'hello christina sorri learn eye problem uk eyesright suggest pleas call helplin pm monday friday difficult advis forum even email need get answer exact diagnosi hospit consult central serou retinopathi csr also known central serou chorioretinopathi csc cscr eye diseas caus visual impair often temporari usual one eye wet macular degener ofetn describ small bleed back eye often treat anti vegf inject eylea lucenti sometim avastin label uk pleas see booklet treatment follow link macularsocieti org site de best wish macular societi',\n",
       " 'one medic ocrevu ocrelizumab approv u food drug administr fda treat primari progress ms well relaps form ms addit diseas modifi therapi wide rang symptomat medic rehabilit strategi use manag ppm back top approv diseas modifi medic help relaps ms work ppm diseas modifi medic current avail primarili target inflamm central nervou system cn shown reduc number acut relaps also call attack exacerb number new lesion also call plaqu magnet reson imag mri scan ppm involv much less inflamm gradual destruct loss nerv fiber result peopl ppm tend fewer brain lesion also call plaqu peopl relaps ms lesion tend contain fewer inflammatori cell avail diseas modifi medic effect slow neural damag occur ppm back top doctor told kind ms recommend start diseas modifi therapi tell diseas cours medic harm ppm doctor may still unsur diseas cours physician scientist identifi four cours ms person diseas cours uniqu may fit precis within one anoth may take time doctor decid cours person ms follow peopl transit inflammatori relaps remit diseas cours less inflammatori secondari progress diseas cours may may continu relaps may doctor determin transit occur inform would factor decis diseas modifi therapi would right doctor determin ppm may recommend start ocrevu medic approv fda treatment ppm well relaps form ms back top ms keep get wors everyon ppm becom sever disabl ms variabl unpredict diseas although ppm character fairli steadi progress one person symptom may progress differ rapidli someon els symptom spinal cord lesion also call plaqu common brain lesion ppm problem walk common symptom may occur well medic ocrevu approv treat ppm well relaps form ms medic may slow progress experienc time ongo symptom manag rehabilit strategi help stay activ maintain safeti independ enhanc qualiti life back top read differ symptom ms caus sinc diagnosi ppm biggest problem walk develop symptom well peopl ppm tend spinal cord lesion brain lesion problem walk common fact onset ppm usual character gradual increas problem gait lesion spinal cord also caus bladder bowel symptom well sexual dysfunct fatigu lesion brain could caus symptom develop includ visual disturb cognit chang mood chang balanc problem tremor among other howev way predict ahead time primari challeng may continu walk',\n",
       " 'feb chucksan wrote pleas click name andread post opdivo keytruda also tencentriq good result mayb less patient much better chemo significantli less side effect wife one lucki gone complet remiss opdivo stage nsclc squamou opioid ok pain plain otc ibuporfen advil motrin good result mani wife sinc pain caus tumor push bone ibuprofen anti inflammatori drug help wife lot immunolgi drug work cancer differ manner thank chuck actual came across post post felt happi know work stage ever sinc dad diagnos tell go remiss plain blind hope thank inform appreci spread hope us share experi help inde',\n",
       " 'hi quantummechan like wait ocrevu ppm yet anyth although assess suitabl take fampyra st month free expens otherwis like worri take might negat tri ocrevu get approv also experienc gradual symptom tough think ask power neurologist ms nurs advis regret though stumbler wise say tti stick though grasp run wall walk wheelchair keep sens humour howev difficult essenti get quagmir ms pair good boot keep fight xxx',\n",
       " 'hi diagnos two year ago sinc copaxon mri three month ago show small new small lesion want talk doctor switch gilenya unfortun inject damag skin big ugli dent leg small one arm part terrifi gilenya macular edema would like know feel take develop vision problem macular edema gilenya websit say stop immedi first sign vision problem rebif thank',\n",
       " 'husband amd one shot lucenti affect eye per doctor eye good dr said folk take care one sever treatment dh lucki',\n",
       " 'realli want thing normal anyway never realli need normalci normal new normal typic sens normal live metastat cancer live well must say need develop mani strategi work around lot help definit worth qualiti life realli matter mayb strategi work other learn rememb energi limit import kind tricki move target day great energi deep deep odd tired day though wake get go go strong noon anybodi guess learn week longer abl push like alway old life done done kind like babi okay priorit sometim bonu time someth love love alway believ make great sens well lot thing love anymor yet normal okay discov love lot thing focus time one still like photographi natur mayb adjust learn new thing thing like write blog sure time read love read pretti much anyth four book go right one fiction two health relat one nonfict natur base none educ first short breath huf puf realli found good strategi except go slow steadi like much run spring determin walk new orthofeet sneaker digest system issu first start crizotinib took differ med system could toler imodium went everywher never knew bout diarrhea advanc notic usual pad dispos underwear extra cloth dispos wipe carri backpack everywher seem normal becam routin addit cloth tri rememb carri food know eat case eat avail queen lorlatinib current target therapi drug digest system issu much less time finger cross lorlatinib brought new challeng refer earlier one neuropathi common peopl chemotherapi drug peopl diabet much love go barefoot cannot even hous anyon inkl neuropathi feet start wear shoe slipper time learn hard way hand neuropathi tri acupunctur help tremend tri ointment cannabinoid oil found someth yet say give relief neuropathi wear glove work even drive keep feet well pad work best stand still long period time lot peel veggi thing sure bother fortun tri work luckili good sleeper bother much night oh ye ignor feel tick crawl ankl mayb probabl neuropathi best check spend lot time look ankl weight interest problem past year four month fire fall decid buy absolut need cloth becam sick began lose weight time start crizotinib march lost lb ever terribl overweight cancer take toll radiat number esophagu month eat much eat mostli liquid form food etc far cloth went thank radiat stand anyth near neck wear bra daughter bought size small stretchi pant v neck loos top prefer wardrob ever sinc eventu gain weight back crizotinib weight gain common drug idea store lorlatinib began juli everyon know target therapi drug still clinic trial problem degre start gain pound week ye one pound per week eeek simpli feel better eat abl exercis enough thank stretchi cloth move medium keep mind fire resolut bought need begin feel uncomfort extra weight januari gain sinc begin lorlatinib juli januari much pregnanc weight gain march januari lb weight gain pregnanc combin without even tri lose gain back plu final januari trial nurs mention someon success paleo diet tri wrote earlier paleo work immedi lost pound gain long feel well learn weight loss cancer treatment weight gain side effect common work around eat well wear comfi cloth final tri understand normal think mayb greatest lesson greatest bless gain journey okay let even ask other thing anyth someon els littl ill began truli understand gratitud express grate grate peopl care want thing make life easier brighter struggl someth life still want everyth feel badli ask help let someon els energi strength feel love grate like look thing brighten day late week go dana farber scan blood work brain mri ekg oncolog appoint dan drive wait patient everi step day post updat hope weekend prayer posit energi thought follow cancer journey give strength basebal softbal start children fun time grandpar find joy everyday everi day dan famili littl dachshund dotti matilda nigerian dwarf goat',\n",
       " 'biosimilar rituximab avastin come roch go give fight cash ocrelizumab glad swedish neurologist show common sens fight back price new drug hideou',\n",
       " 'ye u doctor avail make comment thank diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'hello want see doctor would tri combin carbo alimta tarceva either togeth intercal stage lung cancer egfr mutat mother respond initi tagrisso part treatment possibl lepto carcinomatosi cn fine develop possibl pneumon tagrisso stop restart tarceva week next pet month tarceva show signific reduct size activ primari lung mass progress lymph pleura stop tarceva start chemotherapi two week one cycl chemotherapi increas size primari mass pleural effus gone think cell respond chemo cell respond tarceva oncologist say studi shown benefit increas toxic combin read good data pf combin thought thank',\n",
       " 'alesia trial compris treatment na patient advanc anaplast lymphoma kinas transloc posit non small cell lung cancer confirm system intracrani efficaci alectinib crizotinib asian popul',\n",
       " 'thank janin diagnos back jan underw carbo almita cycl good result next put mainten treatment almita progress cycl went afatinib tagrisso fail put carbo taxol howev side effect harsh opt opdivo know immunotherapi usual bode well egfr howev mutat kra includ mutat load high enough may indic good respons understand chemo probabl safest way go term get good respons fast someth els compat almita efficaci side effect get back taxol would probabl difficult thank much help ilan p sort radiat treatment option liver met numer mayb target main one thank',\n",
       " 'fail remicad cimzia humira entivyo sigh insur cover stelara experiment unsubstanti yo male northwood wisconsin dx crohn sept sb resect laproscop ileocecectomi medic issu anxieti depress panic attack med cymbalta xanax',\n",
       " 'hi tia diagnos rrm prescrib avonex made realiti ms miser help think mani folk poorli drug miss dose needl case longer year copaxon got hard administ inject site degrad neuro put techdidera take ever sinc familiar gilenya side effect got past first dose techfidera problem flash friend ask sun warn first dose start mg thought go visit emerg room stomach pain intens warn thought needl previou med push great techfidera would recommend give go caution medic effect us differ give bodi chanc get use cogniz possibl initi side effect make sure start lower dose hope help good luck michael',\n",
       " 'dekkor locat pretti close lucki two good ms center near ucsf stanford wife diagnos year ago went process go go stanford locat penisula think given qualiti ms center area main question might want consid compliementari treament improv odd treatment horizon may impact decis particular treatment today diagnost might done default consid refer later area given effici seem move process like given choic tecfidera gileyna ocrevu let us know offer went tecfidera avoid gileyna littl tricki come ocrevu new offici less year sinc full fda approv term point would strongli recommend order copi overcom ms point would make sure test jcv may default would also see mri mri resolut make big differ decid year didnt push anoth month thing consid would recommend start get familar thing get lot appoint come prepar knowledg video would recommend well long bit dri worth time reput ms center us',\n",
       " 'helli realis answer half question think cladribin might cure peopl mayb sens cladribin seem stop deterior someth like half peopl see improv well think cladribin lemtrada lot cheaper drug take rest life effect drug compani want close huge market tecifidera tysabri gilenya etc etc probabl think cladribin better drug lemtrada effect less side effect cladribin may good drug compani want',\n",
       " 'vitrectomis eye slower equal respons intravitr anti vegf histori vitrectomi contraind anti vegf therapi eye diabet macular oedema dme new research suggest prospect studi statist signific differ safeti efficaci intravitr ranibizumab vitrectomis non vitrectomis [ ]',\n",
       " 'kick ass morn new workout stood feet record minut omg incred grant feet move much ok tremend amount time physic therapi one main thing peopl multipl sclerosi peopl realli stand anymor put devic either stand strap bar hold big thing stand feet especi without hold feet might move danc step arm move whole time therefor minut arm move hold new spectscular amount time stand concret evid tell pool three day week pool kind ton thing pool never land type therapi extrem help pool feet whole time say anoth huge compon vital pack take doterra first foremost sleep better sleep longer stretch sleep deeper sleep wake feel rest nap afternoon week energi level seem much higher honestli believ vitamin game changer work insid support cell bodi natur vitamin miner omega capsul huge differ noth much chang go back ocrevu infus wednesday first full dose infus certainli blog still whole heartedli agre biotin high dosag take would definit speak doctor howev talk year half think big chang right bodi today go back gener doctor go emerg room visit last week doctor decid realli need see cardiologist regard elev muscular skelet enzym neurologist seem believ statin prescrib decis stay drug buy one actual anyth final end endocrinologist see weight still creep indic definit ms relat like believ proud morn feel good abl accomplish workout still even ms',\n",
       " 'hi afi welcom grace good hear opdivo show good result understand interest readi futur treatment option point clear well neg egfr posit patient fare tagrisso dr west wrote month ago third gener egfr tki may prove offer meaning benefit patient neg acquir resist may need search better option elsewher http cancergrac org lung osi vs roci regard howev new biopsi perform test cancer progress tarceva post seem genet test done prior treatment junctur mutat would de novo mutat one present start rather one develop treatment new biopsi possibl mutat present anoth question cancer progress initi therapi carbo alimta chang tarceva come prescrib number chemo cycl without evid progress patient stop treatment respond progress reason consid return treatment case sinc repeat platinum agent advis due increas toxic return pemetrex alimta could consid jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'tri post repli site problem accept hi daxi mum rel rare egfr mutat exon g x thought respond better second gener tki like afatinib st rd gener see egfr exon mutat lung cancer molecular predictor augment sensit afatinib neratinib compar first third gener tki exon mutat includ g x e x exon delet present egfr mutat lung cancer harbor mutat appear higher sensit second gener tki especi afatinib neratinib first third gener tki base vitro experi well clinic data although current avail vitro diagnost kit detect exon mutat lung cancer harbor exon mutat overlook clinic practic patient tumor best treat afatinib neratinib http clincancerr aacrjourn org content clincanr earli ccr full pdf also pattern resist rare mutat differ usual one exon like mum pick mutat seem promis look erlotinib osimertinib look see find anyth promis one option might quadrupl therapi impow trial would tri hard get tissu biopsi chest xray found nodul part physic symptom upper left lobe lingula preserv lobectomi stage b cm invas adenocarcinoma addit mm ai nodul found patholog sixteen week adjuv cisplatin vinorelbin durvalumab adjuv clinic trial discontinu st dose knock thyroid revis stage b due vpi new guidelin multifoc lepid lung cancer next scan',\n",
       " 'thank info word honest probabl nervou chemo glad found place question come place ask thank hour ago repli durvalumab eagl repli robert macaulay topic immunotherapi ask biomark test minimum get pdl test see good candid durvalamb biomark test realli way go found treatment good candid durvalamb sinc pdl test prior start treatment biomark test done target therapi day take tagrisso sinc egfr mutat b went stage durvalamb target therapi stop progress cancer revers lymph node base measur ct scan spot power prayer',\n",
       " 'flik e mab index term avakin infliximab recombin infliximab abda infliximab dyyb infliximab qbtx ixifi dosag form excipi inform present avail limit particularli gener consult specif product label solut reconstitut intraven inflectra infliximab dyyb mg ea [contain polysorb ] solut reconstitut intraven [preserv free] remicad mg ea [contain polysorb ] renflexi infliximab abda mg ea [contain polysorb ] brand name u inflectra remicad renflexi pharmacolog categori antirheumat diseas modifi gastrointestin agent miscellan immunosuppress agent monoclon antibodi tumor necrosi factor tnf block agent pharmacolog infliximab chimer monoclon antibodi bind human tumor necrosi factor alpha tnf therebi interf endogen tnf activ elev tnf level found involv tissu fluid patient rheumatoid arthriti ankylos spondyl psoriat arthriti plaqu psoriasi crohn diseas ulcer coliti biolog activ tnf includ induct proinflammatori cytokin interleukin enhanc leukocyt migrat activ neutrophil eosinophil induct acut phase reactant tissu degrad enzym anim model shown tnf express caus polyarthr infliximab prevent diseas well allow diseas joint heal distribut within vascular compart v l klotz onset action crohn diseas week rheumatoid arthriti day durat action crohn diseas week rheumatoid arthriti week half life elimin day klotz use label indic ankylos spondyl treatment adult activ ankylos spondyl reduc sign symptom crohn diseas treatment adult pediatr patient year moder sever activ crohn diseas inadequ respons convent therapi reduc sign symptom induc maintain clinic remiss reduc number drain enterocutan rectovagin fistula maintain fistula closur adult plaqu psoriasi treatment adult chronic sever extens disabl plaqu psoriasi altern system therapi psoriat arthriti treatment adult psoriat arthriti reduc sign symptom activ arthriti inhibit progress structur damag improv physic function rheumatoid arthriti treatment adult moder sever activ rheumatoid arthriti methotrex reduc sign symptom activ arthriti inhibit progress structur damag improv physic function ulcer coliti treatment adult pediatr patient year remicad moder sever activ ulcer coliti inadequ respons convent therapi reduc sign symptom induc maintain clinic remiss mucos heal elimin corticosteroid use note renflexi inflectra ixifi remsima [canadian product] approv biosimilar remicad approv use may vari see product label label use beh et syndrom uveiti initi data case seri suggest iv infliximab may play benefici role manag uveiti associ beh et syndrom addit control trial need verifi result crohn diseas manag surgic resect data small random doubl blind placebo control trial prospect random open trial meta analysi support use infliximab manag crohn diseas surgic resect demonstr infliximab lower endoscop recurr possibl histolog clinic recurr rate [regueiro ] [regueiro ] [singh ] [yoshida ] base american gastroenterolog associ institut guidelin manag crohn diseas surgic resect american colleg gastroenterolog guidelin manag crohn diseas adult infliximab effect first line agent prophylact therapi patient higher risk clinic recurr juvenil idiopath arthriti data random placebo control trial support use infliximab treatment juvenil idiopath arthriti jia [ruperto ] [ruperto ] [ visvanathan ] addit trial may necessari defin role infliximab condit base american colleg rheumatolog guidelin treatment jia infliximab effect recommend manag patient system jia requir addit therapi due continu diseas activ follow initi therapi pustular psoriasi data noncontrol studi case seri report limit number patient support use infliximab treatment pustular psoriasi addit trial may necessari defin role infliximab condit base nation psoriasi foundat npf medic board consensu statement infliximab recommend first line treatment option adult pustular psoriasi particularli sever acut gener form diseas pyoderma gangrenosum initi data suggest infliximab may benefici treatment refractori pyoderma gangrenosum larger control trial need fulli assess efficaci infliximab treatment pyoderma gangrenosum [brooklyn ] [ljung ] [regueiro ] contraind hypersensit infliximab murin protein compon formul dose mg kg patient moder sever heart failur nyha class iii iv canadian label addit contraind us label sever infect eg sepsi abscess tuberculosi opportunist infect use patient moder sever heart failur nyha class iii iv dose adult note premed antihistamin h antagonist h antagonist acetaminophen corticosteroid may consid prevent manag infus relat reaction renflexi inflectra ixifi remsima [canadian product] approv biosimilar remicad approv use biosimilar agent may vari consult product label ankylos spondyl iv mg kg week follow mg kg everi week thereaft crohn diseas iv mg kg week follow mg kg everi week thereaft dose may increas mg kg patient respond lose respons respons week consid discontinu therapi crohn diseas manag surgic resect label use iv mg kg week follow mg kg everi week thereaft armuzzi regueiro singh mg kg everi week regueiro yoshida note administ first infus within week surgeri high risk patient lichtenstein plaqu psoriasi iv mg kg week follow mg kg everi week thereaft psoriat arthriti without methotrex iv mg kg week follow mg kg everi week thereaft rheumatoid arthriti combin methotrex therapi iv mg kg week follow mg kg everi week thereaft remicad dose rang mg kg repeat week interv ulcer coliti iv mg kg week follow mg kg everi week thereaft dose mg kg studi clinic trial similar efficaci observ dose rutgeert pustular psoriasi label use iv mg kg week follow mg kg everi week week suguira torii dosag adjust heart failur hf weigh risk versu benefit individu patient mild hf nyha class ii dosag adjust necessari use caution monitor close worsen hf moder sever nyha class iii iv mg kg dose geriatr refer adult dose dose pediatr note premed antihistamin h antagonist h antagonist acetaminophen corticosteroid may consid prevent manag infus relat reaction renflexi inflectra ixifi remsima [canadian product] approv biosimilar remicad approv use biosimilar agent may vari consult product label crohn diseas children year adolesc iv mg kg week follow mg kg everi week thereaft adult patient crohn diseas observ patient respond week unlik respond continu dose consid discontinu therapi ulcer coliti children year adolesc iv remicad mg kg week follow mg kg everi week thereaft juvenil idiopath arthriti label use children year adolesc iv initi mg kg week mg kg dose everi week thereaft combin methotrex induct mainten ruperto altern studi use mg kg start week methotrex induct regimen week repeat dose mg kg week everi week thereaft ruperto visvanathan dose renal impair dosag adjust provid manufactur label dose hepat impair dosag adjust provid manufactur label reconstitut reconstitut vial ml steril water inject swfi gaug smaller needl direct swfi toward wall vial swirl vial gentli dissolv powder shake allow solut stand minut total dose reconstitut product dilut ml ns inject add reconstitut infliximab slowli final concentr mg ml dilut reconstitut infliximab solut diluent infus begin within hour prepar see storag stabil addit inform administr iv infus begin within hour reconstitut dilut infus least hour infus agent use line low protein bind filter micron temporarili discontinu decreas infus rate infus relat reaction antihistamin h antagonist h antagonist acetaminophen corticosteroid may use manag reaction infus may reiniti lower rate upon resolut mild moder symptom guidelin treatment prophylaxi infus reaction note limit adult patient dosag use crohn diseas prospect data popul [pediatr indic dosing] avail protocol treatment infus reaction well prophylact therapi repeat infus publish mayer treatment infus reaction medic treatment hypersensit reaction avail immedi use mild reaction rate infus decreas ml hour initi normal salin infus ml hour appropri symptomat treatment eg acetaminophen diphenhydramin monitor vital sign everi minut normal minut infus may increas minut interv toler complet initi increas ml hour ml hour ml hour etc [maximum ml hour] moder reaction infus stop slow initi normal salin infus ml hour appropri symptomat treatment monitor vital sign everi minut normal minut infus may reinstitut ml hour increas minut interv toler complet initi increas ml hour ml hour ml hour etc [maximum ml hour] sever reaction infus stop administr appropri symptomat treatment eg hydrocortison methylprednisolon diphenhydramin epinephrin frequent monitor vital consult institut polici avail treatment sever reaction done benefit outweigh risk appropri prophylaxi delay infus reaction typic occur day infus treatment consist appropri symptomat treatment eg acetaminophen antihistamin methylprednisolon prophylaxi infus reaction premed acetaminophen diphenhydramin minut prior infus may consid patient prior infus reaction patient sever reaction corticosteroid administr recommend steroid dose may oral prednison mg oral everi hour dose prior infus intraven singl dose hydrocortison mg methylprednisolon mg administ minut prior infus initi infus begin test dose ml hour minut thereaft infus may increas minut interv toler complet initi increas ml hour ml hour ml hour etc maximum rate ml hour recommend patient experienc prior mild moder reaction ml hour recommend patient experienc prior sever reaction patient cutan flush aspirin may consid becker delay infus reaction premed acetaminophen diphenhydramin minut prior infus initi infus begin test dose ml hour minut thereaft infus may increas infus hour postinfus therapi acetaminophen day antihistamin day recommend storag store intact vial c c f f may store room temperatur maximum c [ f] month exceed origin expir date return refriger storag manufactur recommend solut dilut ns infus use within hour prepar howev stabil studi infliximab mg ml prepar ns polyvinyl chlorid pvc bag found loss biolog activ store refriger c day ikeda drug interact abatacept anti tnf agent may enhanc advers toxic effect abatacept increas risk seriou infect concomit use report avoid combin adalimumab may enhanc immunosuppress effect infliximab avoid combin anakinra anti tnf agent may enhanc advers toxic effect anakinra increas risk seriou infect concomit use report avoid combin azathioprin infliximab may enhanc advers toxic effect azathioprin specif risk cell non hodgkin lymphoma includ hepatosplen cell lymphoma may increas infliximab may increas serum concentr activ metabolit azathioprin monitor therapi baricitinib may enhanc advers toxic effect biolog diseas modifi antirheumat drug dmard avoid combin bcg intraves immunosuppress may diminish therapeut effect bcg intraves avoid combin belimumab monoclon antibodi may enhanc advers toxic effect belimumab avoid combin canakinumab anti tnf agent may enhanc advers toxic effect canakinumab specif risk seriou infect neutropenia may increas avoid combin certolizumab pegol anti tnf agent may enhanc immunosuppress effect certolizumab pegol avoid combin coccidioid immiti skin test immunosuppress may diminish diagnost effect coccidioid immiti skin test monitor therapi denosumab may enhanc advers toxic effect immunosuppress specif risk seriou infect may increas monitor therapi echinacea may diminish therapeut effect immunosuppress consid therapi modif etanercept may enhanc immunosuppress effect infliximab avoid combin fingolimod immunosuppress may enhanc immunosuppress effect fingolimod manag avoid concomit use fingolimod immunosuppress possibl combin monitor patient close addit immunosuppress effect eg infect consid therapi modif golimumab may enhanc immunosuppress effect infliximab avoid combin leflunomid immunosuppress may enhanc advers toxic effect leflunomid specif risk hematolog toxic pancytopenia agranulocytosi thrombocytopenia may increas manag consid use leflunomid load dose patient receiv immunosuppress patient receiv leflunomid anoth immunosuppress monitor bone marrow suppress least monthli consid therapi modif natalizumab immunosuppress may enhanc advers toxic effect natalizumab specif risk concurr infect may increas avoid combin nivolumab immunosuppress may diminish therapeut effect nivolumab consid therapi modif ocrelizumab may enhanc immunosuppress effect immunosuppress monitor therapi pidotimod immunosuppress may diminish therapeut effect pidotimod monitor therapi pimecrolimu may enhanc advers toxic effect immunosuppress avoid combin rilonacept anti tnf agent may enhanc advers toxic effect rilonacept avoid combin roflumilast may enhanc immunosuppress effect immunosuppress consid therapi modif sipuleucel immunosuppress may diminish therapeut effect sipuleucel monitor therapi tacrolimu topic may enhanc advers toxic effect immunosuppress avoid combin tertomotid immunosuppress may diminish therapeut effect tertomotid monitor therapi thiopurin analog anti tnf agent may enhanc advers toxic effect thiopurin analog specif risk cell non hodgkin lymphoma includ hepatosplen cell lymphoma may increas monitor therapi tocilizumab may enhanc immunosuppress effect anti tnf agent avoid combin tofacitinib biolog diseas modifi antirheumat drug dmard may enhanc advers toxic effect tofacitinib avoid combin trastuzumab may enhanc neutropen effect immunosuppress monitor therapi ustekinumab may enhanc immunosuppress effect infliximab avoid combin vaccin inactiv immunosuppress may diminish therapeut effect vaccin inactiv manag vaccin efficaci may reduc complet age appropri vaccin least week prior start immunosuppress vaccin immunosuppress therapi revaccin least month immunosuppress discontinu consid therapi modif vaccin live immunosuppress may enhanc advers toxic effect vaccin live immunosuppress may diminish therapeut effect vaccin live manag avoid use live organ vaccin immunosuppress live attenu vaccin given least month immunosuppress avoid combin vedolizumab anti tnf agent may enhanc advers toxic effect vedolizumab avoid combin advers reaction central nervou system headach gastrointestin abdomin pain crohn diseas rheumatoid arthriti nausea hematolog oncolog anemia adult children adolesc crohn diseas hepat increas serum alt x uln x uln x uln immunolog increas ana titer antibodi develop doubl strand dna antibodi develop immunogen given singl induct dose episod treatment monotherapi mayer infect infect adult crohn diseas children adolesc crohn diseas indic seriou infect children adolesc abscess crohn diseas patient fistul diseas respiratori upper respiratori tract infect rheumatoid arthriti children adolesc ulcer coliti sinus cough pharyng miscellan infus relat reaction sever cardiovascular flush children adolesc crohn diseas hypertens central nervou system fatigu pain dermatolog skin rash pruritu gastrointestin dyspepsia genitourinari urinari tract infect hematolog oncolog leukopenia children adolesc crohn diseas indic neutropenia children adolesc crohn diseas hypersensit hypersensit reaction children adolesc crohn diseas indic type iv hypersensit reaction plaqu psoriasi serum sick infect viral infect children adolesc crohn diseas bacteri infect children adolesc crohn diseas candidiasi neuromuscular skelet arthralgia bone fractur children adolesc crohn diseas respiratori bronchiti pneumonia miscellan fever postmarket case report acut hepat failur agranulocytosi anaphylaxi autoimmun hepat bradycardia bronchospasm bullou dermat linear iga bryant cardiac arrhythmia cellul cerebrovascular accid cholestasi chronic inflammatori demyelin polyneuropathi coccidioidomycosi constip cytomegaloviru diseas dehydr demyelin diseas central nervou system demyelin diseas peripher dermal ulcer diaphoresi dizzi edema erythema multiform erythemat rash exacerb psoriasi guillain barr syndrom hemolyt anemia hepat failur hepat injuri hepat hepatotox idiosyncrat chalasani hepatosplen cell lymphoma mainli young adult adolesc male herp zoster histoplasmosi hodgkin lymphoma hypotens immun thrombocytopenia increas serum ast interstiti pulmonari diseas intestin obstruct ischem heart diseas jaundic laryng edema leukemia liver enzym disord transient lower respiratori tract infect lupu like syndrom lymphadenopathi malign lymphoma malign melanoma malign neoplasm malign neoplasm breast malign neoplasm cervix malign neoplasm colon rectum merkel cell carcinoma multipl sclerosi myocardi infarct neuropathi includ multifoc motor nocardiosi non hodgkin lymphoma opportunist infect optic neuriti pancytopenia pericardi effus pharyng edema pleurisi pneumonia due pneumocysti jirovecii psoriasi includ new onset palmoplantar pustular pulmonari edema pulmonari fibrosi reactiv tuberculosi reactiv hbv sarcoidosi seizur sepsi steven johnson syndrom thrombocytopenia thrombophleb thrombot thrombocytopen purpura toxic epiderm necrolysi transvers myeliti tuberculosi urticaria vascul system cutan temporari vision loss alert u box warn seriou infect patient treat infliximab increas risk develop seriou infect may lead hospit death patient develop infect take concomit immunosuppress methotrex corticosteroid discontinu infliximab patient develop seriou infect sepsi report infect includ follow activ tuberculosi tb includ reactiv latent tb patient tb frequent present dissemin extrapulmonari diseas patient test latent tb infliximab use therapi treatment latent infect initi prior infliximab use invas fungal infect includ histoplasmosi coccidioidomycosi candidiasi aspergillosi blastomycosi pneumocystosi patient histoplasmosi invas fungal infect may present dissemin rather local diseas antigen antibodi test histoplasmosi may neg patient activ infect empir antifung therapi consid patient risk invas fungal infect develop sever system ill bacteri viral infect caus opportunist pathogen includ legionella listeria risk benefit treatment infliximab care consid prior initi therapi patient chronic recurr infect patient close monitor develop sign symptom infect treatment infliximab includ possibl develop tb patient test neg latent tb infect prior initi therapi malign lymphoma malign fatal report children adolesc patient treat tumor necrosi factor tnf blocker includ infliximab postmarket case hepatosplen cell lymphoma rare type cell lymphoma report patient treat tnf blocker includ infliximab case aggress diseas cours fatal almost patient receiv treatment azathioprin mercaptopurin concomitantli tnf blocker prior diagnosi major report infliximab case occur patient crohn diseas ulcer coliti adolesc young adult male warn precaut concern relat advers effect autoimmun disord posit antinuclear antibodi titer detect patient neg baselin rare case autoimmun disord includ lupu like syndrom report monitor discontinu symptom develop cardiovascular cerebrovascular reaction follow infus cerebrovascular accid mi fatal hypotens hypertens arrhythmia report within hour infus transient vision loss also report within hour infus discontinu therapi seriou reaction occur hematolog disord hematolog toxic eg leukopenia neutropenia thrombocytopenia pancytopenia report may fatal patient must advis seek medic attent develop sign symptom suggest blood dyscrasia eg persist fever discontinu signific hematolog abnorm confirm use caution patient histori hematolog abnorm hepat reaction sever hepat reaction includ hepat jaundic acut hepat failur cholestasi report treatment reaction occur week year initi therapi case fatal necessit liver transplant discontinu jaundic mark increas liver enzym time uln hepat b reactiv hepat b viru hbv occur chronic carrier viru usual patient receiv concomit immunosuppress may fatal evalu hbv prior initi patient monitor sever month follow discontinu treatment hbv carrier interrupt therapi reactiv occur treat appropri antivir therapi resumpt therapi deem necessari exercis caution monitor patient close hypersensit infus reaction acut infus reaction may occur hypersensit reaction includ anaphylaxi may occur within hour infus medic equip manag hypersensit reaction avail immedi use interrupt reinstitut slower rate may requir consult protocol pretreat may consid may warrant patient prior infus reaction serum sick like reaction occur may associ decreas respons treatment develop antibodi infliximab may increas risk hypersensit infus reaction concomit use immunosuppress may lessen develop anti infliximab antibodi risk infus reaction may increas treatment interrupt discontinu prior mainten therapi treatment psoriasi patient resum schedul mainten regimen without induct dose use induct regimen use cautious treatment patient infect [u box warning] patient receiv infliximab increas risk seriou infect may result hospit fatal infect usual develop patient receiv concomit immunosuppress agent eg methotrex corticosteroid may present dissemin rather local diseas activ tuberculosi reactiv latent tuberculosi invas fungal includ aspergillosi blastomycosi candidiasi coccidioidomycosi histoplasmosi pneumocystosi bacteri viral opportunist infect includ legionellosi listeriosi report monitor close sign symptom infect discontinu seriou infect sepsi consid risk versu benefit prior use patient histori chronic recurr infect consid empir antifung therapi patient risk invas fungal infect develop sever system ill caution exercis consid use elderli patient condit predispos infect eg diabet resid travel area endem mycos blastomycosi coccidioidomycosi histoplasmosi latent local infect initi infliximab therapi patient activ infect includ clinic import local infect patient develop new infect undergo treatment monitor close malign [u box warning] lymphoma malign may fatal report children adolesc patient receiv tnf block agent includ infliximab half case lymphoma hodgkin non hodgkin case vari includ malign typic observ popul [u box warning] postmarket case hepatosplen cell lymphoma report patient treat infliximab almost patient receiv concurr prior treatment azathioprin mercaptopurin prior diagnosi major report case occur adolesc young adult male crohn diseas ulcer coliti malign occur median month rang month first dose tnf blocker therapi patient receiv concomit immunosuppress impact infliximab develop cours malign fulli defin compar gener popul increas risk lymphoma note clinic trial howev rheumatoid arthriti alon previous associ increas rate lymphoma use caution patient histori copd higher rate malign report copd patient treat infliximab psoriasi patient histori phototherapi higher incid nonmelanoma skin cancer melanoma merkel cell carcinoma report patient receiv tnf block agent includ infliximab perform period skin examin patient therapi particularli increas risk skin cancer women rheumatoid arthriti higher incid invas cervic cancer period screen continu women treat infliximab tuberculosi [u box warning] infliximab treatment associ activ tuberculosi may dissemin extrapulmonari reactiv latent infect evalu patient tuberculosi risk factor latent tuberculosi infect tuberculin skin test prior therapi treatment latent tuberculosi initi use patient initi neg tuberculin skin test receiv continu monitor tuberculosi throughout treatment case reactiv report within first coupl month treatment caution exercis consid use patient expos tuberculosi diseas relat concern demyelin cn diseas use caution patient preexist recent onset cn demyelin disord rare case optic neuriti demyelin diseas includ multipl sclerosi system vascul guillain barr syndrom report consid discontinu therapi patient develop signific cn reaction heart failur hf use caution patient mild hf nyha class ii decreas left ventricular function worsen new onset hf report dose mg kg administ patient moder sever hf nyha class iii iv discontinu therapi onset new worsen symptom scientif statement american heart associ tnf blocker determin agent may either caus direct myocardi toxic exacerb underli myocardi dysfunct magnitud major aha [page ] seizur disord use caution patient histori seizur discontinu signific cn advers reaction develop concurr drug therapi issu drug drug interact potenti signific interact may exist requir dose frequenc adjust addit monitor select altern therapi consult drug interact databas detail inform special popul pediatr malign report among children adolesc receiv tnf block agent efficaci establish studi evalu infliximab use juvenil idiopath arthriti jia dosag form specif issu polysorb dosag form may contain polysorb also known tween hypersensit reaction usual delay reaction report follow exposur pharmaceut product contain polysorb certain individu isaksson lucent shelley thrombocytopenia ascit pulmonari deterior renal hepat failur report prematur neonat receiv parenter product contain polysorb alad cdc see manufactur label warn precaut immun patient brought date immun initi therapi live vaccin given concurr data avail concern secondari transmiss live vaccin patient receiv therapi fatal outcom report infant receiv live vaccin bcg utero exposur infliximab infliximab cross placenta detect infant serum month recommend wait month follow birth administ live vaccin infant expos infliximab utero monitor paramet monitor improv symptom physic function assess infus reaction note monitor vital sign everi minut depend reaction sever normal seriou reaction occur eg cardiovascular cerebrovascular reaction discontinu infus activ latent tb screen prior initi therapi sign symptom infect prior follow therapi cbc differenti sign symptom worsen heart failur hbv screen prior initi patient hbv carrier sever month follow therapi sign symptom hypersensit reaction symptom lupu like syndrom lft discontinu time uln sign symptom malign eg splenomegali hepatomegali abdomin pain persist fever night sweat weight loss psoriasi patient histori phototherapi monitor nonmelanoma skin cancer women screen period cervic cancer american gastroenterolog associ suggest reactiv therapeut drug monitor guid treatment chang adult patient treat infliximab activ inflammatori bowel diseas feuerstein pregnanc risk factor b pregnanc consider anim reproduct studi conduct infliximab cross placenta detect serum infant month follow utero exposur agranulocytosi report infant expos infliximab utero fatal outcom report infant receiv live vaccin bcg utero exposur infliximab recommend wait month follow birth administ live vaccin infant expos infliximab utero biolog agent infliximab need treat inflammatori bowel diseas pregnanc recommend hold therapi week gestat habal health care provid also encourag enrol women expos infliximab pregnanc mothertobabi autoimmun diseas studi contact organ teratolog inform specialist oti patient educ discuss specif use drug side effect patient relat treatment hcahp hospit stay given medicin taken give new medicin often hospit staff tell medicin often hospit staff describ possibl side effect way could understand patient may experi nausea vomit abdomin pain common cold symptom flush inject site irrit patient report immedi prescrib sign infect sign lupu rash cheek bodi part sunburn easi muscl joint pain angina short breath swell arm leg sign sever cerebrovascular diseas chang strength one side greater difficulti speak think chang balanc vision chang angina sign liver problem dark urin fatigu lack appetit nausea abdomin pain light color stool vomit jaundic sign heart problem cough short breath new wors swell ankl leg abnorm heartbeat weight gain five pound hour dizzi pass infus reaction skin eczema excess weight loss burn numb feel sever back pain sever headach difficulti swallow pale skin swollen gland night sweat vision chang blind black tarri bloodi stool mole chang skin growth dizzi pass bradycardia tachycardia seizur extrem weak bruis bleed sever loss strength energi sign steven johnson syndrom toxic epiderm necrolysi red swollen blister peel skin [with without fever] red irrit eye sore mouth throat nose eye hcahp educ patient sign signific reaction eg wheez chest tight fever itch bad cough blue skin color seizur swell face lip tongu throat note comprehens list side effect patient consult prescrib addit question intend use disclaim print given patient inform intend serv concis initi refer health care profession use discuss medic patient must ultim reli discret experi judgment diagnos treat advis patient',\n",
       " 'boxer rochdal fought prove british box board control type diabet hold back ring absolut amaz feel fda assess new treatment retinopathi use eye inject current use treat diabet retinopathi dme may expand includ treatment diabet retinopathi pend fda review eylea use expand want know eat go public go consult whether calori content meal publish restaur menu come part push halv childhood obes calori consult pioneer type diabet centr open centr research way type diabet treatment could improv open novo nordisk pursu innov medicin help treat prevent condit push research boundari labour deputi leader put type remiss diagnosi type diabet gave wake call tom watson lost weight cut sugar starchi carb point abl come diabet medic overcom medic need low carb eton mess member low carb program follow great british bake seri absolut treat tonight scrumptiou low carb eton mess recip mouth water write',\n",
       " 'hi fighter life happi hear keytruda work well must relief ask stage type mom squamou cell stage rd treatment far thing go well side effect except fatigu bit hoars voic time time horribl cough well treatment requir liquid codein order sleep night taken codein week cough better thank respond thread happi hear good news peopl god bless deb',\n",
       " 'sorri deal love diseas extra experi next step stelara fail everi drug imagin fail sooner later start canabi let us know work proctocolectomi result transvers colostomi current receiv stelara',\n",
       " 'true enough guess surgeri realli last option ulcer coliti diagnos meslamin entyvio remicad prednison fail three step pouch surgeri colon remov two go ipoop forum moder join aug post post yesterday gmt sure get adjust period surgeri fulli heal feel like million buck normal hang moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa shower thought peopl surpris see blood toilet paper uc patient surpris ks veteran member join sep post post yesterday gmt problem skip entyvio go right surgeri miser want wait anymor justifi save entyvio futur use ever develop chronic pouchiti develop use yet gi prefer stelara entyvio stelara also faster act keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f timechamp veteran member join oct post post yesterday pm gmt lifestyl thing get better everyday adjust make sure u drink enough get rest walk also incis belli button',\n",
       " 'hi sharonk welcom msworld sorri hear son person vote start tysabri asap efficaci greater gilenya although individu respond differ diseas modifi therapi aka dmt risk contract pml extrem low first two year even jcv member continu year drug despit jcv higher titer though higher risk new dmt call ocrevu approv fda yesterday expect rival tysabri might present anoth option futur besid gilenya son best luck son',\n",
       " 'wonder decis forc compani bring eyelea lucenti competit price start avastin move eyelea move differ health board move hous biggest differ found avastin administ consult hospit eyelea administ nurs guess one effici pleasant',\n",
       " 'speaker scott gold md theresa patient advoc patient educ dinner discov ocrevu may right choic treat relaps ms pre registr requir contact organ regist',\n",
       " 'review literatur found date pembrolizumab pd pd li inhibitor show signific surviv benefit chemotherapi given monotherapi part combin therapi metastat squamou nonsquam nsclc [non small cell lung cancer] statement research write new england journal medicin also present new data iaslc th world confer lung cancer toronto canada septemb base data merck sharp dohm maker pembrolizumab add treatment pembrolizumab combin chemotherapi result significantli longer overal surviv os progress free surviv pf compar chemotherapi alon squamou nsclc accord articl kaplan meier estim rate surviv year pembrolizumab combin arm placebo combin arm though trial conclud estim conclus date decis report second interim result occur efficaci boundari primari hypothes overal surviv progress free surviv met investig wrote origin set goalpost interim analysi occur event diseas progress death occur relat articl head head battl brigatinib appear best crizotinib durvalumab show overal surviv benefit patient stage iii nsclc despit promis trial result skeptic rais red flag anlotinib efficaci heavili treat nsclc doubl blind phase trial research run keynot trial randomli assign untreat metastat squamou nsclc patient receiv either mg pembrolizumab salin placebo cycl patient patient respect patient also treat carboplatin either paclitaxel nanoparticl albumin bound [nab] paclitaxel first cycl patient receiv paclitaxel also receiv premed glucocorticoid antihistamin patient allow crossov certain circumst patient switch placebo pembrolizumab diseas progress patient receiv subsequ pd pd l inhibitor prescrib outsid trial pd l express statu assess use agil technolog pd l ihc c pharmdx assay tumor imag schedul week everi week week everi week thereaft result use tool patient exclud trial could provid tumor sampl determin pd l statu os pf respons rate durat respons calcul use blind independ central review radiolog imag pd l tumor proport score greater seen patient regardless patient pd l express level overal surviv benefit observ across pembrolizumab combin group group median os follow month compar month placebo combin group hazard ratio death confid interv [ci] p median pf month month respect hazard ratio diseas progress death ci p risk death lower risk diseas progress death lower pembrolizumab combin group placebo combin group author wrote ad patient pd l posit tumor current avail data permit determin whether pembrolizumab plu chemotherapi greater efficaci pembrolizumab alon respons rate howev higher among individu receiv pembrolizumab base regimen compar rate observ placebo regimen patient place subgroup defin pd l tumor proport score outcom improv across categori pd l tumor proport score pembrolizumab chemotherapi group make studi author question use pd l biomark guid drug select advers event ae similar across treatment group although treatment discontinu pembrolizumab combin group occur frequent placebo combin group vs respect death due ae pembrolizumab base arm ae relat death placebo base arm read cancer therapi advisor coverag iaslc meet visit confer page refer',\n",
       " 'remicad uc med sometim need multipl med simultan conquer flare remicad infliximab concentr antibodi test see level typic run hour prior nest infus see true minimum concentr http www labcorp com test menu infliximab concentr anti infliximab antibodi moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa unpatriot wipe bumm georg washington bill tp stall otherwis dire straight think georg would understand',\n",
       " 'written space mean newli diagnos multipl sclerosi life start mark major diseas event first mri first dmt first time end hospit relaps first cane first time wheel around place place big event tax brain give someth focu life suddenli look feel noth like event bad suck give brain someth handl someth keep thought occupi next crisi hit shingl experi pass third ocrevu infus bag start wait period happen might happen septemb see great scott feel bit lost long languid period time noth much happen one right start physic therapi coupl week ago realiz someth probabl surpris shit hard someon evalu everi aspect physic life start think serious mess thing realli low platform simpl side leg lift realiz hard tri move stupid leg done step pt step pt realiz littl bit activ go take rest day start day air cool felt kind ok feel like could handl end feel like shit shingl complet demor complet overwhelm come back someth like long go take ten side leg lift feel like lift dead weight tree trunk happen connect bodi long walk feet without feel like go collaps almost three year god sake long go take sure shout answer question comput screen hope hear loud clear right interweb go take realli long time beth go take long go think never go end go take long take fuck choic shut know realli know friend ardra said recent comment might help much realli option even help tiniest bit also offici join ms gym familiar free facebook page learn learn paid membership site short stori trevor wicken develop program around rebuild neuro muscular pathway help improv ms symptom ms brain block slow lesion get way normal pathway creat difficulti spastic pain walk kind thing amaz resourc pretti fantast abil benefit trevor experi dedic onlin join plan follow program one video per day everi day day week also went back work week staycat realiz obviou alreadi thing realli difficult simultan one recov shingl one bodi felt even remot decent month year total honest drag offic outsid world good mental speak exactli need physic yeh much tire spent almost imposs imagin could accomplish regular life stuff pt ms gym routin everi singl day week surpris learn pull cancel pt work meet friday love massag afternoon minut got home wobbl leg lift straight truth got floor damn good possibl abl get might pull simpl neck pain video someth settl night also might spend time summer hide heat accompani squid bodi effect keep work continu feel least littl bit like old squeez pt exercis start wonder long last long old life new life long thing start feel even littl bit normal simpl truth matter alreadi long enough almost rememb use fun forget day day limit stupid leg refus oper like leg forget feel like plan forget use mayb much anyway mayb long sinc anyth felt normal sincer rememb work got random email cakebread cellar favorit wine maker napa visit year ago travel buddi friend mari back littl jaunt napa check wineri someth would total mari use take awesom littl adventur throughout year feel like anoth life long ago particular trip must sign cakebread mail list get occasion email news varieti great deal cakebread like thing find love cheap click open email read case deal reserv chardonnay without even think click link order case wine like use back drink wine one thing realli love much wine past year sinc diagnosi coupl reason biggest one insan cocktail prescript medic take throughout everi day mix well alcohol shaki feet without help wine need help land face first concret hardwood decid go drink wine summer one glass week still worth share friend might lure home promis realli good wine nice porch sit even better accept realiti visitor would take like unclean sport bed head certainli cover cat hair definit yoga pant tank top would also accept realiti much talk day relat curs diseas peopl ask new honestli say much materi relat damag central nervou system talk book read show watch beyond got whole lot materi crappi feel new drug consid havoc may wreak bodi tell nobodi want hear even want talk think lure peopl wine listen tell live stori adventur long take stori adventur revolv around struggl someth realli easi fall flat face live room day also drink glass wine alon sit swing listen breez leav magnific front yard tree twinkl mani set wind chime day ridicul hot enjoy solitud without think drug diseas injuri exercis long take drink one glass wine rememb use enjoy good glass chardonnay still even though everi littl thing new life would utterli strang foreign old old would wonder like center attent anymor old would wonder gave makeup semblanc fashion sens old would wonder action new enjoy glass cakebread chard allow enough new rememb exercis struggl meet rememb attend much keep bodi tri settl kind new normal new normal arriv good readi might well enjoy great glass wine wait',\n",
       " 'diarrhea number week oncologist schedul colonoscopi determin keytruda caus read',\n",
       " 'brvo macular edema light grey cloud shape like v upper middl vision start right center amsler grid first avastin shot cloud becam lighter dissip slightli retin specialist said notic blood absorb second shot cloud move higher seem break coupl week back bad first time grid line also still wavi edema see md monday prob get anoth avastin shot eylea question anyon vision return disappoint process fuzzi realli affect vision make almost dizzi thank advanc',\n",
       " 'go pump seven year ago c hover victrctami right eye five year ago along subsequ inject vision improv two year howev new retinologist say first oper either well perform membran regrew left eye oper victrctami three year ago subsequ eylea inject year vision improv stabl free inject eighteen month note may revers vision ratio',\n",
       " 'drug stelara may eas crohn diseas medic potenti help find relief treatment research say sourc healthday relat medlineplu page crohn diseas medicin sourc medlineplu health news',\n",
       " 'marlo person opinion cladribin gilenya stop go spm may stop relaps spm case nice better rrm spm beast dont want addit troubl caus dmd hard alreadi cladribin stop relaps brainer give less secondari effect gambl need take',\n",
       " 'hi due nh mess enough gilenya get week away toward end week see get respons anyon respons suppos care anyon day week without gilenya within nd month start big impact lost x job due gilenya nurs mess afraid go thank stuart',\n",
       " 'first diseas modifi therapi relaps remit multipl sclerosi interferon b approv fda follow year seen rapid expans therapeut option evolv understand diseas enabl develop therapi differ mode action result complex treatment landscap includ variou inject oral drug monoclon antibodi advantag risk mileston track develop treatment multipl sclerosi interact timelin approv first diseas modifi therapi latest breakthrough seen unpreced efficaci approv first drug primari progress multipl sclerosi produc support produc support mileston natur research mileston dawn therapeut era ms charlott ridler natur research mileston first monoclon antibodi therapi katharin barn natur research mileston risk natalizumab associ pml reveal rebecca kelsey natur research mileston oral drug expand therapeut option megan culli natur research mileston high low second gener monoclon antibodi isobel leak natur research mileston treatment creat clinic dilemma louis adam mileston nr neurolog review natur review neurolog perspect treatment multipl sclerosi success bench bedsid develop treatment multipl sclerosi past year success translat medicin timelin articl tintor et al chart major develop discuss implic current futur patient manag mar tintor angela vidal jordana jaum sastr garriga natur review neurolog review articl assess treatment outcom multipl sclerosi trial clinic set clinic trial outcom measur might determin whether drug worthi develop clinic might guid import treatment decis tur colleagu help clinician research navig maze option clinic neuroimag patient report composit outcom measur multipl sclerosi carmen tur marcello moccia frederik barkhof jeremi chataway jaum sastr garriga alan j thompson olga ciccarelli natur review neurolog scienc societi tension earli diagnosi misdiagnosi multipl sclerosi benefit earli treatment multipl sclerosi ms place pressur physician make diagnosi earli therebi increas risk misdiagnosi consider consequ patient health care system solomon corboy examin problem ms misdiagnosi includ probabl caus associ risk discuss tension earli diagnosi misdiagnosi might address andrew j solomon john r corboy natur review neurolog review articl autolog haematopoiet stem cell transplant treatment multipl sclerosi autolog haematopoiet stem cell transplant produc strike result patient aggress multipl sclerosi small trial review muraro et al provid overview procedur detail evid high efficaci multipl sclerosi provid recommend clinic use futur trial paolo muraro roland martin giovanni luigi mancardi richard nichola maria pia sormani riccardo saccardi natur review neurolog review articl treatment decis multipl sclerosi insight real world observ studi real world observ studi potenti answer question multipl sclerosi ms treatment random control trial cannot trojano colleagu discuss pitfal necessari safeguard observ studi insight studi provid treatment decis patient ms maria trojano mar tintor xavier montalban jan hillert toma kalincik pietro iaffaldano tim spelman maria pia sormani helmut butzkueven natur review neurolog review articl diseas modifi therapi infecti risk multipl sclerosi rang immunomodulatori therapi treat multipl sclerosi ms widen markedli recent year ms treatment becom effici improv efficaci accompani increas risk treatment associ infect review winkelman et al discuss mode action current avail ms therapi detail specif infect associ treatment consid inform influenc daili clinic use ms therapi minim associ infecti risk alexand winkelmann micha loebermann emil c reising han peter hartung uwe k zettl nr neurolog review addit review research natur review diseas primer primer multipl sclerosi multipl sclerosi character format demyelin lesion throughout central nervou system lead neurolog dysfunct primer provid overview immunopatholog diagnosi manag multipl sclerosi massimo filippi amit bar fredrik piehl paolo preziosa alessandra solari sandra vukus maria rocca natur immunolog review articl reassess b cell contribut multipl sclerosi focu review bar colleagu discuss latest evid b cell play import antibodi independ role multipl sclerosi prospect hold therapeut intervent rui li kristina r patterson amit bar advertis featur mileston multipl sclerosi biogen commit advanc field richard rudick michael r edward bernd c kieseier alfr sandrock scientif report articl open fingolimod reduc circul tight junction protein level vitro peripher blood mononuclear cell migrat multipl sclerosi patient pasqual annunziata chiara cioni gianni masi maristella tassi giusepp marotta sauro severi scientif report articl open dimethyl fumar induc persist chang composit innat adapt immun system multipl sclerosi patient g mont diaz j fraussen b van wijmeersch r huppert v somer natur commun articl open systemat screen gener drug progress multipl sclerosi identifi clomipramin promis therapeut progress multipl sclerosi inflammatori degen diseas central nervou system effect treatment lack author carri screen identifi oral avail gener medic show antidepress clomipramin reduc patholog mous model simon faissner manoj mishra deepak k kaushik jianxiong wang yan fan claudia silva gail rauw luann metz marcu koch v wee yong addit review research news comment natur review neurolog news view aan unveil new guidelin ms diseas modifi therapi follow recent european academi neurolog guidelin pharmacolog treatment multipl sclerosi ms american academi neurolog issu updat practic guidelin diseas modifi therapi dmt ms guidelin provid gener recommend initi switch stop dmt indic futur research direct stefan bittner frauk zipp natur review neurolog comment unifi understand ms cours requir drug develop treatment multipl sclerosi ms evolv remark past year progress enabl advanc research drug develop activ engag scientif commun regulatori author howev inconsist approach ms diseas cours could neg impact drug develop process timothi coetze alan j thompson natur review neurolog news view multipl sclerosi progress multifoc leukoencephalopathi risk stratif compel need exist reliabl risk evalu natalizumab associ progress multifoc leukoencephalopathi pml new report propos refin protocol use updat patient base data cumul risk evalu provid improv assess annual risk pml patient posit jc viru kalliopi pitarokoili ralf gold natur review neurolog comment cladribin old newcom puls immun reconstitut ms heinz wiendl natur review neurolog news view multipl sclerosi safe time discontinu therapi ms yet clear strategi develop discontinu diseas modifi therapi multipl sclerosi recent observ studi add new inform inform patient group still assess comprehens sever question need address prospect studi mark freedman natur review neurolog news view multipl sclerosi dimethyl fumar come age recent publish find endors studi provid year random safeti efficaci data two dose dimethyl fumar dmf multipl sclerosi report complement result pivot confirm defin trial howev postmarket data clinic practic need complet risk benefit profil dmf',\n",
       " 'ocrelizumab recommend licens european medicin agenc multipl sclerosi trust http www mstrust org uk news news ms ocrelizumab recommend licens european medicin agenc',\n",
       " 'produc lucenti eylea claim surplu money gain use research better eye treatment drug produc avastin interest cancer treatment rather eye care low cost would anyth left research',\n",
       " 'comment dismiss natalizumab spm trial ascend trial neg simpli move one person said spm intract problem best prevent earli effect treatment anoth said expect ascend anoth neg spm trial could easili predict experi interferon trial cynic sad attitud entrench concept therapeut window ms perpetu concept futil tri develop treatment spm disagre posit prepar go limb hypothesis therapeut window remain open throughout cours ms futil tri develop treatment spm give peopl ms hope opinion ascend trial clearli posit although studi hit desir primari outcom natalizumab show effect virtual flatten loss upper limb function sure treatment protect upper limb function peopl spm worth explor quot one spmser wheelchair hand arm becom leg click see download pdf gall oratorio trial ocrelizumab ppm posit ocrelizumab realli superior natalizumab ppm differ spm would argu account differ ascend oratorio trial explain differ studi popul ascend spm popul older disabl studi subject edss word lost meaning reserv capac motor system leg know studi disabl level edss unilater support bilater support edss good outcom measur year mser level disabl spend mani year level progress higher level disabl measur speak refer ceil effect edss comparison ppmser oratorio studi edss less henc level disabl edss scale like move addit disabl edss reserv capac motor system allow recoveri function get read two year period word lower level disabl less therapeut lag last year discuss two concept hypothes blog e therapeut lag length depend result two studi evid new old strongli support relat hypothes therapeut lag state reserv lost specif pathway longer take see treatment effect relat therapi target ms specif mechan oratorio trial posit edss time foot walk fw ascend trial neg outcom measur would predict ascend trial longer durat may posit outcom particular fw sensit chang edss unfortun ascend trial allow therapeut lag hypothes correct treatment effect ocrelizumab greatest comparison placebo oratorio trial relat upper limb function assess use hole peg test wait detail analys oratorio trial publish see case learnt ascend trial non relaps spm tractabl problem focu relev outcom e neuron system suffici reserv capac demonstr treatment effect use respons outcom measur hpt abilhand chanc posit trial abilhand valid patient relat outcom measur hand upper limb function go continu use edss outcom measur either go studi earlier popul similar oratorio studi popul longer studi allow therapeut lag opinion need ditch edss primari outcom measur progress ms trial us old enough rememb seen evid argument relat interferon spm trial european interferon beta b spm trial posit north american studi neg former younger less disabl popul wherea latter older disabl go studi advanc ms need focu attent neuron system function reserv exampl upper limb bulbar function speech swallow occur need bring regul ema fda board think possibl urgent suspect realist chanc modifi non relaps progress phase ms need use highli effect dmt surpris ocrelizumab natalizumab produc posit trial result popul pleas note emphasi posit lob pharma trial advanc progress ms ppm spm combin highli effect dmt e alemtuzumab ocrelizumab daclizumab ofatumumab cladribin let see brave enough take challeng pharma caveat cynic worri payer regul cost effect calcul relat dmt base cost treatment versu save individu societi person ms lost mobil alreadi accru larg amount person societ cost includ direct medic cost indirect cost exampl loss employ sad thing person becom unemploy worth societi drop case payer exampl nice may judg cost effect dmt advanc ms less favour word expens high cost drug natalizumab ocrelizumab may cost effect advanc ms compar earli ms preserv function save societi money one reason pharma reluct take risk develop drug advanc progress ms potenti way counter allow pharma payer agre differenti payment scale disabl person ms less compani abl charg drug may sound crazi make lot sens would forc pharma move outcom base remuner system system payer get better valu money pwm get treatment work allow us move away fix price system valu base price system seem get use mani sector surg price system use airlin softwar industri uber use uber know surg price see world agent expens use earli ms patient becom disabl price drug less question nh pharmaceut sector readi valu base price think alreadi explor oncolog nh individu pay someth work hand deni peopl progress ms drug x consid cost effect stage diseas see fire aan mani idea whizz around head minut day attend confer provid think talk network downtim aan except would like conclud post huge thank biogen ball ascend studi spmser volunt take part studi without studi insight final appreci thank well mean gener pharma execut gave first class upgrad tri help get good night sleep sit ba loung wait board return flight vancouv senior pharma execut know well came chat heard fli economi back london tri get busi class upgrad call ba desk first class upgrad turn ask ba could upgrad instead said would tri howev got board origin alloc seat grate someon would tri give comfort first class upgrad tri help get good night sleep howev would prefer lobbi compani spm trial base insight ascend studi coi multipl',\n",
       " 'hi kspell welcom grace sorri wait unfortun answer clear come mainten without avaistin mani larg clinic trial conduct attempt identifi best treatment strategi patient nsclc addit agent target vegf use histolog guid chemotherapi decis addit mainten therapi shown increment improv os particularli nonsquam histolog target egfr wild type nsclc also result success improv os pemetrex bevacizumab transform treatment option patient nonsquam nsclc along erlotinib recast treatment paradigm includ well toler mainten therapi extend surviv patient nsclc data support combin mainten therapi superior singl agent whether optim singl agent exist clear author favor choos platinum partner typic pemetrex paclitaxel base desir toxic profil ad bevacizumab unless contraind induct phase follow mainten bevacizumab paclitaxel base chemotherapi mainten pemetrex combin pemetrex bevacizumab mainten pemetrex base chemotherapi provid patient stabl respons diseas manag toxic four cycl platinum chemotherapi ecog trial may help determin whether increment benefit bevacizumab possibl ad mainten pemetrex therapi http theoncologist alphamedpress org content full question ask checkpoint inhibitor consid possibl autoimmun problem could caus problem cont',\n",
       " 'decid second child ms found ms month birth daughter back nisthagmu seriou balanc problem start treatment copaxon relaps month switch gilenya sight back normal balanc use bother normal life except yoga sinc extreemli tire tire activ hour spread day convers neurologist second child worri would end wheelchair seriou relaps region brain realli worri sinc feel like absent mum alreadi would also duabl partner take care kid sinc realli rest day realli still brack heart make hard decis count bless accept fact kid option us tire guess would tri expand famili would ask neurologist advic know peopl kid get diagnos',\n",
       " 'keep eye scuse pun haemorrhag upper vision refer doctor perform wash out retina guess vitrectomi help feel complet like read mani horror stori made vision wors help either fulli trust profession look eye everi time clinic laser differ consult peopl laser eye prefer one meddl back know work one said coupl month back eye look like improv assur get wors month well truli fill hope bodi differ idea',\n",
       " 'crohn diseas also call ileiti enter affect part gut mouth way anu major case howev lower part small intestin ileum affect symptom unpleas includ intestin ulcer discomfort pain accord center diseas control prevent crohn diseas affect peopl per although crohn diseas typic start age start age symptom pain commonli felt lower right side abdomen affect mani area gut crohn diseas symptom vari depend part gut affect symptom often includ pain level pain vari individu depend inflamm gut commonli pain felt lower right side abdomen ulcer gut ulcer raw area gut may bleed bleed patient might notic blood stool mouth ulcer common symptom diarrhea rang mild sever sometim may mucu blood pu patient may get urg go find noth come fatigu individu often feel extrem tire fever also possibl fatigu alter appetit may time appetit low weight loss result loss appetit anemia loss blood lead anemia rectal bleed anal fissur skin anu becom crack lead pain bleed possibl symptom arthriti uveiti eye inflamm skin rash inflamm liver bile duct inflamm delay growth sexual develop children ulcer coliti vs crohn diseas ulcer coliti caus inflamm ulcer top layer line larg intestin layer intestin may inflam ulcer crohn diseas also inflamm occur crohn diseas anywher along gut ulcer coliti appear larg intestin colon rectum crohn diseas patient bowel normal healthi section diseas part wherea ulcer coliti damag appear continu pattern diet children crohn diseas might need high calori liquid formula especi growth affect patient crohn diseas say follow food increas diarrhea cramp bulki grain dairi product spici food alcohol peopl feel like eat sever case may need feed intraven short period treatment bulki grain like contain bread worsen crohn diseas treatment may involv medic surgeri nutrit supplement aim control inflamm correct nutrit problem reliev symptom cure crohn diseas treatment help reduc number time patient experi recurr crohn diseas treatment depend inflamm situat sever diseas complic patient respons previou treatment recur symptom peopl long period even year without symptom known remiss howev usual recurr period remiss vari much hard know effect treatment imposs predict long period remiss go best food crohn diseas flare eat right food help peopl manag symptom crohn diseas find read medic crohn diseas anti inflamm drug doctor like start mesalamin sulfasalazin help control inflamm cortison steroid corticosteroid drug contain cortison steroid antibiot fistula strictur prior surgeri may caus bacteri overgrowth doctor gener treat prescrib ampicillin sulfonamid cephalosporin tetracyclin metronidazol anti diarrheal fluid replac inflamm subsid diarrhea usual becom less problem howev sometim patient may need someth diarrhea abdomin pain biolog biolog new type drug scientist develop live organ reduc bodi immun respons target protein lead inflamm biolog appear help peopl crohn diseas exampl biolog crohn includ infliximab remicad adalimumab humira mercaptopurin purinethol methotrex imuran azathioprin certolizumab pegol cimzia biolog treatment side effect includ vomit nausea weaker resist infect studi suggest use biolog reduc chanc person need abdomin surgeri within year percent introduct biolog research put figur percent biolog also appear reduc risk advers effect aris person use corticosteroid differ type biolog drug individu react differ doctor recommend suitabl option may suggest tri altern combin drug first one work surgeri major crohn diseas patient may need surgeri point medic longer control symptom solut oper surgeri reliev symptom respond medic correct complic abscess perfor bleed blockag remov part intestin help cure crohn diseas inflamm often return area next affect part gut remov crohn diseas patient may requir one oper live case colectomi need whole colon remov surgeon make small open front abdomin wall tip ileum brought skin surfac form open call stoma fece exit bodi stoma pouch collect fece doctor say patient stoma carri lead normal activ life surgeon remov diseas section intestin connect intestin stoma need patient doctor need consid surgeri care appropri everyon patient bear mind oper diseas recur peopl crohn diseas live normal activ live hold job rais famili function success caus exact caus crohn diseas unclear thought stem abnorm reaction immun system theori immun system attack food good bacteria benefici substanc unwant substanc attack white blood cell build line gut buildup trigger inflamm inflamm lead ulcer bowel injuri howev unclear whether abnorm immun system caus crohn diseas result factor may increas risk inflamm includ genet factor individu immun system environment factor around peopl crohn close rel condit ident twin crohn diseas twin percent chanc bacterium viru may play role e coli bacteria link crohn diseas instanc smoke anoth risk factor diagnosi doctor ask person sign symptom physic examin may reveal lump abdomen caus loop inflam bowel becom stuck togeth follow test may help diagnosi stool blood test biopsi sigmoidoscopi short flexibl tube sigmoidoscop use investig lower bowel colonoscopi long flexibl tube colonoscop use investig colon endoscopi symptom occur upper part gut long thin flexibl telescop endoscop goe esophagu stomach ct scan barium enema x ray reveal chang insid bowel complic symptom sever frequent likelihood complic higher follow complic may requir surgeri intern bleed strictur part gut narrow caus build scar tissu partial complet blockag intestin perfor small hole develop wall gut content leak caus infect abscess fistula channel form two part gut may also persist iron defici food absorpt problem slightli higher risk develop bowel cancer relat coverag stage crohn diseas crohn diseas caus chronic inflamm digest tract although crohn diseas tend get wors time symptom vari consider may sometim disappear week even year reason doctor usual classifi crohn differ stage learn read diet tip crohn diseas crohn diseas affect gastrointestin tract choic diet nutrit may make differ individu feel spici food alcohol fatti sugari item exampl trigger flare peopl find dietari tip recommend may help manag condit read crohn diseas pregnanc crohn diseas pregnanc affect howev women conceiv crohn diseas remiss normal pregnanc healthi babi learn read expect crohn infus crohn infus medic call biolog help reduc crohn symptom learn type crohn infus side effect expect read crohn diseas surgeri know surgeri cannot cure crohn diseas help reduc person symptom prevent life threaten complic articl learn differ type crohn diseas surgeri prepar expect recoveri read email email print share share crohn ibd gastrointestin gastroenterolog immun system vaccin addit inform articl last updat yvett brazier wed decemb visit crohn ibd categori page latest news subject sign newslett receiv latest updat crohn ibd refer avail refer tab refer content requir javascript enabl baumgart dogan b rishniw weitzman g bosworth b yantiss r berg cultur independ analysi ileal mucosa reveal select increas invas escherichia coli novel phylogeni rel deplet clostridial crohn diseas involv ileum ism journal retriev http www natur com ismej journal v n ab ismej html crohn diseas n american societi colon rectal surgeon retriev http www fascr org patient diseas condit crohn diseas crohn diseas caus april retriev http www nh uk condit crohn diseas page caus aspx epidemiolog ibd march cdc retriev http www cdc gov ibd ibd epidemiolog htm leena halm paulina paavola sakki ulla turunen maarit lappalaccinen martti f rkkil kimmo kontula june world journal gastroenterolog retriev http www ncbi nlm nih gov pmc articl pmc lichtenstein g r loftu e v isaac k l regueiro gerson l b sand b e march manag crohn diseas adult american colleg gastroenterolog retriev http gi org guidelin manag crohn diseas adult crohn diseas n cleveland clinic retriev http clevelandclin org health articl crohn diseas citat pleas use one follow format cite articl essay paper report mla nordqvist christian crohn diseas medic news today medilexicon intl dec web feb http www medicalnewstoday com articl php apa nordqvist c decemb crohn diseas medic news today retriev http www medicalnewstoday com articl php pleas note author inform provid sourc cite instead recommend relat news latest news acupunctur may reduc menopaus symptom recent studi investig whether acupunctur might use nonpharmaceut way minim symptom occur menopaus japanes plant could hold key extend youth new research find compound tradit japanes medicin plant could boost cellular health protect ill effect age bacteria live insect could provid new antibiot insect harbor bacteria protect infect tap sourc could yield new antibiot combat grow threat drug resist halt cellular age new drug combo show promis first clinic trial human research test promis drug combin could help fight effect cellular age aggress brain cancer immunotherapi fail new research help explain glioblastoma tumor respond immunotherapi wherea major aggress cancer',\n",
       " 'read option thought use chemo radiat place surgeri word state option either nivolumab chemotherapi success surgeri chemorad would pretti typic approach treatment stage iiia surgeri possibl otherwis chemo radiat far danger surgeri one situat often case arguabl resect stage iiia lung cancer demand particip experienc thorac surgeon special type surgeri oppos surgeon surgeri mani type sure mskcc surgeon meet criteria unusu begin chemo regimen adjust dosag switch cisplatin carboplatin side effect difficult dr west said term activ agent post oper evid stronger cisplatin expert typic favor cisplatin patient toler nearli mani studi carboplatin data set suggest carboplatin may shade less activ want give effect treatment go valuabl therapi patient success get without prohibit side effect would hesit recommend carboplatin base chemo someon thought cisplatin base chemo like feasibl mani patient done extrem well either switch cisplatin carboplatin due side effect start carboplatin begin one reason anoth http cancergrac org forum index php topic msg msg pleas note comment dr sanborn regard pair platinum alimta like recommend alimta good choic squamou jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'blog beleiv gavin tell lazi mani keyword choos absenc site map proximu consid time pain possibl use inform treatment strategi time tysabri best bet jcv ocrelizumab chang thing slightli ocrelizumab get rid plasma cell idea hunt b cell ocrel first matur stage infnaci memori etc reach plasma stage deal plasma cell kept bay tysabri ocrel let back know pain feel start get b cell busi hope persist equal help other understand toni',\n",
       " 'result keynot studi confirm os advantag pembrolizumab arm docetaxel patient higher pd l express tp pembrolizumab mg kg improv surviv month hazard ratio [hr] p pembrolizumab mg kg month hr p rpf month longer pembrolizumab treatment arm compar docetaxel among patient pd l tp author conclud surviv advantag patient tp dose pembrolizumab improv surviv month docetaxel median surviv month result report separ pd l tp strata tp versu possibl strong os improv seen higher pd l tumor express drive os benefit toward statist signific total studi popul rpf differ treatment arm total studi popul perhap address concern abstract american societi clinic oncolog asco annual meet june present result analys subgroup patient lower pd l express tp patient lower pd l express tp pembrolizumab mg kg fail meet statist signific os compar docetaxel hr ci higher dose pembrolizumab mg kg appear improv os docetaxel month hr ci patient tp appear howev author employ rigor determin statist signific threshold main analys pembrolizumab arm lower median rpf compar docetaxel cannot evalu side hypothesi test inher ignor effect opposit direct second abstract pool data pembrolizumab arm contrast docetaxel quartil base pd l express demonstr superior surviv pembrolizumab docetaxel tp strata surviv benefit observ tp strata weak associ versu month p found pembrolizumab docetaxel pd l tp sinc data pembrolizumab arm pool analys consid exploratori result interpret caution relat aggress local therapi improv surviv limit metastat nsclc case highlight import watch neglig use statist form conclus one research research other close inspect aspect clinic trial necessari evalu drug efficaci includ mechan action patient popul tria l conduct statist method check see p valu met threshold statist signific refer goodman sn align statist scientif reason misunderstand misus statist signific imped scienc jun scienc doi scienc aaf herbst rs baa p kim dw et al pembrolizumab versu docetaxel previous treat pd l posit advanc non small cell lung cancer keynot random control trial apr lancet doi [epub ahead print] garon eb herbst rs kim dw et al pembrolizumab vs docetaxel previous treat advanc nsclc pd l tumor proport score tp result keynot j clin oncol suppl abstr baa p garon eb herbst rs et al relationship level pd l express outcom keynot studi pembrolizumab vs docetaxel previous treat pd l posit nsclc j clin oncol suppl abstr',\n",
       " 'januari biotim enter agreement orbit biomed deliveri opregen cell dri amd advertis biotim inc enter research option agreement orbit biomed limit two compani collabor use orbit proprietari inject technolog deliv opregen retin pigment epithelium transplant therapi phase iia develop treatment dri amd orbit system design precis consist deliv therapeut sub retin space via suprachoroid rout avoid need vitrectomi perfor retina inform found http globenewswir com news releas en biotim enter exclus agreement orbit biomed ltd access innov devic sub retin deliveri opregen cell treatment dri amd html aeri announc accept ind applic ar aeri pharmaceut announc u food drug administr review investig new drug applic ind ar dexamethason intravitr implant effect allow aeri initi human studi treatment macular edema due retin vein occlus ind submit decemb aeri expect initi phase clinic studi later first quarter ar bio erod implant administ intravitr inject design releas dexamethason six month sustain period potenti benefit ar compar steroid product includ six month durat efficaci improv administr due smaller needl size possibl better safeti profil due lower peak drug level inform found http investor aeriepharma com news releas news releas detail aeri pharmaceut announc accept investig result publish phase trial neurotech nt use treat mactel neurotech pharmaceut collabor lowi medic research institut recent announc result phase studi nt publish ophthalmolog nt renexu devic manufactur neurotech novel cell base drug deliveri system cell encapsul semiperm hollow fiber membran releas ciliari neurotroph factor cntf shown reduc photoreceptor cell loss anim model retin degener implant renexu devic result sustain deliveri cntf local retina studi phase multi center random clinic trial test effect encapsul cell base deliveri cntf retin degener patient macular telangiectasia type mactel studi show nt treatment slow progress retin degener compar particip given sham treatment addit nt provid function benefit read speed stabil patient receiv implant inform found http www prnewswir com news releas neurotech pharmaceut inc lowi medic research institut announc public nt phase result html flavoprotein fluoresc may detect improv patient dme treat anti vegf ocusci announc onlin public diabet macular edema studi find suggest compani flavoprotein fluoresc fpf detect improv metabol function directli correl vision improv improv macular thick measur oct dme patient treat anti vegf studi follow eight patient clinic signific dme treatment anti vegf inject research found chang fpf inject measur ocusci flagship devic ocumet beacon close correl chang bcva chang central macular thick bcva inform found http www businesswir com news home en ocusci announc public show flavoprotein fluoresc detect protect effect adm ramp system may make new therapeut target rvo investig util newli develop model central retin vein occlus crvo mice mimic mani clinic featur crvo human studi patholog effect retin occlus demonstr retinoprotect effect peptid adrenomedullin adm receptor activ modifi protein ramp report recent publish american journal patholog crvo model gener combin intraperiton inject rose bengal photo activ dye enhanc thrombu format laser photocoagul promin chang note retin hemorrhag venou dilat tortuos measur retin thick reveal promin edema earli crvo induc follow gradual atrophi base find investig propos retinoprotect effect adm ramp system make novel therapeut target treatment crvo inform found http www eurekalert org pub_releas e peo php gemini therapeut announc clariti diseas registri natur histori studi dri amd gemini therapeut announc initi clariti diseas registri natur histori studi design identifi character diseas progress subject non central geograph atrophi nc ga secondari dri amd carrier high risk genet variant clariti genet screen consent thousand subject enrol hundr base genet criteria use inform optim design futur intervent trial clariti investig dant pieramici md partner california retina consult said date precis medicin limit select field oncolog lung metabol rare diseas clariti advanc field ophthalmolog evalu complex retin diseas use precis medicin approach inform found http www businesswir com news home en gemini therapeut announc initi clariti diseas registri resourc month calendar event imag month supplement magazin subscript newslett subscript retin physician public archiv articl feedback contact us social media facebook twitter linkedin retin physician therapeut surgic treatment posterior segment deliv depth coverag latest advanc amd diabet retinopathi macular edema retin vein occlus well surgic intervent posterior segment care reach retin specialist gener ophthalmologist practic insight regard current futur treatment strategi medic surgic retina care comprehens retin care journal retin physician put perspect scientif develop mean today practic discuss ramif new studi treatment patient manag strategi publish nine time per year',\n",
       " 'time decis person issu crohn v uc diagnosi relev decisionmak peopl good luck biolog remicad humira entyvio husband tri three work thing prednison point felt comfort decis move forward surgeri person import feel tri option case addit drug option becam avail last minut xeljanz put remiss fulli acknowledg day xeljanz stop work surgeri unless anoth great drug option time grate colon think wrong answer spous diagnos uc develop antibodi remicad humira entyvio work infus thing seem work prednison earli march start xeljanz label work uc symptom abl eat almost everyth fresh fruit veget first time year struggl final taper prednison',\n",
       " 'object character use safeti newer diseas modifi therapi dmt children multipl sclerosi ms clinic isol syndrom ci treat year age method cohort studi includ children ms ci follow outpati practic particip us network pediatr ms center dmt use includ durat dose side effect analyz newer dmt defin agent receiv food drug administr approv increas use adult ms result juli pediatr patient ms n ci n enrol femal mean onset year mean follow year median visit per year n ms n ci receiv dmt year age consist least one newer dmt includ dimethyl fumar n natalizumab n rituximab n fingolimod n daclizumab n teriflunomid n among initi dmt prescrib newer agent dimethyl fumar natalizumab rituximab fingolimod teriflunomid last year use newer agent increas particularli year lesser extent year short term side effect profil newer dmt differ report adult conclus newer dmt often use pediatr ms similar short term safeti toler side effect profil adult find may help inform pediatr ms manag',\n",
       " 'chicago combin therapi gefitinib carboplatin pemetrex gcp may lead superior surviv outcom compar gefitinib monotherapi among patient advanc epiderm growth factor receptor egfr mutat posit non small cell lung cancer nsclc accord data present american societi clinic oncolog annual meet monday june standard care among patient advanc egfr mutat nsclc egfr tyrosin kinas inhibitor tki monotherapi improv progress free surviv pf overal surviv os compar chemotherapi previou studi shown gefitinib plu platinum doublet chemotherapi may improv overal surviv popul open label phase nej studi research randomli assign previous untreat patient advanc stage stage iii iv recurr nsclc harbor egfr activ mutat receiv oral gefitinib mg alon daili gefitinib mg carboplatin auc pemetrex mg gcp everi week baselin characterist studi group compar primari outcom progress free surviv pf progress next line therapi pf overal surviv os relat articl keynot pembrolizumab improv overal surviv non small cell lung cancer prophylact cranial irradi reduc incid brain metastas nsclc result show patient receiv gcp significantli prolong pf compar patient treat gefitinib alon vs month hazard ratio [hr] ci p os also increas among patient treat gcp month versu month among patient treat gefitinib alon hazard ratio [hr] p overal respons rate combin group monotherapi group respect analysi show howev pf differ significantli studi arm median pf among patient receiv gcp month versu month among patient receiv gefitinib monotherapi hr ci p grade wors advers effect observ greater frequenc gcp arm includ neutropenia anemia thrombocytopenia author conclud gefitinib combin carboplatin pemetrex may effect treatment option first line treatment advanc egfr mutat nsclc read cancer therapi advisor coverag american societi clinic oncolog asco meet visit confer page refer',\n",
       " 'hello eyeprotect second ozurdex implant th may also see wormlik floater vision improv day one four eyelia doctor switch implant ozurdex work great',\n",
       " 'thank respons jimc catdand doctor seem reluct biopsi mention previous happen land far far away europ mayb way thing done might seem somewhat odd differ consult best surgeon countri special adren surgeri state would perform biopsi given evid histolog verifi primari nsclc ct scan lesion size growth recommend chemotherapi instead immunotherapi know ramucirumab pembrolizumab nivolumab avail sure state insur fund would cover father case given year old ex smoker advanc lung cancer thank respons support',\n",
       " 'wife keytruda sinc mg kg everi week sinc may everi week find also difficult know effect long term treatment pneumon cough sometim strong could either caus lung cyberknif treatment immunotherapi strang effect appear stope opdivo feel effect antibodi taken year still badli known',\n",
       " 'januari follow recent discuss u fda compani today announc voluntari withdraw u supplement biolog licens applic opdivo low dose yervoy ipilimumab combin treatment first line advanc non small cell lung cancer patient tumour mutat burden mutat megabas mut mb octob compani announc submiss exploratori overal surviv os analysi tumour mutat burden tmb mut mb subgroup fda fda determin time submiss new inform constitut major amend applcat extend review period three month move prescript drug user fee act date may recent discuss fda compani believ evid relationship tmb pd l requir fulli evalu impact opdivo plu yervoy os first line non small cell lung cancer patient analysi requir avail final data checkmat part opdivo plu low dose yervoy opdivo monotherapi versu chemotherapi patient whose tumour express pd l compani anticip avail first half sinc data checkmat part avail within review cycl current applic compani decid withdraw read bm press releas',\n",
       " 'progress ms treat long b c cree f paul univers california san francisco san francisco ca unit state neurocur clinic research center charit universit tsmedizin berlin germani vex therapeut challeng multipl sclerosi progress neurolog disabl occur independ relaps progress ms occur clinic onset primari progress follow histori relaps secondari progress progress ms classifi associ without diseas activ e set ongo clinic relaps radiograph evid diseas activ determin mri recent clinic trial immunomodulatori therapi known effect relaps ms yield disappoint result trial either primari progress secondari progress ms howev recent sever clinic trial target progress ms show benefit ocrelizumab b cell deplet anti cd monoclon antibodi first medic prove slow disabl progress subgroup patient primari progress ms receiv regulatori approv treatment primari progress ms countri siponimod next gener select p p sphingosin receptor modul shown larg registr trial slow accumul disabl patient secondari progress ms regulatori review md high dose biotin shown improv disabl patient either primari secondari progress ms multicent random control trial investig ongo multin studi md also avail countri name patient basi given success studi neurologist first time understand therapeut select progress form multipl sclerosi case base cours review date understand progress form ms treat data recent success clinic trial provid insight therapeut select base patient characterist review inform case vignett present addit diseas modifi therapi use symptomat treatment highlight lastli clinic import unansw question direct futur research outlin ______________________ disclosur prof bruce cree md phd ma receiv person compens consult abbvi biogen emd serono novarti sanofi genzym prof friedemann paul md receiv person compens consult speak alexion biogen chugai medimmun merck serono novarti sanofi genzym shire',\n",
       " 'speaker donald negroski md patient educ dinner discov ocrevu may right choic treat relaps ms pre registr requir contact organ regist',\n",
       " 'hey want give updat sleep slightli improv think lot go realli low fiber diet although prednison seem take appetit never end eat meal everi hour day seem like feel like put weight eat especi sinc eat least three full high protein low fiber meal day also averag three sometim four stool hour period still get one form stool usual even low fiber other loos wateri occasion blood morn realli much still thought want tri entyvio get remiss realli need get darn steroid talk gi want stay current plan next appoint week sinc shown improv tell ya could get rid pain orm stool occur scream joy diagnos summer left side coliti current prednison mg humira everi week imuran mg current tri gluten free mostli dairi free sinc jan flare sinc june signific inflamm doc word',\n",
       " 'mlgilber hope goe well understand feel littl nervou good hand worri much shame ocrevu pass ppm suffer uk best',\n",
       " 'jarthur wife nonsmok dx stage iv nsclc left lung egfr tarceva continu year excel respons year chemo carbo alimta avastin local recurr good respons repeat chemo carbo alimta avastin local recurr good respons avastin mainten needl bx local recurr result includ egfr pd rx tarceva avastin c pend rx decis diseas still confin left chest would option system rx indic tagrisso checkpoint inhibitor one two agent chemo grate wife respond least temporarili rx thu far never would expect longev date dx first made thank input',\n",
       " 'diabet retinopathi clinic research network protocol establish intravitr inject ranibizumab mg lucenti novarti new strategi manag prolif diabet retinopathi pdr howev applic studi result clinic practic challeng mani question pharmacotherapi panretin photocoagul prp need answer said francisco j rodriguez md woc guadalajara mexico ranibizumab allow us avoid complic prp includ peripher visual field loss decreas visual acuiti va develop worsen diabet macular oedema dme sever visual loss per cent patient howev treatment select individu patient influenc number paramet includ long term efficaci predictor respons potenti side effect conveni patient famili physician importantli cost introduc payer anoth player note dr rodriguez scientif director fundaci n oftalmol gica nacion chairman depart ophthalmolog escuela de medicina ciencia de la salud universidad del rosario bogota colombia time need answer question chronic use anti vascular endotheli growth factor anti vegf therapi pdr determin best long term strategi perhap combin laser pharmacotherapi ad emerg data protocol undertaken emerg data dme clinic trial show anti vegf treatment modul progress dr studi randomis patient prompt prp complet one three sit within eight week ranibizumab mg four mandatori inject continu frequent everi four week primari outcom analysi mean chang va two year show ranibizumab non inferior prp howev ranibizumab treatment offer advantag compar prp group eye assign anti vegf inject group superior mean va two year better visual field decreas chanc vitrectomi less frequent develop dme also know prp advantag compar anti vegf therapi less expens carri risk endophthalm system vegf inhibit furthermor treatment typic complet one two visit often long last dr rodriguez said look ahead dr rodriguez outlin sever issu need address better guidanc use anti vegf therapi pdr need know outcom achiev treat pdr mg dose ranibizumab anti vegf agent said francisco j rodriguez fjrodriguez fon org co',\n",
       " 'welcom lori realli realli tough stuff coincid stori came bloomberg news right post ms patient chose death risk potent drug treatment http www businessweek com news ent health husband dx rrm dx dual jugular vein stenosi ccsvi http ccsviinm blogspot com top harryz famili elder post join tue may pm locat london canada contact contact harryz icq updat tysabri may quot post harryz fri may hi cheer first time drug appear alway said danger go caus lot problem line biogen market savior ms patient around world alway downplay nasti dark side drug busi make money collater damag ms patient along way life billion dollar revenu involv cours told agenda held grudg biogen name call nasti comment came dozen like alway told potenti tysabri user learn could medic decid use pressur neuro start immedi alway hear benefit vs risk real risk surfac nice harri',\n",
       " 'ms specialist advoc earli intervent although differ opinion exist within ms commun hawkin vs amato pittock et al vs frohman et al follow imag natur histori ms indic signific amount mri activ occur pre clinic phase earli relaps remit ms gradual decreas inflammatori attack relaps time increas mri burden diseas occur along decreas brain volum schemat support role dmt earli diseas cours explain patient famili member purpos diseas modifi therapi ms manag rio et al set realist expect treatment unrealist expect common reason patient discontinu medic mohr et al instruct patient proper use medic particularli inject techniqu rotat regimen minim skin reaction inject medic saunder et al webb monitor diseas activ mri see revis recommend cmsc task forc standard mri protocol clinic guidelin diagnosi follow multipl sclerosi monitor side effect provid manag strategi inadequ manag side effect anoth key reason peopl discontinu medic webb identifi sub optim respons cohen et al waubant treat sub optim respond increas lower dose higher dose ifn beta medic durelli et al panitch et al schwid panitch absenc neutral antibodi switch ifn beta medic glatiram acet vice versa freedman et al caon switch inject fingolimod marriott connor also consid first line option fda switch first line medic natalizumab mitoxantron rudick polman combin agent differ mechan action rudick polman consensu criteria consensu criteria sub optim respons cohen et al relaps rate reduct relaps year month continu dmt recurr new spinal cord brainstem lesion incomplet recoveri repeat relaps especi edss pdf score increas progress cognit motor impair disrupt adl regardless neurolog exam chang elimin influenc medic depress superimpos concurr ill polyregion diseas develop affect multipl neurolog system',\n",
       " 'object assess whether presenc concomit diseas multipl sclerosi ms diagnosi associ choic treatment persist italian ms cohort method includ newli diagnos patient follow ms center collect demograph clinic data evalu baselin factor relat presenc comorbid associ comorbid clinic cours ms time first treatment switch result studi cohort includ patient data comorbid avail patient total patient least comorbid ms diagnosi age diagnosi odd ratio confid interv [ci] p baselin factor independ relat presenc comorbid comorbid significantli associ choic first diseas modifi treatment significantli associ higher risk switch first treatment due intoler hazard ratio ci p associ comorbid risk switch intoler significantli heterogen among treatment interferon glatiram acet natalizumab fingolimod interact test p conclus comorbid diagnosi taken account first treatment choic associ lower persist treatment',\n",
       " 'yay peg glad ocrevu help today get th ivig infus take hour repli quot follow user say thank agat howi jeani z jendi stillstannd',\n",
       " 'cc stelara work matter day gi will jump hoop get probabl worth consid one anti tnf stop work anoth pm ulcer coliti next surgeri schedul problem skin loop ad setup pm ulcer coliti next surgeri schedul familiar hollist probabl go first cut hole stoma go place directli skin protect leak stay skin pm ulcer coliti humira remicad cimzia simponi anti tnf shot base upon weight xeljanz also weight base stelara weightbas remicad well studi drug pm ulcer coliti unexpect scope result j pouch buckey think appoint gi go know issu complex mine see post anyth ulcer coliti next surgeri schedul congratul recommend get convex wafer new ostomi realli help liquid output probabl know loop ileo time littl pm ulcer coliti remicad infus get test remicad antibodi symptom serum sick ignor mine got wors start drop thing memori loss bone joint pain pm ulcer coliti super donor phenomenon fecal microbiota transplant segment cbc radio quirk quark show http www cbc ca radio quirk poop creat equal super pooper could life saver test ulcer coliti saw gi recommend xeljanz scare start thread check box includ signatur see med thought ad entyvio either prednison entocort blood test pm ulcer coliti saw gi recommend xeljanz scare anti tnf med like remicad anyth list signatur use rectal med steroid pm ulcer coliti recent taken friend heard take month jpouch fulli adjust pm ulcer coliti still experienc issu cuffiti song ladi ga diarrhea also caus sibo easi test taken test previous also home test sibo happen jpoucher certain antibiot',\n",
       " 'find colonoscopi anxieti ridden freak inconveni af ibd gi minut away need someon pick sedat top need miss day work thursday recoveri day need book week go upper endoscopi pouchoscop put long everyon reason scope keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'hi jimc would like know often docetaxel use cyramza compar docetaxel alon circumst combo prefer cyramza cross blood brain barrier cyramza somewhat similar avastin use mainten know docetaxel approv fda nd line agent tri find recent research articl show advantag combo docetaxel cyramza tri find stanford oncologist prefer combo research articl back support request may abl convinc kaiser oncologist prescrib hope find answer thank kkh diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'talk dmard methotrex biolog humira realli import visit iriti specialist fortun quit locat',\n",
       " 'wow thank much help well new test came back friend spot brain big enough take trial guess good thing alway nice drug target cancer rest bodi could potenti candid trial futur shall see go put tagrisso also test trial found tumor spine explain vision problem shoulder neck pain current two week radiat diagnos juli amaz fight wonder think tagrisso facebook mayb get account go check site thank info bonni j addario foundat heard check thank',\n",
       " 'dh follow appoint today lymph node biopsi unfortun cancer return port placement schedul begin folfiri avastin aug dr also order mri femur spine brain rule met anyth look suspici biopsi bone clear pet scan show improv month send consult dr david bartlet upmc hillman center surgeri consult might also undergo anoth lymph node biopsi look braf kra mutat call oper super heroic oper said young strong otherwis healthi excel candid grate left option husband look forward hell chemo life come especi diahrreah still cant spell damn word hi brother age die lung cancer novemb anyhow lot digest today appoint grate friendship site',\n",
       " 'updat summari u food drug administr approv expans use oral ms therapi gilenya fingolimod novarti ag includ treatment children adolesc year age older relaps ms first therapi specif approv treat pediatr ms larg phase clinic trial show benefit reduc relaps diseas activ mri common side effect headach liver enzym elev diarrhea cough flu sinus back pain abdomin pain pain extrem medic guid help inform patient famili use potenti risk inform contact gilenya go program onlin phone gilenya',\n",
       " 'wonder rituxan good hope ocrevu good hope preciou state',\n",
       " 'lung pair cone shape breath organ chest lung bring oxygen bodi breath releas carbon dioxid wast product bodi cell breath lung section call lobe left lung two lobe right lung slightli larger three lobe two tube call bronchi lead trachea windpip right left lung bronchi sometim also involv lung cancer tini air sac call alveoli small tube call bronchiol make insid lung enlarg anatomi respiratori system show trachea lung lobe airway lymph node diaphragm also shown oxygen inhal lung pass thin membran alveoli bloodstream see inset thin membran call pleura cover outsid lung line insid wall chest caviti creat sac call pleural caviti pleural caviti normal contain small amount fluid help lung move smoothli chest breath two main type lung cancer non small cell lung cancer small cell lung cancer see follow pdq summari inform lung cancer small cell lung cancer treatment unusu cancer childhood treatment lung cancer prevent lung cancer screen sever type non small cell lung cancer type non small cell lung cancer differ kind cancer cell cancer cell type grow spread differ way type non small cell lung cancer name kind cell found cancer cell look microscop squamou cell carcinoma cancer begin squamou cell thin flat cell look like fish scale also call epidermoid carcinoma larg cell carcinoma cancer may begin sever type larg cell adenocarcinoma cancer begin cell line alveoli make substanc mucu less common type non small cell lung cancer pleomorph carcinoid tumor salivari gland carcinoma unclassifi carcinoma smoke major risk factor non small cell lung cancer anyth increas chanc get diseas call risk factor risk factor mean get cancer risk factor mean get cancer talk doctor think may risk lung cancer risk factor lung cancer includ follow smoke cigarett pipe cigar past import risk factor lung cancer earlier life person start smoke often person smoke year person smoke greater risk lung cancer expos secondhand smoke expos asbesto arsen chromium beryllium nickel soot tar workplac expos radiat follow radiat therapi breast chest radon home workplac imag test ct scan atom bomb radiat live air pollut famili histori lung cancer infect human immunodefici viru hiv take beta caroten supplement heavi smoker older age main risk factor cancer chanc get cancer increas get older smoke combin risk factor risk lung cancer increas sign non small cell lung cancer includ cough go away short breath sometim lung cancer caus sign symptom may found chest x ray done anoth condit sign symptom may caus lung cancer condit check doctor follow chest discomfort pain cough go away get wors time troubl breath wheez blood sputum mucu cough lung hoars loss appetit weight loss known reason feel tire troubl swallow swell face vein neck test examin lung use detect find diagnos stage non small cell lung cancer test procedur detect diagnos stage non small cell lung cancer often done time follow test procedur may use physic exam histori exam bodi check gener sign health includ check sign diseas lump anyth els seem unusu histori patient health habit includ smoke past job ill treatment also taken laboratori test medic procedur test sampl tissu blood urin substanc bodi test help diagnos diseas plan check treatment monitor diseas time chest x ray x ray organ bone insid chest x ray type energi beam go bodi onto film make pictur area insid bodi enlarg x ray chest x ray use take pictur organ bone chest x ray pass patient onto film ct scan cat scan procedur make seri detail pictur area insid bodi chest taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi sputum cytolog procedur pathologist view sampl sputum mucu cough lung microscop check cancer cell thoracentesi remov fluid space line chest lung use needl pathologist view fluid microscop look cancer cell lung cancer suspect biopsi done one follow type biopsi usual use fine needl aspir fna biopsi lung remov tissu fluid lung use thin needl ct scan ultrasound imag procedur use locat abnorm tissu fluid lung small incis may made skin biopsi needl insert abnorm tissu fluid sampl remov needl sent laboratori pathologist view sampl microscop look cancer cell chest x ray done procedur make sure air leak lung chest enlarg fine needl aspir biopsi lung patient lie tabl slide comput tomographi ct machin take x ray pictur insid bodi x ray pictur help doctor see abnorm tissu lung biopsi needl insert chest wall area abnorm lung tissu small piec tissu remov needl check microscop sign cancer endoscop ultrasound eu type ultrasound may use guid fna biopsi lung lymph node area eu procedur endoscop insert bodi endoscop thin tube like instrument light len view probe end endoscop use bounc high energi sound wave ultrasound intern tissu organ make echo echo form pictur bodi tissu call sonogram enlarg endoscop ultrasound guid fine needl aspir biopsi endoscop ultrasound probe biopsi needl insert mouth esophagu probe bounc sound wave bodi tissu make echo form sonogram comput pictur lymph node near esophagu sonogram help doctor see place biopsi needl remov tissu lymph node tissu check microscop sign cancer bronchoscopi procedur look insid trachea larg airway lung abnorm area bronchoscop insert nose mouth trachea lung bronchoscop thin tube like instrument light len view may also tool remov tissu sampl check microscop sign cancer enlarg bronchoscopi bronchoscop insert mouth trachea major bronchi lung look abnorm area bronchoscop thin tube like instrument light len view may also cut tool tissu sampl may taken check microscop sign diseas thoracoscopi surgic procedur look organ insid chest check abnorm area incis cut made two rib thoracoscop insert chest thoracoscop thin tube like instrument light len view may also tool remov tissu lymph node sampl check microscop sign cancer case procedur use remov part esophagu lung certain tissu organ lymph node reach thoracotomi may done procedur larger incis made rib chest open mediastinoscopi surgic procedur look organ tissu lymph node lung abnorm area incis cut made top breastbon mediastinoscop insert chest mediastinoscop thin tube like instrument light len view may also tool remov tissu lymph node sampl check microscop sign cancer enlarg mediastinoscopi mediastinoscop insert chest incis breastbon look abnorm area lung mediastinoscop thin tube like instrument light len view may also cut tool tissu sampl may taken lymph node right side chest check microscop sign cancer anterior mediastinotomi chamberlain procedur incis made besid breastbon remov tissu sampl lymph node left side chest anterior mediastinotomi surgic procedur look organ tissu lung breastbon heart abnorm area incis cut made next breastbon mediastinoscop insert chest mediastinoscop thin tube like instrument light len view may also tool remov tissu lymph node sampl check microscop sign cancer also call chamberlain procedur lymph node biopsi remov part lymph node pathologist view tissu microscop look cancer cell one follow laboratori test may done studi tissu sampl molecular test laboratori test check certain gene protein molecul sampl tissu blood bodi fluid molecular test check certain gene chromosom chang occur non small cell lung cancer immunohistochemistri test use antibodi check certain antigen sampl tissu antibodi usual link radioact substanc dye caus tissu light microscop type test may use tell differ differ type cancer certain factor affect prognosi chanc recoveri treatment option prognosi chanc recoveri treatment option depend follow stage cancer size tumor whether lung spread place bodi type lung cancer whether cancer mutat chang certain gene epiderm growth factor receptor egfr gene anaplast lymphoma kinas alk gene whether sign symptom cough troubl breath patient gener health patient non small cell lung cancer current treatment cure cancer lung cancer found take part one mani clinic trial done improv treatment consid clinic trial take place part countri patient stage non small cell lung cancer inform ongo clinic trial avail nci websit stage non small cell lung cancer key point lung cancer diagnos test done find cancer cell spread within lung part bodi three way cancer spread bodi cancer may spread began part bodi follow stage use non small cell lung cancer occult hidden stage stage stage stage ii stage iii stage iv lung cancer diagnos test done find cancer cell spread within lung part bodi process use find cancer spread within lung part bodi call stage inform gather stage process determin stage diseas import know stage order plan treatment test use diagnos non small cell lung cancer also use stage diseas see gener inform section test procedur may use stage process includ follow mri magnet reson imag procedur use magnet radio wave comput make seri detail pictur area insid bodi brain procedur also call nuclear magnet reson imag nmri ct scan cat scan procedur make seri detail pictur area insid bodi brain abdomen lymph node taken differ angl pictur made comput link x ray machin dye may inject vein swallow help organ tissu show clearli procedur also call comput tomographi computer tomographi computer axial tomographi pet scan positron emiss tomographi scan procedur find malign tumor cell bodi small amount radioact glucos sugar inject vein pet scanner rotat around bodi make pictur glucos use bodi malign tumor cell show brighter pictur activ take glucos normal cell enlarg pet positron emiss tomographi scan patient lie tabl slide pet machin head rest white strap help patient lie still small amount radioact glucos sugar inject patient vein scanner make pictur glucos use bodi cancer cell show brighter pictur take glucos normal cell bone scan procedur check rapidli divid cell cancer cell bone small amount radioact materi inject vein travel bloodstream radioact materi collect bone cancer detect scanner pulmonari function test pft test see well lung work measur much air lung hold quickli air move lung also measur much oxygen use much carbon dioxid given breath also call lung function test bone marrow aspir biopsi remov bone marrow blood small piec bone insert hollow needl hipbon breastbon pathologist view bone marrow blood bone microscop look sign cancer three way cancer spread bodi cancer spread tissu lymph system blood tissu cancer spread began grow nearbi area lymph system cancer spread began get lymph system cancer travel lymph vessel part bodi blood cancer spread began get blood cancer travel blood vessel part bodi cancer may spread began part bodi cancer spread anoth part bodi call metastasi cancer cell break away began primari tumor travel lymph system blood lymph system cancer get lymph system travel lymph vessel form tumor metastat tumor anoth part bodi blood cancer get blood travel blood vessel form tumor metastat tumor anoth part bodi metastat tumor type cancer primari tumor exampl non small cell lung cancer spread brain cancer cell brain actual lung cancer cell diseas metastat lung cancer brain cancer view video youtub mani cancer death caus cancer move origin tumor spread tissu organ call metastat cancer anim show cancer cell travel place bodi first form part bodi follow stage use non small cell lung cancer occult hidden stage occult hidden stage cancer cannot seen imag bronchoscopi cancer cell found sputum bronchial wash sampl cell taken insid airway lead lung cancer may spread part bodi stage stage abnorm cell found line airway abnorm cell may becom cancer spread nearbi normal tissu stage may adenocarcinoma situ ai squamou cell carcinoma situ sci stage stage cancer form stage divid stage ia ib stage ia tumor lung centimet smaller cancer spread lymph node stage ib tumor larger centimet larger centimet cancer spread lymph node tumor centimet smaller one follow found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node stage ii stage ii divid stage iia iib stage iia tumor larger centimet larger centimet cancer spread lymph node one follow may found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon stage iib tumor centimet smaller cancer spread lymph node side chest primari tumor lymph node cancer lung near bronchu also one follow may found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node one follow found tumor larger centimet larger centimet one separ tumor lobe lung primari tumor cancer spread follow membran line insid chest wall chest wall nerv control diaphragm outer layer tissu sac around heart stage iii stage iii divid stage iiia iiib iiic stage iiia tumor centimet smaller cancer spread lymph node side chest primari tumor lymph node cancer around trachea trachea divid bronchi also one follow may found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon cancer spread lymph node side chest primari tumor lymph node cancer lung near bronchu also one follow found tumor larger centimet larger centimet one separ tumor lobe lung primari tumor cancer spread follow membran line insid chest wall chest wall nerv control diaphragm outer layer tissu sac around heart cancer may spread lymph node side chest primari tumor lymph node cancer lung near bronchu also one follow found tumor larger centimet one separ tumor differ lobe lung primari tumor tumor size cancer spread follow trachea carina esophagu breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iiib tumor centimet smaller cancer spread lymph node collarbon side chest primari tumor lymph node opposit side chest primari tumor also one follow may found cancer spread main bronchu spread carina cancer spread innermost layer membran cover lung part lung whole lung collaps develop pneumon tumor may size cancer spread lymph node side chest primari tumor lymph node cancer around trachea trachea divid bronchi also one follow found one separ tumor lobe differ lobe lung primari tumor cancer spread follow membran line insid chest wall chest wall nerv control diaphragm outer layer tissu sac around heart trachea carina esophagu breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iiic tumor may size cancer spread lymph node collarbon side chest primari tumor lymph node opposit side chest primari tumor also one follow found one separ tumor lobe differ lobe lung primari tumor cancer spread follow membran line insid chest wall chest wall nerv control diaphragm outer layer tissu sac around heart trachea carina esophagu breastbon backbon diaphragm heart major blood vessel lead heart nerv control larynx voic box stage iv stage iv divid stage iva ivb stage iva tumor may size cancer may spread lymph node one follow found one tumor lung primari tumor cancer found fluid around lung heart cancer spread one place organ near lung brain liver adren gland kidney bone sac around heart lymph node near lung stage ivb cancer spread multipl place one organ near lung recurr non small cell lung cancer recurr non small cell lung cancer cancer recur come back treat cancer may come back brain lung part bodi treatment option overview key point differ type treatment patient non small cell lung cancer ten type standard treatment use surgeri radiat therapi chemotherapi target therapi immunotherapi laser therapi photodynam therapi pdt cryosurgeri electrocauteri watch wait new type treatment test clinic trial chemoprevent radiosensit new combin treatment non small cell lung cancer may caus side effect patient may want think take part clinic trial patient enter clinic trial start cancer treatment follow test may need differ type treatment patient non small cell lung cancer differ type treatment avail patient non small cell lung cancer treatment standard current use treatment test clinic trial treatment clinic trial research studi meant help improv current treatment obtain inform new treatment patient cancer clinic trial show new treatment better standard treatment new treatment may becom standard treatment patient may want think take part clinic trial clinic trial open patient start treatment ten type standard treatment use surgeri four type surgeri use treat lung cancer wedg resect surgeri remov tumor normal tissu around slightli larger amount tissu taken call segment resect enlarg wedg resect lung part lung lobe contain cancer small amount healthi tissu around remov lobectomi surgeri remov whole lobe section lung enlarg lobectomi lobe lung remov pneumonectomi surgeri remov one whole lung enlarg pneumonectomi whole lung remov sleev resect surgeri remov part bronchu doctor remov cancer seen time surgeri patient may given chemotherapi radiat therapi surgeri kill cancer cell left treatment given surgeri lower risk cancer come back call adjuv therapi radiat therapi radiat therapi cancer treatment use high energi x ray type radiat kill cancer cell keep grow two type radiat therapi extern radiat therapi use machin outsid bodi send radiat toward cancer intern radiat therapi use radioact substanc seal needl seed wire cathet place directli near cancer stereotact bodi radiat therapi type extern radiat therapi special equip use place patient posit radiat treatment day sever day radiat machin aim larger usual dose radiat directli tumor patient posit treatment less damag nearbi healthi tissu procedur also call stereotact extern beam radiat therapi stereotax radiat therapi stereotact radiosurgeri type extern radiat therapi use treat lung cancer spread brain rigid head frame attach skull keep head still radiat treatment machin aim singl larg dose radiat directli tumor brain procedur involv surgeri also call stereotax radiosurgeri radiosurgeri radiat surgeri tumor airway radiat given directli tumor endoscop way radiat therapi given depend type stage cancer treat also depend cancer found extern intern radiat therapi use treat non small cell lung cancer chemotherapi chemotherapi cancer treatment use drug stop growth cancer cell either kill cell stop divid chemotherapi taken mouth inject vein muscl drug enter bloodstream reach cancer cell throughout bodi system chemotherapi chemotherapi place directli cerebrospin fluid organ bodi caviti abdomen drug mainli affect cancer cell area region chemotherapi way chemotherapi given depend type stage cancer treat see drug approv non small cell lung cancer inform target therapi target therapi type treatment use drug substanc attack specif cancer cell target therapi usual caus less harm normal cell chemotherapi radiat therapi monoclon antibodi tyrosin kinas inhibitor two main type target therapi use treat advanc metastat recurr non small cell lung cancer monoclon antibodi monoclon antibodi therapi cancer treatment use antibodi made laboratori singl type immun system cell antibodi identifi substanc cancer cell normal substanc blood tissu may help cancer cell grow antibodi attach substanc kill cancer cell block growth keep spread monoclon antibodi given infus may use alon carri drug toxin radioact materi directli cancer cell differ type monoclon antibodi therapi vascular endotheli growth factor vegf inhibitor therapi cancer cell make substanc call vegf caus new blood vessel form angiogenesi help cancer grow vegf inhibitor block vegf stop new blood vessel form may kill cancer cell need new blood vessel grow bevacizumab ramucirumab vegf inhibitor angiogenesi inhibitor epiderm growth factor receptor egfr inhibitor therapi egfr protein found surfac certain cell includ cancer cell epiderm growth factor attach egfr surfac cell caus cell grow divid egfr inhibitor block receptor stop epiderm growth factor attach cancer cell stop cancer cell grow divid cetuximab necitumumab egfr inhibitor tyrosin kinas inhibitor tyrosin kinas inhibitor small molecul drug go cell membran work insid cancer cell block signal cancer cell need grow divid tyrosin kinas inhibitor also angiogenesi inhibitor effect differ type tyrosin kinas inhibitor epiderm growth factor receptor egfr tyrosin kinas inhibitor egfr protein found surfac insid certain cell includ cancer cell epiderm growth factor attach egfr insid cell send signal tyrosin kinas area cell tell cell grow divid egfr tyrosin kinas inhibitor stop signal stop cancer cell grow divid erlotinib gefitinib afatinib osimertinib type egfr tyrosin kinas inhibitor drug work better also mutat chang egfr gene kinas inhibitor affect cell certain gene chang certain chang alk ro gene caus much protein made block protein may stop cancer grow spread crizotinib use stop protein made alk ro gene ceritinib alectinib brigatinib use stop protein made alk gene dabrafenib use stop protein made braf gene trametinib use stop protein made mek gene see drug approv non small cell lung cancer inform immunotherapi immunotherapi treatment use patient immun system fight cancer substanc made bodi made laboratori use boost direct restor bodi natur defens cancer type cancer treatment also call biotherapi biolog therapi immun checkpoint inhibitor therapi type immunotherapi immun checkpoint inhibitor therapi pd protein surfac cell help keep bodi immun respons check pd attach anoth protein call pdl cancer cell stop cell kill cancer cell pd inhibitor attach pdl allow cell kill cancer cell nivolumab pembrolizumab atezolizumab durvalumab type immun checkpoint inhibitor enlarg immun checkpoint inhibitor checkpoint protein pd l tumor cell pd cell help keep immun respons check bind pd l pd keep cell kill tumor cell bodi left panel block bind pd l pd immun checkpoint inhibitor anti pd l anti pd allow cell kill tumor cell right panel view video youtub immunotherapi use bodi immun system fight cancer anim explain one type immunotherapi use immun checkpoint inhibitor treat cancer see drug approv non small cell lung cancer inform laser therapi laser therapi cancer treatment use laser beam narrow beam intens light kill cancer cell photodynam therapi pdt photodynam therapi pdt cancer treatment use drug certain type laser light kill cancer cell drug activ expos light inject vein drug collect cancer cell normal cell fiberopt tube use carri laser light cancer cell drug becom activ kill cell photodynam therapi caus littl damag healthi tissu use mainli treat tumor skin line intern organ tumor airway pdt given directli tumor endoscop cryosurgeri cryosurgeri treatment use instrument freez destroy abnorm tissu carcinoma situ type treatment also call cryotherapi tumor airway cryosurgeri done endoscop electrocauteri electrocauteri treatment use probe needl heat electr current destroy abnorm tissu tumor airway electrocauteri done endoscop watch wait watch wait close monitor patient condit without give treatment sign symptom appear chang may done certain rare case non small cell lung cancer new type treatment test clinic trial summari section describ treatment studi clinic trial may mention everi new treatment studi inform clinic trial avail nci websit chemoprevent chemoprevent use drug vitamin substanc reduc risk cancer reduc risk cancer recur come back lung cancer chemoprevent use lessen chanc new tumor form lung radiosensit radiosensit substanc make tumor cell easier kill radiat therapi combin chemotherapi radiat therapi given radiosensit studi treatment non small cell lung cancer new combin new combin treatment studi clinic trial treatment non small cell lung cancer may caus side effect inform side effect caus treatment cancer see side effect page patient may want think take part clinic trial patient take part clinic trial may best treatment choic clinic trial part cancer research process clinic trial done find new cancer treatment safe effect better standard treatment mani today standard treatment cancer base earlier clinic trial patient take part clinic trial may receiv standard treatment among first receiv new treatment patient take part clinic trial also help improv way cancer treat futur even clinic trial lead effect new treatment often answer import question help move research forward patient enter clinic trial start cancer treatment clinic trial includ patient yet receiv treatment trial test treatment patient whose cancer gotten better also clinic trial test new way stop cancer recur come back reduc side effect cancer treatment clinic trial take place mani part countri inform clinic trial support nci found nci clinic trial search webpag clinic trial support organ found clinicaltri gov websit follow test may need test done diagnos cancer find stage cancer may repeat test repeat order see well treatment work decis whether continu chang stop treatment may base result test test continu done time time treatment end result test show condit chang cancer recur come back test sometim call follow test check up treatment option stage inform treatment list see treatment option overview section occult non small cell lung cancer treatment occult non small cell lung cancer depend stage diseas occult tumor often found earli stage tumor lung sometim cure surgeri use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage treatment stage may includ follow surgeri wedg resect segment resect photodynam therapi electrocauteri cryosurgeri laser surgeri tumor near bronchu use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage non small cell lung cancer treatment stage ia non small cell lung cancer stage ib non small cell lung cancer may includ follow surgeri wedg resect segment resect sleev resect lobectomi extern radiat therapi includ stereotact bodi radiat therapi patient cannot surgeri choos surgeri clinic trial chemotherapi radiat therapi follow surgeri clinic trial treatment given endoscop photodynam therapi pdt clinic trial surgeri follow chemoprevent use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage ii non small cell lung cancer treatment stage iia non small cell lung cancer stage iib non small cell lung cancer may includ follow surgeri wedg resect segment resect sleev resect lobectomi pneumonectomi chemotherapi follow surgeri surgeri follow chemotherapi extern radiat therapi patient cannot surgeri clinic trial radiat therapi follow surgeri use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage iiia non small cell lung cancer treatment stage iiia non small cell lung cancer remov surgeri may includ follow surgeri follow chemotherapi surgeri follow radiat therapi chemotherapi follow surgeri surgeri follow chemotherapi combin radiat therapi chemotherapi radiat therapi follow surgeri clinic trial new combin treatment treatment stage iiia non small cell lung cancer cannot remov surgeri may includ follow chemotherapi radiat therapi given period time one follow extern radiat therapi alon patient cannot treat combin therapi palli treatment reliev symptom improv qualiti life intern radiat therapi laser surgeri palli treatment reliev symptom improv qualiti life chemotherapi radiat therapi follow immunotherapi immun checkpoint inhibitor durvalumab clinic trial new combin treatment inform support care sign symptom includ cough short breath chest pain see pdq summari cardiopulmonari syndrom non small cell lung cancer superior sulcu often call pancoast tumor begin upper part lung spread nearbi tissu chest wall larg blood vessel spine treatment pancoast tumor may includ follow radiat therapi alon surgeri chemotherapi radiat therapi follow surgeri clinic trial new combin treatment stage iiia non small cell lung tumor grown chest wall may complet remov treatment chest wall tumor may includ follow surgeri surgeri radiat therapi radiat therapi alon chemotherapi combin radiat therapi surgeri clinic trial new combin treatment use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail stage iiib stage iiic non small cell lung cancer treatment stage iiib non small cell lung cancer stage iiic non small cell lung cancer may includ follow chemotherapi follow extern radiat therapi chemotherapi radiat therapi given separ treatment period time chemotherapi radiat therapi given separ treatment period time dose radiat therapi increas time chemotherapi radiat therapi given separ treatment period time chemotherapi alon given treatment chemotherapi radiat therapi follow immunotherapi immun checkpoint inhibitor durvalumab extern radiat therapi alon patient cannot treat chemotherapi extern radiat therapi palli therapi reliev symptom improv qualiti life laser therapi intern radiat therapi reliev symptom improv qualiti life clinic trial new extern radiat therapi schedul new type treatment clinic trial chemotherapi radiat therapi combin radiosensit clinic trial target therapi combin chemotherapi radiat therapi inform support care sign symptom cough short breath chest pain see follow pdq summari cardiopulmonari syndrom cancer pain use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail newli diagnos stage iv relaps recurr non small cell lung cancer treatment newli diagnos stage iv relaps recurr non small cell lung cancer may includ follow combin chemotherapi combin chemotherapi target therapi monoclon antibodi bevacizumab cetuximab necitumumab combin chemotherapi follow chemotherapi mainten therapi help keep cancer progress target therapi epiderm growth factor receptor egfr tyrosin kinas inhibitor osimertinib gefitinib erlotinib afatinib target therapi anaplast lymphoma kinas alk inhibitor alectinib crizotinib ceritinib target therapi braf mek inhibitor dabrafenib trametinib immunotherapi immun checkpoint inhibitor pembrolizumab without chemotherapi laser therapi intern radiat therapi tumor block airway extern radiat therapi palli therapi reliev symptom improv qualiti life surgeri remov second primari tumor surgeri remov cancer spread brain follow radiat therapi whole brain stereotact radiosurgeri tumor spread brain cannot treat surgeri clinic trial new drug combin treatment use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail progress stage iv relaps recurr non small cell lung cancer treatment progress stage iv relaps recurr non small cell lung cancer may includ follow chemotherapi target therapi epiderm growth factor receptor egfr tyrosin kinas inhibitor erlotinib gefitinib afatinib osimertinib target therapi anaplast lymphoma kinas alk inhibitor crizotinib ceritinib alectinib brigatinib target therapi braf mek inhibitor dabrafenib trametinib immunotherapi immun checkpoint inhibitor nivolumab pembrolizumab atezolizumab clinic trial new drug combin treatment use clinic trial search find nci support cancer clinic trial accept patient search trial base type cancer age patient trial done gener inform clinic trial also avail learn non small cell lung cancer inform nation cancer institut non small cell lung cancer see follow lung cancer home page lung cancer prevent lung cancer screen drug approv non small cell lung cancer target cancer therapi laser cancer treatment photodynam therapi cancer cryosurgeri cancer treatment tobacco includ help quit secondhand smoke cancer gener cancer inform resourc nation cancer institut see follow cancer stage chemotherapi support peopl cancer radiat therapi support peopl cancer cope cancer question ask doctor cancer survivor caregiv pdq summari pdq physician data queri pdq nation cancer institut nci comprehens cancer inform databas pdq databas contain summari latest publish inform cancer prevent detect genet treatment support care complementari altern medicin summari come two version health profession version detail inform written technic languag patient version written easi understand nontechn languag version cancer inform accur date version also avail spanish pdq servic nci nci part nation institut health nih nih feder govern center biomed research pdq summari base independ review medic literatur polici statement nci nih purpos summari pdq cancer inform summari current inform treatment non small cell lung cancer meant inform help patient famili caregiv give formal guidelin recommend make decis health care review updat editori board write pdq cancer inform summari keep date board made expert cancer treatment specialti relat cancer summari review regularli chang made new inform date summari updat date recent chang inform patient summari taken health profession version review regularli updat need pdq adult treatment editori board clinic trial inform clinic trial studi answer scientif question whether one treatment better anoth trial base past studi learn laboratori trial answer certain scientif question order find new better way help cancer patient treatment clinic trial inform collect effect new treatment well work clinic trial show new treatment better one current use new treatment may becom standard patient may want think take part clinic trial clinic trial open patient start treatment clinic trial list pdq found onlin nci websit inform call cancer inform servic cancer permiss use summari pdq regist trademark content pdq document use freeli text cannot identifi nci pdq cancer inform summari unless whole summari shown updat regularli howev user would allow write sentenc nci pdq cancer inform summari breast cancer prevent state risk follow way [includ excerpt summary] best way cite pdq summari pdq adult treatment editori board pdq non small cell lung cancer treatment bethesda md nation cancer institut updat mm dd yyyi avail http www cancer gov type lung patient non small cell lung treatment pdq access mm dd yyyi [pmid ] imag summari use permiss author artist publish use pdq summari want use imag pdq summari use whole summari must get permiss owner cannot given nation cancer institut inform use imag summari along mani imag relat cancer found visual onlin visual onlin collect scientif imag disclaim inform summari use make decis insur reimburs inform insur coverag avail cancer gov manag cancer care page contact us inform contact us receiv help cancer gov websit found contact us help page question also submit cancer gov websit e mail us',\n",
       " 'take humira imuran felt aw flu like symptom dizzi could bare function mom also crohn stelara clinic trial hopkin take remiss hope success thank repli',\n",
       " 'evid progress nep new outcom measur coin oratorio clinic trial studi peopl primari progress ms ppm randomli assign receiv either ocrelizumab ocrevu placebo compar placebo group receiv ocrevu high likelihood progress month period time definit state signific chang month period differ neurolog test edss nine hole peg test time foot walk test describ video excit invent new metric explain amaz clinic find evid progress amaz medic increas likelihood one patient experienc nep pleas leav question comment wehavem ms view news make impact affect multipl sclerosi',\n",
       " 'believ gilenya back around look back post mani ms treatment choos one side effect caution special dosag requir inform deal skyhigh cost huge question pay drug keep busi full time figur one might work one seem work well go process keep tri variou avail option least quit peopl seem stop tri two type treatment tempt new one keep come along consid tri treatment ms diagnos avonex copaxon member ms board sinc repli quot follow user say thank howi jeani z salpals stillstannd sunshin suze q',\n",
       " 'patient receiv tremelimumab iv durvalumab iv minut everi week week absenc diseas progress unaccept toxic patient receiv durvalumab iv minut week last combin dose addit dose biolog durvalumab given iv name imfinzi immunoglobulin g anti human protein b h human monoclon medi heavi chain disulfid human monoclon medi kappa chain dimer medi medi laboratori biomark analysi correl studi biolog tremelimumab given iv name anti ctla human monoclon antibodi cp cp cp cp ticilimumab experiment arm b tremelimumab durvalumab rt patient receiv tremelimumab durvalumab arm begin week patient receiv high dose radiat therapi qd day fraction biolog durvalumab given iv name imfinzi immunoglobulin g anti human protein b h human monoclon medi heavi chain disulfid human monoclon medi kappa chain dimer medi medi laboratori biomark analysi correl studi radiat radiat therapi undergo radiat therapi name cancer radiotherapi irradi irradi irradi radiat radiotherapeut radiotherapi rt therapi radiat biolog tremelimumab given iv name anti ctla human monoclon antibodi cp cp cp cp ticilimumab experiment arm c tremelimumab durvalumab rt patient receiv tremelimumab durvalumab arm begin week patient receiv low dose radiat therapi everi hour bid week biolog durvalumab given iv name imfinzi immunoglobulin g anti human protein b h human monoclon medi heavi chain disulfid human monoclon medi kappa chain dimer medi medi laboratori biomark analysi correl studi radiat radiat therapi undergo radiat therapi name cancer radiotherapi irradi irradi irradi radiat radiotherapeut radiotherapi rt therapi radiat biolog tremelimumab given iv name anti ctla human monoclon antibodi cp cp cp cp ticilimumab outcom measur go top page studi descript studi design arm intervent outcom measur elig criteria contact locat inform primari outcom measur overal respons rate determin respons evalu criteria solid tumor recist [ time frame year ] proport patient respons complet respons partial respons accord recist compar pair wise comparison radiotherapi rt contain therapi control use chi squar test differ proport respond present confid interv colorect cancer respons rate within two stage design calcul present confid interv estim use method atkinson brown allow two stage design secondari outcom measur progress free surviv pf [ time frame date random object diseas progress death whichev occur first assess year ] distribut summar use kaplan meier method median time therapi arm accompani confid interv base log log endpoint methodolog cohort pairwis comparison durvalumab tremelimumab alon durvalumab tremelimumab rt arm conduct use log rank test overal surviv os [ time frame time random death caus assess year ] distribut summar use kaplan meier method median time therapi arm accompani confid interv base log log endpoint methodolog cohort pairwis comparison durvalumab tremelimumab alon durvalumab tremelimumab rt arm conduct use log rank test object respons per immun relat respons irorr criteria [ time frame year ] present exact binomi confid interv cohort size cohort patient cohort confid interv wider respect cohort pairwis comparison irorr rt control arm conduct use chi squar test incid advers event assess common terminolog criteria advers event version [ time frame year ] safeti data summar treatment arm within cohort proport subject grade higher advers event present exact binomi confid interv local control rate abscop respons rate [ time frame year ] proport patient local control within irradi field report within rt treatment arm present exact binomi confid interv similar present use abscop respons rate cohort size cohort patient cohort confid interv wider respect prognost effect pd l express [ time frame year ] clinic respons compar accord pd l express use fisher exact test prognost effect cell infiltr [ time frame year ] clinic respons compar accord infiltr use fisher exact test outcom measur patient report symptomat advers event ae [ time frame year ] data evalu data qualiti character baselin symptom statu patient studi chang time explor develop symptomat ae chang time explor patient score relev clinic inform includ limit clinician grade ae feasibl electron collect well complianc patient report captur elig criteria go top page studi descript studi design arm intervent outcom measur elig criteria contact locat inform inform nation librari medicin choos particip studi import person decis talk doctor famili member friend decid join studi learn studi doctor may contact studi research staff use contact provid gener inform learn clinic studi age elig studi year older adult older adult sex elig studi accept healthi volunt criteria inclus criteria patient must histolog cytolog confirm non small cell lung cancer cohort colorect cancer cohort patient must measur diseas defin least one lesion accur measur least one dimens longest diamet record non nodal lesion short axi nodal lesion mm cm convent techniqu mm cm spiral comput tomographi ct scan magnet reson imag mri calip clinic exam patient cohort must progress diseas follow prior therapi specif cohort nsclc patient must evid radiolog clinic diseas progress previou treatment system pd direct therapi deem deriv clinic benefit pd direct treatment includ patient demonstr initi respons subsequ progress prior treatment chemotherapi target agent requir interven therapi allow previou pd direct treatment requir interv prior pd treatment requir pd direct treatment includ treatment antibodi target pd receptor pembrolizumab nivolumab well pd l target antibodi medi durvalumab atezolizumab avelumab agent may administ part clinic trial cohort colorect cancer patient must progress one line chemotherapi least day must elaps prior system therapi chemotherapi radiat eastern cooper oncolog group ecog perform statu karnofski life expect greater month furthermor enrol patient greater measur lesion discourag patient must normal organ marrow function independ transfus least day prior screen independ growth factor support least day prior screen hemoglobin hgb g dl absolut neutrophil count mcl platelet mcl total bilirubin x normal institut limit appli patient confirm gilbert syndrom persist recurr hyperbilirubinemia [predominantli unconjug bilirubin] absenc evid hemolysi hepat patholog allow consult physician aspart aminotransferas ast serum glutam oxaloacet transaminas [sgot] alanin aminotransferas alt serum glutam pyruv transaminas [sgpt] x institut upper limit normal patient hepat metastas alt ast x ult measur creatinin clearanc cl ml min calcul creatinin clearanc cl ml min determin cockcroft gault use actual bodi weight patient must least one lesion previous irradi within previous radiat field palli radiat potenti indic could safe deliv radiat dose specifi protocol lesion must measur lesion still possibl determin respons rate outsid radiat treatment field lesion must within central nervou system cn brain spinal cord requir urgent emerg palli radiat given time radiat specifi protocol furthermor lesion cohort nsclc cohort lesion irradi must lung lymph node adren gland liver cohort colorect cohort lesion irradi must liver evid post menopaus statu neg urinari serum pregnanc test femal pre menopaus patient requir women consid post menopaus amenorrh month without altern medic caus follow age specif requir appli women year age would consid post menopaus amenorrh month follow cessat exogen hormon treatment lutein hormon follicl stimul hormon level post menopaus rang institut underw surgic steril bilater oophorectomi hysterectomi women year age would consid post menopaus amenorrh month follow cessat exogen hormon treatment radiat induc oophorectomi last mens year ago chemotherapi induc menopaus year interv sinc last mens underw surgic steril bilater oophorectomi hysterectomi femal childbear potenti sexual activ non steril male partner must use least highli effect method contracept time screen must agre continu use precaut day last dose durvalumab tremelimumab combin therapi day last dose durvalumab monotherapi non steril male partner femal patient must use male condom plu spermicid throughout period cessat birth control point discuss respons physician engag sexual activ total durat drug treatment drug washout period accept practic howev period abstin rhythm method withdraw method accept method birth control femal patient also refrain breastfeed throughout period non steril male sexual activ femal partner childbear potenti must use male condom plu spermicid screen day receipt final dose durvalumab tremelimumab combin therapi day receipt final dose durvalumab monotherapi engag sexual activ accept practic howev occasion abstin rhythm method withdraw method accept method contracept male patient refrain sperm donat throughout period femal partner childbear potenti male patient must also use highli effect method contracept throughout period woman becom pregnant suspect pregnant partner particip studi inform treat physician immedi abil patient legal author repres lar understand willing sign written inform consent document bodi weight kg must life expect least week cohort nsclc cohort abil undergo fresh tumor biopsi purpos screen clinic trial includ abl will give valid written consent abil provid avail archiv tumor sampl taken less month prior studi enrol obtain prior progress pd pd l inhibitor fresh tumor biopsi feasibl accept clinic risk tumor lesion use fresh biopsi lesion irradi possibl lesion use respons evalu criteria solid tumor recist target lesion unless lesion access addit option archiv tumor tissu also request prior pd direct therapi cohort colorect cohort abil undergo fresh tumor biopsi purpos screen clinic trial includ abl will give valid written consent abil provid avail archiv tumor sampl taken less month prior studi enrol fresh tumor biopsi feasibl accept clinic risk tumor lesion use fresh biopsi lesion irradi possibl lesion use recist target lesion unless lesion access microsatellit stabl mss tumor document either immunohistochemistri ihc test suggest loss mlh msh pm msh polymeras chain reaction pcr test suggest microsatellit instabl msi exclus criteria patient system chemotherapi biolog therapi radiotherapi within week week nitrosourea mitomycin c prior enter studi receipt prior radiotherapi condit reason would contribut radiat dose would exceed toler normal tissu discret treat physician patient recov advers event due prior anti cancer therapi e residu toxic grade patient receiv investig agent patient untreat brain metastas spinal cord compress leptomening carcinomatosi exclud clinic trial patient whose brain metastas treat may particip provid show radiograph stabil defin brain imag obtain treatment brain metastas imag scan obtain least four week apart show evid intracrani progress addit neurolog symptom develop either result brain metastas treatment must resolv stabl either without use steroid stabl steroid dose mg day prednison equival anti convuls least day prior start treatment histori allerg reaction attribut compound similar chemic biolog composit tremelimumab medi previou toxic attribut medi pd pd l direct therapi led drug discontinu prior exposur immun mediat therapi includ durvalumab tremelimumab except anti pd anti pd l therapi includ durvalumab nsclc patient includ anti ctla agent prior treatment agent allow either cohort exclud therapeut anticanc vaccin exclud therapeut anticanc vaccin exposur investig agent may permit discuss studi princip investig pi uncontrol intercurr ill includ limit ongo activ infect symptomat congest heart failur unstabl angina pectori cardiac arrhythmia psychiatr ill social situat would limit complianc studi requir pregnant women exclud studi breastfeed discontinu mother treat medi durvalumab tremelimumab radiat femal patient pregnant breastfeed male femal patient reproduct potenti will employ effect birth control screen day last dose durvalumab monotherapi day last dose durvalumab tremelimumab combin therapi whichev later human immunodefici viru hiv posit patient inelig appropri studi undertaken patient receiv combin antiretrovir therapi indic concurr chemotherapi immun therapi biolog hormon therapi cancer treatment current prior use immunosuppress medic within day first dose assign ip follow except criterion intranas inhal topic steroid local steroid inject e g intra articular inject system corticosteroid physiolog dose exceed mg day prednison equival steroid pre medic hypersensit reaction e g ct scan pre medic major surgic procedur defin investig within day prior first dose ip note local surgeri isol lesion palli intent accept histori allogen organ transplant activ prior document autoimmun inflammatori disord includ inflammatori bowel diseas diverticul [with except diverticulosis] sarcoidosi syndrom seriou gastrointestin [gi] chronic condit associ diarrhea system lupu erythematosu wegen syndrom [granulomatosi polyangiitis] myasthenia gravi grave diseas rheumatoid arthriti hypophys uveiti sarcoidosi syndrom etc within past year prior start treatment follow except criterion patient vitiligo alopecia patient hypothyroid e g follow hashimoto syndrom stabl hormon replac psoriasi requir system treatment chronic skin condit requir system therapi patient without activ diseas last year may includ consult studi physician patient celiac diseas control diet alon histori anoth primari malign except malign treat cur intent known activ diseas year first dose studi drug low potenti risk recurr adequ treat non melanoma skin cancer lentigo maligna without evid diseas adequ treat carcinoma situ without evid diseas e g cervic cancer situ mean qt interv correct heart rate qtc ms calcul electrocardiogram ecg use fridericia correct abnorm ecg repeat histori activ primari immunodefici known histori previou clinic diagnosi tuberculosi activ infect includ hepat b known posit hepat b viru [hbv] surfac antigen [hbsag] result hepat c patient past resolv hbv infect defin presenc hepat b core antibodi [anti hbc] absenc hbsag elig patient posit hepat c hcv antibodi elig polymeras chain reaction neg hcv ribonucl acid rna neg serolog document past year suffici evid receipt live attenu vaccin within day prior first dose investig treatment note patient enrol receiv live vaccin studi day last dose investig treatment condit opinion investig would interfer evaluati contact locat go top page studi descript studi design arm intervent outcom measur elig criteria contact locat inform inform nation librari medicin learn studi doctor may contact studi research staff use contact inform provid sponsor pleas refer studi clinicaltri gov identifi nct number nct show studi locat sponsor collabor nation cancer institut nci',\n",
       " 'yesterday bad day first doctor visit went expect nowher mean much could done point symptom treat symptomat realli think experienc ms hug even think realli understood ms hug doctor year first time ever littl shock especi sinc first thing discuss soon walk offic new drug ocrelizumab versu rituxan also occur yesterday offic increas baclofen hurt shoulder also took upon decreas baclofen wonder caus muscl spasm return either way decid want bring back neurontin anoth symptom came back start either way decid want bring back neurontin anoth symptom came back start everi time leav one neurologist doctor offic visit sort depress kick someth go feel great walk still feel great realli know st point noth help feel better tri treat symptom allevi discomfort pain noth take away complet basic everi time leav doctor noth ever differ get depress know love say end day mention past blog realli go today accid time got home yesterday came complet blue know even complet threw edg yesterday walk even make stair cours deal mess shower chang guess ms stuff exhaust top everyth exhaust tri short time els go alon thought hit fuck alon daughter go colleg next year two dog love heart help mom stepdad god know still work middl mom call leav quick messag machin check someth know whatev say curs bathroom like fault call back absolut hyster thing think head moment enough enough ms enough diseas enough done could imagin get phone call kid walk work even talk pull ledg one minut somebodi wait took minut come back everyth clean includ abl go sit couch put tv one dog came lick tear puppi came first time ever laid lap instead crazi one abl text mom tell ok convers later even mayb look get help part time year old marbl multipl sclerosi realli bad day yesterday normal tri make blog posit shitti post sad post hope humor post one post real realli daili life experi multipl sclerosi',\n",
       " 'blog alway thought driver relaps atrophi differ although relaps caus atrophi treatment need differ suspect ocrelizumab get rid plasma cell suspect major effect ocb',\n",
       " 'debilit uc tri usual drug except biolog like humira decad littl relief resist biolog sever reason horrifi patient testimoni help final threw towel year ago knew continu path resist go take road disabl jobless famili abl care properli support doc put prednisob taper follow initi humira remiss ever sinc nurs iron work endoscopi guess want peopl know ok go optim tri visual med heal agent truli save life hope continu work readi give tri',\n",
       " 'today mark third month gilenya rough ride sinc first dose march fatigu start gone wors howev still give chanc see goe anoth coupl month read numer feedback got patient gilenya feel better later go tri stick hope get better time',\n",
       " 'hello bit background info got ms diagnos epilepsi due lesion tempor lobe take gilenya oxcarbazepin told april gilenya work well progress last year extrem happi rd med tri epilepsi control year award drive licenc back last octob annoyingli today seizur morn angri upset feel like step forward one back cant help wonder seizur start sensori issu leg coupl week ago epilept aura feel like back crap bu guess wonder anyon anyth similar expect want medic test etc thought abit time consid mri februari came back fine thank read x',\n",
       " 'know attack diagnos year ago major fall immedi went tysabri ever recal attack awar symptom everi day',\n",
       " 'sure allow take vitamin c tarceva spoke oncologist mind also heard japan give iv vitamin c tarceva accord protocol',\n",
       " 'hi mous pleas meet post quit either start new job januari get much free time use work term time often pop see happen work everi day far good although get tire save housework chore weekend finger cross stay healthi least worri tax credit cut gilenya trick ms far thought better show virtual face tracey x',\n",
       " 'set cladribin uk group facebook gilenya treatment possibl start april easter',\n",
       " 'help prednison feel like second diseas even make first one go away hug yr old mother moder pancol hosp week solumedrol delzicol apriso pred switch balsazid mg uceri mg wk minor flare august flare sinc oct acut pancreat balsalazid hosp day start humira reaction entyvio taper pred mg mg',\n",
       " 'lucki sue good neurolog team never nurs copaxon gilenya good nurs gp offic blood need great nurs infus centr tysabri ms nurs peopl know say without ms nurs know hear great thing place everi place madden cheer',\n",
       " 'facebook group gilenya user sever report fewer smaller lesion mri time g symptom clear within year copaxon clear follow year g year latter necessarili sign remyelin help g could',\n",
       " 'see list tri dmt diagnos neurologist start predict drug sinc around start rebif tecfidera day hit hard drug like lemtrada gilenya start diagnos new hard hit drug younger peopl crazi rebif made feel like get flu help hole vision heal close lesion touch optic nerv took five year skin reject time tecfidera offer ms patient take year get sever week stomach issu side effect relaps consid safe come long term problem blood check month problem might come drug quirk problem tri see one work best system two aunt ms treatment knew thing went exercis good nutrit medit seem help start research find think work work alway quit chang anoth dmt potter',\n",
       " 'remiss primari goal peopl crohn diseas biolog therapi help achiev remiss reduc symptom well heal damag intestin caus inflamm biolog therapi usual prescrib peopl sever crohn symptom found relief method guidelin recommend howev doctor prescrib biolog patient signific diseas first line approach biolog therapi work block certain chemic caus inflamm intestin biolog crohn diseas block protein call tumor necrosi factor tnf biolog block immun cell call integrin other act protein call interleukin il interleukin il biolog therapi stop inflamm gut anti tnf biolog bind block protein promot inflamm intestin also organ tissu mani peopl benefit medic sometim see improv immedi anywher eight week three anti tnf biolog humira remicad cimzia humira humira self administ treatment follow initi demonstr healthcar profession doctor decid handl inject give set pen dosag control medic insid also given instruct mani inject take first day initi day period patient typic use one humira pen everi two week remicad remicad may help patient gain control flare up may also help maintain remiss prevent symptom return remicad given directli bloodstream allow work immedi reliev symptom administ medic facil experienc healthcar profession close monitor side effect treatment remicad taken everi day three starter dose patient often see benefit six dose per year downsid remicad must given intraven medic facil two hour period cimzia cimzia administ small inject inject either given doctor offic home choos receiv treatment doctor offic option receiv treatment powder form powder mix steril water inject option use prefil syring syring contain medic alreadi mix measur dose use home doctor offic choos treatment get packag two syring instruct give treatment first three dose given everi two week abl take cimzia everi four week two anti integrin biolog crohn tysabri entyvio tysabri type biolog prevent inflamm caus white blood cell enter tissu block protein surfac cell tysabri given intraven everi four week take hour receiv full dose patient usual observ hour afterward tysabri typic use peopl respond well intoler tnf blocker immunomodul corticosteroid crohn patient consid tysabri awar seriou side effect tysabri user increas risk develop rare brain diseas call progress multifoc leukoencephalopathi pml result viru test advanc physician prescrib tysabri crohn warn patient risk also explain enrol prescrib program call touch program way receiv tysabri entyvio like tysabri entyvio approv treat adult moder sever crohn diseas respond well intoler reason take tnf blocker immunomodul corticosteroid work similarli tysabri act certain white blood cell prevent caus bowel inflamm associ crohn entyvio howev gut specif appear risk pml entyvio given doctor care intraven infus given minut first day therapi repeat week two week six everi eight week thereaft improv crohn diseas symptom occur week entyvio therapi discontinu prior start entyvio patient date immun stelara third class biolog il il agonist stelara drug class approv treat adult moder sever crohn respond well enough convent therapi drug target specif protein play key role inflamm process stelara initi given intraven supervis healthcar profession follow dose given via inject skin everi eight week either healthcar provid self administ patient train side effect although benefit often far outweigh risk biolog therapi present seriou side effect process biolog therapi reduc bodi abil fight infect caus tuberculosi infect includ brain infect also increas chanc certain type cancer patient take biolog especi younger patient one call hepatosplen cell lymphoma type cancer often fatal biolog therapi work differ other side effect may caus also vari ask doctor thoroughli explain possibl side effect discuss biolog therapi right takeaway biolog offer advantag treat crohn diseas drug specif target substanc bodi caus bowel inflamm doctor discuss option benefit risk help find effect treatment case biosimilar gener version biolog drug may avail manag crohn also save money doctor tell option',\n",
       " 'would like cm mm sinc bare see mm nodul biopsi cm major cancer center take care judi stage iiia adeno dx sr chemo carbo alimta x ned local recurr surgeri remov lrl cm involv pleura chemo carbo alimta x ned',\n",
       " 'thank kind word help found liver auto immunu diseas want get check heard come pair take fingolimod also affect liver gp never heard see got explain ms team said err side caution come possibl infect partner block bile duct due gallston certainli agoni thank good grumbl constant sore keep fight good fight answer advic hope goe away mean time best rebecca xx',\n",
       " 'wonder stori four cat sooth soul whole ordeal knew worst day curl next keep joke tri purr inflamm colon congratul remiss f diagnos feb mildli activ uc sigmoid colon prednison mg cortifoam x daili previous tri rowasa balsalazid bad reaction mesalamin intoler start remicad diet modifi low residu dairi free daili multivitamin supplement',\n",
       " 'drug stelara may eas crohn diseas titl drug stelara may eas crohn diseasecategori health newscreat amlast editori review sourc medicinenet digest gener',\n",
       " 'pleas pleas pleas diagnos read tysabri decid drug want time patient prove abc work faith avonex shot week two month later develop two week major major flare neuro spent entir day phone biogen prove case seriou put emerg tysabri took month start feel normal damag done first diagnos still function walk live full life could stop progress point think could carri normal flare came damag done get cane numb feet memori problem fatigu imagin mention wonder bladder bowel problem let damag start ye concern pml ms progress might well pml still good news ocrelizumab might come soon like power tysabri less risk lucki seiz opportun save ms go tysabri switch ocrelizumab got made expens someth worri plenti assist program pleas go tysabri pleas pleas pleas',\n",
       " 'feel like wrote get laser sinc may week bleed stop drip blood laser still contain week ago vitrectomi still bleed well start bleed day vitrectomi scare everi day pray much knightmar end tight control wors eye hard know think sure say know feel',\n",
       " 'last may wife start combo tafinlar mekinist combo show great promis melanoma trial patient braf v e mutat melanoma mutat braf v e type soon smaller trial initi nsclc patient mutat abt lc patient trial al show great promis earli last year trial longer admit new patient reopen treatment naiv patient could consid wife chemopaus time fortun got approv combo outsid trial two earlier scan show improv last week scan brought good news groundless densiti resolv discret mass seen minim residu stabl sub pleural interstiti infiltr like reflect minor fibrot chang continu treatment next scan month grate gotten point fortun new better drug becam avail time benefit mani includ wife wife yr dx mar nsclc mbac ai mar lobectomi left lower ul scan may clean juli bilater ggo sep promin ggo dec worsen ggo w foci dens consolid feb scan growth met braf posit v e mar start carbo alimta chemo follow alimta mainten initi shrinkag stabl till aptil june trial immunotherapi mpdl docetaxel assign docetaxel late octob stop docetaxel cours side effect sever chemo paus may start tafinlar mekinist combo initi sever side effect mostli high fever chill grade uveiti eye earli august reduc tafinlar dosag mg mg day kept mekinist mg day side effect manag scan earli aug late oct show improv latest scan wa',\n",
       " 'updat alectinib month result first pet scan begin alectinib previous identifi focal area hypermetabol activ involv pleura right middl lobe anteriorli significantli decreas hypermetabol activ max suv compar prior exam max suv significan measur mass remain previous identifi hypermetabol activ involv pleura right lung medial longer visual today exam stabl hypermetabol activ associ pleural thicken apex right lung significantli chang compar prior examin take',\n",
       " 'rememb back januari februari struggl pulmonari embol well happi say feel better fatigu easili lack exercis total caus gain weight ugh mad anymor come excit news still aliv surpass year file bankruptci day later day hospit stay medic bill alreadi roll total afford dad friend hammer bar grill next atlanta airport hold benefit help pay start rebuild credit cancer ruin financ credit card cushion anyth go wrong know last thing worri money plan live need credit score go back set date yet sinc work around scan schedul like one last weekend april first weekend may post soon find want say thank health blink eye could chang warn may stage lung cancer realiz get wors bless god heal process go quickli pray went still go thing nicol thought call us twinzi wish instead took us free give much peac hard world part may get knock lung cancer commun tight famili caregiv lose spous know never lose famili fight togeth patient caregiv alway love commun well get sleepi thought superwoman past day crash hous clean thank sweet word encourag throughout part life thank continu prayer us need inspir get back god bless sinc realli pic post show made self wig non made self without rare event show would like thank tarceva make hair crazi refus grow save life far think look like two differ peopl almost forgot happi cancerversari stefani wardrep',\n",
       " 'strang back post new question site like wife start gemzar would love know latest treat particularli nsclc type side effect encount start read initi look like better side effect mani agent stope cell divis wife like consid option also wonder anyon thought afatinib versu gemzar afatinib direct toward egfr famili mutat like wife seem effect seem rel short last month pretti hefti side effect familiar gemzar seem much better side effect profil still gener effect tumor well dna base chemotherapi like carbo work well wife particular sens rang time peopl gemzar degre caus problem wbc rbc would appreci anyth els think go oncologist discuss option thank wife lifelong non smoker dx adeno nsclc stage iv poorli diff bone met lymph node exon mutat x carbo alimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo effect add l growth clinic trial drug larg reduct tumor met tumor growth liver met stabl stabl add l growth trial gemzar tumor reduct stabl topic modifi month week ago catdand forum moder topic modifi month week ago catdand forum moder',\n",
       " 'agre would worth ask team put one lowest efficaci dmt current think treat earli hard judg post neuro team follow put copaxon serv well eleven year noth stronger avail would definit gone imo ms need stop track good thing copaxon four low efficaci crab copaxon rebif avonex betaseron least side effect flu ey reaction chill etc possibl skin reaction issu interestingli mode action never fulli understood crab aim reduc relaps averag newer drug upward power found shut ms altogeth mani case howev told relaps figur averag lot better eleven year three four minor relaps avoid even minor flare up vital relaps may leav degre perman damag drawback howev effect copaxon daili inject time leg follow advic chang inject site nonetheless notic disfigur dip thigh fat cell implod result daili inject lipoatrophi believ quit common occurr develop new sensori symptom neuro offer move second three level drug gilenya sinc daili pill much easier inject far relaps realli matter judg risk benefit treatment offer know untreat ms get wors noth imo definit riski although mani mser site categor disagre crab drug least toxic system go second third level drug potent carri risk howev consider risk well known neuro patient regularli monitor blood test mri etc problem spot dealt often switch drug complic pictur hope read stumbler suggest abl ask neuro team right question decid best x',\n",
       " 'done blood test long ago check much need surpris said none test test start gilenya said everyth stabl need noth vitamin calcium reason alway ignor shelv',\n",
       " 'indygirl gilenya seem well toler diseas modifi therapi dmt document list side effect seem scari manufactur legal oblig detail everi possibl side effect ever experienc dmt ye immuno suppress leav vulner common bug go around ye power drug may seriou side effect regularli monitor risk factor breach accept risk threshold use dmt would review hope make feel bit comfort choic dmt',\n",
       " 'hi jimc regimen irinotecan avastin actual recommend stanford oncologist also want dad get radiat shrink main lung tumor big invad pericardium ban kaiser oncologist prefer go standard care treatment taxol next line treatment like said standard care old school style cancer patient treat individu base patient condit concurr med ethnic gene mutat irinotecan potent radiosensit agent access medic research articl onlin unless pay pocket get permiss read found far http meetinglibrari asco org content http www researchg net public http www ncbi nlm nih gov pubm come ask help kkh diagnos stage nsclc egfr also posit year tarceva month rociletinib wbr follow month tarcrva puls carboplatin avastin alimta month tagrisso diagnos leptomening metastasi nov cm big tumor multipl nodul differ size recent guardant test feb tp c f egfr exon delet egfr amp met h met amp fgfr amp pik ca amp ccne amp braf amp myc amp addit alter brca r c mtor k e nf v v met e k jak v f nd map k e k nd dec liver biopsi report egfr non small cell lung cancer got mutat chang small cell lung cancer',\n",
       " 'dr gandhi said like pd inhibitor chemotherapi combin may provid similar benefit shown impow clinicaltri gov identifi nct evalu efficaci atezolizumab plu bevacizumab chemotherapi find clinic meaning pf benefit patient includ egfr alk genom alter previous treat target therapi lot figur combin work togeth said keynot realli pure clinic studi quickli combin drug research need term sequenc analyz drug determin actual happen serial biopsi said need build base knowledg pembrolizumab chemotherapi clinic keynot address whether combin pembrolizumab chemotherapi superior pembrolizumab alon still may good option patient greater pd l express multipl option clinician patient chemotherapi alon longer one said relat articl immunotherapi lung cancer combin regimen path forward time report palli care need lead appropri end life care nsclc osimertinib improv qualiti life global health statu non small cell lung cancer date data sequenc pembrolizumab pemetrex platinum base drug keynot keynot suggest earli introduct immunotherapi may import given dramat surviv differ studi despit crossov immunotherapi second line would hesit extrapol regimen context combin would evid base medicin said slightli higher risk kidney toxic pembrolizumab group pd pd l inhibitor affect kidney dr gandhi ad rate seriou acut kidney injuri still futur hold clear pembrolizumab chemotherapi highli effect patient nsclc research still need determin combin superior pembrolizumab alon high pd l expressor emerg present studi chemotherapi alon longer standard care nonsquam nsclc backbon therapi immunotherapi form dr gandhi conclud whether immunotherapi combin immunotherapi combin chemotherapi yet address studi clearli demonstr benefit patient could use patient clinician abil nuanc decis make refer gandhi l rodriguez abreu gadgeel et al pembrolizumab plu chemotherapi metastat non small cell lung cancer n engl j med doi nejmoa hellmann md ciuleanu pluzanski et al nivolumab nivo ipilimumab ipi vs platinum doublet chemotherapi pt dc first line l treatment tx advanc non small cell lung cancer nsclc initi result checkmat present american associ cancer research annual meet april chicago il kowantz socinski zou w et al impow efficaci atezolizumab atezo plu bevacizumab bev chemotherapi chemo l metastat nonsquam nsclc mnsclc across key subgroup present american associ cancer research annual meet april chicago il',\n",
       " 'found site must say point talk experi decemb diagnos small cell lung cancer fight everi step way find pain gall bladder remov still relief told schedul pet scan worri cancer spread fast back ground inform said done chemo radiat treatment told oncologist good result next scan saw scar tissu radiat given steroid scan growth origin spot addit spot show tri opdivo christian trust god complet thought qualiti life abl told cure live one day time know futur hold know control go cruis week went punta cana niagra fall earlier year intend see pray struggl form cancer',\n",
       " 'thank carm pdl relev opdivo believ think may keytruda stat dianem understand say good advic cancer includ nsclc sclc nsclc mani new advanc stat longer reflect someon diagnos today luck sclc noth new long time though potenti sign progress recent know stat reflect individu case reflect overal realiti type cancer hope someth rather avoid given prognosi rather focu concret decis step take time someon write lot encourag thing typic turn thet basic talk involv nsclc sclc anoth ball wax unfortun fatal danger get excit gener progress cancer treatment appli case overal tri thank day take balanc view toward futur basic educ make plan make much room either hope worri despair',\n",
       " 'marmizuko similar problem start gilenya month ago month vision start get blurri day light bright place vision wors neuro say might gilenya sign macular edema sure yet gilenya problem someon similar problem said could thin retin nerv fiber layer wonder case proceed appreci advic input might thank',\n",
       " 'plan get pregnant right moment soon probabl worri right got yeast infect usual get antibiot surpris go away antibiot day still realli annoy want becom chronic anyth gilenya',\n",
       " 'sara decid return school full time school work incred time consum crank ten blog worth essay paper last three year last day monday graduat excit around move san francisco ca silicon valley area two year ago work sell home move cross countri get settl new job incred busi sara see neurologist ucsf ms research center one premier ms research facil world realli incred experi team eager share detail sara also lot excit gilenya last year would like provid updat sinc earli adopte pass fda trial lot peopl follow experi sara interest experi tri find ms support group bay area hope better luck find new one soon kill forum year half ago vanilla forum open sourc solut get much love ton gap spam prevent peopl tri use run link farm ride seo rank everi time wordpress updat broke forum hope would foster rich engag among commun like mind ms suffer support network never got ground may revisit site go plugin theme site gener lot love last three year tonight notic site due broken plugin least week notic sever similar problem time time last three year go spend time next week lot clean work implement new theme revisit plugin notic month ago sever implement ad cross site promot network stuff intent put site make site look like someth use modern visitor lot peopl still use site actual see visitor publish site regularli ms becom well known understood diseas huge number treatment research develop like discuss',\n",
       " 'remov german noth disagre f r aza konnten konsistent effekt auf schubratenredukt und edss progress berwiegend durch metaanalysen gezeigt werden prospekt im rahmen von phase iii studien erhoben daten zu mr tomographischen endpunkten existieren nicht dar ber hinau wird die bewertung der studiendaten durch den einschluss heterogen studienpopulationen sehr erschwert im gegensatz dazu konnt f r parenteral cladribin und cladribin tabletten ein hoch signifikant schubratenredukt sowi ein redukt gd anreichernd und neuer l sionen mehreren phase ii und iii studien gezeigt werden dar ber hinau konnt ein effekt auf die edss progress bei rrm mit cladribin tabletten nachgewiesen werden interpret evid effect relaps reduct azathioprin howev mainli meta analys paper luca massacesi et al publish discuss studi http multipl sclerosi research blogspot com cheap chip azathioprin better html without underpin mri data quit heterogen studi popul cladribin specif highlight parenter oral formul highli signific reduct relaps rate well reduct gd enhanc lesion signific effect edss shown fact azathioprin induct treatment rel modest efficaci pwm quit often well toler use autoimmun condit exampl myasthenia gravi',\n",
       " 'pilot studi warm cold compress reduc inject site erythema due peginterferon beta multipl sclerosi get detail research studi vitamin research studi compar level vitamin peopl relaps remit secondari progress multipl sclerosi normal vitamin level supplement vitamin get normal level read get detail research studi gener stem cell ms research investig new york stem cell foundat nyscf laboratori recruit peopl relaps remit secondari progress primari progress form ms undergo skin biopsi purpos gener stem cell line get detail clinic trial plegridi peginterferon real world effect safeti observ program purpos observ studi find long term safeti effect plegridi approxim five year time period inform side effect exampl flu like symptom [fls] inject site reaction [isrs] serio get detail ofatumumab versu teriflunomid compar efficaci safeti ofatumumab administ subcutan sc everi week versu teriflunomid administ oral daili patient relaps multipl sclerosi get detail research studi investig seek tissu sampl previous obtain peopl ms similar diseas order discov trigger ms nation ms societi fund investig univers utah seek collect exist brain biopsi tissu individu nationwid underw brain biopsi diagnos episod acut demyelin diseas get detail clinic trial gilenya fingolimod purpos studi monitor safeti fingolimod diseas modifi treatment patient relaps multipl sclerosi condit routin medic practic updat june studi finish enrol particip med get detail clinic trial effect intermitt vs continu walk gait kinemat person ms previou studi shown person ms better gait endur less fatigu practic walk intermitt rather continu purpos studi determin differ gait characterist intermitt con get detail clinic trial complementari altern medicin telerehabilit intervent purpos studi compar effect two deliveri model evid base complementari altern medicin cam program combin neurorehabilit function exercis yoga pilat individu multipl sclerosi ms cam get detail clinic trial vitamin supplement compar effect current recommend amount vitamin supplement versu high dose vitamin supplement reduc ms diseas activ ad standard therapi glatiram acet copaxon teva pharmaceut industri peop',\n",
       " 'hi terri thank ask fine next week husband start third cycl chemo cislatin alimta far bad tast mouth sore throat complain much blood count normal rang said oncologist suggest rat target therapi sinc tilerar chemo well egfr posit henc made decis yet read lot day empow knowledg help anxieti read book like anti cancer etc whi h ake angri sad time noth book follow cut sugar white floor etc year ago alway plant base diet highli medit cardiovascular exercis never smoke alchoh live far smooth work relat stress trauma one bless two beauti kid still struggl wish answer',\n",
       " 'repli post ahainlin son start humira abl first dose start get anxiou ask take think could continu said needl bad burn medic went switch citrat free humira burn nearli gone one click pen syring easi use unfortun son develop antibodi humira switch differ biolog regret take methotrex humira perhap would allow stay longer send best wish success new medic',\n",
       " 'coupl question turmer search first seem recent thread relev question year old thought broach question wife never smoker diagnos stage iv nsclc adenocarcenoma lung septemb infus carboplatin alimta get alimta mainten main tumor smaller cm regular oncologist ucsf mt zion gave referr integr oncologist across street much demand first open earlier month almost month got referr oncologist expert kind support treatment regimen help cancer patient diet medit acupunctur becom familiar wife case recommend varieti thing includ specif medicin mushroom turmer curcumin howev surpris learn unawar fresh turmer avail presum would take supplement consequ could recommend specif amount turmer add daili fresh veget juic carrot ginger black pepper cucumb celeri etc juic piec size pinki finger know might compar effect amount supplement search around line result anyth use never smoker nsclc use turmer form approv oncologist anyon know anyth recommend amount might juic input would appreci wife never smoker dx w stage iv nsclc adenocarcenoma main cm mass upper right lobe met lymph node liver bone egfr rare submut round carbo alimta maint alimta progr tarceva mg daili rad x ea hip stabl',\n",
       " 'well copaxon year relaps worth speak although effect earlier one led diagnosi never remit three year ago start thought minor sensori symptom neuro immedi offer second line drug gilenya far good think realli must find nut bolt healthcar decis offici guidelin somewher certainli person netherland want better choic treatment peopl buck system may qualifi second line drug new symptom appear may neuro interpret guidelin creativ exampl diagnos overheard consult say student difficult say ladi attack whether symptom continu origin relaps go presum new attack qualifi drug therapi xx',\n",
       " 'hi ant made decis medic take current gilenya well need reevalu medic soon neuro diagnos almost year ago day retreat follow om last year',\n",
       " 'prefac insur cover humira whatev dose necessari howev month use began flare antibiodi built therapeut level system stop work infect either sever test flex sig insur cove remicad simponi entyvio cover cimzia believ doc recommend want use medic thing approv especi doctor never mention seem crohn total oppos use infus drug like remicad sinc cover insur option anyway far steroid go hospit decemb due lack respond steroid even iv dose high steroid still symptomat improv doctor said becom steroid resist achiev brief month remiss humira start show symptom march doctor never prescrib multipl medic initi steroid wean drug choic also never rectal med antibiot said help prescrib definit look afford option post well perhap financi assist make feasibl suck afford diseas sigh',\n",
       " 'hello year daughter offici diagnos week chron wait result auto immun blood test ensur caus gi alreadi told us want go remicad base endoscopi colonoscopi one rare case remicad approv st line treatment loss mean wonder would insight kind question ask need know daughter symptom primarili extra intestin seem extrem consid healthi tall show defici howev endoscopi colonoscopi show lesion upper track rectum insight would greatli appreci thank',\n",
       " 'hi samdig welcom grace sorri know mom cancer stage iv nsclc diseas want treat marathon oppos sprint slow steadi full forc ahead metaphor mind mom take iressa one mildest anticanc agent avail partli due compar low dose compar tarceva well congrat continu progress iressa tarceva gilotrif may next option possibl well low dose tki long period time year progress show longer benefit iressa move anoth treatment next treatment may may tarceva gilotrif acquir mutat case like would move rd gen drug tagrisso hope well best janin',\n",
       " 'neurologist today gave option ocrelizumab natalizumab anyon experi share thank',\n",
       " 'unfortun laser photocoagul session massiv pain ophthalmologist explain due nerv eye deterior badli retin vasculatur say without doubt session profoundli pain incid life even though c level never higher rang last decad four laser session perhap result hyperglycem memori hyperglycemia back decad mid invent home glucomet first made blood sugar control possibl also publish theori peer review journal retinopathi caus thing hyperglycemia genet continu autoimmun play role noth avastin without problem sinc peopl like one type diabet diabet blog stroke month could speak articul fortun articul return diagnos banner diabet progress sinc first time nephrologist becam will accept diabet dialysi laser photocoagul develop retinopathi someth better half centuri later sinc laser photocoagul slash burn rather cure amount littl new version amput treat cannot fix',\n",
       " 'accord articl fighterm post ido cell activ clear activ cell studi drug design benefit cancer resist cell seem like administ keytruda opdivo combin instead need agent weaken cancer resist cell chemo tumor disrupt sure found synergi pembro cell activ reactiv disclaim field medicin biolog analysi may entir correct',\n",
       " 'hi wonder anyon crohn stelara bruis issu problem blood draw stelara sinc end work great howev someth notic awhil whenev get blood work done whenev stelara inject bruis area certainli minor issu curiou anyon els experienc year old femal crohn termin ileum sinc mid small bowel resect first stop humira due neurolog side effect humira year current stelara sinc allerg hypersensit pentasa entocort mp',\n",
       " 'hello diagnos relaps least one per year copaxon sinc diagnosi neuro want take gilenya trifecedera anyon either scare pml',\n",
       " 'enrol clinic trial use tecentriq infus surgeri patholog report came back lymph node test posit neg cancer part tumor shrunk work well',\n",
       " 'ms specialist expect ocrelizumab approv fda long submit data correctli first thought would approv latter part year sinc genzym submit data yet rrm ocrelizumab receiv breakthrough statu design ppm fda speed approv process approv ppm http www nationalmssocieti org abo py design talk safeti drug thu far progress still progress believ pretti much thing whether spm w relaps ppm good hear experienc posit result biotin thank suppli us link',\n",
       " 'deep grey matter volum loss brain drive multipl sclerosi ms progress disabl particularli evid peopl progress form diseas retrospect multi center studi suggest http onlinelibrari wiley com doi ana full howev recent studi found gilenya halt grey matter atrophi http www sciencedirect com scienc articl pii x howev gilenya less effect tysabri delay progress http onlinelibrari ectrim congress eu ectrim actrim ectrim j william l brown effect diseas modifi treatment convers html f media speaker risk assess hazard ratio convert spm among patient treat inject follow year gilenya follow year tysabri follow year lemtrada follow year compar match untreat patient higher hazard ratio lesser risk hmmm',\n",
       " 'meta analysi trial cladribin say cancer risk higher dmt view dmt would prefer drug take forev know peopl see thing differ effect lemtrada cladribin good stop gilenya tecfidera would advis anyon tri decid dmt follow second link post inform cladribin peopl ms know drug',\n",
       " 'updat u food drug administr approv first gener form mg glatiram acet inject produc mylan gener form mg copaxon teva pharmaceut industri ltd taken three time per week inject skin agenc also approv mylan gener daili mg dose second approv gener glatiram acet mg glatopa sandoz becam avail june approv mean mylan provid evid gener medic equival brand name copaxon inform yet gener becom avail prescript might cost addit gener option potenti increas afford access ms diseas modifi therapi comment dr bruce bebo execut vice presid research nation ms societi earli ongo treatment fda approv ms diseas modifi therapi current best way know reduc futur diseas activ peopl relaps form ms ad select therapi done peopl ms collabor ms doctor take account varieti factor includ effect therapi current use weigh potenti risk benefit cost lifestyl factor detail fda approv gener medic shown equival mg glatiram acet taken three time week mg taken daili subcutan skin inject glatiram acet synthet protein mimic myelin basic protein compon myelin insul nerv fiber brain spinal cord therapi seem block myelin damag cell mechan complet understood therapi long track record effect safeti part gener medic approv process fda requir gener activ ingredi strength dosag mode administr brand name medic manufactur accord feder qualiti control regul clinic trial gener requir prove equival brand name medic nation ms societi provid inform gener form glatiram acet becom avail download prescrib inform mylan mg glatiram acet pdf download prescrib inform mylan mg glatiram acet pdf read diseas modifi therapi treatment ms ms symptom frequent ask question approv gener glatiram acet new gener therapi avail prescript inform yet medic may avail unit state glatopa gener daili glatiram acet avail sinc gener glatiram acet mylan cost inform yet cost gener mean therapi go gener copaxon still avail prescript mani medic avail gener brand name medic remain market inform current avail expect copaxon continu avail prescript mg daili dose mg dose taken three time week insur coverag gener copaxon forc switch current medic coverag prescript differ among variou insur point know insur handl coverag copaxon versu gener glatiram acet gener mg mg dose therapeut benefit copaxon fda thorough review process guidelin place evalu equival propos gener drug brand name drug product fda review approv gener medic mean medic maker provid suffici evid gener therapeut benefit brand name product u fda empow congress evalu gener drug candid abbrevi new drug applic nation ms societi confid fda process patient support servic avail peopl prescrib new gener mylan point specif inform support servic mylan announc intent provid type support mylan ms advoc tm patient support servic addit inform becom avail provid updat copaxon regist trademark teva pharmaceut industri ltd glatopa trademark novarti ag mylan ms advoc trademark mylan faq gener biosimilar medic follow provid inform gener drug biosimilar may mean ms commun gener medic gener medic product equival brand name drug whose patent protect expir part gener medic approv process fda requir gener activ ingredi strength dosag mode administr brand name medic manufactur accord feder qualiti control regul gener maker requir show gener drug deliv amount activ ingredi person bloodstream amount time brand name product refer bioequival societi view gener therapi ms nation ms societi advoc increas treatment option peopl form ms earli ongo treatment current best known way reduc futur diseas activ approv gener potenti increas individu access ms therapi provid ms commun treatment option nation ms societi recommend use new gener ms therapi nation ms societi make individu treatment recommend approv therapi make inform avail constitu make inform decis treatment choic gener medic therapeut benefit name brand medic fda thorough review process guidelin place evalu equival propos gener drug brand name drug product fda review approv gener medic mean medic maker provid suffici evid gener therapeut benefit brand name product u fda empow congress evalu gener drug candid abbrevi new drug applic nation ms societi confid fda process equival medic ms therapi possibl eventu medic may copi patent protect brand name medic must expir maker equival medic would need appli fda request approv medic term gener technic appli product consid drug made chemic manufactur process ms therapi classifi chemic drug patent expir would like elig manufactur gener fda approv therapi classifi chemic drug aubagio copaxon gilenya tecfidera ms therapi avonex betaseron extavia lemtrada ocrevu plegridi rebif tysabri zinbryta technic classifi biolog biolog product differ biolog biolog gener complex made human anim materi rather chemic process technic term equival medic biolog biosimilar follow biolog biosimilar product evalu fda fda approv biosimilar product mechan action rout administr dosag form strength refer product addit biosimilar approv indic condit use previous approv refer product law pass biolog product may demonstr biosimilar data show product highli similar alreadi approv biolog product clinic meaning differ term safeti puriti potenc refer product propos biosimilar expect produc clinic result current progress toward develop equival medic ms therapi fda approv three gener form glatiram acet agenc receiv abbrevi new drug applic gener form medic except novantron copaxon diseas modifi ms medic avail gener form get inform gener drug biosimilar fda websit inform gener drug biosimilar process approv',\n",
       " 'hello much coimbra protocol cost per month year cheaper interferon gilenya tysabri',\n",
       " 'hi five welcom grace sorri hear stepmom diagnosi post rais question may affect futur treatment decis treatment alimta effect stop alimta due progress cancer progress later shown progress keytruda grow slowli rapidli stage iv diseas usual expect evid diseas disappear although small number patient achiev statu instead tumor shrinkag stabil good result treatment even slow growth toler agent may accept want get maximum benefit treatment move anoth line therapi immunotherapi keytruda patient show benefit immedi patient deriv long last benefit treatment base said assum time therapi chang especi sinc oncologist chang treatment first sign even minor progress would help know cancer cell ever test egfr alk target genet alter approv drug tarceva xalkori well agent target mutat current test clinic trial combin immunotherapi agent also studi number convent chemotherapi agent avail need chang treatment let us know answer question rais tri provid addit inform jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'much better interact mom doctor today regard clinic trial recent advanc sclc care advis even though still first line treatment bad idea get understand second line fast diseas recur spread lot new develop avail clinic trial even exist drug label use pick rout go depend lot specif characterist tumor exampl attract rout vs standard chemo effect first line opdivo yervoy label clinic trial particularli effect cancer high tumor mutat burden tmb keytruda label clinic trial particularli effect high pdl express rova clinic trial particularli effect high dll express question test specif characterist usual done sclc inde patholog report got test rather randomli pick second line treatment like opt one like work liter test order biopsi send away lab advis proactiv would biopsi pain damag worth sure go',\n",
       " 'hi mazza glad hear osmertinib work well flauta trial sure moder answer want let know wife experi cours last three year wife ct scan occasion shown sclerot lesion bone place even know cancer explan oncologist often bone site cancer resid small easili detect chemotherapi success reduc remov cancer spot bone regrow place cancer resid result slightli greater bone densiti result show sclerot e solid spot basic oncologist said conjunct chemotherapi sclerot spot almost alway suggest place chemotherapi work bone natur regrow hope continu great check up best scohn wife lifelong non smoker dx adeno nsclc stage iv poorli diff bone met lymph node exon mutat x carbo alimta reduct primari tumor lymph node bone alimta maint effect tumor growth new liver met opdivo effect add l growth clinic trial drug larg reduct tumor met main tumor growth liver met stabl stabl add l growth trial start gemzar larg tumor reduct',\n",
       " 'greet mom age diagnos adeno carcinoma stage iv non small cell lung cancer april abl walk talk abl basic thing extens met brain bone lung adenoid later two month june spinal tap indic cancer cell spine fluid diagnos lepto mening metastas base egfr mutat given tarceva mg work beauti reduc met brain week stop work unabl breath properli lot inflamm lung due met reemerg switch tagrisso mg take daili basi recogn us walk move abl understand medic work diseas progress stress see struggl respond recogn us even abl get bed anyon help advis share progress diseas medic work loos anyth save near end life pleas help bank someon help apolog typo stress seek help please give suggest god bless angara',\n",
       " 'hi carolmcn welcom site glad sorri hear feel abandon onc everi right feel know empow next treatment plan everyon cancer journey uniqu jorola may abl share knowledg point get inform rout take possibl next step get concern address tell us need med chang tagrisso must mutat test mutat',\n",
       " 'aubagio work schedul take first dose gilenya april th scari lie everyth ms scare bad luck side effect aubagio neuro said pill form option rrm aubagio gilenya tecfidera want tecfidera alot side effect lot paitent gilenya see yearli quarterli checkup relaps seen tremend improv paper work scari tylenol warn label could scare someon guess right ekg appoint opthomologist would give okay',\n",
       " 'dr h jack west medic director thorac oncolog program swedish cancer institut presid ceo grace karen kelli associ director clinic research uc davi comprehens cancer center sandip patel medic oncologist associ professor medicin moor cancer center uc san diego health gather post meet discuss new inform asco regard lung cancer roundtabl video doctor discuss checkmat combin nivolumab ipilimumab nivolumab chemotherapi grace thank follow sponsor support relat content asco roundtabl lung cancer keynot trial keytruda pembrolizumab singl agent compar doublet chemotherapi nsclc asco roundtabl lung cancer keynot cisplatin carboplatin alimta keytruda practic chang approach asco roundtabl lung cancer potenti showdown two posit trial keynot impow video languag english join convers pleas feel free offer comment rais question discuss forum join convers articl video categori cancer journey remiss treatment diagnos survivorship cancer journey diagnos treatment remiss survivorship cancer type lung cancer blood cancer head neck cancer diseas learn lung cancer blood cancer head neck cancer howard jack west md founder presid medic director thorac oncolog program swedish cancer institut presid ceo global resourc advanc cancer educ grace seattl washington dr jack west medic oncologist medic director thorac oncolog program swedish cancer institut seattl washington also serv presid medic educ websit onctalk llc global resourc advanc cancer educ grace read search form search relat content lung cancer video librari mandarin chemotherapi immunotherapi combin advanc non squamou nsclc video mandarin speak commun jenni j li md hematolog oncolog fellow mayo clinic rochest mn offer translat updat lung cancer video librari video translat dr li discuss immunotherapi combin advanc non squamou non small cell lung cancer qualifi social secur disabl benefit cancer articl articl provid disabl benefit help independ organ dedic help peopl age get social secur disabl benefit chanc cure advanc cancer older patient believ articl asco dr melissa loh present studi titl chanc cure advanc cancer older patient believ belief relat prefer studi look patient belief regard cure cancer specif older patient advanc cancer patient certain could cure pose uniqu challeng physician show need clear commun patient physician regard outcom treatment qualiti life',\n",
       " 'good luck ucfireman current fight insur get entyvio approv fail remicad primari non respond also want fail humira first nice xeljanz next drug choic good facebook group start xeljanz folk call xeljanz uc small group folk nice rate also tacrolimu add remicad coupl time good see someon els suppositori mg day tac level high dose per day oral tacrolimu thank good luck f diagnos feb left side uc steroid refractori fail mesalamin intoler remicad partial respons short remiss fall winter flare sinc feb current tacrolimu supp x daili wait start entyvio zoloft mostli dairi free avoid carrageenan like plagu',\n",
       " 'bhaskar sorri hear worsen symptom although fatigu could certainli caus anti cancer treatment includ tagrix tagrisso symptom typic treatment presenc progress lmd someth appear scan particularli well primari method determin efficaci lmd treatment observ central nervou system symptom stabl improv drug work hand cancer progress anoth part bodi could caus least symptom chest ct might help determin side effect drug monitor clinic examin patient exam report new symptom doctor symptom appear relat treatment appropri follow measur initi jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'longboat first diagnos drank lot say alcohol level everi day even would drink wife either breastfeed pregnant lot thing chang life ms first child quit job depress etc alway self medic alcohol past get tough time got point wife liter pack bag threaten leav chang habit cut drank weekend even thing go fine still crave drink everi day mayb alcohol level need realli want gilenya mess liver neuro ration two drink per week put addit pressur liver hard good two drink tast good booz effect symptom help forget ms',\n",
       " 'sever year drug develop asthma chronic bronchiti end sever bout pneumonia happen despit take vaccin pleas awar problem told doctor realli listen got sick agre part remicad',\n",
       " 'patient untreat non small cell lung cancer nsclc mutat epiderm growth factor receptor egfr central nervou system cn metastas baselin report better cn progress free surviv pf compar first gener egfr tyrosin kinas inhibitor tki gefitinib erlotinib cn pf reach certain subset patient administ osimertinib month standard egfr tki therapi p result preplan exploratori analysi phase flaura studi registr studi got osimertinib approv use first line therapi patient egfr mutat advanc nsclc report journal clinic oncolog flaura studi random doubl blind studi patient untreat egfr nsclc compar osimertinib standard egfr tki therapi gefitinib erlotinib subset analysi patient flaura cn metastas subset patient flaura includ current analys document cn metastas baselin seen brain scan assess neurologist blind manner relat articl pd pd l inhibitor may increas risk hyperprogress diseas nsclc plu carboplatin may effect nsclc patient interstiti lung diseas gefitinib continu therapi may effect nsclc post progress patient includ studi data provid patient measur nonmeasur cn metastas avail baselin brain scan cn full analysi set [cfas] sixti one patient treat osimertinib standard egfr tki end point assess includ cn pf cn object respons rate orr cn durat respons dor cn diseas control rate dcr cn progress median follow cn pf month patient osimertinib month patient standard egfr tki patient characterist balanc baselin median sum baselin cn tumor lesion size larger patient standard egfr tki vs mm osimertinib arm end point cn pf differ arm consid nomin statist signific cn progress seen approxim twice mani patient standard egfr tki vs osimertinib result new cn lesion patient osimertinib patient standard egfr tki cnn orr patient osimertinib patient standard egfr tki odd ratio [or] p patient least measur lesion baselin cn evalu respons set [cefr] osimertinib patient standard egfr tki patient cn orr patient osimertinib patient standard egfr tki p cn evalu respons set cefr popul median time respons week group howev median cn dor longer patient receiv egfr tki compar osimertinib vs month respect also popul cn dcr similar across group osimertinib egfr tki p studi author note taken togeth data report flaura data indic subgroup patient without known treat cn metastas baselin osimertinib provid protect effect develop brain metastas',\n",
       " 'use treat type skin cancer melanoma use treat lung cancer need tell doctor take tafinlar allergi dabrafenib part tafinlar dabrafenib allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign breast feed breast feed take tafinlar dabrafenib week last dose medicin may interact drug health problem tell doctor pharmacist drug prescript otc natur product vitamin health problem must check make sure safe take tafinlar dabrafenib drug health problem start stop chang dose drug without check doctor thing need know take tafinlar tell health care provid take tafinlar dabrafenib includ doctor nurs pharmacist dentist sometim dabrafenib taken trametinib take dabrafenib trametinib sure know side effect happen drug drug taken togeth chanc certain side effect may rais side effect bad sometim deadli includ bleed bleed brain blood clot eye problem fever heart problem like heart failur high blood sugar cancer skin problem talk doctor chanc side effect drug medicin may add chanc get type cancer talk doctor skin check tell doctor skin chang like new wart skin sore reddish bump bleed heal chang color size mole blood work check told doctor talk doctor high blood sugar diabet talk doctor medicin may rais blood sugar check blood sugar told doctor common get rash tafinlar dabrafenib skin reaction may also happen sometim rash skin reaction bad may need treatment hospit call doctor right away acn skin red skin rash bother go away call doctor right away red irrit palm hand sole feet bad eye problem happen tafinlar dabrafenib sometim led loss eyesight call doctor right away blur eyesight loss eyesight chang eyesight call doctor right away see color dot halo bright light bother care g pd defici anemia may happen older use tafinlar dabrafenib care could side effect medicin may affect fertil fertil problem may lead abl get pregnant father child talk doctor medicin may caus harm unborn babi take pregnant use birth control trust prevent pregnanc take tafinlar dabrafenib least week stop drug birth control pill hormon base birth control may work well prevent pregnanc use kind birth control also like condom take tafinlar dabrafenib week stop tafinlar dabrafenib get pregnant take tafinlar dabrafenib within week last dose call doctor right away medicin tafinlar best taken use tafinlar dabrafenib order doctor read inform given follow instruct close take empti stomach take hour hour meal swallow whole chew open crush talk doctor drink lot fluid way prevent fluid loss lot fluid loss may side effect tafinlar dabrafenib gain benefit miss dose keep take tafinlar dabrafenib told doctor health care provid even feel well miss dose take miss dose soon think less hour next dose skip miss dose go back normal time take dose time extra dose see also dosag inform detail side effect need call doctor right away warn caution even though may rare peopl may bad sometim deadli side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign bleed like throw blood throw look like coffe ground cough blood blood urin black red tarri stool bleed gum vagin bleed normal bruis without reason get bigger bleed bad cannot stop sign fluid electrolyt problem like mood chang confus muscl pain weak heartbeat feel normal bad dizzi pass fast heartbeat thirst seizur feel tire weak hungri unabl pass urin chang amount urin produc dri mouth dri eye bad upset stomach throw sign high blood sugar like confus feel sleepi thirst hungri pass urin often flush fast breath breath smell like fruit sign kidney problem like unabl pass urin chang much urin pass blood urin big weight gain weak side bodi troubl speak think chang balanc droop one side face blur eyesight fever chill dark urin yellow skin eye eye pain chest pain pressur bad headach medicin may caus heart failur need heart function check take tafinlar dabrafenib call doctor right away sign heart problem like cough short breath new wors swell ankl leg heartbeat feel normal weight gain pound hour dizzi pass side effect tafinlar drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away hair loss chang skin hard thick headach muscl joint pain back pain constip cough nose throat irrit side effect may occur question side effect call doctor call doctor medic advic side effect may report side effect fda fda may also report side effect http www fda gov medwatch see also side effect detail overdos suspect think overdos call poison control center get medic care right away readi tell show taken much happen store throw tafinlar store room temperatur store dri place store bathroom keep drug safe place keep drug reach children pet throw away unus expir drug flush toilet pour drain unless told check pharmacist question best way throw drug may drug take back program area consum inform use symptom health problem get better becom wors call doctor share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin medicin come extra patient fact sheet call medic guid read care read time tafinlar dabrafenib refil question tafinlar dabrafenib pleas talk doctor pharmacist health care provid think overdos call poison control center get medic care right away readi tell show taken much happen',\n",
       " 'fda approv lucenti treat form diabet retinopathi',\n",
       " 'niec made blond scalp show got shorter cute cut stop come bald like wanna worri year old symptom sinc octob diagnos januari ibd ulcer coliti pancol current apriso humira uceri valtrex vari tri almost everi healthfood thing world help could cure herb vitamin diet good day bad day lot sleep',\n",
       " 'sewingchick im goin stick tysabri see goe suppos best fingolimod year neuro said wasnt work dont know drug stop deteriort tri tysabri mo id love tri hsct sometim want stop ms get wors thank jimmi',\n",
       " 'hi father nsclc plureal effus start st cycl pembrolizumab due work schedul would like check possibl delay nd cycl day day delay make differ treatment follow day cycl thank alot kind assist',\n",
       " 'genentech announc today ocrelizumab investig medicin long term treatment relaps form ms also shown posit studi result phase iii oratorio studi primari progress multipl sclerosi ppm first medic show posit effect disabl form diseas affect approxim percent ms popul date diseas modifi therapi dmt approv long term treatment relaps form ms exhibit flare up remiss often seen ms howev treatment avail individu diagnos ppm whose ms steadili progress without remiss accord genentech phase iii oratorio studi met primari endpoint show treatment ocrelizumab significantli reduc progress clinic disabl sustain least week compar placebo measur expand disabl statu scale edss also state overal incid advers event associ ocrelizumab similar placebo common advers event mild moder infus relat reaction incid seriou advers event associ ocrelizumab includ seriou infect also similar placebo oratorio random doubl blind global multi center trial studi effect safeti ocrelizumab peopl ppm everi six month two mg infus total mg given two week apart member treatment group compar placebo group primari endpoint studi time onset confirm disabl progress defin increas edss sustain least week juli msaa post news item titl ocrelizumab show posit result phase iii trial announc ocrelizumab met primari major secondari endpoint phase iii opera opera ii studi studi evalu effect safeti ocrelizumab relaps form ms accord genentech compar rebif ocrelizumab show signific reduct annual relaps rate arr two year period progress clinic disabl measur expand disabl statu scale edss number lesion brain area diseas activ measur mri ocrelizumab investig human monoclon antibodi design select target cd posit b cell genentech note specif type immun cell thought key contributor myelin axon damag result disabl peopl ms base preclin studi ocrelizumab bind cd cell surfac protein express certain b cell stem cell plasma cell therefor import function immun system may preserv genentech plan submit data three studi unit state food drug administr fda earli approv medic could potenti use treat relaps form ms also primari progress ms would repres first treatment avail latter form diseas msaa chief medic offic dr jack burk state excit news ocrelizumab first dmt posit disabl result addit safeti data similar placebo control howev fda approv requir intens scrutini data effect combin safeti magic formula see fda agre ocrelizumab meet requir approv relaps form ms ppm well inform speak train client servic specialist pleas call msaa helplin extens question msaa client servic depart may also email msquestion mymsaa org written susan well courtney msaa senior writer creativ director review jack burk md msaa chief medic offic',\n",
       " 'hello snigdha father diagnos lung cancer juli took tarceva iressa tagrisso took tagrisso last ten month unfortun pass away week ago hospit sinc decemb rd end last year live well travel lot collater damag tagrisso realli good like tell hospit admiss heart issu doctor say may caus tagrisso father done heart exam start tagrisso know exam could made live mayb would good talk cardiologist send posit vibe hope mom continu without pain think mani year hapi father lot time tell much love pleas contact whenev want best wish lm',\n",
       " 'meet limit recent pair promin immunologist took except hint blockad interleukin perceiv fail ms modest efficaci challeng repli say work counter much better beta interferon said work drop oper reason oper reason wonder simpli realli mean good enough one know read blog care comment time trial secrukinumab cosentyx stop earli said proof concept prove activ although primari endpoint met mean trial fail point suggest novarti anoth anti il cjm better yet secrukinumab good enough use psoriasi skin autoimmun diseas havrdov e belova goloborodko tisser wright wallstroem e garren h maguir rp john dr activ secukinumab anti il antibodi brain lesion rrm result random proof concept studi j neurol howev endpoint indic interleukin effect main endpoint cumul uniqu activ lesion almost show differ chang p almost signific number cumul new gadolinium lesion reduc p annualis relaps rate drop drop week immunologist said peopl amaz well ye peopl well even get noth simpli cherri pick like eae experi amaz hear immunologist say put context beta interferon week reduct mean cumul number new gadolinium lesion subcutan interferon beta p efficaci safeti subcutan interferon relaps remit multipl sclerosi outcom improv studi j neurol sci jan contrast ocrelizumab reduct mri lesion phase ii get excit reduct annualis relaps rate vers seen alemtuzumab cladribin ocrelizumab name three activ agent ye know differ trial condit durat meanwhil seem plan quietli shelv next ms studi effect anti il year line noth happen anim th dogma gener happen block il eae il knockout get eae sever drop sever bit hardli impress believ tri anoth studi antibodi could go simpl answer impress acut eae howev rememb anti il inert act b cell th may creat b cell aggreg eae howev import look data rhetor bee knee best thing',\n",
       " 'definit make logic next step humira actual think remicad first choic either one would good last sentenc say year age take anti tnf long enough worri life long effect hope work daughter diagnos feb yr old time diagnosi crohn termin illium use prednison pentasa start imuran abdomin abscess cm strictur start remicad feb along mg imuran',\n",
       " 'two cours alemtuzumab scan remain year see deterior hand function deterior due residu damag keep mind posit therapeut lag opt anoth therapi one elig stem cell neither cladribin ocrelizumab effect littl definit guidelin treatment depend ms present mser go treatment consult favour time hope question get answer feel though peopl bounc treatment treatment',\n",
       " 'hello everyon remicad year final develop antibodi tri entyvio coupl year ago advers reaction larg bowel resect end colostomi octob crohn diseas symptom improv sinc surgeri howev eye joint muscl pain inflamm poorli stop remicad antibodi gi wonder howev said well tri humira cimzia stelara one prefer like crap shoot lol toss name cup draw one suggest would greatli appreci develop crohn small intestin besid remicad mg prednison daili thank much juli',\n",
       " 'relaps remit ms thought primarili inflammatori diseas myelin cn diseas process character period relaps follow complet incomplet recoveri simultan howev irrevers axon damag transect known occur trapp et al control inflamm earli diseas may also reduc damag axon coyl medic current avail treat ms appear effect earli inflammatori phase ms becom less potent diseas transit neurodegen process sinc medic approv u food drug administr fda treatment relaps form ms jefferi one also approv primari progress ms inform present design allow side view medic option without suggest inter medic comparison except specif support result head head clinic trial compar efficaci medic across trial mislead key differ popul outcom measur statist analys use studi fda approv diseas modifi therapi dmt fda approv dozen agent treatment relaps form ms one also approv primari progress ms anoth also approv secondari progress ms deliv inject infus other oral inject option daclizumab zinbryta glatiram acet copaxon glatiram acet glatopa gener equival copaxon interferon b avonex interferon b rebif interferon b b betaseron interferon b b extavia pegyl interferon b plegridi oral option dimethyl fumar tecfidera fingolimod gilenya teriflunomid aubagio infus option alemtuzumab lemtrada mitoxantron novantron natalizumab tysabri ocrelizumab ocrevu ms coalit evid base consensu paper dmt multipl sclerosi coalit publish evid base consensu paper entitl use diseas modifi therapi multipl sclerosi principl current evid consensu paper multipl sclerosi coalit document develop endors eight coalit member organ subsequ endors america committe treatment research multipl sclerosi actrim paper design summar current evid diseas modif ms highlight import earli ongo treatment provid support broad access fda approv ms diseas modifi therapi peopl ms unit state companion summari paper gener audienc current develop fda approv dmt bird eye view indic dose rout administr pregnanc rate warn safeti manag strategi common side effect patient support program drug develop pipelin read compound current investig therapeut use ms',\n",
       " 'origin clinic trial diseas modifi therapi approv treatment ms women requir use contracept trial discontinu trial becam pregnant result littl inform effect medic pregnanc sinc ms primarili affect women childbear age becom pregnant unintent consid extrem import acquir inform medic affect pregnanc unborn children august food drug administr issu guidelin requir manufactur medic develop pregnanc registri monitor women taken one drug within week becom pregnant pregnant although none medic approv use pregnanc woman may unintent becom pregnant treatment woman unawar pregnant sever week may pass stop medic purpos registri identifi outcom pregnanc includ miscarriag birth defect inform registri avonex registri complet final result report betaseron registri complet final result report rebif registri complet final result report tysabri registri complet final result report aubagio registri although aubagio approv use pregnanc registri establish monitor fetal outcom pregnant women expos aubagio physician encourag enrol pregnant women aubagio pregnanc registri women enrol call option gilenya registri although gilenya approv use pregnanc registri establish monitor fetal outcom pregnant women expos gilenya physician encourag enrol pregnant women gilenya pregnanc registri women enrol call visit gilenya pregnanc registri websit tecfidera registri although tecfidera approv use pregnanc registri establish monitor fetal outcom pregnant women expos tecfidera physician encourag enrol pregnant women tecfidera pregnanc registri women enrol call',\n",
       " 'mother diagnos stage b lung cancer jan finish chemo round juli ct scan end treatment clear six month check ct show nodular activ fluid lung fluid remov liter test show cancer cell fluid pet scan show cancer lymph node lung suggest manag chemo give carboplatin taxol session follow avastin anyon experi drug lung cancer stage stage cancer area left lung began last year comment would appreci',\n",
       " 'hi angi thank ask sacroplasti procedur went well feel anyth haha term stabil whole right flank area well walk around hous eas ventur still painful feet long although pain chang think patient give time heal yesterday one fortnightli opdivo treatment make feel bit tire day stop thing go think dad may need stimul keep go dwell much cancer learnt live cannot chang go clinic pilat given physiotherapist room keep leg arm muscl go mayb dad check area live privat insur get refund session clinic pilat kept go twice week assum dad retir hobbi concentr best thing cancer keep go let catch speak wish well think clinic pilat first thing look take care margo',\n",
       " 'diagnos inflammatori arthriti ra septemb year old first plaquenil never seem help top develop terribl hive rash went away stop take next tri humira work great month symptom came back remicad almost year work great get infus everi week symptom love remicad gave life back slightli concern though develop anoth rash seem go away month deal tri steroid etc etc cross finger remicad caus rash cri',\n",
       " 'come across anyth regard ocrelizumab induc remyelin suppos patient take earli enough diseas process drug would inhibit inflamm would allow bodi natur remyelin think drug remyelin properti',\n",
       " 'hello interest nivolumab trial mom msi statu non msi high msi high henri wrote hello latest cea valu almost normal hope next month finger cross',\n",
       " 'hag second dose ocrevu day christma went fine week flare sure normal went away like week realli cannot tell differ symptom differ day hope feel amaz soon best luck',\n",
       " 'repli mser train view post marinadca quick updat thing go well quick updat thing go well bike day week walk hour day week yoga class week ocrevu infus glad',\n",
       " 'thursday genentech announc new ceo assum role march alexand hardi current execut roch basel move san francisco assum genentech head post compani relat news jnj dismal outlook may indic store year big pharma firm bluebird bio outlin timelin expect compani next five year big blow oncolog program bristol myer pull opdivo yervoy combo nsclc advaxi also dealt blow fda put partial clinic hold cervic cancer studi elsewher basilea enter urotheli cancer studi roch vertex gene edit collabor merck kgaa come fruition',\n",
       " 'diabet retinopathi dr chronic progress potenti sight threaten diseas retin microvasculatur associ prolong hyperglycaemia diabet mellitu diabet mellitu link condit hypertens diabet mellitu caus varieti eye problem common dr common caus sever sight impair among peopl work age england wale scotland [ ] condit associ diabet eye includ cataract rubeosi iridi glaucoma ocular motor nerv palsi diabet retinopathi exact mechan diabet lead dr fulli understood microvascular occlus caus retin ischaemia lead arterioven shunt neovascularis leakag result intraretin haemorrhag localis diffus oedema process result characterist featur seen variou stage dr microaneurysm physic weaken capillari wall predispos leakag hard exud precipit lipoprotein protein leak retin blood vessel haemorrhag ruptur weaken capillari appear small dot larger blot flame haemorrhag track along nerv fibr bundl superfici retin layer haemorrhag aris larger superfici arteriol cotton wool spot build axon debri due poor axon metabol margin ischaem infarct neovascularis attempt residu healthi retina revascularis hypox retin tissu classif dr base part retina affect degre patholog seen slit lamp examin eye necessarili correl degre vision may almost normal late stage diseas littl done save broadli speak dr fall two type diabet retinopathi background mild non prolif dr least one microaneurysm moder non prolif dr microaneurysm intraretin haemorrhag cotton wool spot venou bead intraretin microvascular abnorm irma sever sever non prolif dr sometim refer pre prolif diseas minimum number featur requir minimum number retin quadrant defin sever sever diseas non high risk prolif dr new vessel disc nvd within one disc diamet new vessel elsewher nve high risk prolif dr larg nvd nve defin compar optic disc surfac area presenc pre retin haemorrhag advanc diseas may also accompani retin detach diabet maculopathi focal diffus macular oedema area leakag may well circumscrib diffus ischaem maculopathi clinic appear may rel normal visual acuiti drop ischaemia seen fluorescein angiographi clinic signific macular oedema csmo may thicken retina hard exud found within specif distanc fovea found certain size defin csmo epidemiolog diabet common caus sever sight impair work age peopl england wale scotland [ ] one studi found macular oedema present popul diabet [ ] type diabet microaneurysm start appear five year case affect half case year nearli patient year prolif retinopathi defin format new vessel appear year affect year maculopathi follow similar pattern final affect case type diabet chang may found diagnosi subclin hyperglycaemia may present prolong preced period [ ] year signific cumul rate progress dr diabet macular oedema csmo [ ] risk factor progress retinopathi associ sever length time hyperglycaemia exist diabet diagnos age incid dr year rise year set glycaem threshold predict presenc otherwis dr [ ] hypertens cardiovascular risk factor influenc onset progress retinopathi [ ] mark individu variat suscept retinopathi given vascular risk profil renal diseas evidenc proteinuria elev urea creatinin level excel predictor presenc retinopathi pregnanc associ rapid progress dr particularli [ ] sever baselin retinopathi poor glycaem control concept pregnanc postpartum period rapid improv diabet control diabet present long time patient hypertens chronic pregnanc induc minor ethnic commun type diabet uk prone dr includ sight threaten retinopathi maculopathi compar white european [ ] thought intraocular surgeri may possibl increas risk progress dr see separ eye system diseas articl inform eye pregnanc present histori mani patient retain normal eyesight experi minim sometim unnotic reduct even presenc sight threaten diseas diabet maculopathi prolif diseas painless gradual reduct central vision may associ type dr similarli painless gradual visual loss associ cataract format diabet otherwis haemorrhag result sudden onset dark painless floater may resolv sever day sever haemorrhag may obscur vitreou altogeth result painless visual loss acut attack glaucoma precipit rubeosi iridi see eye condit less commonli associ diabet one situat patient present acut pain urgent referr essenti examin without slit lamp magnif fundu fundal photograph difficult make accur assess alway start check patient visual acuiti acut reduct good sign suggest urgenc referr caution prognost outcom discuss patient best view obtain dilat pupil rememb patient abl drive six hour afterward home fundu check red reflex spot within suggest vitreou haemorrhag start disc systemat work way along main arteri branch effect end macula look directli light make bit quick comfort look vessel note littl red dot dot haemorrhag small aneurysm irregular notch venou bead new vessel tend thinner disorganis pre exist vessel go along note well demarc creami yellow lesion often appear like cluster spot hard exud paler lesion less well defin edg cotton wool spot realli possibl assess csmo without slit lamp presenc haemorrhag macula import find diagnosi [ ] gold standard diagnosi dilat retin photographi accompani ophthalmoscopi retin photograph inadequ qualiti eg cataract cloud view dr present classifi investig optic coher tomographi sort visual biopsi obtain similar fashion ultrasound scan use light wave fluorescein angiographi may requir refin diagnosi guid manag screen referr adult type type diabet [ ] arrang perform eye screen around time diagnosi adult type type diabet arrang repeat structur eye screen annual use mydriasi tropicamid photograph retina prior inform agreement follow discuss advantag disadvantag discuss includ precaut drive use qualiti assur digit retin photographi programm use appropri train staff perform visual acuiti test routin part eye screen programm depend find follow structur eye screen routin review one year earlier review referr ophthalmologist arrang emerg review ophthalmologist sudden loss vision rubeosi iridi pre retin vitreou haemorrhag retin detach arrang rapid review ophthalmologist new vessel format refer ophthalmologist accord nation screen committe criteria timelin refer hospit eye servic within four week result featur present refer maculopathi exud retin thicken within disc diamet centr fovea circin group exud within macula macula defin circl centr fovea diamet distanc tempor border optic disc fovea microaneurysm haemorrhag within disc diamet centr fovea associ deterior best visual acuiti wors refer pre prolif retinopathi cotton wool spot present look care follow featur howev cotton wool spot defin pre prolif retinopathi venou bead venou redupl intraretin microvascular abnorm multipl deep round blot haemorrhag larg sudden unexplain drop visual acuiti children young adult [ ] monitor dr begin year age type type diabet consid refer children young peopl type diabet younger year ophthalmologist retin examin blood glucos control suboptim investig fundu photographi examin suffici patient howev optic coher tomographi play increasingli import role assess presenc macular oedema record progress sever visit fluorescein angiographi may help csmo present guid laser treatment vision unexpectedli poor assess macular ischaemia manag primari prevent glycaem control optim glycaem control usual aim bring hba c level ideal around associ improv long term outcom delay progress retinopathi [ ] howev case particularli pre prolif prolif retinopathi intens glycaem control eg hba c initi bring decompens worsen symptom sign also associ increas mortal [ ] blood pressur control good control blood pressur target mm hg lower reduc progress dr significantli associ reduct diabet relat death [ ] possibl aim systol mm hg establish retinopathi nephropathi specif therapi block renin angiotensin system ra may addit benefit particularli mild retinopathi discontinu pregnanc lipid control lipid lower therapi shown reduc risk progress diabet retinopathi particularli macular oedema exud consid ad fenofibr statin non prolif retinopathi type diabet healthi balanc diet exercis discuss patient smoke cessat recent trial look done individu glycaem blood pressur control good dr progress [ ] diabet retinopathi candesartan trial direct look effect candesartan angiotensin ii receptor antagonist patient found somewhat equivoc result patient type diabet modestli reduc incid retinopathi effect progress exist retinopathi patient type diabet significantli increas regress exist retinopathi progress reduc last find statist signific fenofibr intervent event lower diabet field studi promis show fenofibr lipid lower fibrat reduc need laser treatment sight threaten dr either macular oedema prolif retinopathi five year ophthalm intervent [ ] patient dr need treatment sever treatment modal avail laser treatment mainstay treatment period year aim induc regress new blood vessel reduc central macular thicken thought procedur work reduc releas vasoprolif mediat hypox retin vessel allow easier direct diffus oxygen choroid blood suppli laser treatment arrest progress dr unlik restor lost vision treatment target specif area focal treatment deliv entir peripheri retina panretin photocoagul prp burn may place retina session choic depend natur dr macular oedema treat focal laser burn wherea retinopathi amen prp retinopathi maculopathi macular oedema often treat first separ treatment prp laser treatment carri laser treatment clinic outpati basi later date area laser treatment easili identifi well demarc pale spot distinct dark brown centr help patient cannot rememb previous treatment decis whether carri laser treatment alway clear cut eg asymptomat patient csmo visual loss intravitr steroid [ ] larg trial demonstr intravitr steroid initi effect treatment laser photocoagul two year post treatment eye treat laser actual better visual acuiti less maculopathi intravitr triamcinolon appear reduc csmo improv visual acuiti advanc case may use primari adjunct therapi effect maxim week may last six month mechan action corticosteroid fulli understood treatment modal associ complic see complic fluocinolon acetonid fluocinolon acetonid intravitr implant corticosteroid anti inflammatori anti vascular endotheli growth factor properti fluocinolon acetonid intravitr implant recommend nation institut health care excel nice option treat chronic diabet macular oedema insuffici respons avail therapi implant use eye intraocular pseudophak len [ ] anti vascular endotheli growth factor treatment recent trial anti vascular endotheli growth factor drug shown definit small benefit compar current therapeut option treatment diabet macular oedema [ ] pegaptanib bevacizumab ranibizumab investig promis result [ ] current price frequenc attend requir inject follow limit use treatment clinic practic ranibizumab current recommend nice treatment visual impair due diabet macular oedema [ ] surgeri vitrectomi remov vitreou may requir follow intravitr bleed prolif dr physic remov blood allow vision clear medium retin detach also repair intra oper prp reduc stimulu neovascularis complic main complic dr visual loss secondari macular oedema macular ischaemia vitreou haemorrhag traction retin detach howev treatment modal also associ risk complic focal grid photocoagul impair central vision paracentr scotoma choroid neovascularis epiretin membran format worsen macular oedema minor complic panretin photocoagul prp constrict visual field nocturn diminut vision burn affect fovea centrali worsen macular oedema serou choroid detach ocular pain anterior chamber advers effect eg burn affect cornea len complic intravitr steroid triamcinolon [ ] cataract format rais intraocular pressur prognosi background retinopathi eventu progress sever form major individu left untreat prolif dr lose sight within two year risk lose use vision year [ ] patient undergo treatment risk moder visual loss reduc subsequ three year prp risk sever visual loss reduc compar untreat individu similar sever diseas eye condit associ diabet cataract classic diabet cataract rare cataract manifest snowflak opac occur young person diabet may resolv spontan matur commonli age relat cataract precipit diabet patient form earlier would done otherwis eye condit less commonli associ diabet prematur presbyopia refract error due reduc pliabil len secondari alter metabol rubeosi iridi describ process sever ischaemia caus neovascularis extent vessel grow forward iri vessel may seen larg individu entiti els give iri gener red appear block peripher trabecular meshwork aqueou drain way may precipit acut glaucoma need urgent treatment see separ primari open angl glaucoma articl occasion ocular motor nerv palsi occur presum due damag microvascular suppli cranial nerv patient presum intracrani mass proven otherwis via imag truli palsi relat diabet microvasculopathi often resolv period month orthopt input may need eye condit commonli found peopl diabet includ dri eye corneal abras anterior uveiti ocular ischaem syndrom papil orbit infect corneal abnorm may also found patient group asteroid hyalosi condit characteris littl white fleck seen vitreou occur number reason usual asymptomat unless sever affect vision left alon eye condit rare associ diabet problem occasion seen trace back diabet includ papillopathi variou problem relat optic disc pupillari light near dissoci see separ examin eye pupillari abnorm articl rhino orbit mucormycosi',\n",
       " 'doctor like prednison fairli good reason long term use good multipl cours year good mani tri limit unless realli realli suffer know frustrat wound hospit doc would put back pred third time year honest doctor qualiti life may want tri uceri budesonid experi better mild flare help knock back sever flare signific back normal way much stupid diseas bide time suffer walk line handl dramat differ maladi ever experienc symptomat reliev greater extent normal come time unlik get want obvious dire accept way goe need patient made bit easier deal imodium help bit function tho found alway paid next day gasx help bit cramp rectal med help interim dx left side flare sinc ct suggest advanc pancol rx lialda gx uceri sometim humira fail xeljanz toler current pred remicad',\n",
       " 'diagnosi adenocarcinoma nsclc met adren gland possibl liver posit r neg alk kra ro pd pd l met treatment st carboplatin pemetrex shrinkag nd tarceva shrinkag week progress week rd pemetrex avastin toler th opdivo stabl week progress week th docetaxel toler th begin tagrisso question tagrisso good altern neg never smoker altern current treatment yale dr roggerio lilenbaum suggest suitabl clinic trial ct mass ny suggest doctor second opinion',\n",
       " 'hi maia know understand differ drug keytruda look like pd inhibitor wonder stop respond one anoth might work depend exactli differenti drug',\n",
       " 'hi melissa nurs compani suppli drug adveva kept call check told white cell low reliabl co witter may suscept infect far noth shingl said common cold sore nada must sound like mavenclad stalker co alway repli post hardli info onlin new apolog repetit get blood done week let know good luck anna x',\n",
       " 'went neurologist today headach back guess put quick furiou pred taper knew use pred headach mg today mg taper per day day total thought mg day lot fli high know quit mani headach prior month pred anyway headach continu like might go prevent also check make sure sinu infect read back post one reason make post remind see headach spot sinc start entyvio worri would darn doubl edg sword thing cure also make bare function anyway someth work sure take headach matter sick miser make miser uc symptom time tell overal happi free tenesmu poop day night confess mini accid morn pull pj sit toilet migrain med tend give diarrhea sh load last day eta nurs said pred mg look packag mg mg yesterday duh thank heal well forum let tell deep dirti secret great know understand gross tmi post edit flowersg gmt',\n",
       " 'hi michel quit list good stuff understand oncologist astonish use natur medicin know work today updat stage c adenocarcinoma lung cancer went c far tumor week start radiat day week chemo time gram oil day gram vit c iv twice week treatment put remiss start someth call duvalumab year immunotherapi genet test tumor proport score tp high pd l express nsclc hope scan clear enjoy season',\n",
       " 'tashia mom diagnosi non small cell adenocarcinoma origin diagnosi first recurr diagnos lobectomi follow chemo radiat immunotherapi avail initi diagnos recurr test pd l test posit cancer cell went keytruda carbo alimta fda approv month prior work wonder come without side effect keytruda alon side effect mild noth cure uncl cancer mom lung cancer persist often pop back slow cancer make disappear ask treatment prolong life give qualiti life mom cant tell happen uncl uncl receiv standard care advanc stage lung cancer infus uncl anoth ct chest xray may well look wors mom first scan look wors like lot peopl tumor nodul mass typic becom inflam look bigger scan month begin treatment alway time question worri question concern typic pleas feel free continu reach question concern take care steff',\n",
       " 'pete farley unpreced effect relaps form diseas find show effect new strategi treat multipl sclerosi ms research report posit result three larg intern multicent phase iii clinic trial investig drug ocrelizumab brand name ocrevu relaps multipl sclerosi rm primari progress multipl sclerosi ppm trial result publish onlin dec new england journal medicin nejm discuss accompani editori stephen hauser examin one ms patientsstephen hauser md serv chair scientif steer committe opera trial correspond author nejm paper report result trial photo barbara rie multipl sclerosi immun system attack bodi make call autoimmun diseas date ms drug target immun system cell ocrelizumab contrast deplet popul immun system b cell two companion paper nejm present data drug two ident design studi rm known opera opera ii trial trial involv patient ppm call oratorio studi three trial involv hundr patient dozen research sever countri sponsor f hoffman la roch roch hold patent ocrelizumab opera trial compar effect safeti ocrelizumab interferon beta rebif current standard care medic rm magnet reson imag conduct trial show inflammatori lesion brain ocrelizumab treat group reduc percent compar receiv interferon reduc percent baselin level begin trial imag result accompani percent reduct relaps symptom percent reduct disabl compar interferon unpreced result trial reduct inflammatori brain lesion seen opera trial unpreced said uc san francisco stephen hauser md serv chair scientif steer committe opera trial correspond author nejm paper report result trial hauser professor chair ucsf depart neurolog colleagu long champion idea b cell play central role ms research mani decad instrument bring ocrelizumab clinic trial exist treatment ppm oratorio trial compar ocrelizumab placebo clinic meaning reduct disabl progress marker worsen diseas seen result never observ ppm three trial common advers event associ ocrelizumab infus relat reaction infect mostli mild moder sever work hope great benefit million peopl ms result longstand collabor global scientif commun industri said hauser also director ucsf weill institut neurosci ms chronic diseas affect estim million peopl around world includ estim peopl unit state mani approv drug aim keep rm check approxim percent percent peopl ms diagnos ppm approv treatment current cure either condit ms occur immun system abnorm attack myelin sheath fatti substanc insul support axon radiat nerv cell brain spinal cord optic nerv caus inflamm consequ damag interrupt normal flow commun nervou system damag caus wide rang symptom includ muscl weak fatigu difficulti see may eventu lead perman disabl peopl ms experi first symptom year age make diseas lead caus non traumat disabl younger adult rm common form diseas character episod new worsen sign symptom relaps follow period full partial recoveri ppm debilit form diseas mark steadili worsen symptom typic without distinct relaps period remiss drug review fda market applic ocrelizumab brand name ocrevu submit rm ppm genentech member roch group current review u food drug administr fda european medicin agenc ocrevu grant prioriti review design fda initi target action date dec extend march extens result submiss addit data genentech regard commerci manufactur process ocrevu requir addit time fda review extens relat drug efficaci safeti new public indic b cell play central role ms hauser said opera opera ii rm studi ocrelizumab consist significantli reduc diseas activ disabl progress compar standard care high dose interferon demonstr favor safeti profil consist data effect seen clinic studi favor safeti profil may support treat ms earlier high efficaci diseas modifi medicin http www ucsf edu news posit multipl sclerosi clinic trial result support new treatment',\n",
       " 'good reason honest want write post situat found last friday afternoon time stone cold panic think notion share someth incred horrifi phone call came make delight discoveri local boutiqu groceri store feast brilliant carri favorit ice cream brand call jeni splendid ice cream previous avail via mail order click link right trust thank later sit car text fantast news niec phone start ring saw great scott call pm friday immedi got pit stomach well maribeth done littl stump base blood work appear test posit hepat b convers end place convers felt like person anoth diseas highli contagi communic diseas freak std even get ironi statement see liver specialist determin inform new condit tg schedul monday morn holi crap fast would work determin chanc get approv get new goo damag infect liver situat tg alreadi spoken peopl genentech manufactur market ocrevu keen prospect get approv take new drug would danger high likelihood develop liver complic mayb even liver cancer like idea tg tri calm tell give work togeth new liver doctor make case roll new medicin much inform unknown optimist said give think either know explain went head minut discuss reel frantic horrifi asham outrag mad rage like wildfir burn brain could happen kind joke univers play cosmic entiti mightili thing like keep happen enough enough alreadi love god panic would mild word desper would come closer hope high know buzz ms circl full hyperbol come ocrevu get complic might might danger anyon know blah blah blah get realli option good otherwis tysabri one aggress dmt option take dr scott extrem optimist get someth new good thing time tysabri run jc posit statu alway meant short time tysabri gone month origin agre year risk would accept probabl great idea stay drug fifteen month mean three month danger zone excit sinc realli honest blown away notion diseas probabl got unsaf sex year wild reckless abandon insan took live life like littl tini death wish great big death wish seem littl iron thing prove lack worth undeserv shame exist might actual ruin life prevent treat properli ms mark giant letter b stand beth actual stood dirti whore infect get close know way insan know mani way contract hepat b unsaf sex seem like like option inform read mani web site chat room reddit thread dedic topic spent weekend feel like live altern dimens everyth look like regular life noth made sens told peopl even know felt like kind dirti secret disclos least three peopl make feel even littl bit real disclos therapist best friend closest famili member want anyon know realli time want everyon know mayb everyon knew would make feel real drink water bottl peopl love god kiss jesu diseas joke highli contagi horribl thing bodi mostli liver base non stop scour interweb weekend whole lot good say current circumst sudden found full empathi peopl infect dastardli ill want meet tell good peopl probabl deserv deal realiz probabl impract still count minut appoint new liver specialist weekend felt like time would never come page full question want ask least tell danger call everyon ever sex mean jesu pleas tell make buddi spend rest life wrap plastic head toe like old ladi plastic bubbl protect everyon around infecti horribl dr goswami new liver doctor see actual due date second child feet tall great child ask million question answer honest even look confus go test said test tell noth expos hbv viru mani thing may need medic rest life figur hand four page blood work order order liver ultrasound pat head promis someon would probabl touch lord help hope babi born alreadi quit ador felt like shit situat good hand favorit part appoint dr goswami current sexual activ multipl partner um quit frankli sexual inact zero partner jesu think time dr goswami last time unprotect sex um sure mayb um god kind embarrass realli rememb mayb year ago jason nurs room us entir time loudli clear throat cough also say bullshit turn bright red ok actual say bullshit choke turn love shade crimson wonder realli cut whole deal delic convers thing think mine embarrass convers privi dr goswami exam room mayb left head straight lab less vial blood drawn vein could taken would ok kind like idea take blood mayb replac better improv cleaner blood entir realist think went back work head still whirl wonder kind hepat inform would learn vial blood would ever learn live could tell peopl late ish tuesday night blood result sudden got post health portal sat front comput feel sick tri figur nerv click rather wait inevit phone call list danger drug hullabaloo would result confirm latest diagnosi make light tell stori suppos dark place long time visit dark place one felt realli bad mayb age mayb much uncertainti life even littl felt like much handl went work past coupl day act like normal person feel like normal person anymor even normal person chronic ill like ms felt decidedli bad felt damag tuesday night click result held breath littl cursor arrow land top first line six differ hepat test non reactiv non reactiv non reactiv non reactiv non reactiv non reactiv stare screen blankli non reactiv mean neg think mean neg afraid believ better googl ye think realli mean neg mayb liver ultrasound schedul next morn mayb ultrasound would show diseas pathet liver prove test wrong went bed feel muddl want happi afraid happi next morn ultrasound drove work like normal person like email doctor offic left messag voic mail nobodi call back today got word great scott time voic mail maribeth seem wrong first impress first test fals posit investig howev deepli concern need find happen touch good news good good news bad news probabl caus fret coupl day good investig lab get back soon know email receiv later afternoon explain particular test drug compani requir ocrevu sensit rate fals posit tg team unawar experi investig discuss liver specialist enlighten order particular test origin test requir ocrevu studi tg want apolog make go brand new drug learn drug requir togeth said two good thing came liver fine second set test verifi move forward get switch ocrevu know fact nurs work prior author walk back infus center inform approv move forward medic lesson learn lot lesson realli panic get inform assum bad person deserv bad thing keep happen probabl nobodi peopl lot deal learn hepat b mad lost weekend research tell peopl suffer badli impact diseas incred burden judg harshli mani peopl around empathet peopl suffer empathet gener peopl around deal heavi shit may look fine may look littl tire may mostli look fine liter idea go none zero nada judg cruel tri understand oh also learn never forget alway fals posit never believ thing thought deserv new bad thing happen top bad thing alreadi happen know probabl either ladi sit across bu kind tri understand peopl deal lot even see wors see promis kind end',\n",
       " 'entri post multipl sclerosi associ america tag cog fog ms forum ms onlin support ocrevu onlin commun msaa bookmark permalink msaa nation nonprofit organ multipl sclerosi associ america lead resourc entir ms commun improv live today vital servic support msaa provid free program servic toll free helplin award win public includ magazin motiv websit featur educ video research updat e r c h program assist ms commun learn differ treatment choic mobil phone app ms manag resourc databas ms resourc locat equip distribut rang grab bar wheelchair cool accessori heat sensit individu educ event activ mri fund insur advocaci addit inform pleas visit http www mymsaa org call view post msaa',\n",
       " 'brainz feel unfortun digress less effect dmt suggest gain access lemtrada consid cladribin uk near would park bart sign cladribin possibl get tysabri possibl tri gilenya probabl efficaci oral dmd would use dmd could get lemtrada cladribin sew chick review cladribin inform agre impress would definit interest approv fda live close bart hospit safeti profil look good seen anyth regard abil halt revers progress ms like lemtrada clinic trial also would see whether recommend form relaps ms includ relaps secondari progress show languag like would appreci requir anoth dmt lemtrada would definit interest',\n",
       " 'must difficult time famili share week ago realli bad shape sad read may peac yo femal diagnos w uc mid transvers uc crohn coliti remiss sinc confirm scope dec current med entyvio asacol hd tab x day capozid day hypertens omeprazol otc loratadin day multivitamin day',\n",
       " 'california offici alleg tuesday biopharma giant abbvi abbv made illeg kickback boost prescript ion blockbust drug humira accord complaint abbvi engag far reach scheme includ classic kickback cash meal drink gift trip patient referr sophist one free valuabl profession good servic physician induc reward humira prescript ion www investor com news technolog abbvi kickback humira charg california moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa long minut depend side bathroom door',\n",
       " 'rituxan ocrevu great safeti record almost side effect peopl take infus easili time evid repair limit repair real talk game changer linda kind woman feet hit floor morn devil say oh crap repli quot follow user say thank agat howi jeani z pegakafarmgirl stillstannd sunshin suze q',\n",
       " 'sorri pred truli aw remind temporari hope humira longterm ticket club remiss pred tri limit salt intak reduc bloat water retent prevent limit salt limit calcium potassium intak pred wast two thing system light weight bear exercis slow calcium wast pred number time year worst flare lost pound weight due flare regain pound weight due insati pred appetit week ceas pred notic coupl pound disappear water retent howev major weight gain sustain due increas calor intak eat big meal minut later starv like eaten day long tri eat fill low calor thing exampl air fill thing like bowl butter free popcorn water fill thing like bowl soup broth fill stomach free bit longer chronic ill easier get uc real rough bodi caus dramat weight loss pred caus dramat weight gain loos hair thing entir control fret thing let go one remicad infus spoke nice ladi crohn year say keep two set cloth one larger size one smaller size flare well got tire throw rebuy cloth differ size feel well prioriti els worri cannot control noth make uc wors moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa might uc leav hous wear sock return none emerg tp post edit ipoop gmt',\n",
       " 'durvalumab twin crack',\n",
       " 'oh yeah ive talk peopl done much im entyvio thought zeljanz doctor read studi say low rate especi compar placebo good good remicad humira entyvio guess',\n",
       " 'immunotherapi checkpoint inhibitor anti program cell death pd program death ligand pd l pembrolizumab nivolumab anti cytotox lymphocyt antigen ctla ipilimumab high dose interleukin il dual immunomodul dual checkpoint inhibit ctla inhibitor plu pd inhibitor signal transduct inhibitor braf v raf murin sarcoma viral oncogen homolog b inhibitor patient test posit braf v mutat vemurafenib dabrafenib mek inhibitor trametinib cobimetinib kit inhibitor multikinas inhibitor sorafenib combin therapi signal transduct inhibitor braf inhibitor plu mek inhibitor dabrafenib plu trametinib vemurafenib plu cobimetinib chemotherapi palli local therapi two approach checkpoint inhibit target mitogen activ protein kinas mapk pathway demonstr improv progress free surviv pf overal surviv os random trial anti pd monotherapi pembrolizumab nivolumab demonstr improv efficaci outcom better safeti profil compar treatment use singl agent anti ctla ipilimumab investig choic chemotherapi combin anti pd anti ctla immunotherapi nivolumab ipilimumab also prolong pf os compar ipilimumab combin associ signific toxic rapid develop new agent combin remain question patient physician encourag consid clinic trial initi treatment time progress clinic trial address follow issu optim dose combin immunotherapi decreas toxic preserv efficaci select patient benefit combin immunotherapi versu monotherapi role pd l express biomark efficaci role mainten therapi valu sequenc therapi immunotherapi target therapi intralesion therapi talimogen laherparepvec vec vec genet modifi herp simplex viru type hsv oncolyt therapi approv local intralesion inject unresect cutan subcutan nodal lesion patient melanoma recur initi surgeri vec design replic within tumor caus lysi produc granulocyt macrophag coloni stimul factor gm csf releas antigen togeth viral deriv gm csf may promot antitumor immun respons howev exact mechan action unknown approv vec u food drug administr fda base data demonstr shrinkag lesion howev improv os effect viscer metastas improv qualiti life shown evid vec multin random open label trial nct patient randomli assign intralesion vec subcutan gm csf least month inject lesion [ ][ level evid iidiv ] elig patient stage iiib iiic iv melanoma unresect bidimension measur lesion primari endpoint durabl respons rate drr complet respons [cr] partial respons [pr] last month assess independ review studi stratifi site first recurr presenc liver metastas diseas stage previou nonadjuv system treatment median patient age year rang year patient baselin eastern cooper oncolog group ecog perform statu ps score stage iii diseas stage iv diseas b c previou therapi melanoma receiv patient first dose administ plaqu form unit pfu ml maximum ml lesion combin subsequ dose administ pfu ml ml inject lesion combin inject volum base size lesion inject viscer lesion allow patient treat vec confid interv [ci] drr versu ci patient receiv gm csf subgroup analysi suggest differ drr vec versu gm csf may greater earlier stage diseas treatment na diseas patient stage iiib iiic drr vec versu gm csf versu respect patient stage iv diseas versu respect patient stage iv b diseas versu respect patient stage iv c diseas patient treat vec gm csf first line therapi drr versu howev patient receiv treatment second line therapi greater drr versu median durat exposur vec week month patient expos year common advers event ae vec group fatigu chill pyrexia nausea influenza like ill inject site pain rate discontinu result toxic vec versu gm csf group ten death patient treat vec eight death consid result pd salmonella infect one myocardi infarct none consid relat therapi base find investig precaut vec live attenu hsv may caus life threaten dissemin herpet infect contraind immunocompromis pregnant patient healthcar provid close contact avoid direct contact inject lesion biohazard precaut prepar administr handl provid label detail prescrib inform treatment cycl lesion size provid fda label immunotherapi checkpoint inhibitor anti pd pd l pd pathway key immunoinhibitori mediat cell exhaust blockad pathway lead cell activ expans enhanc effector function pd two ligand pd l pd l two anti pd antibodi pembrolizumab nivolumab approv fda basi improv os random trial pembrolizumab evid pembrolizumab previous treat patient total patient unresect metastat melanoma diseas progress within week last dose ipilimumab braf v mutat posit previou treatment braf inhibitor randomli assign one two dose pembrolizumab mg kg mg kg everi week trial exclud patient autoimmun diseas condit requir immunosuppress histori sever immun relat advers event ira treatment ipilimumab median age year male ecog ps ecog ps eighteen percent patient tumor braf v mutat posit elev lactat dehydrogenas ldh c diseas brain metastas undergon two therapi advanc diseas primari outcom measur overal respons rate orr accord respons evalu criteria solid tumor recist version criteria assess blind independ central review [ ][ level evid iidiv ] orr determin independ central review ci p mg kg arm consist one cr pr patient median follow month patient minimum month follow among patient object respons ongo respons rang month month respons rate mg kg arm similar consist respons patient respons seen patient without braf v mutat approv dose mg kg administ intraven iv infus minut everi week pembrolizumab discontinu ae patient treat mg kg consid drug relat ae investig common ae mg kg versu mg kg arm fatigu vs pruritu vs rash vs common ae includ cough nausea decreas appetit constip arthralgia diarrhea frequent seriou ae occur total patient treat pembrolizumab includ renal failur dyspnea pneumonia cellul addit clinic signific ira includ pneumon coliti hypophys hyperthyroid hypothyroid nephriti hepat fda label provid recommend suspect ira includ withhold drug administ corticosteroid previous untreat treat patient multicent intern trial keynot [nct ] randomli assign patient metastat melanoma ratio receiv pembrolizumab mg kg iv q week q week four cycl ipilimumab mg kg q week [ ] patient stratifi ecog ps vs line therapi first line vs second line pd l express posit vs neg primari endpoint pf os [ ][ level evid iia ] approxim patient receiv previou system therapi advanc melanoma braf v mutat present patient approxim receiv previou braf inhibitor treatment studi enrol patient braf v mutat high ldh level symptomat rapidli progress diseas receiv anti braf therapi could provid rapid clinic benefit approxim patient pd l posit tissu sampl time second interim analysi os result cross prespecifi efficaci boundari two pembrolizumab group superior os ipilimumab group prespecifi one side alpha level data monitor safeti board dmsb recommend studi result unblind pembrolizumab made avail patient diseas progress ipilimumab group median durat follow time second interim analysi month patient death median os reach treatment group year estim surviv patient receiv pembrolizumab everi week hazard ratio [hr] death compar ipilimumab group ci p patient receiv pembrolizumab everi week hr death compar ipilimumab ci p patient treat ipilimumab benefit seen across subgroup except patient pd l neg tumor howev sinc subset small patient ci wide definit conclus could drawn studi grade ae consid relat studi drug pembrolizumab everi week pembrolizumab everi week ipilimumab rate studi drug discontinu result toxic pembrolizumab everi week pembrolizumab everi week ipilimumab one death result cardiac arrest occur ipilimumab group patient type diabet mellitu caus metabol imbal associ ipilimumab induc diarrhea nivolumab evid nivolumab previous treat patient acceler approv base plan noncompar interim analysi first patient receiv nivolumab least month follow multicent open label trial checkmat [nct ] randomli assign patient nivolumab mg kg q week investig choic chemotherapi either dtic mg iv q week combin carboplatin [area curv ] plu paclitaxel mg q week [fda label ][ level evid iiidiv ] patient requir unresect metastat melanoma progress treatment ipilimumab braf v mutat posit braf inhibitor trial exclud patient autoimmun diseas condit requir immunosuppress histori sever ira treatment ipilimumab median age patient year patient male ecog ps patient braf v mutat present patient c diseas elev ldh histori brain metastas receiv two system therapi previous metastat diseas orr os coprimari endpoint orr ci four cr pr assess recist criteria independ central review among patient respons ongo respons durat month respons seen patient without braf v mutat safeti analysi base patient nivolumab discontinu ae patient seriou ae occur patient grade grade ae occur patient common ae rash cough upper respiratori tract infect peripher edema import ae includ ventricular arrhythmia iridocycl increas amylas lipas dizzi neuropathi fda label provid recommend suspect ira includ withhold drug administ corticosteroid previous untreat patient total patient unresect stage iii stage iv melanoma without braf mutat randomli assign doubl blind multicent trial receiv nivolumab mg kg q week dtic match placebo q week dtic mg q week nivolumab match placebo q week primari endpoint os [ ][ level evid ia ] trial conduct center europ israel australia canada south america countri dtic standard first line treatment patient without braf mutat dmsb note potenti differ os safeti review june abbrevi report unplan interim databas lock review show signific differ os favor nivolumab dmsb recommend studi unblind allow patient dtic receiv nivolumab intend sampl size approxim patient total patient enter result doubl blind portion studi crossov amend show median os reach nivolumab group month ci dtic group os rate year ci nivolumab group ci dacarbazin group hr death ci p common ae nivolumab group fatigu pruritu nausea diarrhea nivolumab group patient discontinu studi treatment ae compar patient discontinu studi treatment dtic group ae potenti immunolog etiolog occur includ gastrointestin hepat pulmonari renal endocrin skin howev major resolv delay studi treatment glucocorticoid administr per manag guidelin nivolumab death attribut drug relat ae either group chang dose regimen nivolumab metastat melanoma popul pharmacokinet respons analysi dose exposur respons analysi flat dose mg nivolumab everi week consid pharmacokinet equival dose regimen mg kg clinic safeti efficaci two dose appear similar across bodi weight tumor type melanoma non small cell lung cancer renal cell carcinoma [ ] dose regimen approv fda monotherapi chang mg kg mg iv everi week diseas progress intoler toxic dose regimen mg kg iv nivolumab combin ipilimumab remain unchang therapi ipilimumab complet regimen chang mg dose everi week diseas progress intoler toxic anti cytotox lymphocyt antigen ctla ipilimumab ipilimumab human monoclon antibodi bind ctla therebi block abil regul cell activ prolifer effector function ipilimumab demonstr clinic benefit prolong os random trial approv fda two prospect random intern trial one previous untreat treat patient support use ipilimumab [ ] evid ipilimumab previous treat patient total patient previous treat unresect stage iii stage iv diseas hla posit enter three arm multin random doubl blind doubl placebo trial total patient randomli assign receiv ipilimumab mg kg q week dose glycoprotein gp peptid vaccin one hundr thirti seven patient receiv ipilimumab mg kg q week dose patient receiv gp vaccin patient stratifi baselin metastas previou receipt nonreceipt il therapi eighti two patient metastas brain baselin [ ][ level evid ia ] median os month among patient receiv ipilimumab alon month among receiv ipilimumab gp vaccin compar month patient receiv vaccin alon hr ipilimumab alon vs gp alon p hr ipilimumab plu vaccin vs gp alon p analysi year show among patient treat ipilimumab treat ipilimumab treat ipilimumab vaccin aliv compar patient receiv vaccin grade grade ira occur patient treat ipilimumab ira often includ diarrhea coliti endocrin relat event e g inflamm pituitari event requir cessat therapi institut anti inflammatori agent corticosteroid four case infliximab antitumor necrosi factor alpha antibodi drug relat death seven death associ ira previous untreat patient multicent intern trial randomli assign patient untreat metastat diseas adjuv treatment allow ratio receiv ipilimumab mg kg plu dtic mg placebo plu dtic mg week follow dtic alon everi week week patient stabl diseas object respons dose limit toxic effect receiv ipilimumab placebo everi week thereaft mainten therapi primari endpoint surviv patient stratifi accord ecog ps metastat stage approxim patient ecog ps remaind patient ecog ps approxim patient stage c diseas [ ][ level evid ia ] median os month ci ipilimumab dtic group versu month ci placebo dtic group estim surviv rate ipilimumab dtic group year year year hr death p placebo dtic group rate year year year common studi drug relat ae classifi immun relat grade grade ira seen patient treat ipilimumab plu dtic versu patient treat placebo plu dtic common event hepat enterocol drug relat death occur clinician patient awar immun mediat advers reaction may sever fatal earli identif treatment includ potenti administr system glucocorticoid immunosuppress accord immun mediat advers reaction manag guid provid manufactur necessari [ ] high dose il il approv fda basi durabl cr eight phase ii studi phase iii trial compar high dose il retreat provid assess rel impact os conduct evid high dose il base pool analysi patient eight singl multi institut trial institut conduct high dose il demonstr cr rate [ ] median follow time surviv patient least year median durat cr reach least month [ ] strategi improv therapi activ area investig dual immunomodul cell coexpress sever receptor inhibit cell function preclin data earli clinic data suggest coblockad two inhibitori receptor ctla pd may effect blockad either alon [ ] led phase iii trial nct compar singl agent combin dual checkpoint inhibit ctla inhibitor plu pd inhibitor evid ipilimumab plu nivolumab previous untreat patient intern random doubl blind trial checkmat previous untreat patient unresect stage iii iv melanoma randomli assign ratio arm nivolumab alon mg kg q week plu placebo arm nivolumab mg kg q week plu ipilimumab mg kg q week dose follow mg nivolumab q week arm ipilimumab alon mg kg q week dose plu placebo pf os coprimari endpoint studi power compar combin nivolumab plu ipilimumab ipilimumab monotherapi nivolumab monotherapi ipilimumab monotherapi studi power compar combin ipilimumab plu nivolumab nivolumab patient stratifi accord tumor pd l statu assess central laboratori immunohistochem test posit vs neg indetermin braf mutat statu v mutat posit vs wild type american joint committe cancer stage [ ][ level evid iia ] characterist baselin includ patient ecog ps elev ldh braf mutat c diseas minor patient pd l posit tumor prospect defin coprimari analysi pf occur patient least month follow treatment nivolumab alon combin ipilimumab result significantli longer pf ipilimumab alon result consist across prespecifi stratif factor median pf month ci nivolumab month ci nivolumab plu ipilimumab month ci ipilimumab prospect specifi coprimari analysi os occur month death rate os time point nivolumab group combin group ipilimumab group hr death combin vs ipilimumab [ ci p ] hr death nivolumab vs ipilimumab [ ci p ] [ ] descript analysi minimum follow month follow data found os rate nivolumab group patient treat combin ipilimumab group median os reach combin arm ci month reach median os singl agent nivolumab ipilimumab group month ci reach month ci respect hr death combin versu ipilimumab ci p nivolumab versu ipilimumab hr ci p ae highest combin arm need monitor care grade treatment relat ae occur patient nivolumab group patient ipilimumab group patient combin group frequent reason treatment discontinu diseas progress two monotherapi arm nivolumab ipilimumab frequent reason discontinu combin group toxic four therapi relat death report attribut neutropenia nivolumab group colon perfor ipilimumab group liver necrosi autoimmun myocard combin ipilimumab nivolumab analys pd l express level associ os year indic level express alon poor predict biomark os signal transduct inhibitor studi date indic braf mek mitogen activ erk [extracellular signal regul kinase] activ kinas inhibitor singl agent combin significantli impact natur histori melanoma although appear provid cure braf inhibitor vemurafenib vemurafenib oral avail small molecul select braf kinas inhibitor approv fda patient unresect metastat melanoma test posit braf v e mutat treatment vemurafenib discourag wild type braf melanoma data preclin model demonstr braf inhibitor enhanc rather regul mapk pathway tumor cell wild type braf upstream ra mutat [ ] evid vemurafenib previous untreat patient approv vemurafenib support intern multicent trial brim [nct ] screen patient previous untreat stage iiic iv melanoma braf v mutat identifi patient via coba braf v mutat test [ ] patient randomli assign receiv either vemurafenib mg po bid dtic mg iv q week coprimari endpoint rate os pf plan interim analysi dmsb determin os pf endpoint met prespecifi criteria statist signific favor vemurafenib recommend patient dtic group allow cross receiv vemurafenib [ ][level evid iia iidiii ] total patient evalu os although median surviv yet reach vemurafenib data immatur reliabl kaplan meier estim surviv curv os vemurafenib arm clearli superior dtic arm hr death vemurafenib group ci p surviv benefit vemurafenib group observ prespecifi subgroup exampl age sex ecog ps tumor stage ldh geograph region hr tumor progress vemurafenib arm ci p estim median pf month vemurafenib arm versu month dtic arm twenti patient non braf v e mutat braf v k braf v four patient braf v k mutat respons vemurafenib ae requir dose modif interrupt patient receiv vemurafenib receiv dtic common ae vemurafenib cutan event e arthralgia fatigu cutan squamou cell carcinoma scc keratoacanthoma develop patient treat simpl excis common ae dtic fatigu nausea vomit neutropenia refer pdq summari support palli care inform cope cancer previous treat patient total patient braf v e braf v k mutat enrol multicent phase ii trial vemurafenib administ mg po bid enrol patient stage c diseas elev ldh level patient receiv one previou therapi advanc diseas median follow month [ ][ level evid iiidiv ] independ review committe irc report respons rate ci eight patient achiev cr median durat respons per irc assess month ci respons evid first radiolog assess week howev patient respond receiv therapi month dabrafenib dabrafenib oral avail small molecul select braf inhibitor approv fda patient unresect metastat melanoma test posit braf v e mutat detect fda approv test dabrafenib braf inhibitor recommend treatment braf wild type melanoma vitro experi suggest may paradox stimul mapk signal result tumor promot evid dabrafenib intern multicent trial break [nct ] compar dabrafenib dtic total patient unresect stage iii iv melanoma braf v e mutat randomli assign ratio dabrafenib mg po qd dtic mg iv q week il allow previou treatment advanc diseas primari endpoint pf patient could cross time progress diseas confirm blind irc [ ][ level evid iidiii ] event hr pf ci p estim median pf month dabrafenib versu month dtic os data limit median durat follow crossov pr rate cr rate patient receiv dabrafenib versu pr rate cr rate receiv dtic frequent ae patient treat dabrafenib cutan find e hyperkeratosi papilloma palmar plantar erythrodysesthesia pyrexia fatigu headach arthralgia cutan scc keratoacanthoma occur patient basal cell carcinoma occur four patient mycosi fungoid occur one patient new melanoma occur two patient mek inhibitor trametinib trametinib oral avail small molecul select inhibitor mek mek braf activ mek mek protein turn activ mapk preclin data suggest mek inhibitor restrain growth induc cell death braf mutat human melanoma tumor braf activ mek mek protein turn activ mapk trametinib approv fda patient unresect metastat melanoma braf v e v k mutat determin fda approv test evid trametinib total patient screen braf mutat result elig patient braf v e braf v k one mutat [ ] one previou treatment biolog chemotherapi allow howev previou treatment braf mek inhibitor permit patient randomli assign ratio receiv trametinib mg qd iv chemotherapi either dtic mg q week paclitaxel mg q week crossov patient randomli assign chemotherapi allow therefor primari endpoint pf investig assess pf month patient receiv trametinib versu month chemotherapi group hr pf death ci p radiolog review blind treatment arm result similar outcom median os reach ae lead dose interrupt occur patient trametinib group chemotherapi group ae lead dose reduct occur patient receiv trametinib receiv chemotherapi common ae includ rash diarrhea nausea vomit fatigu peripher edema alopecia hypertens constip cardiomyopathi interstiti lung diseas central serou retinopathi retin vein occlus uncommon seriou ae associ trametinib studi cutan scc observ refer pdq summari support palli care inform cope cancer cobimetinib cobimetinib small molecul select mek inhibitor approv fda use combin braf inhibitor vemurafenib refer combin therapi signal transduct inhibitor section summari inform kit inhibitor earli data suggest mucos acral melanoma activ mutat amplif c kit may sensit varieti c kit inhibitor [ ] phase ii phase iii trial avail patient unresect stage iii stage iv melanoma harbor c kit mutat multikinas inhibitor sorafenib multikinas inhibitor sorafenib activ vascular endotheli growth factor signal raf mek erk pathway agent minim activ singl agent melanoma treatment two larg multicent placebo control random trial carboplatin paclitaxel without sorafenib show improv chemotherapi alon either first line treatment second line treatment [ ] combin therapi signal transduct inhibitor secondari resist braf inhibitor monotherapi patient braf v mutat may associ reactiv mapk pathway therefor combin signal transduct inhibitor block differ site pathway site multipl pathway activ area research braf inhibitor plu mek inhibitor dabrafenib plu trametinib evid dabrafenib plu trametinib previous untreat intern doubl blind phase iii trial without crossov randomli assign previous untreat patient unresect stage iiic stage iv melanoma braf v e v k mutat receiv combin dabrafenib mg po bid plu trametinib mg po qd dabrafenib plu placebo primari endpoint investig assess pf protocol includ prespecifi interim analysi os time analysi primari endpoint patient stratifi baselin ldh braf genotyp [ ][ level evid idiii ] median pf month combin versu month dabrafenib plu placebo hr death progress ci p updat data time final analysi os reveal median pf month combin versu month dabrafenib plu placebo hr pf death ci p unadjust multipl test [ ] prespecifi final analysi os conduct event median os month dabrafenib plu trametinib group event versu month dabrafenib plu placebo group event hr ci p perman discontinu studi drug report patient combin patient treat dabrafenib incid grade grade ae similar group incid combin incid dabrafenib pyrexia occur frequent combin treat immedi temporari cessat studi drug either group prophylact glucocorticoid may prevent recur episod hyperprolif cutan event includ cutan scc consid relat paradox activ mapk pathway occur less frequent addit mek inhibitor rare seriou ae includ decreas eject fraction chorioretinopathi previous untreat intern open label phase iii trial randomli assign previous untreat patient metastat melanoma braf v mutat receiv standard dose either combin dabrafenib plu trametinib vemurafenib first line therapi primari endpoint os [ ][ level evid iia ] interim analysi os plan final event occur per protocol dmsb use adjust efficaci boundari actual event side p efficaci p futil dmsb recommend stop efficaci interim analysi consid final analysi os protocol amend issu allow crossov combin therapi arm total patient combin arm vemurafenib group die hr ci p median os patient treat vemurafenib month median reach combin therapi arm vemurafenib plu cobimetinib evid vemurafenib plu cobimetinib previous untreat intern phase iii trial randomli assign patient previous untreat unresect stage iiic stage iv melanoma braf v mutat posit melanoma receiv combin vemurafenib mg po qd cobimetinib mg po qd day follow day rest period vemurafenib plu placebo primari endpoint investig assess pf crossov time pf allow patient stratifi stage geograph region two interim analys os prespecifi first specifi time analysi primari endpoint [ ][ level evid idiii ] median pf month combin versu month patient treat vemurafenib plu placebo hr death progress ci p first interim analysi os immatur event arm therefor median surviv reach either studi group rate withdraw therapi caus ae similar group rate found patient treat combin rate found patient treat vemurafenib six death attribut ae combin group three death attribut ae vemurafenib group incid grade grade ae similar group incid rate found patient treat combin rate found patient treat vemurafenib alon rare seriou ae includ chorioretinopathi retin detach decreas eject fraction qt prolong hyperprolif cutan event includ cutan scc consid relat paradox activ mapk pathway occur less frequent addit mek inhibitor chemotherapi dtic approv basi orr phase iii trial indic orr rare cr observ impact os demonstr random trial [ ] use control arm recent registr trial ipilimumab vemurafenib previous untreat patient metastat melanoma dtic shown inferior os temozolomid oral alkyl agent hydrolyz activ moieti dtic appear similar dtic iv administr random phase iii trial primari endpoint os howev trial design superior sampl size inadequ prove equival [ ] object respons rate dtic nitrosourea carmustin lomustin approxim [ ] respons usual short live rang month although long term remiss occur limit number patient attain cr [ ] random trial compar iv dtic temozolomid oral agent os month dtic versu month temozolomid hr ci data suggest similar dtic temozolomid benefit surviv demonstr either dtic temozolomid therefor demonstr similar result approv temozolomid fda [ ][ level evid iia ] extend schedul escal dose temozolomid compar dtic multicent trial european organis research treatment cancer eortc eortc [nct ] randomli assign patient improv seen os pf temozolomid group dose schedul result toxic standard dose singl agent dtic [ ][ level evid iia ] two random phase iii trial previous untreat patient metastat melanoma result fda approv vemurafenib [ ] ipilimumab [ ] includ dtic standard therapi arm vemurafenib braf v mutant melanoma ipilimumab show superior os compar dtic two separ trial agent modest singl agent activ includ vinca alkaloid platinum compound taxan [ ] attempt develop combin regimen incorpor chemotherapi e g multiag chemotherapi [ ] combin chemotherapi tamoxifen [ ] combin chemotherapi immunotherapi [ ] demonstr improv os publish data meta analysi random trial surviv inform compar chemotherapi biochemotherapi e chemotherapi plu interferon alon il report impact os [ ][ level evid iia ] palli local therapi melanoma metastat distant lymph node bear area may palliat region lymphadenectomi isol metastas lung gastrointestin tract bone sometim brain may palliat resect occasion long term surviv [ ] although melanoma rel radiat resist tumor palli radiat therapi may allevi symptom retrospect studi shown symptom relief shrinkag tumor radiat therapi may occur patient follow [ ] multipl brain metastas bone metastas spinal cord compress effect dose fraction schedul palliat melanoma metastat bone spinal cord unclear high dose per fraction schedul sometim use overcom tumor resist refer pdq summari cancer pain inform treatment option clinic evalu unresect stage iii stage iv recurr melanoma immunotherapi singl agent combin immunomodul target therapi singl agent combin therapi signal transduct inhibitor includ p k phosphoinositid kinas akt protein kinas b inhibitor cdk cyclin depend kinas addit braf mek inhibitor antiangiogenesi agent preclin data suggest increas vascular endotheli growth factor product may implic resist braf inhibitor [ ] target therapi specif melanoma popul smaller subset melanoma activ mutat may occur nra neuroblastoma ra viral [v ras] oncogen homolog c kit melanoma aris chronic sun damag skin acral mucos melanoma cdk cyclin depend kinas wherea gnaq frequent mutat uveal melanoma drug develop target pathway activ mutat current clinic trial',\n",
       " 'novel crizotinib resist solvent front mutat respons cabozantinib therapi patient ro rearrang lung cancer http www ncbi nlm nih gov pubm pleas updat blog first time cabo shown work patient criz resist thank',\n",
       " 'happi new year focus sole journey obtain gilenya continu use threw away needl felt great go meantim montel got ccsvi new stem cell trial without chemotherapi almost underway new medic ahem bg wind way pipelin also time much discov multipl sclerosi research recent reveal natur multipl sclerosi diseas need ever illumin discoveri find excit right fatti acid relaps link diet ms noth new think heard swank diet great name opinion even wrote book upon time doctor notic ms patient never ate red meat dairi anyth delici significantli less relaps us love chees filet mignon last night develop diet essenti involv red meat year limit serv unfortun absolut scientif proof back diet uc san diego skagg school pharmaci pharmaceut scienc specif mariann manchest leah p shriver discov someth fascin studi quasi evil immun cell central nervou system oxid fatti acid glucos fuel inflam tissu mous tissu inhibit specif enzym aid immun cell exploit fatti acid caus cell starv die word glucos prevent immun cell like kill brain use fatti acid prevent relaps furthermor treatment involv target enzym mean model also work human littl risk compar medic avail us anoth bonu enzym inhibitor use studi alreadi use human congest heart failur even loom challeng seem incred promis break blood brain barrier one challeng virtual everi ms treatment safe effect deliv therapi blood brain barrier cornel univers work issu discov adenosin occur natur bodi control passag larg molecul brain believ exist drug lexiscan current use heart imag trigger receptor open barrier treatment deliveri least work mice hope work us remyelin stem cell paul tesar case western reserv univers school medicin actual found way mice myelin cell rapidli use stem cell use pluripot epiblast stem cell sound like neon past attempt fail team use signal protein growth factor thyroid hormon caus restor normal myelin day neurosteroid rage seem like everi day bring hope even realist pessimist like univers alberta edmonton notabl alberta canada highest concentr ms world made discoveri add yet anoth piec ms puzzl us multipl sclerosi remark less neruosteroid everyon els appar thing call neurosteroid appar neurosteroid make brain cell work correctli brain cell obvious neither brain cell mice use studi research discov peopl ms significantli lower level brain chemic specif allopregnanolon help build brain cell maintain function connect differ area activ brain trial via pill form alreadi underway neurolog diseas look especi promis ms mice studi treat allopregnanolon normal deriv cholesterol vitamin result reduc inflamm repair nerv fiber reduct ms like sever increas mobil day',\n",
       " 'phase b trial capmatinib plu gefitinib show accept safeti efficaci patient epiderm growth factor receptor egfr mutat mesenchym epitheli transit factor met dysregul non small cell lung cancer nsclc capmatinib inc met inhibitor shown preclin activ trial result publish journal clinic oncolog patient enrol trial egfr mutat met dysregul nsclc progress prior egfr tyrosin kinas inhibitor tki treatment total patient treat phase b portion trial patient treat phase phase b patient receiv gefitinib mg daili plu capmatinib capsul either mg per day twice per day phase patient treat recommend phase dose capmatinib mg twice per day plu gefitinib mg per day primari endpoint phase overal respons rate orr phase patient orr patient met amplifi tumor orr diseas control rate median durat respons month ci month nausea peripher edema decreas appetit rash common advers event report phase b patient increas amylas lipas level common grade advers event relat articl world confer lung cancer key find treatment relat hyperprogress concern continu mount palli care survivorship combin capmatinib gefitinib shown feasibl ration data studi suggest combin capmatinib egfr tki may promis treatment option patient egfr mutat met dysregul nsclc particularli patient met amplifi tumor studi author conclud disclosur studi fund novarti pharma ag refer',\n",
       " 'neuro suggest cholesterol level wife high due gilenya take apo_atorvastatin pill month wonder sinc side effect mention om book keep strictli om diet calori intak low take pill realli necessari',\n",
       " 'hello find truli suck time symptom come quickli year find prm happen like alway ach pain like anyon els one day dizzi fall faint collaps weak pain one year bodi alway like never get break anyth get wors work physic labor anyon bino bino never goe away go lose abil walk soon prm affect happen quickli seem like bodi fall piec fast progress fast activ tri feel stop die keep push bodi physic anymor take gilenya day thank help',\n",
       " 'embed video asco roundtabl lung cancer keynot cisplatin carboplatin alimta amp amp keytruda practic chang approach asco roundtabl lung cancer keynot cisplatin carboplatin alimta keytruda practic chang approach dr h jack west medic director thorac oncolog program swedish cancer institut presid ceo grace karen kelli associ cancer journey treatment cancer type lung cancer diseas learn gener lung cancer non small cell lung cancer chemo medic immunotherapi chemotherapi embed video asco roundtabl lung cancer keynot trial keytruda pembrolizumab singl agent compar doublet chemotherapi nsclc asco roundtabl lung cancer keynot trial keytruda pembrolizumab singl agent compar doublet chemotherapi nsclc dr h jack west medic director thorac oncolog program swedish cancer institut presid ceo grace karen kelli associ cancer journey treatment cancer type lung cancer diseas learn gener lung cancer non small cell lung cancer chemo medic immunotherapi chemotherapi embed video lung cancer video librari chemo immuno therapi combin advanc squamou nsclc lung cancer video librari chemo immuno therapi combin advanc squamou nsclc dr h jack west medic director thorac oncolog program swedish cancer institut presid ceo grace offer updat lung cancer cancer journey treatment cancer type lung cancer diseas learn gener lung cancer non small cell lung cancer chemotherapi immunotherapi embed video case base panel discuss advanc non squamou nsclc high pd l driver mutat optim st line case base panel discuss advanc non squamou nsclc high pd l driver mutat optim st line dr zofia piotrowska h jack west taofeek owonikoko sit discuss seri case base scenario video doctor discuss optim st line treatment patient advanc non squamou non small cell lung cancer high pd l driver mutat cancer journey diagnos treatment cancer type lung cancer diseas learn gener lung cancer non small cell lung cancer chemotherapi mainten therapi adjuv therapi target therapi immunotherapi embed video case base panel discuss advanc non squamou nsclc low pd l driver mutat best system therapi option case base panel discuss advanc non squamou nsclc low pd l driver mutat best system therapi option dr zofia piotrowska h jack west taofeek owonikoko sit discuss seri case base scenario video doctor discuss best system therapi option patient advanc non squamou nsclc low pd l driver mutat cancer journey diagnos treatment cancer type lung cancer diseas learn gener lung cancer non small cell lung cancer chemotherapi mainten therapi adjuv therapi target therapi immunotherapi',\n",
       " 'hello recent diagnos rrm februari start first dose gilenya saturday feel bit nervou make heart rate drop medicin make real go overal got good handl thing good day bad anyon use gilenya thought know everyon diseas process differ react differ would like input thank advanc',\n",
       " 'well choic case diagnos never treatment think start gilenya although condit still fine disabl anyhow futur said guess year better accept take treatment see goe',\n",
       " 'hello everyon year ago test posit jcv connect gilenya came stop take med went dr jelinek overcom ms diet lost lb month felt great great diet past sever month put back ugh start needless say saw neurologist today happi stop take med flare up tingl burn stab dizzi blurri thing feel come go fortun linger effect decid tri scare histor go dmt bad relaps hit hard within year two final gotten realli good job famili well dont want take med dont also dont want get sucker punch bad relaps lose ground posit gain past month suggest aubagio anyon got experi pleas let know new bloodwork new mri lesion brain spinal cord know soon thank everyon wayn',\n",
       " 'wow ncot epic stori case lost pill cam someth never one alway told tradit method better wonder neon colour someth trace like kinda microchip dog time ever come sure poop plastic contain pass start entyvio yet opp ye notic chang',\n",
       " 'hello smurf could forget name like smurf might right offer dmd criteria usual relaps last year often neurologist manag get categoris activ base new lesion get onto dmd anyway problem wbc past may take drug tabl may depend type white blood cell deplet lymphocyt dmd perhap eg tecfidera neutrophil eg gilenya could rule sinc side effect occur specif drug other effect may get onto decent treatment whatev happen know alway sue',\n",
       " 'klau schmierer saw recommend treatment end march four week wash period stop gilenya first lot cladribin begin may two week ago say alreadi littl bit better leg work bit better mainli probabl even full first dose yet get lymphocyt count done four week first treatment depend give inject week',\n",
       " 'recombin human fusion protein vascular endotheli growth factor vegf placent growth factor plgf antagonist use eylea neovascular age relat macular degener treatment neovascular wet age relat macular degener clinic equival ranibizumab may provid advantag e g decreas treatment burden agent e g bevacizumab ranibizumab less frequent administr see dosag dosag administr macular edema follow retin vein occlus treatment macular edema follow retin vein occlus diabet macular edema treatment diabet macular edema diabet retinopathi patient diabet macular edema treatment diabet retinopathi patient diabet macular edema eylea dosag administr administr ophthalm administ intravitr inject affect eye must administ qualifi physician prior intravitr administr withdraw entir content aflibercept vial steril gaug filter needl provid manufactur ml syring provid manufactur use asept techniqu prior intravitr inject replac filter needl steril gaug inch needl provid manufactur obtain appropri dose mg expel content syring plunger tip align line mark ml syring inject control asept condit includ surgic hand disinfect use steril glove steril drape steril eyelid speculum [or equivalent] follow adequ anesthesia administr topic broad spectrum anti infect agent monitor patient elev iop immedi follow intravitr inject monitor may includ evalu optic nerv head perfus tonometri steril paracentesi needl avail requir use vial treatment singl eye discard unus portion contralater eye requir treatment use new vial chang steril field syring glove drape eyelid speculum filter inject needl administ eye dosag adult neovascular age relat macular degener ophthalm intravitr inject mg affect eye everi week week mg everi week addit efficaci demonstr follow administr everi week compar everi week macular edema follow retin vein occlus ophthalm intravitr inject mg affect eye everi week diabet macular edema ophthalm intravitr inject mg affect eye everi week first inject follow mg everi week addit efficaci demonstr follow administr everi week compar everi week diabet retinopathi patient diabet macular edema ophthalm intravitr inject mg affect eye everi week first inject follow mg everi week addit efficaci demonstr follow administr everi week compar everi week special popul hepat impair specif dosag recommend time renal impair dosag adjust requir geriatr patient dosag adjust requir caution eylea contraind ocular periocular infect activ intraocular inflamm known hypersensit e g sever intraocular inflamm aflibercept ingredi formul warn precaut sensit reaction hypersensit reaction report see contraind caution endophthalm retin detach intravitr inject includ aflibercept associ endophthalm retin detach alway use proper asept inject techniqu sign symptom endophthalm retin detach e g red sensit light pain chang vision [includ blur vision] occur manag appropri increas iop acut increas iop observ within minut intravitr inject sustain increas iop also observ follow repeat intravitr inject vegf antagonist monitor iop perfus optic nerv head manag appropri thromboembol event potenti risk arteri thromboembol event follow intravitr inject vegf antagonist includ aflibercept immunogen incid immunoreact aflibercept similar week therapi differ efficaci safeti patient without immunoreact specif popul pregnanc categori c adequ well control studi pregnant women anim studi suggest possibl advers embryofet effect use potenti benefit justifi potenti risk fetu women childbear potenti use effect contracept prior initi therapi treatment month last intravitr inject administ lactat known whether aflibercept distribut milk use recommend nurs women discontinu nurs drug pediatr use safeti efficaci establish geriatr use substanti differ safeti efficaci rel younger adult renal impair differ plasma concentr observ variou degre renal impair see special popul pharmacokinet common advers effect conjunctiv hemorrhag eye pain cataract vitreou detach vitreou floater increas iop interact eylea formal drug interact studi date eylea pharmacokinet absorpt bioavail follow intravitr inject mean peak plasma concentr attain day peak plasma concentr estim fold lower concentr requir half maxim bind system vegf free aflibercept undetect plasma week intravitr inject accumul observ follow repeat intravitr inject e everi week special popul follow intravitr inject everi week differ free plasma aflibercept concentr observ patient mild moder sever renal impair distribut extent known whether aflibercept distribut milk elimin metabol expect undergo elimin target mediat disposit via bind free endogen vegf via proteolysi half life approxim day follow iv administr dose mg kg stabil storag ophthalm c freez protect light store origin carton use action act solubl decoy receptor bind vegf plgf inhibit biolog activ vegf induc neovascular angiogenesi increas vascular permeabl appear play role pathogenesi progress neovascular wet age relat macular degener macular edema follow retin vein occlus diabet macular edema diabet retinopathi bind vegf plgf prevent factor bind endogen vegf receptor e vegfr vegfr reduc endotheli cell prolifer angiogenesi vascular permeabl bind affin aflibercept vegf isoform higher endogen receptor aflibercept block vegf bind activ vegfr vegfr even low concentr advic patient possibl temporari visual disturb intravitr inject associ eye examin import avoid drive vehicl oper machineri visual function recov suffici risk endophthalm retin detach import immedi seek care ophthalmologist chang vision occur treat eye becom red sensit light pain import women inform clinician plan becom pregnant plan breast feed import inform clinician exist contempl concomit therapi includ prescript otc drug well concomit ill import inform patient import precautionari inform see caution',\n",
       " 'thank jim alway much appreci input guardant test result came offer carbo alimta tagrisso trial opdivo second agent explan offer pd l statu seem matter low level autoimmun diseas natur reluct go immunotherapi rout even though new evid suggest peopl low level autoimmun might still abl success tri option skeptic want find potenti life threaten situat tri figur combin opdivo agent increas current low respons rate patient popul continu tagrisso therapi lung tumor reach certain size caus cough hoars cm rang right still first diagnos cm hilar lymph node also increas densiti locat includ brain ned moment love add stereotact radiat treatment regiment know controversi stage also slim chanc take mother load might delay progress somewhat opinion kempten',\n",
       " 'jarthur wife nonsmok dx stage iv nsclc left lung egfr tarceva continu year excel respons year chemo carbo alimta avastin local recurr good respons repeat chemo carbo alimta avastin local recurr good respons avastin mainten needl bx local recurr result includ egfr pd rx tarceva avastin c pend rx decis diseas still confin left chest would option system rx indic tagrisso checkpoint inhibitor one two agent chemo grate wife respond least temporarili rx thu far never would expect longev date dx first made thank input',\n",
       " 'hi jacki wonder kidney failur due platinum drug still abl tri singl chemo like alimta alon peopl egfr mutat well howev like jim hope well tagrisso long time best janin',\n",
       " 'electrolyt certain nutrient chemic present bodi mani import function regul heartbeat allow muscl contract move major electrolyt found within bodi includ calcium magnesium potassium sodium phosphat chlorid ibd result electrolyt imbal mani reason rang dehydr due high output ostomi diarrhoea sick heat lack absorpt due scar intestin resect import replac miss electrolyt becom rebalanc done depend sever imbal minor imbal dietari chang may possibl drink rehydr solut anoth option treatment sever case includ fluid replac intraven hospit stay post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit mri definit magnet reson imag mri type scan use strong magnet field radio wave produc detail imag insid bodi mri scanner larg tube contain power magnet lie insid tube scan mri help identifi activ diseas ibd help locat strictur narrow intestin complic abscess post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask mri ulcer coliti ulcer coliti definit immunosuppress definit immunosuppress drug class drug suppress reduc strength bodi immun system exampl immunosuppress azathioprin imuran mercaptopurin purinethol infliximab remicad adalimumab humira certolizumab pegol cimzia methotrex rheumatrex cyclosporin gengraf neoral sandimmun tacrolimu astagraf xl hecoria natalizumab tysabri vedolizumab entyvio ustekinumab stelara post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit adhes definit adhes commonli caus scar surgeri less commonli scar due activ inflammatori bowel diseas adhes fibrou band form tissu caus pain blockag intestin post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit resect definit bowel resect surgic procedur part larg small intestin remov post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit proctocolectomi definit proctocolectomi surgic remov rectum part colon post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit hemicolectomi definit hemicolectomi involv surgeri remov right left portion colon post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas crohn diseas definit hemicolectomi ibd ibd definit ibd term unmask ulcer coliti ulcer coliti definit partial subtot colectomi definit partial colectomi involv remov part colon may also refer subtot colectomi post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas ibd ibd definit ibd term unmask ulcer coliti total colectomi definit entir colon remov call total colectomi also known lane oper post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas ibd ibd definit ibd term unmask inflammatori bowel diseas ulcer coliti colectomi definit colectomi surgic procedur remov part colon colon also call larg intestin long tubelik organ end digest tract colectomi may necessari treat prevent diseas condit affect colon variou type colectomi oper total colectomi involv remov entir colon partial colectomi involv remov part colon may also call subtot colectomi hemicolectomi involv remov right left portion colon proctocolectomi involv remov colon rectum sourc post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti crohn crohn diseas ibd ibd definit ibd term unmask surgeri ulcer coliti extens total coliti pancol definit extens coliti extend along colon extens coliti affect whole colon may call total coliti pancol extens total coliti caus frequent diarrhoea blood mucu sometim pu may also sever abdomin cramp pain tenesmu weight loss milder flare up main symptom may diarrhoea looser stool without blood rare inflamm sever digest gase may get trap colon make swell known toxic megacolon caus high fever well pain tender abdomen essenti get treatment quickli condit may need surgeri post ibd superhero comment email blogthi share twitter share facebook share pinterest label ibdsuperhero awar blog coliti ibd ibd definit left side distal coliti definit type ulcer coliti inflamm start rectum continu left side colon also known distal descend colon symptom includ diarrhoea blood mucu pain left hand side abdomen urgenc tenesmu',\n",
       " 'appear differ monoclon antibodi develop copi follow part neuro immunolog exactli look turn rituximab patent expir us mean time phase iii patent profit invest surpass inconveni genentech invent new drug anticd well human rituximab chimer call ocrelizumab start whole process obvious got phase ii trial ocrelizumab ms result publish yet present ectrim meet show expect almost equal efficaci profil rituximab patient die ocrelizumab arm unexpect system inflammatori syndrom could chanc still hope larger studi assur chanc sever rheumatoid arthriti trial ocrelizumab termin overal benefit risk profil ocrelizumab favor ra realli mean patient die unexpectedli high ocrelizumab dose arm trial rituximab extraordinarili effect therapi use quit long time pretti safe never approv ms phase iii trial perform phase iii trial plan perform drug becom unprofit hand equal effect therapi test phase ii trial date show pretti less safe profil point stop diseas potenti profit compani overcom safeti issu guess wich one approv year terribl mani choic give patient throw away best one wait sever year terribl ms patient rituximab test small case seri myasthenia gravi neuromyel optica nmdar enceph lambert eaton myasthen syndrom cidp anti mag neuropathi diseas ms may rituximab phase iii trial sure case seri shown pretti good result need confirm order approv use routin bad commerci decis halt rituximab develop commerci diseas ms includ shame stori neuroimmunolog big pharma consortium neuroimmunolog depart perform expect phase iii trial bring rituximab back neuroimmunolog therapi meantim ocrelizumab ofatumumab treatment develop result posit welcom singl effect drug left behind advertis linda kind woman feet hit floor morn devil say oh crap repli quot follow user say thank agat jeani z jendi stillstannd sunshin',\n",
       " 'oxycodon somehow manag end realli high dose oxycodon coupl month first surgeri sure anyon knew tbh long stori short tri taper still went hell week first week worst skin constantli altern hot cold mad sensit prickli worst sens restless agit ever liter keep still get wink sleep night first week everyth becam bearabl apart skin sensit last month unfortun even year still slight residu sensit occasion annoy still better height doubt get skin issu x dose oxi obvious bugger skin possibl surgeri someth well damag nerv end perhap yeah think fun week honesti rememb pass perman dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'think patent end rituxan cheaper gener avail rebrand market ocrevu tri keep cash cow come pleas note post may arbitrarili alter moder may reflect origin content per mike wein admin mod team provid forewarn warn mention alter member post matter fix link remov link fix typo whatev repli quot follow user say thank howi jeani z jendi lazaru parsi stillstannd',\n",
       " 'last week panorama ran stori wonder hsct autolog haematopoiet stem cell transplant remark headlin bbc news site use http www bbc co uk news health also seen much nois made potenti ocrelizumab two thing though first hsct aggress treatment second ocrelizumab like go expens cladribin seem data suggest effect current nice treatment far cheaper ocrelizumab ever fight financi battl nh trust get treatment seem pretti safe cancer scare appear proven fals one know ms degen know smoulder lesion might caus damag far line know cognit impair burden effect even benign ms cladribin appear believ done read realli realli good altern much chose go recent frank result wonder limp gone brain fog clear eyesight improv first time long time feel normal one regret get offer treatment year ago know bad ms get patient awar get bad degener might happen even feel abl function late start treatment perhap never earli start treatment perhap diagnosi cladribin seem drug work seem drug cheap seem drug safe least worth risk chat neurologist chose campath tysabri felt better year',\n",
       " 'among opdivo ketruda tecentriq checkpoint inhibitor show effect nsclc patient opdivo ketruda littl effect egfr nsclc sub group patient howev tecentriq approv fda use egfr patient progress tki therapi three checkpoint inhibitor use sclc patient opdivo yervoy submit',\n",
       " 'eugina sorri hear mom diagnosi mom lung cancer non small cell adenocarcinoma st recurr took alimta carbo keytruda assum also chemo combo mom prescrib mom cancer cell pd l great candid keytruda cancer respond well like mani other prescrib treatment unfamiliar cancer center mom go suggest sin area live wa get second opinion anytim even mom get treatment mom get nd opinion initi diagnosi recurr treatment suggest standard care time feel reason nd opinion everyon differ choos whether seek nd opinion far support mom let eat want well balanc diet alway best chemo affect tast good sit well let vent need let know strong take battl pleas rememb question may support may need take care steff',\n",
       " 'octob report subject midwest cepac meet may icer assess compar clinic effect valu new therapi secondari progress multipl sclerosi spm treatment resist depress upcom report report set review public meet midwest compar effect public advisori council midwest cepac may spm review expect assess clinic effect valu siponimod novarti current undergo fda review approv decis expect march treatment resist depress review expect assess clinic effect valu esketamin janssen current undergo fda review approv decis expect may read icer announc',\n",
       " 'durvalumab month work develop plural efus thoracentisi procedur remov fluid fluid test cancer came back posit move stage luckili biomark test fluid came back egfr switch tagrisso tagrisso shut plueral effus fluid remov sinc start tagrisso coupl month ago told pharmacist pleural effus possibl side effect durvalumab start experienc sever short breath go see pulmanologist check fluid build around lung biomark test done would ask opinion target therapi determin biomark test right approach design goe genet code engin cancer btw thoracentisi procedur big deal seem littl scarri hear fluid build notic major improv breath remov check youtub video thoracentisi procedur underestim power prayer',\n",
       " 'problem diseas especi chronic diseas struggl diseas also face treatment diagnos multipl sclerosi ms hard face uncertainti ms also manag side effect incred potent oftentim riski medic wonder mani peopl diagnos forgo use diseas modifi therapi altogeth understand struggl howev possibl live full healthi life ms like take medicin fortun mani option year ago let take look sort good bad come whatev path choos copaxon begin noth well sometim copaxon glatiram acet came onto market copaxon inject medic shown reduc relaps rate shown reduct clinic disabl time side effect copaxon flu anxieti flush short breath swell inject site seriou symptom includ problem heart liver gastrointestin hematopoiet lymphat musculoskelet nervou respiratori urogenit system copaxon first market ms unfortun carri larg amount side effect less effect gener form market call glatopa mg dose glatiram acet interferon next drug come market interferon group also come inject form varianc medic usual matter choos differ size dosag fit lifestyl drug avonex interferon beta betaseron interferon beta b extavia interferon beta b plegridi peginterferon beta rebif interferon beta side effect come along med matter choos differ side effect stretch differ length time base upon dosag size interv set given medicin side effect interferon hepat injuri anaphylaxi allerg reaction depress suicid congest heart failur inject site necrosi reaction leukopenia thrombot microangiopathi flu like symptom complex drug induc lupu erythematosu peopl feel like flu get inject site reaction sever side effect unlik nevertheless drug risk must taken consider interferon around mani year mani choic peopl find interferon fit lifestyl also interferon effect copaxon reduc relaps rate clinic diseas progress see also multipl sclerosi care ms treatment center ms treatment medic ms symptom treatment might also like say someon ms zinbryta zinbryta daclizumab anoth inject administ month howev medic riski save peopl tri two medic without avail potenti side effect zinbryta allerg reaction seriou problem liver kidney heart swollen lymph gland fever rash swell face tongu throat troubl breath infect depress suicid inject medicin fair share side effect long time choos next page aubagio libbi experi ms medic aubagio aubagio medicin person experi fairli new market effect modifi diseas cours ms side effect seem scari possibl side effect aubagio headach nausea abnorm liver test hair loss diarrhea reduc white blood cell count numb tingl seriou skin problem breath problem new worsen high blood pressur libbi ms medic experi diagnos four medic choos either interferon copaxon terrifi commit took almost two year fail clinic trial final commit rebif tell straight never thought could get use give shot three time week eventu even got use one peopl never use auto injector part rebif good side effect becam predict would get flu symptom night inject remain relaps free five year five year pass start think oral medic emerg convers friend tri pill push curios decis transit rebif onto tecfidera tecfidera tecfidera newer medicin effect interferon main benefit fewer normal side effect peopl bonu worri needl fatigu bruis side effect tecfidera allerg reaction progress multifoc leukoencephalopathi pml rare brain infect flush stomach problem friend take tecfidera love side effect minim person experi tecfidera fun medic two year extrem flush sever stomach pain twice day everi day take also medicin new side effect might emerg time pass found tecfidera seem greatli affect menstrual cycl hormon regul first month began medicin first time life period chang flow becam heavi first cours month period dwindl noth sex drive went right along two year forc feed hope turn oompa loompa twice day pound extra bodi weight said eat menstrual cycl sex drive complet disappear quit decemb sinc bodi slowli crept back normal never tecfidera like said peopl love see also multipl sclerosi care ms treatment center ms treatment medic ms symptom treatment might also like cope loss appetit gilenya final bring gilenya favorit pill market highli effect prevent ms progress medic januari april year unfortun bodi react well forc stop take minut gilenya felt like take noth serious would take pill morn breakfast would go day often forgot even ms med great howev one unlucki one major white blood cell deplet point doctor took morn blood test forc stay insid hous away love germ virus week potenti side effect gilenya slow heart rate low white blood cell count pml macular edema posterior revers encephalopathi syndrom pre breath problem liver problem higher blood pressur basal cell carcinoma medicin horizon mani better safeti profil even effect user friendli know risk high tough choic need made left liter pick poison believ alway way believ mani mani wonder opportun horizon choic hope stay strong peopl',\n",
       " 'success anti cd monoclon antibodi put focu cd b cell could mechan action deplet cd cell ocrelizumab deplet cd cell multipl sclerosi patient http www mdpi com ocrelizumab human monoclon anti cd antibodi shown pronounc effect reduct diseas activ multipl sclerosi ms patient recent approv treatment patient relaps ms rm primari progress ms ppm cd mainli express b cell subset cell cd cd cell also express cd cd cell known highli activ cell popul blood ms patient analyz multicolor flow cytometri two week treatment ocrelizumab regard phenotyp peripher blood mononuclear cell cd express cd cell found blood sampl ms patient account cd lymphocyt constitut signific proport cd cell cd cd cell cd cd b cell effect deplet two week singl administr mg ocrelizumab result demonstr treatment ocrelizumab exclus target b cell also cd cell account substanti amount cd express cell thu specul efficaci ocrelizumab might also mediat deplet cd express cell view full text',\n",
       " 'helpingmom happi hear mom cancer stabl happi danc uncommon peopl need take period treatment break immunotherapi mom differ break past year keytruda effect day system keytruda may still work mean immun system still work overtim take break session usual big deal nice give bodi break happi new year',\n",
       " 'insur pay humira cost month bless sure go see gi next wednesday thought yr old work life two employ avascular necrosi alreadi got hip replac past decemb cd joint problem seem marriag made heaven disabl job good ltd go discuss doc right point energi much anyth focu think abil compromis guess question get right med right dose ok tri get high stress environ attempt save question forum',\n",
       " 'older biolog humira remicad cheapest biolog insur tri get first reason fact biosimilar closest thing gener biolog remicad e inflectra also humira newer biolog like entyvio xeljanz stelara two three time cost remi humira justifi reason might prefer xeljanz safer simpl pill etc moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa never realli appreci got gone toilet paper good exampl nealzi regular member join apr post post pm gmt week dosag remicad cost insur ml yet gotten approv doubl dose move week gi decid switch xeljanz actual work wherea remicad zippo estim cost insur day suppli xeljanz mg pill bottl told compar appl appl timefram week k xeljanz vs remicad sure resist fact take month updat approv overal formulari someth get fda approv formulari whole pre author appeal appeal process fortun pfizer interim servic hold free believ month suppli go approv given clindamycin staph infect stye kick whole uc fun c diff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzi q regular member join sep post post pm gmt bc bs maryland also massachusett approv xeljanz appeal handl quickli although approv one pill day instead four doctor offic realli top thing take longer week recollect downsid follow directli doc offic also call insur make sure went spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week curiou crapper regular member join may post post pm gmt remicad cash price approxim per mg bottl could extrapol whatev dosag get factor cost infus get hospit set cost usual lot clinic home infus servic cash price list xeljanz monthli suppli mg day would ra patient get cash price uc would doubl around k month cash price though depend insur provid decid bill cover thing could make differ feelinglesscrappi new member join oct post post pm gmt bcb doctor get approv bcb approv first dr explain current qualiti life approv nealzi regular member join apr post post gmt help respons thank let know bcb approv process differ side fda approv week pre author process bit longer readi taper mg pred monday st time sinc last year hope continu sever pancol patient given clindamycin staph infect stye kick whole uc fun c diff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzi q regular member join sep post post gmt blue cross blue shield maryland massachusett approv xeljanz us appeal whole process fast less two week believ primarili think doctor offic knew feel free call doc offic also insur directli make sure realli submit correct specialti pharmaci spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week nealzi regular member join apr post post gmt suzi q long spous prednison see long took get wonder mg sinc april gi direct drop everi day far good energi touch slow return eat still hook current monday go day mg day assum xeljanz take uc get stuck whatev level get stuck see spous experi think either need extend taper mayb suzi q spous pred high level year given clindamycin staph infect stye kick whole uc fun c diff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred suzi q regular member join sep post post pm gmt realli glad hear xeljanz may work steroid almost constantli time diagnos even though full remiss octob xeljanz lesson process gi understand prednison taper especi long term start feel quit ill oppos usual prednison lousi feel mg short breath memori issu usual also neuropathi seem get wors point saw endocrinologist said taper correctli may take longer feel sick went back slowli taper mg everi four week point went onto hydrocortison depend toler feel lousi associ worri get mg may want go slower peopl get low everi day see feel alway go back level feel lousi adjust thing go spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week nealzi regular member join apr post post pm gmt great advic one cut mg pred pill mani way dot powder thank felt short breath occasion heart palpit like one week sluggish glad ask year wow imagin pray uc symptom stay bay taper cautious optimist thank share suzi q given clindamycin staph infect stye kick whole uc fun c diff twice flagyl vancomycin mg fix sever pancol confirm mesalamin gm uceri mg x day ok first flare pred mg stepdown good remicad treatment done good unabl lower beyond mg pred start xeljanz mg twice day tri taper pred andrina veteran member join aug post post pm gmt stewiecat said start notic improv coupl week xeljanz doubl dose x mg twice per day seem dose guidelin uc interest take x mg spoke pharmacist said dose uc guess outcom glad fewer pill swallow uc sinc suzi q regular member join sep post post pm gmt nealzi mg prednison tablet end need slowli taper spous diagnos uc remicad humira entyvio work thing work prednison march start xeljanz remiss within month work endocrinologist get prednison neurologist deal neuropathi feet appear prednison taper took year complet get steroid taper mg everi week feelinglesscrappi new member join oct post post pm gmt think prednison taper depend person length time prednison year last mg done month felt fine nealzi regular member join apr post post gmt feelinglesscrappi good know drop mg start tomorrow path month day roughli taper mg complet xeljanz hold mg',\n",
       " 'anyon know lemtrada effect alreadi lot lesion probabl ms long time got diagnos rrm last year sudden onset symptom seem like probabl ms quit year keep read lemtrada work earli fifti realli would appreci guidanc drug could move one cladribin quit new even harder find much realli confus',\n",
       " 'good news brain surgeri recoveri come along realli well even approv start drive jason take drive practic weekend howev life metastat lung cancer continu keep toe seemingli endless doctor appoint plan target radiat area surround remov cerebellum also move new target medicin lorlatinib henc endless doctor appoint penultim appoint entrectinib trial current go washout period prepar expand access protocol trial lorlatinib may recal crizotinib washout withdraw power med remark pain everi muscl bodi ach even muscl know monday radiat plan appoint radiat session everi day begin follow week main side effect fatigu even fatigu surgeri yet due begin eap lorlatinib tuesday wednesday side effect come along one fatigu oh get wrong immens grate treatment option grate anoth target med switch anoth trial one grate well enough withstand treatment immens grate time famili admit lot deal know everi day treatment anoth day get live grate day almost overwhelm grate support commun support go lean next week thank much folk brought meal famili recoveri comfort help share particularli ador theme meal receiv great work jenni tast great news novemb lung cancer awar month ro der rais money research treatment rare cancer start fundrais back th birthday rais reviv hope hit link donat http www supportalcf org ro toritomalia also make sure get vote tuesday natur citizen take vote serious serious fact vote absente mail ballot hit road surgeri know kind shape would novemb way go miss vote post tori tomalia pm email blogthi share twitter share facebook share pinterest label advocaci brain metastasi brain surgeri clinic trial commun entrectinib lorlatinib ro stage iv stereotact radiosurgeri comment unknown said continu amaz blog tori god bless may continu give strength fight horrid diseas pm anna brogan knight said send love energi pm anonym said glad hear surgeri smooth loratinib got approv past friday check doctor whether wash period would minim best wish famili pm dearmaizi said grace persever face challeng inspir thank share experi pm paul said comment remov blog administr monika davar said courag stamina face battl inspir lab work ro even frustrat time research stori journey fight realli keep us go work thank share best good recoveri shaadi foral said use inform thank share may read',\n",
       " 'ocrevu matern grandmoth name old countri coincid',\n",
       " 'bad news multipl sclerosi drugmak coverag get narrow even wors news spread best worst cover med get wider formulari show big drop overal ms coverag sank last year accord number crunch bernstein analyst formulari exclus also gone track commerci plan use strategi lead exclus exposur commerci cover live analyst ronni gal wrote wednesday note client gap have not expand rule see chang prescript trend parallel coverag gal wrote except note bottom feeder aubagio oral therapi sanofi seem quit well despit poor coverag mark teva blockbust copaxon lead pack term coverag follow biogen tecfidera avonex payer pressur come gal predict whenev addit product get market see round price correct figur addit product certainli way roch one close watch prospect ocrelizumab come pipelin gal forecast last summer med would increas intermedi term formulari pressur expand scope payer avail choic read',\n",
       " 'definit apolog shakespear perplex stage crohn norm becom go day w singl bm total opposit suffer year mainli start add gastric regul could bm day regul caus lower right quadrant cramp sometim sever stab pain took remicad dose yesterday discuss issu doctor gave remi ask whether get cramp constip said perfectli fine cramp hit bm explain constip caus blood clot got recent recommend continu regul mention gi decid last time saw start slower taper budesonid reach mg pace mg cortiment budesonid act colon steroid gener almost year steroid depend get spasmod sooth pain becom constip wherea take regul bm pain hit thing continu like complain problem almost three month overshadow dental abscess clear till gerd perian fistula cd ib persist mouth ulcer fissur ___________________ med remicad cortiment nexium imuran colifoam monthli b inj pred mg oct till jan previou mesalamin tablet supp fail azathioprin gener methotrex',\n",
       " 'agre minim risk cancer mole biolog newer gut specif biolog like entyvio stelara may affect mole specul may want discuss gi dermatologist oncologist keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara sulfasalazin rotat antibiot',\n",
       " 'fact first comment keynot phase iii trial compar pembrolizumab pembro placebo plu pemetrex carboplatin first line therapi metastat nsclc n random patient stratifi base pd l tumor proport score median follow month median overal surviv reach pembro arm vs month control arm compar patient control arm patient receiv pembro less like die overal high pd l score group less like die p median time diseas progress month control arm patient pembro chemo p present keynot leena gandhi md phd director thorac medic oncolog laura isaac perlmutt cancer center nyu langon health rational studi see io might add chemo rather see chemotherapi immunogen add expand benefit io monotherapi patient might high pd l express inde see alic shaw md phd director center thorac cancer massachusett gener hospit cancer center landmark studi establish triplet new standard care advanc non squamou lung cancer improv os addit pembro standard chemo across patient regardless pd l statu realli strike checkmat nivolumab nivo plu ipilimumab ipi vs platinum doublet chemotherapi first line treatment advanc nsclc note studi amend includ co primari endpoint base propos new biomark tumor mutat burden tmb high tmb defin greater mutat per megabas mut mb interim report relat patient tmb statu avail n random phase iii trial patient identifi high tmb receiv nivo ipi receiv standard chemo minimum follow month io io patient high tmb less like diseas progress compar chemo patient p patient tmb mut mb show differ benefit treatment arm durat respons one year vs favor io io treatment group p valu given present checkmat matthew hellmann md memori sloan ketter cancer center overal sens studi opportun introduc two new standard care patient nsclc first studi demonstr clinic valu nivo plu ipi treatment option patient tmb high durabl benefit spare st line chemo therebi preserv effect nd line option second studi valid tmb import independ biomark routin test treatment na advanc nsclc patient texa talk comment investor event sponsor bloomberg intellig day prior aacr confer john heymach chair thorac cancer program md anderson cancer center specul outcom two trial regard keynot alreadi wide use regimen keynot g result report realli surpris hazard ratio pf result look practic chang result look practic confirm result g power surviv confirm pf would solidifi regimen front line hr report today regard use front line pd l high express commun oncologist less experi nivo ipi outsid melanoma ye manag chemotherapi side effect good chanc patient prefer io first delay chemo later uneas io io checkmat versu pembro easi give question high pd l express qualifi io io pembro monotherapi peopl go give battl regard use tmb treatment manag decis cost major issu use tmb approv interest see lot differ assay produc tmb mani center smaller panel includ typic run plu gene mayb enough right get good tmb data mean center go chang use foundat medicin signific potenti barrier adopt view street quick q patrick river vice presid research aquillo capit obr result today strike find river hr kn realli impress strength phase ii data much smaller group patient enough get regimen approv first line non squamou nsclc result substanti go regimen broad number patient surpris abl demonstr benefit egfr alk mutant patient well obr result today realli suggest winner would need see yet unseen would true differenti two pd drug river believ nivolumab pembrolizumab appreci differ term actual drug properti test differ clinic set differ patient select strategi like given rise differ result observ way truli differenti would test head head know go happen one question answer may critic move forward much benefit observ pd plu chemo look tmb stratif ipi plu nivo vs chemo obr given scienc background river came bench tmb vs pd l stain opinion util river independ variabl play import role may repres differ biolog principl pd l marker inflamm tmb surrog neoantigen burden surpris show correl one anoth independ predict likelihood respons differ popul examin key distinct pd l stain cheaper faster well integr routin patholog current util sever year next gen sequenc panel give tmb read routin clinic practic obr data swamp conceiv reason pursu next gen anti pd river believ reason pursu addit gener pd monoval antibodi still need explor addit combin reveal new element biolog mani environment factor tumor properli address pd ctla chemotherapi alon bi specif antibodi bind pd l one arm anoth target anoth arm may also yet reveal interest new approach overlap current pd use case final word pepsi vs coke dr hellman result two studi zero sum huge step forward patient anyway look two posit phase iii studi differ complimentari messag use anti pd therapi first line set huge advanc although new question answer make best decis first line set great question grappl realli pleas data togeth neil canavan soleburi trout',\n",
       " 'home ms inform public motiv motiv summer fall health well shingl overview vaccin safeti health well shingl overview vaccin safeti live attenu vaccin may issu individu ms compil susan well courtney review jack burk md shingl overview shingl caus reactiv varicella zoster viru vzv viru caus varicella chickenpox usual occur decad initi chickenpox infect reactiv viru caus pain rash cluster fluid fill blister shingl contagi blister dri viru fill fluid transmit chickenpox someon previous expos viru come close contact open rash symptom shingl includ fever headach chill upset stomach last week month even year postherpet neuralgia phn common complic shingl caus chronic sometim excruci pain area rash occur chronic debilit pain vari mild sever disrupt one sleep mood activ daili live phn reduc one qualiti life potenti lead social withdraw depress even suicid report scar anoth potenti long term complic shingl rare case shingl infect lead pneumonia hear problem blind brain inflamm enceph death peopl one episod shingl second third episod possibl older individu ms risk shingl complic great without ms individu ms take immunosuppress medic associ risk becom even greater everyon risk shingl greatli increas get older particularli age risk develop phn caus continu chronic pain complic shingl increas age likelihood experienc longer last sever pain phn addit individu compromis suppress immun system also like experi complic shingl shingl vaccin accord center diseas control prevent cdc vaccin shingl also known herp zoster zoster recommend use peopl year older reduc risk shingl includ everyon age group contraind well peopl previou episod shingl chronic medic condit specif chronic medic condit list cdc includ kidney failur diabet rheumatoid arthriti chronic pulmonari diseas shingl vaccin approv food drug administr fda market brand name zostavax shingl vaccin given one dose subcutan skin arm common side effect vaccin includ red sore swell itch shot site headach receiv vaccin individu may around infant young children pregnant women peopl weaken immun system report made someon get chickenpox anoth person receiv shingl vaccin peopl may develop chickenpox like rash near inject site occur simpli precaut rash cover disappear shingl vaccin contain thimeros preserv contain mercuri sometim use vaccin seriou advers event seen shingl vaccin test approxim peopl without ms age older vaccin appear effect least six year may last longer older individu may get vaccin age appear effect peopl year studi found shingl vaccin reduc risk shingl percent older adult reduc risk phn percent also reduc sever durat pain associ phn safeti shingl vaccin difficult judg individu ms current data support use reassur complet vaccin fulli investig ms shingl vaccin thoroughli investig ill includ peopl whose immun system may compromis diseas drug use treat diseas shingl vaccin live attenu vaccin issu individu ms mani vaccin use virus inactiv e kill viru chanc infect anyon shingl vaccin contain live virus attenu mean strength reduc point infect someon healthi uncompromis immun system mani individu variou health condit larg number individu ms take medic may modul suppress immun system live viru vaccin may conceiv abl infect someon whose immun system fulli function result either ill medic given treat ill addit fda approv long term diseas modifi therapi ms larg dose extend use steroid frequent prescrib treat ms relaps also suppress immun system less common treatment consid evalu safeti shingl vaccin includ experiment treatment ms studi clinic trial ms patient label treatment methotrex imuran azathioprin hematopoiet stem cell transplanta tion hsct antivir medic guidelin shingl vaccin safeti accord extens report advisori committe immun practic harpaz r et al differ treatment need consid shingl vaccin may consid safe individu report origin nation center immun respiratori diseas divis viral diseas part center diseas control prevent follow gener guidelin remind individu strongli advis consult physician safeti shingl vaccin doctor need look person situat case case basi individu get shingl vaccin wait includ anyon ever life threaten sever allerg reaction gelatin antibiot neomycin anoth compon shingl vaccin individu weaken immun system hiv aid diseas affect immun system someon take medic weaken immun system peopl immunosuppress therapi includ high dose corticosteroid mg per day prednison equival last two week wait least one month discontinu therapi anyon moder sever acut ill includ anyon temperatur degre fahrenheit higher usual wait recov get vaccin individu may receiv vaccin includ anyon minor acut ill cold may vaccin peopl receiv short term corticosteroid therapi less two week low moder dose less mg per day prednison equival topic given via nasal skin inhal administr long term altern day treatment low moder dose short act system corticosteroid consid suppress immun system enough caus concern vaccin safeti therapi low dose methotrex equal less mg kg week azathioprin equal less mg kg day consid suppress immun system enough caus concern vaccin safeti special group circumst peopl previous shingl may vaccin although need wait rash clear peopl normal immun system anticip immunosuppress pleas see next bullet point without prior shingl vaccin receiv vaccin soon possibl immun intact vaccin administ least day initi immunosuppress therapi although expert advis wait one month accord msaa chief medic offic jack burk md ms drug consid immunosuppress consid immunomodul affect immun system differ nonetheless recommend patient consult doctor regard cdc recommend exampl recommend gilenya fingolimod immun day start gilenya regard individu receiv recombin human immun mediat immun modul especi antitumor necrosi factor agent adalimumab infliximab etanercept safeti efficaci shingl vaccin administ concurr unknown possibl administ vaccin initi therapi patient immun statu assess physician determin relev risk benefit otherwis vaccin defer least one month stop medic categori would includ ms medic tysabri [natalizumab] well mani experiment therapi present clinic trial lemtrada [alemtuzumab formerli campath] daclizumab [also known zenapax ] rituxan [rituximab] ocrelizumab ofatumumab [also known arzerra ] individu take one drug advis talk doctor assess risk benefit shingl vaccin conjunct type diseas modifi therapi peopl receiv blood product includ antibodi contain blood product may receiv shingl vaccin time list includ intraven immun globulin ivig plasma exchang would also fall categori specifi report patient receiv type treatment advis consult physician get shingl vaccin experi individu undergo hematopoiet stem cell transplant hsct limit consid case case basi patient immun statu assess physician determin relev risk benefit shingl vaccin approv administ least two year month transplant antivir medic may interfer replic live viru vaccin anyon take zovirax acyclovir famvir famciclovir valtrex valacyclovir regularli discontinu medic least hour administr shingl vaccin possibl medic use least day vaccin addit note shingl vaccin accord cdc shingl vaccin may given simultan vaccin includ flu vaccin vaccin must administ use separ syring differ inject site vaccin administ time shingl vaccin may still given time vaccin provid inactiv vaccin receiv anoth live attenu vaccin addit shingl vaccin time patient need wait least four week shingl vaccin receiv differ live attenu vaccin shingl vaccin recommend anyon receiv varicella chickenpox vaccin howev chickenpox vaccin becom avail unit state virtual peopl receiv vaccin chickenpox young receiv shingl vaccin reason cdc state healthcar provid need inquir one varicella vaccin histori sinc virtual person recommend age group least next decad receiv chickenpox vaccin addit cdc note anyon older without contraind get shingl vaccin regardless whether rememb chickenpox studi show percent american age chickenpox patient need ask histori chickenpox blood test antibodi insur coverag resourc follow inform provid cdc websit www cdc gov shingl vaccin avail pharmaci doctor offic find local facil offer vaccin pleas visit www zostavax com medicar part plan cover shingl vaccin cost share vaccin vari medicar part b cover shingl vaccin medicaid may may cover vaccin privat health insur plan cover vaccin peopl age cover peopl age merck vaccin patient assist program provid free vaccin elig adult usual individu without insur inform pleas visit www merck com merckhelp vaccin home html call vaccin inform statement avail spanish languag pleas see www immun org vi interest individu may also go cdc websit inform shingl visit www cdc gov vaccin vpd vac shingl default htm inform vaccin ms pleas refer msaa onlin articl vaccin safeti ms news msaa inform addit msaa websit individu may call msaa inform ms treatment question msaa client servic depart may email msquestion mymsaa org refer much inform articl obtain center diseas control cdc prevent harpaz r et al recommend advisori committe immun practic acip nation center immun respiratori diseas center diseas control prevent back',\n",
       " 'ami tsang andrew pollack novarti bolster portfolio multipl sclerosi treatment friday agre buy experiment drug glaxosmithklin billion compani said novarti swiss pharmaceut giant acquir right year use drug ofatumumab treat cancer sell name arzerra part broader swap asset complet march novarti took glaxo cancer drug glaxo took much novarti vaccin busi deal announc friday give novarti remain right ofatumumab develop treat relaps remit multipl sclerosi autoimmun condit right one ownership would avoid complic could aris two compani sell drug differ use deal also bolster portfolio drug novarti develop multipl sclerosi center around blockbust pill gilenya novarti pay million upfront glaxo anoth million late stage clinic trial start novarti would make payment million top depend whether develop target reach compani also pay royalti percent glaxo futur net sale drug novarti pleas reinforc commit neurosci add excit new treatment strong ms portfolio david epstein divis head novarti pharmaceut said news releas addit gilenya novarti sell multipl sclerosi drug call extavia recent began market gener version teva copaxon one wide use drug diseas also drug develop gilenya could lose patent protect start fill loss could anoth reason novarti want new drug market multipl sclerosi drug crowd could limit sale new drug like ofatumumab could moreov ofatumumab readi enter late stage clinic trial put coupl year behind ocrelizumab similar drug develop roch drug deplet b cell white blood cell part immun system b cell necessari fight infect go awri contribut autoimmun diseas like multipl sclerosi lymphoma drug bind molecul surfac b cell known cd roch big sell cancer drug rituxan rituxan approv multipl sclerosi approv treat rheumatoid arthriti anoth autoimmun diseas ofatumumab type protein call monoclon antibodi develop initi genmab danish biotechnolog compani receiv royalti sale david redfern chief strategi offic glaxo said news releas sale would allow compani focu core area includ h v oncolog vaccin pleas complet transact divest remain right ofatumumab crystal signific addit valu g k sharehold mr redfern said deal expect complet end year',\n",
       " 'aabreu took inject form cladribin label ms treatment peopl bart london develop protocol follow got neuro prescrib drug found special pharmaci sacramento would sell sub q inject home easi toler abl miss work day minim blood monitor requir stop ms pretti sure slow lot year sinc start ms non relaps type easi tell also take simvastatin potenti neuroprotect mg day biotin realli wish could taken back much nerv damag fact cladribin small molecul get brain lymph node slowli deplet b cell make think drug best chanc slow progress ms bart websit lot info cladribin http multipl sclerosi research blogspot com cladribin ms html took fair amount effort get go peopl comfort let self inject iv cancer drug home send pm want info',\n",
       " 'thank wk preach sever year may borrow cynic thank big fan wrote blog diagnos admittedli slack conveni recipi treatment cure year also know rituxan ocrevu controversi ye ocrevu damn would bet donut dollar cure right need figur hey make money wk mad moment',\n",
       " 'link news stori last week may interest peopl uk link beneath item take origin stori pleas note ms trust write origin item endors content claim made keep date latest news view research multipl sclerosi sign open door free newslett regular email alert cognit affect abil work peopl ms employ reduc hour like show sign cognit symptom accord uk studi sourc ms news today ms trust link think memori problem gender differ diagnosi review trend diagnosi found proport women men diagnos grow women averag diagnos five year younger primari progress ms slightli men women diagnos averag age diagnosi around sourc ms news today ms trust link diagnosi rare gilenya side effect warn fda us drug regul issu warn peopl stop gilenya fingolimod may experi wors symptom start treatment effect describ rare recommend stop drug requir monitor sourc naton ms societi usa sourc medpag today ms trust link gilenya fingolimod fampyra turn scotland scottish medicin consortium smc turn fampyra fampridin second time sourc ms news today ms trust link fampyra fampridin',\n",
       " 'okay look everyon list awesom list get complet hard agre everyth everyon said firstli come two sit repli drive nut today much like erash annoy symptom one bother present moment specif everi singl morn drive nut go stiff throughout entir bodi torso leg sometim slide right chair without abl stop realli stink past sever infus ocrevu seem control sever month much much better past infus earli januari though effect specif ask know secondli athlet well coordin person entir life ms robb drive nut tri take someth simpl straw get hand put straw hole cup drink water hand simpli respond mind tell quit often truli hate enough go go back work face awesom love everi one fanci',\n",
       " 'jose e mart nez rodr guez particip attend nd congress european committe treatment research multipl sclerosi ectrim st annual confer rehabilit ms london septemb th th congress highlight last updat news ms field regard scientif clinic research present sever parallel session describ recent advanc neuroprotect neurodegener repair remyelin neuromyel optica neuroimmunolog symptomat therapi new techniqu neuroimag ci prognosi ms cognit comorbid diseas rehabilit sever present focus area innat immun system increas promin role myeloid cell antigen present cell effector cell neuroinflamm recogn benefici effect block mac fibrin receptor shown experiment murin model support involv innat immun system ms open potenti therapeut pathway futur new advanc present immunolog lymphocyt migrat cn particip neuroinflamm regard involv integrin alpha dicam alcam claudin work assess sever aspect cortic patholog ms studi base intrathec inflamm new anim model cortic lesion area gut food ms also extens cover studi support link gut microbiota immun regul research remyelin oligodendrocyt go describ potenti pathway favor myelin repair oligodendrocyt regener clinic side ectrim provid addit evid diseas modifi drug dmd start earli possibl confid diagnosi made order delay irrevers disabl differ argument support escal versu induct therapi sever studi present assess convent new risk model predict diseas evolut innov concept therapeut inertia brilliantli introduc dr g saposnik failur escal therapi evid diseas activ dmd treat patient compel ms physician assert upcom chang field ms treatment research environment factor continu evalu regard influenc herpesviru smoke obes pregnanc vitamin ms search biomark ms assess risk stratif ongo highlight use serum neurofila light chain level promis biomark assess diseas activ disabl result sever clinic trial neuroprotect amilorid lipoid acid fluoxetin also present variabl result special mention goe neg result phase b clinic trial present dr cadavid evalu opicinumab anti lingo relaps ms even though primari end point studi reach subanalysi result encourag investig keep go area remyelin studi b cell implic ms hot topic ectrim year import number present describ sever aspect b cell biolog ms huge swedish experi label use rituximab present dr f piehl retrospect compar anti cd monoclon antibodi fingolimod natalizumab await final public clinic trial perform ocrelizumab rrm ppm new data present ectrim describ safeti profil drug support posit clinic radiolog efficaci ms patient meanwhil studi anti cd deplet therapi ofatumumab move forward phase iii dr l kappo present much expect preliminari result phase iii studi siponimod secondari progress ms describ effect risk reduct three month confirm disabl progress subanalysi evalu result accord clinic activ edss time diseas evolut moreov evid present support clinic radiolog efficaci upcom new drug cladribin daclizumab special attent deserv first present ectrim ean clinic practic guidelin pharmacolog manag ms joint effort societi guidelin await public introduc dr susana otero romero use evid base recommend follow grade methodolog guidelin establish recommend consensu statement concern dmd manag ms patient concern rais among audienc definit qualifi center ms treatment present gener recommend base infrastructur avail assess treat patient capabl deal potenti side effect requir clarif aspect aim guidelin fulli implement routin clinic ms practic europ never ms field got mani differ drug avail clinic use better measur outcom predict prevent futur diseas although still far comprehens view better understand ms develop progress studi sponsor pharmaceut industri paramount battl ms howev want fulli defeat diseas futur nation intern collabor addit need answer question industri never go address dr hutchinson remain us clinic highlight present result clinic trial ms shown us last year learn failur even abl properli manag success best ms commun thank collabor effort huge amount differ profession specialti ectrim one event feel inflect point understand manag ms reach jose e mart nez rodr guez md phd associ professor neurolog universitat aut noma de barcelona ms unit neurolog depart hospit del mar imim passeig mar tim barcelona email jmartinezr hospitaldelmar cat disclosur jose e mart nez rodr guez receiv academ research grant merck serono biogen travel support compens lectur particip advisori board bayer roch merck serono',\n",
       " 'del gefitinib exhibit increas flexibl compar afatinib increas flexibl observ gefitinib gener aris noncoval natur interact kd contrast afatinib make coval bond cy kd restrict mobil due increas flexibl gefitinib water mediat halogen bond interact stabl result loos bound trap water molecul contrast erlotinib lack halogen atom reduc interact result higher flexibl one loos bound water molecul resid time ns complex egfr wt egfr l r egfr',\n",
       " 'thankyou word true day first lucenti inject keep think work drive crazi scotland would mean lucenti made differ would tri eyelea read one hope caught time week total distort appear get inject sight deterior went normal optician soon happen refer hospit wait week get seen consult inject week later would day clinic full sinc inject notic chang eye fine',\n",
       " 'hi carolin great hear anoth aussi region vic coupl hour melbourn thought would take long also impress ms neuro pick mayb see new one come week get done mark urgent im definit follow info ocrevu reason someth follow tysabri becom jcv hope get asap wonder drug thank good wish actual bounc back brilliantli time steroid infus finish pretti much back realli realli want keep way long possibl',\n",
       " 'sarcasm intend work st bartholomew hospit centr cancer research deal complic hsct weekli basi rang graft vs host diseas pml leukoencephalopathi develop new autoimmun disord idiosyncrat se blind pulmonari emboli guillain barr syndrom hsct appeal clinician clinician use also know manag complic lui high dose chemo follow autolog haematopoiet sct treatment pcnsl hsct provid good outcom atrophi better say natalizumab sheffield group complet studi hsct versu tecfidera gilenya tysabri nov mayb report next aan interest see result',\n",
       " 'glad vision respond fairli well lucenti similar place requir monthli inject eylea tri increas interv everi five week work happi holiday',\n",
       " 'diagnos earli may neurologist suggest either lemtrada tecfidera also mention ocrelizumab said would avail next year effect think shock diagnosi start first full blown relaps get opt tecfidera start day said would like swap ocrelizumab next year hope goe plan especi sinc discov site read mani posit comment lemtrada realis everyth within nh take long time funni told stress make ms wors yet stress suffer worri time take get treatment',\n",
       " 'pd crp low flare soon start reduc med prior surgeri start rise sed rate entir time alway elev alway pancol backwash ileu alway thought uc even colectomi bioposi surgeon well known crohn surgeon crohn surgic procedur name said pretti confid uc remov colon keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'mlgilber would assum make suggest let continu choos appoint discuss briefli talk phone far definit consid switch neurologist alreadi obvious respect decis definit switch get would switch seem good argument neuro bring major long term side effect concern ocrevu never told',\n",
       " 'correl made time taken becom resist patient receiv st nd rd gener tki exampl patient becam resist tarceva month would expect similar time frame patient exhibit resist take afatinib tagrisso thank jacki',\n",
       " 'ikhlaq standard treatment brain metastas radiat high rate success tend provid symptom relief faster system therapi chemo target therapi although alectinib long track record success radiat option make choic would import consid current level symptom brain met whether symptom get wors rel quickli signific burdensom symptom fast rate progress symptom would tend tilt balanc favor radiat met less symptomat reason tri alectinib follow scan show effect symptom start get wors radiat would still option alimta stop due side effect diseas progress could tri point like brain met brought control alimta use treat diseas rest bodi jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'cora interest thing articl studi evid lucenti eye inject may effect laser trial peopl found',\n",
       " 'greater patient select may need first line nivolumab improv progress free surviv chemotherapi advanc lung cancer checkmat trial gave neg result broad group patient express pd l tumour cell find present esmo congress copenhagen nivolumab repres standard care second line treatment advanc non small cell lung cancer nsclc improv overal surviv compar docetaxel phase iii trial patient said lead author dr mark socinski execut medic director florida hospit cancer institut us first line set nivolumab show promis respons rate phase trial advanc nsclc patient greater pd l express tumour cell continu phase iii checkmat trial investig efficaci first line treatment nivolumab compar platinum base doublet chemotherapi patient advanc nsclc pd l posit tumour defin present tumour cell patient egfr activ mutat alk transloc sensit target therapi exclud primari endpoint progress free surviv assess independ radiolog review committe patient pd l tumour cell total patient randomis nivolumab chemotherapi patient progress chemotherapi could crossov nivolumab second line treatment patient greater pd l express progress free surviv month nivolumab month chemotherapi hazard ratio [hr] confid interv [ci] p overal surviv month nivolumab versu month chemotherapi hr ci among treat patient seriou treatment relat advers event nivolumab chemotherapi respect new safeti signal nivolumab less toxic chemotherapi said socinski number possibl reason disappoint progress free surviv result ad regard overal surviv high rate crossov immunotherapi chemotherapi arm overal surviv chemotherapi arm better histor standard could due fact greater proport women asian patient conduct analys evalu result platinum base chemotherapi standard first line treatment make patient live longer palliat symptom said socinski go replac immunotherapi need confid identifi patient deriv greater benefit socinski conclud combin immunotherapi may increas proport patient benefit first line phase iii checkmat trial investig treatment nivolumab plu ipilimumab first line set rel standard chemotherapi comment result professor johan vansteenkist professor medicin cathol univers leuven chief oncolog physician unit respiratori oncolog univers hospit ku leuven belgium said nivolumab improv progress free surviv chemotherapi studi view reason trial includ broad rang patient low pd l express threshold greater standard first line treatment platinum doublet chemotherapi give progress free surviv six month beat may requir select receiv drug continu research need use pd l biomark select patient treatment nivolumab addit phase studi suggest combin immunotherapi improv respons rate outcom expens increas toxic compar singl agent immunotherapi nsclc import investig strategi sourc esmo',\n",
       " 'imuran pretti safe drug peopl mp sister med coupl year zero side effect may get nausea week two first start normal goe away vast major peopl rarer seriou side effect blood test detect problem would strongli recommend go imuran take month start work slow act drug scd diet work would take amaz testimoni pinch salt discourag seen lot peopl crohn uc forum help know unless tri mean give go month see goe consid tri ibd aid diet updat version scd slightli less restrict www ncbi nlm nih gov pmc articl pmc high drop rate one stuck diet everybodi saw improv symptom although nobodi appear go complet remiss diet dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'canada rate ibd would highish mayb statist pancol uc sinc sept averag bm day time respons remiss therapi salofalk asa enema oral g clinic trial drug fail therapi entyvio anti madcam antibodi mg inject week studi drug remicad ml nicotin patch mg imuran mg',\n",
       " 'fail remicad cimzia humira entivyo sigh insur cover stelara experiment unsubstanti sure experiment fda approv stelara last year crohn appeal decis probabl good chanc win appeal get gi offic involv appeal also state insur regul keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri total hip replac thank prednison current condit chronic pouchiti bad thought would current med stelara',\n",
       " 'hi ub tall lb sound overweight feel slightli overweight lb weight stay steadi sinc last surgeri never natur sylph come short irish peasant stock look like short irish peasant stock bother diet think occasion lose live thought calori count drop thought went obsess food calori realli underweight year ago due crohn cours think larg part scare go back eat disorderli way would starv lose weight like feel eat enough feel full stuf decent full enough keep go sever hour without feel hungri think food sorri horribl obviou question consid gym lose weight walk lot give good bodi found becam skinni fat much els actual well defin bodi flat stomach etc either need right gene hit gym spend lot time work dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start notsosicklygirl forum moder join dec post post pm gmt thank hear much better know anyth stelara know feel well eat lot suffer long perhap indulg bit activ level diet sound good though fact gain strang pound lot gain short time thyroid check gone gp test time went normal weight type weight prednison moder uc current med step j pouch surgeri complet step complet step complet sickli uc free give man fish eat day teach man fish eat lifetim give man religion die pray fish',\n",
       " 'updat first treatment ocrevu morn last hour side effect metal tast mouth lump throat alert nurs slow current treatment side effect clear around minut feel went well look forward second cours two week everi six month disclaim everybodi differ react differ diseas modifi drug pleas seek advic neurologist ms specialist',\n",
       " 'myopic cnv haemorrhag imag courtesi adrian koh md frc avail anti vegf agent intravitr ranibizumab lucenti genentech revolutionis manag variou form ocular neovascularis includ myopic cnv mcnv accord professor adrian koh md frc current gold standard treatment myopic cnv anti vegf therapi achiev good visual result minim number treatment unlik age relat macular degener cnv prof koh said th euretina congress barcelona myopic cnv sight threaten complic patholog myopia characteris neurosensori detach sub retin haemorrhag fibrot membran format said prof koh individu patholog myopia cnv develop approxim eye caucasian approxim asian said sever theori put forward explain caus mcnv said prof koh mechan theori posit excess elong retina associ chang caus imbal angiogen antiangiogen factor therebi trigger condit heredodegen theori argu refract error genet predetermin hemodynam theori propos perfus chang choroid circul myopic eye possibl caus standard test diagnos mcnv includ fundu biomicroscopi fluorescein angiographi optic coher tomographi oct fluorescein angiographi demonstr leakag cnv still current gold standard diagnosi said prof koh prior introduct anti vegf agent verteporfin photodynam therapi vpdt approv treatment mcnv said prof koh pdt shown benefit placebo two year may delay visual acuiti deterior howev improv vision may induc chorioretin damag leakag cnv may persist said introduct anti vegf treatment chang paradigm mcnv manag radianc trial ranibizumab demonstr letter gain median two inject said prof koh patient treat ranibizumab gain letter month proport patient cnv leakag intraretin oedema decreas ranibizumab group recent trial intravitr aflibercept eylea bayer pharma ag mcnv demonstr clinic import visual anatom benefit limit inject conclud prof koh adrian koh dradriankoh eyeretinasurgeon com',\n",
       " 'msk sever clinic trial evalu immunotherapi variou sarcoma type learn http www mskcc org cancer care clinic trial search key immunoth sarcoma carri type mutat call mmr defect may also treatabl immunotherapi drug pembrolizumab therapi approv fda cancer carri mutat requir particip clinic trial thank comment',\n",
       " 'henri wrote question patient opdivo told avoid sunlight exposur new updat keytruda opdivo folfox butt told avoid sun rememb correctli make suscept sunburn take opdivo alon conjunct chemo lee',\n",
       " 'phi round cisplatin alimta steroid mani bag fluid gave round look like pillsburi doughboy right infus second one face eye even swollen gradual went away nausea even learn peppermint candi work well better pain med constip food issu food tast realli nasti peppermint lemon ice cream tast pretti good also donut healthi eater lose weight thank steroid thing think infus long took hour read elsewher best bet keep record symptom first time plan deal time infus last one tire drench night sweat lost hair textur becam fine continu lose afterward everyon differ experi bring symptom forum get good suggest way deal hope goe well destroy littl evil cancer critter judi',\n",
       " 'hi sch sorri hear uncl diagnosi note wife nsclc mutat similar exon mutat egfr differ relat protein agre janin found exon group help lot inform current develop treatment exon mutat may suggest thing talk oncologist mix result chemo definit two case line treatment great lung noth liver tumor case howev line treatment seem effect tumor although differ degre work better liver better lung wife cancer hip seem good indic treatment work pain goe away quickli pain come back usual treatment work overal wife carbo alimta work great alimta alon well opdivo two clinic trial one work month one mix result standard chemotherapi carbo gemzar abraxan type taxol one actual work best overal pleas let know question answer wish famili new year full peac health scohn',\n",
       " 'nikki sorri hear mom diagnosi daughter mom advanc stage lung cancer mom non small cell adenocarcinoma current deal st recurr bout mom receiv carbo alimta keytruda pd l receiv cycl chemo keytruda went year keytruda current treatment break due side effect check first year mom treatment [ url mom handl platinum base chemo well first bout treatment worst side effect sever acid reflux great time though mom well flu like symptom day nd infus felt crappi day month combin treatment import thing evid diseas nearli year say hesit receiv result month ct scan tomorrow alway scare might jinx good news question mom journey happi share take care steff',\n",
       " 'could comfort bathroom instead one bathroom floor access quantiti keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'check http multipl sclerosi research blogspot com cladribin html click cladribin ms project top page',\n",
       " 'sharon video releas two day ago excel inform current ms drug highlight ocrevu discuss current drug thought might find interest http www youtub com watch v j prso fdz',\n",
       " 'last may wife start combo tafinlar mekinist combo show great promis melanoma trial patient braf v e mutat melanoma mutat braf v e type soon smaller trial initi nsclc patient mutat abt lc patient trial al show great promis earli last year trial longer admit new patient reopen treatment naiv patient could consid wife chemopaus time fortun got approv combo outsid trial two earlier scan show improv last week scan brought good news groundless densiti resolv discret mass seen minim residu stabl sub pleural interstiti infiltr like reflect minor fibrot chang continu treatment next scan month grate gotten point fortun new better drug becam avail time benefit mani includ wife wife yr dx mar nsclc mbac ai mar lobectomi left lower ul scan may clean juli bilater ggo sep promin ggo dec worsen ggo w foci dens consolid feb scan growth met braf posit v e mar start carbo alimta chemo follow alimta mainten initi shrinkag stabl till aptil june trial immunotherapi mpdl docetaxel assign docetaxel late octob stop docetaxel cours side effect sever chemo paus may start tafinlar mekinist combo initi sever side effect mostli high fever chill grade uveiti eye earli august reduc tafinlar dosag mg mg day kept mekinist mg day side effect manag scan earli aug late oct show improv latest scan wa',\n",
       " 'hi femal asian dx stage adneo del egfr tarceva almost year progress small progress almita carbo cycl hold tissu biopsi lepid predomin adeno start tagrisso tomorrow repeat ct long longest document durat progress free surviv tagrisso lepid predomin histolog make differ respons tagrisso good clinic trial patient develop resist tagrisso depend find someth grow biopsi see new mutat one area grow sbrt help keep tagrisso go sorri mani question tri proactiv god bless help topic modifi month week ago bfarz topic modifi month week ago bfarz',\n",
       " 'take humira imuran felt aw flu like symptom dizzi could bare function mom also crohn stelara clinic trial hopkin take remiss hope success thank repli',\n",
       " 'mayb say repress immun system work suppress bodi natur immun cours noth els work take question show u cabl tv call monster insid parasit know mani episod discuss variou parasit worm fungu bacteria larva everyday environ part harmless us normal immun system easili overwhelm someon compromis immun system previou studi alreadi indic increas risk infect lymphoma evid publish journal american medic associ suggest remicad tripl risk skin cancer anoth black box issu describ cancer occur children young adult began take tnf blocker remicad humira cimzia along immunesuppress medicin mp fda fix problem updat warn section drug label www huffingtonpost com rebecca kaplan social secur administr_b_ html patient ibd depend medic antibiot anti inflammatori steroid immunosuppress control inflamm ulcer pain caus diseas benefici medic caus sever side effect includ nausea vomit heartburn night sweat insomnia hyperact high blood pressur stunt growth children patient immunosuppress risk develop lymphoma tuberculosi kidney liver damag anaphylaxi seizur potenti seriou fatal infect',\n",
       " 'dear jimc thank prompt thorough respons apolog specif symptom thu far far know sure progress diseas everyth happen fast past month mother mention surgeri discharg hospit imag test perform discharg follow dr chest pa show signific improv pleural effus hope control besid mani symptom mother start develop regular cough last day hospit seem worsen discharg cough almost gone complet chang nutrit implement daili deep breath exercis could also combo tarceva work sure day tarceva could help cough quickli sleep around hour day occas activ short nap afternoon fatigu yet issu drastic chang life qualiti experienc mild skin acn face sensit palat better bowel movement prior tarceva bowel movement would sporad usual resort sort lax aid howev consist bowel movement could also due increas amount fluid water green tea drink natur veget fruit consum diarrhea like form surfac yet reach two week anniversari tarceva partial reason crossroad administ adjuv wbrt moment hope well inform possibl want regret influenti life chang decis take knowingli easier said hope done mani thank',\n",
       " 'recent year excit develop treat lung cancer genet test tumor sampl doctor identifi specif type lung tumor prescrib treatment design target immunotherapi also emerg treatment option certain type lung cancer advanc made treatment effect often fewer side effect type lung cancer two major type lung cancer non small cell lung cancer nsclc small cell lung cancer sclc nsclc account percent lung cancer includ adenocarcinoma common form lung cancer unit state among men women squamou cell carcinoma larg cell carcinoma sclc tumor account remain percent lung cancer unit state tend grow quickli nsclc tumor tumor classifi stage stage base whether cancer local lung local advanc spread nearbi lymph node lung area metastat spread part bodi treatment option print email share tweet lungev lung cancer helplin cancer care partner lungev nation lead lung cancer focus nonprofit organ provid lungev lung cancer helplin call lung view cancer care resourc help better cope lung cancer editor heather wakele md associ professor depart medicin divis oncolog stanford univers stanford cancer institut listen surgeri surgeri sometim combin chemotherapi common treatment option tumor confin lung advanc surgic techniqu allow doctor make much smaller incis remov tumor section lung affect cancer use video assist thoracoscop surgeri vat surgeon insert tube call thoracoscop chest devic light tini camera connect video monitor radiat therapi case surgeri possibl mani local advanc cancer radiat therapi sometim use either alon combin chemotherapi treatment may also use surgeri shrink tumor surgeri help prevent cancer come back recur extern beam radiat commonli use treat lung cancer standard extern beam radiat use machin direct beam multipl beam radiat tumor use ct computer tomographi mri magnet reson imag pet positron emiss tomographi scan allow radiat oncologist accur target tumor shape radiat beam size dimens tumor help spare healthi tissu newer form radiat call sbrt stereotact radiat stereotact abl radiat therapi sabr sometim use treatment earli stage lung cancer instead surgeri sbrt deliv higher dose radiat shorter period time approach minim impact healthi tissu patient high risk surgeri sbrt shown cur rate close expect rate surgeri ongo research tri determin patient could type focus radiat instead surgeri chemotherapi chemotherapi long effect treatment lung cancer continu one import element treatment mani patient chemotherapi extrem effect treat sclc also use treat nsclc chemotherapi help patient earli stage cancer remov surgeri combin radiat local advanc cancer also import part treatment patient advanc stage lung cancer chemotherapi drug approv fda treatment lung cancer includ cisplatin platinol carboplatin paraplatin common medic use treat lung cancer treatment approach includ either cisplatin carboplatin combin anoth chemotherapi drug pemetrex alimta pemetrex use combin chemotherapi cisplatin initi treatment advanc non squamou nsclc pemetrex also approv use alon treat advanc non squamou nsclc anoth chemotherapi given pemetrex use adenocarcinoma lung activ squamou cell lung cancer small cell lung cancer gemcitabin gemzar other drug use treat nsclc either combin cisplatin carboplatin initi treatment singl drug chemotherapi given drug work type nsclc paclitaxel taxol nab paclitaxel abraxan docetaxel taxoter drug form taxan chemotherapi given combin cisplatin carboplatin nsclc docetaxel frequent given alon later line therapi advanc stage lung cancer etoposid etopopho vepesid etoposid use combin cancer medic treatment sclc target treatment destroy cancer cell target therapi focus specif cell mechan thought import growth surviv tumor medic caus differ often less sever side effect chemotherapi research discov mutat gene call epiderm growth factor receptor egfr caus develop growth spread lung cancer approxim ten percent peopl lung cancer egfr mutat present tumor egfr inhibitor target therapi given pill form often use treat type lung cancer today four medic approv treatment option unit state lung cancer patient gene mutat erlotinib tarceva other u food drug administr fda first approv use erlotinib lung cancer erlotinib approv initi treatment patient nsclc spread part bodi certain type egfr mutat piec miss call delet egfr gene afatinib gilotrif fda approv afatinib initi treatment metastat nsclc patient egfr gene mutat delet treat success erlotinib gefitinib iressa juli fda approv gefitinib initi treatment patient nsclc whose tumor harbor specif type egfr gene mutat detect fda approv test osimertinib tagrisso novemb fda approv osimertinib treatment patient nsclc whose tumor specif egfr gene mutat start regrow treatment erlotinib afatinib gefitinib resist develop one drug tumor start grow newer egfr inhibitor drug call osimertinib tagrisso often work shrink cancer stop grow anoth gene mutat found lung cancer refer alk four target treatment fda approv option peopl whose cancer mutat crizotinib xalkori treatment approv fda treat metastat nsclc tumor alk gene mutat crizotinib block mutat alk gene stop growth tumor clinic trial found effect chemotherapi addit crizotinib approv treat peopl metastat nsclc tumor mutat ro gene ceritinib zykadia medic approv peopl metastat alk posit lung cancer cannot toler crizotinib whose cancer continu grow treat crizotinib approv newli diagnos patient alk posit lung cancer alectinib alcensa alectinib approv decemb patient lung cancer alreadi treat crizotinib result larg clinic trial novemb alectinib approv given first line treatment choic prior treatment brigatinib alunbrig april brigatinib approv patient alreadi treat crizotinib june fda approv target therapi dabrafenib trametinib administ combin patient nsclc mutat braf v e gene detect fda approv test gene mutat seen nsclc target therapi option may avail gene mutat tend common adenocarcinoma type nsclc import patient adenocarcinoma discuss valu genet test oncologist gene cancer cell evolv tumor may becom resist target therapi treatment medic meet challeng studi clinic trial cut blood suppli tumor anoth approach destroy cancer cell chang blood suppli tumor need grow blood vessel grow sever way process depend presenc substanc call vascular endotheli growth factor vegf produc tumor normal cell substanc stimul blood vessel penetr tumor suppli oxygen miner nutrient feed growth bevacizumab avastin monoclon antibodi work stop vegf stimul growth new blood vessel combin chemotherapi bevacizumab shown like shrink tumor help patient certain type nsclc adenocarcinoma live longer ramucirumab cyramza also use treat nsclc monoclon antibodi target vegf receptor help stop format new blood vessel ramucirumab often given chemotherapi drug docetaxel later line therapi anoth treatment stop work immunotherapi immun system constantli work keep us healthi recogn fight danger infect virus grow cancer cell gener term immunotherapi use immun system treatment cancer march fda approv immunotherapi nivolumab opdivo treatment metastat squamou nsclc unsuccess treat chemotherapi nivolumab work interf molecular brake known pd prevent bodi immun system attack tumor two addit drug categori approv octob atezolizumab tecentriq pembrolizumab keytruda pembrolizumab drug categori approv first line initi treatment lung cancer februari fda approv immunotherapi durvalumab imfinzi treatment patient stage iii nsclc whose tumor unabl surgic remov whose cancer progress treatment chemotherapi radiat treatment approach studi effect combin immunotherapi treatment nsclc studi mani clinic trial one promis approach pair nivolumab ipilimumab yervoy immunotherapi current approv fda treatment metastat melanoma anoth area ongo research combin immunotherapi chemotherapi first line treatment option fda approv use pembrolizumab combin chemotherapi first line treatment metastat nsclc addit effect potenti side effect ad radiat therapi immunotherapi current studi introduct manag treatment side effect print email share tweet import clinic trial clinic trial standard measur worth new treatment qualiti life patient receiv treatment reason doctor research urg peopl cancer take part clinic trial doctor guid make decis whether clinic trial right thing know often peopl take part clinic trial gain access benefit new treatment particip clinic trial fulli inform risk benefit trial includ possibl side effect clinic trial design test new treatment standard treatment find whether new treatment ad benefit stop take part clinic trial time reason listen cancer treatment caus side effect import report side effect experi health care team help manag report right away wait next appoint improv qualiti life allow stick treatment plan import rememb patient experi side effect patient may experi side effect list side effect chemotherapi side effect chemotherapi depend type dose drug given length time use includ fatigu tire hair loss diarrhea constip increas risk infect white blood cell easi bruis bleed chang memori think peripher neuropathi numb tingl hand feet side effect radiat therapi treatment chang skin includ dryness swell peel red blister reaction occur contact health care team appropri treatment prescrib especi import contact health care team open skin pain area could indic infect infect treat oral antibiot topic antibiot cream side effect target therapi target therapi drug effect bodi chemotherapi drug still caus side effect potenti side effect target therapi includ rash diarrhea liver problem elev liver enzym problem blood clot wound heal high blood pressur side effect immunotherapi immunotherapi travel bloodstream help prompt immun respons trigger attack healthi cell well cancer cell certain side effect may experienc includ fatigu decreas appetit digest tract symptom manag potenti side effect discuss later next section booklet manag digest tract symptom nausea vomit avoid food strong odor well overli sweet greasi fri highli season food nibbl dri cracker toast bland food easi stomach someth stomach take medic may help eas nausea mani effect medic nausea vomit develop recent year talk doctor whether may right diarrhea drink plenti water ask doctor use drink gatorad provid electrolyt well liquid electrolyt bodi salt must stay balanc cell work properli counter medicin loperamid imodium other prescript drug avail diarrhea use necessari diarrhea bad enough need medicin discuss doctor nurs choos food contain solubl fiber exampl bean oat cereal orang flaxse high pectin food peach appl orang grapefruit banana apricot also help avoid diarrhea loss appetit help maintain weight eat small meal throughout day easi way take protein calori tri includ protein everi meal keep feel full earli avoid liquid meal take small sip unless need liquid help swallow drink liquid meal focu liquid nutrit valu physic activ sometim take short walk hour meal help feel hungri keep high calori high protein snack hand hard boil egg peanut butter chees ice cream granola bar liquid nutrit supplement pud nut can tuna trail mix struggl maintain appetit talk health care team whether appetit build medic could right manag fatigu fatigu extrem tired help sleep one common side effect mani cancer treatment take medic doctor may lower dose drug long make treatment less effect experienc fatigu talk doctor whether take smaller dose right number tip reduc fatigu take sever short nap break take short walk light exercis possibl tri easier shorter version activ enjoy ask famili friend help task find difficult tire save energi thing find import also prescript medic may help modafinil health care team provid guidanc whether medic right approach individu circumst manag pain number option pain relief includ prescript counter medic import talk member health care team take counter medic determin safe interfer treatment treatment option commun health care team print email share tweet listen manag lung cancer import rememb consum health care best way make decis health care educ diagnosi member health care team includ nurs social worker patient navig tip improv commun health care team start health care journal health care journal notebook allow keep health inform one place may want write name contact inform member health care team well question doctor keep diari daili experi cancer treatment separ journal notebook differ section help keep organ prepar list question next medic appoint write question concern doctor may limit time ask import question first specif brief possibl bring someon appoint even journal prepar list question concern alway help support go appoint person accompani serv second set ear may also think question ask doctor rememb detail symptom treatment may forgotten write doctor answer take note help rememb doctor respons advic instruct cannot write answer ask person accompani mobil devic use take note write note help review inform later record visit doctor allow record convers doctor give chanc hear specif inform share famili member friend incorpor health care profession team oncologist oncolog nurs essenti member health care team health care profession help manag diagnosi treatment make sure oncologist know medic condit pain experienc consult primari care physician specialist need rememb thing commun manag treatment side effect faq print email share tweet cancer care free support servic program oncolog social worker provid emot support peopl cancer love one profession help cope challeng cancer diagnosi guid resourc cancer care offer free counsel profession oncolog social worker understand challeng face peopl cancer caregiv work one one develop strategi cope treatment side effect oncolog social worker also help commun doctor member medic care team health care issu import support group provid care environ share concern other similar circumst support group member come togeth help one anoth provid insight suggest way cope cancercar peopl cancer famili particip support group person onlin telephon financi help offer cancer care number organ assist cancer relat expens transport treatment child care home care learn cancer care help pleas call us hope visit www cancercar org www lungcanc org listen frequent ask question q breath affect surgeri chemotherapi surgeri reduc size lung cannot take much air medic also chang lung function lead short breath time difficulti breath report doctor prescrib pulmonari lung rehabilit therapi therapi may includ exercis train energi conserv techniqu breath strategi nutrit counsel improv lung function q lung cancer ret gene mutat drug studi type tumor ret protein send signal cell tell divid matur special perform specif function mutat ret gene signal get stuck caus uncheck cell growth discov mutat ret gene mutat link lung cancer three medic approv fda peopl type cancer ret mutat cabozantinib cometriq vandetanib caprelsa peopl thyroid cancer sunitinib sutent kidney cancer pancreat cancer gastrointestin stromal tumor gist talk doctor lung cancer clinic trial peopl ret gene mutat ask whether recommend prescrib medic label use prescript drug legal treat cancer drug approv fda q happen treatment stop work happen discuss altern treatment option doctor recommend base uniqu situat includ factor relat overal health note sever drug late phase clinic trial intend use initi lung cancer treatment becom less effect stop work q stage lung cancer surgic remov doctor say need chemo type treatment get second opinion cancer truli stage treatment surgeri recommend howev import get ct scan everi six month first two year surgeri check recurr new cancer first two year doctor recommend frequent get ct scan commun health care team print email share tweet resourc cancer care hope american cancer societi cancer net cancer support commun lungcan lungcanc org hope lung cancer allianc nation cancer institut find clinic trial emergingm',\n",
       " 'transit new med would second previou recommend stelara stelara get good review new drug seem rival remicad effect hope get thing work soon',\n",
       " 'ulcer coliti year went sever year undiagnos went steroid asacol pantroprzol hospit asacol coupl year kept flare went humira year stop work went remicad stop work ileostomi total colectomi surgeri half year ago hardli eat anyth far varieti eat fruit ripe avocado fiber fresh veget etc realli eat chicken fish gluten free oatmeal mash potato drink kale cucumb juic pulp filter complet eat time day ounc per meal extens test chrohn h pylori stomach function pancrea issu etc neg heat burn toler proton pump inhibitor bloat ga throat feel like close eat wonder anyon els symptom know might caus',\n",
       " 'repli post cbertucci anyon commun forum treat dr albert snow ulcer coliti put remiss claim cure mild case uc year recent bad flare remicad prednison work next step surgeri inform would appreci',\n",
       " 'hi wschoop treatment year diag time relaps lesion mri gilenya first dmt well last year relaps stabl mri sinc feel good side effect report elev liver enzym coupl month good luck hope thing go well',\n",
       " 'chipofbag opdivo keytruda equival go target cell would unnecessari opdivo yervoy combo make lot sens opdivo mostli act cell tumor wherea yervoy mostli act cell circul cytotox lymphocyt associ protein ctla blockad impact human immun system expand pool circul cell may mechanist relat induct autoimmun inflammatori toxic http clincancerr aacrjourn org content full say reason pd inhibitor well toler wherea ctla inhibitor sever side effect also blockad differ target cell shut immun escap rout cancer usual use',\n",
       " 'would make appoint gi asap technic inflectra ident remicad similar henc term biosimilar howev bodi may like small differ perhap develop antibodi inflectra idea honesti better nd rd infus would fight go back origin remicad dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'alic shaw director center thorac cancer paula keeff endow chair thorac oncolog massachusett gener hospit also associ professor medicin harvard medic school receiv b biochemistri harvard ph degre harvard medic school resid intern medicin massachusett gener hospit complet fellowship hematolog oncolog dana farber massachusett gener hospit complet postdoctor work laboratori dr read alic shaw md ph grace faculti karen reckamp md ms grace faculti karen reckamp md ms associ professor depart medic oncolog therapeut research citi hope comprehens cancer center cohccc receiv medic degre univers chicago master degre clinic investig ucla complet resid train intern medicin barn jewish hospit hematolog oncolog fellowship david geffen school medicin ucla read karen reckamp md ms grace faculti matt hiznay live forum moder patient advoc matt hiznay five year survivor metastat alk posit non small cell lung cancer born youngstown ohio grew small town poland ohio matt graduat poland seminari high school john carrol univers bachelor scienc degre magna cum laud read matt hiznay live forum moder patient advoc janet freeman daili patient advoc live forum moder janet freeman daili writer scienc geek lung cancer patient activist receiv diagnosi advanc non small cell lung cancer may becam metastat despit chemotherapi radiat learn genom test precis medicin onlin patient commun join clinic trial ro posit lung cancer evid diseas four year read janet freeman daili patient advoc live forum moder john cherol live forum moder patient advoc john cherol diagnos januari stage iv egfr lung cancer age start gilotrif afatinib acquir resist month luckili blood test show develop mutat start tagrisso april year also treat nine brain met gamma knife cleveland clinic read john cherol live forum moder patient advoc heather wakele md grace faculti dr wakele assist professor medicin stanford univers divis oncolog co leader lung cancer diseas manag group focu clinic research lung cancer patient particular interest anti angiogenesi agent dr wakele princip investig ongo intern lung cancer intergroup trial e investig potenti role bevacizumab addit adjuv chemotherapi resect earli stage non small cell lung cancer read heather wakele md grace faculti rachel sanborn md grace faculti graduat oregon health scienc univers medic degre dr rachel sanborn complet resid intern medicin univers illinoi chicago return portland fellowship hematolog medic oncolog oregon health scienc univers board certifi medic oncolog intern medicin read rachel sanborn md grace faculti boon wilder goodgam md grace faculti boon wilder goodgam md grew uganda father taught nation medic school move texa age complet high school earn undergradu degre univers texa austin mechan engin complet medic school baylor colleg medicin houston read boon wilder goodgam md grace faculti melissa johnson md grace faculti dr melissa johnson assist professor northwestern univers feinberg school medicin chicago',\n",
       " 'profg need solid scientif evid back point agre want trial cladribin peopl advanc ms moment evid dmt make differ pwppm ocrelizumab moment ocrelizumab avail nh',\n",
       " 'sorri repli chemo carboplatin taxol commoni use drug hope help best mom chuck ps caregiv done mani mani hundr hour research might consid second opinion even call bm opdivo whether work even pd l express link read leav articl one year old interest comment pd l protein center clinic decis select patient like benefit treatment anti pd anti pd l drug none three fda approv mention express pd l prerequisit prescrib drug still consensu regard valu pd l express nsclc predict marker respons across board posit pd l predict respons alway guarante lack pd l exclud respons lead clinician agre would give anti pd drug patient metastat lung cancer melanoma regardless pd l statu right pd l good enough biomark exclud patient receiv anti pd drug even pd l neg patient deriv benefit pd blockad docetaxel standard chemotherapi drug know lot digest one year old least imo worth consid wife never pdl test opdivo work great platin type chemo drug gemzar patient react quit differ god bless',\n",
       " 'diagnos regular annoy symptom mani list start tysabri infus june point jcv neg see said jcv posit think may relat copaxon mayb talk doctor medic neuro alreadi plan b go jcv posit ocrevu suppos similar tysabri understand identifi success dmt ms friend church wheel chair start tysabri within day wheel chair walk assist cane like said tysabri sinc jcv neg posit rule least greatli increas risk get pml doctor would even sign switch tysabri pretti sure doctor would sign give tysari jcv prosit sure know ms uniqu everyon success dmt uniqu everyon copaxon work anoth friend church copaxon year work great gave autoject sinc purpos',\n",
       " 'entyvio slow work week moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa offic stand man held hostag hour pain within bathroom kept bowel sound like misunderstand',\n",
       " 'mani patient rituxan switch ocrevu due insur issu problem imo reason switch rituxan develop antibodi drug rituxan year safeti profil',\n",
       " 'camidg r et al brigatinib vs crizotinib patient advanc alk inhibitor naiv advanc alk nsclc first report phase trial alta l world confer lung cancer abstract pl',\n",
       " 'hi janiceb stori sound like futur cross road diagnos coupl month ago neuro sent blood test prepar gilenya keen realli want take drug symptom sound bad side effect mobil apart back pain tingl littl brain fog deal fulli om sinc last month plant base last month think go wait see hope everyon well',\n",
       " 'biosimilar readi pounc abbvi humira europ biosimilar compani gear pounc abbvi inflamm blockbust humira adalimumab lose patent exclus across europ octob humira earn bn ex us sale abbvi last year came europ expect see revenu rapidli erod earli amgen copi amgevita samsung biogen imraldi gain full eu approv last year give lot time prepar market permit launch octob red letter day meanwhil sandoz novarti divis announc friday gain european approv biosimilar known hyrimoz biosimilar expect undercut humira origin price healthcar system across europ get use drive hard bargain exploit competit firm get lowest price possibl case seen origin compani match price biosimilar entrant order hold onto market share mani biosimilar compani look get slice humira spend europ accord iqvia data worth annual uk alon hyrimoz approv use humira mani indic rheumatoid arthriti psoriasi crohn diseas kavya gopal head specialti sandoz uk said approv hyrimoz potenti posit impact nh term reduc medicin spend ultim increas patient access effect treatment nh current spend year humira avail hyrimoz competit environ provid opportun lower cost per patient allow patient treat support sustain healthcar system england budget holder nh england expect four adalimumab biosimilar avail uk octob abbvi origin product humira three biosimilar amgen samsung biogen sandoz potenti save great nh england commerci medicin unit cmu co ordin nation procur process adalimumab loss patent exclus octob nh england say ambit nh achiev recurr annual save increas use best valu biolog medicin phrase mean preclud stick origin product provid best valu price say alreadi achiev save use biosimilar medicin figur read nh intern brief adalimumab biosimilar may hong kong could new biotech hub say beigen head bn floatat beigen part wave new china base biotech compani emerg rapidli thank new rule hong kong stock market hkex introduc late april year new rule allow biotech compani without revenu launch initi public offer ipo allow compani alreadi list elsewher launch secondari list hong kong total eight compani biotech research file sinc may beigen plan biggest yet alreadi list us biotech specialist exchang nasdaq beigen plan float hong kong august aim rais bn would record break sum biotech compani product yet market speak south china morn post compani chief execut john oyler pictur said lot global investor know biotechnolog know littl china hong kong lot investor know china know littl biotechnolog hope list hong kong help educ type investor ad hong kong potenti attract mani biotechnolog firm list well investor trade research analyst relat parti follow creat ecosystem biotechnolog industri hong kong beij base biotech toplin data pivot trial pd inhibitor chines patient relaps refractori classic hodgkin lymphoma hope file approv home market later year read biotech investor comment brad loncar blog eight biotech alreadi file hkex kymab report earli data lead antibodi uk biotech compani kymab releas phase data ox ligand monoclon antibodi ky cambridg uk base compani tip one countri brightest biotech hope year ago quick move candid clinic trial compani reassur top line phase data show antibodi favour safeti pharmacokinet pharmacodynam properti kymab say data support take ky patient phase ii studi patient atop dermat ox ox ligand ox l potenti treat number immun mediat inflammatori disord includ use oncolog number big pharma compani x candid pipelin includ pfizer although roch abandon phase candid rg solid tumour last year rna drug specialist moderna also ox l candid mrna earli stage trial next clinic studi ky test patient atop dermat condit especi high level ox l found phase iia trial atop dermat expect begin late',\n",
       " 'final got approv cimzia spell remicad ten year stop work novemb last year got final dose remicad januari listen complaint pain june tri humira reaction put high dose steroid mainten dose mg gain much weight stop eat final rx sent specialti pharmaci august th frustrat go look anoth doctor trust anymor pleas say prayer take crohn pain symptom anymor hate diseas mad hope',\n",
       " 'april unit state food drug administr fda grant approv inject drug lucenti gener name ranibizumab treatment prolif diabet retinopathi pdr seriou vision relat complic diabet previous fda approv lucenti treatment diabet macular edema dme buildup fluid macula center retina thu latest treatment advanc fda approv physician use lucenti manag diabet retinopathi peopl without diabet macular edema import background research journal american medic associ result import clinic trial reveal inject drug lucenti highli effect treat prolif diabet retinopathi seriou vision relat complic diabet research titl panretin photocoagul [i e laser treatment] vs intravitr ranibizumab [i e lucenti injection] prolif diabet retinopathi random clinic trial publish onlin open sourc articl novemb edit journal american medic associ time coincid present studi author annual meet american academi ophthalmolog author member write committe diabet retinopathi clinic research network diabet retinopathi clinic research network drcr net collabor research group support identif design implement multi center clinic research studi focus diabet relat eye retin disord includ diabet retinopathi diabet macular edema drcr net form septemb current includ particip site physician throughout unit state fund nation eye institut nei find said dr paul siev director nation eye institut nei provid crucial evid safe effect altern laser therapi prolif diabet retinopathi clinic trial fund nei describ lucenti first major advanc therapi prolif diabet retinopathi nearli year although longer term follow need lucenti may provid reason treatment altern least two year person prolif diabet retinopathi diabet eye diseas diabet retinopathi although peopl diabet like develop cataract younger age twice like develop glaucoma peopl diabet primari vision problem caus diabet diabet retinopathi lead caus new case blind low vision adult age person diabet retinopathi see retinopathi gener term describ damag retina retina thin light sensit tissu line insid surfac eye nerv cell retina convert incom light electr impuls electr impuls carri optic nerv brain interpret visual imag diabet retinopathi occur damag small blood vessel nourish tissu nerv cell retina prolif gener term mean grow increas rapid rate produc new tissu cell term prolif use relat diabet retinopathi describ growth prolifer abnorm new blood vessel retina non prolif indic process yet occur prolif diabet retinopathi affect approxim individu diseas four stage diabet retinopathi accord nation eye institut diabet retinopathi four stage mild non prolif retinopathi earli stage small area balloon like swell occur retina tini blood vessel moder non prolif retinopathi diseas progress blood vessel nourish retina becom block sever non prolif retinopathi mani blood vessel becom block disrupt blood suppli nourish retina damag retina signal bodi produc new blood vessel prolif retinopathi advanc stage signal sent retina trigger develop new blood vessel grow prolifer retina vitreou transpar gel fill interior eye new blood vessel abnorm ruptur bleed caus hemorrhag retina vitreou scar tissu develop tug retina caus damag even retin detach addit fluid leak macula small sensit area center retina provid detail vision fluid caus macular edema swell occur stage diabet retinopathi although like occur diseas progress lucenti anti angiogen drug treat retin bleed angiogenesi term use describ growth new blood vessel play crucial role normal develop bodi organ tissu sometim howev excess abnorm blood vessel develop occur diseas cancer tumor growth retin diseas substanc stop growth excess blood vessel call anti angiogen anti angio vessel genic develop anti neovascular anti neo new vascular blood vessel focu current anti angiogen drug treatment retin diseas reduc level particular protein vascular endotheli growth factor vegf stimul abnorm blood vessel growth retina macula thu drug classifi anti vegf treatment administ inject directli eye surfac numb present anti vegf drug lucenti avastin eylea requir monthli inject pro nata [mean need ] prn regimen monthli control inject recurr persist blood vessel growth retin bleed lucenti diabet retinopathi research excerpt lucenti prove effect prolif diabet retinopathi via scienc codex clinic trial among patient found drug ranibizumab lucenti highli effect treat prolif diabet retinopathi pdr complic diabet sever damag eyesight result demonstr first major therapi advanc condit nearli year trial compar lucenti inject type laser therapi call panretin photocoagul remain gold standard pdr sinc mid although laser therapi preserv central vision damag night side vision research sought therapi lack side effect patient receiv lucenti show littl bit better central vision much less loss side vision substanti less risk surgeri patient receiv laser treatment said lloyd paul aiello ph director beetham eye institut joslin diabet center professor ophthalmolog harvard medic school find chang avail treatment option patient pdr drcr net enrol particip eye pdr one eye clinic site across countri eye assign randomli treatment lucenti laser half eye assign laser group requir one round laser treatment group lucenti inject eye per month three consecut month need diseas resolv stabil lucenti commonli inject treat diabet macular edema dme build fluid center retina studi permit use lucenti dme laser group necessari slightli half percent eye laser group receiv lucenti inject treat dme percent eye lucenti group receiv laser therapi mostli issu dme two year vision lucenti group improv averag half line eye chart compar virtual chang laser group particip treat laser gener lost substanti peripher vision given inject addit need vitrectomi surgeri lower lucenti group eye laser group eye overal drug benefit particularli clear peopl pdr dme know drug help treat condit time especi appeal treatment altern patient dr aiello note studi also suggest lucenti may help prevent dme among peopl without condit start studi percent lucenti treat eye develop compar percent laser group scientist follow result drcr net continu track patient total five year studi journal american medic associ excerpt articl abstract full articl avail onlin import panretin photocoagul prp standard treatment reduc sever visual loss prolif diabet retinopathi howev prp damag retina result peripher vision loss worsen diabet macular edema dme object evalu non inferior intravitr ranibizumab [i e lucenti injections] compar [laser] visual acuiti outcom patient prolif diabet retinopathi design set particip random clinic trial conduct us site among adult prolif diabet retinopathi enrol februari decemb mean age year femal white eye enrol particip eye studi group total studi eye final year visit complet januari intervent individu eye randomli assign receiv prp treatment complet visit n eye [lucentis] mg intravitr [i e within eye] inject baselin frequent everi week base structur treatment protocol n eye eye treatment group could receiv [lucentis] dme main outcom measur primari outcom mean visual acuiti chang year letter non inferior margin intent treat analysi secondari outcom includ visual acuiti area curv peripher visual field loss vitrectomi dme develop retin neovascular result mean visual acuiti letter improv year [lucentis] group vs prp group mean treatment group differ visual acuiti area curv year mean peripher visual field sensit loss wors vitrectomi frequent dme develop frequent [laser] group vs [lucentis] group respect eye without activ regress neovascular year significantli differ one eye [lucentis] group develop endophthalm [i e inflamm eye usual caus infection] signific differ group rate major cardiovascular event identifi conclus relev among eye prolif diabet retinopathi treatment [lucentis] result visual acuiti non inferior wors [laser] treatment year although longer term follow need [lucentis] may reason treatment altern least year patient prolif diabet retinopathi',\n",
       " 'adjuv treatment erlotinib may benefit patient earli stage non small cell lung cancer nsclc epiderm growth factor receptor egfr mutat new studi publish journal clinic oncolog found egfr mutant earli stage nsclc patient treat erlotinib experienc improv year diseas free surviv df rate compar histor genotyp match control research found recurr rare patient receiv adjuv erlotinib addit patient rechalleng erlotinib recurr found durabl benefit nathan pennel md phd cleveland clinic taussig cancer institut ohio colleagu conduct open label phase trial includ patient resect stage ia iiia egfr mutant nsclc patient treat small molecul egfr tyrosin kinas inhibitor tki erlotinib mg per day year standard adjuv chemotherapi without radiotherapi agent demonstr superior patient metastat lung cancer harbor egfr mutat theoriz erlotinib could help improv outcom patient earli stage egfr mutant lung cancer research found unexpect toxic grade advers event howev patient requir dose reduct mg per day dose reduct mg per day intend year cours achiev patient relat articl fulvestr plu erlotinib may improv progress free surviv egfr wild type nsclc resist mechan identifi nsclc progress first line osimertinib bevacizumab plu erlotinib may new standard care non small cell lung cancer research found year df rate stage stage ii stage iii median follow year median df overal surviv os rate reach time public studi show year df rate year os rate diseas recur patient recurr report erlotinib treatment median time recurr month stop erlotinib refer pennel na neal jw chaft je et al select phase ii trial adjuv erlotinib patient resect epiderm growth factor receptor mutant non small cell lung cancer [publish onlin novemb ] j clin oncol doi jco',\n",
       " 'ocrelizumab versu interferon beta relaps multipl sclerosi',\n",
       " 'crizotinib effect mass stage iv nsclc ro need stop side effect resum week interrupt affect resist factor studi determin effect interrupt target therapi',\n",
       " 'predictor respons vedolizumab ustekinumab ibd predictor respons vedolizumab ustekinumab ibd factor patient characterist might help predict initi long term respons vedolizumab ustekinumab inflammatori bowel diseas alimentari pharmacolog therapeut sourc medscap today headlin',\n",
       " 'hi kempten think initi question would slight progress lung mass compar overal size thought continu tagrisso bit confirm progress determin rate growth dr west often state often make sens stay well toler treatment even face slow progress bad brake better brake cours local doctor best abl judg question origin percentag exon mutat unchang seem indic exon posit portion cancer progress sinc would expect percentag rise either way specul sinc unfortun understand resist progress well yet discuss treat tarceva failur tagrisso use tagrisso first line set even context good evid yet efficaci dr ramalingam state two month ago tagrisso studi first line therapi set see shut escap resist mechan pro activ improv outcom patient approach shown promis earli result studi larg clinic trial trial compar tagrisso directli tarceva iressa still learn mechan resist observ patient treat tagrisso first line set possibl subset patient use iressa tarceva receiv tagrisso might benefici earli time make firm statement issu present avail data base laboratori experi confirm patient http cancergrac org topic tagrisso first line tarceva therapi post [continu jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa repli modifi year month ago jimc forum moder repli modifi year month ago jimc forum moder',\n",
       " 'multipl sclerosi ms chronic demyelin diseas affect central nervou system pharmacolog therapi ms includ symptomat drug treatment relaps corticosteroid intraven immunoglobulin diseas modifi drug dmd defin pharmacolog agent impact relaps rate disabl accumul radiolog outcom two differ therapeut approach wide use ms escal induct therapi escal therapi consist earli start first line dmd beta interferon glatiram acet teriflunomid dimethyl fumar dmd ineffect partial effect switch second line drug mitoxantron natalizumab fingolimod induct therapi consist earli use immunosuppress drug follow long term mainten treatment gener immunomodulatori agent use natalizumab fingolimod first line drug indic aggress form ms indic mitoxantron induct treatment aris random studi demonstr induct therapi mitoxantron follow dmd mainten effect monotherapi beta interferon howev safeti profil induct drug indic accept therapeut strategi ms patient phase diseas upcom challeng identifi patient high risk disabl develop clinic characterist radiolog find biomark furthermor futur studi establish individu safeti profil stratif need',\n",
       " 'gener tumor resect best option follow chemoradi mani case valu nivolumab context unproven sure chemoradi would offer unless someth locat particular tumor make radiat infeas certainli question ask reason obtain second opinion jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa',\n",
       " 'bizarr chop chang biolog bet cost issu humira cheaper mean work remicad work still dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'want tell experi suggest differ drug might think diagnos probabl ms least five year saw slowish steadi deterior next seven eight year start go downhil lot quicker also episod like relaps bad relaps got back bit function lost time offer rang interferon avail time understand time reduc relaps rate sinc thought slow progress start dmt use one stick lot problem bladder control late year start tysabri hope slow progress came end walk poor slow use two stick walker indoor wheelchair mobil scooter outsid thought lemtrada drug offer hope end ms activ chose cladribin lemtrada cladribin three inject three day outpati stay overnight may one two three inject month later anoth set inject year later end cladribin lemtrada offer end ms treatment goe ever offer reduc diseas activ cladribin lead thyroid problem often seen lemtrada howev cladribin offer bart licens treatment ms australia russia impress neurologist seen bart dr schmierer might find kind doctor want see want read cladribin find inform http multipl sclerosi research blogspot com suppos therapi html',\n",
       " 'fail coupl biolog alreadi one anti tnf medic humira similar remicad would tri find good surgeon consult took month get book surgeri chose wait best surgeon could find suffer time gi scope last week said pouch best ever seen gi said coupl time best color blood flow pouch time zero inflamm thank stelara pouch keith dx sever pancol june previou med asa predison mp remicad humira simponi cimzia cyclosporin step j pouch surgeri current condit chronic pouchiti bad thought would current med stelara total hip replac thank prednison www healingwel com commun default aspx f',\n",
       " 'xalkori month current ct scan show stage nsclc ro stabl ekg show higher qtc sinc last ekg month ago sinc xalkori may affect would mere stop drug wait week two followup ekg recommend concern',\n",
       " 'hi leanne came across post comment kind go thing gilenya two year pretti well relaps month ago decid lemtrada way go stop take gilenya right away lymphocyt count stop told washout period would still take week get back start infus major relaps rebound even full week sinc stop measur lymphocyt count month recov steroid approv start lemtrada guess want say stay top get blood work done awar symptom washout may take long say gluck manni',\n",
       " 'leader alcmi alcf recent attend world confer lung cancer toronto banner year nearli attende around globe share latest updat advanc lung cancer research treatment palpabl energi enthusiasm among particip highlight progress made field four confer present coincid public new england journal medicin among mani excit find present confer result pacif studi show durvalumab lead meaning improv overal surviv patient stage iii unresect non small cell lung cancer nsclc progress follow chemoradiotherapi alta l studi show first line brigatinib improv progress free surviv treatment na alk nslcl patient advanc diseas result keynot studi found pembrolizumab plu chemotherapi significantli prolong overal surviv progress free surviv among patient untreat metastat squamou nsclc impow studi found addit pd l inhibitor atezolizumab carboplatin etoposid provid signific improv overal progress free surviv first line manag extens stage small cell lung cancer es sclc mark first major advanc sclc two decad nelson screen studi found reduct mortal risk male pave way rollout low dose ct screen europ dacomitinib receiv fda approv first line treatment patient metastat nsclc egfr exon delet exon l r substitut mutat',\n",
       " 'link articl ocrelizumab work dmt ppm well rrm avail yet come http www managedcaremag com news multipl sclerosi drug ocrelizumab',\n",
       " 'say uc soy scope show uc obvious uc would say howev diet seem work well still activ inflamm dx crohn june yay tri asa azathioprin mp remicad methotrex humira diet st surgeri subtot colectomi end ileostomi nd surgeri ileorect anastomosi stoma revers ileum connect rectum current statu chronic flare kind current med mg mp entyvio start',\n",
       " 'studi immun system recogn friend foe immunologist sir macfarlan burnet phrase distinguish self non self driven import discoveri transform abil treat cancer last centuri scientist clinician unravel complex interact innat adapt immun lead erad virus bacteria parasit cancer notabl cellular player includ cell b cell natur killer nk cell neutrophil eosinophil basophil dendrit cell macrophag along host secret mediat antibodi complement cytokin chemokin fulfil particular immunolog function immun system fail regul process autoimmun diseas consequ diseas also occur share antigen recogn immun system normal cancer cell one exampl lambert eaton syndrom monoclon antibodi target tumor reactiv cell eg nivolumab pembrolizumab also caus autoimmun diseas exampl includ graft vs host diseas gvhd allogen bone marrow transplant recipi cytokin releas syndrom cr associ adopt cell therapi relat articl understand gut microbiom improv clinic oncolog soft tissu sarcoma nivolumab trabectedin safe clinic activ spontan regress cancer explan predict effort thousand investig start dr william coley centuri ago recent includ research dr macfarlan burnet lewi thoma steven rosenberg carl june jame allison lloyd old oncologist offer patient effect us food drug administr fda approv immunotherapi treatment design directli indirectli attack cancer histor timelin fda approv repres immunotherapi relat drug select indic recombivax prevent hepat b infect hepatocellular cancer caus viral infect interferon alfa b hairi cell leukemia subsequ approv renal cell cancer melanoma kaposi sarcoma bcg superfici bladder cancer filgrastim neutropenia chemotherapi interleukin renal cell cancer subsequ approv melanoma epoetin alfa anemia chemotherapi rituximab non hodgkin lymphoma subsequ approv cancer type indic trastuzumab breast cancer subsequ approv gastric cancer esophag cancer alemtuzumab chronic lymphocyt leukemia bevacizumab colorect cancer subsequ approv mani cancer breast lung glioblastoma multiform uterin cervic cetuximab colorect cancer subsequ approv head neck cancer sipuleucel prostat cancer ipilimumab melanoma nivolumab melanoma subsequ approv mani cancer type includ non small cell lung cancer hepatocellular cancer hodgkin lymphoma bladder cancer renal cancer colorect cancer pembrolizumab melanoma subsequ approv non small cell lung cancer gastric cancer mani cancer microsatellit high express defici mismatch repair function gardasil prevent human papilloma viru hpv infect cervic cancer cancer caus viral infect talimogen laherparepvec melanoma durvalumab non small cell lung cancer bladder cancer tisagenlecleucel acut lymphoblast leukemia axicabtagen ciloleucel lymphoma',\n",
       " 'hello ann nice meet cours worri understand complet one lc pal shock learn diagnosi follow broken arm minor car accid keytruda well today read post best news onc will consult big dog denver top lc expert denver knee deep cut edg research real box thinker might want check lung cancer live room bonni j addario foundat websit denver lc doc featur guest creativ doc will go beyond help advanc scienc sound like awesom doc team captain faith doc god guid join countri largest prayer poss togeth michel',\n",
       " 'san diego baselin expand disabl statu scale score number relaps first year consist predictor disabl worsen relaps subsequ year long term analysi three phase fingolimod trial patient identifi higher risk wors long term clinic outcom could benefit earli review multipl sclerosi ms treatment regimen help prevent worsen disabl pavl repov md phd said interview damian mcnamara frontlin medic news dr pavl repov idea time figur tell whether patient respond therapi earli dr repov said actrim forum held america committe treatment research multipl sclerosi explor long term clinic predictor disabl progress relaps risk dr repov colleagu analyz three phase trial assess fingolimod gilenya evalu paramet baselin first year freedom freedom ii transform studi',\n",
       " 'thought ought give latest updat cladribin experi neg deterior great deal sinc walk much wors longer walk two stick best use rollat worst wheelchair day need wheelchair cladribin use stick hous rollat need carri someth need clonazepam tablet control leg twitch night mg gradual increas one tablet take year bladder control less reliabl fall frequent week return trigemin neuralgia realli badli last year quit mild compar last time seem confirm see inflamatori activ rather nerv death take someth like hour get dress morn slightli less time get undress even fact everyth take much longer come enough time live life want tri get back gilenya hope slow deterior see feel tri cladribin probabl one biggest mistak ever made',\n",
       " 'ok forgot mention gi gave rx cipro flagyl finish day worth antibiot immedi made feel better also fistula definit heal notic much week hope day antibiot enough took humira booster shot last weekend realli felt better well first hour inject suck feel better drop prednison mg mg monday feel good start uceri foam day ago think help look complic clip dispos applic foam cannist realli easi way comfort use rowasa enema enough energi thing hous clean list check make recip found pinterest keep toddler wherea sick stay awak troubl sleep need pace though excit energi must rememb still heal moder hard mri bone densiti scan today told fast made awar would drink bunch icki slimi liquid time interv forget brand name clear slimi tast like squirt soda still better barium drink twice pee mri held minut left pee bit girl could get machin luckili wear depend harm foul becom fan dispos underwear knock til tri take th humira inject tomorrow later usual toddler nd birthday want feel like crap hope exhaust discomfort caus lessen heal want plan weekend around humira shot updat result mri bone scan next week yr femal diagnos hospit uc current humira apriso prednison mg taper mg week buproprion synthroid start humira feb previous fail remicaid previous use asacol lialda delzicol pentasa cortenema rowasa canasa entocort uceri gluten free supp vsl cal mag vit krill oil post edit plucki pm gmt',\n",
       " 'profi say base london ask dad refer royal london contact team would abl discuss whether cladribin good option use labl probabl best bet',\n",
       " 'u food drug administr fda recent accept supplement biolog licens applic sbla grant prioriti review atezolizumab tecentriq combin bevacizumab avastin paclitaxel carboplatin first line treatment metastat nonsquam non small cell lung cancer nsclc fda expect make decis approv septemb phase iii result show atezolizumab combin bevacizumab paclitaxel carboplatin potenti provid signific surviv benefit initi treatment metastat nonsquam non small cell lung cancer said sandra horn md chief medic offic head global product develop genentech sbla base result phase iii impow studi met coprimari endpoint overal surviv progress free surviv initi treatment patient advanc nonsquam nsclc safeti profil combin consist safeti profil individu medicin new safeti signal identifi atezolizumab current approv fda treat patient metastat nsclc diseas progress follow platinum contain chemotherapi appropri fda approv target therapi tumor alk egfr gene abnorm impow studi impow multicent open label random control phase iii studi evalu efficaci safeti atezolizumab combin carboplatin paclitaxel without bevacizumab peopl stage iv nonsquam nsclc treat chemotherapi advanc diseas enrol peopl alk egfr mutat exclud primari intent treat analysi peopl random receiv atezolizumab plu carboplatin paclitaxel atezolizumab bevacizumab plu carboplatin paclitaxel bevacizumab plu carboplatin paclitaxel control arm coprimari endpoint overal progress free surviv determin investig use respons evalu criteria solid tumor version recist version primari analysi coprimari progress free surviv endpoint impow assess two popul random peopl without alk egfr genet mutat intent treat wild type subgroup peopl specif biomark effector cell [teff] gene signatur express coprimari overal surviv endpoint assess random peopl without alk egfr genet mutat intent treat wild type key secondari endpoint includ investig assess progress free overal surviv safeti intent treat popul egfr alk mutat subgroup content post review american societi clinic oncolog inc asco necessarili reflect idea opinion asco',\n",
       " 'repli post croninstc ulcer coliti diagnos year old youngest sister child never even broken bone never sick child famili histori ibd diagnos disbelief research found highli rate activ involv research gi central iowa area also happen director iowa digest diseas center pcp request take patient thank end confirm diagnosi seen ever sinc rememb hard mom handl diagnosi convinc diseas come someth someth could pinpoint understand healthiest daughter fight lifetim diseas unfortun dieas came quickli believ stress factor dad go life threaten complic diabet also stress job collect client overdrawn account diet handl stress import factor manag ibd medic also import realli sick first year diagnosi steriod mani medic fail final approach gi discuss remicad serious medic chang life went abl walk block hunch pain exhaust pain continu abl live activ normal life start remicad abl leav unhealthi relationship later find healthi relationship healthi pregnanc husband hope son abl find medic help diseas get wors unfortun option handl diseas oral medic thank option sorri hear would impact plan rotc life continu up down say thank diseas charact becom stronger trial face sinc diagnosi becom understand compassion other understand diseas visabl good luck son support everyth lucki parent care much get input other learn diseas treatment option connect other ibd commun read countless book tri understand diseas',\n",
       " 'greet everyon first post introduc name karen diagnos moder ibd probabl ulcer coliti might crohn diseas dr uncertain septemb sinc decemb remicad littl chang symptom start thotrex may slight improv symptom far suffer emetophobia phobia vomit like vomit fear paralyz affect lot aspect life manag start r micad treatment learn would lower immun system would vulner infect food intox ad thotrex help much bare eat anymor made mistak read internet indic follow compromis immun system scare pretti much everi type food needless say avoid restaur well comfort reassur one cook live ensur toast sometim pasta seek help deal phobia wonder r micad r micad thotrex much chang eat habbit besid food unabl eat due ibd avoid anyth els like mayonnais raw egg etc keep go restaur notic differ catch food intox often usual peopl around tip offer would help current issu would love hear',\n",
       " 'well know remicad work well consid anoth similar biolog within class remicad cimzia humira tnf alpha block biolog develop antibodi one tnf alpha blocker mean develop antibodi cimzia humira molecular structur differ enough immun system must start ground antibodi develop process might never develop antibodi cimzia humira could increas odd stelara complet differ class biolog complet differ mechan action gambl much like entyvio anoth entir differ class biolog aforement biolog class moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa two certainti life pay tax prednison side effect',\n",
       " 'chemotherapi treatment chemic kill cell divid grow rapidli like cancer cell unfortun normal cell e g skin line digest tract hair follicl also rapidli divid grow chemotherapi also affect cell may caus unwant side effect kind chemotherapi doctor recommend depend individu situat type lung cancer non small cell small cell diagnos overal health goal treatment person prefer taken consider initi first line chemotherapi lung cancer often includ platinum base drug cisplatin carboplatin anoth drug drug paclitaxel taxol docetaxel taxoter etoposid vp gemcitabin gemzar vinorelbin navelbin pemetrex alimta bevacizumab avastin may also use instead addit drug first line chemotherapi decreas size cancer continu grow drug may use togeth separ chemotherapi initi round call second line type chemotherapi neo adjuv chemotherapi neo adjuv chemotherapi treatment chemotherapi use anoth treatment lung cancer typic use tri shrink tumor surgeri possibl adjuv chemotherapi adjuv chemotherapi treatment chemotherapi use anoth treatment lung cancer typic use goal kill stray cancer cell may remain surgeri chemotherapi recommend surgeri stage ia lung cancer lung cancer stage ii remov surgeri chemotherapi typic recommend use chemotherapi surgeri stage ib lung cancer remain controversi sure talk doctor risk benefit adjuv chemotherapi make inform decis mainten chemotherapi mainten chemotherapi chemotherapi continu usual cycl continu mainten switch mainten new drug given longer period first treatment cycl complet one type chemotherapi pemetrex alimta approv mainten chemotherapi non small cell lung cancer other may use doctor part clinic trial set one target drug erlotinib tarceva also approv use mainten non small cell lung cancer certain circumst lung cancer specialist agre mainten chemotherapi use lung cancer come back recur success treatment differ chemotherapi may use alon togeth',\n",
       " 'ncot brelax terrif idea look univers psycholog care univers psycholog phd program train clinic train graduat student becom psychologist see real patient fee oper slide scale even top price fairli inexpens anyon patient clinic student clinician student student alway supervis one faculti member actual get top notch care realli experienc peopl overse case usual use cut edg treatment see wide varieti patient uk locat like help find clinic first hand knowledg year old male diagnos crohn age happi humira year august fail remicad cimzia imuran mp mtx ileostomi april began entyvio juli med except nexium',\n",
       " 'repli post andygibson remicad half year recent switch entivyo remicad would sometim get someth similar bodi ach sure awar remicad treat certain auto immun disord also caus one thing look pain continu consist basi rheumatoid arthriti remicad diagnos psoriasi told like diagnos psoriat arthriti point happen yet love remicad total game changer get psoriasi worth abl function without intens pain uc also gi bone densiti scan prior go remicad prednison longer ideal period also someth may want discuss gi sever round steriod thank longest stint prednison month even long enough damag still sometim wake feel like intens workout day prior without normal physic activ day chalk either season winter suck iowa bodi low nutrient need hope help',\n",
       " 'hello slept last night sm woke pm holiday begun stress work two week ago ad eyelin eye liquid one make soducrem hope that written face that feaur thing ive done felt huge pain eye ive dont corneal contact implant scare load even felt implant contact bit two week got pimpl eye eyel anoth pimpl next ear dont ever get pimpl accur suddenli feel hate face regardless feel period pain period time feel exactli like tum back sleepi tire fatigu way much usual sinc oppen eye stair wors think gilenya twice one day forgot',\n",
       " 'nation ms societi fast forward invest enabl tg therapeut inc laboratori test tgr umbralisib potenti oral treatment option progress ms renown ms research dr lawrenc steinman stanford univers lead research team effort invest stem request propos releas fast forward project focus test exist therapi drug candid determin protect nervou system damag repair damag especi treatment progress ms tgr alreadi test peopl blood cancer readi test ms lab test suggest potenti benefit hope proof concept studi support rational clinic develop tgr progress form ms treatment option said mark allegretta phd associ vice presid commerci research societi invest exemplifi effort identifi clinic readi candid expand pipelin therapi test use ms tgr use novel mechan inhibit product immun b cell known involv ms diseas activ anoth b cell therapi ocrevu ocrelizumab genentech member roch group recent approv primari progress relaps ms read read fast forward read research progress ms ocrevu trademark genentech member roch group',\n",
       " 'american academi neurolog aan th annual meet took place philadelphia pennsylvania april th may rd aan associ neurologist neurosci profession dedic advanc care individu neurolog diseas everi year profession gather hear latest find research treatment neurolog condit includ multipl sclerosi ms follow import highlight pleas note time write drug approv unit state food drug administr fda long term treatment ms known diseas modifi therapi dmt nearli drug continu show long term safeti signific effect reduc ms diseas activ addit dmt sever experiment treatment make way approv process fda approv medic ms result prospect evalu use avonex pen autoinjector self administ avonex interferon beta intramuscularli report user self report demonstr fear inject decreas percent percent month proport requir assist inject decreas percent percent betaseron interferon beta first drug approv fda long term treatment ms benefit trial individu clinic isol syndrom ci random receiv earli treatment betaseron advanc clinic definit ms cdm quickli began treatment later time studi particip began betaseron earli also experienc lower relaps rate treat later time patient report outcom qualiti life qol remain high group treat patient two year extens studi gala trial assess efficaci safeti copaxon glatiram acet newer mg dose inject subcutan three time weekli open label extens studi observ effect higher dose less frequent administr particip rrm dose administr origin approv mg inject subcutan daili studi conclud earli treatment newer dose copaxon lower risk relaps well rate disabl progress rel start therapi later time safeti data similar copaxon well establish safeti profil advers event note gener mild major peopl relaps form ms use rebismart autoinjector self administ rebif interferon beta rate conveni devic posit separ studi research conduct post hoc analysi prism studi look data determin relaps rate patient rebif versu placebo cours one year studi conclud treatment rebif associ rapid onset action zero three month despit titrat titrat refer start lower dose increas full dose time treat patient improv rate percent fewer relaps first year compar placebo two import factor contribut good outcom tysabri natalizumab treat individu diagnos progress multifoc leukoencephalopathi pml rare sever complic treatment earli diagnosi treatment case report patient success treat diagnos pml follow six year treatment tysabri specif instanc patient went hospit follow disturb gait pml diagnos underw prescrib therapi remov tysabri system plasma exchang accord studi patient clinic stabl entir period initi gait disturb diminish week percent individu treat tysabri edss score progress edss score six year later addit affirm studi tysabri shown increas probabl confirm improv walk speed ciw post hoc analysi found patient confirm improv walk speed better self report physic function rate seriou infect opportunist infect patient treat aubagio teriflunomid year differ treat placebo opportunist infect one caus organ normal affect person healthi immun system may caus ill person compromis immun system anoth studi look two phase iii trial aubagio temso tower studi evalu drug effect clinic ms diseas activ studi particip post hoc analysi studi perform determin proport patient remain free clinic ms diseas activ take aubagio studi conclud approv diseas modifi therapi reduc risk clinic diseas activ consist effect across wide rang patient relaps form ms percent patient relaps remit ms rrm begin treatment gilenya fingolimod fti experienc cardiac rhythm abnorm find consist previou studi individu rrm enrol one week open label start studi studi particip addit diagnost requir includ hour electrocardiogram ecg screen studi baselin e start studi cardiologist evalu ecg record research also look effect gilenya reduc amount brain volum loss individu ms treat gilenya phase iii extens trial studi conclud annual percentag brain volum chang pbvc patient individu show consist low rate brain atrophi versu placebo phase iii trial freedom freedom ii well versu avonex one year extens studi transform accord author support previou observ individu studi half individu relaps remit ms [rrms] take tecfidera dimethyl fumar report experienc gastrointestin symptom half report flush rate similar found prior clinic trial sixteen percent discontinu treatment due side effect rate slightli higher found previou studi effort reduc symptom ongo use tecfidera frequent associ gastrointestin gi symptom includ abdomin discomfort diarrhea nausea vomit within group four individu took oral asthma medic montelukast mg daili continu treatment tecfidera gi symptom decreas within hour improv persist day symptom sever measur gastrointestin symptom rate scale gsr decreas percent four year follow conduct determin integr clinic efficaci result three studi use tecfidera treat rrm studi includ phase iii defin confirm studi well five year endors extens studi result analysi show low relaps rate low disabl progress continu four year follow addit neuroradiolog efficaci found mri scan accept safeti profil ms treatment review fda efficaci better individu receiv plegridi pegyl interferon beta everi two week receiv everi four week second year advanc phase ii studi peopl rrm safeti profil consist year one advanc beta interferon versu placebo dose frequenc plegridi everi two week everi four week significantli reduc risk week confirm disabl progress percent dosag significantli reduc annual relaps rate percent percent respect given lower risk disabl year one author studi suggest plegridi may improv recoveri follow relaps four year follow data ongo care ms extens studi found year zero four percent individu receiv lemtrada alemtuzumab formerli campath experienc thyroid advers event well known risk treatment drug none event result discontinu treatment lemtrada thyroid relat advers event treat convent treatment incid event peak month decreas thereaft ongo patient educ quarterli laboratori monitor allow time detect treatment three year follow data care ms ii extens studi demonstr lemtrada durabl treatment effect eighti percent individu rrm receiv two yearli cours drug care ms ii trial receiv third cours treatment seventi percent edss score stabl improv year three compar baselin measur upon entri trial impair visual function impact disabl individu diagnos rrm care ms ii studi individu take lemtrada improv visual outcom compar take rebif studi progress ms random trial adult chronic progress ms arm use neuroplast brain capac chang adapt improv use therapi call constraint induc movement therapi ci therapi forc use affect arm restrain unaffect arm sling result suggest ci therapi may counteract progress loss function well central nervou system cn degener progress ms pixantron pix investig altern effect cardio toxic drug novantron mitoxantron mix treatment aggress rrm secondari progress ms spm phase ii studi patient aggress diseas pixantron effect novantron less cardiotox accord studi abstract pixantron structur similar novantron drug similar immunosuppress properti anim studi howev author state pixantron less toxic heart phase ii doubl blind placebo control studi peopl spm sr crh well toler result signific improv sever secondari endpoint endpoint includ ms function composit msfc time foot walk mean hole peg test hpt sr crh stabil neuropeptid also known aimspro larger longer term studi warrant given promis result allegro bravo trial studi effect laquinimod individu rrm pool data trial examin determin effect laquinimod confirm disabl progress cdp sever subgroup includ group least favor msfc score result encourag suggest laquinimod may benefit peopl progress type ms laquinimod experiment oral medic work immunomodul retrospect evalu clinic outcom individu spm demonstr percent stabil percent significantli improv follow treatment rituxan rituximab signific advers event report rituxan like continu develop treatment ms data support continu develop next gener anti cd monoclon antibodi experiment treatment ms vitamin total peopl ms rrm treat either mcg alfacalcidol vitamin analog daili six month placebo patient alfacalcidol treat group reduc number relaps compar placebo group also experienc signific improv fatigu base fatigu improv scale fi compar placebo group qualiti life scale posit affect well seriou advers event occur either arm studi stem cell transplant safeti feasibl autolog patient mesenchym stem cell transplant studi stream phase ii trial individu highli activ ms advers event seen five patient infus date total patient recruit preliminari result support safeti feasibl mesenchym stem cell transplant popul data avail indic whether ms affect ofatumumab result mirror week phase ii studi compar sever dose ofatumumab also known arzerra rrm report signific reduct new gadolinium enhanc lesion seen treatment group compar placebo five seriou advers event report highest dose treatment group case pml observ ofatumumab also known arzerra anti cd monoclon antibodi given via iv anti lingo design synergi phase ii trial studi safeti efficaci anti lingo monoclon antibodi biib present total subject activ rrm spm random intraven iv infus experiment medic placebo subject also receiv weekli inject avonex result expect aid decis develop drug cn neuroprotect repair anti lingo agent investig potenti remyelin properti anim studi show block protein respons stop growth myelin daclizumab hyp result select select extens studi indic treatment daclizumab hyp high yield process may result reduct rate brain atrophi ms patient suggest drug may long term neuroprotect effect daclizumab also known zenapax genet engin monoclon antibodi administ via iv studi individu rrm spm siponomid baf oral drug class drug gilenya safeti efficaci result bold extens studi individu rrm demonstr sustain efficaci find consist core bold studi new safeti concern identifi pregnanc take dmt despit requir reliabl contracept pregnanc report women either take aubagio clinic trial b partner men take aubagio clinic trial upon learn pregnanc women instruct discontinu aubagio undergo procedur result rapid elimin drug pregnanc outcom consist non ms popul structur function problem report infant expos aubagio context clinic trial women rrm plan becom pregnant advis discontinu treatment tysabri concept howev known high risk sever relaps follow discontinu tysabri relaps frequent requir high dose steroid treatment manag result prospect control studi women rrm discontinu treatment pregnanc report compar healthi diseas match control group rate major malform low birth weight prematur birth differ significantli import weigh risk benefit continu treatment tysabri risk benefit high dose steroid treatment pregnanc percent women ms respond reproduct event questionnair said reason want becom pregnant concern rais child parent ms reason record percent want children percent unsuccess tri becom pregnant percent spous percent consid pregnanc percent adopt retrospect analysi popul base databas british columbia found evid infant born father expos betaseron copaxon around time concept associ alter birth weight gestat age italian studi found infant father ms take one dmt betaseron copaxon around time concept similar outcom infant father ms take drug ever around time concept differ observ birth weight length frequenc pre term deliveri incid spontan abort pregnanc deliveri complic infant malform report follow exposur drug cognit studi peopl rrm found ms relaps caus signific declin test measur cognit function treatment tysabri shown superior placebo preserv cognit function first two year therapi interim analysi data observ studi patient treat tysabri continu two year suggest treatment preserv possibl improv cognit function beyond two year continu therapi exampl interest studi estim percent case ms diagnos age pediatr ms hispan one studi found pediatr onset occur percent peopl ms includ studi observ studi peopl diagnos ms smoke cessat found significantli reduc risk progress either edss spm group peopl rrm individu high sodium intak time like develop new lesion averag eight lesion mri low moder sodium intak peopl medium high sodium intak fold greater chanc experienc worsen diseas low sodium intak find replic separ studi peopl ms previou studi estim preval rate tast dysfunct percent ms studi peopl ms match control found almost percent peopl ms exhibit tast dysfunct type tast affect includ sweet sour bitter salti pleas see msaa ms research updat addit detail fda approv diseas modifi therapi experiment treatment ms research inform speak train helplin consult pleas call msaa question msaa client servic depart may also email msquestion mymsaa org written margaret mccormick rn bsn mscn review jack burk md msaa chief medic offic edit susan well courtney msaa senior writer creativ director editor note msaa endors recommend specif product therapi reader advis consult physician make chang medic diet exercis treatment regimen initi studi result therapeut agent investig consid preliminari sinc addit studi evalu may need prove safeti efficaci agent pleas note differ length text dedic topic way consid favorit toward one product inform given articl sampl variou highlight aan meet',\n",
       " 'hello absent site felt good took littl cancer vacat lead rel normal life thank stereotact control met show resist tagrisso therapi current month new brain met discov cerebellum need zap soon light balanc issu bring back old question sep guy answer time suggest chemo tagrisso resist agre effect brain kadmon trial tesevatinib show success brain develop trial meantim sinc last year question might ask sever time sorri bug difficult research site length without activ reader along diagnos decemb brain met along egfr po exon adenocarcinoma lung decemb reach year surviv stage desper tri delay leptomening carcinomatosi thank much suggest kempten',\n",
       " 'cladribin easier far',\n",
       " 'type monoclon antibodi use cancer detect therapi monoclon antibodi laboratori produc substanc locat bind cancer cell aap alanin aminopeptidas enzym use biomark detect damag kidney may use help diagnos certain kidney disord found high level urin kidney problem also call alanin aminopeptidas abarelix ba rel ik drug use reduc amount testosteron made patient advanc symptomat prostat cancer treatment option avail belong famili drug call gonadotropin releas hormon gnrh antagonist also call plenaxi abcd rate stage system prostat cancer use abcd b refer cancer confin prostat c refer cancer grown prostat spread lymph node place bodi refer cancer spread lymph node place bodi also call jewett stage system whitmor jewett stage system abdomen ab doh men area bodi contain pancrea stomach intestin liver gallbladd organ abdomin abdomen part bodi chest hip contain pancrea stomach intestin liver gallbladd organ abdomin x ray ab dah mih nul ex ray x ray organ insid abdomen x ray type radiat pass bodi onto film make pictur area insid bodi x ray may use help diagnos diseas abdominoperin resect surgeri remov anu rectum part sigmoid colon incis made abdomen end intestin attach open surfac abdomen bodi wast collect dispos bag outsid bodi open call colostomi lymph node contain cancer may also remov oper aberr crypt foci uh bayr unt kript foh sy acf cluster abnorm tube like gland line colon rectum aberr crypt foci form colorect polyp one earliest chang seen colon may lead cancer also call acf abi drug use treat breast cancer spread come back within month chemotherapi also studi treatment newli diagnos breast cancer type cancer abi type mitot inhibitor also call nanoparticl paclitaxel protein bound paclitaxel paclitaxel albumin stabil nanoparticl formul abraxan ablat blay shun medicin remov destruct bodi part tissu function ablat may perform surgeri hormon drug radiofrequ heat method abnorm normal abnorm lesion growth may cancer premalign like becom cancer benign abraxan uh brax ayn drug use treat breast cancer spread come back within month chemotherapi also studi treatment newli diagnos breast cancer type cancer abraxan type mitot inhibitor also call nanoparticl paclitaxel protein bound paclitaxel paclitaxel albumin stabil nanoparticl formul abi abscess enclos collect pu tissu organ confin space bodi abscess sign infect usual swollen inflam absorpt ub sorp shun process take nutrient digest system blood use bodi abt substanc studi treatment lymphoma type cancer block enzym keep cancer cell die type bcl famili inhibitor abt substanc studi treatment cancer type angiogenesi inhibitor abt substanc studi treatment cancer belong famili drug call sulfonamid abt substanc studi treatment type cancer block enzym repair dna damag caus cancer treatment radiat drug abt type poli adp ribos polymeras inhibitor abx egf human monoclon antibodi use treat colorect cancer spread part bodi use patient whose diseas gotten better treatment anticanc drug also studi treatment type cancer monoclon antibodi made laboratori locat bind cancer cell abx egf bind epiderm growth factor receptor egfr may block tumor cell growth also call panitumumab vectibix acceler phase chronic myelogen leukemia ak seh leh ray ted fayz krah nik eh lah jeh nu loo kee mee uh phase chronic myelogen leukemia diseas progress phase cell blood bone marrow blast cell immatur blood cell ace inhibitor angiotensin convert enzym inhibitor drug use lower blood pressur ace inhibitor type antihypertens agent also call angiotensin convert enzym inhibitor acetaminophen drug reduc pain fever inflamm belong famili drug call analges acetylcystein drug usual use reduc thick mucu eas remov also use revers toxic high dose acetaminophen also call n acetylcystein n acetyl l cystein acf aberr crypt foci cluster abnorm tube like gland line colon rectum acf form colorect polyp one earliest chang seen colon may lead cancer also call aberr crypt foci achlorhydria klor hy dree lack hydrochlor acid digest juic stomach hydrochlor acid help digest food acitretin substanc use prevent cancer treatment psoriasi belong famili drug call retinoid acn substanc studi treatment type cancer acn weaken adenoviru carri p gene tumor cell caus die type gene therapi also call recombin adenoviru p rad p sch acn disord skin oil gland hair gland becom inflam acoust ah koo tik sound hear acoust neurofibromatosi koo tik noor oh fy broh muh toh si genet condit tumor form nerv inner ear caus loss hear balanc tumor may also occur brain nerv skull spinal cord may caus loss speech eye movement abil swallow also call neurofibromatosi type nf acquir immunodefici syndrom uh kwi erd ih myoo noh dih fih shun see sin drome aid diseas caus human immunodefici viru hiv peopl acquir immunodefici syndrom increas risk develop certain cancer infect usual occur individu weak immun system also call aid acridin carboxamid daca substanc studi treatment cancer type topoisomeras inhibitor also call daca acromegali kroh meh guh lee condit pituitari gland make much growth hormon normal growth skeleton finish caus bone hand feet head face grow larger normal acromegali caus pituitari gland tumor acrylonitril ak ri low nye tril substanc use make plastic rubber textil expos acrylonitril may increas risk develop certain cancer lung brain prostat cancer acth hormon made pituitari gland acth act outer part adren gland control releas corticosteroid hormon acth made time stress also call adrenocorticotrop hormon corticotropin actinex drug put skin treat growth caus sun exposur form nordihydroguaiaret acid taken mouth studi treatment prostat cancer nordihydroguaiaret acid antioxid may block certain enzym need tumor growth also call nordihydroguaiaret acid ndga masoprocol actin keratosi ak tih nik kayr uh toh si precancer condit thick scali patch skin also call solar keratosi senil keratosi action studi cancer prevent clinic trial studi focus find whether action peopl take prevent cancer activas ak tih vay form tissu plasminogen activ made laboratori help dissolv blood clot use treat heart attack stroke clot lung also studi treatment cancer type system thrombolyt agent also call recombin tissu plasminogen activ r tpa alteplas activ biolog stimul cell rest state becom activ caus biochem function chang activ cell activ daili live adl task everyday life activ includ eat dress get bed chair take bath shower use toilet instrument activ daili live activ relat independ live includ prepar meal manag money shop housework use telephon also call adl acto drug use treat type diabet studi prevent head neck cancer may abl stop leukoplakia precancer condit affect mouth develop cancer belong famili drug call thiazolidinedion also call pioglitazon acupoint ak yoo poynt specif spot bodi acupunctur needl may insert control pain symptom also call acupunctur point acupressur ak yoo preh sher applic pressur local massag specif site bodi control symptom pain nausea type complementari altern medicin acupunctur ak yoo punk cher techniqu insert thin needl skin specif point bodi control pain symptom type complementari altern medicin acupunctur needl ak yoo punk cher nee dul stainless steel needl slightli thicker human hair acupunctur needl insert skin specif point bodi control pain symptom acupunctur point ak yoo punk cher poynt specif spot bodi acupunctur needl may insert control pain symptom also call acupoint acupunctur point inject ak yoo punk cher poynt jek shun procedur drug vitamin herbal extract fluid inject bodi acupunctur point use syring needl acustimul mild electr stimul acupunctur point control symptom nausea vomit acut uh kyoot symptom sign begin worsen quickli chronic acut leukemia uh kyoot loo kee mee uh rapidli progress cancer start blood form tissu bone marrow caus larg number white blood cell produc enter blood stream acut lymphoblast leukemia lim foh bla tik loo kee mee uh fast grow type leukemia blood cancer mani lymphoblast immatur white blood cell found blood bone marrow also call acut lymphocyt leukemia acut lymphocyt leukemia lim foh sih tik loo kee mee uh fast grow type leukemia blood cancer mani lymphoblast immatur white blood cell found blood bone marrow also call acut lymphoblast leukemia acut myeloblast leukemia uh kyoot eh loh bla tik loo kee mee uh quickli progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call aml acut myeloid leukemia acut myelogen leukemia acut nonlymphocyt leukemia anll acut myelogen leukemia uh kyoot eh lah jeh nu loo kee mee uh quickli progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call aml acut myeloid leukemia acut myeloblast leukemia acut nonlymphocyt leukemia anll acut myeloid leukemia uh kyoot eh loyd loo kee mee uh quickli progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call aml acut myelogen leukemia acut myeloblast leukemia acut nonlymphocyt leukemia anll acut nonlymphocyt leukemia uh kyoot non lim foh sih tik loo kee mee uh quickli progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call acut myelogen leukemia acut myeloid leukemia acut myeloblast leukemia aml anll acut pain uh kyoot payn pain come quickli sever last rel short time acut promyelocyt leukemia uh kyoot pro eh loh sih tik loo kee mee uh apl aggress fast grow type acut myeloid leukemia mani immatur blood form cell blood bone marrow usual mark exchang part chromosom also call apl promyelocyt leukemia acyclovir substanc use prevent treat cytomegaloviru herp simplex infect may occur bodi immunosuppress belong famili drug call antivir ad drug use treat bladder cancer respond bcg bacillu calmett guerin anthracyclin type antitumor antibiot also call valrubicin adderal combin drug use treatment attent deficit hyperact disord adhd narcolepsi sleep disord type stimul also call dextroamphetamin amphetamin addict uncontrol crave seek use substanc drug alcohol adenocarcinoma den oh kar sih noh muh cancer begin cell line certain intern organ gland like secretori properti adenoid cystic carcinoma deh noyd si tik kar sih noh muh rare type cancer usual begin salivari gland adenoma deh noh muh noncancer tumor adenopathi deh nah puh thee larg swollen lymph gland adenosin triphosph uh deh nuh seen tri fo fayt atp substanc present live cell provid energi mani metabol process involv make rna adenosin triphosph made laboratori studi patient advanc solid tumor see decreas weight loss improv muscl strength also call atp adenosquam carcinoma den oh skway mu kar sih noh muh type cancer contain two type cell squamou cell thin flat cell line certain organ gland like cell adenoviru den oh vy ru group virus caus respiratori tract eye infect adenovirus use gene therapi alter carri specif tumor fight gene adi peg substanc studi treatment melanoma liver cancer type cancer break amino acid arginin may block growth cancer cell need arginin grow type iminohydrolas also call pegyl arginin deiminas adjunct agent junkt ay jent cancer therapi drug substanc use addit primari therapi adjunct therapi junkt thayr uh pee anoth treatment use togeth primari treatment purpos assist primari treatment also call adjunct therapi adjunct therapi junk tiv thayr uh pee anoth treatment use togeth primari treatment purpos assist primari treatment also call adjunct therapi adjust disord uh ment di der condit person respond stress event ill job loss divorc extrem emot action caus problem work home adjuv therapi joo vant thayr uh pee treatment given primari treatment increas chanc cure adjuv therapi may includ chemotherapi radiat therapi hormon therapi biolog therapi adl activ daili live task everyday life basic adl includ eat dress get bed chair take bath shower use toilet instrument activ daili live iadl activ relat independ live includ prepar meal manag money shop housework use telephon also call activ daili live administr ad mih nih stray shun medicin act give treatment drug patient also refer way given dose often given adnex mass ad nek sul lump tissu near uteru usual ovari fallopian tube adnex mass includ ovarian cyst ectop tubal pregnanc benign noncancer malign cancer tumor adren cancer uh dree nul kan ser cancer form tissu adren gland two gland locat kidney adren gland make hormon control heart rate blood pressur import bodi function adren cancer start outsid layer adren gland call adrenocort carcinoma adren cancer start center adren gland call malign pheochromocytoma adren cortex uh dree nul kor tex outer part adren gland small organ top kidney adren cortex make androgen corticosteroid hormon adren gland uh dree nul small gland make steroid hormon adrenalin noradrenalin hormon help control heart rate blood pressur import bodi function two adren gland one top kidney also call supraren gland adren medulla uh dree nul meh doo luh inner part adren gland small organ top kidney adren medulla make chemic epinephrin adrenalin norepinephrin noradrenalin involv send nerv signal adrenalectomi uh dree nul ek toh mee surgeri remov one adren gland small organ top kidney adrenalin hormon neurotransmitt also call epinephrin adrenocort uh dree noh kor tih kol made outer layer adren gland produc steroid hormon adren gland top kidney adrenocort cancer uh dree noh kor tih kol kan ser rare cancer form outer layer tissu adren gland small organ top kidney make steroid hormon adrenalin noradrenalin control heart rate blood pressur bodi function also call adrenocort carcinoma cancer adren cortex adrenocort carcinoma uh dree noh kor tih kol kar sih noh muh rare cancer form outer layer tissu adren gland small organ top kidney make steroid hormon adrenalin noradrenalin control heart rate blood pressur bodi function also call adrenocort cancer cancer adren cortex adrenocorticotrop hormon uh dree noh kor tih koh troh pik hor mone acth hormon made pituitari gland adrenocorticotrop hormon act outer part adren gland control releas corticosteroid hormon adrenocorticotrop hormon made time stress also call corticotropin acth adriamycin pf ay dree uh sin drug use treat mani type cancer studi treatment type cancer adriamycin pf come bacterium streptomyc peucetiu damag dna molecul insid cell carri genet inform stop cell grow rapidli grow tumor cell take adriamycin pf may die type anthracyclin antitumor antibiot also call doxorubicin hydrochlorid doxorubicin adriamycin rdf rubex adriamycin rdf ay dree uh sin drug use treat mani type cancer studi treatment type cancer adriamycin rdf come bacterium streptomyc peucetiu damag dna molecul insid cell carri genet inform stop cell grow rapidli grow tumor cell take adriamycin rdf may die type anthracyclin antitumor antibiot also call doxorubicin hydrochlorid doxorubicin adriamycin pf rubex adult cell leukemia lymphoma atll aggress fast grow type cell non hodgkin lymphoma caus human cell leukemia viru type htlv mark bone skin lesion high calcium level enlarg lymph node spleen liver also call atll advanc direct legal document state treatment care person wish receiv receiv becom unabl make medic decis exampl due unconsci coma type advanc direct live will resuscit dnr order advanc cancer ad vanst kan ser cancer spread place bodi usual cannot cure control treatment advanc malign mesothelioma muh lig nunt meh zuh thee lee oh muh malign mesothelioma stage ii iii iv advers effect unwant side effect treatment advers event ad ver eh vent unexpect medic problem happen treatment drug therapi advers event caus drug therapi may mild moder sever ae substanc made shark cartilag studi abil prevent growth new blood vessel solid tumor belong famili drug call angiogenesi inhibitor aee substanc studi treatment cancer belong famili drug call protein tyrosin kinas inhibitor angiogenesi inhibitor aeg substanc studi treatment type cancer aeg may block protein call xiap chemotherapi abl kill tumor cell type antisens oligonucleotid also call gem aerob biochemistri reaction need oxygen happen happen oxygen present aerob metabol chemic process oxygen use make energi carbohydr sugar also call aerob respir oxid metabol cell respir aerob respir chemic process oxygen use make energi carbohydr sugar also call oxid metabol cell respir aerob metabol aerodigest tract combin organ tissu respiratori tract upper part digest tract includ lip mouth tongu nose throat vocal cord part esophagu windpip aerosol medicin turn liquid drug fine mist inhal aflatoxin fluh tok sin harm substanc made certain type mold aspergillu flavu aspergillu parasiticu often found poorli store grain nut consumpt food contamin aflatoxin risk factor primari liver cancer afp alpha fetoprotein protein normal produc fetu afp level usual undetect blood healthi adult men women pregnant elev level afp suggest presenc either primari liver cancer germ cell tumor also call alpha fetoprotein afp substanc studi treatment cancer afp kill cancer cell stop divid type aminoflavon ag substanc studi treatment cancer belong famili drug call angiogenesi inhibitor protein tyrosin kinas inhibitor ag substanc studi treatment cancer belong famili drug call glycinamid ribonucleotid formyl transferas inhibitor ag substanc studi treatment cancer matrix metalloproteinas inhibitor belong famili drug call angiogenesi inhibitor also call prinomastat ag substanc studi treatment liver cancer belong famili drug call thymidyl synthas inhibitor also call thymitaq nolatrex agent studi cancer prevent clinic trial studi whether take certain medicin vitamin miner food supplement prevent cancer also call chemoprevent studi agglutinin substanc make particl bacteria cell stick togeth form clump mass aggrav factor gruh vay ting fak ter someth make condit wors exampl tobacco smoke aggrav factor asthma aggress quickli grow cancer aggress lymphoma type lymphoma grow spread quickli sever symptom seen frequent patient hiv posit aid relat lymphoma also call intermedi grade lymphoma high grade lymphoma agit jih tay shun condit person unabl relax still person may tens irrit becom easili annoy small thing may eager argument unwil work caregiv make situat better agnogen myeloid metaplasia ag noh jen ik eh loyd meh tuh play zhuh progress chronic diseas bone marrow replac fibrou tissu blood made organ liver spleen instead bone marrow diseas mark enlarg spleen progress anemia also call chronic idiopath myelofibrosi primari myelofibrosi myelosclerosi myeloid metaplasia idiopath myelofibrosi agonist drug trigger action cell anoth drug agranulocyt ay gran yoo loh site type white blood cell monocyt lymphocyt agranulocyt aid acquir immunodefici syndrom diseas caus human immunodefici viru hiv peopl aid increas risk develop certain cancer infect usual occur individu weak immun system also call acquir immunodefici syndrom aid relat cancer reh layt id kan ser certain cancer type like occur peopl infect human immunodefici viru hiv common type kaposi sarcoma non hodgkin lymphoma aid relat cancer includ hodgkin diseas cancer lung mouth cervix digest system ajcc stage system stay jing si tem system develop american joint committe cancer describ extent cancer patient bodi descript includ tnm describ size tumor invad nearbi tissu n describ lymph node involv describ metastasi spread cancer one bodi part anoth alanin aminopeptidas aap enzym use biomark detect damag kidney may use help diagnos certain kidney disord found high level urin kidney problem also call aap alanin transferas enzym found liver tissu high level alanin transferas releas blood may sign liver damag cancer diseas also call serum glutam pyruv transaminas sgpt alanosin substanc studi treatment cancer belong famili drug call antimetabolit also call sdx albin al bye niz em group genet condit mark littl none pigment melanin skin hair eye peopl albin may vision problem white yellow hair reddish violet blue brown eye pale skin alcl aggress fast grow type non hodgkin lymphoma usual cell type cancer cell express marker call cd ki surfac may appear lymph node skin bone soft tissu lung liver also call anaplast larg cell lymphoma alcohol al kuh hol chemic substanc found beer wine liquor alcohol also found medicin mouthwash essenti oil scent liquid taken plant household product alcohol depend diseas person crave alcohol unabl limit drink need drink greater amount get effect withdraw symptom stop alcohol use alcohol depend affect physic mental health caus problem famili friend work also call alcohol alcohol al kuh haw lih zum diseas person crave alcohol unabl limit drink need drink greater amount get effect withdraw symptom stop alcohol use alcohol affect physic mental health caus problem famili friend work also call alcohol depend aldara al dar uh drug use treat earli basal cell skin cancer certain skin condit studi treatment type cancer aldara belong famili drug call biolog respons modifi also call imiquimod aldehyd al deh hide type chemic substanc made alcohol aldehyd found essenti oil scent liquid taken plant aldesleukin al de loo kin drug use treat type cancer interleukin cytokin normal made immun cell bodi made laboratori aldesleukin increas activ growth white blood cell call cell b cell type biolog respons modifi also call recombin human interleukin proleukin aldrich syndrom al drich sin drome inherit immun disord occur young boy caus eczema type skin inflamm decreas number platelet blood cell help prevent bleed frequent bacteri infect peopl aldrich syndrom increas risk develop leukemia lymphoma also call wiskott aldrich syndrom alefacept uh leh fuh sept drug use treat certain skin condit studi treatment cutan skin relat cell cancer cell non hodgkin lymphoma alefacept made combin part antibodi protein block growth type cell type fusion protein immunosuppress also call amev alemtuzumab type monoclon antibodi use treatment leukemia monoclon antibodi laboratori produc substanc locat bind cancer cell also call campath h alendron sodium uh len droh nayt soh dee um drug use treat osteoporosi paget diseas also studi treatment hypercalcemia abnorm high level calcium blood bone pain caus cancer alendron sodium increas bone densiti slow bone destruct prevent loss calcium type bisphosphon also call fosamax alimta uh lim tuh drug use treat malign pleural mesothelioma advanc non small cell lung cancer studi treatment type cancer type enzym inhibitor also call pemetrex disodium ly alkalin al ka lin ih zay shun process substanc becom alkali alkali opposit acid alkaloid member larg group chemic made plant nitrogen alkaloid shown work cancer alkeran drug use treat multipl myeloma ovarian epitheli cancer studi treatment type cancer belong famili drug call alkyl agent also call melphalan alkyl agent drug use treatment cancer interfer cell dna inhibit cancer cell growth acut lymphoblast leukemia fast grow type leukemia blood cancer mani lymphoblast immatur white blood cell found blood bone marrow also call acut lymphoblast leukemia acut lymphocyt leukemia tran retino acid tranz reh tih noh ik sid atra form vitamin made bodi also made laboratori use treat acut promyelocyt leukemia usual togeth drug treat acn studi treatment prevent type cancer also call atra tretinoin retino acid vitamin acid allergen al er jen substanc caus allerg respons exampl includ pollen mold certain food allerg respons uh ler jik reh spont hypersensit immun reaction substanc normal harmless would caus immun respons everyon allerg respons may caus harm symptom itch inflamm tissu injuri allogen loh jeh nay ik taken differ individu speci also call allogen allogen bone marrow transplant loh jeh nay ik bone mayr oh tranz plan tay shun procedur person receiv stem cell cell blood cell develop genet similar ident donor allogen stem cell transplant loh jeh nay ik stem sel tranz plan tay shun procedur person receiv blood form stem cell cell blood cell develop genet similar ident donor often sister brother could unrel donor allogen taken differ individu speci also call allogen allopath medicin loh pa thik meh dih sin system medic doctor healthcar profession nurs pharmacist therapist treat symptom diseas use drug radiat surgeri also call convent medicin western medicin mainstream medicin orthodox medicin biomedicin allopurinol drug lower high level uric acid byproduct metabol blood caus cancer treatment allovectin substanc studi gene therapi agent treatment cancer increas abil immun system recogn cancer cell kill alo emodin substanc found certain plant includ alo vera belong famili compound call anthraquinon shown anti inflammatori anticanc effect alopecia al oh pee shuh lack loss hair area bodi hair usual found alopecia side effect cancer treatment alpha fetoprotein al fuh fee toh proh teen afp protein normal produc fetu afp level usual undetect blood healthi adult men women pregnant elev level afp suggest presenc either primari liver cancer germ cell tumor also call afp alpha lipoic acid al fuh lih poh ik sid substanc studi abil protect normal cell side effect chemotherapi prevent peripher neuropathi numb tingl burn weak hand feet alpha lipoic acid made bodi found food organ meat spinach broccoli pea brussel sprout rice bran also made laboratori alpha lipoic acid type antioxid chemoprotect agent alprazolam al pray zoh lam drug use treat anxieti disord panic attack studi treatment nausea vomit caus cancer treatment type benzodiazepin also call xanax alteplas al teh play form tissu plasminogen activ made laboratori help dissolv blood clot use treat heart attack stroke clot lung also studi treatment cancer type system thrombolyt agent also call recombin tissu plasminogen activ r tpa activas alter chang result someth differ origin altern medicin ter nuh tiv meh dih sin practic use instead standard treatment gener recogn medic commun standard convent medic approach altern medicin includ dietari supplement megados vitamin herbal prepar special tea acupunctur massag therapi magnet therapi spiritu heal medit altretamin anticanc drug belong famili drug call alkyl agent alum type immun adjuv substanc use help boost immun respons vaccin also call aluminum sulfat aluminum sulfat type immun adjuv substanc use help boost immun respons vaccin also call alum alvac cea vaccin cancer vaccin contain canari pox viru alvac combin human carcinoembryon antigen cea gene alveoli al vee oh ly tini air sac end bronchiol lung alzheim dementia alt hy mer dih men shuh brain disord usual start late middl age old age get wors time symptom includ loss memori confus problem think chang languag behavior person also call alzheim diseas alzheim diseas alt hy mer dih zeez brain disord usual start late middl age old age get wors time symptom includ loss memori confus problem think chang languag behavior person also call alzheim dementia amanita phalloid type poison mushroom harm effect kidney liver respons fatal case mushroom poison also call death cap ambien drug use treat insomnia inabl sleep anxieti type imidazopyridin sed hypnot also call zolpidem amd substanc studi abil move stem cell bone marrow circul blood collect use stem cell transplant stem cell transplant method replac blood form stem cell destroy cancer treatment amd belong famili drug call stem cell mobil cxcr inhibitor amelanot melanoma type skin cancer cell make melanin skin lesion often irregular may pink red light brown tan gray edg amethopterin uh meth ope tayr drug use treat type cancer sever skin condit psoriasi rheumatoid arthriti amethopterin stop cell make dna type antimetabolit also call methotrex rheumatrex amev eh veev drug use treat certain skin condit studi treatment cutan skin relat cell cancer cell non hodgkin lymphoma amev made combin part antibodi protein block growth type cell type fusion protein immunosuppress also call alefacept amg type monoclon antibodi studi treatment multipl myeloma cancer form bone prevent treatment bone metastas cancer spread bone anoth organ monoclon antibodi made laboratori locat bind substanc bodi includ cancer cell amg bind protein rankl help keep bone break also call denosumab amg substanc studi treatment type cancer belong famili drug call angiogenesi inhibitor protein kinas inhibitor amifostin drug use chemoprotect drug control side effect chemotherapi radiat therapi amikacin antibiot drug use treat infect belong famili drug call aminoglycosid antibiot amino acid uh mee noh sid one sever molecul join togeth form protein common amino acid found protein amino acid sequenc uh mee noh sid see kwent arrang amino acid protein protein made differ kind amino acid structur function type protein determin kind amino acid use make arrang aminocamptothecin anticanc drug belong famili drug call topoisomeras inhibitor aminoglutethimid mee gloo teth ih mide anticanc drug belong famili drug call nonsteroid aromatas inhibitor aminoglutethimid use decreas product sex hormon estrogen women testosteron men suppress growth tumor need sex hormon grow aminoglycosid antibiot type antibiot work mani type bacteria includ streptomycin gentamicin neomycin aminoglycosid use treat bacteri infect aminolevulin acid uh mee noh lev yoo lin ik sid activ ingredi drug use treat precancer skin condit call actin keratosi also studi treatment skin cancer type cancer absorb cell includ cancer cell expos blue light aminolevulin acid becom activ kill cell type pro drug type pro photosensit agent aminopterin anticanc drug belong famili drug call antimetabolit aml quickli progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call acut myelogen leukemia acut myeloid leukemia acut myeloblast leukemia acut nonlymphocyt leukemia anll amonafid substanc studi treatment cancer belong famili drug call topoisomeras inhibitor intercal agent amoxicillin uh mok see sih lun drug use treat bacteri infect amoxicillin form penicillin made laboratori weaken bacteri cell wall caus bacteria break apart type antibiot amoxicillin clavulan potassium uh mok sih sih lin kla vyoo lan ayt puh ta see um drug use treat bacteri infect ad chemic clavulan potassium antibiot amoxicillin increas amount time antibiot stay activ bodi amoxicillin clavulan potassium type combin antibiot also call augmentin amphotericin b fuh tayr ih sin drug use treatment infect caus fungi type antifung amplimexon plih mek son substanc studi treatment type cancer includ pancreat lung breast prostat melanoma multipl myeloma belong famili drug call cyanoaziridin deriv also call imexon ampulla sac like enlarg canal duct ampulla vater enlarg duct liver pancrea point enter small intestin ampulla vater cancer puh luh vah ter kan ser cancer form ampulla vater enlarg duct liver pancrea join enter small intestin symptom includ jaundic abdomin pain nausea vomit weight loss also call ampullari cancer ampullari cancer puh layr ee kan ser cancer form ampulla vater enlarg duct liver pancrea join enter small intestin symptom includ jaundic abdomin pain nausea vomit weight loss also call ampulla vater cancer amput pyoo tay shun surgeri remov part limb appendag amrubicin roo bih sin substanc studi treatment lung cancer type anthracyclin analog amsacrin anticanc drug belong famili drug call topoisomeras inhibitor amygdalin uh mig duh lin substanc found pit mani fruit apricot papaya food tri countri treatment cancer shown work clinic studi amygdalin approv use unit state also call laetril amylas il aze enzym help bodi digest starch amyloidosi loy doe si group diseas protein deposit specif organ local amyloidosi throughout bodi system amyloidosi amyloidosi may either primari known caus secondari caus anoth diseas includ type cancer gener primari amyloidosi affect nerv skin tongu joint heart liver secondari amyloidosi often affect spleen kidney liver adren gland anagrelid ag lide drug use decreas number platelet blood order prevent blood clot anakinra kin ra substanc use treat rheumatoid arthriti studi treatment cancer anakinra block action interleukin il type interleukin receptor antagonist also call kinaret anal ay nul anu posterior open larg bowel anal cancer ay nul kan ser cancer form tissu anu anu open rectum last part larg intestin outsid bodi analgesia ul jee zee uh pain relief analges drug reduc pain analges includ aspirin acetaminophen ibuprofen analog chemistri substanc similar ident anoth analysi process anyth complex separ simpl less complex part anaphylact shock sever sometim life threaten immun system reaction antigen person previous expos reaction may includ itchi skin edema collaps blood vessel faint difficulti breath anaplast ah pla tik term use describ cancer cell divid rapidli littl resembl normal cell anaplast larg cell lymphoma nuh pla tik lim foh muh aggress fast grow type non hodgkin lymphoma usual cell type cancer cell express marker call cd ki surfac may appear lymph node skin bone soft tissu lung liver also call alcl anaplast thyroid cancer nuh pla tik thi royd kan ser rare aggress type thyroid cancer malign cancer cell look differ normal thyroid cell anastomosi ta mo si procedur connect healthi section tubular structur bodi diseas portion surgic remov anastrozol anticanc drug use decreas estrogen product suppress growth tumor need estrogen grow belong famili drug call nonsteroid aromatas inhibitor anatom nuh tah mik anatomi studi structur plant anim anatomi uh na toh mee studi structur plant anim ancestim sess tim drug studi abil increas number stem cell blood belong famili drug call hematopoiet cell growth factor also call stem cell factor scf stemgen androblastoma droh bla toh muh rare type ovarian tumor tumor cell secret male sex hormon may caus viril appear male physic characterist femal also call arrhenoblastoma sertoli leydig cell tumor ovari androgen droh jen type hormon promot develop mainten male sex characterist androgen ablat droh jen blay shun treatment suppress block product action male hormon done testicl remov take femal sex hormon take drug call antiandrogen also call androgen suppress androgen depriv androgen depriv droh jen deh prih vay shun treatment suppress block product action male hormon done testicl remov take femal sex hormon take drug call antiandrogen also call androgen suppress androgen ablat androgen suppress droh jen suh preh shun treatment suppress block product action male hormon done testicl remov take femal sex hormon take drug call antiandrogen also call androgen ablat androgen depriv androgen independ droh jen describ abil tumor cell grow absenc androgen hormon promot develop mainten male sex characterist mani earli prostat cancer requir androgen growth advanc prostat cancer often androgen independ anecdot report incomplet descript medic treatment histori one patient anecdot report may publish place peer review scientif journal anemia nee mee condit number red blood cell normal anesthesia ne thee zhuh drug substanc caus loss feel awar local anesthet caus loss feel part bodi gener anesthet put person sleep anesthesiologist ne thee zee ah loh jist doctor special give drug agent prevent reliev pain surgeri procedur done hospit anesthet ne theh tik substanc caus loss feel awar local anesthet caus loss feel part bodi gener anesthet put person sleep anetholtrithion substanc studi treatment cancer angelica root jeh lih kuh root root group herb call angelica use cultur treat certain medic problem includ gastrointestin problem loss appetit feel full ga angiogenesi jee oh jen eh si blood vessel format tumor angiogenesi growth blood vessel surround tissu solid tumor caus releas chemic tumor angiogenesi inhibitor substanc may prevent format blood vessel anticanc therapi angiogenesi inhibitor prevent growth blood vessel surround tissu solid tumor angiogram jee gram x ray blood vessel person receiv inject dye outlin vessel x ray angiographi jee ah gruh fee procedur x ray blood vessel blood vessel seen inject dye show x ray pictur angioimmunoblast cell lymphoma aggress fast grow type cell non hodgkin lymphoma mark enlarg lymph node hypergammaglobulinemia increas antibodi blood symptom may includ skin rash fever weight loss night sweat angiomyolipoma jee oh oh lih poh muh benign noncanc tumor fat muscl tissu usual found kidney angiomyolipoma rare caus symptom may bleed grow larg enough pain caus kidney failur common patient tuber sclerosi genet disord benign tumor grow kidney brain eye heart lung skin caus seizur mental problem skin lesion angiosarcoma jee sar ko type cancer begin cell line blood vessel lymph vessel cancer begin blood vessel call hemangiosarcoma cancer begin lymph vessel call lymphangiosarcoma angiostatin protein normal made bodi also made laboratori studi treatment cancer angiostatin may prevent growth new blood vessel surround tissu solid tumor belong famili drug call angiogenesi inhibitor angiotensin convert enzym inhibitor ace inhibitor drug use lower blood pressur angiotensin convert enzym inhibitor type antihypertens agent also call ace inhibitor angiozym substanc studi treatment kidney cancer may prevent growth blood vessel surround tissu tumor belong famili drug call vegf receptor angiogenesi inhibitor also call rpi anhydrovinblastin anticanc drug belong famili drug call mitot inhibitor anidulafungin drug use treat infect caus fungi belong famili drug call antifung anim model anim diseas either like diseas human anim model use studi develop progress diseas test new treatment given human anim transplant human cancer tissu call xenograft model anim studi ih mul stuh dee laboratori experi use anim studi develop progress diseas anim studi also test safe effect new treatment test peopl anim assist therapi nih mul uh si ted thayr uh pee type therapi use dog pet improv physic mental health patient certain acut chronic diseas studi way reliev distress cancer patient undergo treatment pain also call pet facilit therapi anll quickli progress diseas mani immatur white blood cell lymphocyt found blood bone marrow also call acut nonlymphocyt leukemia acut myelogen leukemia acut myeloblast leukemia acut myeloid leukemia aml annamycin substanc studi treatment cancer belong famili drug call anthracyclin antibiot anorexia abnorm loss appetit food anorexia caus cancer aid mental disord e anorexia nervosa diseas anorexia nervosa eat disord mark intens fear gain weight refus maintain healthi weight distort bodi imag peopl anorexia nervosa abnorm loss appetit food tri avoid eat eat littl possibl an autonom nervou system part nervou system control muscl intern organ heart blood vessel lung stomach intestin gland salivari gland sweat gland one part an help bodi rest relax digest food anoth part help person fight take flight emerg also call autonom nervou system involuntari nervou system ansamycin anticanc drug belong famili drug call antineoplast antibiot antagonist medicin substanc stop action effect anoth substanc exampl drug block stimul effect estrogen tumor cell call estrogen receptor antagonist anterior teer ee er human anatomi front structur structur found toward front bodi anterior mediastinotomi teer ee er mee dee stih nah toh mee procedur tube insert chest view tissu organ area lung breastbon heart tube insert incis next breastbon procedur usual use get tissu sampl lymph node left side chest also call chamberlain procedur anterior mediastinum area front part chest lung also call prevascular space anterior pelvic exenter teer ee er pel vik ek zen ter ay shun surgeri remov urethra lower part uret uteru cervix vagina bladder anterior urethr cancer teer ee er yoo ree thrul kan ser diseas malign cancer cell found part urethra tube urin leav bodi closest outsid bodi anthracenedion anticanc drug belong famili drug call anticanc antibiot anthracyclin type antibiot come fungu streptococcu peucetiu anthracyclin use treatment cancer daunorubicin doxorubicin epirubicin anthracyclin anthraquinon type anticanc drug anti cd immunotoxin ih myoo noh tok sin monoclon antibodi link toxic substanc studi treatment type b cell cancer anti cd immunotoxin made laboratori bind cd protein surfac normal b cell b cell tumor kill cell anti cd immunotoxin ih myoo noh tok sin monoclon antibodi link toxic substanc studi treatment type b cell cancer anti cd immunotoxin made laboratori bind cd protein surfac normal b cell b cell tumor kill cell anti cd immunotoxin cat ih myoo noh tok sin monoclon antibodi link toxic substanc studi treatment type b cell cancer anti cd immunotoxin cat made laboratori bind cd protein surfac normal b cell b cell tumor kill cell also call cat anti cea antibodi antibodi carcinoembryon antigen cea protein present certain type cancer cell anti epcam pseudomona exotoxin fusion protein soo doh moh nu ek soh tok sin fyoo zhun proh teen substanc studi treatment certain type head neck cancer anti epcam pseudomona exotoxin fusion protein made link monoclon antibodi fragment toxic protein may kill cancer cell bind epcam protein surfac epitheli cell type cancer cell also call vb proxinium anti idiotyp vaccin vaccin made antibodi see antibodi antigen bind anti idiotyp vaccin stimul bodi produc antibodi tumor cell anti il chimer monoclon antibodi ky meer ik mah noh kloh nul tih bah dee chimer made human mous protein monoclon antibodi studi treatment advanc kidney cancer type cancer monoclon antibodi made laboratori locat bind substanc bodi includ cancer cell anti il chimer monoclon antibodi work block inflamm tumor growth also call cnto cclb anti inflammatori reduc inflamm anti mesothelin monoclon antibodi morab tee mez oh thee lin mah noh kloh nul tee bah dee monoclon antibodi studi treatment type cancer monoclon antibodi made laboratori locat bind substanc bodi includ cancer cell anti mesothelin monoclon antibodi morab bind mesothelin protein made cancer cell stop cell divid also call morab anti tgf beta monoclon antibodi gc mah noh kloh nul tee bah dee monoclon antibodi studi treatment kidney cancer melanoma pulmonari fibrosi monoclon antibodi made laboratori locat bind substanc bodi includ cancer cell anti tgf beta monoclon antibodi gc bind protein transform growth factor beta tgf may block growth cancer cell make also call gc antiandrogen tee droh jen drug use block product interfer action male sex hormon antiandrogen therapi tee droh jen thayr uh pee treatment drug use block product interfer action male sex hormon antiangiogenesi prevent growth new blood vessel antiangiogen reduc growth new blood vessel antiapoptot someth prevent apoptosi apoptosi type cell death seri molecular step cell lead death antibacteri tee bak teer ee ul substanc kill bacteria stop grow caus diseas antibiot tih ah tik drug use treat infect caus bacteria microorgan antibodi tee bah dee type protein made plasma cell type white blood cell respons antigen foreign substanc antibodi bind one specif antigen purpos bind help destroy antigen antibodi work sever way depend natur antigen antibodi destroy antigen directli other make easier white blood cell destroy antigen antibodi therapi tee bah dee thayr uh pee treatment antibodi substanc directli kill specif tumor cell stimul immun system kill tumor cell anticachexia tee ka kek see describ drug effect work cachexia loss bodi weight muscl mass anticanc antibiot type anticanc drug block cell growth interf dna genet materi cell also call antitumor antibiot antineoplast antibiot anticarcinogen tee kar sin jen ik prevent delay develop cancer anticoagul drug help prevent blood clot form also call blood thinner anticonvuls tee kon vul sant drug substanc use prevent stop seizur convuls also call antiepilept antidepress drug use treat depress antidiarrh tee dy uh ree ul substanc use treat diarrhea frequent wateri bowel movement antiemet tee eh meh tik drug prevent reduc nausea vomit antiepilept tee eh pih lep tik drug substanc use prevent stop seizur convuls also call anticonvuls antiestrogen substanc block activ estrogen famili hormon promot develop mainten femal sex characterist antifol substanc block activ folic acid antifol use treat cancer also call folat antagonist antifung drug treat infect caus fungi antigen substanc caus immun system make specif immun respons antigen present cell apc cell show antigen surfac cell immun system import part immun respons also call apc antigen present cell vaccin vaccin made antigen antigen present cell apc also call apc vaccin antiglobulin test laboratori test identifi antibodi bind surfac red blood cell platelet destroy test use diagnos certain blood disord patient make antibodi red blood cell platelet also use determin blood type also call coomb test antihistamin tee tuh meen type drug block action histamin caus fever itch sneez runni nose wateri eye antihistamin use prevent fever patient receiv blood transfus treat allergi cough cold antihormon therapi tee hor mone thayr uh pee treatment drug surgeri radiat order block product action hormon antihormon therapi may use cancer treatment certain hormon abl stimul growth type tumor antimetabolit drug similar natur chemic normal biochem reaction cell differ enough interfer normal divis function cell antimicrobi tee kroh bee ul substanc kill microorgan bacteria mold stop grow caus diseas antimicrotubul agent type drug block cell growth stop mitosi cell divis antimicrotubul agent interfer microtubul cellular structur help move chromosom mitosi use treat cancer antimitot agent type drug block cell growth stop mitosi cell divis use treat cancer also call mitot inhibitor antineoplast substanc block format neoplasm growth may becom cancer antineoplast antibiot type anticanc drug block cell growth interf dna genet materi cell also call anticanc antibiot antitumor antibiot antineoplaston substanc isol normal human blood urin test type treatment tumor aid antioxid tee ok sih dent substanc protect cell damag caus free radic unstabl molecul made process oxid normal metabol free radic may play part cancer heart diseas stroke diseas age antioxid includ beta caroten lycopen vitamin c e natur manufactur substanc antiparasit drug use treat infect caus bacteria parasit also use treatment cancer antiprogestin tee proh je tin substanc prevent cell make use progesteron hormon play role menstrual cycl pregnanc antiprogestin may stop cancer cell grow studi treatment breast cancer antiprogestin type hormon antagonist antiretrovir therapi tee reh troh vy rul thayr uh pee treatment drug inhibit abil human immunodefici viru hiv type retrovirus multipli bodi antisens c fo synthet genet materi may slow stop growth cancer cell antithymocyt globulin tee thigh mo site glob yoo lin protein use reduc risk treat graft versu host diseas antituberculosi tee ber kyoo low si describ drug effect work tuberculosi contagi bacteri infect usual affect lung antitumor tee mer stop abnorm cell growth antitumor antibiot type anticanc drug block cell growth interf dna genet materi cell also call anticanc antibiot antineoplast antibiot antivir drug use treat infect caus virus anu ay nu open rectum outsid bodi anxieti ang zy uh tee feel fear dread uneasi may occur reaction stress person anxieti may sweat feel restless tens rapid heart beat extrem anxieti happen often time may sign anxieti disord anxiolyt drug use treatment anxieti muscl spasm aorta tuh largest arteri bodi carri oxygen rich blood away heart vessel reach rest bodi aortocoronari bypass ay toh kor uh nayr ee pass surgeri healthi blood vessel taken anoth part bodi use make new path blood around block arteri lead heart restor flow oxygen nutrient heart also call coronari arteri bypass cab ap drug use treat soft tissu bone sarcoma also studi treatment solid tumor hematolog cancer ap may control growth blood vessel cancer belong famili drug call rapamycin analog ap substanc studi treatment head neck cancer may kill cancer cell carri anticanc drug tumor type platinum compound apc antigen present cell cell show antigen surfac cell immun system import part immun respons also call antigen present cell apc vaccin vaccin made antigen antigen present cell apc also call antigen present cell vaccin apc vaccin made immun system cell collect patient prostat cancer cell treat laboratori growth factor attach protein found prostat cell cancer cell apc inject patient may stimul lymphocyt kill tumor cell express prostat protein also call proveng sipuleucel apheresi procedur blood collect part blood platelet white blood cell taken rest blood return donor also call pheresi apl acut promyelocyt leukemia aggress fast grow type acut myeloid leukemia mani immatur blood form cell blood bone marrow usual mark exchang part chromosom also call acut promyelocyt leukemia promyelocyt leukemia aplast anemia condit bone marrow unabl produc blood cell aplidin substanc studi treatment cancer obtain marin organ apocrin gland type gland found skin breast eyelid ear apocrin gland breast secret fat droplet breast milk ear help form earwax apocrin gland skin eyelid sweat gland apocrin gland skin armpit groin area around nippl breast apocrin gland skin scent gland secret usual odor anoth type gland eccrin gland simpl sweat gland produc sweat apolizumab type monoclon antibodi studi treatment hematolog blood cancer monoclon antibodi laboratori produc substanc locat bind cancer cell apoptosi pop toh si type cell death seri molecular step cell lead death bodi normal way get rid unneed abnorm cell process apoptosi may block cancer cell also call program cell death appendectomi pen dek toh mee surgeri remov appendix small finger shape pouch end first part larg intestin appendix small fingerlik pouch stick cecum first part larg intestin near end small intestin appetit peh tite desir satisfi physic mental need food sex adventur aprepit uh preh pih tunt drug use prevent control nausea vomit caus chemotherapi use togeth anti vomit medicin belong famili drug call antiemet agent also call emend aqueou water arctigenin substanc found certain plant includ burdock shown antivir anticanc effect arctigenin belong group substanc call lignan arctiin substanc found certain plant includ burdock shown anticanc effect arctiin belong group substanc call lignan areola ree la area dark color skin breast surround nippl arginin ar jih neen one twenti common amino acid build block protein arginin studi nutrit supplement treatment prevent cancer condit also call l arginin arginin butyr substanc studi treatment cancer arixtra uh rik truh drug use prevent blood clot form insid blood vessel leg studi prevent blood clot cancer patient includ women surgeri cancer reproduct tract type anticoagul also call fondaparinux fondaparinux sodium aromasin uh roh muh sin drug use treat advanc breast cancer prevent recurr breast cancer postmenopaus women alreadi treat tamoxifen also studi treatment type cancer aromasin caus decreas amount estrogen made bodi belong famili drug call aromatas inhibitor also call exemestan aromatas inhibitor uh roh muh tayz hih bih ter drug prevent format estradiol femal hormon interf aromatas enzym aromatas inhibitor use type hormon therapi postmenopaus women hormon depend breast cancer aromatherapist uh roh muh thayr uh pist person practic type complementari medicin call aromatherapi therapi use plant oil give strong pleasant smell promot relax sens well plant oil usual inhal put skin use wet cloth bath massag aromatherapi uh roh muh thayr uh pee type complementari altern medicin use plant oil give strong pleasant aroma smell promot relax sens well heal aromatherapi infus uh roh muh thayr uh pee fyoo zhun process heat without boil mixtur water essenti oil scent liquid taken plant releas pleasant aroma aromatherapi infus may also refer process heat herb liquid releas essenti oil inhal oxygen scent aromatherapi infus studi complementari therapi use addit standard treatment reliev pain shorten recoveri time patient undergo colonoscopi aromatherapi massag uh roh muh thayr uh pee muh sazh type complementari altern medicin use rub knead skin plant oil give strong pleasant aroma smell promot relax sens well heal aromat ruh tik odor often pleasant spici arous uh row zul state alert readi respond wake sleep arranon ayr rah non drug use treat certain type cell acut lymphoblast leukemia cell lymphoblast lymphoma lbl belong famili drug call antimetabolit also call nelarabin u arrhenoblastoma uh ree noh bla toh muh rare type ovarian tumor tumor cell secret male sex hormon may caus viril appear male physic characterist femal also call androblastoma sertoli leydig cell tumor ovari arsen poison chemic use kill weed pest also use cancer therapi arsen trioxid ar seh nik tri ok side drug use treat acut promyelocyt leukemia apl gotten better come back treatment anticanc drug also studi treatment type cancer also call trisenox arteri embol ar tee ree al em bo lih zay shun block arteri clot foreign materi done treatment block flow blood tumor arteriogram ar teer ee gram x ray arteri person receiv inject dye outlin vessel x ray arteriographi ar tee ree ah gruh fee procedur x ray arteri arteri seen inject dye outlin vessel x ray arteri ar tuh ree blood vessel carri blood heart tissu organ bodi arthralgia ar thral juh joint pain arthriti diseas caus inflamm pain joint artifici pacemak ar tih fih shul pay may ker electron devic implant bodi monitor heart rate rhythm give heart electr stimul beat normal run batteri long thin wire connect heart also call pacemak cardiac pacemak asbesto be tu natur materi made tini fiber asbesto caus sever seriou diseas includ cancer ascit uh sy teez abnorm buildup fluid abdomen may caus swell late stage cancer tumor cell may found fluid abdomen ascit also occur patient liver diseas ascorb acid uh skor bik sid key nutrient bodi need fight infect heal wound keep tissu healthi includ blood vessel cartilag ligament tendon bone muscl skin teeth gum antioxid help prevent tissu damag caus free radic bodi make store ascorb acid must taken everi day found mani fruit veget especi green pepper citru strawberri tomato broccoli leafi green potato cantaloup also call vitamin c asparaginas enzym use treatment cancer belong famili drug call antineoplast aspart transaminas enzym found liver heart tissu high level aspart transaminas releas blood may sign liver heart damag cancer diseas also call serum glutam oxaloacet transaminas sgot aspergillosi infecti fungal diseas occur often skin ear nasal sinus lung peopl suppress immun system aspergillu famili fungi commonli found soil certain type may caus diseas especi peopl suppress immun system aspir pi rit fluid withdrawn lump often cyst nippl aspir per ay shun remov fluid tissu needl also accident breath food fluid lung aspirin drug reduc pain fever inflamm blood clot aspirin belong famili drug call nonsteroid anti inflammatori agent also studi cancer prevent assay say laboratori test find measur amount specif substanc assess uh sess ment healthcar process use learn patient condit may includ complet medic histori medic test physic exam test learn skill test find patient abl carri task daili live mental health evalu review social support commun resourc avail patient assist devic uh siss tiv tool help person disabl certain task exampl cane wheelchair scooter walker hear aid special bed assist technolog uh si tiv tek nah loh jee devic technolog help disabl person exampl special grip hold utensil comput screen monitor help person low vision read easili comput control talk telephon make sound louder lifter help person rise chair asthenia weak lack energi strength asthma az muh chronic diseas bronchial airway lung becom narrow swollen make difficult breath symptom includ wheez cough tight chest short breath rapid breath attack may brought pet hair dust smoke pollen mold exercis cold air stress astrocyt troh site star shape cell help nerv cell brain spinal cord work way astrocyt type glial cell astrocytoma troh sy toh muh tumor begin brain spinal cord small star shape cell call astrocyt asymmetri lack absenc balanc proport part thing asymptomat sign symptom diseas',\n",
       " 'would like see ongo forum topic admor data becom avail educ decis csn made specif protocol stay keytruda ned patient year old male diagnos stage iv adeo nsclc follow pleural effus cancer lung pleural caviti lymph node upper abdomen pdl express keytruda three month remark pet scan show full remiss ned side effect ftom keytruda new data potenti immun system learn find cancer use protocol establish continu treatment topic modifi month ago hherpel topic modifi month ago hherpel',\n",
       " 'know good blogger right tri find time energi verv mayb kind challeng post infus week cannot lie hell realli coupl damn day infus day brought yet anoth allerg reaction ocrevu stop drip give benedryl twice turn infus day hour joy ride lie joy benedryl made feel hop instead sleepi like usual sleep wink entir time infus also slept like crap night got home mostli new crop fellow infuse room time die write bring next challeng left hand suddenli numb complet blue feel left hand especi left pinki finger made type anyth phone real challeng write phone work pinch gener led insight prolif work avoid hell avoid mainli unconsci hope feel human next open eye numb hand help matter promis better entertain write soon usual post infus thing like tri panic get lot lot rest eat properli eff liquid diet enjoy gray day pajama whilst variou confer call tomorrow better tomorrow better day tri cultiv posit outlook thing keep post blog entri mere eff word page upon page without end suggest might get reader color use languag tri resist urg realli would dumb noth els get realli good resist urg upsid detect wonder twin power activ shape posit form mental patient anyway hang numb hand die write thumb type start irrit gonna cut one bit short thank reach check good know disappear without trace nari soul notic guy realli awesom way everi way longer numb sleep hour day stay well friend back rid easili namast',\n",
       " 'first thank much help histolog hear high unaccept risk pneumon go specif tagrisso azd immunotherapi read articl said pdl lower risk pneumon pd due method action see opdivo pd tecentriq pdl advertis egfr patient progress chemo egfr target therapi wife inform whether aforement higher risk go tagrisso immunotherapi true risk lower go pdl tecentriq option us point appear chemo applic trial egf asp hm recruit immunotherapi appear toxic sequenti treatment egfr inhibitor tagrisso immunotherapi stage iv nsclc adeno egfr mutat tarceva help carbo avastin alimta month avastin mainten month afatanib month clovi co month tagrisso azd month progress',\n",
       " 'hi post often read time took final gilenya tablet last sunday begun scari wash period pre lamtrada week cours steroid go hope begin round lemtrada regard listeria diet stay away take away diet sheet say ensur food wash heat correctli cours cant ensur take away also luncheon meat includ ham ask lemtrada specif page also thank x',\n",
       " 'u ixifi pharmacolog class infliximab use infliximab qbtx infliximab qbtx inject use adult treat crohn diseas ulcer coliti rheumatoid arthriti ankylos spondyl psoriat arthriti chronic sever plaqu psoriasi also use children treat crohn diseas infliximab qbtx inject monoclon antibodi work enhanc improv immun system infliximab qbtx avail doctor prescript use infliximab qbtx decid use medicin risk take medicin must weigh good decis doctor make infliximab qbtx follow consid allergi tell doctor ever unusu allerg reaction infliximab qbtx medicin also tell health care profession type allergi food dye preserv anim non prescript product read label packag ingredi care pediatr appropri studi perform date demonstr pediatr specif problem would limit use infliximab qbtx inject treatment crohn diseas ulcer coliti children year age older howev safeti efficaci establish children younger year age appropri studi perform date demonstr infliximab qbtx inject help children juvenil rheumatoid arthriti efficaci establish geriatr appropri studi perform date demonstr geriatr specif problem would limit use infliximab qbtx inject elderli howev elderli patient like infect may requir caution patient receiv infliximab qbtx inject breast feed adequ studi women determin infant risk use medic breastfeed weigh potenti benefit potenti risk take medic breastfeed interact medicin although certain medicin use togeth case two differ medicin may use togeth even interact might occur case doctor may want chang dose precaut may necessari receiv infliximab qbtx especi import healthcar profession know take medicin list follow interact select basi potenti signific necessarili inclus use infliximab qbtx follow medicin usual recommend may requir case medicin prescrib togeth doctor may chang dose often use one medicin abatacept adalimumab adenoviru vaccin type live adenoviru vaccin type live alefacept anakinra bacillu calmett guerin vaccin live brodalumab certolizumab pegol cyclosporin etanercept fosphenytoin golimumab guselkumab influenza viru vaccin live ixekizumab measl viru vaccin live mump viru vaccin live natalizumab paclitaxel phenytoin polioviru vaccin live quinidin rilonacept rituximab rotaviru vaccin live rubella viru vaccin live sarilumab sirolimu smallpox vaccin tacrolimu tocilizumab tofacitinib typhoid vaccin ustekinumab varicella viru vaccin live vedolizumab warfarin yellow fever vaccin zoster vaccin live interact food tobacco alcohol certain medicin use around time eat food eat certain type food sinc interact may occur use alcohol tobacco certain medicin may also caus interact occur discuss healthcar profession use medicin food alcohol tobacco medic problem presenc medic problem may affect use infliximab qbtx make sure tell doctor medic problem especi aspergillosi fungu infect histori blastomycosi fungu infect histori blood bone marrow problem eg pancytopenia histori candidiasi fungu infect histori coccidioidomycosi fungu infect histori diabet guillain barr syndrom nervou system disord histori hepat b activ histori histoplasmosi fungu infect histori legionellosi bacteri infect histori leukopenia neutropenia low white blood cell listeriosi bacteri infect histori liver diseas multipl sclerosi histori optic neuriti eye problem pneumocystosi fungu infect histori psoriasi skin diseas seizur convuls histori thrombocytopenia low platelet blood use caution may make condit wors cancer activ histori chronic obstruct pulmonari diseas copd use caution may increas chanc new cancer congest heart failur moder sever given patient condit tuberculosi histori use caution patient may need addit tuberculosi treatment proper use infliximab qbtx doctor train health profession give infliximab qbtx given needl place one vein must given slowli needl remain place least hour infliximab qbtx come medic guid read follow instruct care ask doctor question may also receiv medicin eg allergi medicin fever medicin steroid help prevent possibl unwant effect inject precaut use infliximab qbtx import doctor check progress regular visit make sure infliximab qbtx work properli blood test may need check unwant effect infliximab qbtx may caus infus reaction receiv right infus end check doctor nurs right away chest pain fever chill itch hive rash dizzi faint lightheaded headach joint pain difficulti swallow short breath troubl breath swell face tongu throat bodi abil fight infect may reduc use infliximab qbtx import call doctor first sign infect check doctor right away fever chill cough flu like symptom unusu tired weak need skin test tuberculosi start receiv infliximab qbtx tell doctor anyon home ever posit reaction tuberculosi skin test small number peopl includ children teenag use infliximab qbtx develop certain type cancer common patient lung diseas eg emphysema copd heavi smoker psoriasi patient phototherapi treatment long time phototherapi treatment ultraviolet light sunlight combin oral medicin make skin sensit light teenag young adult crohn diseas ulcer coliti also develop rare type cancer call hepatosplen cell lymphoma talk doctor unusu bleed bruis weak swollen lymph node neck underarm groin unexplain weight loss red scali patch rais bump pu skin receiv infliximab qbtx may increas risk get skin cancer eg melanoma merkel cell carcinoma cervic cancer chang growth skin abnorm vagin bleed pelvic pain check doctor right away import heart check close receiv infliximab qbtx call doctor right away difficulti breath swell ankl feet sudden weight gain seriou skin reaction occur receiv infliximab qbtx check doctor right away blister peel loosen skin chill cough diarrhea fever itch joint muscl pain red skin lesion sore throat sore ulcer white spot mouth unusu tired weak infliximab qbtx may increas chanc lupu like syndrom liver diseas call autoimmun hepat check doctor right away dark brown color urin fever chill gener feel discomfort ill weak joint pain light color stool nausea vomit rash cheek arm wors sun sever tired upper right side stomach pain yellow eye skin treat infliximab qbtx immun vaccin without doctor approv live viru vaccin given infliximab qbtx child vaccin must current receiv infliximab qbtx talk child doctor question women babi receiv infliximab qbtx make sure babi doctor know receiv infliximab qbtx need wait month give certain vaccin babi talk babi doctor question take medicin unless discuss doctor includ abatacept orencia anakinra kineret tocilizumab actemra medicin call biolog use treat condit infliximab qbtx use medicin togeth infliximab qbtx may increas chanc seriou unwant effect infliximab qbtx side effect along need effect medicin may caus unwant effect although side effect may occur occur may need medic attent check doctor nurs immedi follow side effect occur common black tarri stool bladder pain bloodi cloudi urin blur vision bodi ach pain chest pain chill cough cough produc mucu difficult burn pain urin difficulti breath dizzi dryness sore throat ear congest fever frequent urg urin headach hoars itch rash loss voic lower back side pain nasal congest nervous pain swell arm leg pain tender around eye cheekbon pain difficult urin pale skin pound ear slow fast heartbeat sneez sore ulcer white spot lip mouth stuffi runni nose swollen gland tender swollen gland neck tight chest troubl swallow troubl breath troubl breath exert unusu bleed bruis unusu tired weak voic chang rare bleed gum blood stool blue lip fingernail blur vision chang skin color tender foot leg chest discomfort confus cough sometim produc pink frothi sputum dark urin decreas urin dizzi faint lightheaded get suddenli lie sit posit dri mouth fast noisi breath feel discomfort gener feel ill gener tired weak high fever hive increas heart rate increas sweat inflamm joint irregular heartbeat light color stool muscl ach nausea pinpoint red spot skin puffi swell eyelid around eye face lip tongu rapid shallow breath sunken eye thirst upper right abdomin pain vomit weight loss wrinkl skin yellow eye skin incid known back pain sudden sever blister peel loosen skin bloodi nose burn tingl numb pain hand arm feet leg chang mental statu clay color stool diarrhea difficulti speak dilat neck vein doubl vision heavier menstrual period inabl move arm leg facial muscl inabl speak loss appetit muscl weak sudden progress red irrit eye red skin lesion often purpl center seizur sensat pin needl slow irregular breath slow speech stab pain temporari vision loss vomit blood weight gain side effect may occur usual need medic attent side effect may go away treatment bodi adjust medicin also health care profession may abl tell way prevent reduc side effect check health care profession follow side effect continu bothersom question common belch diarrhea difficulti move feel warmth heartburn indigest muscl stiff red face neck arm occasion upper chest less common constip sever side effect list may also occur patient notic effect check healthcar profession call doctor medic advic side effect may report side effect fda fda',\n",
       " 'chronic lymphocyt leukemia cll common leukemia adult focu headlin recent year enorm progress treatment within past six year seven novel drug approv health canada treat condit four monoclon antibodi rituxan rituximab campath alemtuzumab gazyva obinutuzumab arzerra ofatumumab three small molecul inhibitor imbruvica ibrutinib zydelig idelalisib venclexta venetoclax treanda bendamustin standard chemotherapi agent recent approv combin rituxan new treatment would great news clinician patient except equal access across provinc fact canada numer health system mean patient access often determin postal code still cll care continu chang outlook live cll cll origin bone marrow blood cell form b lymphocyt matur type white blood cell start grow surviv beyond normal life span leukemia cell may look somewhat normal microscop reproduc rapidli surviv longer normal cell crowd blood cell mainli red cell involv oxygen deliveri platelet cell fragment help blood clot sever case number neutrophil white blood cell part immun system may affect cancer cell receiv growth surviv signal bone marrow lymph node caus circul blood system regular basi result patient may symptom diagnosi except abnorm lymphocyt count year peopl diagnos cll canada peopl die symptom cll diagnosi peopl cll awar symptom say versha banerji md frcpc hematologist cll clinic univers manitoba cancercar manitoba often primari physician see elev white blood cell count routin blood test say sometim patient may fever chill notic weight loss mostli advanc stage diseas symptom addit fatigu chang appetit sleep bleed bruis easili enlarg spleen liver lymph node call visit doctor cll diagnos stage cll diagnos simpl blood test person come high white cell count basic use flow cytometri type electron cell analysi look cll cell say banerji see patient everi year result posit patient sent cll clinic treatment plan discuss two stage system doctor use predict diseas progress rai stage system binet stage system banerji use rai system classifi cll five stage rang low risk vari degre high risk associ presenc enlarg lymph node spleen elev lymphocyt count low platelet count low level hemoglobin protein whose job transport oxygen within bodi treatment decis determin right treatment plan cll complic ever banerji say initi standard treatment rang watch wait chemotherapi intermedi high risk cll target therapi use chemotherapi cancer longer respond recur stem cell transplant still avail longer consid part routin care banerji consid three factor determin treatment age fit molecular marker age broken two categori year year fit score use cir ill rate scale predict patient abil toler certain treatment consid fit deem unfit grade subject use heavili clinic trial cll identifi molecular marker genet mutat treatabl drug also import molecular marker help us determin patient live long period without treatment progress diseas say abil identifi marker realli chang cll experi mani peopl one exampl test look mutat igvh gene know peopl igvh mutat tend better outcom unmut igvh say need test tell us manitoba exampl access unfortun everi patient cll access test canada fragment come test capabl say banerji frustrat clinician patient may get treatment appropri target could sever provinc unless compassion program offer manufactur patient privat insur option left pay pocket quit burdensom opt prompt banerji take role advoc addit busi role clinician senior scientist togeth clinic team work provinci diagnost lab cancercar manitoba make treatment guid test like one igvh avail manitoba chang dialogu even without univers access test outlook patient cll improv greatli mani option cll even year ago chang everyth banerji say earli discuss patient use desper hope would tell patient chemotherapi transplant treatment would deal side effect went along choic patient also play activ role health patient engag ever say talk prognosi also want life goal futur import support despit good news cll cancer diagnosi still scari connect commun familiar journey critic better understand diseas move forward treatment one commun canadian cll patient advocaci group reach cllpag ca resourc includ leukemia lymphoma societi canada lymphoma canada lymphoma coalit cll challeng diagnosi say deborah baker past chair cll patient advocaci group board director one way patient caregiv feel control access commun peopl share experi peopl valuabl sourc educ advic support end connect greatli improv outcom articl part bring cll commun togeth program fund provid unrestrict educ grant pharmacycl abbvi compani janssen biotech inc',\n",
       " 'aw diseas get least lot less fund oppos breast cancer etc due stigma origin attach smoker get guess even time present symptom cancer perhap alreadi progress would like guess feel let oncologist slightli alway name mum one special patient due fact fit healthi last summer right gene mutat perhap put much pedest patient azd tagrisso fine say wonder made right decis put faith doctor medic staff expect get letter oncologist still noth sure tagrisso would work even though struggl get bed seat left hospit even realis would gone less two hour later feel like let ask dad die said doctor overli clear look back think nurs tri tell us alway thought would ok even though knew diagnos termin take care jim',\n",
       " 'med like fingolimod affect respons vaccin still respons bodi immun system flu jab live vaccin safe take peopl dmt alway flu vaccin flu could trigger relaps may unlucki get doubl viral infect run first obsess hand wash hand sanit work educ student germ pool wish better',\n",
       " 'sure week pred accomplish minimum durat treatment month moder ulcer coliti john uc proctosigmoid rx remicad mg kg wk daili mg mp g gener lialda rowasa cannot spell suck without uc',\n",
       " 'hi liz consid ms around long time much fund spent drug chose none medic rout experi guinea pig trial mani natur remidi exercis eat balanc diet far better health offer fingolimod experi baclofen anti depress pot luck stuff life far better tri differ approach life seem work wonder along avoid stress head folk stuck routin best terri',\n",
       " 'hello everyon remicad year final develop antibodi tri entyvio coupl year ago advers reaction larg bowel resect end colostomi octob crohn diseas symptom improv sinc surgeri howev eye joint muscl pain inflamm poorli stop remicad antibodi gi wonder howev said well tri humira cimzia stelara one prefer like crap shoot lol toss name cup draw one suggest would greatli appreci develop crohn small intestin besid remicad mg prednison daili thank much juli',\n",
       " 'mom diagnos progress ms late stage wheelchair walk past year write post get advic got first dose drug name ocrevu anyon els take drug one post feel help work inform would greatli appreci',\n",
       " 'cladribin label uk mayb start everyon clad fail tri one other think would save nh alot cash hope lost legal fee listen mexican doctor mayb infus need hsct data',\n",
       " 'home ms inform public ms research updat ocrevu ocrelizumab ocrevu ocrelizumab updat main articl introduct fda approv medic experiment medic new direct ms research close note approv diseas modifi therapi ms pdf refer fda approv medic new data compani genentech roch pharma ag mg given via iv infus everi six month approv rm ppm next zinbryta ocrevu anti cd monoclon antibodi similar medic rituxan rituximab ocrevu potenti advantag human antibodi rituxan human monoclon antibodi antibodi non human speci mice whose protein sequenc modifi increas similar antibodi produc natur human march ocrevu fda approv use rm ppm approv base larg result three import studi announc relaps ms ocrelizumab met primari major secondari endpoint phase iii opera opera ii studi opera studi ident design total combin enrol studi individu relaps form ms opera studi individu receiv either mg ocrelizumab via intraven iv infus everi six month approv mcg dose rebif interferon beta given via subcutan inject three time weekli particip receiv ocrelizumab signific reduct studi annual relaps rate percent two year period versu interferon group addit ocrelizumab group new mri lesion reduc percent brain atrophi decreas percent risk progress sustain clinic disabl decreas percent analysi opera trial data report februari found patient receiv ocrevu fare better receiv interferon beta composit measur assess absenc relaps confirm disabl progress mri diseas activ endpoint known evid progress activ diseas nepad research found percent patient receiv ocrevu nepad week studi start versu percent peopl receiv interferon beta fda approv ocrevu ppm base part result oratorio studi publish prior studi phase iii studi ppm success despit multipl attempt oratorio random doubl blind global multi center trial studi effect safeti ocrevu compar placebo peopl ppm everi six month two mg infus total mg given two week apart member treatment group compar placebo group studi primari endpoint time onset confirm disabl progress defin increas expand disabl statu scale edss sustain least week edss score function scale higher score refer disabl oratorio studi met primari endpoint show ocrelizumab significantli reduc progress clinic disabl sustain least week percent compar placebo walk speed measur time foot walk improv percent mri hyper intens lesion actual reduc ocrevu brain volum loss view mri reduc percent incid advers event associ ocrevu similar placebo common advers event mild moder infus relat reaction post hoc set analys report februari investig found ocrevu reduc risk progress sever upper extrem disabl function impair frequent occur ppm patient enter oratorio trial everi week thereaft throughout studi particip complet test involv place peg hole confirm progress measur chang time requir perform test compar placebo ocrevu reduc risk confirm signific progress percent greater increas test time hand percent week percent week ocrevu also reduc risk progress term patient self identifi best hand worst hand period sinc fda approv ocrevu also seen first report case progress multifoc leukoencephalopathi pml rare potenti fatal brain infect patient take medic assess role ocrevu may play develop pml advers event quit complic particularli individu previous taken dmt known associ risk event exampl first person take ocrevu report pml taken tysabri natalizumab three year prior begin ocrevu increas risk pml previous link tysabri fda approv use relaps form ms also decemb post market surveil ocrevu record death among patient treat medic worldwid addit eight peopl die clinic trial involv roughli particip caus death vari case unknown cancer death report physician regul medic manufactur other monitor post approv efficaci safeti profil ocrevu difficult point discern signific data meanwhil januari european commiss approv ocrevu use treat rm ppm ongo research ocrevu includ open label studi peopl rrm assess impact medic individu suboptim respons dmt next zinbryta daclizumab',\n",
       " 'earli analysi studi human embryon stem cell hesc deriv retin pigment epithelium rpe implant suggest procedur well toler patient dri amd indic structur retin improv accord eyal banin md phd hadassah hebrew univers medic center jerusalem israel dr banin group collabor dr benjamin reubinoff hadassah develop xeno free direct differenti protocol deriv rpe cell hesc vitro proprietari product call opregen develop carri translat phase cellcur ltd subsidiari biotim inc test fda approv phase iia clinic trial israel usa nct dr banin present inform first nine patient advanc dri amd geograph atrophi ga receiv subretin inject opregen cell suspens associ research vision ophthalmolog annual meet honolulu hawaii patient dri amd geograph atrophi best correct acuiti wors time enrol patient receiv k k cell deliv balanc salin suspens cell deliv subretin inject follow convent gaug vitrectomi patient receiv system immunosuppress one week prior treatment one year procedur appear well toler seriou system treatment relat advers effect note two year follow best correct acuiti remain stabl treat eye best correct acuiti also remain stabl untreat eye improv note one treat eye could probabl attribut clear vitreou posterior capsul opac surgeri dr banin note imag studi research perform retin function structur assess throughout studi addit best correct acuiti use colour fundu photographi optic coher tomographi oct fundu autofluoresc imag techniqu imag studi show creation subretin bleb surgeri follow absorpt subretin fluid within hour heal inject site within week imag also show sign subretin pigment treat area accompani hypo hyperfluoresc spot fundu autofluoresc imag develop first one three month postop particularli interest appear irregular subretin hyperfluoresc oct imag treat area taken togeth imag result suggest potenti engraft transplant cell find persist throughout follow two year first treat patient although slow loss cell could occur structur improv patient sign alter reduc drusen treat area possibl restor rpe layer potenti structur improv seen photoreceptor layer ellipsoid zone cell inject surgeri relat advers event includ conjunctiv haemorrhag worsen cataract epiretin membran format seven nine patient develop new worsen epiretin membran four consid mild three advanc none case requir intervent case may associ incomplet vitrectomi efflux rpe cell note unexpect ocular advers event occur phase ii studi ongo new cohort involv patient less advanc diseas visual acuiti wors smaller area geograph atrophi opregen cell creat use proprietari process drive differenti human pluripot stem cell gener high puriti rpe cell idelson et al cell stem cell cell gener system xeno free deriv nih approv hesc line produc gmp condit underw extens safeti test prior approv us fda current clinic trial prior test stem cell deriv rpe cell human research conduct anim studi upon inject rat rpe cell form monolay polaris began function structur function improv observ mcgill et al transl vi sci technol current studi also compar find observ pig eye human studi particip vivo oct studi conduct follow transplant show similar find form irregular subretin hyper reflect area transplant pig eye follow enucl subretin layer human hesc rpe transplant cell evid proven immunohistochem stain use human specif marker research thu believ hyper reflect oct also seen human patient correl presenc transplant cell dozen research group around world work approach stem cell base rpe cell transplant dri amd one group recent report promis phase result clinic grade retin implant made hesc deriv rpe grown synthet substrat implant well toler one patient show improv visual function ah kashani scienc translat medicin vol issu eaao',\n",
       " 'diagnos ms year ago ms retreat twice year old beta feron year take drug month ago second jelinek retreat well month ago describ mini relaps follow coupl stress day cancel everyth stay home week slowli get back normal need get physic stronger phone ms nurs set back advis investig start gilyenya express concern return dmd well last month book see neurologist mri book come tuesday divid thought realli would like remain drug free possibl also understand drug might help may avail futur current edss scale believ qualifi gilenya score edss scale although sure feel pressur go medic rout feel like failur succumb drug well om program would appreci thought comment regard thank',\n",
       " 'hi everyon updat dad lung tumor grew cm week gemzar stop next week start combo opdivo yervoy stop respond keytruda hope combo work harsh bodi nurs comment today definit fighter take everi treatment throw pretti well hope toler well get good result happi new year everyon',\n",
       " 'j poucher whose diagnosi chang uc crohn colon remov j pouch form connect bump along way fissur skintag excis help reduc fissur strictur inlet pouch surgeri open everyth start fall apart diagnos iron defici anemia start get iron infus rectal area becam realli angri inflam feel well overal suspect crohn put remicad love remicad develop antibodi year tri humira cimzia luck develop two fistula went seton path miser sick time got cleveland clinic left j pouch gave temp ileo sone relief realli babi seton hate ha cleveland clinic remzi move ny told seen uc crohn diagnosi chang patient usual occur peopl pouch longer guess mechan surgic error complic rather diseas often common caus earli pouch problem think symptom point definit crohn either never problem eat anyth abdomin pain promin symptom feel like issu peri anal realiz everyon differ seem like peopl varieti symptom shen told seen peopl terribl diseas minim symptom vice versa diseas tricki mental drain etc hope get answer caus problem b c unknown frustrat good luck hang',\n",
       " 'biolog price competit innov act bpci act sign law march part afford care act bpci act creat abbrevi approv process biosimilar goal demonstr biosimilar propos product origin product independ establish safeti effect propos product total evid approach taken fda evalu biosimilar approv result clinic trial import data preclin work also consid biosimilar approv use fda approv addit indic condit base concept call extrapol data data collect biosimilar preclin work show clinic result origin product biolog addit clinic trial conduct instanc clinic trial biosimilar filgrastim sndz studi effect safeti clinic trial whose particip treat breast cancer approv grant fda filgrastim sndz bone marrow stimul five indic approv origin product filgrastim patient cancer receiv myelosuppress chemotherapi treatment stop slow growth blood form cell bone marrow patient acut myeloid leukemia receiv chemotherapi patient cancer undergo bone marrow transplant patient undergo autolog peripher blood progenitor cell collect therapi method replac blood form stem cell destroy cancer treatment patient sever chronic neutropenia abnorm low count type white blood cell biosimilar approv fda includ filgrastim sndz current twelv biosimilar approv fda treatment specif condit fda approv six immunosuppres drug treatment certain form arthriti psoriasi ulcer coliti crohn diseas drug list order approv infliximab dyyb inflectra origin product infliximab remicad etanercept szz erelzi origin product etanercept enbrel adalimumab atto amjevita origin product adalimumab humira infliximab abda renflexi origin product infliximab remicad adalimumab adbm cyltezo origin product adalimumab humira infliximab qbtx ixifi origin product infliximab remicad septemb fda approv bevacizumab awwb mvasi treatment five type cancer non squamou non small cell lung cancer nsclc metastat colorect cancer mcrc glioblastoma metastat renal cell carcinoma persist recurr metastat carcinoma cervix bevacizumab awwb approv indic origin drug bevacizumab avastin could reach u market soon patent bevacizumab expir decemb fda approv trastuzumab dkst ogivri treatment peopl posit breast cancer posit gastric cancer growth promot protein found surfac cancer cell origin drug trastuzumab herceptin patent expir',\n",
       " 'use treat skin cancer use treat lung cancer need tell doctor take trametinib allergi trametinib part trametinib allerg drug like one drug food substanc tell doctor allergi sign like rash hive itch short breath wheez cough swell face lip tongu throat sign breast feed breast feed take trametinib month last dose medicin may interact drug health problem tell doctor pharmacist drug prescript otc natur product vitamin health problem must check make sure safe take trametinib drug health problem start stop chang dose drug without check doctor thing need know take trametinib tell health care provid take trametinib includ doctor nurs pharmacist dentist sometim dabrafenib taken trametinib take dabrafenib trametinib sure know side effect happen drug drug taken togeth chanc certain side effect may rais side effect bad sometim deadli includ bleed bleed brain blood clot eye problem fever heart problem like heart failur high blood sugar cancer skin problem talk doctor chanc side effect drug high blood pressur happen trametinib blood pressur check told doctor blood work check told doctor talk doctor eye pressur eyesight check told doctor blood clot happen trametinib tell doctor ever blood clot talk doctor call doctor right away sign blood clot like chest pain pressur cough blood short breath swell warmth numb chang color pain leg arm troubl speak swallow common get rash trametinib skin reaction may also happen sometim rash skin reaction bad may need treatment hospit call doctor right away acn skin red skin rash bother go away call doctor right away red irrit palm hand sole feet bad eye problem happen trametinib sometim led loss eyesight call doctor right away blur eyesight loss eyesight chang eyesight call doctor right away see color dot halo bright light bother bowel problem coliti hole bowel happen trametinib sometim deadli call doctor right away diarrhea stomach pain cramp fever upset stomach older use trametinib care could side effect medicin may caus fertil problem may affect abl children talk doctor medicin may caus harm unborn babi take pregnant use birth control trust prevent pregnanc take trametinib month last dose get pregnant take trametinib within month last dose call doctor right away medicin trametinib best taken use trametinib order doctor read inform given follow instruct close take trametinib time day take empti stomach take hour hour meal gain benefit miss dose keep take trametinib told doctor health care provid even feel well miss dose take miss dose soon think less hour next dose skip miss dose go back normal time take dose time extra dose see also dosag inform detail side effect need call doctor right away warn caution even though may rare peopl may bad sometim deadli side effect take drug tell doctor get medic help right away follow sign symptom may relat bad side effect sign allerg reaction like rash hive itch red swollen blister peel skin without fever wheez tight chest throat troubl breath swallow talk unusu hoars swell mouth face lip tongu throat sign bleed like throw blood throw look like coffe ground cough blood blood urin black red tarri stool bleed gum vagin bleed normal bruis without reason get bigger bleed bad cannot stop sign lung breath problem like short breath troubl breath cough fever sign fluid electrolyt problem like mood chang confus muscl pain weak heartbeat feel normal bad dizzi pass fast heartbeat thirst seizur feel tire weak hungri unabl pass urin chang amount urin produc dri mouth dri eye bad upset stomach throw sign high blood pressur like bad headach dizzi pass chang eyesight sign kidney problem like unabl pass urin chang much urin pass blood urin big weight gain fever chill feel tire weak medicin may caus heart failur need heart function check take trametinib call doctor right away sign heart problem like cough short breath new wors swell ankl leg heartbeat feel normal weight gain pound hour dizzi pass side effect trametinib drug may caus side effect howev mani peopl side effect minor side effect call doctor get medic help side effect side effect bother go away dri skin chang nail mouth irrit mouth sore upset stomach throw feel tire weak hungri side effect may occur question side effect call doctor call doctor medic advic side effect may report side effect fda fda may also report side effect http www fda gov medwatch see also side effect detail overdos suspect think overdos call poison control center get medic care right away readi tell show taken much happen store throw trametinib store refriger freez keep tablet bottl come move pill holder store origin contain take antimoistur cube packet protect light keep drug safe place keep drug reach children pet throw away unus expir drug flush toilet pour drain unless told check pharmacist question best way throw drug may drug take back program area consum inform use symptom health problem get better becom wors call doctor share drug other take anyon els drug keep list drug prescript natur product vitamin otc give list doctor talk doctor start new drug includ prescript otc natur product vitamin drug may anoth patient inform leaflet check pharmacist question trametinib pleas talk doctor nurs pharmacist health care provid think overdos call poison control center get medic care right away readi tell show taken much happen',\n",
       " 'jasoncohen although would ad benefit express pd l ligand nesessari opdivo pertin karnofski score activ level sound like would meet criteria correct mani option scc mortal rate high aggress howev option mani immunotherapi often given label long stay strong good qualiti life manag diseas success best luck alway around need addit inform carm',\n",
       " 'dear bmj great news happi hear tarceva help bmet pleas keep updat aggress approach seem doctor seen take bmet research understand specialist prefer recommend lengthen systemat treatment long possibl patient symptom side effect allow even light progress mother specif would mean bmet respond tarceva primari lung tumor rest bodi good respons tarceva local treatment option bmet may explor combin tarceva oppos test switch systemat care tarceva work rel well everyth bmet believ pleas correct wrong much clinic studi evid switch erlotinib treatment osimertinib erlotinib still elicit good overal respons treat bmet sure would effect overal durat pf erlotinib may fulli exhaust seem walk road limit option need valu everi option long abl howev interest hear feedback receiv allegra elomet cream knowledg medic compar drug doxycylin person experi standpoint mother start develop facial acn especi zone eye nose around mouth roughen red rash cheek week take tarceva acn bearabl noth highli discomfort inflam blemish would pu nurs refer us dermatologist take medic appli ointment skin condit improv within one week rash disappear acn lessen repli modifi year month ago jc repli modifi year month ago jc',\n",
       " 'hi khlaq understand desir make good treatment decis grace provid inform specif advic patient brother medic team great deal inform situat provid could provid need make good therapi choic add prematur state alectinib good leptomening articl link janin provid state evid alectinib report activ alk nsclc patient leptomening diseas footnot statement refer two report one discuss singl patient anoth dealt four patient might imagin doctor tend write success stori necessarili hear patient respond inform like appear result larg clinic trial yet full data effect alectinib leptomening diseas lung cancer addit report state earli small data set show intracrani respons rate alectinib rang two thing note statement small data set may reflect experi observ larger group patient respons rate quot indic percent patient treat alectinib respond way attempt talk tri alectinib purpos site provid relev inform help brother doctor make good choic leptomenig diseas difficult treat report cite articl encourag warrant studi enough data point jimc forum moder jul wife liz never smoker dx stage iv nsclc egfr exon cycl carbo alimta shrinkag tarceva mainten mar progress ad alimta stabl sep multipl brain met wbr oct larg pericardi effus tamponad jan progress start abraxan jun new liver brain met add tarceva oct dx leptomening carcinomatosi puls tarceva rest nov sinc http cancergrac org blog jim lisa repli modifi month week ago jimc forum moder repli modifi month week ago jimc forum moder',\n",
       " 'stage sinc everi treatment chemo radiat resect done use option went opdivo day approv took year job cancer free last year half f work work say work stop take need still work realli never know road btw pharmaceut compani plan pay deduct expens stuff cheap get doctor request',\n",
       " 'congrat get hand latest poison ms excit even reader blog per usual keep us updat posit neg drug read today ocrevu quickli becom first line medic choic ms alway thought would best tackl diseas aggress start',\n",
       " 'thank repli male notsosickli think rule time month lol havent spoken doctor yet last day happen havent start new med chang diet bit mysteri think face look swollen could imagin sure see acn improv come week fact appear exactli area pred taper strang ulcer coliti sinc juli pred anoth year stint upadacitinib clinic trial colazid g entyvio vedolizumab sinc januari stop oct lost respons azathioprin mg stop due clinic trial',\n",
       " ...]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## print the test corpus\n",
    "corpus_test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Creating the bag of words model - training model\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "cv = CountVectorizer(max_features = 2000)\n",
    "X = cv.fit_transform(corpus).toarray()\n",
    "y = data.iloc[:, 3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## BOW - test data\n",
    "cv_test = CountVectorizer(max_features = 2000)\n",
    "X_test = cv.fit_transform(corpus_test).toarray()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Splitting the dataset into train and validation\n",
    "from sklearn.model_selection import train_test_split\n",
    "X_train, X_val, y_train, y_val = train_test_split(X, y, test_size = 0.2, random_state = 0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Fitting the Naive Bayes model to the training data set\n",
    "from sklearn.naive_bayes import GaussianNB\n",
    "classifier = GaussianNB()\n",
    "classifier.fit(X_train, y_train)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Predicting the validation result\n",
    "y_pred = classifier.predict(X_val)\n",
    "y_pred"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Confusion matrix\n",
    "from sklearn.metrics import confusion_matrix\n",
    "cm = confusion_matrix(y_val, y_pred)\n",
    "cm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "Accuracy = ((24+127+141)/(19+96+17+9+130+17+82+548+138))*100\n",
    "Accuracy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Predicting the test results\n",
    "y_test = classifier.predict(X_test)\n",
    "y_test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "result = y_test.tolist()\n",
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "unique_hash = unique_hash.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "type(unique_hash)\n",
    "len(unique_hash)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "type(result)\n",
    "len(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.DataFrame({\"unique_hash\":unique_hash, \"sentiment\": result}, index = None)\n",
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv(\"sixth_submission.csv\", index = None)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
